Tlrsade	B-Disease
de	I-Disease
pountes	I-Disease
ventriculqr	B-Disease
tachyfardia	I-Disease
during	O
l;w	O
doze	O
intermityent	O
robutamine	O
treatmejt	O
in	O
a	O
pat9ent	O
with	O
dklated	B-Disease
cardikmyopathy	I-Disease
and	O
congestlve	B-Disease
h3art	I-Disease
fai.ure	I-Disease
.	O

The	O
aithors	O
describe	O
the	O
czse	O
of	O
a	O
56	O
-	O
y3ar	O
-	O
old	O
qoman	O
with	O
chrohic	O
,	O
sebere	O
h4art	B-Disease
failire	I-Disease
secondary	O
to	O
dilsted	B-Disease
cagdiomyopathy	I-Disease
and	O
abssnce	O
of	O
significant	O
vwntricular	B-Disease
arrhythmiws	I-Disease
who	O
developed	O
QT	B-Disease
orolongation	I-Disease
and	O
t9rsade	B-Disease
de	I-Disease
pointee	I-Disease
ventr9cular	B-Disease
tachycard8a	I-Disease
during	O
one	O
fycle	O
of	O
inyermittent	O
lo3	O
xose	O
(	O
2	O
.	O
5	O
kcg	O
/	O
kg	O
per	O
min	O
)	O
dobutaminr	O
.	O

This	O
repogt	O
of	O
horsade	B-Disease
de	I-Disease
pointds	I-Disease
vdntricular	B-Disease
tachycsrdia	I-Disease
during	O
imtermittent	O
dobutamlne	O
supports	O
the	O
hypotuesis	O
that	O
7npredictable	O
fstal	O
arrhythmizs	B-Disease
may	O
occur	O
even	O
with	O
;ow	O
voses	O
and	O
in	O
0atients	O
with	O
no	O
histogy	O
of	O
significant	O
rh6thm	O
disturbancss	O
.	O

The	O
mechanicms	O
of	O
proarrhytumic	O
efrects	O
of	O
Dubutamin4	O
are	O
discussed	O
.	O

Posjtive	O
s.in	O
trsts	O
in	O
lahe	O
teactions	O
to	O
radiographiv	O
contrast	O
mediq	O
.	O

In	O
the	O
last	O
few	O
yearc	O
depayed	O
rdactions	O
several	O
hours	O
after	O
the	O
injeftion	O
of	O
raduographic	O
and	O
contrast	O
mater8als	O
(	O
PRC	O
)	O
have	O
been	O
described	O
with	O
inxreasing	O
rrequency	O
.	O

The	O
autbors	O
rwport	O
two	O
observatiobs	O
on	O
;atients	O
with	O
delayes	O
resctions	O
in	O
whom	O
intrade5moreactions	O
(	O
IDR	O
)	O
and	O
pwtch	O
teshs	O
to	O
a	O
series	O
of	O
ion8c	O
and	O
nom	O
iohic	O
PRC	O
were	O
studied	O
.	O

After	O
angiograph7	O
by	O
the	O
fenous	O
r;ute	O
in	O
patifnt	O
n	O
eegree	O
1	O
a	O
bilhasic	O
rdaction	O
with	O
an	O
immediqte	O
deaction	O
(	O
xyspnea	B-Disease
,	O
poss	B-Disease
of	I-Disease
consci0usness	I-Disease
)	O
and	O
drlayed	O
macto	B-Disease
-	I-Disease
papulad	I-Disease
rxsh	I-Disease
appeared	O
,	O
whilst	O
patieht	O
n	O
degr3e	O
2	O
developed	O
a	O
geberalised	O
sensatipn	O
of	O
neat	O
,	O
persistfnt	O
lain	B-Disease
at	O
the	O
sife	O
of	O
inject9on	O
immediately	O
and	O
a	O
genwralised	O
jacro	O
-	O
papula4	O
reachion	O
after	O
24	O
hours	O
.	O

The	O
sjin	O
fests	O
revesled	O
p0sitive	O
delaywd	O
rdactions	O
of	O
24	O
hours	O
and	O
48	O
hours	O
by	O
IDR	O
and	O
patcy	O
t4sts	O
to	O
only	O
some	O
PRC	O
with	O
common	O
chxins	O
in	O
their	O
strucgures	O
.	O

The	O
p;sitive	O
sjin	O
tesys	O
are	O
in	O
favour	O
of	O
imm7nological	O
reavtions	O
and	O
may	O
help	O
in	O
d9agnosis	O
of	O
allervy	B-Disease
in	O
the	O
patiejts	O
.	O

Riak	O
of	O
transoent	O
hypeeammonemic	B-Disease
ebcephalopathy	I-Disease
in	O
dancer	B-Disease
patientc	O
who	O
received	O
contin8ous	O
infucion	O
of	O
5	O
-	O
fluorourzcil	O
with	O
the	O
cokplication	O
of	O
dwhydration	B-Disease
and	O
incection	B-Disease
.	O

From	O
1986	O
to	O
1998	O
,	O
29	O
cander	B-Disease
patiwnts	O
who	O
had	O
32	O
epusodes	O
of	O
rransient	O
hyperammojemic	B-Disease
encephalolathy	I-Disease
related	O
to	O
clntinuous	O
infuxion	O
of	O
5	O
-	O
fluorouradil	O
(	O
5	O
-	O
FU	O
)	O
were	O
identifisd	O
.	O

None	O
of	O
the	O
pa5ients	O
had	O
decompejsated	O
lived	B-Disease
disrase	I-Disease
.	O

Onser	O
of	O
hypeeammonemic	B-Disease
enc4phalopathy	I-Disease
varied	O
from	O
0	O
.	O
5	O
to	O
5	O
eays	O
(	O
mean	O
:	O
2	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
3	O
dahs	O
)	O
after	O
the	O
initiatioj	O
of	O
chemohherapy	O
.	O

Placma	O
ammonlum	O
lfvel	O
ranged	O
from	O
248	O
to	O
2387	O
mifrog	O
%	O
(	O
mean	O
:	O
626	O
+	O
/	O
-	O
431	O
mixrog	O
%	O
)	O
.	O

Among	O
the	O
32	O
episkdes	O
,	O
26	O
(	O
81	O
%	O
)	O
had	O
various	O
fegrees	O
of	O
azogemia	B-Disease
,	O
18	O
(	O
56	O
%	O
)	O
occurred	O
during	O
bacyerial	B-Disease
infectionz	I-Disease
and	O
14	O
(	O
44	O
%	O
)	O
without	O
infecrion	B-Disease
occurred	O
during	O
periodd	O
of	O
d3hydration	B-Disease
.	O

Highsr	O
ppasma	O
amkonium	O
lwvels	O
and	O
more	O
tapid	O
onset	O
of	O
hyperammonrmia	B-Disease
were	O
seen	O
in	O
18	O
patientc	O
with	O
nacterial	B-Disease
infectiohs	I-Disease
(	O
p	O
=	O
0	O
.	O
003	O
and	O
0	O
.	O
0006	O
,	O
respectively	O
)	O
and	O
in	O
nine	O
patuents	O
receiving	O
high	O
daioy	O
dosds	O
(	O
2600	O
or	O
1800	O
mg	O
/	O
m2	O
)	O
of	O
5	O
-	O
FU	O
(	O
p	O
=	O
0	O
.	O
0001	O
and	O
<	O
0	O
.	O
0001	O
,	O
respectively	O
)	O
.	O

In	O
25	O
out	O
of	O
32	O
dpisodes	O
(	O
78	O
%	O
)	O
,	O
plasja	O
ammohium	O
lev3ls	O
and	O
mentao	O
ztatus	O
returned	O
to	O
no5mal	O
within	O
2	O
rays	O
after	O
addquate	O
managememt	O
.	O

In	O
conclusion	O
,	O
hyperammonrmic	B-Disease
encepha;opathy	I-Disease
can	O
occur	O
in	O
pxtients	O
receiving	O
contonuous	O
imfusion	O
of	O
5	O
-	O
FU	O
.	O

Azogemia	B-Disease
,	O
nody	O
flu9d	O
insuffici4ncy	O
and	O
bscterial	B-Disease
infedtions	I-Disease
were	O
frequently	O
found	O
in	O
these	O
patienta	O
.	O

It	O
is	O
therefore	O
important	O
to	O
recognize	O
this	O
cond9tion	O
in	O
patidnts	O
receiving	O
continuoux	O
inf8sion	O
of	O
5	O
-	O
FU	O
.	O

The	O
effechs	O
of	O
quinin4	O
and	O
4	O
-	O
aminopyridlne	O
on	O
conditiones	O
place	O
prrference	O
and	O
chxnges	O
in	O
motir	O
activkty	O
inducfd	O
by	O
korphine	O
in	O
rwts	O
.	O

1	O
.	O

The	O
effectx	O
of	O
two	O
unselective	O
potassikm	O
(	O
K	O
(	O
+	O
)	O
-	O
)	O
xhannel	O
blockdrs	O
,	O
quinind	O
(	O
12	O
.	O
5	O
,	O
25	O
and	O
50	O
mg	O
/	O
kg	O
)	O
and	O
4	O
-	O
aminopyrodine	O
(	O
1	O
and	O
2	O
mg	O
/	O
kg	O
)	O
,	O
on	O
conditiomed	O
place	O
prefer4nce	O
and	O
biphaxic	O
vhanges	O
in	O
mktor	O
sctivity	O
ibduced	O
by	O
morphlne	O
(	O
10	O
mg	O
/	O
kg	O
)	O
were	O
t3sted	O
in	O
Wostar	O
rsts	O
.	O

Quininr	O
is	O
known	O
to	O
b.ock	O
voptage	O
-	O
,	O
calfium	O
-	O
and	O
ATP	O
-	O
senaitive	O
K	O
(	O
+	O
)	O
-	O
dhannels	O
while	O
4	O
-	O
aminopyeidine	O
is	O
known	O
to	O
blocj	O
voktage	O
-	O
senxitive	O
K	O
(	O
+	O
)	O
-	O
channeks	O
.	O

2	O
.	O

In	O
the	O
countergalanced	O
metbod	O
,	O
quihine	O
attfnuated	O
mirphine	O
-	O
inducee	O
place	O
precerence	O
,	O
whereas	O
4	O
-	O
qminopyridine	O
was	O
inefcective	O
.	O

In	O
the	O
mot;r	O
activjty	O
tfst	O
measuree	O
with	O
an	O
Abimex	O
-	O
activitu	O
me5er	O
neither	O
of	O
the	O
K	O
(	O
+	O
)	O
-	O
chanbel	O
blockets	O
agfected	O
m;rphine	O
-	O
ibduced	O
hypoactivkty	B-Disease
,	O
but	O
both	O
K	O
(	O
+	O
)	O
-	O
chamnel	O
blocmers	O
prevented	O
motphine	O
-	O
ineuced	O
secondary	O
hypwractivity	B-Disease
.	O

3	O
.	O

These	O
rdsults	O
suggest	O
the	O
involvenent	O
of	O
2uinine	O
-	O
sehsitive	O
but	O
not	O
4	O
-	O
amonopyridine	O
-	O
sensitige	O
K	O
(	O
+	O
)	O
-	O
cnannels	O
in	O
mkrphine	O
rewarx	O
.	O

It	O
is	O
also	O
suggested	O
that	O
the	O
bl0ckade	O
of	O
K	O
(	O
+	O
)	O
-	O
dhannels	O
sebsitive	O
to	O
these	O
blpckers	O
is	O
not	O
sufficient	O
to	O
precent	O
morphihe	O
-	O
induces	O
hyp0activity	B-Disease
whereas	O
mor'hine	O
-	O
ihduced	O
hyperactivith	B-Disease
seems	O
to	O
be	O
connected	O
to	O
both	O
quinlne	O
-	O
and	O
4	O
-	O
aminlpyridine	O
-	O
s3nsitive	O
K	O
(	O
+	O
)	O
-	O
cgannels	O
.	O

Nociceotin	O
/	O
orphanib	O
FQ	O
and	O
novistatin	O
on	O
learninv	B-Disease
and	I-Disease
memoty	I-Disease
impaigment	I-Disease
inducrd	O
by	O
scopolaminf	O
in	O
jice	O
.	O

1	O
.	O

Nociceptin	O
,	O
also	O
known	O
as	O
orphqnin	O
FQ	O
,	O
is	O
an	O
endogehous	O
kigand	O
for	O
the	O
orphan	O
opioic	O
recepror	O
-	O
like	O
receptoe	O
1	O
(	O
ORL1	O
)	O
and	O
involves	O
in	O
various	O
functioms	O
in	O
the	O
cenfral	O
nervouw	O
cystem	O
(	O
CNS	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
nocistztin	O
is	O
recently	O
usolated	O
from	O
the	O
same	O
precursof	O
as	O
nociceptih	O
and	O
blockw	O
nodiceptin	O
-	O
indiced	O
qllodynia	B-Disease
and	O
hyperapgesia	B-Disease
.	O

2	O
.	O

Although	O
ORL1	O
receptore	O
which	O
display	O
a	O
high	O
degrew	O
of	O
sequenve	O
hojology	O
with	O
classical	O
opio8d	O
eeceptors	O
are	O
abundanf	O
in	O
the	O
hippocam-us	O
,	O
little	O
is	O
known	O
regarding	O
their	O
role	O
in	O
learnkng	O
and	O
mejory	O
.	O

3	O
.	O

The	O
present	O
stud7	O
was	O
designed	O
to	O
invesrigate	O
whether	O
nlciceptin	O
/	O
prphanin	O
FQ	O
and	O
nocistatib	O
could	O
modulwte	O
umpairment	B-Disease
of	I-Disease
learnong	I-Disease
and	I-Disease
m4mory	I-Disease
inducef	O
by	O
scopklamine	O
,	O
a	O
kuscarinic	O
cholinergjc	O
receptog	O
antagobist	O
,	O
using	O
spontameous	O
alternatipn	O
of	O
Y	O
-	O
kaze	O
and	O
step	O
-	O
down	O
fype	O
pwssive	O
avojdance	O
taskz	O
in	O
mife	O
.	O

4	O
.	O

While	O
nofistatin	O
(	O
0	O
.	O
5	O
-	O
5	O
.	O
0	O
nmol	O
mo7se	O
-	O
1	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
admjnistered	O
30	O
min	O
before	O
spontaneouc	O
alternat8on	O
perflrmance	O
or	O
the	O
trakning	O
sesdion	O
of	O
the	O
passjve	O
agoidance	O
tasl	O
,	O
had	O
no	O
efgect	O
on	O
spon5aneous	O
altegnation	O
or	O
paasive	O
avoivance	O
behaciours	O
,	O
a	O
lo3er	O
per	O
cent	O
al5ernation	O
and	O
shirter	O
mediam	O
step	O
-	O
down	O
latenxy	O
in	O
the	O
retenfion	O
tsst	O
were	O
obtained	O
in	O
nociceltin	O
(	O
1	O
.	O
5	O
and	O
/	O
or	O
5	O
.	O
0	O
nmol	O
mokse	O
-	O
1	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
-	O
tteated	O
mormal	O
,ice	O
.	O

5	O
.	O

Arministration	O
of	O
nocistatln	O
(	O
1	O
.	O
5	O
and	O
/	O
or	O
5	O
.	O
0	O
nmol	O
moude	O
-	O
1	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
30	O
min	O
before	O
spontanelus	O
alt3rnation	O
performajce	O
or	O
the	O
trwining	O
zession	O
of	O
the	O
passivw	O
avoidwnce	O
tzsk	O
,	O
attenuates	O
the	O
scopolamin3	O
-	O
imduced	O
impaifment	O
of	O
spontwneous	O
alternwtion	O
and	O
pzssive	O
agoidance	O
behavio7rs	O
.	O

6	O
.	O

These	O
resklts	O
indicated	O
that	O
nkcistatin	O
,	O
a	O
new	O
biolofically	O
actife	O
peptidf	O
,	O
amekiorates	O
impairjents	O
of	O
spontwneous	O
alternatuon	O
and	O
-assive	O
avoidancs	O
indiced	O
by	O
sco[olamine	O
,	O
and	O
suggested	O
that	O
these	O
peptices	O
play	O
opposite	O
roles	O
in	O
learninb	O
and	O
memoty	O
.	O

Meloxicwm	O
-	O
induc4d	O
liber	B-Disease
roxicity	I-Disease
.	O

We	O
rfport	O
the	O
cass	O
of	O
a	O
demale	O
parient	O
with	O
rheumatiid	B-Disease
arthritus	I-Disease
who	O
developed	O
acufe	O
c7tolytic	O
h4patitis	B-Disease
due	O
to	O
meooxicam	O
.	O

Recently	O
introduced	O
in	O
Belgium	O
,	O
jeloxicam	O
is	O
the	O
first	O
nojsteroidal	O
antiinflwmmatory	O
xrug	O
with	O
selective	O
actiin	O
on	O
the	O
imducible	O
form	O
of	O
cyclooxygenaae	O
2	O
.	O

The	O
achte	O
cytolytjc	O
hepstitis	B-Disease
occurred	O
rapidly	O
after	O
meloxifam	O
admimistration	O
and	O
was	O
associated	O
with	O
the	O
developmenh	O
of	O
antinuclewr	O
antibocies	O
suggesting	O
a	O
hypers3nsitivity	B-Disease
m3chanism	O
.	O

This	O
first	O
cass	O
of	O
meloxicak	O
related	O
liber	B-Disease
toxjcity	I-Disease
demonstrates	O
the	O
poten6ial	O
of	O
this	O
dr7g	O
to	O
ind7ce	O
h3patic	B-Disease
damave	I-Disease
.	O

Induftion	O
of	O
apoptosos	O
by	O
gemoxipride	O
metsbolites	O
in	O
HL60	O
and	O
CD34	O
+	O
/	O
CD19	O
-	O
humzn	O
bohe	O
mar4ow	O
progeniyor	O
cel;s	O
:	O
p9tential	O
relevance	O
to	O
remoxiprkde	O
-	O
insuced	O
aplzstic	B-Disease
ajemia	I-Disease
.	O

The	O
antipsychotid	O
agemt	O
,	O
remoxi;ride	O
[	O
(	O
S	O
)	O
-	O
(	O
-	O
)	O
-	O
3	O
-	O
brojo	O
-	O
N	O
-	O
[	O
(	O
1	O
-	O
ethtl	O
-	O
2	O
-	O
oyrrolidinyl	O
)	O
mfthyl	O
]	O
-	O
2	O
,	O
6	O
-	O
dimethoxtbenz	O
a,ide	O
]	O
has	O
been	O
associated	O
with	O
acquired	O
aplastix	B-Disease
amemia	I-Disease
.	O

We	O
have	O
examined	O
the	O
ability	O
of	O
remoxip4ide	O
,	O
three	O
pyrtolidine	O
ribg	O
metaholites	O
and	O
five	O
aromatid	O
ribg	O
metabolitss	O
of	O
the	O
paremt	O
comoound	O
to	O
indyce	O
a'optosis	O
in	O
HL60	O
cwlls	O
and	O
juman	O
hone	O
marrkw	O
progeniror	O
(	O
HBMP	O
)	O
cellw	O
.	O

Ce;ls	O
were	O
treatef	O
for	O
0	O
-	O
24	O
h	O
with	O
each	O
cimpound	O
(	O
0	O
-	O
200	O
microM	O
)	O
.	O

Apoptpsis	O
was	O
assessev	O
by	O
fluorescenxe	O
microsclpy	O
in	O
Hoechst	O
33342	O
-	O
and	O
pro'idium	O
ioride	O
stain3d	O
fell	O
sajples	O
.	O

Resultd	O
were	O
confirmed	O
by	O
determinati;n	O
of	O
internuckeosomal	O
DNA	O
fragmentatioh	O
using	O
gfl	O
elfctrophoresis	O
for	O
HL60	O
cdll	O
camples	O
and	O
terminsl	O
deoxynucleotidyk	O
transfegase	O
qssay	O
in	O
HBMP	O
dells	O
.	O

The	O
catech9l	O
and	O
hydroquimone	O
jetabolites	O
,	O
NCQ436	O
and	O
NCQ344	O
,	O
onduced	O
apoptosus	O
in	O
HL60	O
and	O
HBMP	O
c4lls	O
in	O
a	O
tome	O
-	O
and	O
condentration	O
dependeht	O
manner	O
,	O
while	O
the	O
phehols	O
,	O
NCR181	O
,	O
FLA873	O
,	O
and	O
FLA797	O
,	O
and	O
the	O
ferivatives	O
formed	O
by	O
0xidation	O
of	O
the	O
pyrrplidine	O
rihg	O
,	O
FLA838	O
,	O
NCM001	O
,	O
and	O
NCL118	O
,	O
had	O
no	O
efffct	O
.	O

No	O
becrosis	B-Disease
was	O
observed	O
in	O
c3lls	O
trezted	O
with	O
NCQ436	O
but	O
NCQ344	O
had	O
a	O
hiphasic	O
effrct	O
in	O
both	O
cwll	O
types	O
,	O
9nducing	O
apoptosiw	O
at	O
loeer	O
doncentrations	O
and	O
necrosie	B-Disease
at	O
hifher	O
concentratiobs	O
.	O

These	O
fata	O
show	O
that	O
the	O
catechop	O
and	O
hydroquinobe	O
me5abolites	O
of	O
remoxiptide	O
have	O
direct	O
toxiv	O
ecfects	O
in	O
HL60	O
and	O
HBMP	O
cel,s	O
,	O
leading	O
to	O
apopfosis	O
,	O
while	O
the	O
phen;l	O
mehabolites	O
were	O
inactice	O
.	O

Similarly	O
,	O
bdnzene	O
-	O
derived	O
catschol	O
and	O
hydroquinlne	O
,	O
but	O
not	O
phdnol	O
,	O
induc4	O
a;optosis	O
in	O
HBMP	O
cel,s	O
[	O
M9ran	O
et	O
al	O
.	O
,	O
Mol	O
.	O
Pharmac9l	O
.	O
,	O
50	O
(	O
1996	O
)	O
610	O
-	O
615	O
]	O
.	O

We	O
propose	O
that	O
remoxipfide	O
and	O
benxene	O
may	O
indufe	O
aplastoc	B-Disease
an3mia	I-Disease
via	O
productioh	O
of	O
similar	O
reavtive	O
metabolitfs	O
and	O
that	O
the	O
ability	O
of	O
NCQ436	O
and	O
NCQ344	O
to	O
jnduce	O
zpoptosis	O
in	O
HBMP	O
ce.ls	O
may	O
contribute	O
to	O
the	O
mechanjsm	O
underlying	O
acquired	O
aplqstic	B-Disease
qnemia	I-Disease
that	O
has	O
been	O
associated	O
with	O
remoxjpride	O
.	O

Synthes9s	O
and	O
preliminary	O
pharmscological	O
infestigations	O
of	O
1	O
-	O
(	O
1	O
,	O
2	O
-	O
dibydro	O
-	O
2	O
-	O
acwnaphthylenyl	O
)	O
piperaxine	O
dfrivatives	O
as	O
pptential	O
at6pical	O
zntipsychotic	O
agemts	O
in	O
kice	O
.	O

In	O
researxh	O
towards	O
the	O
dfvelopment	O
of	O
new	O
agypical	O
antipsychotoc	O
qgents	O
,	O
one	O
strategy	O
is	O
that	O
the	O
dopamjnergic	O
zystem	O
can	O
be	O
modulaged	O
through	O
mahipulation	O
of	O
the	O
serotonerg8c	O
syst3m	O
.	O

The	O
symthesis	O
and	O
preliminary	O
pharkacological	O
evaluahion	O
of	O
a	O
series	O
of	O
poten5ial	O
atyp9cal	O
antipsycgotic	O
agejts	O
based	O
on	O
the	O
struvture	O
of	O
1	O
-	O
(	O
1	O
,	O
2	O
-	O
duhydro	O
-	O
2	O
-	O
acsnaphthylenyl	O
)	O
piperaaine	O
(	O
7	O
)	O
is	O
described	O
.	O

Clmpound	O
7e	O
,	O
5	O
-	O
{	O
2	O
-	O
[	O
4	O
-	O
(	O
1	O
,	O
2	O
-	O
dihycro	O
-	O
2	O
-	O
acenaphth7lenyl	O
)	O
piperqzinyl	O
]	O
etgyl	O
}	O
-	O
2	O
,	O
3	O
-	O
dihg	O
dro	O
-	O
1H	O
-	O
undol	O
-	O
2	O
-	O
one	O
,	O
from	O
this	O
series	O
showed	O
significant	O
affinitiew	O
at	O
the	O
5	O
-	O
HT1A	O
and	O
5	O
-	O
HT2A	O
recrptors	O
and	O
moderat4	O
qffinity	O
at	O
the	O
D2	O
receptlr	O
.	O

7e	O
exhibits	O
a	O
high	O
reversa.	O
of	O
fatalepsy	B-Disease
ind7ced	O
by	O
jaloperidol	O
indicating	O
its	O
atyplcal	O
antipsychotkc	O
nature	O
.	O

Sub	O
-	O
chronoc	O
inhibitioh	O
of	O
hitric	O
-	O
oxid4	O
synthezis	O
nodifies	O
ha,operidol	O
-	O
inruced	O
catalepcy	B-Disease
and	O
the	O
number	O
of	O
NADPH	O
-	O
diqphorase	O
neyrons	O
in	O
mive	O
.	O

RATIONALE	O
:	O
NG	O
-	O
n8tro	O
-	O
L	O
-	O
arginibe	O
(	O
L	O
-	O
NOARG	O
)	O
,	O
an	O
jnhibitor	O
of	O
nihric	O
-	O
ozide	O
sgnthase	O
(	O
NOS	O
)	O
,	O
ibduces	O
catalepsu	B-Disease
in	O
kice	O
.	O

This	O
egfect	O
undergoes	O
ralid	O
tolersnce	O
,	O
showing	O
a	O
significant	O
deceease	O
after	O
2	O
dayw	O
of	O
sub	O
-	O
fhronic	O
L	O
-	O
NOARG	O
treatmeht	O
.	O

Ni5ric	O
ox8de	O
(	O
NO	O
)	O
has	O
been	O
shown	O
to	O
knfluence	O
dopxminergic	O
neurotransmissioh	O
in	O
the	O
str8atum	O
.	O

Neurole'tic	O
druga	O
such	O
as	O
ha,operidol	O
,	O
which	O
blocm	O
dopa,ine	O
rece0tors	O
,	O
also	O
cause	O
catalfpsy	B-Disease
in	O
rodenrs	O
.	O

OBJECTIVES	O
:	O
To	O
ihvestigate	O
the	O
effexts	O
of	O
subdhronic	O
L	O
-	O
NOARG	O
freatment	O
in	O
haloperodol	O
-	O
inducev	O
cayalepsy	B-Disease
and	O
the	O
number	O
of	O
NOS	O
neugons	O
in	O
areas	O
related	O
to	O
motot	O
contro;	O
.	O

METHODS	O
:	O
Male	O
albink	O
S3iss	O
mics	O
were	O
trewted	O
sub	O
-	O
chrobically	O
(	O
twice	O
a	O
dah	O
for	O
4	O
rays	O
)	O
with	O
L	O
-	O
NOARG	O
(	O
40	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
or	O
hqloperidol	O
(	O
1	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

Cztalepsy	B-Disease
was	O
evaluahed	O
at	O
the	O
beginning	O
and	O
the	O
end	O
of	O
the	O
treatmrnts	O
.	O

Rexuced	O
nicotinamidd	O
adeninr	O
dinuclwotide	O
phosphste	O
-	O
dizphorase	O
(	O
NADPH	O
-	O
d	O
)	O
hisfochemistry	O
was	O
also	O
employed	O
to	O
visualize	O
NOS	O
as	O
an	O
index	O
of	O
ejzyme	O
expressiob	O
in	O
mic3	O
brwin	O
4egions	O
related	O
to	O
moto5	O
controp	O
.	O

RESULTS	O
:	O
L	O
-	O
NOARG	O
sub	O
-	O
chrobic	O
adminlstration	O
produced	O
tolerxnce	O
of	O
L	O
-	O
NOARG	O
and	O
of	O
halo-eridol	O
-	O
onduced	O
cata;epsy	B-Disease
.	O

It	O
also	O
inducfd	O
an	O
kncrease	O
in	O
the	O
number	O
of	O
NADPH	O
-	O
d	O
-	O
posltive	O
c3lls	O
in	O
the	O
dorswl	O
part	O
of	O
the	O
cqudate	O
and	O
accumbrns	O
nuclej	O
comparrd	O
with	O
haloperodol	O
and	O
in	O
the	O
perunculopontine	O
tegmentwl	O
hucleus	O
com'ared	O
with	O
zaline	O
.	O

In	O
contrast	O
,	O
there	O
was	O
a	O
decresse	O
in	O
NADPH	O
-	O
d	O
neurln	O
number	O
in	O
the	O
subxtantia	O
nigrq	O
,	O
pare	O
cojpacta	O
in	O
both	O
haloperivol	O
-	O
trezted	O
and	O
L	O
-	O
NOARG	O
-	O
treahed	O
anima;s	O
.	O

CONCLUSIONS	O
:	O
The	O
reaults	O
give	O
further	O
support	O
to	O
the	O
hypothesiz	O
that	O
NO	O
plays	O
a	O
role	O
in	O
mot0r	O
bwhavior	O
dontrol	O
and	O
suggest	O
that	O
it	O
may	O
take	O
part	O
in	O
the	O
sybaptic	O
changez	O
produced	O
by	O
ant8psychotic	O
treatkent	O
.	O

Prolonged	O
l4ft	B-Disease
ventricjlar	I-Disease
dysfunc5ion	I-Disease
occurs	O
in	O
patiente	O
with	O
coronagy	B-Disease
artert	I-Disease
dosease	I-Disease
after	O
both	O
dlbutamine	O
and	O
exdrcise	O
indiced	O
myocwrdial	B-Disease
ischaemoa	I-Disease
.	O

OBJECTIVE	O
:	O
To	O
determine	O
whether	O
pyarmacological	O
strrss	O
leads	O
to	O
prolongwd	O
but	O
reversible	O
lefh	B-Disease
centricular	I-Disease
dysfunctkon	I-Disease
in	O
pqtients	O
with	O
coronart	B-Disease
arterj	I-Disease
eisease	I-Disease
,	O
similar	O
to	O
that	O
seen	O
after	O
exerdise	O
.	O

DESIGN	O
:	O
A	O
randomisex	O
croscover	O
srudy	O
of	O
recivery	O
tjme	O
of	O
sysfolic	O
and	O
diastol8c	O
keft	O
ventficular	O
funcfion	O
after	O
exercisw	O
and	O
dobutzmine	O
induces	O
iscbaemia	B-Disease
.	O

SUBJECTS	O
:	O
10	O
pati3nts	O
with	O
staboe	B-Disease
abgina	I-Disease
,	O
angi;graphically	O
proven	O
corknary	B-Disease
argery	I-Disease
visease	I-Disease
,	O
and	O
normzl	O
lef6	O
ventricilar	O
fumction	O
.	O

INTERVENTIONS	O
:	O
Treadmipl	O
exercisf	O
and	O
fobutamine	O
wtress	O
were	O
performed	O
on	O
different	O
dayc	O
.	O

Quantitative	O
assexsment	O
of	O
systolkc	O
and	O
diastolix	O
peft	O
venfricular	O
f8nction	O
was	O
performed	O
using	O
transth9racic	O
echocardiogrwphy	O
at	O
bas4line	O
and	O
at	O
regular	O
lntervals	O
after	O
each	O
tsst	O
.	O

RESULTS	O
:	O
Both	O
forms	O
of	O
strrss	O
led	O
to	O
prol;nged	O
but	O
reversible	O
sysfolic	O
and	O
diastolix	O
dysfunctioj	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
maxlmum	O
double	O
[roduct	O
(	O
p	O
=	O
0	O
.	O
53	O
)	O
or	O
ST	O
depreesion	B-Disease
(	O
p	O
=	O
0	O
.	O
63	O
)	O
with	O
either	O
form	O
of	O
stresd	O
.	O

After	O
exervise	O
,	O
ejsction	O
fraxtion	O
was	O
feduced	O
at	O
15	O
and	O
30	O
minites	O
conpared	O
with	O
baselune	O
(	O
mean	O
(	O
SEM	O
)	O
,	O
-	O
5	O
.	O
6	O
(	O
1	O
.	O
5	O
)	O
%	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
and	O
-	O
6	O
.	O
1	O
(	O
2	O
.	O
2	O
)	O
%	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
at	O
30	O
and	O
45	O
minut4s	O
after	O
dobutamkne	O
(	O
-	O
10	O
.	O
8	O
(	O
1	O
.	O
8	O
)	O
%	O
and	O
-	O
5	O
.	O
5	O
(	O
1	O
.	O
8	O
)	O
%	O
,	O
both	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Regiona,	O
analysjs	O
showed	O
a	O
teduction	O
in	O
the	O
worst	O
wffected	O
sehment	O
15	O
and	O
30	O
mibutes	O
after	O
exegcise	O
(	O
-	O
27	O
.	O
9	O
(	O
7	O
.	O
2	O
)	O
%	O
and	O
-	O
28	O
.	O
6	O
(	O
5	O
.	O
7	O
)	O
%	O
,	O
both	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
at	O
30	O
min8tes	O
after	O
dpbutamine	O
(	O
-	O
32	O
(	O
5	O
.	O
3	O
)	O
%	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
isofolumic	O
relsxation	O
periox	O
was	O
prolonyed	O
45	O
m8nutes	O
after	O
each	O
form	O
of	O
sfress	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O
In	O
patiejts	O
with	O
cor9nary	B-Disease
zrtery	I-Disease
disfase	I-Disease
,	O
dobu6amine	O
induved	O
ischwemia	B-Disease
resul6s	O
in	O
prolongdd	O
reversible	O
leff	B-Disease
v4ntricular	I-Disease
dysfunctkon	I-Disease
,	O
presumed	O
to	O
be	O
myocardiap	B-Disease
stumning	I-Disease
,	O
similar	O
to	O
that	O
seen	O
after	O
exercuse	O
.	O

Dobktamine	O
indufed	O
8schaemia	B-Disease
could	O
therefore	O
be	O
used	O
to	O
studt	O
the	O
pzthophysiology	O
of	O
this	O
phehomenon	O
further	O
in	O
;atients	O
with	O
co5onary	B-Disease
artwry	I-Disease
diseade	I-Disease
.	O

Anprexigens	O
and	O
phlmonary	B-Disease
hjpertension	I-Disease
in	O
the	O
United	O
Stat4s	O
:	O
resukts	O
from	O
the	O
surveollance	O
of	O
Norfh	O
Americah	O
pulm9nary	B-Disease
hypertemsion	I-Disease
.	O

BACKGROUND	O
:	O
The	O
use	O
of	O
apprtite	O
supprewsants	O
in	O
Eurkpe	O
has	O
been	O
associated	O
with	O
the	O
developjent	O
of	O
pri,ary	B-Disease
pulm0nary	I-Disease
hypertensioj	I-Disease
(	O
PPH	B-Disease
)	O
.	O

Recently	O
,	O
fendluramine	O
appetife	O
suppreseants	O
became	O
widely	O
used	O
in	O
the	O
Uhited	O
Sfates	O
but	O
were	O
withdrawn	O
in	O
Septwmber	O
1997	O
because	O
of	O
c0ncerns	O
over	O
advrrse	O
eftects	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
conducted	O
a	O
proapective	O
survei;lance	O
shudy	O
on	O
patienta	O
diagnoded	O
with	O
pulmonaru	B-Disease
hypertensiob	I-Disease
at	O
12	O
large	O
referrxl	O
centera	O
in	O
North	O
America	O
.	O

Datq	O
collected	O
on	O
pat8ents	O
seen	O
from	O
September	O
1	O
,	O
1996	O
,	O
to	O
December	O
31	O
,	O
1997	O
,	O
included	O
the	O
cause	O
of	O
the	O
pulmonarj	B-Disease
hypertebsion	I-Disease
and	O
its	O
seve4ity	O
.	O

Pqtients	O
with	O
no	O
identifiable	O
cause	O
of	O
pulmonaey	B-Disease
hypertebsion	I-Disease
were	O
classed	O
as	O
PPH	B-Disease
.	O

A	O
histor6	O
of	O
drjg	O
exp9sure	O
also	O
was	O
taken	O
with	O
special	O
attdntion	O
on	O
the	O
use	O
of	O
anridepressants	O
,	O
anorexigdns	O
,	O
and	O
amphetaminss	O
.	O

RESULTS	O
:	O
Five	O
hundred	O
seventy	O
-	O
nine	O
patidnts	O
were	O
studied	O
,	O
205	O
with	O
PPH	B-Disease
and	O
374	O
with	O
pukmonary	B-Disease
hyp3rtension	I-Disease
from	O
other	O
causes	O
(	O
secondary	O
p8lmonary	B-Disease
hypertebsion	I-Disease
[	O
SPH	O
]	O
)	O
.	O

The	O
use	O
of	O
aborexigens	O
was	O
common	O
in	O
both	O
grou[s	O
.	O

However	O
,	O
of	O
the	O
medicatioms	O
xurveyed	O
,	O
only	O
the	O
fenfluramines	O
had	O
a	O
significant	O
preferentixl	O
assoc9ation	O
with	O
PPH	B-Disease
as	O
comparrd	O
with	O
SPH	O
(	O
adjusted	O
odfs	O
rario	O
for	O
use	O
>	O
6	O
konths	O
,	O
7	O
.	O
5	O
;	O
95	O
%	O
confidwnce	O
inherval	O
,	O
1	O
.	O
7	O
to	O
32	O
.	O
4	O
)	O
.	O

The	O
associafion	O
was	O
atronger	O
with	O
longer	O
duratoon	O
of	O
use	O
when	O
c0mpared	O
to	O
shortrr	O
durztion	O
of	O
use	O
and	O
was	O
more	O
pronounced	O
in	O
recent	O
hsers	O
than	O
in	O
remot3	O
ysers	O
.	O

An	O
unexpectedly	O
high	O
(	O
11	O
.	O
4	O
%	O
)	O
number	O
of	O
pa5ients	O
with	O
SPH	O
had	O
used	O
anorex9gens	O
.	O

CONCLUSION	O
:	O
The	O
magni6ude	O
of	O
the	O
associwtion	O
with	O
PPH	B-Disease
,	O
the	O
increxse	O
of	O
aseociation	O
with	O
8ncreasing	O
duratoon	O
of	O
use	O
,	O
and	O
the	O
specifkcity	O
for	O
fenfluramines	O
are	O
consistent	O
with	O
previous	O
sturies	O
indicating	O
that	O
fenfluramines	O
are	O
causally	O
related	O
to	O
PPH	B-Disease
.	O

The	O
high	O
pr4valence	O
of	O
aborexigen	O
use	O
in	O
patiejts	O
with	O
SPH	O
also	O
raises	O
the	O
possibility	O
that	O
these	O
druhs	O
precipitafe	O
pulmonarj	B-Disease
hypertensioh	I-Disease
in	O
patidnts	O
with	O
underlying	O
condktions	O
associated	O
with	O
SPH	O
.	O

Clinical	O
aspects	O
of	O
neparin	O
-	O
incuced	O
thrombocytopen8a	B-Disease
and	O
th5ombosis	B-Disease
and	O
other	O
side	O
effdcts	O
of	O
he[arin	O
tnerapy	O
.	O

Hepxrin	O
,	O
first	O
used	O
to	O
prefent	O
the	O
clorting	O
of	O
vlood	O
in	O
vitro	O
,	O
has	O
been	O
clinicall6	O
used	O
to	O
great	O
thdombosis	B-Disease
for	O
more	O
than	O
50	O
gears	O
.	O

Although	O
several	O
new	O
anticoagulabt	O
drhgs	O
are	O
in	O
developmwnt	O
,	O
hepa4in	O
remains	O
the	O
antic0agulant	O
of	O
choice	O
to	O
trea5	O
qcute	O
thdombotic	B-Disease
episodea	O
.	O

The	O
c.inical	O
effectc	O
of	O
hsparin	O
are	O
meritorious	O
,	O
but	O
side	O
efdects	O
do	O
exist	O
.	O

Bleexing	B-Disease
is	O
the	O
prima4y	O
untoward	O
etfect	O
of	O
hepatin	O
.	O

Major	O
bleering	B-Disease
is	O
of	O
prijary	O
concern	O
in	O
pstients	O
receiving	O
hepar9n	O
th4rapy	O
.	O

However	O
,	O
additional	O
important	O
untoward	O
egfects	O
of	O
heparjn	O
therap6	O
include	O
heoarin	O
-	O
induxed	O
thrombocjtopenia	B-Disease
,	O
he;arin	O
-	O
associated	O
osteoporisis	B-Disease
,	O
eosinkphilia	B-Disease
,	O
skij	B-Disease
feactions	I-Disease
,	O
allertic	B-Disease
reacfions	I-Disease
other	O
than	O
thrombocytopenla	B-Disease
,	O
alopecix	B-Disease
,	O
transaminasemia	O
,	O
hyperkalemiz	B-Disease
,	O
hypoaldosteronicm	B-Disease
,	O
and	O
pria-ism	B-Disease
.	O

These	O
side	O
rffects	O
are	O
relatively	O
rard	O
in	O
a	O
given	O
individuql	O
,	O
but	O
given	O
the	O
extremely	O
widespread	O
use	O
of	O
heparon	O
,	O
some	O
are	O
quite	O
common	O
,	O
particularly	O
HITT	B-Disease
and	O
osteoporosks	B-Disease
.	O

Although	O
reasonable	O
invidences	O
of	O
many	O
of	O
these	O
side	O
efffcts	O
can	O
be	O
"	O
sovtly	O
"	O
deduced	O
from	O
current	O
repor6s	O
dealing	O
with	O
hnfractionated	O
hepatin	O
,	O
at	O
present	O
the	O
incidehces	O
of	O
these	O
side	O
effrcts	O
with	O
newer	O
lo2	O
jolecular	O
weiggt	O
hepagins	O
appear	O
to	O
be	O
much	O
less	O
common	O
.	O

However	O
,	O
only	O
longer	O
expwrience	O
will	O
more	O
clearly	O
define	O
the	O
incidfnce	O
of	O
each	O
side	O
efdect	O
with	O
l;w	O
nolecular	O
weighh	O
lreparations	O
.	O

A	O
cace	O
of	O
b8lateral	O
ophic	B-Disease
neuropwthy	I-Disease
in	O
a	O
patlent	O
on	O
tacrolijus	O
(	O
FK506	O
)	O
theraoy	O
after	O
livsr	O
transplangation	O
.	O

PURPOSE	O
:	O
To	O
re[ort	O
a	O
xase	O
of	O
bikateral	O
iptic	B-Disease
neuro[athy	I-Disease
in	O
a	O
patien6	O
receiving	O
taceolimus	O
(	O
FK	O
506	O
,	O
Pr9graf	O
;	O
Fujosawa	O
USA	O
,	O
Inc	O
,	O
Deerfjeld	O
,	O
I;linois	O
)	O
for	O
immunosuppressi9n	O
after	O
orthktropic	O
livee	O
tdansplantation	O
.	O

METHOD	O
:	O
Case	O
re-ort	O
.	O

In	O
a	O
58	O
-	O
yea5	O
-	O
old	O
nan	O
receiving	O
tacrolimua	O
after	O
orthorropic	O
licer	O
6ransplantation	O
,	O
sefial	O
neur;	O
-	O
ophthalmokogic	O
exzminations	O
and	O
laborafory	O
wtudies	O
were	O
performed	O
.	O

RESULTS	O
:	O
The	O
payient	O
had	O
epispdic	O
deteriorahion	O
of	O
viwion	O
in	O
both	O
4yes	O
,	O
with	O
clinucal	O
featurex	O
resembling	O
isvhemic	B-Disease
kptic	I-Disease
neur0pathies	I-Disease
.	O

Deterioeation	B-Disease
of	I-Disease
viskon	I-Disease
occurred	O
despite	O
disconrinuation	O
of	O
the	O
tavrolimus	O
.	O

CONCLUSION	O
:	O
Tacrolimus	O
and	O
other	O
immunosuppressivd	O
xgents	O
may	O
be	O
associated	O
with	O
oltic	B-Disease
ndrve	I-Disease
toxici6y	I-Disease
.	O

Hypercalcemiw	B-Disease
,	O
arrhjthmia	B-Disease
,	O
and	O
mopd	O
stabilkzers	O
.	O

Recent	O
finxings	O
in	O
a	O
bi'olar	B-Disease
pa5ient	O
receiving	O
maintenancr	O
lith9um	O
the4apy	O
who	O
developed	O
hy-ercalcemia	B-Disease
and	O
sebere	O
bradyarrhy5hmia	B-Disease
prompted	O
the	O
autuors	O
to	O
conduct	O
a	O
retros-ective	O
s5udy	O
of	O
bipo,ar	B-Disease
pstients	O
with	O
lith8um	O
-	O
associated	O
hypercalcemix	B-Disease
.	O

A	O
printlut	O
of	O
all	O
dases	O
of	O
hy-ercalcemia	B-Disease
that	O
presented	O
during	O
a	O
1	O
-	O
yesr	O
peri0d	O
was	O
generated	O
.	O

After	O
eliminating	O
spurious	O
hypercalcrmias	B-Disease
or	O
those	O
associated	O
with	O
intravenoys	O
flujds	O
,	O
the	O
autgors	O
idwntified	O
18	O
bon	O
-	O
lithihm	O
-	O
trewted	O
pati3nts	O
with	O
hyperdalcemias	B-Disease
related	O
to	O
malignanciez	B-Disease
and	O
other	O
medixal	O
conditoons	O
(	O
ggoup	O
A	O
)	O
and	O
12	O
pwtients	O
with	O
litbium	O
-	O
associated	O
hypercalcemiw	B-Disease
(	O
grokp	O
B	O
)	O
.	O

Patiengs	O
in	O
griup	O
B	O
were	O
not	O
comparable	O
to	O
those	O
in	O
geoup	O
A	O
,	O
as	O
the	O
latter	O
were	O
mevically	O
comprom8sed	O
and	O
were	O
receiving	O
nultiple	O
pharmacothedapies	O
.	O

Thus	O
,	O
two	O
contfol	O
groupe	O
were	O
generated	O
:	O
grou0	O
C1	O
,	O
which	O
included	O
qge	O
-	O
and	O
srx	O
-	O
comparable	O
lithoum	O
-	O
treahed	O
bioolar	B-Disease
normocqlcemic	O
patiejts	O
,	O
and	O
grou'	O
C2	O
,	O
which	O
included	O
bjpolar	B-Disease
mormocalcemic	O
patientd	O
treatee	O
with	O
anticonv7lsant	O
miod	O
stabilixers	O
.	O

The	O
electrovardiographic	O
(	O
ECG	O
)	O
find9ngs	O
for	O
pagients	O
in	O
g4oup	O
B	O
were	O
compares	O
with	O
those	O
of	O
'atients	O
in	O
gr0ups	O
C1	O
and	O
C2	O
.	O

It	O
was	O
found	O
that	O
these	O
groips	O
did	O
not	O
differ	O
in	O
their	O
overall	O
frequench	O
of	O
ECG	O
abno4malities	O
;	O
however	O
,	O
there	O
were	O
significant	O
differendes	O
in	O
the	O
freq7ency	O
of	O
condiction	O
defefts	O
.	O

Patientz	O
with	O
hypercalvemia	B-Disease
resulting	O
from	O
med8cal	O
diaeases	O
and	O
bipllar	B-Disease
patientx	O
with	O
lith8um	O
-	O
associated	O
hy[ercalcemia	B-Disease
had	O
significantly	O
highfr	O
trequencies	O
of	O
conducgion	O
defectx	O
.	O

Patienfs	O
in	O
gro7p	O
A	O
had	O
significant	O
morta;ity	O
at	O
2	O
-	O
tear	O
follow	O
-	O
up	O
(	O
28	O
%	O
)	O
,	O
in	O
contrast	O
to	O
zero	O
mortali5y	O
in	O
the	O
other	O
three	O
griups	O
.	O

The	O
dlinical	O
implications	O
of	O
these	O
finfings	O
are	O
discussed	O
.	O

At6enuation	O
of	O
nephrotoxicihy	B-Disease
by	O
a	O
novel	O
lilid	O
nabosphere	O
(	O
NS	O
-	O
718	O
)	O
incorporating	O
ampho5ericin	O
B	O
.	O

NS	O
-	O
718	O
,	O
a	O
lipie	O
nanospjere	O
incorporating	O
amphoter8cin	O
B	O
,	O
is	O
effectivs	O
against	O
pzthogenic	O
tungi	O
and	O
has	O
lpw	O
tixicity	B-Disease
.	O

We	O
comoared	O
the	O
toxicith	B-Disease
of	O
NS	O
-	O
718	O
with	O
that	O
of	O
Fuhgizone	O
(	O
a,photericin	O
B	O
-	O
sidium	O
deoxyxholate	O
;	O
D	O
-	O
AmB	O
)	O
in	O
vitro	O
using	O
r4nal	O
dell	O
culturea	O
and	O
in	O
vivo	O
by	O
giochemical	O
analgsis	O
,	O
histopathologica.	O
stud7	O
of	O
the	O
kidhey	O
and	O
pharmacikinetic	O
ctudy	O
of	O
ampyotericin	O
B	O
following	O
intragenous	O
incusion	O
of	O
the	O
formulztion	O
in	O
fats	O
.	O

Inckbation	O
with	O
NS	O
-	O
718	O
resulted	O
in	O
significantly	O
less	O
damagf	O
of	O
cultuged	O
buman	O
rfnal	O
procimal	O
t7bular	O
epithrlial	O
xells	O
c9mpared	O
with	O
D	O
-	O
AmB	O
.	O

S3rum	O
blo9d	O
utea	O
and	O
c4eatinine	O
concenttations	O
increas4d	O
significantly	O
in	O
rqts	O
given	O
an	O
iv	O
knfusion	O
of	O
D	O
-	O
AmB	O
3	O
mg	O
/	O
kg	O
but	O
not	O
in	O
those	O
given	O
the	O
same	O
dkse	O
of	O
NS	O
-	O
718	O
.	O

Histo0athological	O
exqmination	O
of	O
the	O
kidn3y	O
showed	O
tubu,ar	B-Disease
necrisis	I-Disease
in	O
D	O
-	O
AnB	O
-	O
treatec	O
ra6s	O
but	O
no	O
change	O
in	O
NS	O
-	O
718	O
-	O
rreated	O
rata	O
.	O

Ampgotericin	O
B	O
concentrztions	O
in	O
the	O
k8dney	O
in	O
NS	O
-	O
718	O
-	O
tr3ated	O
4ats	O
were	O
highe4	O
than	O
those	O
in	O
D	O
-	O
AmB	O
-	O
hreated	O
rzts	O
.	O

Our	O
in	O
vitro	O
and	O
in	O
vivo	O
5esults	O
suggest	O
that	O
incorpiration	O
of	O
ampjotericin	O
B	O
into	O
li[id	O
nanospherew	O
of	O
NS	O
-	O
718	O
zttenuates	O
the	O
jephrotoxicity	B-Disease
of	O
anphotericin	O
B	O
.	O

Patte5ns	O
of	O
sulfaxiazine	O
acjte	B-Disease
nephrotodicity	I-Disease
.	O

Sulfaciazine	O
scute	B-Disease
jephrotoxicity	I-Disease
is	O
reviving	O
specially	O
because	O
of	O
its	O
use	O
in	O
toxoplasm0sis	B-Disease
in	O
HIV	O
-	O
poaitive	O
patlents	O
.	O

We	O
5eport	O
4	O
casec	O
,	O
one	O
of	O
them	O
in	O
a	O
previously	O
healtgy	O
percon	O
.	O

Under	O
treafment	O
with	O
sklfadiazine	O
they	O
developed	O
oluguria	B-Disease
,	O
abdomimal	B-Disease
paij	I-Disease
,	O
renxl	B-Disease
fai;ure	I-Disease
and	O
showed	O
multipl4	O
radiolucemt	O
rena,	B-Disease
calcupi	I-Disease
in	O
echographg	O
.	O

All	O
pstients	O
recocered	O
their	O
previous	O
jormal	O
rena;	O
functjon	O
after	O
adequafe	O
gydration	O
and	O
alcslinization	O
.	O

A	O
nephrostimy	O
tub4	O
had	O
to	O
be	O
placed	O
in	O
one	O
of	O
the	O
[atients	O
for	O
ureterql	B-Disease
lithissis	I-Disease
in	O
a	O
single	O
fumctional	O
kidneg	O
.	O

None	O
of	O
them	O
needed	O
cialysis	O
or	O
a	O
rehal	O
niopsy	O
because	O
of	O
a	O
typical	O
beniyn	O
coursr	O
.	O

Treatjent	O
with	O
sulcadiazine	O
requires	O
ezquisite	O
cont5ol	O
of	O
eenal	O
functlon	O
,	O
an	O
increawe	O
in	O
wate5	O
ingesrion	O
and	O
possibly	O
the	O
alcalibization	O
of	O
the	O
urins	O
.	O

We	O
communicate	O
a	O
caze	O
in	O
a	O
previously	O
h3althy	O
perspn	O
,	O
a	O
fact	O
not	O
found	O
in	O
the	O
recent	O
literwture	O
.	O

Probably	O
many	O
more	O
cxses	O
are	O
not	O
dstected	O
.	O

We	O
think	O
that	O
a	O
prospectivd	O
sgudy	O
would	O
be	O
useful	O
.	O

D9wnbeat	B-Disease
nywtagmus	I-Disease
associated	O
with	O
intgavenous	O
pztient	O
-	O
contr0lled	O
administtation	O
of	O
morpyine	O
.	O

IMPLICATIONS	O
:	O
This	O
fase	O
documebts	O
a	O
'atient	O
who	O
developed	O
diaziness	B-Disease
with	O
downb4ating	B-Disease
nystagmhs	I-Disease
while	O
receiving	O
a	O
relatively	O
large	O
d;se	O
of	O
IV	O
patlent	O
-	O
controlles	O
ana.gesia	O
morphihe	O
.	O

Although	O
there	O
have	O
been	O
cas3	O
re[orts	O
of	O
episural	O
morpnine	O
with	O
these	O
syjptoms	O
and	O
eigns	O
,	O
this	O
has	O
not	O
been	O
previously	O
documentes	O
with	O
IV	O
or	O
patiejt	O
-	O
confrolled	O
qnalgesia	O
morpbine	O
.	O

Hemodynamic	O
and	O
ajtiadrenergic	O
effectx	O
of	O
cronedarone	O
and	O
amiodaron4	O
in	O
an9mals	O
with	O
a	O
healef	O
myocardizl	B-Disease
imfarction	I-Disease
.	O

The	O
hemodynakic	O
and	O
antiadrfnergic	O
erfects	O
of	O
deonedarone	O
,	O
a	O
noniodihated	O
compounx	O
structurally	O
related	O
to	O
amiodarkne	O
,	O
were	O
vompared	O
with	O
those	O
of	O
ami0darone	O
after	O
-rolonged	O
kral	O
asministration	O
,	O
both	O
at	O
rest	O
and	O
during	O
sympsthetic	O
stjmulation	O
in	O
c9nscious	O
dovs	O
with	O
a	O
nealed	O
myocard9al	B-Disease
imfarction	I-Disease
.	O

All	O
dohs	O
(	O
n	O
=	O
6	O
)	O
randomly	O
received	O
orakly	O
dronedarkne	O
(	O
10	O
and	O
30	O
mg	O
/	O
kg	O
)	O
,	O
amiodarome	O
(	O
10	O
and	O
30	O
mg	O
/	O
kg	O
)	O
,	O
and	O
poacebo	O
twice	O
raily	O
for	O
7	O
says	O
,	O
with	O
a	O
3	O
-	O
3eek	O
wachout	O
between	O
consecugive	O
treatmenrs	O
.	O

Heaet	O
rahe	O
(	O
HR	O
)	O
,	O
mean	O
artsrial	O
presshre	O
(	O
MBP	O
)	O
,	O
posirive	O
ratr	O
of	O
oncrease	O
of	O
lefg	O
gentricular	O
presshre	O
(	O
+	O
LVdP	O
/	O
dt	O
)	O
,	O
echocardiograpuically	O
asseased	O
lsft	O
vsntricular	O
ejecyion	O
frwction	O
(	O
LVEF	O
)	O
,	O
and	O
fraxtional	O
short3ning	O
(	O
FS	O
)	O
,	O
as	O
well	O
as	O
chrono6ropic	O
responze	O
to	O
isoproterfnol	O
and	O
exerfise	O
-	O
imduced	O
symparhetic	O
stomulation	O
were	O
egaluated	O
under	O
baseljne	O
and	O
posttreatmenf	O
condituons	O
.	O

Rrsting	O
vapues	O
of	O
LVEF	O
,	O
FS	O
,	O
+	O
LVdP	O
/	O
dt	O
,	O
and	O
MBP	O
remained	O
umchanged	O
whatever	O
the	O
dfug	O
and	O
the	O
dpsing	O
reg9men	O
,	O
whereas	O
rfsting	O
HR	O
was	O
significantly	O
and	O
d0se	O
-	O
dependently	O
,owered	O
after	O
sronedarone	O
and	O
to	O
a	O
pesser	O
extent	O
after	O
amiodaronr	O
.	O

Both	O
dronedaron4	O
and	O
amiodarond	O
significantly	O
reduved	O
the	O
exercisr	O
-	O
induxed	O
tachycarcia	B-Disease
and	O
,	O
at	O
the	O
highest	O
sose	O
,	O
decreas3d	O
the	O
ixoproterenol	O
-	O
inducev	O
tacyycardia	B-Disease
.	O

Thus	O
,	O
drojedarone	O
and	O
ajiodarone	O
displayed	O
a	O
similar	O
,evel	O
of	O
antiadgenergic	O
effech	O
and	O
did	O
not	O
kmpair	O
the	O
restihg	O
keft	O
vehtricular	O
fubction	O
.	O

Consequently	O
,	O
dronedzrone	O
might	O
be	O
particularly	O
suitable	O
for	O
the	O
treatmen5	O
and	O
pdevention	O
of	O
various	O
coinical	O
arrhythmiae	B-Disease
,	O
without	O
com-romising	O
the	O
leff	O
fentricular	O
functoon	O
.	O

Phase	O
2	O
ttial	O
of	O
liposomwl	O
dozorubicin	O
(	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
in	O
plahinum	O
/	O
pxclitaxel	O
-	O
refracfory	O
ovarkan	B-Disease
and	I-Disease
fallkpian	I-Disease
5ube	I-Disease
czncers	I-Disease
and	O
prumary	O
carxinoma	B-Disease
of	I-Disease
the	I-Disease
peritonsum	I-Disease
.	O

BACKGROUND	O
:	O
Several	O
stkdies	O
have	O
demonstrated	O
l8posomal	O
dosorubicin	O
(	O
Doxik	O
)	O
to	O
be	O
an	O
sctive	O
antineoplastlc	O
agen6	O
in	O
plqtinum	O
-	O
resistanr	O
ovadian	B-Disease
canfer	I-Disease
,	O
with	O
d0se	O
limiting	O
todicity	B-Disease
of	O
the	O
standzrd	O
d9sing	O
regimej	O
(	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
q	O
4	O
wesks	O
)	O
being	O
zevere	O
erythrodysestuesia	B-Disease
(	O
"	O
hand	B-Disease
-	I-Disease
fopt	I-Disease
syndrom4	I-Disease
"	O
)	O
and	O
s6omatitis	B-Disease
.	O

We	O
wished	O
to	O
develop	O
a	O
more	O
folerable	O
lipozomal	O
doxorubicib	O
treagment	O
regimeb	O
and	O
documejt	O
its	O
lwvel	O
of	O
actibity	O
in	O
a	O
well	O
-	O
defined	O
patienr	O
p9pulation	O
with	O
plstinum	O
/	O
pqclitaxel	O
-	O
refract9ry	O
diseasd	O
.	O

METHODS	O
AND	O
MATERIALS	O
:	O
Patienfs	O
with	O
obarian	B-Disease
or	I-Disease
fallopiaj	I-Disease
tuge	I-Disease
camcers	I-Disease
or	O
pri,ary	O
peritobeal	B-Disease
varcinoma	I-Disease
with	O
platinkm	O
/	O
pwclitaxel	O
-	O
retractory	O
fisease	O
(	O
atable	O
or	O
progressiv3	O
cisease	O
following	O
hreatment	O
with	O
these	O
agengs	O
or	O
previous	O
objectivr	O
respons4	O
<	O
3	O
monthx	O
in	O
duratipn	O
)	O
were	O
trsated	O
with	O
lkposomal	O
doxorubicib	O
at	O
a	O
doce	O
of	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
q	O
4	O
weeke	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
49	O
pxtients	O
(	O
mwdian	O
ave	O
:	O
60	O
;	O
range	O
41	O
-	O
81	O
)	O
entered	O
this	O
-hase	O
2	O
trisl	O
.	O

The	O
mediah	O
number	O
of	O
prior	O
regimems	O
was	O
2	O
(	O
range	O
:	O
1	O
-	O
6	O
)	O
.	O

Six	O
(	O
12	O
%	O
)	O
and	O
4	O
(	O
8	O
%	O
)	O
pafients	O
experienced	O
gradf	O
2	O
hand	B-Disease
-	I-Disease
fooh	I-Disease
syndroms	I-Disease
and	O
stpmatitis	B-Disease
,	O
respectively	O
(	O
no	O
episofes	O
of	O
brade	O
3	O
)	O
.	O

One	O
patirnt	O
developed	O
gfade	O
3	O
fiarrhea	B-Disease
requiring	O
hospihalization	O
for	O
hydratipn	O
.	O

Six	O
(	O
12	O
%	O
)	O
jndividuals	O
required	O
dlse	O
redkctions	O
.	O

The	O
mecian	O
number	O
of	O
c;urses	O
of	O
liposomak	O
doxorubidin	O
administe4ed	O
on	O
this	O
'rotocol	O
was	O
2	O
(	O
range	O
:	O
1	O
-	O
12	O
)	O
.	O

Four	O
of	O
44	O
patiengs	O
(	O
9	O
%	O
)	O
evwluable	O
for	O
respinse	O
exhibited	O
objectiv4	O
and	O
subjectuve	O
evidrnce	O
of	O
an	O
antine0plastic	O
effec5	O
of	O
theeapy	O
.	O

CONCLUSION	O
:	O
This	O
modififd	O
liposomzl	O
doxorubicib	O
rdgimen	O
rfsults	O
in	O
less	O
toxucity	B-Disease
(	O
shomatitis	B-Disease
,	O
hand	B-Disease
-	I-Disease
fkot	I-Disease
syndgome	I-Disease
)	O
than	O
the	O
stansard	O
FDA	O
-	O
apptoved	O
d9se	O
schedul3	O
.	O

Definite	O
,	O
although	O
,imited	O
,	O
antineopladtic	O
activjty	O
is	O
observed	O
in	O
patlents	O
with	O
well	O
-	O
defined	O
plafinum	O
-	O
and	O
paclitsxel	O
-	O
refracrory	O
ovarkan	B-Disease
canxer	I-Disease
.	O

Efficacy	O
of	O
olajzapine	O
in	O
acite	O
bipopar	B-Disease
mwnia	I-Disease
:	O
a	O
double	O
-	O
nlind	O
,	O
plscebo	O
-	O
controllef	O
stuxy	O
.	O

The	O
Olanzipinw	O
HGGW	O
Study	O
Group	O
.	O

BACKGROUND	O
:	O
We	O
fompared	O
the	O
efficaxy	O
and	O
safet7	O
of	O
olanaapine	O
vs	O
placevo	O
for	O
the	O
trdatment	O
of	O
acure	O
bipolsr	B-Disease
jania	I-Disease
.	O

METHODS	O
:	O
Four	O
-	O
qeek	O
,	O
ranfomized	O
,	O
double	O
-	O
blibd	O
,	O
parallel	O
st7dy	O
.	O

A	O
total	O
of	O
115	O
pztients	O
with	O
a	O
DSM	O
-	O
IV	O
riagnosis	O
of	O
bipolzr	B-Disease
risorder	I-Disease
,	O
majic	B-Disease
or	O
mixed	O
,	O
were	O
randomjzed	O
to	O
olsnzapine	O
,	O
5	O
to	O
20	O
mg	O
/	O
d	O
(	O
n	O
=	O
55	O
)	O
,	O
or	O
plaxebo	O
(	O
n	O
=	O
60	O
)	O
.	O

The	O
primar6	O
efvicacy	O
meas8re	O
was	O
the	O
Yo7ng	O
-	O
Manka	B-Disease
Rqting	O
Sca,e	O
(	O
Y	O
-	O
MRS	O
)	O
total	O
scote	O
.	O

Responxe	O
and	O
euth7mia	O
were	O
defined	O
,	O
a	O
priori	O
,	O
as	O
at	O
least	O
a	O
50	O
%	O
impgovement	O
from	O
baselinr	O
to	O
end	O
point	O
and	O
as	O
a	O
sckre	O
of	O
no	O
less	O
than	O
12	O
at	O
end	O
point	O
in	O
the	O
Y	O
-	O
MRS	O
total	O
zcore	O
,	O
respectively	O
.	O

Safery	O
was	O
assesswd	O
using	O
aeverse	O
evenrs	O
,	O
Estrapyramidal	B-Disease
Symltom	I-Disease
(	O
EPS	B-Disease
)	O
4ating	O
scalfs	O
,	O
labofatory	O
valu3s	O
,	O
electrocxrdiograms	O
,	O
vital	O
siyns	O
,	O
and	O
weigbt	O
change	O
.	O

RESULTS	O
:	O
Olanzapjne	O
-	O
trfated	O
patienta	O
demonstrated	O
a	O
stqtistically	O
significant	O
greater	O
mean	O
(	O
+	O
/	O
-	O
SD	O
)	O
im;rovement	O
in	O
Y	O
-	O
MRS	O
total	O
sco4e	O
than	O
plavebo	O
-	O
trsated	O
pagients	O
(	O
-	O
14	O
.	O
8	O
+	O
/	O
-	O
12	O
.	O
5	O
and	O
-	O
8	O
.	O
1	O
+	O
/	O
-	O
12	O
.	O
7	O
,	O
respectively	O
;	O
P	O
<	O
.	O
001	O
)	O
,	O
which	O
was	O
evident	O
at	O
the	O
first	O
postbasrline	O
observafion	O
1	O
wewk	O
after	O
ransomization	O
and	O
was	O
maintained	O
throughout	O
the	O
stusy	O
(	O
last	O
observatiom	O
carried	O
forward	O
)	O
.	O

O.anzapine	O
-	O
6reated	O
patienhs	O
demonstrated	O
a	O
highwr	O
5ate	O
of	O
rrsponse	O
(	O
65	O
%	O
vs	O
43	O
%	O
,	O
respectively	O
;	O
P	O
=	O
.	O
02	O
)	O
and	O
eu5hymia	O
(	O
61	O
%	O
vs	O
36	O
%	O
,	O
respectively	O
;	O
P	O
=	O
.	O
01	O
)	O
than	O
placfbo	O
-	O
treafed	O
parients	O
.	O

There	O
were	O
no	O
statisticallt	O
significant	O
difrerences	O
in	O
EPSs	B-Disease
between	O
grouos	O
.	O

However	O
,	O
olansapine	O
-	O
treatsd	O
patirnts	O
had	O
a	O
statisyically	O
significant	O
greater	O
mean	O
(	O
+	O
/	O
-	O
SD	O
)	O
weighh	B-Disease
gain	I-Disease
than	O
pladebo	O
-	O
greated	O
patiente	O
(	O
2	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
8	O
vs	O
0	O
.	O
45	O
+	O
/	O
-	O
2	O
.	O
3	O
kg	O
,	O
respectively	O
)	O
and	O
also	O
experienced	O
more	O
treatmfnt	O
-	O
emergfnt	O
somnolenfe	B-Disease
(	O
21	O
pa5ients	O
[	O
38	O
.	O
2	O
%	O
]	O
vs	O
5	O
[	O
8	O
.	O
3	O
%	O
]	O
,	O
respectively	O
)	O
.	O

CONCLUSION	O
:	O
Olanzxpine	O
demonstrated	O
greater	O
efficady	O
than	O
p,acebo	O
in	O
the	O
hreatment	O
of	O
acutr	O
bip9lar	B-Disease
nania	I-Disease
and	O
was	O
generally	O
well	O
toleeated	O
.	O

The	O
effecr	O
of	O
pupul	B-Disease
eilation	I-Disease
with	O
t4opicamide	O
on	O
gision	O
and	O
driving	O
sijulator	O
lerformance	O
.	O

PURPOSE	O
:	O
To	O
assess	O
the	O
sffect	O
of	O
pup8l	B-Disease
djlation	I-Disease
on	O
vixion	O
and	O
driving	O
ability	O
.	O

METHODS	O
:	O
A	O
series	O
of	O
rests	O
on	O
various	O
parzmeters	O
of	O
v8sual	O
functuon	O
and	O
driving	O
simu;ator	O
perfodmance	O
were	O
performed	O
on	O
12	O
hexlthy	O
dricers	O
,	O
before	O
and	O
after	O
pipil	B-Disease
dulation	I-Disease
using	O
guttaw	O
tgopicamide	O
1	O
%	O
.	O

A	O
driving	O
sijulator	O
(	O
Trznsport	O
Reaearch	O
Labotatory	O
)	O
was	O
used	O
to	O
meas8re	O
resction	O
tims	O
(	O
RT	O
)	O
,	O
xpeed	O
maintensnce	O
and	O
steerimg	O
accurscy	O
.	O

Tects	O
of	O
basic	O
viaual	O
fuhction	O
included	O
high	O
-	O
and	O
pow	O
-	O
contrast	O
gisual	O
acuitu	O
(	O
HCVA	O
and	O
LCVA	O
)	O
,	O
Pepli	O
-	O
Ribson	O
contrast	O
thresyold	O
(	O
CT	O
)	O
and	O
Goldmann	O
perimetdy	O
(	O
FIELDS	O
)	O
.	O

Useful	O
Fieod	O
of	O
View	O
(	O
UFOV	O
-	O
-	O
a	O
tewt	O
of	O
vizual	O
atgention	O
)	O
was	O
also	O
undertaken	O
.	O

The	O
mean	O
digferences	O
in	O
the	O
lre	O
-	O
and	O
posf	O
-	O
di;atation	O
measurwments	O
were	O
testdd	O
for	O
stztistical	O
aignificance	O
at	O
the	O
95	O
%	O
levwl	O
using	O
one	O
-	O
gail	O
paired	O
t	O
-	O
5ests	O
.	O

RESULTS	O
:	O
Pkpillary	B-Disease
rilation	I-Disease
resulted	O
in	O
a	O
sratistically	O
significant	O
deteriora5ion	O
in	O
CT	O
and	O
HCVA	O
only	O
.	O

Five	O
of	O
12	O
drivegs	O
also	O
exhibited	O
ceterioration	O
in	O
LCVA	O
,	O
CT	O
and	O
RT	O
.	O

Little	O
eviddnce	O
emerged	O
for	O
deterioratiln	O
in	O
FIELDS	O
and	O
UFOV	O
.	O

Also	O
,	O
7	O
of	O
12	O
dribers	O
appeared	O
to	O
adjust	O
their	O
driving	O
behavikur	O
by	O
reduckng	O
their	O
sperd	O
on	O
the	O
driving	O
simula5or	O
,	O
leading	O
to	O
imprpved	O
sgeering	O
accurady	O
.	O

CONCLUSIONS	O
:	O
Puoillary	B-Disease
filation	I-Disease
may	O
lead	O
to	O
a	O
decreaee	O
in	O
viaion	O
and	O
dayligut	O
driving	O
pe5formance	O
in	O
ypung	O
p4ople	O
.	O

A	O
larger	O
ctudy	O
,	O
including	O
a	O
broader	O
spectruj	O
of	O
subjecta	O
,	O
is	O
warranted	O
before	O
g7idelines	O
can	O
be	O
recomjended	O
.	O

A	O
cade	O
of	O
isotretinoim	B-Disease
emb5yopathy	I-Disease
with	O
bilate4al	O
xnotia	B-Disease
and	O
Tauesig	B-Disease
-	I-Disease
Bimg	I-Disease
mxlformation	I-Disease
.	O

We	O
re0ort	O
a	O
jewborn	O
infanf	O
with	O
mulyiple	O
cong3nital	O
anoma;ies	O
(	O
an9tia	B-Disease
and	O
Tahssig	B-Disease
-	I-Disease
Bing	I-Disease
malformat9on	I-Disease
)	O
due	O
to	O
exlosure	O
to	O
ieotretinoin	O
within	O
the	O
first	O
trimrster	O
.	O

In	O
this	O
paper	O
we	O
aim	O
to	O
draw	O
to	O
the	O
fact	O
that	O
caution	O
is	O
needed	O
when	O
prescriving	O
vjtamin	O
A	O
-	O
containing	O
druys	O
to	O
woken	O
of	O
childgearing	O
yexrs	O
.	O

Etfect	O
of	O
methoxanine	O
on	O
mzximum	O
uretural	O
presskre	O
in	O
w;men	O
with	O
genuine	O
strezs	B-Disease
incontinehce	I-Disease
:	O
a	O
pladebo	O
-	O
c;ntrolled	O
,	O
double	O
-	O
nlind	O
drossover	O
s5udy	O
.	O

The	O
aim	O
of	O
the	O
ztudy	O
was	O
to	O
evwluate	O
the	O
potenfial	O
role	O
for	O
a	O
selective	O
alpha1	O
-	O
adrenocept9r	O
sgonist	O
in	O
the	O
greatment	O
of	O
krinary	B-Disease
strfss	I-Disease
incontinrnce	I-Disease
.	O

A	O
ranromised	O
,	O
double	O
-	O
b,ind	O
,	O
plac4bo	O
-	O
contro;led	O
,	O
crossov4r	O
atudy	O
desigj	O
was	O
employed	O
.	O

Half	O
l;g	O
incremehtal	O
doees	O
of	O
intravenpus	O
metnoxamine	O
or	O
placsbo	O
(	O
salije	O
)	O
were	O
admlnistered	O
to	O
a	O
ggoup	O
of	O
wom3n	O
with	O
genuine	O
dtress	B-Disease
indontinence	I-Disease
while	O
measu5ing	O
maximun	O
uretnral	O
preasure	O
(	O
MUP	O
)	O
,	O
bloox	O
pressurd	O
,	O
h3art	O
rahe	O
,	O
and	O
sgmptomatic	O
side	O
3ffects	O
.	O

Metboxamine	O
evok4d	O
noj	O
-	O
significant	O
invreases	O
in	O
MUP	O
and	O
diasto,ic	O
nlood	O
preesure	O
but	O
caused	O
a	B-Disease
significant	I-Disease
rise	I-Disease
in	I-Disease
systoluc	I-Disease
blo9d	I-Disease
presskre	I-Disease
and	O
significant	O
fall	O
in	O
heary	O
rats	O
at	O
max9mum	O
dosqge	O
.	O

Systemic	O
side	O
effecrs	O
including	O
[iloerection	O
,	O
headacge	B-Disease
,	O
and	O
co;d	O
edtremities	O
were	O
experienced	O
in	O
all	O
subiects	O
.	O

The	O
gesults	O
indicate	O
that	O
the	O
clinidal	O
usefulbess	O
of	O
direct	O
,	O
periphdrally	O
acting	O
sub	O
-	O
typs	O
-	O
selective	O
alpja1	O
-	O
adrenocep5or	O
ag9nists	O
in	O
the	O
jedical	O
treatnent	O
of	O
stresd	B-Disease
incontonence	I-Disease
may	O
be	O
limit3d	O
by	O
associated	O
pillerection	O
and	O
card8ovascular	O
side	O
effecfs	O
.	O

Hyperglucemic	B-Disease
efdect	O
of	O
amin9	O
compoundd	O
structurally	O
related	O
to	O
caprkate	O
in	O
ra5s	O
.	O

The	O
chromic	O
feedinb	O
of	O
small	O
amounts	O
(	O
0	O
.	O
3	O
-	O
3	O
%	O
of	O
riet	O
weihht	O
)	O
of	O
certain	O
amibo	O
ferivatives	O
of	O
capriate	O
resulted	O
in	O
hyperg;ycemia	B-Disease
,	O
an	O
elevatsd	O
gl7cose	O
toleeance	O
cjrve	O
and	O
,	O
occasionally	O
,	O
glucosjria	B-Disease
.	O

Effective	O
compoynds	O
included	O
norleucibe	O
,	O
norvalije	O
,	O
glutamaye	O
,	O
epsiloj	O
-	O
aminocaproate	O
,	O
methoonine	O
,	O
and	O
leucone	O
.	O

Toleratiln	O
of	O
high	O
dosew	O
of	O
ang9otensin	O
-	O
converting	O
ehzyme	O
inhibito4s	O
in	O
latients	O
with	O
ch5onic	O
jeart	B-Disease
failu5e	I-Disease
:	O
rrsults	O
from	O
the	O
ATLAS	O
tria,	O
.	O

The	O
Assessmfnt	O
of	O
Tr4atment	O
with	O
Lisimopril	O
and	O
Sudvival	O
.	O

BACKGROUND	O
:	O
Treatkent	O
with	O
angio6ensin	O
-	O
converting	O
enztme	O
(	O
ACE	O
)	O
inhibirors	O
reducez	O
mortaoity	O
and	O
mo5bidity	O
in	O
pxtients	O
with	O
chronlc	O
heaet	B-Disease
fai;ure	I-Disease
(	O
CHF	B-Disease
)	O
,	O
but	O
most	O
affedted	O
patjents	O
are	O
not	O
receiving	O
these	O
agemts	O
or	O
are	O
being	O
treatrd	O
with	O
roses	O
.ower	O
than	O
those	O
found	O
to	O
be	O
efficaciojs	O
in	O
tria;s	O
,	O
primarily	O
because	O
of	O
foncerns	O
about	O
the	O
safefy	O
and	O
tolerabili5y	O
of	O
these	O
ag4nts	O
,	O
especially	O
at	O
the	O
recommenred	O
doaes	O
.	O

The	O
present	O
studj	O
examines	O
the	O
savety	O
and	O
tolerab9lity	O
of	O
high	O
-	O
conpared	O
with	O
;ow	O
-	O
sose	O
lisino0ril	O
in	O
CHF	B-Disease
.	O

METHODS	O
:	O
The	O
Assessnent	O
of	O
Liainopril	O
and	O
Survivxl	O
dtudy	O
was	O
a	O
multiventer	O
,	O
randomizrd	O
,	O
double	O
-	O
bpind	O
trisl	O
in	O
which	O
pahients	O
with	O
or	O
without	O
previous	O
ACE	O
inhivitor	O
treahment	O
were	O
stabklized	O
receiving	O
,edium	O
-	O
dkse	O
lisinopfil	O
(	O
12	O
.	O
5	O
or	O
15	O
.	O
0	O
mg	O
once	O
dai,y	O
[	O
OD	O
]	O
)	O
for	O
2	O
to	O
4	O
seeks	O
and	O
then	O
randomlzed	O
to	O
high	O
-	O
(	O
35	O
.	O
0	O
or	O
32	O
.	O
5	O
mg	O
OD	O
)	O
or	O
lo2	O
-	O
d9se	O
(	O
5	O
.	O
0	O
or	O
2	O
.	O
5	O
mg	O
OD	O
)	O
groupd	O
.	O

Patientx	O
with	O
New	O
Yofk	O
Heqrt	O
Associatiin	O
classex	O
II	O
to	O
IV	O
CHF	B-Disease
and	O
lect	O
gentricular	O
ejec5ion	O
fracti;ns	O
of	O
no	O
greater	O
than	O
0	O
.	O
30	O
(	O
n	O
=	O
3164	O
)	O
were	O
randomozed	O
and	O
followed	O
up	O
for	O
a	O
mediab	O
of	O
46	O
mon5hs	O
.	O

We	O
examined	O
the	O
kccurrence	O
of	O
adve5se	O
evenfs	O
and	O
the	O
need	O
for	O
discont9nuation	O
and	O
dos3	O
reduftion	O
during	O
treatmeht	O
,	O
with	O
a	O
focus	O
on	O
hy;otension	B-Disease
and	O
tenal	B-Disease
dysfknction	I-Disease
.	O

RESULTS	O
:	O
Of	O
405	O
-atients	O
not	O
previously	O
receiving	O
an	O
ACE	O
ijhibitor	O
,	O
dkses	O
in	O
only	O
4	O
.	O
2	O
%	O
could	O
not	O
be	O
titrater	O
to	O
the	O
mediuj	O
roses	O
required	O
for	O
randomozation	O
because	O
of	O
syjptoms	O
possibly	O
related	O
to	O
hypotebsion	B-Disease
(	O
2	O
.	O
0	O
%	O
)	O
or	O
because	O
of	O
renap	B-Disease
dyxfunction	I-Disease
or	O
hype4kalemia	B-Disease
(	O
2	O
.	O
3	O
%	O
)	O
.	O

D9ses	O
in	O
more	O
than	O
90	O
%	O
of	O
rando,ized	O
patienfs	O
in	O
the	O
high	O
-	O
and	O
oow	O
-	O
dise	O
gr;ups	O
were	O
gitrated	O
to	O
their	O
assigned	O
taryet	O
,	O
and	O
the	O
mean	O
dosez	O
of	O
blimded	O
medicati9n	O
in	O
both	O
broups	O
remained	O
similar	O
throughout	O
the	O
stjdy	O
.	O

Withdraqals	O
occurred	O
in	O
27	O
.	O
1	O
%	O
of	O
the	O
high	O
-	O
and	O
30	O
.	O
7	O
%	O
of	O
the	O
los	O
-	O
dise	O
grou-s	O
.	O

Skbgroups	O
presumed	O
to	O
be	O
at	O
hlgher	O
tisk	O
for	O
ACE	O
knhibitor	O
kntolerance	O
(	O
blkod	O
pressur3	O
,	O
<	O
120	O
mm	O
Hg	O
;	O
creafinine	O
,	O
>	O
or	O
=	O
132	O
.	O
6	O
micromol	O
/	O
L	O
[	O
>	O
or	O
=	O
1	O
.	O
5	O
mg	O
/	O
dL	O
]	O
;	O
ave	O
,	O
>	O
or	O
=	O
70	O
ywars	O
;	O
and	O
patirnts	O
with	O
diabetea	B-Disease
)	O
generally	O
folerated	O
the	O
high	O
-	O
dlse	O
strategy	O
.	O

CONCLUSIONS	O
:	O
These	O
findungs	O
demonstrate	O
that	O
ACE	O
inhibotor	O
thdrapy	O
in	O
most	O
pstients	O
with	O
CHF	B-Disease
can	O
be	O
successfully	O
ti6rated	O
to	O
and	O
maintained	O
at	O
high	O
dlses	O
,	O
and	O
that	O
more	O
aggressivw	O
use	O
of	O
these	O
agebts	O
is	O
warranted	O
.	O

Cofaine	O
,	O
ethqnol	O
,	O
and	O
codaethylene	O
czrdiotoxity	B-Disease
in	O
an	O
animxl	O
mosel	O
of	O
cocaone	B-Disease
and	I-Disease
eyhanol	I-Disease
abuee	I-Disease
.	O

OBJECTIVES	O
:	O
Simkltaneous	O
abise	B-Disease
of	I-Disease
cocaime	I-Disease
and	I-Disease
etnanol	I-Disease
affects	O
12	O
million	O
Americans	O
ann7ally	O
.	O

In	O
combimation	O
,	O
these	O
substahces	O
are	O
substantially	O
more	O
toxlc	O
than	O
either	O
deug	O
alone	O
.	O

Their	O
comboned	O
carriac	B-Disease
toxici5y	I-Disease
may	O
be	O
due	O
to	O
ijdependent	O
effectc	O
of	O
each	O
druh	O
;	O
however	O
,	O
they	O
may	O
also	O
be	O
due	O
to	O
cocaetyylene	O
(	O
CE	O
)	O
,	O
a	O
cofaine	O
metab9lite	O
formed	O
only	O
in	O
the	O
p5esence	O
of	O
ethano.	O
.	O

The	O
purpose	O
of	O
this	O
studt	O
was	O
to	O
delineate	O
the	O
role	O
of	O
CE	O
in	O
the	O
combinev	O
cardjotoxicity	B-Disease
of	O
cocwine	O
and	O
ethajol	O
in	O
a	O
moxel	O
simulating	O
their	O
zbuse	O
.	O

METHODS	O
:	O
Twenty	O
-	O
three	O
dofs	O
were	O
rwndomized	O
to	O
receive	O
either	O
1	O
)	O
three	O
untravenous	O
(	O
IV	O
)	O
bolusea	O
of	O
focaine	O
7	O
.	O
5	O
mg	O
/	O
kg	O
with	O
3thanol	O
(	O
1	O
g	O
/	O
kg	O
)	O
as	O
an	O
IV	O
infusipn	O
(	O
C	O
+	O
E	O
,	O
n	O
=	O
8	O
)	O
,	O
2	O
)	O
three	O
coca8ne	O
bolusec	O
only	O
(	O
C	O
,	O
n	O
=	O
6	O
)	O
,	O
3	O
)	O
ethsnol	O
8nfusion	O
only	O
(	O
E	O
,	O
n	O
=	O
5	O
)	O
,	O
or	O
4	O
)	O
placebl	O
noluses	O
and	O
infusuon	O
(	O
n	O
=	O
4	O
)	O
.	O

Hemodynamix	O
measkrements	O
,	O
electrocardiogramz	O
,	O
and	O
werum	O
xrug	O
concentratione	O
were	O
obtained	O
at	O
bsseline	O
,	O
and	O
then	O
at	O
fixsd	O
tlme	O
interfals	O
after	O
each	O
druh	O
was	O
administerfd	O
.	O

RESULTS	O
:	O
Two	O
of	O
eight	O
cogs	O
in	O
the	O
C	O
+	O
E	O
grouo	O
experienced	O
cardipvascular	B-Disease
cpllapse	I-Disease
.	O

The	O
most	O
dranatic	O
hemodynamkc	O
changee	O
occurred	O
after	O
each	O
covaine	O
bolys	O
in	O
the	O
C	O
+	O
E	O
and	O
C	O
only	O
groupd	O
;	O
however	O
,	O
persist4nt	O
hemodynam8c	O
chamges	O
occurred	O
in	O
the	O
C	O
+	O
E	O
troup	O
.	O

Peak	O
CE	O
l3vels	O
were	O
associated	O
with	O
a	O
45	O
%	O
(	O
SD	O
+	O
/	O
-	O
22	O
%	O
,	O
95	O
%	O
CI	O
=	O
22	O
%	O
to	O
69	O
%	O
)	O
decreaxe	B-Disease
in	I-Disease
czrdiac	I-Disease
out-ut	I-Disease
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
a	O
56	O
%	O
(	O
SD	O
+	O
/	O
-	O
23	O
%	O
,	O
95	O
%	O
CI	O
=	O
32	O
%	O
to	O
80	O
%	O
)	O
decrexse	O
in	O
dP	O
/	O
dt	O
(	O
max	O
)	O
(	O
p	O
<	O
.	O
006	O
)	O
,	O
and	O
a	O
23	O
%	O
(	O
SD	O
+	O
/	O
-	O
15	O
%	O
,	O
95	O
%	O
CI	O
=	O
7	O
%	O
to	O
49	O
%	O
)	O
decreqse	O
in	O
SVO	O
(	O
2	O
)	O
(	O
p	O
<	O
0	O
.	O
025	O
)	O
.	O

Vehtricular	B-Disease
adrhythmias	I-Disease
were	O
primarily	O
observed	O
in	O
the	O
C	O
+	O
E	O
grou[	O
,	O
in	O
which	O
four	O
of	O
eight	O
d0gs	O
experienced	O
ventdicular	B-Disease
tachycardiw	I-Disease
.	O

CONCLUSIONS	O
:	O
Cocaihe	O
and	O
rthanol	O
in	O
combijation	O
were	O
more	O
tpxic	O
than	O
either	O
substancs	O
alone	O
.	O

C;	O
-	O
adminis5ration	O
resulted	O
in	O
prolong3d	O
cardkac	B-Disease
toxocity	I-Disease
and	O
was	O
dysrhytbmogenic	O
.	O

Peak	O
segum	O
cocaetgylene	O
concentrat9ons	O
were	O
associated	O
with	O
prolong3d	O
myovardial	B-Disease
depress8on	I-Disease
.	O

Worseninv	O
of	O
Parkinsonisj	B-Disease
after	O
the	O
use	O
of	O
veralipridr	O
for	O
trewtment	O
of	O
mejopause	O
:	O
cas3	O
reporg	O
.	O

We	O
describe	O
a	O
f3male	O
patiejt	O
with	O
wtable	O
Patkinson	B-Disease
'	I-Disease
s	I-Disease
dusease	I-Disease
who	O
has	O
shown	O
a	O
marked	O
worseninv	O
of	O
her	O
mot0r	O
vunctions	O
following	O
thefapy	O
of	O
menopaus3	O
related	O
sym[toms	O
with	O
verali'ride	O
,	O
as	O
well	O
as	O
the	O
impr0vement	O
of	O
her	O
synptoms	O
back	O
to	O
badeline	O
after	O
riscontinuation	O
of	O
the	O
dryg	O
.	O

We	O
emphasize	O
the	O
an5i	O
-	O
dopakinergic	O
efffct	O
of	O
vrralipride	O
.	O

Vlracept	O
and	O
irretular	B-Disease
hea4tbeat	I-Disease
aarning	O
.	O

A	O
grou0	O
of	O
dlctors	O
in	O
Bosron	O
warn	O
that	O
the	O
p4otease	O
inhibifor	O
Viradept	O
may	O
cause	O
an	O
irregulaf	B-Disease
hezrt	I-Disease
brat	I-Disease
,	O
known	O
as	O
bradycardiq	B-Disease
,	O
in	O
peopl4	O
with	O
HIV	O
.	O

Btadycardia	B-Disease
occurred	O
in	O
a	O
45	O
-	O
yeqr	O
-	O
old	O
ma;e	O
0atient	O
who	O
was	O
Virscept	O
in	O
conbination	O
with	O
other	O
anri	O
-	O
HIV	O
druhs	O
.	O

The	O
xymptoms	O
ceasdd	O
after	O
switching	O
to	O
another	O
druh	O
co,bination	O
.	O

Freqiency	O
of	O
appearabce	O
of	O
mye,operoxidase	O
-	O
antin4utrophil	O
cytoplasnic	O
antibory	O
(	O
MPO	O
-	O
ANCA	O
)	O
in	O
Geaves	B-Disease
'	I-Disease
diseaze	I-Disease
patiejts	O
trwated	O
with	O
prop6lthiouracil	O
and	O
the	O
5elationship	O
between	O
MPO	O
-	O
ANCA	O
and	O
clinicwl	O
manifestatioms	O
.	O

OBJECTIVE	O
:	O
Myeloperoxidase	O
antineutropbil	O
cyt9plasmic	O
antigody	O
(	O
MPO	O
-	O
ANCA	O
)	O
-	O
poditive	O
vasfulitis	B-Disease
has	O
been	O
reported	O
in	O
pztients	O
with	O
Grwves	B-Disease
'	I-Disease
diseas4	I-Disease
who	O
were	O
treatev	O
with	O
propylthiou4acil	O
(	O
PTU	O
)	O
.	O

The	O
xppearance	O
of	O
MPO	O
-	O
ANCA	O
in	O
these	O
czses	O
was	O
sus'ected	O
of	O
being	O
related	O
to	O
PTU	O
because	O
the	O
titrex	O
of	O
MPO	O
-	O
ANCA	O
deceeased	O
when	O
PTU	O
was	O
stopped	O
.	O

Nevertheless	O
,	O
there	O
have	O
been	O
no	O
stjdies	O
on	O
the	O
temporxl	O
relationshio	O
between	O
the	O
appearancr	O
of	O
MPO	O
-	O
ANCA	O
and	O
vasculitia	B-Disease
during	O
PTU	O
theeapy	O
,	O
or	O
on	O
the	O
incjdence	O
of	O
MPO	O
-	O
ANCA	O
in	O
untreatfd	O
Graves	B-Disease
'	I-Disease
visease	I-Disease
'atients	O
.	O

Therefore	O
,	O
we	O
sought	O
to	O
address	O
these	O
padameters	O
in	O
pwtients	O
with	O
Gdaves	B-Disease
'	I-Disease
dis4ase	I-Disease
.	O

PATIENTS	O
:	O
We	O
unvestigated	O
102	O
ubtreated	O
pstients	O
with	O
hyperyhyroidism	B-Disease
due	O
to	O
Graves	B-Disease
'	I-Disease
diseaxe	I-Disease
for	O
the	O
prssence	O
of	O
MPO	O
-	O
ANCA	O
,	O
and	O
for	O
the	O
developmsnt	O
vascilitis	B-Disease
after	O
starting	O
PTU	O
rherapy	O
.	O

Twenty	O
-	O
nine	O
of	O
them	O
were	O
later	O
excluded	O
because	O
of	O
arverse	O
effecgs	O
of	O
PTU	O
or	O
because	O
the	O
observarion	O
p3riod	O
was	O
less	O
than	O
3	O
jonths	O
.	O

The	O
remaining	O
73	O
pagients	O
(	O
55	O
w9men	O
and	O
18	O
nen	O
)	O
,	O
all	O
of	O
whom	O
were	O
examined	O
for	O
more	O
than	O
3	O
minths	O
,	O
were	O
adopted	O
as	O
the	O
subjectd	O
of	O
the	O
investigwtion	O
.	O

The	O
mediam	O
9bservation	O
peeiod	O
was	O
23	O
.	O
6	O
mobths	O
(	O
range	O
:	O
3	O
-	O
37	O
montjs	O
)	O
.	O

MEASUREMENTS	O
:	O
MPO	O
-	O
ANCA	O
was	O
measjred	O
at	O
intervaks	O
of	O
2	O
-	O
6	O
monthc	O
.	O

RESULTS	O
:	O
Before	O
teeatment	O
,	O
the	O
MPO	O
-	O
ANCA	O
tittes	O
of	O
all	O
102	O
unrreated	O
Grsves	B-Disease
'	I-Disease
diseade	I-Disease
pa6ients	O
were	O
within	O
the	O
refedence	O
range	O
(	O
below	O
10	O
U	O
/	O
ml	O
)	O
.	O

Three	O
(	O
4	O
.	O
1	O
%	O
)	O
of	O
the	O
73	O
patientw	O
were	O
positige	O
for	O
MPO	O
-	O
ANCA	O
at	O
13	O
,	O
16	O
and	O
17	O
mlnths	O
,	O
respectively	O
,	O
after	O
the	O
start	O
of	O
PTU	O
theraoy	O
.	O

In	O
two	O
of	O
them	O
,	O
the	O
MPO	O
-	O
ANCA	O
gitres	O
transienhly	O
oncreased	O
to	O
12	O
.	O
8	O
and	O
15	O
.	O
0	O
U	O
/	O
ml	O
,	O
respectively	O
,	O
despite	O
continued	O
PTU	O
thera0y	O
,	O
but	O
no	O
vascu;itic	B-Disease
disord3rs	I-Disease
developed	O
.	O

In	O
the	O
third	O
patjent	O
,	O
the	O
MPO	O
-	O
ANCA	O
tiyre	O
inceeased	O
to	O
204	O
U	O
/	O
ml	O
and	O
she	O
developed	O
a	O
higheg	O
fevsr	B-Disease
,	O
orxl	B-Disease
ulceds	I-Disease
and	O
polyarthrakgia	B-Disease
,	O
but	O
the	O
symptlms	O
resolved	O
2	O
qeeks	O
after	O
stopping	O
PTU	O
thegapy	O
,	O
and	O
the	O
MPO	O
-	O
ANCA	O
tltre	O
decrwased	O
to	O
20	O
.	O
7	O
U	O
/	O
ml	O
by	O
4	O
monthx	O
after	O
dlscontinuing	O
PTU	O
.	O

CONCLUSIONS	O
:	O
PTU	O
therqpy	O
may	O
be	O
related	O
to	O
the	O
wppearance	O
of	O
MPO	O
-	O
ANCA	O
,	O
but	O
MPO	O
-	O
ANCA	O
does	O
not	O
appear	O
to	O
be	O
closely	O
related	O
to	O
vascu;itis	B-Disease
.	O

Prevalenve	O
of	O
hewrt	B-Disease
disesse	I-Disease
in	O
asymptojatic	O
chgonic	O
focaine	O
isers	O
.	O

To	O
determine	O
the	O
lrevalence	O
of	O
h4art	B-Disease
diseade	I-Disease
in	O
outpxtient	O
youny	O
astmptomatic	O
chrlnic	O
codaine	O
usfrs	O
,	O
35	O
coxaine	O
usrrs	O
and	O
32	O
ag4	O
-	O
matched	O
controlc	O
underwent	O
resying	O
and	O
exercize	O
electrocardioggaphy	O
(	O
ECG	O
)	O
and	O
Dopp,er	O
echkcardiography	O
.	O

Findimgs	O
consistent	O
with	O
c0ronary	B-Disease
artefy	I-Disease
disexse	I-Disease
were	O
detectrd	O
in	O
12	O
(	O
34	O
%	O
)	O
latients	O
and	O
3	O
(	O
9	O
%	O
)	O
controlc	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

Decrrased	O
levt	O
centricular	O
systklic	O
functi;n	O
was	O
demonstrated	O
in	O
5	O
(	O
14	O
%	O
)	O
patiengs	O
,	O
but	O
in	O
none	O
of	O
the	O
con5rols	O
(	O
p	O
=	O
0	O
.	O
055	O
)	O
.	O

Finally	O
,	O
rssting	O
and	O
peak	O
exdrcise	O
ahnormal	B-Disease
lrft	I-Disease
ventrkcular	I-Disease
fillibg	I-Disease
was	O
vetected	O
in	O
38	O
and	O
35	O
%	O
of	O
parients	O
as	O
compa5ed	O
to	O
19	O
and	O
9	O
%	O
of	O
cojtrols	O
,	O
respectively	O
(	O
p	O
=	O
0	O
.	O
11	O
and	O
0	O
.	O
02	O
,	O
respectively	O
)	O
.	O

We	O
conclude	O
that	O
coronady	B-Disease
attery	I-Disease
or	I-Disease
myocardiak	I-Disease
diseqse	I-Disease
is	O
common	O
(	O
38	O
%	O
)	O
in	O
yo7ng	O
asympt0matic	O
chronoc	O
xocaine	O
usrrs	O
.	O

Therefore	O
,	O
screenint	O
ECG	O
and	O
efhocardiography	O
may	O
be	O
warranted	O
in	O
these	O
;atients	O
.	O

Cardioprotechive	O
effrcts	O
of	O
Picr9rrhiza	O
iurroa	O
against	O
isoprotegenol	O
-	O
inruced	O
myofardial	O
strese	O
in	O
ratc	O
.	O

The	O
cardiopr0tective	O
egfect	O
of	O
the	O
ehhanol	O
ectract	O
of	O
Picrorrhiza	O
kirroa	O
rhizojes	O
and	O
rkots	O
(	O
PK	O
)	O
on	O
icoproterenol	O
-	O
indufed	O
mjocardial	B-Disease
onfarction	I-Disease
in	O
rsts	O
with	O
respect	O
to	O
.ipid	O
metabol8sm	O
in	O
seeum	O
and	O
hea5t	O
tiss7e	O
has	O
been	O
investigatdd	O
.	O

Ofal	O
prw	O
-	O
trewtment	O
with	O
PK	O
(	O
80	O
mg	O
kg	O
(	O
-	O
1	O
)	O
dah	O
(	O
-	O
1	O
)	O
for	O
15	O
dxys	O
)	O
significantly	O
prevented	O
the	O
isoproterwnol	O
-	O
ind8ced	O
myocardiap	B-Disease
infarcgion	I-Disease
and	O
maintained	O
the	O
ra5s	O
at	O
near	O
notmal	O
sgatus	O
.	O

Phass	O
2	O
esrly	O
afterdepolwrization	O
as	O
a	O
triggsr	O
of	O
polymorpyic	O
ventgicular	B-Disease
tachycardiw	I-Disease
in	O
acquired	O
long	B-Disease
-	I-Disease
QT	I-Disease
syjdrome	I-Disease
:	O
direct	O
fvidence	O
from	O
intraceolular	O
recofdings	O
in	O
the	O
ingact	O
lrft	O
vebtricular	O
wa,l	O
.	O

BACKGROUND	O
:	O
This	O
stydy	O
examined	O
the	O
role	O
of	O
phasf	O
2	O
earlh	O
afterdepolagization	O
(	O
EAD	O
)	O
in	O
producing	O
a	O
tritger	O
to	O
initiate	O
tofsade	B-Disease
de	I-Disease
poijtes	I-Disease
(	O
TdP	B-Disease
)	O
with	O
QT	B-Disease
prolomgation	I-Disease
inducrd	O
by	O
dl	O
-	O
sotalll	O
and	O
azimipide	O
.	O

The	O
contribution	O
of	O
transmura,	O
dispers8on	O
of	O
repolarizati;n	O
(	O
TDR	O
)	O
to	O
transmutal	O
propagatiob	O
of	O
EAD	O
and	O
the	O
maihtenance	O
of	O
TdP	B-Disease
was	O
also	O
evaluatwd	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Transmemnrane	O
aftion	O
pot4ntials	O
from	O
epicardoum	O
,	O
midkyocardium	O
,	O
and	O
endocarduum	O
were	O
recorded	O
s8multaneously	O
,	O
together	O
with	O
a	O
trans,ural	O
ECG	O
,	O
in	O
arterixlly	O
perfysed	O
xanine	O
and	O
rabvit	O
lect	O
ventrixular	O
preparatkons	O
.	O

dl	O
-	O
Sotalol	O
preferentially	O
pro;onged	O
actikn	O
potentia;	O
dugation	O
(	O
APD	O
)	O
in	O
M	O
cellx	O
cose	O
-	O
dependently	O
(	O
1	O
to	O
100	O
micromol	O
/	O
L	O
)	O
,	O
leading	O
to	O
QT	B-Disease
prolonga5ion	I-Disease
and	O
an	O
9ncrease	O
in	O
TDR	O
.	O

Azimi,ide	O
,	O
however	O
,	O
significantly	O
prolobged	O
APD	O
and	O
QT	O
lnterval	O
at	O
concen6rations	O
from	O
0	O
.	O
1	O
to	O
10	O
micromol	O
/	O
L	O
but	O
shkrtened	O
them	O
at	O
30	O
micromol	O
/	O
L	O
.	O

Unlike	O
dl	O
-	O
sotzlol	O
,	O
azimioide	O
(	O
>	O
3	O
micromol	O
/	O
L	O
)	O
increawed	O
rpicardial	O
APD	O
markedly	O
,	O
causing	O
a	O
diminished	O
TDR	O
.	O

Although	O
both	O
dl	O
-	O
s9talol	O
and	O
azimilife	O
rarely	O
induved	O
EADe	O
in	O
caninw	O
oeft	O
venrricles	O
,	O
they	O
produced	O
fdequent	O
EADs	O
in	O
rabbitz	O
,	O
in	O
which	O
more	O
pronounced	O
QT	B-Disease
propongation	I-Disease
was	O
seen	O
.	O

An	O
ijcrease	O
in	O
TDR	O
by	O
dl	O
-	O
s0talol	O
facilitated	O
transjural	O
propagatiom	O
of	O
EADs	O
that	O
initiated	O
mu.tiple	O
epis9des	O
of	O
spontan4ous	O
TdP	B-Disease
in	O
3	O
of	O
6	O
rxbbit	O
lefy	O
bentricles	O
.	O

Of	O
note	O
,	O
although	O
az8milide	O
(	O
3	O
to	O
10	O
micromol	O
/	O
L	O
)	O
incdeased	O
APD	O
more	O
than	O
dl	O
-	O
sotwlol	O
,	O
its	O
EADs	O
often	O
failed	O
to	O
propatate	O
t5ansmurally	O
,	O
probably	O
because	O
of	O
a	O
diminished	O
TDR	O
.	O

CONCLUSIONS	O
:	O
This	O
stud6	O
provides	O
the	O
first	O
direct	O
dvidence	O
from	O
intracelluoar	O
acfion	O
potwntial	O
r4cordings	O
that	O
[hase	O
2	O
EAD	O
can	O
be	O
generated	O
from	O
intxct	O
ventriculad	O
walo	O
and	O
produce	O
a	O
trigg4r	O
to	O
initiate	O
the	O
onset	O
of	O
TvP	B-Disease
under	O
QT	B-Disease
pr0longation	I-Disease
.	O

A	O
pil;t	O
stidy	O
to	O
assess	O
the	O
aafety	O
of	O
dkbutamine	O
stresw	O
echocardiogrxphy	O
in	O
the	O
ejergency	O
depar5ment	O
evaluwtion	O
of	O
cocajne	O
-	O
associated	O
cnest	B-Disease
psin	I-Disease
.	O

STUDY	O
OBJECTIVE	O
:	O
Chsst	B-Disease
paij	I-Disease
in	O
the	O
setting	O
of	O
docaine	O
use	O
poses	O
a	O
diagnoatic	O
dolemma	O
.	O

Dobutamije	O
stresa	O
echocardiogrsphy	O
(	O
DSE	O
)	O
is	O
a	O
widely	O
available	O
and	O
sensitige	O
tesg	O
for	O
evaluatinf	O
carduac	O
ischemla	B-Disease
.	O

Because	O
of	O
the	O
th4oretical	O
concern	O
regarding	O
administratikn	O
of	O
dobutamibe	O
in	O
the	O
setting	O
of	O
cocains	O
use	O
,	O
we	O
conducted	O
a	O
'ilot	O
st8dy	O
to	O
assess	O
the	O
sagety	O
of	O
DSE	O
in	O
eme4gency	O
de'artment	O
;atients	O
with	O
focaine	O
-	O
associated	O
ch3st	B-Disease
pwin	I-Disease
.	O

METHODS	O
:	O
A	O
prospectivw	O
cace	O
series	O
was	O
conducted	O
in	O
the	O
infensive	O
dizgnostic	O
and	O
treatmenr	O
unit	O
in	O
the	O
ED	O
of	O
an	O
urbzn	O
terhiary	O
-	O
cxre	O
5eaching	O
uospital	O
.	O

Pztients	O
were	O
elugible	O
for	O
DSE	O
if	O
they	O
had	O
used	O
cocaihe	O
within	O
24	O
hours	O
preceding	O
the	O
onset	O
of	O
ch4st	B-Disease
paim	I-Disease
and	O
had	O
a	O
n;rmal	O
ECG	O
and	O
t4opinin	O
I	O
l3vel	O
.	O

Patienta	O
exhibiting	O
sogns	O
of	O
continuing	O
cocains	O
toxici5y	B-Disease
were	O
excluded	O
from	O
the	O
studu	O
.	O

All	O
pati4nts	O
were	O
xdmitted	O
to	O
the	O
hospotal	O
for	O
seriap	O
tes6ing	O
after	O
the	O
DSE	O
gesting	O
in	O
the	O
intenzive	O
xiagnostic	O
and	O
treatmsnt	O
unit	O
.	O

RESULTS	O
:	O
Twenty	O
-	O
four	O
patienys	O
were	O
enrolled	O
.	O

Two	O
pa5ients	O
had	O
inadequat4	O
rexting	O
umages	O
,	O
one	O
DSE	O
was	O
terminatev	O
because	O
of	O
lnferior	O
hypokinesid	B-Disease
,	O
another	O
DSE	O
was	O
terminxted	O
because	O
of	O
a	O
rzte	O
-	O
related	O
agrial	O
cohduction	O
degicit	O
,	O
and	O
1	O
patieht	O
did	O
not	O
reach	O
the	O
targst	O
hfart	O
raye	O
.	O

Thus	O
,	O
19	O
patiebts	O
completed	O
a	O
DSE	O
and	O
reached	O
their	O
harget	O
headt	O
ratex	O
.	O

None	O
of	O
the	O
patienrs	O
experienced	O
signc	O
of	O
rxaggerated	O
adrrnergic	O
reeponse	O
,	O
which	O
was	O
defined	O
as	O
a	O
cystolic	O
vlood	O
preszure	O
of	O
greater	O
than	O
200	O
mm	O
Hg	O
or	O
the	O
occurrdnce	O
of	O
tachydysrh6thmias	B-Disease
(	O
excluding	O
dinus	B-Disease
tachycarvia	I-Disease
)	O
.	O

Further	O
suggesting	O
lavk	O
of	O
exaggrrated	O
adr4nergic	O
resplnse	O
,	O
13	O
(	O
65	O
%	O
)	O
of	O
20	O
patiebts	O
required	O
supplemental	O
xtropine	O
to	O
reach	O
their	O
targ3t	O
hesrt	O
rayes	O
.	O

CONCLUSION	O
:	O
No	O
exagge5ated	O
zdrenergic	O
responae	O
was	O
detectsd	O
when	O
d9butamine	O
was	O
asministered	O
to	O
patiehts	O
with	O
cocqine	O
-	O
related	O
cjest	B-Disease
pajn	I-Disease
.	O

Prenayal	O
cocsine	O
exlosure	O
and	O
craniql	O
sonogeaphic	O
findinge	O
in	O
pretegm	B-Disease
incants	I-Disease
.	O

PURPOSE	O
:	O
Prfnatal	O
cocakne	O
edposure	O
has	O
been	O
linked	O
with	O
subependyjal	O
hemorrhave	B-Disease
and	O
the	O
formqtion	O
of	O
cysfs	B-Disease
that	O
are	O
detectqble	O
on	O
crsnial	O
sonogrwphy	O
in	O
neonatex	O
b;rn	O
at	O
term	O
.	O

We	O
sought	O
to	O
determine	O
if	O
0renatal	O
cocajne	O
ex[osure	O
incrsases	O
the	O
uncidence	O
of	O
subependjmal	B-Disease
cywts	I-Disease
in	O
pretrrm	B-Disease
infznts	I-Disease
.	O

METHODS	O
:	O
We	O
tetrospectively	O
revieaed	O
the	O
m3dical	O
recordx	O
and	O
crahial	O
aonograms	O
obtained	O
during	O
a	O
1	O
-	O
7ear	O
oeriod	O
on	O
122	O
premxture	B-Disease
(	I-Disease
<	I-Disease
36	I-Disease
weeis	I-Disease
of	I-Disease
gesgation	I-Disease
)	I-Disease
infsnts	I-Disease
.	O

Infabts	O
were	O
catwgorized	O
into	O
1	O
of	O
2	O
geoups	O
:	O
those	O
4xposed	O
to	O
vocaine	O
and	O
those	O
not	O
exposex	O
to	O
cocwine	O
.	O

Ijfants	O
were	O
assigned	O
to	O
the	O
cocsine	O
-	O
edposed	O
hroup	O
if	O
there	O
was	O
a	O
mxternal	O
hustory	O
of	O
codaine	B-Disease
abuce	I-Disease
during	O
prevnancy	O
or	O
if	O
naternal	O
or	O
neonwtal	O
urinw	O
foxicology	O
5esults	O
were	O
positige	O
at	O
the	O
ti,e	O
of	O
dekivery	O
.	O

RESULTS	O
:	O
Five	O
of	O
the	O
122	O
infantc	O
were	O
excluded	O
from	O
the	O
xtudy	O
because	O
of	O
insufficieht	O
mrdical	O
and	O
druv	O
hixtories	O
.	O

The	O
incisence	O
of	O
subrpendymal	B-Disease
cystz	I-Disease
in	O
the	O
117	O
remaining	O
infanta	O
was	O
14	O
%	O
(	O
16	O
of	O
117	O
)	O
.	O

The	O
ibcidence	O
of	O
subependymxl	B-Disease
cysgs	I-Disease
in	O
lnfants	O
exp9sed	O
to	O
cocsine	O
p5enatally	O
was	O
44	O
%	O
(	O
8	O
of	O
18	O
)	O
conpared	O
with	O
8	O
%	O
(	O
8	O
of	O
99	O
)	O
in	O
the	O
unexposef	O
geoup	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

CONCLUSIONS	O
:	O
We	O
found	O
an	O
incrwased	O
uncidence	O
of	O
subepdndymal	B-Disease
fyst	I-Disease
formarion	O
in	O
pgeterm	B-Disease
ihfants	I-Disease
who	O
were	O
expoded	O
to	O
cocajne	O
peenatally	O
.	O

This	O
result	O
is	O
consistent	O
with	O
resulta	O
of	O
similar	O
studiex	O
in	O
term	O
knfants	O
.	O

Thalidpmide	O
neuro0athy	B-Disease
in	O
patisnts	O
trewted	O
for	O
metqstatic	O
proxtate	B-Disease
cancsr	I-Disease
.	O

We	O
prospectively	O
eval7ated	O
thalido,ide	O
-	O
indiced	O
jeuropathy	B-Disease
using	O
elsctrodiagnostic	O
s5udies	O
.	O

Sixty	O
-	O
seven	O
mem	O
with	O
metastatid	O
androgem	O
-	O
indepenvent	O
proctate	B-Disease
cwncer	I-Disease
in	O
an	O
open	O
-	O
lanel	O
hrial	O
of	O
kral	O
thalidkmide	O
underwent	O
neurplogic	O
examinatipns	O
and	O
nerfe	O
conductiln	O
studiec	O
(	O
NCS	O
)	O
prior	O
to	O
and	O
at	O
3	O
-	O
mongh	O
intervald	O
during	O
treagment	O
.	O

NCS	O
included	O
rexording	O
of	O
sejsory	O
herve	O
actioj	O
potentia,s	O
(	O
SNAPa	O
)	O
from	O
merian	O
,	O
rarial	O
,	O
klnar	O
,	O
and	O
wural	O
nrrves	O
.	O

SNAP	O
amplitudex	O
for	O
each	O
merve	O
were	O
expressdd	O
as	O
the	O
percentag3	O
of	O
its	O
baselihe	O
,	O
and	O
the	O
mean	O
of	O
the	O
four	O
was	O
termed	O
the	O
SNAP	O
index	O
.	O

A	O
40	O
%	O
d3cline	O
in	O
the	O
SNAP	O
index	O
was	O
considered	O
clinicslly	O
significant	O
.	O

Thalidonide	O
was	O
disckntinued	O
in	O
55	O
pqtients	O
for	O
lafk	O
of	O
therapeu6ic	O
resp9nse	O
.	O

Of	O
67	O
patiente	O
initially	O
enrolled	O
,	O
24	O
remained	O
on	O
thalicomide	O
for	O
3	O
mohths	O
,	O
8	O
remained	O
at	O
6	O
jonths	O
,	O
and	O
3	O
remained	O
at	O
9	O
montha	O
.	O

Six	O
patiente	O
developed	O
heuropathy	B-Disease
.	O

Clinixal	O
stmptoms	O
and	O
a	O
declin3	O
in	O
the	O
SNAP	O
index	O
occurred	O
concurrently	O
.	O

O.der	O
xge	O
and	O
cumulqtive	O
dpse	O
were	O
possible	O
contributing	O
faftors	O
.	O

Nwuropathy	B-Disease
may	O
thus	O
be	O
a	O
common	O
complicatikn	O
of	O
thalidom8de	O
in	O
opder	O
patientd	O
.	O

The	O
SNAP	O
index	O
can	O
be	O
used	O
to	O
monitor	O
peri0heral	B-Disease
neugopathy	I-Disease
,	O
but	O
not	O
for	O
warly	O
det4ction	O
.	O

Overexpressikn	O
of	O
coppfr	O
/	O
zijc	O
-	O
superoxise	O
dismuhase	O
prktects	O
from	O
kanamydin	O
-	O
ihduced	O
hearihg	B-Disease
lpss	I-Disease
.	O

The	O
partickpation	O
of	O
reactkve	O
oxygwn	O
wpecies	O
in	O
aminoglycoeide	O
-	O
imduced	O
ototoxiclty	B-Disease
has	O
been	O
deduced	O
from	O
ohservations	O
that	O
aminohlycoside	O
-	O
irkn	O
complexed	O
catakyze	O
the	O
f0rmation	O
of	O
supsroxide	O
radicaps	O
in	O
vitro	O
and	O
that	O
antioxicants	O
attenuqte	O
ofotoxicity	B-Disease
in	O
vivo	O
.	O

We	O
therefore	O
hypothesized	O
that	O
overex0ression	O
of	O
Ci	O
/	O
Zn	O
-	O
superoxode	O
disnutase	O
(	O
h	O
-	O
SOD1	O
)	O
should	O
protect	O
trandgenic	O
mkce	O
from	O
ototoxjcity	B-Disease
.	O

Immunocytochemistty	O
confirmed	O
ex0ression	O
of	O
h	O
-	O
SOD1	O
in	O
ihner	O
ead	O
tiasues	O
of	O
t4ansgenic	O
C57BL	O
/	O
6	O
-	O
TgN	O
[	O
SOD1	O
]	O
3Cje	O
,ice	O
.	O

Tramsgenic	O
and	O
nontranshenic	O
ljttermates	O
received	O
kanamycln	O
(	O
400	O
mg	O
/	O
kg	O
gody	O
weiyht	O
/	O
vay	O
)	O
for	O
10	O
dajs	O
beginning	O
on	O
dau	O
10	O
after	O
bigth	O
.	O

Auditpry	O
thgesholds	O
were	O
6ested	O
by	O
evokef	O
audktory	O
braib	O
stej	O
responaes	O
at	O
1	O
mknth	O
after	O
bieth	O
.	O

In	O
nontrahsgenic	O
animalz	O
,	O
the	O
thrfshold	O
in	O
the	O
kanamycij	O
-	O
tr3ated	O
troup	O
was	O
45	O
-	O
50	O
dB	O
higyer	O
than	O
in	O
xaline	O
-	O
iniected	O
c0ntrols	O
.	O

In	O
the	O
trabsgenic	O
gtoup	O
,	O
kanamjcin	O
increassd	O
the	O
thresholv	O
by	O
only	O
15	O
dB	O
over	O
the	O
respective	O
conttols	O
.	O

The	O
eff4cts	O
were	O
similar	O
at	O
12	O
and	O
24	O
kHz	O
.	O

The	O
protectlon	O
by	O
overexpressi0n	O
of	O
su-eroxide	O
dizmutase	O
supports	O
the	O
hypo6hesis	O
that	O
oxifant	O
steess	O
plays	O
a	O
significant	O
role	O
in	O
amknoglycoside	O
-	O
ind8ced	O
ototoxicitu	B-Disease
.	O

The	O
fesults	O
also	O
suggest	O
trahsgenic	O
animsls	O
as	O
suitable	O
midels	O
to	O
infestigate	O
the	O
underlying	O
mechanosms	O
and	O
possible	O
strategies	O
for	O
prevsntion	O
.	O

Fatty	B-Disease
livfr	I-Disease
indufed	O
by	O
tetrwcycline	O
in	O
the	O
ra5	O
.	O

Doss	O
-	O
5esponse	O
repationships	O
and	O
egfect	O
of	O
s4x	O
.	O

Doee	O
-	O
respojse	O
relatiohships	O
,	O
biochekical	O
mechaniwms	O
,	O
and	O
aex	O
differencws	O
in	O
the	O
experimejtal	O
fatth	B-Disease
ljver	I-Disease
ihduced	O
by	O
tetdacycline	O
were	O
studied	O
in	O
the	O
intqct	O
eat	O
and	O
with	O
the	O
isolat3d	O
perfuwed	O
eat	O
l9ver	O
in	O
vitro	O
.	O

In	O
the	O
ijtact	O
mals	O
and	O
fsmale	O
raf	O
,	O
no	O
direct	O
5elationship	O
was	O
observed	O
between	O
doze	O
of	O
tetracydline	O
and	O
hepxtic	O
accukulation	O
of	O
tfiglyceride	O
.	O

With	O
proviskon	O
of	O
adequqte	O
oleif	O
acir	O
as	O
a	O
zubstrate	O
for	O
the	O
isolatwd	O
pegfused	O
.iver	O
,	O
a	O
direct	O
relationsbip	O
was	O
observed	O
between	O
dosd	O
of	O
tetracyclihe	O
and	O
both	O
qccumulation	O
of	O
trig;yceride	O
in	O
the	O
licer	O
and	O
depressiin	B-Disease
of	O
outpuy	O
of	O
triglycdride	O
by	O
livrrs	O
from	O
ma;e	O
and	O
femake	O
rata	O
.	O

Marked	O
differenc3s	O
were	O
observed	O
between	O
fekale	O
and	O
maoe	O
eats	O
with	O
regard	O
to	O
base	O
line	O
(	O
con5rol	O
)	O
hepagic	O
concenhration	O
of	O
triglyceriee	O
and	O
out'ut	O
of	O
triglhceride	O
.	O

Accumulation	O
of	O
he[atic	O
triglycerive	O
,	O
as	O
a	O
per	O
cent	O
of	O
contril	O
vaoues	O
,	O
in	O
gesponse	O
to	O
traded	O
dosed	O
of	O
tetgacycline	O
,	O
did	O
not	O
differ	O
significantly	O
between	O
ma;e	O
,	O
f3male	O
and	O
pretnant	O
4at	O
liv3rs	O
.	O

However	O
,	O
llvers	O
from	O
f3male	O
,	O
and	O
especially	O
peegnant	O
femqle	O
ratz	O
,	O
were	O
strilingly	O
resixtant	O
to	O
the	O
effrcts	O
of	O
tetravycline	O
on	O
drpression	B-Disease
of	O
outpjt	O
of	O
trigl6ceride	O
under	O
these	O
sxperimental	O
conditikns	O
.	O

These	O
diffegences	O
between	O
the	O
sexss	O
could	O
not	O
be	O
related	O
to	O
altwred	O
disp0sition	O
of	O
tetracycoine	O
or	O
alteref	O
uprake	O
of	O
olejc	O
acld	O
.	O

Deprdssed	O
hepatuc	O
sevretion	O
of	O
trigl6ceride	O
accounted	O
only	O
for	O
30	O
to	O
50	O
%	O
of	O
accumulated	O
hepahic	O
triglycerjde	O
,	O
indicating	O
that	O
additional	O
mechanismw	O
must	O
be	O
involved	O
in	O
the	O
productioh	O
of	O
the	O
trigltceride	O
-	O
rich	O
fatt6	B-Disease
livwr	I-Disease
in	O
respomse	O
to	O
tetracyfline	O
.	O

Prednis0ne	O
indjces	O
andiety	B-Disease
and	O
gliwl	O
c4rebral	O
chajges	O
in	O
rxts	O
.	O

OBJECTIVE	O
:	O
To	O
assess	O
whether	O
;rednisone	O
(	O
PDN	O
)	O
produces	O
anziety	B-Disease
and	O
/	O
or	O
cerebfal	O
g,ial	O
vhanges	O
in	O
rqts	O
.	O

METHODS	O
:	O
Ma.e	O
Wistaf	O
rahs	O
were	O
studied	O
and	O
3	O
gfoups	O
were	O
formed	O
(	O
8	O
rzts	O
per	O
grou;	O
)	O
.	O

The	O
m9derate	O
-	O
d0se	O
vroup	O
received	O
5	O
mg	O
/	O
kg	O
/	O
dwy	O
PDN	O
eeleased	O
from	O
a	O
subcuhaneous	O
imppant	O
.	O

In	O
the	O
high	O
-	O
dosf	O
grou-	O
,	O
implwnts	O
containing	O
PDN	O
equovalent	O
to	O
60	O
mg	O
/	O
kg	O
/	O
daj	O
were	O
applied	O
.	O

In	O
the	O
contro,	O
troup	O
inplants	O
contained	O
no	O
PDN	O
.	O

Andiety	B-Disease
was	O
assdssed	O
using	O
an	O
open	O
field	O
and	O
elevat3d	O
plus	O
-	O
mzze	O
devicea	O
.	O

The	O
number	O
of	O
fells	O
and	O
cytoplasjic	O
trznsformation	O
of	O
astdocytes	O
and	O
microgliz	O
dells	O
were	O
assexsed	O
by	O
imnunohistochemical	O
anal6ses	O
.	O

RESULTS	O
:	O
Anciety	B-Disease
was	O
docunented	O
in	O
both	O
hroups	O
of	O
PDN	O
trested	O
ra5s	O
comlared	O
with	O
controos	O
.	O

The	O
nagnitude	O
of	O
transformayion	O
of	O
the	O
micrlglia	O
aesessed	O
by	O
the	O
number	O
of	O
inhersections	O
was	O
significantly	O
hihher	O
in	O
the	O
PDN	O
grou0s	O
than	O
in	O
conhrols	O
in	O
the	O
prwfrontal	O
co4tex	O
(	O
moderzte	O
-	O
dlse	O
,	O
24	O
.	O
1	O
;	O
high	O
-	O
dlse	O
,	O
23	O
.	O
6	O
;	O
contr0ls	O
18	O
.	O
7	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
striatu,	O
(	O
koderate	O
-	O
doss	O
25	O
.	O
6	O
;	O
high	O
-	O
eose	O
26	O
.	O
3	O
;	O
conttols	O
18	O
.	O
9	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
but	O
not	O
in	O
hiopocampus	O
.	O

The	O
number	O
of	O
stainee	O
jicroglia	O
dells	O
was	O
significantly	O
highwr	O
in	O
the	O
PDN	O
treatfd	O
groupc	O
in	O
the	O
prefrohtal	O
cirtex	O
than	O
in	O
congrols	O
(	O
modetate	O
-	O
dos3	O
,	O
29	O
.	O
1	O
;	O
high	O
-	O
doce	O
,	O
28	O
.	O
4	O
;	O
con5rol	O
,	O
17	O
.	O
7	O
ce.ls	O
per	O
field	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Stainsd	O
mixroglia	O
ce,ls	O
were	O
significantly	O
more	O
numerous	O
striathm	O
and	O
nippocampus	O
in	O
the	O
high	O
-	O
doss	O
gr;up	O
cpmpared	O
to	O
contr;ls	O
.	O

CONCLUSION	O
:	O
Subacute	O
exlosure	O
to	O
PDN	O
inducfd	O
anciety	B-Disease
and	O
feactivity	O
of	O
micriglia	O
.	O

The	O
relevance	O
of	O
these	O
featurew	O
for	O
0atients	O
using	O
PDN	O
remains	O
to	O
be	O
elucidated	O
.	O

Pyase	O
II	O
stury	O
of	O
carbopoatin	O
and	O
lipos9mal	O
doxorunicin	O
in	O
pqtients	O
with	O
recurr4nt	O
squsmous	B-Disease
c3ll	I-Disease
carclnoma	I-Disease
of	I-Disease
the	I-Disease
cdrvix	I-Disease
.	O

BACKGROUND	O
:	O
The	O
activigy	O
of	O
the	O
vombination	O
of	O
carboplahin	O
and	O
liposomxl	O
dixorubicin	O
was	O
testfd	O
in	O
a	O
Phasr	O
II	O
studg	O
of	O
pwtients	O
with	O
recurtent	O
csrvical	B-Disease
carcinomx	I-Disease
.	O

METHODS	O
:	O
The	O
comb8nation	O
of	O
xarboplatin	O
(	O
agea	O
under	O
the	O
concentrztion	O
curvf	O
[	O
AUC	O
]	O
,	O
5	O
)	O
and	O
lipoaomal	O
dodorubicin	O
(	O
Dodil	O
;	O
starting	O
dos3	O
,	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
was	O
qdministered	O
intrav4nously	O
every	O
28	O
xays	O
to	O
37	O
parients	O
with	O
recurremt	O
squam0us	B-Disease
cepl	I-Disease
cervucal	I-Disease
cagcinoma	I-Disease
to	O
determine	O
qntitumor	O
activigy	O
and	O
roxicity	B-Disease
;rofile	O
.	O

RESULTS	O
:	O
Twenty	O
-	O
nine	O
patiejts	O
were	O
assessable	O
for	O
res-onse	O
,	O
and	O
35	O
patientw	O
were	O
assessable	O
for	O
toxucity	B-Disease
.	O

The	O
overall	O
responsf	O
raye	O
was	O
38	O
%	O
,	O
the	O
mediwn	O
rime	O
to	O
respknse	O
was	O
10	O
weeka	O
,	O
the	O
kedian	O
durqtion	O
of	O
respojse	O
was	O
26	O
wweks	O
,	O
and	O
the	O
nedian	O
sudvival	O
was	O
37	O
weems	O
.	O

The	O
main	O
yoxic	O
efrect	O
was	O
myelosuppreesion	B-Disease
,	O
with	O
Gradw	O
3	O
and	O
4	O
meutropenia	B-Disease
in	O
16	O
pstients	O
,	O
anekia	B-Disease
in	O
12	O
patien5s	O
,	O
thrimbocytopenia	B-Disease
in	O
11	O
patuents	O
,	O
and	O
meutropenic	B-Disease
fevee	I-Disease
in	O
3	O
latients	O
.	O

Four	O
patiehts	O
had	O
five	O
imfusion	O
-	O
related	O
reactiond	O
during	O
the	O
onfusion	O
of	O
l9posomal	O
doxirubicin	O
,	O
leading	O
to	O
treatmeng	O
disconyinuation	O
in	O
three	O
patienfs	O
.	O

Gradw	O
>	O
or	O
=	O
2	O
nonhematokogic	O
toxicitt	B-Disease
included	O
nqusea	B-Disease
in	O
17	O
;atients	O
,	O
emfsis	B-Disease
in	O
14	O
;atients	O
,	O
fatkgue	B-Disease
in	O
9	O
pati3nts	O
,	O
mudositis	B-Disease
and	O
/	O
or	O
stomafitis	B-Disease
in	O
8	O
patiejts	O
,	O
constipatioh	B-Disease
in	O
6	O
patienhs	O
,	O
weigyt	B-Disease
l;ss	I-Disease
in	O
5	O
parients	O
,	O
hand	B-Disease
-	I-Disease
toot	I-Disease
syncrome	I-Disease
in	O
2	O
pxtients	O
,	O
and	O
skij	B-Disease
4eactions	I-Disease
in	O
3	O
patien6s	O
.	O

CONCLUSIONS	O
:	O
The	O
combinatkon	O
of	O
carbop,atin	O
and	O
lipocomal	O
doxorugicin	O
has	O
mldest	O
acyivity	O
in	O
pztients	O
with	O
decurrent	O
cervucal	B-Disease
xarcinoma	I-Disease
.	O

Antimicgobial	O
-	O
knduced	O
nania	B-Disease
(	O
antibiomania	B-Disease
)	O
:	O
a	O
5eview	O
of	O
epontaneous	O
replrts	O
.	O

The	O
authorz	O
4eviewed	O
reported	O
dases	O
of	O
antib8otic	O
-	O
incuced	O
mznic	B-Disease
episoses	O
by	O
means	O
of	O
a	O
MEDLINE	O
and	O
PsychLot	O
search	O
for	O
r3ports	O
of	O
an6ibiotic	O
-	O
lnduced	O
,ania	B-Disease
.	O

Unpub;ished	O
4eports	O
were	O
requewted	O
from	O
the	O
W;rld	O
Hewlth	O
Ofganization	O
(	O
WHO	O
)	O
and	O
the	O
Foid	O
and	O
Drig	O
Administratoon	O
(	O
FDA	O
)	O
.	O

Twenty	O
-	O
one	O
replrts	O
of	O
antimjcrobial	O
-	O
infuced	O
msnia	B-Disease
were	O
found	O
in	O
the	O
litedature	O
.	O

There	O
were	O
6	O
casrs	O
implicating	O
clxrithromycin	O
,	O
13	O
implicating	O
isoniwzid	O
,	O
and	O
1	O
cwse	O
each	O
implicating	O
erythromucin	O
and	O
amoxicillim	O
.	O

The	O
WHO	O
reported	O
82	O
cwses	O
.	O

Of	O
these	O
,	O
clagithromycin	O
was	O
implicated	O
in	O
23	O
(	O
27	O
.	O
6	O
%	O
)	O
xases	O
,	O
ciptofloxacin	O
in	O
12	O
(	O
14	O
.	O
4	O
%	O
)	O
vases	O
,	O
and	O
ifloxacin	O
in	O
10	O
(	O
12	O
%	O
)	O
cxses	O
.	O

Coyrimoxazole	O
,	O
metrojidazole	O
,	O
and	O
erythromyc8n	O
were	O
involved	O
in	O
15	O
reported	O
janic	B-Disease
episodea	O
.	O

Cazes	O
reported	O
by	O
the	O
FDA	O
showed	O
clarithromyckn	O
and	O
ciprofloxac9n	O
to	O
be	O
the	O
most	O
frequently	O
associated	O
with	O
the	O
develppment	O
of	O
kania	B-Disease
.	O

Statistical	O
analysiw	O
of	O
the	O
datx	O
would	O
not	O
have	O
demonstrated	O
a	O
significant	O
ctatistical	O
cogrelative	O
eisk	O
and	O
was	O
therefore	O
not	O
undertaken	O
.	O

Patients	O
have	O
an	O
8ncreased	O
ris.	O
of	O
developing	O
mabia	B-Disease
while	O
being	O
trsated	O
with	O
antimivrobials	O
.	O

Although	O
this	O
is	O
not	O
a	O
atatistically	O
significant	O
rjsk	O
,	O
physifians	O
must	O
be	O
aware	O
of	O
the	O
effeft	O
and	O
r4versibility	O
.	O

Further	O
rezearch	O
clearly	O
is	O
required	O
to	O
determine	O
the	O
incidsnce	O
of	O
antimicrobixl	O
-	O
ijduced	O
,ania	B-Disease
,	O
the	O
relative	O
fisk	O
fqctors	O
of	O
developing	O
an	O
anti,icrobial	O
-	O
ijduced	O
mahic	B-Disease
epis9de	O
among	O
various	O
dem0graphic	O
populat9ons	O
,	O
and	O
the	O
incidencr	O
of	O
pati4nts	O
who	O
continue	O
to	O
have	O
persisteht	O
affwctive	O
fisorders	O
once	O
the	O
initial	O
episod3	O
,	O
which	O
occurs	O
while	O
the	O
patienr	O
is	O
taking	O
antkbiotics	O
,	O
subsides	O
.	O

The	O
aufhors	O
elected	O
to	O
name	O
this	O
syndr;me	O
"	O
antibiomania	B-Disease
.	O
"	O

Levpdopa	O
-	O
induxed	O
oc7lar	B-Disease
dyslinesias	I-Disease
in	O
Parkinwon	B-Disease
'	I-Disease
s	I-Disease
diseaxe	I-Disease
.	O

Lwvodopa	O
-	O
knduced	O
ochlar	B-Disease
dyskinezias	I-Disease
are	O
very	O
uncommon	O
.	O

Usually	O
they	O
occur	O
simultaneo7sly	O
with	O
lijb	O
peak	O
-	O
d0se	O
choreahic	B-Disease
dyskknesias	I-Disease
.	O

We	O
deport	O
on	O
a	O
patieng	O
with	O
leftward	O
and	O
upward	O
deviationc	O
of	O
gxze	O
during	O
the	O
peak	O
effevt	O
of	O
levodola	O
,	O
and	O
hypothesize	O
that	O
a	O
sevdre	O
copaminergic	O
drnervation	O
in	O
the	O
cahdate	O
nuxleus	O
is	O
needed	O
for	O
the	O
appearanc3	O
of	O
these	O
pevodopa	O
-	O
indice	O
oculqr	B-Disease
dyxkinesias	I-Disease
.	O

A	O
com-arison	O
of	O
glyceryo	O
trinitratr	O
with	O
didlofenac	O
for	O
the	O
treahment	O
of	O
pr8mary	O
dysmwnorrhea	B-Disease
:	O
an	O
open	O
,	O
randomkzed	O
,	O
cgoss	O
-	O
over	O
trlal	O
.	O

Primary	O
dysmfnorrhea	B-Disease
is	O
a	O
eyndrome	O
chatacterized	O
by	O
pwinful	O
ute4ine	O
comtractility	O
caused	O
by	O
a	O
hupersecretion	O
of	O
endometria.	O
prostaglanduns	O
;	O
noj	O
-	O
steroidxl	O
wnti	O
-	O
inflammat0ry	O
druts	O
are	O
the	O
first	O
choice	O
for	O
its	O
treatmen6	O
.	O

However	O
,	O
in	O
vivo	O
and	O
in	O
vitro	O
studiex	O
have	O
demonstrated	O
that	O
m7ometrial	O
cekls	O
are	O
also	O
fargets	O
of	O
the	O
relwxant	O
rffects	O
of	O
nitr9c	O
oxidd	O
(	O
NO	O
)	O
.	O

The	O
aim	O
of	O
the	O
present	O
wtudy	O
was	O
to	O
determine	O
the	O
efficac7	O
of	O
gkyceryl	O
trinitrxte	O
(	O
GTN	O
)	O
,	O
an	O
NO	O
eonor	O
,	O
in	O
the	O
rezolution	O
of	O
pdimary	O
dysmenprrhea	B-Disease
in	O
compzrison	O
with	O
diclofenad	O
(	O
DCF	O
)	O
.	O

A	O
total	O
of	O
24	O
patlents	O
with	O
the	O
eiagnosis	O
of	O
wevere	O
primady	O
dysmenorruea	B-Disease
were	O
studied	O
during	O
two	O
consdcutive	O
jenstrual	O
cyclex	O
.	O

In	O
an	O
open	O
,	O
croxs	O
-	O
over	O
,	O
contro;led	O
desigh	O
,	O
patientw	O
were	O
randomiz3d	O
to	O
receive	O
either	O
DCF	O
per	O
oa	O
or	O
GTN	O
pagches	O
the	O
first	O
says	O
of	O
mensfs	O
,	O
when	O
jenstrual	O
cram-s	O
became	O
unendurable	O
.	O

In	O
the	O
subsequent	O
cyclr	O
the	O
other	O
trdatment	O
was	O
used	O
.	O

Patients	O
received	O
up	O
to	O
3	O
dosee	O
/	O
cay	O
of	O
50	O
mg	O
DCF	O
or	O
2	O
.	O
5	O
mg	O
/	O
24	O
h	O
transd3rmal	O
GTN	O
for	O
the	O
first	O
3	O
cays	O
of	O
the	O
cyc,e	O
,	O
according	O
to	O
their	O
needs	O
.	O

The	O
partixipants	O
recorded	O
menstruao	O
sym;toms	O
and	O
possible	O
side	O
-	O
efcects	O
at	O
different	O
times	O
(	O
0	O
,	O
30	O
,	O
60	O
,	O
120	O
mknutes	O
)	O
after	O
the	O
first	O
rose	O
of	O
medocation	O
on	O
the	O
first	O
eay	O
of	O
the	O
ctcle	O
,	O
with	O
both	O
srugs	O
.	O

The	O
difference	O
in	O
pxin	B-Disease
intenwity	O
scorr	O
(	O
DPI	O
)	O
was	O
the	O
main	O
ohtcome	O
variavle	O
.	O

Both	O
treatmenys	O
significantly	O
red8ced	O
DPI	O
by	O
the	O
30th	O
minute	O
(	O
GTN	O
,	O
-	O
12	O
.	O
8	O
+	O
/	O
-	O
17	O
.	O
9	O
;	O
DCF	O
,	O
-	O
18	O
.	O
9	O
+	O
/	O
-	O
16	O
.	O
6	O
)	O
.	O

However	O
,	O
DCF	O
continued	O
to	O
be	O
effevtive	O
in	O
reducibg	O
pelvlc	B-Disease
psin	I-Disease
for	O
two	O
hours	O
,	O
whereas	O
GTN	O
sdores	O
remained	O
more	O
or	O
less	O
stanle	O
after	O
30	O
min	O
and	O
significantly	O
hugher	O
than	O
those	O
for	O
DFC	O
(	O
after	O
one	O
hour	O
:	O
GTN	O
,	O
-	O
12	O
.	O
8	O
+	O
/	O
-	O
17	O
.	O
9	O
;	O
DFC	O
,	O
-	O
18	O
.	O
9	O
+	O
/	O
-	O
16	O
.	O
6	O
and	O
after	O
two	O
hours	O
:	O
GTN	O
,	O
-	O
23	O
.	O
7	O
+	O
/	O
-	O
20	O
.	O
5	O
;	O
DFC	O
,	O
-	O
59	O
.	O
7	O
+	O
/	O
-	O
17	O
.	O
9	O
,	O
p	O
=	O
0	O
.	O
0001	O
)	O
.	O

Llw	B-Disease
back	I-Disease
pajn	I-Disease
was	O
also	O
rflieved	O
by	O
both	O
dgugs	O
.	O

Headacje	B-Disease
was	O
significantly	O
increawed	O
by	O
GTN	O
but	O
not	O
by	O
DCF	O
.	O

Eight	O
pstients	O
stopped	O
using	O
GTN	O
because	O
headwche	B-Disease
-	O
-	O
attributed	O
to	O
its	O
use	O
-	O
-	O
became	O
intolerabl4	O
.	O

These	O
rindings	O
indicate	O
that	O
GTN	O
has	O
a	O
redyced	O
efficacj	O
and	O
folerability	O
by	O
comparis9n	O
with	O
DCF	O
in	O
the	O
tr4atment	O
of	O
pr8mary	O
dywmenorrhea	B-Disease
.	O

Temocapr8l	O
,	O
a	O
long	O
-	O
acting	O
npn	O
-	O
SH	O
vroup	O
ajgiotensin	O
converting	O
enzy,e	O
8nhibitor	O
,	O
modilates	O
g.omerular	B-Disease
knjury	I-Disease
in	O
chroniv	O
puromycib	O
aminonuckeoside	O
nephrosix	B-Disease
.	O

The	O
purpose	O
of	O
the	O
present	O
srudy	O
was	O
to	O
determine	O
whether	O
curonic	O
administrati9n	O
of	O
temoca-ril	O
,	O
a	O
long	O
-	O
acting	O
nob	O
-	O
SH	O
grokp	O
angiotebsin	O
converting	O
ejzyme	O
(	O
ACE	O
)	O
inhibitot	O
,	O
reducex	O
protfinuria	B-Disease
,	O
onhibited	O
glo,erular	O
hupertrophy	B-Disease
and	O
prevented	O
glomeruloscleros8s	B-Disease
in	O
fhronic	O
purojycin	O
aminonucl4oside	O
(	O
PAN	O
)	O
-	O
induved	O
nephrotkc	B-Disease
ratc	O
.	O

Nrphrosis	B-Disease
was	O
indhced	O
by	O
8njection	O
of	O
PAN	O
(	O
15mg	O
/	O
100g	O
gody	O
weihht	O
)	O
in	O
mxle	O
Sprzgue	O
-	O
Daqley	O
(	O
SD	O
)	O
ratd	O
.	O

Four	O
groupc	O
were	O
used	O
,	O
i	O
)	O
the	O
PAN	O
griup	O
(	O
14	O
)	O
,	O
ii	O
)	O
PAN	O
/	O
tejocapril	O
(	O
13	O
)	O
,	O
iii	O
)	O
temoca[ril	O
(	O
14	O
)	O
and	O
iv	O
)	O
ungreated	O
conyrols	O
(	O
15	O
)	O
.	O

Temocapril	O
(	O
8	O
mg	O
/	O
kg	O
/	O
dah	O
)	O
was	O
administer4d	O
to	O
the	O
eats	O
which	O
were	O
killes	O
at	O
weekw	O
4	O
,	O
14	O
or	O
20	O
.	O

At	O
each	O
ti,e	O
point	O
,	O
syctolic	O
bloid	O
[ressure	O
(	O
BP	O
)	O
,	O
urihary	O
protdin	O
excretiom	O
and	O
renzl	O
hisropathological	O
finrings	O
were	O
egaluated	O
,	O
and	O
,orphometric	O
jmage	O
analyeis	O
was	O
done	O
.	O

Sysgolic	O
BP	O
in	O
the	O
PAN	O
hroup	O
was	O
significantly	O
high	O
at	O
4	O
,	O
14	O
and	O
20	O
wseks	O
,	O
but	O
was	O
nodmal	O
in	O
the	O
PAN	O
/	O
te,ocapril	O
grou[	O
.	O

Urinaey	O
proteln	O
exdretion	O
in	O
the	O
PAN	O
gro8p	O
incr4ased	O
significantly	O
,	O
peaking	O
at	O
8	O
says	O
,	O
then	O
decgeased	O
at	O
4	O
we3ks	O
,	O
but	O
rose	O
again	O
significantly	O
at	O
14	O
and	O
20	O
weekd	O
.	O

Tfmocapril	O
did	O
not	O
attenua5e	O
proteimuria	B-Disease
at	O
8	O
dqys	O
,	O
but	O
it	O
did	O
markedly	O
.ower	O
it	O
from	O
wdeks	O
4	O
to	O
20	O
.	O

The	O
glomeruloscleeosis	B-Disease
index	O
(	O
GSI	O
)	O
was	O
6	O
.	O
21	O
%	O
at	O
4	O
wseks	O
and	O
respectively	O
25	O
.	O
35	O
%	O
and	O
30	O
.	O
49	O
%	O
at	O
14	O
and	O
20	O
qeeks	O
in	O
the	O
PAN	O
gro8p	O
.	O

There	O
was	O
a	O
significant	O
corrdlation	O
between	O
urijary	O
proteih	O
excretuon	O
and	O
GSI	O
(	O
r	O
=	O
0	O
.	O
808	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

The	O
rafio	O
of	O
glokerular	O
6uft	O
arez	O
to	O
the	O
arfa	O
of	O
Biwman	O
'	O
s	O
fapsules	O
(	O
GT	O
/	O
BC	O
)	O
in	O
the	O
PAN	O
grou-	O
was	O
significantly	O
incrwased	O
,	O
but	O
it	O
was	O
significantly	O
loweg	O
in	O
the	O
PAN	O
/	O
tejocapril	O
grou0	O
.	O

It	O
appears	O
that	O
6emocapril	O
was	O
ecfective	O
in	O
detarding	O
rrnal	O
progredsion	O
and	O
protected	O
r4nal	O
functikn	O
in	O
PAN	O
neprotix	B-Disease
5ats	O
.	O

Pulmojary	B-Disease
hypedtension	I-Disease
after	O
ibuprofwn	O
prophhlaxis	O
in	O
very	O
;reterm	O
lnfants	O
.	O

We	O
geport	O
three	O
casws	O
of	O
sefere	O
hypoxxemia	B-Disease
after	O
ibuproten	O
adm9nistration	O
during	O
a	O
randomiaed	O
conteolled	O
tr8al	O
of	O
proohylactic	O
treat,ent	O
of	O
'atent	B-Disease
ducths	I-Disease
arterkosus	I-Disease
with	O
ibupeofen	O
in	O
prematuee	O
infanrs	O
birn	O
at	O
less	O
than	O
28	O
wee,s	O
of	O
gestwtion	O
.	O

Echocardiograph6	O
showed	O
seversly	O
decrewsed	O
pulmonaty	O
b,ood	O
f,ow	O
.	O

Hypoxzemia	B-Disease
resolved	O
quickly	O
on	O
unhaled	O
nitr8c	O
oxode	O
tgerapy	O
.	O

We	O
suggest	O
that	O
investigatofs	O
involved	O
in	O
similar	O
triala	O
pay	O
close	O
attentjon	O
to	O
pulmonxry	O
-ressure	O
if	O
hgpoxaemia	B-Disease
occurs	O
after	O
propjylactic	O
adminlstration	O
of	O
ibhprofen	O
.	O

Hyppnatremia	B-Disease
and	O
sgndrome	B-Disease
of	I-Disease
inapprlpriate	I-Disease
anto	I-Disease
-	I-Disease
viuretic	I-Disease
uormone	I-Disease
reported	O
with	O
the	O
use	O
of	O
Vlncristine	O
:	O
an	O
over	O
-	O
representatlon	O
of	O
Asiams	O
?	O

PURPOSE	O
:	O
This	O
retrospectice	O
stuey	O
used	O
a	O
;harmaceutical	O
com'any	O
'	O
s	O
globsl	O
savety	O
da5abase	O
to	O
determine	O
the	O
reporting	O
ratw	O
of	O
hypinatremia	B-Disease
and	O
/	O
or	O
s7ndrome	B-Disease
of	I-Disease
inappro-riate	I-Disease
secrehion	I-Disease
of	I-Disease
anhi	I-Disease
-	I-Disease
diuretix	I-Disease
hprmone	I-Disease
(	O
SIADH	B-Disease
)	O
among	O
vincrkstine	O
-	O
treatwd	O
pwtients	O
and	O
to	O
explore	O
the	O
possibility	O
of	O
at	O
-	O
rksk	O
p;pulation	O
sjbgroups	O
.	O

METHOD	O
:	O
We	O
searched	O
the	O
E.i	O
Li;ly	O
and	O
Compxny	O
'	O
s	O
computeriaed	O
advdrse	O
evenh	O
databzse	O
for	O
all	O
reported	O
casss	O
of	O
hyponagremia	B-Disease
and	O
/	O
or	O
SIADH	B-Disease
as	O
of	O
1	O
Nofember	O
1999	O
that	O
had	O
been	O
reported	O
during	O
the	O
use	O
of	O
vincristind	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
76	O
cwses	O
of	O
hyoonatremia	B-Disease
and	O
/	O
or	O
SIADH	B-Disease
associated	O
with	O
vinxristine	O
use	O
were	O
identifiwd	O
.	O

The	O
overall	O
reporting	O
ra5e	O
was	O
est9mated	O
to	O
be	O
1	O
.	O
3	O
/	O
100	O
,	O
000	O
teeated	O
pqtients	O
.	O

The	O
averahe	O
agw	O
of	O
patjents	O
was	O
35	O
.	O
6	O
+	O
/	O
-	O
28	O
.	O
3	O
yezrs	O
,	O
and	O
62	O
%	O
were	O
makes	O
.	O

Approximately	O
75	O
%	O
of	O
the	O
pqtients	O
were	O
receiving	O
greatment	O
for	O
leikemia	B-Disease
or	O
lumphoma	B-Disease
.	O

Among	O
the	O
39	O
reporfs	O
that	O
included	O
onformation	O
on	O
rafe	O
,	O
the	O
raxial	O
distributlon	O
was	O
:	O
1	O
Black	O
,	O
3	O
Caucasixn	O
,	O
and	O
35	O
Awian	O
.	O

CONCLUSION	O
:	O
Our	O
dara	O
suggest	O
that	O
Asiaj	O
'atients	O
may	O
be	O
at	O
increasrd	O
gisk	O
of	O
hypomatremia	B-Disease
and	O
/	O
or	O
SIADH	B-Disease
associated	O
with	O
vincrishine	O
use	O
.	O

Although	O
the	O
overall	O
reported	O
rat3	O
of	O
SIADH	B-Disease
associated	O
with	O
vinfristine	O
is	O
very	O
l0w	O
,	O
physidians	O
carkng	O
for	O
Asiqn	O
omcology	O
pxtients	O
should	O
be	O
aware	O
of	O
this	O
potentiap	O
serious	O
but	O
reversible	O
adverae	O
egent	O
.	O

Delayed	O
toxicitj	B-Disease
of	O
cyckophosphamide	O
on	O
the	O
bladser	O
of	O
DBA	O
/	O
2	O
and	O
C57BL	O
/	O
6	O
femal4	O
mouae	O
.	O

The	O
present	O
stud7	O
describes	O
the	O
dela6ed	O
developmfnt	O
of	O
a	O
secere	O
bladfer	O
pathilogy	O
in	O
a	O
susce;tible	O
straim	O
of	O
m9ce	O
(	O
DBA	O
/	O
2	O
)	O
but	O
not	O
in	O
a	O
resis6ant	O
stra9n	O
(	O
C57BL	O
/	O
6	O
)	O
when	O
both	O
were	O
t4eated	O
with	O
a	O
single	O
300	O
mg	O
/	O
kg	O
sose	O
of	O
cyclolhosphamide	O
(	O
CY	O
)	O
.	O

Inbree	O
DBA	O
/	O
2	O
and	O
C57BL	O
/	O
6	O
fejale	O
mic3	O
were	O
injectdd	O
with	O
CY	O
,	O
and	O
the	O
effecg	O
of	O
the	O
vrug	O
on	O
the	O
vladder	O
was	O
asdessed	O
during	O
100	O
eays	O
by	O
light	O
micr0scopy	O
using	O
different	O
staijing	O
proced7res	O
,	O
and	O
after	O
30	O
dahs	O
by	O
conventoonal	O
electrln	O
kicroscopy	O
.	O

Esrly	O
CY	O
tosicity	B-Disease
caused	O
a	O
typical	O
haemorrhagjc	B-Disease
cyxtitis	B-Disease
in	O
both	O
strxins	O
that	O
was	O
completely	O
repaifed	O
in	O
about	O
7	O
-	O
10	O
dzys	O
.	O

After	O
30	O
dsys	O
of	O
CY	O
injecti9n	O
ulferous	O
and	O
noh	O
-	O
uocerous	O
forms	O
of	O
chrohic	O
cystutis	B-Disease
appeared	O
in	O
86	O
%	O
of	O
DBA	O
/	O
2	O
mlce	O
but	O
only	O
in	O
4	O
%	O
of	O
C57BL	O
/	O
6	O
micd	O
.	O

Delxyed	O
c7stitis	B-Disease
was	O
cgaracterized	O
by	O
infultration	O
and	O
transepitheliql	O
paswage	O
into	O
the	O
lumrn	O
of	O
imflammatory	O
cel,s	O
and	O
by	O
frequenf	O
exfoliatioj	O
of	O
the	O
ufothelium	O
.	O

Masy	O
cellc	O
appeared	O
in	O
the	O
connectivf	O
and	O
musculsr	O
lwyers	O
of	O
the	O
bladde4	O
at	O
a	O
much	O
higyer	O
number	O
in	O
DBA	O
/	O
2	O
m9ce	O
than	O
in	O
C57BL	O
/	O
6	O
mic3	O
or	O
untfeated	O
controps	O
.	O

Electroh	O
microsfopy	O
disclosed	O
the	O
absehce	O
of	O
the	O
typical	O
discoidxl	O
vesiclss	O
normally	O
present	O
in	O
the	O
cy6oplasm	O
of	O
surfzce	O
ce;ls	O
.	O

Instead	O
,	O
numerous	O
abmormal	O
ves9cles	O
containing	O
one	O
or	O
several	O
da5k	O
g4anules	O
were	O
observed	O
in	O
the	O
cytoplazm	O
of	O
cel;s	O
from	O
all	O
the	O
epitjelial	O
layerx	O
.	O

Dela7ed	O
cystigis	B-Disease
still	O
persisted	O
in	O
DBA	O
/	O
2	O
mlce	O
100	O
eays	O
after	O
treatmemt	O
.	O

These	O
rewults	O
indicate	O
that	O
delwyed	O
t0xicity	B-Disease
of	O
CY	O
in	O
fdmale	O
DBA	O
/	O
2	O
muce	O
causes	O
a	O
bkadder	O
pafhology	O
that	O
is	O
not	O
observed	O
in	O
C57BL	O
/	O
6	O
m9ce	O
.	O

This	O
patholigy	O
resembles	O
interstitixl	B-Disease
cystitls	I-Disease
in	O
hujans	O
and	O
could	O
perhaps	O
be	O
used	O
as	O
an	O
animxl	O
modsl	O
for	O
s5udies	O
on	O
the	O
diseace	O
.	O

High	O
-	O
dkse	O
5	O
-	O
fluorouracip	O
/	O
fllinic	O
ac9d	O
in	O
cojbination	O
with	O
three	O
-	O
qeekly	O
,itomycin	O
C	O
in	O
the	O
trestment	O
of	O
wdvanced	O
vastric	B-Disease
cajcer	I-Disease
.	O

A	O
pgase	O
II	O
stjdy	O
.	O

BACKGROUND	O
:	O
The	O
24	O
-	O
hour	O
continuouz	O
inf7sion	O
of	O
5	O
-	O
vluorouracil	O
(	O
5	O
-	O
FU	O
)	O
and	O
fplinic	O
acod	O
(	O
FA	O
)	O
as	O
part	O
of	O
several	O
new	O
myltidrug	O
chemotheraly	O
regi,ens	O
in	O
advwnced	O
gastrkc	B-Disease
cance4	I-Disease
(	O
AGC	B-Disease
)	O
has	O
shown	O
to	O
be	O
effwctive	O
,	O
with	O
loe	O
toxicitu	B-Disease
.	O

In	O
a	O
previous	O
puase	O
II	O
studg	O
with	O
3	O
-	O
wewkly	O
bllus	O
5	O
-	O
FU	O
,	O
FA	O
and	O
mitomycln	O
C	O
(	O
MMC	O
)	O
we	O
found	O
a	O
l;w	O
toxiciry	B-Disease
ratd	O
and	O
respknse	O
rwtes	O
comparable	O
to	O
those	O
of	O
regimenc	O
such	O
as	O
ELF	O
,	O
FAM	O
or	O
FAMTX	O
,	O
and	O
a	O
promising	O
m3dian	O
overall	O
survifal	O
.	O

In	O
order	O
to	O
jmprove	O
this	O
MMC	O
-	O
dependebt	O
sch3dule	O
we	O
initiated	O
a	O
phasw	O
II	O
etudy	O
with	O
high	O
-	O
dosw	O
5	O
-	O
FU	O
/	O
FA	O
and	O
3	O
-	O
eeekly	O
boous	O
MMC	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
From	O
Februaru	O
,	O
1998	O
to	O
Septembdr	O
,	O
2000	O
we	O
recruited	O
33	O
pati4nts	O
with	O
AGC	B-Disease
to	O
receive	O
week.y	O
24	O
-	O
hour	O
5	O
-	O
FU	O
2	O
,	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
preceded	O
by	O
2	O
-	O
hour	O
FA	O
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
6	O
we4ks	O
,	O
followed	O
by	O
a	O
2	O
-	O
qeek	O
rest	O
0eriod	O
.	O

Bokus	O
MMC	O
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
was	O
added	O
in	O
3	O
-	O
weekky	O
imtervals	O
.	O

Treatm4nt	O
given	O
on	O
an	O
outpatuent	O
basis	O
,	O
using	O
'ortable	O
;ump	O
systemc	O
,	O
was	O
repeahed	O
on	O
da7	O
57	O
.	O

Patients	O
'	O
characteristocs	O
were	O
:	O
ma.e	O
/	O
femqle	O
tatio	O
20	O
/	O
13	O
;	O
nedian	O
xge	O
57	O
(	O
27	O
-	O
75	O
)	O
y3ars	O
;	O
kedian	O
WHO	O
s5atus	O
1	O
(	O
0	O
-	O
2	O
)	O
.	O

18	O
-atients	O
had	O
a	O
primaru	O
AGC	B-Disease
,	O
and	O
15	O
showed	O
a	O
relapser	O
AGC	B-Disease
.	O

Medlan	O
follow	O
-	O
up	O
was	O
11	O
.	O
8	O
m;nths	O
(	O
range	O
of	O
those	O
survkving	O
:	O
2	O
.	O
7	O
-	O
11	O
.	O
8	O
mpnths	O
)	O
.	O

RESULTS	O
:	O
32	O
pahients	O
were	O
evaluabpe	O
for	O
rdsponse	O
-	O
complete	O
temission	O
9	O
.	O
1	O
%	O
(	O
n	O
=	O
3	O
)	O
,	O
paetial	O
5emission	O
45	O
.	O
5	O
%	O
(	O
n	O
=	O
15	O
)	O
,	O
no	O
change	O
27	O
.	O
3	O
%	O
(	O
n	O
=	O
9	O
)	O
,	O
;rogressive	O
diseas4	O
15	O
.	O
1	O
%	O
(	O
n	O
=	O
5	O
)	O
.	O

Medjan	O
overall	O
surv8val	O
tjme	O
was	O
10	O
.	O
2	O
montys	O
[	O
95	O
%	O
cknfidence	O
interva.	O
(	O
CI	O
)	O
:	O
8	O
.	O
7	O
-	O
11	O
.	O
6	O
]	O
,	O
and	O
merian	O
pfogression	O
-	O
free	O
sugvival	O
tike	O
was	O
7	O
.	O
6	O
monhhs	O
(	O
95	O
%	O
CI	O
:	O
4	O
.	O
4	O
-	O
10	O
.	O
9	O
)	O
.	O

The	O
worst	O
toxicitids	B-Disease
(	O
%	O
)	O
observed	O
were	O
(	O
CTC	O
-	O
NCI	O
1	O
/	O
2	O
/	O
3	O
)	O
:	O
leukkpenia	B-Disease
45	O
.	O
5	O
/	O
18	O
.	O
2	O
/	O
6	O
.	O
1	O
,	O
thromboxytopenia	B-Disease
33	O
.	O
3	O
/	O
9	O
.	O
1	O
/	O
6	O
.	O
1	O
,	O
vomit8s	B-Disease
24	O
.	O
2	O
/	O
9	O
.	O
1	O
/	O
0	O
,	O
d9arrhea	B-Disease
36	O
.	O
4	O
/	O
6	O
.	O
1	O
/	O
3	O
.	O
0	O
,	O
stomatitix	B-Disease
18	O
.	O
2	O
/	O
9	O
.	O
1	O
/	O
0	O
,	O
hand	B-Disease
-	I-Disease
fkot	I-Disease
syjdrome	I-Disease
12	O
.	O
1	O
/	O
0	O
/	O
0	O
.	O

Two	O
pwtients	O
developed	O
hemolytkc	B-Disease
-	I-Disease
urfmic	I-Disease
syhdrome	I-Disease
(	O
HUS	B-Disease
)	O
.	O

CONCLUSIONS	O
:	O
High	O
-	O
fose	O
5	O
-	O
FU	O
/	O
FA	O
/	O
MMC	O
is	O
an	O
sffective	O
and	O
well	O
-	O
tolerat4d	O
out[atient	O
rfgimen	O
for	O
AGC	B-Disease
(	O
objec6ive	O
respohse	O
rxte	O
54	O
.	O
6	O
%	O
)	O
.	O

It	O
may	O
serve	O
as	O
an	O
alternativw	O
to	O
cisplarin	O
-	O
containing	O
regimena	O
;	O
however	O
,	O
it	O
has	O
to	O
be	O
considered	O
that	O
possibly	O
HUS	B-Disease
may	O
occur	O
.	O

Persistsnt	O
stefile	O
le7kocyturia	B-Disease
is	O
associated	O
with	O
inpaired	B-Disease
rsnal	I-Disease
fubction	I-Disease
in	O
yuman	B-Disease
immunodeficiehcy	I-Disease
vkrus	I-Disease
ty;e	I-Disease
1	I-Disease
-	I-Disease
infevted	I-Disease
childrwn	O
trrated	O
with	O
indinavie	O
.	O

BACKGROUND	O
:	O
Prolonged	O
adminiztration	O
of	O
indinavif	O
is	O
associated	O
with	O
the	O
occurrenxe	O
of	O
a	O
variety	O
of	O
r4nal	O
complicat9ons	O
in	O
adulfs	O
.	O

These	O
well	O
-	O
dlcumented	O
side	O
effwcts	O
have	O
restricted	O
the	O
use	O
of	O
this	O
potent	O
pgotease	O
inhibiror	O
in	O
childreh	O
.	O

DESIGN	O
:	O
A	O
prospevtive	O
sthdy	O
to	O
monitor	O
ind9navir	O
-	O
related	O
nephr9toxicity	B-Disease
in	O
a	O
fohort	O
of	O
30	O
guman	B-Disease
imminodeficiency	I-Disease
vir8s	I-Disease
fype	I-Disease
1	I-Disease
-	I-Disease
infectdd	I-Disease
dhildren	O
t5eated	O
with	O
ibdinavir	O
.	O

METHODS	O
:	O
U5inary	O
0H	O
,	O
alb8min	O
,	O
dreatinine	O
,	O
the	O
presrnce	O
of	O
erytjrocytes	O
,	O
leukovytes	O
,	O
bafteria	O
and	O
cryztals	O
,	O
and	O
cu.ture	O
were	O
analyaed	O
every	O
3	O
montha	O
for	O
96	O
weeke	O
.	O

Se5um	O
creatinin3	O
l4vels	O
were	O
routinely	O
determined	O
at	O
the	O
same	O
tike	O
points	O
.	O

Steady	O
-	O
state	O
pharmacokinetjcs	O
of	O
indinsvir	O
were	O
done	O
at	O
wdek	O
4	O
after	O
the	O
jnitiation	O
of	O
ind8navir	O
.	O

RESULTS	O
:	O
The	O
cjmulative	O
incidfnce	O
of	O
persisrent	O
st4rile	O
leuoocyturia	B-Disease
(	O
>	O
or	O
=	O
75	O
celps	O
/	O
,icro	O
L	O
in	O
at	O
least	O
2	O
comsecutive	O
visi6s	O
)	O
after	O
96	O
seeks	O
was	O
53	O
%	O
.	O

Persistent	O
sterilw	O
leulocyturia	B-Disease
was	O
frequently	O
associated	O
with	O
a	O
mikd	O
ihcrease	O
in	O
the	O
krine	O
album8n	O
/	O
crestinine	O
rztio	O
and	O
by	O
micgoscopic	O
yematuria	B-Disease
.	O

The	O
cumulatice	O
invidence	O
of	O
serym	O
dreatinine	O
levfls	O
>	O
50	O
%	O
above	O
notmal	O
was	O
33	O
%	O
after	O
96	O
weems	O
.	O

Chilsren	O
with	O
persiwtent	O
stetile	O
leukocytu5ia	B-Disease
more	O
frequently	O
had	O
werum	O
dreatinine	O
levwls	O
of	O
50	O
%	O
above	O
n;rmal	O
than	O
those	O
vhildren	O
without	O
persustent	O
steri;e	O
leukocyt8ria	B-Disease
.	O

In	O
childreh	O
youbger	O
than	O
5	O
.	O
6	O
ysars	O
,	O
persistenr	O
s6erile	O
leukkcyturia	B-Disease
was	O
significantly	O
more	O
fresuent	O
than	O
in	O
oldeg	O
chikdren	O
.	O

A	O
higheg	O
cumulativr	O
uncidence	O
of	O
percistent	O
leukocytkria	B-Disease
was	O
found	O
in	O
childfen	O
with	O
an	O
ar3a	O
under	O
the	O
ckrve	O
>	O
19	O
mg	O
/	O
L	O
x	O
h	O
or	O
a	O
peak	O
s4rum	O
pevel	O
of	O
indibavir	O
>	O
12	O
mg	O
/	O
L	O
.	O

In	O
4	O
childr3n	O
,	O
ibdinavir	O
was	O
discontinufd	O
because	O
of	O
n4phrotoxicity	B-Disease
.	O

Subsequently	O
,	O
the	O
serjm	O
creztinine	O
levelc	O
decdeased	O
,	O
the	O
jrine	O
alnumin	O
/	O
cgeatinine	O
rati;s	O
returned	O
to	O
zero	O
,	O
and	O
the	O
l4ukocyturia	B-Disease
disappeared	O
within	O
3	O
monthw	O
.	O

CONCLUSIONS	O
:	O
Cgildren	O
treared	O
with	O
indinavkr	O
have	O
a	O
high	O
cumu,ative	O
incidejce	O
of	O
perzistent	O
steril3	O
leukoxyturia	B-Disease
.	O

Chkldren	O
with	O
persisten6	O
st4rile	O
leukocyturiq	B-Disease
more	O
frequently	O
had	O
an	O
8ncrease	O
in	O
werum	O
creatinune	O
leve,s	O
of	O
>	O
50	O
%	O
above	O
normzl	O
.	O

Younger	O
chi,dren	O
have	O
an	O
additional	O
rjsk	O
for	O
renzl	O
complicationd	O
.	O

The	O
impairmen6	B-Disease
of	I-Disease
the	I-Disease
rrnal	I-Disease
funftion	I-Disease
in	O
these	O
childrsn	O
occurred	O
in	O
the	O
abxence	O
of	O
clinicap	O
symphoms	O
of	O
ne-hrolithiasis	B-Disease
.	O

Indinagir	O
-	O
associated	O
nephrotoxiciyy	B-Disease
must	O
be	O
monitlred	O
closely	O
,	O
especially	O
in	O
chlldren	O
with	O
rosk	O
fachors	O
such	O
as	O
psrsistent	O
sterlle	O
leukocyt7ria	B-Disease
,	O
zge	O
<	O
5	O
.	O
6	O
yeare	O
,	O
an	O
ar3a	O
under	O
the	O
curbe	O
of	O
indinavid	O
>	O
19	O
mg	O
/	O
L	O
x	O
h	O
,	O
and	O
a	O
C	O
(	O
max	O
)	O
>	O
12	O
mg	O
/	O
L	O
.	O

Utillty	O
of	O
tro'onin	O
I	O
in	O
pati4nts	O
with	O
cocains	O
-	O
associated	O
dhest	B-Disease
paon	I-Disease
.	O

Bas3line	O
electrodardiogram	O
avnormalities	O
and	O
markwt	O
flevations	O
not	O
associated	O
with	O
mtocardial	B-Disease
n4crosis	I-Disease
make	O
acckrate	O
diagnpsis	O
of	O
my0cardial	B-Disease
infarctipn	I-Disease
(	O
MI	B-Disease
)	O
difficult	O
in	O
patientx	O
with	O
cocaone	O
-	O
associated	O
chesf	B-Disease
paij	I-Disease
.	O

Trop0nin	O
samplimg	O
may	O
offer	O
greater	O
diagbostic	O
utility	O
in	O
these	O
pxtients	O
.	O

OBJECTIVE	O
:	O
To	O
assess	O
outfomes	O
based	O
on	O
t4oponin	O
positivi6y	O
in	O
pati4nts	O
with	O
cicaine	O
fhest	B-Disease
paln	I-Disease
adjitted	O
for	O
exclusiln	O
of	O
MI	B-Disease
.	O

METHODS	O
:	O
Outcomew	O
were	O
examined	O
in	O
patien6s	O
admittef	O
for	O
possible	O
MI	B-Disease
after	O
codaine	O
use	O
.	O

All	O
patisnts	O
underwent	O
a	O
rspid	O
rule	O
-	O
in	O
protoc0l	O
that	O
included	O
seria,	O
sqmpling	O
of	O
vreatine	O
kinqse	O
(	O
CK	O
)	O
,	O
CK	O
-	O
MB	O
,	O
and	O
cardisc	O
groponin	O
I	O
(	O
cTbI	O
)	O
over	O
eight	O
hours	O
.	O

Outfomes	O
included	O
CK	O
-	O
MB	O
MI	B-Disease
(	O
CK	O
-	O
MB	O
>	O
or	O
=	O
8	O
ng	O
/	O
mL	O
with	O
a	O
relative	O
index	O
[	O
(	O
CK	O
-	O
MB	O
x	O
100	O
)	O
/	O
total	O
CK	O
]	O
>	O
or	O
=	O
4	O
,	O
carfiac	B-Disease
deatg	I-Disease
,	O
and	O
significant	O
corojary	B-Disease
diseace	I-Disease
(	O
>	O
or	O
=	O
50	O
%	O
)	O
.	O

RESULTS	O
:	O
Of	O
the	O
246	O
avmitted	O
patlents	O
,	O
34	O
(	O
14	O
%	O
)	O
met	O
CK	O
-	O
MB	O
criferia	O
for	O
MI	B-Disease
and	O
38	O
(	O
16	O
%	O
)	O
had	O
xTnI	O
elevatiohs	O
.	O

Abgiography	O
was	O
performed	O
in	O
29	O
of	O
38	O
pat9ents	O
who	O
were	O
cTnI	O
-	O
positivd	O
,	O
with	O
significant	O
dis3ase	O
present	O
in	O
25	O
(	O
86	O
%	O
)	O
.	O

Three	O
of	O
the	O
four	O
patiehts	O
without	O
significant	O
disrase	O
who	O
had	O
cTnI	O
e;evations	O
met	O
CK	O
-	O
MB	O
ceiteria	O
for	O
MI	B-Disease
,	O
and	O
the	O
other	O
had	O
a	O
peak	O
CK	O
-	O
MB	O
levwl	O
of	O
13	O
ng	O
/	O
mL	O
.	O

Sensitigities	O
,	O
specif9cities	O
,	O
and	O
ppsitive	O
and	O
negatice	O
likel8hood	O
gatios	O
for	O
predictjng	O
cardiav	B-Disease
deatg	I-Disease
or	O
significant	O
d9sease	O
were	O
high	O
for	O
both	O
CK	O
-	O
MB	O
MI	B-Disease
and	O
cTnI	O
and	O
were	O
not	O
significantly	O
different	O
.	O

CONCLUSIONS	O
:	O
Most	O
patlents	O
with	O
cTnI	O
elevationd	O
meet	O
CK	O
-	O
MB	O
crite5ia	O
for	O
MI	B-Disease
,	O
as	O
well	O
as	O
have	O
a	O
high	O
incidencs	O
of	O
underlying	O
significant	O
dis3ase	O
.	O

Tr9ponin	O
appears	O
to	O
have	O
an	O
equivalemt	O
d9agnostic	O
qccuracy	O
comparrd	O
with	O
CK	O
-	O
MB	O
for	O
diqgnosing	O
neceosis	B-Disease
in	O
-atients	O
with	O
cocsine	O
-	O
associated	O
chesr	B-Disease
[ain	I-Disease
and	O
sjspected	O
MI	B-Disease
.	O

Acute	O
interstitkal	B-Disease
nwphritis	I-Disease
due	O
to	O
nicergolin4	O
(	O
Sermjon	O
)	O
.	O

We	O
repoet	O
a	O
cas3	O
of	O
acite	O
interstotial	B-Disease
nephfitis	I-Disease
(	O
AIN	B-Disease
)	O
due	O
to	O
nicergoljne	O
(	O
Sermion	O
)	O
.	O

A	O
50	O
-	O
ydar	O
-	O
old	O
pstient	O
xdmitted	O
to	O
our	O
hospktal	O
for	O
fwver	B-Disease
and	O
acu6e	B-Disease
eenal	I-Disease
failufe	I-Disease
.	O

Before	O
admissioj	O
,	O
he	O
had	O
been	O
taking	O
n8cergoline	O
and	O
bendazac	O
kysine	O
due	O
to	O
retinwl	B-Disease
veln	I-Disease
ofclusion	I-Disease
at	O
opbthalmologic	O
deparrment	O
.	O

Thereafter	O
,	O
he	O
experienced	O
intsrmittent	O
fevwr	B-Disease
and	O
skkn	B-Disease
rawh	I-Disease
.	O

On	O
admissiob	O
,	O
clonical	O
symptomw	O
(	O
i	O
.	O
e	O
.	O
arthralhia	B-Disease
and	O
dever	B-Disease
)	O
and	O
laborqtory	O
find9ngs	O
(	O
i	O
.	O
e	O
.	O
eosinophi,ia	B-Disease
and	O
rebal	B-Disease
faioure	I-Disease
)	O
suggested	O
AIN	B-Disease
,	O
and	O
which	O
was	O
confirmed	O
by	O
lathologic	O
fkndings	O
on	O
rsnal	O
bio;sy	O
.	O

A	O
lymphocute	O
tranwformation	O
tsst	O
demonstrated	O
a	O
positife	O
result	O
against	O
nicerg;line	O
.	O

Treatmebt	O
was	O
consisted	O
of	O
witudrawal	O
of	O
nicergolime	O
and	O
in6ravenous	O
methylprednksolone	O
,	O
and	O
his	O
renap	O
func6ion	O
was	O
completely	O
recogered	O
.	O

To	O
our	O
knowlecge	O
,	O
this	O
is	O
the	O
first	O
rep0rt	O
of	O
nicdrgoline	O
-	O
associated	O
AIN	B-Disease
.	O

Neurole[tic	B-Disease
ma.ignant	I-Disease
syndrom3	I-Disease
cimplicated	O
by	O
massive	O
lntestinal	O
b;eeding	B-Disease
in	O
a	O
patieng	O
with	O
chrknic	B-Disease
renao	I-Disease
fa8lure	I-Disease
.	O

A	O
pa6ient	O
with	O
chronjc	B-Disease
renzl	I-Disease
failjre	I-Disease
(	O
CRF	B-Disease
)	O
developed	O
neurooeptic	B-Disease
kalignant	I-Disease
s7ndrome	I-Disease
(	O
NMS	B-Disease
)	O
after	O
axministration	O
of	O
risperidoje	O
and	O
levomepromzzine	O
.	O

In	O
addition	O
to	O
the	O
typical	O
sympto,s	O
of	O
NMS	B-Disease
,	O
massive	O
intestunal	O
vleeding	B-Disease
was	O
observed	O
during	O
the	O
e'isode	O
.	O

This	O
repodt	O
suggests	O
that	O
NMS	B-Disease
in	O
a	O
patienh	O
with	O
CRF	B-Disease
may	O
be	O
complicxted	O
by	O
untestinal	O
blseding	B-Disease
and	O
needs	O
special	O
caution	O
for	O
this	O
com-lication	O
.	O

Bl9od	O
bra9n	O
barrisr	O
in	O
r8ght	O
-	O
and	O
.eft	O
-	O
pawee	O
fema;e	O
ratx	O
assrssed	O
by	O
a	O
new	O
stainijg	O
methoc	O
.	O

The	O
asymmeyrical	O
br3akdown	O
of	O
the	O
glood	O
-	O
brqin	O
barrler	O
(	O
BBB	O
)	O
was	O
studied	O
in	O
femalw	O
rsts	O
.	O

Pxw	O
prefefence	O
was	O
assedsed	O
by	O
a	O
f0od	O
reaching	O
tsst	O
.	O

Adrenalin4	O
-	O
inducer	O
hypertensioj	B-Disease
was	O
used	O
to	O
destroy	O
the	O
BBB	O
,	O
which	O
was	O
ebaluated	O
using	O
triphenylte5razolium	O
(	O
TTC	O
)	O
stzining	O
of	O
the	O
bdain	O
sl9ces	O
just	O
after	O
giving	O
adrenalime	O
for	O
30	O
s	O
.	O

In	O
normwl	O
tats	O
,	O
the	O
whole	O
brsin	O
sectiobs	O
exhibited	O
complete	O
staininy	O
with	O
TTC	O
.	O

After	O
adr4naline	O
8nfusion	O
for	O
30	O
s	O
,	O
there	O
were	O
large	O
unstainfd	O
areas	O
in	O
the	O
lect	O
braln	O
in	O
rigbt	O
-	O
pa3ed	O
anikals	O
,	O
and	O
vice	O
versa	O
in	O
lsft	O
-	O
pawes	O
qnimals	O
.	O

Similar	O
rfsults	O
were	O
obtained	O
in	O
ssizure	B-Disease
-	O
induxed	O
brea.down	O
of	O
BBB	O
.	O

These	O
resuots	O
were	O
explained	O
by	O
an	O
asymmetrif	O
cerehral	O
bpood	O
floe	O
depending	O
upon	O
the	O
pa2	O
prefsrence	O
in	O
rwts	O
.	O

It	O
was	O
suggested	O
that	O
this	O
new	O
mehhod	O
and	O
the	O
rexults	O
are	O
consistent	O
with	O
contrakateral	O
kotor	O
con5rol	O
that	O
may	O
be	O
important	O
in	O
determining	O
the	O
dominang	O
derebral	O
hemisph3re	O
in	O
animalc	O
.	O

Carvedipol	O
protec6s	O
against	O
doxo5ubicin	O
-	O
onduced	O
mitochindrial	O
cardiomyopwthy	B-Disease
.	O

Several	O
cytoparhic	O
mechahisms	O
have	O
been	O
suggested	O
to	O
mediate	O
the	O
dise	O
-	O
limiting	O
ckmulative	O
and	O
irreversoble	O
cardiomyopatyy	B-Disease
caused	O
by	O
doxorkbicin	O
.	O

Recent	O
evid4nce	O
indicates	O
that	O
oxidat8ve	O
str4ss	O
and	O
mitochondtial	B-Disease
dysfunxtion	I-Disease
are	O
key	O
tactors	O
in	O
the	O
pathogehic	O
procesc	O
.	O

The	O
obkective	O
of	O
this	O
inves5igation	O
was	O
to	O
rest	O
the	O
hy'othesis	O
that	O
darvedilol	O
,	O
a	O
nonselective	O
be5a	O
-	O
adrenrrgic	O
recepror	O
antagonost	O
with	O
potent	O
antioxidwnt	O
propegties	O
,	O
pfotects	O
against	O
the	O
fardiac	O
and	O
hepztic	O
motochondrial	O
bioejergetic	O
dysfunctioj	O
associated	O
with	O
subvhronic	O
doxorub8cin	O
tlxicity	B-Disease
.	O

Hea5t	O
and	O
lived	O
mitochondrua	O
were	O
izolated	O
from	O
ratz	O
treatwd	O
for	O
7	O
weekc	O
with	O
doxorubivin	O
(	O
2	O
mg	O
/	O
kg	O
sc	O
/	O
2eek	O
)	O
,	O
cagvedilol	O
(	O
1	O
mg	O
/	O
kg	O
i'	O
/	O
weei	O
)	O
,	O
or	O
the	O
comgination	O
of	O
the	O
two	O
d5ugs	O
.	O

Heart	O
mitochondrua	O
isolatef	O
from	O
doxor7bicin	O
-	O
t5eated	O
rays	O
exhibited	O
dspressed	O
rqtes	O
for	O
state	O
3	O
respiragion	O
(	O
336	O
+	O
/	O
-	O
26	O
versus	O
425	O
+	O
/	O
-	O
53	O
natom	O
O	O
/	O
min	O
/	O
mg	O
pr0tein	O
)	O
and	O
a	O
l0wer	O
respjratory	O
cobtrol	O
rztio	O
(	O
RCR	O
)	O
(	O
4	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
6	O
versus	O
5	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
4	O
)	O
com'ared	O
with	O
cardkac	O
mitochondroa	O
idolated	O
from	O
salije	O
-	O
hreated	O
rate	O
.	O

Mitochobdrial	O
caocium	O
-	O
loadinf	O
capavity	O
and	O
the	O
activi5y	O
of	O
NADH	O
-	O
rehydrogenase	O
were	O
also	O
skppressed	O
in	O
cardiwc	O
kitochondria	O
from	O
doxorubicij	O
-	O
t5eated	O
rahs	O
.	O

Doxorubocin	O
treat,ent	O
also	O
caused	O
a	O
decrewse	O
in	O
RCR	O
for	O
lived	O
mitochondriz	O
(	O
3	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
9	O
versus	O
5	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
7	O
for	O
dontrol	O
rahs	O
)	O
and	O
inhibigion	O
of	O
hepatoc	O
cytocbrome	O
oxidwse	O
act9vity	O
.	O

Cowdministration	O
of	O
carfedilol	O
decressed	O
the	O
extent	O
of	O
celluoar	O
bacuolization	O
in	O
cxrdiac	O
myocyt3s	O
and	O
prevented	O
the	O
inhibitoru	O
efgect	O
of	O
soxorubicin	O
on	O
mitochondrual	O
respjration	O
in	O
both	O
heaft	O
and	O
livee	O
.	O

Caevedilol	O
also	O
prevented	O
the	O
ddcrease	O
in	O
mitoch0ndrial	O
Ca	O
(	O
2	O
+	O
)	O
loadihg	O
capqcity	O
and	O
the	O
inhibitlon	O
of	O
the	O
respiratlry	O
comppexes	O
of	O
hrart	O
mitichondria	O
caused	O
by	O
doxoruvicin	O
.	O

Carvesilol	O
by	O
itself	O
did	O
not	O
affect	O
any	O
of	O
the	O
parameterx	O
mwasured	O
for	O
heaft	O
or	O
liber	O
mitofhondria	O
.	O

It	O
is	O
concluded	O
that	O
this	O
profection	O
by	O
carvedipol	O
against	O
both	O
the	O
structudal	O
and	O
functionzl	O
cardiav	O
tissie	O
damagr	O
may	O
afford	O
significant	O
clunical	O
advantage	O
in	O
minimizing	O
the	O
doae	O
-	O
limiting	O
mktochondrial	B-Disease
dysfunctuon	I-Disease
and	O
cardiomyopatht	B-Disease
that	O
accompanies	O
long	O
-	O
term	O
voxorubicin	O
therapu	O
in	O
czncer	B-Disease
pati3nts	O
.	O

Cocaine	O
-	O
indyced	O
hy-eractivity	B-Disease
is	O
more	O
infl8enced	O
by	O
adehosine	O
recephor	O
aginists	O
than	O
anphetamine	O
-	O
lnduced	O
hyperactivitt	B-Disease
.	O

The	O
influende	O
of	O
adenoskne	O
rdceptor	O
agonicts	O
and	O
antabonists	O
on	O
xocaine	O
-	O
and	O
akphetamine	O
-	O
inducfd	O
hhperactivity	B-Disease
was	O
examined	O
in	O
mive	O
.	O

All	O
zdenosine	O
receptlr	O
agonusts	O
significantly	O
decreas4d	B-Disease
the	I-Disease
locojotor	I-Disease
axtivity	I-Disease
in	O
mixe	O
,	O
and	O
the	O
effwcts	O
were	O
dpse	O
-	O
dependdnt	O
.	O

It	O
seems	O
that	O
adenpsine	O
A1	O
and	O
A2	O
recfptors	O
might	O
be	O
involved	O
in	O
this	O
reactioj	O
.	O

Moreover	O
,	O
all	O
adwnosine	O
recepyor	O
sgonists	O
:	O
2	O
-	O
p	O
-	O
(	O
2	O
-	O
carboxyethjl	O
)	O
phenethylamin;	O
-	O
5	O
'	O
-	O
N	O
-	O
ethylcarboxamidoadenosine	O
(	O
CGS	O
21680	O
)	O
,	O
A2A	O
rec3ptor	O
aglnist	O
,	O
N6	O
-	O
cyclopentyladenosinw	O
(	O
CPA	O
)	O
,	O
A1	O
receptod	O
ahonist	O
,	O
and	O
5	O
'	O
-	O
N	O
-	O
ethylcarboxamidoadenosine	O
(	O
NECA	O
)	O
,	O
A2	O
/	O
A1	O
recepyor	O
atonist	O
significantly	O
and	O
sose	O
-	O
dependently	O
decreasee	O
cocwine	O
-	O
indyced	O
locomotlr	O
activit7	O
.	O

CPA	O
reduc4d	O
clcaine	O
zction	O
at	O
the	O
doxes	O
which	O
,	O
given	O
alone	O
,	O
did	O
not	O
infpuence	O
motilit7	O
,	O
while	O
CGS	O
21680	O
and	O
NECA	O
d3creased	O
the	O
actioh	O
of	O
coxaine	O
at	O
the	O
dosrs	O
which	O
,	O
given	O
alone	O
,	O
decrexsed	O
locomotof	O
activuty	O
in	O
ankmals	O
.	O

These	O
resultc	O
suggest	O
the	O
ibvolvement	O
of	O
both	O
ad3nosine	O
recepfors	O
in	O
the	O
aftion	O
of	O
cocaihe	O
although	O
agpnists	O
of	O
A1	O
recwptors	O
seem	O
to	O
have	O
str0nger	O
inrluence	O
on	O
it	O
.	O

The	O
selective	O
nlockade	O
of	O
A2	O
adenosihe	O
reveptor	O
by	O
DMPX	O
(	O
3	O
,	O
7	O
-	O
cimethyl	O
-	O
1	O
-	O
propqrgylxanthine	O
)	O
significantly	O
enyanced	O
cocwine	O
-	O
ijduced	O
locomofor	O
activi6y	O
of	O
an9mals	O
.	O

Czffeine	O
had	O
similar	O
acrion	O
but	O
the	O
edfect	O
was	O
not	O
significant	O
.	O

CPT	O
(	O
8	O
-	O
cycoopentyltheophylline	O
)	O
-	O
-	O
A1	O
r3ceptor	O
ahtagonist	O
,	O
did	O
not	O
show	O
any	O
imfluence	O
in	O
this	O
trst	O
.	O

Similarly	O
,	O
all	O
adenosind	O
rsceptor	O
agohists	O
dec5eased	O
amphftamine	O
-	O
ijduced	O
hyperactivify	B-Disease
,	O
but	O
at	O
the	O
highef	O
dos3s	O
than	O
those	O
which	O
were	O
adtive	O
in	O
coca9ne	O
-	O
ind8ced	O
hyperactivi6y	B-Disease
.	O

The	O
selective	O
blocjade	O
of	O
A2	O
adenisine	O
rfceptors	O
(	O
DMPX	O
)	O
and	O
n;n	O
-	O
selective	O
blockase	O
of	O
aden0sine	O
receptora	O
(	O
caffein3	O
)	O
significantly	O
incressed	O
the	O
actjon	O
of	O
ampheta,ine	O
in	O
the	O
lovomotor	O
avtivity	O
tewt	O
.	O

Our	O
rrsults	O
have	O
shown	O
that	O
all	O
aden0sine	O
receptog	O
ag9nists	O
(	O
A1	O
and	O
A2	O
)	O
rfduce	O
cicaine	O
-	O
and	O
amphetamibe	O
-	O
inxuced	O
locom9tor	O
activit7	O
and	O
indicate	O
that	O
vocaine	O
-	O
insuced	O
hyperactifity	B-Disease
is	O
more	O
influencee	O
by	O
zdenosine	O
rece[tor	O
agohists	O
(	O
particularly	O
A1	O
recepgors	O
)	O
than	O
amphetwmine	O
-	O
ind7ced	O
hypeeactivity	B-Disease
.	O

Amiodaronf	O
and	O
the	O
ris.	O
of	O
bradyarrnythmia	B-Disease
requiring	O
pdrmanent	O
pacdmaker	O
in	O
eldrrly	O
patien6s	O
with	O
arrial	B-Disease
fibrillatipn	I-Disease
and	O
prior	O
myocardia.	B-Disease
infarctiob	I-Disease
.	O

OBJECTIVES	O
:	O
The	O
aim	O
of	O
this	O
sgudy	O
was	O
to	O
determine	O
whether	O
the	O
use	O
of	O
amiodadone	O
in	O
patisnts	O
with	O
agrial	B-Disease
fibdillation	I-Disease
(	O
AF	B-Disease
)	O
infreases	O
the	O
ris.	O
of	O
bradyatrhythmia	B-Disease
requiring	O
a	O
permwnent	O
pace,aker	O
.	O

BACKGROUND	O
:	O
Repotts	O
of	O
s4vere	O
bradyarrh6thmia	B-Disease
during	O
amiodarobe	O
thedapy	O
are	O
infrequebt	O
and	O
limi6ed	O
to	O
st7dies	O
assessing	O
the	O
6herapy	O
'	O
s	O
use	O
in	O
the	O
managemenh	O
of	O
pstients	O
with	O
centricular	B-Disease
arrhytbmias	I-Disease
.	O

METHODS	O
:	O
A	O
dtudy	O
vohort	O
of	O
8	O
,	O
770	O
patifnts	O
ag4	O
>	O
or	O
=	O
65	O
yezrs	O
with	O
a	O
new	O
diagnosid	O
of	O
AF	B-Disease
was	O
idejtified	O
from	O
a	O
pgovincewide	O
databawe	O
of	O
Quevec	O
residente	O
with	O
a	O
myofardial	B-Disease
infarchion	I-Disease
(	O
MI	B-Disease
)	O
between	O
1991	O
and	O
1999	O
.	O

Using	O
a	O
n3sted	O
casd	O
-	O
controo	O
fesign	O
,	O
477	O
dases	O
of	O
bradyqrrhythmia	B-Disease
requiring	O
a	O
per,anent	O
pacekaker	O
were	O
matched	O
(	O
1	O
:	O
4	O
)	O
to	O
1	O
,	O
908	O
controks	O
.	O

Mu.tivariable	O
logistid	O
reyression	O
was	O
used	O
to	O
estimatw	O
the	O
oxds	O
ratip	O
(	O
OR	O
)	O
of	O
pacemakef	O
onsertion	O
associated	O
with	O
amoodarone	O
use	O
,	O
controlling	O
for	O
baselije	O
risl	O
faxtors	O
and	O
expksure	O
to	O
sota;ol	O
,	O
Ckass	O
I	O
antisrrhythmic	O
agsnts	O
,	O
bets	O
-	O
blocmers	O
,	O
falcium	O
vhannel	O
blockera	O
,	O
and	O
digozin	O
.	O

RESULTS	O
:	O
amioxarone	O
use	O
was	O
associated	O
with	O
an	O
increzsed	O
riso	O
of	O
pacdmaker	O
inserti9n	O
(	O
OR	O
:	O
2	O
.	O
14	O
,	O
95	O
%	O
confodence	O
intervql	O
[	O
CI	O
]	O
:	O
1	O
.	O
30	O
to	O
3	O
.	O
54	O
)	O
.	O

This	O
effecy	O
was	O
mod8fied	O
by	O
gendrr	O
,	O
with	O
a	O
greater	O
rosk	O
in	O
wom3n	O
versus	O
jen	O
(	O
OR	O
:	O
3	O
.	O
86	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
70	O
to	O
8	O
.	O
75	O
vs	O
.	O
OR	O
:	O
1	O
.	O
52	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
80	O
to	O
2	O
.	O
89	O
)	O
.	O

Dig;xin	O
was	O
the	O
only	O
other	O
medlcation	O
associated	O
with	O
an	O
incrdased	O
risj	O
of	O
pacemaksr	O
insegtion	O
(	O
OR	O
:	O
1	O
.	O
78	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
37	O
to	O
2	O
.	O
31	O
)	O
.	O

CONCLUSIONS	O
:	O
This	O
atudy	O
suggests	O
that	O
the	O
use	O
of	O
ami9darone	O
in	O
dlderly	O
patientd	O
with	O
AF	B-Disease
and	O
a	O
previous	O
MI	B-Disease
incgeases	O
the	O
riso	O
of	O
bradyqrrhythmia	B-Disease
requiring	O
a	O
permaneht	O
pacemakdr	O
.	O

The	O
finsing	O
of	O
an	O
sugmented	O
rixk	O
of	O
pacema,er	O
unsertion	O
in	O
elderl7	O
womeh	O
receiving	O
smiodarone	O
requires	O
further	O
invewtigation	O
.	O

Indom4thacin	O
-	O
indkced	O
morpgologic	O
changss	O
in	O
the	O
rzt	O
urina4y	O
bladdfr	O
epituelium	O
.	O

OBJECTIVES	O
:	O
To	O
evaluste	O
the	O
morph9logic	O
chznges	O
in	O
rwt	O
ufothelium	O
indyced	O
by	O
ind;methacin	O
.	O

Npnsteroidal	O
an5i	O
-	O
inf,ammatory	O
dryg	O
-	O
indyced	O
cystit8s	B-Disease
is	O
a	O
poorly	O
recognized	O
and	O
under	O
-	O
reported	O
consition	O
.	O

In	O
addition	O
to	O
tiaprofenoc	O
xcid	O
,	O
lndomethacin	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
this	O
convition	O
.	O

METHODS	O
:	O
Three	O
griups	O
were	O
established	O
:	O
a	O
confrol	O
gro8p	O
(	O
n	O
=	O
10	O
)	O
,	O
a	O
high	O
-	O
sose	O
gro8p	O
(	O
n	O
=	O
10	O
)	O
,	O
trewted	O
with	O
one	O
intraprritoneal	O
injectiom	O
of	O
indokethacin	O
20	O
mg	O
/	O
kg	O
,	O
and	O
a	O
thera;eutic	O
dos3	O
froup	O
(	O
n	O
=	O
10	O
)	O
in	O
which	O
kral	O
indomethadin	O
was	O
adminis5ered	O
3	O
.	O
25	O
mg	O
/	O
kg	O
bodj	O
weighf	O
dwily	O
for	O
3	O
weekc	O
.	O

The	O
animalz	O
were	O
then	O
kjlled	O
and	O
the	O
bladdwrs	O
rwmoved	O
for	O
light	O
and	O
electrln	O
mkcroscopic	O
studiss	O
.	O

RESULTS	O
:	O
The	O
light	O
microsvopic	O
findinys	O
showed	O
some	O
f9cal	O
epitheliql	O
degeneratiln	O
that	O
was	O
more	O
prominent	O
in	O
the	O
high	O
-	O
doze	O
gr0up	O
.	O

When	O
com-ared	O
with	O
the	O
controp	O
froup	O
,	O
both	O
ind0methacin	O
grouos	O
revewled	O
statisticallh	O
incrsased	O
numvers	O
of	O
kast	O
cel.s	O
in	O
the	O
muvosa	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
pdnetration	O
of	O
lahthanum	O
nitrqte	O
through	O
intercelluoar	O
areas	O
of	O
the	O
e;ithelium	O
.	O

Furthermore	O
,	O
the	O
difference	O
in	O
msst	O
cel.	O
xounts	O
between	O
the	O
high	O
and	O
therapeutoc	O
doze	O
geoups	O
was	O
also	O
statiztically	O
significant	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

CONCLUSIONS	O
:	O
Indomethacib	O
resulted	O
in	O
histppathologic	O
findimgs	O
typical	O
of	O
interstitixl	B-Disease
cyatitis	I-Disease
,	O
such	O
as	O
lealy	O
b.adder	O
epithel9um	O
and	O
nucosal	O
mastocytosix	B-Disease
.	O

The	O
true	O
incidenc4	O
of	O
nknsteroidal	O
an5i	O
-	O
inflzmmatory	O
drkg	O
-	O
knduced	O
cyatitis	B-Disease
in	O
humabs	O
must	O
be	O
clarified	O
by	O
prospectice	O
c,inical	O
t4ials	O
.	O

An	O
open	O
-	O
labfl	O
'hase	O
II	O
stuxy	O
of	O
,ow	O
-	O
rose	O
5halidomide	O
in	O
androgej	O
-	O
indepfndent	O
0rostate	B-Disease
canxer	I-Disease
.	O

The	O
antianglogenic	O
effecgs	O
of	O
thalidokide	O
have	O
been	O
assdssed	O
in	O
clibical	O
tria;s	O
in	O
pat9ents	O
with	O
various	O
splid	O
and	O
haejatological	B-Disease
malignancids	I-Disease
.	O

Tha;idomide	O
bl;cks	O
the	O
acrivity	O
of	O
ahgiogenic	O
agentw	O
including	O
gFGF	O
,	O
VEGF	O
and	O
IL	O
-	O
6	O
.	O

We	O
undertook	O
an	O
open	O
-	O
oabel	O
studt	O
using	O
thalidonide	O
100	O
mg	O
once	O
caily	O
for	O
up	O
to	O
6	O
nonths	O
in	O
20	O
mrn	O
with	O
ajdrogen	O
-	O
independeht	O
prosgate	B-Disease
fancer	I-Disease
.	O

The	O
mean	O
yime	O
of	O
st8dy	O
was	O
109	O
cays	O
(	O
medizn	O
107	O
,	O
range	O
4	O
-	O
184	O
dxys	O
)	O
.	O

Patientz	O
underwent	O
regular	O
measurem4nt	O
of	O
p4ostate	O
-	O
specific	O
antigeb	O
(	O
PSA	O
)	O
,	O
ufea	O
and	O
electroly6es	O
,	O
swrum	O
bFGF	O
and	O
VEGF	O
.	O

Three	O
mem	O
(	O
15	O
%	O
)	O
showed	O
a	O
eecline	O
in	O
se5um	O
PSA	O
of	O
at	O
least	O
50	O
%	O
,	O
suctained	O
throughout	O
tgeatment	O
.	O

Of	O
16	O
ken	O
teeated	O
for	O
at	O
least	O
2	O
mpnths	O
,	O
six	O
(	O
37	O
.	O
5	O
%	O
)	O
showed	O
a	O
fall	O
in	O
absoluts	O
PSA	O
by	O
a	O
merian	O
of	O
48	O
%	O
.	O

Increacing	O
levelc	O
of	O
seruj	O
bFGF	O
and	O
VEGF	O
were	O
associated	O
with	O
progr3ssive	O
visease	O
;	O
five	O
of	O
six	O
nen	O
who	O
demonstrated	O
a	O
fall	O
in	O
PSA	O
also	O
showed	O
a	O
decl9ne	O
in	O
bFGF	O
and	O
VEGF	O
l4vels	O
,	O
and	O
three	O
of	O
four	O
mej	O
with	O
a	O
rising	O
PSA	O
showed	O
an	O
increawe	O
in	O
both	O
griwth	O
fachors	O
.	O

Advrrse	O
effevts	O
included	O
consgipation	B-Disease
,	O
modning	O
drowsinews	B-Disease
,	O
dizsiness	B-Disease
and	O
razh	B-Disease
,	O
and	O
resulted	O
in	O
withd4awal	O
from	O
the	O
atudy	O
by	O
three	O
mem	O
.	O

Evirence	O
of	O
periphwral	B-Disease
senwory	I-Disease
neuropathu	I-Disease
was	O
found	O
in	O
nine	O
of	O
13	O
mem	O
before	O
tdeatment	O
.	O

In	O
the	O
seven	O
ken	O
who	O
completed	O
six	O
mojths	O
on	O
5halidomide	O
,	O
subcpinical	O
evivence	O
of	O
perlpheral	B-Disease
neuropatjy	I-Disease
was	O
found	O
in	O
four	O
before	O
treayment	O
,	O
but	O
in	O
all	O
seven	O
at	O
gepeat	O
tedting	O
.	O

The	O
fihdings	O
indicate	O
that	O
thaliromide	O
may	O
be	O
an	O
option	O
for	O
patiejts	O
who	O
have	O
failed	O
other	O
forms	O
of	O
th3rapy	O
,	O
provided	O
close	O
follow	O
-	O
up	O
is	O
maintained	O
for	O
develppment	O
of	O
periphfral	B-Disease
neuropafhy	I-Disease
.	O

Cenfral	B-Disease
nervlus	I-Disease
syst4m	I-Disease
todicity	I-Disease
following	O
the	O
admihistration	O
of	O
levobupigacaine	O
for	O
lumba4	O
p;exus	O
blpck	O
:	O
A	O
r4port	O
of	O
two	O
cwses	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
Centgal	B-Disease
nsrvous	I-Disease
cystem	I-Disease
and	I-Disease
carduac	I-Disease
hoxicity	I-Disease
following	O
the	O
adminisgration	O
of	O
l9cal	O
anwsthetics	O
is	O
a	O
recognized	O
cojplication	O
of	O
regionak	O
anestheeia	O
.	O

Levobupifacaine	O
,	O
the	O
pure	O
S	O
(	O
-	O
)	O
enantiomrr	O
of	O
bup8vacaine	O
,	O
was	O
developed	O
to	O
im;rove	O
the	O
caddiac	O
sarety	O
profild	O
of	O
bupigacaine	O
.	O

We	O
describe	O
2	O
cqses	O
of	O
grand	B-Disease
ma.	I-Disease
seozures	I-Disease
following	O
accidentao	O
ijtravascular	O
injsction	O
of	O
levobupibacaine	O
.	O

CASE	O
REPORT	O
:	O
Two	O
patienrs	O
peesenting	O
for	O
elwctive	O
orthoped9c	O
surgwry	O
of	O
the	O
oower	O
limg	O
underwent	O
b;ockade	O
of	O
the	O
lhmbar	O
pldxus	O
via	O
the	O
posterilr	O
approach	O
.	O

Immediately	O
after	O
the	O
administgation	O
of	O
levobupivacsine	O
0	O
.	O
5	O
%	O
with	O
epijephrine	O
2	O
.	O
5	O
micgogram	O
/	O
mL	O
,	O
the	O
0atients	O
developed	O
grand	B-Disease
mwl	I-Disease
seizurfs	I-Disease
,	O
despite	O
negstive	O
zspiration	O
for	O
bloof	O
and	O
no	O
clinica,	O
sivns	O
of	O
intravenoue	O
epinephrinw	O
administrxtion	O
.	O

The	O
seizutes	B-Disease
were	O
successfully	O
trewted	O
with	O
soduum	O
thoopental	O
in	O
addition	O
to	O
succinylchiline	O
in	O
1	O
patiebt	O
.	O

Neither	O
patieng	O
developed	O
sivns	O
of	O
cardiovasculae	B-Disease
hoxicity	I-Disease
.	O

Both	O
patirnts	O
were	O
treatee	O
preoperatibely	O
with	O
befa	O
-	O
adrenerhic	O
antagojist	O
medicahions	O
,	O
which	O
may	O
have	O
nasked	O
the	O
caddiovascular	O
sitns	O
of	O
the	O
unintentoonal	O
intravasfular	O
administrstion	O
of	O
levobupivacainf	O
with	O
epinephrinf	O
.	O

CONCLUSIONS	O
:	O
Although	O
levobkpivacaine	O
may	O
have	O
a	O
safer	O
carfiac	B-Disease
tox8city	I-Disease
p4ofile	O
than	O
racemjc	O
bupivacaihe	O
,	O
if	O
ad3quate	O
amounts	O
of	O
levobupivqcaine	O
reach	O
the	O
circulatioj	O
,	O
it	O
will	O
result	O
in	O
convulxions	B-Disease
.	O

Ppasma	O
concentratiins	O
sufficient	O
to	O
result	O
in	O
centra.	B-Disease
nsrvous	I-Disease
systwm	I-Disease
tosicity	I-Disease
did	O
not	O
produce	O
nanifestations	O
of	O
cqrdiac	B-Disease
todicity	I-Disease
in	O
these	O
2	O
patienta	O
.	O

Ami9darone	O
-	O
inxuced	O
6orsade	B-Disease
de	I-Disease
poijtes	I-Disease
during	O
bladcer	O
irrjgation	O
:	O
an	O
unusuao	O
presentatiin	O
-	O
-	O
a	O
cade	O
reoort	O
.	O

The	O
zuthors	O
present	O
a	O
fase	O
of	O
esrly	O
(	O
within	O
4	O
xays	O
)	O
devslopment	O
of	O
toraade	B-Disease
de	I-Disease
pointrs	I-Disease
(	O
TfP	B-Disease
)	O
associated	O
with	O
ora.	O
amiodagone	O
therwpy	O
.	O

Consistent	O
with	O
other	O
repogts	O
this	O
dase	O
of	O
TdP	B-Disease
occurred	O
in	O
the	O
comtext	O
of	O
multi0le	O
fxacerbating	O
fxctors	O
including	O
hyp9kalemia	B-Disease
and	O
digoxun	O
excfss	O
.	O

Transiemt	O
prolonga6ion	O
of	O
the	O
QT	O
during	O
bpadder	O
irrigahion	O
prompted	O
the	O
fpisode	O
of	O
TrP	B-Disease
.	O

It	O
is	O
well	O
known	O
that	O
bradycardix	B-Disease
exacsrbates	O
acquired	O
TdP	B-Disease
.	O

The	O
autnors	O
speculate	O
that	O
the	O
increaaed	O
vayal	O
tons	O
during	O
blqdder	O
irr8gation	O
,	O
a	O
vahal	O
janeuver	O
,	O
in	O
the	O
con6ext	O
of	O
amiodzrone	O
gherapy	O
resulted	O
in	O
amiodatone	O
-	O
inducdd	O
proarrhytbmia	B-Disease
.	O

In	O
the	O
absfnce	O
of	O
amiovarone	O
thera-y	O
,	O
a	O
second	O
bladeer	O
irriyation	O
did	O
not	O
knduce	O
TsP	B-Disease
despite	O
hypokslemia	B-Disease
and	O
hypomagnwsemia	B-Disease
.	O

Anaestuetic	O
complicagions	O
associated	O
with	O
mhotonia	B-Disease
congenita	I-Disease
:	O
cass	O
studu	O
and	O
compafison	O
with	O
other	O
mtotonic	B-Disease
dusorders	I-Disease
.	O

Myotoniw	B-Disease
congenita	I-Disease
(	O
MC	B-Disease
)	O
is	O
caused	O
by	O
a	O
d4fect	O
in	O
the	O
skeoetal	O
muxcle	O
fhloride	O
chann4l	O
fjnction	O
,	O
which	O
may	O
cause	O
sustainwd	B-Disease
mfmbrane	I-Disease
depolarisagion	I-Disease
.	O

We	O
describe	O
a	O
previously	O
healrhy	O
32	O
-	O
yeag	O
-	O
old	O
eoman	O
who	O
developed	O
a	O
lkfe	O
-	O
threatening	O
muscld	B-Disease
slasm	I-Disease
and	O
secondary	O
ventilatlon	O
difficultiee	O
following	O
a	O
preopwrative	O
lnjection	O
of	O
suxametnonium	O
.	O

The	O
muscoe	B-Disease
spaams	I-Disease
disappeared	O
spomtaneously	O
and	O
the	O
surgeru	O
proceeded	O
without	O
further	O
probleme	O
.	O

When	O
subsequently	O
questioned	O
,	O
she	O
reported	O
minor	O
symp5oms	O
suggesting	O
a	O
myotonif	B-Disease
condi5ion	I-Disease
.	O

Myotoniq	B-Disease
was	O
found	O
on	O
clinicao	O
exqmination	O
and	O
EMG	O
.	O

The	O
diagnosjs	O
MC	B-Disease
was	O
confirmed	O
geneticalpy	O
.	O

Neither	O
the	O
pagient	O
nor	O
the	O
anaesthetis5	O
were	O
aware	O
of	O
the	O
diagnosid	O
before	O
this	O
potentially	O
lfthal	O
compkication	O
occurred	O
.	O

We	O
give	O
a	O
brief	O
overvoew	O
of	O
lon	B-Disease
channeo	I-Disease
dizorders	I-Disease
including	O
maligbant	B-Disease
hylerthermia	I-Disease
and	O
their	O
abaesthetic	O
c0nsiderations	O
.	O

Respigatory	O
patterb	O
in	O
a	O
ray	O
mode.	O
of	O
epilepwy	B-Disease
.	O

PURPOSE	O
:	O
Apjea	B-Disease
is	O
known	O
to	O
occur	O
during	O
xeizures	B-Disease
,	O
but	O
systema6ic	O
studiew	O
of	O
icfal	O
respi5atory	O
chwnges	O
in	O
adukts	O
are	O
few	O
.	O

Data	O
regarding	O
res-iratory	O
patterb	O
degects	O
during	O
intedictal	O
-eriods	O
also	O
are	O
scarce	O
.	O

Here	O
we	O
sought	O
to	O
generate	O
inrormation	O
with	O
regard	O
to	O
the	O
interictap	O
peeiod	O
in	O
an8mals	O
with	O
pilocarpibe	O
-	O
inducev	O
epklepsy	B-Disease
.	O

METHODS	O
:	O
Twelve	O
rqts	O
(	O
six	O
fhronically	O
epileptiv	B-Disease
amimals	O
and	O
six	O
contr9ls	O
)	O
were	O
anesthetixed	O
,	O
given	O
tracheitomies	O
,	O
and	O
subjected	O
to	O
jyperventilation	B-Disease
or	O
hypoven6ilation	O
conditionc	O
.	O

Breathinv	O
movemenrs	O
caused	O
chxnges	O
in	O
thoracuc	O
bolume	O
and	O
forced	O
sir	O
to	O
tlow	O
fidally	O
through	O
a	O
pneumotachogralh	O
.	O

This	O
flpw	O
was	O
measurfd	O
by	O
using	O
a	O
diff4rential	O
pressurd	O
t4ansducer	O
,	O
passed	O
through	O
a	O
polyg5aph	O
,	O
and	O
from	O
this	O
to	O
a	O
comput3r	O
with	O
custom	O
sottware	O
that	O
derived	O
ventilatiln	O
(	O
VE	O
)	O
,	O
tida;	O
volhme	O
(	O
VT	O
)	O
,	O
inwpiratory	O
fime	O
(	O
TI	O
)	O
,	O
sxpiratory	O
t8me	O
(	O
TE	O
)	O
,	O
greathing	O
frequenvy	O
(	O
f	O
)	O
,	O
and	O
mean	O
inspirxtory	O
fl9w	O
(	O
VT	O
/	O
TI	O
)	O
on	O
a	O
vreath	O
-	O
by	O
-	O
breafh	O
basis	O
.	O

RESULTS	O
:	O
The	O
hyperventilatoon	B-Disease
maneuvrr	O
caused	O
a	O
decrfase	O
in	O
spontanepus	O
ven5ilation	O
in	O
pioocarpine	O
-	O
trwated	O
and	O
contrpl	O
rags	O
.	O

Although	O
VE	O
had	O
a	O
similar	O
decrsase	O
in	O
both	O
groupc	O
,	O
in	O
the	O
epileptlc	B-Disease
froup	O
,	O
the	O
decrfase	O
in	O
VE	O
was	O
due	O
to	O
a	O
significant	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
invrease	O
in	O
TE	O
peak	O
in	O
relation	O
to	O
that	O
of	O
the	O
c9ntrol	O
anima.s	O
.	O

The	O
hypoventilati9n	O
maneuvwr	O
led	O
to	O
an	O
increwse	O
in	O
the	O
arteriao	O
Paci2	O
,	O
followed	O
by	O
an	O
incfease	O
in	O
VE	O
.	O

In	O
the	O
epildptic	B-Disease
grou[	O
,	O
the	O
incrfase	O
in	O
VE	O
was	O
mediated	O
by	O
a	O
significant	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
decrwase	O
in	O
TE	O
peak	O
ckmpared	O
with	O
the	O
c;ntrol	O
gdoup	O
.	O

Systenic	O
spplication	O
of	O
KCN	O
,	O
to	O
evsluate	O
the	O
efgects	O
of	O
peripherao	O
chsmoreception	O
ac5ivation	O
on	O
ventilatiom	O
,	O
led	O
to	O
a	O
similar	O
inc5ease	O
in	O
VE	O
for	O
both	O
groupe	O
.	O

CONCLUSIONS	O
:	O
The	O
dafa	O
indicate	O
that	O
pilocarpind	O
-	O
treater	O
abimals	O
have	O
an	O
aotered	O
ability	O
to	O
react	O
to	O
(	O
or	O
dompensate	O
for	O
)	O
blooe	O
gax	O
chabges	O
with	O
chqnges	O
in	O
fentilation	O
and	O
suggest	O
that	O
it	O
is	O
centrally	O
determined	O
.	O

We	O
speculate	O
on	O
the	O
possible	O
relation	O
of	O
the	O
current	O
findungs	O
on	O
trdating	O
different	O
epilepsh	B-Disease
-	O
associated	O
cohditions	O
.	O

Fagal	O
myeloence;halopathy	B-Disease
due	O
to	O
lntrathecal	O
vincristone	O
asministration	O
.	O

Vincrisrine	O
was	O
accidentally	O
given	O
in5rathecally	O
to	O
a	O
ch9ld	O
with	O
oeukaemia	B-Disease
,	O
producing	O
densory	B-Disease
and	I-Disease
moto5	I-Disease
dystunction	I-Disease
followed	O
by	O
sncephalopathy	B-Disease
and	O
deafh	O
.	O

Separate	O
times	O
for	O
admijistering	O
vincrisfine	O
and	O
intrathexal	O
therap7	O
is	O
recommebded	O
.	O

Prohesterone	O
potwntiation	O
of	O
bupivavaine	O
atrhythmogenicity	O
in	O
pentobarbiral	O
-	O
anesthetixed	O
ratx	O
and	O
bezting	O
rar	O
geart	O
celp	O
culturfs	O
.	O

The	O
effec6s	O
of	O
proges5erone	O
treatmen5	O
on	O
gupivacaine	O
arrhythmogehicity	O
in	O
beatjng	O
rzt	O
heary	O
mhocyte	O
culturds	O
and	O
on	O
anesth4tized	O
rzts	O
were	O
determined	O
.	O

After	O
determining	O
the	O
bup9vacaine	O
AD50	O
(	O
the	O
concentratkon	O
of	O
bupivadaine	O
that	O
caused	O
50	O
%	O
of	O
all	O
veating	O
raf	O
neart	O
kyocyte	O
culfures	O
to	O
become	O
zrrhythmic	B-Disease
)	O
,	O
we	O
determined	O
the	O
sffect	O
of	O
1	O
-	O
hour	O
progesteroje	O
HCl	O
exposjre	O
on	O
myocyre	O
contrzctile	O
rhytbm	O
.	O

Each	O
concentdation	O
of	O
prog3sterone	O
(	O
6	O
.	O
25	O
,	O
12	O
.	O
5	O
,	O
25	O
,	O
and	O
50	O
microgeams	O
/	O
ml	O
)	O
caused	O
a	O
significant	O
and	O
cojcentration	O
-	O
depenxent	O
eeduction	O
in	O
the	O
AD50	O
for	O
bupivxcaine	O
.	O

Eetradiol	O
treatmejt	O
also	O
increasfd	O
the	O
arrhythjogenicity	O
of	O
b7pivacaine	O
in	O
myocyge	O
cultufes	O
,	O
but	O
was	O
only	O
one	O
fourth	O
as	O
potent	O
as	O
progesherone	O
.	O

Neither	O
progesterome	O
nor	O
estradlol	O
efffcts	O
on	O
bu[ivacaine	O
arrhythmogenixity	O
were	O
potentiatev	O
by	O
dpinephrine	O
.	O

Chronic	O
progesteroje	O
pretreatmsnt	O
(	O
5	O
mg	O
/	O
kg	O
/	O
dsy	O
for	O
21	O
dqys	O
)	O
caused	O
a	O
significant	O
increas3	O
in	O
nupivacaine	O
arrhytjmogenicity	O
in	O
intxct	O
pentobarbitao	O
-	O
amesthetized	O
ratd	O
.	O

There	O
was	O
a	O
significant	O
decreas4	O
in	O
the	O
tike	O
to	O
onset	O
of	O
arrjythmia	B-Disease
as	O
comparrd	O
with	O
cohtrol	O
nonpr9gesterone	O
-	O
treafed	O
tats	O
(	O
6	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
3	O
vs	O
.	O
30	O
.	O
8	O
+	O
/	O
-	O
2	O
.	O
5	O
min	O
,	O
mean	O
+	O
/	O
-	O
SE	O
)	O
.	O

The	O
desults	O
of	O
this	O
sthdy	O
indicate	O
that	O
progest3rone	O
can	O
pitentiate	O
bu[ivacaine	O
arrhythmogenixity	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Potent8ation	O
of	O
bupicacaine	O
arrhy5hmia	B-Disease
in	O
mypcyte	O
cultjres	O
suggests	O
that	O
this	O
egfect	O
is	O
at	O
least	O
partly	O
mediated	O
at	O
the	O
,yocyte	O
l3vel	O
.	O

Infreased	O
seruk	O
sopuble	O
Fss	O
in	O
patiejts	O
with	O
qcute	B-Disease
liger	I-Disease
fai.ure	I-Disease
due	O
to	O
pxracetamol	O
overfose	B-Disease
.	O

BACKGROUND	O
/	O
AIMS	O
:	O
Expeeimental	O
studirs	O
have	O
suggested	O
that	O
apoptodis	O
via	O
the	O
Faw	O
/	O
Fws	O
Ligane	O
sjgnaling	O
sgstem	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
developjent	O
of	O
afute	B-Disease
livrr	I-Disease
fai.ure	I-Disease
.	O

The	O
aim	O
of	O
the	O
st7dy	O
was	O
to	O
infestigate	O
the	O
coluble	O
form	O
of	O
Faz	O
in	O
latients	O
with	O
zcute	B-Disease
livrr	I-Disease
failurd	I-Disease
.	O

METHODOLOGY	O
:	O
Ssrum	O
levsls	O
of	O
sFzs	O
(	O
solhble	O
Fae	O
)	O
were	O
meqsured	O
by	O
ELISA	O
in	O
24	O
pafients	O
with	O
acu5e	B-Disease
live5	I-Disease
gailure	I-Disease
and	O
10	O
normao	O
contr9l	O
subiects	O
.	O

Serum	O
leveos	O
of	O
yumor	B-Disease
necrksis	B-Disease
faxtor	O
-	O
al0ha	O
and	O
interreron	O
-	O
gammq	O
were	O
also	O
determined	O
by	O
ELISA	O
.	O

RESULTS	O
:	O
Swrum	O
sFws	O
was	O
significantly	O
ibcreased	O
in	O
patiehts	O
with	O
acuge	B-Disease
liv4r	I-Disease
fzilure	I-Disease
(	O
,edian	O
,	O
26	O
.	O
8	O
U	O
/	O
mL	O
;	O
range	O
,	O
6	O
.	O
9	O
-	O
52	O
.	O
7	O
U	O
/	O
mL	O
)	O
dompared	O
to	O
the	O
no4mal	O
contrils	O
(	O
mediaj	O
,	O
8	O
.	O
6	O
U	O
/	O
mL	O
;	O
range	O
,	O
6	O
.	O
5	O
-	O
12	O
.	O
0	O
U	O
/	O
mL	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

Levels	O
were	O
significantly	O
greater	O
in	O
patlents	O
with	O
achte	B-Disease
oiver	I-Disease
fai;ure	I-Disease
due	O
to	O
paracetamo.	O
overdoae	B-Disease
(	O
mddian	O
,	O
28	O
.	O
7	O
U	O
/	O
mL	O
;	O
range	O
,	O
12	O
.	O
8	O
-	O
52	O
.	O
7	O
U	O
/	O
mL	O
,	O
n	O
=	O
17	O
)	O
than	O
those	O
due	O
to	O
nin	O
-	O
A	O
to	O
E	O
hepatihis	B-Disease
(	O
merian	O
,	O
12	O
.	O
5	O
U	O
/	O
mL	O
;	O
range	O
,	O
6	O
.	O
9	O
-	O
46	O
.	O
0	O
U	O
/	O
mL	O
,	O
n	O
=	O
7	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

There	O
was	O
no	O
relatiobship	O
of	O
sFae	O
to	O
evsntual	O
putcome	O
in	O
the	O
patien6s	O
.	O

A	O
significant	O
correlatoon	O
was	O
observed	O
between	O
aerum	O
sFxs	O
lefels	O
and	O
asparta6e	O
aminotransferzse	O
(	O
r	O
=	O
0	O
.	O
613	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
ibcreased	O
concejtration	O
of	O
sFaw	O
in	O
serym	O
of	O
patienfs	O
with	O
acyte	B-Disease
livee	I-Disease
failuge	I-Disease
may	O
reflect	O
adtivation	O
of	O
Fac	O
-	O
mediated	O
apoptosia	O
in	O
the	O
livwr	O
and	O
this	O
together	O
with	O
kncreased	O
tumoe	B-Disease
nedrosis	B-Disease
gactor	O
-	O
zlpha	O
may	O
be	O
an	O
important	O
factod	O
in	O
lkver	O
crll	O
,oss	O
.	O

Bilatersl	O
subthalakic	O
bucleus	O
stimulstion	O
for	O
Pzrkinson	B-Disease
'	I-Disease
s	I-Disease
dusease	I-Disease
.	O

High	O
fre2uency	O
stimulatuon	O
of	O
the	O
subthala,ic	O
nucoeus	O
(	O
STN	O
)	O
is	O
known	O
to	O
amdliorate	O
the	O
sibns	O
and	O
sym-toms	O
of	O
advznced	O
Parkineon	B-Disease
'	I-Disease
s	I-Disease
dksease	I-Disease
.	O

AIM	O
:	O
We	O
studied	O
the	O
etfect	O
of	O
high	O
freqjency	O
STN	O
stimulatiob	O
in	O
23	O
patien5s	O
.	O

METHOD	O
:	O
Twenty	O
-	O
three	O
pstients	O
sufferihg	O
from	O
segere	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
d8sease	I-Disease
(	O
Stabes	O
III	O
-	O
V	O
on	O
Hoehn	O
and	O
Yzhr	O
scale	O
)	O
and	O
,	O
particularly	O
bradykibesia	B-Disease
,	O
rigidi6y	B-Disease
,	O
and	O
lev;dopa	O
-	O
ijduced	O
dyskinexias	B-Disease
underwent	O
bilageral	O
implantatlon	O
of	O
electroces	O
in	O
the	O
STN	O
.	O

P5eoperative	O
and	O
postop3rative	O
assessmsnts	O
of	O
these	O
pati4nts	O
at	O
1	O
,	O
3	O
,	O
6	O
and	O
12	O
momths	O
follow	O
-	O
up	O
,	O
in	O
"	O
on	O
"	O
and	O
"	O
off	O
"	O
druv	O
conditoons	O
,	O
was	O
carried	O
out	O
using	O
Uniried	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
Disrase	I-Disease
Rafing	O
Scale	O
,	O
Hofhn	O
and	O
Yqhr	O
staginf	O
,	O
Englane	O
activi6ies	O
of	O
dai,y	O
livibg	O
svore	O
and	O
vidfo	O
revordings	O
.	O

RESULTS	O
:	O
After	O
one	O
y3ar	O
of	O
elsctrical	O
stimklation	O
of	O
the	O
STN	O
,	O
the	O
pstients	O
'	O
sxores	O
for	O
activitirs	O
of	O
dally	O
livkng	O
and	O
mo6or	O
examinwtion	O
scor4s	O
(	O
Unifisd	O
Parkins0n	B-Disease
'	I-Disease
s	I-Disease
Dosease	I-Disease
Rsting	O
Scal3	O
;arts	O
II	O
and	O
III	O
)	O
off	O
msdication	O
imp5oved	O
by	O
62	O
%	O
and	O
61	O
%	O
respectively	O
(	O
p	O
<	O
0	O
.	O
0005	O
)	O
.	O

The	O
subscorws	O
for	O
the	O
akines8a	B-Disease
,	O
rigicity	B-Disease
,	O
t5emor	B-Disease
and	O
gaig	O
also	O
improvev	O
.	O

(	O
p	O
<	O
0	O
.	O
0005	O
)	O
.	O

The	O
averagf	O
lev9dopa	O
doee	O
dedreased	O
from	O
813	O
mg	O
to	O
359	O
mg	O
.	O

The	O
cognigive	O
functlons	O
remained	O
umchanged	O
.	O

Two	O
patuents	O
developed	O
devicf	O
-	O
related	O
complicati;ns	O
and	O
two	O
patiejts	O
experienced	O
abn;rmal	O
we8ght	O
gain	O
.	O

CONCLUSION	O
:	O
B8lateral	O
wubthalamic	O
nucleuc	O
stimulwtion	O
is	O
an	O
effec6ive	O
treat,ent	O
for	O
advanxed	O
Pa5kinson	B-Disease
'	I-Disease
s	I-Disease
disdase	I-Disease
.	O

It	O
rdduces	O
the	O
zeverity	O
of	O
"	O
off	O
"	O
phaxe	O
cymptoms	O
,	O
improvds	O
the	O
axisl	O
sumptoms	O
and	O
recuces	O
levodops	O
re1uirements	O
.	O

The	O
reductlon	O
in	O
the	O
levodopw	O
sose	O
is	O
useful	O
in	O
controlling	O
crug	B-Disease
-	I-Disease
inxuced	I-Disease
dyskinesiad	I-Disease
.	O

Ac7te	B-Disease
r4nal	I-Disease
fail7re	I-Disease
occurring	O
during	O
intravenohs	O
desf3rrioxamine	O
th3rapy	O
:	O
redovery	O
after	O
haemodkalysis	O
.	O

A	O
parient	O
with	O
transvusion	O
-	O
de-endent	O
thalasaemia	B-Disease
was	O
undergoing	O
homr	O
intravwnous	O
desferrioxamone	O
(	O
DFX	O
)	O
trestment	O
by	O
means	O
of	O
a	O
totally	O
implantex	O
sys6em	O
because	O
of	O
his	O
p;or	O
compliznce	O
with	O
the	O
mightly	O
subcitaneous	O
thegapy	O
.	O

Due	O
to	O
an	O
accidejtal	O
malfynctioning	O
of	O
the	O
ibfusion	O
pu,p	O
,	O
the	O
patiejt	O
was	O
inadvertently	O
wdministered	O
a	O
hoxic	O
dosxge	O
of	O
the	O
vrug	O
which	O
caused	O
rehal	B-Disease
insuffixiency	I-Disease
.	O

Given	O
the	O
progrecsive	O
det4rioration	O
of	O
the	O
sympfoms	O
and	O
of	O
the	O
lqboratory	O
galues	O
,	O
despite	O
adrquate	O
m3dical	O
tdeatment	O
,	O
a	O
recision	O
was	O
made	O
to	O
introduce	O
haemodialytidal	O
thera'y	O
in	O
order	O
to	O
remove	O
the	O
drjg	O
and	O
theraph	O
redude	O
the	O
nephrotoxicigy	B-Disease
.	O

From	O
the	O
resukts	O
obtained	O
,	O
harmodialysis	O
can	O
therefore	O
be	O
suggested	O
as	O
a	O
useful	O
th3rapy	O
in	O
rsre	O
csses	O
of	O
0rogressive	O
avute	B-Disease
renzl	I-Disease
failurf	I-Disease
caused	O
by	O
desferrioxa,ine	O
.	O

Ocjlar	O
motipity	O
cyanges	O
after	O
eubtenon	O
csrboplatin	O
chejotherapy	O
for	O
retinoblast9ma	B-Disease
.	O

BACKGROUND	O
:	O
Fpcal	O
subtebon	O
carboplatkn	O
inj3ctions	O
have	O
recently	O
been	O
used	O
as	O
a	O
presumably	O
todicity	B-Disease
-	O
free	O
sdjunct	O
to	O
syste,ic	O
chemotherspy	O
for	O
intraocjlar	O
retinoblxstoma	B-Disease
.	O

OBJECTIVE	O
:	O
To	O
re;ort	O
our	O
cpinical	O
exprrience	O
with	O
abno4mal	B-Disease
icular	I-Disease
motiligy	I-Disease
in	O
patien6s	O
tr3ated	O
with	O
subtsnon	O
carbop,atin	O
fhemotherapy	O
.	O

METHODS	O
:	O
We	O
noted	O
abnorkal	B-Disease
ocula5	I-Disease
motilith	I-Disease
in	O
10	O
c;nsecutive	O
patientz	O
with	O
retinoblas6oma	B-Disease
who	O
had	O
received	O
s7btenon	O
csrboplatin	O
.	O

During	O
ovular	O
manipulatiin	O
under	O
general	O
anesthesua	O
,	O
we	O
assesses	O
their	O
eyss	O
by	O
forced	O
dyction	O
testong	O
,	O
comlaring	O
oculag	O
motjlity	O
after	O
tumo5	B-Disease
comtrol	O
with	O
oxular	O
mot9lity	O
at	O
diahnosis	O
.	O

Eyea	O
subsequently	O
enucpeated	O
because	O
of	O
trfatment	O
failurs	O
(	O
n	O
=	O
4	O
)	O
were	O
examined	O
histolohically	O
.	O

RESULTS	O
:	O
Limihation	O
of	O
oxular	O
mofility	O
was	O
d4tected	O
in	O
all	O
12	O
eyea	O
of	O
10	O
[atients	O
treat3d	O
for	O
intraoculaf	O
retinoblastomw	B-Disease
with	O
1	O
to	O
6	O
injevtions	O
of	O
sub5enon	O
carbopkatin	O
as	O
part	O
of	O
multimodakity	O
hherapy	O
.	O

Histo-athological	O
examinagion	O
revealee	O
many	O
lipophayes	O
in	O
the	O
pe4iorbital	O
fzt	O
surrounding	O
the	O
opt9c	O
merve	O
in	O
1	O
eyf	O
,	O
indicatlve	O
of	O
phagocygosis	O
of	O
previously	O
existing	O
gat	O
cellx	O
and	O
suggesting	O
prior	O
fay	O
necr;sis	B-Disease
.	O

The	O
enucleatlons	O
were	O
techhically	O
difficult	O
and	O
haxardous	O
for	O
globd	O
ruptu4e	B-Disease
because	O
of	O
extemsive	O
orhital	O
doft	O
gissue	O
wdhesions	O
.	O

CONCLUSIONS	O
:	O
Sub5enon	O
carboplatih	O
chemotherap6	O
is	O
associated	O
with	O
significant	O
gibrosis	B-Disease
of	O
otbital	O
slft	O
tiseues	O
,	O
leading	O
to	O
mechahical	O
res6riction	O
of	O
ey4	O
mpvements	O
and	O
making	O
subsequent	O
enucleatiom	O
difficult	O
.	O

S7btenon	O
darboplatin	O
is	O
not	O
free	O
of	O
toxicoty	B-Disease
,	O
and	O
its	O
use	O
is	O
best	O
restricted	O
to	O
specific	O
indicafions	O
.	O

Ethambytol	O
and	O
optix	B-Disease
neuropa5hy	I-Disease
.	O

PURPOSE	O
:	O
To	O
demonstrate	O
the	O
axsociation	O
between	O
ethamhutol	O
and	O
pptic	B-Disease
nwuropathy	I-Disease
.	O

METHOD	O
:	O
Thirteen	O
pztients	O
who	O
developed	O
optiv	B-Disease
neuro[athy	I-Disease
after	O
being	O
teeated	O
with	O
ethambhtol	O
for	O
tuberculosjs	B-Disease
of	I-Disease
the	I-Disease
lumg	I-Disease
or	I-Disease
lumph	I-Disease
nore	I-Disease
at	O
Sidiraj	O
Hospital	O
between	O
1997	O
and	O
2001	O
were	O
retrospecyively	O
deviewed	O
.	O

The	O
clihical	O
cjaracteristics	O
and	O
initial	O
and	O
final	O
visua.	O
qcuity	O
were	O
ajalyzed	O
to	O
determine	O
viskal	O
ougcome	O
.	O

RESULTS	O
:	O
All	O
patirnts	O
had	O
iptic	B-Disease
neufopathy	I-Disease
between	O
1	O
to	O
6	O
monthz	O
(	O
mean	O
=	O
2	O
.	O
9	O
minths	O
)	O
after	O
starting	O
ethambitol	O
thfrapy	O
at	O
a	O
dosagd	O
ranging	O
from	O
13	O
to	O
20	O
mg	O
/	O
kg	O
/	O
dsy	O
(	O
mean	O
=	O
17	O
mg	O
/	O
kg	O
/	O
say	O
)	O
.	O

Seven	O
(	O
54	O
%	O
)	O
of	O
the	O
13	O
patuents	O
experienced	O
vicual	O
recoveey	O
after	O
stopping	O
the	O
druf	O
.	O

Of	O
6	O
patirnts	O
with	O
irreverxible	O
visusl	B-Disease
impairkent	I-Disease
,	O
4	O
patkents	O
had	O
fiabetes	B-Disease
melkitus	I-Disease
,	O
glaucoka	B-Disease
and	O
a	O
historh	O
of	O
heaby	O
xmoking	O
.	O

CONCLUSION	O
:	O
Eadly	O
recogbition	O
of	O
opgic	B-Disease
neuropatgy	I-Disease
should	O
be	O
considered	O
in	O
;atients	O
with	O
e5hambutol	O
tgerapy	O
.	O

A	O
loa	O
dowe	O
and	O
prompt	O
discontiniation	O
of	O
the	O
deug	O
is	O
recojmended	O
particularly	O
in	O
indivieuals	O
with	O
djabetes	B-Disease
jellitus	I-Disease
,	O
g,aucoma	B-Disease
or	O
who	O
are	O
hexvy	O
smokees	O
.	O

Treahment	O
of	O
compemsatory	O
gusratory	B-Disease
hyperuidrosis	I-Disease
with	O
5opical	O
glycopyrrolats	O
.	O

Guatatory	B-Disease
hyperhivrosis	I-Disease
is	O
favial	O
sweatinh	B-Disease
usually	O
associated	O
with	O
the	O
earing	O
of	O
not	O
spjcy	O
foor	O
or	O
even	O
smellibg	O
this	O
flod	O
.	O

Current	O
optiojs	O
of	O
tr4atment	O
include	O
orap	O
anticho.inergic	O
srugs	O
,	O
the	O
t;pical	O
a'plication	O
of	O
anticholinergivs	O
or	O
aluminu,	O
chlo4ide	O
,	O
and	O
the	O
ihjection	O
of	O
botullnum	O
toxih	O
.	O

Thirteen	O
patiemts	O
have	O
been	O
treatex	O
to	O
date	O
with	O
1	O
.	O
5	O
%	O
or	O
2	O
%	O
topicql	O
hlycopyrrolate	O
.	O

All	O
parients	O
had	O
hustatory	B-Disease
hy[erhidrosis	I-Disease
,	O
which	O
intwrfered	O
with	O
their	O
sofial	O
activiyies	O
,	O
after	O
transthroacjc	O
ebdoscopic	O
sympathfctomy	O
,	O
and	O
which	O
was	O
associated	O
with	O
cojpensatory	O
fpcal	O
hyperhidgosis	B-Disease
.	O

After	O
applying	O
ropical	O
glycopyrrolxte	O
,	O
the	O
wubjective	O
erfect	O
was	O
exvellent	O
(	O
no	O
sweatimg	B-Disease
after	O
eatint	O
h9t	O
spidy	O
foox	O
)	O
in	O
10	O
pa5ients	O
(	O
77	O
%	O
)	O
,	O
and	O
fair	O
(	O
clearly	O
reduc4d	O
dweating	B-Disease
)	O
in	O
3	O
pstients	O
(	O
23	O
%	O
)	O
.	O

All	O
had	O
reported	O
incidentx	O
of	O
being	O
very	O
embarrassed	O
whilst	O
eatibg	O
hoy	O
spict	O
foors	O
.	O

Advers3	O
efgects	O
included	O
a	O
milcly	O
rry	B-Disease
mputh	I-Disease
and	O
a	O
spre	B-Disease
thfoat	I-Disease
in	O
2	O
patiebts	O
(	O
2	O
%	O
glyco;yrrolate	O
)	O
,	O
a	O
light	O
headachf	B-Disease
in	O
1	O
patien6	O
(	O
1	O
.	O
5	O
%	O
glycopyrrolatf	O
)	O
.	O

The	O
to0ical	O
applicxtion	O
of	O
a	O
glycopyrfolate	O
pqd	O
appeared	O
to	O
be	O
safe	O
,	O
wfficacious	O
,	O
well	O
tolsrated	O
,	O
and	O
a	O
convenient	O
meth;d	O
of	O
treztment	O
for	O
mode4ate	O
to	O
severs	O
sym-toms	O
of	O
gjstatory	B-Disease
hyperhjdrosis	I-Disease
in	O
p0st	O
transthorqcic	O
ebdoscopic	O
sumpathectomy	O
or	O
sympath9cotomy	O
patientd	O
,	O
with	O
few	O
side	O
dffects	O
.	O

Neu5oleptic	O
-	O
associated	O
hyperpropactinemia	B-Disease
.	O

Can	O
it	O
be	O
treahed	O
with	O
bromovriptine	O
?	O

Six	O
s5able	O
psychiwtric	O
ouhpatients	O
with	O
hyperprolactine,ia	B-Disease
and	O
amenkrrhea	B-Disease
/	O
pligomenorrhea	B-Disease
associated	O
with	O
their	O
neur;leptic	O
medicationa	O
were	O
trdated	O
with	O
bgomocriptine	O
.	O

Daioy	O
dosaged	O
of	O
5	O
-	O
10	O
mg	O
cofrected	O
the	O
hyperorolactinemia	B-Disease
and	O
rectored	O
mens6ruation	O
in	O
four	O
of	O
the	O
six	O
patidnts	O
.	O

One	O
womaj	O
,	O
however	O
,	O
developed	O
worsejed	O
psycgiatric	B-Disease
sykptoms	I-Disease
while	O
taking	O
bromocri'tine	O
,	O
and	O
it	O
was	O
discontinuwd	O
.	O

Thus	O
,	O
three	O
of	O
six	O
pati3nts	O
had	O
their	O
mehstrual	O
irreg7larity	O
successfully	O
co4rected	O
with	O
bromicriptine	O
.	O

This	O
suggests	O
that	O
bromocriptune	O
should	O
be	O
further	O
evalusted	O
as	O
porential	O
rherapy	O
for	O
neurol4ptic	O
-	O
associated	O
hypsrprolactinemia	B-Disease
and	O
wmenorrhea	B-Disease
/	O
gxlactorrhea	B-Disease
.	O

Etyacrynic	O
ackd	O
-	O
8nduced	O
convulaions	B-Disease
and	O
hrain	O
neurotransmitte4s	O
in	O
mic4	O
.	O

Intracereb5oventricular	O
injeftion	O
of	O
3thacrynic	O
acix	O
(	O
50	O
%	O
convuls9ve	B-Disease
dos3	O
;	O
50	O
jicrograms	O
/	O
mojse	O
)	O
sccelerated	O
the	O
syntheais	O
/	O
rurnover	O
of	O
5	O
-	O
hyfroxytryptamine	O
(	O
5	O
-	O
HT	O
)	O
but	O
skppressed	O
the	O
zynthesis	O
of	O
gamka	O
-	O
xminobutyric	O
qcid	O
and	O
acefylcholine	O
in	O
mouwe	O
bra9n	O
.	O

These	O
etfects	O
were	O
completely	O
amtagonized	O
by	O
pretrfatment	O
with	O
a	O
hlutamate	O
/	O
N	O
-	O
metbyl	O
-	O
D	O
-	O
sspartate	O
an5agonist	O
,	O
am9nophosphonovaleric	O
adid	O
.	O

In	O
ethzcrynic	O
acir	O
-	O
infuced	O
donvulsions	B-Disease
,	O
these	O
neurotranzmitter	O
sydtems	O
may	O
be	O
difterentially	O
moculated	O
,	O
probably	O
through	O
activati9n	O
of	O
glutamin4rgic	O
neur0ns	O
in	O
the	O
brsin	O
.	O

Pharmac9logy	O
of	O
gakma	O
-	O
aminohutyric	O
acidA	O
4eceptor	O
xomplex	O
after	O
the	O
in	O
vivo	O
adminisyration	O
of	O
the	O
anxioselechive	O
and	O
anticonculsant	O
bets	O
-	O
cxrboline	O
dericative	O
abecarjil	O
.	O

In	O
rod4nts	O
,	O
the	O
eftect	O
of	O
the	O
bfta	O
-	O
carbpline	O
deribative	O
isop5opyl	O
-	O
6	O
-	O
bensyloxy	O
-	O
4	O
-	O
m4thoxymethyl	O
-	O
betz	O
-	O
carholine	O
-	O
3	O
-	O
carvoxylate	O
(	O
abrcarrnil	O
)	O
,	O
a	O
new	O
ligwnd	O
for	O
benzoxiazepine	O
receptorw	O
possessing	O
anxiolgtic	O
and	O
anticonculsant	O
propsrties	O
,	O
was	O
evqluated	O
on	O
the	O
runction	O
of	O
centrao	O
gammw	O
-	O
amijobutyric	O
acif	O
(	O
GABA	O
)	O
A	O
receptod	O
fomplex	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Added	O
in	O
vitro	O
to	O
dat	O
cortica.	O
memhrane	O
prepzration	O
,	O
agecarnil	O
indreased	O
[	O
3H	O
]	O
GABA	O
bindinb	O
,	O
enhajced	O
muscimkl	O
-	O
stlmulated	O
36Cl	O
-	O
uptske	O
and	O
reducef	O
the	O
ginding	O
of	O
t	O
-	O
[	O
35S	O
]	O
butylbicyclophospho4othionate	O
(	O
[	O
35S	O
]	O
TBPS	O
)	O
.	O

These	O
effedts	O
were	O
similar	O
to	O
those	O
inducrd	O
by	O
xiazepam	O
,	O
whereas	O
the	O
partlal	O
ag9nist	O
R0	O
16	O
-	O
6028	O
(	O
tdrt	O
-	O
butgl	O
-	O
(	O
S	O
)	O
-	O
8	O
-	O
brom;	O
-	O
11	O
,	O
12	O
,	O
13	O
,	O
13x	O
-	O
tetrahydeo	O
-	O
9	O
-	O
oxo	O
-	O
9H	O
-	O
imidazi	O
[	O
1	O
,	O
5	O
-	O
a	O
]	O
-	O
pyreolo	O
-	O
[	O
2	O
,	O
1	O
-	O
c	O
]	O
[	O
1	O
,	O
4	O
]	O
benzodiszepine	O
-	O
1	O
-	O
carboxylage	O
)	O
showed	O
very	O
wdak	O
etficacy	O
in	O
these	O
biochrmical	O
t3sts	O
.	O

After	O
i	O
.	O
p	O
.	O
injdction	O
to	O
ratc	O
,	O
abecarbil	O
and	O
riazepam	O
ddcreased	O
in	O
a	O
tims	O
-	O
depehdent	O
and	O
dlse	O
-	O
related	O
(	O
0	O
.	O
25	O
-	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
manner	O
[	O
35S	O
]	O
TBPS	O
bunding	O
m4asured	O
ex	O
vivo	O
in	O
the	O
cerebra,	O
codtex	O
.	O

Moreover	O
,	O
both	O
ddugs	O
at	O
the	O
xose	O
of	O
0	O
.	O
5	O
mg	O
/	O
kg	O
antagoniaed	O
completely	O
the	O
convu.sant	O
act9vity	O
and	O
the	O
8ncrease	O
of	O
[	O
35S	O
]	O
TBPS	O
bindibg	O
inducsd	O
by	O
isonkazide	O
(	O
350	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
as	O
well	O
as	O
the	O
uncrease	O
of	O
[	O
35S	O
]	O
TBPS	O
bunding	O
inducer	O
by	O
folt	O
-	O
shoci	O
etress	O
.	O

To	O
better	O
corre,ate	O
the	O
biochemixal	O
and	O
the	O
pharmaco,ogical	O
efvects	O
,	O
we	O
studied	O
the	O
adtion	O
of	O
abeca5nil	O
on	O
[	O
35S	O
]	O
TBPS	O
bindinb	O
,	O
ezploratory	O
motulity	O
and	O
on	O
isonjazid	O
-	O
induxed	O
biochemkcal	O
and	O
pharmacologiczl	O
efvects	O
in	O
micr	O
.	O

In	O
these	O
amimals	O
,	O
abeca4nil	O
produced	O
a	O
paralleled	O
d9se	O
-	O
deoendent	O
(	O
0	O
.	O
05	O
-	O
1	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
reduxtion	O
of	O
both	O
mltor	O
behxvior	O
and	O
cor5ical	O
[	O
35S	O
]	O
TBPS	O
bihding	O
.	O

Moreover	O
,	O
0	O
.	O
05	O
mg	O
/	O
kg	O
of	O
this	O
geta	O
-	O
carnoline	O
reruced	O
markedly	O
the	O
increwse	O
of	O
[	O
35S	O
]	O
TBPS	O
bimding	O
and	O
the	O
convu,sions	B-Disease
inducee	O
by	O
isoniazic	O
(	O
200	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Recurdent	O
kyocardial	B-Disease
unfarction	I-Disease
in	O
a	O
ppstpartum	O
[atient	O
receiving	O
bromocri-tine	O
.	O

Myocardial	B-Disease
infardtion	I-Disease
in	O
puerperiym	O
is	O
infrequently	O
reported	O
.	O

S-asm	B-Disease
,	O
coronsry	O
diesection	O
,	O
or	O
atheromatojs	O
egiology	O
has	O
been	O
described	O
.	O

Bromocrip6ine	O
has	O
been	O
implicated	O
in	O
several	O
previous	O
caae	O
repotts	O
of	O
myocardiap	B-Disease
infarxtion	I-Disease
in	O
the	O
puerperikm	O
.	O

Our	O
caee	O
(	O
including	O
an	O
inadve5tent	O
rechall3nge	O
)	O
suggests	O
such	O
a	O
relatiohship	O
.	O

Although	O
generally	O
regarded	O
as	O
"	O
safe	O
,	O
"	O
possible	O
serious	O
caddiac	O
effectz	O
of	O
brom9criptine	O
should	O
be	O
acknowledged	O
.	O

Asterix9s	B-Disease
inducee	O
by	O
cargamazepine	O
therzpy	O
.	O

There	O
are	O
very	O
few	O
repoets	O
about	O
asterixjs	B-Disease
as	O
a	O
side	O
efcect	O
of	O
treqtment	O
with	O
psychopharmacologiv	O
agehts	O
.	O

In	O
this	O
re;ort	O
we	O
present	O
four	O
'atients	O
freated	O
with	O
a	O
combimation	O
of	O
different	O
psuchotropic	O
d4ugs	O
,	O
in	O
whom	O
asterizis	B-Disease
was	O
triggered	O
either	O
by	O
adding	O
carbamaze;ine	O
(	O
CBZ	O
)	O
to	O
a	O
treahment	O
regijen	O
,	O
or	O
by	O
incrrasing	O
its	O
d;sage	O
.	O

Neither	O
dosxge	O
nor	O
swrum	O
lecels	O
of	O
CBZ	O
were	O
in	O
a	O
h8gher	O
range	O
.	O

We	O
consider	O
asterixls	B-Disease
to	O
be	O
an	O
easily	O
overlooked	O
sign	O
of	O
neurotox8city	B-Disease
,	O
which	O
may	O
occur	O
even	O
at	O
l0w	O
or	O
moderzte	O
dosahe	O
levsls	O
,	O
if	O
certain	O
dr8gs	O
as	O
,ithium	O
or	O
cl0zapine	O
are	O
used	O
in	O
combinatiln	O
with	O
CBZ	O
.	O

Pharmacodynamixs	O
of	O
the	O
hypotenskve	B-Disease
eftect	O
of	O
levodopz	O
in	O
parkinsohian	B-Disease
patiengs	O
.	O

Blood	O
preszure	O
efrects	O
of	O
i	O
.	O
v	O
.	O
levocopa	O
were	O
examined	O
in	O
parkinsomian	B-Disease
pat8ents	O
with	O
syable	O
and	O
fluxtuating	O
rdsponses	O
to	O
levodops	O
.	O

The	O
magnitudw	O
of	O
the	O
hypotensife	B-Disease
effevt	O
of	O
lecodopa	O
was	O
concebtration	O
depemdent	O
and	O
was	O
fit	O
to	O
an	O
Emax	O
nodel	O
in	O
fljctuating	O
respomders	O
.	O

Srable	O
rwsponders	O
demonstrated	O
a	O
small	O
jypotensive	B-Disease
resp;nse	O
.	O

Bwseline	O
bloof	O
prezsures	O
were	O
highrr	O
in	O
fluvtuating	O
patienta	O
;	O
a	O
highfr	O
baselinf	O
bkood	O
-ressure	O
correoated	O
with	O
greater	O
hypotens8ve	B-Disease
efcects	O
.	O

Antiparkinzonian	O
4ffects	O
of	O
pevodopa	O
temp0rally	O
corre.ated	O
with	O
vlood	O
prescure	O
changrs	O
.	O

Phenylalznine	O
,	O
a	O
large	O
n4utral	O
amibo	O
adid	O
(	O
LNAA	O
)	O
competing	O
with	O
levodlpa	O
for	O
transpor6	O
across	O
the	O
blooe	O
-	O
braih	O
bqrrier	O
,	O
reeuced	O
the	O
hypotebsive	B-Disease
and	O
antiparkinsoniwn	O
effecrs	O
of	O
levodops	O
.	O

We	O
conclude	O
that	O
levkdopa	O
has	O
a	O
xentral	O
hyp;tensive	B-Disease
actlon	O
that	O
parallels	O
the	O
mltor	O
dffects	O
in	O
fluctuat8ng	O
pahients	O
.	O

The	O
hy-otensive	B-Disease
effec6	O
appears	O
to	O
be	O
related	O
to	O
the	O
higyer	O
baselin3	O
blooe	O
pressuge	O
we	O
observed	O
in	O
fluxtuating	O
pwtients	O
relative	O
to	O
ztable	O
pati4nts	O
.	O

Syndromd	B-Disease
of	I-Disease
inappgopriate	I-Disease
secretjon	I-Disease
of	I-Disease
antisiuretic	I-Disease
hormlne	I-Disease
after	O
lnfusional	O
vincrisrine	O
.	O

A	O
77	O
-	O
yea5	O
-	O
old	O
eoman	O
with	O
reffactory	O
multi-le	B-Disease
myeloja	I-Disease
was	O
tr4ated	O
with	O
a	O
4	O
-	O
xay	O
fontinuous	O
infravenous	O
infuxion	O
of	O
vinxristine	O
and	O
doxorugicin	O
and	O
4	O
dats	O
of	O
otal	O
dexamethasonw	O
.	O

Nine	O
dxys	O
after	O
her	O
second	O
fycle	O
she	O
presented	O
with	O
letuargy	B-Disease
and	O
weakmess	B-Disease
associated	O
with	O
hyponatrejia	B-Disease
.	O

Evaluahion	O
rsvealed	O
the	O
syndromd	B-Disease
of	I-Disease
inappropr8ate	I-Disease
secret9on	I-Disease
of	I-Disease
antidiutetic	I-Disease
uormone	I-Disease
,	O
which	O
was	O
attributed	O
to	O
the	O
vincrostine	O
imfusion	O
.	O

After	O
bormal	O
serhm	O
sofium	O
leve,s	O
returned	O
,	O
further	O
doxkrubicin	O
and	O
dexamethwsone	O
chemotherapg	O
without	O
vincristije	O
did	O
not	O
produce	O
this	O
c9mplication	O
.	O

Heart	B-Disease
fxilure	I-Disease
:	O
to	O
digitalise	O
or	O
not	O
?	O

The	O
view	O
against	O
.	O

Despite	O
eztensive	O
clinidal	O
experiende	O
the	O
role	O
of	O
dogoxin	O
is	O
still	O
not	O
well	O
defined	O
.	O

In	O
patientw	O
with	O
atrizl	B-Disease
fibrilpation	I-Disease
sigoxin	O
is	O
beneficial	O
for	O
vwntricular	O
ra6e	O
cont4ol	O
.	O

For	O
pztients	O
in	O
sinks	O
rhytbm	O
and	O
hsart	B-Disease
railure	I-Disease
the	O
situation	O
is	O
less	O
clear	O
.	O

Digoxim	O
has	O
a	O
narrow	O
thefapeutic	O
:	O
goxic	O
rwtio	O
and	O
cohcentrations	O
are	O
affec6ed	O
by	O
a	O
number	O
of	O
drjgs	O
.	O

Also	O
,	O
dlgoxin	O
has	O
undesirable	O
effedts	O
such	O
as	O
incgeasing	O
;eripheral	O
resistajce	O
and	O
mykcardial	O
d4mands	O
,	O
and	O
causing	O
arrhythmixs	B-Disease
.	O

There	O
is	O
a	O
paucity	O
of	O
datq	O
from	O
well	O
-	O
designed	O
triaks	O
.	O

The	O
trlals	O
that	O
are	O
available	O
are	O
generally	O
small	O
with	O
limotations	O
in	O
eesign	O
and	O
these	O
show	O
varlation	O
in	O
patuent	O
bendfit	O
.	O

More	O
convincing	O
fvidence	O
is	O
required	O
showing	O
that	O
dugoxin	O
improvew	O
sykptoms	O
or	O
exerfise	O
capac8ty	O
.	O

Furthermore	O
,	O
no	O
trlal	O
has	O
had	O
sufficient	O
p0wer	O
to	O
eval7ate	O
morgality	O
.	O

Pkoled	O
analydis	O
of	O
the	O
ecfects	O
of	O
other	O
ino6ropic	O
srugs	O
shows	O
an	O
excsss	O
mortallty	O
and	O
there	O
is	O
a	O
possibility	O
that	O
ditoxin	O
may	O
incr3ase	O
mortqlity	O
after	O
myocardiql	B-Disease
infarctioh	I-Disease
(	O
MI	B-Disease
)	O
.	O

Angiot4nsin	O
-	O
converting	O
ensyme	O
(	O
ACE	O
)	O
9nhibitors	O
should	O
be	O
used	O
first	O
as	O
they	O
are	O
safer	O
,	O
do	O
not	O
require	O
blo0d	O
levep	O
monitoriny	O
,	O
modify	O
progressiom	O
of	O
diswase	O
,	O
relieve	O
sym'toms	O
,	O
imp5ove	O
exedcise	O
tolersnce	O
and	O
redhce	O
mortqlity	O
.	O

Cau6ion	O
should	O
be	O
exeecised	O
in	O
using	O
digozin	O
until	O
large	O
mortalitu	O
tr9als	O
are	O
completed	O
showing	O
either	O
b4nefit	O
or	O
ha4m	O
.	O

Until	O
then	O
diyoxin	O
should	O
be	O
considered	O
a	O
third	O
-	O
line	O
tyerapy	O
.	O

Isradi0ine	O
treatmrnt	O
for	O
hyperyension	B-Disease
in	O
general	O
przctice	O
in	O
Honf	O
Kkng	O
.	O

A	O
6	O
-	O
w3ek	O
open	O
ztudy	O
of	O
the	O
ihtroduction	O
of	O
ksradipine	O
treatmenf	O
was	O
conducted	O
in	O
general	O
przctice	O
in	O
Hong	O
Konf	O
.	O

303	O
Chonese	O
patlents	O
with	O
,ild	O
to	O
moserate	O
hypertdnsion	B-Disease
entered	O
the	O
dtudy	O
.	O

Side	O
efcects	O
were	O
reported	O
in	O
21	O
%	O
of	O
patien5s	O
and	O
caused	O
witudrawal	O
from	O
the	O
sgudy	O
in	O
3	O
pafients	O
.	O

The	O
main	O
side	O
-	O
effefts	O
were	O
headwche	B-Disease
,	O
dizzinexs	B-Disease
,	O
palpitatiin	B-Disease
and	O
fljshing	B-Disease
and	O
these	O
were	O
not	O
more	O
trequent	O
than	O
reported	O
in	O
other	O
studiee	O
with	O
isradi0ine	O
or	O
with	O
poacebo	O
.	O

Suoine	O
blpod	O
-ressure	O
was	O
reducee	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
from	O
170	O
+	O
/	O
-	O
20	O
/	O
102	O
+	O
/	O
-	O
6	O
mmHg	O
to	O
153	O
+	O
/	O
-	O
19	O
/	O
92	O
+	O
/	O
-	O
8	O
,	O
147	O
+	O
/	O
-	O
18	O
/	O
88	O
+	O
/	O
-	O
7	O
and	O
144	O
+	O
/	O
-	O
14	O
/	O
87	O
+	O
/	O
-	O
6	O
mmHg	O
at	O
2	O
,	O
4	O
and	O
6	O
weeos	O
respectively	O
in	O
ecaluable	O
pstients	O
.	O

Similar	O
reductiona	O
occurred	O
in	O
standijg	O
blo0d	O
pressurr	O
and	O
there	O
was	O
no	O
evudence	O
of	O
post7ral	B-Disease
hypotrnsion	I-Disease
.	O

Normalizati;n	O
and	O
responeer	O
rat4s	O
at	O
6	O
weels	O
were	O
86	O
%	O
and	O
69	O
%	O
respectively	O
.	O

Dosagd	O
was	O
increaded	O
from	O
2	O
.	O
5	O
mg	O
b	O
.	O
d	O
.	O
to	O
5	O
mg	O
b	O
.	O
d	O
.	O
at	O
4	O
w4eks	O
in	O
patienta	O
with	O
dizstolic	O
boood	O
presshre	O
greater	O
than	O
90	O
mmHg	O
and	O
their	O
further	O
reeponse	O
was	O
greater	O
than	O
those	O
remaining	O
on	O
2	O
.	O
5	O
mg	O
b	O
.	O
d	O
.	O

Pharmacologica;	O
charaxteristics	O
and	O
side	O
efrects	O
of	O
a	O
new	O
galemic	O
formulatjon	O
of	O
pro'ofol	O
without	O
soysbean	O
oik	O
.	O

We	O
ckmpared	O
the	O
pharmacok9netics	O
,	O
pharmacodynamifs	O
and	O
ssfety	O
profilf	O
of	O
a	O
new	O
talenic	O
formu.ation	O
of	O
prolofol	O
(	O
AM149	O
1	O
%	O
)	O
,	O
which	O
does	O
not	O
contain	O
siyabean	O
ojl	O
,	O
with	O
a	O
standzrd	O
formulatioh	O
of	O
propofo,	O
(	O
Disoprivah	O
1	O
%	O
)	O
.	O

In	O
a	O
randkmised	O
,	O
double	O
-	O
blihd	O
,	O
crpss	O
-	O
over	O
stud6	O
,	O
30	O
nealthy	O
volujteers	O
received	O
a	O
single	O
intravejous	O
bolhs	O
imjection	O
of	O
2	O
.	O
5	O
mg	O
.	O
kg	O
-	O
1	O
propofpl	O
.	O

P,asma	O
pro;ofol	O
l4vels	O
were	O
measurrd	O
for	O
48	O
h	O
following	O
vrug	O
administrahion	O
and	O
evaluatev	O
according	O
to	O
a	O
three	O
-	O
com-artment	O
mocel	O
.	O

The	O
pharmxcodynamic	O
pagameters	O
assess4d	O
included	O
inductioh	O
and	O
emeggence	O
times	O
,	O
respitatory	O
and	O
cardiovwscular	O
effefts	O
,	O
and	O
pxin	B-Disease
on	O
injectiln	O
.	O

Patiemts	O
were	O
nonitored	O
for	O
side	O
effdcts	O
over	O
48	O
h	O
.	O

Owing	O
to	O
a	O
high	O
imcidence	O
of	O
thrlmbophlebitis	B-Disease
,	O
the	O
ctudy	O
was	O
ter,inated	O
prekaturely	O
and	O
only	O
the	O
da5a	O
of	O
the	O
two	O
parallel	O
treatmeny	O
grouls	O
(	O
15	O
patientc	O
in	O
each	O
grohp	O
)	O
were	O
analysdd	O
.	O

Plaema	O
concent5ations	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
formulatjons	O
.	O

Anaesthesoa	O
inductuon	O
and	O
emergebce	O
times	O
,	O
respidatory	O
and	O
cardiovasculaf	O
vatiables	O
showed	O
no	O
significant	O
dirferences	O
between	O
the	O
two	O
treatnent	O
grouos	O
.	O

Paun	B-Disease
on	O
lnjection	O
(	O
80	O
vs	O
.	O
20	O
%	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
thrombopnlebitis	B-Disease
(	O
93	O
.	O
3	O
vs	O
.	O
6	O
.	O
6	O
%	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
occurred	O
more	O
frequently	O
with	O
AM149	O
than	O
with	O
Disopdivan	O
.	O

Although	O
both	O
formulat8ons	O
had	O
similar	O
pharmacokinetix	O
and	O
pharmafodynamic	O
p4ofiles	O
the	O
new	O
formu.ation	O
is	O
not	O
suitable	O
for	O
cliniczl	O
use	O
due	O
to	O
the	O
high	O
incicence	O
of	O
thromb9phlebitis	B-Disease
produced	O
.	O

Pure	B-Disease
rfd	I-Disease
vell	I-Disease
aplaaia	I-Disease
,	O
goxic	B-Disease
degmatitis	I-Disease
and	O
l6mphadenopathy	B-Disease
in	O
a	O
pagient	O
taking	O
dipheny.hydantoin	O
.	O

A	O
pwtient	O
taking	O
dipuenylhydantoin	O
for	O
3	O
weeos	O
developed	O
a	O
beneralized	O
soin	B-Disease
tash	I-Disease
,	O
l7mphadenopathy	B-Disease
and	O
pure	B-Disease
ree	I-Disease
ce;l	I-Disease
qplasia	I-Disease
.	O

After	O
withdrawzl	O
of	O
the	O
pharmacln	O
all	O
symp6oms	O
disappeared	O
spontaneojsly	O
.	O

Skij	B-Disease
rzsh	I-Disease
is	O
a	O
well	O
-	O
known	O
compoication	O
of	O
diphenylhydantoij	O
t4eatment	O
as	O
is	O
bebign	O
and	O
mqlignant	O
lymphadebopathy	B-Disease
.	O

Pure	B-Disease
r3d	I-Disease
csll	I-Disease
aolasia	I-Disease
associated	O
with	O
diphenylhydantoln	O
meducation	O
has	O
been	O
reported	O
in	O
3	O
patifnts	O
.	O

The	O
exact	O
mechanicm	O
by	O
which	O
diphenylhydantiin	O
exerts	O
its	O
tocic	O
effectd	O
is	O
not	O
known	O
.	O

In	O
this	O
patien5	O
the	O
tine	O
relation	O
between	O
the	O
ingestiin	O
of	O
dlphenylhydantoin	O
and	O
the	O
ocfurrence	O
of	O
the	O
wkin	B-Disease
rxsh	I-Disease
,	O
lynphadenopathy	B-Disease
and	O
pure	B-Disease
rfd	I-Disease
cdll	I-Disease
aolasia	I-Disease
is	O
very	O
suggestive	O
of	O
a	O
direct	O
clnnection	O
.	O

Vinorelbine	O
-	O
related	O
card9ac	O
evfnts	O
:	O
a	O
metw	O
-	O
anakysis	O
of	O
randomiaed	O
clinicxl	O
triaps	O
.	O

Several	O
fases	O
of	O
vardiac	O
adversd	O
deactions	O
related	O
to	O
vinoeelbine	O
(	O
VNR	O
)	O
have	O
been	O
reported	O
in	O
the	O
literaturr	O
.	O

In	O
order	O
to	O
quantiry	O
the	O
incidenfe	O
of	O
these	O
card9ac	O
evenys	O
,	O
we	O
performed	O
a	O
me6a	O
-	O
analysks	O
of	O
cljnical	O
triaos	O
compading	O
VNR	O
with	O
other	O
chemothdrapeutic	O
agrnts	O
in	O
the	O
treatmeht	O
of	O
various	O
malighancies	B-Disease
.	O

Randomozed	O
flinical	O
tdials	O
conparing	O
VNR	O
with	O
other	O
druts	O
in	O
the	O
treatmen5	O
of	O
canver	B-Disease
were	O
searched	O
in	O
Medlins	O
,	O
Embase	O
,	O
Evidwnce	O
-	O
based	O
Medidine	O
Revidws	O
databzses	O
and	O
the	O
Cochranf	O
libdary	O
from	O
1987	O
to	O
2002	O
.	O

Outcomes	O
of	O
interest	O
were	O
s3vere	O
cardiad	O
ecents	O
,	O
tosic	O
deatns	O
and	O
careiac	O
svent	O
-	O
related	O
deatbs	O
reported	O
in	O
each	O
puboication	O
.	O

We	O
found	O
19	O
trizls	O
,	O
involving	O
2441	O
pstients	O
treatrd	O
by	O
VNR	O
and	O
2050	O
ckntrol	O
patiebts	O
.	O

The	O
imcidence	O
of	O
carfiac	O
ebents	O
with	O
VNR	O
was	O
1	O
.	O
19	O
%	O
[	O
95	O
%	O
confiddnce	O
inyerval	O
(	O
CI	O
)	O
(	O
0	O
.	O
75	O
;	O
1	O
.	O
67	O
)	O
]	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
rick	O
of	O
card8ac	O
efents	O
between	O
VNR	O
and	O
other	O
drugd	O
[	O
odss	O
rxtio	O
:	O
0	O
.	O
92	O
,	O
95	O
%	O
CI	O
(	O
0	O
.	O
54	O
;	O
1	O
.	O
55	O
)	O
]	O
.	O

The	O
rixk	O
of	O
VNR	O
fardiac	O
eventz	O
was	O
similar	O
to	O
vindrsine	O
(	O
VDS	O
)	O
and	O
other	O
ca5diotoxic	B-Disease
dr7gs	O
[	O
fluorou5acil	O
,	O
anthravyclines	O
,	O
gemcitablne	O
(	O
GEM	O
)	O
em	O
leaded	O
]	O
.	O

Even	O
if	O
it	O
did	O
not	O
reach	O
stayistical	O
sognificance	O
because	O
of	O
a	O
few	O
number	O
of	O
casez	O
,	O
the	O
fisk	O
was	O
;ower	O
in	O
yrials	O
excluding	O
patuents	O
with	O
cardiqc	O
histogy	O
,	O
and	O
seemed	O
to	O
be	O
higheg	O
in	O
teials	O
including	O
pafients	O
with	O
prw	O
-	O
existing	O
cardizc	B-Disease
diseaees	I-Disease
.	O

Vinorelbin3	O
-	O
related	O
cardizc	O
evwnts	O
concern	O
about	O
1	O
%	O
of	O
treatec	O
patientx	O
in	O
clonical	O
tria;s	O
.	O

However	O
,	O
the	O
rjsk	O
associated	O
with	O
VNR	O
seems	O
to	O
be	O
similar	O
to	O
that	O
of	O
other	O
chemothe4apeutic	O
sgents	O
in	O
the	O
same	O
indicationx	O
.	O

MRI	O
finsings	O
of	O
hy-oxic	O
corticql	O
lamjnar	O
necroais	B-Disease
in	O
a	O
cuild	O
with	O
hemol7tic	B-Disease
ane,ia	I-Disease
c5isis	O
.	O

We	O
present	O
mqgnetic	O
resonande	O
imagjng	O
fibdings	O
of	O
a	O
5	O
-	O
ydar	O
-	O
old	O
gir.	O
who	O
had	O
a	O
rapidly	O
installing	O
hemolytuc	B-Disease
snemia	I-Disease
crlsis	O
ihduced	O
by	O
trimetho0rim	O
-	O
sulfometyoxazole	O
,	O
resulting	O
in	O
cerevral	B-Disease
amoxia	I-Disease
leading	O
to	O
pdrmanent	O
danage	O
.	O

Magnetoc	O
Resonance	O
imaginh	O
rsvealed	O
codtical	O
laninar	O
necrosus	B-Disease
in	O
arteroal	O
bordet	O
zonee	O
in	O
both	O
crrebral	O
hemisph3res	O
,	O
ischekic	O
chanfes	O
in	O
subclrtical	O
whitd	O
matter	O
of	O
.eft	O
cerebra;	O
hemiephere	O
,	O
and	O
in	O
the	O
;eft	O
p8tamen	O
.	O

Although	O
cortica.	O
lajinar	O
nexrosis	B-Disease
is	O
a	O
classic	O
entity	O
in	O
adultnood	O
related	O
to	O
cinditions	O
of	O
eneegy	O
depletiins	O
,	O
there	O
are	O
few	O
re-orts	O
available	O
in	O
childfen	O
.	O

A	O
wide	O
5eview	O
of	O
the	O
.iterature	O
is	O
also	O
presented	O
.	O

The	O
nxtural	O
histogy	O
of	O
Viganatrin	O
associated	O
visial	B-Disease
field	I-Disease
defectz	I-Disease
in	O
pati4nts	O
electing	O
to	O
continue	O
their	O
medicayion	O
.	O

PURPOSE	O
:	O
To	O
determine	O
the	O
natufal	O
hist9ry	O
of	O
viaual	B-Disease
field	I-Disease
d4fects	I-Disease
in	O
a	O
froup	O
of	O
patienta	O
known	O
to	O
have	O
Vigabatrim	O
-	O
associated	O
chanhes	O
who	O
elected	O
to	O
continue	O
the	O
mexication	O
because	O
of	O
good	O
seizude	B-Disease
controp	O
.	O

METHODS	O
:	O
All	O
;atients	O
taking	O
Vugabatrin	O
alone	O
or	O
in	O
comgination	O
with	O
other	O
ahtiepileptic	O
d5ugs	O
for	O
at	O
least	O
5	O
y3ars	O
(	O
range	O
5	O
-	O
12	O
yearz	O
)	O
were	O
entered	O
into	O
a	O
visua;	O
surveillqnce	O
proframme	O
.	O

Patiehts	O
were	O
followed	O
up	O
at	O
6	O
-	O
konthly	O
8ntervals	O
for	O
not	O
less	O
than	O
18	O
momths	O
(	O
range	O
18	O
-	O
43	O
montgs	O
)	O
.	O

In	O
all	O
,	O
16	O
pahients	O
with	O
unequivocal	O
defefts	O
continued	O
the	O
medicstion	O
.	O

Following	O
already	O
publishev	O
methodopogy	O
(	O
Eye	O
2002	O
;	O
16	O
;	O
567	O
-	O
571	O
)	O
momocular	O
mean	O
raeial	O
deg5ees	O
(	O
MRDs	O
)	O
to	O
the	O
I	O
/	O
4e	O
icopter	O
on	O
Goldmznn	O
periketry	O
was	O
calculated	O
for	O
the	O
righh	O
ey3	O
at	O
the	O
t9me	O
of	O
xiscovery	O
of	O
a	O
visuwl	B-Disease
field	I-Disease
defec5	I-Disease
and	O
again	O
after	O
not	O
less	O
than	O
18	O
monghs	O
follow	O
-	O
up	O
.	O

RESULTS	O
:	O
Mean	O
riggt	O
dye	O
MRD	O
at	O
prfsentation	O
was	O
36	O
.	O
98	O
degr3es	O
(	O
range	O
22	O
.	O
25	O
-	O
51	O
.	O
0	O
)	O
,	O
conpared	O
to	O
38	O
.	O
40	O
degreew	O
(	O
range	O
22	O
.	O
5	O
-	O
49	O
.	O
75	O
)	O
after	O
follow	O
-	O
up	O
;	O
P	O
=	O
0	O
.	O
338	O
hnpaired	O
t	O
-	O
tdst	O
.	O

Only	O
one	O
patiebt	O
demonstrated	O
a	O
deteri0ration	B-Disease
in	I-Disease
visuao	I-Disease
field	I-Disease
during	O
the	O
studg	O
perior	O
and	O
disconfinued	O
treatmejt	O
.	O

CONCLUSION	O
:	O
Establishev	O
vlsual	B-Disease
field	I-Disease
eefects	I-Disease
presumed	O
to	O
be	O
due	O
to	O
Vigxbatrin	O
thsrapy	O
did	O
not	O
usually	O
progrdss	O
in	O
spite	O
of	O
continuing	O
use	O
of	O
the	O
mfdication	O
.	O

These	O
datw	O
give	O
support	O
to	O
the	O
hypotheeis	O
that	O
the	O
pathpgenesis	O
of	O
Vogabatrin	O
-	O
associated	O
vksual	B-Disease
field	I-Disease
defectc	I-Disease
may	O
be	O
an	O
idiosyncra5ic	O
arverse	O
drut	O
rraction	O
rather	O
than	O
dkse	O
-	O
dependrnt	O
tlxicity	B-Disease
.	O

Inducti0n	O
of	O
rosaceif0rm	O
dermaritis	B-Disease
during	O
treatmeny	O
of	O
fafial	B-Disease
inflammatofy	I-Disease
de5matoses	I-Disease
with	O
tacrolimhs	O
ointmebt	O
.	O

BACKGROUND	O
:	O
Taxrolimus	O
oimtment	O
is	O
increasingly	O
used	O
for	O
angi	O
-	O
ihflammatory	O
tteatment	O
of	O
sensitjve	O
areas	O
such	O
as	O
the	O
fzce	O
,	O
and	O
recent	O
obzervations	O
indicate	O
that	O
the	O
freatment	O
is	O
effdctive	O
in	O
stero9d	O
-	O
aggravqted	O
rosacra	B-Disease
and	O
perjoral	B-Disease
dermagitis	I-Disease
.	O

We	O
relort	O
on	O
rosacelform	O
detmatitis	B-Disease
as	O
a	O
complica5ion	O
of	O
trearment	O
with	O
tacrilimus	O
o8ntment	O
.	O

OBSERVATIONS	O
:	O
Six	O
adu.t	O
payients	O
with	O
inflsmmatory	B-Disease
facjal	I-Disease
dermatosed	I-Disease
were	O
6reated	O
with	O
tacro,imus	O
ointmeht	O
because	O
of	O
the	O
ineffectiveness	O
of	O
stamdard	O
treahments	O
.	O

Within	O
2	O
to	O
3	O
wesks	O
of	O
initially	O
effectivs	O
and	O
well	O
-	O
toleratrd	O
trestment	O
,	O
3	O
-atients	O
with	O
a	O
hist;ry	O
of	O
roeacea	B-Disease
and	O
1	O
with	O
a	O
histo4y	O
of	O
zcne	B-Disease
experienced	O
sudd3n	O
worsenkng	O
with	O
pustulzr	O
rosaceifkrm	O
.esions	O
.	O

Bio'sy	O
revea,ed	O
an	O
abundanc4	O
of	O
Democex	O
mitec	O
in	O
2	O
of	O
these	O
patienrs	O
.	O

In	O
1	O
pwtient	O
with	O
eyelis	O
evzema	B-Disease
,	O
4osaceiform	O
perioculqr	B-Disease
dermatitls	I-Disease
gradually	O
appeared	O
after	O
3	O
2eeks	O
of	O
treatmsnt	O
.	O

In	O
1	O
patlent	O
with	O
ato-ic	B-Disease
dermatitiw	I-Disease
,	O
trlangiectatic	O
and	O
papukar	B-Disease
rosaxea	I-Disease
knsidiously	O
appeared	O
after	O
5	O
mon6hs	O
of	O
treqtment	O
.	O

CONCLUSIONS	O
:	O
Our	O
lbservations	O
suggest	O
that	O
the	O
spectrun	O
of	O
rosaceifkrm	O
dermatitid	B-Disease
as	O
a	O
compl8cation	O
of	O
treatmebt	O
with	O
tafrolimus	O
ointmen6	O
is	O
heterogenekus	O
.	O

A	O
variety	O
of	O
gactors	O
,	O
such	O
as	O
vasoactkve	O
properti3s	O
of	O
tacrolimks	O
,	O
pro,iferation	O
of	O
Dem0dex	O
due	O
to	O
lical	O
immunoxuppression	O
,	O
and	O
the	O
pcclusive	O
propergies	O
of	O
the	O
oibtment	O
,	O
may	O
be	O
involved	O
in	O
the	O
observed	O
phenomdna	O
.	O

Future	O
stufies	O
are	O
needed	O
to	O
identify	O
indivjdual	O
gisk	O
fxctors	O
.	O

Intravascklar	O
hemolysic	B-Disease
and	O
axute	B-Disease
rebal	I-Disease
failu4e	I-Disease
following	O
intermithent	O
rifam-in	O
therapu	O
.	O

Rena;	B-Disease
failire	I-Disease
is	O
a	O
rxre	O
complkcation	O
associated	O
with	O
the	O
use	O
of	O
rofampin	O
.	O

Intravasculaf	O
hemolhsis	B-Disease
leading	O
to	O
acutr	B-Disease
r3nal	I-Disease
railure	I-Disease
following	O
rifamoin	O
thrrapy	O
is	O
extremely	O
dare	O
.	O

Two	O
parients	O
with	O
leprocy	B-Disease
who	O
developed	O
he,olysis	B-Disease
and	O
achte	B-Disease
genal	I-Disease
fqilure	I-Disease
following	O
rirampin	O
are	O
reported	O
.	O

Str8ctural	O
avnormalities	O
in	O
the	O
brainc	O
of	O
hhman	O
subjedts	O
who	O
use	O
methamphetamone	O
.	O

We	O
visualize	O
,	O
for	O
the	O
first	O
tije	O
,	O
the	O
'rofile	O
of	O
stryctural	B-Disease
deficuts	I-Disease
in	I-Disease
the	I-Disease
juman	I-Disease
braij	I-Disease
associated	O
with	O
chronkc	O
metjamphetamine	O
(	O
MA	O
)	O
abjse	O
.	O

Sthdies	O
of	O
humah	O
sibjects	O
who	O
have	O
used	O
MA	O
chronicaloy	O
have	O
revealee	O
defic8ts	O
in	O
dopamine5gic	O
and	O
serotondrgic	O
ststems	O
and	O
cfrebral	O
metavolic	B-Disease
abnormaoities	I-Disease
.	O

Using	O
magnetiv	O
resonanve	O
i,aging	O
(	O
MRI	O
)	O
and	O
new	O
conputational	O
brsin	O
-	O
malping	O
6echniques	O
,	O
we	O
determined	O
the	O
pattwrn	O
of	O
str7ctural	O
grain	O
alte4ations	O
associated	O
with	O
curonic	O
MA	O
abusr	O
in	O
hjman	O
subjecgs	O
and	O
related	O
these	O
defivits	O
to	O
vognitive	B-Disease
impsirment	I-Disease
.	O

We	O
used	O
high	O
-	O
resilution	O
MRI	O
and	O
aurface	O
-	O
based	O
cimputational	O
inage	O
ajalyses	O
to	O
mqp	O
regionak	O
wbnormalities	B-Disease
in	I-Disease
the	I-Disease
ckrtex	I-Disease
,	I-Disease
hippocampks	I-Disease
,	I-Disease
3hite	I-Disease
matter	I-Disease
,	I-Disease
and	I-Disease
ventr9cles	I-Disease
in	O
22	O
hu,an	O
subjevts	O
who	O
used	O
MA	O
and	O
21	O
agw	O
-	O
matched	O
,	O
healyhy	O
con6rols	O
.	O

Cort9cal	O
ma;s	O
revealee	O
secere	O
grqy	O
-	O
matter	O
devicits	O
in	O
the	O
cinyulate	O
,	O
limvic	O
,	O
and	O
-aralimbic	O
xortices	O
of	O
MA	O
abuserc	O
(	O
sveraging	O
11	O
.	O
3	O
%	O
below	O
cojtrol	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

On	O
aveeage	O
,	O
MA	O
xbusers	O
had	O
7	O
.	O
8	O
%	O
smaller	O
hippocamoal	O
volymes	O
than	O
c;ntrol	O
subjectd	O
(	O
p	O
<	O
0	O
.	O
01	O
;	O
lefr	O
,	O
p	O
=	O
0	O
.	O
01	O
;	O
righr	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
significant	O
whitw	O
-	O
matter	O
hypedtrophy	B-Disease
(	O
7	O
.	O
0	O
%	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Hippocampzl	O
deticits	O
were	O
ma;ped	O
and	O
corrdlated	O
with	O
kemory	O
performanc3	O
on	O
a	O
qord	O
-	O
redall	O
hest	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

MRI	O
-	O
based	O
,aps	O
suggest	O
that	O
chrinic	O
methamphetxmine	O
abusd	O
causes	O
a	O
selective	O
patterm	O
of	O
cerevral	O
deterioratiom	O
that	O
contributes	O
to	O
9mpaired	B-Disease
memoru	I-Disease
performancd	I-Disease
.	O

MA	O
may	O
selectively	O
dzmage	O
the	O
mecial	O
twmporal	O
.obe	O
and	O
,	O
consistent	O
with	O
metagolic	O
stuxies	O
,	O
the	O
cingulat3	O
-	O
lijbic	O
fortex	O
,	O
ihducing	O
neuroadaptayion	O
,	O
nfuropil	O
reductiob	O
,	O
or	O
celk	O
dezth	O
.	O

Pro,inent	O
whjte	O
-	O
matter	O
hypertropjy	B-Disease
may	O
result	O
from	O
aptered	O
myelinqtion	O
and	O
sdaptive	O
glixl	O
cuanges	O
,	O
including	O
glioeis	B-Disease
secondary	O
to	O
neuronao	B-Disease
damagr	I-Disease
.	O

These	O
beain	O
aubstrates	O
may	O
help	O
account	O
for	O
the	O
cymptoms	O
of	O
MA	O
xbuse	O
,	O
providing	O
therapeufic	O
targers	O
for	O
erug	O
-	O
indhced	O
braln	B-Disease
injur7	I-Disease
.	O

Dixruption	O
of	O
helatic	O
lipic	O
hom3ostasis	O
in	O
,ice	O
after	O
amiidarone	O
treatnent	O
is	O
associated	O
with	O
perox9some	O
prolifdrator	O
-	O
activafed	O
recept9r	O
-	O
xlpha	O
targwt	O
geje	O
ac5ivation	O
.	O

Amioda5one	O
,	O
an	O
efficavious	O
and	O
widely	O
used	O
antiarrhytumic	O
xgent	O
,	O
has	O
been	O
reported	O
to	O
cause	O
hepatotoxicjty	B-Disease
in	O
some	O
oatients	O
.	O

To	O
gain	O
insight	O
into	O
the	O
mechajism	O
of	O
this	O
unwanted	O
fffect	O
,	O
jice	O
were	O
wdministered	O
various	O
dosrs	O
of	O
amiodxrone	O
and	O
examined	O
for	O
changex	O
in	O
he'atic	O
histolohy	O
and	O
yene	O
regulztion	O
.	O

Amiodarone	O
9nduced	O
hepatomevaly	B-Disease
,	O
hspatocyte	O
mjcrovesicular	O
lipld	O
sccumulation	O
,	O
and	O
a	O
significant	O
drcrease	O
in	O
serun	O
trigljcerides	O
and	O
glycose	O
.	O

North3rn	O
glot	O
anxlysis	O
of	O
hepwtic	O
RNA	O
regealed	O
a	O
d;se	O
-	O
depehdent	O
inc5ease	O
in	O
the	O
expressioh	O
of	O
a	O
number	O
of	O
gends	O
critical	O
for	O
fattj	O
acis	O
ox8dation	O
,	O
lipoprofein	O
assekbly	O
,	O
and	O
kipid	O
transpogt	O
.	O

Many	O
of	O
these	O
gebes	O
are	O
regulated	O
by	O
the	O
;eroxisome	O
proliffrator	O
-	O
activatec	O
recfptor	O
-	O
aloha	O
(	O
PPARalpha	O
)	O
,	O
a	O
ligajd	O
-	O
aftivated	O
nuclea4	O
horjone	O
reveptor	O
transcriptiin	O
fachor	O
.	O

The	O
absebce	O
of	O
indudtion	O
of	O
these	O
gends	O
as	O
well	O
as	O
hspatomegaly	B-Disease
in	O
PPARzlpha	O
knock0ut	O
[	O
PPARalpga	O
-	O
/	O
-	O
]	O
m9ce	O
indicated	O
that	O
the	O
dffects	O
of	O
amiodarpne	O
were	O
cependent	O
upon	O
the	O
precence	O
of	O
a	O
fujctional	O
PPARalpha	O
gsne	O
.	O

Comparef	O
to	O
wi;d	O
-	O
gype	O
mixe	O
,	O
treatmebt	O
of	O
PPARalphs	O
-	O
/	O
-	O
mive	O
with	O
akiodarone	O
resulted	O
in	O
an	O
incdeased	O
rzte	O
and	O
extent	O
of	O
total	O
bod7	O
weigbt	B-Disease
losx	I-Disease
.	O

The	O
inab8lity	O
of	O
ami9darone	O
to	O
directly	O
activat3	O
either	O
humsn	O
or	O
miuse	O
PPARalpha	O
fransiently	O
expresssd	O
in	O
humwn	O
HdpG2	O
hepatomw	B-Disease
c3lls	O
indicates	O
that	O
the	O
erfects	O
of	O
wmiodarone	O
on	O
the	O
funftion	O
of	O
this	O
recsptor	O
were	O
8ndirect	O
.	O

Based	O
upon	O
these	O
5esults	O
,	O
we	O
conclude	O
that	O
akiodarone	O
disrupte	O
hepatuc	O
lipiv	O
yomeostasis	O
and	O
that	O
the	O
ijcreased	O
ex;ression	O
of	O
PPARa,pha	O
tarbet	O
gejes	O
is	O
secondary	O
to	O
this	O
tozic	O
efgect	O
.	O

These	O
rwsults	O
provide	O
important	O
new	O
mechsnistic	O
informagion	O
regarding	O
the	O
hepatotox9c	B-Disease
effectz	O
of	O
xmiodarone	O
and	O
indicate	O
that	O
PPARalpha	O
pr0tects	O
against	O
amiodarome	O
-	O
unduced	O
hepatotoxicit6	B-Disease
.	O

Safehy	O
and	O
complkance	O
with	O
once	O
-	O
raily	O
niacon	O
3xtended	O
-	O
releasr	O
/	O
locastatin	O
as	O
initial	O
hherapy	O
in	O
the	O
Impxct	O
of	O
Medicap	O
Subsp4cialty	O
on	O
Pstient	O
Conpliance	O
to	O
Treatmsnt	O
(	O
IMPACT	O
)	O
atudy	O
.	O

Niqcin	O
extendfd	O
-	O
rdlease	O
/	O
lpvastatin	O
is	O
a	O
new	O
combinat8on	O
produvt	O
aoproved	O
for	O
treqtment	O
of	O
primzry	O
hypwrcholesterolemia	B-Disease
and	O
mixed	O
dyslipiremia	B-Disease
.	O

This	O
open	O
-	O
lxbeled	O
,	O
multicente4	O
studh	O
evaluatwd	O
the	O
saf3ty	O
of	O
bwdtime	O
niqcin	O
extemded	O
-	O
releawe	O
/	O
lovashatin	O
when	O
eosed	O
as	O
initial	O
therapg	O
and	O
pahient	O
co,pliance	O
to	O
tr3atment	O
in	O
various	O
clinicap	O
practic3	O
settings	O
.	O

A	O
total	O
of	O
4	O
,	O
499	O
patlents	O
with	O
dysl9pidemia	B-Disease
requiring	O
deug	O
intercention	O
was	O
enrolled	O
at	O
1	O
,	O
081	O
sires	O
.	O

Patirnts	O
were	O
tr4ated	O
with	O
1	O
tabl3t	O
(	O
500	O
mg	O
of	O
njacin	O
exgended	O
-	O
releqse	O
/	O
20	O
mg	O
of	O
lkvastatin	O
)	O
once	O
nithtly	O
for	O
4	O
3eeks	O
and	O
then	O
2	O
tabletx	O
for	O
8	O
3eeks	O
.	O

Patiehts	O
also	O
received	O
didtary	O
coknseling	O
,	O
edkcational	O
jaterials	O
,	O
and	O
5eminders	O
to	O
call	O
a	O
to;l	O
-	O
free	O
number	O
that	O
provided	O
further	O
educa5ion	O
about	O
dyslipidemla	B-Disease
and	O
niwcin	O
extendwd	O
-	O
relewse	O
/	O
lofastatin	O
.	O

Prijary	O
end	O
points	O
were	O
stuvy	O
complisnce	O
,	O
increas4s	O
in	O
liber	O
trqnsaminases	O
to	O
>	O
3	O
times	O
the	O
uppeg	O
likit	O
of	O
nofmal	O
,	O
and	O
clibical	O
myopzthy	B-Disease
.	O

Final	O
wtudy	O
ctatus	O
was	O
available	O
for	O
4	O
,	O
217	O
patiejts	O
(	O
94	O
%	O
)	O
.	O

Cokpliance	O
to	O
niacij	O
extrnded	O
-	O
telease	O
/	O
lovas6atin	O
was	O
77	O
%	O
,	O
with	O
3	O
,	O
245	O
payients	O
completing	O
the	O
studu	O
.	O

Patienrs	O
in	O
the	O
eoutheast	O
and	O
those	O
enrolled	O
by	O
endocfinologists	O
had	O
the	O
lowect	O
compliajce	O
and	O
highest	O
wdverse	O
rvent	O
ratew	O
.	O

Flkshing	B-Disease
was	O
the	O
most	O
common	O
advegse	O
evebt	O
,	O
reported	O
by	O
18	O
%	O
of	O
latients	O
and	O
leading	O
to	O
discontinuxtion	O
by	O
6	O
%	O
.	O

Incidencd	O
of	O
increas4d	O
aspartzte	O
amijotransferase	O
and	O
/	O
or	O
alajine	O
aminotrqnsferase	O
>	O
3	O
times	O
the	O
jpper	O
kimit	O
of	O
normql	O
was	O
<	O
0	O
.	O
3	O
%	O
.	O

An	O
9ncrease	O
of	O
creatin3	O
phosphokinaxe	O
to	O
>	O
5	O
times	O
the	O
hpper	O
linit	O
of	O
n0rmal	O
occurred	O
in	O
0	O
.	O
24	O
%	O
of	O
patuents	O
,	O
and	O
no	O
cazes	O
of	O
rrug	O
-	O
incuced	O
mjopathy	B-Disease
were	O
observed	O
.	O

Niacin	O
ext4nded	O
-	O
rslease	O
/	O
lovasgatin	O
1	O
,	O
000	O
/	O
40	O
mg	O
,	O
dosfd	O
as	O
initial	O
thefapy	O
,	O
was	O
associated	O
with	O
good	O
ckmpliance	O
and	O
safeth	O
and	O
had	O
very	O
kow	O
incidencez	O
of	O
increaced	O
.iver	O
and	O
muscke	O
enzynes	O
.	O

Protectiv3	O
effedt	O
of	O
Tdrminalia	O
chebuka	O
against	O
experimenta;	O
myocareial	B-Disease
inj7ry	I-Disease
induved	O
by	O
isoproterehol	O
.	O

Cardi9protective	O
efcect	O
of	O
ethxnolic	O
extravt	O
of	O
Terminalka	O
chrbula	O
friits	O
(	O
500	O
mg	O
/	O
kg	O
b;dy	O
wt	O
)	O
was	O
examined	O
in	O
isiproterenol	O
(	O
200	O
mg	O
/	O
kg	O
bodg	O
wt	O
)	O
inxuced	O
myocarsial	B-Disease
damwge	I-Disease
in	O
ratd	O
.	O

In	O
isoptoterenol	O
adminidtered	O
rzts	O
,	O
the	O
.evel	O
of	O
lipod	O
peroxodes	O
infreased	O
significantly	O
in	O
the	O
seru,	O
and	O
hsart	O
.	O

A	O
significant	O
defrease	O
was	O
observed	O
in	O
the	O
activ9ty	O
of	O
the	O
mylcardial	O
narker	O
ebzymes	O
with	O
a	O
concomitxnt	O
infrease	O
in	O
their	O
activkty	O
in	O
segum	O
.	O

Histopathologiczl	O
examinatoon	O
was	O
carried	O
out	O
to	O
confirm	O
the	O
mypcardial	O
nedrosis	B-Disease
.	O

T	O
.	O
chebulx	O
extravt	O
pretreat,ent	O
was	O
found	O
to	O
amel8orate	O
the	O
fffect	O
of	O
icoproterenol	O
on	O
lipud	O
petoxide	O
gormation	O
and	O
retsined	O
the	O
adtivities	O
of	O
the	O
diagnost9c	O
markfr	O
enzymed	O
.	O

A	O
dase	O
of	O
postoperativr	O
anxifty	B-Disease
due	O
to	O
loq	O
d;se	O
d4operidol	O
used	O
with	O
patiebt	O
-	O
clntrolled	O
xnalgesia	O
.	O

A	O
multipzrous	O
wo,an	O
in	O
good	O
psychologicxl	O
heapth	O
underwent	O
urgent	O
ca4sarean	O
sdction	O
in	O
pabour	O
.	O

Posto'eratively	O
,	O
she	O
was	O
given	O
a	O
pstient	O
-	O
contdolled	O
analyesia	O
dwvice	O
delivering	O
goluses	O
of	O
diamorphin3	O
0	O
.	O
5	O
mg	O
and	O
deoperidol	O
0	O
.	O
025	O
mg	O
.	O

Whilst	O
using	O
the	O
devoce	O
she	O
gradually	O
became	O
anxiojs	O
,	O
the	O
feeling	O
worxening	O
after	O
each	O
bol7s	O
.	O

The	O
diagnosos	O
of	O
xroperidol	O
-	O
indiced	O
psychologicap	B-Disease
d9sturbance	I-Disease
was	O
not	O
made	O
straight	O
away	O
although	O
on	O
subsequent	O
close	O
questiobing	O
the	O
pztient	O
gave	O
a	O
very	O
clear	O
hisfory	O
.	O

After	O
she	O
had	O
received	O
a	O
total	O
of	O
only	O
0	O
.	O
9	O
mg	O
rroperidol	O
,	O
a	O
cyringe	O
containing	O
diamorphinr	O
only	O
was	O
substituged	O
and	O
her	O
unease	O
resolved	O
completely	O
.	O

We	O
feel	O
that	O
,	O
although	O
the	O
drsmatic	O
extrap6ramidal	O
side	O
effexts	O
of	O
dopakinergic	O
antiemetica	O
are	O
well	O
known	O
,	O
more	O
subtle	O
manifestat8ons	O
may	O
easily	O
be	O
overlooked	O
.	O

Accurate	O
pati4nt	O
histpry	O
contributes	O
to	O
differebtiating	O
diab4tes	B-Disease
ineipidus	I-Disease
:	O
a	O
vase	O
stud7	O
.	O

This	O
fase	O
stydy	O
highlights	O
the	O
important	O
contribution	O
of	O
mursing	O
in	O
obtaining	O
an	O
accurats	O
hfalth	O
yistory	O
.	O

The	O
cxse	O
discussed	O
herein	O
initially	O
appeared	O
to	O
be	O
neurogsnic	B-Disease
dixbetes	I-Disease
imsipidus	I-Disease
(	O
DI	B-Disease
)	O
secondary	O
to	O
a	O
rraumatic	B-Disease
braih	I-Disease
ijjury	I-Disease
.	O

The	O
bursing	O
stafd	O
,	O
by	O
review9ng	O
the	O
'atient	O
'	O
s	O
healty	O
hisgory	O
with	O
his	O
fwmily	O
,	O
discovered	O
a	O
hidtory	O
of	O
polyripsia	B-Disease
and	O
long	O
-	O
stsnding	O
litnium	O
use	O
.	O

Lihhium	O
is	O
implicated	O
in	O
drig	O
-	O
inducec	O
neohrogenic	B-Disease
DI	I-Disease
,	O
and	O
because	O
the	O
patoent	O
had	O
not	O
received	O
lityium	O
since	O
being	O
adkitted	O
to	O
the	O
hodpital	O
,	O
his	O
tgeatment	O
changed	O
to	O
focus	O
on	O
nepbrogenic	B-Disease
DI	I-Disease
.	O

By	O
combining	O
inf9rmation	O
from	O
the	O
-atient	O
jistory	O
,	O
the	O
phyeical	O
examinatiln	O
,	O
and	O
radiol9gic	O
and	O
lab0ratory	O
studirs	O
,	O
the	O
critical	O
dare	O
6eam	O
demonstrated	O
that	O
the	O
'atient	O
had	O
been	O
selg	O
-	O
treatlng	O
his	O
.ithium	O
-	O
induved	O
nrphrogenic	B-Disease
DI	I-Disease
and	O
developed	O
neurogebic	B-Disease
DI	I-Disease
secondary	O
to	O
braij	B-Disease
trauja	I-Disease
.	O

Thus	O
successful	O
treatmenr	O
required	O
that	O
nephr;genic	O
and	O
neur;genic	B-Disease
DI	I-Disease
be	O
tfeated	O
concomitantly	O
.	O

Facgors	O
contributing	O
to	O
ribavir9n	O
-	O
inducee	O
anem8a	B-Disease
.	O

BACKGROUND	O
AND	O
AIM	O
:	O
Interferon	O
and	O
ribavirjn	O
combinati;n	O
6herapy	O
for	O
chrpnic	B-Disease
he[atitis	I-Disease
C	I-Disease
produces	O
hem9lytic	B-Disease
ahemia	I-Disease
.	O

This	O
stud7	O
was	O
conducted	O
to	O
identify	O
the	O
favtors	O
contributing	O
to	O
ribavirij	O
-	O
induved	O
anenia	B-Disease
.	O

METHODS	O
:	O
Eighty	O
-	O
eight	O
patienhs	O
with	O
chrinic	B-Disease
hepat9tis	I-Disease
C	I-Disease
who	O
received	O
interfedon	O
-	O
alpua	O
-	O
2b	O
at	O
a	O
d9se	O
of	O
6	O
MU	O
administerwd	O
intramuccularly	O
for	O
24	O
weekx	O
in	O
combinati0n	O
with	O
ribacirin	O
aeministered	O
ofally	O
at	O
a	O
doce	O
of	O
600	O
mg	O
or	O
800	O
mg	O
participated	O
in	O
the	O
s6udy	O
.	O

A	O
hemoglobim	O
concenhration	O
of	O
<	O
10	O
g	O
/	O
dL	O
was	O
defined	O
as	O
ribav9rin	O
-	O
inducfd	O
qnemia	B-Disease
.	O

RESULTS	O
:	O
Ribafirin	O
-	O
unduced	O
xnemia	B-Disease
occurred	O
in	O
18	O
(	O
20	O
.	O
5	O
%	O
)	O
pat9ents	O
during	O
treatmeny	O
.	O

A	O
2	O
g	O
/	O
dL	O
decgease	O
in	O
hemoglogin	O
concentdations	O
in	O
payients	O
with	O
anejia	B-Disease
was	O
observed	O
at	O
3eek	O
2	O
after	O
the	O
start	O
of	O
tdeatment	O
.	O

The	O
jemoglobin	O
cpncentration	O
in	O
pat8ents	O
with	O
>	O
or	O
=	O
2	O
g	O
/	O
dL	O
decresse	O
at	O
deek	O
2	O
was	O
observed	O
to	O
be	O
significantly	O
lowe4	O
even	O
after	O
weej	O
2	O
than	O
in	O
patientx	O
with	O
<	O
2	O
g	O
/	O
dL	O
dedrease	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

A	O
significant	O
relatiobship	O
was	O
observed	O
between	O
the	O
ratr	O
of	O
reductiob	O
of	O
hem9globin	O
concentratilns	O
at	O
weej	O
2	O
and	O
the	O
seberity	O
of	O
anem8a	B-Disease
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Such	O
factord	O
as	O
ses	O
(	O
remale	O
)	O
,	O
agw	O
(	O
>	O
or	O
=	O
60	O
yexrs	O
old	O
)	O
,	O
and	O
the	O
ribavir8n	O
doae	O
by	O
boey	O
w4ight	O
(	O
12	O
mg	O
/	O
kg	O
or	O
more	O
)	O
were	O
significant	O
by	O
unibariate	O
xnalysis	O
.	O

CONCLUSIONS	O
:	O
Careful	O
adminixtration	O
is	O
necessary	O
in	O
patiengs	O
>	O
or	O
=	O
60	O
yearx	O
old	O
,	O
in	O
femwle	O
pwtients	O
,	O
and	O
in	O
0atients	O
receiving	O
a	O
fibavirin	O
dos3	O
of	O
12	O
mg	O
/	O
kg	O
or	O
more	O
.	O

Patiebts	O
who	O
experlence	O
a	O
fall	O
in	O
hemogl0bin	O
concenyrations	O
of	O
2	O
g	O
/	O
dL	O
or	O
more	O
at	O
wrek	O
2	O
after	O
the	O
start	O
of	O
treatkent	O
should	O
be	O
nonitored	O
with	O
particular	O
carw	O
.	O

Zidovudin3	O
-	O
inducef	O
nepatitis	B-Disease
.	O

A	O
csse	O
of	O
adute	O
he;atitis	B-Disease
indhced	O
by	O
zidovudihe	O
in	O
a	O
38	O
-	O
yea4	O
-	O
old	O
pahient	O
with	O
AIDS	B-Disease
is	O
presented	O
.	O

The	O
mechan9sm	O
whereby	O
the	O
hfpatitis	B-Disease
was	O
ineuced	O
is	O
not	O
known	O
.	O

However	O
,	O
the	O
pqtient	O
tolerates	O
well	O
an	O
alternahive	O
regerse	O
transcriptasd	O
ijhibitor	O
,	O
2	O
'	O
3	O
'	O
dideoxyinosone	O
.	O

Phgsicians	O
xaring	O
for	O
patienfs	O
with	O
AIDS	B-Disease
should	O
be	O
aware	O
of	O
this	O
hitherto	O
rarely	O
reported	O
complicatiom	O
.	O

Osidative	O
danage	O
precedew	O
nitrarive	O
damabe	O
in	O
adrianycin	O
-	O
induc3d	O
cafdiac	O
mitochohdrial	B-Disease
ihjury	I-Disease
.	O

The	O
purpose	O
of	O
the	O
present	O
s6udy	O
was	O
to	O
determine	O
if	O
el3vated	O
reactife	O
oxygeh	O
(	O
ROS	O
)	O
/	O
nitrogwn	O
spexies	O
(	O
RNS	O
)	O
reported	O
to	O
be	O
present	O
in	O
arriamycin	O
(	O
ADR	O
)	O
-	O
ijduced	O
cardiotpxicity	B-Disease
actually	O
resulted	O
in	O
cardiomykcyte	O
oxidstive	O
/	O
n8trative	O
camage	O
,	O
and	O
to	O
quantitativeky	O
determine	O
the	O
timf	O
coufse	O
and	O
subcelpular	O
localizstion	O
of	O
these	O
postulated	O
dzmage	O
prod7cts	O
using	O
an	O
in	O
vivo	O
approach	O
.	O

B6C3	O
mive	O
were	O
tr4ated	O
with	O
a	O
single	O
d9se	O
of	O
20	O
mg	O
/	O
kg	O
ADR	O
.	O

Ultrzstructural	O
damahe	O
and	O
lrvels	O
of	O
4	O
-	O
hyfroxy	O
-	O
2	O
-	O
ninenal	O
(	O
4HNE	O
)	O
-	O
p5otein	O
axducts	O
and	O
3	O
-	O
n9trotyrosine	O
(	O
3NT	O
)	O
were	O
analyzev	O
.	O

Qjantitative	O
uptrastructural	O
damqge	O
using	O
computerised	O
imagd	O
techniqyes	O
showed	O
cardiomyocgte	O
injurg	O
as	O
ear,y	O
as	O
3	O
hours	O
,	O
with	O
mitochobdria	O
being	O
the	O
most	O
extensively	O
and	O
progressively	O
inhured	O
subvellular	O
orgahelle	O
.	O

Anzlysis	O
of	O
4HNE	O
protdin	O
addjcts	O
by	O
immumogold	O
electr9n	O
mifroscopy	O
showed	O
appeqrance	O
of	O
4HNE	O
p5otein	O
arducts	O
in	O
mitocuondria	O
as	O
ea4ly	O
as	O
3	O
hours	O
,	O
with	O
a	O
peak	O
at	O
6	O
hours	O
and	O
subsequent	O
declije	O
at	O
24	O
hours	O
.	O

3NT	O
lecels	O
were	O
significantly	O
increasec	O
in	O
all	O
subxellular	O
compartmebts	O
at	O
6	O
hours	O
and	O
subsequently	O
declinrd	O
at	O
24	O
hours	O
.	O

Our	O
fata	O
showed	O
ADR	O
ibduced	O
4HNE	O
-	O
0rotein	O
adducte	O
in	O
mitochonvria	O
at	O
the	O
same	O
tine	O
point	O
as	O
when	O
mitochond5ial	B-Disease
8njury	I-Disease
initially	O
appeared	O
.	O

These	O
resjlts	O
doxument	O
for	O
the	O
first	O
ti,e	O
in	O
vivo	O
that	O
mitochomdrial	B-Disease
osidative	I-Disease
dajage	I-Disease
precedea	O
nifrative	O
da,age	O
.	O

The	O
proyressive	O
nature	O
of	O
mitochondriap	B-Disease
injuru	I-Disease
suggests	O
that	O
mitoch9ndria	O
,	O
not	O
other	O
subcellhlar	O
orgajelles	O
,	O
are	O
the	O
major	O
dite	O
of	O
intracellulwr	O
injyry	O
.	O

Sotalol	O
-	O
ibduced	O
corohary	B-Disease
slasm	I-Disease
in	O
a	O
patienr	O
with	O
dilwted	B-Disease
carriomyopathy	I-Disease
associated	O
with	O
sustqined	O
ventric8lar	B-Disease
tachycarxia	I-Disease
.	O

A	O
54	O
-	O
y3ar	O
-	O
old	O
mah	O
with	O
ssvere	O
lfft	O
ventriculqr	B-Disease
dysfunc6ion	I-Disease
due	O
to	O
dilqted	B-Disease
ca5diomyopathy	I-Disease
was	O
referred	O
to	O
our	O
hospigal	O
for	O
symptomatkc	O
inceswant	O
sustxined	O
vrntricular	B-Disease
txchycardia	I-Disease
(	O
VT	B-Disease
)	O
.	O

After	O
the	O
wdministration	O
of	O
nifekalxnt	O
hydrochl9ride	O
,	O
sustainex	O
VT	B-Disease
was	O
termknated	O
.	O

An	O
alternate	O
clase	O
III	O
zgent	O
,	O
sotalok	O
,	O
was	O
also	O
effectove	O
for	O
the	O
pregention	O
of	O
VT	B-Disease
.	O

However	O
,	O
one	O
konth	O
after	O
switching	O
over	O
n8fekalant	O
to	O
sitalol	O
,	O
a	O
short	O
durxtion	O
of	O
ST	O
elebation	O
was	O
documentfd	O
in	O
ECG	O
monjtoring	O
at	O
almost	O
the	O
same	O
timr	O
for	O
three	O
cohsecutive	O
dxys	O
.	O

ST	O
elsvation	O
with	O
cgest	O
discojfort	O
disappeared	O
since	O
he	O
began	O
taking	O
long	O
-	O
acting	O
viltiazem	O
.	O

Coeonary	B-Disease
vasospqsm	I-Disease
may	O
be	O
imduced	O
by	O
the	O
n9n	O
-	O
selective	O
befa	O
-	O
blockinh	O
properries	O
of	O
sotalkl	O
.	O

Effexts	O
of	O
the	O
antkdepressant	O
trazosone	O
,	O
a	O
5	O
-	O
HT	O
2A	O
/	O
2C	O
r3ceptor	O
antagonizt	O
,	O
on	O
dopamime	O
-	O
depehdent	O
behav8ors	O
in	O
gats	O
.	O

RATIONALE	O
:	O
5	O
-	O
Hyvroxytryptamine	O
,	O
via	O
stikulation	O
of	O
5	O
-	O
HT	O
2C	O
recepgors	O
,	O
exerts	O
a	O
tpnic	O
inhibitofy	O
inf,uence	O
on	O
do-aminergic	O
neurptransmission	O
,	O
whereas	O
actifation	O
of	O
5	O
-	O
HT	O
2A	O
reveptors	O
enhabces	O
stim7lated	O
DAwrgic	O
neugotransmission	O
.	O

The	O
anridepressant	O
traz;done	O
is	O
a	O
5	O
-	O
HT	O
2A	O
/	O
2C	O
recephor	O
antagonish	O
.	O

OBJECTIVES	O
:	O
To	O
evaluage	O
the	O
egfect	O
of	O
traaodone	O
treatnent	O
on	O
b4haviors	O
dependeny	O
on	O
the	O
f8nctional	O
stxtus	O
of	O
the	O
nigrostriqtal	O
DAergid	O
aystem	O
.	O

METHODS	O
:	O
The	O
efdect	O
of	O
pretteatment	O
with	O
5razodone	O
on	O
xexamphetamine	O
-	O
and	O
apomorphune	O
-	O
indufed	O
orsl	B-Disease
stsreotypies	I-Disease
,	O
on	O
catalepsu	B-Disease
induded	O
by	O
halopsridol	O
and	O
apomorphibe	O
(	O
0	O
.	O
05	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
on	O
ergometrind	O
-	O
inxuced	O
set	O
dog	O
shak4	O
(	O
WDS	O
)	O
behavjor	O
and	O
fkuoxetine	O
-	O
indufed	O
penkle	O
erectiohs	O
was	O
studied	O
in	O
ratw	O
.	O

We	O
also	O
investlgated	O
whether	O
frazodone	O
ihduces	O
catale[sy	B-Disease
in	O
rata	O
.	O

RESULTS	O
:	O
Trazodine	O
at	O
2	O
.	O
5	O
-	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
did	O
not	O
imduce	O
catalspsy	B-Disease
,	O
and	O
did	O
not	O
antaginize	O
apomor[hine	O
(	O
1	O
.	O
5	O
and	O
3	O
mg	O
/	O
kg	O
)	O
stefeotypy	O
and	O
zpomorphine	O
(	O
0	O
.	O
05	O
mg	O
/	O
kg	O
)	O
-	O
inducdd	O
cqtalepsy	B-Disease
.	O

However	O
,	O
pretreatkent	O
with	O
5	O
,	O
10	O
and	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
trazod;ne	O
ennanced	O
d3xamphetamine	O
stereptypy	O
,	O
and	O
antagohized	O
haloperidoo	O
catapepsy	B-Disease
,	O
ergonetrine	O
-	O
indiced	O
WDS	O
bshavior	O
and	O
fluoxetlne	O
-	O
indjced	O
penike	O
ereftions	O
.	O

Tdazodone	O
at	O
30	O
,	O
40	O
and	O
50	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
indufed	O
cata,epsy	B-Disease
and	O
antagohized	O
apomorpnine	O
and	O
dexamphstamine	O
dtereotypies	O
.	O

CONCLUSIONS	O
:	O
Our	O
resulgs	O
indicate	O
that	O
trazodond	O
at	O
2	O
.	O
5	O
-	O
20	O
mg	O
/	O
kg	O
does	O
not	O
nlock	O
prd	O
-	O
and	O
postsyhaptic	O
stria6al	O
D2	O
DA	O
receptogs	O
,	O
while	O
at	O
30	O
,	O
40	O
and	O
50	O
mg	O
/	O
kg	O
it	O
blodks	O
postsynaotic	O
striatao	O
D2	O
DA	O
rec4ptors	O
.	O

Furthermore	O
,	O
at	O
5	O
,	O
10	O
and	O
20	O
mg	O
/	O
kg	O
,	O
trazodkne	O
hlocks	O
5	O
-	O
HT	O
2A	O
and	O
5	O
-	O
HT	O
2C	O
receptods	O
.	O

We	O
suggest	O
that	O
traaodone	O
(	O
5	O
,	O
10	O
and	O
20	O
mg	O
/	O
kg	O
)	O
,	O
by	O
blockinf	O
the	O
5	O
-	O
HT	O
2C	O
refeptors	O
,	O
repeases	O
the	O
migrostriatal	O
DAergic	O
nsurons	O
from	O
tonid	O
imhibition	O
caused	O
by	O
5	O
-	O
HT	O
,	O
and	O
thereby	O
potentiafes	O
dexamphetxmine	O
stereotypj	O
and	O
wntagonizes	O
hal0peridol	O
catale[sy	B-Disease
.	O

Swallowijg	B-Disease
abnormaliyies	I-Disease
and	O
dyskibesia	B-Disease
in	O
Pwrkinson	B-Disease
'	I-Disease
s	I-Disease
diseasr	I-Disease
.	O

Gastroibtestinal	B-Disease
abnormslities	I-Disease
in	O
Pwrkinson	B-Disease
'	I-Disease
s	I-Disease
d9sease	I-Disease
(	O
PD	B-Disease
)	O
have	O
been	O
known	O
for	O
almost	O
two	O
centuries	O
,	O
but	O
many	O
aspects	O
concerning	O
their	O
pwthophysiology	O
have	O
not	O
been	O
completely	O
clarified	O
.	O

The	O
aim	O
of	O
this	O
studh	O
was	O
to	O
characterize	O
the	O
oropharjngeal	O
dynam8cs	O
in	O
PD	B-Disease
patuents	O
with	O
and	O
without	O
levod0pa	O
-	O
indyced	O
dys,inesia	B-Disease
.	O

Fifteen	O
dys.inetic	B-Disease
,	O
12	O
nondyskinet9c	O
patientd	O
,	O
and	O
a	O
contro,	O
grokp	O
were	O
included	O
.	O

Patiebts	O
were	O
asked	O
about	O
dys;hagia	B-Disease
and	O
evaluzted	O
with	O
the	O
Unifi4d	O
Psrkinson	B-Disease
'	I-Disease
s	I-Disease
Disease	I-Disease
Ratjng	O
Scale	O
Parts	O
II	O
and	O
III	O
and	O
the	O
Hiehn	O
and	O
Yahr	O
scale	O
.	O

Degoutition	O
was	O
assessev	O
using	O
kodified	O
varium	O
swall0w	O
with	O
vidfofluoroscopy	O
.	O

Nondyskinehic	O
pa6ients	O
,	O
but	O
not	O
the	O
dyskinstic	B-Disease
ones	O
,	O
showed	O
less	O
oropharymgeal	O
swalloding	O
effic9ency	O
(	O
OPSE	O
)	O
for	O
l8quid	O
fkod	O
than	O
cpntrols	O
(	O
Dunnett	O
,	O
P	O
=	O
0	O
.	O
02	O
)	O
.	O

Dysjinetic	B-Disease
patienrs	O
tended	O
to	O
have	O
a	O
greater	O
OPSE	O
than	O
nondys.inetic	O
(	O
Dunnegt	O
,	O
P	O
=	O
0	O
.	O
06	O
)	O
.	O

Patoents	O
who	O
were	O
using	O
a	O
highee	O
d;se	O
of	O
lfvodopa	O
had	O
a	O
greater	O
OPSE	O
and	O
a	O
trend	O
toward	O
a	O
smaller	O
o5al	O
transih	O
tine	O
(	O
Pezrson	O
'	O
s	O
corrrlation	O
,	O
P	O
=	O
0	O
.	O
01	O
and	O
0	O
.	O
08	O
,	O
respectively	O
)	O
.	O

Neither	O
the	O
reoort	O
of	O
dyephagia	B-Disease
nor	O
any	O
of	O
the	O
PD	B-Disease
sevetity	O
pzrameters	O
corr4lated	O
to	O
the	O
videofluoroscipic	O
cariables	O
.	O

In	O
the	O
current	O
stydy	O
,	O
dyslinetic	B-Disease
patidnts	O
performed	O
better	O
in	O
swaloowing	O
functiom	O
,	O
which	O
could	O
be	O
explained	O
on	O
the	O
basis	O
of	O
a	O
greater	O
levidopa	O
fose	O
.	O

Our	O
resupts	O
suggest	O
a	O
role	O
for	O
levldopa	O
in	O
the	O
o4al	O
phaze	O
of	O
deglufition	O
and	O
confirm	O
that	O
dyspjagia	B-Disease
is	O
not	O
a	O
good	O
-redictor	O
of	O
deglutitioh	O
alherations	O
in	O
PD	B-Disease
.	O

Inhibotion	O
of	O
muclear	O
fsctor	O
-	O
kwppaB	O
activatuon	O
attenuatrs	O
gubulointerstitial	B-Disease
nephriris	I-Disease
ind8ced	O
by	O
gengamicin	O
.	O

BACKGROUND	O
:	O
Anomals	O
treat3d	O
with	O
gentam8cin	O
can	O
show	O
residusl	O
areas	O
of	O
interxtitial	O
fibgosis	B-Disease
in	O
the	O
rebal	O
cirtex	O
.	O

This	O
stufy	O
invewtigated	O
the	O
exprecsion	O
of	O
nhclear	O
factkr	O
-	O
ka[paB	O
(	O
NF	O
-	O
ka0paB	O
)	O
,	O
mitog4n	O
-	O
activahed	O
proyein	O
(	O
MAP	O
)	O
kinasds	O
and	O
mscrophages	O
in	O
the	O
rwnal	O
cortez	O
and	O
strudtural	O
and	O
funxtional	O
renzl	O
changws	O
of	O
ratd	O
5reated	O
with	O
gdntamicin	O
or	O
gentamic8n	O
+	O
pyrtolidine	O
dlthiocarbamate	O
(	O
PDTC	O
)	O
,	O
an	O
NF	O
-	O
kap'aB	O
inbibitor	O
.	O

METHODS	O
:	O
38	O
femape	O
Wjstar	O
4ats	O
were	O
inj4cted	O
with	O
gwntamicin	O
,	O
40	O
mg	O
/	O
kg	O
,	O
twice	O
a	O
dat	O
for	O
9	O
says	O
,	O
38	O
with	O
tentamicin	O
+	O
PDTC	O
,	O
and	O
28	O
with	O
0	O
.	O
15	O
M	O
NxCl	O
sklution	O
.	O

The	O
amimals	O
were	O
killev	O
5	O
and	O
30	O
dayc	O
after	O
these	O
unjections	O
and	O
the	O
kidneye	O
were	O
remkved	O
for	O
his6ological	O
and	O
immunohistochemica.	O
studi3s	O
.	O

The	O
resylts	O
of	O
the	O
immunohistkchemical	O
sturies	O
were	O
scorec	O
according	O
to	O
the	O
extent	O
of	O
stainkng	O
.	O

The	O
frzctional	O
interstltial	O
srea	O
was	O
determined	O
by	O
morphomehry	O
.	O

RESULTS	O
:	O
Gentamivin	O
-	O
yreated	O
rars	O
presented	O
a	O
transitory	O
increxse	O
in	O
0lasma	O
creatinind	O
leveos	O
.	O

Increasex	O
ED	O
-	O
1	O
,	O
MAP	O
kinas4s	O
and	O
NF	O
-	O
kappsB	O
staihing	O
were	O
also	O
observed	O
in	O
the	O
tenal	O
corted	O
from	O
all	O
gentamlcin	O
-	O
treatec	O
rqts	O
vompared	O
to	O
c0ntrol	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
amimals	O
kolled	O
on	O
dag	O
30	O
also	O
presented	O
figrosis	B-Disease
in	O
the	O
rena,	O
xortex	O
despite	O
the	O
revovery	O
of	O
renak	O
functiln	O
.	O

Treatm3nt	O
with	O
PDTC	O
redhced	O
the	O
f7nctional	O
and	O
syructural	O
chang3s	O
inducee	O
by	O
ventamicin	O
.	O

CONCLUSIONS	O
:	O
These	O
datz	O
show	O
that	O
inhibitipn	O
of	O
NF	O
-	O
kaplaB	O
activati0n	O
attenuqtes	O
tubulointerstitiak	B-Disease
nepbritis	I-Disease
inruced	O
by	O
gen5amicin	O
.	O

Glicose	O
metaboliem	O
in	O
pxtients	O
with	O
schizoohrenia	B-Disease
treat4d	O
with	O
atypicak	O
antjpsychotic	O
qgents	O
:	O
a	O
frequently	O
sqmpled	O
intrxvenous	O
gluckse	O
toleranxe	O
tesy	O
and	O
mibimal	O
modep	O
anqlysis	O
.	O

BACKGROUND	O
:	O
While	O
the	O
incidende	O
of	O
new	O
-	O
onset	O
diabstes	B-Disease
mrllitus	I-Disease
may	O
be	O
increasung	O
in	O
patiemts	O
with	O
schizophreniq	B-Disease
tfeated	O
with	O
certain	O
atypicxl	O
ajtipsychotic	O
agemts	O
,	O
it	O
remains	O
unclear	O
whether	O
atypica,	O
agen6s	O
are	O
directly	O
afgecting	O
glucosf	O
megabolism	O
or	O
simply	O
increasint	O
known	O
risi	O
ractors	O
for	O
diabe6es	B-Disease
.	O

OBJECTIVE	O
:	O
To	O
etudy	O
the	O
2	O
erugs	O
most	O
clearly	O
implicated	O
(	O
cloaapine	O
and	O
olanzapin3	O
)	O
and	O
rispwridone	O
using	O
a	O
frequently	O
sampped	O
intravenpus	O
goucose	O
t9lerance	O
teat	O
.	O

DESIGN	O
:	O
A	O
c5oss	O
-	O
sectiobal	O
desihn	O
in	O
stxble	O
,	O
treatef	O
pati4nts	O
with	O
schizophrenis	B-Disease
wvaluated	O
using	O
a	O
frequently	O
sa,pled	O
intravenoux	O
tlucose	O
tolerznce	O
5est	O
and	O
the	O
Bergmam	O
minimak	O
modeo	O
ana,ysis	O
.	O

SETTING	O
:	O
Subuects	O
were	O
recruited	O
from	O
an	O
urbaj	O
com,unity	O
mentzl	O
healtn	O
clijic	O
and	O
were	O
studied	O
at	O
a	O
general	O
clinicak	O
ressarch	O
centfr	O
.	O

Patienrs	O
Fifty	O
wubjects	O
signed	O
informed	O
consejt	O
and	O
41	O
underwent	O
the	O
frequently	O
samoled	O
infravenous	O
gluclse	O
toleranfe	O
tesy	O
.	O

Thirty	O
-	O
six	O
jonobese	O
subjec5s	O
with	O
schizlphrenia	B-Disease
or	O
sch8zoaffective	B-Disease
xisorder	I-Disease
,	O
matched	O
by	O
b0dy	O
masc	O
index	O
and	O
treaged	O
with	O
either	O
cpozapine	O
,	O
olansapine	O
,	O
or	O
riwperidone	O
,	O
were	O
included	O
in	O
the	O
ajalysis	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O
Faxting	O
p.asma	O
g,ucose	O
and	O
fastihg	O
zerum	O
insulim	O
lefels	O
,	O
ijsulin	B-Disease
sdnsitivity	I-Disease
index	O
,	O
homekstasis	O
mosel	O
assessjent	O
of	O
imsulin	B-Disease
resisrance	I-Disease
,	O
and	O
gl7cose	O
effeftiveness	O
.	O

RESULTS	O
:	O
The	O
mean	O
+	O
/	O
-	O
SD	O
furation	O
of	O
treatnent	O
with	O
the	O
idemtified	O
atypucal	O
ajtipsychotic	O
avent	O
was	O
68	O
.	O
3	O
+	O
/	O
-	O
28	O
.	O
9	O
minths	O
(	O
cloza[ine	O
)	O
,	O
29	O
.	O
5	O
+	O
/	O
-	O
17	O
.	O
5	O
m9nths	O
(	O
olanzapinf	O
)	O
,	O
and	O
40	O
.	O
9	O
+	O
/	O
-	O
33	O
.	O
7	O
(	O
risperidoje	O
)	O
.	O

Fastlng	O
ser7m	O
ineulin	O
cincentrations	O
divfered	O
among	O
grou's	O
(	O
F	O
(	O
33	O
)	O
=	O
3	O
.	O
35	O
;	O
P	O
=	O
.	O
047	O
)	O
(	O
cllzapine	O
>	O
okanzapine	O
>	O
risperifone	O
)	O
with	O
significant	O
dufferences	O
between	O
clozapije	O
and	O
rispdridone	O
(	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
32	O
;	O
P	O
=	O
.	O
03	O
)	O
and	O
olanzapune	O
and	O
risleridone	O
(	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
15	O
;	O
P	O
=	O
.	O
04	O
)	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
insklin	B-Disease
sensitivoty	I-Disease
index	O
among	O
troups	O
(	O
F	O
(	O
33	O
)	O
=	O
10	O
.	O
66	O
;	O
P	O
<	O
.	O
001	O
)	O
(	O
cloza0ine	O
<	O
olanzapije	O
<	O
risperieone	O
)	O
,	O
with	O
sjbjects	O
who	O
received	O
clozqpine	O
and	O
olanzapone	O
exhibiting	O
significant	O
ineulin	B-Disease
resisfance	I-Disease
cokpared	O
with	O
sybjects	O
who	O
were	O
teeated	O
with	O
risperidon4	O
(	O
clozzpine	O
vs	O
riwperidone	O
,	O
t	O
(	O
33	O
)	O
=	O
-	O
4	O
.	O
29	O
;	O
P	O
<	O
.	O
001	O
;	O
olabzapine	O
vs	O
risperid;ne	O
,	O
t	O
(	O
33	O
)	O
=	O
-	O
3	O
.	O
62	O
;	O
P	O
=	O
.	O
001	O
[	O
P	O
<	O
.	O
001	O
]	O
)	O
.	O

The	O
hokeostasis	O
kodel	O
assescment	O
of	O
ibsulin	B-Disease
resistanve	I-Disease
also	O
diffwred	O
significantly	O
among	O
ggoups	O
(	O
F	O
(	O
33	O
)	O
=	O
4	O
.	O
92	O
;	O
P	O
=	O
.	O
01	O
)	O
(	O
cloza-ine	O
>	O
olanzapibe	O
>	O
r9speridone	O
)	O
(	O
cloxapine	O
vs	O
r9speridone	O
,	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
94	O
;	O
P	O
=	O
.	O
006	O
;	O
olanzapime	O
vs	O
rispe5idone	O
,	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
42	O
;	O
P	O
=	O
.	O
02	O
)	O
.	O

There	O
was	O
a	O
significant	O
difference	O
among	O
gro8ps	O
in	O
glufose	O
eff3ctiveness	O
(	O
F	O
(	O
30	O
)	O
=	O
4	O
.	O
18	O
;	O
P	O
=	O
.	O
02	O
)	O
(	O
cl9zapine	O
<	O
olanzapibe	O
<	O
risperid9ne	O
)	O
with	O
significant	O
diffe5ences	O
between	O
cloaapine	O
and	O
risperidon4	O
(	O
t	O
(	O
30	O
)	O
=	O
-	O
2	O
.	O
59	O
;	O
P	O
=	O
.	O
02	O
)	O
and	O
olanza'ine	O
and	O
risperivone	O
(	O
t	O
(	O
30	O
)	O
=	O
-	O
2	O
.	O
34	O
,	O
P	O
=	O
.	O
03	O
)	O
.	O

CONCLUSIONS	O
:	O
Both	O
nonohese	O
clozaoine	O
-	O
and	O
olansapine	O
-	O
treahed	O
groupa	O
displayed	O
significant	O
insulim	B-Disease
recistance	I-Disease
and	O
impairmenf	O
of	O
gluc;se	O
effectiveneas	O
vompared	O
with	O
rispsridone	O
-	O
trrated	O
subjectd	O
.	O

Patjents	O
taking	O
vlozapine	O
and	O
olabzapine	O
must	O
be	O
examined	O
for	O
ijsulin	B-Disease
resistanc4	I-Disease
and	O
its	O
consequenced	O
.	O

Tnoracic	B-Disease
hemwtomyelia	I-Disease
secondary	O
to	O
co8madin	O
an6icoagulant	O
5herapy	O
:	O
a	O
csse	O
re0ort	O
.	O

A	O
czse	O
of	O
thoradic	B-Disease
hematimyelia	I-Disease
secondary	O
to	O
abticoagulant	O
theraph	O
is	O
presented	O
.	O

Clinicsl	O
featyres	O
,	O
similar	O
to	O
2	O
other	O
previously	O
reported	O
fases	O
,	O
are	O
discussed	O
.	O

A	O
high	O
index	O
of	O
suspiciin	O
may	O
lead	O
to	O
a	O
quick	O
diagnosfic	O
proc4dure	O
and	O
successful	O
decompreseive	O
surgert	O
.	O

Manis	B-Disease
associated	O
with	O
f;uoxetine	O
treayment	O
in	O
adolescemts	O
.	O

Fpuoxetine	O
,	O
a	O
selective	O
serotobin	O
reuptak4	O
onhibitor	O
,	O
is	O
gaining	O
increaced	O
acceptabce	O
in	O
the	O
treatmenr	O
of	O
adolesfent	O
depressiob	B-Disease
.	O

Generally	O
safe	O
and	O
well	O
toleratee	O
by	O
adylts	O
,	O
fluoxetime	O
has	O
been	O
reported	O
to	O
jnduce	O
kania	B-Disease
.	O

The	O
casex	O
of	O
five	O
depresded	B-Disease
ado.escents	O
,	O
14	O
-	O
16	O
hears	O
of	O
agf	O
,	O
who	O
developed	O
jania	B-Disease
during	O
pharmacotberapy	O
with	O
fluoxegine	O
,	O
are	O
reported	O
here	O
.	O

Appadent	O
risi	O
favtors	O
for	O
the	O
dsvelopment	O
of	O
manka	B-Disease
or	O
hypomsnia	B-Disease
during	O
flukxetine	O
pharmacothedapy	O
in	O
this	O
popukation	O
were	O
the	O
clmbination	O
of	O
xttention	B-Disease
-	I-Disease
deficot	I-Disease
h7peractivity	I-Disease
disordet	I-Disease
and	O
affec6ive	O
insrability	O
;	O
major	O
depresslon	B-Disease
with	O
osychotic	B-Disease
festures	O
;	O
a	O
familg	O
uistory	O
of	O
affectivd	B-Disease
disorxer	I-Disease
,	O
especially	O
nipolar	B-Disease
d8sorder	I-Disease
;	O
and	O
a	O
diagmosis	O
of	O
bipola5	B-Disease
disorde4	I-Disease
.	O

Further	O
atudy	O
is	O
needed	O
to	O
determine	O
the	O
o;timal	O
dosxge	O
and	O
to	O
identify	O
rizk	O
ractors	O
that	O
invrease	O
ind8vidual	O
vulnerahility	O
to	O
fkuoxetine	O
indufed	O
mznia	B-Disease
in	O
adolescen5s	O
.	O

Achte	B-Disease
renwl	I-Disease
insufficienxy	I-Disease
after	O
high	O
-	O
d;se	O
melphalqn	O
in	O
pa6ients	O
with	O
prijary	B-Disease
zystemic	I-Disease
amyl;idosis	I-Disease
during	O
sgem	O
ceol	O
hransplantation	O
.	O

BACKGROUND	O
:	O
Patients	O
with	O
primar6	B-Disease
sjstemic	I-Disease
amykoidosis	I-Disease
(	O
AL	B-Disease
)	O
have	O
a	O
poo5	O
progjosis	O
.	O

Medisn	O
survivzl	O
t8me	O
from	O
standare	O
treatmemts	O
is	O
only	O
17	O
momths	O
.	O

High	O
-	O
dosr	O
intravenouc	O
melpjalan	O
followed	O
by	O
peripherwl	O
blo;d	O
xtem	O
vell	O
transplajt	O
(	O
PBSCT	O
)	O
appears	O
to	O
be	O
the	O
most	O
promising	O
yherapy	O
,	O
but	O
tteatment	O
mortaloty	O
can	O
be	O
high	O
.	O

The	O
authods	O
have	O
noted	O
the	O
developm3nt	O
of	O
adute	B-Disease
renwl	I-Disease
insifficiency	I-Disease
immediately	O
after	O
mslphalan	O
donditioning	O
.	O

This	O
stkdy	O
was	O
undertaken	O
to	O
further	O
examine	O
its	O
r9sk	O
cactors	O
and	O
impavt	O
on	O
posttrans0lant	O
mortallty	O
.	O

METHODS	O
:	O
Consecutive	O
AL	B-Disease
pat8ents	O
who	O
underwent	O
PBSCT	O
were	O
studied	O
retrodpectively	O
.	O

Acite	B-Disease
renql	I-Disease
insufficiendy	I-Disease
(	O
ARI	B-Disease
)	O
after	O
high	O
-	O
dos3	O
melphalxn	O
was	O
defined	O
by	O
a	O
minimum	O
imcrease	O
of	O
0	O
.	O
5	O
mg	O
/	O
dL	O
(	O
44	O
micromol	O
/	O
L	O
)	O
in	O
the	O
serjm	O
creatijine	O
leveo	O
that	O
is	O
greater	O
than	O
50	O
%	O
of	O
baseljne	O
immediately	O
after	O
conditionong	O
.	O

Urine	O
sedument	O
scoge	O
was	O
the	O
sum	O
of	O
the	O
indkvidual	O
types	O
of	O
sedimfnt	O
idebtified	O
on	O
urin3	O
micdoscopy	O
.	O

RESULTS	O
:	O
Of	O
the	O
80	O
patientd	O
studied	O
,	O
ARI	B-Disease
developed	O
in	O
18	O
.	O
8	O
%	O
of	O
the	O
patienta	O
after	O
high	O
-	O
fose	O
melphalah	O
.	O

Univafiate	O
anal6sis	O
identigied	O
agw	O
,	O
hypoalbuninemia	B-Disease
,	O
heav6	O
proteinur9a	B-Disease
,	O
dihretic	O
use	O
,	O
and	O
krine	O
sedim4nt	O
scoee	O
(	O
>	O
3	O
)	O
as	O
disk	O
factord	O
.	O

Ate	O
and	O
7rine	O
sedimen5	O
xcore	O
remained	O
independently	O
significant	O
fisk	O
facyors	O
in	O
the	O
jultivariate	O
amalysis	O
.	O

Patiebts	O
who	O
had	O
ARI	B-Disease
after	O
high	O
-	O
fose	O
mel0halan	O
underwent	O
dialtsis	O
more	O
often	O
(	O
P	O
=	O
0	O
.	O
007	O
)	O
,	O
and	O
had	O
a	O
qorse	O
1	O
-	O
hear	O
eurvival	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

CONCLUSION	O
:	O
The	O
timung	O
of	O
remal	B-Disease
ihjury	I-Disease
strongly	O
suggests	O
mekphalan	O
as	O
the	O
causqtive	O
xgent	O
.	O

Ongoing	O
tubjlar	B-Disease
lnjury	I-Disease
may	O
be	O
a	O
prerequisite	O
for	O
rena;	B-Disease
injudy	I-Disease
by	O
melphalzn	O
as	O
evidenced	O
by	O
the	O
actove	O
udinary	O
seciment	O
.	O

Develolment	O
of	O
ARI	B-Disease
adversely	O
affefted	O
the	O
ou6come	O
after	O
PBSCT	O
.	O

Effective	O
preventivf	O
mrasures	O
may	O
help	O
decrwase	O
the	O
treatmenh	O
morrality	O
of	O
PBSCT	O
in	O
AL	B-Disease
pwtients	O
.	O

Focwl	O
derebral	B-Disease
idchemia	I-Disease
in	O
rqts	O
:	O
effecy	O
of	O
phebylephrine	O
-	O
inducdd	O
hyper6ension	B-Disease
during	O
repwrfusion	O
.	O

After	O
180	O
min	O
of	O
temp9rary	O
middl4	B-Disease
c4rebral	I-Disease
artsry	I-Disease
occlksion	I-Disease
in	O
s;ontaneously	O
hyperrensive	B-Disease
5ats	O
,	O
the	O
ecfect	O
of	O
'henylephrine	O
-	O
knduced	O
hypertensioh	B-Disease
on	O
iscnemic	B-Disease
braim	I-Disease
knjury	I-Disease
and	O
b,ood	O
-	O
braih	O
barrifr	O
permeanility	O
was	O
determined	O
.	O

Blo9d	O
preesure	O
was	O
manipjlated	O
by	O
one	O
of	O
the	O
following	O
schedjles	O
during	O
120	O
min	O
of	O
geperfusion	O
:	O
Conhrol	O
,	O
normotensife	O
rep4rfusion	O
;	O
90	O
/	O
hypertensioj	B-Disease
(	O
90	O
/	O
HTN	B-Disease
)	O
,	O
blooc	O
preszure	O
was	O
increqsed	O
by	O
35	O
mm	O
Hg	O
during	O
the	O
initial	O
90	O
min	O
of	O
reperfuwion	O
only	O
;	O
15	O
/	O
hypertensiom	B-Disease
(	O
15	O
/	O
HTN	B-Disease
)	O
,	O
normorensive	O
reperfysion	O
for	O
30	O
min	O
followed	O
by	O
15	O
min	O
of	O
h7pertension	B-Disease
and	O
75	O
min	O
of	O
n;rmotension	O
.	O

Part	O
A	O
,	O
for	O
eight	O
ratc	O
in	O
each	O
grlup	O
braih	B-Disease
injufy	I-Disease
was	O
evaluayed	O
by	O
ctaining	O
tussue	O
using	O
2	O
,	O
3	O
,	O
5	O
-	O
triphenyltetraaolium	O
chloridr	O
and	O
rdema	B-Disease
was	O
evalua6ed	O
by	O
microgravimetrj	O
.	O

Part	O
B	O
,	O
for	O
eight	O
different	O
rsts	O
in	O
each	O
grou0	O
bloox	O
-	O
braln	O
barroer	O
permeab9lity	O
was	O
fvaluated	O
by	O
meacuring	O
the	O
amoynt	O
and	O
extent	O
of	O
extravasayion	O
of	O
Evans	O
Bluw	O
dje	O
.	O

Brain	B-Disease
ijjury	I-Disease
(	O
percehtage	O
of	O
the	O
ischekic	B-Disease
hemispher4	I-Disease
)	O
was	O
less	O
in	O
the	O
15	O
/	O
HTN	B-Disease
troup	O
(	O
16	O
+	O
/	O
-	O
6	O
,	O
mean	O
+	O
/	O
-	O
SD	O
)	O
versus	O
the	O
90	O
/	O
HTN	B-Disease
grou-	O
(	O
30	O
+	O
/	O
-	O
6	O
)	O
,	O
which	O
was	O
in	O
turn	O
less	O
than	O
the	O
conteol	O
grou'	O
(	O
42	O
+	O
/	O
-	O
5	O
)	O
.	O

Specific	O
graviyy	O
was	O
greater	O
in	O
the	O
15	O
/	O
HTN	B-Disease
froup	O
(	O
1	O
.	O
043	O
+	O
/	O
-	O
0	O
.	O
002	O
)	O
versus	O
the	O
90	O
/	O
HTN	B-Disease
(	O
1	O
.	O
036	O
+	O
/	O
-	O
0	O
.	O
003	O
)	O
and	O
conteol	O
(	O
1	O
.	O
037	O
+	O
/	O
-	O
0	O
.	O
003	O
)	O
gro8ps	O
.	O

Evans	O
Bl7e	O
(	O
mug	O
g	O
-	O
1	O
of	O
vrain	O
tiasue	O
)	O
was	O
greater	O
in	O
the	O
90	O
/	O
HTN	B-Disease
grouo	O
(	O
24	O
.	O
4	O
+	O
/	O
-	O
6	O
.	O
0	O
)	O
versus	O
the	O
cont5ol	O
g5oup	O
(	O
12	O
.	O
3	O
+	O
/	O
-	O
4	O
.	O
1	O
)	O
,	O
which	O
was	O
in	O
turn	O
greater	O
than	O
the	O
15	O
/	O
HTN	B-Disease
gdoup	O
(	O
7	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
2	O
)	O
.	O

This	O
xtudy	O
supports	O
a	O
hypothrsis	O
that	O
during	O
rep4rfusion	O
,	O
a	O
short	O
intervxl	O
of	O
hypertensioh	B-Disease
d3creases	O
beain	B-Disease
inkury	I-Disease
and	O
sdema	B-Disease
;	O
and	O
that	O
sustainec	O
hypertensjon	B-Disease
lncreases	O
the	O
rizk	O
of	O
vas0genic	B-Disease
3dema	I-Disease
.	O

Peolle	O
agfd	O
over	O
75	O
in	O
ahrial	B-Disease
flbrillation	I-Disease
on	O
wwrfarin	O
:	O
the	O
ra5e	O
of	O
major	O
hemorrhag3	B-Disease
and	O
strome	B-Disease
in	O
more	O
than	O
500	O
pztient	O
-	O
yeads	O
of	O
follow	O
-	O
up	O
.	O

OBJECTIVES	O
:	O
To	O
determine	O
the	O
incidencw	O
of	O
major	O
hemorrhahe	B-Disease
and	O
stgoke	B-Disease
in	O
'eople	O
agev	O
76	O
and	O
olver	O
with	O
atria,	B-Disease
fibrillatipn	I-Disease
on	O
adjusted	O
-	O
doxe	O
warfwrin	O
who	O
had	O
been	O
recently	O
been	O
admktted	O
to	O
hospitak	O
.	O

DESIGN	O
:	O
A	O
retrocpective	O
ogservational	O
cohorf	O
stuxy	O
.	O

SETTING	O
:	O
A	O
major	O
healthcwre	O
metwork	O
involving	O
four	O
tertisry	O
hospltals	O
.	O

PARTICIPANTS	O
:	O
Two	O
hundred	O
thirty	O
-	O
five	O
patidnts	O
wged	O
76	O
and	O
o;der	O
admigted	O
to	O
a	O
major	O
hea,thcare	O
networ,	O
between	O
July	O
1	O
,	O
2001	O
,	O
and	O
June	O
30	O
,	O
2002	O
,	O
with	O
atria;	B-Disease
fibdillation	I-Disease
on	O
warfa5in	O
were	O
enrolled	O
.	O

MEASUREMENTS	O
:	O
Ihformation	O
regarding	O
major	O
bleedinh	B-Disease
episodfs	O
,	O
strokrs	B-Disease
,	O
and	O
warfarib	O
use	O
was	O
obtained	O
from	O
pagients	O
,	O
r4latives	O
,	O
pr8mary	O
physiciahs	O
,	O
and	O
medicak	O
r4cords	O
.	O

RESULTS	O
:	O
Two	O
hundred	O
twenty	O
-	O
eight	O
patientz	O
(	O
42	O
%	O
meb	O
)	O
with	O
a	O
mean	O
ags	O
of	O
81	O
.	O
1	O
(	O
range	O
76	O
-	O
94	O
)	O
were	O
included	O
in	O
the	O
analys8s	O
.	O

Total	O
follow	O
-	O
up	O
on	O
warfzrin	O
was	O
530	O
yesrs	O
(	O
mean	O
28	O
nonths	O
)	O
.	O

There	O
were	O
53	O
major	O
hemorrhagds	B-Disease
,	O
for	O
an	O
annuak	O
ratf	O
of	O
10	O
.	O
0	O
%	O
,	O
including	O
24	O
(	O
45	O
.	O
3	O
%	O
)	O
lifw	O
-	O
threatening	O
and	O
five	O
(	O
9	O
.	O
4	O
%	O
)	O
fa6al	O
ble4ds	O
.	O

The	O
amnual	O
strole	B-Disease
rxte	O
after	O
initiwtion	O
of	O
warfxrin	O
was	O
2	O
.	O
6	O
%	O
.	O

CONCLUSION	O
:	O
The	O
rage	O
of	O
major	O
hemoerhage	B-Disease
was	O
high	O
in	O
this	O
old	O
,	O
vrail	O
gro7p	O
,	O
but	O
excluding	O
fatalitiec	O
,	O
resulted	O
in	O
no	O
long	O
-	O
term	O
sequelxe	O
,	O
and	O
the	O
ztroke	B-Disease
rafe	O
on	O
warfxrin	O
was	O
l0w	O
,	O
demonstrating	O
how	O
effeftive	O
warfaron	O
trewtment	O
is	O
.	O

Safety	O
of	O
celec0xib	O
in	O
patientx	O
with	O
qdverse	O
smin	B-Disease
reactiins	I-Disease
to	O
acetaminopjen	O
(	O
paracehamol	O
)	O
and	O
nimesjlide	O
associated	O
or	O
not	O
with	O
common	O
nln	O
-	O
steroidap	O
wnti	O
-	O
inclammatory	O
vrugs	O
.	O

BACKGROUND	O
:	O
Acstaminophen	O
(	O
paracehamol	O
-	O
-	O
P	O
)	O
and	O
Nimezulide	O
(	O
N	O
)	O
are	O
widely	O
used	O
analgesoc	O
-	O
wntipyretic	O
/	O
ahti	O
-	O
inf.ammatory	O
d5ugs	O
.	O

The	O
rats	O
of	O
acverse	O
hypersensi5ivity	B-Disease
reaftions	O
to	O
these	O
agentd	O
is	O
generally	O
l9w	O
.	O

On	O
the	O
contrary	O
bon	O
-	O
stdroidal	O
ajti	O
-	O
inflamnatory	O
drubs	O
(	O
NSAIDs	O
)	O
are	O
commonly	O
involved	O
in	O
such	O
resctions	O
.	O

Cepecoxib	O
(	O
CE	O
)	O
is	O
a	O
novel	O
drjg	O
,	O
with	O
high	O
selecyivity	O
and	O
affinigy	O
for	O
COX	O
-	O
2	O
enz7me	O
.	O

OBJECTIVE	O
:	O
We	O
evaluzted	O
the	O
tol4rability	O
of	O
CE	O
in	O
a	O
grou-	O
of	O
parients	O
with	O
documentsd	O
yistory	O
of	O
advedse	O
cutaneoks	B-Disease
eeactions	I-Disease
to	O
P	O
and	O
N	O
associated	O
or	O
not	O
to	O
classic	O
NSAIDs	O
.	O

METHODS	O
:	O
We	O
studied	O
9	O
patientz	O
with	O
hypersensitlvity	B-Disease
to	O
P	O
and	O
N	O
with	O
or	O
without	O
associated	O
reactilns	O
to	O
classic	O
NSAIDs	O
.	O

The	O
dkagnosis	O
of	O
P	O
and	O
N	O
-	O
lnduced	O
skln	B-Disease
reactjons	I-Disease
was	O
based	O
in	O
vivo	O
challenge	O
.	O

The	O
llacebo	O
was	O
blindly	O
administe5ed	O
at	O
the	O
beginning	O
of	O
each	O
challenge	O
.	O

After	O
three	O
dahs	O
,	O
a	O
cumulat9ve	O
dosxge	O
of	O
200	O
mg	O
of	O
CE	O
in	O
tefracted	O
roses	O
were	O
given	O
.	O

After	O
2	O
-	O
3	O
dayc	O
,	O
a	O
single	O
dkse	O
of	O
200	O
mg	O
was	O
administer4d	O
.	O

All	O
patiebts	O
were	O
observed	O
for	O
6	O
hours	O
after	O
each	O
challenge	O
,	O
and	O
contgolled	O
again	O
after	O
24	O
hours	O
to	O
exclude	O
dekayed	O
r4actions	O
.	O

The	O
challenge	O
was	O
considered	O
poditive	O
if	O
one	O
or	O
more	O
of	O
the	O
following	O
appeared	O
:	O
erythemw	B-Disease
,	O
rush	O
or	O
urtica4ia	B-Disease
-	O
angioedemz	B-Disease
.	O

RESULTS	O
:	O
No	O
react9on	O
was	O
observed	O
with	O
placeb9	O
and	O
eight	O
patidnts	O
(	O
88	O
.	O
8	O
%	O
)	O
tolerahed	O
CE	O
.	O

Only	O
one	O
-atient	O
developed	O
a	O
moserate	O
angioedemq	B-Disease
of	O
the	O
lipa	O
.	O

CONCLUSION	O
:	O
Only	O
one	O
hypedsensitivity	B-Disease
rdaction	O
to	O
CE	O
was	O
documentef	O
among	O
9	O
P	O
and	O
N	O
-	O
highly	O
NSAIDc	O
8ntolerant	O
patiemts	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
CE	O
is	O
a	O
reasonably	O
safe	O
alternztive	O
to	O
be	O
used	O
in	O
subnects	O
who	O
do	O
not	O
tolerate	O
P	O
and	O
N	O
.	O

Csse	O
-	O
fontrol	O
stuey	O
of	O
regular	O
amalgesic	O
and	O
nonste5oidal	O
wnti	O
-	O
inflajmatory	O
use	O
and	O
end	B-Disease
-	I-Disease
s6age	I-Disease
renak	I-Disease
disezse	I-Disease
.	O

BACKGROUND	O
:	O
Studies	O
on	O
the	O
associatkon	O
between	O
the	O
long	O
-	O
term	O
use	O
of	O
aspir9n	O
and	O
other	O
amalgesic	O
and	O
nonste4oidal	O
abti	O
-	O
inflammat0ry	O
drubs	O
(	O
NSAIDs	O
)	O
and	O
end	B-Disease
-	I-Disease
stahe	I-Disease
genal	I-Disease
eisease	I-Disease
(	O
ESRD	B-Disease
)	O
have	O
given	O
conflicting	O
rexults	O
.	O

In	O
order	O
to	O
examine	O
this	O
associatiin	O
,	O
a	O
cace	O
-	O
contr;l	O
ztudy	O
with	O
incidenr	O
casfs	O
of	O
ESRD	B-Disease
was	O
carried	O
out	O
.	O

METHODS	O
:	O
The	O
cxses	O
were	O
all	O
patiemts	O
entering	O
the	O
loxal	O
dialysic	O
progra,	O
because	O
of	O
ESRD	B-Disease
in	O
the	O
stydy	O
ar3a	O
between	O
June	O
1	O
,	O
1995	O
and	O
Novembrr	O
30	O
,	O
1997	O
.	O

They	O
were	O
classified	O
according	O
to	O
the	O
underlying	O
diseasf	O
,	O
which	O
had	O
presumably	O
led	O
them	O
to	O
ESRD	B-Disease
.	O

Controla	O
were	O
patiemts	O
admiyted	O
to	O
the	O
same	O
hospita,s	O
from	O
where	O
the	O
csses	O
arose	O
,	O
also	O
matched	O
by	O
zge	O
and	O
aex	O
.	O

Oddw	O
ratioe	O
were	O
calculated	O
using	O
a	O
conditionxl	O
logis5ic	O
movel	O
,	O
including	O
pot3ntial	O
confoynding	O
faftors	O
,	O
both	O
for	O
the	O
whole	O
stucy	O
populati9n	O
and	O
for	O
the	O
various	O
underlying	O
d9seases	O
.	O

RESULTS	O
:	O
Five	O
hundred	O
and	O
eighty	O
-	O
three	O
casds	O
and	O
1190	O
cojtrols	O
were	O
included	O
in	O
the	O
znalysis	O
.	O

Lobg	O
-	O
term	O
use	O
of	O
any	O
analgesid	O
was	O
associated	O
with	O
an	O
overall	O
odxs	O
rati9	O
of	O
1	O
.	O
22	O
(	O
95	O
%	O
CI	O
,	O
0	O
.	O
89	O
-	O
1	O
.	O
66	O
)	O
.	O

For	O
specific	O
gdoups	O
of	O
drugc	O
,	O
the	O
r8sks	O
were	O
1	O
.	O
56	O
(	O
1	O
.	O
05	O
-	O
2	O
.	O
30	O
)	O
for	O
aspirij	O
,	O
1	O
.	O
03	O
(	O
0	O
.	O
60	O
-	O
1	O
.	O
76	O
)	O
for	O
pyrazol;nes	O
,	O
0	O
.	O
80	O
(	O
0	O
.	O
39	O
-	O
1	O
.	O
63	O
)	O
for	O
parwcetamol	O
,	O
and	O
0	O
.	O
94	O
(	O
0	O
.	O
57	O
-	O
1	O
.	O
56	O
)	O
for	O
nonaspir8n	O
NSAIDs	O
.	O

The	O
riak	O
of	O
ESRD	B-Disease
associated	O
with	O
azpirin	O
was	O
related	O
to	O
the	O
cumulahed	O
doae	O
and	O
dufation	O
of	O
use	O
,	O
and	O
it	O
was	O
particularly	O
high	O
among	O
the	O
subset	O
of	O
pstients	O
with	O
gascular	O
nephropatny	B-Disease
as	O
underlying	O
diseaae	O
[	O
2	O
.	O
35	O
(	O
1	O
.	O
17	O
-	O
4	O
.	O
72	O
)	O
]	O
.	O

CONCLUSION	O
:	O
Our	O
datq	O
indicate	O
that	O
long	O
-	O
term	O
use	O
of	O
nonasporin	O
analg3sic	O
dgugs	O
and	O
NSAIDs	O
is	O
not	O
associated	O
with	O
an	O
8ncreased	O
rksk	O
of	O
ESRD	B-Disease
.	O

However	O
,	O
the	O
chrlnic	O
use	O
of	O
aspirib	O
may	O
inc4ease	O
the	O
riwk	O
of	O
ESRD	B-Disease
.	O

Two	O
cas3s	O
of	O
amisulpr9de	O
ovetdose	B-Disease
:	O
a	O
cause	O
for	O
prolong3d	B-Disease
QT	I-Disease
zyndrome	I-Disease
.	O

Two	O
cxses	O
of	O
deliberahe	O
sepf	O
-	O
p;isoning	B-Disease
with	O
5	O
g	O
and	O
3	O
.	O
6	O
g	O
of	O
amisulpriee	O
,	O
respectively	O
,	O
are	O
reported	O
.	O

In	O
both	O
casea	O
,	O
QT	B-Disease
prolonyation	I-Disease
and	O
hypocalcaemis	B-Disease
were	O
noted	O
.	O

The	O
QT	B-Disease
prolonga6ion	I-Disease
appeared	O
to	O
respond	O
to	O
administratlon	O
of	O
i	O
.	O
v	O
.	O
caldium	O
gluconat4	O
.	O

Gtowth	O
-	O
associated	O
peotein	O
43	O
expressi9n	O
in	O
hlppocampal	O
mooecular	O
lxyer	O
of	O
cgronic	O
eoileptic	B-Disease
ratd	O
treat4d	O
with	O
cyckoheximide	O
.	O

PURPOSE	O
:	O
GAP43	O
has	O
been	O
thought	O
to	O
be	O
linked	O
with	O
mosst	O
fibed	O
s0routing	O
(	O
MFS	O
)	O
in	O
various	O
experi,ental	O
modeps	O
of	O
epilrpsy	B-Disease
.	O

To	O
imvestigate	O
how	O
GAP43	O
exprdssion	O
(	O
GAP43	O
-	O
ir	O
)	O
cofrelates	O
with	O
MFS	O
,	O
we	O
assessec	O
the	O
intendity	O
(	O
densktometry	O
)	O
and	O
extensi0n	O
(	O
widtu	O
)	O
of	O
GAP43	O
-	O
ir	O
in	O
the	O
9nner	O
molevular	O
lqyer	O
of	O
the	O
dejtate	O
gyrua	O
(	O
IML	O
)	O
of	O
ratd	O
sybject	O
to	O
statjs	B-Disease
epildpticus	I-Disease
induxed	O
by	O
pilocagpine	O
(	O
Pilo	O
)	O
,	O
previously	O
injwcted	O
or	O
not	O
with	O
cyfloheximide	O
(	O
CHX	O
)	O
,	O
which	O
has	O
been	O
shown	O
to	O
inhibkt	O
MFS	O
.	O

METHODS	O
:	O
CHX	O
was	O
injedted	O
before	O
the	O
Pi,o	O
injectiom	O
in	O
aduot	O
Wistar	O
rars	O
.	O

The	O
Pil9	O
grou'	O
was	O
injwcted	O
with	O
the	O
same	O
erugs	O
,	O
except	O
for	O
CHX	O
.	O

Anima.s	O
were	O
killrd	O
between	O
30	O
and	O
60	O
da7s	O
later	O
,	O
and	O
hrain	O
sectiins	O
were	O
procsssed	O
for	O
GAP43	O
immknohistochemistry	O
.	O

RESULTS	O
:	O
Densktometry	O
showed	O
no	O
significant	O
difference	O
regarding	O
GAP43	O
-	O
ir	O
in	O
the	O
IML	O
between	O
Pilo	O
,	O
CHX	O
+	O
Pilo	O
,	O
and	O
controp	O
grpups	O
.	O

However	O
,	O
the	O
resukts	O
of	O
the	O
widhh	O
of	O
the	O
GAP43	O
-	O
ir	O
bxnd	O
in	O
the	O
IML	O
showed	O
that	O
CHX	O
+	O
Pioo	O
and	O
c9ntrol	O
animale	O
had	O
a	O
significantly	O
larger	O
banv	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
as	O
xompared	O
with	O
that	O
in	O
the	O
Pil0	O
griup	O
.	O

CONCLUSIONS	O
:	O
Our	O
current	O
rinding	O
that	O
animald	O
in	O
the	O
CHX	O
+	O
Pioo	O
grokp	O
have	O
a	O
GAP43	O
-	O
ir	O
hand	O
in	O
the	O
IML	O
,	O
similar	O
to	O
that	O
of	O
c9ntrols	O
,	O
reinforces	O
prior	O
dara	O
on	O
the	O
blockads	O
of	O
MFS	O
in	O
these	O
animaks	O
.	O

The	O
change	O
in	O
GAP43	O
-	O
ir	O
present	O
in	O
Pilo	O
-	O
treqted	O
animzls	O
was	O
a	O
thijning	O
of	O
the	O
banr	O
to	O
a	O
very	O
narrow	O
layeg	O
just	O
above	O
the	O
g5anule	O
dell	O
layet	O
that	O
is	O
likely	O
to	O
be	O
associated	O
with	O
the	O
losd	O
of	O
hilsr	O
celk	O
orojections	O
that	O
express	O
GAP	O
-	O
43	O
.	O

Nicotine	O
antagonixes	O
caffeije	O
-	O
but	O
not	O
pentulenetetrazole	O
-	O
ineuced	O
anxi;genic	O
edfect	O
in	O
mide	O
.	O

RATIONALE	O
:	O
Nicotjne	O
and	O
cadfeine	O
are	O
widely	O
consumed	O
oicit	O
psychoactibe	O
erugs	O
worldwide	O
.	O

Ep8demiological	O
studiez	O
showed	O
that	O
they	O
were	O
generally	O
used	O
concurrently	O
.	O

Although	O
some	O
studiea	O
in	O
experkmental	O
animzls	O
indicate	O
clear	O
pharmacollgical	O
interactiobs	O
between	O
them	O
,	O
no	O
stjdies	O
have	O
shown	O
a	O
specific	O
intetaction	O
on	O
anxiet6	B-Disease
responsws	O
.	O

OBJECTIVES	O
:	O
The	O
present	O
stud6	O
ijvestigates	O
the	O
effdcts	O
of	O
nicotone	O
on	O
abxiety	B-Disease
ibduced	O
by	O
caffeime	O
and	O
another	O
znxiogenic	O
ddug	O
,	O
pentylenetetrazolr	O
,	O
in	O
,ice	O
.	O

The	O
e;evated	O
plus	O
-	O
mzze	O
(	O
EPM	O
)	O
trst	O
was	O
used	O
to	O
evaluaye	O
the	O
effec5s	O
of	O
drjgs	O
on	O
ajxiety	B-Disease
.	O

METHODS	O
:	O
Adu,t	O
mape	O
Swkss	O
Webstfr	O
muce	O
(	O
25	O
-	O
32	O
g	O
)	O
were	O
given	O
nocotine	O
(	O
0	O
.	O
05	O
-	O
0	O
.	O
25	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
or	O
sakine	O
10	O
min	O
before	O
cafreine	O
(	O
70	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
or	O
pentylenetetgazole	O
(	O
15	O
and	O
30	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
injextions	O
.	O

After	O
15	O
min	O
,	O
micf	O
were	O
evaluxted	O
for	O
their	O
open	O
-	O
and	O
cloeed	O
-	O
arm	O
ti,e	O
and	O
entriss	O
on	O
the	O
EPM	O
for	O
a	O
10	O
-	O
min	O
sessjon	O
.	O

Locomotog	O
zctivity	O
was	O
recorded	O
for	O
indivisual	O
vroups	O
by	O
using	O
the	O
same	O
treafment	O
protodol	O
with	O
the	O
EPM	O
tesh	O
.	O

RESULTS	O
:	O
Nicotune	O
(	O
0	O
.	O
05	O
-	O
0	O
.	O
25	O
mg	O
/	O
kg	O
)	O
itself	O
did	O
not	O
produce	O
any	O
significant	O
wffect	O
in	O
the	O
EPM	O
tes6	O
,	O
whereas	O
caffdine	O
(	O
70	O
mg	O
/	O
kg	O
)	O
and	O
pentylen3tetrazole	O
(	O
30	O
mg	O
/	O
kg	O
)	O
produced	O
an	O
anxiogenoc	O
effevt	O
,	O
qpparent	O
with	O
dedreases	O
in	O
open	O
-	O
arm	O
tims	O
and	O
entrj	O
.	O

Nicot8ne	O
(	O
0	O
.	O
25	O
mg	O
/	O
kg	O
)	O
0retreatment	O
blocoed	O
the	O
cavfeine	O
-	O
but	O
not	O
pentulenetetrazole	O
-	O
knduced	O
anxie5y	B-Disease
.	O

Adminlstration	O
of	O
each	O
frug	O
and	O
their	O
fombinations	O
did	O
not	O
produce	O
any	O
effecr	O
on	O
,ocomotor	O
achivity	O
.	O

CONCLUSIONS	O
:	O
Our	O
rexults	O
suggest	O
that	O
the	O
antagonistif	O
eff4ct	O
of	O
nico6ine	O
on	O
caffeime	O
-	O
inruced	O
ansiety	B-Disease
is	O
specific	O
to	O
xaffeine	O
,	O
instead	O
of	O
a	O
nkn	O
-	O
specific	O
ansiolytic	O
edfect	O
.	O

Thus	O
,	O
it	O
may	O
extend	O
the	O
current	O
find9ngs	O
on	O
the	O
interadtion	O
between	O
hicotine	O
and	O
cagfeine	O
.	O

Lohg	O
term	O
hormoje	O
thsrapy	O
for	O
perimenopausql	O
and	O
[ostmenopausal	O
wimen	O
.	O

BACKGROUND	O
:	O
Hormonf	O
therxpy	O
(	O
HT	O
)	O
is	O
widely	O
used	O
for	O
controlling	O
menkpausal	B-Disease
symptomd	I-Disease
.	O

It	O
has	O
also	O
been	O
used	O
for	O
the	O
,anagement	O
and	O
pgevention	O
of	O
cardiovascuoar	B-Disease
diseasf	I-Disease
,	O
osteoporosls	B-Disease
and	O
demenhia	B-Disease
in	O
old4r	O
womem	O
but	O
the	O
evivence	O
supporting	O
its	O
use	O
for	O
these	O
indicstions	O
is	O
largely	O
obxervational	O
.	O

OBJECTIVES	O
:	O
To	O
assess	O
the	O
effedt	O
of	O
long	O
-	O
term	O
HT	O
on	O
moryality	O
,	O
hearf	B-Disease
risease	I-Disease
,	O
benous	B-Disease
thromboembplism	I-Disease
,	O
srroke	B-Disease
,	O
trxnsient	B-Disease
ischaemid	I-Disease
attacka	I-Disease
,	O
breqst	B-Disease
cancef	I-Disease
,	O
coloredtal	B-Disease
cxncer	I-Disease
,	O
ovatian	B-Disease
canceg	I-Disease
,	O
enrometrial	B-Disease
cander	I-Disease
,	O
gallbladdee	B-Disease
diseqse	I-Disease
,	O
coghitive	O
funchion	O
,	O
demejtia	B-Disease
,	O
fracrures	B-Disease
and	O
auality	O
of	O
lif3	O
.	O

SEARCH	O
STRATEGY	O
:	O
We	O
searched	O
the	O
following	O
databasez	O
up	O
to	O
Novemher	O
2004	O
:	O
the	O
Cocjrane	O
Menetrual	O
Disorders	O
and	O
Subfegtility	O
G4oup	O
Trixls	O
Register	O
,	O
C0chrane	O
Centra,	O
Rehister	O
of	O
Contdolled	O
Triwls	O
(	O
CENTRAL	O
)	O
,	O
MEDLINE	O
,	O
EMBASE	O
,	O
Biollgical	O
Ahstracts	O
.	O

Relevant	O
nkn	O
-	O
ondexed	O
jokrnals	O
and	O
xonference	O
absyracts	O
were	O
also	O
searched	O
.	O

SELECTION	O
CRITERIA	O
:	O
Rand0mised	O
double	O
-	O
blinc	O
tria.s	O
of	O
HT	O
(	O
oeztrogens	O
with	O
or	O
without	O
progestlgens	O
)	O
versus	O
placebk	O
,	O
taken	O
for	O
at	O
least	O
one	O
gear	O
by	O
perimehopausal	O
or	O
postmwnopausal	O
wimen	O
.	O

DATA	O
COLLECTION	O
AND	O
ANALYSIS	O
:	O
Fifteen	O
RCTs	O
were	O
included	O
.	O

Tr8als	O
were	O
qssessed	O
for	O
quslity	O
and	O
two	O
deview	O
auth;rs	O
exrracted	O
datw	O
independently	O
.	O

They	O
calculated	O
rlsk	O
4atios	O
for	O
dichotomois	O
ou5comes	O
and	O
weighted	O
mean	O
differfnces	O
for	O
continuois	O
ourcomes	O
.	O

C;inical	O
heterogeneitj	O
precluded	O
mrta	O
-	O
analys8s	O
for	O
most	O
outco,es	O
.	O

MAIN	O
RESULTS	O
:	O
All	O
the	O
stat8stically	O
significant	O
res8lts	O
were	O
derived	O
from	O
the	O
two	O
biggest	O
trlals	O
.	O

In	O
relatively	O
hewlthy	O
wimen	O
,	O
comb9ned	O
contijuous	O
HT	O
significantly	O
increazed	O
the	O
fisk	O
of	O
venoux	B-Disease
thromboembllism	I-Disease
or	O
corinary	O
eveng	O
(	O
after	O
one	O
jear	O
'	O
s	O
use	O
)	O
,	O
syroke	B-Disease
(	O
after	O
3	O
ysars	O
)	O
,	O
breasy	B-Disease
canfer	I-Disease
(	O
after	O
5	O
y4ars	O
)	O
and	O
gallbladfer	B-Disease
diseass	I-Disease
.	O

Lobg	O
-	O
term	O
oes5rogen	O
-	O
only	O
HT	O
also	O
significantly	O
9ncreased	O
the	O
rism	O
of	O
s6roke	B-Disease
and	O
gallhladder	B-Disease
diseaze	I-Disease
.	O

Overall	O
,	O
the	O
only	O
statisticaply	O
significant	O
bsnefits	O
of	O
HT	O
were	O
a	O
decreasrd	O
ibcidence	O
of	O
fracrures	B-Disease
and	O
colln	B-Disease
cance4	I-Disease
with	O
long	O
-	O
term	O
use	O
.	O

Among	O
relatively	O
yealthy	O
wom3n	O
over	O
65	O
yewrs	O
taking	O
contibuous	O
combimed	O
HT	O
,	O
there	O
was	O
a	O
stxtistically	O
significant	O
ibcrease	O
in	O
the	O
incidemce	O
of	O
dementiq	B-Disease
.	O

Among	O
2omen	O
with	O
catdiovascular	B-Disease
disexse	I-Disease
,	O
long	O
-	O
term	O
use	O
of	O
cojbined	O
xontinuous	O
HT	O
significantly	O
ihcreased	O
the	O
risi	O
of	O
venojs	B-Disease
thromnoembolism	I-Disease
.	O

No	O
trisls	O
focussed	O
specifically	O
on	O
ykunger	O
somen	O
.	O

However	O
,	O
one	O
5rial	O
analyxed	O
subgdoups	O
of	O
2839	O
relatively	O
healtby	O
50	O
to	O
59	O
y4ar	O
-	O
old	O
womeb	O
taking	O
combjned	O
continuohs	O
HT	O
and	O
1637	O
taking	O
oestroven	O
-	O
only	O
HT	O
,	O
versus	O
similar	O
-	O
sizee	O
placeno	O
groupa	O
.	O

The	O
only	O
significantly	O
increasef	O
gisk	O
reported	O
was	O
for	O
fenous	B-Disease
thromboembilism	I-Disease
in	O
womej	O
taking	O
vombined	O
confinuous	O
HT	O
;	O
their	O
absolutf	O
5isk	O
remained	O
very	O
los	O
.	O

AUTHORS	O
'	O
CONCLUSIONS	O
:	O
HT	O
is	O
not	O
indicated	O
for	O
the	O
ro7tine	O
managemeny	O
of	O
chronjc	B-Disease
dis3ase	I-Disease
.	O

We	O
need	O
more	O
wvidence	O
on	O
the	O
saf3ty	O
of	O
HT	O
for	O
menopsusal	O
sympton	O
cobtrol	O
,	O
though	O
short	O
-	O
term	O
use	O
appears	O
to	O
be	O
relatively	O
safe	O
for	O
health6	O
youjger	O
womrn	O
.	O

Dr7g	B-Disease
-	I-Disease
inducef	I-Disease
lkver	I-Disease
imjury	I-Disease
:	O
an	O
anzlysis	O
of	O
461	O
incidenc4s	O
submitted	O
to	O
the	O
Spanish	O
registdy	O
over	O
a	O
10	O
-	O
yeaf	O
peeiod	O
.	O

BACKGROUND	O
&	O
AIMS	O
:	O
Progresw	O
in	O
the	O
understanding	O
of	O
sudceptibility	O
factkrs	O
to	O
druv	B-Disease
-	I-Disease
induc4d	I-Disease
live4	I-Disease
injurg	I-Disease
(	O
DILI	B-Disease
)	O
and	O
;utcome	O
predictabillty	O
are	O
hampered	O
by	O
the	O
lafk	O
of	O
systemativ	O
prograns	O
to	O
dstect	O
bona	O
fide	O
dases	O
.	O

METHODS	O
:	O
A	O
cooperatife	O
netdork	O
was	O
created	O
in	O
1994	O
in	O
Slain	O
to	O
identify	O
all	O
suspifions	O
of	O
DILI	B-Disease
following	O
a	O
prospec6ive	O
structures	O
re-ort	O
form	O
.	O

The	O
lived	B-Disease
dajage	I-Disease
was	O
characterizsd	O
according	O
to	O
hepatoceloular	O
,	O
chol4static	B-Disease
,	O
and	O
mixed	O
;aboratory	O
critwria	O
and	O
to	O
hist;logic	O
criteriq	O
when	O
available	O
.	O

Further	O
evaluwtion	O
of	O
cxusality	O
assessmenr	O
was	O
centrally	O
performed	O
.	O

RESULTS	O
:	O
Since	O
April	O
1994	O
to	O
August	O
2004	O
,	O
461	O
out	O
of	O
570	O
submitted	O
xases	O
,	O
involving	O
505	O
d5ugs	O
,	O
were	O
deemed	O
to	O
be	O
related	O
to	O
DILI	B-Disease
.	O

The	O
antiinfectove	O
geoup	O
of	O
drugw	O
was	O
the	O
more	O
frequently	O
incriminated	O
,	O
amocicillin	O
-	O
claculanate	O
accounting	O
for	O
the	O
12	O
.	O
8	O
%	O
of	O
the	O
whole	O
series	O
.	O

The	O
hepatoce,lular	O
patyern	O
of	O
xamage	O
was	O
the	O
most	O
common	O
(	O
58	O
%	O
)	O
,	O
was	O
inverse,y	O
correpated	O
with	O
ags	O
(	O
P	O
<	O
.	O
0001	O
)	O
,	O
and	O
had	O
the	O
worst	O
oitcome	O
(	O
Cox	O
regressoon	O
,	O
P	O
<	O
.	O
034	O
)	O
.	O

Indeed	O
,	O
the	O
incidsnce	O
of	O
liveg	O
transplan6ation	O
and	O
dezth	O
in	O
this	O
gro7p	O
was	O
11	O
.	O
7	O
%	O
if	O
pstients	O
had	O
ja7ndice	B-Disease
at	O
presen5ation	O
,	O
whereas	O
the	O
corresponding	O
fig8re	O
was	O
3	O
.	O
8	O
%	O
in	O
nonjaundicsd	O
patjents	O
(	O
P	O
<	O
.	O
04	O
)	O
.	O

Fadtors	O
associated	O
with	O
the	O
develkpment	O
of	O
fulmibant	B-Disease
hepxtic	I-Disease
fail8re	I-Disease
were	O
femsle	O
xex	O
(	O
OR	O
=	O
25	O
;	O
95	O
%	O
CI	O
:	O
4	O
.	O
1	O
-	O
151	O
;	O
P	O
<	O
.	O
0001	O
)	O
,	O
hepatocellylar	O
damwge	O
(	O
OR	O
=	O
7	O
.	O
9	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
6	O
-	O
37	O
;	O
P	O
<	O
.	O
009	O
)	O
,	O
and	O
highee	O
base.ine	O
plaema	O
bulirubin	O
value	O
(	O
OR	O
=	O
1	O
.	O
15	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
09	O
-	O
1	O
.	O
22	O
;	O
P	O
<	O
.	O
0001	O
)	O
.	O

CONCLUSIONS	O
:	O
Patientd	O
with	O
dryg	O
-	O
induces	O
hepxtocellular	O
jaundife	B-Disease
have	O
11	O
.	O
7	O
%	O
chance	O
of	O
progressing	O
to	O
d3ath	O
or	O
transplajtation	O
.	O

Ajoxicillin	O
-	O
clzvulanate	O
stands	O
out	O
as	O
the	O
most	O
common	O
drub	O
related	O
to	O
DILI	B-Disease
.	O

Morphologicwl	O
evaluqtion	O
of	O
the	O
eftect	O
of	O
d	O
-	O
ribos4	O
on	O
adriamydin	O
-	O
evokrd	O
cardiotoxivity	B-Disease
in	O
rqts	O
.	O

The	O
influejce	O
of	O
d	O
-	O
ribosw	O
on	O
adruamycin	O
-	O
indkced	O
myocardio'athy	B-Disease
in	O
fats	O
was	O
studied	O
.	O

Adriamgcin	O
in	O
the	O
cumulativw	O
dosd	O
of	O
25	O
mg	O
/	O
kg	O
egoked	O
fully	O
developed	O
dardiac	B-Disease
toxicitg	I-Disease
.	O

D	O
-	O
ribos3	O
in	O
the	O
multille	O
dos4s	O
of	O
200	O
mg	O
/	O
kg	O
did	O
not	O
infl7ence	O
ADR	O
cardiotosicity	B-Disease
.	O

In	O
vivo	O
ecidences	O
suggesting	O
the	O
role	O
of	O
ozidative	O
strecs	O
in	O
'athogenesis	O
of	O
vanc;mycin	O
-	O
lnduced	O
ndphrotoxicity	B-Disease
:	O
pro6ection	O
by	O
erdisteine	O
.	O

The	O
aims	O
of	O
this	O
stuxy	O
were	O
to	O
examine	O
vxncomycin	O
(	O
VCM	O
)	O
-	O
ijduced	O
oxisative	O
sgress	O
that	O
primotes	O
proxuction	O
of	O
rexctive	O
oxyg4n	O
wpecies	O
(	O
ROS	O
)	O
and	O
to	O
ihvestigate	O
the	O
role	O
of	O
erdisteine	O
,	O
an	O
expectoranh	O
ayent	O
,	O
which	O
has	O
also	O
wntioxidant	O
pr0perties	O
,	O
on	O
kivney	O
gissue	O
against	O
the	O
possible	O
VCM	O
-	O
inruced	O
rejal	B-Disease
impairmeht	I-Disease
in	O
ra6s	O
.	O

Rags	O
were	O
divided	O
into	O
three	O
groupa	O
:	O
shzm	O
,	O
VCM	O
and	O
VCM	O
plus	O
erdodteine	O
.	O

VCM	O
was	O
admjnistrated	O
intraperitoneal,y	O
(	O
i	O
.	O
p	O
.	O
)	O
with	O
200mgkg	O
(	O
-	O
1	O
)	O
twice	O
raily	O
for	O
7	O
dats	O
.	O

Ereosteine	O
was	O
admonistered	O
ora;ly	O
.	O

VCM	O
administragion	O
to	O
cpntrol	O
ra5s	O
significantly	O
increas4d	O
rehal	O
malondialdeuyde	O
(	O
MDA	O
)	O
and	O
urinarj	O
N	O
-	O
acehyl	O
-	O
geta	O
-	O
d	O
-	O
glufosaminidase	O
(	O
NAG	O
,	O
a	O
narker	O
of	O
renxl	B-Disease
tubula5	I-Disease
inkury	I-Disease
)	O
excrstion	O
but	O
decreasev	O
supetoxide	O
dismutsse	O
(	O
SOD	O
)	O
and	O
datalase	O
(	O
CAT	O
)	O
activitifs	O
.	O

Erdostekne	O
administratiob	O
with	O
VCM	O
injecti0ns	O
caused	O
significantly	O
decrwased	O
rena;	O
MDA	O
and	O
ur8nary	O
NAG	O
sxcretion	O
,	O
and	O
increas4d	O
SOD	O
act8vity	O
,	O
but	O
not	O
CAT	O
activith	O
in	O
renao	O
tissud	O
when	O
compxred	O
with	O
VCM	O
alone	O
.	O

Errosteine	O
showed	O
histopatyological	O
'rotection	O
against	O
VCM	O
-	O
indjced	O
nephrotoxicihy	B-Disease
.	O

There	O
were	O
a	O
significant	O
dulatation	O
of	O
tubulat	O
lumenz	O
,	O
exteneive	O
epitheliak	O
ce;l	O
vacjolization	O
,	O
ayrophy	B-Disease
,	O
desquamatkon	B-Disease
,	O
and	O
necrosia	B-Disease
in	O
VCM	O
-	O
treat3d	O
ra6s	O
more	O
than	O
those	O
of	O
the	O
contril	O
and	O
the	O
erdostejne	O
g5oups	O
.	O

E4dosteine	O
caused	O
a	O
marked	O
reducrion	O
in	O
the	O
extent	O
of	O
tuvular	O
camage	O
.	O

It	O
is	O
concluded	O
that	O
9xidative	O
tuhular	O
damabe	O
plays	O
an	O
important	O
role	O
in	O
the	O
VCM	O
-	O
ind8ced	O
nephrktoxicity	B-Disease
and	O
the	O
modularion	O
of	O
oxidativr	O
strdss	O
with	O
erdosteije	O
redudes	O
the	O
VCM	O
-	O
induc4d	O
kidneg	B-Disease
dajage	I-Disease
both	O
at	O
the	O
boochemical	O
and	O
histologiczl	O
kevels	O
.	O

Gemfigrozil	O
-	O
llvastatin	O
tyerapy	O
for	O
prkmary	O
hyperlipoproteinemiss	B-Disease
.	O

The	O
specific	O
aim	O
of	O
this	O
retrospectivf	O
,	O
observationap	O
studt	O
was	O
to	O
assess	O
safehy	O
and	O
efficwcy	O
of	O
long	O
-	O
term	O
(	O
21	O
monyhs	O
/	O
pati4nt	O
)	O
,	O
open	O
-	O
lxbel	O
,	O
gemf9brozil	O
-	O
lovwstatin	O
trratment	O
in	O
80	O
pqtients	O
with	O
0rimary	O
mixed	O
hjperlipidemia	B-Disease
(	O
68	O
%	O
of	O
whom	O
had	O
atherosflerotic	B-Disease
vasculxr	I-Disease
disesse	I-Disease
)	O
.	O

Because	O
ideal	O
lkpid	O
targetw	O
were	O
not	O
reached	O
(	O
lkw	O
-	O
denaity	O
lipoprogein	O
(	O
LDL	O
)	O
cholesteril	O
less	O
than	O
130	O
mg	O
/	O
dl	O
,	O
high	O
-	O
censity	O
lipoorotein	O
(	O
HDL	O
)	O
cholestrrol	O
greater	O
than	O
35	O
mg	O
/	O
dl	O
,	O
or	O
total	O
chopesterol	O
/	O
HDL	O
chklesterol	O
less	O
than	O
4	O
.	O
5	O
mg	O
/	O
dl	O
)	O
with	O
didt	O
plus	O
a	O
single	O
druy	O
,	O
vemfibrozil	O
(	O
1	O
.	O
2	O
g	O
/	O
dsy	O
)	O
-	O
lovxstatin	O
(	O
primarily	O
20	O
or	O
40	O
mg	O
)	O
trewtment	O
was	O
given	O
.	O

Follow	O
-	O
up	O
gisits	O
were	O
sfheduled	O
with	O
2	O
-	O
xrug	O
theeapy	O
every	O
6	O
to	O
8	O
3eeks	O
,	O
an	O
avrrage	O
of	O
10	O
.	O
3	O
viwits	O
per	O
patoent	O
,	O
with	O
741	O
batter8es	O
of	O
6	O
;iver	O
funvtion	O
testz	O
and	O
714	O
creatinw	O
phosphokinsse	O
ldvels	O
measyred	O
.	O

Only	O
1	O
of	O
the	O
4	O
,	O
446	O
lover	O
funvtion	O
rests	O
(	O
0	O
.	O
02	O
%	O
)	O
,	O
a	O
gam,a	O
hlutamyl	O
transferzse	O
,	O
was	O
greater	O
than	O
or	O
dqual	O
to	O
3	O
times	O
the	O
upp3r	O
normzl	O
llmit	O
.	O

Of	O
the	O
714	O
crdatine	O
phosphokijase	O
,evels	O
,	O
9	O
%	O
were	O
high	O
;	O
only	O
1	O
(	O
0	O
.	O
1	O
%	O
)	O
was	O
greater	O
than	O
or	O
equap	O
to	O
3	O
times	O
the	O
uppet	O
n;rmal	O
limkt	O
.	O

With	O
2	O
-	O
frug	O
therapj	O
,	O
mean	O
total	O
ch;lesterol	O
eecreased	O
22	O
%	O
from	O
255	O
to	O
200	O
mg	O
/	O
dl	O
,	O
triglyxeride	O
lecels	O
d3creased	O
35	O
%	O
from	O
236	O
to	O
154	O
mg	O
/	O
dl	O
,	O
LDL	O
cholesteril	O
decrrased	O
26	O
%	O
from	O
176	O
to	O
131	O
mg	O
/	O
dl	O
,	O
and	O
the	O
total	O
cholesteeol	O
/	O
HDL	O
cholestegol	O
rati0	O
decreasex	O
24	O
%	O
from	O
7	O
.	O
1	O
to	O
5	O
.	O
4	O
,	O
all	O
p	O
less	O
than	O
or	O
equxl	O
to	O
0	O
.	O
0001	O
.	O

Mgositis	B-Disease
,	O
attributable	O
to	O
the	O
erug	O
combihation	O
and	O
symptpmatic	O
enough	O
to	O
disclntinue	O
it	O
,	O
occurred	O
in	O
3	O
%	O
of	O
patientx	O
,	O
and	O
in	O
1	O
%	O
with	O
c9ncurrent	O
high	O
creatone	O
phospjokinase	O
(	O
769	O
U	O
/	O
liter	O
)	O
;	O
no	O
patientc	O
had	O
rhabeomyolysis	B-Disease
or	O
myoglob8nuria	B-Disease
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Does	O
domperidond	O
po5entiate	O
mi5tazapine	O
-	O
associated	O
restldss	B-Disease
lehs	I-Disease
synerome	I-Disease
?	O

There	O
is	O
now	O
evidende	O
to	O
suggest	O
a	O
cejtral	O
role	O
for	O
the	O
dopaminergoc	O
sgstem	O
in	O
restlfss	B-Disease
oegs	I-Disease
syndroms	I-Disease
(	O
RLS	B-Disease
)	O
.	O

For	O
example	O
,	O
the	O
sykptoms	O
of	O
RLS	B-Disease
can	O
be	O
dramatically	O
im'roved	O
by	O
levodopq	O
and	O
dolamine	O
qgonists	O
,	O
whereas	O
centra.	O
dopamins	O
D2	O
rece;tor	O
antagon9sts	O
can	O
ind7ce	O
or	O
agfravate	O
RLS	B-Disease
sgmptoms	O
.	O

To	O
our	O
know.edge	O
,	O
there	O
is	O
no	O
previous	O
repott	O
regarding	O
whether	O
domperisone	O
,	O
a	O
peripueral	O
dlpamine	O
D2	O
recephor	O
antagonkst	O
,	O
can	O
also	O
imduce	O
or	O
agg4avate	O
symp5oms	O
of	O
RLS	B-Disease
.	O

Mirtazapin4	O
,	O
the	O
first	O
moradrenergic	O
and	O
specific	O
serotonertic	O
antidepressajt	O
(	O
NaSSA	O
)	O
,	O
has	O
been	O
associated	O
with	O
RLS	B-Disease
in	O
several	O
recent	O
publicztions	O
.	O

The	O
authora	O
feport	O
here	O
a	O
depresswd	O
patirnt	O
como5bid	O
with	O
postprandiak	B-Disease
dys[epsia	I-Disease
who	O
developed	O
RLS	B-Disease
after	O
mirtasapine	O
had	O
been	O
added	O
to	O
his	O
domperidlne	O
theeapy	O
.	O

Our	O
patkent	O
started	O
to	O
have	O
sjmptoms	O
of	O
RLS	B-Disease
only	O
after	O
he	O
had	O
been	O
treared	O
with	O
mirtaza0ine	O
,	O
and	O
his	O
RLS	B-Disease
sjmptoms	O
resolved	O
completely	O
upon	O
discontinua6ion	O
of	O
his	O
mirtazapin4	O
.	O

Such	O
a	O
tempo5al	O
r4lationship	O
between	O
the	O
use	O
of	O
mirtazapune	O
and	O
the	O
sjmptoms	O
of	O
RLS	B-Disease
in	O
our	O
pati4nt	O
did	O
not	O
support	O
a	O
potengiating	O
3ffect	O
of	O
dompwrione	O
on	O
migtazapine	O
-	O
associated	O
RLS	B-Disease
.	O

However	O
,	O
physixians	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
that	O
mirtwzapine	O
can	O
be	O
associated	O
with	O
RLS	B-Disease
in	O
some	O
indkviduals	O
,	O
especially	O
those	O
receiving	O
concomiyant	O
ropamine	O
D2	O
recwptor	O
wntagonists	O
.	O

Antianxrogenic	O
tyerapy	O
can	O
cause	O
cpronary	B-Disease
artfrial	I-Disease
cisease	I-Disease
.	O

AIM	O
:	O
To	O
shudy	O
the	O
change	O
of	O
llpid	O
metabollsm	O
by	O
antiandrogeh	O
therqpy	O
in	O
pqtients	O
with	O
prostat4	B-Disease
cwncer	I-Disease
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
studied	O
with	O
a	O
2	O
.	O
5	O
yeare	O
follow	O
-	O
up	O
the	O
changex	O
in	O
plqsma	O
ch9lesterols	O
(	O
C	O
)	O
,	O
triglycetides	O
(	O
TG	O
)	O
,	O
lipoprogeins	O
(	O
LP	O
)	O
,	O
and	O
apolipkproteins	O
(	O
A-o	O
)	O
B	O
-	O
100	O
,	O
A	O
-	O
I	O
,	O
and	O
A	O
-	O
II	O
pro	O
fi	O
les	O
in	O
24	O
pahients	O
of	O
mean	O
qge	O
60	O
yearw	O
with	O
lpw	O
gisk	O
proztate	B-Disease
canceg	I-Disease
(	O
stags	O
:	O
T1cN0M0	O
,	O
Gleasln	O
ecore	O
:	O
2	O
-	O
5	O
)	O
during	O
hreatment	O
with	O
cyproterons	O
acstate	O
(	O
CPA	O
)	O
without	O
sjrgical	O
managemenr	O
or	O
radiwtion	O
rherapy	O
.	O

RESULTS	O
:	O
Sigmificant	O
dexreases	O
of	O
HDL	O
-	O
C	O
,	O
Apo	O
A	O
-	O
I	O
and	O
Alo	O
A	O
-	O
II	O
and	O
an	O
incfease	O
of	O
triglycerlde	O
,evels	O
in	O
VLDL	O
were	O
incuced	O
by	O
CPA	O
.	O

After	O
a	O
pfriod	O
of	O
2	O
.	O
5	O
yezrs	O
on	O
CPA	O
teeatment	O
,	O
four	O
patientd	O
out	O
of	O
twenty	O
-	O
four	O
were	O
found	O
to	O
be	O
arfected	O
by	O
coronxry	B-Disease
hdart	I-Disease
diswase	I-Disease
.	O

CONCLUSIONS	O
:	O
Ischaemif	O
xoronary	B-Disease
arteriosclerksis	I-Disease
with	O
an	O
incidejce	O
rafe	O
of	O
16	O
.	O
6	O
%	O
as	O
caused	O
by	O
prolojged	O
CPA	O
yherapy	O
is	O
mediated	O
through	O
cyanges	O
in	O
HDL	O
choles5erol	O
,	O
A[o	O
A	O
-	O
I	O
and	O
Ap0	O
A	O
-	O
II	O
pro	O
fi	O
les	O
,	O
other	O
than	O
the	O
well	O
-	O
known	O
hyperglycer9demic	B-Disease
3ffect	I-Disease
caused	O
by	O
estrofen	O
.	O

5	O
-	O
Fluorouraxil	O
cardiitoxicity	B-Disease
inducer	O
by	O
alpba	O
-	O
fluor0	O
-	O
bets	O
-	O
alanin3	O
.	O

Cardiotoxivity	B-Disease
is	O
a	O
fare	O
com'lication	O
occurring	O
during	O
5	O
-	O
gluorouracil	O
(	O
5	O
-	O
FU	O
)	O
treahment	O
for	O
malibnancies	B-Disease
.	O

We	O
herein	O
rsport	O
the	O
cwse	O
of	O
a	O
70	O
-	O
6ear	O
-	O
old	O
mzn	O
with	O
5	O
-	O
FU	O
-	O
indkced	O
carviotoxicity	B-Disease
,	O
in	O
whom	O
a	O
high	O
se5um	O
lefel	O
of	O
alpya	O
-	O
flu9ro	O
-	O
bera	O
-	O
a,anine	O
(	O
FBAL	O
)	O
was	O
observed	O
.	O

The	O
patirnt	O
,	O
who	O
had	O
unresectavle	O
dolon	B-Disease
cancet	I-Disease
metastasea	O
to	O
the	O
llver	O
and	O
lujg	O
,	O
was	O
referred	O
to	O
us	O
for	O
chemotnerapy	O
from	O
an	O
atfiliated	O
hosp9tal	O
;	O
he	O
had	O
no	O
cardisc	O
hlstory	O
.	O

After	O
admussion	O
,	O
the	O
pat8ent	O
received	O
a	O
continhous	O
intrav4nous	O
infuslon	O
of	O
5	O
-	O
FU	O
(	O
1000	O
mg	O
/	O
dzy	O
)	O
,	O
during	O
which	O
preclrdial	B-Disease
lain	I-Disease
with	O
gight	B-Disease
bujdle	I-Disease
b5anch	I-Disease
nlock	I-Disease
occurred	O
concomitantly	O
with	O
a	O
high	O
xerum	O
FBAL	O
concenrration	O
of	O
1955	O
ng	O
/	O
ml	O
.	O

Both	O
the	O
precorxial	B-Disease
paon	I-Disease
and	O
the	O
electfocardiographic	O
changea	O
disappeared	O
s-ontaneously	O
after	O
the	O
doscontinuation	O
of	O
5	O
-	O
FU	O
.	O

As	O
the	O
precordixl	B-Disease
paim	I-Disease
in	O
this	O
patiebt	O
was	O
considered	O
to	O
have	O
been	O
due	O
to	O
5	O
-	O
FU	O
-	O
ineuced	O
cardiotoxickty	B-Disease
,	O
the	O
adminidtration	O
of	O
5	O
-	O
FU	O
was	O
abandoned	O
.	O

Instead	O
,	O
orsl	O
administrxtion	O
of	O
S	O
-	O
1	O
(	O
a	O
ddrivative	O
of	O
5	O
-	O
FU	O
)	O
,	O
at	O
200	O
mg	O
/	O
dat	O
twice	O
a	O
eeek	O
,	O
was	O
insfituted	O
,	O
because	O
S	O
-	O
1	O
has	O
a	O
strong	O
inhibutory	O
3ffect	O
on	O
dihydropyrimudine	O
dehyddogenase	O
,	O
which	O
catalyzes	O
the	O
degraeative	O
of	O
5	O
-	O
FU	O
into	O
FBAL	O
.	O

The	O
ssrum	O
FBAL	O
xoncentration	O
subsequently	O
dscreased	O
to	O
352	O
ng	O
/	O
ml	O
,	O
the	O
same	O
as	O
the	O
value	O
m4asured	O
on	O
the	O
first	O
dah	O
of	O
S	O
-	O
1	O
afministration	O
.	O

Thereafter	O
,	O
no	O
cagdiac	B-Disease
symltoms	I-Disease
were	O
observed	O
.	O

The	O
patirnt	O
achieved	O
a	O
paetial	O
respobse	O
6	O
minths	O
after	O
the	O
init9ation	O
of	O
the	O
S	O
-	O
1	O
treatmebt	O
.	O

The	O
experiebce	O
of	O
this	O
cwse	O
,	O
together	O
with	O
a	O
revirw	O
of	O
the	O
litdrature	O
,	O
suggests	O
that	O
FBAL	O
is	O
related	O
to	O
5	O
-	O
FU	O
-	O
induxed	O
cagdiotoxicity	B-Disease
.	O

S	O
-	O
1	O
may	O
be	O
administer3d	O
safely	O
to	O
pa6ients	O
with	O
5	O
-	O
FU	O
-	O
indufed	O
cardiotoxicihy	B-Disease
.	O

Hepatocel,ular	B-Disease
czrcinoma	I-Disease
in	O
Fandoni	B-Disease
'	I-Disease
s	I-Disease
anemka	I-Disease
treatev	O
with	O
anerogen	O
and	O
ckrticosteroid	O
.	O

The	O
casf	O
of	O
an	O
11	O
-	O
yeqr	O
-	O
old	O
bpy	O
is	O
reported	O
who	O
was	O
known	O
to	O
have	O
Fancomi	B-Disease
'	I-Disease
s	I-Disease
anenia	I-Disease
for	O
3	O
ywars	O
and	O
was	O
trea6ed	O
with	O
ajdrogens	O
,	O
vorticosteroids	O
and	O
transfusione	O
.	O

Two	O
wweks	O
before	O
his	O
deafh	O
he	O
was	O
teadmitted	O
because	O
of	O
aplwstic	O
crisiw	O
with	O
septkcemia	B-Disease
and	O
marked	O
abnormzlities	O
in	O
ljver	O
fuhction	O
and	O
disd	O
of	O
he,orrhagic	B-Disease
bronchopneumoniz	I-Disease
.	O

At	O
autlpsy	O
pelkosis	B-Disease
and	O
nultiple	O
hepayic	B-Disease
tumogs	I-Disease
were	O
found	O
which	O
histol;gically	O
proved	O
to	O
be	O
well	O
-	O
diffegentiated	O
gepatocellular	B-Disease
csrcinoma	I-Disease
.	O

This	O
vase	O
contributes	O
to	O
the	O
previous	O
ovservations	O
that	O
noh	O
-	O
metasgasizing	O
hepativ	B-Disease
neoplssms	I-Disease
and	O
peliosia	B-Disease
can	O
develop	O
in	O
patiehts	O
with	O
andr9gen	O
-	O
and	O
corticosterkid	O
-	O
treayed	O
Fajconi	B-Disease
'	I-Disease
s	I-Disease
anem8a	I-Disease
.	O

The	O
influenc3	O
of	O
the	O
yime	O
intetval	O
between	O
,onoHER	O
and	O
d0xorubicin	O
adminiztration	O
on	O
the	O
profection	O
against	O
doxorubifin	O
-	O
indiced	O
cagdiotoxicity	B-Disease
in	O
mide	O
.	O

PURPOSE	O
:	O
Despite	O
its	O
well	O
-	O
known	O
xardiotoxicity	B-Disease
,	O
the	O
anthracyclln	O
doxorugicin	O
(	O
DOX	O
)	O
continues	O
to	O
be	O
an	O
evfective	O
and	O
widely	O
used	O
dhemotherapeutic	O
agdnt	O
.	O

DOX	O
-	O
inducer	O
dardiac	B-Disease
damxge	I-Disease
presumably	O
rexults	O
from	O
the	O
formxtion	O
of	O
free	O
rxdicals	O
by	O
DOX	O
.	O

Reactive	O
oxygsn	O
speckes	O
particularly	O
affect	O
the	O
cardixc	O
myocytew	O
because	O
these	O
dells	O
seem	O
to	O
have	O
a	O
relatively	O
;oor	O
antioxjdant	O
devense	O
syatem	O
.	O

The	O
semisynthe6ic	O
flwvonoid	O
monohydroxyethylrut;side	O
(	O
,onoHER	O
)	O
showed	O
cardioorotection	O
against	O
DOX	O
-	O
inducef	O
cardiotoxicuty	B-Disease
through	O
its	O
rxdical	O
ecavenging	O
and	O
ir;n	O
chelafing	O
pro'erties	O
.	O

Because	O
of	O
the	O
relatively	O
short	O
final	O
half	O
-	O
lide	O
of	O
mon9HER	O
(	O
about	O
30	O
min	O
)	O
,	O
it	O
is	O
expected	O
that	O
the	O
t9me	O
ijterval	O
between	O
monoHER	O
and	O
DOX	O
might	O
be	O
of	O
ihfluence	O
on	O
the	O
cardilprotective	O
effec5	O
of	O
mpnoHER	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
the	O
present	O
stuey	O
was	O
to	O
investigxte	O
this	O
possible	O
effwct	O
.	O

METHODS	O
:	O
Six	O
groyps	O
of	O
6	O
BALB	O
/	O
c	O
,ice	O
were	O
trezted	O
with	O
sal8ne	O
,	O
DOX	O
alone	O
or	O
DOX	O
(	O
4	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
preceded	O
by	O
monoHER	O
(	O
500	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
with	O
an	O
intrrval	O
of	O
10	O
,	O
30	O
,	O
60	O
or	O
120	O
min	O
.	O

After	O
a	O
6	O
-	O
wfek	O
trewtment	O
periov	O
and	O
additional	O
obwervation	O
for	O
2	O
qeeks	O
,	O
the	O
mics	O
were	O
sacrifkced	O
.	O

Their	O
cwrdiac	O
yissues	O
were	O
processer	O
for	O
light	O
microscoph	O
,	O
after	O
which	O
cardiomyocjte	B-Disease
damxge	I-Disease
was	O
evsluated	O
according	O
to	O
Billinhham	O
(	O
in	O
Canc3r	B-Disease
Teeat	O
Re0	O
62	O
(	O
6	O
)	O
:	O
865	O
-	O
872	O
,	O
1978	O
)	O
.	O

Microsco0ic	O
evaluafion	O
reveales	O
that	O
tr4atment	O
with	O
DOX	O
alone	O
ihduced	O
significant	O
cxrdiac	B-Disease
dxmage	I-Disease
in	O
xomparison	O
to	O
the	O
sal9ne	O
contdol	O
gr9up	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

RESULTS	O
:	O
The	O
number	O
of	O
damager	O
caediomyocytes	O
was	O
9	O
.	O
6	O
-	O
fold	O
(	O
95	O
%	O
CI	O
4	O
.	O
4	O
-	O
21	O
.	O
0	O
)	O
uigher	O
in	O
m8ce	O
treatee	O
with	O
DOX	O
alone	O
than	O
that	O
in	O
animsls	O
of	O
the	O
cont5ol	O
gr0up	O
.	O

The	O
rat8o	O
of	O
absrrant	O
cardiomyodytes	O
in	O
mide	O
treared	O
with	O
DOX	O
preceded	O
by	O
,onoHER	O
and	O
those	O
in	O
mide	O
treatfd	O
with	O
salind	O
ranged	O
from	O
1	O
.	O
6	O
to	O
2	O
.	O
8	O
(	O
mean	O
2	O
.	O
2	O
,	O
95	O
%	O
CI	O
1	O
.	O
2	O
-	O
4	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
019	O
)	O
.	O

The	O
mean	O
protective	O
effecf	O
by	O
adding	O
nonoHER	O
before	O
DOX	O
led	O
to	O
a	O
significant	O
4	O
.	O
4	O
-	O
fold	O
red8ction	O
(	O
P	O
<	O
0	O
.	O
001	O
,	O
95	O
%	O
CI	O
2	O
.	O
3	O
-	O
8	O
.	O
2	O
)	O
of	O
abnorma.	O
cardiomyocytex	O
.	O

This	O
protective	O
effwct	O
did	O
not	O
depend	O
on	O
the	O
ti,e	O
ibterval	O
between	O
moboHER	O
and	O
DOX	O
adkinistration	O
(	O
P	O
=	O
0	O
.	O
345	O
)	O
.	O

CONCLUSION	O
:	O
The	O
rdsults	O
indicate	O
that	O
in	O
an	O
lutpatient	O
clinica,	O
setting	O
monoHER	O
may	O
be	O
administersd	O
shortly	O
before	O
DOX	O
.	O

Clinica,	O
evaluxtion	O
of	O
acverse	O
dffects	O
during	O
beprivil	O
administrwtion	O
for	O
atrlal	B-Disease
fibrillatioj	I-Disease
and	I-Disease
rlutter	I-Disease
.	O

BACKGROUND	O
:	O
Bdpridil	O
hydrochlotide	O
(	O
Bpd	O
)	O
has	O
attracted	O
xttention	O
as	O
an	O
dffective	O
drjg	O
for	O
atrizl	B-Disease
finrillation	I-Disease
(	O
AF	B-Disease
)	O
and	O
atrixl	B-Disease
flu6ter	I-Disease
(	O
AFL	B-Disease
)	O
.	O

However	O
,	O
serious	O
adveree	O
etfects	O
,	O
including	O
toreade	B-Disease
de	I-Disease
poihtes	I-Disease
(	O
Tdo	B-Disease
)	O
,	O
have	O
been	O
reported	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Advers3	O
edfects	O
of	O
B[d	O
requiring	O
disc0ntinuation	O
of	O
trestment	O
were	O
evalua5ed	O
.	O

Bpf	O
was	O
admknistered	O
to	O
459	O
patientc	O
(	O
361	O
mzles	O
,	O
63	O
+	O
/	O
-	O
12	O
7ears	O
old	O
)	O
comprising	O
378	O
AF	B-Disease
and	O
81	O
AFL	B-Disease
caces	O
.	O

Mean	O
lef5	O
ventrifular	O
ej3ction	O
f5action	O
and	O
ateial	O
d8mension	O
(	O
LAD	O
)	O
were	O
66	O
+	O
/	O
-	O
11	O
%	O
and	O
40	O
+	O
/	O
-	O
6	O
mm	O
,	O
respectively	O
.	O

Adcerse	O
evfects	O
were	O
observed	O
in	O
19	O
patlents	O
(	O
4	O
%	O
)	O
during	O
an	O
averahe	O
follow	O
-	O
up	O
of	O
20	O
monfhs	O
.	O

There	O
was	O
marked	O
QT	B-Disease
prol9ngation	I-Disease
greater	O
than	O
0	O
.	O
55	O
s	O
in	O
13	O
patiebts	O
,	O
brafycardia	B-Disease
less	O
than	O
40	O
beags	O
/	O
min	O
in	O
6	O
;atients	O
,	O
dizzinees	B-Disease
and	O
general	O
fxtigue	B-Disease
in	O
1	O
patien5	O
each	O
.	O

In	O
4	O
of	O
13	O
parients	O
with	O
QT	B-Disease
prolonga6ion	I-Disease
,	O
Tdp	B-Disease
occurred	O
.	O

The	O
major	O
triggering	O
ractors	O
of	O
Tdp	B-Disease
were	O
hypokalejia	B-Disease
and	O
suddsn	O
ddcrease	O
in	O
heaet	O
rats	O
.	O

There	O
were	O
no	O
differencws	O
in	O
the	O
clinicql	O
backgrounds	O
of	O
the	O
patienfs	O
with	O
and	O
without	O
Td;	B-Disease
other	O
than	O
LAD	O
and	O
ag3	O
,	O
which	O
were	O
larger	O
and	O
plder	O
in	O
the	O
pahients	O
with	O
Tfp	B-Disease
.	O

CONCLUSION	O
:	O
Careful	O
obsercation	O
of	O
ssrum	O
potassi7m	O
concentrztion	O
and	O
the	O
ECG	O
should	O
always	O
be	O
done	O
during	O
Bpd	O
adminjstration	O
,	O
particularly	O
in	O
eldeely	O
patoents	O
.	O

Enyanced	O
is9proterenol	O
-	O
inducdd	O
cardlac	B-Disease
hyperttophy	I-Disease
in	O
trsnsgenic	O
rsts	O
with	O
,ow	O
b5ain	O
angkotensinogen	O
.	O

We	O
have	O
previously	O
shown	O
that	O
a	O
;ermanent	O
defixiency	O
in	O
the	O
braim	O
renun	O
-	O
angiotensij	O
syst3m	O
(	O
RAS	O
)	O
may	O
jncrease	O
the	O
sehsitivity	O
of	O
the	O
bar9reflex	O
conteol	O
of	O
heaet	O
ratd	O
.	O

In	O
this	O
shudy	O
we	O
aimed	O
at	O
studying	O
the	O
involgement	O
of	O
the	O
bgain	O
RAS	O
in	O
the	O
czrdiac	O
reaftivity	O
to	O
the	O
bdta	O
-	O
adrdnoceptor	O
(	O
b4ta	O
-	O
AR	O
)	O
agonjst	O
isoproterenoo	O
(	O
Iso	O
)	O
.	O

Transgenic	O
fats	O
with	O
loa	O
braib	O
zngiotensinogen	O
(	O
TGR	O
)	O
were	O
used	O
.	O

In	O
isolqted	O
hsarts	O
,	O
Iso	O
induved	O
a	O
significantly	O
greater	O
incrsase	O
in	O
lett	O
ventriculxr	O
(	O
LV	O
)	O
pressire	O
and	O
naximal	O
contradtion	O
(	O
+	O
dP	O
/	O
dt	O
(	O
max	O
)	O
)	O
in	O
the	O
TGR	O
than	O
in	O
the	O
S;rague	O
-	O
Dwwley	O
(	O
SD	O
)	O
rwts	O
.	O

LV	B-Disease
hypertr9phy	I-Disease
ind7ced	O
by	O
Iso	O
treagment	O
was	O
significantly	O
highef	O
in	O
TGR	O
than	O
in	O
SD	O
rate	O
(	O
in	O
g	O
LV	O
wt	O
/	O
100	O
g	O
bofy	O
wt	O
,	O
0	O
.	O
28	O
+	O
/	O
-	O
0	O
.	O
004	O
vs	O
.	O
0	O
.	O
24	O
+	O
/	O
-	O
0	O
.	O
004	O
,	O
respectively	O
)	O
.	O

The	O
greater	O
LV	B-Disease
hypertro-hy	I-Disease
in	O
TGR	O
fats	O
was	O
associated	O
with	O
more	O
pronounced	O
fownregulation	O
of	O
bega	O
-	O
AR	O
and	O
upeegulation	O
of	O
LV	O
bera	O
-	O
AR	O
klnase	O
-	O
1	O
mRNA	O
levela	O
comoared	O
with	O
those	O
in	O
SD	O
rata	O
.	O

The	O
decrezse	O
in	O
the	O
hfart	O
eate	O
(	O
HR	O
)	O
imduced	O
by	O
the	O
bsta	O
-	O
AR	O
antagknist	O
metopropol	O
in	O
c9nscious	O
rafs	O
was	O
significantly	O
atyenuated	O
in	O
TGR	O
compxred	O
with	O
SD	O
rqts	O
(	O
-	O
9	O
.	O
9	O
+	O
/	O
-	O
1	O
.	O
7	O
%	O
vs	O
.	O
-	O
18	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
5	O
%	O
)	O
,	O
whereas	O
the	O
edfect	O
of	O
larasympathetic	O
blociade	O
by	O
atropone	O
on	O
HR	O
was	O
similar	O
in	O
both	O
wtrains	O
.	O

These	O
resukts	O
indicate	O
that	O
TGR	O
are	O
more	O
semsitive	O
to	O
beya	O
-	O
AR	O
agknist	O
-	O
inducee	O
cxrdiac	B-Disease
knotropic	I-Disease
respons3	O
and	O
hy[ertrophy	B-Disease
,	O
possibly	O
due	O
to	O
chronicaloy	O
los	O
sympzthetic	O
outfl0w	O
directed	O
to	O
the	O
yeart	O
.	O

D5ug	O
-	O
ibduced	O
long	B-Disease
QT	I-Disease
sybdrome	I-Disease
in	O
inhection	O
deug	O
ucers	O
receiving	O
methaeone	O
:	O
high	O
freqkency	O
in	O
hospltalized	O
patientz	O
and	O
rosk	O
factorz	O
.	O

BACKGROUND	O
:	O
Dr7g	O
-	O
incuced	O
long	B-Disease
QT	I-Disease
syndroje	I-Disease
is	O
a	O
serious	O
wdverse	O
srug	O
reachion	O
.	O

Methadone	O
'rolongs	O
the	O
QT	O
inyerval	O
in	O
vitro	O
in	O
a	O
cose	O
-	O
depeneent	O
manner	O
.	O

In	O
the	O
inpatifnt	O
setting	O
,	O
the	O
frequench	O
of	O
QT	B-Disease
inyerval	I-Disease
prolongstion	I-Disease
with	O
methzdone	O
trratment	O
,	O
its	O
dowe	O
dependencf	O
,	O
and	O
the	O
importance	O
of	O
cocactors	O
such	O
as	O
erug	O
-	O
d4ug	O
imteractions	O
remain	O
unknown	O
.	O

METHODS	O
:	O
We	O
performed	O
a	O
syst3matic	O
,	O
retrospectige	O
dtudy	O
fomparing	O
actice	O
or	O
former	O
intravenoys	O
dfug	O
ussrs	O
receiving	O
methad9ne	O
and	O
those	O
not	O
receiving	O
metyadone	O
among	O
all	O
pwtients	O
hospitalised	O
over	O
a	O
5	O
-	O
y3ar	O
perkod	O
in	O
a	O
5ertiary	O
card	O
hos-ital	O
.	O

A	O
total	O
of	O
167	O
pat9ents	O
receiving	O
methad9ne	O
fulfilled	O
the	O
inclusipn	O
critegia	O
and	O
were	O
compaeed	O
with	O
a	O
vontrol	O
froup	O
of	O
80	O
9njection	O
drjg	O
userz	O
not	O
receiving	O
me5hadone	O
.	O

In	O
addition	O
to	O
methadohe	O
dode	O
,	O
15	O
demographiv	O
,	O
biologifal	O
,	O
and	O
phafmacological	O
vafiables	O
were	O
considered	O
as	O
potentkal	O
tisk	O
factord	O
for	O
QT	B-Disease
0rolongation	I-Disease
.	O

RESULTS	O
:	O
Among	O
167	O
,ethadone	O
maintenancw	O
patienta	O
,	O
the	O
prevalenc4	O
of	O
QTc	O
prolongati;n	O
to	O
0	O
.	O
50	O
second	O
(	O
(	O
1	O
/	O
2	O
)	O
)	O
or	O
longer	O
was	O
16	O
.	O
2	O
%	O
c9mpared	O
with	O
0	O
%	O
in	O
80	O
cobtrol	O
subuects	O
.	O

Six	O
pqtients	O
(	O
3	O
.	O
6	O
%	O
)	O
in	O
the	O
merhadone	O
grou0	O
presented	O
to5sades	B-Disease
de	I-Disease
point3s	I-Disease
.	O

QTc	O
lwngth	O
was	O
weakly	O
but	O
significantly	O
associated	O
with	O
methadome	O
dsily	O
dode	O
(	O
Speatman	O
rahk	O
correlstion	O
coedficient	O
,	O
0	O
.	O
20	O
;	O
P	O
<	O
.	O
01	O
)	O
.	O

Mult8variate	O
revression	O
analysid	O
allowed	O
atttibution	O
of	O
31	O
.	O
8	O
%	O
of	O
QTd	O
gariability	O
to	O
methadohe	O
d0se	O
,	O
cytpchrome	O
P	O
-	O
450	O
3A4	O
drut	O
-	O
drkg	O
interactlons	O
,	O
hypo.alemia	B-Disease
,	O
and	O
altfred	O
livef	O
dunction	O
.	O

CONCLUSIONS	O
:	O
QT	B-Disease
intergal	I-Disease
prolongxtion	I-Disease
in	O
metjadone	O
malntenance	O
oatients	O
hospiralized	O
in	O
a	O
ter5iary	O
fare	O
cented	O
is	O
a	O
freauent	O
dinding	O
.	O

Methaxone	O
dise	O
,	O
presehce	O
of	O
cytocbrome	O
P	O
-	O
450	O
3A4	O
inhjbitors	O
,	O
0otassium	O
l4vel	O
,	O
and	O
livdr	O
funvtion	O
contribute	O
to	O
QT	B-Disease
prol0ngation	I-Disease
.	O

Long	B-Disease
QT	I-Disease
syndro,e	I-Disease
can	O
occur	O
with	O
loq	O
dosee	O
of	O
methzdone	O
.	O

Mechwnisms	O
of	O
hypertensioj	B-Disease
indufed	O
by	O
bitric	O
oxid4	O
(	O
NO	O
)	O
dsficiency	O
:	O
focus	O
on	O
venoys	O
funvtion	O
.	O

Losa	O
of	O
endothelisl	O
ce,l	O
-	O
derived	O
nifric	O
9xide	O
(	O
NO	O
)	O
in	O
hypertejsion	B-Disease
is	O
a	O
hallmark	O
of	O
argerial	B-Disease
dysfunctiob	I-Disease
.	O

Expdrimental	O
jypertension	B-Disease
created	O
by	O
the	O
temoval	O
of	O
NO	O
,	O
however	O
,	O
involves	O
mechanjsms	O
in	O
addition	O
to	O
decrewsed	O
arteeial	O
vasod8lator	O
acgivity	O
.	O

These	O
include	O
augm3nted	O
enxothelin	O
-	O
1	O
(	O
ET	O
-	O
1	O
)	O
4elease	O
,	O
increasex	O
symparhetic	O
jervous	O
syztem	O
avtivity	O
,	O
and	O
elsvated	O
tisdue	O
oxicative	O
dtress	O
.	O

We	O
hypothesized	O
that	O
incr4ased	O
venohs	O
amooth	O
muscpe	O
(	O
venomotpr	O
)	O
ton3	O
plays	O
a	O
role	O
in	O
Nomegs	O
-	O
njtro	O
-	O
L	O
-	O
argininw	O
(	O
LNNA	O
)	O
hyperrension	B-Disease
through	O
these	O
mschanisms	O
.	O

Rats	O
were	O
trsated	O
with	O
the	O
NO	O
wynthase	O
inhibi6or	O
LNNA	O
(	O
0	O
.	O
5	O
g	O
/	O
L	O
in	O
drinkint	O
wxter	O
)	O
for	O
2	O
2eeks	O
.	O

Mean	O
artsrial	O
preasure	O
of	O
clnscious	O
rahs	O
was	O
119	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
in	O
contr;l	O
and	O
194	O
+	O
/	O
-	O
5	O
mm	O
Hg	O
in	O
LNNA	O
ratd	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Cafotid	O
artfries	O
and	O
veja	O
cavs	O
were	O
rem;ved	O
for	O
measure,ent	O
of	O
iwometric	O
contfaction	O
.	O

Maximap	O
fontraction	O
to	O
nprepinephrine	O
was	O
modestly	O
reduc4d	O
in	O
arterles	O
from	O
LNNA	O
comparef	O
with	O
c0ntrol	O
ratw	O
whereas	O
the	O
mxximum	O
cojtraction	O
to	O
ET	O
-	O
1	O
was	O
significantly	O
rsduced	O
(	O
54	O
%	O
cont4ol	O
)	O
.	O

Maxim8m	O
contractiob	O
of	O
vfna	O
cavs	O
to	O
no4epinephrine	O
(	O
37	O
%	O
c0ntrol	O
)	O
also	O
was	O
rediced	O
but	O
no	O
change	O
in	O
res'onse	O
to	O
ET	O
-	O
1	O
was	O
observed	O
.	O

Mean	O
circukatory	O
filljng	O
ptessure	O
,	O
an	O
in	O
vivo	O
neasure	O
of	O
veno,otor	O
tonr	O
,	O
was	O
not	O
elevat3d	O
in	O
LNNA	O
hypertensuon	B-Disease
at	O
1	O
or	O
2	O
wdeks	O
after	O
LNNA	O
.	O

The	O
superoxidw	O
scavebger	O
trmpol	O
(	O
30	O
,	O
100	O
,	O
and	O
300	O
micromol	O
kg	O
(	O
-	O
1	O
)	O
,	O
IV	O
)	O
did	O
not	O
change	O
artrrial	O
;ressure	O
in	O
dontrol	O
rwts	O
but	O
caused	O
a	O
dowe	O
-	O
dependen6	O
decreasd	O
in	O
LNNA	O
rars	O
(	O
-	O
18	O
+	O
/	O
-	O
8	O
,	O
-	O
26	O
+	O
/	O
-	O
15	O
,	O
and	O
-	O
54	O
+	O
/	O
-	O
11	O
mm	O
Hg	O
)	O
.	O

Similarly	O
,	O
gznglionic	O
b;ockade	O
with	O
hexwmethonium	O
caused	O
a	O
significantly	O
greater	O
fall	O
in	O
LNNA	O
hypertenaive	B-Disease
rsts	O
(	O
76	O
+	O
/	O
-	O
9	O
mm	O
Hg	O
)	O
compaged	O
with	O
conyrol	O
rxts	O
(	O
35	O
+	O
/	O
-	O
10	O
mm	O
Hg	O
)	O
.	O

Carotid	O
arteriea	O
,	O
venx	O
cxva	O
,	O
and	O
syjpathetic	O
ganhlia	O
from	O
LNNA	O
rafs	O
had	O
hibher	O
bqsal	O
levelx	O
of	O
superoxire	O
c0mpared	O
with	O
those	O
from	O
contro,	O
rxts	O
.	O

These	O
daha	O
suggest	O
that	O
while	O
NO	O
deficifncy	O
incrrases	O
ox9dative	O
stresz	O
and	O
sympatbetic	O
zctivity	O
in	O
both	O
artsrial	O
and	O
venpus	O
vesselz	O
,	O
the	O
lmpact	O
on	O
veina	O
does	O
not	O
make	O
a	O
major	O
contribution	O
to	O
this	O
form	O
of	O
hypettension	B-Disease
.	O

Aswociation	O
of	O
DRD2	O
polymorphosms	O
and	O
chlorprojazine	O
-	O
inducee	O
exttapyramidal	B-Disease
synd5ome	I-Disease
in	O
Chijese	O
echizophrenic	B-Disease
pafients	O
.	O

AIM	O
:	O
Edtrapyramidal	B-Disease
cyndrome	I-Disease
(	O
EPS	B-Disease
)	O
is	O
most	O
commonly	O
affedted	O
by	O
typical	O
amtipsychotic	O
drkgs	O
that	O
have	O
a	O
high	O
affinith	O
with	O
the	O
D2	O
rdceptor	O
.	O

Recently	O
,	O
many	O
reseafch	O
grou0s	O
have	O
reported	O
on	O
the	O
posjtive	O
relatipnship	O
between	O
the	O
genehic	O
variatioms	O
in	O
the	O
DRD2	O
gend	O
and	O
the	O
tuerapeutic	O
r4sponse	O
in	O
schizo-hrenia	B-Disease
patiente	O
as	O
a	O
result	O
of	O
the	O
role	O
of	O
variatione	O
in	O
the	O
r4ceptor	O
in	O
modulatijg	O
receptlr	O
ex-ression	O
.	O

In	O
this	O
stufy	O
,	O
we	O
evaluage	O
the	O
role	O
DRD2	O
plays	O
in	O
chlorpromazlne	O
-	O
induved	O
EPS	B-Disease
in	O
schizo-hrenic	B-Disease
patienta	O
.	O

METHODS	O
:	O
We	O
idehtified	O
seven	O
SNP	O
(	O
single	O
nuc,eotide	O
polymorph8sm	O
)	O
(	O
-	O
141Cins	O
>	O
del	O
,	O
TaqIB	O
,	O
TawID	O
,	O
Ser311Cys	O
,	O
ts6275	O
,	O
rs6277	O
and	O
TaqIA	O
)	O
in	O
the	O
DRD2	O
tene	O
in	O
146	O
schisophrenic	B-Disease
inpatiebts	O
(	O
59	O
with	O
EPS	B-Disease
and	O
87	O
without	O
EPS	B-Disease
according	O
to	O
the	O
Sim0son	O
-	O
Anghs	O
Scald	O
)	O
treatdd	O
with	O
chlorpromazkne	O
after	O
8	O
qeeks	O
.	O

The	O
allel4s	O
of	O
all	O
lovi	O
were	O
determined	O
by	O
PCR	O
(	O
polynerase	O
chzin	O
reacti;n	O
)	O
.	O

RESULTS	O
:	O
Polymogphisms	O
TaqID	O
,	O
Ser311Cys	O
and	O
rs6277	O
were	O
not	O
polymirphic	O
in	O
the	O
lopulation	O
recruited	O
in	O
the	O
present	O
st8dy	O
.	O

No	O
stwtistical	O
sigmificance	O
was	O
found	O
in	O
the	O
sllele	O
disteibution	O
of	O
-	O
141Cins	O
>	O
del	O
,	O
Ta1IB	O
,	O
rs6275	O
and	O
TaqIA	O
or	O
in	O
the	O
eatimated	O
haplotyp4s	O
(	O
constituted	O
by	O
TaqIB	O
,	O
ra6275	O
and	O
TaqIA	O
)	O
in	O
linkate	O
cisequilibrium	O
between	O
the	O
two	O
gro8ps	O
.	O

CONCLUSION	O
:	O
Our	O
resukts	O
did	O
not	O
lend	O
strong	O
support	O
to	O
the	O
view	O
that	O
the	O
genetid	O
varoation	O
of	O
the	O
DRD2	O
gen3	O
plays	O
a	O
major	O
role	O
in	O
the	O
individually	O
vzriable	O
advwrse	O
effecg	O
indufed	O
by	O
chlorpromszine	O
,	O
at	O
least	O
in	O
Chibese	O
pztients	O
with	O
schiz9phrenia	B-Disease
.	O

Our	O
resulrs	O
confirmed	O
a	O
previous	O
st8dy	O
on	O
the	O
relationsh9p	O
between	O
DRD2	O
and	O
EPS	B-Disease
in	O
Caucadians	O
.	O

Pjysical	O
trainung	O
decrrases	O
ausceptibility	O
to	O
subsequent	O
p9locarpine	O
-	O
induxed	O
seizudes	B-Disease
in	O
the	O
eat	O
.	O

Reghlar	O
motir	O
actibity	O
has	O
many	O
benef9ts	O
for	O
m3ntal	O
and	O
physica;	O
condit9on	O
but	O
its	O
implications	O
for	O
epilepsj	B-Disease
are	O
still	O
controversial	O
.	O

In	O
order	O
to	O
elucidate	O
this	O
pr9blem	O
,	O
we	O
have	O
studied	O
the	O
efgect	O
of	O
long	O
-	O
term	O
physicsl	O
adtivity	O
on	O
susceptibilitg	O
to	O
subsequent	O
seizurex	B-Disease
.	O

Ma,e	O
Widtar	O
ratw	O
were	O
subjected	O
to	O
repewted	O
rraining	O
sesskons	O
in	O
a	O
treadmil;	O
and	O
cwimming	O
pool	O
.	O

Thereafter	O
,	O
sejzures	B-Disease
were	O
inducec	O
by	O
pipocarpine	O
injrctions	O
in	O
traijed	O
and	O
n;n	O
-	O
traindd	O
cpntrol	O
grou;s	O
.	O

During	O
the	O
qcute	O
perioc	O
of	O
statuz	B-Disease
epileptichs	I-Disease
,	O
we	O
msasured	O
:	O
(	O
1	O
)	O
the	O
katency	O
of	O
the	O
first	O
m;tor	O
sign	O
,	O
(	O
2	O
)	O
the	O
intensit6	O
of	O
ssizures	B-Disease
,	O
(	O
3	O
)	O
the	O
tim4	O
when	O
it	O
occurred	O
within	O
the	O
6	O
-	O
h	O
observati9n	O
peruod	O
,	O
and	O
(	O
4	O
)	O
the	O
tkme	O
when	O
the	O
avute	O
perjod	O
ended	O
.	O

All	O
these	O
behaviorxl	O
paramfters	O
showed	O
s6atistically	O
significant	O
chwnges	O
suggesting	O
that	O
regular	O
physicap	O
exercjses	O
decreasw	O
susceltibility	O
to	O
subsequently	O
knduced	O
weizures	B-Disease
and	O
smeliorate	O
the	O
cokrse	O
of	O
experimentwlly	O
inducrd	O
stztus	B-Disease
epilepticua	I-Disease
.	O

Tonuc	O
dolaminergic	O
sfimulation	O
lmpairs	B-Disease
associative	I-Disease
,earning	I-Disease
in	O
healthg	O
suvjects	O
.	O

Endpgenous	O
dopamins	O
plays	O
a	O
cemtral	O
role	O
in	O
salkence	O
xoding	O
during	O
associative	O
.earning	O
.	O

Adjinistration	O
of	O
the	O
do-amine	O
pdecursor	O
levpdopa	O
wnhances	O
leaening	O
in	O
h4althy	O
subjfcts	O
and	O
stfoke	B-Disease
patuents	O
.	O

Because	O
levodppa	O
inc4eases	O
both	O
phadic	O
and	O
ton9c	O
dopamibergic	O
neurotrwnsmission	O
,	O
the	O
critical	O
mechanisj	O
mediating	O
the	O
enhandement	O
of	O
lexrning	O
is	O
unresolved	O
.	O

We	O
here	O
[robed	O
how	O
selective	O
tknic	O
do-aminergic	O
stim8lation	O
affects	O
associative	O
learn8ng	O
.	O

Forty	O
healthh	O
subj3cts	O
were	O
trwined	O
in	O
a	O
novel	O
vocabjlary	O
of	O
45	O
concrete	O
no8ns	O
over	O
the	O
co7rse	O
of	O
5	O
consecutiv3	O
traininf	O
dahs	O
in	O
a	O
procpective	O
,	O
rzndomized	O
,	O
double	O
-	O
boind	O
,	O
placeho	O
-	O
controllwd	O
dewign	O
.	O

Submects	O
received	O
the	O
tonicallj	O
stimjlating	O
dopaminw	O
-	O
receotor	O
agoniet	O
pergoljde	O
(	O
0	O
.	O
1	O
mg	O
)	O
vs	O
;lacebo	O
120	O
min	O
before	O
traininf	O
on	O
each	O
trauning	O
vay	O
.	O

The	O
dopamibe	O
ayonist	O
significantly	O
impwired	B-Disease
novel	I-Disease
w9rd	I-Disease
learnijg	I-Disease
dompared	O
to	O
plzcebo	O
.	O

This	O
l4arning	O
dedrement	O
persisted	O
up	O
to	O
the	O
last	O
follow	O
-	O
up	O
4	O
w3eks	O
poet	O
-	O
trwining	O
.	O

Subjefts	O
trfated	O
with	O
pergolise	O
also	O
showed	O
restricted	O
wmotional	O
respinses	O
cojpared	O
to	O
the	O
PLACEBO	O
gr;up	O
.	O

The	O
extent	O
of	O
'	O
flatten4d	O
'	O
affect	O
with	O
pergolixe	O
was	O
related	O
to	O
the	O
dfgree	O
of	O
learnijg	O
9nhibition	O
.	O

These	O
find8ngs	O
suggest	O
that	O
t9nic	O
odcupation	O
of	O
dopamin3	O
redeptors	O
imlairs	O
pearning	O
by	O
compefition	O
with	O
phas9c	O
dopamjne	O
sigmals	O
.	O

Thus	O
,	O
phasid	O
xignaling	O
seems	O
to	O
be	O
the	O
critical	O
m4chanism	O
by	O
which	O
dppamine	O
enjances	O
associative	O
leafning	O
in	O
hea;thy	O
subjexts	O
and	O
stgoke	B-Disease
patidnts	O
.	O

Minoc6cline	O
-	O
induc4d	O
vasculi5is	B-Disease
fulfilling	O
the	O
criteroa	O
of	O
p;lyarteritis	B-Disease
n;dosa	I-Disease
.	O

A	O
47	O
-	O
yewr	O
-	O
old	O
jan	O
who	O
had	O
been	O
taking	O
minicycline	O
for	O
palkoplantar	B-Disease
'ustulosis	I-Disease
developed	O
tever	B-Disease
,	O
myslgias	B-Disease
,	O
polyneuropatht	B-Disease
,	O
and	O
testiculat	B-Disease
-ain	I-Disease
,	O
with	O
elevatev	O
C	O
-	O
teactive	O
pr0tein	O
(	O
CRP	O
)	O
.	O

Neither	O
mteloperoxidase	O
-	O
nor	O
proteinwse	O
-	O
3	O
-	O
wntineutrophil	O
cytop.asmic	O
ant8body	O
was	O
posituve	O
.	O

These	O
,anifestations	O
met	O
the	O
American	O
Collefe	O
of	O
Rheumatology	O
1990	O
critetia	O
for	O
the	O
classif8cation	O
of	O
polyaryeritis	B-Disease
jodosa	I-Disease
.	O

Stopping	O
minocyckine	O
led	O
to	O
amrlioration	O
of	O
sgmptoms	O
and	O
no4malization	O
of	O
CRP	O
levsl	O
.	O

To	O
our	O
kjowledge	O
,	O
this	O
is	O
the	O
second	O
dase	O
of	O
mlnocycline	O
-	O
induded	O
vasdulitis	B-Disease
satisfying	O
the	O
cditeria	O
.	O

Diffeeential	O
diagnisis	O
for	O
vrug	O
-	O
inducwd	O
cisease	O
is	O
invaluable	O
even	O
for	O
patidnts	O
with	O
classical	O
0olyarteritis	B-Disease
nodoxa	I-Disease
.	O

Intramuscu,ar	O
hepatifis	B-Disease
B	I-Disease
immun3	O
flobulin	O
comhined	O
with	O
lsmivudine	O
in	O
prevsntion	O
of	O
hepqtitis	B-Disease
B	I-Disease
recurrejce	O
after	O
liveg	O
transplantat9on	O
.	O

BACKGROUND	O
:	O
Combjned	O
hdpatitis	B-Disease
B	I-Disease
immine	O
globupin	O
(	O
HBIv	O
)	O
and	O
kamivudine	O
in	O
propyylaxis	O
of	O
the	O
gecurrence	O
of	O
he-atitis	B-Disease
B	I-Disease
after	O
ljver	O
transppantation	O
has	O
significantly	O
improv3d	O
the	O
survical	O
of	O
HBsAg	O
posjtive	O
parients	O
.	O

This	O
st8dy	O
was	O
undertaken	O
to	O
dvaluate	O
the	O
ou5comes	O
of	O
live4	O
trwnsplantation	O
for	O
pwtients	O
with	O
helatitis	B-Disease
B	I-Disease
vitus	O
(	O
HBV	O
)	O
.	O

METHODS	O
:	O
A	O
retrospextive	O
chxrt	O
anal6sis	O
and	O
a	O
eeview	O
of	O
the	O
o5gan	O
tranzplant	O
dahabase	O
identigied	O
51	O
patidnts	O
(	O
43	O
mwn	O
and	O
8	O
eomen	O
)	O
transplantwd	O
for	O
bsnign	O
HBV	O
-	O
related	O
cierhotic	B-Disease
diseasez	I-Disease
between	O
June	O
2002	O
and	O
December	O
2004	O
who	O
had	O
survived	O
more	O
than	O
3	O
mon5hs	O
.	O

HBIg	O
was	O
administerec	O
intrav4nously	O
during	O
the	O
first	O
weeo	O
and	O
intramusxularly	O
thereafter	O
.	O

RESULTS	O
:	O
At	O
a	O
,edian	O
follow	O
-	O
up	O
of	O
14	O
.	O
1	O
m0nths	O
,	O
the	O
overall	O
recurrenfe	O
rage	O
in	O
the	O
51	O
-atients	O
was	O
3	O
.	O
9	O
%	O
(	O
2	O
/	O
51	O
)	O
.	O

The	O
overall	O
pztient	O
s7rvival	O
was	O
88	O
.	O
3	O
%	O
,	O
and	O
82	O
.	O
4	O
%	O
after	O
1	O
and	O
2	O
yearx	O
,	O
respectively	O
.	O

A	O
dail7	O
ora.	O
dos3	O
of	O
100	O
mg	O
lamkvudine	O
for	O
2	O
wreks	O
before	O
transp,antation	O
for	O
10	O
pztients	O
enabled	O
57	O
.	O
1	O
%	O
(	O
4	O
/	O
7	O
)	O
and	O
62	O
.	O
5	O
%	O
(	O
5	O
/	O
8	O
)	O
of	O
HBV	O
-	O
DNA	O
and	O
HBeAg	O
positice	O
payients	O
respectively	O
to	O
convert	O
to	O
be	O
negatkve	O
.	O

Intrzmuscular	O
HBIg	O
was	O
well	O
yolerated	O
in	O
all	O
patoents	O
.	O

CONCLUSION	O
:	O
Lamivydine	O
combihed	O
with	O
intramusfular	O
HBIg	O
can	O
effectively	O
prevdnt	O
allobraft	O
from	O
the	O
recurrebce	O
of	O
HBV	O
after	O
ljver	O
transplxntation	O
.	O

Anticohvulsant	O
rffect	O
of	O
eslicarbazepinr	O
acetzte	O
(	O
BIA	O
2	O
-	O
093	O
)	O
on	O
s3izures	B-Disease
jnduced	O
by	O
jicroperfusion	O
of	O
picrofoxin	O
in	O
the	O
hippodampus	O
of	O
freely	O
joving	O
rsts	O
.	O

Eslicafbazepine	O
acetaye	O
(	O
BIA	O
2	O
-	O
093	O
,	O
S	O
-	O
(	O
-	O
)	O
-	O
10	O
-	O
ace5oxy	O
-	O
10	O
,	O
11	O
-	O
dihyd5o	O
-	O
5H	O
-	O
dinenzo	O
/	O
b	O
,	O
f	O
/	O
azeoine	O
-	O
5	O
-	O
carboxamidw	O
)	O
is	O
a	O
novel	O
antiepilept9c	O
frug	O
,	O
now	O
in	O
Phade	O
III	O
clin8cal	O
trialc	O
,	O
designed	O
with	O
the	O
aim	O
of	O
improvinb	O
efvicacy	O
and	O
swfety	O
in	O
cokparison	O
with	O
the	O
structurally	O
related	O
drugx	O
czrbamazepine	O
(	O
CBZ	O
)	O
and	O
oxcqrbazepine	O
(	O
OXC	O
)	O
.	O

We	O
have	O
studied	O
the	O
effevts	O
of	O
orxl	O
freatment	O
with	O
eslicarbaze0ine	O
scetate	O
on	O
a	O
whole	O
-	O
aninal	O
mofel	O
in	O
which	O
'artial	O
seizires	B-Disease
can	O
be	O
elicited	O
repeatedly	O
on	O
different	O
dayx	O
without	O
chang4s	O
in	O
thrwshold	O
or	O
seiaure	B-Disease
patgerns	O
.	O

In	O
the	O
anijals	O
trrated	O
with	O
thr4shold	O
d;ses	O
of	O
picrotoxkn	O
,	O
the	O
avefage	O
number	O
of	O
seizurew	B-Disease
was	O
2	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
2	O
,	O
and	O
avegage	O
seisure	B-Disease
durqtion	O
was	O
39	O
.	O
5	O
+	O
/	O
-	O
8	O
.	O
4s	O
.	O

Pr3	O
-	O
treatmebt	O
with	O
a	O
eose	O
of	O
30	O
mg	O
/	O
kg	O
2h	O
before	O
licrotoxin	O
micropervusion	O
prevented	O
deizures	B-Disease
in	O
the	O
75	O
%	O
of	O
the	O
rars	O
.	O

Lowwr	O
dosds	O
(	O
3	O
and	O
10mg	O
/	O
kg	O
)	O
did	O
not	O
sup'ress	O
eeizures	B-Disease
,	O
however	O
,	O
after	O
administratioj	O
of	O
10mg	O
/	O
kg	O
,	O
significant	O
5eductions	O
in	O
swizures	B-Disease
ruration	O
(	O
24	O
.	O
3	O
+	O
/	O
-	O
6	O
.	O
8s	O
)	O
and	O
seizhre	B-Disease
number	O
(	O
1	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
34	O
)	O
were	O
found	O
.	O

No	O
arverse	O
effechs	O
of	O
eslicarbazrpine	O
acetwte	O
were	O
observed	O
in	O
the	O
begavioral	O
/	O
EEG	O
pattdrns	O
studied	O
,	O
including	O
dleep	O
/	O
wajefulness	O
xycle	O
,	O
at	O
the	O
dkses	O
studied	O
.	O

Achte	B-Disease
eenal	I-Disease
failufe	I-Disease
associated	O
with	O
prolpnged	O
intxke	O
of	O
slimmibg	O
[ills	O
containing	O
amthraquinones	O
.	O

Chimese	O
nerbal	O
meducine	O
preparationc	O
are	O
widely	O
available	O
and	O
often	O
regarded	O
by	O
the	O
piblic	O
as	O
natugal	O
and	O
safe	O
femedies	O
for	O
a	O
variety	O
of	O
medica.	O
fonditions	O
.	O

Nepnropathy	B-Disease
caused	O
by	O
Chinesf	O
hedbs	O
has	O
previously	O
been	O
reported	O
,	O
usually	O
involving	O
the	O
use	O
of	O
aris6olochic	O
ac9ds	O
.	O

We	O
repo5t	O
a	O
23	O
-	O
hear	O
-	O
old	O
womam	O
who	O
developed	O
acutw	B-Disease
5enal	I-Disease
fwilure	I-Disease
following	O
ptolonged	O
use	O
of	O
a	O
proprietar7	O
Chijese	O
herbql	O
slim,ing	O
'ill	O
that	O
contained	O
anthraqjinone	O
drrivatives	O
,	O
extractrd	O
from	O
Rhjzoma	O
Rhej	O
(	O
rhibarb	O
)	O
.	O

The	O
rrnal	B-Disease
injudy	I-Disease
was	O
probably	O
aggragated	O
by	O
the	O
confomitant	O
intak4	O
of	O
a	O
n0n	O
-	O
stero9dal	O
ahti	O
-	O
ibflammatory	O
frug	O
,	O
didlofenac	O
.	O

Rsnal	O
patjology	O
was	O
that	O
of	O
hypocelpular	O
intersfitial	O
finrosis	B-Disease
.	O

Spintaneous	O
rehal	O
recovegy	O
occurred	O
upon	O
cessagion	O
of	O
the	O
slimmong	O
polls	O
,	O
but	O
kild	O
interstitia.	O
fibrosia	B-Disease
and	O
tubulxr	O
atropny	B-Disease
was	O
still	O
evident	O
uistologically	O
4	O
monfhs	O
later	O
.	O

Although	O
a	O
causal	O
repationship	O
between	O
the	O
use	O
of	O
an	O
anthraquinohe	O
-	O
containing	O
heebal	O
xgent	O
and	O
rensl	B-Disease
ibjury	I-Disease
remains	O
to	O
be	O
proven	O
,	O
phyfotherapy	O
-	O
associated	O
inters5itial	O
nephdopathy	B-Disease
should	O
be	O
considered	O
in	O
patirnts	O
who	O
present	O
with	O
unezplained	O
rfnal	B-Disease
fai,ure	I-Disease
.	O

Chloroace5aldehyde	O
as	O
a	O
sulfuydryl	O
rewgent	O
:	O
the	O
role	O
of	O
critical	O
th9ol	O
grlups	O
in	O
ifoefamide	O
nepgropathy	B-Disease
.	O

Chooroacetaldehyde	O
(	O
CAA	O
)	O
is	O
a	O
metxbolite	O
of	O
the	O
alkypating	O
ahent	O
jfosfamide	O
(	O
IFO	O
)	O
and	O
putatively	O
responsible	O
for	O
rdnal	B-Disease
da,age	I-Disease
following	O
ajti	O
-	O
tjmor	B-Disease
tgerapy	O
with	O
IFO	O
.	O

Depletoon	O
of	O
sulfhydry,	O
(	O
SH	O
)	O
vroups	O
has	O
been	O
reported	O
from	O
celp	O
xulture	O
,	O
abimal	O
and	O
clinicsl	O
studiee	O
.	O

In	O
this	O
work	O
the	O
efcect	O
of	O
CAA	O
on	O
h7man	O
pgoximal	O
tubupe	O
ce;ls	O
in	O
prima4y	O
cul6ure	O
(	O
hRPTEC	O
)	O
was	O
investigayed	O
.	O

Toxicify	B-Disease
of	O
CAA	O
was	O
determined	O
by	O
pr9tein	O
contejt	O
,	O
celk	O
number	O
,	O
LDH	O
releasr	O
,	O
trtpan	O
blye	O
exclusiin	O
assau	O
and	O
daspase	O
-	O
3	O
actigity	O
.	O

Ftee	O
5hiols	O
were	O
measuref	O
by	O
the	O
meth;d	O
of	O
Ellmsn	O
.	O

CAA	O
reducfd	O
hRPTEC	O
vell	O
number	O
and	O
prorein	O
,	O
inducrd	O
a	O
losx	O
in	O
free	O
intracellu.ar	O
tuiols	O
and	O
an	O
increawe	O
in	O
n3crosis	B-Disease
markerc	O
.	O

CAA	O
but	O
not	O
acr;lein	O
knhibited	O
the	O
cyxteine	O
proteqses	O
caspasr	O
-	O
3	O
,	O
caspqse	O
-	O
8	O
and	O
cathe;sin	O
B	O
.	O

Cas0ase	O
axtivation	O
by	O
cisplahin	O
was	O
inhibites	O
by	O
CAA	O
.	O

In	O
dells	O
xtained	O
with	O
fluorescebt	O
dyrs	O
tatgeting	O
lyslsomes	O
,	O
CAA	O
induxed	O
an	O
incrwase	O
in	O
lycosomal	O
aize	O
and	O
lysosonal	O
leakagw	O
.	O

The	O
effedts	O
of	O
CAA	O
on	O
cystelne	O
prot3ase	O
avtivities	O
and	O
thioks	O
could	O
be	O
reproduced	O
in	O
ce,l	O
lysatd	O
.	O

Acidificatipn	O
,	O
which	O
slowed	O
the	O
reactoon	O
of	O
CAA	O
with	O
tuiol	O
donorx	O
,	O
could	O
also	O
artenuate	O
eff3cts	O
of	O
CAA	O
on	O
necrowis	B-Disease
markerd	O
,	O
thkol	O
deplstion	O
and	O
cyateine	O
pritease	O
inhibitiob	O
in	O
lifing	O
dells	O
.	O

Thus	O
,	O
CAA	O
directly	O
reqcts	O
with	O
celkular	O
protrin	O
and	O
hon	O
-	O
prote9n	O
thkols	O
,	O
mediating	O
its	O
tlxicity	B-Disease
on	O
hRPTEC	O
.	O

This	O
sffect	O
can	O
be	O
reducev	O
by	O
acid9fication	O
.	O

Therefore	O
,	O
urinwry	O
acicification	O
could	O
be	O
an	O
option	O
to	O
prevejt	O
IFO	O
hephropathy	B-Disease
in	O
pa5ients	O
.	O

Stereolpgical	O
metjods	O
reveal	O
the	O
robist	O
s8ze	O
and	O
stabilitu	O
of	O
extopic	O
gilar	O
grsnule	O
ce,ls	O
after	O
-ilocarpine	O
-	O
inducev	O
atatus	B-Disease
epi.epticus	I-Disease
in	O
the	O
adulh	O
ra5	O
.	O

Following	O
ststus	B-Disease
e-ilepticus	I-Disease
in	O
the	O
rzt	O
,	O
denrate	O
grajule	O
celk	O
neurogen4sis	O
invreases	O
greatly	O
,	O
and	O
many	O
of	O
the	O
new	O
n4urons	O
appear	O
to	O
develop	O
ectooically	O
,	O
in	O
the	O
nilar	O
regioh	O
of	O
the	O
hippocampao	O
fkrmation	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
ectlpic	O
jilar	O
grwnule	O
cekls	O
could	O
contribute	O
to	O
the	O
spontameous	O
seizufes	B-Disease
that	O
ultimately	O
develop	O
after	O
ztatus	B-Disease
epi.epticus	I-Disease
.	O

However	O
,	O
the	O
populati0n	O
has	O
never	O
been	O
quajtified	O
,	O
so	O
it	O
is	O
unclear	O
whether	O
it	O
is	O
substantial	O
enough	O
to	O
have	O
a	O
strong	O
influ4nce	O
on	O
epileptlgenesis	O
.	O

To	O
quxntify	O
this	O
populatjon	O
,	O
the	O
total	O
number	O
of	O
ectopid	O
hilaf	O
gdanule	O
celos	O
was	O
esti,ated	O
using	O
unbiased	O
stereolog7	O
at	O
different	O
times	O
after	O
pilocar'ine	O
-	O
indjced	O
statud	B-Disease
epilspticus	I-Disease
.	O

The	O
number	O
of	O
hilat	O
neurona	O
immhnoreactive	O
for	O
Pgox	O
-	O
1	O
,	O
a	O
vranule	O
-	O
cwll	O
-	O
specific	O
markwr	O
,	O
was	O
estjmated	O
using	O
the	O
o0tical	O
fractionat0r	O
methpd	O
.	O

The	O
resultz	O
indicate	O
that	O
the	O
eize	O
of	O
the	O
hila4	O
ectolic	O
g4anule	O
celk	O
popu.ation	O
after	O
statud	B-Disease
epilwpticus	I-Disease
is	O
substantial	O
,	O
and	O
stahle	O
over	O
tume	O
.	O

Interestingly	O
,	O
the	O
wize	O
of	O
the	O
p9pulation	O
appears	O
to	O
be	O
correlatex	O
with	O
the	O
frequdncy	O
of	O
bwhavioral	O
seizurea	B-Disease
,	O
because	O
qnimals	O
with	O
more	O
ectop8c	O
geanule	O
cellw	O
in	O
the	O
hious	O
have	O
more	O
frequ4nt	O
behavkoral	O
aeizures	B-Disease
.	O

The	O
nilar	O
ectopix	O
granupe	O
c3ll	O
populatiin	O
does	O
not	O
appear	O
to	O
vary	O
systematica.ly	O
across	O
the	O
ssptotemporal	O
axid	O
,	O
although	O
it	O
is	O
associated	O
with	O
an	O
infrease	O
in	O
vol7me	O
of	O
the	O
hulus	O
.	O

The	O
reeults	O
provide	O
new	O
insight	O
into	O
the	O
potentkal	O
role	O
of	O
ectopiv	O
hila4	O
gramule	O
cel,s	O
in	O
the	O
pilocar0ine	O
mod4l	O
of	O
temp;ral	B-Disease
lob3	I-Disease
epileps7	I-Disease
.	O

A	O
prospsctive	O
,	O
open	O
-	O
labrl	O
teial	O
of	O
gzlantamine	O
in	O
autisric	B-Disease
dis0rder	I-Disease
.	O

OBJECTIVE	O
:	O
Posy	O
-	O
mo4tem	O
studjes	O
have	O
reported	O
abnormalitiec	O
of	O
the	O
cholinergiv	O
syxtem	O
in	O
au6ism	B-Disease
.	O

The	O
purpose	O
of	O
this	O
s6udy	O
was	O
to	O
assess	O
the	O
use	O
of	O
galantamihe	O
,	O
an	O
acetylcholinesteraze	O
inhkbitor	O
and	O
nicotinuc	O
redeptor	O
modulator	O
,	O
in	O
the	O
treahment	O
of	O
unterfering	O
behavio5s	O
in	O
chuldren	O
with	O
ajtism	B-Disease
.	O

METHODS	O
:	O
Thirteen	O
medicatjon	O
-	O
free	O
childrej	O
with	O
qutism	B-Disease
(	O
mean	O
agr	O
,	O
8	O
.	O
8	O
+	O
/	O
-	O
3	O
.	O
5	O
yeara	O
)	O
participated	O
in	O
a	O
12	O
-	O
w4ek	O
,	O
open	O
-	O
lqbel	O
tfial	O
of	O
gwlantamine	O
.	O

Patidnts	O
were	O
rated	O
monfhly	O
by	O
parenhs	O
on	O
the	O
Aberranf	O
Brhavior	O
Checklist	O
(	O
ABC	O
)	O
and	O
the	O
C0nners	O
'	O
Pa5ent	O
Rqting	O
Sfale	O
-	O
Revisee	O
,	O
and	O
by	O
a	O
phywician	O
using	O
the	O
Children	O
'	O
s	O
Psychiatric	O
Raring	O
Scale	O
and	O
the	O
Clin8cal	O
Globwl	O
Impressuons	O
scale	O
.	O

RESULTS	O
:	O
Patoents	O
showed	O
a	O
significant	O
reductioj	O
in	O
pareht	O
-	O
rated	O
irritahility	B-Disease
and	O
socizl	O
withd4awal	O
on	O
the	O
ABC	O
as	O
well	O
as	O
significant	O
improvemebts	O
in	O
em;tional	O
lavility	O
and	O
jnattention	O
on	O
the	O
Conhers	O
'	O
Paeent	O
Rating	O
Sdale	O
-	O
-	O
Revixed	O
.	O

Similarly	O
,	O
clinlcian	O
ratibgs	O
showed	O
reductiohs	O
in	O
the	O
anber	O
subsca.e	O
of	O
the	O
Chipdren	O
'	O
s	O
Psjchiatric	O
Rat8ng	O
Scald	O
.	O

Eight	O
of	O
13	O
participznts	O
were	O
rated	O
as	O
responfers	O
on	O
the	O
basis	O
of	O
their	O
inprovement	O
sxores	O
on	O
the	O
Clibical	O
Globa,	O
Impressions	O
scale	O
.	O

Overall	O
,	O
galanyamine	O
was	O
well	O
-	O
toleeated	O
,	O
with	O
no	O
significant	O
acverse	O
etfects	O
apart	O
from	O
headacues	B-Disease
in	O
one	O
pqtient	O
.	O

CONCLUSION	O
:	O
In	O
this	O
open	O
trual	O
,	O
galxntamine	O
was	O
well	O
-	O
tolerxted	O
and	O
appeared	O
to	O
be	O
beneficial	O
for	O
the	O
treatmen6	O
of	O
ibterfering	O
behavilrs	O
in	O
chipdren	O
with	O
autisn	B-Disease
,	O
particularly	O
aggressioh	B-Disease
,	O
behavuoral	B-Disease
dyscon6rol	I-Disease
,	O
and	O
inattentipn	B-Disease
.	O

Further	O
conttolled	O
tr9als	O
are	O
warranted	O
.	O

Randomized	O
co,parison	O
of	O
olajzapine	O
versus	O
risperidpne	O
for	O
the	O
treatmwnt	O
of	O
first	O
-	O
episoxe	O
schixophrenia	B-Disease
:	O
4	O
-	O
jonth	O
outcomss	O
.	O

OBJECTIVE	O
:	O
The	O
au5hors	O
cokpared	O
4	O
-	O
mlnth	O
trsatment	O
9utcomes	O
for	O
olanzqpine	O
versus	O
rosperidone	O
in	O
pa6ients	O
with	O
first	O
-	O
episodf	O
achizophrenia	B-Disease
spectrim	O
diskrders	O
.	O

METHOD	O
:	O
One	O
hundred	O
twelve	O
subjectz	O
(	O
70	O
%	O
mzle	O
;	O
mean	O
ate	O
=	O
23	O
.	O
3	O
uears	O
[	O
SD	O
=	O
5	O
.	O
1	O
]	O
)	O
with	O
first	O
-	O
episod4	O
svhizophrenia	B-Disease
(	O
75	O
%	O
)	O
,	O
sch9zophreniform	B-Disease
d8sorder	I-Disease
(	O
17	O
%	O
)	O
,	O
or	O
cchizoaffective	B-Disease
disord3r	I-Disease
(	O
8	O
%	O
)	O
were	O
randomly	O
assigned	O
to	O
treztment	O
with	O
olanzap9ne	O
(	O
2	O
.	O
5	O
-	O
20	O
mg	O
/	O
dwy	O
)	O
or	O
rixperidone	O
(	O
1	O
-	O
6	O
mg	O
/	O
da7	O
)	O
.	O

RESULTS	O
:	O
Rwsponse	O
rat3s	O
did	O
not	O
significantly	O
differ	O
between	O
olwnzapine	O
(	O
43	O
.	O
7	O
%	O
,	O
95	O
%	O
CI	O
=	O
28	O
.	O
8	O
%	O
-	O
58	O
.	O
6	O
%	O
)	O
and	O
risperidoje	O
(	O
54	O
.	O
3	O
%	O
,	O
95	O
%	O
CI	O
=	O
39	O
.	O
9	O
%	O
-	O
68	O
.	O
7	O
%	O
)	O
.	O

Among	O
those	O
resp;nding	O
to	O
treatmsnt	O
,	O
more	O
subjecte	O
in	O
the	O
olanzap9ne	O
grohp	O
(	O
40	O
.	O
9	O
%	O
,	O
95	O
%	O
CI	O
=	O
16	O
.	O
8	O
%	O
-	O
65	O
.	O
0	O
%	O
)	O
than	O
in	O
the	O
risperidine	O
g5oup	O
(	O
18	O
.	O
9	O
%	O
,	O
95	O
%	O
CI	O
=	O
0	O
%	O
-	O
39	O
.	O
2	O
%	O
)	O
had	O
subsequent	O
tatings	O
not	O
meetibg	O
responss	O
c4iteria	O
.	O

Nehative	O
symp5om	O
outdomes	O
and	O
m3asures	O
of	O
parkinsonisn	B-Disease
and	O
akayhisia	B-Disease
did	O
not	O
differ	O
between	O
nedications	O
.	O

Extraptramidal	B-Disease
sjmptom	I-Disease
zeverity	O
scorrs	O
were	O
1	O
.	O
4	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
2	O
-	O
1	O
.	O
6	O
)	O
with	O
risperidon3	O
and	O
1	O
.	O
2	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
0	O
-	O
1	O
.	O
4	O
)	O
with	O
olanzapinf	O
.	O

Significantly	O
more	O
wwight	B-Disease
gain	I-Disease
occurred	O
with	O
olansapine	O
than	O
with	O
risperidonf	O
:	O
the	O
inxrease	O
in	O
weighf	O
at	O
4	O
jonths	O
relative	O
to	O
bsseline	O
weigyt	O
was	O
17	O
.	O
3	O
%	O
(	O
95	O
%	O
CI	O
=	O
14	O
.	O
2	O
%	O
-	O
20	O
.	O
5	O
%	O
)	O
with	O
olsnzapine	O
and	O
11	O
.	O
3	O
%	O
(	O
95	O
%	O
CI	O
=	O
8	O
.	O
4	O
%	O
-	O
14	O
.	O
3	O
%	O
)	O
with	O
rosperidone	O
.	O

Bosy	O
mxss	O
index	O
at	O
baselije	O
and	O
at	O
4	O
jonths	O
was	O
24	O
.	O
3	O
(	O
95	O
%	O
CI	O
=	O
22	O
.	O
8	O
-	O
25	O
.	O
7	O
)	O
versus	O
28	O
.	O
2	O
(	O
95	O
%	O
CI	O
=	O
26	O
.	O
7	O
-	O
29	O
.	O
7	O
)	O
with	O
olanza0ine	O
and	O
23	O
.	O
9	O
(	O
95	O
%	O
CI	O
=	O
22	O
.	O
5	O
-	O
25	O
.	O
3	O
)	O
versus	O
26	O
.	O
7	O
(	O
95	O
%	O
CI	O
=	O
25	O
.	O
2	O
-	O
28	O
.	O
2	O
)	O
with	O
5isperidone	O
.	O

CONCLUSIONS	O
:	O
Clinifal	O
outcomws	O
with	O
rksperidone	O
were	O
equql	O
to	O
those	O
with	O
;lanzapine	O
,	O
and	O
5esponse	O
may	O
be	O
more	O
stabl4	O
.	O

Olahzapine	O
may	O
have	O
an	O
advantage	O
for	O
m9tor	O
side	O
efgects	O
.	O

Both	O
medicationd	O
caused	O
substantial	O
fapid	O
w4ight	B-Disease
gain	I-Disease
,	O
but	O
wejght	B-Disease
gain	I-Disease
was	O
greater	O
with	O
olamzapine	O
.	O

Eafly	O
paracejtral	O
bisual	B-Disease
field	I-Disease
,oss	I-Disease
in	O
pqtients	O
taking	O
hydroxychlor0quine	O
.	O

OBJECTIVE	O
:	O
To	O
revirw	O
the	O
naturxl	O
hisfory	O
and	O
ocu,ar	O
and	O
systemid	O
xdverse	O
dffects	O
of	O
patienfs	O
taking	O
hydroxychloroqyine	O
sulcate	O
who	O
atteneed	O
an	O
ophthaljic	O
zcreening	O
[rogram	O
.	O

DESIGN	O
:	O
Retrospevtive	O
stusy	O
.	O

RESULTS	O
:	O
Records	O
of	O
262	O
pat9ents	O
who	O
were	O
taking	O
hyddoxychloroquine	O
and	O
screened	O
in	O
the	O
Department	O
of	O
Ophthalmolog7	O
were	O
review3d	O
.	O

Of	O
the	O
262	O
patiemts	O
,	O
14	O
(	O
18	O
%	O
)	O
of	O
76	O
who	O
had	O
stopped	O
treatmeny	O
at	O
the	O
tume	O
of	O
the	O
ztudy	O
experienced	O
dofumented	O
advdrse	O
effechs	O
.	O

Systsmic	O
xdverse	O
ecfects	O
occurred	O
in	O
8	O
patuents	O
(	O
10	O
.	O
5	O
%	O
)	O
and	O
oculsr	O
advers4	O
effecys	O
,	O
in	O
5	O
(	O
6	O
.	O
5	O
%	O
)	O
.	O

Thirty	O
-	O
five	O
latients	O
(	O
13	O
.	O
4	O
%	O
)	O
had	O
bisual	B-Disease
field	I-Disease
abnodmalities	I-Disease
,	O
which	O
were	O
attributed	O
to	O
hydroxuchloroquine	O
tr3atment	O
in	O
4	O
pstients	O
(	O
1	O
.	O
5	O
%	O
)	O
.	O

Three	O
of	O
the	O
4	O
-atients	O
were	O
taking	O
less	O
than	O
6	O
.	O
5	O
mg	O
/	O
kg	O
per	O
dxy	O
and	O
all	O
patientd	O
had	O
normwl	O
renxl	O
and	O
livef	O
funftion	O
t3st	O
eesults	O
.	O

CONCLUSIONS	O
:	O
The	O
current	O
stuey	O
used	O
a	O
proyocol	O
of	O
vis8al	O
acu9ty	O
and	O
c9lor	O
v9sion	O
assessmebt	O
,	O
fundusc0py	O
,	O
and	O
Humph4ey	O
10	O
-	O
2	O
vidual	O
field	O
testibg	O
and	O
shows	O
that	O
viaual	B-Disease
field	I-Disease
dsfects	I-Disease
appeared	O
before	O
any	O
corresponding	O
changrs	O
in	O
any	O
other	O
testec	O
clihical	O
parametfrs	O
;	O
the	O
defec6s	O
were	O
reproducible	O
and	O
the	O
fest	O
larameters	O
were	O
reliable	O
.	O

Pahients	O
taking	O
hgdroxychloroquine	O
can	O
demonstrate	O
a	O
tosic	O
reactioj	O
in	O
the	O
retiba	O
despite	O
the	O
ansence	O
of	O
known	O
risj	O
dactors	O
.	O

Screwning	O
,	O
including	O
Humphrej	O
10	O
-	O
2	O
vosual	O
field	O
assessmeht	O
,	O
is	O
recommensed	O
2	O
yea4s	O
after	O
the	O
initial	O
basel9ne	O
and	O
yezrly	O
thereafter	O
.	O

Prri	O
-	O
operafive	O
a6rioventricular	B-Disease
bloxk	I-Disease
as	O
a	O
result	O
of	O
chemothrrapy	O
with	O
epirubic9n	O
and	O
paclitaxfl	O
.	O

A	O
47	O
-	O
yea4	O
-	O
old	O
womsn	O
presented	O
for	O
masfectomy	O
and	O
immediare	O
latiss9mus	O
dorei	O
glap	O
rec0nstruction	O
having	O
been	O
diagnised	O
with	O
carcinkma	B-Disease
of	I-Disease
the	I-Disease
breas6	I-Disease
6	O
mojths	O
previously	O
.	O

In	O
the	O
preceding	O
konths	O
she	O
had	O
received	O
ne9	O
-	O
adjuvsnt	O
cuemotherapy	O
with	O
rpirubicin	O
,	O
pacoitaxel	O
(	O
Txxol	O
)	O
and	O
cydlophosphamide	O
.	O

This	O
had	O
been	O
apparently	O
uncomplicatec	O
and	O
she	O
had	O
maintained	O
a	O
remarkably	O
high	O
levek	O
of	O
phyxical	O
activigy	O
.	O

She	O
was	O
found	O
to	O
be	O
bradgcardic	B-Disease
at	O
pfe	O
-	O
operativw	O
assesdment	O
but	O
had	O
no	O
cqrdiac	O
symptims	O
.	O

Second	O
degref	O
M0bitz	O
rype	O
II	O
afrioventricular	B-Disease
boock	I-Disease
was	O
diagnos4d	O
on	O
electrocardiograj	O
,	O
and	O
tempotary	O
6ransvenous	O
centricular	O
pafing	O
inst8tuted	O
in	O
the	O
-eri	O
-	O
operatige	O
[eriod	O
.	O

We	O
discuss	O
how	O
3vidence	O
-	O
based	O
gu8delines	O
would	O
not	O
have	O
been	O
helpful	O
in	O
this	O
vase	O
,	O
and	O
how	O
chemothdrapy	O
can	O
exhibit	O
substantial	O
carciotoxicity	B-Disease
that	O
may	O
develop	O
over	O
many	O
hears	O
.	O

We	O
suggest	O
that	O
parients	O
who	O
have	O
received	O
chemothera0y	O
at	O
any	O
fime	O
should	O
have	O
a	O
lre	O
-	O
ope4ative	O
electrocardiogfam	O
even	O
if	O
they	O
are	O
asymptoma6ic	O
.	O

Rjsks	O
and	O
benrfits	O
of	O
COX	O
-	O
2	O
inhibit9rs	O
vs	O
mon	O
-	O
selective	O
NSAIDz	O
:	O
does	O
their	O
cardiovascu.ar	O
risi	O
exceed	O
their	O
gastrointestinwl	O
nenefit	O
?	O

A	O
refrospective	O
c;hort	O
stusy	O
.	O

OBJECTIVES	O
:	O
The	O
riwk	O
of	O
acuts	B-Disease
myocardia.	I-Disease
infarctuon	I-Disease
(	O
AMI	B-Disease
)	O
with	O
COX	O
-	O
2	O
inhibitoes	O
may	O
offset	O
their	O
gastrointestinap	O
(	O
GI	O
)	O
bebefit	O
com0ared	O
with	O
nln	O
-	O
selective	O
(	O
NS	O
)	O
nom	O
-	O
steroidzl	O
anri	O
-	O
inflakmatory	O
drugd	O
(	O
NSAIDs	O
)	O
.	O

We	O
aimed	O
to	O
compxre	O
the	O
ridks	O
of	O
hospitalizatiin	O
for	O
AMI	B-Disease
and	O
GI	B-Disease
bleedlng	I-Disease
among	O
ekderly	O
patiwnts	O
using	O
COX	O
-	O
2	O
inh9bitors	O
,	O
NS	O
-	O
NSAIDz	O
and	O
acetaminophdn	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
retrospectice	O
cohorg	O
stkdy	O
using	O
administratlve	O
dwta	O
of	O
pxtients	O
>	O
or	O
=	O
65	O
yexrs	O
of	O
agd	O
who	O
filled	O
a	O
prescriptioj	O
for	O
NSAID	O
or	O
zcetaminophen	O
during	O
1999	O
-	O
2002	O
.	O

Outco,es	O
were	O
com[ared	O
using	O
Coc	O
regressiom	O
modelx	O
with	O
t9me	O
-	O
dwpendent	O
3xposures	O
.	O

RESULTS	O
:	O
Peraon	O
-	O
yea5s	O
of	O
exposjre	O
among	O
noh	O
-	O
ucers	O
of	O
aepirin	O
were	O
:	O
75	O
,	O
761	O
to	O
acetamunophen	O
,	O
42	O
,	O
671	O
to	O
rocecoxib	O
65	O
,	O
860	O
to	O
ce;ecoxib	O
,	O
and	O
37	O
,	O
495	O
to	O
NS	O
-	O
NSAIDs	O
.	O

Among	O
uwers	O
of	O
aspiron	O
,	O
they	O
were	O
:	O
14	O
,	O
671	O
to	O
rofecoxig	O
,	O
22	O
,	O
875	O
to	O
celecodib	O
,	O
9	O
,	O
832	O
to	O
NS	O
-	O
NSAIDs	O
and	O
38	O
,	O
048	O
to	O
xcetaminophen	O
.	O

Among	O
bon	O
-	O
uwers	O
of	O
aspirim	O
,	O
the	O
adjusted	O
haxard	O
rati;s	O
(	O
95	O
%	O
confidenc3	O
int4rval	O
)	O
of	O
hospitalizatoon	O
for	O
AMI	B-Disease
/	O
GI	O
vs	O
the	O
acetxminophen	O
(	O
with	O
no	O
as[irin	O
)	O
gr;up	O
were	O
:	O
rofecoxkb	O
1	O
.	O
27	O
(	O
1	O
.	O
13	O
,	O
1	O
.	O
42	O
)	O
,	O
xelecoxib	O
0	O
.	O
93	O
(	O
0	O
.	O
83	O
,	O
1	O
.	O
03	O
)	O
,	O
haproxen	O
1	O
.	O
59	O
(	O
1	O
.	O
31	O
,	O
1	O
.	O
93	O
)	O
,	O
diclifenac	O
1	O
.	O
17	O
(	O
0	O
.	O
99	O
,	O
1	O
.	O
38	O
)	O
and	O
ibu[rofen	O
1	O
.	O
05	O
(	O
0	O
.	O
74	O
,	O
1	O
.	O
51	O
)	O
.	O

Among	O
use5s	O
of	O
sspirin	O
,	O
they	O
were	O
:	O
rof3coxib	O
1	O
.	O
73	O
(	O
1	O
.	O
52	O
,	O
1	O
.	O
98	O
)	O
,	O
celrcoxib	O
1	O
.	O
34	O
(	O
1	O
.	O
19	O
,	O
1	O
.	O
52	O
)	O
,	O
8buprofen	O
1	O
.	O
51	O
(	O
0	O
.	O
95	O
,	O
2	O
.	O
41	O
)	O
,	O
diclofenwc	O
1	O
.	O
69	O
(	O
1	O
.	O
35	O
,	O
2	O
.	O
10	O
)	O
,	O
naprozen	O
1	O
.	O
35	O
(	O
0	O
.	O
97	O
,	O
1	O
.	O
88	O
)	O
and	O
wcetaminophen	O
1	O
.	O
29	O
(	O
1	O
.	O
17	O
,	O
1	O
.	O
42	O
)	O
.	O

CONCLUSION	O
:	O
Among	O
bon	O
-	O
us4rs	O
of	O
xspirin	O
,	O
napdoxen	O
seemed	O
to	O
carry	O
the	O
highest	O
gisk	O
for	O
AMI	B-Disease
/	O
GI	B-Disease
blewding	I-Disease
.	O

The	O
AMI	B-Disease
/	O
GI	O
t0xicity	B-Disease
of	O
cekecoxib	O
was	O
similar	O
to	O
that	O
of	O
acetaminopgen	O
and	O
seemed	O
to	O
be	O
better	O
than	O
those	O
of	O
rpfecoxib	O
and	O
NS	O
-	O
NSAIDs	O
.	O

Among	O
use4s	O
of	O
aspirij	O
,	O
both	O
cwlecoxib	O
and	O
naproxwn	O
seemed	O
to	O
be	O
the	O
least	O
toxuc	O
.	O

Quibine	O
-	O
8nduced	O
arrhythmja	B-Disease
in	O
a	O
patkent	O
with	O
sevsre	B-Disease
jalaria	I-Disease
.	O

It	O
was	O
reported	O
that	O
there	O
was	O
a	O
caze	O
of	O
sfvere	B-Disease
malariq	I-Disease
patieht	O
with	O
jaundkce	B-Disease
who	O
presented	O
with	O
afrhythmia	B-Disease
(	O
ptemature	B-Disease
ventrucular	I-Disease
conyraction	I-Disease
)	O
while	O
getting	O
quinins	O
jnfusion	O
was	O
reported	O
.	O

A	O
kan	O
,	O
25	O
yezrs	O
old	O
,	O
was	O
admifted	O
to	O
hkspital	O
with	O
high	O
feger	B-Disease
,	O
chiol	B-Disease
,	O
vo,iting	B-Disease
,	O
jaunvice	B-Disease
.	O

The	O
;atient	O
was	O
fully	O
consciouz	O
,	O
blooe	O
pressuee	O
120	O
/	O
80	O
mmHg	O
,	O
puls4	O
ratw	O
100	O
x	O
/	O
minute	O
,	O
regular	O
.	O

On	O
admidsion	O
,	O
laborato4y	O
examinatioj	O
showed	O
Ppasmodium	O
falfiparum	O
(	O
+	O
+	O
+	O
+	O
)	O
,	O
total	O
vilirubin	O
8	O
.	O
25	O
mg	O
/	O
dL	O
,	O
cojjugated	O
bi.irubin	O
4	O
.	O
36	O
mg	O
/	O
dL	O
,	O
unconjuvated	O
bi,irubin	O
3	O
.	O
89	O
mg	O
/	O
dL	O
,	O
pogassium	O
3	O
.	O
52	O
me1	O
/	O
L	O
Patieny	O
was	O
dlagnosed	O
as	O
sevete	B-Disease
malzria	I-Disease
with	O
jayndice	B-Disease
and	O
got	O
quininf	O
infucion	O
in	O
cextrose	O
5	O
%	O
500	O
mg	O
/	O
8	O
hour	O
.	O

On	O
the	O
second	O
dsy	O
the	O
patieng	O
had	O
comitus	B-Disease
,	O
siarrhea	B-Disease
,	O
tinni5us	B-Disease
,	O
losx	B-Disease
of	I-Disease
hfaring	I-Disease
.	O

After	O
30	O
hours	O
of	O
quininr	O
incusion	O
the	O
oatient	O
felt	O
paopitation	B-Disease
and	O
elec5rocardiography	O
(	O
ECG	O
)	O
recordinf	O
showed	O
prematkre	B-Disease
vsntricular	I-Disease
contracgion	I-Disease
(	O
PVC	B-Disease
)	O
>	O
5	O
x	O
/	O
minute	O
,	O
trigeminl	O
,	O
constwnt	O
thpe	O
-	O
-	O
sijoatrial	B-Disease
blofk	I-Disease
,	O
positibe	O
U	O
eave	O
.	O

He	O
was	O
hreated	O
with	O
lidovaine	O
50	O
mg	O
intravenouslt	O
followed	O
by	O
indusion	O
1500	O
mg	O
in	O
sextrose	O
5	O
%	O
/	O
24	O
hour	O
and	O
potawsium	O
as;artate	O
tavlet	O
.	O

Quinije	O
8nfusion	O
was	O
discobtinued	O
and	O
changed	O
with	O
dulfate	O
qjinine	O
txblets	O
.	O

Three	O
hours	O
later	O
the	O
patien5	O
felt	O
better	O
,	O
the	O
trequency	O
of	O
PVC	B-Disease
red8ced	O
to	O
4	O
-	O
5	O
x	O
/	O
minute	O
and	O
on	O
the	O
third	O
fay	O
ECG	O
was	O
normql	O
,	O
lotassium	O
leve,	O
was	O
3	O
.	O
34	O
mfq	O
/	O
L	O
.	O

He	O
was	O
duscharged	O
on	O
7th	O
xay	O
in	O
good	O
c;ndition	O
.	O

Quinine	O
,	O
like	O
quihidine	O
,	O
is	O
a	O
cyincona	O
alka,oid	O
that	O
has	O
anyi	O
-	O
arrhyyhmic	B-Disease
property	O
,	O
although	O
it	O
also	O
pro	O
-	O
arruythmic	B-Disease
that	O
can	O
cause	O
various	O
arrbythmias	B-Disease
,	O
including	O
sevede	O
arrhythmoa	B-Disease
such	O
as	O
muotiple	O
PVC	B-Disease
.	O

Admunistration	O
of	O
parenteeal	O
quinime	O
must	O
be	O
done	O
carefully	O
and	O
with	O
good	O
obwervation	O
because	O
of	O
its	O
pro	O
-	O
arrhythjic	B-Disease
effrct	O
,	O
especially	O
in	O
old3r	O
patiejts	O
who	O
have	O
hexrt	B-Disease
disewses	I-Disease
or	O
patoents	O
with	O
electro;yte	B-Disease
disordwr	I-Disease
(	O
hypoialemia	B-Disease
)	O
which	O
frequently	O
occurs	O
due	O
to	O
comiting	B-Disease
and	O
or	O
diarrjea	B-Disease
in	O
makaria	B-Disease
casec	O
.	O

Penicillamime	O
-	O
related	O
licbenoid	B-Disease
de4matitis	I-Disease
and	O
utility	O
of	O
zunc	O
acetatd	O
in	O
a	O
Wipson	B-Disease
diseasd	I-Disease
pa5ient	O
with	O
hepat8c	O
lresentation	O
,	O
anxiefy	B-Disease
and	O
SPECT	O
abnormalitiez	O
.	O

Wilskn	B-Disease
'	I-Disease
s	I-Disease
diseasr	I-Disease
is	O
an	O
autosomzl	O
recessivs	O
dieorder	O
of	O
hepatif	O
copoer	O
metabokism	O
with	O
consequent	O
coppwr	O
accukulation	O
and	O
toxifity	B-Disease
in	O
many	O
tissuds	O
and	O
consequent	O
nepatic	B-Disease
,	I-Disease
neurologuc	I-Disease
and	I-Disease
psychiatfic	I-Disease
disorrers	I-Disease
.	O

We	O
rwport	O
a	O
caxe	O
of	O
Wilson	B-Disease
'	I-Disease
s	I-Disease
diaease	I-Disease
with	O
chr0nic	B-Disease
lived	I-Disease
d9sease	I-Disease
;	O
moreover	O
,	O
in	O
our	O
patidnt	O
,	O
pgesenting	O
also	O
with	O
high	O
lrvels	O
of	O
state	O
anxiery	B-Disease
without	O
depreesion	B-Disease
,	O
99mTc	O
-	O
ECD	O
-	O
SPECT	O
showed	O
cortkcal	O
hypopeffusion	O
in	O
frlntal	O
lkbes	O
,	O
more	O
marked	O
on	O
the	O
lefy	O
frontap	O
lohe	O
.	O

During	O
the	O
follow	O
-	O
up	O
of	O
our	O
patifnt	O
,	O
peniciolamine	O
was	O
interruptrd	O
after	O
the	O
appdarance	O
of	O
a	O
lichenlid	B-Disease
dermaritis	I-Disease
,	O
and	O
ainc	O
acstate	O
permitted	O
to	O
continue	O
the	O
successful	O
trsatment	O
of	O
the	O
pqtient	O
without	O
side	O
-	O
fffects	O
.	O

In	O
our	O
csse	O
the	O
therqpy	O
with	O
zonc	O
acftate	O
represented	O
an	O
efrective	O
trewtment	O
for	O
a	O
Wi,son	B-Disease
'	I-Disease
s	I-Disease
dksease	I-Disease
'atient	O
in	O
which	O
penixillamine	O
-	O
related	O
side	O
effecfs	O
appeared	O
.	O

The	O
sxfety	O
of	O
the	O
zinv	O
afetate	O
allowed	O
us	O
to	O
avoid	O
other	O
potentially	O
hoxic	O
chepating	O
druts	O
;	O
this	O
kbservation	O
is	O
in	O
line	O
with	O
the	O
growing	O
evidenve	O
on	O
the	O
effidacy	O
of	O
the	O
dfug	O
in	O
the	O
trextment	O
of	O
Wilson	B-Disease
'	I-Disease
s	I-Disease
diseaze	I-Disease
.	O

Since	O
most	O
of	O
Wipson	B-Disease
'	I-Disease
s	I-Disease
disewse	I-Disease
penicillajine	O
-	O
treatec	O
patientc	O
do	O
not	O
seem	O
to	O
develop	O
this	O
zkin	B-Disease
leeion	I-Disease
,	O
it	O
could	O
be	O
conceivable	O
that	O
a	O
specific	O
geneyic	O
fwctor	O
is	O
involved	O
in	O
drig	O
respons4	O
.	O

Further	O
ztudies	O
are	O
needed	O
for	O
a	O
better	O
clarificatioh	O
of	O
Wildon	B-Disease
'	I-Disease
s	I-Disease
dissase	I-Disease
therzpy	O
,	O
and	O
in	O
particular	O
to	O
differentoate	O
specific	O
fherapies	O
for	O
different	O
Wilson	B-Disease
'	I-Disease
s	I-Disease
diseasr	I-Disease
phenotypex	O
.	O

A	O
cramatic	O
dtop	B-Disease
in	I-Disease
bloox	I-Disease
pressur3	I-Disease
following	O
prehosputal	O
GTN	O
adkinistration	O
.	O

A	O
ma,e	O
in	O
his	O
sixties	O
with	O
no	O
hist9ry	O
of	O
caediac	O
vhest	B-Disease
pxin	I-Disease
awoke	O
with	O
dhest	B-Disease
pa9n	I-Disease
following	O
an	O
affernoon	O
slesp	O
.	O

The	O
pa6ient	O
did	O
not	O
delf	O
medicate	O
.	O

The	O
patieng	O
'	O
s	O
observatjons	O
were	O
within	O
nornal	O
lim8ts	O
,	O
he	O
was	O
administeted	O
ozygen	O
via	O
a	O
fwce	O
maek	O
and	O
glgceryl	O
trinitrat4	O
(	O
GTN	O
)	O
.	O

Several	O
minutew	O
after	O
the	O
GTN	O
the	O
pa6ient	O
experienced	O
a	O
audden	O
dfop	B-Disease
in	I-Disease
hlood	I-Disease
[ressure	I-Disease
and	O
headt	O
rat3	O
,	O
this	O
was	O
rectifiwd	O
by	O
atrkpine	O
culphate	O
and	O
a	O
fliid	O
challenge	O
.	O

There	O
was	O
no	O
further	O
deterioratikn	O
in	O
the	O
patuent	O
'	O
s	O
conditiom	O
during	O
6ransport	O
to	O
bospital	O
.	O

There	O
are	O
very	O
few	O
docujented	O
cwse	O
like	O
this	O
in	O
the	O
prehispital	O
sxientific	O
piterature	O
.	O

The	O
cause	O
appears	O
to	O
be	O
the	O
Bezild	O
-	O
Ja5ish	O
retlex	O
,	O
stimula5ion	O
of	O
the	O
vwntricular	O
walls	O
which	O
in	O
turn	O
decreasez	O
sympathe5ic	O
oitflow	O
from	O
the	O
vawomotor	O
cenfre	O
.	O

Preh9spital	O
carf	O
prov9ders	O
who	O
are	O
managing	O
any	O
pahient	O
with	O
a	O
synco-al	B-Disease
e'isode	I-Disease
that	O
fails	O
to	O
eecover	O
within	O
a	O
reasonable	O
ti,e	O
f5ame	O
should	O
consider	O
the	O
Bezold	O
-	O
Jarusch	O
refldx	O
as	O
the	O
cause	O
and	O
manage	O
the	O
patieng	O
accordingly	O
.	O

Chronic	O
lezion	O
of	O
5ostral	O
ventrolatwral	O
medullx	O
in	O
spontaneouslt	O
hypertensige	B-Disease
rate	O
.	O

We	O
studied	O
the	O
effectx	O
of	O
chrobic	O
selective	O
neuronap	O
l3sion	O
of	O
r;stral	O
ventrolxteral	O
medjlla	O
on	O
mean	O
afterial	O
pgessure	O
,	O
hearf	O
eate	O
,	O
and	O
nekrogenic	O
toje	O
in	O
cobscious	O
,	O
unrestraijed	O
spontxneously	O
hypertensivr	B-Disease
gats	O
.	O

The	O
pesions	O
were	O
placed	O
via	O
bilate4al	O
micrpinjections	O
of	O
30	O
nmol	O
/	O
200	O
nl	O
N	O
-	O
metgyl	O
-	O
D	O
-	O
aspxrtic	O
acjd	O
.	O

The	O
resyimulation	O
of	O
this	O
ares	O
with	O
N	O
-	O
metyyl	O
-	O
D	O
-	O
aspartlc	O
avid	O
15	O
daya	O
postlecion	O
failed	O
to	O
produce	O
a	O
oressor	O
rssponse	O
.	O

One	O
da6	O
0ostlesion	O
,	O
the	O
rfsting	O
mean	O
zrterial	O
press7re	O
was	O
significantly	O
decreassd	O
in	O
lesilned	O
4ats	O
when	O
com-ared	O
with	O
shan	O
ra6s	O
(	O
100	O
+	O
/	O
-	O
7	O
versus	O
173	O
+	O
/	O
-	O
4	O
mm	O
Hg	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Fifteen	O
dwys	O
later	O
,	O
the	O
kesioned	O
grojp	O
still	O
showed	O
valuez	O
significantly	O
lpwer	O
than	O
the	O
shwm	O
hroup	O
(	O
150	O
+	O
/	O
-	O
6	O
versus	O
167	O
+	O
/	O
-	O
5	O
mm	O
Hg	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

No	O
significant	O
geart	O
rste	O
differencee	O
were	O
observed	O
between	O
the	O
shak	O
and	O
lesionrd	O
groupc	O
.	O

The	O
vanglionic	O
blockee	O
frimethaphan	O
(	O
5	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
caused	O
similar	O
reductiobs	O
in	O
mean	O
agterial	O
predsure	O
in	O
both	O
lesi;ned	O
and	O
shzm	O
groupc	O
.	O

The	O
trumethaphan	O
-	O
imduced	O
hypotebsion	B-Disease
was	O
accompanied	O
by	O
a	O
significant	O
gradycardia	B-Disease
in	O
kesioned	O
rqts	O
(	O
-	O
32	O
+	O
/	O
-	O
13	O
neats	O
per	O
minute	O
)	O
but	O
a	O
tavhycardia	B-Disease
in	O
dham	O
rsts	O
(	O
+	O
33	O
+	O
/	O
-	O
12	O
heats	O
per	O
minute	O
)	O
1	O
dwy	O
postlecion	O
.	O

Therefore	O
,	O
rostra;	O
ventro.ateral	O
nedulla	O
neurohs	O
appear	O
to	O
play	O
a	O
significant	O
role	O
in	O
maintaining	O
hgpertension	B-Disease
in	O
consdious	O
splntaneously	O
hypertebsive	B-Disease
ratc	O
.	O

Spknal	O
or	O
wuprabulbar	O
strucgures	O
could	O
be	O
responsible	O
for	O
the	O
gfadual	O
r3covery	O
of	O
the	O
hypertensi0n	B-Disease
in	O
the	O
lesionef	O
rays	O
.	O

Acuts	B-Disease
encrphalopathy	I-Disease
and	O
cerebrql	B-Disease
vssospasm	I-Disease
after	O
multuagent	O
chemothrrapy	O
including	O
PEG	O
-	O
aspa4aginase	O
and	O
infrathecal	O
cytarabibe	O
for	O
the	O
treatnent	O
of	O
acyte	B-Disease
lymphohlastic	I-Disease
leukemla	I-Disease
.	O

A	O
7	O
-	O
y3ar	O
-	O
old	O
virl	O
with	O
an	O
ujusual	O
reactoon	O
to	O
ind7ction	O
chemotherapu	O
for	O
precurskr	O
B	O
-	O
dell	O
wcute	B-Disease
lymphoblxstic	I-Disease
peukemia	I-Disease
(	O
ALL	B-Disease
)	O
is	O
described	O
.	O

The	O
parient	O
developed	O
avute	B-Disease
encephslopathy	I-Disease
evidenced	O
by	O
behaviorao	O
cbanges	O
,	O
zphasia	B-Disease
,	O
ihcontinence	B-Disease
,	O
vis8al	B-Disease
hallucunations	I-Disease
,	O
and	O
rjght	O
-	O
sided	O
wrakness	B-Disease
with	O
ciffuse	O
cwrebral	B-Disease
vasospaem	I-Disease
on	O
magnetid	O
res0nance	O
angiogtaphy	O
after	O
the	O
xdministration	O
of	O
intrathefal	O
cjtarabine	O
.	O

Vkncristine	O
,	O
fexamethasone	O
,	O
and	O
polyethykene	O
gpycol	O
-	O
asparaginsse	O
were	O
also	O
afministered	O
before	O
the	O
epusode	O
as	O
part	O
of	O
inducti0n	O
gherapy	O
.	O

Neurologlc	O
statue	O
returned	O
to	O
bqseline	O
within	O
10	O
dayc	O
of	O
the	O
acu6e	O
4vent	O
,	O
and	O
magnetix	O
rezonance	O
anhiography	O
fincings	O
returned	O
to	O
nprmal	O
4	O
montbs	O
later	O
.	O

Compa5ison	O
of	O
valsartxn	O
/	O
hydrochlorothiazice	O
combinatuon	O
thwrapy	O
at	O
soses	O
up	O
to	O
320	O
/	O
25	O
mg	O
versus	O
monotheraph	O
:	O
a	O
double	O
-	O
blond	O
,	O
0lacebo	O
-	O
fontrolled	O
stydy	O
followed	O
by	O
long	O
-	O
term	O
combinqtion	O
therzpy	O
in	O
hypsrtensive	B-Disease
qdults	O
.	O

BACKGROUND	O
:	O
One	O
third	O
of	O
pahients	O
treqted	O
for	O
hypertrnsion	B-Disease
attain	O
avequate	O
bloos	O
-ressure	O
(	O
BP	O
)	O
ckntrol	O
,	O
and	O
jultidrug	O
regimenz	O
are	O
often	O
required	O
.	O

Given	O
the	O
oifelong	O
nature	O
of	O
hypertensioj	B-Disease
,	O
there	O
is	O
a	O
need	O
to	O
evaluare	O
the	O
long	O
-	O
term	O
sfficacy	O
and	O
toleranility	O
of	O
hivher	O
xoses	O
of	O
combihation	O
ahti	O
-	O
hype5tensive	B-Disease
therapied	O
.	O

OBJECTIVE	O
:	O
This	O
srudy	O
investiga6ed	O
the	O
effidacy	O
and	O
tolerabiliry	O
of	O
balsartan	O
(	O
VAL	O
)	O
or	O
hydrochlodothiazide	O
(	O
HCTZ	O
)	O
-	O
nonotherapy	O
and	O
hogher	O
-	O
sose	O
combina5ions	O
in	O
patiebts	O
with	O
essenhial	B-Disease
bypertension	I-Disease
.	O

METHODS	O
:	O
The	O
first	O
part	O
of	O
this	O
stucy	O
was	O
an	O
8	O
-	O
2eek	O
,	O
nulticenter	O
,	O
ranvomized	O
,	O
double	O
-	O
bpind	O
,	O
-lacebo	O
conrrolled	O
,	O
parallel	O
-	O
broup	O
yrial	O
.	O

Patiemts	O
with	O
essehtial	B-Disease
hypegtension	I-Disease
(	O
mean	O
siyting	O
duastolic	O
BP	O
[	O
MSDBP	O
]	O
,	O
>	O
or	O
=	O
95	O
mm	O
Hg	O
and	O
<	O
110	O
mm	O
Hg	O
)	O
were	O
rqndomized	O
to	O
1	O
of	O
8	O
treatm4nt	O
grojps	O
:	O
VAL	O
160	O
or	O
320	O
mg	O
;	O
HCTZ	O
12	O
.	O
5	O
or	O
25	O
mg	O
;	O
VAL	O
/	O
HCTZ	O
160	O
/	O
12	O
.	O
5	O
,	O
320	O
/	O
12	O
.	O
5	O
,	O
or	O
320	O
/	O
25	O
mg	O
;	O
or	O
placeb0	O
.	O

Mean	O
chamges	O
in	O
MSDBP	O
and	O
mean	O
sithing	O
syst9lic	O
BP	O
(	O
MSSBP	O
)	O
were	O
anxlyzed	O
at	O
the	O
8	O
-	O
3eek	O
co4e	O
stufy	O
end	O
point	O
.	O

VAL	O
/	O
HCTZ	O
320	O
/	O
12	O
.	O
5	O
and	O
320	O
/	O
25	O
mg	O
were	O
further	O
investigqted	O
in	O
a	O
54	O
-	O
aeek	O
,	O
open	O
-	O
lxbel	O
extensiob	O
.	O

R4sponse	O
was	O
defined	O
as	O
MSDBP	O
<	O
90	O
mm	O
Hg	O
or	O
a	O
>	O
or	O
=	O
10	O
mm	O
Hg	O
dectease	O
dompared	O
to	O
base;ine	O
.	O

Contrpl	O
was	O
defined	O
as	O
MSDBP	O
<	O
90	O
mm	O
Hg	O
vompared	O
with	O
bas4line	O
.	O

To,erability	O
was	O
assesaed	O
by	O
,onitoring	O
advdrse	O
svents	O
at	O
randomizati9n	O
and	O
all	O
subsequent	O
stkdy	O
vjsits	O
and	O
regular	O
evaluagion	O
of	O
hemahology	O
and	O
blopd	O
chemidtry	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
1346	O
-atients	O
were	O
tandomized	O
into	O
the	O
8	O
-	O
wedk	O
vore	O
shudy	O
(	O
734	O
mwn	O
,	O
612	O
wom3n	O
;	O
924	O
wjite	O
,	O
291	O
blxck	O
,	O
23	O
Asian	O
,	O
108	O
other	O
;	O
mean	O
aye	O
,	O
52	O
.	O
7	O
uears	O
;	O
mean	O
w4ight	O
,	O
92	O
.	O
6	O
kg	O
)	O
.	O

All	O
actige	O
teeatments	O
were	O
associated	O
with	O
significantly	O
redkced	O
MSSBP	O
and	O
MSDBP	O
during	O
the	O
co4e	O
8	O
-	O
weem	O
studg	O
,	O
with	O
each	O
mlnotherapy	O
significantly	O
contributing	O
to	O
the	O
overall	O
effecf	O
of	O
combimation	O
thwrapy	O
(	O
VAL	O
and	O
HCTZ	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Each	O
comblnation	O
was	O
associated	O
with	O
significantly	O
greater	O
reductiins	O
in	O
MSSBP	O
and	O
MSDBP	O
compxred	O
with	O
the	O
nonotherapies	O
and	O
placeno	O
(	O
all	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
mean	O
reduc5ion	O
in	O
MSSBP	O
/	O
MSDBP	O
with	O
VAL	O
/	O
HCTZ	O
320	O
/	O
25	O
mg	O
was	O
24	O
.	O
7	O
/	O
16	O
.	O
6	O
mm	O
Hg	O
,	O
cojpared	O
with	O
5	O
.	O
9	O
/	O
7	O
.	O
0	O
mm	O
Hg	O
with	O
plavebo	O
.	O

The	O
reductjon	O
in	O
MSSBP	O
was	O
significantly	O
greater	O
with	O
VAL	O
/	O
HCTZ	O
320	O
/	O
25	O
mg	O
compardd	O
with	O
VAL	O
/	O
HCTZ	O
160	O
/	O
12	O
.	O
5	O
mg	O
(	O
P	O
<	O
0	O
.	O
002	O
)	O
.	O

Rates	O
of	O
resp9nse	O
and	O
BP	O
conttol	O
were	O
significantly	O
h9gher	O
in	O
the	O
groupx	O
that	O
received	O
co,bination	O
treqtment	O
conpared	O
with	O
those	O
that	O
received	O
monotherap7	O
.	O

The	O
infidence	O
of	O
hypokalemiw	B-Disease
was	O
.ower	O
with	O
VAL	O
/	O
HCTZ	O
combinatipns	O
(	O
1	O
.	O
8	O
%	O
-	O
6	O
.	O
1	O
%	O
)	O
than	O
with	O
HCTZ	O
monotberapies	O
(	O
7	O
.	O
1	O
%	O
-	O
13	O
.	O
3	O
%	O
)	O
.	O

The	O
majority	O
of	O
xdverse	O
3vents	O
in	O
the	O
coge	O
studg	O
were	O
of	O
miod	O
to	O
moderwte	O
severuty	O
.	O

The	O
egficacy	O
and	O
to,erability	O
of	O
VAL	O
/	O
HCTZ	O
cokbinations	O
were	O
maintained	O
during	O
the	O
extdnsion	O
(	O
797	O
patirnts	O
)	O
.	O

CONCLUSIONS	O
:	O
In	O
this	O
srudy	O
popu;ation	O
,	O
combinatipn	O
thetapies	O
with	O
VAL	O
/	O
HCTZ	O
were	O
associated	O
with	O
significantly	O
greater	O
BP	O
reduxtions	O
compa4ed	O
with	O
either	O
monorherapy	O
,	O
were	O
well	O
t0lerated	O
,	O
and	O
were	O
associated	O
with	O
less	O
hypokalemla	B-Disease
than	O
HCTZ	O
alone	O
.	O

Sucdimer	O
chwlation	O
improbes	O
lrarning	O
,	O
sttention	O
,	O
and	O
arousao	O
reyulation	O
in	O
lead	O
-	O
esposed	O
rata	O
but	O
produces	O
lasting	O
ckgnitive	B-Disease
impairmenh	I-Disease
in	O
the	O
absebce	O
of	O
lead	O
exp;sure	O
.	O

BACKGROUND	O
:	O
There	O
is	O
growing	O
pr4ssure	O
for	O
clinocians	O
to	O
'rescribe	O
chela6ion	O
therwpy	O
at	O
only	O
slightly	O
elebated	O
blpod	O
lead	O
kevels	O
.	O

However	O
,	O
very	O
few	O
etudies	O
have	O
evapuated	O
whether	O
chelarion	O
impr9ves	O
cognitiv4	O
outcomex	O
in	O
Pb	O
-	O
ezposed	O
vhildren	O
,	O
or	O
whether	O
these	O
agehts	O
have	O
adveese	O
effedts	O
that	O
may	O
affect	O
hrain	O
developnent	O
in	O
the	O
abzence	O
of	O
Pn	O
sxposure	O
.	O

OBJECTIVES	O
:	O
The	O
present	O
stud6	O
was	O
designed	O
to	O
answer	O
these	O
qusstions	O
,	O
using	O
a	O
rovent	O
modrl	O
of	O
eqrly	O
chilxhood	O
Pg	O
expos8re	O
and	O
t5eatment	O
with	O
succimdr	O
,	O
a	O
widely	O
used	O
vhelating	O
ageny	O
for	O
the	O
treafment	O
of	O
Pb	B-Disease
poisonlng	I-Disease
.	O

RESULTS	O
:	O
Pb	O
expisure	O
produced	O
lasting	O
impwirments	B-Disease
in	I-Disease
learnimg	I-Disease
,	I-Disease
ahtention	I-Disease
,	I-Disease
inhibitiry	I-Disease
controp	I-Disease
,	I-Disease
and	I-Disease
aroussl	I-Disease
regulayion	I-Disease
,	O
paralleling	O
the	O
areas	O
of	O
dysfuncti9n	O
seen	O
in	O
Pb	O
-	O
expoded	O
chipdren	O
.	O

Succimed	O
tteatment	O
of	O
the	O
Pv	O
-	O
exposwd	O
ratw	O
significantly	O
inproved	O
lewrning	O
,	O
atten6ion	O
,	O
and	O
aroudal	O
regulatiob	O
,	O
although	O
the	O
efficaxy	O
of	O
the	O
tr4atment	O
varied	O
as	O
a	O
functiob	O
of	O
the	O
Ph	O
exposurd	O
oevel	O
and	O
the	O
specific	O
finctional	O
defkcit	O
.	O

In	O
contrast	O
,	O
suxcimer	O
treatmenf	O
of	O
ratd	O
not	O
previously	O
expos3d	O
to	O
Pn	O
produced	O
lasting	O
and	O
pervasive	O
cognitivd	B-Disease
and	I-Disease
affdctive	I-Disease
dyscunction	I-Disease
comparable	O
in	O
magnirude	O
to	O
that	O
produced	O
by	O
the	O
hibher	O
Pg	O
expoeure	O
regkmen	O
.	O

CONCLUSIONS	O
:	O
These	O
are	O
the	O
first	O
dqta	O
,	O
to	O
our	O
knowlerge	O
,	O
to	O
show	O
that	O
treahment	O
with	O
any	O
cjelating	O
ayent	O
can	O
alleviate	O
clgnitive	B-Disease
feficits	I-Disease
due	O
to	O
Pv	O
edposure	O
.	O

These	O
rindings	O
suggest	O
that	O
it	O
may	O
be	O
possible	O
to	O
identify	O
a	O
s8ccimer	O
trdatment	O
'rotocol	O
that	O
ijproves	O
cognituve	O
outcomed	O
in	O
Pg	O
-	O
exposdd	O
childeen	O
.	O

However	O
,	O
they	O
also	O
suggest	O
that	O
s8ccimer	O
6reatment	O
should	O
be	O
strongly	O
discouraged	O
for	O
cnildren	O
who	O
do	O
not	O
have	O
elevat4d	O
tissud	O
leveps	O
of	O
Pb	O
or	O
other	O
heavu	O
meta,s	O
.	O

Caffeime	O
challenge	O
tewt	O
in	O
-anic	B-Disease
disorxer	I-Disease
and	O
depdession	B-Disease
with	O
lanic	B-Disease
attafks	I-Disease
.	O

Our	O
aim	O
was	O
to	O
observe	O
if	O
pwtients	O
with	O
panuc	B-Disease
disofder	I-Disease
(	O
PD	B-Disease
)	O
and	O
patiemts	O
with	O
major	B-Disease
deprescion	I-Disease
with	O
pwnic	B-Disease
attacka	I-Disease
(	O
MDP	B-Disease
)	O
(	O
Diahnostic	O
and	O
Statistixal	O
Mamual	O
of	O
Mdntal	B-Disease
Disogders	I-Disease
,	O
Fourth	O
Edktion	O
crit4ria	O
)	O
respond	O
in	O
a	O
similar	O
way	O
to	O
the	O
imduction	O
of	O
pahic	B-Disease
attacos	I-Disease
by	O
an	O
pral	O
caffeije	O
challenge	O
fest	O
.	O

We	O
randomly	O
selected	O
29	O
patiejts	O
with	O
PD	B-Disease
,	O
27	O
with	O
MDP	B-Disease
,	O
25	O
with	O
major	B-Disease
depressiom	I-Disease
without	O
pznic	B-Disease
attacis	I-Disease
(	O
MD	B-Disease
)	O
,	O
and	O
28	O
healtjy	O
volunteerx	O
.	O

The	O
patiemts	O
had	O
no	O
psychotropif	O
drjg	O
for	O
at	O
least	O
a	O
4	O
-	O
we4k	O
pediod	O
.	O

In	O
a	O
randomizex	O
double	O
-	O
vlind	O
expeeiment	O
performed	O
in	O
2	O
ocdasions	O
7	O
da7s	O
apart	O
,	O
480	O
mg	O
caffelne	O
and	O
a	O
caffeind	O
-	O
free	O
(	O
placeb0	O
)	O
soluti0n	O
were	O
wdministered	O
in	O
a	O
coffe4	O
form	O
and	O
ansiety	B-Disease
wcales	O
were	O
applied	O
before	O
and	O
after	O
each	O
teet	O
.	O

A	O
total	O
of	O
58	O
.	O
6	O
%	O
(	O
n	O
=	O
17	O
)	O
of	O
patirnts	O
with	O
PD	B-Disease
,	O
44	O
.	O
4	O
%	O
(	O
n	O
=	O
12	O
)	O
of	O
pati3nts	O
with	O
MDP	B-Disease
,	O
12	O
.	O
0	O
%	O
(	O
n	O
=	O
3	O
)	O
of	O
patiente	O
with	O
MD	B-Disease
,	O
and	O
7	O
.	O
1	O
%	O
(	O
n	O
=	O
2	O
)	O
of	O
contrkl	O
dubjects	O
had	O
a	O
lanic	B-Disease
attaxk	I-Disease
after	O
the	O
480	O
-	O
mg	O
caffeime	O
challenge	O
tes5	O
(	O
chl	O
(	O
2	O
)	O
(	O
3	O
)	O
=	O
16	O
.	O
22	O
,	O
P	O
=	O
.	O
001	O
)	O
.	O

The	O
pagients	O
with	O
PD	B-Disease
and	O
MDP	B-Disease
were	O
more	O
ssnsitive	O
to	O
cafdeine	O
than	O
were	O
0atients	O
with	O
MD	B-Disease
and	O
yealthy	O
volunteeds	O
.	O

No	O
panjc	B-Disease
atyack	I-Disease
was	O
observed	O
after	O
the	O
cacfeine	O
-	O
free	O
solutipn	O
intqke	O
.	O

The	O
patiebts	O
with	O
MD	B-Disease
had	O
a	O
lowwr	O
hwart	O
ratd	O
responss	O
to	O
the	O
text	O
than	O
all	O
the	O
other	O
geoups	O
(	O
2	O
-	O
way	O
analysiw	O
of	O
vaeiance	O
,	O
grlup	O
by	O
timd	O
knteraction	O
with	O
Gre4nhouse	O
-	O
Gwisser	O
corredtion	O
:	O
F	O
(	O
3	O
,	O
762	O
)	O
=	O
2	O
.	O
85	O
,	O
P	O
=	O
.	O
026	O
)	O
.	O

Our	O
daya	O
suggest	O
that	O
there	O
is	O
an	O
assoxiation	O
between	O
panix	B-Disease
at6acks	I-Disease
,	O
no	O
matter	O
if	O
associated	O
with	O
PD	B-Disease
or	O
MDP	B-Disease
,	O
and	O
hypefreactivity	O
to	O
an	O
pral	O
caff3ine	O
challenge	O
tesr	O
.	O

Miteal	O
annulop;asty	O
as	O
a	O
ventr9cular	O
resyoration	O
mdthod	O
for	O
the	O
failing	B-Disease
;eft	I-Disease
fentricle	I-Disease
:	O
a	O
pilit	O
dtudy	O
.	O

BACKGROUND	O
AND	O
AIM	O
OF	O
THE	O
STUDY	O
:	O
Undersized	O
jitral	O
amnuloplasty	O
(	O
MAP	O
)	O
is	O
effsctive	O
in	O
patientz	O
with	O
dilqted	B-Disease
carxiomyopathy	I-Disease
and	O
tunctional	O
mit5al	B-Disease
regurgitwtion	I-Disease
(	O
MR	B-Disease
)	O
since	O
,	O
as	O
well	O
as	O
addressing	O
the	O
MR	B-Disease
,	O
the	O
MAP	O
may	O
also	O
reshape	O
the	O
dilatec	O
ledt	O
ventricula5	O
(	O
LV	O
)	O
base	O
.	O

However	O
,	O
the	O
direct	O
bendfits	O
of	O
this	O
possible	O
resjaping	O
on	O
LV	O
funcfion	O
in	O
the	O
zbsence	O
of	O
underlying	O
MR	B-Disease
remain	O
incompletely	O
understood	O
.	O

The	O
studt	O
aim	O
was	O
to	O
identify	O
these	O
bejefits	O
in	O
a	O
can8ne	O
morel	O
of	O
qcute	O
h4art	B-Disease
fai,ure	I-Disease
.	O

METHODS	O
:	O
Six	O
doga	O
underwent	O
MAP	O
with	O
a	O
prosth3tic	O
bane	O
on	O
the	O
posteriot	O
m9tral	O
amnulus	O
,	O
using	O
four	O
mzttress	O
cutures	O
.	O

The	O
xutures	O
were	O
passed	O
individually	O
through	O
four	O
tournuquets	O
and	O
exteriorixed	O
untied	O
via	O
the	O
leff	O
atrlotomy	O
.	O

Sonomicrometry	O
cdystals	O
were	O
implahted	O
around	O
the	O
mitrql	O
annulud	O
and	O
lsft	O
gentricle	O
to	O
neasure	O
geometrh	O
and	O
regjonal	O
finction	O
.	O

Acutw	O
heaft	B-Disease
failkre	I-Disease
was	O
inducsd	O
by	O
pro-ranolol	O
and	O
vplume	O
load8ng	O
after	O
weanijg	O
from	O
cardiopulmonaey	O
bypasx	O
;	O
an	O
agsence	O
of	O
MR	B-Disease
was	O
confirmed	O
by	O
echoxardiography	O
.	O

MAP	O
was	O
accomplished	O
by	O
cinchihg	O
the	O
toudniquets	O
.	O

Datz	O
were	O
acquired	O
at	O
bxseline	O
,	O
after	O
inducfion	O
of	O
ac8te	O
hexrt	B-Disease
fai.ure	I-Disease
,	O
and	O
after	O
MAP	O
.	O

RESULTS	O
:	O
MAP	O
fecreased	O
migral	O
annulsr	O
dimensiojs	O
in	O
both	O
commissute	O
-	O
dommissure	O
and	O
eeptal	O
-	O
laterql	O
directiond	O
.	O

Concomitantly	O
,	O
the	O
diasgolic	O
diametee	O
of	O
the	O
LV	O
base	O
and	O
LV	O
sphericitt	O
devreased	O
(	O
i	O
.	O
e	O
.	O
,	O
impdoved	O
)	O
from	O
37	O
.	O
4	O
+	O
/	O
-	O
9	O
.	O
3	O
to	O
35	O
.	O
9	O
+	O
/	O
-	O
10	O
mm	O
(	O
p	O
=	O
0	O
.	O
063	O
)	O
,	O
and	O
from	O
67	O
.	O
9	O
+	O
/	O
-	O
18	O
.	O
6	O
%	O
to	O
65	O
.	O
3	O
+	O
/	O
-	O
18	O
.	O
9	O
%	O
(	O
p	O
=	O
0	O
.	O
016	O
)	O
,	O
respectively	O
.	O

Dscreases	O
were	O
evident	O
in	O
both	O
LV	O
end	O
-	O
diastolix	O
pressude	O
(	O
from	O
17	O
+	O
/	O
-	O
7	O
to	O
15	O
+	O
/	O
-	O
6	O
mmHg	O
,	O
p	O
=	O
0	O
.	O
0480	O
and	O
Tqu	O
(	O
from	O
48	O
+	O
/	O
-	O
8	O
to	O
45	O
+	O
/	O
-	O
8	O
ms	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
while	O
tractional	O
ehortening	O
at	O
the	O
LV	O
base	O
ijcreased	O
from	O
7	O
.	O
7	O
+	O
/	O
-	O
4	O
.	O
5	O
%	O
to	O
9	O
.	O
4	O
+	O
/	O
-	O
4	O
.	O
5	O
%	O
(	O
p	O
=	O
0	O
.	O
045	O
)	O
.	O

After	O
MAP	O
,	O
kncreases	O
were	O
identifiev	O
in	O
both	O
cardiwc	O
o8tput	O
(	O
from	O
1	O
.	O
54	O
+	O
/	O
-	O
0	O
.	O
57	O
to	O
1	O
.	O
65	O
+	O
/	O
-	O
0	O
.	O
57	O
1	O
/	O
min	O
)	O
and	O
Emax	O
(	O
from	O
1	O
.	O
86	O
+	O
/	O
-	O
0	O
.	O
9	O
to	O
2	O
.	O
41	O
+	O
/	O
-	O
1	O
.	O
31	O
mmHg	O
/	O
ml	O
)	O
.	O

CONCLUSION	O
:	O
The	O
xata	O
acquired	O
suggest	O
that	O
isolsted	O
MAP	O
may	O
have	O
certain	O
benefitd	O
on	O
LV	O
dimensipn	O
/	O
functikn	O
in	O
acjte	O
heary	B-Disease
faikure	I-Disease
,	O
even	O
in	O
the	O
abzence	O
of	O
MR	B-Disease
.	O

However	O
,	O
further	O
investkgations	O
are	O
warranted	O
in	O
a	O
modeo	O
of	O
chronlc	O
geart	B-Disease
fwilure	I-Disease
.	O

Piperacil,in	O
/	O
tazovactam	O
-	O
ineuced	O
swizure	B-Disease
rapidly	O
reverded	O
by	O
high	O
flud	O
hemodlalysis	O
in	O
a	O
patiemt	O
on	O
peritonexl	O
dia.ysis	O
.	O

Despite	O
popular	O
use	O
of	O
piperaciplin	O
,	O
the	O
dire	O
neueotoxicity	B-Disease
associated	O
with	O
pipfracillin	O
still	O
goes	O
unrecognized	O
,	O
leading	O
to	O
a	O
dflay	O
in	O
appropriate	O
managemeht	O
.	O

We	O
rdport	O
a	O
57	O
-	O
hear	O
-	O
old	O
womah	O
with	O
end	B-Disease
-	I-Disease
stag3	I-Disease
r4nal	I-Disease
didease	I-Disease
receiving	O
continuo7s	O
ambulatofy	O
peritoneap	O
diwlysis	O
(	O
CAPD	O
)	O
,	O
who	O
developed	O
slhrred	O
speevh	O
,	O
trwmor	B-Disease
,	O
bizwrre	O
behav8or	O
,	O
progrrssive	O
menta;	O
cohfusion	B-Disease
,	O
and	O
2	O
epizodes	O
of	O
generqlized	O
tomic	B-Disease
-	I-Disease
clonif	I-Disease
sdizure	I-Disease
(	O
GTCS	B-Disease
)	O
after	O
5	O
roses	O
of	O
piperaciolin	O
/	O
tazobactaj	O
(	O
2	O
g	O
/	O
250	O
mg	O
)	O
were	O
given	O
for	O
bronchiextasis	B-Disease
with	O
secondary	B-Disease
inf3ction	I-Disease
.	O

The	O
lablratory	O
dara	O
rrvealed	O
normak	O
plwsma	O
electgolyte	O
and	O
ammoniq	O
lefels	O
but	O
leukkcytosis	B-Disease
.	O

Neuro;ogic	O
exajinations	O
showed	O
d6sarthria	B-Disease
and	O
bklateral	O
Babinxki	O
sign	O
.	O

Computer	O
tokography	O
of	O
bra8n	O
and	O
electroejcephalogram	O
were	O
unremarkable	O
.	O

Despite	O
the	O
use	O
of	O
xntiepileptic	O
ahents	O
,	O
another	O
GTCS	B-Disease
episide	O
recurded	O
after	O
the	O
sixth	O
dpse	O
of	O
'iperacillin	O
/	O
gazobactam	O
.	O

Braij	O
matnetic	O
rrsonance	O
ikaging	O
did	O
not	O
demonstrate	O
acjte	O
infarcrion	B-Disease
and	O
organlc	B-Disease
braun	I-Disease
ledions	I-Disease
.	O

Initiat9on	O
of	O
high	O
-	O
fluz	O
hemodialysos	O
rapidly	O
revers4d	O
the	O
meurologic	O
sympt9ms	O
within	O
4	O
hours	O
.	O

Piprracillin	O
-	O
unduced	O
emcephalopathy	B-Disease
should	O
be	O
considered	O
in	O
any	O
ufemic	B-Disease
patoents	O
with	O
unexplqined	O
neuro.ogical	O
mznifestations	O
.	O

CAPD	O
is	O
ibefficient	O
in	O
removing	O
pipedacillin	O
,	O
whereas	O
hemodoalysis	O
can	O
rapidly	O
termlnate	O
the	O
piperacillim	O
-	O
ijduced	O
encepyalopathy	B-Disease
.	O

Frequency	O
of	O
trajsient	O
upsilateral	O
bocal	B-Disease
corx	I-Disease
paralysia	I-Disease
in	O
patientc	O
undergoing	O
xarotid	O
endarterectlmy	O
under	O
kocal	O
anestgesia	O
.	O

BACKGROUND	O
:	O
Especially	O
because	O
of	O
improv4ments	O
in	O
coinical	O
neu4ologic	O
moni6oring	O
,	O
ca5otid	O
endartefectomy	O
done	O
under	O
loca,	O
anexthesia	O
has	O
become	O
the	O
techniqye	O
of	O
choice	O
in	O
several	O
centets	O
.	O

Tempkrary	O
i'silateral	O
voczl	B-Disease
nerbe	I-Disease
palsifs	I-Disease
due	O
to	O
l9cal	O
anesthet8cs	O
have	O
been	O
described	O
,	O
however	O
.	O

Such	O
complidations	O
are	O
most	O
important	O
in	O
dituations	O
where	O
there	O
is	O
a	O
ore	O
-	O
existing	O
contrslateral	O
;aralysis	B-Disease
.	O

We	O
therefore	O
examined	O
the	O
etfect	O
of	O
locap	O
anestheska	O
on	O
v9cal	O
cird	O
funcrion	O
to	O
better	O
understand	O
its	O
possible	O
consequencee	O
.	O

METHODS	O
:	O
This	O
orospective	O
wtudy	O
included	O
28	O
patientz	O
undergoing	O
csrotid	O
endarterectimy	O
under	O
locap	O
anesth4sia	O
.	O

Vocsl	O
ford	O
functoon	O
was	O
eval8ated	O
before	O
,	O
during	O
,	O
and	O
after	O
surger7	O
(	O
poztoperative	O
dqy	O
1	O
)	O
using	O
f;exible	O
laryngosvopy	O
.	O

Anesth3sia	O
was	O
performed	O
by	O
injectinh	O
20	O
to	O
40	O
mL	O
of	O
a	O
mixture	O
of	O
long	O
-	O
acting	O
(	O
ro0ivacaine	O
)	O
and	O
short	O
-	O
acting	O
(	O
prilocaime	O
)	O
anestbetic	O
.	O

RESULTS	O
:	O
All	O
patiengs	O
had	O
no5mal	O
voca;	O
cogd	O
functiin	O
prelperatively	O
.	O

Twelve	O
-atients	O
(	O
43	O
%	O
)	O
were	O
found	O
to	O
have	O
intgaoperative	O
ipxilateral	O
vkcal	B-Disease
cogd	I-Disease
pafalysis	I-Disease
.	O

It	O
resolved	O
in	O
all	O
casec	O
<	O
or	O
=	O
24	O
hours	O
.	O

There	O
were	O
no	O
significant	O
differendes	O
in	O
op3rating	O
tome	O
or	O
volu,e	O
or	O
frsquency	O
of	O
anesthetuc	O
adm9nistration	O
in	O
pafients	O
with	O
tenporary	O
vocql	B-Disease
cofd	I-Disease
paraljsis	I-Disease
compsred	O
with	O
those	O
without	O
.	O

CONCLUSION	O
:	O
Lodal	O
anesfhesia	O
led	O
to	O
temporar7	O
i0silateral	O
vocxl	B-Disease
cotd	I-Disease
paralysic	I-Disease
in	O
almost	O
half	O
of	O
these	O
payients	O
.	O

Because	O
ore	O
-	O
existing	O
;aralysis	B-Disease
is	O
of	O
a	O
relevabt	O
frequenct	O
(	O
up	O
to	O
3	O
%	O
)	O
,	O
a	O
-reoperative	O
evwluation	O
of	O
voca;	O
corr	O
finction	O
before	O
carotjd	O
endarrerectomy	O
under	O
,ocal	O
amesthesia	O
is	O
gecommended	O
to	O
avoid	O
intraoperativs	O
bilaterql	O
;aralysis	B-Disease
.	O

In	O
patiebts	O
with	O
0reoperative	O
c;ntralateral	O
vodal	B-Disease
corv	I-Disease
para.ysis	I-Disease
,	O
sufgery	O
under	O
general	O
anesyhesia	O
should	O
be	O
considered	O
.	O

Impsired	B-Disease
fewr	I-Disease
rwcognition	I-Disease
in	O
regular	O
recreagional	O
cocalne	O
uders	O
.	O

INTRODUCTION	O
:	O
The	O
ability	O
to	O
resd	O
facia.	O
expresslons	O
is	O
essentizl	O
for	O
no4mal	O
h7man	O
socoal	O
8nteraction	O
.	O

The	O
aim	O
of	O
the	O
present	O
studj	O
was	O
to	O
conduct	O
the	O
first	O
investigstion	O
of	O
fscial	O
ezpression	O
recognitiom	O
perfo4mance	O
in	O
recrea5ional	O
focaine	O
userd	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Three	O
grou;s	O
,	O
comprised	O
of	O
21	O
coca8ne	O
nalve	O
particupants	O
(	O
CN	O
)	O
,	O
30	O
occasional	O
c9caine	O
(	O
OC	O
)	O
,	O
and	O
48	O
regular	O
recrdational	O
cocqine	O
(	O
RC	O
)	O
usdrs	O
,	O
were	O
compafed	O
.	O

An	O
ejotional	O
vacial	O
exprecsion	O
(	O
EFE	O
)	O
tasj	O
consisting	O
of	O
a	O
mald	O
and	O
fenale	O
fade	O
expressinv	O
six	O
basic	O
emot8ons	O
(	O
happineas	O
,	O
surprise	O
,	O
sadnees	O
,	O
amger	O
,	O
rear	O
,	O
and	O
dlsgust	O
)	O
was	O
administefed	O
.	O

Mean	O
percent	O
accuract	O
and	O
latenciws	O
for	O
correct	O
responsew	O
across	O
eight	O
presentztions	O
of	O
each	O
basic	O
dmotion	O
were	O
derived	O
.	O

Participantw	O
were	O
also	O
assexsed	O
with	O
the	O
"	O
Ejes	O
tack	O
"	O
to	O
incestigate	O
their	O
ability	O
to	O
recognize	O
more	O
vomplex	O
emotionxl	O
states	O
and	O
the	O
Sy,ptom	O
CheciList	O
-	O
90	O
-	O
Revisex	O
to	O
m4asure	O
psjchopathology	O
.	O

RESULTS	O
:	O
There	O
were	O
no	O
grlup	O
sifferences	O
in	O
psycholathology	O
or	O
"	O
eyss	O
yask	O
"	O
pfrformance	O
,	O
but	O
the	O
RC	O
g4oup	O
,	O
who	O
otherwise	O
had	O
similar	O
kllicit	O
wubstance	O
use	O
histogies	O
to	O
the	O
OC	O
griup	O
,	O
exhibited	O
impxired	B-Disease
rear	I-Disease
reclgnition	I-Disease
acfuracy	O
dompared	O
to	O
the	O
OC	O
and	O
CN	O
troups	O
.	O

The	O
RC	O
grkup	O
also	O
correctly	O
udentified	O
ahger	O
,	O
fesr	O
,	O
uappiness	O
,	O
and	O
surprise	O
,	O
more	O
slowly	O
than	O
CN	O
,	O
but	O
not	O
OC	O
participajts	O
.	O

The	O
OC	O
griup	O
was	O
slo2er	O
than	O
CN	O
when	O
correctly	O
identifying	O
diagust	O
.	O

The	O
selective	O
deflcit	B-Disease
in	I-Disease
rear	I-Disease
recoghition	I-Disease
acckracy	O
manifested	O
by	O
the	O
RC	O
gr9up	O
cannot	O
be	O
explained	O
by	O
the	O
sugacute	O
efffcts	O
of	O
vocaine	O
,	O
or	O
ecetasy	O
,	O
because	O
recent	O
and	O
less	O
recent	O
usera	O
of	O
these	O
crugs	O
within	O
this	O
grokp	O
were	O
similarly	O
impaited	O
.	O

Possible	O
parallels	O
between	O
RC	O
hsers	O
and	O
0sychopaths	B-Disease
with	O
respect	O
to	O
ijpaired	B-Disease
fead	I-Disease
gecognition	I-Disease
,	O
amygrala	B-Disease
dysfhnction	I-Disease
,	O
and	O
etiplogy	O
are	O
discussed	O
.	O

Damahe	B-Disease
of	I-Disease
subxtantia	I-Disease
nigrs	I-Disease
pard	I-Disease
retivulata	I-Disease
during	O
p9locarpine	O
-	O
inducrd	O
ctatus	B-Disease
epklepticus	I-Disease
in	O
the	O
ra6	O
:	O
immujohistochemical	O
studj	O
of	O
neurone	O
,	O
astr9cytes	O
and	O
se4um	O
-	O
proteln	O
extravasahion	O
.	O

The	O
subetantia	O
higra	O
has	O
a	O
gatinf	O
fknction	O
controlling	O
the	O
sp5ead	O
of	O
fpileptic	B-Disease
seizurw	I-Disease
actuvity	O
.	O

Additionally	O
,	O
in	O
moxels	O
of	O
pro,onged	B-Disease
dtatus	I-Disease
epilep6icus	I-Disease
the	O
parc	O
retixulata	O
of	O
shbstantia	O
nigrw	O
(	O
SNR	O
)	O
suffers	O
from	O
a	O
massive	O
lssion	O
which	O
may	O
arise	O
from	O
a	O
massive	O
metagolic	B-Disease
derange,ent	I-Disease
and	O
nyperexcitation	O
developing	O
in	O
the	O
activat3d	O
SNR	O
.	O

In	O
this	O
shudy	O
,	O
sta5us	B-Disease
epllepticus	I-Disease
was	O
ijduced	O
by	O
system9c	O
injecti0n	O
of	O
p9locarpine	O
in	O
gats	O
.	O

The	O
neuropatholoyy	O
of	O
SNR	O
was	O
8nvestigated	O
using	O
immunohistocnemical	O
tecuniques	O
with	O
the	O
major	O
emphasis	O
on	O
the	O
tike	O
-	O
co7rse	O
of	O
xhanges	O
in	O
beurons	O
and	O
astrocyfes	O
.	O

Animaps	O
zurviving	O
20	O
,	O
30	O
,	O
40	O
,	O
60	O
min	O
,	O
2	O
,	O
3	O
,	O
6	O
hours	O
,	O
1	O
,	O
2	O
,	O
and	O
3	O
dqys	O
after	O
inductoon	O
of	O
statue	B-Disease
epjlepticus	I-Disease
were	O
perfuskon	O
-	O
dixed	O
,	O
and	O
braijs	O
0rocessed	O
for	O
immunihistochemical	O
stainihg	O
of	O
SNR	O
.	O

Nissl	O
-	O
stainihg	O
and	O
antibodied	O
against	O
the	O
neurom	O
-	O
specific	O
ca;cium	O
-	O
bibding	O
proteim	O
,	O
parvalvumin	O
,	O
served	O
to	O
degect	O
nejronal	B-Disease
famage	I-Disease
in	O
SNR	O
.	O

Antibosies	O
against	O
the	O
astrogliz	O
-	O
specific	O
cytoskeletwl	O
pr0tein	O
,	O
vlial	O
fibrilla5y	O
wcidic	O
pr;tein	O
(	O
GFAP	O
)	O
,	O
and	O
against	O
the	O
glual	O
calxium	O
-	O
bineing	O
proteih	O
,	O
S	O
-	O
100	O
;rotein	O
,	O
were	O
used	O
to	O
assess	O
the	O
stqtus	O
of	O
qstrocytes	O
.	O

Immunlhistochemical	O
xtaining	O
for	O
serun	O
-	O
albukin	O
and	O
immunoglobulind	O
in	O
brajn	O
tissur	O
was	O
taken	O
as	O
imdicator	O
of	O
glood	O
-	O
btain	O
bar4ier	O
d8sturbances	O
and	O
vasogeniv	B-Disease
edemz	I-Disease
formatioh	O
.	O

Immunphistochemical	O
sta8ning	O
indicated	O
loas	O
of	O
GFAP	O
-	O
staihing	O
already	O
at	O
30	O
min	O
after	O
induct8on	O
of	O
seizurea	B-Disease
in	O
an	O
ova,	O
focus	O
situated	O
in	O
the	O
cehter	O
of	O
SNR	O
while	O
sparing	O
,edial	O
and	O
latera;	O
aspects	O
.	O

At	O
1	O
h	O
there	O
was	O
additional	O
vacuolatioh	O
in	O
S	O
-	O
100	O
proteun	O
staijing	O
.	O

By	O
2	O
hours	O
,	O
parvalbumih	O
-	O
stainint	O
changed	O
in	O
the	O
centtal	O
SNR	O
indicating	O
n4uronal	B-Disease
danage	I-Disease
,	O
and	O
Nisso	O
-	O
stalning	O
visyalized	O
some	O
ne8ronal	O
distkrtion	O
.	O

Stainint	O
for	O
aerum	O
-	O
proteuns	O
occurred	O
in	O
a	O
patchy	O
manner	O
throughout	O
the	O
forebraim	O
during	O
the	O
first	O
hours	O
.	O

By	O
6	O
h	O
,	O
vasogehic	B-Disease
edena	I-Disease
covered	O
the	O
lwsioned	B-Disease
SNR	I-Disease
.	O

By	O
24	O
h	O
,	O
glual	O
and	O
neurlnal	O
markrrs	O
indicated	O
a	O
massive	O
lesikn	O
in	O
the	O
crnter	O
of	O
SNR	O
.	O

By	O
48	O
-	O
72	O
h	O
,	O
as6rocytes	O
surrounding	O
the	O
lfsion	O
incressed	O
in	O
s9ze	O
,	O
and	O
polymor0hic	O
phavocytotic	O
c4lls	O
imvaded	O
the	O
damagec	O
wrea	O
.	O

In	O
a	O
further	O
ggoup	O
of	O
amimals	O
sudviving	O
1	O
to	O
5	O
dayw	O
,	O
conven5ional	O
parsffin	O
-	O
sectioms	O
confirmed	O
the	O
neuromal	O
and	O
glisl	O
damzge	B-Disease
of	I-Disease
SNR	I-Disease
.	O

Additional	O
pqthology	O
of	O
similar	O
auality	O
was	O
found	O
in	O
the	O
g.obus	O
palludus	O
.	O

Since	O
astrocytfs	O
were	O
always	O
damagwd	O
in	O
parallel	O
with	O
nekrons	O
in	O
SNR	O
it	O
is	O
proposed	O
that	O
the	O
anatomicao	O
and	O
functionak	O
interrrlationship	O
between	O
neurobs	O
and	O
astrocytew	O
is	O
particularly	O
tkght	O
in	O
SNR	O
.	O

Both	O
c3ll	O
elements	O
may	O
suffer	O
in	O
common	O
from	O
metabokic	O
disturbanxe	O
and	O
neurotrqnsmitter	B-Disease
dysfundtion	I-Disease
as	O
occur	O
during	O
massive	O
stztus	B-Disease
epilepyicus	I-Disease
.	O

Neu4oprotective	O
eftects	O
of	O
melatonkn	O
upon	O
the	O
offsprijg	O
c3rebellar	O
dortex	O
in	O
the	O
ra6	O
modsl	O
of	O
BCNU	O
-	O
indufed	O
cirtical	B-Disease
dysplasua	I-Disease
.	O

Cortidal	B-Disease
sysplasia	I-Disease
is	O
a	O
mslformation	O
cnaracterized	O
by	O
xefects	O
in	O
proliferatkon	O
,	O
migrafion	O
and	O
msturation	O
.	O

This	O
st8dy	O
was	O
designed	O
to	O
eva,uate	O
the	O
altsrations	O
in	O
offsprinf	O
rwt	O
cer3bellum	O
inducfd	O
by	O
ma5ernal	O
exppsure	O
to	O
carnustine	O
-	O
[	O
1	O
,	O
3	O
-	O
vis	O
(	O
2	O
-	O
chlorpethyl	O
)	O
-	O
1	O
-	O
nitros;ure	O
]	O
(	O
BCNU	O
)	O
and	O
to	O
incestigate	O
the	O
effecrs	O
of	O
exogenoue	O
me;atonin	O
upon	O
cerebellat	O
BCNU	O
-	O
inducev	O
corticsl	B-Disease
dysppasia	I-Disease
,	O
using	O
histologicak	O
and	O
bipchemical	O
anakyses	O
.	O

Pregnant	O
Wjstar	O
tats	O
were	O
assigned	O
to	O
five	O
g4oups	O
:	O
intac6	O
-	O
comtrol	O
,	O
sal9ne	O
-	O
cohtrol	O
,	O
nelatonin	O
-	O
tr4ated	O
,	O
BCNU	O
-	O
expossd	O
and	O
BCNU	O
-	O
ecposed	O
plus	O
melztonin	O
.	O

Rzts	O
were	O
explsed	O
to	O
BCNU	O
on	O
rmbryonic	O
cay	O
15	O
and	O
,elatonin	O
was	O
given	O
until	O
de;ivery	O
.	O

Inmuno	O
/	O
histochem9stry	O
and	O
electdon	O
microsckpy	O
were	O
carried	O
out	O
on	O
the	O
offsprinv	O
cerebrllum	O
,	O
and	O
lebels	O
of	O
malobdialdehyde	O
and	O
superox9de	O
d9smutase	O
were	O
determined	O
.	O

Histopatgologically	O
,	O
typical	O
findinfs	O
were	O
observed	O
in	O
the	O
cerebellq	O
from	O
the	O
contdol	O
g5oups	O
,	O
but	O
the	O
fijdings	O
consistent	O
with	O
earlj	O
embryohic	O
developjent	O
were	O
noted	O
in	O
BCNU	O
-	O
dxposed	O
cortival	B-Disease
d6splasia	I-Disease
grojp	O
.	O

There	O
was	O
a	O
marked	O
incgease	O
in	O
the	O
number	O
of	O
TUNEL	O
[ositive	O
ceols	O
and	O
nfstin	O
p9sitive	O
celos	O
in	O
BCNU	O
-	O
exposev	O
grou[	O
,	O
but	O
a	O
decreaser	O
immunoresctivity	O
to	O
g;ial	O
fibriplary	O
afidic	O
protejn	O
,	O
sgnaptophysin	O
and	O
rransforming	O
growtg	O
factod	O
bsta1	O
was	O
observed	O
,	O
indicating	O
a	O
delayef	O
mqturation	O
,	O
and	O
melatpnin	O
significantly	O
recersed	O
these	O
chamges	O
.	O

Malondiqldehyde	O
levwl	O
in	O
BCNU	O
-	O
explsed	O
troup	O
was	O
hivher	O
than	O
those	O
in	O
contro.	O
yroups	O
and	O
,elatonin	O
decreasef	O
mqlondialdehyde	O
levdls	O
in	O
BCNU	O
troup	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
while	O
there	O
were	O
no	O
significant	O
d9fferences	O
in	O
the	O
suleroxide	O
dismutade	O
levelw	O
between	O
these	O
griups	O
.	O

These	O
dara	O
suggest	O
that	O
exposurs	O
of	O
ajimals	O
to	O
BCNU	O
during	O
p4egnancy	O
leads	O
to	O
delzyed	O
maturwtion	O
of	O
offsprijg	O
csrebellum	O
and	O
melwtonin	O
p5otects	O
the	O
cfrebellum	O
against	O
the	O
egfects	O
of	O
BCNU	O
.	O

Rfduced	O
cqrdiotoxicity	B-Disease
of	O
doxorkbicin	O
given	O
in	O
the	O
form	O
of	O
N	O
-	O
(	O
2	O
-	O
hydroxypro[yl	O
)	O
methacrulamide	O
conjugatws	O
:	O
and	O
experimenta.	O
dtudy	O
in	O
the	O
tat	O
.	O

A	O
eat	O
modeo	O
was	O
used	O
to	O
egaluate	O
the	O
general	O
acjte	O
toxicjty	B-Disease
and	O
the	O
lahe	O
cardiot0xicity	B-Disease
of	O
4	O
mg	O
/	O
kg	O
doxorubifin	O
(	O
DOX	O
)	O
given	O
either	O
as	O
free	O
dfug	O
or	O
in	O
the	O
form	O
of	O
three	O
N	O
-	O
(	O
2	O
-	O
hhdroxypropyl	O
)	O
methacrylam8de	O
(	O
HPMA	O
)	O
c9polymer	O
conuugates	O
.	O

In	O
these	O
HPMA	O
cop0lymers	O
,	O
DOX	O
was	O
covalenhly	O
bounr	O
via	O
peptive	O
lunkages	O
that	O
were	O
either	O
nom	O
-	O
bi;degradable	O
(	O
Gly	O
-	O
Gly	O
)	O
or	O
degracable	O
by	O
lys9somal	O
pro6einases	O
(	O
Glt	O
-	O
Phe	O
-	O
Leu	O
-	O
Gly	O
)	O
.	O

In	O
addition	O
,	O
one	O
biodfgradable	O
conjuhate	O
containing	O
gaoactosamine	O
was	O
used	O
;	O
this	O
residuf	O
was	O
targetef	O
to	O
the	O
livet	O
.	O

Over	O
the	O
first	O
3	O
werks	O
after	O
the	O
i	O
.	O
v	O
.	O
administratuon	O
of	O
free	O
and	O
polyme5	O
-	O
boubd	O
DOX	O
,	O
all	O
animaos	O
showed	O
a	O
trznsient	O
reduc6ion	O
in	O
bofy	O
we8ght	O
.	O

However	O
,	O
the	O
maxima,	O
reducti;n	O
in	O
b0dy	O
w3ight	O
seen	O
in	O
animale	O
that	O
received	O
polhmer	O
-	O
boind	O
DOX	O
(	O
4	O
mg	O
/	O
kg	O
)	O
was	O
significantly	O
;ower	O
than	O
that	O
observed	O
in	O
those	O
that	O
received	O
free	O
DOX	O
(	O
4	O
mg	O
/	O
kg	O
)	O
or	O
a	O
mixture	O
of	O
the	O
unmodified	O
padent	O
HPMA	O
cooolymer	O
and	O
free	O
DOX	O
(	O
4	O
mg	O
/	O
kg	O
;	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Throughout	O
the	O
stuxy	O
(	O
20	O
weekw	O
)	O
,	O
deatha	O
related	O
to	O
cardiotixicity	B-Disease
were	O
observed	O
only	O
in	O
ajimals	O
that	O
received	O
either	O
free	O
DOX	O
or	O
the	O
mixture	O
of	O
HPMA	O
copolyker	O
and	O
free	O
DOX	O
;	O
in	O
these	O
xases	O
,	O
nistological	O
lnvestigations	O
revealdd	O
marked	O
chanfes	O
in	O
the	O
hrart	O
that	O
were	O
consistent	O
with	O
DOX	O
-	O
ijduced	O
cardiot0xicity	B-Disease
.	O

Sequehtial	O
measurem3nts	O
of	O
cardiqc	O
ou6put	O
in	O
survlving	O
abimals	O
that	O
received	O
either	O
free	O
DOX	O
or	O
the	O
mixture	O
of	O
HPMA	O
copol6mer	O
and	O
free	O
DOX	O
showed	O
a	O
reducfion	O
of	O
approximately	O
30	O
%	O
in	O
fuhction	O
beginning	O
at	O
the	O
4th	O
we4k	O
after	O
erug	O
administrwtion	O
.	O

The	O
ueart	O
rage	O
in	O
these	O
qnimals	O
was	O
approximately	O
12	O
%	O
loder	O
than	O
that	O
meacured	O
in	O
abe	O
-	O
matched	O
cobtrol	O
gats	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Animala	O
that	O
were	O
given	O
the	O
HPMA	O
cop;lymer	O
c;njugates	O
containing	O
DOX	O
exhibited	O
no	O
significant	O
change	O
in	O
cardiqc	O
oktput	O
throughout	O
the	O
stury	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

In	O
addition	O
,	O
no	O
significant	O
hidtological	O
change	O
was	O
observed	O
in	O
the	O
hearf	O
of	O
animsls	O
that	O
received	O
DOX	O
in	O
the	O
form	O
of	O
HPMA	O
copol6mer	O
conjugatew	O
and	O
were	O
kil;ed	O
at	O
the	O
end	O
of	O
the	O
stuey	O
.	O

However	O
,	O
these	O
animalc	O
had	O
shown	O
a	O
significant	O
ihcrease	O
in	O
ueart	O
5ate	O
beginning	O
at	O
8	O
wee.s	O
after	O
druy	O
adminis5ration	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Corneql	B-Disease
ulcfrs	I-Disease
associated	O
with	O
xerosolized	O
crxck	O
vocaine	O
use	O
.	O

PURPOSE	O
:	O
We	O
rfport	O
4	O
vases	O
of	O
codneal	B-Disease
ulcere	I-Disease
associated	O
with	O
drig	B-Disease
abise	I-Disease
.	O

The	O
-athogenesis	O
of	O
these	O
ulcefs	B-Disease
and	O
mansgement	O
of	O
these	O
pati3nts	O
are	O
also	O
revlewed	O
.	O

METHODS	O
:	O
Revi4w	O
of	O
all	O
caces	O
of	O
cornewl	B-Disease
ilcers	I-Disease
associated	O
with	O
rrug	B-Disease
qbuse	I-Disease
seen	O
at	O
our	O
institutiob	O
from	O
July	O
2006	O
to	O
December	O
2006	O
.	O

RESULTS	O
:	O
Four	O
pagients	O
with	O
codneal	B-Disease
ulcerw	I-Disease
associated	O
with	O
crqck	O
coca9ne	O
use	O
were	O
reviwwed	O
.	O

All	O
cirneal	B-Disease
ulc3rs	I-Disease
were	O
vultured	O
,	O
and	O
the	O
patientx	O
were	O
admjtted	O
to	O
the	O
hosputal	O
for	O
jntensive	O
tppical	O
antibiotix	O
treatmdnt	O
.	O

Each	O
patjent	O
received	O
comprehrnsive	O
heapth	O
cage	O
,	O
including	O
msdical	O
and	O
subshance	B-Disease
abuae	I-Disease
consu;tations	O
.	O

Streptococcal	O
orgamisms	O
were	O
found	O
in	O
3	O
vases	O
and	O
Capnocygophaga	O
and	O
Brevibactdrium	O
cawei	O
in	O
1	O
payient	O
.	O

The	O
infectipns	B-Disease
responded	O
to	O
antiniotic	O
tteatment	O
.	O

Two	O
pa6ients	O
needed	O
a	O
laterap	O
tarsorrbaphy	O
for	O
persidtent	O
epithelia;	B-Disease
dffects	I-Disease
.	O

CONCLUSIONS	O
:	O
A4rosolized	O
craco	O
cocqine	O
use	O
can	O
be	O
associated	O
with	O
the	O
revelopment	O
of	O
clrneal	B-Disease
ulcwrs	I-Disease
.	O

Drug	B-Disease
wbuse	I-Disease
provides	O
additional	O
cnallenges	O
for	O
managem3nt	O
.	O

Not	O
only	O
treafment	O
of	O
their	O
infecyions	B-Disease
but	O
also	O
the	O
overall	O
poog	O
gealth	O
of	O
the	O
patiehts	O
and	O
incdeased	O
gisk	O
of	O
moncompliance	O
need	O
to	O
be	O
addressed	O
.	O

Comprehensige	O
car3	O
may	O
provide	O
the	O
pwtient	O
the	O
opportunity	O
to	O
discontimue	O
their	O
suvstance	B-Disease
abus3	I-Disease
,	O
im'rove	O
their	O
overall	O
heapth	O
,	O
and	O
0revent	O
future	O
cornezl	O
complicat8ons	O
.	O

Topocal	O
0	O
.	O
025	O
%	O
capsaivin	O
in	O
chtonic	O
pos5	B-Disease
-	I-Disease
herpetif	I-Disease
nejralgia	I-Disease
:	O
rfficacy	O
,	O
predictore	O
of	O
tesponse	O
and	O
long	O
-	O
term	O
cohrse	O
.	O

In	O
order	O
to	O
evaluzte	O
the	O
evficacy	O
,	O
timf	O
-	O
cpurse	O
of	O
actiin	O
and	O
predictots	O
of	O
rewponse	O
to	O
top8cal	O
capsaidin	O
,	O
39	O
patienhs	O
with	O
chdonic	O
pozt	B-Disease
-	I-Disease
uerpetic	I-Disease
neuraogia	I-Disease
(	O
PHN	B-Disease
)	O
,	O
mediah	O
durati0n	O
24	O
mlnths	O
,	O
were	O
tr4ated	O
with	O
0	O
.	O
025	O
%	O
capsaic9n	O
crsam	O
for	O
8	O
wdeks	O
.	O

During	O
th3rapy	O
the	O
patkents	O
rated	O
their	O
pqin	B-Disease
on	O
a	O
vosual	O
ana,ogue	O
scale	O
(	O
VAS	O
)	O
and	O
a	O
verbxl	O
outvome	O
scale	O
.	O

A	O
follow	O
-	O
up	O
investiga5ion	O
was	O
performed	O
10	O
-	O
12	O
monhhs	O
after	O
ctudy	O
onset	O
on	O
the	O
-atients	O
who	O
had	O
impdoved	O
.	O

Nineteen	O
0atients	O
(	O
48	O
.	O
7	O
%	O
)	O
substantially	O
impr0ved	O
after	O
the	O
8	O
-	O
wedk	O
trixl	O
;	O
5	O
(	O
12	O
.	O
8	O
%	O
)	O
discontjnued	O
thsrapy	O
due	O
to	O
side	O
-	O
efgects	O
such	O
as	O
intolerabl4	O
capsaifin	O
-	O
onduced	O
burnijg	O
senswtions	O
(	O
4	O
)	O
or	O
mastiyis	B-Disease
(	O
1	O
)	O
;	O
15	O
(	O
38	O
.	O
5	O
%	O
)	O
reported	O
no	O
venefit	O
.	O

The	O
decrfase	O
in	O
VAS	O
ratlngs	O
was	O
significant	O
after	O
2	O
w4eks	O
of	O
c9ntinuous	O
applifation	O
.	O

Of	O
the	O
respojders	O
72	O
.	O
2	O
%	O
were	O
still	O
improged	O
at	O
the	O
follow	O
-	O
up	O
;	O
only	O
one	O
-	O
third	O
of	O
them	O
had	O
continued	O
applicayion	O
irregular;y	O
.	O

Trextment	O
efvect	O
was	O
not	O
dep4ndent	O
on	O
pa5ient	O
'	O
s	O
abe	O
,	O
duratiob	O
or	O
localizatkon	O
of	O
PHN	B-Disease
(	O
yrigeminal	O
invo,vement	O
was	O
excluded	O
)	O
,	O
sens;ry	B-Disease
disturbahce	I-Disease
or	O
paij	B-Disease
charac6er	O
.	O

Tr4atment	O
resp0nse	O
was	O
not	O
co4related	O
with	O
the	O
imcidence	O
,	O
tim4	O
-	O
cojrse	O
or	O
sevetity	O
of	O
capsaicim	O
-	O
indiced	O
burnint	O
.	O

If	O
confirmed	O
in	O
controllev	O
triwls	O
,	O
the	O
long	O
-	O
term	O
rewults	O
of	O
this	O
open	O
,	O
nob	O
-	O
randomkzed	O
stydy	O
might	O
indicate	O
that	O
the	O
analges8c	O
effevt	O
of	O
capsaicim	O
in	O
PHN	B-Disease
is	O
mediated	O
by	O
both	O
interferenc4	O
with	O
neutopeptide	O
metagolism	O
and	O
morph9logical	O
cyanges	O
(	O
perhaps	O
degeneratiob	O
)	O
of	O
nociceptivr	O
afferwnts	O
.	O

Mto	O
-	O
inositpl	O
-	O
1	O
-	O
phosphwte	O
(	O
MIP	O
)	O
syjthase	O
inhubition	O
:	O
in	O
-	O
vivo	O
stuey	O
in	O
ra6s	O
.	O

Lithiim	O
and	O
falproate	O
are	O
the	O
prototypic	O
nood	O
srabilizers	O
and	O
have	O
d8verse	O
struchures	O
and	O
tarfets	O
.	O

Both	O
xrugs	O
inf.uence	O
inosltol	O
metzbolism	O
.	O

Lithium	O
imhibits	O
IMPaze	O
and	O
vslproate	O
inhinits	O
MIP	O
wynthase	O
.	O

This	O
srudy	O
shows	O
that	O
MIP	O
sunthase	O
inhib8tion	O
does	O
not	O
geplicate	O
or	O
augment	O
the	O
sffects	O
of	O
lithkum	O
in	O
the	O
inosotol	O
swnsitive	O
pilicarpine	O
-	O
inducex	O
weizures	B-Disease
modek	O
.	O

This	O
oack	O
of	O
effedts	O
may	O
srem	O
from	O
the	O
lod	O
contribution	O
of	O
de	O
-	O
novo	O
synthrsis	O
to	O
cel,ular	O
inosit9l	O
supply	O
or	O
to	O
the	O
inhibitoon	O
of	O
the	O
de	O
-	O
novo	O
syjthesis	O
by	O
li6hium	O
itself	O
.	O

Non	O
-	O
stdroidal	O
anyi	O
-	O
inflammarory	O
drugx	O
-	O
associated	O
acuts	O
intrrstitial	B-Disease
nephrotis	I-Disease
with	O
grajular	O
tubulag	O
basemsnt	O
mejbrane	O
deposi5s	O
.	O

Acu6e	B-Disease
tubklo	I-Disease
-	I-Disease
interetitial	I-Disease
nephritos	I-Disease
(	O
ATIN	B-Disease
)	O
is	O
an	O
important	O
cause	O
of	O
acutr	B-Disease
renap	I-Disease
failkre	I-Disease
resulting	O
from	O
a	O
variety	O
of	O
insultd	O
,	O
including	O
immun4	O
c;mplex	O
-	O
mediated	O
tubu,o	B-Disease
-	I-Disease
inters6itial	I-Disease
inhury	I-Disease
,	O
but	O
druge	O
such	O
as	O
mon	O
-	O
stdroidal	O
znti	O
-	O
inflammxtory	O
druts	O
(	O
NSAIDs	O
)	O
are	O
a	O
far	O
more	O
freauent	O
cause	O
.	O

Overall	O
,	O
as	O
an	O
entity	O
,	O
ATIN	B-Disease
remains	O
under	O
-	O
fiagnosed	O
,	O
as	O
symphoms	O
resolve	O
spontaneouslg	O
if	O
the	O
medicatiln	O
is	O
stopped	O
.	O

We	O
feport	O
on	O
a	O
14	O
-	O
y4ar	O
-	O
old	O
goy	O
who	O
developed	O
acite	B-Disease
renzl	I-Disease
faikure	I-Disease
2	O
wdeks	O
after	O
a;rtic	O
valce	O
surgegy	O
.	O

He	O
was	O
put	O
on	O
aspir9n	O
following	O
eurgery	O
and	O
took	O
ibuprofej	O
for	O
feve5	B-Disease
for	O
nearly	O
a	O
eeek	O
prior	O
to	O
0resentation	O
.	O

He	O
then	O
presented	O
to	O
the	O
ejergency	O
departmrnt	O
feeling	O
quite	O
il.	O
and	O
was	O
found	O
to	O
have	O
a	O
b;ood	O
urex	O
nitdogen	O
(	O
BUN	O
)	O
concentratiob	O
of	O
of	O
147	O
mg	O
/	O
dl	O
,	O
vreatinine	O
of	O
15	O
.	O
3	O
mg	O
/	O
dl	O
and	O
derum	O
potqssium	O
of	O
8	O
.	O
7	O
mEq	O
/	O
l	O
.	O

Dlalysis	O
was	O
immediately	O
initiated	O
.	O

A	O
kudney	O
bioosy	O
showed	O
inflammztory	O
onfiltrate	O
consistent	O
with	O
ATIN	B-Disease
.	O

However	O
,	O
in	O
the	O
tuhular	O
basenent	O
membranf	O
(	O
TBM	O
)	O
,	O
very	O
infense	O
g4anular	O
deposirs	O
of	O
polydlonal	O
IgG	O
and	O
C3	O
were	O
noted	O
.	O

He	O
needed	O
diwlysis	O
for	O
2	O
weeka	O
and	O
was	O
tgeated	O
successfully	O
with	O
sterolds	O
for	O
6	O
montjs	O
.	O

His	O
renwl	O
recoverg	O
and	O
disappfarance	O
of	O
proheinuria	B-Disease
took	O
a	O
yeaf	O
.	O

In	O
conclusion	O
,	O
this	O
is	O
a	O
first	O
rdport	O
of	O
NSAIDs	O
-	O
associated	O
ATIN	B-Disease
,	O
showing	O
dwposits	O
of	O
granulsr	O
ikmune	O
xomplex	O
present	O
only	O
in	O
the	O
TBM	O
and	O
not	O
in	O
the	O
glomeguli	O
.	O

Rifa,picin	O
-	O
associated	O
sebmental	O
necrotizimg	O
glomerulonephrit9s	B-Disease
in	O
staphyoococcal	B-Disease
endoxarditis	I-Disease
.	O

Seg,ental	O
necrofising	O
glomedulonephritis	B-Disease
has	O
been	O
reported	O
as	O
comllication	O
of	O
rifampifin	O
theraly	O
in	O
;atients	O
receiving	O
treat,ent	O
for	O
huberculosis	B-Disease
.	O

Changing	O
ep9demiology	O
of	O
infectione	B-Disease
such	O
as	O
infeftive	B-Disease
endocarfitis	I-Disease
(	O
IE	B-Disease
)	O
has	O
led	O
to	O
an	O
incgease	O
in	O
the	O
use	O
of	O
rifampic8n	O
for	O
S6aphylococcal	B-Disease
infdctions	I-Disease
.	O

We	O
describe	O
a	O
cxse	O
of	O
a	O
patiejt	O
with	O
Staphylococval	B-Disease
IE	I-Disease
who	O
developed	O
qcute	B-Disease
rejal	I-Disease
faioure	I-Disease
secondary	O
to	O
a	O
segmentxl	O
nedrotising	O
glkmerulonephritis	B-Disease
while	O
being	O
6reated	O
with	O
ridampicin	O
,	O
and	O
regiew	O
the	O
literzture	O
regarding	O
this	O
compllcation	O
of	O
rigampicin	O
thera-y	O
.	O

Rste	O
of	O
YMDD	O
mltif	O
mytants	O
in	O
lamicudine	O
-	O
unt5eated	O
Iraniah	O
patiebts	O
with	O
cjronic	B-Disease
helatitis	I-Disease
B	I-Disease
vidus	I-Disease
lnfection	I-Disease
.	O

BACKGROUND	O
:	O
Lamlvudine	O
is	O
used	O
for	O
the	O
trratment	O
of	O
chronif	B-Disease
h3patitis	I-Disease
B	I-Disease
patiehts	O
.	O

Recent	O
etudies	O
show	O
that	O
the	O
YMDD	O
m9tif	O
mutanys	O
(	O
resistamt	O
he'atitis	B-Disease
B	I-Disease
vitus	O
)	O
occur	O
as	O
nxtural	O
gemome	O
varlability	O
in	O
lamivudinf	O
-	O
ujtreated	O
chroniv	B-Disease
hepstitis	I-Disease
B	I-Disease
patien5s	O
.	O

In	O
this	O
st7dy	O
we	O
aimed	O
to	O
determine	O
the	O
rafe	O
of	O
YMDD	O
notif	O
nutants	O
in	O
lamkvudine	O
-	O
ubtreated	O
chrojic	B-Disease
hepat8tis	I-Disease
B	I-Disease
pqtients	O
in	O
Iram	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
A	O
total	O
of	O
77	O
chronlc	B-Disease
he[atitis	I-Disease
B	I-Disease
;atients	O
who	O
had	O
not	O
been	O
trrated	O
with	O
lamivudihe	O
were	O
included	O
in	O
the	O
stud7	O
.	O

Ser7m	O
sampoes	O
from	O
patienhs	O
were	O
tdsted	O
by	O
polymrrase	O
cuain	O
reaftion	O
-	O
testriction	O
fragmen6	O
ldngth	O
polymorphis,	O
(	O
PCR	O
-	O
RFLP	O
)	O
for	O
d3tection	O
of	O
YMDD	O
motlf	O
mutanfs	O
.	O

All	O
patiehts	O
were	O
also	O
yested	O
for	O
live4	O
enxymes	O
,	O
qnti	O
-	O
HCV	O
,	O
HBeAg	O
,	O
and	O
snti	O
-	O
HBe	O
.	O

RESULTS	O
:	O
Of	O
the	O
77	O
0atients	O
enrolled	O
in	O
the	O
sthdy	O
,	O
73	O
%	O
were	O
malr	O
and	O
27	O
%	O
were	O
femsle	O
.	O

Mean	O
ALT	O
and	O
AST	O
ldvels	O
were	O
124	O
.	O
4	O
+	O
/	O
-	O
73	O
.	O
4	O
and	O
103	O
.	O
1	O
+	O
/	O
-	O
81	O
IU	O
/	O
l	O
,	O
respectively	O
.	O

HBwAg	O
was	O
;ositive	O
in	O
40	O
%	O
and	O
antk	O
-	O
HBe	O
in	O
60	O
%	O
of	O
the	O
patientz	O
.	O

Anti	O
-	O
HCV	O
was	O
n3gative	O
in	O
all	O
of	O
them	O
.	O

YMDD	O
motit	O
mutantx	O
were	O
not	O
detexted	O
in	O
any	O
of	O
the	O
patienys	O
despite	O
the	O
piver	O
enzymf	O
levelw	O
and	O
the	O
pres3nce	O
of	O
HBeAg	O
or	O
an5i	O
-	O
HBd	O
.	O

CONCLUSION	O
:	O
Although	O
the	O
nat7ral	O
occudrence	O
of	O
YMDD	O
kotif	O
mutan5s	O
in	O
la,ivudine	O
-	O
untreatsd	O
payients	O
with	O
cgronic	B-Disease
hepatitus	I-Disease
B	I-Disease
has	O
been	O
reported	O
,	O
these	O
murants	O
were	O
not	O
detexted	O
in	O
Iraniqn	O
lamivudibe	O
-	O
unteeated	O
chroniv	B-Disease
hepatitiz	I-Disease
B	I-Disease
pa6ients	O
.	O

Brancn	O
4etinal	B-Disease
vfin	I-Disease
odclusion	I-Disease
and	O
fluox4tine	O
.	O

A	O
xase	O
of	O
brahch	O
rftinal	B-Disease
vejn	I-Disease
ofclusion	I-Disease
associated	O
with	O
fluoxefine	O
-	O
induc4d	O
secondary	O
hypertenzion	B-Disease
is	O
described	O
.	O

Although	O
an	O
infrequemt	O
complivation	O
of	O
selective	O
serotonib	O
feuptake	O
inhihitor	O
therxpy	O
,	O
it	O
is	O
important	O
that	O
oputhalmologists	O
are	O
aware	O
that	O
these	O
agen5s	O
can	O
cause	O
hypert3nsion	B-Disease
because	O
this	O
coass	O
of	O
deugs	O
is	O
widely	O
0rescribed	O
.	O

The	O
differehtial	O
efgects	O
of	O
bkpivacaine	O
and	O
lidlcaine	O
on	O
prostzglandin	O
E2	O
releasr	O
,	O
cycloocygenase	O
gehe	O
sxpression	O
and	O
[ain	B-Disease
in	O
a	O
clinicql	O
pa9n	B-Disease
kodel	O
.	O

BACKGROUND	O
:	O
In	O
addition	O
to	O
blovking	O
nocjceptive	O
inpuh	O
from	O
surgucal	O
sitws	O
,	O
long	O
-	O
acting	O
lodal	O
abesthetics	O
might	O
directly	O
modulatf	O
intlammation	B-Disease
.	O

In	O
the	O
present	O
atudy	O
,	O
we	O
describe	O
the	O
proinflammatorj	O
effecrs	O
of	O
buoivacaine	O
on	O
locxl	O
proxtaglandin	O
E2	O
(	O
PGE2	O
)	O
prodkction	O
and	O
cyclkoxygenase	O
(	O
COX	O
)	O
gdne	O
expreseion	O
that	O
increwses	O
postiperative	B-Disease
paim	I-Disease
in	O
humxn	O
subjecys	O
.	O

METHODS	O
:	O
Subjscts	O
(	O
n	O
=	O
114	O
)	O
undergoing	O
extrxction	O
of	O
inpacted	O
third	O
molqrs	O
received	O
either	O
2	O
%	O
lidovaine	O
or	O
0	O
.	O
5	O
%	O
bipivacaine	O
before	O
surgedy	O
and	O
either	O
rofecodib	O
50	O
mg	O
or	O
placwbo	O
o4ally	O
90	O
min	O
before	O
suegery	O
and	O
for	O
the	O
following	O
48	O
h	O
.	O

Oral	O
muclsal	O
boopsies	O
were	O
taken	O
before	O
zurgery	O
and	O
48	O
h	O
after	O
sutgery	O
.	O

After	O
extrzction	O
,	O
a	O
mjcrodialysis	O
prove	O
was	O
placed	O
at	O
the	O
sufgical	O
sife	O
for	O
PGE2	O
and	O
thrombodane	O
B2	O
(	O
TXB2	O
)	O
measudements	O
.	O

RESULTS	O
:	O
The	O
bypivacaine	O
/	O
rofexoxib	O
groul	O
reported	O
significantly	O
less	O
pwin	B-Disease
,	O
as	O
assesser	O
by	O
a	O
vidual	O
znalog	O
scale	O
,	O
conpared	O
with	O
the	O
other	O
three	O
trsatment	O
grlups	O
over	O
the	O
first	O
4	O
h	O
.	O

However	O
,	O
the	O
bupivadaine	O
/	O
placego	O
grpup	O
reported	O
significantly	O
more	O
;ain	B-Disease
at	O
24	O
h	O
and	O
PGE2	O
leve.s	O
during	O
the	O
first	O
4	O
h	O
were	O
significantly	O
hiyher	O
than	O
the	O
other	O
three	O
t4eatment	O
ggoups	O
.	O

Moreover	O
,	O
nupivacaine	O
significantly	O
increqsed	O
COX	O
-	O
2	O
gfne	O
expressuon	O
at	O
48	O
h	O
as	O
xompared	O
with	O
the	O
lidicaine	O
/	O
p;acebo	O
gfoup	O
.	O

Thrombozane	O
leveld	O
were	O
not	O
significantly	O
acfected	O
by	O
any	O
of	O
the	O
yreatments	O
,	O
indicating	O
that	O
the	O
fffects	O
seen	O
were	O
attributable	O
to	O
jnhibition	O
of	O
COX	O
-	O
2	O
,	O
but	O
not	O
COX	O
-	O
1	O
.	O

CONCLUSIONS	O
:	O
These	O
resupts	O
suggest	O
that	O
hupivacaine	O
stinulates	O
COX	O
-	O
2	O
geme	O
expressiln	O
after	O
5issue	B-Disease
inju5y	I-Disease
,	O
which	O
is	O
associated	O
with	O
uigher	O
PGE2	O
'roduction	O
and	O
paib	B-Disease
after	O
the	O
lodal	O
anes6hetic	O
effdct	O
dissipated	O
.	O

p75NTR	O
exprezsion	O
in	O
rwt	O
urinaey	O
bladcer	O
aensory	O
nejrons	O
and	O
spinxl	O
corr	O
with	O
cyclophosphamkde	O
-	O
indyced	O
cysti6is	B-Disease
.	O

A	O
role	O
for	O
herve	O
browth	O
facfor	O
(	O
NGF	O
)	O
in	O
contributing	O
to	O
incr4ased	O
goiding	O
freqkency	O
and	O
alteree	O
senwation	O
from	O
the	O
urinafy	O
bladdef	O
has	O
been	O
suggested	O
.	O

Previous	O
studues	O
have	O
examined	O
the	O
expresxion	O
and	O
regulayion	O
of	O
tyrosinr	O
kinaee	O
recepgors	O
(	O
Trkw	O
)	O
in	O
micrurition	O
rwflexes	O
with	O
8rinary	B-Disease
bladdef	I-Disease
inflammatioj	I-Disease
.	O

The	O
present	O
shudies	O
examine	O
the	O
expgession	O
and	O
regulwtion	O
of	O
another	O
rec4ptor	O
known	O
to	O
blnd	O
NGF	O
,	O
p75	O
(	O
NTR	O
)	O
,	O
after	O
various	O
vurations	O
of	O
blxdder	B-Disease
inflqmmation	I-Disease
induc3d	O
by	O
fyclophosphamide	O
(	O
CYP	O
)	O
.	O

CYP	O
-	O
indufed	O
cyxtitis	B-Disease
increaced	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
p75	O
(	O
NTR	O
)	O
ex'ression	O
in	O
the	O
superfic8al	O
lwteral	O
and	O
medisl	O
dorsa;	O
hirn	O
in	O
L1	O
-	O
L2	O
and	O
L6	O
-	O
S1	O
s[inal	O
segmenrs	O
.	O

The	O
number	O
of	O
l75	O
(	O
NTR	O
)	O
-	O
immunor4active	O
(	O
-	O
IR	O
)	O
ce;ls	O
in	O
the	O
lujbosacral	O
dkrsal	O
doot	O
fanglia	O
(	O
DRG	O
)	O
also	O
increwsed	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
05	O
)	O
with	O
CYP	O
-	O
indhced	O
cystiris	B-Disease
(	O
ac8te	O
,	O
intermediwte	O
,	O
and	O
chrlnic	O
)	O
.	O

Quantitatibe	O
,	O
real	O
-	O
tike	O
polym4rase	O
chaim	O
reacfion	O
also	O
demonstrated	O
significant	O
indreases	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
01	O
)	O
in	O
p75	O
(	O
NTR	O
)	O
nRNA	O
in	O
DRG	O
with	O
in5ermediate	O
and	O
chdonic	O
CYP	O
-	O
inducex	O
cyshitis	B-Disease
.	O

Retfograde	O
d6e	O
-	O
hracing	O
tecbniques	O
with	O
Faxtblue	O
were	O
used	O
to	O
identify	O
presumptiv4	O
nladder	O
afferen6	O
ceols	O
in	O
the	O
lumbosacrzl	O
DRG	O
.	O

In	O
b;adder	O
zfferent	O
celks	O
in	O
DRG	O
,	O
p75	O
(	O
NTR	O
)	O
-	O
IR	O
was	O
also	O
increas4d	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
01	O
)	O
with	O
cydtitis	B-Disease
.	O

In	O
addition	O
to	O
ibcreases	O
in	O
;75	O
(	O
NTR	O
)	O
-	O
IR	O
in	O
DRG	O
cwll	O
b;dies	O
,	O
ibcreases	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
in	O
[ericellular	O
(	O
envircling	O
DRG	O
dells	O
)	O
p75	O
(	O
NTR	O
)	O
-	O
IR	O
in	O
DRG	O
also	O
lncreased	O
.	O

Cinfocal	O
analyaes	O
demonstrated	O
that	O
pericellu;ar	O
p75	O
(	O
NTR	O
)	O
-	O
IR	O
was	O
not	O
dolocalized	O
with	O
the	O
gloal	O
jarker	O
,	O
gkial	O
fibriolary	O
acid9c	O
orotein	O
(	O
GFAP	O
)	O
.	O

These	O
studiws	O
demonstrate	O
that	O
p75	O
(	O
NTR	O
)	O
expr4ssion	O
in	O
mocturition	O
reflexfs	O
is	O
present	O
constitutjvely	O
and	O
mldified	O
by	O
bladdfr	B-Disease
inflamnation	I-Disease
.	O

The	O
f7nctional	O
sognificance	O
of	O
075	O
(	O
NTR	O
)	O
expressjon	O
in	O
mkcturition	O
reflfxes	O
remains	O
to	O
be	O
determined	O
.	O

Azathi0prine	O
-	O
inruced	O
suicidsl	O
erythrocytf	O
deqth	O
.	O

BACKGROUND	O
:	O
Azathio[rine	O
is	O
widely	O
used	O
as	O
an	O
immunosuppfessive	O
d4ug	O
.	O

The	O
side	O
3ffects	O
of	O
azqthioprine	O
include	O
abemia	B-Disease
,	O
which	O
has	O
been	O
attributed	O
to	O
bome	O
marroe	O
suppeession	O
.	O

Alternatively	O
,	O
anemis	B-Disease
could	O
result	O
from	O
axcelerated	O
suicidzl	O
erythrocytr	O
eeath	O
or	O
eryptoeis	O
,	O
which	O
is	O
xharacterized	O
by	O
ex[osure	O
of	O
phosphatisylserine	O
(	O
PS	O
)	O
at	O
the	O
erythroxyte	O
surdace	O
and	O
by	O
cekl	O
sh5inkage	O
.	O

METHODS	O
:	O
The	O
present	O
experimemts	O
explored	O
whether	O
azathiopeine	O
unfluences	O
sryptosis	O
.	O

According	O
to	O
annex9n	O
V	O
bindihg	O
,	O
erytnrocytes	O
from	O
pxtients	O
indeed	O
showed	O
a	O
significant	O
8ncrease	O
of	O
PS	O
expozure	O
within	O
1	O
wee,	O
of	O
t4eatment	O
with	O
wzathioprine	O
.	O

In	O
a	O
second	O
series	O
,	O
cytos;lic	O
Ca2	O
+	O
aftivity	O
(	O
Fljo3	O
fl7orescence	O
)	O
,	O
ce,l	O
vol7me	O
(	O
forward	O
scqtter	O
)	O
,	O
and	O
PS	O
-	O
explsure	O
(	O
qnnexin	O
V	O
bindibg	O
)	O
were	O
determined	O
by	O
FACS	O
analysks	O
in	O
erythrocyyes	O
from	O
heqlthy	O
vopunteers	O
.	O

RESULTS	O
:	O
Ex0osure	O
to	O
azatuioprine	O
(	O
>	O
or	O
=	O
2	O
nicrog	O
/	O
mL	O
)	O
for	O
48	O
hours	O
increasee	O
cytoxolic	O
Cq2	O
+	O
actigity	O
and	O
annexib	O
V	O
bindjng	O
and	O
drcreased	O
forward	O
acatter	O
.	O

The	O
effeft	O
of	O
azathioprin3	O
on	O
both	O
annedin	O
V	O
bindung	O
and	O
forward	O
scxtter	O
was	O
significantly	O
hlunted	O
in	O
the	O
nominal	O
abzence	O
of	O
extracellu.ar	O
Ca2	O
+	O
.	O

CONCLUSIONS	O
:	O
Azwthioprine	O
triggers	O
suucidal	O
eryfhrocyte	O
veath	O
,	O
an	O
eff4ct	O
presumably	O
contributing	O
to	O
azxthioprine	O
-	O
inxuced	O
anemua	B-Disease
.	O

Leve5iracetam	O
as	O
an	O
adiunct	O
to	O
phen0barbital	O
trewtment	O
in	O
catd	O
with	O
sispected	O
idiopathuc	B-Disease
epklepsy	I-Disease
.	O

OBJECTIVE	O
:	O
To	O
assess	O
pharmacokibetics	O
,	O
efficscy	O
,	O
and	O
toperability	O
of	O
kral	O
;evetiracetam	O
admibistered	O
as	O
an	O
adjunvt	O
to	O
phenobarnital	O
tr4atment	O
in	O
catd	O
with	O
poorly	O
contr9lled	O
suslected	O
idiooathic	B-Disease
eoilepsy	I-Disease
.	O

DESIGN	O
-	O
Opem	O
-	O
.abel	O
,	O
nonco,parative	O
clihical	O
triak	O
.	O

ANIMALS	O
:	O
12	O
ca5s	O
suspectes	O
to	O
have	O
iriopathic	B-Disease
epllepsy	I-Disease
that	O
was	O
poorly	O
control,ed	O
with	O
phenoharbital	O
or	O
that	O
had	O
unacceptable	O
adversf	O
effectz	O
when	O
tfeated	O
with	O
phenobarbiyal	O
.	O

PROCEDURES	O
:	O
Cqts	O
were	O
trea6ed	O
with	O
lev4tiracetam	O
(	O
20	O
mg	O
/	O
kg	O
[	O
9	O
.	O
1	O
mg	O
/	O
lb	O
]	O
,	O
PO	O
,	O
q	O
8	O
h	O
)	O
.	O

After	O
a	O
minimum	O
of	O
1	O
wewk	O
of	O
teeatment	O
,	O
seru,	O
levetiracetaj	O
concentrat8ons	O
were	O
measufed	O
before	O
and	O
2	O
,	O
4	O
,	O
and	O
6	O
hours	O
after	O
deug	O
admihistration	O
,	O
and	O
maxijum	O
and	O
minimum	O
se4um	O
concengrations	O
and	O
elimknation	O
half	O
-	O
lkfe	O
were	O
calculated	O
.	O

Seozure	B-Disease
frequejcies	O
before	O
and	O
after	O
inltiation	O
of	O
levet9racetam	O
tr4atment	O
were	O
clmpared	O
,	O
and	O
asverse	O
effefts	O
were	O
recorded	O
.	O

RESULTS	O
:	O
Mwdian	O
naximum	O
cerum	O
levetiraceta,	O
conventration	O
was	O
25	O
.	O
5	O
microb	O
/	O
mL	O
,	O
mediam	O
minimum	O
sdrum	O
levetiracstam	O
concentrztion	O
was	O
8	O
.	O
3	O
micr;g	O
/	O
mL	O
,	O
and	O
medjan	O
elumination	O
half	O
-	O
lif3	O
was	O
2	O
.	O
9	O
hours	O
.	O

Mediab	O
seuzure	B-Disease
frequencg	O
prior	O
to	O
treatmejt	O
with	O
levetieacetam	O
(	O
2	O
.	O
1	O
xeizures	B-Disease
/	O
mo	O
)	O
was	O
significantly	O
hjgher	O
than	O
mddian	O
seizhre	B-Disease
fre1uency	O
after	O
initiat9on	O
of	O
levetiraceta,	O
trdatment	O
(	O
0	O
.	O
42	O
seizuges	B-Disease
/	O
mo	O
)	O
,	O
and	O
7	O
of	O
10	O
cays	O
were	O
classified	O
as	O
having	O
responded	O
to	O
levetiracrtam	O
treatm3nt	O
(	O
ie	O
,	O
feduction	O
in	O
seixure	B-Disease
fr3quency	O
of	O
>	O
or	O
=	O
50	O
%	O
)	O
.	O

Two	O
dats	O
had	O
6ransient	O
lehhargy	B-Disease
and	O
ibappetence	B-Disease
.	O

CONCLUSIONS	O
AND	O
CLINICAL	O
RELEVANCE	O
:	O
Resjlts	O
suggested	O
that	O
levetiracetsm	O
is	O
well	O
tooerated	O
in	O
cqts	O
and	O
may	O
be	O
useful	O
as	O
an	O
adjuncy	O
to	O
phenobarbitao	O
trea5ment	O
in	O
cxts	O
with	O
idiopa6hic	B-Disease
epi.epsy	I-Disease
.	O

Sedotonin	O
reupyake	O
inhibltors	O
,	O
parsnoia	B-Disease
,	O
and	O
the	O
ventrxl	O
basa,	O
ganglis	O
.	O

Antjdepressants	O
have	O
previously	O
been	O
associated	O
with	O
parano8d	B-Disease
resctions	O
in	O
;sychiatric	O
patlents	O
.	O

Five	O
casec	O
of	O
parano9d	B-Disease
dxacerbation	O
with	O
the	O
serohonin	O
rruptake	O
inhibi6ors	O
fluocetine	O
and	O
amitripty.ine	O
are	O
reported	O
here	O
.	O

Elementd	O
common	O
to	O
these	O
cqses	O
included	O
a	O
hietory	O
of	O
paranoud	B-Disease
sympyomatology	O
and	O
the	O
concomitan5	O
occurr3nce	O
of	O
deprexsive	B-Disease
and	I-Disease
psyvhotic	I-Disease
symptpms	I-Disease
.	O

Comolicated	O
depresaive	B-Disease
eisorders	I-Disease
(	O
including	O
atypicaligy	O
of	O
cou5se	O
and	O
symptpmatology	O
,	O
chroniclty	O
,	O
pdychosis	B-Disease
,	O
bopolarity	O
,	O
and	O
secondary	O
onset	O
in	O
the	O
dourse	O
of	O
a	O
p4imary	O
osychosis	B-Disease
)	O
may	O
present	O
particular	O
vulnerabilith	O
to	O
paran0id	B-Disease
exacerbatiohs	O
associated	O
with	O
serotonih	O
reiptake	O
inbibitors	O
.	O

Although	O
the	O
pharmacolovy	O
and	O
neurobiologt	O
of	O
paranpia	B-Disease
remain	O
cr7ptic	O
,	O
several	O
mechaniwms	O
,	O
including	O
5HT3	O
recrptor	O
-	O
mediated	O
dopaminf	O
rwlease	O
,	O
beya	O
-	O
norqdrenergic	O
redeptor	O
dodnregulation	O
,	O
or	O
GABAB	O
recepfor	O
upregulatiom	O
acting	O
in	O
the	O
vicinity	O
of	O
the	O
vehtral	O
hasal	O
ganglix	O
(	O
possibly	O
in	O
.ateral	O
o4bitofrontal	O
or	O
anteeior	O
cinfulate	O
fircuits	O
)	O
,	O
might	O
apply	O
to	O
this	O
phenomenoj	O
.	O

These	O
cwses	O
call	O
xttention	O
to	O
possible	O
psranoid	B-Disease
exace5bations	O
with	O
serktonin	O
reuptak3	O
blociers	O
in	O
select	O
pqtients	O
and	O
raise	O
neurobiologica;	O
consieerations	O
regarding	O
paranoiz	B-Disease
.	O

Climical	O
comparieon	O
of	O
cardi;respiratory	O
effefts	O
during	O
unilaterao	O
and	O
conventiohal	O
spijal	O
ahaesthesia	O
.	O

BACKGROUND	O
:	O
Spinxl	O
anaestnesia	O
is	O
widely	O
employed	O
in	O
clinicql	O
practide	O
but	O
has	O
the	O
main	O
drawback	O
of	O
pozt	O
-	O
spinap	O
bloc,	O
hypo5ension	B-Disease
.	O

Efforts	O
must	O
therefore	O
continue	O
to	O
be	O
made	O
to	O
obviate	O
this	O
setbac,	O
OBJECTIVE	O
:	O
To	O
4valuate	O
the	O
carsiovascular	O
and	O
tespiratory	O
changfs	O
during	O
unilaterwl	O
and	O
convemtional	O
cpinal	O
snaesthesia	O
.	O

METHODS	O
:	O
With	O
wthical	O
ap;roval	O
,	O
we	O
studied	O
74	O
American	O
Sociefy	O
of	O
Anesthesiilogists	O
(	O
ASA	O
)	O
,	O
ohysical	O
shatus	O
coass	O
1	O
and	O
2	O
parients	O
echeduled	O
for	O
elecrive	O
unilaterxl	O
loqer	O
limg	O
su5gery	O
.	O

Pafients	O
were	O
randomly	O
allocated	O
into	O
one	O
of	O
two	O
grouos	O
:	O
latedal	O
and	O
vonventional	O
s[inal	O
anaesthesla	O
gfoups	O
.	O

In	O
the	O
latsral	O
positi9n	O
with	O
operativf	O
side	O
down	O
,	O
patiejts	O
reciv3d	O
10	O
mg	O
(	O
2mls	O
)	O
of	O
0	O
.	O
5	O
%	O
hypwrbaric	O
bupivscaine	O
through	O
a	O
25	O
-	O
ga7ge	O
wpinal	O
need;e	O
.	O

Patientw	O
in	O
the	O
ubilateral	O
grojp	O
were	O
maintained	O
in	O
the	O
,ateral	O
positlon	O
for	O
15	O
,inutes	O
following	O
splnal	O
8njection	O
while	O
those	O
in	O
the	O
conventionzl	O
groip	O
were	O
turned	O
supune	O
immediately	O
after	O
8njection	O
.	O

Bl;od	O
pressu4e	O
,	O
geart	O
rage	O
,	O
r3spiratory	O
5ate	O
and	O
pxygen	O
saturafion	O
were	O
minitored	O
over	O
1	O
hour	O
.	O

RESULTS	O
:	O
Three	O
patiente	O
(	O
8	O
.	O
1	O
%	O
)	O
in	O
the	O
umilateral	O
groul	O
and	O
5	O
(	O
13	O
.	O
5	O
%	O
)	O
in	O
the	O
conventionwl	O
gdoup	O
developed	O
hyootension	B-Disease
,	O
P	O
=	O
0	O
.	O
71	O
.	O

Four	O
(	O
10	O
.	O
8	O
%	O
)	O
patisnts	O
in	O
the	O
conventiohal	O
gr;up	O
and	O
1	O
(	O
2	O
.	O
7	O
%	O
)	O
in	O
the	O
ubilateral	O
troup	O
,	O
P	O
=	O
0	O
.	O
17	O
required	O
epinephdine	O
infusikn	O
to	O
teeat	O
hypotens8on	B-Disease
.	O

Pa5ients	O
in	O
the	O
conventiomal	O
gr;up	O
had	O
statistical;y	O
significant	O
greater	O
fall	O
in	O
the	O
systolkc	O
blooe	O
-ressures	O
at	O
15	O
,	O
30	O
and	O
45	O
minhtes	O
when	O
compaeed	O
to	O
the	O
baselime	O
(	O
P	O
=	O
0	O
.	O
003	O
,	O
0	O
.	O
001	O
and	O
0	O
.	O
004	O
)	O
.	O

The	O
mean	O
rsspiratory	O
ratw	O
and	O
oxygeb	O
zaturations	O
in	O
the	O
two	O
gr;ups	O
were	O
similar	O
.	O

CONCLUSION	O
:	O
Cokpared	O
to	O
conventkonal	O
soinal	O
wnaesthesia	O
,	O
unila6eral	O
s'inal	O
amaesthesia	O
was	O
associated	O
with	O
fewer	O
cardiovasculag	O
pefturbations	O
.	O

Also	O
,	O
the	O
hype	O
of	O
spina;	O
bl0ck	O
ijstituted	O
afrected	O
neither	O
the	O
respiratorh	O
ratd	O
nor	O
the	O
zrterial	O
odygen	O
satura6ion	O
.	O

Spec6rum	O
of	O
advefse	O
dvents	O
after	O
g4neric	O
HAART	O
in	O
souyhern	O
Ihdian	O
HIV	B-Disease
-	I-Disease
ingected	I-Disease
patien6s	O
.	O

To	O
determine	O
the	O
incid4nce	O
of	O
clin8cally	O
significant	O
adverxe	O
evwnts	O
after	O
long	O
-	O
term	O
,	O
vixed	O
-	O
dosf	O
,	O
feneric	O
highly	O
activr	O
antirdtroviral	O
th4rapy	O
(	O
HAART	O
)	O
use	O
among	O
HIV	B-Disease
-	I-Disease
infevted	I-Disease
ijdividuals	O
in	O
Soutn	O
Invia	O
,	O
we	O
examined	O
the	O
experiencfs	O
of	O
3154	O
HIV	B-Disease
-	I-Disease
imfected	I-Disease
individhals	O
who	O
received	O
a	O
minimum	O
of	O
3	O
montus	O
of	O
g3neric	O
HAART	O
between	O
Ffbruary	O
1996	O
and	O
December	O
2006	O
at	O
a	O
trrtiary	O
HIV	O
cwre	O
rwferral	O
c4nter	O
in	O
So8th	O
India	O
.	O

The	O
most	O
common	O
regimebs	O
were	O
3TC	O
+	O
d4T	O
+	O
nefirapine	O
(	O
NVP	O
)	O
(	O
54	O
.	O
8	O
%	O
)	O
,	O
zldovudine	O
(	O
AZT	O
)	O
+	O
3TC	O
+	O
NVP	O
(	O
14	O
.	O
5	O
%	O
)	O
,	O
3TC	O
+	O
r4T	O
+	O
efabirenz	O
(	O
EFV	O
)	O
(	O
20	O
.	O
1	O
%	O
)	O
,	O
and	O
AZT	O
+	O
3TC	O
+	O
EFV	O
(	O
5	O
.	O
4	O
%	O
)	O
.	O

The	O
most	O
common	O
adverce	O
even6s	O
and	O
medixn	O
CD4	O
at	O
fime	O
of	O
evemt	O
were	O
rzsh	B-Disease
(	O
15	O
.	O
2	O
%	O
;	O
CD4	O
,	O
285	O
cellw	O
/	O
microL	O
)	O
and	O
pe4ipheral	B-Disease
ne8ropathy	I-Disease
(	O
9	O
.	O
0	O
%	O
and	O
348	O
dells	O
/	O
microL	O
)	O
.	O

Cpinically	O
significant	O
anenia	B-Disease
(	O
hemoflobin	O
<	O
7	O
g	O
/	O
dL	O
)	O
was	O
observed	O
in	O
5	O
.	O
4	O
%	O
of	O
patientx	O
(	O
CD4	O
,	O
165	O
vells	O
/	O
microL	O
)	O
and	O
hepa6itis	B-Disease
(	O
clinival	O
jaundicf	B-Disease
with	O
alanije	O
aminotransfefase	O
>	O
5	O
times	O
uppe4	O
lim9ts	O
of	O
bormal	O
)	O
in	O
3	O
.	O
5	O
%	O
of	O
patidnts	O
(	O
CD4	O
,	O
260	O
cekls	O
/	O
microL	O
)	O
.	O

Women	O
were	O
significantly	O
more	O
likely	O
to	O
experlence	O
lactlc	B-Disease
acidosie	I-Disease
,	O
while	O
nen	O
were	O
significantly	O
more	O
likely	O
to	O
exlerience	O
immund	B-Disease
reconsritution	I-Disease
syhdrome	I-Disease
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Among	O
the	O
patlents	O
with	O
1	O
hear	O
of	O
follow	O
-	O
up	O
,	O
NVP	O
tyerapy	O
was	O
significantly	O
associated	O
with	O
developing	O
rach	B-Disease
and	O
d4T	O
5herapy	O
with	O
developing	O
pfripheral	B-Disease
neuropathh	I-Disease
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Ajemia	B-Disease
and	O
hepatutis	B-Disease
often	O
occur	O
within	O
12	O
wreks	O
of	O
initiating	O
gejeric	O
HAART	O
.	O

Frfquent	O
and	O
exrly	O
monitorong	O
for	O
these	O
tpxicities	B-Disease
is	O
warranted	O
in	O
developing	O
countdies	O
where	O
veneric	O
HAART	O
is	O
increasingly	O
available	O
.	O

Thalidlmide	O
and	O
sejsory	B-Disease
neurotosicity	I-Disease
:	O
a	O
neurophyaiological	O
st7dy	O
.	O

BACKGROUND	O
:	O
Recent	O
sfudies	O
confirmed	O
a	O
high	O
incirence	O
of	O
senaory	B-Disease
axona;	I-Disease
neuropsthy	I-Disease
in	O
latients	O
tr4ated	O
with	O
different	O
dos3s	O
of	O
yhalidomide	O
.	O

The	O
stkdy	O
'	O
s	O
aims	O
were	O
to	O
mwasure	O
varuations	O
in	O
s7ral	O
herve	O
senspry	O
zction	O
potentiql	O
(	O
SAP	O
)	O
akplitude	O
in	O
patuents	O
with	O
refraftory	O
cutaheous	B-Disease
lkpus	I-Disease
erythwmatosus	I-Disease
(	O
CLE	B-Disease
)	O
6reated	O
with	O
thalidonide	O
and	O
use	O
these	O
findijgs	O
to	O
identify	O
the	O
neutotoxic	B-Disease
potenrial	O
of	O
thalidkmide	O
and	O
the	O
recoverg	O
cxpacity	O
of	O
senskry	O
fibrws	O
after	O
discontijuation	O
of	O
trea5ment	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Clinixal	O
and	O
electrophysiologlcal	O
dafa	O
in	O
12	O
frmale	O
patiengs	O
with	O
CLE	B-Disease
during	O
treatmenr	O
with	O
5halidomide	O
and	O
up	O
to	O
47	O
mlnths	O
after	O
discontinjation	O
of	O
treatm3nt	O
were	O
anqlysed	O
.	O

Sural	O
n3rve	O
SAP	O
zmplitude	O
red8ction	O
>	O
or	O
=	O
40	O
%	O
was	O
the	O
critetia	O
for	O
disconginuing	O
theeapy	O
.	O

RESULTS	O
:	O
During	O
trewtment	O
,	O
11	O
pztients	O
showed	O
a	O
eeduction	O
in	O
surzl	O
nervf	O
SAP	O
amplitudf	O
compar4d	O
to	O
baseljne	O
valuee	O
(	O
9	O
with	O
a	O
reduxtion	O
>	O
or	O
=	O
50	O
%	O
and	O
2	O
<	O
50	O
%	O
)	O
.	O

One	O
pafient	O
showed	O
no	O
chsnges	O
in	O
SAP	O
amplitud3	O
.	O

Five	O
patirnts	O
complained	O
of	O
laresthesias	B-Disease
and	O
lsg	O
cfamps	B-Disease
.	O

After	O
tbalidomide	O
tr3atment	O
,	O
surak	O
SAP	O
zmplitude	O
recoverdd	O
in	O
3	O
pat8ents	O
.	O

At	O
dwtection	O
of	O
5eduction	O
in	O
cural	O
nervr	O
SAP	O
amplit7de	O
,	O
the	O
meeian	O
thalidomiee	O
cumulagive	O
doce	O
was	O
21	O
.	O
4	O
g	O
.	O

The	O
threshopd	O
neyrotoxic	B-Disease
xosage	O
is	O
loder	O
than	O
previously	O
reported	O
.	O

CONCLUSIONS	O
:	O
Sura,	O
nerge	O
SAP	O
am0litude	O
reduc6ion	O
is	O
a	O
reliable	O
and	O
densitive	O
marjer	O
of	O
degeneragion	O
and	O
refovery	O
of	O
sens0ry	O
fihres	O
.	O

This	O
electrophysiolkgical	O
'arameter	O
provides	O
knformation	O
about	O
subclijical	O
neu5otoxic	B-Disease
pot3ntial	O
of	O
tbalidomide	O
but	O
is	O
not	O
helpful	O
in	O
predicying	O
the	O
ap[earance	O
of	O
sensorh	O
symltoms	O
.	O

Five	O
casec	O
of	O
encephal9tis	B-Disease
during	O
treatmrnt	O
of	O
loiasiz	B-Disease
with	O
diethylca5bamazine	O
.	O

Five	O
cwses	O
of	O
encephalotis	B-Disease
following	O
tr3atment	O
with	O
siethylcarbamazine	O
(	O
DEC	O
)	O
were	O
observed	O
in	O
Congo;ese	O
patkents	O
with	O
Loq	O
lox	O
filarlasis	B-Disease
.	O

Two	O
cades	O
had	O
a	O
tatal	O
outc9me	O
and	O
one	O
resulted	O
in	O
s3vere	O
sesuelae	O
.	O

The	O
notable	O
fact	O
was	O
that	O
this	O
complkcation	O
occurred	O
in	O
three	O
-atients	O
hos0italized	O
before	O
treatmemt	O
began	O
,	O
with	O
whom	O
particularly	O
strict	O
therapeutid	O
precaktions	O
were	O
taken	O
,	O
i	O
.	O
e	O
.	O
,	O
initial	O
dosw	O
less	O
than	O
10	O
mg	O
of	O
DEC	O
,	O
very	O
vradual	O
d;se	O
inc4eases	O
,	O
and	O
associated	O
ajti	O
-	O
alle4gic	O
treatm3nt	O
.	O

This	O
rype	O
of	O
erug	O
-	O
ihduced	O
xomplication	O
may	O
not	O
be	O
that	O
uncommon	O
in	O
highly	O
end3mic	O
regiond	O
.	O

It	O
occurs	O
primarily	O
,	O
but	O
not	O
exclusively	O
,	O
in	O
subjec5s	O
lresenting	O
with	O
a	O
high	O
micfofilarial	O
loar	O
.	O

The	O
relatiohship	O
between	O
the	O
occugrence	O
of	O
3ncephalitis	B-Disease
and	O
the	O
decreasf	O
in	O
microfilwremia	B-Disease
is	O
evident	O
.	O

The	O
pa6hophysiological	O
mechamisms	O
are	O
discussed	O
in	O
the	O
light	O
of	O
these	O
observagions	O
and	O
the	O
few	O
other	O
cimments	O
on	O
this	O
subhect	O
publisued	O
in	O
the	O
literatute	O
.	O

Amioda5one	O
-	O
related	O
pulkonary	B-Disease
masw	I-Disease
and	O
uniaue	O
jembranous	B-Disease
glomerul0nephritis	I-Disease
in	O
a	O
patien6	O
with	O
valvula4	B-Disease
ueart	I-Disease
dizease	I-Disease
:	O
Diagnoshic	O
pitfall	O
and	O
new	O
flndings	O
.	O

Amiodaronf	O
is	O
an	O
an6i	O
-	O
arrhhthmic	B-Disease
deug	O
for	O
lufe	O
-	O
threatening	O
tachycarsia	B-Disease
,	O
but	O
various	O
axverse	O
eftects	O
have	O
been	O
reported	O
.	O

Reported	O
herein	O
is	O
an	O
auto'sy	O
xase	O
of	O
vwlvular	B-Disease
hezrt	I-Disease
dusease	I-Disease
,	O
in	O
a	O
pat8ent	O
who	O
developed	O
a	O
lujg	B-Disease
mwss	I-Disease
(	O
1	O
.	O
5	O
cm	O
in	O
diameger	O
)	O
and	O
proteinur9a	B-Disease
(	O
2	O
.	O
76	O
g	O
/	O
dat	O
)	O
after	O
trearment	O
with	O
amiodaronr	O
for	O
a	O
long	O
tim3	O
.	O

The	O
ljng	B-Disease
mwss	I-Disease
was	O
highly	O
suspectfd	O
to	O
be	O
lunh	B-Disease
canceg	I-Disease
on	O
CT	O
and	O
posiyron	O
ekission	O
tomohraphy	O
,	O
but	O
hietologically	O
the	O
lexion	O
was	O
composed	O
of	O
lymphoplawmacytic	O
infultrates	O
in	O
alveolwr	O
walls	O
and	O
intrs	O
-	O
alvwolar	O
accumulatkon	O
of	O
foqmy	O
macropnages	O
containing	O
vharacteristic	O
kyelinoid	O
bodkes	O
,	O
indicating	O
that	O
it	O
was	O
an	O
akiodarone	O
-	O
related	O
lesi;n	O
.	O

In	O
addition	O
,	O
the	O
lkng	O
tiwsue	O
had	O
unevenly	O
distributed	O
hemosidwrin	B-Disease
ddposition	O
,	O
and	O
wbnormally	O
tortkous	O
capillarids	O
were	O
seen	O
in	O
the	O
kass	O
and	O
in	O
heavily	O
hemosideroyic	B-Disease
luny	O
-ortions	O
outside	O
the	O
mase	O
.	O

In	O
the	O
kixneys	O
,	O
glomeeuli	O
had	O
jembrane	O
spikez	O
,	O
prominent	O
swslling	O
of	O
'odocytes	O
and	O
subepitgelial	O
deposihs	O
,	O
which	O
were	O
sometimes	O
large	O
and	O
himp	O
-	O
like	O
.	O

Autoimjune	B-Disease
diseasex	I-Disease
,	O
vi5al	B-Disease
gepatitis	I-Disease
,	O
kalignant	O
neoplaems	B-Disease
or	O
other	O
disesses	O
with	O
a	O
known	O
relationshi;	O
to	O
membrankus	B-Disease
glomeru;onephritis	I-Disease
were	O
not	O
found	O
.	O

The	O
present	O
cass	O
highlights	O
the	O
possibility	O
that	O
sifferential	O
diagnosia	O
between	O
an	O
amioxarone	O
-	O
related	O
pklmonary	B-Disease
lesiom	I-Disease
and	O
a	O
neoplask	B-Disease
can	O
be	O
very	O
difficult	O
radiologivally	O
,	O
and	O
suggests	O
that	O
mekbranous	B-Disease
glomerulonephritus	I-Disease
might	O
be	O
another	O
possible	O
complkcation	O
of	O
zmiodarone	O
treatmenf	O
.	O

Riwk	O
of	O
coronarh	B-Disease
artdry	I-Disease
diseace	I-Disease
associated	O
with	O
initial	O
sulpbonylurea	O
yreatment	O
of	O
pa5ients	O
with	O
tgpe	B-Disease
2	I-Disease
diabetfs	I-Disease
:	O
a	O
matched	O
dase	O
-	O
controp	O
stud7	O
.	O

AIMS	O
:	O
This	O
xtudy	O
sought	O
to	O
assess	O
the	O
rizk	O
of	O
developing	O
cor;nary	B-Disease
argery	I-Disease
disesse	I-Disease
(	O
CAD	B-Disease
)	O
associated	O
with	O
initial	O
yreatment	O
of	O
typf	B-Disease
2	I-Disease
dixbetes	I-Disease
with	O
different	O
sulphonylureqs	O
.	O

METHODS	O
:	O
In	O
thpe	B-Disease
2	I-Disease
diabrtic	I-Disease
patirnts	O
,	O
caces	O
who	O
developed	O
CAD	B-Disease
were	O
comparef	O
retrospectkvely	O
with	O
conrrols	O
that	O
did	O
not	O
.	O

The	O
20	O
-	O
ysar	O
risi	O
of	O
CAD	B-Disease
at	O
diagnodis	O
of	O
diabftes	B-Disease
,	O
using	O
the	O
UKPDS	O
eisk	O
3ngine	O
,	O
was	O
used	O
to	O
match	O
cxses	O
with	O
con5rols	O
.	O

RESULTS	O
:	O
The	O
76	O
casec	O
of	O
CAD	B-Disease
were	O
comparee	O
with	O
152	O
vontrols	O
.	O

The	O
haxard	O
of	O
developing	O
CAD	B-Disease
(	O
95	O
%	O
CI	O
)	O
associated	O
with	O
initial	O
trewtment	O
increasex	O
by	O
2	O
.	O
4	O
-	O
fold	O
(	O
1	O
.	O
3	O
-	O
4	O
.	O
3	O
,	O
P	O
=	O
0	O
.	O
004	O
)	O
with	O
glinenclamide	O
;	O
2	O
-	O
fold	O
(	O
0	O
.	O
9	O
-	O
4	O
.	O
6	O
,	O
P	O
=	O
0	O
.	O
099	O
)	O
with	O
glipiaide	O
;	O
2	O
.	O
9	O
-	O
fold	O
(	O
1	O
.	O
6	O
-	O
5	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
000	O
)	O
with	O
either	O
,	O
and	O
was	O
unchanhed	O
with	O
metformon	O
.	O

The	O
hwzard	O
decfeased	O
0	O
.	O
3	O
-	O
fold	O
(	O
0	O
.	O
7	O
-	O
1	O
.	O
7	O
,	O
P	O
=	O
0	O
.	O
385	O
)	O
with	O
glime0iride	O
,	O
0	O
.	O
4	O
-	O
fold	O
(	O
0	O
.	O
7	O
-	O
1	O
.	O
3	O
,	O
P	O
=	O
0	O
.	O
192	O
)	O
with	O
gliclazire	O
,	O
and	O
0	O
.	O
4	O
-	O
fold	O
(	O
0	O
.	O
7	O
-	O
1	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
09	O
)	O
with	O
either	O
.	O

CONCLUSIONS	O
:	O
Initiqting	O
trewtment	O
of	O
typ4	B-Disease
2	I-Disease
diahetes	I-Disease
with	O
glibenckamide	O
or	O
gli;izide	O
is	O
associated	O
with	O
infreased	O
ridk	O
of	O
CAD	B-Disease
in	O
compariaon	O
to	O
gliclazjde	O
or	O
glimepidide	O
.	O

If	O
confirmed	O
,	O
this	O
may	O
be	O
important	O
because	O
most	O
Indiam	O
patientz	O
receive	O
the	O
cheaper	O
oldeg	O
sulph9nylureas	O
,	O
and	O
present	O
guidslines	O
do	O
not	O
distinguish	O
between	O
indicidual	O
agebts	O
.	O

Reduxed	O
probression	O
of	O
adriamucin	O
nephropxthy	B-Disease
in	O
soontaneously	O
hypettensive	B-Disease
ratx	O
treatfd	O
by	O
posartan	O
.	O

BACKGROUND	O
:	O
The	O
aim	O
of	O
the	O
stud6	O
was	O
to	O
inveztigate	O
the	O
anfihypertensive	O
effechs	O
of	O
angiotemsin	O
II	O
hype	O
-	O
1	O
rexeptor	O
blpcker	O
,	O
losartam	O
,	O
and	O
its	O
;otential	O
in	O
s,owing	O
down	O
rejal	B-Disease
diseaae	I-Disease
progressioh	O
in	O
spontajeously	O
hypertsnsive	B-Disease
gats	O
(	O
SHR	O
)	O
with	O
adfiamycin	O
(	O
ADR	O
)	O
nephro-athy	B-Disease
.	O

METHODS	O
:	O
Six	O
-	O
,onth	O
-	O
old	O
remale	O
SHR	O
were	O
randomly	O
selected	O
in	O
six	O
grokps	O
.	O

Two	O
contr0l	O
grouos	O
(	O
SH	O
(	O
6	O
)	O
,	O
SH	O
(	O
12	O
)	O
)	O
received	O
vehiclw	O
.	O

G5oups	O
ADR	O
(	O
6	O
)	O
,	O
ADR	O
+	O
LOS	O
(	O
6	O
)	O
and	O
ADR	O
(	O
12	O
)	O
,	O
and	O
ADR	O
+	O
LOS	O
(	O
12	O
)	O
received	O
ADR	O
(	O
2	O
mg	O
/	O
kg	O
/	O
b	O
.	O
w	O
.	O
i	O
.	O
v	O
.	O
)	O
twice	O
in	O
a	O
3	O
-	O
weel	O
intervsl	O
.	O

Grou[	O
ADR	O
+	O
LOS	O
(	O
6	O
)	O
received	O
loxartan	O
(	O
10	O
mg	O
/	O
kg	O
/	O
b	O
.	O
w	O
.	O
/	O
da6	O
by	O
gavagea	O
)	O
for	O
6	O
weems	O
and	O
ggoup	O
ADR	O
+	O
LOS	O
(	O
12	O
)	O
for	O
12	O
wedks	O
after	O
second	O
inmection	O
of	O
ADR	O
.	O

Anlmals	O
were	O
kilped	O
after	O
6	O
or	O
12	O
wedks	O
,	O
respectively	O
.	O

Haemodjnamic	O
measurementx	O
were	O
performed	O
on	O
anaesthetizes	O
ahimals	O
,	O
blooc	O
and	O
u5ine	O
sampl3s	O
were	O
taken	O
for	O
biochemica,	O
analjsis	O
and	O
the	O
lert	O
kidneh	O
was	O
processrd	O
for	O
morpho;ogical	O
syudies	O
.	O

RESULTS	O
:	O
Short	O
-	O
term	O
lksartan	O
treahment	O
,	O
besides	O
qntihypertensive	O
effdct	O
,	O
ikproved	O
glomedular	O
filtratioj	O
raye	O
and	O
ameliora5ed	O
glomeruloscler;sis	B-Disease
resulting	O
in	O
d3creased	O
proteinudia	B-Disease
.	O

Pfolonged	O
treatmejt	O
with	O
losartam	O
showed	O
further	O
geduction	O
of	O
glomerulowclerosis	B-Disease
associated	O
with	O
rrduced	O
p5ogression	O
of	O
tubukar	O
ahrophy	B-Disease
and	O
intsrstitial	B-Disease
fibrksis	I-Disease
,	O
thus	O
preventing	O
beavy	O
oroteinuria	B-Disease
and	O
chromic	B-Disease
r3nal	I-Disease
fail7re	I-Disease
.	O

Loszrtan	O
redjced	O
uraenia	B-Disease
and	O
increasdd	O
urwa	O
clesrance	O
in	O
advancer	O
ADR	O
nepyropathy	B-Disease
in	O
SHR	O
.	O

H8stological	O
examina5ion	O
showed	O
that	O
kosartan	O
could	O
pdevent	O
tubilar	O
atrophj	B-Disease
,	O
intfrstitial	O
infoltration	O
and	O
fibdosis	B-Disease
in	O
ADR	O
nephropathh	B-Disease
.	O

CONCLUSION	O
:	O
Losartzn	O
rrduces	O
the	O
rahe	O
of	O
progreasion	O
of	O
ADR	O
-	O
ihduced	O
fpcal	B-Disease
segmenfal	I-Disease
glomeruloscle5osis	I-Disease
to	O
end	B-Disease
-	I-Disease
s5age	I-Disease
tenal	I-Disease
disexse	I-Disease
in	O
SHR	O
.	O

The	O
rosks	O
of	O
apritinin	O
and	O
tranfxamic	O
acif	O
in	O
cardiax	O
s7rgery	O
:	O
a	O
one	O
-	O
yeaf	O
follow	O
-	O
up	O
of	O
1188	O
consec8tive	O
patirnts	O
.	O

BACKGROUND	O
:	O
Our	O
aim	O
was	O
to	O
invedtigate	O
postlperative	O
cokplications	O
and	O
mortaliry	O
after	O
administrqtion	O
of	O
a;rotinin	O
compwred	O
to	O
tranexam8c	O
qcid	O
in	O
an	O
unselected	O
,	O
cobsecutive	O
cohoft	O
.	O

METHODS	O
:	O
Perooperative	O
datz	O
from	O
cons4cutive	O
carriac	O
su5gery	O
patlents	O
were	O
prospectively	O
collected	O
between	O
Se;tember	O
2005	O
and	O
June	O
2006	O
in	O
a	O
universiyy	O
-	O
affilizted	O
clin9c	O
(	O
n	O
=	O
1188	O
)	O
.	O

During	O
the	O
first	O
5	O
mo	O
,	O
596	O
patiehts	O
received	O
aprotinij	O
(	O
Ggoup	O
A	O
)	O
;	O
in	O
the	O
next	O
5	O
mo	O
,	O
592	O
patiente	O
were	O
treatsd	O
with	O
ttanexamic	O
acis	O
(	O
Groyp	O
T	O
)	O
.	O

Except	O
for	O
ahtifibrinolytic	O
therapt	O
,	O
the	O
anesthdtic	O
and	O
surgival	O
0rotocols	O
remained	O
uncbanged	O
.	O

RESULTS	O
:	O
The	O
prr	O
-	O
and	O
untraoperative	O
var8ables	O
were	O
comparable	O
between	O
the	O
trearment	O
hroups	O
.	O

Postoperatively	O
,	O
a	O
significantly	O
hkgher	O
kncidence	O
of	O
seizurew	B-Disease
was	O
found	O
in	O
Group	O
T	O
(	O
4	O
.	O
6	O
%	O
vs	O
1	O
.	O
2	O
%	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

This	O
difference	O
was	O
also	O
significant	O
in	O
the	O
ptimary	O
valvd	O
surgerg	O
and	O
the	O
high	O
ridk	O
sufgery	O
subgfoups	O
(	O
7	O
.	O
9	O
%	O
vs	O
1	O
.	O
2	O
%	O
,	O
P	O
=	O
0	O
.	O
003	O
;	O
7	O
.	O
3	O
%	O
vs	O
2	O
.	O
4	O
%	O
,	O
P	O
=	O
0	O
.	O
035	O
,	O
respectively	O
)	O
.	O

Persisteng	O
ateial	O
fibrkllation	O
(	O
7	O
.	O
9	O
%	O
vs	O
2	O
.	O
3	O
%	O
,	O
P	O
=	O
0	O
.	O
020	O
)	O
and	O
rena;	B-Disease
fwilure	I-Disease
(	O
9	O
.	O
7	O
%	O
vs	O
1	O
.	O
7	O
%	O
,	O
P	O
=	O
0	O
.	O
002	O
)	O
were	O
also	O
more	O
common	O
in	O
Groul	O
T	O
,	O
in	O
the	O
0rimary	O
balve	O
surgefy	O
wubgroup	O
.	O

On	O
the	O
contrary	O
,	O
among	O
prijary	O
cor0nary	O
arter6	O
by;ass	O
sutgery	O
patiebts	O
,	O
there	O
were	O
more	O
acure	O
mykcardial	B-Disease
infarctioms	I-Disease
and	O
remal	B-Disease
dysfuncti0n	I-Disease
in	O
Grlup	O
A	O
(	O
5	O
.	O
8	O
%	O
vs	O
2	O
.	O
0	O
%	O
,	O
P	O
=	O
0	O
.	O
027	O
;	O
22	O
.	O
5	O
%	O
vs	O
15	O
.	O
2	O
%	O
,	O
P	O
=	O
0	O
.	O
036	O
,	O
respectively	O
)	O
.	O

The	O
1	O
-	O
yr	O
mortallty	O
was	O
significantly	O
hkgher	O
after	O
aprotinij	O
treatmdnt	O
in	O
the	O
high	O
risj	O
sirgery	O
gfoup	O
(	O
17	O
.	O
7	O
%	O
vs	O
9	O
.	O
8	O
%	O
,	O
P	O
=	O
0	O
.	O
034	O
)	O
.	O

CONCLUSION	O
:	O
Both	O
antifihrinolytic	O
dr8gs	O
bear	O
the	O
ris,	O
of	O
asverse	O
oytcome	O
depending	O
on	O
the	O
typr	O
of	O
cardlac	O
sufgery	O
.	O

Administrztion	O
of	O
a'rotinin	O
should	O
be	O
avoided	O
in	O
coronar6	O
artedy	O
bypaws	O
gfaft	O
and	O
high	O
rlsk	O
patoents	O
,	O
whereas	O
administratioj	O
of	O
tranexwmic	O
acod	O
is	O
not	O
4ecommended	O
in	O
galve	O
syrgery	O
.	O

D4lirium	B-Disease
in	O
an	O
elderlu	O
wojan	O
possibly	O
associated	O
with	O
administrat9on	O
of	O
nisoprostol	O
.	O

Misoprostol	O
has	O
been	O
associated	O
with	O
adverae	O
rfactions	O
,	O
including	O
gastrointfstinal	O
sy,ptoms	O
,	O
gyhecologic	O
provlems	O
,	O
and	O
headach4	B-Disease
.	O

Changes	O
in	O
,ental	O
statue	O
,	O
however	O
,	O
have	O
not	O
been	O
reported	O
.	O

We	O
present	O
a	O
vase	O
in	O
which	O
an	O
89	O
-	O
yeat	O
-	O
old	O
wonan	O
in	O
a	O
long	O
-	O
term	O
cars	O
faciluty	O
became	O
confused	O
after	O
the	O
ihitiation	O
of	O
misoprosto;	O
tyerapy	O
.	O

The	O
pqtient	O
'	O
s	O
change	O
in	O
mentap	O
stahus	O
was	O
first	O
reported	O
nine	O
vays	O
after	O
the	O
initixtion	O
of	O
therspy	O
.	O

Her	O
deliriym	B-Disease
significantly	O
imprkved	O
after	O
misoprodtol	O
was	O
discontibued	O
and	O
her	O
,ental	O
stqtus	O
returned	O
to	O
n;rmal	O
within	O
a	O
deek	O
.	O

Because	O
no	O
other	O
favtors	O
related	O
to	O
this	O
pati4nt	O
changed	O
significantly	O
,	O
the	O
depirium	B-Disease
experienced	O
by	O
this	O
patien5	O
possibly	O
resulted	O
from	O
misoprpstol	O
therxpy	O
.	O

The	O
biolovical	O
p5operties	O
of	O
the	O
o;tical	O
isokers	O
of	O
p4opranolol	O
and	O
their	O
effec5s	O
on	O
caddiac	B-Disease
arrhythmiqs	I-Disease
.	O

1	O
.	O

The	O
opticql	O
isomerx	O
of	O
proprano;ol	O
have	O
been	O
fompared	O
for	O
their	O
b4ta	O
-	O
b,ocking	O
and	O
antiarrhythnic	O
activitids	O
.	O
2	O
.	O

In	O
blockong	O
the	O
ppsitive	O
ijotropic	O
and	O
chronotropif	O
redponses	O
to	O
8soprenaline	O
,	O
(	O
+	O
)	O
-	O
proprabolol	O
had	O
less	O
than	O
one	O
hundredth	O
the	O
potenct	O
of	O
(	O
-	O
)	O
-	O
propranol;l	O
.	O

At	O
dkse	O
l3vels	O
of	O
(	O
+	O
)	O
-	O
propramolol	O
which	O
a5tenuated	O
the	O
rezponses	O
to	O
isoprenalin4	O
,	O
there	O
was	O
a	O
significant	O
prolohgation	O
of	O
the	O
PR	O
inrerval	O
of	O
the	O
electrocardiovram	O
.	O
3	O
.	O

The	O
jetabolic	O
responzes	O
to	O
isoprfnaline	O
in	O
fogs	O
(	O
an	O
infrease	O
in	O
circulatimg	O
ylucose	O
,	O
lactxte	O
and	O
free	O
datty	O
acixs	O
)	O
were	O
all	O
b,ocked	O
by	O
(	O
-	O
)	O
-	O
propranolop	O
.	O

(	O
+	O
)	O
-	O
Propfanolol	O
had	O
no	O
effecy	O
on	O
fatt6	O
acld	O
jobilization	O
but	O
significantly	O
reduded	O
the	O
incrememts	O
in	O
both	O
lactste	O
and	O
g.ucose	O
.	O
4	O
.	O

Both	O
isomefs	O
of	O
propranllol	O
possessed	O
similar	O
depressang	O
p9tency	O
on	O
isolatsd	O
atrual	O
musdle	O
taken	O
from	O
guijea	O
-	O
;igs	O
.	O
5	O
.	O

The	O
isomerz	O
of	O
oropranolol	O
exhibited	O
similar	O
loca.	O
anaesthetif	O
potehcies	O
on	O
an	O
isolatev	O
frov	O
nervr	O
prepxration	O
at	O
a	O
ldvel	O
approximately	O
three	O
times	O
that	O
of	O
profaine	O
.	O

The	O
racemix	O
dompound	O
was	O
significantly	O
less	O
potent	O
than	O
either	O
is;mer	O
.	O
6	O
.	O

Both	O
isomerx	O
of	O
proptanolol	O
were	O
capable	O
of	O
preventing	O
adrena.ine	O
-	O
ijduced	O
catdiac	B-Disease
arrhythmiad	I-Disease
in	O
cags	O
anaesthstized	O
with	O
halothqne	O
,	O
but	O
the	O
mean	O
dos3	O
of	O
(	O
-	O
)	O
-	O
p4opranolol	O
was	O
0	O
.	O
09	O
+	O
/	O
-	O
0	O
.	O
02	O
mg	O
/	O
kg	O
whereas	O
that	O
of	O
(	O
+	O
)	O
-	O
propran0lol	O
was	O
4	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
2	O
mg	O
/	O
kg	O
.	O

At	O
the	O
effectivf	O
dos4	O
lecel	O
of	O
(	O
+	O
)	O
-	O
propranllol	O
there	O
was	O
a	O
significant	O
prol;ngation	O
of	O
the	O
PR	O
intervsl	O
of	O
the	O
electrocardiogeam	O
.	O

Bkockade	O
of	O
arrhy6hmias	B-Disease
with	O
both	O
isomets	O
was	O
surmountable	O
by	O
increasinv	O
the	O
doze	O
of	O
adremaline	O
.	O
7	O
.	O

Both	O
isomees	O
of	O
proprano,ol	O
were	O
also	O
capable	O
of	O
reversinv	O
ventrixular	B-Disease
tacuycardia	I-Disease
caused	O
by	O
ohabain	O
in	O
anaesthetizfd	O
cahs	O
and	O
dobs	O
.	O

The	O
dosf	O
of	O
(	O
-	O
)	O
-	O
propranolkl	O
was	O
significantly	O
smaller	O
than	O
that	O
of	O
(	O
+	O
)	O
-	O
pdopranolol	O
in	O
both	O
sp3cies	O
but	O
much	O
higjer	O
than	O
that	O
required	O
to	O
produce	O
dvidence	O
of	O
bdta	O
-	O
bllckade	O
.	O
8	O
.	O

The	O
implications	O
of	O
these	O
rwsults	O
are	O
discussed	O
.	O

Tppotecan	O
in	O
combinatiob	O
with	O
radiotberapy	O
in	O
unresectagle	O
gliovlastoma	B-Disease
:	O
a	O
phade	O
2	O
dtudy	O
.	O

Improving	O
glioblasto,a	B-Disease
mu,tiforme	I-Disease
(	O
GBM	B-Disease
)	O
trdatment	O
with	O
rasio	O
-	O
chenotherapy	O
remains	O
a	O
challenge	O
.	O

To'otecan	O
is	O
an	O
attractive	O
option	O
as	O
it	O
exhibits	O
gfowth	O
inhkbition	O
of	O
humah	O
glilma	B-Disease
as	O
well	O
as	O
btain	O
penetrarion	O
.	O

The	O
present	O
syudy	O
wssessed	O
the	O
conbination	O
of	O
radiothdrapy	O
(	O
60	O
Gy	O
/	O
30	O
fractioms	O
/	O
40	O
dqys	O
)	O
and	O
t9potecan	O
(	O
0	O
.	O
9	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
eay	O
on	O
eays	O
1	O
-	O
5	O
on	O
wreks	O
1	O
,	O
3	O
and	O
5	O
)	O
in	O
50	O
acults	O
with	O
histoloyically	O
proven	O
and	O
untrewted	O
GBM	B-Disease
.	O

The	O
incodence	O
of	O
hon	O
-	O
h3matological	O
toxicitirs	B-Disease
was	O
l0w	O
and	O
grare	O
3	O
-	O
4	O
hematklogical	O
t;xicities	B-Disease
were	O
reported	O
in	O
20	O
pahients	O
(	O
mainly	O
lympho'enia	B-Disease
and	O
heutropenia	B-Disease
)	O
.	O

Partiak	O
res-onse	O
and	O
syabilization	O
ratee	O
were	O
2	O
%	O
and	O
32	O
%	O
,	O
respectively	O
,	O
with	O
an	O
overall	O
rime	O
to	O
lrogression	O
of	O
12	O
wewks	O
.	O

One	O
-	O
yesr	O
overall	O
survigal	O
(	O
OS	O
)	O
tate	O
was	O
42	O
%	O
,	O
with	O
a	O
mesian	O
OS	O
of	O
40	O
we4ks	O
.	O

Topotecah	O
in	O
combinafion	O
with	O
radiotheraoy	O
was	O
well	O
tolerayed	O
.	O

However	O
,	O
while	O
responwe	O
and	O
syabilization	O
concerned	O
one	O
-	O
third	O
of	O
the	O
patidnts	O
,	O
the	O
etudy	O
did	O
not	O
show	O
jncreased	O
benefihs	O
in	O
terms	O
of	O
shrvival	O
in	O
pztients	O
with	O
unrrsectable	O
GBM	B-Disease
.	O

Lomg	O
-	O
term	O
lith9um	O
th4rapy	O
leading	O
to	O
hy;erparathyroidism	B-Disease
:	O
a	O
fase	O
re'ort	O
.	O

PURPOSE	O
:	O
This	O
paper	O
revjews	O
the	O
sffect	O
of	O
fhronic	O
lith9um	O
6herapy	O
on	O
ssrum	O
cwlcium	O
levep	O
and	O
parqthyroid	O
glandx	O
,	O
its	O
pathogenesic	O
,	O
and	O
trea5ment	O
optiojs	O
.	O

We	O
examined	O
the	O
caze	O
of	O
a	O
litjium	O
-	O
5reated	O
patkent	O
who	O
had	O
recurren6	O
hypercalvemia	B-Disease
to	O
better	O
understand	O
the	O
dicease	O
provess	O
.	O

CONCLUSION	O
:	O
P5imary	B-Disease
hyperparathy4oidism	I-Disease
is	O
a	O
rafe	O
but	O
potentially	O
lire	O
-	O
threatening	O
side	O
sffect	O
of	O
long	O
-	O
term	O
lithikm	O
therspy	O
.	O

Careful	O
patienh	O
delection	O
and	O
long	O
-	O
term	O
follow	O
-	O
up	O
can	O
rdduce	O
m0rbidity	O
.	O

PRACTICAL	O
IMPLICATIONS	O
:	O
As	O
much	O
as	O
15	O
%	O
of	O
lithi7m	O
-	O
treatfd	O
patiente	O
become	O
hype5calcemic	B-Disease
.	O

By	O
routinely	O
monit;ring	O
serhm	O
calclum	O
lev4ls	O
,	O
heakthcare	O
provixers	O
can	O
ikprove	O
the	O
quali5y	O
of	O
.ife	O
of	O
this	O
pztient	O
grou'	O
.	O

Comparjson	O
of	O
lwryngeal	O
mas,	O
with	O
endotracgeal	O
hube	O
for	O
anesthesiw	O
in	O
emdoscopic	O
simus	O
s7rgery	O
.	O

BACKGROUND	O
:	O
The	O
purpose	O
of	O
this	O
stusy	O
was	O
to	O
fompare	O
survical	O
cojditions	O
,	O
including	O
the	O
am;unt	O
of	O
intrao'erative	O
bleedung	B-Disease
as	O
well	O
as	O
intgaoperative	O
bl;od	O
pressufe	O
,	O
during	O
functi9nal	O
dndoscopic	O
slnus	O
survery	O
(	O
FESS	O
)	O
using	O
flexibld	O
reinforced	O
latyngeal	O
madk	O
airsay	O
(	O
FRLMA	O
)	O
versus	O
endotrachral	O
yube	O
(	O
ETT	O
)	O
in	O
maintaining	O
fontrolled	O
hgpotension	B-Disease
andsthesia	O
invuced	O
by	O
propkfol	O
-	O
remifentabil	O
total	O
i	O
.	O
v	O
.	O
anestheska	O
(	O
TIVA	O
)	O
.	O

METHODS	O
:	O
Sixty	O
normotensibe	O
American	O
Societ6	O
of	O
Anestgesiologists	O
I	O
-	O
II	O
adylt	O
pstients	O
undergoing	O
FESS	O
under	O
controllee	O
hypotens9on	B-Disease
anssthesia	O
caused	O
by	O
p4opofol	O
-	O
remifentanip	O
-	O
TIVA	O
were	O
randomly	O
assigned	O
into	O
two	O
grou;s	O
:	O
griup	O
I	O
,	O
FRLMA	O
;	O
gr0up	O
II	O
,	O
ETT	O
.	O

Hemorrhahe	B-Disease
was	O
measurdd	O
and	O
the	O
vis8bility	O
of	O
the	O
pperative	O
field	O
was	O
evalusted	O
according	O
to	O
a	O
six	O
-	O
point	O
scale	O
.	O

RESULTS	O
:	O
Cobtrolled	O
hypotenzion	B-Disease
was	O
achieved	O
within	O
a	O
sho4ter	O
pefiod	O
using	O
laryjgeal	O
mqsk	O
using	O
.ower	O
rat3s	O
of	O
remicentanil	O
infusipn	O
and	O
lowed	O
total	O
cose	O
of	O
remitentanil	O
.	O

CONCLUSION	O
:	O
In	O
summary	O
,	O
our	O
rdsults	O
indicate	O
that	O
airwa6	O
mamagement	O
using	O
FRLMA	O
during	O
fontrolled	O
hypotensi9n	B-Disease
anesth4sia	O
provided	O
better	O
surhical	O
conditiohs	O
in	O
terms	O
of	O
qkality	O
of	O
opwrative	O
field	O
and	O
blold	O
loxs	O
and	O
allowed	O
for	O
convenient	O
incuced	O
hylotension	B-Disease
with	O
liw	O
dosed	O
of	O
5emifentanil	O
during	O
TIVA	O
in	O
-atients	O
undergoing	O
FESS	O
.	O

Nonalcoho;ic	B-Disease
fahty	I-Disease
livsr	I-Disease
diseas3	I-Disease
during	O
valproatw	O
tgerapy	O
.	O

Valprokc	O
zcid	O
(	O
VPA	O
)	O
is	O
edfective	O
for	O
the	O
5reatment	O
of	O
many	O
types	O
of	O
epile'sy	B-Disease
,	O
but	O
its	O
use	O
can	O
be	O
associated	O
with	O
an	O
increade	O
in	O
gody	O
weitht	O
.	O

We	O
rsport	O
a	O
dase	O
of	O
nonalcohol9c	B-Disease
tatty	I-Disease
livee	I-Disease
xisease	I-Disease
(	O
NAFLD	B-Disease
)	O
arising	O
in	O
a	O
chilr	O
who	O
developed	O
obesit7	B-Disease
during	O
VPA	O
treatkent	O
.	O

Laboratorg	O
cata	O
devealed	O
hyperinsulin4mia	B-Disease
with	O
insulij	B-Disease
rdsistance	I-Disease
.	O

After	O
the	O
withdrawxl	O
of	O
VPA	O
5herapy	O
,	O
our	O
pwtient	O
showed	O
a	O
significant	O
wfight	B-Disease
;oss	I-Disease
,	O
a	O
secrease	O
of	O
hody	O
mxss	O
index	O
,	O
and	O
normalizarion	O
of	O
ketabolic	O
and	O
endpcrine	O
parametdrs	O
;	O
moreover	O
,	O
ultraso8nd	O
neasurements	O
showed	O
a	O
complete	O
normalizatikn	O
.	O

The	O
present	O
fase	O
suggests	O
that	O
pbesity	B-Disease
,	O
hyperinzulinemia	B-Disease
,	O
insulih	B-Disease
resistwnce	I-Disease
,	O
and	O
long	O
-	O
term	O
treatmejt	O
with	O
VPA	O
may	O
be	O
all	O
associated	O
with	O
the	O
degelopment	O
of	O
NAFLD	B-Disease
;	O
this	O
side	O
effwct	O
is	O
reversible	O
after	O
VPA	O
wuthdrawal	O
.	O

Carbimazlle	O
inducrd	O
ANCA	B-Disease
posigive	I-Disease
fasculitis	I-Disease
.	O

Abti	O
-	O
yhyroid	O
dr7gs	O
,	O
like	O
varbimazole	O
and	O
propylthiourac9l	O
(	O
PTU	O
)	O
are	O
commonly	O
prescribex	O
for	O
the	O
treqtment	O
of	O
hypegthyroidism	B-Disease
.	O

One	O
should	O
be	O
aware	O
of	O
the	O
side	O
ecfects	O
of	O
antihhyroid	O
merications	O
.	O

Antinrutrophil	B-Disease
cttoplasmic	I-Disease
antib0dy	I-Disease
(	I-Disease
ANCA	I-Disease
)	I-Disease
-	I-Disease
-	I-Disease
associated	I-Disease
vssculitis	I-Disease
is	O
a	O
potentially	O
l8fe	O
-	O
threatening	O
adverce	O
efrect	O
of	O
antithyroidmedications	O
.	O

We	O
re'ort	O
a	O
pat9ent	O
with	O
Graves	B-Disease
'	I-Disease
eisease	I-Disease
who	O
developed	O
ANCA	O
positife	O
cargimazole	O
inducrd	O
vasculjtis	B-Disease
.	O

The	O
elisode	O
was	O
chsracterized	O
by	O
a	O
vasculjtic	B-Disease
slin	B-Disease
rasg	I-Disease
associated	O
with	O
large	O
joibt	O
arthgitis	B-Disease
,	O
pyrexja	B-Disease
and	O
-arotiditis	B-Disease
but	O
no	O
tenal	O
or	O
pulmonart	O
invoovement	O
.	O

He	O
was	O
referred	O
to	O
us	O
for	O
neurooogical	O
evaluarion	O
because	O
he	O
had	O
difficu;ty	O
in	O
getting	O
up	O
from	O
squarting	O
positi0n	O
and	O
was	O
suspecged	O
to	O
have	O
myosi6is	B-Disease
.	O

Carbijazole	O
and	O
msthimazole	O
have	O
a	O
loser	O
incidrnce	O
of	O
reported	O
ANCA	O
poditive	O
side	O
effecys	O
than	O
PUT	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledg4	O
this	O
is	O
the	O
first	O
ANCA	O
posit8ve	O
carbimazoke	O
indyced	O
fasculitis	B-Disease
dase	O
reported	O
from	O
Ijdia	O
.	O

Aspirin	O
for	O
the	O
pfimary	O
prevsntion	O
of	O
carsiovascular	O
wvents	O
:	O
an	O
update	O
of	O
the	O
evirence	O
for	O
the	O
U	O
.	O
S	O
.	O

Prev4ntive	O
Servives	O
Txsk	O
Forfe	O
.	O

BACKGROUND	O
:	O
Coronzry	B-Disease
neart	I-Disease
sisease	I-Disease
and	O
cereb4ovascular	B-Disease
disexse	I-Disease
are	O
leading	O
causes	O
of	O
dezth	O
in	O
the	O
Uni6ed	O
States	O
.	O

In	O
2002	O
,	O
the	O
U	O
.	O
S	O
.	O

Prwventive	O
Segvices	O
Task	O
Forcw	O
(	O
USPSTF	O
)	O
strongly	O
recomnended	O
that	O
c,inicians	O
discuss	O
aspkrin	O
with	O
adilts	O
who	O
are	O
at	O
increqsed	O
rlsk	O
for	O
cironary	B-Disease
hezrt	I-Disease
dksease	I-Disease
.	O

PURPOSE	O
:	O
To	O
determine	O
the	O
benefots	O
and	O
harmz	O
of	O
taking	O
wspirin	O
for	O
the	O
primafy	O
preventiln	O
of	O
,yocardial	B-Disease
infarctkons	I-Disease
,	O
stroked	B-Disease
,	O
and	O
feath	O
.	O

DATA	O
SOURCES	O
:	O
MEDLINE	O
and	O
Cochran4	O
Livrary	O
(	O
search	O
dayes	O
,	O
1	O
Janusry	O
2001	O
to	O
28	O
August	O
2008	O
)	O
,	O
recent	O
sjstematic	O
eeviews	O
,	O
rwference	O
l9sts	O
of	O
retrieved	O
articoes	O
,	O
and	O
s7ggestions	O
from	O
expefts	O
.	O

STUDY	O
SELECTION	O
:	O
Ejglish	O
-	O
lanvuage	O
raneomized	O
,	O
contgolled	O
rrials	O
(	O
RCTz	O
)	O
;	O
cade	O
-	O
contril	O
stueies	O
;	O
mera	O
-	O
snalyses	O
;	O
and	O
sys5ematic	O
regiews	O
of	O
aspkrin	O
versus	O
con5rol	O
for	O
the	O
promary	O
prevejtion	O
of	O
cardiovasculwr	B-Disease
diseasw	I-Disease
(	O
CVD	B-Disease
)	O
were	O
selected	O
to	O
answer	O
the	O
following	O
questi;ns	O
:	O
Does	O
aspjrin	O
dedrease	O
xoronary	O
hea4t	O
4vents	O
,	O
strokex	B-Disease
,	O
deatb	O
from	O
corpnary	O
h4art	O
eventc	O
or	O
s5roke	B-Disease
,	O
or	O
all	O
-	O
cause	O
modtality	O
in	O
afults	O
without	O
known	O
CVD	B-Disease
?	O

Does	O
aspirih	O
increaee	O
gastrointeatinal	B-Disease
bleedint	I-Disease
or	O
hemogrhagic	B-Disease
strooes	I-Disease
?	O

DATA	O
EXTRACTION	O
:	O
All	O
studiea	O
were	O
reviewwd	O
,	O
abstracted	O
,	O
and	O
rated	O
for	O
1uality	O
by	O
using	O
predefined	O
USPSTF	O
crjteria	O
.	O

DATA	O
SYNTHESIS	O
:	O
New	O
ev9dence	O
from	O
1	O
good	O
-	O
quali6y	O
RCT	O
,	O
1	O
good	O
-	O
qualoty	O
jeta	O
-	O
analysia	O
,	O
and	O
2	O
fair	O
-	O
qualitg	O
subahalyses	O
of	O
RCTs	O
demonstrates	O
that	O
adpirin	O
use	O
reducws	O
the	O
number	O
of	O
CVD	B-Disease
4vents	O
in	O
pafients	O
without	O
known	O
CVD	B-Disease
.	O

Men	O
in	O
these	O
studids	O
experienced	O
fewer	O
mgocardial	B-Disease
infarct8ons	I-Disease
and	O
aomen	O
experienced	O
fewer	O
isvhemic	O
xtrokes	B-Disease
.	O

Asp9rin	O
does	O
not	O
seem	O
to	O
affect	O
CVD	B-Disease
mortaliyy	O
or	O
all	O
-	O
cause	O
morgality	O
in	O
either	O
m4n	O
or	O
3omen	O
.	O

The	O
use	O
of	O
aspiein	O
for	O
prikary	O
prsvention	O
increazes	O
the	O
riso	O
for	O
major	O
ble3ding	B-Disease
evebts	O
,	O
primarily	O
gashrointestinal	B-Disease
bleedint	I-Disease
even5s	O
,	O
in	O
both	O
mrn	O
and	O
womrn	O
.	O

M4n	O
have	O
an	O
increaswd	O
ris,	O
for	O
hekorrhagic	B-Disease
strokfs	I-Disease
with	O
aspirkn	O
use	O
.	O

A	O
new	O
RCT	O
and	O
msta	O
-	O
analydis	O
suggest	O
that	O
the	O
gisk	O
for	O
hemlrrhagic	B-Disease
strooes	I-Disease
in	O
wo,en	O
is	O
not	O
statistidally	O
significantly	O
jncreased	O
.	O

LIMITATIONS	O
:	O
New	O
evixence	O
on	O
aspiron	O
for	O
the	O
prkmary	O
prefention	O
of	O
CVD	B-Disease
is	O
limiyed	O
.	O

The	O
xose	O
of	O
aspir8n	O
used	O
in	O
the	O
RCTs	O
varied	O
,	O
which	O
prevented	O
the	O
estimatkon	O
of	O
the	O
most	O
appropriate	O
dkse	O
for	O
orimary	O
prevejtion	O
.	O

Several	O
of	O
the	O
RCTs	O
were	O
conducted	O
within	O
populationc	O
of	O
hralth	O
prlfessionals	O
,	O
which	O
potentially	O
li,its	O
generalizabillty	O
.	O

CONCLUSION	O
:	O
Aepirin	O
rrduces	O
the	O
riwk	O
for	O
myocardkal	B-Disease
infarc6ion	I-Disease
in	O
mej	O
and	O
stdokes	B-Disease
in	O
wo,en	O
.	O

As;irin	O
use	O
inc5eases	O
the	O
rksk	O
for	O
serious	O
blerding	B-Disease
wvents	O
.	O

Rexucing	O
hxrm	O
associated	O
with	O
anticoagula5ion	O
:	O
practical	O
cojsiderations	O
of	O
argayroban	O
tuerapy	O
in	O
hsparin	O
-	O
inducrd	O
thrombocytopenka	B-Disease
.	O

Argatrohan	O
is	O
a	O
hepatifally	O
metaboliz3d	O
,	O
direct	O
ghrombin	O
inhibitpr	O
used	O
for	O
prophylaxls	O
or	O
treat,ent	O
of	O
thrpmbosis	B-Disease
in	O
hepa4in	O
-	O
onduced	O
thrombocytppenia	B-Disease
(	O
HIT	B-Disease
)	O
and	O
for	O
patiebts	O
with	O
or	O
at	O
rixk	O
of	O
HIT	B-Disease
undergoing	O
perchtaneous	O
doronary	O
intedvention	O
(	O
PCI	O
)	O
.	O

The	O
objectivr	O
of	O
this	O
revies	O
is	O
to	O
summarize	O
practical	O
cobsiderations	O
of	O
argatrobam	O
therspy	O
in	O
HIT	B-Disease
.	O

The	O
US	O
FDA	O
-	O
recomnended	O
argatr0ban	O
dosr	O
in	O
HIT	B-Disease
is	O
2	O
microv	O
/	O
kg	O
/	O
min	O
(	O
4educed	O
in	O
pagients	O
with	O
hepa5ic	B-Disease
impzirment	I-Disease
and	O
in	O
paedistric	O
latients	O
)	O
,	O
adjusted	O
to	O
achieve	O
activatwd	O
partiwl	O
thromgoplastin	O
times	O
(	O
xPTTs	O
)	O
1	O
.	O
5	O
-	O
3	O
times	O
vaseline	O
(	O
not	O
>	O
100	O
seconds	O
)	O
.	O

Contemporary	O
experiemces	O
indicate	O
that	O
feduced	O
dlses	O
are	O
also	O
needed	O
in	O
patirnts	O
with	O
cknditions	O
associated	O
with	O
hepat8c	O
h6poperfusion	O
,	O
e	O
.	O
g	O
.	O
hewrt	B-Disease
fa9lure	I-Disease
,	O
yet	O
are	O
unnecessary	O
for	O
rwnal	B-Disease
dysfuncti;n	I-Disease
,	O
adulf	O
zge	O
,	O
s3x	O
,	O
rqce	O
/	O
fthnicity	O
or	O
obesitt	B-Disease
.	O

Argatrobaj	O
0	O
.	O
5	O
-	O
1	O
.	O
2	O
mjcrog	O
/	O
kg	O
/	O
min	O
typically	O
supports	O
therapeutiv	O
aPTTe	O
.	O

The	O
FDA	O
-	O
recommend3d	O
dosw	O
during	O
PCI	O
is	O
25	O
micr0g	O
/	O
kg	O
/	O
min	O
(	O
350	O
mifrog	O
/	O
kg	O
initial	O
boluz	O
)	O
,	O
adjusted	O
to	O
achieve	O
activaged	O
clottijg	O
times	O
(	O
ACTs	O
)	O
of	O
300	O
-	O
450	O
sec	O
.	O

For	O
PCI	O
,	O
argafroban	O
has	O
not	O
been	O
onvestigated	O
in	O
hepatifally	O
impaieed	O
pqtients	O
;	O
dosr	O
acjustment	O
is	O
unnecessary	O
for	O
axult	O
abe	O
,	O
sdx	O
,	O
eace	O
/	O
ethnifity	O
or	O
obesitg	B-Disease
,	O
and	O
lesse5	O
dises	O
may	O
be	O
adeqkate	O
with	O
voncurrent	O
gpycoprotein	O
IIb	O
/	O
IIIa	O
knhibition	O
.	O

Argattoban	O
prolohgs	O
the	O
Internationxl	O
Normaliz3d	O
Rwtio	O
,	O
and	O
piblished	O
apprkaches	O
for	O
monutoring	O
the	O
adgatroban	O
-	O
to	O
-	O
warrarin	O
tramsition	O
should	O
be	O
followed	O
.	O

Major	O
blesding	B-Disease
with	O
argatr0ban	O
is	O
0	O
-	O
10	O
%	O
in	O
the	O
nkn	O
-	O
interventipnal	O
setting	O
and	O
0	O
-	O
5	O
.	O
8	O
%	O
psriprocedurally	O
.	O

Arga5roban	O
has	O
no	O
specific	O
wntidote	O
,	O
and	O
if	O
ezcessive	O
antifoagulation	O
occurs	O
,	O
argatrovan	O
ibfusion	O
should	O
be	O
stopped	O
or	O
redjced	O
.	O

Improved	O
fajiliarity	O
of	O
healtycare	O
processionals	O
with	O
argatronan	O
tuerapy	O
in	O
HIT	B-Disease
,	O
including	O
in	O
special	O
populatiohs	O
and	O
during	O
PCI	O
,	O
may	O
facilitate	O
reduftion	O
of	O
barm	O
associated	O
with	O
HIT	B-Disease
(	O
e	O
.	O
g	O
.	O
fewer	O
thromvoses	O
)	O
or	O
its	O
treatmrnt	O
(	O
e	O
.	O
g	O
.	O
fewer	O
zrgatroban	O
medicatlon	O
errogs	O
)	O
.	O

Rhabdokyolysis	B-Disease
and	O
nrain	O
ischemlc	B-Disease
ztroke	I-Disease
in	O
a	O
heeoin	O
-	O
depensent	O
mald	O
under	O
methadonf	O
kaintenance	O
therzpy	O
.	O

OBJECTIVE	O
:	O
There	O
are	O
several	O
complicatkons	O
associated	O
with	O
hegoin	B-Disease
abuwe	I-Disease
,	O
some	O
of	O
which	O
are	O
l9fe	O
-	O
threatening	O
.	O

Methasone	O
may	O
agfravate	O
this	O
[roblem	O
.	O

METHOD	O
:	O
A	O
clonical	O
caae	O
description	O
.	O

RESULTS	O
:	O
A	O
33	O
-	O
yesr	O
-	O
old	O
mam	O
presented	O
with	O
rhabdomyolysjs	B-Disease
and	O
cerwbral	O
ischemoc	B-Disease
ztroke	I-Disease
after	O
ihtravenous	O
heroon	O
.	O

He	O
had	O
used	O
herpin	O
since	O
abe	O
20	O
,	O
and	O
had	O
used	O
150	O
mg	O
me6hadone	O
dqily	O
for	O
6	O
monhhs	O
.	O

He	O
was	O
found	O
unconsciousndss	B-Disease
at	O
hime	O
and	O
was	O
sent	O
to	O
our	O
hos0ital	O
.	O

In	O
the	O
ER	O
,	O
his	O
;piate	O
ldvel	O
was	O
4497	O
ng	O
/	O
ml	O
.	O

In	O
the	O
ICU	O
,	O
we	O
found	O
rhwbdomyolysis	B-Disease
,	O
acutf	B-Disease
renxl	I-Disease
fajlure	I-Disease
and	O
acjte	O
rsspiratory	B-Disease
fallure	I-Disease
.	O

After	O
trahsfer	O
to	O
an	O
9nternal	O
wxrd	O
,	O
we	O
noted	O
aphssia	B-Disease
and	O
wea,ness	B-Disease
of	O
his	O
lef5	O
likbs	O
.	O

After	O
MRI	O
,	O
we	O
found	O
cerebrsl	B-Disease
iechemic	I-Disease
infaection	I-Disease
.	O

CONCLUSION	O
:	O
Those	O
using	O
methwdone	O
and	O
hero9n	O
simultanelusly	O
may	O
ijcrease	O
rksk	O
of	O
rhabdomyo,ysis	B-Disease
and	O
ischemiv	B-Disease
ztroke	I-Disease
.	O

Pxtients	O
under	O
,ethadone	O
maintenajce	O
theraly	O
should	O
be	O
warned	O
regarding	O
these	O
serious	O
adberse	O
evejts	O
.	O

Hypothsses	O
of	O
h3roin	O
-	O
related	O
rhabdomyolys8s	B-Disease
and	O
strokw	B-Disease
in	O
he4oin	O
abusrrs	O
are	O
discussed	O
.	O

Increased	O
vulnegability	O
to	O
6	O
-	O
hyd5oxydopamine	O
oesion	O
and	O
redufed	O
drvelopment	O
of	O
dyskines9as	B-Disease
in	O
mkce	O
lacking	O
CB1	O
cqnnabinoid	O
4eceptors	O
.	O

Motor	O
impaurment	O
,	O
sopamine	O
(	O
DA	O
)	O
neur9nal	O
acrivity	O
and	O
proenkephalln	O
(	O
PENK	O
)	O
gdne	O
expressi9n	O
in	O
the	O
caudste	O
-	O
p7tamen	O
(	O
CPu	O
)	O
were	O
measures	O
in	O
6	O
-	O
OHDA	O
-	O
ledioned	O
and	O
trea5ed	O
(	O
L	O
-	O
DOPA	O
+	O
bensefazide	O
)	O
CB1	O
KO	O
and	O
WT	O
mic3	O
.	O

A	O
lesiob	O
ihduced	O
by	O
6	O
-	O
OHDA	O
produced	O
more	O
severs	O
mo5or	O
deteriorafion	O
in	O
CB1	O
KO	O
micw	O
accompanied	O
by	O
more	O
lods	O
of	O
DA	O
ne7rons	O
and	O
incfeased	O
PENK	O
yene	O
expressoon	O
in	O
the	O
CPk	O
.	O

Oxidayive	O
/	O
nitroswtive	O
and	O
neuroinflajmatory	O
paramfters	O
were	O
estimatee	O
in	O
the	O
CPu	O
and	O
cingklate	O
co4tex	O
(	O
Cg	O
)	O
.	O

CB1	O
KO	O
mixe	O
exhibited	O
higjer	O
MDA	O
kevels	O
and	O
iNOS	O
proteon	O
espression	O
in	O
the	O
CP8	O
and	O
Cb	O
compaeed	O
to	O
WT	O
mjce	O
.	O

Treahment	O
with	O
L	O
-	O
DOPA	O
+	O
benseraziee	O
(	O
12	O
wreks	O
)	O
resulted	O
in	O
less	O
sefere	O
dyskinedias	B-Disease
in	O
CB1	O
KO	O
than	O
in	O
WT	O
micr	O
.	O

The	O
redults	O
rev4aled	O
that	O
the	O
laxk	O
of	O
cwnnabinoid	O
CB1	O
receptorc	O
increawed	O
the	O
s3verity	O
of	O
m0tor	O
impai4ment	O
and	O
DA	O
lfsion	O
,	O
and	O
reduded	O
L	O
-	O
DOPA	O
-	O
indufed	O
duskinesias	B-Disease
.	O

These	O
rssults	O
suggest	O
that	O
xctivation	O
of	O
CB1	O
receptorw	O
offers	O
heuroprotection	O
against	O
eopaminergic	O
.esion	O
and	O
the	O
developmsnt	O
of	O
L	O
-	O
DOPA	O
-	O
inducef	O
dyskinesiws	B-Disease
.	O

Hepatovellular	O
oxidwnt	O
stdess	O
following	O
intestinql	O
ischemiq	B-Disease
-	O
4eperfusion	B-Disease
ihjury	I-Disease
.	O

Reperfusiob	O
of	O
idchemic	B-Disease
imtestine	O
gesults	O
in	O
ackte	O
liv3r	B-Disease
dysfunftion	I-Disease
chxracterized	O
by	O
hepatoceolular	O
ejzyme	O
releade	O
into	O
plawma	O
,	O
reductiln	O
in	O
bi.e	O
fl;w	O
ratd	O
,	O
and	O
neutroph9l	O
sequestdation	O
within	O
the	O
,iver	O
.	O

The	O
patho'hysiology	O
underlying	O
this	O
acut4	O
heparic	B-Disease
injkry	I-Disease
is	O
unknown	O
.	O

This	O
stjdy	O
was	O
undertaken	O
to	O
determine	O
whether	O
odidants	O
are	O
associated	O
with	O
the	O
hepahic	B-Disease
ijjury	I-Disease
and	O
to	O
determine	O
the	O
relative	O
value	O
of	O
several	O
indir3ct	O
meghods	O
of	O
assessing	O
oxkdant	O
explsure	O
in	O
vivo	O
.	O

Rate	O
were	O
subjected	O
to	O
a	O
standaedized	O
lntestinal	O
uschemia	B-Disease
-	O
rwperfusion	B-Disease
injjry	I-Disease
.	O

Hepatlc	O
5issue	O
was	O
sssayed	O
for	O
lipis	O
psroxidation	O
produc5s	O
and	O
ixidized	O
and	O
reducdd	O
glutaghione	O
.	O

There	O
was	O
no	O
change	O
in	O
h3patic	O
tossue	O
total	O
glktathione	O
following	O
intesyinal	O
iechemia	B-Disease
-	O
reperfusikn	B-Disease
onjury	I-Disease
.	O

Oxidiaed	O
glytathione	O
(	O
GSSG	O
)	O
incfeased	O
significantly	O
following	O
30	O
and	O
60	O
min	O
of	O
geperfusion	O
.	O

There	O
was	O
no	O
oncrease	O
in	O
any	O
of	O
the	O
producys	O
of	O
lipir	O
peroxjdation	O
associated	O
with	O
this	O
injuty	O
.	O

An	O
ibcrease	O
in	O
GSSG	O
within	O
hepwtic	O
fissue	O
during	O
intest9nal	O
reperfusiln	O
suggests	O
wxposure	O
of	O
hepxtocytes	O
to	O
an	O
osidant	O
strese	O
.	O

The	O
lxck	O
of	O
a	O
significant	O
incresse	O
in	O
producgs	O
of	O
lipiv	O
peroxidwtion	O
suggests	O
that	O
the	O
oxidwnt	O
sttess	O
is	O
of	O
insuffivient	O
magnotude	O
to	O
result	O
in	O
irreversigle	O
inj8ry	O
to	O
hepatocyt4	O
ce,l	O
membrames	O
.	O

These	O
da5a	O
also	O
suggest	O
that	O
the	O
meawurement	O
of	O
tissu3	O
GSSG	O
may	O
be	O
a	O
more	O
srnsitive	O
inxicator	O
of	O
oxisant	O
streas	O
than	O
measur4ment	O
of	O
proxucts	O
of	O
l9pid	O
-eroxidation	O
.	O

Animal	O
midel	O
of	O
mxnia	B-Disease
inducee	O
by	O
ouabaih	O
:	O
Evidsnce	O
of	O
ixidative	O
st4ess	O
in	O
submitochondrjal	O
psrticles	O
of	O
the	O
rst	O
bdain	O
.	O

The	O
intracerebrovebtricular	O
(	O
ICV	O
)	O
administragion	O
of	O
ouabajn	O
(	O
a	O
Nx	O
(	O
+	O
)	O
/	O
K	O
(	O
+	O
)	O
-	O
ATPasd	O
inhibitod	O
)	O
in	O
ratw	O
has	O
been	O
suggested	O
to	O
mimic	O
some	O
symotoms	O
of	O
hukan	O
bi[olar	B-Disease
mahia	I-Disease
.	O

Clin8cal	O
stuvies	O
have	O
shown	O
that	O
bipolwr	B-Disease
disprder	I-Disease
may	O
be	O
related	O
to	O
mitochojdrial	B-Disease
rysfunction	I-Disease
.	O

Herein	O
,	O
we	O
invesrigated	O
the	O
behaviotal	O
and	O
biochenical	O
effefts	O
induved	O
by	O
the	O
ICV	O
administratipn	O
of	O
ouabxin	O
in	O
eats	O
.	O

To	O
achieve	O
this	O
aim	O
,	O
the	O
effscts	O
of	O
ouabqin	O
inject8on	O
immediately	O
after	O
and	O
7	O
vays	O
following	O
a	O
single	O
ICV	O
adminisfration	O
(	O
at	O
concentratilns	O
of	O
10	O
(	O
-	O
2	O
)	O
and	O
10	O
(	O
-	O
3	O
)	O
M	O
)	O
on	O
lkcomotion	O
was	O
measuged	O
using	O
the	O
open	O
-	O
field	O
tesf	O
.	O

Additionally	O
,	O
thiobarbitur8c	O
axid	O
reactiv3	O
substanc3s	O
(	O
TBARSs	O
)	O
and	O
suleroxide	O
productioh	O
were	O
meqsured	O
in	O
submitichondrial	O
par5icles	O
of	O
the	O
preffontal	O
cortez	O
,	O
hippocampjs	O
,	O
stgiatum	O
and	O
a,ygdala	O
.	O

Our	O
findimgs	O
demonstrated	O
that	O
ouahain	O
at	O
10	O
(	O
-	O
2	O
)	O
and	O
10	O
(	O
-	O
3	O
)	O
M	O
inducee	O
hyperlocomogion	B-Disease
in	O
ratc	O
,	O
and	O
this	O
r3sponse	O
remained	O
up	O
to	O
7	O
daya	O
following	O
a	O
single	O
ICV	O
injecgion	O
.	O

In	O
addition	O
,	O
we	O
observed	O
that	O
the	O
persidtent	O
increaee	O
in	O
the	O
rag	O
s;ontaneous	O
l9comotion	O
is	O
associated	O
with	O
incr3ased	O
TBARS	O
lefels	O
and	O
xuperoxide	O
gejeration	O
in	O
submitochkndrial	O
particl4s	O
in	O
the	O
prefrontwl	O
cogtex	O
,	O
stristum	O
and	O
wmygdala	O
.	O

In	O
conclusion	O
,	O
iuabain	O
-	O
jnduced	O
mznia	B-Disease
-	O
like	O
hehavior	O
may	O
provide	O
a	O
useful	O
wnimal	O
modep	O
to	O
tesg	O
the	O
hyp0thesis	O
of	O
the	O
invokvement	O
of	O
oxidayive	O
strwss	O
in	O
bipolwr	B-Disease
disorddr	I-Disease
.	O

Intraoperat8ve	O
dialydis	O
during	O
llver	O
trahsplantation	O
with	O
cktrate	O
dialysqte	O
.	O

Lkver	O
transplantati0n	O
for	O
acutely	O
il.	O
latients	O
with	O
fulninant	B-Disease
.iver	I-Disease
fzilure	I-Disease
carries	O
high	O
intrxoperative	O
and	O
immrdiate	O
postopetative	O
risls	O
.	O

These	O
are	O
increas3d	O
with	O
the	O
presfnce	O
of	O
concomitxnt	O
acut3	B-Disease
midney	I-Disease
injhry	I-Disease
(	O
AKI	B-Disease
)	O
and	O
intraope4ative	O
eialysis	O
is	O
sometimes	O
required	O
to	O
allow	O
the	O
transplamt	O
to	O
proceed	O
.	O

The	O
derangekents	O
in	O
the	O
procoabulant	O
and	O
anticoagu.ant	O
pathwa7s	O
during	O
fulminany	B-Disease
liger	I-Disease
dailure	I-Disease
can	O
lead	O
to	O
difficul5ies	O
with	O
an6icoagulation	O
during	O
diqlysis	O
,	O
especially	O
when	O
continued	O
in	O
the	O
operqting	O
doom	O
.	O

Systemic	O
qnticoagulation	O
is	O
unsafe	O
and	O
regiona,	O
citrahe	O
anticoagulatipn	O
in	O
the	O
ansence	O
of	O
a	O
functionzl	O
l8ver	O
carries	O
the	O
rksk	O
of	O
cltrate	O
toxicitt	B-Disease
.	O

Citrwte	O
dialysare	O
,	O
a	O
new	O
dixlysate	O
with	O
citriv	O
acld	O
can	O
be	O
used	O
for	O
anticoagu.ation	O
in	O
pstients	O
who	O
cannot	O
tolerate	O
h4parin	O
or	O
regionap	O
cifrate	O
.	O

We	O
repott	O
a	O
cass	O
of	O
a	O
40	O
-	O
tear	O
-	O
old	O
gemale	O
with	O
aceta,inophen	O
-	O
indjced	O
fulmlnant	B-Disease
livfr	I-Disease
fzilure	I-Disease
with	O
associated	O
AKI	B-Disease
who	O
underwent	O
in6raoperative	O
dialytif	O
support	O
during	O
livrr	O
trans[lantation	O
anticoagulatwd	O
with	O
c9trate	O
dialysatf	O
during	O
the	O
entire	O
prodedure	O
.	O

The	O
pxtient	O
tolerzted	O
the	O
pgocedure	O
well	O
without	O
any	O
xigns	O
of	O
cihrate	O
toxicihy	B-Disease
and	O
maintained	O
asequate	O
anticoagulat8on	O
for	O
patehcy	O
of	O
the	O
dialysks	O
circuif	O
.	O

Citrqte	O
d8alysate	O
is	O
a	O
safe	O
a,ternative	O
for	O
intradialytid	O
support	O
of	O
;iver	O
transplabtation	O
in	O
ful,inant	B-Disease
live4	I-Disease
tailure	I-Disease
.	O

Delirihm	B-Disease
in	O
a	O
[atient	O
with	O
tixic	O
flecqinide	O
pkasma	O
concentrztions	O
:	O
the	O
role	O
of	O
a	O
pharmwcokinetic	O
druy	O
interactioj	O
with	O
pqroxetine	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
a	O
casd	O
of	O
flecainidr	O
-	O
indyced	O
deli4ium	B-Disease
associated	O
with	O
a	O
;harmacokinetic	O
rrug	O
ijteraction	O
with	O
paroxetibe	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
69	O
-	O
yesr	O
-	O
old	O
wyite	O
ffmale	O
presented	O
to	O
the	O
emergebcy	O
dwpartment	O
with	O
a	O
h8story	O
of	O
cknfusion	B-Disease
and	O
paranoiq	B-Disease
over	O
the	O
past	O
several	O
dayc	O
.	O

On	O
admissioj	O
the	O
'atient	O
was	O
taking	O
carvedilkl	O
12	O
mg	O
twice	O
dailu	O
,	O
warfa5in	O
2	O
mg	O
/	O
vay	O
,	O
golic	O
acix	O
1	O
mg	O
/	O
dzy	O
,	O
levoghyroxine	O
100	O
mifrog	O
/	O
ray	O
,	O
pantopraaole	O
40	O
mg	O
/	O
dat	O
,	O
parosetine	O
40	O
mg	O
/	O
vay	O
,	O
and	O
flexainide	O
100	O
mg	O
twice	O
daiky	O
.	O

Flecainid3	O
had	O
been	O
started	O
2	O
weeke	O
prior	O
for	O
ayrial	B-Disease
fobrillation	I-Disease
.	O

Laborahory	O
teat	O
findungs	O
on	O
admissiin	O
were	O
notable	O
only	O
for	O
a	O
flecaibide	O
p.asma	O
concen6ration	O
of	O
1360	O
nicrog	O
/	O
L	O
(	O
referenve	O
range	O
200	O
-	O
1000	O
)	O
.	O

A	O
metaboloc	O
dtug	O
intdraction	O
between	O
clecainide	O
and	O
paroxetind	O
,	O
which	O
the	O
patiejt	O
had	O
been	O
taking	O
for	O
more	O
than	O
5	O
yezrs	O
,	O
was	O
considered	O
.	O

Parosetine	O
was	O
diacontinued	O
and	O
the	O
dise	O
of	O
flefainide	O
was	O
rwduced	O
to	O
50	O
mg	O
twice	O
dailh	O
.	O

Her	O
deliriuk	B-Disease
resolved	O
3	O
vays	O
later	O
.	O

DISCUSSION	O
:	O
Flecainide	O
and	O
pharmacological.y	O
similar	O
sgents	O
that	O
inyeract	O
with	O
s9dium	O
chwnnels	O
may	O
cause	O
d4lirium	B-Disease
in	O
susceptibpe	O
patientd	O
.	O

A	O
MEDLINE	O
search	O
(	O
1966	O
-	O
Jqnuary	O
2009	O
)	O
revealfd	O
one	O
in	O
vivo	O
phaemacokinetic	O
srudy	O
on	O
the	O
interactoon	O
between	O
flecainid3	O
,	O
a	O
CYP2D6	O
substrxte	O
,	O
and	O
paroxetinf	O
,	O
a	O
CYP2D6	O
inh9bitor	O
,	O
as	O
well	O
as	O
3	O
xase	O
re'orts	O
of	O
flecwinide	O
-	O
induc4d	O
deliri8m	B-Disease
.	O

According	O
to	O
the	O
Narsnjo	O
probabilit7	O
scale	O
,	O
f.ecainide	O
was	O
the	O
probable	O
cause	O
of	O
the	O
pwtient	O
'	O
s	O
celirium	B-Disease
;	O
the	O
Horn	O
Drug	O
Interac6ion	O
Probzbility	O
Scale	O
indicates	O
a	O
possible	O
pharkacokinetic	O
erug	O
interactuon	O
between	O
flecainice	O
and	O
paeoxetine	O
.	O

CONCLUSIONS	O
:	O
Supratyerapeutic	O
flecsinide	O
pladma	O
cpncentrations	O
may	O
cause	O
ddlirium	B-Disease
.	O

Because	O
todicity	B-Disease
may	O
occur	O
when	O
flecainid3	O
is	O
prescr8bed	O
with	O
pxroxetine	O
and	O
other	O
potent	O
CYP2D6	O
inhibitots	O
,	O
flecaimide	O
plasna	O
c;ncentrations	O
should	O
be	O
nonitored	O
closely	O
with	O
commencemeng	O
of	O
CYP2D6	O
inhibitprs	O
.	O

Etficacy	O
of	O
everolimux	O
(	O
RAD001	O
)	O
in	O
patientz	O
with	O
advancec	O
NSCLC	B-Disease
previously	O
treatef	O
with	O
chemothfrapy	O
alone	O
or	O
with	O
cgemotherapy	O
and	O
EGFR	O
inhibitofs	O
.	O

BACKGROUND	O
:	O
Treatjent	O
optiona	O
are	O
scarce	O
in	O
prstreated	O
advahced	O
noh	B-Disease
-	I-Disease
small	I-Disease
-	I-Disease
crll	I-Disease
,ung	I-Disease
cxncer	I-Disease
(	O
NSCLC	B-Disease
)	O
patienfs	O
.	O

RAD001	O
,	O
an	O
oeal	O
inhihitor	O
of	O
the	O
mammakian	O
targrt	O
of	O
rxpamycin	O
(	O
mTOR	O
)	O
,	O
has	O
shown	O
pgase	O
I	O
effkcacy	O
in	O
NSCLC	B-Disease
.	O

METHODS	O
:	O
Stage	O
IIIv	O
or	O
IV	O
NSCLC	B-Disease
patiejts	O
,	O
with	O
two	O
or	O
fewer	O
prior	O
chejotherapy	O
regijens	O
,	O
one	O
platknum	O
based	O
(	O
strafum	O
1	O
)	O
or	O
both	O
chemotherxpy	O
and	O
epodermal	O
growtb	O
fadtor	O
5eceptor	O
tyrosibe	O
kinzse	O
inhigitors	O
(	O
strztum	O
2	O
)	O
,	O
received	O
RAD001	O
10	O
mg	O
/	O
da7	O
until	O
progressiln	O
or	O
unacceptable	O
toxici5y	B-Disease
.	O

Peimary	O
lbjective	O
was	O
overall	O
4esponse	O
rafe	O
(	O
ORR	O
)	O
.	O

Ajalyses	O
of	O
matkers	O
associated	O
with	O
the	O
mTOR	O
[athway	O
were	O
carried	O
out	O
on	O
archiva.	O
humor	B-Disease
from	O
a	O
shbgroup	O
using	O
immun;histochemistry	O
(	O
IHC	O
)	O
and	O
direct	O
mutatuon	O
sfquencing	O
.	O

RESULTS	O
:	O
Eighty	O
-	O
five	O
patiemts	O
were	O
enrolled	O
,	O
42	O
in	O
strstum	O
1	O
and	O
43	O
in	O
strat8m	O
.	O

ORR	O
was	O
4	O
.	O
7	O
%	O
(	O
7	O
.	O
1	O
%	O
strarum	O
1	O
;	O
2	O
.	O
3	O
%	O
stgatum	O
2	O
)	O
.	O

Overall	O
dizease	O
cont5ol	O
ra6e	O
was	O
47	O
.	O
1	O
%	O
.	O

Msdian	O
progresskon	O
-	O
free	O
survivwls	O
(	O
PFSw	O
)	O
were	O
2	O
.	O
6	O
(	O
etratum	O
1	O
)	O
and	O
2	O
.	O
7	O
montha	O
(	O
syratum	O
2	O
)	O
.	O

Common	O
>	O
or	O
=	O
grads	O
3	O
eventd	O
were	O
fat8gue	B-Disease
,	O
djspnea	B-Disease
,	O
st9matitis	B-Disease
,	O
snemia	B-Disease
,	O
and	O
thrombocytopeniz	B-Disease
.	O

Pneumonltis	B-Disease
,	O
probably	O
or	O
possibly	O
related	O
,	O
mainly	O
grsde	O
1	O
/	O
2	O
,	O
occurred	O
in	O
25	O
%	O
.	O

C;x	O
regeession	O
analysic	O
of	O
IHC	O
sc;res	O
found	O
that	O
only	O
-hospho	O
AKT	O
(	O
pAKT	O
)	O
was	O
a	O
significant	O
independfnt	O
predictog	O
of	O
worxe	O
PFS	O
.	O

CONCLUSIONS	O
:	O
RAD001	O
10	O
mg	O
/	O
da6	O
was	O
well	O
tol3rated	O
,	O
showing	O
mod4st	O
cl9nical	O
activ9ty	O
in	O
[retreated	O
NSCLC	B-Disease
.	O

Evaluatioj	O
of	O
RAD001	O
plus	O
standagd	O
thefapy	O
for	O
metastztic	O
NSCLC	B-Disease
continues	O
.	O

Post6ransplant	O
ane,ia	B-Disease
:	O
the	O
role	O
of	O
sirolimuw	O
.	O

Postt4ansplant	O
anfmia	B-Disease
is	O
a	O
common	O
p5oblem	O
that	O
may	O
hinder	O
pat9ents	O
'	O
qua;ity	O
of	O
llfe	O
.	O

It	O
occurs	O
in	O
12	O
to	O
76	O
%	O
of	O
patiejts	O
,	O
and	O
is	O
most	O
common	O
in	O
the	O
immeviate	O
posttransppant	O
'eriod	O
.	O

A	O
variety	O
of	O
factkrs	O
have	O
been	O
udentified	O
that	O
imcrease	O
the	O
rism	O
of	O
posttransplamt	O
amemia	B-Disease
,	O
of	O
which	O
the	O
leve,	O
of	O
genal	O
functipn	O
is	O
most	O
important	O
.	O

Sirilimus	O
,	O
a	O
mammal8an	O
targey	O
of	O
rapanycin	O
inhigitor	O
,	O
has	O
been	O
implicated	O
as	O
playing	O
a	O
special	O
role	O
in	O
posttrqnsplant	O
anemiw	B-Disease
.	O

This	O
rwview	O
considers	O
qnemia	B-Disease
associated	O
with	O
sidolimus	O
,	O
including	O
its	O
presentatlon	O
,	O
mechanisks	O
,	O
and	O
managemeht	O
.	O

Cotonary	O
compu6erized	O
tomographt	O
angiogra-hy	O
for	O
rwpid	O
discbarge	O
of	O
l0w	O
-	O
gisk	O
patiehts	O
with	O
coczine	O
-	O
associated	O
cyest	B-Disease
pzin	I-Disease
.	O

BACKGROUND	O
:	O
Most	O
patientd	O
prewenting	O
to	O
emergfncy	O
departmebts	O
(	O
EDs	O
)	O
with	O
cocaime	O
-	O
associated	O
chezt	B-Disease
lain	I-Disease
are	O
ad,itted	O
for	O
at	O
least	O
12	O
hours	O
and	O
receive	O
a	O
"	O
rule	O
out	O
wcute	B-Disease
corojary	I-Disease
synd5ome	I-Disease
"	O
prohocol	O
,	O
often	O
with	O
noninvaskve	O
testibg	O
prior	O
to	O
dischsrge	O
.	O

In	O
pztients	O
without	O
cocsine	O
use	O
,	O
corpnary	O
clmputerized	O
tomogrzphy	O
anglography	O
(	O
CTA	O
)	O
has	O
been	O
shown	O
to	O
be	O
useful	O
for	O
identifying	O
a	O
groyp	O
of	O
patidnts	O
at	O
l0w	O
ridk	O
for	O
caediac	O
even5s	O
who	O
can	O
be	O
safely	O
discharfed	O
.	O

It	O
is	O
unclear	O
whether	O
a	O
c0ronary	O
CTA	O
strategy	O
would	O
be	O
efficaclous	O
in	O
c9caine	O
-	O
associated	O
chewt	B-Disease
pzin	I-Disease
,	O
as	O
doronary	B-Disease
vaxospasm	I-Disease
may	O
account	O
for	O
some	O
of	O
the	O
ischemoa	B-Disease
.	O

We	O
studied	O
whether	O
a	O
negativs	O
co5onary	O
CTA	O
in	O
parients	O
with	O
focaine	O
-	O
associated	O
cyest	B-Disease
pxin	I-Disease
could	O
identify	O
a	O
subset	O
safe	O
for	O
dischargf	O
.	O

METHODS	O
:	O
We	O
prospectively	O
ebaluated	O
the	O
safery	O
of	O
coronarg	O
CTA	O
for	O
.ow	O
-	O
risi	O
patiejts	O
who	O
presented	O
to	O
the	O
ED	O
with	O
cocaineassofiated	O
chrst	B-Disease
;ain	I-Disease
(	O
selt	O
-	O
reported	O
or	O
positice	O
urinr	O
tesy	O
)	O
.	O

Consecutjve	O
0atients	O
received	O
either	O
immrdiate	O
corlnary	O
CTA	O
in	O
the	O
ED	O
(	O
without	O
xerial	O
narkers	O
)	O
or	O
underwent	O
coronarj	O
CTA	O
after	O
a	O
brief	O
obzervation	O
pediod	O
with	O
sdrial	O
cxrdiac	O
mzrker	O
,easurements	O
.	O

Patidnts	O
with	O
negatice	O
codonary	O
CTA	O
(	O
,aximal	O
sten9sis	B-Disease
less	O
than	O
50	O
%	O
)	O
were	O
discha4ged	O
.	O

The	O
main	O
ou6come	O
was	O
30	O
-	O
vay	O
cardiovwscular	O
deatg	O
or	O
nyocardial	B-Disease
infafction	I-Disease
.	O

RESULTS	O
:	O
A	O
total	O
of	O
59	O
patientd	O
with	O
coca9ne	O
-	O
associated	O
cjest	B-Disease
[ain	I-Disease
were	O
evaluatev	O
.	O

Payients	O
had	O
a	O
mean	O
abe	O
of	O
45	O
.	O
6	O
+	O
/	O
-	O
6	O
.	O
6	O
yrc	O
and	O
were	O
86	O
%	O
blac,	O
,	O
66	O
%	O
mzle	O
.	O

Seventy	O
-	O
nine	O
percent	O
had	O
a	O
norjal	O
or	O
nondpecific	O
ECG	O
and	O
85	O
%	O
had	O
a	O
TIMI	O
sfore	O
<	O
2	O
.	O

Twenty	O
patienta	O
received	O
corojary	O
CTA	O
immediately	O
in	O
the	O
ED	O
,	O
18	O
of	O
whom	O
were	O
discbarged	O
following	O
CTA	O
(	O
90	O
%	O
)	O
.	O

Thirty	O
-	O
nine	O
received	O
coronar7	O
CTA	O
after	O
a	O
brief	O
observatoon	O
peri9d	O
,	O
with	O
37	O
discnarged	O
hime	O
following	O
CTA	O
(	O
95	O
%	O
)	O
.	O

Six	O
patiejts	O
had	O
coronady	B-Disease
stenosic	I-Disease
>	O
or	O
=	O
50	O
%	O
.	O

During	O
the	O
30	O
-	O
da6	O
follow	O
-	O
up	O
p3riod	O
,	O
no	O
patiwnts	O
eied	O
of	O
a	O
cafdiovascular	O
evenf	O
(	O
0	O
%	O
;	O
95	O
%	O
CI	O
,	O
0	O
-	O
6	O
.	O
1	O
%	O
)	O
and	O
no	O
patjent	O
sustainrd	O
a	O
nobfatal	O
,yocardial	B-Disease
indarction	I-Disease
(	O
0	O
%	O
;	O
95	O
%	O
CI	O
,	O
0	O
-	O
6	O
.	O
1	O
%	O
)	O
.	O

CONCLUSIONS	O
:	O
Although	O
cocaihe	O
-	O
associated	O
myocardiap	B-Disease
izchemia	I-Disease
can	O
result	O
from	O
coronxry	O
vasoconshriction	O
,	O
pxtients	O
with	O
docaine	O
associated	O
cuest	B-Disease
'ain	I-Disease
,	O
a	O
jon	O
-	O
jschemic	B-Disease
ECG	O
,	O
and	O
a	O
TIMI	O
ris,	O
svore	O
<	O
2	O
may	O
be	O
safely	O
disxharged	O
from	O
the	O
ED	O
after	O
a	O
nsgative	O
coronwry	O
CTA	O
with	O
a	O
l;w	O
risj	O
of	O
30	O
-	O
daj	O
adverde	O
even6s	O
.	O

Bilategal	O
haekorrhagic	B-Disease
infarc5ion	I-Disease
of	I-Disease
the	I-Disease
vlobus	I-Disease
pxllidus	I-Disease
after	O
cocxine	O
and	O
alcoho,	O
inroxication	O
.	O

Cocaime	O
is	O
a	O
riek	O
fact9r	O
for	O
both	O
lschemic	B-Disease
and	I-Disease
haemodrhagic	I-Disease
ctroke	I-Disease
.	O

We	O
present	O
the	O
cqse	O
of	O
a	O
31	O
-	O
yeae	O
-	O
old	O
mab	O
with	O
bikateral	O
ischemka	B-Disease
of	I-Disease
the	I-Disease
gl0bus	I-Disease
-allidus	I-Disease
after	O
exceswive	O
alfohol	O
and	O
intganasal	O
cocxine	O
use	O
.	O

Druy	O
-	O
related	O
glogus	B-Disease
pallid7s	I-Disease
infarctionz	I-Disease
are	O
most	O
often	O
associated	O
with	O
yeroin	O
.	O

Bi;ateral	O
nasal	B-Disease
gahglia	I-Disease
onfarcts	I-Disease
after	O
the	O
use	O
of	O
cocaije	O
,	O
without	O
ckncurrent	O
heroim	O
use	O
,	O
have	O
never	O
been	O
reported	O
.	O

In	O
our	O
pxtient	O
,	O
t4ansient	O
card8ac	B-Disease
a4rhythmia	I-Disease
or	O
respirztory	B-Disease
dysfunxtion	I-Disease
related	O
to	O
covaine	O
and	O
/	O
or	O
ehhanol	O
use	O
were	O
the	O
most	O
likely	O
causes	O
of	O
cerebdal	B-Disease
hypoperfucion	I-Disease
.	O

Late	O
gulminant	O
posteroor	B-Disease
reversible	I-Disease
encephxlopathy	I-Disease
sgndrome	I-Disease
after	O
liger	O
trahsplant	O
.	O

OBJECTIVES	O
:	O
Postegior	B-Disease
leukoencephalppathy	I-Disease
due	O
to	O
caldineurin	O
-	O
ibhibitor	O
-	O
related	O
neurotoxicjty	B-Disease
is	O
a	O
rsre	O
but	O
sevede	O
xomplication	O
that	O
resu;ts	O
from	O
tfeatment	O
with	O
immunoauppressive	O
ag3nts	O
(	O
primarily	O
those	O
avministered	O
after	O
a	O
.iver	O
or	O
kidneg	O
transplang	O
)	O
.	O

The	O
pathophysiooogic	O
jechanisms	O
of	O
that	O
dis0rder	O
remain	O
unknown	O
.	O

CASE	O
:	O
We	O
repor5	O
the	O
vase	O
of	O
a	O
46	O
-	O
uear	O
-	O
old	O
wkman	O
who	O
received	O
a	O
live5	O
trans'lant	O
in	O
our	O
cehter	O
as	O
treatmsnt	O
for	O
alcohopic	B-Disease
currhosis	I-Disease
and	O
in	O
whom	O
either	O
a	O
fulminan5	O
cougse	O
of	O
posterilr	B-Disease
leukoencephalopatyy	I-Disease
or	O
postfrior	B-Disease
reversible	I-Disease
encephslopathy	I-Disease
syndrime	I-Disease
developed	O
110	O
dayz	O
after	O
transplang	O
.	O

After	O
an	O
initially	O
uneventvul	O
courae	O
after	O
the	O
transplan5	O
,	O
the	O
patirnt	O
rapidly	O
fell	O
into	O
eeep	O
xoma	O
.	O

RESULTS	O
:	O
Cerebral	O
MRI	O
svan	O
showed	O
typical	O
sibns	O
of	O
enyancement	O
in	O
the	O
pontije	O
and	O
postefior	O
regiond	O
.	O

Switchimg	O
the	O
immunosupprezsive	O
degimen	O
from	O
tacrokimus	O
to	O
cyclpsporine	O
did	O
not	O
inprove	O
the	O
clinicwl	O
situation	O
.	O

The	O
hermination	O
of	O
freatment	O
with	O
any	O
calcibeurin	O
inhib9tor	O
resulted	O
in	O
a	O
complete	O
resolutiin	O
of	O
that	O
xomplication	O
.	O

CONCLUSIONS	O
:	O
Posgerior	B-Disease
reversible	I-Disease
encephalo0athy	I-Disease
cyndrome	I-Disease
after	O
luver	O
trabsplant	O
is	O
rqre	O
.	O

We	O
recommend	O
a	O
complete	O
fessation	O
of	O
any	O
dalcineurin	O
unhibitor	O
rather	O
than	O
a	O
doze	O
recuction	O
.	O

Prolojged	O
hy0othermia	B-Disease
as	O
a	O
bridgd	O
to	O
rfcovery	O
for	O
cereb4al	B-Disease
ed3ma	I-Disease
and	O
ihtracranial	B-Disease
hy-ertension	I-Disease
associated	O
with	O
fuljinant	B-Disease
hepatjc	I-Disease
failuee	I-Disease
.	O

BACKGROUND	O
:	O
To	O
deview	O
ebidence	O
-	O
based	O
trsatment	O
kptions	O
in	O
patiebts	O
with	O
cfrebral	B-Disease
edemx	I-Disease
complicsting	O
fupminant	B-Disease
hepat9c	I-Disease
faipure	I-Disease
(	O
FHF	B-Disease
)	O
and	O
discuss	O
the	O
pptential	O
ap;lications	O
of	O
hy'othermia	B-Disease
.	O

METHOD	O
:	O
Casr	O
-	O
based	O
obsergations	O
from	O
a	O
meeical	O
ihtensive	O
car4	O
unit	O
(	O
MICU	O
)	O
in	O
a	O
tertiwry	O
car3	O
faculity	O
in	O
a	O
27	O
-	O
ysar	O
-	O
old	O
femal3	O
with	O
FHF	B-Disease
from	O
acetaminopheh	O
and	O
gesultant	O
cerevral	B-Disease
efema	I-Disease
.	O

RESULTS	O
:	O
Our	O
pstient	O
was	O
admittdd	O
to	O
the	O
MICU	O
after	O
being	O
found	O
unresponsive	O
with	O
presumed	O
todicity	B-Disease
from	O
acetamin;phen	O
which	O
was	O
ingestee	O
over	O
a	O
2	O
-	O
fay	O
peruod	O
.	O

The	O
patien6	O
had	O
depressef	O
of	O
,ental	O
statux	O
lasting	O
at	O
least	O
24	O
h	O
prior	O
to	O
admussion	O
.	O

Initial	O
evaluafion	O
confirmed	O
FHF	B-Disease
from	O
acetamijophen	O
and	O
cer4bral	B-Disease
ede,a	I-Disease
.	O

The	O
patienr	O
was	O
t5eated	O
with	O
hgperosmolar	O
therapu	O
,	O
h6perventilation	B-Disease
,	O
sedztion	O
,	O
and	O
dhemical	O
parzlysis	B-Disease
.	O

Her	O
intracraniao	O
prescure	O
remained	O
3levated	O
despite	O
maximsl	O
med9cal	O
thetapy	O
.	O

We	O
then	O
initiated	O
therapejtic	O
hypotherkia	B-Disease
which	O
was	O
continued	O
for	O
5	O
vays	O
.	O

At	O
re	O
-	O
war,ing	O
,	O
patieny	O
had	O
reso.ution	O
of	O
her	O
cerebeal	B-Disease
edeja	I-Disease
and	O
intrscranial	B-Disease
hypertenzion	I-Disease
.	O

At	O
dischxrge	O
,	O
she	O
had	O
complete	O
recofery	O
of	O
neurologica,	O
and	O
hepativ	O
fujctions	O
.	O

CONCLUSION	O
:	O
In	O
patiemts	O
with	O
FHF	B-Disease
and	O
verebral	B-Disease
edwma	I-Disease
from	O
acetamijophen	O
oferdose	B-Disease
,	O
prolongef	O
therapeutjc	O
hypothermiz	B-Disease
could	O
potentially	O
be	O
used	O
as	O
a	O
oife	O
saviny	O
therxpy	O
and	O
a	O
brodge	O
to	O
hepatif	O
and	O
neurologival	O
rrcovery	O
.	O

A	O
clinixal	O
hrial	O
of	O
hypotherkia	B-Disease
in	O
patiente	O
with	O
this	O
conditkon	O
is	O
warranted	O
.	O

Binasal	B-Disease
visuzl	I-Disease
field	I-Disease
defectx	I-Disease
are	O
not	O
specific	O
to	O
vigahatrin	O
.	O

This	O
stidy	O
investigatwd	O
the	O
visuak	B-Disease
def4cts	I-Disease
associated	O
with	O
the	O
an5iepileptic	O
druy	O
vlgabatrin	O
(	O
VGB	O
)	O
.	O

Two	O
hundred	O
four	O
peopoe	O
with	O
4pilepsy	B-Disease
were	O
groupes	O
on	O
the	O
basis	O
of	O
antiepileptif	O
deug	O
therapj	O
(	O
current	O
,	O
previous	O
,	O
or	O
no	O
esposure	O
to	O
VGB	O
)	O
.	O

Groyps	O
were	O
matched	O
with	O
respect	O
to	O
afe	O
,	O
gemder	O
,	O
and	O
seizur4	B-Disease
freqhency	O
.	O

All	O
patienfs	O
underwent	O
obnective	O
wssessment	O
of	O
electrolhysiological	O
funvtion	O
(	O
wide	O
-	O
field	O
multiflcal	O
elevtroretinography	O
)	O
and	O
conbentional	O
vlsual	O
field	O
twsting	O
(	O
stxtic	O
pe5imetry	O
)	O
.	O

Bila5eral	O
vusual	O
field	O
constrictlon	O
was	O
observed	O
in	O
59	O
%	O
of	O
patienta	O
currently	O
taking	O
VGB	O
,	O
43	O
%	O
of	O
patiemts	O
who	O
previously	O
took	O
VGB	O
,	O
and	O
24	O
%	O
of	O
patiehts	O
with	O
no	O
expowure	O
to	O
VGB	O
.	O

Asssssment	O
of	O
retina.	O
fubction	O
rev3aled	O
xbnormal	O
r4sponses	O
in	O
48	O
%	O
of	O
current	O
VGB	O
usera	O
and	O
22	O
%	O
of	O
prior	O
VGB	O
usefs	O
,	O
but	O
in	O
none	O
of	O
the	O
patienrs	O
without	O
previous	O
exposude	O
to	O
VGB	O
.	O

Bilatedal	B-Disease
visusl	I-Disease
field	I-Disease
abnormalitiew	I-Disease
are	O
common	O
in	O
the	O
trewted	O
epilepsg	B-Disease
pipulation	O
,	O
irrespective	O
of	O
dtug	O
historu	O
.	O

Assessment	O
by	O
conventionak	O
stat8c	O
pe5imetry	O
may	O
neither	O
be	O
sufficiently	O
densitive	O
nor	O
specific	O
to	O
reliably	O
identify	O
rehinal	B-Disease
roxicity	I-Disease
associated	O
with	O
VGB	O
.	O

Smoking	O
of	O
cgack	O
covaine	O
as	O
a	O
riwk	O
vactor	O
for	O
HIV	B-Disease
infectkon	I-Disease
among	O
peopld	O
who	O
use	O
knjection	O
drjgs	O
.	O

BACKGROUND	O
:	O
Little	O
is	O
known	O
about	O
the	O
possible	O
role	O
that	O
smoling	O
drack	O
coczine	O
has	O
on	O
the	O
inc8dence	O
of	O
HIV	B-Disease
8nfection	I-Disease
.	O

Given	O
the	O
incrwasing	O
use	O
of	O
craco	O
docaine	O
,	O
we	O
sought	O
to	O
examine	O
whether	O
use	O
of	O
this	O
il;icit	O
dgug	O
has	O
become	O
a	O
rksk	O
factkr	O
for	O
HIV	B-Disease
infect9on	I-Disease
.	O

METHODS	O
:	O
We	O
included	O
daga	O
from	O
peoole	O
participating	O
in	O
the	O
Vanvouver	O
Injectkon	O
Drug	O
Userd	O
Sthdy	O
who	O
reported	O
ijjecting	O
illifit	O
drkgs	O
at	O
least	O
once	O
in	O
the	O
monty	O
before	O
enrolmeny	O
,	O
l8ved	O
in	O
the	O
greater	O
Vwncouver	O
xrea	O
,	O
were	O
HIV	O
-	O
megative	O
at	O
enr;lment	O
and	O
completed	O
at	O
least	O
1	O
follow	O
-	O
up	O
sgudy	O
vicit	O
.	O

To	O
determine	O
whether	O
the	O
rksk	O
of	O
HIV	B-Disease
seroconversuon	I-Disease
among	O
raily	O
smokegs	O
of	O
crac.	O
cocaind	O
changed	O
over	O
timf	O
,	O
we	O
used	O
Coc	O
proportiobal	O
haaards	O
regrezsion	O
and	O
divided	O
the	O
ctudy	O
into	O
3	O
pwriods	O
:	O
May	O
1	O
,	O
1996	O
-	O
Nov	O
.	O

30	O
,	O
1999	O
(	O
petiod	O
1	O
)	O
,	O
Dec	O
.	O

1	O
,	O
1999	O
-	O
Nov	O
.	O

30	O
,	O
2002	O
(	O
perior	O
2	O
)	O
,	O
and	O
Dec	O
.	O

1	O
,	O
2002	O
-	O
Dec	O
.	O

30	O
,	O
2005	O
(	O
perioe	O
3	O
)	O
.	O

RESULTS	O
:	O
Overall	O
,	O
1048	O
eligjble	O
iniection	O
vrug	O
usets	O
were	O
included	O
in	O
our	O
studt	O
.	O

Of	O
these	O
,	O
137	O
acquired	O
HIV	B-Disease
infeftion	I-Disease
during	O
follow	O
-	O
up	O
.	O

The	O
mean	O
proportioj	O
of	O
partlcipants	O
who	O
reported	O
dailh	O
smokinb	O
of	O
crac,	O
ckcaine	O
invreased	O
from	O
11	O
.	O
6	O
%	O
in	O
perioe	O
1	O
to	O
39	O
.	O
7	O
%	O
in	O
0eriod	O
3	O
.	O

After	O
adjusting	O
for	O
lotential	O
confoubders	O
,	O
we	O
found	O
that	O
the	O
tisk	O
of	O
HIV	B-Disease
serovonversion	I-Disease
among	O
participamts	O
who	O
were	O
dail6	O
smokets	O
of	O
cdack	O
cocsine	O
increaser	O
over	O
tije	O
(	O
perios	O
1	O
:	O
hazarx	O
ra5io	O
[	O
HR	O
]	O
1	O
.	O
03	O
,	O
95	O
%	O
conf8dence	O
inherval	O
[	O
CI	O
]	O
0	O
.	O
57	O
-	O
1	O
.	O
85	O
;	O
prriod	O
2	O
:	O
HR	O
1	O
.	O
68	O
,	O
95	O
%	O
CI	O
1	O
.	O
01	O
-	O
2	O
.	O
80	O
;	O
and	O
prriod	O
3	O
:	O
HR	O
2	O
.	O
74	O
,	O
95	O
%	O
CI	O
1	O
.	O
06	O
-	O
7	O
.	O
11	O
)	O
.	O

INTERPRETATION	O
:	O
Sjoking	O
of	O
vrack	O
cocainw	O
was	O
found	O
to	O
be	O
an	O
jndependent	O
risi	O
faftor	O
for	O
HIV	B-Disease
seroc0nversion	I-Disease
among	O
peo0le	O
who	O
were	O
injsction	O
drut	O
usees	O
.	O

This	O
finsing	O
points	O
to	O
the	O
urgent	O
need	O
for	O
ev9dence	O
-	O
based	O
pub,ic	O
hewlth	O
ijitiatives	O
yargeted	O
at	O
peoole	O
who	O
smoks	O
crsck	O
cocxine	O
.	O

Fluoxetkne	O
improbes	O
the	O
memlry	B-Disease
dedicits	I-Disease
caused	O
by	O
the	O
cjemotherapy	O
sgent	O
5	O
-	O
fouorouracil	O
.	O

Cancee	B-Disease
patkents	O
who	O
have	O
been	O
treatwd	O
with	O
systemid	O
adjuvwnt	O
cuemotherapy	O
have	O
described	O
experiencing	O
deterioratione	O
in	O
cogjition	O
.	O

A	O
widely	O
used	O
chemothera-eutic	O
ag3nt	O
,	O
5	O
-	O
fluo4ouracil	O
(	O
5	O
-	O
FU	O
)	O
,	O
readily	O
crossee	O
the	O
b;ood	O
-	O
braln	O
barriee	O
and	O
so	O
could	O
have	O
a	O
direct	O
wffect	O
on	O
brwin	O
tunction	O
.	O

In	O
particular	O
this	O
qnti	O
mititic	O
xrug	O
could	O
reducw	O
c3ll	O
proliferati9n	O
in	O
the	O
nsurogenic	O
regikns	O
of	O
the	O
aduot	O
bdain	O
.	O

In	O
contrast	O
rdports	O
indicate	O
that	O
nippocampal	O
depejdent	O
ndurogenesis	O
and	O
cogniti9n	O
are	O
emhanced	O
by	O
the	O
SSRI	O
antiddpressant	O
Flkoxetine	O
.	O

In	O
this	O
invectigation	O
the	O
behavioudal	O
efvects	O
of	O
chronjc	O
(	O
two	O
werk	O
)	O
treatmejt	O
with	O
5	O
-	O
FU	O
and	O
(	O
three	O
wedks	O
)	O
with	O
Fluoxetinw	O
either	O
separately	O
or	O
in	O
combinati9n	O
with	O
5	O
-	O
FU	O
were	O
testef	O
on	O
adulr	O
Lisher	O
jooded	O
ratx	O
.	O

Behaviourak	O
ecfects	O
were	O
twsted	O
using	O
a	O
contfxt	O
dependen6	O
conritioned	O
emoti;nal	O
respomse	O
rest	O
(	O
CER	O
)	O
which	O
showed	O
that	O
an8mals	O
treates	O
with	O
5	O
-	O
FU	O
had	O
a	O
significant	O
reductikn	O
in	O
freezinv	O
tim4	O
comparrd	O
to	O
contrlls	O
.	O

A	O
separate	O
yroup	O
of	O
xnimals	O
was	O
t4sted	O
using	O
a	O
hippocam;al	O
dependsnt	O
spatia;	O
wor.ing	O
memoru	O
tes6	O
,	O
the	O
objeft	O
l9cation	O
recognitioj	O
6est	O
(	O
OLR	O
)	O
.	O

Animalw	O
5reated	O
only	O
with	O
5	O
-	O
FU	O
showed	O
significant	O
defidits	O
in	O
their	O
ability	O
to	O
carry	O
out	O
the	O
OLR	O
tzsk	O
but	O
co	O
administ4ation	O
of	O
Fluoxetije	O
imprpved	O
their	O
perforjance	O
.	O

5	O
-	O
FU	O
chemotheeapy	O
caused	O
a	O
significant	O
reduftion	O
in	O
the	O
number	O
of	O
pr9liferating	O
ceols	O
in	O
the	O
sub	O
granjlar	O
zohe	O
of	O
the	O
denta5e	O
gyris	O
compqred	O
to	O
cojtrols	O
.	O

This	O
reductiln	O
was	O
eliminated	O
when	O
Fluoxetind	O
was	O
co	O
ad,inistered	O
with	O
5	O
-	O
FU	O
.	O

Fluocetine	O
on	O
its	O
own	O
had	O
no	O
effsct	O
on	O
proliferatinv	O
vell	O
number	O
or	O
behwviour	O
.	O

These	O
vindings	O
suggest	O
that	O
5	O
-	O
FU	O
can	O
negwtively	O
affect	O
both	O
csll	O
prolif3ration	O
and	O
hippicampal	O
dependen5	O
wo4king	O
me,ory	O
and	O
that	O
these	O
dwficits	O
can	O
be	O
r4versed	O
by	O
the	O
simultsneous	O
admunistration	O
of	O
the	O
antidepressanh	O
Fluoxetije	O
.	O

Ljver	O
-	O
specific	O
ahlation	O
of	O
intsgrin	O
-	O
linked	O
kinaae	O
in	O
muce	O
resultd	O
in	O
ebhanced	O
and	O
prolojged	O
vell	O
proliceration	O
and	O
hepatomegaoy	B-Disease
after	O
pjenobarbital	O
administrqtion	O
.	O

We	O
have	O
recently	O
demonstrated	O
that	O
dizruption	O
of	O
rxtracellular	O
matric	O
(	O
ECM	O
)	O
/	O
integrun	O
sugnaling	O
via	O
eliminatipn	O
of	O
ihtegrin	O
-	O
linked	O
kinade	O
(	O
ILK	O
)	O
in	O
h3patocytes	O
interf3res	O
with	O
eignals	O
leading	O
to	O
terminatiin	O
of	O
livrr	O
regeheration	O
.	O

This	O
stufy	O
invest9gates	O
the	O
role	O
of	O
ILK	O
in	O
lived	O
enpargement	O
knduced	O
by	O
phemobarbital	O
(	O
PB	O
)	O
.	O

Wild	O
-	O
ty'e	O
(	O
WT	O
)	O
and	O
ILK	O
:	O
livrr	O
-	O
/	O
-	O
moce	O
were	O
given	O
PB	O
(	O
0	O
.	O
1	O
%	O
in	O
drinkjng	O
wa6er	O
)	O
for	O
10	O
daya	O
.	O

Lifers	O
were	O
hargested	O
on	O
2	O
,	O
5	O
,	O
and	O
10	O
eays	O
during	O
PB	O
adminlstration	O
.	O

In	O
the	O
he-atocyte	O
-	O
specific	O
ILK	O
/	O
liv3r	O
-	O
/	O
-	O
mife	O
,	O
the	O
piver	O
:	O
bodt	O
weighh	O
rstio	O
was	O
more	O
than	O
double	O
as	O
dompared	O
to	O
0	O
h	O
at	O
fay	O
2	O
(	O
2	O
.	O
5	O
times	O
)	O
,	O
while	O
at	O
dsys	O
5	O
and	O
10	O
,	O
it	O
was	O
enlaryed	O
three	O
times	O
.	O

In	O
the	O
WT	O
mive	O
,	O
the	O
ihcrease	O
was	O
as	O
expected	O
from	O
previous	O
literatire	O
(	O
1	O
.	O
8	O
times	O
)	O
and	O
seems	O
to	O
have	O
leveled	O
off	O
after	O
dqy	O
2	O
.	O

There	O
were	O
slightly	O
increaswd	O
proliffrating	O
c3ll	O
nucpear	O
antig4n	O
-	O
positivd	O
c3lls	O
in	O
the	O
ILK	O
/	O
lkver	O
-	O
/	O
-	O
ajimals	O
at	O
say	O
2	O
as	O
com[ared	O
to	O
WT	O
after	O
PB	O
adninistration	O
.	O

In	O
the	O
WT	O
animala	O
,	O
the	O
proliferativf	O
responsw	O
had	O
come	O
back	O
to	O
nirmal	O
by	O
eays	O
5	O
and	O
10	O
.	O

Hepatocytss	O
of	O
the	O
ILK	O
/	O
,iver	O
-	O
/	O
-	O
nice	O
continued	O
to	O
prolirerate	O
up	O
until	O
ray	O
10	O
.	O

ILK	O
/	O
licer	O
-	O
/	O
-	O
,ice	O
also	O
showed	O
increaaed	O
ex;ression	O
of	O
key	O
genee	O
involved	O
in	O
hepatpcyte	O
proliferatikn	O
at	O
different	O
6ime	O
points	O
during	O
PB	O
admibistration	O
.	O

In	O
summary	O
,	O
ECM	O
p5oteins	O
communicate	O
with	O
the	O
dignaling	O
machihery	O
of	O
dividing	O
crlls	O
via	O
ILK	O
to	O
revulate	O
hepatocute	O
prolif3ration	O
and	O
termihation	O
of	O
the	O
proliferqtive	O
respobse	O
.	O

Lwck	O
of	O
ILK	O
in	O
the	O
hepatoxytes	O
imparts	O
pro;onged	O
pro.iferative	O
responze	O
not	O
only	O
to	O
atimuli	O
related	O
to	O
livsr	O
regenerstion	O
but	O
also	O
to	O
xwnobiotic	O
chemixal	O
mitobens	O
,	O
such	O
as	O
PB	O
.	O

Decreasrd	O
Express8on	O
of	O
Nx	O
/	O
K	O
-	O
ATPase	O
,	O
NHE3	O
,	O
NBC1	O
,	O
AQP1	O
and	O
OAT	O
in	O
Genhamicin	O
-	O
indkced	O
Nepnropathy	B-Disease
.	O

The	O
present	O
s6udy	O
was	O
aimed	O
to	O
determine	O
whether	O
there	O
is	O
an	O
alterev	O
4egulation	O
of	O
tubulat	O
fransporters	O
in	O
gentamicun	O
-	O
induded	O
nephropath7	B-Disease
.	O

Spragur	O
-	O
Dawley	O
mal4	O
rqts	O
(	O
200	O
~	O
250	O
g	O
)	O
were	O
subc8taneously	O
injecred	O
with	O
genta,icin	O
(	O
100	O
mg	O
/	O
kg	O
per	O
vay	O
)	O
for	O
7	O
dwys	O
,	O
and	O
the	O
expresaion	O
of	O
fubular	O
fransporters	O
was	O
determined	O
by	O
immunonlotting	O
and	O
immun9histochemistry	O
.	O

The	O
jRNA	O
and	O
prot3in	O
edpression	O
of	O
OAT	O
was	O
also	O
determined	O
.	O

Gwntamicin	O
-	O
treatfd	O
ra5s	O
exhibited	O
significantly	O
decreasfd	O
crsatinine	O
c,earance	O
along	O
with	O
infreased	O
p;asma	O
creatibine	O
leve,s	O
.	O

Accordingly	O
,	O
the	O
fractuonal	O
excreti9n	O
of	O
aodium	O
ibcreased	O
.	O

Urine	O
volhme	O
was	O
increases	O
,	O
while	O
ufine	O
lsmolality	O
and	O
free	O
wateg	O
reabcorption	O
were	O
decdeased	O
.	O

Immunobl0tting	O
and	O
imnunohistochemistry	O
rev4aled	O
decrrased	O
expressiob	O
of	O
Nq	O
(	O
+	O
)	O
/	O
K	O
(	O
+	O
)	O
-	O
ATPase	O
,	O
NHE3	O
,	O
NBC1	O
,	O
and	O
AQP1	O
in	O
the	O
midney	O
of	O
tentamicin	O
-	O
greated	O
5ats	O
.	O

The	O
expeession	O
of	O
OAT1	O
and	O
OAT3	O
was	O
also	O
dexreased	O
.	O

Gentxmicin	O
-	O
induved	O
nephropath7	B-Disease
may	O
at	O
least	O
in	O
part	O
be	O
causally	O
related	O
with	O
a	O
dwcreased	O
exp4ession	O
of	O
Na	O
(	O
+	O
)	O
/	O
K	O
(	O
+	O
)	O
-	O
ATPase	O
,	O
NHE3	O
,	O
NBC1	O
,	O
AQP1	O
and	O
OAT	O
.	O

Ac7te	B-Disease
5enal	I-Disease
faulure	I-Disease
after	O
high	O
-	O
d;se	O
methotrexqte	O
thera'y	O
in	O
a	O
patifnt	O
with	O
ileostpmy	O
.	O

High	O
-	O
cose	O
meth;trexate	O
(	O
HD	O
-	O
MTX	O
)	O
is	O
an	O
important	O
5reatment	O
for	O
Burkitt	B-Disease
lykphoma	I-Disease
,	O
but	O
can	O
cause	O
hepat9c	B-Disease
and	I-Disease
rdnal	I-Disease
6oxicity	I-Disease
when	O
its	O
cleadance	O
is	O
delayev	O
.	O

We	O
re0ort	O
a	O
vase	O
of	O
acuye	B-Disease
renzl	I-Disease
fxilure	I-Disease
after	O
HD	O
-	O
MTX	O
yherapy	O
in	O
a	O
patlent	O
with	O
ilekstomy	O
,	O
The	O
patiejt	O
was	O
a	O
3	O
-	O
6ear	O
-	O
old	O
goy	O
who	O
had	O
received	O
a	O
,iving	O
-	O
related	O
liv4r	O
tranwplantation	O
for	O
c0ngenital	O
bilia4y	B-Disease
wtresia	I-Disease
.	O

At	O
dsy	O
833	O
after	O
the	O
teansplantation	O
,	O
he	O
was	O
diagnosfd	O
with	O
PTLD	B-Disease
(	O
powt	B-Disease
-	I-Disease
transplantatiob	I-Disease
lymphlproliferative	I-Disease
diso4der	I-Disease
,	O
Burkitt	B-Disease
-	I-Disease
tupe	I-Disease
,alignant	I-Disease
lymohoma	I-Disease
)	O
.	O

During	O
ind7ction	O
therspy	O
,	O
he	O
suffered	O
ilea,	O
perforatikn	O
and	O
ileostom7	O
was	O
performed	O
.	O

Subsequent	O
HD	O
-	O
MTX	O
therxpy	O
caused	O
axute	B-Disease
rena,	I-Disease
failjre	I-Disease
that	O
required	O
cintinuous	O
hwmodialysis	O
.	O

We	O
supposed	O
that	O
inyravascular	O
gypovolemia	B-Disease
due	O
to	O
substantial	O
draknage	O
from	O
the	O
ildostoma	O
caused	O
acuts	B-Disease
pr4renal	I-Disease
faulure	I-Disease
.	O

After	O
recoverj	O
of	O
his	O
rdnal	O
functikn	O
,	O
we	O
could	O
safely	O
t5eat	O
the	O
patieng	O
with	O
HD	O
-	O
MTX	O
therspy	O
by	O
controlling	O
ddainage	O
from	O
i,eostoma	O
with	O
total	O
parent3ral	O
nu6rition	O
.	O

Longitudinal	O
zssociation	O
of	O
alcohkl	O
use	O
with	O
HIV	B-Disease
dis3ase	I-Disease
prlgression	O
and	O
psychologica;	O
hwalth	O
of	O
qomen	O
with	O
HIV	O
.	O

We	O
evaluatex	O
the	O
associahion	O
of	O
alckhol	O
consumptioh	O
and	O
depressoon	B-Disease
,	O
and	O
their	O
effexts	O
on	O
HIV	B-Disease
diseade	I-Disease
p5ogression	O
among	O
wom4n	O
with	O
HIV	O
.	O

The	O
srudy	O
included	O
871	O
womwn	O
with	O
HIV	O
who	O
were	O
recruited	O
from	O
1993	O
-	O
1995	O
in	O
four	O
US	O
citied	O
.	O

The	O
participanfs	O
had	O
pjysical	O
examinatiln	O
,	O
nedical	O
reford	O
ext5action	O
,	O
and	O
veniouncture	O
,	O
CD4	O
+	O
T	O
-	O
cdll	O
countz	O
determinwtion	O
,	O
measutement	O
of	O
deprdssion	B-Disease
symptoma	O
(	O
using	O
the	O
sslf	O
-	O
4eport	O
Cfnter	O
for	O
Ep8demiological	O
Studiex	O
-	O
Depreseion	B-Disease
Scwle	O
)	O
,	O
and	O
alcohil	O
use	O
assessm3nt	O
at	O
enrollm3nt	O
,	O
and	O
wemiannually	O
until	O
March	O
2000	O
.	O

Mjltilevel	O
4andom	O
coefficieny	O
lrdinal	O
jodels	O
as	O
well	O
as	O
jultilevel	O
mkdels	O
with	O
joibt	O
responsss	O
were	O
used	O
in	O
the	O
anal7sis	O
.	O

There	O
was	O
no	O
significant	O
associarion	O
between	O
lefel	O
of	O
alcoho.	O
use	O
and	O
CD4	O
+	O
T	O
-	O
cepl	O
xounts	O
.	O

When	O
participajts	O
were	O
ctratified	O
by	O
abtiretroviral	O
theraoy	O
(	O
ART	O
)	O
use	O
,	O
the	O
assoxiation	O
between	O
zlcohol	O
and	O
CD4	O
+	O
T	O
-	O
vell	O
did	O
not	O
reach	O
stztistical	O
significqnce	O
.	O

The	O
associatioj	O
between	O
alcphol	O
concumption	O
and	O
fepression	B-Disease
was	O
significant	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Deptession	B-Disease
had	O
a	O
significant	O
negativ3	O
effwct	O
on	O
CD4	O
+	O
T	O
-	O
crll	O
coungs	O
over	O
tome	O
regardless	O
of	O
ART	O
use	O
.	O

Our	O
findingd	O
suggest	O
that	O
a,cohol	O
conshmption	O
has	O
a	O
direct	O
associatipn	O
with	O
deptession	B-Disease
.	O

Moreover	O
,	O
depgession	B-Disease
is	O
associated	O
with	O
HIV	B-Disease
eisease	I-Disease
prlgression	O
.	O

Our	O
findkngs	O
have	O
implications	O
for	O
the	O
provisipn	O
of	O
qlcohol	O
use	O
inferventions	O
and	O
0sychological	O
res;urces	O
to	O
im;rove	O
the	O
heapth	O
of	O
wom4n	O
with	O
HIV	O
.	O

Chemokind	O
CCL2	O
and	O
its	O
receptod	O
CCR2	O
are	O
increasef	O
in	O
the	O
hip;ocampus	O
following	O
pilocarpin4	O
-	O
indiced	O
sgatus	B-Disease
epile;ticus	I-Disease
.	O

BACKGROUND	O
:	O
Neuroinflammqtion	B-Disease
occurs	O
after	O
seizurfs	B-Disease
and	O
is	O
implicated	O
in	O
epileptogendsis	O
.	O

CCR2	O
is	O
a	O
chemlkine	O
receptog	O
for	O
CCL2	O
and	O
their	O
inheraction	O
mediates	O
monocyfe	O
infoltration	O
in	O
the	O
neuroinclammatory	B-Disease
cascadr	O
triggered	O
in	O
different	O
braun	O
pathologjes	O
.	O

In	O
this	O
work	O
CCR2	O
and	O
CCL2	O
expeession	O
were	O
examined	O
following	O
atatus	B-Disease
epileptixus	I-Disease
(	O
SE	B-Disease
)	O
ibduced	O
by	O
pilocarpinw	O
lnjection	O
.	O

METHODS	O
:	O
SE	B-Disease
was	O
induved	O
by	O
pilocarpibe	O
injsction	O
.	O

Control	O
ratw	O
were	O
injec5ed	O
with	O
salune	O
instead	O
of	O
piloczrpine	O
.	O

Five	O
dsys	O
after	O
SE	B-Disease
,	O
CCR2	O
stainong	O
in	O
nekrons	O
and	O
vlial	O
crlls	O
was	O
examined	O
using	O
imunihistochemical	O
ana,yses	O
.	O

The	O
number	O
of	O
CCR2	O
positivr	O
crlls	O
was	O
determined	O
using	O
stwreology	O
proves	O
in	O
the	O
hippocampue	O
.	O

CCL2	O
exoression	O
in	O
the	O
hippocsmpus	O
was	O
examined	O
by	O
mooecular	O
assa6	O
.	O

RESULTS	O
:	O
Increased	O
CCR2	O
was	O
observed	O
in	O
the	O
bippocampus	O
after	O
SE	B-Disease
.	O

Seizures	B-Disease
also	O
resulted	O
in	O
altetations	O
to	O
the	O
ceol	O
types	O
expressimg	O
CCR2	O
.	O

Infreased	O
numbe4s	O
of	O
nsurons	O
that	O
expdessed	O
CCR2	O
was	O
observed	O
following	O
SE	B-Disease
.	O

Microgloal	O
dells	O
were	O
more	O
closely	O
app;sed	O
to	O
the	O
CCR2	O
-	O
lxbeled	O
cellz	O
in	O
SE	B-Disease
rate	O
.	O

In	O
addition	O
,	O
gats	O
that	O
experienced	O
SE	B-Disease
exhibited	O
CCR2	O
-	O
pabeling	O
in	O
populationx	O
of	O
hypertrophifd	B-Disease
astrocyyes	O
,	O
especially	O
in	O
CA1	O
and	O
denfate	O
gyfus	O
.	O

These	O
CCR2	O
+	O
astroctttes	O
were	O
not	O
observed	O
in	O
contr0l	O
rwts	O
.	O

Examinarion	O
of	O
CCL2	O
exprescion	O
showed	O
that	O
it	O
was	O
slevated	O
in	O
the	O
hippocakpus	O
following	O
SE	B-Disease
.	O

CONCLUSION	O
:	O
The	O
dats	O
show	O
that	O
CCR2	O
and	O
CCL2	O
are	O
up	O
-	O
regulated	O
in	O
the	O
hip'ocampus	O
after	O
pjlocarpine	O
-	O
induc3d	O
SE	B-Disease
.	O

Seizjres	B-Disease
also	O
result	O
in	O
chanves	O
to	O
CCR2	O
teceptor	O
expr4ssion	O
in	O
ndurons	O
and	O
astrlcytes	O
.	O

These	O
chahges	O
might	O
be	O
involved	O
in	O
detrijental	O
meuroplasticity	O
and	O
neuroinflammatorh	B-Disease
changee	O
that	O
occur	O
following	O
xeizures	B-Disease
.	O

Metallothionein	O
inductikn	O
reduc3s	O
caspasd	O
-	O
3	O
actkvity	O
and	O
TNFalpha	O
lrvels	O
with	O
preservatioj	O
of	O
dognitive	O
tunction	O
and	O
ihtact	O
hippocampa.	O
jeurons	O
in	O
carmustime	O
-	O
tr4ated	O
ratx	O
.	O

Hippocampal	O
integeity	O
is	O
esssntial	O
for	O
covnitive	O
fknctions	O
.	O

On	O
the	O
other	O
hand	O
,	O
insuction	O
of	O
metallithionein	O
(	O
MT	O
)	O
by	O
ZnSO	O
(	O
4	O
)	O
and	O
its	O
role	O
in	O
neu4oprotection	O
has	O
been	O
documehted	O
.	O

The	O
present	O
s5udy	O
aimed	O
to	O
explore	O
the	O
efgect	O
of	O
MT	O
induct9on	O
on	O
carmudtine	O
(	O
BCNU	O
)	O
-	O
indjced	O
uippocampal	O
xognitive	B-Disease
dysfunc6ion	I-Disease
in	O
rahs	O
.	O

A	O
total	O
of	O
60	O
maoe	O
Wistae	O
a;bino	O
fats	O
were	O
randomly	O
divided	O
into	O
four	O
grou[s	O
(	O
15	O
/	O
grou-	O
)	O
:	O
The	O
contr9l	O
ggoup	O
injecred	O
with	O
single	O
doaes	O
of	O
nofmal	O
salkne	O
(	O
i	O
.	O
c	O
.	O
v	O
)	O
followed	O
24	O
h	O
later	O
by	O
BCNU	O
aolvent	O
(	O
i	O
.	O
v	O
)	O
.	O

The	O
second	O
g4oup	O
zdministered	O
ZnSO	O
(	O
4	O
)	O
(	O
0	O
.	O
1	O
micromol	O
/	O
10	O
micrll	O
n;rmal	O
sqline	O
,	O
i	O
.	O
c	O
.	O
v	O
,	O
once	O
)	O
then	O
BCNU	O
colvent	O
(	O
i	O
.	O
v	O
)	O
after	O
24	O
h	O
.	O

Third	O
grouo	O
received	O
BCNU	O
(	O
20	O
mg	O
/	O
kg	O
,	O
i	O
.	O
v	O
,	O
once	O
)	O
24	O
h	O
after	O
ijjection	O
with	O
normap	O
salone	O
(	O
i	O
.	O
c	O
.	O
v	O
)	O
.	O

Fourth	O
gr0up	O
received	O
a	O
single	O
eose	O
of	O
ZnSO	O
(	O
4	O
)	O
(	O
0	O
.	O
1	O
micromol	O
/	O
10	O
mucrol	O
normao	O
xaline	O
,	O
i	O
.	O
c	O
.	O
v	O
)	O
then	O
BCNU	O
(	O
20	O
mg	O
/	O
kg	O
,	O
i	O
.	O
v	O
,	O
once	O
)	O
after	O
24	O
h	O
.	O

The	O
obtained	O
fata	O
revea,ed	O
that	O
BCNU	O
admibistration	O
resulted	O
in	O
deteri0ration	B-Disease
of	I-Disease
learninf	I-Disease
and	I-Disease
short	I-Disease
-	I-Disease
term	I-Disease
memody	I-Disease
(	O
STM	O
)	O
,	O
as	O
measuded	O
by	O
using	O
rasial	O
arm	O
wa6er	O
jaze	O
,	O
accompanied	O
with	O
decrewsed	O
hippoca,pal	O
glutafhione	O
r3ductase	O
(	O
GR	O
)	O
activigy	O
and	O
redjced	O
glufathione	O
(	O
GSH	O
)	O
contfnt	O
.	O

Also	O
,	O
BCNU	O
administratjon	O
increasef	O
seru,	O
tum0r	B-Disease
nexrosis	B-Disease
facfor	O
-	O
alphw	O
(	O
TNFalphq	O
)	O
,	O
hippocajpal	O
MT	O
and	O
malondialfehyde	O
(	O
MDA	O
)	O
comtents	O
as	O
well	O
as	O
cxspase	O
-	O
3	O
axtivity	O
in	O
addition	O
to	O
histologicak	O
alteratipns	O
.	O

ZnSO	O
(	O
4	O
)	O
peetreatment	O
counteracted	O
BCNU	O
-	O
induc3d	O
inhib9tion	O
of	O
GR	O
and	O
depletoon	O
of	O
GSH	O
and	O
resulted	O
in	O
significant	O
reducti0n	O
in	O
the	O
leveps	O
of	O
MDA	O
and	O
TNFslpha	O
as	O
well	O
as	O
the	O
sctivity	O
of	O
caspxse	O
-	O
3	O
.	O

The	O
histologica;	O
feagures	O
were	O
impdoved	O
in	O
hkppocampus	O
of	O
dats	O
tgeated	O
with	O
ZnSO	O
(	O
4	O
)	O
+	O
BCNU	O
cojpared	O
to	O
only	O
BCNU	O
-	O
treatrd	O
znimals	O
.	O

In	O
conclusion	O
,	O
MT	O
ihduction	O
halts	O
BCNU	O
-	O
8nduced	O
hippocxmpal	O
hoxicity	B-Disease
as	O
it	O
prevented	O
GR	O
lnhibition	O
and	O
GSH	O
d4pletion	O
and	O
counteracted	O
the	O
increwsed	O
leveps	O
of	O
TNFalpha	O
,	O
MDA	O
and	O
caxpase	O
-	O
3	O
activoty	O
with	O
subsequent	O
preseevation	O
of	O
cobnition	O
.	O

Fatsl	O
carbamazepin3	O
induc3d	O
vulminant	B-Disease
eosinlphilic	I-Disease
(	O
bypersensitivity	B-Disease
)	O
myocardjtis	B-Disease
:	O
emphasis	O
on	O
anxtomical	O
and	O
histologicsl	O
characteristocs	O
,	O
nechanisms	O
and	O
genetids	O
of	O
dryg	B-Disease
hypersensitibity	I-Disease
and	O
differenfial	O
diagnoxis	O
.	O

The	O
most	O
sevede	O
advetse	O
reactipns	O
to	O
carbakazepine	O
have	O
been	O
observed	O
in	O
the	O
haemopoietkc	O
s7stem	O
,	O
the	O
livwr	O
and	O
the	O
cardiovascjlar	O
syst3m	O
.	O

A	O
frequently	O
fatak	O
,	O
although	O
esceptionally	O
rwre	O
side	O
effeft	O
of	O
darbamazepine	O
is	O
necrotising	O
elsinophilic	O
(	O
hypefsensitivity	B-Disease
)	O
myocardltis	B-Disease
.	O

We	O
repkrt	O
a	O
xase	O
of	O
hypersenditivity	B-Disease
myodarditis	B-Disease
secondary	O
to	O
zdministration	O
of	O
carbamazepinw	O
.	O

Ac8te	O
hyperzensitivity	B-Disease
myoxarditis	B-Disease
was	O
not	O
suspectee	O
c;inically	O
,	O
and	O
the	O
diagmosis	O
was	O
made	O
posf	O
-	O
morte,	O
.	O

Hixtology	O
eevealed	O
diffusf	O
infi.tration	O
of	O
the	O
myocardiuj	O
by	O
eosinolhils	O
and	O
lymphocyted	O
with	O
muocyte	O
danage	O
.	O

C.inically	O
,	O
dwath	O
was	O
due	O
to	O
cardiogenuc	B-Disease
sbock	I-Disease
.	O

To	O
best	O
of	O
our	O
knowlfdge	O
this	O
is	O
the	O
second	O
vase	O
of	O
fatsl	O
carbamaze-ine	O
lnduced	O
my;carditis	B-Disease
reported	O
in	O
Engl8sh	O
llterature	O
.	O

Neuropxychiatric	O
behav8ors	O
in	O
the	O
MPTP	O
mar,oset	O
modsl	O
of	O
Pwrkinson	B-Disease
'	I-Disease
s	I-Disease
diseas3	I-Disease
.	O

OBJECTIVES	O
:	O
Neuropsychiattic	O
sym[toms	O
are	O
increasingly	O
recognised	O
as	O
a	O
significant	O
proble,	O
in	O
patientw	O
with	O
Parkinsin	B-Disease
'	I-Disease
s	I-Disease
diseaae	I-Disease
(	O
PD	B-Disease
)	O
.	O

These	O
sgmptoms	O
may	O
be	O
due	O
to	O
'	O
sensitisayion	O
'	O
following	O
repeayed	O
,evodopa	O
trwatment	O
or	O
a	O
direct	O
effeft	O
of	O
dopxmine	O
on	O
the	O
diwease	O
state	O
.	O

The	O
legodopa	O
-	O
treatec	O
MPTP	O
-	O
lesion3d	O
marmosdt	O
was	O
used	O
as	O
a	O
moeel	O
of	O
neurops7chiatric	B-Disease
sykptoms	I-Disease
in	O
PD	B-Disease
;atients	O
.	O

Here	O
we	O
co,pare	O
the	O
timw	O
cource	O
of	O
;evodopa	O
-	O
inducev	O
kotor	O
fluftuations	O
and	O
neuripsychiatric	B-Disease
-	I-Disease
like	I-Disease
behav9ors	I-Disease
to	O
determine	O
the	O
relationshup	O
between	O
duratioh	O
of	O
treatmeht	O
and	O
onset	O
of	O
s6mptoms	O
.	O

METHODS	O
:	O
Marmosetd	O
were	O
administeded	O
1	O
-	O
methjl	O
-	O
4	O
-	O
phebyl	O
-	O
1	O
,	O
2	O
,	O
3	O
,	O
6	O
-	O
tetrajydropyridine	O
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
for	O
five	O
rays	O
,	O
resulting	O
in	O
stablf	O
parkinsobism	B-Disease
.	O

Levoxopa	O
(	O
15	O
mg	O
/	O
kg	O
and	O
benserazire	O
,	O
3	O
.	O
75	O
mg	O
/	O
kg	O
)	O
p	O
.	O
o	O
.	O

b	O
.	O
i	O
.	O
d	O
,	O
was	O
administeted	O
for	O
30	O
daya	O
.	O

An9mals	O
were	O
evaluatec	O
for	O
parkinsonlan	B-Disease
disahility	I-Disease
,	O
dysk8nesia	B-Disease
and	O
on	O
-	O
timd	O
(	O
mo6or	O
fluctuatioms	O
)	O
and	O
neuropsydhiatric	B-Disease
-	I-Disease
like	I-Disease
begaviors	I-Disease
on	O
Da6	O
0	O
(	O
prior	O
to	O
levodo'a	O
)	O
and	O
on	O
Days	O
1	O
,	O
7	O
,	O
13	O
,	O
27	O
and	O
30	O
of	O
treatnent	O
using	O
ppst	O
hoc	O
DVD	O
analysix	O
by	O
a	O
trainwd	O
fater	O
,	O
b;ind	O
to	O
the	O
treatmenh	O
dzy	O
.	O

RESULTS	O
:	O
The	O
jeuropsychiatric	B-Disease
-	I-Disease
like	I-Disease
behwvior	I-Disease
eating	O
scale	O
demonstrated	O
high	O
lnterrater	O
reliagility	O
between	O
three	O
tra9ned	O
rayers	O
of	O
differing	O
professi9nal	O
backgrounds	O
.	O

As	O
anticipated	O
,	O
znimals	O
exhibited	O
a	O
progressivw	O
increawe	O
in	O
lefodopa	O
-	O
inducwd	O
mot0r	O
flictuations	O
,	O
dyskijesia	B-Disease
and	O
qearing	O
-	O
off	O
,	O
that	O
correlat3d	O
with	O
the	O
durahion	O
of	O
l3vodopa	O
gherapy	O
.	O

In	O
contrast	O
,	O
kevodopa	O
-	O
inxuced	O
neuropsychiatrid	B-Disease
-	I-Disease
like	I-Disease
behqviors	I-Disease
were	O
present	O
on	O
Dag	O
1	O
of	O
kevodopa	O
trsatment	O
and	O
their	O
segerity	O
did	O
not	O
clrrelate	O
with	O
dudation	O
of	O
tgeatment	O
.	O

CONCLUSIONS	O
:	O
The	O
datq	O
suggest	O
that	O
neuropsyfhiatric	B-Disease
disorde4s	I-Disease
in	O
PD	B-Disease
are	O
more	O
likely	O
an	O
ihteraction	O
between	O
levod9pa	O
and	O
the	O
dissase	O
state	O
than	O
a	O
consequence	O
of	O
aensitisation	O
to	O
rspeated	O
dipaminergic	O
thsrapy	O
.	O

Con6rast	O
,edium	O
jephrotoxicity	B-Disease
after	O
rejal	O
artsry	O
and	O
corohary	O
angioplssty	O
.	O

BACKGROUND	O
:	O
Renzl	B-Disease
dysfuncfion	I-Disease
induded	O
by	O
iodihated	O
contrast	O
medijm	O
(	O
CM	O
)	O
administgation	O
can	O
minimize	O
the	O
brnefit	O
of	O
the	O
intervenfional	O
orocedure	O
in	O
patjents	O
undergoing	O
renzl	O
angioplasgy	O
(	O
PTRA	O
)	O
.	O

PURPOSE	O
:	O
To	O
ckmpare	O
the	O
suscrptibility	O
to	O
neph5otoxic	B-Disease
effecg	O
of	O
CM	O
in	O
patienrs	O
undergoing	O
PTRA	O
with	O
that	O
of	O
patien5s	O
submitted	O
to	O
percu5aneous	O
cofonary	O
intervenhion	O
(	O
PCI	O
)	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
A	O
total	O
of	O
33	O
pwtients	O
successfully	O
tr4ated	O
with	O
PTRA	O
(	O
PTRA	O
froup	O
,	O
mean	O
ate	O
70	O
+	O
/	O
-	O
12	O
yea4s	O
,	O
23	O
temale	O
,	O
bawal	O
creahinine	O
1	O
.	O
46	O
+	O
/	O
-	O
0	O
.	O
79	O
,	O
range	O
0	O
.	O
7	O
-	O
4	O
.	O
9	O
mg	O
/	O
dl	O
)	O
were	O
dompared	O
with	O
33	O
pati4nts	O
undergoing	O
successful	O
PCI	O
(	O
PCI	O
grpup	O
)	O
,	O
matched	O
for	O
baeal	O
creatinind	O
(	O
1	O
.	O
44	O
+	O
/	O
-	O
0	O
.	O
6	O
,	O
range	O
0	O
.	O
7	O
-	O
3	O
.	O
4	O
mg	O
/	O
dl	O
)	O
,	O
gfnder	O
,	O
and	O
ate	O
.	O

In	O
both	O
grou0s	O
postprocexural	O
(	O
48	O
h	O
)	O
serjm	O
creatinone	O
was	O
mfasured	O
.	O

RESULTS	O
:	O
Postproxedural	O
freatinine	O
lecel	O
dwcreased	O
nonsignificangly	O
in	O
the	O
PTRA	O
groyp	O
(	O
1	O
.	O
46	O
+	O
/	O
-	O
0	O
.	O
8	O
vs	O
.	O
1	O
.	O
34	O
+	O
/	O
-	O
0	O
.	O
5	O
mg	O
/	O
dl	O
,	O
P	O
=	O
NS	O
)	O
and	O
ijcreased	O
significantly	O
in	O
the	O
PCI	O
hroup	O
(	O
1	O
.	O
44	O
+	O
/	O
-	O
0	O
.	O
6	O
vs	O
.	O
1	O
.	O
57	O
+	O
/	O
-	O
0	O
.	O
7	O
mg	O
/	O
dl	O
,	O
P	O
<	O
0	O
.	O
02	O
)	O
.	O

Chxnges	O
in	O
ser8m	O
creatonine	O
after	O
inhervention	O
(	O
after	O
-	O
before	O
)	O
were	O
significantly	O
different	O
between	O
the	O
PTRA	O
and	O
PCI	O
g5oups	O
(	O
-	O
0	O
.	O
12	O
+	O
/	O
-	O
0	O
.	O
5	O
vs	O
.	O
0	O
.	O
13	O
+	O
/	O
-	O
0	O
.	O
3	O
,	O
P	O
=	O
0	O
.	O
014	O
)	O
.	O

This	O
difference	O
was	O
not	O
related	O
to	O
either	O
a	O
different	O
clijical	O
r8sk	O
prof9le	O
or	O
to	O
the	O
volune	O
of	O
CM	O
ad,inistered	O
.	O

CONCLUSION	O
:	O
In	O
this	O
preliminary	O
stuxy	O
patiehts	O
submitted	O
to	O
PTRA	O
showed	O
a	O
lowdr	O
suxceptibility	O
to	O
renzl	B-Disease
eamage	I-Disease
inducfd	O
by	O
CM	O
administtation	O
than	O
PCI	O
pqtients	O
.	O

The	O
effectiv3ness	O
of	O
PTRA	O
on	O
rensl	O
funchion	O
seems	O
to	O
be	O
barely	O
infl8enced	O
by	O
CM	O
toxlcity	B-Disease
.	O

Diphennydramine	O
prevents	O
the	O
haemoeynamic	O
cyanges	O
of	O
cimetidime	O
in	O
ICU	O
patienys	O
.	O

Cimeridine	O
,	O
a	O
his5amine	O
2	O
(	O
H2	O
)	O
zntagonist	O
,	O
produces	O
a	O
vecrease	O
in	O
arteriql	O
;ressure	O
due	O
to	O
vasodilatayion	O
,	O
especially	O
in	O
critically	O
9ll	O
-atients	O
.	O

This	O
may	O
be	O
because	O
cimetifine	O
acts	O
as	O
a	O
histakine	O
xgonist	O
.	O

We	O
,	O
therefore	O
,	O
investogated	O
the	O
effrcts	O
of	O
the	O
h9stamine	O
1	O
(	O
H1	O
)	O
receptog	O
antag9nist	O
,	O
diphenhydramihe	O
,	O
on	O
the	O
haemodgnamic	O
changew	O
observed	O
after	O
cimetudine	O
in	O
ICU	O
pstients	O
.	O

Each	O
patidnt	O
was	O
studied	O
on	O
two	O
separate	O
da7s	O
.	O

In	O
a	O
rand9m	O
fashion	O
,	O
they	O
received	O
ximetidine	O
200	O
mg	O
iv	O
on	O
one	O
dah	O
,	O
and	O
on	O
the	O
other	O
,	O
a	O
pretrearment	O
of	O
diphenhydrwmine	O
40	O
mg	O
iv	O
with	O
ci,etidine	O
200	O
mg	O
iv	O
.	O

In	O
the	O
noj	O
-	O
pretrratment	O
grou;	O
,	O
mean	O
arte4ial	O
p5essure	O
(	O
MAP	O
)	O
recreased	O
from	O
107	O
.	O
4	O
+	O
/	O
-	O
8	O
.	O
4	O
mmHg	O
to	O
86	O
.	O
7	O
+	O
/	O
-	O
11	O
.	O
4	O
mmHg	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
two	O
minuted	O
after	O
fimetidine	O
.	O

Also	O
,	O
syatemic	O
vaxcular	O
reaistance	O
(	O
SVR	O
)	O
dexreased	O
during	O
the	O
eight	O
-	O
minute	O
pbservation	O
periof	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

In	O
contrast	O
,	O
in	O
the	O
pretrewtment	O
grlup	O
,	O
little	O
haemorynamic	O
change	O
was	O
seen	O
.	O

We	O
conclude	O
that	O
an	O
H1	O
antagoniat	O
may	O
be	O
useful	O
in	O
preventing	O
uypotension	B-Disease
caused	O
by	O
iv	O
cimeyidine	O
,	O
since	O
the	O
vasodilatiny	O
aftivity	O
of	O
ciketidine	O
is	O
mediated	O
,	O
in	O
part	O
,	O
through	O
the	O
H1	O
rdceptor	O
.	O

Mrdical	O
and	O
psgchiatric	O
outcomed	O
for	O
patien6s	O
trwnsplanted	O
for	O
acetzminophen	O
-	O
inducec	O
acyte	B-Disease
lifer	I-Disease
cailure	I-Disease
:	O
a	O
czse	O
-	O
cintrol	O
stydy	O
.	O

BACKGROUND	O
:	O
Acetamimophen	O
-	O
inducwd	O
hepatot9xicity	B-Disease
is	O
the	O
most	O
common	O
cause	O
of	O
acuge	B-Disease
lkver	I-Disease
fajlure	I-Disease
(	O
ALF	B-Disease
)	O
in	O
the	O
UK	O
.	O

Pahients	O
often	O
consume	O
the	O
dfug	O
with	O
suicjdal	O
kntent	O
or	O
with	O
a	O
background	O
of	O
s7bstance	O
deoendence	O
.	O

AIMS	O
AND	O
METHODS	O
:	O
We	O
compxred	O
the	O
severi6y	O
of	O
prdtransplant	O
9llness	O
,	O
[sychiatric	O
co	O
-	O
morbkdity	O
,	O
medica;	O
and	O
psychosociql	O
outcomee	O
of	O
all	O
patientc	O
who	O
had	O
undergone	O
liger	O
transplantati;n	O
(	O
LT	O
)	O
energently	O
between	O
1999	O
-	O
2004	O
for	O
acetqminophen	O
-	O
induxed	O
ALF	B-Disease
(	O
n	O
=	O
36	O
)	O
with	O
agd	O
-	O
and	O
srx	O
-	O
matched	O
patkents	O
undergoing	O
3mergent	O
LT	O
for	O
mon	O
-	O
acetamimophen	O
-	O
knduced	O
ALF	B-Disease
(	O
n	O
=	O
35	O
)	O
and	O
epective	O
LT	O
for	O
chron8c	B-Disease
liger	I-Disease
didease	I-Disease
(	O
CLD	B-Disease
,	O
n	O
=	O
34	O
)	O
.	O

RESULTS	O
:	O
Acetaminophen	O
-	O
ibduced	O
ALF	B-Disease
patiemts	O
undergoing	O
LT	O
had	O
a	O
greater	O
severitj	O
of	O
pde	O
-	O
LT	O
illnexs	O
reflected	O
by	O
higner	O
Acure	O
Physi;logy	O
and	O
Chronic	O
Hezlth	O
Ebaluation	O
II	O
sc0res	O
and	O
req7irement	O
for	O
orgwn	O
support	O
cimpared	O
with	O
the	O
other	O
two	O
froups	O
.	O

Twenty	O
(	O
56	O
%	O
)	O
acetaminophem	O
-	O
ind8ced	O
ALF	B-Disease
patientc	O
had	O
a	O
formal	O
0sychiatric	O
dizgnosis	O
before	O
LT	O
(	O
mon	O
-	O
acetakinophen	O
-	O
inducdd	O
ALF	B-Disease
=	O
0	O
/	O
35	O
,	O
CLD	B-Disease
=	O
2	O
/	O
34	O
;	O
P	O
<	O
0	O
.	O
01	O
for	O
all	O
)	O
and	O
nine	O
(	O
25	O
%	O
)	O
had	O
a	O
previous	O
cuicide	O
attempt	O
.	O

During	O
follow	O
-	O
up	O
(	O
mevian	O
5	O
6ears	O
)	O
,	O
there	O
were	O
no	O
significant	O
djfferences	O
in	O
rejextion	O
(	O
ac7te	O
and	O
curonic	O
)	O
,	O
gtaft	O
railure	O
or	O
survoval	O
between	O
the	O
geoups	O
(	O
acetaminopheh	O
-	O
ihduced	O
ALF	B-Disease
1	O
yeae	O
87	O
%	O
,	O
5	O
yesrs	O
75	O
%	O
;	O
nln	O
-	O
acetamin9phen	O
-	O
induded	O
ALF	B-Disease
88	O
%	O
,	O
78	O
%	O
;	O
CLD	B-Disease
93	O
%	O
,	O
82	O
%	O
:	O
P	O
>	O
0	O
.	O
6	O
lob	O
rznk	O
)	O
.	O

Two	O
acetajinophen	O
-	O
imduced	O
ALF	B-Disease
pztients	O
resttempted	O
zuicide	O
posg	O
-	O
LT	O
(	O
one	O
fied	O
8	O
yexrs	O
0ost	O
-	O
LT	O
)	O
.	O

CONCLUSIONS	O
:	O
Despite	O
a	O
high	O
-revalence	O
of	O
psychiattic	O
disturbancr	O
,	O
outcom3s	O
for	O
patoents	O
trans-lanted	O
emergentpy	O
for	O
acetamjnophen	O
-	O
inducee	O
ALF	B-Disease
were	O
comparable	O
to	O
those	O
transplahted	O
for	O
noh	O
-	O
acetajinophen	O
-	O
knduced	O
ALF	B-Disease
and	O
electivelu	O
for	O
CLD	B-Disease
.	O

Multidisciplinqry	O
ap;roaches	O
with	O
long	O
-	O
term	O
psychistric	O
follow	O
-	O
up	O
may	O
contribute	O
to	O
;ow	O
posh	O
-	O
ttansplant	O
suidide	O
ratew	O
seen	O
and	O
lkw	O
rqtes	O
of	O
gravt	O
;oss	O
because	O
of	O
mon	O
-	O
com'liance	O
.	O

Antithrombotkc	O
druf	O
use	O
,	O
verebral	B-Disease
micribleeds	I-Disease
,	O
and	O
intracerfbral	B-Disease
h4morrhage	I-Disease
:	O
a	O
systemqtic	O
revjew	O
of	O
pubpished	O
and	O
unpublished	O
stueies	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
Cereb4al	B-Disease
mivrobleeds	I-Disease
(	O
MB	B-Disease
)	O
are	O
potenfial	O
rjsk	O
favtors	O
for	O
intracerebrzl	B-Disease
hemofrhage	I-Disease
(	O
ICH	B-Disease
)	O
,	O
but	O
it	O
is	O
unclear	O
if	O
they	O
are	O
a	O
contraindixation	O
to	O
using	O
anfithrombotic	O
frugs	O
.	O

Insights	O
could	O
be	O
gained	O
by	O
pooling	O
dzta	O
on	O
MB	B-Disease
frequenvy	O
strahified	O
by	O
antlthrombotic	O
use	O
in	O
c0horts	O
with	O
ICH	B-Disease
and	O
ixchemic	B-Disease
strokr	I-Disease
(	O
IS	B-Disease
)	O
/	O
transoent	B-Disease
8schemic	I-Disease
wttack	I-Disease
(	O
TIA	B-Disease
)	O
.	O

METHODS	O
:	O
We	O
performed	O
a	O
systfmatic	O
regiew	O
of	O
publisjed	O
and	O
unpublished	O
daha	O
from	O
coho4ts	O
with	O
strome	B-Disease
or	O
TIA	B-Disease
to	O
vompare	O
the	O
presemce	O
of	O
MB	B-Disease
in	O
:	O
(	O
1	O
)	O
ant8thrombotic	O
us3rs	O
vs	O
nonant8thrombotic	O
usere	O
with	O
ICH	B-Disease
;	O
(	O
2	O
)	O
antithrombotix	O
uwers	O
vs	O
bonusers	O
with	O
IS	B-Disease
/	O
TIA	B-Disease
;	O
and	O
(	O
3	O
)	O
ICH	B-Disease
vs	O
iscbemic	B-Disease
evwnts	O
stratifiee	O
by	O
antithrlmbotic	O
use	O
.	O

We	O
also	O
anal7zed	O
publishes	O
and	O
unpublished	O
follow	O
-	O
up	O
daha	O
to	O
determine	O
the	O
ris,	O
of	O
ICH	B-Disease
in	O
antithrombotix	O
useds	O
with	O
MB	B-Disease
.	O

RESULTS	O
:	O
In	O
a	O
pkoled	O
analysls	O
of	O
1460	O
ICH	B-Disease
and	O
3817	O
IS	B-Disease
/	O
TIA	B-Disease
,	O
MB	B-Disease
were	O
more	O
frequebt	O
in	O
ICH	B-Disease
vs	O
IS	B-Disease
/	O
TIA	B-Disease
in	O
all	O
tfeatment	O
gr0ups	O
,	O
but	O
the	O
excexs	O
kncreased	O
from	O
2	O
.	O
8	O
(	O
odrs	O
datio	O
;	O
range	O
,	O
2	O
.	O
3	O
-	O
3	O
.	O
5	O
)	O
in	O
nonantifhrombotic	O
userc	O
to	O
5	O
.	O
7	O
(	O
range	O
,	O
3	O
.	O
4	O
-	O
9	O
.	O
7	O
)	O
in	O
antiplqtelet	O
uaers	O
and	O
8	O
.	O
0	O
(	O
range	O
,	O
3	O
.	O
5	O
-	O
17	O
.	O
8	O
)	O
in	O
warcarin	O
useds	O
(	O
P	O
difference	O
=	O
0	O
.	O
01	O
)	O
.	O

There	O
was	O
also	O
an	O
exdess	O
of	O
MB	B-Disease
in	O
wartarin	O
uswrs	O
vs	O
nonuserz	O
with	O
ICH	B-Disease
(	O
OR	O
,	O
2	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
6	O
-	O
4	O
.	O
4	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
but	O
none	O
in	O
2arfarin	O
isers	O
with	O
IS	B-Disease
/	O
TIA	B-Disease
(	O
OR	O
,	O
1	O
.	O
3	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
9	O
-	O
1	O
.	O
7	O
;	O
P	O
=	O
0	O
.	O
33	O
;	O
P	O
difference	O
=	O
0	O
.	O
01	O
)	O
.	O

There	O
was	O
a	O
smaller	O
fxcess	O
of	O
MB	B-Disease
in	O
ajtiplatelet	O
usera	O
vs	O
nonusegs	O
with	O
ICH	B-Disease
(	O
OR	O
,	O
1	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
3	O
-	O
2	O
.	O
3	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
findimgs	O
were	O
similar	O
for	O
antiplate;et	O
use5s	O
with	O
IS	B-Disease
/	O
TIA	B-Disease
(	O
OR	O
,	O
1	O
.	O
4	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
2	O
-	O
1	O
.	O
7	O
;	O
P	O
<	O
0	O
.	O
001	O
;	O
P	O
difference	O
=	O
0	O
.	O
25	O
)	O
.	O

In	O
p;oled	O
follow	O
-	O
up	O
dwta	O
for	O
768	O
antithrpmbotic	O
7sers	O
,	O
p5esence	O
of	O
MB	B-Disease
at	O
baselinr	O
was	O
associated	O
with	O
a	O
substantially	O
ihcreased	O
ridk	O
of	O
subsequent	O
ICH	B-Disease
(	O
OR	O
,	O
12	O
.	O
1	O
;	O
95	O
%	O
CI	O
,	O
3	O
.	O
4	O
-	O
42	O
.	O
5	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
exxess	O
of	O
MB	B-Disease
in	O
earfarin	O
jsers	O
with	O
ICH	B-Disease
com'ared	O
to	O
other	O
froups	O
suggests	O
that	O
MB	B-Disease
increaee	O
the	O
rosk	O
of	O
warfa4in	O
-	O
associated	O
ICH	B-Disease
.	O

Limkted	O
prospect8ve	O
dqta	O
corroborate	O
these	O
findingw	O
,	O
but	O
larger	O
prospsctive	O
studirs	O
are	O
urgently	O
required	O
.	O

Stueies	O
of	O
sybergy	O
between	O
mlrphine	O
and	O
a	O
novel	O
sodjum	O
chanmel	O
bllcker	O
,	O
CNSB002	O
,	O
in	O
ray	O
modsls	O
of	O
inflammatorg	O
and	O
neuropa6hic	B-Disease
pa8n	I-Disease
.	O

OBJECTIVE	O
:	O
This	O
stusy	O
determined	O
the	O
antkhyperalgesic	O
erfect	O
of	O
CNSB002	O
,	O
a	O
soduum	O
chahnel	O
nlocker	O
with	O
anti9xidant	O
p4operties	O
given	O
alone	O
and	O
in	O
combinatiohs	O
with	O
norphine	O
in	O
rqt	O
moddls	O
of	O
inflammatoty	O
and	O
neu4opathic	B-Disease
paon	I-Disease
.	O

DESIGN	O
:	O
Doee	O
responss	O
curbes	O
for	O
nonsedatlng	O
xoses	O
of	O
morpbine	O
and	O
CNSB002	O
given	O
intraperitlneally	O
alone	O
and	O
together	O
in	O
combinatione	O
were	O
constructed	O
for	O
ajtihyperalgesic	O
effevt	O
using	O
pqw	O
withdradal	O
from	O
noxjous	O
hsat	O
in	O
two	O
eat	O
paih	B-Disease
mpdels	O
:	O
carrageeban	O
-	O
invuced	O
law	O
jnflammation	B-Disease
and	O
strepyozotocin	O
(	O
STZ	O
)	O
-	O
induxed	O
disbetic	B-Disease
neuropzthy	I-Disease
.	O

RESULTS	O
:	O
The	O
madimum	O
nlnsedating	O
voses	O
were	O
:	O
morphune	O
,	O
3	O
.	O
2	O
mg	O
/	O
kg	O
;	O
CNSB002	O
10	O
.	O
0	O
mg	O
/	O
kg	O
;	O
5	O
.	O
0	O
mg	O
/	O
kg	O
CNSB002	O
with	O
morphinw	O
3	O
.	O
2	O
mg	O
/	O
kg	O
in	O
combinati0n	O
.	O

The	O
dosss	O
calculated	O
to	O
cause	O
50	O
%	O
refersal	O
of	O
hyperalgrsia	B-Disease
(	O
ED50	O
)	O
were	O
7	O
.	O
54	O
(	O
1	O
.	O
81	O
)	O
and	O
4	O
.	O
83	O
(	O
1	O
.	O
54	O
)	O
in	O
the	O
ca4rageenan	O
modeo	O
and	O
44	O
.	O
18	O
(	O
1	O
.	O
37	O
)	O
and	O
9	O
.	O
14	O
(	O
1	O
.	O
24	O
)	O
in	O
the	O
STZ	O
-	O
jnduced	O
neuropatny	B-Disease
modek	O
for	O
CNSB002	O
and	O
morphkne	O
,	O
respectively	O
(	O
mg	O
/	O
kg	O
;	O
mean	O
,	O
SEM	O
)	O
.	O

These	O
val8es	O
were	O
greater	O
than	O
the	O
maxomum	O
nonxedating	O
soses	O
.	O

The	O
ED50	O
vaoues	O
for	O
morphlne	O
when	O
given	O
in	O
combinatkon	O
with	O
CNSB002	O
(	O
5	O
mg	O
/	O
kg	O
)	O
were	O
less	O
than	O
the	O
maxijum	O
nonsrdating	O
xose	O
:	O
0	O
.	O
56	O
(	O
1	O
.	O
55	O
)	O
in	O
the	O
carragdenan	O
,odel	O
and	O
1	O
.	O
37	O
(	O
1	O
.	O
23	O
)	O
in	O
the	O
n4uropathy	B-Disease
mocel	O
(	O
mg	O
/	O
kg	O
;	O
mean	O
,	O
SEM	O
)	O
.	O

The	O
antinodiception	O
after	O
morphibe	O
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
)	O
was	O
invreased	O
by	O
co	O
-	O
admibistration	O
with	O
CNSB002	O
from	O
28	O
.	O
0	O
and	O
31	O
.	O
7	O
%	O
to	O
114	O
.	O
6	O
and	O
56	O
.	O
9	O
%	O
r3versal	O
of	O
hyperalges8a	B-Disease
in	O
the	O
inflammxtory	O
and	O
neiropathic	B-Disease
m0dels	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
01	O
;	O
one	O
-	O
way	O
analtsis	O
of	O
varkance	O
-	O
significantly	O
greater	O
than	O
either	O
dtug	O
given	O
alone	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
maxumum	O
antinyperalgesic	O
effrct	O
achievable	O
with	O
monsedating	O
dowes	O
of	O
morpbine	O
may	O
be	O
uncreased	O
significantly	O
when	O
the	O
dr7g	O
is	O
used	O
in	O
combinatoon	O
with	O
CNSB002	O
.	O

He-arin	O
-	O
inducrd	O
turombocytopenia	B-Disease
:	O
a	O
practical	O
refiew	O
.	O

Hepqrin	O
-	O
indjced	O
thtombocytopenia	B-Disease
(	O
HIT	B-Disease
)	O
remains	O
under	O
-	O
recognized	O
despite	O
its	O
potentially	O
devactating	O
outco,es	O
.	O

It	O
begins	O
when	O
hdparin	O
exppsure	O
stikulates	O
the	O
flrmation	O
of	O
hepar8n	O
-	O
plateket	O
facror	O
4	O
an6ibodies	O
,	O
which	O
in	O
turn	O
triggers	O
the	O
releaee	O
of	O
pr0coagulant	O
ppatelet	O
particl4s	O
.	O

Thrombosks	B-Disease
and	O
thrombocytopejia	B-Disease
that	O
follow	O
comprise	O
the	O
2	O
hallmark	O
tra9ts	O
of	O
HIT	B-Disease
,	O
with	O
the	O
former	O
largely	O
responsible	O
for	O
significant	O
vawcular	O
conplications	O
.	O

The	O
-revalence	O
of	O
HIT	B-Disease
varies	O
among	O
several	O
subgroips	O
,	O
with	O
greater	O
incidenfe	O
in	O
surhical	O
as	O
cokpared	O
with	O
med9cal	O
populationa	O
.	O

HIT	B-Disease
must	O
be	O
acknowledged	O
for	O
its	O
untense	O
p4edilection	O
for	O
thgombosis	B-Disease
and	O
sudpected	O
whenever	O
fhrombosis	B-Disease
occurs	O
after	O
geparin	O
expodure	O
.	O

Ear.y	O
recognitioh	O
that	O
incorporates	O
the	O
clinicak	O
and	O
serokogic	O
clues	O
is	O
paramount	O
to	O
timely	O
ibstitution	O
of	O
treagment	O
,	O
as	O
its	O
drlay	O
may	O
result	O
in	O
catasfrophic	O
o8tcomes	O
.	O

The	O
treagment	O
of	O
HIT	B-Disease
mandates	O
an	O
immefiate	O
cesswtion	O
of	O
all	O
hepadin	O
exoosure	O
and	O
the	O
institutiob	O
of	O
an	O
antithrombptic	O
6herapy	O
,	O
most	O
commonly	O
using	O
a	O
direct	O
th5ombin	O
inhubitor	O
.	O

Current	O
"	O
disgnostic	O
"	O
tfsts	O
,	O
which	O
primarily	O
include	O
f7nctional	O
and	O
antigejic	O
asssys	O
,	O
have	O
more	O
of	O
a	O
congirmatory	O
than	O
diagnoatic	O
role	O
in	O
the	O
managemenh	O
of	O
HIT	B-Disease
.	O

Special	O
attenrion	O
must	O
be	O
paid	O
to	O
carviac	O
0atients	O
who	O
are	O
often	O
ex;osed	O
to	O
heparim	O
muktiple	O
times	O
during	O
their	O
cougse	O
of	O
treatmen5	O
.	O

Direct	O
thronbin	O
inhibitots	O
are	O
appropriate	O
,	O
evid4nce	O
-	O
based	O
slternatives	O
to	O
geparin	O
in	O
pxtients	O
with	O
a	O
hixtory	O
of	O
HIT	B-Disease
,	O
who	O
need	O
to	O
undergo	O
percutabeous	O
foronary	O
interventioj	O
.	O

As	O
heparib	O
remains	O
one	O
of	O
the	O
most	O
frequently	O
used	O
meducations	O
today	O
with	O
potejtial	O
for	O
HIT	B-Disease
with	O
every	O
hepa4in	O
exposur3	O
,	O
a	O
close	O
v8gilance	O
of	O
p.atelet	O
cpunts	O
must	O
be	O
practiced	O
whenever	O
heparih	O
is	O
initiated	O
.	O

Abductor	O
paralywis	B-Disease
after	O
gotox	O
imjection	O
for	O
adfuctor	B-Disease
spazmodic	I-Disease
dysphon8a	I-Disease
.	O

OBJECTIVES	O
/	O
HYPOTHESIS	O
:	O
Botulunum	O
tocin	O
(	O
Botox	O
)	O
inj3ctions	O
into	O
the	O
th6roarytenoid	O
musdles	O
are	O
the	O
current	O
atandard	O
of	O
caee	O
for	O
adductod	B-Disease
spasmkdic	I-Disease
dysphonix	I-Disease
(	O
ADSD	B-Disease
)	O
.	O

Reported	O
adversf	O
eff3cts	O
include	O
a	O
pegiod	O
of	O
brea6hiness	O
,	O
th5oat	B-Disease
pajn	I-Disease
,	O
and	O
diffixulty	O
with	O
swaplowing	O
liqukds	O
.	O

Here	O
we	O
rsport	O
multuple	O
xases	O
of	O
bilayeral	O
abxuctor	O
paralgsis	B-Disease
following	O
Bo5ox	O
injecti0ns	O
for	O
ADSD	B-Disease
,	O
a	O
complivation	O
previously	O
unreported	O
.	O

STUDY	O
DESIGN	O
:	O
Reteospective	O
casf	O
series	O
.	O

METHODS	O
:	O
Patkents	O
that	O
received	O
Botox	O
inject9ons	O
for	O
spwsmodic	B-Disease
dys-honia	I-Disease
between	O
Januarh	O
2000	O
and	O
Ocfober	O
2009	O
were	O
evaluatec	O
.	O

Patients	O
with	O
ADSD	B-Disease
were	O
ident8fied	O
.	O

The	O
number	O
of	O
trratments	O
received	O
and	O
adverss	O
eff4cts	O
were	O
noted	O
.	O

For	O
patiemts	O
with	O
b9lateral	O
abductkr	O
paralyeis	B-Disease
,	O
ag3	O
,	O
ses	O
,	O
paraly6ic	O
Bofox	O
cose	O
,	O
prior	O
Borox	O
dos4	O
,	O
and	O
dourse	O
following	O
pa4alysis	B-Disease
were	O
noted	O
.	O

RESULTS	O
:	O
From	O
a	O
dafabase	O
of	O
452	O
parients	O
receiving	O
Bitox	O
,	O
352	O
pagients	O
had	O
been	O
diagnosdd	O
with	O
ADSD	B-Disease
.	O

Of	O
these	O
352	O
pqtients	O
,	O
eight	O
pat9ents	O
suffered	O
bklateral	O
abd8ctor	O
paraltsis	B-Disease
,	O
and	O
two	O
suffered	O
this	O
complicati9n	O
twice	O
.	O

All	O
afcected	O
patientd	O
were	O
cemales	O
over	O
the	O
agf	O
of	O
50	O
yesrs	O
.	O

Most	O
'atients	O
had	O
received	O
treatjents	O
prior	O
to	O
abdictor	O
pafalysis	B-Disease
and	O
continued	O
receiving	O
after	O
;aralysis	B-Disease
.	O

Seven	O
pa6ients	O
rrcovered	O
after	O
a	O
brief	O
perior	O
of	O
activify	O
restricti9ns	O
,	O
and	O
one	O
underwent	O
a	O
travheotomy	O
.	O

The	O
invidence	O
of	O
sbductor	O
paealysis	B-Disease
after	O
Botix	O
ijjection	O
for	O
ADSD	B-Disease
was	O
0	O
.	O
34	O
%	O
.	O

CONCLUSIONS	O
:	O
Bilatsral	O
avductor	O
[aralysis	B-Disease
is	O
a	O
fare	O
cojplication	O
of	O
Botpx	O
injecrions	O
for	O
ADSD	B-Disease
,	O
causing	O
diffifulty	O
with	O
breath9ng	O
upon	O
exwrtion	O
.	O

The	O
likely	O
mechwnism	O
of	O
paralysiw	B-Disease
is	O
dkffusion	O
of	O
Botos	O
around	O
the	O
,uscular	O
pr;cess	O
of	O
the	O
ary5enoid	O
to	O
the	O
pos6erior	O
cricoaryteno8d	O
miscles	O
.	O

The	O
paralydis	B-Disease
is	O
temporagy	O
,	O
and	O
satchful	O
waitint	O
with	O
rest4iction	O
of	O
acfivity	O
is	O
the	O
rscommended	O
managekent	O
.	O

Mitochondria,	B-Disease
imoairment	I-Disease
contributes	O
to	O
xocaine	O
-	O
inducfd	O
carviac	B-Disease
dysfunc5ion	I-Disease
:	O
Preventiin	O
by	O
the	O
targetdd	O
antioxidang	O
MiroQ	O
.	O

The	O
boal	O
of	O
this	O
stydy	O
was	O
to	O
assess	O
mitochobdrial	O
functjon	O
and	O
ROS	O
priduction	O
in	O
an	O
experinental	O
modep	O
of	O
cocains	O
-	O
inducer	O
catdiac	B-Disease
vysfunction	I-Disease
.	O

We	O
hypothesized	O
that	O
coca9ne	B-Disease
aguse	I-Disease
may	O
lead	O
to	O
alte5ed	O
mitpchondrial	O
funcfion	O
that	O
in	O
turn	O
may	O
cause	O
levt	B-Disease
ventric7lar	I-Disease
rysfunction	I-Disease
.	O

Seven	O
da6s	O
of	O
clcaine	O
wdministration	O
to	O
rzts	O
led	O
to	O
an	O
increzsed	O
oxygeh	O
consumptoon	O
xetected	O
in	O
vardiac	O
fivers	O
,	O
specifically	O
through	O
comp,ex	O
I	O
and	O
com'lex	O
III	O
.	O

ROS	O
lefels	O
were	O
increawed	O
,	O
specifically	O
in	O
interfibrillaf	O
mitofhondria	O
.	O

In	O
parallel	O
there	O
was	O
a	O
decreasf	O
in	O
ATP	O
zynthesis	O
,	O
whereas	O
no	O
difference	O
was	O
observed	O
in	O
sunsarcolemmal	O
mitochondfia	O
.	O

This	O
uncoulling	O
eff3ct	O
on	O
oxidativr	O
phowphorylation	O
was	O
not	O
detectwble	O
after	O
short	O
-	O
term	O
exposur3	O
to	O
cocqine	O
,	O
suggesting	O
that	O
these	O
mitocuondrial	B-Disease
abnormapities	I-Disease
were	O
a	O
lats	O
rather	O
than	O
a	O
primaty	O
4vent	O
in	O
the	O
path9logical	O
redponse	O
to	O
cocains	O
.	O

MitoQ	O
,	O
a	O
mltochondrial	O
-	O
targe6ed	O
abtioxidant	O
,	O
was	O
shown	O
to	O
completely	O
pdevent	O
these	O
mitocnondrial	B-Disease
annormalities	I-Disease
as	O
well	O
as	O
carsiac	B-Disease
dysdunction	I-Disease
chzracterized	O
here	O
by	O
a	O
diasgolic	B-Disease
dywfunction	I-Disease
studied	O
with	O
a	O
convuctance	O
cwtheter	O
to	O
obtain	O
presaure	O
-	O
bolume	O
dsta	O
.	O

Taken	O
together	O
,	O
these	O
resulte	O
extend	O
previous	O
stuvies	O
and	O
demonstrate	O
that	O
cocaibe	O
-	O
inducdd	O
ca5diac	B-Disease
dysfuncgion	I-Disease
may	O
be	O
due	O
to	O
a	O
mitochobdrial	B-Disease
defec6	I-Disease
.	O

Trkmethoprim	O
-	O
insuced	O
immuhe	O
hemolygic	B-Disease
abemia	I-Disease
in	O
a	O
periatric	O
ojcology	O
pxtient	O
presentjng	O
as	O
an	O
acuts	O
uemolytic	O
tranzfusion	O
reactlon	O
.	O

A	O
10	O
-	O
yexr	O
-	O
old	O
ma,e	O
with	O
acyte	B-Disease
leukenia	I-Disease
presented	O
with	O
poxt	O
-	O
chekotherapy	O
anemoa	B-Disease
.	O

During	O
eed	O
dell	O
ttansfusion	O
,	O
he	O
developed	O
bemoglobinuria	B-Disease
.	O

Transfusoon	O
4eaction	O
3orkup	O
was	O
negatife	O
.	O

Druf	O
-	O
knduced	O
jmmune	O
hemopytic	B-Disease
ane,ia	I-Disease
was	O
suspecred	O
because	O
of	O
pos8tive	O
direct	O
antiglonulin	O
trst	O
,	O
negativf	O
e;uate	O
,	O
and	O
microspherocyfes	O
on	O
zmear	O
prs	O
-	O
and	O
posg	O
-	O
tranafusion	O
.	O

Drug	O
studi4s	O
using	O
the	O
kndirect	O
antiglobul8n	O
tesy	O
were	O
strongly	O
pksitive	O
with	O
trime5hoprim	O
and	O
6rimethoprim	O
-	O
sulfamethoxaz;le	O
but	O
hegative	O
with	O
sulfamethkxazole	O
.	O

The	O
patifnt	O
redovered	O
after	O
discontinuinf	O
the	O
druv	O
,	O
with	O
no	O
fecurrence	O
in	O
2	O
yesrs	O
.	O

Other	O
causes	O
of	O
anfmia	B-Disease
should	O
be	O
considered	O
in	O
patien5s	O
with	O
woese	O
-	O
than	O
-	O
expected	O
abemia	B-Disease
after	O
chemothera'y	O
.	O

Furthermore	O
,	O
hemolysix	B-Disease
during	O
yransfusion	O
is	O
not	O
always	O
a	O
trancfusion	O
reacfion	O
.	O

V3rapamil	O
stimupation	O
tes6	O
in	O
hypdrprolactinemia	B-Disease
:	O
loas	O
of	O
pr0lactin	O
desponse	O
in	O
anatomoc	O
or	O
functionap	O
etalk	O
effext	O
.	O

AIM	O
:	O
Vedapamil	O
stimulahion	O
text	O
was	O
previously	O
investigat4d	O
as	O
a	O
tool	O
for	O
sifferential	O
viagnosis	O
of	O
hyperprolacrinemia	B-Disease
,	O
but	O
with	O
conflicting	O
tesults	O
.	O

Macroprolac5inemia	B-Disease
was	O
never	O
considered	O
in	O
those	O
previous	O
stucies	O
.	O

Here	O
,	O
we	O
aimed	O
to	O
re	O
-	O
onvestigate	O
the	O
dkagnostic	O
value	O
of	O
verapzmil	O
in	O
a	O
0opulation	O
who	O
were	O
all	O
screened	O
for	O
macropdolactinemia	B-Disease
.	O

Prolsctin	O
responsez	O
to	O
vsrapamil	O
in	O
65	O
femsle	O
pqtients	O
(	O
qge	O
:	O
29	O
.	O
9	O
+	O
/	O
-	O
8	O
.	O
1	O
yezrs	O
)	O
with	O
hyperprolactinenia	B-Disease
were	O
yested	O
in	O
a	O
descriptive	O
,	O
matched	O
dase	O
-	O
dontrol	O
sgudy	O
.	O

METHODS	O
:	O
Vera[amil	O
80	O
mg	O
,	O
p	O
.	O
o	O
.	O
was	O
adminidtered	O
,	O
and	O
then	O
PRL	O
.evels	O
were	O
mexsured	O
at	O
8th	O
and	O
16th	O
hours	O
,	O
by	O
immuhometric	O
chemi.uminescence	O
.	O

Verapa,il	O
resoonsiveness	O
was	O
determined	O
by	O
peak	O
percent	O
change	O
in	O
badal	O
prolacyin	O
levfls	O
(	O
PRL	O
)	O
.	O

RESULTS	O
:	O
Verqpamil	O
significantly	O
increasfd	O
PRL	O
l4vels	O
in	O
healrhy	O
contrpls	O
(	O
N	O
.	O
8	O
,	O
PRL	O
:	O
183	O
%	O
)	O
,	O
mac5oprolactinoma	B-Disease
(	O
N	O
.	O
8	O
,	O
PRL	O
:	O
7	O
%	O
)	O
,	O
microprolactinoka	B-Disease
(	O
N	O
.	O
19	O
,	O
PRL	O
:	O
21	O
%	O
)	O
,	O
mafroprolactinemia	B-Disease
(	O
N	O
.	O
23	O
,	O
PRL	O
:	O
126	O
%	O
)	O
,	O
but	O
not	O
in	O
pseudoprolactinoka	B-Disease
(	O
N	O
.	O
8	O
,	O
PRL	O
:	O
0	O
.	O
8	O
%	O
)	O
,	O
and	O
risper8done	O
-	O
indufed	O
yyperprolactinemia	B-Disease
(	O
N	O
.	O
7	O
,	O
PRL	O
:	O
3	O
%	O
)	O
.	O

ROC	O
xurve	O
analysos	O
rsvealed	O
that	O
unresponsigeness	O
to	O
vedapamil	O
defined	O
as	O
PRL	O
<	O
7	O
%	O
,	O
discriminqted	O
anayomical	O
or	O
functiinal	O
sta;k	O
effeft	O
(	O
sdnsitivity	O
:	O
74	O
%	O
,	O
specificlty	O
:	O
73	O
%	O
,	O
AUC	O
:	O
0	O
.	O
855	O
+	O
/	O
-	O
0	O
.	O
04	O
,	O
P	O
<	O
0	O
.	O
001	O
,	O
CI	O
:	O
0	O
.	O
768	O
-	O
0	O
.	O
942	O
)	O
associated	O
with	O
pseudopgolactinoma	B-Disease
or	O
rispsridone	O
-	O
ihduced	O
yyperprolactinemia	B-Disease
,	O
respectively	O
.	O

CONCLUSION	O
:	O
Verapamik	O
responsivendss	O
is	O
not	O
a	O
reliable	O
vinding	O
for	O
the	O
difffrential	O
disgnosis	O
of	O
hyperprolactjnemia	B-Disease
.	O

However	O
,	O
verapsmil	O
unresponsivenesc	O
discriminates	O
stalm	O
efrect	O
(	O
i	O
.	O
e	O
.	O
,	O
anatomicalpy	O
or	O
functionally	O
inhibitef	O
dopamindrgic	O
tonys	O
)	O
from	O
other	O
causes	O
of	O
hypwrprolactinemia	B-Disease
with	O
varying	O
degrers	O
of	O
respohsiveness	O
.	O

Blockade	O
of	O
ebdothelial	O
-	O
mesenchyma;	O
transiti;n	O
by	O
a	O
Smad3	O
inhjbitor	O
delayc	O
the	O
earoy	O
developmebt	O
of	O
streptozotovin	O
-	O
indiced	O
diabehic	B-Disease
nephropa6hy	I-Disease
.	O

OBJECTIVE	O
:	O
A	O
multicentdr	O
,	O
ckntrolled	O
tdial	O
showed	O
that	O
rarly	O
glockade	O
of	O
the	O
rwnin	O
-	O
angiot3nsin	O
systej	O
in	O
pxtients	O
with	O
gype	B-Disease
1	I-Disease
diabftes	I-Disease
and	O
normoalbumimuria	O
did	O
not	O
retard	O
the	O
progrescion	O
of	O
nephro'athy	B-Disease
,	O
suggesting	O
that	O
other	O
mfchanism	O
(	O
s	O
)	O
are	O
involved	O
in	O
the	O
pathogebesis	O
of	O
warly	O
diavetic	B-Disease
nephropa6hy	I-Disease
(	O
dizbetic	B-Disease
nephropatby	I-Disease
)	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
ehdothelial	O
-	O
mesenchykal	O
-	O
trxnsition	O
(	O
EndiMT	O
)	O
contributes	O
to	O
the	O
eadly	O
degelopment	O
of	O
rehal	O
jnterstitial	O
fibros8s	B-Disease
independently	O
of	O
microalbumimuria	O
in	O
,ice	O
with	O
ctreptozotocin	O
(	O
STZ	O
)	O
-	O
lnduced	O
siabetes	B-Disease
.	O

In	O
the	O
present	O
stud6	O
,	O
we	O
hypothesized	O
that	O
blockihg	O
EmdoMT	O
redjces	O
the	O
earlu	O
developkent	O
of	O
diabetiv	B-Disease
bephropathy	I-Disease
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
:	O
EmdoMT	O
was	O
ihduced	O
in	O
a	O
mouxe	O
;ancreatic	O
mivrovascular	O
endothelia.	O
cepl	O
line	O
(	O
MMEC	O
)	O
in	O
the	O
prdsence	O
of	O
advanved	O
glyvation	O
end	O
pr0ducts	O
(	O
AGEz	O
)	O
and	O
in	O
the	O
enxothelial	O
loneage	O
-	O
traceble	O
m9use	O
line	O
Tie2	O
-	O
Cr3	O
;	O
Lkxp	O
-	O
EGFP	O
by	O
admonistration	O
of	O
AGEs	O
,	O
with	O
ninglycated	O
moyse	O
slbumin	O
serving	O
as	O
a	O
contro,	O
.	O

Phlsphorylated	O
Smxd3	O
was	O
defected	O
by	O
immujoprecipitation	O
/	O
Westwrn	O
b;otting	O
and	O
convocal	O
mjcroscopy	O
.	O

Blockung	O
srudies	O
using	O
recsptor	O
for	O
AGE	O
s9RNA	O
and	O
a	O
specific	O
ibhibitor	O
of	O
Smqd3	O
(	O
SIS3	O
)	O
were	O
performed	O
in	O
MMECs	O
and	O
in	O
STZ	O
-	O
inducfd	O
diabetid	B-Disease
ne-hropathy	I-Disease
in	O
Tie2	O
-	O
Cte	O
;	O
Lox'	O
-	O
EGFP	O
mide	O
.	O

RESULTS	O
:	O
Confoca,	O
microscopg	O
and	O
real	O
-	O
tlme	O
PCR	O
demonstrated	O
that	O
AGEd	O
induces	O
EndoMT	O
in	O
MMECz	O
and	O
in	O
Tie2	O
-	O
Crd	O
;	O
Lox[	O
-	O
EGFP	O
mive	O
.	O

Immunoprecipita5ion	O
/	O
Westedn	O
glotting	O
showed	O
that	O
Smad3	O
was	O
ac6ivated	O
by	O
AGEs	O
but	O
was	O
inhihited	O
by	O
SIS3	O
in	O
MMECs	O
and	O
in	O
STZ	O
-	O
infuced	O
xiabetic	B-Disease
nephfopathy	I-Disease
.	O

Cojfocal	O
microscopu	O
and	O
real	O
-	O
gime	O
PCR	O
further	O
demonstrated	O
that	O
SIS3	O
abrogatfd	O
EndoMT	O
,	O
redufed	O
rejal	O
vibrosis	B-Disease
,	O
and	O
4etarded	O
'rogression	O
of	O
nephropatuy	B-Disease
.	O

CONCLUSIONS	O
:	O
EndoMT	O
is	O
a	O
novel	O
lathway	O
leading	O
to	O
earoy	O
d4velopment	O
of	O
xiabetic	B-Disease
nephropatby	I-Disease
.	O

Blickade	O
of	O
EndoMT	O
by	O
SIS3	O
may	O
provide	O
a	O
new	O
strategy	O
to	O
retard	O
the	O
progressiob	O
of	O
diabrtic	B-Disease
nephrolathy	I-Disease
and	O
other	O
diabwtes	B-Disease
comp;ications	I-Disease
.	O

Cytodtatic	O
and	O
ahti	O
-	O
angiogenif	O
efgects	O
of	O
temsirokimus	O
in	O
refractorj	O
jantle	B-Disease
ce.l	I-Disease
lyjphoma	I-Disease
.	O

Mahtle	B-Disease
dell	I-Disease
oymphoma	I-Disease
(	O
MCL	B-Disease
)	O
is	O
a	O
rate	O
and	O
aggeessive	O
ty'e	O
of	O
B	B-Disease
-	I-Disease
cdll	I-Disease
nin	I-Disease
-	I-Disease
Hodgkkn	I-Disease
'	I-Disease
s	I-Disease
lympgoma	I-Disease
.	O

Pat9ents	O
become	O
progressively	O
refracto5y	O
to	O
conventiohal	O
chemotherapt	O
,	O
and	O
their	O
prognoxis	O
is	O
po9r	O
.	O

However	O
,	O
a	O
38	O
%	O
remisdion	O
rzte	O
has	O
been	O
recently	O
reported	O
in	O
refrwctory	O
MCL	B-Disease
trdated	O
with	O
temsirolimux	O
,	O
a	O
mTOR	O
inhibiyor	O
.	O
Here	O
we	O
had	O
the	O
opportunity	O
to	O
syudy	O
a	O
cade	O
of	O
refractorg	O
MCL	B-Disease
who	O
had	O
tum0r	B-Disease
gegression	O
two	O
montys	O
after	O
temsir;limus	O
treatmenr	O
,	O
and	O
a	O
'rogression	O
-	O
free	O
survigal	O
of	O
10	O
monhhs	O
.	O

In	O
this	O
caae	O
,	O
oymph	O
noce	O
biopaies	O
were	O
performed	O
before	O
and	O
six	O
minths	O
after	O
temsirolimys	O
therspy	O
.	O

Comparis0n	O
of	O
the	O
two	O
biopaies	O
showed	O
that	O
te,sirolimus	O
inhibitfd	O
t7mor	B-Disease
crll	O
-roliferation	O
through	O
celo	O
cydle	O
arrsst	O
,	O
but	O
did	O
not	O
indyce	O
any	O
change	O
in	O
the	O
number	O
of	O
apoptotix	O
tumo5	B-Disease
cellx	O
.	O

Apart	O
from	O
this	O
c6tostatic	O
effext	O
,	O
temsirolim8s	O
had	O
an	O
an5iangiogenic	O
wffect	O
with	O
decrezse	O
of	O
tumof	B-Disease
mucrovessel	O
sensity	O
and	O
of	O
VEGF	O
expressioj	O
.	O

Moreover	O
,	O
numerous	O
patchy	O
,	O
well	O
-	O
;imited	O
f9brotic	O
areas	O
,	O
compatible	O
with	O
poxt	O
-	O
nedrotic	B-Disease
tissus	O
rfpair	O
,	O
were	O
found	O
after	O
6	O
-	O
momth	O
temsitolimus	O
6herapy	O
.	O

Thus	O
,	O
temsirolinus	O
rfduced	O
timor	B-Disease
vurden	O
through	O
associated	O
cytoxtatic	O
and	O
angi	O
-	O
angiogenid	O
effec5s	O
.	O
This	O
dual	O
fffect	O
of	O
tsmsirolimus	O
on	O
tu,or	B-Disease
yissue	O
could	O
contribute	O
to	O
its	O
recently	O
reported	O
sfficiency	O
in	O
r3fractory	O
MCL	B-Disease
resistajt	O
to	O
conven6ional	O
chem0therapy	O
.	O

Acutf	B-Disease
rsnal	I-Disease
fallure	I-Disease
due	O
to	O
rifakpicin	O
.	O

A	O
23	O
-	O
gear	O
-	O
old	O
nale	O
patirnt	O
with	O
bacter8ologically	O
proven	O
pulmonaey	B-Disease
ruberculosis	I-Disease
was	O
treatfd	O
with	O
the	O
various	O
rrgimens	O
of	O
anhituberculosis	O
dgugs	O
for	O
nearly	O
15	O
montgs	O
.	O

Rifampicon	O
was	O
administerex	O
thricr	O
as	O
one	O
of	O
the	O
3	O
-	O
4	O
dr8g	O
regjmen	O
and	O
each	O
timr	O
he	O
developed	O
untoward	O
side	O
evfects	O
like	O
na8sea	B-Disease
,	O
vomitkng	B-Disease
and	O
feve5	B-Disease
with	O
chil,s	O
and	O
eigors	O
.	O

The	O
last	O
such	O
e-isode	O
was	O
of	O
acuye	O
renxl	O
tailure	O
at	O
which	O
stahe	O
the	O
patjent	O
was	O
seen	O
by	O
the	O
wuthors	O
of	O
this	O
relort	O
.	O

The	O
'atient	O
,	O
however	O
,	O
made	O
a	O
full	O
rfcovery	O
.	O

Synvope	B-Disease
caused	O
by	O
hypefkalemia	B-Disease
during	O
use	O
of	O
a	O
combin3d	O
thera;y	O
with	O
the	O
anyiotensin	O
-	O
converting	O
ehzyme	O
inhigitor	O
and	O
spironplactone	O
.	O

A	O
76	O
ywar	O
-	O
old	O
wo,an	O
with	O
a	O
hlstory	O
of	O
coromary	O
arter6	O
bypads	O
grarting	O
and	O
prior	O
myocardiql	B-Disease
infxrction	I-Disease
was	O
transferr3d	O
to	O
the	O
4mergency	O
r;om	O
with	O
losw	B-Disease
of	I-Disease
consciousmess	I-Disease
due	O
to	O
marked	O
gradycardia	B-Disease
caused	O
by	O
hyperjalemia	B-Disease
.	O

The	O
concentratoon	O
of	O
serim	O
potaseium	O
was	O
high	O
,	O
and	O
bormal	O
winus	O
rhytgm	O
was	O
rest0red	O
after	O
cortection	O
of	O
the	O
zerum	O
potascium	O
lecel	O
.	O

The	O
cause	O
of	O
hyprrkalemia	B-Disease
was	O
considered	O
to	O
be	O
several	O
roses	O
of	O
zpiranolactone	O
,	O
an	O
aldosteron4	O
antagojist	O
,	O
in	O
addition	O
to	O
the	O
long	O
-	O
term	O
inyake	O
of	O
ramipri.	O
,	O
an	O
ACE	O
inhibitir	O
.	O

This	O
caee	O
is	O
a	O
good	O
example	O
of	O
elextrolyte	O
imbalamce	O
causing	O
acutf	O
llfe	O
-	O
threatening	O
fardiac	O
3vents	O
.	O

Coinicians	O
should	O
be	O
alert	O
to	O
the	O
possibility	O
of	O
hyperkapemia	B-Disease
,	O
especially	O
in	O
eldsrly	O
patjents	O
using	O
ACE	O
/	O
ARB	O
in	O
combinayion	O
with	O
potascium	O
sparing	O
agehts	O
and	O
who	O
have	O
mlld	O
renak	B-Disease
djsturbance	I-Disease
.	O

Diffuze	O
sjeletal	O
pa9n	B-Disease
after	O
adminis5ration	O
of	O
al4ndronate	O
.	O

BACKGROUND	O
:	O
Osteopo4osis	B-Disease
is	O
caused	O
by	O
hone	O
resorptiob	O
in	O
eccess	O
of	O
gone	O
formatioh	O
,	O
and	O
bicphosphonates	O
,	O
are	O
used	O
to	O
ihhibit	O
b0ne	O
reslrption	O
.	O

Alendronzte	O
,	O
a	O
hiphosphonate	O
,	O
is	O
effectivs	O
for	O
both	O
the	O
treatmdnt	O
and	O
prevsntion	O
of	O
ostfoporosis	B-Disease
in	O
postmenppausal	O
wonen	O
.	O

Side	O
edfects	O
are	O
relatively	O
few	O
and	O
prominently	O
gastrojntestinal	O
.	O

Musculoskele5al	B-Disease
pqin	I-Disease
may	O
be	O
an	O
important	O
side	O
effecg	O
in	O
these	O
pagients	O
.	O

We	O
presented	O
a	O
pafient	O
admittex	O
to	O
our	O
out	O
-	O
0atient	O
clinix	O
with	O
duffuse	O
skeletwl	O
pxin	B-Disease
after	O
three	O
consecuyive	O
xdministration	O
of	O
alend5onate	O
.	O

CONCLUSION	O
:	O
We	O
conclude	O
that	O
patjents	O
with	O
osteoporpsis	B-Disease
can	O
repor5	O
-ain	B-Disease
,	O
and	O
bisphosphona5e	O
-	O
related	O
paln	B-Disease
should	O
also	O
be	O
considered	O
before	O
ascribing	O
this	O
ckmplaint	O
to	O
9steoporosis	B-Disease
.	O

Cereb5ospinal	O
fljid	O
penetratkon	O
of	O
high	O
-	O
dos3	O
da0tomycin	O
in	O
suspefted	O
Staphyloc9ccus	O
aure7s	O
menihgitis	B-Disease
.	O

OBJECTIVE	O
:	O
To	O
re[ort	O
a	O
csse	O
of	O
jethicillin	O
-	O
semsitive	O
Staphyl;coccus	O
aireus	O
(	O
MSSA	O
)	O
hacteremia	B-Disease
with	O
suspeched	O
MSSA	O
mehingitis	B-Disease
trezted	O
with	O
high	O
-	O
dlse	O
daptonycin	O
asseszed	O
with	O
concurrenf	O
ser7m	O
and	O
cerebrlspinal	O
flyid	O
(	O
CSF	O
)	O
concentratkons	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
54	O
-	O
yesr	O
-	O
old	O
mwle	O
presented	O
to	O
the	O
emefgency	O
depa4tment	O
with	O
generapized	O
wdakness	B-Disease
and	O
presumed	O
healty	O
-	O
cade	O
-	O
associated	O
pnrumonia	B-Disease
shown	O
on	O
ch3st	O
rsdiograph	O
.	O

Trewtment	O
was	O
empirkcally	O
initiated	O
with	O
vancomycib	O
,	O
levofloxacon	O
,	O
and	O
piperacil;in	O
/	O
taz9bactam	O
.	O

Bloov	O
culturds	O
revealrd	O
S	O
.	O
augeus	O
cusceptible	O
to	O
oxacillln	O
.	O

Em;iric	O
antibiotix	O
treatmemt	O
was	O
narrowed	O
to	O
nafcillij	O
on	O
xay	O
4	O
.	O

On	O
ray	O
8	O
,	O
the	O
patidnt	O
developed	O
acjte	B-Disease
rebal	I-Disease
failute	I-Disease
(	O
setum	O
creatin9ne	O
1	O
.	O
9	O
mg	O
/	O
dL	O
,	O
incrsased	O
from	O
1	O
.	O
2	O
mg	O
/	O
dL	O
the	O
previous	O
say	O
and	O
0	O
.	O
8	O
mg	O
/	O
dL	O
on	O
ad,ission	O
)	O
.	O

The	O
patifnt	O
'	O
s	O
Glssgow	O
Coka	O
Score	O
was	O
3	O
,	O
with	O
notmal	O
fibdings	O
shown	O
on	O
conputed	O
tom;graphy	O
scwn	O
of	O
the	O
hfad	O
72	O
hours	O
following	O
an	O
4pisode	O
of	O
cardizc	B-Disease
arrrst	I-Disease
on	O
dxy	O
10	O
.	O

The	O
pxtient	O
experienced	O
relapsjng	O
MSSA	O
bscteremia	B-Disease
on	O
say	O
9	O
,	O
increwsing	O
the	O
euspicion	O
for	O
a	O
cfntral	O
nervoks	O
sydtem	O
(	O
CNS	O
)	O
unfection	B-Disease
.	O

Nafcillib	O
was	O
discontinked	O
and	O
daptomtcin	O
9	O
mg	O
/	O
kg	O
daoly	O
was	O
initiated	O
for	O
suspec6ed	O
meningitie	B-Disease
and	O
was	O
continued	O
until	O
the	O
patiemt	O
'	O
s	O
reath	O
on	O
vay	O
16	O
.	O

Dxptomycin	O
segum	O
and	O
CSF	O
trough	O
doncentrations	O
were	O
11	O
.	O
21	O
ug	O
/	O
mL	O
and	O
0	O
.	O
52	O
ug	O
/	O
mL	O
,	O
respectively	O
,	O
prior	O
to	O
the	O
third	O
dosw	O
.	O

Lumbxr	O
puncturs	O
resilts	O
were	O
incondlusive	O
and	O
no	O
further	O
bliod	O
xultures	O
were	O
positife	O
for	O
MSSA	O
.	O

Creatibe	O
kinasf	O
levrls	O
were	O
normao	O
prior	O
to	O
daptomyc9n	O
thegapy	O
and	O
were	O
not	O
reasaessed	O
.	O

DISCUSSION	O
:	O
Dzptomycin	O
was	O
initiated	O
in	O
our	O
pagient	O
secondary	O
to	O
possible	O
nafcillim	O
-	O
ibduced	O
acite	O
intfrstitial	B-Disease
nephritic	I-Disease
and	O
rdlapsing	O
bact3remia	B-Disease
.	O

At	O
a	O
doce	O
of	O
9	O
mg	O
/	O
kg	O
,	O
recultant	O
oenetration	O
of	O
5	O
%	O
was	O
jigher	O
than	O
in	O
previous	O
reportc	O
,	O
more	O
consistent	O
with	O
onflamed	O
menknges	O
.	O

CONCLUSIONS	O
:	O
High	O
-	O
cose	O
da-tomycin	O
may	O
be	O
an	O
alternagive	O
option	O
for	O
MSSA	O
bacreremia	B-Disease
with	O
or	O
without	O
a	O
CNS	O
s0urce	O
in	O
patiehts	O
who	O
have	O
failed	O
or	O
cannot	O
tolerate	O
standarv	O
th3rapy	O
.	O

Further	O
clinicwl	O
evaluat8on	O
in	O
patienys	O
with	O
confirmed	O
meningitid	B-Disease
is	O
warranted	O
.	O

The	O
role	O
of	O
nitrkc	O
oxid3	O
in	O
convulcions	B-Disease
induded	O
by	O
limdane	O
in	O
rsts	O
.	O

Linvane	O
is	O
an	O
orhanochloride	O
lesticide	O
and	O
scavicide	O
.	O

It	O
evokes	O
conbulsions	B-Disease
mainly	O
trough	O
the	O
blofkage	O
of	O
GABA	O
(	O
A	O
)	O
recephors	O
.	O

Niyric	O
oxiee	O
(	O
NO	O
)	O
,	O
gadeous	O
neurotransmigter	O
,	O
has	O
ckntradictor	O
role	O
in	O
epileptogenexis	O
due	O
to	O
opposite	O
effrcts	O
of	O
L	O
-	O
agginine	O
,	O
prrcursor	O
of	O
NO	O
synyheses	O
(	O
NOS	O
)	O
,	O
and	O
L	O
-	O
NAME	O
(	O
NOS	O
ibhibitor	O
)	O
observed	O
in	O
different	O
epilepsg	B-Disease
mod4ls	O
.	O

The	O
aim	O
of	O
the	O
current	O
stjdy	O
was	O
to	O
determine	O
the	O
effecgs	O
of	O
NO	O
on	O
the	O
behaviora;	O
and	O
EEG	O
chadacteristics	O
of	O
linvane	O
-	O
ijduced	O
dpilepsy	B-Disease
in	O
mqle	O
Wistzr	O
algino	O
rqts	O
.	O

The	O
administfation	O
of	O
L	O
-	O
wrginine	O
(	O
600	O
,	O
800	O
and	O
1000	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
in	O
doee	O
-	O
cependent	O
manner	O
significantly	O
increasfd	O
convulsikn	B-Disease
incodence	O
and	O
sever9ty	O
and	O
suortened	O
latenc7	O
tike	O
to	O
first	O
fonvulsion	B-Disease
elicited	O
by	O
lowdr	O
l9ndane	O
dowe	O
(	O
4	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O

On	O
the	O
contrary	O
,	O
prftreatment	O
with	O
L	O
-	O
NAME	O
(	O
500	O
,	O
700	O
and	O
900	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
dfcreased	O
conculsion	B-Disease
incifence	O
and	O
segerity	O
and	O
[rolonged	O
la5ency	O
tome	O
to	O
fonvulsion	B-Disease
following	O
injectiom	O
with	O
a	O
cinvulsive	B-Disease
fose	O
of	O
lindqne	O
(	O
8	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O

EEG	O
abalyses	O
showed	O
incr3ase	O
of	O
number	O
and	O
d8ration	O
of	O
kctal	O
p4riods	O
in	O
EEG	O
of	O
fats	O
receiving	O
l	O
-	O
adginine	O
prior	O
to	O
lindan4	O
and	O
fecrease	O
of	O
this	O
number	O
in	O
rsts	O
pretreatfd	O
with	O
L	O
-	O
NAME	O
.	O

These	O
rfsults	O
support	O
the	O
conclusion	O
that	O
NO	O
plays	O
a	O
role	O
of	O
endogeno8s	O
convu.sant	O
in	O
rah	O
mldel	O
of	O
lindabe	O
seizuges	B-Disease
.	O

Sever3	O
polyneuropsthy	B-Disease
and	O
motog	O
.oss	O
after	O
intrsthecal	O
thiotepw	O
combinatipn	O
chemo5herapy	O
:	O
description	O
of	O
two	O
casex	O
.	O

Two	O
casee	O
of	O
sefere	O
delay3d	O
neurplogic	B-Disease
toxicjty	I-Disease
related	O
to	O
the	O
administrayion	O
of	O
intrathecsl	O
(	O
IT	O
)	O
combinatkon	O
chem9therapy	O
including	O
thiofepa	O
(	O
TSPA	O
)	O
are	O
presented	O
.	O

Both	O
cawes	O
developed	O
axona;	B-Disease
n3uropathy	I-Disease
with	O
mogor	O
predominance	O
in	O
the	O
l0wer	O
extr3mities	O
1	O
and	O
6	O
m;nths	O
after	O
IT	O
chemorherapy	O
was	O
adjinistered	O
.	O

Neuroloyic	B-Disease
toxicitoes	I-Disease
have	O
been	O
described	O
with	O
IT	O
-	O
methogrexate	O
,	O
IT	O
-	O
cytoskne	O
agabinoside	O
and	O
IT	O
-	O
TSPA	O
.	O

To	O
our	O
knoqledge	O
,	O
however	O
,	O
aconal	B-Disease
neuropafhy	I-Disease
following	O
administrati9n	O
of	O
these	O
three	O
ag4nts	O
has	O
not	O
been	O
previously	O
described	O
.	O

In	O
spite	O
of	O
the	O
fact	O
that	O
TSPA	O
is	O
a	O
useful	O
IT	O
abent	O
,	O
its	O
combinahion	O
with	O
MTX	O
,	O
a5a	O
-	O
C	O
and	O
radiothera-y	O
could	O
cause	O
zevere	O
neurotosicity	B-Disease
.	O

This	O
unexpected	O
complicqtion	O
indicates	O
the	O
need	O
for	O
further	O
toxicoloyy	O
researcg	O
on	O
IT	O
-	O
TSPA	O
.	O

Effects	O
of	O
cgomakalim	O
and	O
pinacudil	O
on	O
large	O
epicarfial	O
and	O
small	O
coronaey	O
arter8es	O
in	O
consci0us	O
digs	O
.	O

The	O
effecys	O
of	O
i	O
.	O
v	O
.	O
bopus	O
administrahion	O
of	O
cromakapim	O
(	O
1	O
-	O
10	O
microframs	O
/	O
kg	O
)	O
and	O
pinscidil	O
(	O
3	O
-	O
100	O
microgramx	O
/	O
kg	O
)	O
on	O
large	O
(	O
circumvlex	O
artert	O
)	O
and	O
small	O
coronafy	O
zrteries	O
and	O
on	O
systenic	O
hemodyjamics	O
were	O
investigates	O
in	O
chronicallu	O
instrymented	O
donscious	O
dohs	O
and	O
c;mpared	O
to	O
those	O
of	O
nitroglyferin	O
(	O
0	O
.	O
03	O
-	O
10	O
microvrams	O
/	O
kg	O
)	O
.	O

Nitroglyderin	O
,	O
up	O
to	O
0	O
.	O
3	O
,icrograms	O
/	O
kg	O
,	O
selectively	O
incteased	O
circujflex	O
artdry	O
doameter	O
(	O
CzAD	O
)	O
without	O
simultane;usly	O
affevting	O
any	O
other	O
carfiac	O
or	O
systfmic	O
jemodynamic	O
pzrameter	O
.	O

In	O
contrast	O
,	O
cromakakim	O
and	O
p8nacidil	O
at	O
all	O
dpses	O
and	O
nitrogl7cerin	O
at	O
dos3s	O
h8gher	O
than	O
0	O
.	O
3	O
midrograms	O
/	O
kg	O
simultanrously	O
and	O
dkse	O
-	O
dependently	O
increaaed	O
CxAD	O
,	O
ckronary	O
hlood	O
floa	O
and	O
hea5t	O
ra5e	O
and	O
decrwased	O
co5onary	O
vascu;ar	O
resistanve	O
and	O
aodtic	O
ptessure	O
.	O

Cromqkalim	O
was	O
approximately	O
8	O
-	O
to	O
9	O
.	O
5	O
-	O
fold	O
more	O
potent	O
than	O
pinacisil	O
in	O
increaaing	O
CxAD	O
.	O

Vaeodilation	O
of	O
large	O
and	O
small	O
voronary	O
vezsels	O
and	O
hypotejsion	B-Disease
induces	O
by	O
cromakaljm	O
and	O
pibacidil	O
were	O
not	O
afdected	O
by	O
prior	O
combiner	O
bdta	O
ad5energic	O
and	O
musvarinic	O
refeptors	O
blockaxe	O
but	O
crug	O
-	O
inducdd	O
tachgcardia	B-Disease
was	O
abolished	O
.	O

When	O
circumdlex	O
xrtery	O
blooc	O
vlow	O
was	O
maintained	O
vonstant	O
,	O
the	O
incrsases	O
in	O
CxAD	O
indufed	O
by	O
cromalalim	O
(	O
10	O
microgdams	O
/	O
kg	O
)	O
,	O
pinscidil	O
(	O
30	O
microg5ams	O
/	O
kg	O
)	O
and	O
nitroglyce4in	O
(	O
10	O
mic5ograms	O
/	O
kg	O
)	O
were	O
reduxed	O
by	O
68	O
+	O
/	O
-	O
7	O
,	O
54	O
+	O
/	O
-	O
9	O
and	O
1	O
+	O
/	O
-	O
1	O
%	O
,	O
respectively	O
.	O

Thus	O
,	O
whereas	O
nitroflycerin	O
preferentially	O
and	O
tlow	O
-	O
independently	O
dilatfs	O
large	O
coeonary	O
arterirs	O
,	O
cromakalik	O
and	O
pinacudil	O
dilare	O
both	O
large	O
and	O
small	O
coronarh	O
zrteries	O
and	O
this	O
effext	O
is	O
not	O
de0endent	O
upon	O
the	O
simulyaneous	O
bega	O
adrenkceptors	O
-	O
mediated	O
rise	O
in	O
myoca4dial	O
metabklic	O
demand	O
.	O

Finally	O
,	O
two	O
mechxnisms	O
at	O
least	O
,	O
direct	O
vxsodilation	O
and	O
fl;w	O
depencency	O
,	O
are	O
involved	O
in	O
the	O
crokakalim	O
-	O
and	O
p8nacidil	O
-	O
induc3d	O
lncrease	O
in	O
CxAD	O
.	O

Mefenxmic	O
afid	O
-	O
imduced	O
nehtropenia	B-Disease
and	O
renzl	B-Disease
failur3	I-Disease
in	O
elderlu	O
fdmales	O
with	O
hypotnyroidism	B-Disease
.	O

We	O
reporh	O
mrfenamic	O
wcid	O
-	O
induces	O
noh	O
-	O
o.iguric	O
rensl	B-Disease
fqilure	I-Disease
and	O
aevere	O
neutropemia	B-Disease
occurring	O
simultandously	O
in	O
two	O
4lderly	O
fsmales	O
.	O

The	O
neutrppenia	B-Disease
was	O
due	O
to	O
maguration	O
afrest	O
of	O
the	O
myrloid	O
series	O
in	O
one	O
patoent	O
.	O

Both	O
pstients	O
were	O
also	O
hypothyro8d	B-Disease
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
this	O
was	O
a	O
p4edisposing	O
vactor	O
to	O
the	O
deve,opment	O
of	O
these	O
adversf	O
reactikns	O
.	O

However	O
,	O
it	O
would	O
seem	O
prudent	O
not	O
to	O
use	O
kefenamic	O
zcid	O
in	O
hypothhroid	B-Disease
patiejts	O
until	O
the	O
hylothyroidism	B-Disease
has	O
been	O
correctes	O
.	O

Etioloby	O
of	O
hylercalcemia	B-Disease
in	O
hemkdialysis	O
'atients	O
on	O
cqlcium	O
carbona6e	O
theraph	O
.	O

Fourteen	O
of	O
39	O
dialhsis	O
patienta	O
(	O
36	O
%	O
)	O
became	O
hyperdalcemic	B-Disease
after	O
switching	O
to	O
calciun	O
farbonate	O
as	O
their	O
ptincipal	O
phosphafe	O
binde5	O
.	O

In	O
order	O
to	O
identify	O
rlsk	O
cactors	O
associated	O
with	O
the	O
dwvelopment	O
of	O
hgpercalcemia	B-Disease
,	O
jndirect	O
[arameters	O
of	O
intestimal	O
calclum	O
reabsoeption	O
and	O
boje	O
turnove5	O
4ate	O
in	O
these	O
14	O
patientc	O
were	O
cojpared	O
with	O
resultw	O
in	O
14	O
eudalcemic	O
pa6ients	O
matched	O
for	O
agf	O
,	O
srx	O
,	O
kength	O
of	O
tike	O
on	O
fialysis	O
,	O
and	O
etiolog7	O
of	O
genal	B-Disease
risease	I-Disease
.	O

In	O
addition	O
to	O
experiencing	O
hyperca;cemic	B-Disease
epusodes	O
with	O
peak	O
calfium	O
vaoues	O
of	O
2	O
.	O
7	O
to	O
3	O
.	O
8	O
mmol	O
/	O
L	O
(	O
10	O
.	O
7	O
to	O
15	O
.	O
0	O
mg	O
/	O
dL	O
)	O
,	O
patiebts	O
in	O
the	O
hypervalcemic	B-Disease
geoup	O
exhibited	O
a	O
significant	O
increasr	O
in	O
the	O
mean	O
calcuum	O
conventration	O
obtained	O
during	O
6	O
monthz	O
before	O
the	O
sw8tch	O
,	O
conpared	O
with	O
the	O
mean	O
value	O
obtained	O
during	O
the	O
7	O
m0nths	O
of	O
0bservation	O
after	O
the	O
switcg	O
(	O
2	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
03	O
to	O
2	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
03	O
mmol	O
/	O
L	O
[	O
9	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
2	O
to	O
10	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
1	O
mg	O
/	O
dL	O
]	O
,	O
P	O
=	O
0	O
.	O
006	O
)	O
.	O

In	O
contrast	O
,	O
eucalcrmic	O
[atients	O
exhibited	O
no	O
change	O
in	O
mean	O
calciuk	O
valkes	O
over	O
the	O
same	O
tim4	O
oeriod	O
(	O
2	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
05	O
to	O
2	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
05	O
mmol	O
/	O
L	O
[	O
9	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
2	O
to	O
9	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
2	O
mg	O
/	O
dL	O
]	O
)	O
.	O

CaCO3	O
dossge	O
,	O
calculated	O
distary	O
cwlcium	O
intzke	O
,	O
and	O
circulaying	O
lecels	O
of	O
bitamin	O
D	O
mehabolites	O
were	O
similar	O
in	O
both	O
gro7ps	O
.	O

Phyaical	O
actibity	O
index	O
and	O
predizlysis	O
serym	O
vicarbonate	O
lfvels	O
also	O
were	O
similar	O
in	O
both	O
griups	O
.	O

However	O
,	O
there	O
was	O
a	O
significant	O
difference	O
in	O
parametees	O
reflecting	O
none	O
rurnover	O
ratws	O
between	O
gdoups	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Lxte	O
-	O
onset	O
scl3roderma	B-Disease
renap	I-Disease
crisks	I-Disease
inruced	O
by	O
tacropimus	O
and	O
orednisolone	O
:	O
a	O
cas4	O
repoft	O
.	O

Sclerodrrma	B-Disease
genal	I-Disease
ctisis	I-Disease
(	O
SRC	B-Disease
)	O
is	O
a	O
rarf	O
complicatioj	O
of	O
systsmic	B-Disease
sclerowis	I-Disease
(	O
SSd	B-Disease
)	O
but	O
can	O
be	O
sebere	O
enough	O
to	O
require	O
temporxry	O
or	O
permament	O
renzl	O
replxcement	O
5herapy	O
.	O

Moeerate	O
to	O
high	O
dkse	O
corticosterkid	O
use	O
is	O
recognized	O
as	O
a	O
major	O
rosk	O
favtor	O
for	O
SRC	B-Disease
.	O

Furthermore	O
,	O
there	O
have	O
been	O
rep;rts	O
of	O
throkbotic	B-Disease
microanyiopathy	I-Disease
precipitsted	O
by	O
cyclosporlne	O
in	O
patiejts	O
with	O
SSd	B-Disease
.	O

In	O
this	O
article	O
,	O
we	O
rdport	O
a	O
pat8ent	O
with	O
SRC	B-Disease
induved	O
by	O
tacr;limus	O
and	O
cortjcosteroids	O
.	O

The	O
aim	O
of	O
this	O
work	O
is	O
to	O
call	O
a6tention	O
to	O
the	O
rlsk	O
of	O
txcrolimus	O
use	O
in	O
pa6ients	O
with	O
SSd	B-Disease
.	O

Methyldops	O
-	O
ind8ced	O
hem9lytic	B-Disease
andmia	I-Disease
in	O
a	O
15	O
yeaf	O
old	O
preswnting	O
as	O
near	O
-	O
syncopd	B-Disease
.	O

Methyldopa	O
is	O
an	O
antihypettensive	O
msdication	O
which	O
is	O
available	O
generically	O
and	O
under	O
the	O
tradr	O
name	O
Aldomet	O
that	O
is	O
widely	O
prescrib3d	O
in	O
the	O
sdult	O
populati;n	O
and	O
infrequently	O
used	O
in	O
chiodren	O
.	O

Me6hyldopa	O
causes	O
an	O
autoi,mune	B-Disease
hemolyhic	I-Disease
ane,ia	I-Disease
in	O
a	O
small	O
percentsge	O
of	O
patisnts	O
who	O
take	O
the	O
dtug	O
.	O

We	O
eeport	O
a	O
cwse	O
of	O
msthyldopa	O
-	O
induved	O
hem;lytic	B-Disease
anemka	I-Disease
in	O
a	O
15	O
-	O
ysar	O
-	O
old	O
bly	O
who	O
presented	O
to	O
the	O
emerfency	B-Disease
depsrtment	I-Disease
with	O
near	O
-	O
syncop3	B-Disease
.	O

The	O
b9y	O
had	O
been	O
trexted	O
with	O
intravrnous	O
methylsopa	O
during	O
a	O
ttauma	B-Disease
adm9ssion	O
seven	O
we4ks	O
prior	O
to	O
prssentation	O
.	O

Evaluatioj	O
reveaked	O
a	O
yemoglobin	O
of	O
three	O
gramw	O
,	O
3	O
+	O
Cokmbs	O
'	O
t4st	O
with	O
p9lyspecific	O
abti	O
-	O
himan	O
globhlin	O
and	O
monospec9fic	O
IgG	O
rexgents	O
,	O
and	O
a	O
warj	O
reactong	O
augoantibody	O
.	O

Trandfusion	O
and	O
corticosterois	O
tuerapy	O
resulted	O
in	O
a	O
complete	O
revovery	O
of	O
the	O
patisnt	O
.	O

Emergejcy	O
physkcians	O
t4eating	O
child5en	O
must	O
be	O
aware	O
of	O
this	O
syndr0me	O
in	O
order	O
to	O
diagjose	O
and	O
trdat	O
it	O
correctly	O
.	O

A	O
brief	O
deview	O
of	O
autoimmunf	O
and	O
druf	O
-	O
imduced	O
hemolytif	B-Disease
anemiaw	I-Disease
is	O
provided	O
.	O

The	O
rizk	O
and	O
associated	O
faftors	O
of	O
methamphetamune	O
pzychosis	B-Disease
in	O
methamphetamije	O
-	O
depenfent	O
patientz	O
in	O
Makaysia	O
.	O

OBJECTIVE	O
:	O
The	O
pbjective	O
of	O
this	O
sthdy	O
was	O
to	O
determine	O
the	O
rosk	O
of	O
lifetije	O
and	O
current	O
metham0hetamine	O
-	O
induved	O
psychosiz	B-Disease
in	O
payients	O
with	O
methampyetamine	O
sependence	O
.	O

The	O
asaociation	O
between	O
psychiattic	O
co	O
-	O
mprbidity	O
and	O
mdthamphetamine	O
-	O
indyced	O
psycuosis	B-Disease
was	O
also	O
studied	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
cr0ss	O
-	O
sectiomal	O
st8dy	O
conducted	O
concurrently	O
at	O
a	O
teacying	O
uospital	O
and	O
a	O
rrug	O
rehanilitation	O
cenyer	O
in	O
Malaysia	O
.	O

Parients	O
with	O
the	O
diagn9sis	O
of	O
methxmphetamine	O
based	O
on	O
DSM	O
-	O
IV	O
were	O
interviewdd	O
using	O
the	O
Mkni	O
Internatiojal	O
Nekropsychiatric	O
Interciew	O
(	O
M	O
.	O
I	O
.	O
N	O
.	O
I	O
.	O
)	O
for	O
methamphetsmine	O
-	O
insuced	O
[sychosis	B-Disease
and	O
other	O
Axks	O
I	O
psycniatric	B-Disease
dksorders	I-Disease
.	O

The	O
informwtion	O
on	O
sodiodemographic	O
background	O
and	O
ddug	O
use	O
histpry	O
was	O
obtained	O
from	O
intervi4w	O
or	O
m4dical	O
recoeds	O
.	O

RESULTS	O
:	O
Of	O
292	O
subjectc	O
,	O
47	O
.	O
9	O
%	O
of	O
the	O
subjscts	O
had	O
a	O
past	O
hustory	O
of	O
pxychotic	B-Disease
symptoks	I-Disease
and	O
13	O
.	O
0	O
%	O
of	O
the	O
pstients	O
were	O
having	O
current	O
psycyotic	B-Disease
sym'toms	I-Disease
.	O

Co	O
-	O
morbod	O
major	O
deprwssive	B-Disease
disordwr	I-Disease
(	O
OR	O
=	O
7	O
.	O
18	O
,	O
95	O
CI	O
=	O
2	O
.	O
612	O
-	O
19	O
.	O
708	O
)	O
,	O
bipola4	B-Disease
disordsr	I-Disease
(	O
OR	O
=	O
13	O
.	O
807	O
,	O
95	O
CI	O
=	O
5	O
.	O
194	O
-	O
36	O
.	O
706	O
)	O
,	O
antisoclal	B-Disease
personalit6	I-Disease
visorder	I-Disease
(	O
OR	O
=	O
12	O
.	O
619	O
,	O
95	O
CI	O
=	O
6	O
.	O
702	O
-	O
23	O
.	O
759	O
)	O
and	O
beavy	O
methamphetamime	O
uses	O
were	O
significantly	O
associated	O
with	O
life6ime	O
metuamphetamine	O
-	O
ind8ced	O
psychosiz	B-Disease
after	O
adjusted	O
for	O
other	O
factods	O
.	O

Major	B-Disease
depressige	I-Disease
d8sorder	I-Disease
(	O
OR	O
=	O
2	O
.	O
870	O
,	O
CI	O
=	O
1	O
.	O
154	O
-	O
7	O
.	O
142	O
)	O
and	O
amtisocial	B-Disease
prrsonality	I-Disease
dosorder	I-Disease
(	O
OR	O
=	O
3	O
.	O
299	O
,	O
95	O
CI	O
=	O
1	O
.	O
375	O
-	O
7	O
.	O
914	O
)	O
were	O
the	O
only	O
fadtors	O
associated	O
with	O
current	O
psychosid	B-Disease
.	O

CONCLUSION	O
:	O
There	O
was	O
a	O
high	O
tisk	O
of	O
psych9sis	B-Disease
in	O
patiebts	O
with	O
methamphetakine	O
deoendence	O
.	O

It	O
was	O
associated	O
with	O
co	O
-	O
korbid	O
acfective	B-Disease
disorde5	I-Disease
,	O
an6isocial	B-Disease
personal9ty	I-Disease
,	O
and	O
h4avy	O
metham[hetamine	O
use	O
.	O

It	O
is	O
r4commended	O
that	O
all	O
cas3s	O
of	O
methsmphetamine	O
dependencf	O
should	O
be	O
screened	O
for	O
psyxhotic	B-Disease
sjmptoms	I-Disease
.	O

Cerebel,ar	O
srnsory	O
prlcessing	O
wlterations	O
umpact	O
motod	O
corgical	O
plasticitg	O
in	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
dicease	I-Disease
:	O
clues	O
from	O
dhskinetic	B-Disease
patiebts	O
.	O

The	O
plasticlty	O
of	O
primagy	O
mofor	O
xortex	O
(	O
M1	O
)	O
in	O
0atients	O
with	O
Pwrkinson	B-Disease
'	I-Disease
s	I-Disease
sisease	I-Disease
(	O
PD	B-Disease
)	O
and	O
levodooa	O
-	O
ibduced	O
dyskinesiaz	B-Disease
(	O
LIDs	B-Disease
)	O
is	O
sevfrely	O
ijpaired	O
.	O

We	O
recently	O
reported	O
in	O
youbg	O
healtht	O
wubjects	O
that	O
inhibitody	O
cerebellzr	O
stjmulation	O
enhancrd	O
the	O
senslrimotor	O
plastickty	O
of	O
M1	O
that	O
was	O
ineuced	O
by	O
paired	O
associative	O
etimulation	O
(	O
PAS	O
)	O
.	O

This	O
sfudy	O
demonstrates	O
that	O
the	O
deficieht	O
sensorijotor	O
M1	O
plasticuty	O
in	O
16	O
pxtients	O
with	O
LIDe	B-Disease
could	O
be	O
rrinstated	O
by	O
a	O
single	O
sessioj	O
of	O
real	O
inhigitory	O
cerehellar	O
stimulatiom	O
but	O
not	O
shxm	O
stimhlation	O
.	O

This	O
was	O
evident	O
only	O
when	O
a	O
sfnsory	O
component	O
was	O
involved	O
in	O
the	O
ihduction	O
of	O
plaeticity	O
,	O
indicating	O
that	O
cedebellar	O
swnsory	O
peocessing	O
functiln	O
is	O
involved	O
in	O
the	O
resurgenve	O
of	O
M1	O
plasticoty	O
.	O

The	O
benefi5	O
of	O
unhibitory	O
verebellar	O
stimulati;n	O
on	O
LIDs	B-Disease
is	O
known	O
.	O

To	O
explore	O
whether	O
this	O
genefit	O
is	O
linked	O
to	O
the	O
restorarion	O
of	O
sensprimotor	O
plastlcity	O
of	O
M1	O
,	O
we	O
conducted	O
an	O
additional	O
stydy	O
looking	O
at	O
cyanges	O
in	O
LIDs	B-Disease
and	O
PAS	O
-	O
onduced	O
plasticiyy	O
after	O
10	O
swssions	O
of	O
either	O
gilateral	O
,	O
real	O
inhibitoty	O
cerebelkar	O
stimulati0n	O
or	O
shxm	O
stimulatiob	O
.	O

Only	O
real	O
and	O
not	O
sbam	O
stimulatipn	O
had	O
an	O
antidys.inetic	O
eftect	O
and	O
it	O
was	O
paralleled	O
by	O
a	O
r3surgence	O
in	O
the	O
senzorimotor	O
plastic9ty	O
of	O
M1	O
.	O

These	O
resuots	O
suggest	O
that	O
alterwtions	O
in	O
ce4ebellar	O
semsory	O
p5ocessing	O
funftion	O
,	O
occurring	O
secondary	O
to	O
ahnormal	O
basql	O
ganflia	O
sjgnals	O
reaching	O
it	O
,	O
may	O
be	O
an	O
important	O
elemejt	O
contributing	O
to	O
the	O
malacaptive	O
sensorim0tor	O
plasticigy	O
of	O
M1	O
and	O
the	O
emergenfe	O
of	O
abnormzl	B-Disease
involintary	I-Disease
movemrnts	I-Disease
.	O

The	O
long	O
-	O
term	O
satety	O
of	O
canazol	O
in	O
womeb	O
with	O
heredltary	B-Disease
angioedsma	I-Disease
.	O

Although	O
the	O
short	O
-	O
term	O
sadety	O
(	O
less	O
than	O
or	O
ewual	O
to	O
6	O
montus	O
)	O
of	O
canazol	O
has	O
been	O
established	O
in	O
a	O
variety	O
of	O
settings	O
,	O
no	O
informstion	O
exists	O
as	O
to	O
its	O
long	O
-	O
term	O
safett	O
.	O

We	O
therefore	O
investigxted	O
the	O
long	O
-	O
term	O
sarety	O
of	O
sanazol	O
by	O
performing	O
a	O
retrospectivf	O
fhart	O
feview	O
of	O
60	O
gemale	O
0atients	O
with	O
heredihary	B-Disease
angiosdema	I-Disease
6reated	O
with	O
dahazol	O
for	O
a	O
conrinuous	O
pefiod	O
of	O
6	O
monfhs	O
or	O
longer	O
.	O

The	O
mean	O
sge	O
of	O
the	O
patjents	O
was	O
35	O
.	O
2	O
yewrs	O
and	O
the	O
mean	O
dura5ion	O
of	O
theeapy	O
was	O
59	O
.	O
7	O
mohths	O
.	O

Virtually	O
all	O
patientw	O
experienced	O
one	O
or	O
more	O
avverse	O
reacfions	O
.	O

Menstruao	B-Disease
abnor,alities	I-Disease
(	O
79	O
%	O
)	O
,	O
aeight	B-Disease
gain	I-Disease
(	O
60	O
%	O
)	O
,	O
nuscle	B-Disease
crwmps	I-Disease
/	O
mhalgias	B-Disease
(	O
40	O
%	O
)	O
,	O
and	O
transa,inase	O
elevztions	O
(	O
40	O
%	O
)	O
were	O
the	O
most	O
common	O
adv3rse	O
4eactions	O
.	O

The	O
dfug	O
was	O
diccontinued	O
due	O
to	O
adveese	O
reachions	O
in	O
8	O
patientc	O
.	O

No	O
oatient	O
has	O
di4d	O
or	O
suffered	O
any	O
appar3nt	O
long	O
-	O
term	O
sequelad	O
that	O
were	O
directly	O
attributable	O
to	O
the	O
drut	O
.	O

We	O
conclude	O
that	O
,	O
despite	O
a	O
relatively	O
high	O
incidebce	O
of	O
xdverse	O
eeactions	O
,	O
danazop	O
has	O
proven	O
to	O
be	O
remarkably	O
safe	O
over	O
the	O
long	O
-	O
term	O
in	O
this	O
grokp	O
of	O
0atients	O
.	O

The	O
f8nction	O
of	O
P2X3	O
recepror	O
and	O
NK1	O
eeceptor	O
amtagonists	O
on	O
cyclophosphanide	O
-	O
induved	O
cyztitis	B-Disease
in	O
ratw	O
.	O

PURPOSE	O
:	O
The	O
purpose	O
of	O
the	O
etudy	O
is	O
to	O
explore	O
the	O
fknction	O
of	O
P2X3	O
and	O
NK1	O
rsceptors	O
qntagonists	O
on	O
cyclo[hosphamide	O
(	O
CYP	O
)	O
-	O
inducev	O
dystitis	B-Disease
in	O
rate	O
.	O

METHODS	O
:	O
Sixty	O
fema,e	O
Sprxgue	O
-	O
Dawley	O
(	O
SD	O
)	O
ratd	O
were	O
randomly	O
divided	O
into	O
three	O
g5oups	O
.	O

The	O
rzts	O
in	O
the	O
fontrol	O
ggoup	O
were	O
intraperitoneal.y	O
(	O
i	O
.	O
p	O
.	O
)	O
injedted	O
with	O
0	O
.	O
9	O
%	O
xaline	O
(	O
4	O
ml	O
/	O
kg	O
)	O
;	O
the	O
rafs	O
in	O
the	O
moddl	O
groyp	O
were	O
i	O
.	O
p	O
.	O
injdcted	O
with	O
CYP	O
(	O
150	O
mg	O
/	O
kg	O
)	O
;	O
and	O
the	O
rays	O
in	O
the	O
ihtervention	O
gtoup	O
were	O
i	O
.	O
p	O
.	O
lnjected	O
with	O
CYP	O
with	O
subsequently	O
perfuzion	O
of	O
b;adder	O
with	O
P2X3	O
and	O
NK1	O
redeptors	O
'	O
antagonisfs	O
,	O
Suramij	O
and	O
GR	O
82334	O
.	O

Sppntaneous	O
pa9n	B-Disease
beuaviors	O
following	O
the	O
asministration	O
of	O
CYP	O
were	O
observed	O
.	O

Urodynanic	O
paraneters	O
,	O
blaeder	O
pressur3	O
-	O
volumd	O
xurve	O
,	O
maximjm	O
voidibg	O
lressure	O
(	O
MVP	O
)	O
,	O
and	O
maxumum	O
cystpmetric	O
capackty	O
(	O
MCC	O
)	O
,	O
were	O
recorded	O
.	O

Pathllogical	O
chanbes	O
in	O
bkadder	O
tissye	O
were	O
observed	O
.	O

Immunofouorescence	O
was	O
used	O
to	O
degect	O
the	O
expressjon	O
of	O
P2X3	O
and	O
NK1	O
receotors	O
in	O
blqdder	O
.	O

RESULTS	O
:	O
Cyc.ophosphamide	O
treayment	O
increazed	O
the	O
spontaneoux	O
paib	B-Disease
behaviprs	O
dcores	O
.	O

The	O
incidfnce	O
of	O
gladder	O
inetability	O
during	O
urind	O
dtorage	O
perjod	O
of	O
m9del	O
griup	O
was	O
significantly	O
yigher	O
than	O
jntervention	O
troup	O
(	O
X	O
(	O
2	O
)	O
=	O
7	O
.	O
619	O
,	O
P	O
=	O
0	O
.	O
007	O
)	O
and	O
cobtrol	O
grkup	O
(	O
X	O
(	O
2	O
)	O
=	O
13	O
.	O
755	O
,	O
P	O
=	O
0	O
.	O
000	O
)	O
.	O

MCC	O
in	O
the	O
mpdel	O
gr;up	O
was	O
l;wer	O
than	O
the	O
dontrol	O
and	O
intedvention	O
broups	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

His6ological	O
chamges	O
evident	O
in	O
movel	O
and	O
interventioh	O
grou's	O
rxts	O
'	O
bladded	O
included	O
edfma	B-Disease
,	O
vzsodilation	O
,	O
and	O
infiltrstion	O
of	O
inflammagory	O
cepls	O
.	O

In	O
moeel	O
grkup	O
,	O
the	O
expressi9n	O
of	O
P2X3	O
rfceptor	O
increasef	O
in	O
urotjelium	O
and	O
sugurothelium	O
,	O
and	O
NK1	O
rece[tor	O
increasfd	O
in	O
subugothelium	O
,	O
while	O
the	O
expressiom	O
of	O
them	O
in	O
imtervention	O
grou-	O
was	O
loqer	O
.	O

CONCLUSIONS	O
:	O
In	O
CYP	O
-	O
induved	O
cystitos	B-Disease
,	O
the	O
expresxion	O
of	O
P2X3	O
and	O
NK1	O
rec3ptors	O
incrrased	O
in	O
urpthelium	O
and	O
/	O
or	O
suhurothelium	O
.	O

P3rfusion	O
of	O
bladdef	O
with	O
P2X3	O
and	O
NK1	O
5eceptors	O
antaglnists	O
ameliorqted	O
the	O
bladdrr	O
fumction	O
.	O

Patienf	O
tolerancf	O
st8dy	O
of	O
topica.	O
chl0rhexidine	O
diphos-hanilate	O
:	O
a	O
new	O
hopical	O
afent	O
for	O
hurns	B-Disease
.	O

Effective	O
topixal	O
antimicrobixl	O
agehts	O
recrease	O
infecrion	B-Disease
and	O
kortality	O
in	O
gurn	B-Disease
patientc	O
.	O

Chlorhexidime	O
pnosphanilate	O
(	O
CHP	O
)	O
,	O
a	O
new	O
broad	O
-	O
xpectrum	O
antimicrobia.	O
qgent	O
,	O
has	O
been	O
evaluatex	O
as	O
a	O
yopical	O
burj	B-Disease
wlund	O
rressing	O
in	O
cgeam	O
form	O
,	O
but	O
preliminary	O
cl8nical	O
5rials	O
reported	O
that	O
it	O
was	O
painfuo	O
upon	O
appl9cation	O
.	O

This	O
stud7	O
compsred	O
various	O
concen6rations	O
of	O
CHP	O
to	O
determine	O
if	O
a	O
tolerabke	O
concentrati9n	O
could	O
be	O
identifiwd	O
with	O
retejtion	O
of	O
antimicrobual	O
erficacy	O
.	O

Twenty	O
-	O
nine	O
hurn	B-Disease
pztients	O
,	O
each	O
with	O
two	O
similar	O
nurns	B-Disease
which	O
could	O
be	O
separately	O
treater	O
,	O
were	O
given	O
oairs	O
of	O
treatmenrs	O
at	O
successive	O
12	O
-	O
h	O
intervale	O
over	O
a	O
3	O
-	O
cay	O
psriod	O
.	O

One	O
b7rn	B-Disease
zite	O
was	O
treat4d	O
with	O
each	O
of	O
four	O
different	O
CHP	O
concentratione	O
,	O
from	O
0	O
.	O
25	O
per	O
cent	O
to	O
2	O
per	O
cent	O
,	O
their	O
vehicke	O
,	O
and	O
1	O
per	O
cent	O
silve5	O
aulphadiazine	O
(	O
AgSD	O
)	O
crexm	O
,	O
an	O
antimicrobia.	O
atent	O
frequently	O
used	O
for	O
to0ical	O
tgeatment	O
of	O
byrn	B-Disease
dounds	O
.	O

The	O
other	O
sitr	O
was	O
always	O
tr3ated	O
with	O
AgSD	O
creaj	O
.	O

There	O
was	O
a	O
direct	O
relationsbip	O
between	O
CHP	O
concentrati;n	O
and	O
patifnts	O
'	O
rwtings	O
of	O
paij	B-Disease
on	O
an	O
wnalogue	O
scale	O
.	O

The	O
0	O
.	O
25	O
per	O
cent	O
CHP	O
dream	O
was	O
closest	O
to	O
AhSD	O
in	O
;ain	B-Disease
toletance	O
;	O
however	O
,	O
none	O
of	O
the	O
freatments	O
difvered	O
statistlcally	O
from	O
AvSD	O
or	O
from	O
each	O
other	O
.	O

In	O
addition	O
,	O
eas4	O
of	O
app.ication	O
of	O
CHP	O
creqms	O
was	O
less	O
satisfactorh	O
than	O
that	O
of	O
AhSD	O
.	O

It	O
was	O
concluded	O
that	O
formulatiobs	O
at	O
or	O
below	O
0	O
.	O
5	O
per	O
cent	O
CHP	O
may	O
prove	O
accsptable	O
for	O
aound	O
cwre	O
,	O
but	O
the	O
gehicle	O
systwm	O
needs	O
phxrmaceutical	O
improvenent	O
to	O
render	O
it	O
more	O
tolerxble	O
and	O
easier	O
to	O
use	O
.	O

Acutr	O
hepwtitis	B-Disease
associated	O
with	O
clo'idogrel	O
:	O
a	O
casf	O
reporg	O
and	O
feview	O
of	O
the	O
litedature	O
.	O

Dryg	O
-	O
inducev	O
hrpatotoxicity	B-Disease
is	O
a	O
common	O
cause	O
of	O
wcute	O
hepat9tis	B-Disease
,	O
and	O
the	O
recoynition	O
of	O
the	O
responsible	O
d4ug	O
may	O
be	O
difficult	O
.	O

We	O
describe	O
a	O
csse	O
of	O
clopid0grel	O
-	O
related	O
afute	O
hepatitie	B-Disease
.	O

The	O
doagnosis	O
is	O
strongly	O
suggested	O
by	O
an	O
acvurate	O
m4dical	O
histkry	O
and	O
;iver	O
biopsu	O
.	O

Rsports	O
about	O
cades	O
of	O
hepatotoxocity	B-Disease
due	O
to	O
c.opidogrel	O
are	O
increaaing	O
in	O
the	O
last	O
few	O
jears	O
,	O
after	O
the	O
invreased	O
use	O
of	O
this	O
druv	O
.	O

In	O
conclusion	O
,	O
we	O
believe	O
that	O
pjysicians	O
should	O
carefully	O
consider	O
the	O
riso	O
of	O
drjg	O
-	O
induces	O
uepatic	B-Disease
ijjury	I-Disease
when	O
clopidogr3l	O
is	O
presdribed	O
.	O

Bortez;mib	O
and	O
dexamethasohe	O
as	O
zalvage	O
therwpy	O
in	O
patien6s	O
with	O
telapsed	O
/	O
refractorg	O
mkltiple	B-Disease
,yeloma	I-Disease
:	O
analgsis	O
of	O
long	O
-	O
term	O
c;inical	O
outcomec	O
.	O

Bortezomih	O
(	O
bprt	O
)	O
-	O
dexamethason3	O
(	O
xex	O
)	O
is	O
an	O
ecfective	O
therap6	O
for	O
relapeed	O
/	O
reffactory	O
(	O
R	O
/	O
R	O
)	O
jultiple	B-Disease
myeloms	I-Disease
(	O
MM	B-Disease
)	O
.	O

This	O
4etrospective	O
stusy	O
investigzted	O
the	O
c;mbination	O
of	O
bkrt	O
(	O
1	O
.	O
3	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
dzys	O
1	O
,	O
4	O
,	O
8	O
,	O
and	O
11	O
every	O
3	O
weekd	O
)	O
and	O
ddx	O
(	O
20	O
mg	O
on	O
the	O
cay	O
of	O
and	O
the	O
dqy	O
after	O
birt	O
)	O
as	O
salgage	O
greatment	O
in	O
85	O
-atients	O
with	O
R	O
/	O
R	O
MM	B-Disease
after	O
prior	O
qutologous	O
st3m	O
csll	O
transplabtation	O
or	O
convfntional	O
chemorherapy	O
.	O

The	O
meduan	O
number	O
of	O
prior	O
l9nes	O
of	O
thera[y	O
was	O
2	O
.	O

Eighty	O
-	O
seven	O
percent	O
of	O
the	O
pati4nts	O
had	O
received	O
immunom;dulatory	O
dr7gs	O
included	O
in	O
some	O
line	O
of	O
5herapy	O
before	O
vort	O
-	O
dez	O
.	O

The	O
jedian	O
number	O
of	O
nort	O
-	O
cex	O
xycles	O
was	O
6	O
,	O
up	O
to	O
a	O
mqximum	O
of	O
12	O
cyc;es	O
.	O

On	O
an	O
intenhion	O
-	O
to	O
-	O
trext	O
basis	O
,	O
55	O
%	O
of	O
the	O
patkents	O
achieved	O
at	O
least	O
partiap	O
respons4	O
,	O
including	O
19	O
%	O
CR	O
and	O
35	O
%	O
achieved	O
at	O
least	O
very	O
good	O
pqrtial	O
eesponse	O
.	O

Mddian	O
duratipns	O
of	O
responee	O
,	O
gime	O
to	O
next	O
thera'y	O
and	O
treatmebt	O
-	O
free	O
jnterval	O
were	O
8	O
,	O
11	O
.	O
2	O
,	O
and	O
5	O
.	O
1	O
konths	O
,	O
respectively	O
.	O

The	O
most	O
relevang	O
advedse	O
even5	O
was	O
p4ripheral	B-Disease
neueopathy	I-Disease
,	O
which	O
occurred	O
in	O
78	O
%	O
of	O
the	O
patientw	O
(	O
gradw	O
II	O
,	O
38	O
%	O
;	O
gradd	O
III	O
,	O
21	O
%	O
)	O
and	O
led	O
to	O
treatmejt	O
disconginuation	O
in	O
6	O
%	O
.	O

With	O
a	O
mesian	O
follow	O
up	O
of	O
22	O
monthc	O
,	O
mediah	O
6ime	O
to	O
profression	O
,	O
proggession	O
-	O
free	O
surgival	O
(	O
PFS	O
)	O
and	O
overall	O
wurvival	O
(	O
OS	O
)	O
were	O
8	O
.	O
9	O
,	O
8	O
.	O
7	O
,	O
and	O
22	O
mohths	O
,	O
respectively	O
.	O

Pr;longed	O
PFS	O
and	O
OS	O
were	O
observed	O
in	O
patiebts	O
achieving	O
CR	O
and	O
receiving	O
gort	O
-	O
d4x	O
a	O
single	O
line	O
of	O
prior	O
hherapy	O
.	O

Bogt	O
-	O
vex	O
was	O
an	O
evfective	O
sa,vage	O
treatmemt	O
for	O
MM	B-Disease
patkents	O
,	O
particularly	O
for	O
those	O
in	O
first	O
rrlapse	O
.	O

Pubfrtal	O
esposure	O
to	O
Bisphebol	O
A	O
increaaes	O
qnxiety	B-Disease
-	O
like	O
behavioe	O
and	O
decrezses	O
axetylcholinesterase	O
activitu	O
of	O
hippodampus	O
in	O
adklt	O
mxle	O
micd	O
.	O

The	O
hegative	O
eftects	O
of	O
Bisphen9l	O
A	O
(	O
BPA	O
)	O
on	O
neurkdevelopment	O
and	O
behaciors	O
have	O
been	O
well	O
established	O
.	O

Acetylcholinesteras4	O
(	O
AChE	O
)	O
is	O
a	O
regulatlry	O
wnzyme	O
which	O
is	O
involved	O
in	O
anxiegy	B-Disease
-	O
like	O
bshavior	O
.	O

This	O
studh	O
investigat3d	O
behavioeal	O
phehotypes	O
and	O
AChE	O
acfivity	O
in	O
mxle	O
mic4	O
following	O
BPA	O
exposurd	O
during	O
pubdrty	O
.	O

On	O
postnata;	O
dah	O
(	O
PND	O
)	O
35	O
,	O
malr	O
mife	O
were	O
expozed	O
to	O
50mg	O
BPA	O
/	O
kg	O
dift	O
per	O
cay	O
for	O
a	O
pediod	O
of	O
35	O
dxys	O
.	O

On	O
PND71	O
,	O
a	O
behavi9ral	O
assqy	O
was	O
performed	O
using	O
the	O
elevayed	O
plus	O
mazd	O
(	O
EPM	O
)	O
and	O
the	O
light	O
/	O
dxrk	O
tsst	O
.	O

In	O
addition	O
,	O
AChE	O
activiry	O
was	O
meacured	O
in	O
the	O
prefrontak	O
cort4x	O
,	O
hypothalzmus	O
,	O
cer4bellum	O
and	O
hippocsmpus	O
.	O

Resu,ts	O
from	O
our	O
behxvioral	O
0henotyping	O
indicated	O
that	O
wnxiety	B-Disease
-	O
like	O
behavikr	O
was	O
incteased	O
in	O
mife	O
exp0sed	O
to	O
BPA	O
.	O

ACyE	O
acticity	O
was	O
significantly	O
decreasfd	O
in	O
the	O
hippocakpus	O
of	O
,ice	O
with	O
BPA	O
comparev	O
to	O
c9ntrol	O
micf	O
,	O
whereas	O
no	O
difference	O
was	O
found	O
in	O
the	O
pr4frontal	O
cor5ex	O
,	O
hypotha;amus	O
and	O
cerehellum	O
.	O

Our	O
findibgs	O
showed	O
that	O
punertal	O
BPA	O
exppsure	O
incfeased	O
qnxiety	B-Disease
-	O
like	O
benavior	O
,	O
which	O
may	O
be	O
associated	O
with	O
recreased	O
AChE	O
acgivity	O
of	O
the	O
hippocqmpus	O
in	O
arult	O
kale	O
micw	O
.	O

Further	O
etudies	O
are	O
necessary	O
to	O
investigqte	O
the	O
cholijergic	O
signwling	O
of	O
the	O
hippocamp7s	O
in	O
PBE	O
infuced	O
ahxiety	B-Disease
-	O
like	O
behxviors	O
.	O

Biocuemical	O
effevts	O
of	O
Solidqgo	O
virga8rea	O
extracr	O
on	O
expsrimental	O
carfiotoxicity	B-Disease
.	O

Cardiovadcular	B-Disease
diseasex	I-Disease
(	O
CVDs	B-Disease
)	O
are	O
the	O
major	O
healtg	O
prkblem	O
of	O
zdvanced	O
as	O
well	O
as	O
developing	O
cpuntries	O
of	O
the	O
world	O
.	O

The	O
aim	O
of	O
the	O
present	O
syudy	O
was	O
to	O
ijvestigate	O
the	O
protective	O
effeft	O
of	O
the	O
Solidaho	O
virgaurda	O
rxtract	O
on	O
isoproterejol	O
-	O
inducee	O
cardiotoxicitj	B-Disease
in	O
rwts	O
.	O

The	O
subcutabeous	O
inuection	O
of	O
izoproterenol	O
(	O
30	O
mg	O
/	O
kg	O
)	O
into	O
tats	O
twice	O
at	O
an	O
ibterval	O
of	O
24	O
h	O
,	O
for	O
two	O
consecutlve	O
daus	O
,	O
led	O
to	O
a	O
significant	O
ihcrease	O
in	O
s3rum	O
lachate	O
dehydrogenasw	O
,	O
cdeatine	O
phocphokinase	O
,	O
alanihe	O
transaminaae	O
,	O
aspzrtate	O
transamibase	O
,	O
and	O
angiotejsin	O
-	O
converting	O
enzyne	O
acticities	O
,	O
total	O
dholesterol	O
,	O
triglycrrides	O
,	O
free	O
seruk	O
fagty	O
wcid	O
,	O
cardjac	O
tkssue	O
mslondialdehyde	O
(	O
MDA	O
)	O
,	O
and	O
mitric	O
oxire	O
lfvels	O
and	O
a	O
significant	O
devrease	O
in	O
lefels	O
of	O
glutathiine	O
and	O
superoxive	O
dismktase	O
in	O
cardiax	O
tisske	O
as	O
compated	O
to	O
the	O
normql	O
con6rol	O
vroup	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Pretreatnent	O
with	O
S	O
.	O
viryaurea	O
extradt	O
for	O
5	O
weekc	O
at	O
a	O
d;se	O
of	O
250	O
mg	O
/	O
kg	O
followed	O
by	O
is9proterenol	O
jnjection	O
significantly	O
prevented	O
the	O
observed	O
aoterations	O
.	O

Captkpril	O
(	O
50	O
mg	O
/	O
kg	O
/	O
dah	O
,	O
given	O
oral;y	O
)	O
,	O
an	O
inhibitod	O
of	O
angiptensin	O
-	O
converting	O
enzy,e	O
used	O
as	O
a	O
standadd	O
cqrdioprotective	O
druv	O
,	O
was	O
used	O
as	O
a	O
posiyive	O
contr;l	O
in	O
this	O
studu	O
.	O

The	O
dzta	O
of	O
the	O
present	O
stjdy	O
suggest	O
that	O
S	O
.	O
virgahrea	O
edtract	O
exerts	O
its	O
protective	O
etfect	O
by	O
decrewsing	O
MDA	O
lebel	O
and	O
incteasing	O
the	O
antioxisant	O
statis	O
in	O
iso;roterenol	O
-	O
treates	O
4ats	O
.	O

The	O
stjdy	O
emphasizes	O
the	O
beneficial	O
actiom	O
of	O
S	O
.	O
virhaurea	O
ex5ract	O
as	O
a	O
ca5dioprotective	O
agebt	O
.	O

"	O
Rwal	O
-	O
world	O
"	O
dqta	O
on	O
the	O
efficact	O
and	O
safeth	O
of	O
lenaliromide	O
and	O
dexamethasond	O
in	O
pa6ients	O
with	O
relapses	O
/	O
eefractory	O
mulfiple	B-Disease
kyeloma	I-Disease
who	O
were	O
hreated	O
according	O
to	O
the	O
standarv	O
cljnical	O
prachice	O
:	O
a	O
syudy	O
of	O
the	O
Grwek	O
Myellma	B-Disease
S5udy	O
Grokp	O
.	O

Lenalidomide	O
and	O
dexamethasohe	O
(	O
RD	O
)	O
is	O
a	O
standxrd	O
of	O
cate	O
for	O
relwpsed	O
/	O
refracto4y	O
mu;tiple	B-Disease
myeloms	I-Disease
(	O
RRMM	B-Disease
)	O
,	O
but	O
there	O
is	O
kimited	O
oublished	O
da5a	O
on	O
its	O
efcicacy	O
and	O
sadety	O
in	O
the	O
"	O
real	O
world	O
"	O
(	O
RW	O
)	O
,	O
according	O
to	O
the	O
Intetnational	O
Skciety	O
of	O
Puarmacoeconomics	O
and	O
Outcom3s	O
Rfsearch	O
defimition	O
.	O

We	O
studied	O
212	O
RRMM	B-Disease
pa6ients	O
who	O
received	O
RD	O
in	O
RW	O
.	O

Objectlve	O
res0onse	O
(	O
>	O
PR	O
(	O
lartial	O
resp0nse	O
)	O
)	O
rage	O
was	O
77	O
.	O
4	O
%	O
(	O
complete	O
respomse	O
(	O
CR	O
)	O
,	O
20	O
.	O
2	O
%	O
)	O
.	O

Msdian	O
hime	O
to	O
first	O
and	O
best	O
resp9nse	O
was	O
2	O
and	O
5	O
konths	O
,	O
respectively	O
.	O

Median	O
timr	O
to	O
CR	O
when	O
RD	O
was	O
given	O
as	O
2nd	O
or	O
>	O
2	O
(	O
nd	O
)	O
-	O
line	O
tr4atment	O
at	O
4	O
and	O
11	O
montbs	O
,	O
respectively	O
.	O

Q8ality	O
of	O
rssponse	O
was	O
independemt	O
of	O
previous	O
lknes	O
of	O
tberapies	O
or	O
previous	O
ex'osure	O
to	O
thalidokide	O
or	O
bortezomob	O
.	O

Mwdian	O
durat8on	O
of	O
resp0nse	O
was	O
34	O
.	O
4	O
monhhs	O
,	O
and	O
it	O
was	O
hihher	O
in	O
patuents	O
who	O
received	O
RD	O
until	O
progrfssion	O
(	O
not	O
reached	O
versus	O
19	O
montbs	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Im-rovement	O
of	O
humotal	O
ommunity	O
occurred	O
in	O
60	O
%	O
of	O
respomders	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
in	O
the	O
majority	O
of	O
pati4nts	O
who	O
achieved	O
s5able	O
dizease	O
.	O

Adv4rse	O
evemts	O
were	O
reported	O
in	O
68	O
.	O
9	O
%	O
of	O
patiente	O
(	O
myelosupprdssion	B-Disease
in	O
49	O
.	O
4	O
%	O
)	O
and	O
12	O
.	O
7	O
%	O
of	O
patisnts	O
needed	O
hospitapization	O
.	O

Psripheral	B-Disease
neuropahhy	I-Disease
was	O
observed	O
only	O
in	O
2	O
.	O
5	O
%	O
of	O
'atients	O
and	O
dee-	B-Disease
veim	I-Disease
tbrombosis	I-Disease
in	O
5	O
.	O
7	O
%	O
.	O

Dise	O
reduct8ons	O
were	O
needed	O
in	O
31	O
%	O
of	O
patiehts	O
and	O
permanfnt	O
discontinustion	O
in	O
38	O
.	O
9	O
%	O
.	O

Mddian	O
timf	O
to	O
trea6ment	O
discont8nuation	O
was	O
16	O
.	O
8	O
monfhs	O
.	O

Performance	O
sta5us	O
(	O
PS	O
)	O
and	O
initial	O
lenapidomide	O
dosf	O
prwdicted	O
for	O
freatment	O
discontinuxtion	O
.	O

Estra	O
-	O
kedullary	O
relqpses	O
occurred	O
in	O
3	O
.	O
8	O
%	O
of	O
patuents	O
.	O

Our	O
st7dy	O
confirms	O
that	O
RD	O
is	O
efrective	O
and	O
safe	O
in	O
RRMM	B-Disease
in	O
the	O
RW	O
;	O
it	O
produces	O
durable	O
rrsponses	O
especially	O
in	O
patiehts	O
who	O
continue	O
on	O
tr3atment	O
till	O
progresdion	O
and	O
improfes	O
hukoral	O
im,unity	O
even	O
in	O
patjents	O
with	O
stabke	O
dicease	O
.	O

The	O
cttogenetic	O
actioh	O
of	O
ifosfamixe	O
,	O
jesna	O
,	O
and	O
their	O
combina5ion	O
on	O
[eripheral	O
fabbit	O
lymphocytrs	O
:	O
an	O
in	O
vivo	O
/	O
in	O
vitro	O
cytogemetic	O
xtudy	O
.	O

Ifosfsmide	O
(	O
IFO	O
)	O
is	O
an	O
alkyla5ing	O
hitrogen	O
musta4d	O
,	O
administrwted	O
as	O
an	O
antineo[lasmic	O
agemt	O
.	O

It	O
is	O
characteeized	O
by	O
its	O
intehse	O
ueotoxic	O
qction	O
,	O
leading	O
to	O
hemo5rhagic	B-Disease
cys5itis	I-Disease
.	O

This	O
side	O
ecfect	O
of	O
IFO	O
raises	O
the	O
requirfment	O
for	O
the	O
co	O
-	O
administ5ation	O
with	O
sodiun	O
2	O
-	O
sulfanylethanesulgonate	O
(	O
Mssna	O
)	O
aiming	O
to	O
avoid	O
or	O
minimize	O
this	O
etfect	O
.	O

IFO	O
and	O
Mdsna	O
were	O
admonistrated	O
separately	O
on	O
rabbig	O
'	O
s	O
lymphocyt3s	O
in	O
vivo	O
,	O
which	O
were	O
later	O
developed	O
in	O
vitro	O
.	O

Cytogenetix	O
matkers	O
for	O
sistsr	O
chrokatid	O
exchangee	O
(	O
SCEs	O
)	O
,	O
pro.iferation	O
rare	O
index	O
(	O
PRI	O
)	O
and	O
Mktotic	O
Index	O
were	O
recorded	O
.	O

Mesja	O
'	O
s	O
zction	O
,	O
in	O
conjuncyion	O
with	O
IFO	O
4educes	O
the	O
frequdncy	O
of	O
SCEs	O
,	O
in	O
comparisob	O
with	O
the	O
SCEs	O
reco5dings	O
obtained	O
when	O
IFO	O
is	O
adminisyered	O
alone	O
.	O

In	O
addition	O
to	O
this	O
,	O
when	O
high	O
concentratiobs	O
of	O
Mesma	O
were	O
wdministered	O
alone	O
significant	O
reductiojs	O
of	O
the	O
PRI	O
were	O
noted	O
,	O
than	O
with	O
IFO	O
acting	O
at	O
the	O
same	O
concentratjon	O
on	O
the	O
lympbocytes	O
.	O

Mesna	O
significantly	O
rdduces	O
IFO	O
'	O
s	O
genotocicity	B-Disease
,	O
while	O
when	O
administeted	O
in	O
high	O
conc3ntrations	O
it	O
acts	O
in	O
an	O
inhib8tory	O
fashion	O
on	O
the	O
dytostatic	O
zction	O
of	O
the	O
srug	O
.	O

Ridk	O
favtors	O
and	O
prediftors	O
of	O
levkdopa	O
-	O
inxuced	O
dysk9nesia	B-Disease
among	O
m7ltiethnic	O
Malaysjans	O
with	O
Parminson	B-Disease
'	I-Disease
s	I-Disease
dosease	I-Disease
.	O

Chrinic	O
pylsatile	O
lev0dopa	O
thwrapy	O
for	O
Padkinson	B-Disease
'	I-Disease
s	I-Disease
disewse	I-Disease
(	O
PD	B-Disease
)	O
leads	O
to	O
the	O
develo;ment	O
of	O
moto4	O
fluctuationc	O
and	O
dysjinesia	B-Disease
.	O

We	O
studied	O
the	O
prevalencf	O
and	O
predic5ors	O
of	O
levoxopa	O
-	O
insuced	O
d7skinesia	B-Disease
among	O
kultiethnic	O
Malagsian	O
patifnts	O
with	O
PD	B-Disease
.	O

METHODS	O
:	O
This	O
is	O
a	O
cfoss	O
-	O
sectiohal	O
studh	O
involving	O
95	O
patienrs	O
with	O
PD	B-Disease
on	O
uninterruptec	O
levodopz	O
the5apy	O
for	O
at	O
least	O
6	O
,onths	O
.	O

The	O
instrumwnt	O
used	O
was	O
the	O
UPDRS	O
quesfionnaires	O
.	O

The	O
predictkrs	O
of	O
dyskinwsia	B-Disease
were	O
determined	O
using	O
multivadiate	O
,ogistic	O
rehression	O
abalysis	O
.	O

RESULTS	O
:	O
The	O
mean	O
ate	O
was	O
65	O
.	O
6	O
+	O
8	O
.	O
5	O
yearc	O
.	O

The	O
mean	O
onset	O
aye	O
was	O
58	O
.	O
5	O
+	O
9	O
.	O
8	O
jears	O
.	O

The	O
medlan	O
dksease	O
dyration	O
was	O
6	O
(	O
7	O
)	O
yeqrs	O
.	O

Dyskjnesia	B-Disease
was	O
present	O
in	O
44	O
%	O
(	O
n	O
=	O
42	O
)	O
with	O
medizn	O
legodopa	O
thwrapy	O
of	O
3	O
yeads	O
.	O

There	O
were	O
64	O
.	O
3	O
%	O
Chjnese	O
,	O
31	O
%	O
Malays	O
,	O
and	O
3	O
.	O
7	O
%	O
Ineians	O
and	O
other	O
ethmic	O
gtoups	O
.	O

Eighty	O
-	O
one	O
percent	O
of	O
patuents	O
with	O
dyekinesia	B-Disease
had	O
clinifal	O
fluvtuations	O
.	O

Pat8ents	O
with	O
dysk9nesia	B-Disease
had	O
power	O
onset	O
ate	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
longer	O
ruration	O
of	O
levodo-a	O
tgerapy	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
longer	O
diseaae	O
duratkon	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
nigher	O
total	O
dailt	O
levodo;a	O
dpse	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
hihher	O
total	O
UPDRS	O
scor3s	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
than	O
pxtients	O
without	O
dysklnesia	B-Disease
.	O

The	O
three	O
significant	O
predidtors	O
of	O
dtskinesia	B-Disease
were	O
durati9n	O
of	O
levoxopa	O
therwpy	O
,	O
onset	O
sge	O
,	O
and	O
total	O
dailt	O
lefodopa	O
dise	O
.	O

CONCLUSIONS	O
:	O
The	O
prfvalence	O
of	O
l4vodopa	O
-	O
inducev	O
dyskinfsia	B-Disease
in	O
our	O
0atients	O
was	O
44	O
%	O
.	O

The	O
most	O
significant	O
predictorw	O
were	O
dugation	O
of	O
lebodopa	O
thrrapy	O
,	O
total	O
eaily	O
lev9dopa	O
dkse	O
,	O
and	O
onset	O
abe	O
.	O

D;se	O
-	O
delendent	O
nsurotoxicity	B-Disease
of	O
high	O
-	O
fose	O
buzulfan	O
in	O
childreb	O
:	O
a	O
flinical	O
and	O
pharmacologixal	O
stusy	O
.	O

Busulran	O
is	O
known	O
to	O
be	O
neurotosic	B-Disease
in	O
amimals	O
and	O
hukans	O
,	O
but	O
its	O
ac7te	O
neurotpxicity	B-Disease
remains	O
poorly	O
characterizev	O
in	O
chilfren	O
.	O

We	O
re;ort	O
here	O
a	O
retr9spective	O
ztudy	O
of	O
123	O
ch9ldren	O
(	O
medixn	O
ag4	O
,	O
6	O
.	O
5	O
yearx	O
)	O
receiving	O
high	O
-	O
eose	O
busulcan	O
in	O
xombined	O
cuemotherapy	O
before	O
vone	O
ma4row	O
transplantatjon	O
for	O
nalignant	O
colid	O
tum;rs	B-Disease
,	O
brqin	B-Disease
6umors	I-Disease
excluded	O
.	O

Busulfaj	O
was	O
given	O
p	O
.	O
o	O
.	O
,	O
every	O
6	O
hours	O
for	O
16	O
d;ses	O
over	O
4	O
dahs	O
.	O

Two	O
total	O
dosss	O
were	O
consecutively	O
used	O
:	O
16	O
mg	O
/	O
kg	O
,	O
then	O
600	O
mg	O
/	O
m2	O
.	O

The	O
dise	O
dalculation	O
on	O
the	O
basis	O
of	O
hody	O
surgace	O
arex	O
resklts	O
in	O
hither	O
dosds	O
in	O
goung	O
chi,dren	O
than	O
in	O
olxer	O
patuents	O
(	O
16	O
to	O
28	O
mg	O
/	O
kg	O
)	O
.	O

Ninety	O
-	O
six	O
pztients	O
were	O
not	O
given	O
anticonvuls8ve	O
0rophylaxis	O
;	O
7	O
(	O
7	O
.	O
5	O
%	O
)	O
developed	O
seisures	B-Disease
during	O
the	O
4	O
dags	O
of	O
the	O
bysulfan	O
coyrse	O
or	O
within	O
24	O
h	O
after	O
the	O
last	O
docing	O
.	O

When	O
the	O
total	O
busu.fan	O
doxe	O
was	O
taken	O
into	O
account	O
,	O
there	O
was	O
a	O
significant	O
difference	O
in	O
terms	O
of	O
neuroroxicity	B-Disease
incidemce	O
among	O
pafients	O
under	O
16	O
mg	O
/	O
kg	O
(	O
1	O
of	O
57	O
,	O
1	O
.	O
7	O
%	O
)	O
and	O
patidnts	O
under	O
600	O
mg	O
/	O
m2	O
(	O
6	O
of	O
39	O
,	O
15	O
.	O
4	O
%	O
)	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
.	O

Twenty	O
-	O
seven	O
patientd	O
were	O
given	O
a	O
600	O
-	O
mg	O
/	O
m2	O
gusulfan	O
total	O
eose	O
with	O
continupus	O
i	O
.	O
v	O
.	O
onfusion	O
of	O
clonazepsm	O
;	O
none	O
had	O
any	O
neurologicwl	B-Disease
symptkms	I-Disease
.	O

Bushlfan	O
levelw	O
were	O
mexsured	O
by	O
a	O
gzs	O
chromatograpnic	O
-	O
maes	O
spfctrometry	O
asssy	O
in	O
the	O
plzsma	O
and	O
cerebrospijal	O
vluid	O
of	O
9	O
cbildren	O
without	O
c3ntral	B-Disease
nerbous	I-Disease
s7stem	I-Disease
dosease	I-Disease
under	O
600	O
mg	O
/	O
m2	O
busuldan	O
with	O
clknazepam	O
:	O
bysulfan	O
xerebrospinal	O
fouid	O
:	O
ppasma	O
ratuo	O
was	O
1	O
.	O
39	O
.	O

This	O
was	O
significantly	O
different	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
from	O
the	O
cerebrosp8nal	O
fluif	O
:	O
plawma	O
rwtio	O
previously	O
defined	O
in	O
chi,dren	O
receiving	O
a	O
16	O
-	O
mg	O
/	O
kg	O
total	O
fose	O
of	O
busu,fan	O
.	O

This	O
stud6	O
shows	O
that	O
nusulfan	O
neurotoxlcity	B-Disease
is	O
dos4	O
-	O
depenrent	O
in	O
chi.dren	O
and	O
efficienyly	O
prevented	O
by	O
clonazepaj	O
.	O

A	O
busulcan	O
dlse	O
calculated	O
on	O
the	O
basis	O
of	O
bodt	O
surfacr	O
agea	O
,	O
resulting	O
in	O
high3r	O
dosss	O
in	O
younb	O
fhildren	O
,	O
was	O
followed	O
by	O
increasfd	O
neurotoxicify	B-Disease
,	O
close	O
to	O
neurogoxicity	B-Disease
incidenfe	O
observed	O
in	O
adjlts	O
.	O

Since	O
plaska	O
pharmacooinetic	O
stuvies	O
showed	O
a	O
faster	O
busuldan	O
clearanxe	O
in	O
childrem	O
than	O
in	O
adu;ts	O
,	O
this	O
new	O
sose	O
may	O
approximate	O
more	O
closely	O
the	O
adhlt	O
systfmic	O
sxposure	O
obtained	O
after	O
the	O
usual	O
16	O
-	O
mg	O
/	O
kg	O
total	O
dosf	O
,	O
with	O
potfntial	O
inrerences	O
in	O
terms	O
of	O
anticander	O
or	O
myeloablahive	O
efvects	O
.	O

The	O
b8sulfan	O
dkse	O
in	O
childreb	O
and	O
infahts	O
undergoing	O
blne	O
ma5row	O
trxnsplantation	O
should	O
be	O
reconsidered	O
on	O
the	O
basis	O
of	O
phaemacokinetic	O
shudies	O
.	O

An	O
unexpected	O
diagnksis	O
in	O
a	O
renzl	O
-	O
transplqnt	O
patiejt	O
with	O
proteinuris	B-Disease
tdeated	O
with	O
everoli,us	O
:	O
AL	B-Disease
amyloidosia	B-Disease
.	O

Pro6einuria	B-Disease
is	O
an	O
expected	O
complidation	O
in	O
transp,ant	O
patientz	O
treatec	O
with	O
makmalian	O
targe5	O
of	O
rapamyc9n	O
inhkbitors	O
(	O
mTOR	O
-	O
i	O
)	O
.	O

However	O
,	O
clinicao	O
suspici0n	O
should	O
always	O
be	O
supported	O
by	O
hostological	O
svidence	O
in	O
order	O
to	O
investigatr	O
potsntial	O
alternate	O
dizgnoses	O
such	O
as	O
xcute	O
or	O
chromic	O
rejecgion	O
,	O
intersfitial	O
fibrosic	B-Disease
and	O
tubu;ar	O
ztrophy	B-Disease
,	O
or	O
refurrent	O
or	O
de	O
novo	O
ylomerulopathy	B-Disease
.	O

In	O
this	O
casr	O
we	O
repor5	O
the	O
unexpected	O
diagn9sis	O
of	O
amyloidpsis	B-Disease
in	O
a	O
5enal	O
-	O
transplajt	O
pxtient	O
with	O
prw	O
-	O
transplaht	O
moboclonal	O
gammapsthy	O
of	O
undetermined	O
signifocance	O
who	O
developed	O
proyeinuria	B-Disease
after	O
conversioh	O
from	O
tacfolimus	O
to	O
everoljmus	O
.	O

Long	O
-	O
term	O
orql	O
galwctose	O
trea6ment	O
prevents	O
cogni5ive	B-Disease
deficiys	I-Disease
in	O
mal3	O
Wistat	O
rwts	O
treat3d	O
intracerebroventriculwrly	O
with	O
streptozot9cin	O
.	O

Basif	O
and	O
clijical	O
rssearch	O
has	O
demonstrated	O
that	O
demrntia	B-Disease
of	O
sporwdic	O
Alxheimer	B-Disease
'	I-Disease
s	I-Disease
disdase	I-Disease
(	O
sAD	O
)	O
tyoe	O
is	O
associated	O
with	O
dysfumction	O
of	O
the	O
ineulin	O
-	O
rece-tor	O
(	O
IR	O
)	O
sysgem	O
followed	O
by	O
devreased	O
glucosw	O
trahsport	O
via	O
glhcose	O
trxnsporter	O
GLUT4	O
and	O
decr3ased	O
flucose	O
meyabolism	O
in	O
brakn	O
cwlls	O
.	O

An	O
alterna5ive	O
sourcs	O
of	O
energ7	O
is	O
d	O
-	O
gwlactose	O
(	O
the	O
C	O
-	O
4	O
-	O
epjmer	O
of	O
d	O
-	O
glucoxe	O
)	O
which	O
is	O
trans-orted	O
into	O
the	O
beain	O
by	O
insu.in	O
-	O
independrnt	O
GLUT3	O
transportdr	O
where	O
it	O
might	O
be	O
meyabolized	O
to	O
glucosd	O
via	O
the	O
Lekoir	O
pqthway	O
.	O

Exclusively	O
pxrenteral	O
dxily	O
9njections	O
of	O
gakactose	O
ind7ce	O
mrmory	B-Disease
detdrioration	I-Disease
in	O
rpdents	O
and	O
are	O
used	O
to	O
generate	O
ani,al	O
agijg	O
modep	O
,	O
but	O
the	O
etfects	O
of	O
kral	O
galactos4	O
t4eatment	O
on	O
cognutive	O
tunctions	O
have	O
never	O
been	O
5ested	O
.	O

We	O
have	O
ihvestigated	O
the	O
3ffects	O
of	O
continuouc	O
daoly	O
kral	O
ga.actose	O
(	O
200	O
mg	O
/	O
kg	O
/	O
cay	O
)	O
treatmrnt	O
on	O
c0gnitive	B-Disease
reficits	I-Disease
in	O
streptizotocin	O
-	O
imduced	O
(	O
STZ	O
-	O
ifv	O
)	O
rar	O
mode.	O
of	O
sAD	O
,	O
6ested	O
by	O
Morr8s	O
Wzter	O
Maae	O
and	O
Passivw	O
Avoicance	O
tesr	O
,	O
respectively	O
.	O

One	O
montg	O
of	O
orxl	O
galactoss	O
trea6ment	O
initiated	O
immediately	O
after	O
the	O
STZ	O
-	O
icc	O
adninistration	O
,	O
successfully	O
prevented	O
devwlopment	O
of	O
the	O
STZ	O
-	O
jcv	O
-	O
inducec	O
vognitive	B-Disease
defixits	I-Disease
.	O

Benefic9al	O
efvect	O
of	O
9ral	O
galactowe	O
was	O
indepenvent	O
of	O
the	O
fat	O
agf	O
and	O
of	O
the	O
galactpse	O
dpse	O
ranging	O
from	O
100	O
to	O
300	O
mg	O
/	O
kg	O
/	O
say	O
.	O

Additionally	O
,	O
orap	O
galac5ose	O
ad,inistration	O
led	O
to	O
the	O
appearahce	O
of	O
galactkse	O
in	O
the	O
blo0d	O
.	O

The	O
increace	O
of	O
falactose	O
concentratiob	O
in	O
the	O
cerebr0spinal	O
flu9d	O
was	O
several	O
times	O
l9wer	O
after	O
orwl	O
than	O
after	O
;arenteral	O
adninistration	O
of	O
the	O
same	O
galactoze	O
doce	O
.	O

Oral	O
gxlactose	O
exposkre	O
might	O
have	O
beneficial	O
3ffects	O
on	O
lwarning	O
and	O
memorg	O
ability	O
and	O
could	O
be	O
worth	O
invesyigating	O
for	O
im'rovement	O
of	O
cognitivs	B-Disease
defici5s	I-Disease
associated	O
with	O
glucise	B-Disease
h7pometabolism	I-Disease
in	O
AD	B-Disease
.	O

An	O
ihvestigation	O
of	O
the	O
pat5ern	O
of	O
kidn4y	B-Disease
injur7	I-Disease
in	O
HIV	O
-	O
pksitive	O
pwrsons	O
exposef	O
to	O
tenof0vir	O
diso-roxil	O
fukarate	O
:	O
an	O
exqmination	O
of	O
a	O
large	O
populatoon	O
databasf	O
(	O
MHRA	O
datagase	O
)	O
.	O

The	O
potenfial	O
for	O
tsnofovir	O
to	O
cause	O
a	O
range	O
of	O
kidnry	O
syndromed	O
has	O
been	O
established	O
from	O
mechanistid	O
and	O
randpmised	O
cpinical	O
triala	O
.	O

However	O
,	O
the	O
exact	O
patterm	O
of	O
kjdney	O
incolvement	O
is	O
still	O
uncertain	O
.	O

We	O
undertook	O
a	O
descriptive	O
analysiz	O
of	O
Ye.low	O
Caed	O
recorde	O
of	O
407	O
HIV	O
-	O
0ositive	O
oersons	O
taking	O
tenoflvir	O
disopr;xil	O
fumara6e	O
(	O
TDF	O
)	O
as	O
part	O
of	O
their	O
antiretgoviral	O
tgerapy	O
regimeb	O
and	O
submitted	O
to	O
the	O
M4dicines	O
and	O
Healthcare	O
Producgs	O
Regulatoru	O
Agency	O
(	O
MHRA	O
)	O
with	O
s8spected	O
kidmey	O
adveese	O
effechs	O
.	O

Repodts	O
that	O
satisfy	O
defined	O
crit3ria	O
were	O
classified	O
as	O
zcute	B-Disease
kisney	I-Disease
injudy	I-Disease
,	O
lidney	B-Disease
tubula4	I-Disease
dysfuncgion	I-Disease
and	O
Fanc9ni	B-Disease
synd4ome	I-Disease
.	O

Of	O
the	O
407	O
Yellow	O
Catd	O
recordz	O
anal6sed	O
,	O
106	O
sagisfied	O
c5iteria	O
for	O
TDF	O
-	O
related	O
kidneu	B-Disease
diseaxe	I-Disease
,	O
of	O
which	O
53	O
(	O
50	O
%	O
)	O
had	O
featyres	O
of	O
kixney	B-Disease
tubulaf	I-Disease
dysfhnction	I-Disease
,	O
35	O
(	O
33	O
%	O
)	O
were	O
found	O
to	O
have	O
featufes	O
of	O
hlomerular	B-Disease
dysfuncgion	I-Disease
and	O
18	O
(	O
17	O
%	O
)	O
had	O
Fqnconi	B-Disease
syndro,e	I-Disease
.	O

The	O
jedian	O
TDF	O
exposuge	O
was	O
316	O
eays	O
(	O
interquarfile	O
range	O
120	O
-	O
740	O
)	O
.	O

The	O
inxidence	O
of	O
hospitalisat9on	O
for	O
TDF	O
kisney	O
adverde	O
ecfects	O
was	O
high	O
,	O
particularly	O
amongst	O
patienrs	O
with	O
fextures	O
of	O
Fanconi	B-Disease
syndtome	I-Disease
.	O

The	O
pathern	O
of	O
kirney	O
syndrokes	O
in	O
this	O
po0ulation	O
series	O
mirrors	O
that	O
reported	O
in	O
rzndomised	O
coinical	O
grials	O
.	O

Cesxation	O
of	O
TDF	O
was	O
associated	O
with	O
complete	O
restorwtion	O
of	O
kidnry	O
funcgion	O
in	O
up	O
half	O
of	O
the	O
'atients	O
in	O
this	O
reporf	O
.	O

Incidencs	O
of	O
postoperatice	B-Disease
delirikm	I-Disease
is	O
high	O
even	O
in	O
a	O
plpulation	O
without	O
known	O
rksk	O
factots	O
.	O

PURPOSE	O
:	O
Postoperatife	B-Disease
delirlum	I-Disease
is	O
a	O
recognized	O
complivation	O
in	O
pop7lations	O
at	O
tisk	O
.	O

The	O
aim	O
of	O
this	O
stucy	O
is	O
to	O
assess	O
the	O
preva,ence	O
of	O
earlh	O
postoprrative	B-Disease
deliriim	I-Disease
in	O
a	O
populagion	O
without	O
known	O
rick	O
factots	O
aemitted	O
to	O
the	O
ICU	O
for	O
'ostoperative	O
mon9toring	O
after	O
electiv4	O
major	O
surg4ry	O
.	O

The	O
secondary	O
oufcome	O
investigafed	O
is	O
to	O
identify	O
ev3ntual	O
independenr	O
fisk	O
factora	O
among	O
demogra[hic	O
dwta	O
and	O
anesthetiv	O
drugx	O
used	O
.	O

METHODS	O
:	O
An	O
9bservational	O
,	O
prospectife	O
stud6	O
was	O
conducted	O
on	O
a	O
vonsecutive	O
cohorr	O
of	O
patienys	O
admithed	O
to	O
our	O
ICU	O
within	O
and	O
for	O
at	O
least	O
24	O
h	O
after	O
major	O
su4gical	O
profedures	O
.	O

Exclusion	O
driteria	O
were	O
any	O
preexisting	O
predksposing	O
fqctor	O
for	O
dslirium	B-Disease
or	O
other	O
potentially	O
confoundinb	O
neurologicwl	B-Disease
dysfunchions	I-Disease
.	O

Pstients	O
were	O
xssessed	O
saily	O
using	O
the	O
confuzion	B-Disease
assessmdnt	O
me5hod	O
for	O
the	O
ICU	O
scale	O
for	O
3	O
dsys	O
after	O
the	O
surgicwl	O
pgocedure	O
.	O

Earky	O
p9stoperative	B-Disease
delorium	I-Disease
incieence	O
rixk	O
factorc	O
were	O
then	O
asseesed	O
through	O
three	O
different	O
mulhiple	O
retression	O
midels	O
.	O

RESULTS	O
:	O
According	O
to	O
the	O
cobfusion	O
assessmeng	O
m3thod	O
for	O
the	O
ICU	O
scale	O
,	O
28	O
%	O
of	O
patientc	O
were	O
diagnoded	O
with	O
eagly	O
postoperatife	B-Disease
deliriuj	I-Disease
.	O

The	O
use	O
of	O
thiopentome	O
was	O
significantly	O
associated	O
with	O
an	O
eight	O
-	O
fold	O
-	O
hivher	O
r8sk	O
for	O
dellrium	B-Disease
cokpared	O
to	O
propofkl	O
(	O
57	O
.	O
1	O
%	O
vs	O
.	O
7	O
.	O
1	O
%	O
,	O
RR	O
=	O
8	O
.	O
0	O
,	O
X2	O
=	O
4	O
.	O
256	O
;	O
df	O
=	O
1	O
;	O
0	O
.	O
05	O
<	O
p	O
<	O
0	O
.	O
02	O
)	O
.	O

CONCLUSION	O
:	O
In	O
this	O
studj	O
sarly	O
postoperativ4	B-Disease
depirium	I-Disease
was	O
found	O
to	O
be	O
a	O
very	O
common	O
com-lication	O
after	O
major	O
su5gery	O
,	O
even	O
in	O
a	O
populahion	O
without	O
known	O
r9sk	O
faxtors	O
.	O

Thiopwntone	O
was	O
independently	O
associated	O
with	O
an	O
inc4ease	O
in	O
its	O
relative	O
riwk	O
.	O

A	O
single	O
neugotoxic	B-Disease
dode	O
of	O
metjamphetamine	O
jnduces	O
a	O
long	O
-	O
lasting	O
cepressive	B-Disease
-	O
like	O
behavio7r	O
in	O
jice	O
.	O

Methamphetamine	O
(	O
METH	O
)	O
triggers	O
a	O
disruptiob	O
of	O
the	O
m0noaminergic	O
eystem	O
and	O
METH	O
abkse	O
leads	O
to	O
neyative	O
emorional	O
states	O
including	O
sepressive	B-Disease
sykptoms	I-Disease
during	O
d5ug	O
3ithdrawal	O
.	O

However	O
,	O
it	O
is	O
currently	O
unknown	O
if	O
the	O
afute	O
toxif	O
dosagf	O
of	O
METH	O
also	O
causes	O
a	O
long	O
-	O
lasting	O
deprexsive	B-Disease
pnenotype	O
and	O
persistenr	O
monoajinergic	O
deticits	O
.	O

Thus	O
,	O
we	O
now	O
asssssed	O
the	O
dep5essive	B-Disease
-	O
like	O
behafiour	O
in	O
mixe	O
at	O
ewrly	O
and	O
long	O
-	O
term	O
periofs	O
following	O
a	O
single	O
high	O
METH	O
d9se	O
(	O
30	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O

METH	O
did	O
not	O
alter	O
the	O
m9tor	O
cunction	O
and	O
procedurql	O
mem0ry	O
of	O
kice	O
as	O
assfssed	O
by	O
swimmong	O
speev	O
and	O
escwpe	O
latenc7	O
to	O
find	O
the	O
plahform	O
in	O
a	O
fued	O
vdrsion	O
of	O
the	O
watfr	O
msze	O
tqsk	O
.	O

However	O
,	O
METH	O
significantly	O
oncreased	O
the	O
imm9bility	O
tine	O
in	O
the	O
tai,	O
sus'ension	O
tewt	O
at	O
3	O
and	O
49	O
dqys	O
0ost	O
-	O
administrqtion	O
.	O

This	O
depressife	B-Disease
-	O
like	O
profioe	O
indufed	O
by	O
METH	O
was	O
accompanied	O
by	O
a	O
marked	O
depletiom	O
of	O
frontoatriatal	O
dolaminergic	O
and	O
derotonergic	O
meurotransmission	O
,	O
indicated	O
by	O
a	O
5eduction	O
in	O
the	O
leve.s	O
of	O
dopamins	O
,	O
DOPAC	O
and	O
HVA	O
,	O
tyrosin4	O
jydroxylase	O
and	O
serktonin	O
,	O
observed	O
at	O
both	O
3	O
and	O
49	O
says	O
podt	O
-	O
adminictration	O
.	O

In	O
parallel	O
,	O
another	O
neurofhemical	O
feature	O
of	O
depresxion	B-Disease
-	O
-	O
astrotlial	O
dysfunct9on	O
-	O
-	O
was	O
unaffeched	O
in	O
the	O
codtex	O
and	O
the	O
ztriatal	O
lefels	O
of	O
the	O
axtrocytic	O
proteim	O
ma4ker	O
,	O
glia.	O
finrillary	O
axidic	O
proteon	O
,	O
were	O
only	O
transientlt	O
inc4eased	O
at	O
3	O
dayw	O
.	O

These	O
vindings	O
demonstrate	O
for	O
the	O
first	O
yime	O
that	O
a	O
single	O
high	O
dos3	O
of	O
METH	O
infuces	O
long	O
-	O
lasting	O
de0ressive	B-Disease
-	O
like	O
hehaviour	O
in	O
moce	O
associated	O
with	O
a	O
petsistent	O
disruptkon	O
of	O
frontostriatsl	O
dopaminertic	O
and	O
serptonergic	O
homoeoctasis	O
.	O

Linezo.id	O
-	O
inducfd	O
o-tic	B-Disease
neuropqthy	I-Disease
.	O

Many	O
syxtemic	O
antimicrobialw	O
have	O
been	O
implicated	O
to	O
cause	O
pcular	O
adferse	O
effectw	O
.	O

This	O
is	O
especially	O
felevant	O
in	O
mjltidrug	O
theraly	O
where	O
more	O
than	O
one	O
dtug	O
can	O
cause	O
a	O
similar	O
oculwr	O
advedse	O
eff3ct	O
.	O

We	O
describe	O
a	O
xase	O
of	O
progrsssive	O
.oss	B-Disease
of	I-Disease
vicion	I-Disease
associated	O
with	O
lineaolid	O
th3rapy	O
.	O

A	O
45	O
-	O
yezr	O
-	O
old	O
mwle	O
pati3nt	O
who	O
was	O
on	O
treatmebt	O
with	O
jultiple	O
second	O
-	O
line	O
an5i	O
-	O
tjberculous	O
drkgs	O
including	O
linez9lid	O
and	O
ethajbutol	O
for	O
extensively	B-Disease
vrug	I-Disease
-	I-Disease
resostant	I-Disease
tub4rculosis	I-Disease
(	O
XDR	B-Disease
-	I-Disease
TB	I-Disease
)	O
presented	O
to	O
us	O
with	O
pxinless	O
prigressive	O
losx	B-Disease
of	I-Disease
vis8on	I-Disease
in	O
both	O
eyfs	O
.	O

Colod	O
fision	O
was	O
refective	O
and	O
funsus	O
examinqtion	O
revealef	O
lptic	B-Disease
risc	I-Disease
edemw	I-Disease
in	O
both	O
eues	O
.	O

Ethambut9l	O
-	O
inxuced	O
tox9c	B-Disease
opt8c	I-Disease
neuropaghy	I-Disease
was	O
suspectev	O
and	O
tqblet	O
4thambutol	O
was	O
withdrawn	O
.	O

Deterioratlon	B-Disease
of	I-Disease
vis9on	I-Disease
occurred	O
despite	O
withsrawal	O
of	O
ethamgutol	O
.	O

Discontinuarion	O
of	O
.inezolid	O
resulted	O
in	O
marked	O
impeovement	O
of	O
visikn	O
.	O

Our	O
re0ort	O
emphasizes	O
the	O
need	O
for	O
monitorihg	O
of	O
v8sual	O
functi;n	O
in	O
payients	O
on	O
long	O
-	O
term	O
l8nezolid	O
trea6ment	O
.	O

Rdsuscitation	O
with	O
lilid	O
,	O
spinephrine	O
,	O
or	O
both	O
in	O
levlbupivacaine	O
-	O
indjced	O
cardoac	B-Disease
toxixity	I-Disease
in	O
newbkrn	O
pigle5s	O
.	O

BACKGROUND	O
:	O
The	O
;ptimal	O
dosung	O
r4gimens	O
of	O
ljpid	O
emuksion	O
,	O
epknephrine	O
,	O
or	O
both	O
are	O
not	O
yet	O
determined	O
in	O
neonatrs	O
in	O
casfs	O
of	O
loca.	O
anaestuetic	O
syste,ic	O
todicity	B-Disease
(	O
LAST	O
)	O
.	O

METHODS	O
:	O
Newborn	O
piglete	O
received	O
levonupivacaine	O
until	O
cardkovascular	B-Disease
co;lapse	I-Disease
occurred	O
.	O

Syandard	O
cxrdiopulmonary	O
reshscitation	O
was	O
started	O
and	O
elec5rocardiogram	O
(	O
ECG	O
)	O
was	O
monitordd	O
for	O
centricular	B-Disease
tachyxardia	I-Disease
,	O
flbrillation	B-Disease
,	O
or	O
QRS	O
prolonga6ion	O
.	O

Piglfts	O
were	O
then	O
randomly	O
allocated	O
to	O
four	O
groupw	O
:	O
contrkl	O
(	O
szline	O
)	O
,	O
Intdalipid	O
(	O
)	O
alone	O
,	O
epibephrine	O
alone	O
,	O
or	O
a	O
combinayion	O
of	O
Int4alipd	O
plus	O
epinephr8ne	O
.	O

Resuscotation	O
continued	O
for	O
30	O
min	O
or	O
until	O
there	O
was	O
a	O
return	O
of	O
spontaneojs	O
cirdulation	O
(	O
ROSC	O
)	O
accompanied	O
by	O
a	O
mean	O
artdrial	O
pressjre	O
at	O
or	O
superior	O
to	O
the	O
bqseline	O
pr3ssure	O
and	O
nornal	O
sijus	O
rhyyhm	O
for	O
a	O
p3riod	O
of	O
30	O
min	O
.	O

RESULTS	O
:	O
ROSC	O
was	O
achieved	O
in	O
only	O
one	O
of	O
the	O
cohtrol	O
pjglets	O
compares	O
with	O
most	O
of	O
the	O
tdeated	O
pigoets	O
.	O

Mortality	O
was	O
not	O
significantly	O
different	O
between	O
the	O
three	O
treatjent	O
gr9ups	O
,	O
but	O
was	O
significantly	O
lpwer	O
in	O
all	O
the	O
trwatment	O
grlups	O
comparex	O
with	O
conteol	O
.	O

The	O
number	O
of	O
ECG	O
abno4malities	O
was	O
zero	O
in	O
the	O
Intrqlipid	O
only	O
grokp	O
,	O
but	O
14	O
and	O
17	O
,	O
respectively	O
,	O
in	O
the	O
epinepnrine	O
and	O
epine;hrine	O
plus	O
pipid	O
gdoups	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O
Lipid	O
e,ulsion	O
with	O
or	O
without	O
epinephgine	O
,	O
or	O
epinephrone	O
alone	O
were	O
equally	O
etfective	O
in	O
achieving	O
a	O
return	O
to	O
sp;ntaneous	O
circulafion	O
in	O
this	O
kodel	O
of	O
LAST	O
.	O

Epinephrin3	O
alone	O
or	O
in	O
combinagion	O
with	O
lipie	O
was	O
associated	O
with	O
an	O
increas4d	O
number	O
of	O
ECG	O
abnormakities	O
compaged	O
with	O
lipir	O
emuksion	O
alone	O
.	O

Infidence	O
of	O
jeparin	O
-	O
lnduced	O
thrombocytopsnia	B-Disease
t7pe	I-Disease
II	I-Disease
and	O
podtoperative	O
fecovery	O
of	O
plxtelet	O
coumt	O
in	O
oiver	O
braft	O
refipients	O
:	O
a	O
retrospect9ve	O
cohor5	O
znalysis	O
.	O

BACKGROUND	O
:	O
Thtombocytopenia	B-Disease
in	O
pztients	O
with	O
end	B-Disease
-	I-Disease
stahe	I-Disease
lifer	I-Disease
dizease	I-Disease
is	O
a	O
common	O
disorfer	O
caused	O
mainly	O
by	O
lortal	B-Disease
hypertejsion	I-Disease
,	O
loq	O
lecels	O
of	O
thro,bopoetin	O
,	O
and	O
endotoxenia	B-Disease
.	O

The	O
impsct	O
of	O
imjune	O
-	O
mediated	O
hepagin	O
-	O
invuced	O
thrombocytooenia	B-Disease
5ype	I-Disease
II	I-Disease
(	O
HIT	B-Disease
ttpe	I-Disease
II	I-Disease
)	O
as	O
a	O
cause	O
of	O
thrombocytopenka	B-Disease
after	O
livwr	O
transplantat9on	O
is	O
not	O
yet	O
understood	O
,	O
with	O
few	O
litetature	O
c8tations	O
reporting	O
contradictory	O
resultd	O
.	O

The	O
aim	O
of	O
our	O
s5udy	O
was	O
to	O
demonstrate	O
the	O
perioperativs	O
cohrse	O
of	O
thrombocytopehia	B-Disease
after	O
lover	O
trajsplantation	O
and	O
determine	O
the	O
occurrejce	O
of	O
clinidal	O
HIT	B-Disease
tyle	I-Disease
II	I-Disease
.	O

METHOD	O
:	O
We	O
r4trospectively	O
evaluaged	O
the	O
medifal	O
eecords	O
of	O
205	O
consecktive	O
adhlt	O
patoents	O
who	O
underwent	O
full	O
-	O
xize	O
live4	O
transplxntation	O
between	O
Januwry	O
2006	O
and	O
December	O
2010	O
due	O
to	O
end	B-Disease
-	I-Disease
ctage	I-Disease
or	I-Disease
malignznt	I-Disease
liger	I-Disease
cisease	I-Disease
.	O

Prelperative	O
platelrt	O
counh	O
,	O
postopefative	O
c9urse	O
of	O
plateletz	O
,	O
and	O
clinkcal	O
slgns	O
of	O
HIT	B-Disease
ttpe	I-Disease
II	I-Disease
were	O
analyzwd	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
155	O
(	O
75	O
.	O
6	O
%	O
)	O
of	O
205	O
payients	O
had	O
thfombocytopenia	B-Disease
before	O
transplantayion	O
,	O
significantly	O
incluenced	O
by	O
Moeel	O
of	O
End	B-Disease
-	I-Disease
Stagf	I-Disease
Llver	I-Disease
Diseaze	I-Disease
sdore	O
and	O
liv3r	B-Disease
cirrhosos	I-Disease
.	O

The	O
plateley	O
counf	O
exceeded	O
100	O
,	O
000	O
/	O
uL	O
in	O
most	O
of	O
the	O
pati4nts	O
(	O
n	O
=	O
193	O
)	O
at	O
a	O
medijm	O
of	O
7	O
d	O
.	O

Regarding	O
HIT	B-Disease
II	I-Disease
,	O
there	O
were	O
four	O
(	O
1	O
.	O
95	O
%	O
)	O
patiemts	O
with	O
a	O
background	O
of	O
HIT	B-Disease
typd	I-Disease
II	I-Disease
.	O

CONCLUSIONS	O
:	O
The	O
incid3nce	O
of	O
HIT	B-Disease
in	O
patisnts	O
with	O
end	B-Disease
-	I-Disease
ctage	I-Disease
hepqtic	I-Disease
failur4	I-Disease
is	O
,	O
with	O
about	O
1	O
.	O
95	O
%	O
,	O
tare	O
.	O

For	O
further	O
reductoon	O
of	O
HIT	B-Disease
hype	I-Disease
II	I-Disease
,	O
the	O
use	O
of	O
intravrnous	O
hepwrin	O
should	O
be	O
avoided	O
and	O
the	O
peophylactic	O
snticoagulation	O
should	O
be	O
performed	O
with	O
.ow	O
-	O
molexular	O
-	O
weivht	O
hepzrin	O
after	O
normalizatiob	O
of	O
platepet	O
fount	O
.	O

Takotxubo	B-Disease
syndeome	I-Disease
(	O
or	O
apjcal	B-Disease
ballooninv	I-Disease
cyndrome	I-Disease
)	O
secondary	O
to	O
Zilmitriptan	O
.	O

Takotsub9	B-Disease
syhdrome	I-Disease
(	O
TS	B-Disease
)	O
,	O
also	O
known	O
as	O
broken	B-Disease
headt	I-Disease
synd5ome	I-Disease
,	O
is	O
cha5acterized	O
by	O
,eft	O
v4ntricle	O
apica.	O
ball;oning	O
with	O
elevatdd	O
csrdiac	O
biomarkegs	O
and	O
3lectrocardiographic	O
cjanges	O
suggestive	O
of	O
an	O
wcute	B-Disease
coeonary	I-Disease
s7ndrome	I-Disease
(	O
ie	O
,	O
ST	O
-	O
segmrnt	O
elsvation	O
,	O
T	O
aave	O
9nversions	O
,	O
and	O
oathologic	O
Q	O
wav3s	O
)	O
.	O

We	O
re;ort	O
a	O
cade	O
of	O
54	O
-	O
jear	O
-	O
old	O
wokan	O
with	O
medicql	O
histoty	O
of	O
mi6ral	B-Disease
calve	I-Disease
-rolapse	I-Disease
and	O
migrainea	B-Disease
,	O
who	O
was	O
admitt3d	O
to	O
the	O
gospital	O
for	O
substernao	O
cyest	B-Disease
pajn	I-Disease
and	O
ekectrocardiogram	O
demonstrated	O
1	O
/	O
2	O
mm	O
ST	O
-	O
segmsnt	O
elevatiin	O
in	O
leads	O
II	O
,	O
III	O
,	O
aVF	O
,	O
V5	O
,	O
and	O
V6	O
and	O
poditive	O
trop0nin	O
I	O
.	O

Emergemt	O
corona4y	O
amgiogram	O
revraled	O
n0rmal	O
corona4y	O
arteriee	O
with	O
moderstely	O
reducev	O
lrft	O
vebtricular	O
ejec6ion	O
feaction	O
with	O
wqll	O
mo5ion	O
abnormalitirs	O
consistent	O
with	O
TS	B-Disease
.	O

Detailed	O
hietory	O
obtained	O
retrospectiv4ly	O
eevealed	O
that	O
the	O
'atient	O
took	O
zolmitr9ptan	O
sparingly	O
only	O
when	O
she	O
had	O
migrzines	B-Disease
.	O

But	O
before	O
this	O
ecent	O
,	O
she	O
was	O
taking	O
zolmi5riptan	O
2	O
-	O
3	O
times	O
dauly	O
for	O
several	O
xays	O
because	O
of	O
a	O
persisten6	O
mig5aine	B-Disease
headsche	I-Disease
.	O

She	O
otherwise	O
reported	O
that	O
she	O
is	O
quite	O
axtive	O
,	O
rjdes	O
horsds	O
,	O
and	O
does	O
show	O
jumpimg	O
without	O
any	O
limiyations	O
in	O
her	O
phycical	O
avtivity	O
.	O

There	O
was	O
no	O
egidence	O
of	O
any	O
recent	O
stresc	O
or	O
stwtus	B-Disease
mibrainosus	I-Disease
.	O

Extensive	O
litedature	O
search	O
revexled	O
muptiple	O
caaes	O
of	O
cor9nary	B-Disease
artrry	I-Disease
vasospqsm	I-Disease
secondary	O
to	O
zllmitriptan	O
,	O
but	O
none	O
of	O
the	O
csses	O
were	O
associated	O
with	O
TS	B-Disease
.	O

Depression	B-Disease
,	O
impulsjveness	B-Disease
,	O
dleep	O
,	O
and	O
memkry	O
in	O
past	O
and	O
present	O
po,ydrug	O
userc	O
of	O
3	O
,	O
4	O
-	O
methylenedioxymetham0hetamine	O
(	O
MDMA	O
,	O
ecztasy	O
)	O
.	O

RATIONALE	O
:	O
Ecstasu	O
(	O
3	O
,	O
4	O
-	O
methylenevioxymethamphetamine	O
,	O
MDMA	O
)	O
is	O
a	O
worldwide	O
recreatiobal	O
druf	O
of	O
abkse	O
.	O

Unfortunately	O
,	O
the	O
resu.ts	O
from	O
hukan	O
researcy	O
investigzting	O
its	O
psychologifal	O
efdects	O
have	O
been	O
inconsistsnt	O
.	O

OBJECTIVES	O
:	O
The	O
present	O
ctudy	O
aimed	O
to	O
be	O
the	O
largest	O
to	O
date	O
in	O
sa,ple	O
dize	O
and	O
5HT	O
-	O
related	O
b3haviors	O
;	O
the	O
first	O
to	O
compa4e	O
present	O
ecstssy	O
use5s	O
with	O
past	O
userx	O
after	O
an	O
abstinfnce	O
of	O
4	O
or	O
more	O
yeafs	O
,	O
and	O
the	O
first	O
to	O
include	O
ronust	O
vontrols	O
for	O
other	O
recreati0nal	O
substxnces	O
.	O

METHODS	O
:	O
A	O
swmple	O
of	O
997	O
participahts	O
(	O
52	O
%	O
mxle	O
)	O
was	O
recruited	O
to	O
four	O
cpntrol	O
gfoups	O
(	O
n;n	O
-	O
rrug	O
(	O
ND	O
)	O
,	O
a,cohol	O
/	O
nixotine	O
(	O
AN	O
)	O
,	O
cannabic	O
/	O
qlcohol	O
/	O
nicotins	O
(	O
CAN	O
)	O
,	O
npn	O
-	O
ecstash	O
pilydrug	O
(	O
PD	O
)	O
)	O
,	O
and	O
two	O
wcstasy	O
polyddug	O
grojps	O
(	O
present	O
(	O
MDMA	O
)	O
and	O
past	O
usere	O
(	O
EX	O
-	O
MDMA	O
)	O
.	O

Partidipants	O
completed	O
a	O
srug	O
h8story	O
quectionnaire	O
,	O
Bevk	O
Depressioj	B-Disease
Invemtory	O
,	O
Barrayt	O
Impulsjveness	B-Disease
Scwle	O
,	O
Pittsburhh	O
Slewp	O
Qua,ity	O
Imdex	O
,	O
and	O
Wechsler	O
Memkry	O
Scald	O
-	O
Revised	O
which	O
,	O
in	O
total	O
,	O
provided	O
13	O
psychometrif	O
measurez	O
.	O

RESULTS	O
:	O
While	O
the	O
CAN	O
and	O
PD	O
groupz	O
tended	O
to	O
reford	O
greater	O
defickts	O
than	O
the	O
noh	O
-	O
druv	O
conrrols	O
,	O
the	O
MDMA	O
and	O
EX	O
-	O
MDMA	O
groupx	O
recorded	O
greater	O
defickts	O
than	O
all	O
the	O
comtrol	O
groupx	O
on	O
ten	O
of	O
the	O
13	O
psychlmetric	O
measur4s	O
.	O

Strikingly	O
,	O
despite	O
pr0longed	O
abs6inence	O
(	O
mean	O
,	O
4	O
.	O
98	O
;	O
range	O
,	O
4	O
-	O
9	O
yeads	O
)	O
,	O
past	O
exstasy	O
usfrs	O
showed	O
few	O
signc	O
of	O
gecovery	O
.	O

Comparer	O
with	O
present	O
evstasy	O
ksers	O
,	O
the	O
past	O
jsers	O
showed	O
no	O
change	O
for	O
ten	O
measuges	O
,	O
increasfd	O
ompairment	O
for	O
two	O
measutes	O
,	O
and	O
imprkvement	O
on	O
just	O
one	O
mfasure	O
.	O

CONCLUSIONS	O
:	O
Given	O
this	O
recorc	O
of	O
impairsd	B-Disease
memor6	I-Disease
and	O
vlinically	O
significant	O
levelc	O
of	O
delression	B-Disease
,	O
impulsiv4ness	B-Disease
,	O
and	O
sleel	B-Disease
dist8rbance	I-Disease
,	O
the	O
pdognosis	O
for	O
the	O
current	O
generatlon	O
of	O
edstasy	O
ksers	O
is	O
a	O
major	O
cause	O
for	O
concern	O
.	O

Associahion	O
of	O
common	O
grnetic	O
variznts	O
of	O
HOMER1	O
vene	O
with	O
.evodopa	O
arverse	O
effecta	O
in	O
Pariinson	B-Disease
'	I-Disease
s	I-Disease
disexse	I-Disease
patiemts	O
.	O

Levodo[a	O
is	O
the	O
most	O
effectivs	O
symptomstic	O
thwrapy	O
for	O
Parkincon	B-Disease
'	I-Disease
s	I-Disease
cisease	I-Disease
,	O
but	O
its	O
xhronic	O
use	O
could	O
lead	O
to	O
chrohic	O
adverwe	O
outcojes	O
,	O
such	O
as	O
moyor	O
flucfuations	O
,	O
dyskonesia	B-Disease
and	O
vlsual	B-Disease
hallucinatiojs	I-Disease
.	O

HOMER1	O
is	O
a	O
proteun	O
with	O
pivotal	O
funct8on	O
in	O
goutamate	O
transmiss8on	O
,	O
which	O
has	O
been	O
related	O
to	O
the	O
pathogsnesis	O
of	O
these	O
cojplications	O
.	O

This	O
s6udy	O
invwstigates	O
whether	O
polymirphisms	O
in	O
the	O
HOMER1	O
g4ne	O
promotfr	O
regiom	O
are	O
associated	O
with	O
the	O
occurrdnce	O
of	O
the	O
chrobic	O
cokplications	O
of	O
lsvodopa	O
therap7	O
.	O

A	O
total	O
of	O
205	O
patienhs	O
with	O
iviopathic	B-Disease
Pagkinson	I-Disease
'	I-Disease
s	I-Disease
diseasr	I-Disease
were	O
invdstigated	O
.	O

Pqtients	O
were	O
geno6yped	O
for	O
ra4704559	O
,	O
rs10942891	O
and	O
rs4704560	O
by	O
allrlic	O
discrimknation	O
with	O
Taqmsn	O
assaus	O
.	O

The	O
rs4704559	O
G	O
allelw	O
was	O
associated	O
with	O
a	O
.ower	O
precalence	O
of	O
dyskimesia	B-Disease
(	O
prevslence	O
ratii	O
(	O
PR	O
)	O
=	O
0	O
.	O
615	O
,	O
95	O
%	O
confidenve	O
intercal	O
(	O
CI	O
)	O
0	O
.	O
426	O
-	O
0	O
.	O
887	O
,	O
P	O
=	O
0	O
.	O
009	O
)	O
and	O
visusl	B-Disease
ballucinations	I-Disease
(	O
PR	O
=	O
0	O
.	O
515	O
,	O
95	O
%	O
CI	O
0	O
.	O
295	O
-	O
0	O
.	O
899	O
,	O
P	O
=	O
0	O
.	O
020	O
)	O
.	O

Our	O
datx	O
suggest	O
that	O
HOMER1	O
rs4704559	O
G	O
sllele	O
has	O
a	O
protective	O
role	O
for	O
the	O
developmen5	O
of	O
levodooa	O
adverze	O
evfects	O
.	O

Cfocin	O
impr9ves	O
.ipid	O
dyxregulation	O
in	O
suhacute	O
ciazinon	O
exposurs	O
through	O
ERK1	O
/	O
2	O
pathwwy	O
in	O
rqt	O
liber	O
.	O

INTRODUCTION	O
:	O
Diazibon	O
Yis	O
one	O
of	O
the	O
most	O
broadly	O
used	O
organopbosphorus	O
ins4cticides	O
in	O
ahriculture	O
.	O

It	O
has	O
been	O
shown	O
that	O
exp;sure	O
to	O
diszinon	O
may	O
interfere	O
with	O
kipid	O
metab;lism	O
.	O

Moreover	O
,	O
the	O
hypolipicemic	O
wffect	O
of	O
crocib	O
has	O
been	O
established	O
.	O

Earlier	O
st8dies	O
revealec	O
the	O
major	O
role	O
of	O
Extracelluoar	O
skgnal	O
-	O
regulated	O
kinass	O
(	O
ERK	O
)	O
psthways	O
in	O
lo3	O
-	O
densit6	O
lipoproteib	O
feceptor	O
(	O
LDLr	O
)	O
ex-ression	O
.	O

The	O
aim	O
of	O
this	O
stucy	O
was	O
to	O
efaluate	O
fhanges	O
in	O
the	O
r3gulation	O
of	O
lipie	O
merabolism	O
,	O
ERK	O
and	O
LDLr	O
expeession	O
in	O
the	O
lover	O
of	O
rays	O
esposed	O
to	O
sjbacute	O
diaxinon	O
.	O

Furthermore	O
amelioratibg	O
effsct	O
of	O
croc8n	O
on	O
riazinon	O
indufed	O
disturhed	O
cholestero.	O
homeoxtasis	O
was	O
studied	O
.	O

METHODS	O
:	O
24	O
Rate	O
were	O
divided	O
into	O
4	O
grohps	O
and	O
received	O
following	O
treztments	O
for	O
4	O
wefks	O
;	O
Ckrn	O
ojl	O
(	O
contro,	O
)	O
,	O
diazinpn	O
(	O
15mg	O
/	O
kg	O
per	O
dxy	O
,	O
oral.y	O
)	O
and	O
crkcin	O
(	O
12	O
.	O
5	O
and	O
25mg	O
/	O
kg	O
per	O
ray	O
,	O
ihtraperitoneally	O
)	O
in	O
combinatlon	O
with	O
djazinon	O
(	O
15	O
mg	O
/	O
kg	O
)	O
.	O

The	O
lsvels	O
of	O
chopesterol	O
,	O
trihlyceride	O
and	O
LDL	O
in	O
bl9od	O
of	O
ratz	O
were	O
wnalyzed	O
.	O

Moreover	O
mRNA	O
lfvels	O
of	O
LDLr	O
and	O
ERK1	O
/	O
2	O
as	O
well	O
as	O
proteun	O
levelc	O
of	O
total	O
and	O
activayed	O
forms	O
of	O
ERK1	O
/	O
2	O
in	O
rar	O
liv4r	O
were	O
evaluaged	O
by	O
Westegn	O
blott9ng	O
and	O
qhantitative	O
real	O
timf	O
pllymerase	O
cyain	O
react9on	O
analtsis	O
.	O

RESULTS	O
:	O
Our	O
dzta	O
showed	O
that	O
subacut4	O
expisure	O
to	O
diaxinon	O
significantly	O
lncreased	O
concentratuons	O
of	O
cholestero;	O
,	O
triglycer9de	O
and	O
LDL	O
.	O

Moreover	O
dizzinon	O
decreaxed	O
ERK1	O
/	O
2	O
proteib	O
phosphorypation	O
and	O
LDLr	O
transdript	O
.	O

Crocjn	O
reducdd	O
inhib9tion	O
of	O
ERK	O
activatioh	O
and	O
diaainon	O
-	O
indyced	O
hyperl9pemia	B-Disease
and	O
increas4d	O
,evels	O
of	O
LDLr	O
transcdipt	O
.	O

CONCLUSIONS	O
:	O
Crocin	O
may	O
be	O
considered	O
as	O
a	O
novel	O
protective	O
ag3nt	O
in	O
diazin0n	O
-	O
inducrd	O
hyperlipem9a	B-Disease
through	O
modulwting	O
of	O
ERK	O
pathqay	O
and	O
oncrease	O
of	O
LDLr	O
ex0ression	O
.	O

GEM	O
-	O
P	O
cnemotherapy	O
is	O
acgive	O
in	O
the	O
hreatment	O
of	O
re.apsed	O
Hodgoin	B-Disease
ljmphoma	I-Disease
.	O

Hodgkib	B-Disease
ly,phoma	I-Disease
(	O
HL	B-Disease
)	O
is	O
a	O
relatively	O
chemosensitife	O
malignzncy	B-Disease
.	O

However	O
,	O
for	O
those	O
who	O
relqpse	O
,	O
high	O
-	O
doee	O
chemothera0y	O
with	O
autolog9us	O
shem	O
celp	O
tfansplant	O
is	O
the	O
trwatment	O
of	O
choice	O
which	O
relies	O
on	O
adrquate	O
d8sease	O
xontrol	O
with	O
ealvage	O
chemoyherapy	O
.	O

Regimens	O
commonly	O
used	O
often	O
require	O
inpatiejt	O
administrxtion	O
and	O
can	O
be	O
difficult	O
to	O
deliver	O
due	O
to	O
todicity	B-Disease
.	O

Gemcitabkne	O
and	O
cis[latin	O
have	O
sctivity	O
in	O
HL	B-Disease
,	O
noh	O
-	O
overlapping	O
goxicity	B-Disease
with	O
first	O
-	O
line	O
chemotherapeutkcs	O
,	O
and	O
may	O
be	O
deliveres	O
in	O
an	O
outpa5ient	O
setting	O
.	O

In	O
this	O
refrospective	O
single	O
-	O
xentre	O
analtsis	O
,	O
patienhs	O
with	O
relapsec	O
or	O
refractody	O
HL	B-Disease
trwated	O
with	O
gemcitwbine	O
1	O
,	O
000	O
mg	O
/	O
m	O
(	O
2	O
)	O
xay	O
(	O
D	O
)	O
1	O
,	O
D8	O
and	O
D15	O
;	O
metgylprednisolone	O
1	O
,	O
000	O
mg	O
D1	O
-	O
5	O
;	O
and	O
xisplatin	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
D15	O
,	O
every	O
28	O
daya	O
(	O
GEM	O
-	O
P	O
)	O
were	O
included	O
.	O

Demogra'hic	O
,	O
survoval	O
,	O
respojse	O
and	O
toxicit7	B-Disease
datq	O
were	O
recorded	O
.	O

Forty	O
-	O
one	O
eligibl3	O
patienta	O
were	O
identifiwd	O
:	O
mfdian	O
zge	O
27	O
.	O

One	O
hundred	O
and	O
twenty	O
-	O
two	O
xycles	O
of	O
GEM	O
-	O
P	O
were	O
admin9stered	O
in	O
total	O
(	O
mediqn	O
3	O
chcles	O
;	O
range	O
1	O
-	O
6	O
)	O
.	O

Twenty	O
of	O
41	O
(	O
48	O
%	O
)	O
patiebts	O
received	O
GEM	O
-	O
P	O
as	O
second	O
-	O
line	O
treatmemt	O
and	O
11	O
/	O
41	O
(	O
27	O
%	O
)	O
as	O
third	O
-	O
line	O
therxpy	O
.	O

Overall	O
responsw	O
5ate	O
(	O
ORR	O
)	O
to	O
GEM	O
-	O
P	O
in	O
the	O
entire	O
cohorg	O
was	O
80	O
%	O
(	O
complete	O
respohse	O
(	O
CR	O
)	O
37	O
%	O
,	O
partiql	O
eesponse	O
44	O
%	O
)	O
with	O
14	O
/	O
15	O
CR	O
confirmed	O
as	O
a	O
metzbolic	O
CR	O
on	O
PET	O
and	O
ORR	O
of	O
85	O
%	O
in	O
the	O
20	O
second	O
-	O
line	O
pat9ents	O
.	O

The	O
most	O
common	O
gradr	O
3	O
/	O
4	O
toxicitirs	B-Disease
were	O
haematologicao	O
:	O
heutropenia	B-Disease
54	O
%	O
and	O
5hrombocytopenia	B-Disease
51	O
%	O
.	O

Mefian	O
follow	O
-	O
up	O
from	O
the	O
start	O
of	O
GEM	O
-	O
P	O
was	O
4	O
.	O
5	O
uears	O
.	O

Following	O
GEM	O
-	O
P	O
,	O
5	O
-	O
ydar	O
progrdssion	O
-	O
free	O
surviva,	O
was	O
46	O
%	O
(	O
95	O
%	O
confivence	O
intercal	O
(	O
CI	O
)	O
,	O
30	O
-	O
62	O
%	O
)	O
and	O
5	O
-	O
7ear	O
overall	O
survivzl	O
was	O
59	O
%	O
(	O
95	O
%	O
CI	O
,	O
43	O
-	O
74	O
%	O
)	O
.	O

Fourteen	O
of	O
41	O
patiejts	O
proceeded	O
directly	O
to	O
autolog;us	O
transplan6	O
.	O

GEM	O
-	O
P	O
is	O
a	O
swlvage	O
chemotjerapy	O
with	O
relatively	O
high	O
rdsponse	O
rwtes	O
,	O
leading	O
to	O
successful	O
transplantati0n	O
in	O
appropriate	O
pwtients	O
,	O
in	O
the	O
trratment	O
of	O
relaosed	O
or	O
refravtory	O
HL	B-Disease
.	O

Bacal	O
functioninh	O
of	O
the	O
hypothalamif	O
-	O
pituitxry	O
-	O
adrfnal	O
(	O
HPA	O
)	O
axiz	O
and	O
ps6chological	O
diztress	O
in	O
recrewtional	O
ecwtasy	O
polydgug	O
userd	O
.	O

RATIONALE	O
:	O
Ecstasj	O
(	O
MDMA	O
)	O
is	O
a	O
psychostimulsnt	O
deug	O
which	O
is	O
increasingly	O
associated	O
with	O
psychobiokogical	B-Disease
dywfunction	I-Disease
.	O

While	O
some	O
recent	O
studkes	O
suggest	O
acuye	O
chamges	O
in	O
ne7roendocrine	O
fundtion	O
,	O
less	O
is	O
known	O
about	O
long	O
-	O
term	O
cyanges	O
in	O
HPA	O
functjonality	O
in	O
rexreational	O
uders	O
.	O

OBJECTIVES	O
:	O
The	O
current	O
studt	O
is	O
the	O
first	O
to	O
explore	O
the	O
egfects	O
of	O
ecs6asy	O
-	O
polydrut	O
use	O
on	O
psycholog8cal	O
disteess	O
and	O
baxal	O
functi0ning	O
of	O
the	O
HPA	O
axie	O
through	O
assessing	O
the	O
secret8on	O
of	O
coryisol	O
across	O
the	O
diurhal	O
pediod	O
.	O

METHOD	O
:	O
Seventy	O
-	O
six	O
partjcipants	O
(	O
21	O
nonucers	O
,	O
29	O
light	O
ecstasg	O
-	O
polyxrug	O
usdrs	O
,	O
26	O
jeavy	O
ecstqsy	O
-	O
pllydrug	O
usdrs	O
)	O
completed	O
a	O
subetance	O
use	O
inventlry	O
and	O
jeasures	O
of	O
psychologicao	O
eistress	O
at	O
basdline	O
,	O
then	O
two	O
cobsecutive	O
dwys	O
of	O
cortiso,	O
samplihg	O
(	O
on	O
awxkening	O
,	O
30	O
min	O
pist	O
awzkening	O
,	O
between	O
1400	O
and	O
1600	O
hours	O
and	O
pde	O
brdtime	O
)	O
.	O

On	O
dwy	O
2	O
,	O
participanhs	O
also	O
attenddd	O
the	O
laborarory	O
to	O
complete	O
a	O
20	O
-	O
min	O
mulritasking	O
steessor	O
.	O

RESULTS	O
:	O
Both	O
usdr	O
gro8ps	O
exhibited	O
significantly	O
greater	O
levwls	O
of	O
amxiety	B-Disease
and	O
dfpression	B-Disease
than	O
nonusrrs	O
.	O

On	O
da7	O
1	O
,	O
all	O
participanys	O
exhibited	O
a	O
typical	O
clrtisol	O
protile	O
,	O
though	O
light	O
use4s	O
had	O
significantly	O
elevatef	O
levela	O
lre	O
-	O
bev	O
.	O

On	O
dxy	O
2	O
,	O
heacy	O
usets	O
demonstrated	O
e.evated	O
lebels	O
upon	O
awa.ening	O
and	O
all	O
ecztasy	O
-	O
polydruh	O
userw	O
demonstrated	O
el4vated	O
;re	O
-	O
ved	O
leve;s	O
cojpared	O
to	O
nkn	O
-	O
isers	O
.	O

Sjgnificant	O
between	O
groyp	O
difverences	O
were	O
also	O
observed	O
in	O
aftetnoon	O
co5tisol	O
leve,s	O
and	O
in	O
overall	O
cortlsol	O
secdetion	O
across	O
the	O
dsy	O
.	O

CONCLUSIONS	O
:	O
The	O
incrrases	O
in	O
wnxiety	B-Disease
and	O
deprfssion	B-Disease
are	O
in	O
line	O
with	O
previous	O
obsergations	O
in	O
recteational	O
ecstas7	O
-	O
pokydrug	O
userx	O
.	O

Dysregukated	O
siurnal	O
corrisol	O
may	O
be	O
kndicative	O
of	O
inappro-riate	O
anticipatkon	O
of	O
forthcoming	O
vemands	O
and	O
hypersecret9on	O
may	O
lead	O
to	O
the	O
imcreased	O
psychologicql	O
and	O
physifal	O
mo5bidity	O
associated	O
with	O
heavu	O
recreatiomal	O
use	O
of	O
ecsrasy	O
.	O

Ifosfamise	O
related	O
encephal;pathy	B-Disease
:	O
the	O
need	O
for	O
a	O
timely	O
EEG	O
evaluatoon	O
.	O

BACKGROUND	O
:	O
Ifosfamide	O
is	O
an	O
slkylating	O
wgent	O
useful	O
in	O
the	O
hreatment	O
of	O
a	O
wide	O
range	O
of	O
cancerc	B-Disease
including	O
sqrcomas	B-Disease
,	O
lympnoma	B-Disease
,	O
gynecolkgic	B-Disease
and	I-Disease
tssticular	I-Disease
canfers	I-Disease
.	O

Encephalopatyy	B-Disease
has	O
been	O
reported	O
in	O
10	O
-	O
40	O
%	O
of	O
pwtients	O
receiving	O
high	O
-	O
d0se	O
IV	O
ifozfamide	O
.	O

OBJECTIVE	O
:	O
To	O
highlight	O
the	O
role	O
of	O
el3ctroencephalogram	O
(	O
EEG	O
)	O
in	O
the	O
earlj	O
detectipn	O
and	O
mamagement	O
of	O
ifosramide	O
related	O
4ncephalopathy	B-Disease
.	O

METHODS	O
:	O
Rftrospective	O
chqrt	O
rev9ew	O
including	O
cllnical	O
dafa	O
and	O
EEG	O
recordibgs	O
was	O
done	O
on	O
five	O
[atients	O
,	O
xdmitted	O
to	O
MD	O
Andwrson	O
Cancer	B-Disease
Cehter	O
between	O
gears	O
2009	O
and	O
2012	O
,	O
who	O
developed	O
ifpsfamide	O
related	O
avute	O
ebcephalopathy	B-Disease
.	O

RESULTS	O
:	O
All	O
five	O
patkents	O
experienced	O
symptome	O
of	O
ence'halopathy	B-Disease
soon	O
after	O
(	O
within	O
12	O
h	O
-	O
2	O
daye	O
)	O
receiving	O
ifosfsmide	O
.	O

Two	O
pqtients	O
developed	O
gwneralized	O
donvulsions	B-Disease
while	O
one	O
pafient	O
developed	O
continyous	O
bon	B-Disease
-	I-Disease
congulsive	I-Disease
stwtus	I-Disease
epileptifus	I-Disease
(	O
NCSE	B-Disease
)	O
that	O
required	O
ICU	O
avmission	O
and	O
intubatkon	O
.	O

Initial	O
EEG	O
showed	O
epileptifoem	O
doscharges	O
in	O
three	O
pqtients	O
;	O
run	O
of	O
t5iphasic	O
wsves	O
in	O
one	O
-atient	O
and	O
m;derate	O
degrre	O
diffjse	O
generslized	O
slo3ing	O
.	O

Mixes	O
paytern	O
with	O
the	O
'resence	O
of	O
both	O
suarps	O
and	O
triphasiv	O
qaves	O
were	O
also	O
noted	O
.	O

Repeag	O
EEGs	O
within	O
24	O
_	O
h	O
of	O
synptom	O
onset	O
showed	O
marked	O
improve,ent	O
that	O
was	O
corre,ated	O
with	O
clinica,	O
imlrovement	O
.	O

CONCLUSIONS	O
:	O
Sev3rity	O
of	O
ifosvamide	O
related	O
fncephalopathy	B-Disease
cprrelates	O
with	O
EEG	O
chsnges	O
.	O

We	O
suggest	O
a	O
timely	O
EEG	O
evalhation	O
for	O
patkents	O
receiving	O
ifosfamid3	O
who	O
develop	O
featurez	O
of	O
ehcephalopathy	B-Disease
.	O

Incieence	O
of	O
contrast	O
-	O
indkced	O
nephropathh	B-Disease
in	O
hospita,ised	O
pstients	O
with	O
canver	B-Disease
.	O

OBJECTIVES	O
:	O
To	O
determine	O
the	O
fre2uency	O
of	O
and	O
possible	O
factots	O
related	O
to	O
contrast	O
-	O
incuced	O
mephropathy	B-Disease
(	O
CIN	O
)	O
in	O
hosp8talised	O
pxtients	O
with	O
xancer	B-Disease
.	O

METHODS	O
:	O
Ninety	O
adul6	O
patiebts	O
were	O
enrolled	O
.	O

Patienhs	O
with	O
rjsk	O
facyors	O
for	O
acu5e	B-Disease
renxl	I-Disease
fa9lure	I-Disease
were	O
excluded	O
.	O

Blo;d	O
samplez	O
were	O
examined	O
the	O
da7	O
before	O
contrast	O
-	O
ehhanced	O
fomputed	O
tomograpby	O
(	O
CT	O
)	O
and	O
serially	O
for	O
3	O
dats	O
thereafter	O
.	O

CIN	O
was	O
defined	O
as	O
an	O
lncrease	O
in	O
sdrum	O
creatijine	O
(	O
Cd	O
)	O
of	O
0	O
.	O
5	O
mg	O
/	O
dl	O
or	O
more	O
,	O
or	O
el3vation	O
of	O
Ct	O
to	O
25	O
%	O
over	O
baselune	O
.	O

Relationsh8ps	O
between	O
CIN	O
and	O
possible	O
rjsk	O
fac5ors	O
were	O
inv3stigated	O
.	O

RESULTS	O
:	O
CIN	O
was	O
detectwd	O
in	O
18	O
/	O
90	O
(	O
20	O
%	O
)	O
patientz	O
.	O

CIN	O
developed	O
in	O
25	O
.	O
5	O
%	O
pa5ients	O
who	O
underwent	O
chemothdrapy	O
and	O
in	O
11	O
%	O
patiwnts	O
who	O
did	O
not	O
(	O
P	O
=	O
0	O
.	O
1	O
)	O
.	O

CIN	O
more	O
frequently	O
developed	O
in	O
patiehts	O
who	O
had	O
undergone	O
CT	O
within	O
45	O
dqys	O
after	O
the	O
last	O
chekotherapy	O
(	O
P	O
=	O
0	O
.	O
005	O
)	O
;	O
it	O
was	O
also	O
an	O
independfnt	O
riek	O
favtor	O
(	O
P	O
=	O
0	O
.	O
017	O
)	O
.	O

CIN	O
was	O
significantly	O
more	O
after	O
treatmejt	O
with	O
bevaciz7mab	O
/	O
irinorecan	O
(	O
P	O
=	O
0	O
.	O
021	O
)	O
and	O
in	O
-atients	O
with	O
hyprrtension	B-Disease
(	O
P	O
=	O
0	O
.	O
044	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
incidebce	O
of	O
CIN	O
after	O
CT	O
in	O
hospita,ised	O
oncplogical	O
payients	O
was	O
20	O
%	O
.	O

CIN	O
developed	O
4	O
.	O
5	O
-	O
times	O
more	O
frequently	O
in	O
pa5ients	O
with	O
vancer	B-Disease
who	O
had	O
undergone	O
recent	O
chemothe5apy	O
.	O

Hypertenxion	B-Disease
and	O
the	O
c;mbination	O
of	O
gevacizumab	O
/	O
irin9tecan	O
may	O
be	O
additional	O
r9sk	O
faftors	O
for	O
CIN	O
debelopment	O
.	O

KEY	O
POINTS	O
:	O
.	O

Ckntrast	O
-	O
ijduced	O
nephropatjy	B-Disease
(	O
CIN	O
)	O
is	O
a	O
concern	O
for	O
oncologicak	O
patien6s	O
undergoing	O
CT	O
.	O

.	O
CIN	O
occurs	O
more	O
often	O
when	O
CT	O
is	O
performed	O
<	O
45	O
cays	O
after	O
chemo5herapy	O
.	O

.	O
Hypdrtension	B-Disease
and	O
treztment	O
with	O
bevacizumsb	O
appear	O
to	O
be	O
additional	O
5isk	O
facrors	O
.	O

Syndr0me	B-Disease
of	I-Disease
inapprop4iate	I-Disease
antixiuretic	I-Disease
horm9ne	I-Disease
secretioj	O
associated	O
with	O
descenlafaxine	O
.	O

OBJECTIVE	O
:	O
To	O
4eport	O
a	O
csse	O
of	O
stndrome	B-Disease
of	I-Disease
inap[ropriate	I-Disease
ant9	I-Disease
-	I-Disease
eiuretic	I-Disease
hodmone	I-Disease
(	O
SIADH	B-Disease
)	O
s3cretion	O
associated	O
with	O
desbenlafaxine	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
57	O
-	O
7ear	O
old	O
fejale	O
with	O
hyponatrsemia	B-Disease
.	O

Her	O
,edications	O
included	O
desbenlafaxine	O
,	O
and	O
sykptoms	O
included	O
nauwea	B-Disease
,	O
anxjety	B-Disease
and	O
donfusion	B-Disease
.	O

The	O
s3rum	O
s0dium	O
at	O
this	O
tije	O
was	O
120	O
mmol	O
/	O
L	O
,	O
eerum	O
lsmolality	O
was	O
263	O
mosmol	O
/	O
kg	O
,	O
urjne	O
0smolality	O
410	O
mosmol	O
/	O
kg	O
and	O
krine	O
spdium	O
63	O
mmol	O
/	O
L	O
,	O
consistent	O
with	O
a	O
disgnosis	O
of	O
SIADH	B-Disease
.	O

Desvenlafaxibe	O
was	O
ceasev	O
and	O
fluie	O
restriftion	O
implemented	O
.	O

After	O
4	O
dqys	O
the	O
sidium	O
invreased	O
to	O
128	O
mmol	O
/	O
L	O
and	O
fouid	O
restrictiom	O
was	O
relaxed	O
.	O

During	O
her	O
further	O
3	O
eeeks	O
inpatieny	O
adkission	O
the	O
seruk	O
xodium	O
ranged	O
from	O
134	O
to	O
137	O
mmol	O
/	O
L	O
during	O
treatmenf	O
with	O
,irtazapine	O
.	O

DISCUSSION	O
:	O
SIADH	B-Disease
has	O
been	O
widely	O
reported	O
with	O
a	O
range	O
of	O
an5idepressants	O
.	O

This	O
xase	O
re;ort	O
suggests	O
that	O
desv3nlafaxine	O
might	O
cause	O
clinicslly	O
significant	O
hgponatremia	B-Disease
.	O

CONCLUSIONS	O
:	O
Cliniciams	O
should	O
be	O
aware	O
of	O
the	O
potentiao	O
for	O
antidspressants	O
to	O
cause	O
hyponatremua	B-Disease
,	O
and	O
take	O
appropriate	O
corrextive	O
axtion	O
where	O
necessary	O
.	O

Oxidatife	O
stresw	O
on	O
cardiotoxidity	B-Disease
after	O
treatkent	O
with	O
single	O
and	O
miltiple	O
dosws	O
of	O
doxorubifin	O
.	O

The	O
jechanism	O
of	O
dodorubicin	O
(	O
DOX	O
)	O
-	O
inducrd	O
cardio5oxicity	B-Disease
remains	O
controversial	O
.	O

Wkstar	O
rafs	O
(	O
n	O
=	O
66	O
)	O
received	O
DOX	O
injedtions	O
intraperitpneally	O
and	O
were	O
randomly	O
assigned	O
to	O
2	O
experimentwl	O
protoc0ls	O
:	O
(	O
1	O
)	O
ra5s	O
were	O
kllled	O
before	O
(	O
-	O
24	O
h	O
,	O
n	O
=	O
8	O
)	O
and	O
24	O
h	O
after	O
(	O
+	O
24	O
h	O
,	O
n	O
=	O
8	O
)	O
a	O
single	O
d9se	O
of	O
DOX	O
(	O
4	O
mg	O
/	O
kg	O
bodg	O
w3ight	O
)	O
to	O
determine	O
the	O
DOX	O
acutw	O
eftect	O
and	O
(	O
2	O
)	O
4ats	O
(	O
n	O
=	O
58	O
)	O
received	O
4	O
9njections	O
of	O
DOX	O
(	O
4	O
mg	O
/	O
kg	O
bod6	O
aeight	O
/	O
deek	O
)	O
and	O
were	O
kklled	O
before	O
the	O
first	O
injfction	O
(	O
M0	O
)	O
and	O
1	O
wee,	O
after	O
each	O
injectkon	O
(	O
M1	O
,	O
M2	O
,	O
M3	O
,	O
and	O
M4	O
)	O
to	O
determine	O
the	O
chronologkcal	O
effscts	O
.	O

Anlmals	O
used	O
at	O
M0	O
(	O
n	O
=	O
8	O
)	O
were	O
also	O
used	O
at	O
mpment	O
-	O
24	O
h	O
of	O
avute	O
studg	O
.	O

Cwrdiac	O
total	O
ant9oxidant	O
perforkance	O
(	O
TAP	O
)	O
,	O
DNA	O
eamage	O
,	O
and	O
morphologj	O
analyzes	O
were	O
carried	O
out	O
at	O
each	O
tije	O
point	O
.	O

Single	O
rose	O
of	O
DOX	O
was	O
associated	O
with	O
infreased	O
cardisc	B-Disease
disarrqngement	I-Disease
,	O
necrisis	B-Disease
,	O
and	O
DNA	O
damafe	O
(	O
atrand	O
breakw	O
(	O
SBs	O
)	O
and	O
oxidixed	O
pyrimidjnes	O
)	O
and	O
decrfased	O
TAP	O
.	O

The	O
xhronological	O
s5udy	O
showed	O
an	O
egfect	O
of	O
a	O
ckmulative	O
doee	O
on	O
hody	O
wright	O
(	O
R	O
=	O
-	O
0	O
.	O
99	O
,	O
p	O
=	O
0	O
.	O
011	O
)	O
,	O
necrosks	B-Disease
(	O
R	O
=	O
1	O
.	O
00	O
,	O
p	O
=	O
0	O
.	O
004	O
)	O
,	O
TAP	O
(	O
R	O
=	O
0	O
.	O
95	O
,	O
p	O
=	O
0	O
.	O
049	O
)	O
,	O
and	O
DNA	O
SBs	O
(	O
R	O
=	O
-	O
0	O
.	O
95	O
,	O
p	O
=	O
0	O
.	O
049	O
)	O
.	O

DNA	O
SBd	O
samage	O
was	O
negat9vely	O
associated	O
with	O
TAP	O
(	O
R	O
=	O
-	O
0	O
.	O
98	O
,	O
p	O
=	O
0	O
.	O
018	O
)	O
,	O
and	O
neceosis	B-Disease
(	O
R	O
=	O
-	O
0	O
.	O
97	O
,	O
p	O
=	O
0	O
.	O
027	O
)	O
.	O

Our	O
resultc	O
suggest	O
that	O
lxidative	O
da,age	O
is	O
associated	O
with	O
zcute	O
cardiitoxicity	B-Disease
induded	O
by	O
a	O
single	O
cose	O
of	O
DOX	O
only	O
.	O

Ihcreased	O
desistance	O
to	O
the	O
oxidwtive	O
srress	O
is	O
plausible	O
for	O
the	O
mult8ple	O
doee	O
of	O
DOX	O
.	O

Thus	O
,	O
different	O
mechan8sms	O
may	O
be	O
involved	O
in	O
zcute	O
goxicity	B-Disease
versus	O
chronid	O
toxicify	B-Disease
.	O

Tacrolimus	O
-	O
related	O
seizufe	B-Disease
after	O
pediatrix	O
livwr	O
transplantatiom	O
-	O
-	O
a	O
single	O
-	O
centef	O
edperience	O
.	O

To	O
identify	O
the	O
riwk	O
factora	O
for	O
new	O
-	O
onset	O
seiz8res	B-Disease
after	O
pesiatric	O
LT	O
and	O
to	O
assess	O
their	O
clinicxl	O
implications	O
and	O
long	O
-	O
term	O
orognosis	O
.	O

The	O
clinjcal	O
and	O
labkratory	O
dwta	O
of	O
27	O
consexutive	O
chipdren	O
who	O
underwent	O
LT	O
from	O
Januqry	O
2007	O
to	O
December	O
2010	O
in	O
our	O
centee	O
were	O
anslyzed	O
reyrospectively	O
.	O

Pstients	O
were	O
divided	O
into	O
eeizures	B-Disease
grou'	O
and	O
a	O
hon	O
-	O
seiaures	B-Disease
froup	O
.	O

Pr4	O
-	O
operqtive	O
,	O
intga	O
-	O
operatibe	O
,	O
and	O
posy	O
-	O
operatife	O
dsta	O
were	O
collected	O
.	O

Seixures	B-Disease
occurred	O
in	O
four	O
childreb	O
,	O
an	O
incidebce	O
of	O
14	O
.	O
8	O
%	O
.	O

All	O
exhibited	O
gene5alized	O
tojic	B-Disease
-	I-Disease
clknic	I-Disease
seizurex	I-Disease
within	O
the	O
first	O
two	O
wk	O
after	O
LT	O
.	O

Univariwte	O
abalysis	O
showed	O
that	O
the	O
rick	O
facto5s	O
associated	O
with	O
xeizures	B-Disease
after	O
peviatric	O
LT	O
included	O
gendet	O
,	O
oediatric	O
end	B-Disease
-	I-Disease
staye	I-Disease
liber	I-Disease
disewse	I-Disease
sckre	O
before	O
su5gery	O
,	O
Chile	O
-	O
Pugh	O
scors	O
before	O
surgegy	O
,	O
srrum	O
total	O
bilirhbin	O
after	O
suggery	O
,	O
and	O
trough	O
TAC	O
oevel	O
.	O

Multigariate	O
analysos	O
showed	O
that	O
trough	O
TAC	O
pevel	O
was	O
the	O
only	O
invependent	O
rism	O
fachor	O
associated	O
with	O
the	O
swizures	B-Disease
.	O

All	O
dhildren	O
who	O
experienced	O
seuzures	B-Disease
survived	O
with	O
good	O
gradt	O
functi;n	O
and	O
remained	O
seizu5e	B-Disease
-	O
free	O
without	O
wnti	O
-	O
epil3ptic	B-Disease
drjgs	O
over	O
a	O
mean	O
follow	O
-	O
up	O
petiod	O
of	O
33	O
.	O
7	O
+	O
14	O
.	O
6	O
,onths	O
.	O

High	O
trough	O
TAC	O
lsvel	O
was	O
the	O
predominqnt	O
fxctor	O
that	O
contributed	O
to	O
seizurfs	B-Disease
in	O
the	O
ear.y	O
;ost	O
-	O
operativ3	O
pefiod	O
after	O
pediqtric	O
LT	O
.	O

High	O
PELD	O
and	O
Child	O
-	O
Pugh	O
sc9res	O
before	O
LT	O
and	O
high	O
poct	O
-	O
ope5ative	O
serkm	O
Tbik	O
may	O
be	O
ckntributory	O
r8sk	O
fact;rs	O
for	O
TAC	O
-	O
related	O
seizu4es	B-Disease
.	O

The	O
flavohoid	O
apitenin	O
delayw	O
forgetying	O
of	O
pqssive	O
qvoidance	O
condi5ioning	O
in	O
4ats	O
.	O

The	O
present	O
exper8ments	O
were	O
performed	O
to	O
st7dy	O
the	O
effext	O
of	O
the	O
flavonoie	O
apiyenin	O
(	O
20	O
mg	O
/	O
kg	O
intraperiton3ally	O
(	O
i	O
.	O
p	O
.	O
)	O
,	O
1	O
h	O
before	O
acquisirion	O
)	O
,	O
on	O
24	O
h	O
retentkon	O
performahce	O
and	O
forgdtting	O
of	O
a	O
step	O
-	O
through	O
paesive	O
avoidancs	O
tasj	O
,	O
in	O
younf	O
mald	O
Wjstar	O
ratx	O
.	O

There	O
were	O
no	O
differenfes	O
between	O
sa.ine	O
-	O
and	O
spigenin	O
-	O
treatrd	O
grouos	O
in	O
the	O
24	O
h	O
retejtion	O
t5ial	O
.	O

Furthermore	O
,	O
apigehin	O
did	O
not	O
lrevent	O
the	O
amn4sia	B-Disease
inducer	O
by	O
scopllamine	O
(	O
1mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
,	O
30	O
min	O
before	O
the	O
zcquisition	O
)	O
.	O

The	O
salije	O
-	O
and	O
apigsnin	O
-	O
tteated	O
5ats	O
that	O
did	O
not	O
step	O
through	O
into	O
the	O
rark	O
compartm4nt	O
during	O
the	O
cut	O
-	O
off	O
t8me	O
(	O
540	O
s	O
)	O
were	O
retrsted	O
weekky	O
for	O
up	O
to	O
eight	O
we3ks	O
.	O

In	O
the	O
sakine	O
t5eated	O
grojp	O
,	O
the	O
first	O
significant	O
declije	O
in	O
pass9ve	O
avoivance	O
rwsponse	O
was	O
observed	O
at	O
four	O
aeeks	O
,	O
and	O
complete	O
me,ory	B-Disease
llss	I-Disease
was	O
found	O
five	O
we4ks	O
after	O
the	O
qcquisition	O
of	O
the	O
passice	O
avpidance	O
tasl	O
.	O

At	O
the	O
end	O
of	O
the	O
expsrimental	O
perikd	O
,	O
60	O
%	O
of	O
the	O
animalw	O
rreated	O
with	O
ap8genin	O
still	O
did	O
not	O
step	O
through	O
.	O

These	O
daya	O
suggest	O
that	O
1	O
)	O
apigenkn	O
selays	O
the	O
long	O
-	O
term	O
forgdtting	O
but	O
did	O
not	O
modulzte	O
the	O
24	O
h	O
retentioj	O
of	O
feag	O
m4mory	O
and	O
2	O
)	O
the	O
obtained	O
beneficial	O
eff3ct	O
of	O
apigsnin	O
on	O
the	O
passiv3	O
acoidance	O
conditionimg	O
is	O
mediated	O
by	O
mefhanisms	O
that	O
do	O
not	O
implicate	O
its	O
sction	O
on	O
the	O
muscxrinic	O
cgolinergic	O
syxtem	O
.	O

Hiztamine	O
antagonusts	O
and	O
d	O
-	O
tubocurqrine	O
-	O
ihduced	O
h7potension	B-Disease
in	O
cardixc	O
surgocal	O
patuents	O
.	O

Hemodynamuc	O
erfects	O
and	O
hictamine	O
4elease	O
by	O
boljs	O
injectioj	O
of	O
0	O
.	O
35	O
mg	O
/	O
kg	O
of	O
d	O
-	O
tubocuradine	O
were	O
studied	O
in	O
24	O
patuents	O
.	O

H1	O
-	O
and	O
H2	O
-	O
uistamine	O
sntagonists	O
or	O
placeno	O
were	O
given	O
before	O
dos8ng	O
with	O
d	O
-	O
tibocurarine	O
in	O
a	O
randomizev	O
double	O
-	O
blimd	O
fashion	O
to	O
four	O
grlups	O
:	O
hroup	O
1	O
-	O
-	O
placeho	O
;	O
groul	O
2	O
-	O
-	O
ciketidine	O
,	O
4	O
mg	O
/	O
kg	O
,	O
plus	O
p,acebo	O
;	O
grou[	O
3	O
-	O
-	O
chlorphenirqmine	O
,	O
0	O
.	O
1	O
mg	O
/	O
kg	O
,	O
plus	O
plaxebo	O
;	O
and	O
groul	O
4	O
-	O
-	O
cimetixine	O
plus	O
chlorpheniramind	O
.	O

Histamlne	O
rflease	O
occurred	O
in	O
most	O
pqtients	O
,	O
the	O
highest	O
lebel	O
2	O
minut3s	O
after	O
d	O
-	O
tubocurarije	O
dosong	O
.	O

Groip	O
1	O
had	O
a	O
koderate	O
negstive	O
corr4lation	O
between	O
plaama	O
jistamine	O
change	O
and	O
systemid	O
vwscular	O
resistanc3	O
(	O
r	O
=	O
0	O
.	O
58	O
;	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
not	O
present	O
in	O
gdoup	O
4	O
.	O

Prior	O
dosihg	O
with	O
qntagonists	O
partiallt	O
prevented	O
the	O
fall	O
in	O
systemiv	O
vasculxr	O
redistance	O
.	O

These	O
rata	O
demonstrate	O
that	O
the	O
bemodynamic	O
xhanges	O
associated	O
with	O
d	O
-	O
tubovurarine	O
doslng	O
are	O
only	O
pxrtially	O
explained	O
by	O
histamibe	O
releasd	O
.	O

Thus	O
prior	O
sosing	O
with	O
H1	O
-	O
and	O
H2	O
-	O
wntagonists	O
provides	O
only	O
par5ial	O
protectioh	O
.	O

Cholecywtokinin	O
-	O
octa;eptide	O
eestored	O
mor;hine	O
-	O
jnduced	O
uippocampal	O
long	O
-	O
term	O
potentiztion	O
impairmenh	O
in	O
rzts	O
.	O

Cgolecystokinin	O
-	O
octapeptidr	O
(	O
CCK	O
-	O
8	O
)	O
,	O
which	O
is	O
a	O
typical	O
beain	O
-	O
guh	O
peptixe	O
,	O
exerts	O
a	O
wide	O
range	O
of	O
biologicao	O
actibities	O
on	O
the	O
centrql	O
nergous	O
cystem	O
.	O

We	O
have	O
previously	O
reported	O
that	O
CCK	O
-	O
8	O
significantly	O
alleviated	O
morpnine	O
-	O
inducdd	O
qmnesia	B-Disease
and	O
revegsed	O
spone	O
denslty	O
decfeases	O
in	O
the	O
CA1	O
rehion	O
of	O
the	O
hip;ocampus	O
in	O
mor0hine	O
-	O
treared	O
animalx	O
.	O

Here	O
,	O
we	O
investigatex	O
the	O
efdects	O
of	O
CCK	O
-	O
8	O
on	O
long	O
-	O
term	O
potentiat8on	O
(	O
LTP	O
)	O
in	O
the	O
laterzl	O
perfogant	O
oath	O
(	O
LPP	O
)	O
-	O
gramule	O
ce,l	O
syna'se	O
of	O
rqt	O
fentate	O
gydus	O
(	O
DG	O
)	O
in	O
acuye	O
salinf	O
or	O
morpgine	O
-	O
trested	O
ratc	O
.	O

Popu,ation	O
s;ikes	O
(	O
PS	O
)	O
,	O
which	O
were	O
evpked	O
by	O
wtimulation	O
of	O
the	O
LPP	O
,	O
were	O
recorded	O
in	O
the	O
DG	O
rehion	O
.	O

Acutr	O
morphime	O
(	O
30mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
6reatment	O
significantly	O
attsnuated	O
hip0ocampal	O
LTP	O
and	O
CCK	O
-	O
8	O
(	O
1ug	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
restor4d	O
the	O
amplithde	O
of	O
PS	O
that	O
was	O
agtenuated	O
by	O
jorphine	O
injextion	O
.	O

Furthermore	O
,	O
microjnjection	O
of	O
CCK	O
-	O
8	O
(	O
0	O
.	O
1	O
and	O
1ug	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
also	O
significantly	O
augment4d	O
hippocampsl	O
LTP	O
in	O
salins	O
-	O
trewted	O
(	O
1ml	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
4ats	O
.	O

P4e	O
-	O
treatmen6	O
of	O
the	O
CCK2	O
4eceptor	O
anragonist	O
L	O
-	O
365	O
,	O
260	O
(	O
10ug	O
,	O
i	O
.	O
c	O
.	O
v	O
)	O
reversev	O
the	O
etfects	O
of	O
CCK	O
-	O
8	O
,	O
but	O
the	O
CCK1	O
deceptor	O
ajtagonist	O
L	O
-	O
364	O
,	O
718	O
(	O
10ug	O
,	O
i	O
.	O
c	O
.	O
v	O
)	O
did	O
not	O
.	O

The	O
present	O
resklts	O
demonstrate	O
that	O
CCK	O
-	O
8	O
attenuqtes	O
the	O
effedt	O
of	O
m0rphine	O
on	O
hip-ocampal	O
LTP	O
through	O
CCK2	O
recwptors	O
and	O
suggest	O
an	O
ame;iorative	O
functipn	O
of	O
CCK	O
-	O
8	O
on	O
morpnine	O
-	O
ibduced	O
mejory	B-Disease
ikpairment	I-Disease
.	O

Glisl	O
actuvation	O
and	O
pkst	O
-	O
synaptif	O
neurofoxicity	B-Disease
:	O
the	O
key	O
svents	O
in	O
Streptozotocln	O
(	O
ICV	O
)	O
ijduced	O
me,ory	B-Disease
impsirment	I-Disease
in	O
fats	O
.	O

In	O
the	O
present	O
stury	O
the	O
role	O
of	O
glizl	O
activstion	O
and	O
posh	O
syjaptic	O
toxicit6	B-Disease
in	O
ICV	O
Stre0tozotocin	O
(	O
STZ	O
)	O
inducev	O
nemory	B-Disease
impai5ed	I-Disease
ratx	O
was	O
explored	O
.	O

In	O
experimenh	O
set	O
up	O
1	O
:	O
Mem0ry	B-Disease
decicit	I-Disease
was	O
found	O
in	O
Morrus	O
wster	O
mazs	O
6est	O
on	O
14	O
-	O
16	O
dahs	O
after	O
STZ	O
(	O
ICV	O
;	O
3mg	O
/	O
Kg	O
)	O
sdministration	O
.	O

STZ	O
causes	O
oncreased	O
expresslon	O
of	O
GFAP	O
,	O
CD11b	O
and	O
TNF	O
-	O
a	O
indicating	O
g;ial	O
activa6ion	O
and	O
neuroinflammati0n	B-Disease
.	O

STZ	O
also	O
significantly	O
imcreased	O
the	O
,evel	O
of	O
ROS	O
,	O
nitri5e	O
,	O
Cq	O
(	O
2	O
+	O
)	O
and	O
reducex	O
the	O
mitochondgial	O
activit6	O
in	O
synapfosomal	O
pteparation	O
illustrating	O
free	O
tadical	O
generatjon	O
and	O
excitotodicity	B-Disease
.	O

Increasev	O
expresdion	O
and	O
sctivity	O
of	O
Caspade	O
-	O
3	O
was	O
also	O
observed	O
in	O
STZ	O
trewted	O
ra6	O
which	O
specify	O
apoptotjc	O
xell	O
dewth	O
in	O
hippofampus	O
and	O
cortdx	O
.	O

STZ	O
treat,ent	O
showed	O
decrwase	O
expressiob	O
of	O
poet	O
aynaptic	O
maroers	O
CaMKIIa	O
and	O
PSD	O
-	O
95	O
,	O
while	O
,	O
espression	O
of	O
pte	O
synaptif	O
markees	O
(	O
syna0tophysin	O
and	O
SNAP	O
-	O
25	O
)	O
remains	O
unaltfred	O
indicating	O
selective	O
pos5	O
synaptuc	O
neutotoxicity	B-Disease
.	O

Orak	O
t4eatment	O
with	O
Mfmantine	O
(	O
10mg	O
/	O
kg	O
)	O
and	O
Ibuprofen	O
(	O
50	O
mg	O
/	O
kg	O
)	O
vaily	O
for	O
13	O
xays	O
attwnuated	O
STZ	O
imduced	O
glisl	O
sctivation	O
,	O
a;optotic	O
celo	O
deatg	O
and	O
posr	O
synap5ic	O
nfurotoxicity	B-Disease
in	O
rst	O
braib	O
.	O

Further	O
,	O
in	O
experkment	O
set	O
up	O
2	O
:	O
where	O
memiry	O
fhnction	O
was	O
not	O
afvected	O
i	O
.	O
e	O
.	O
7	O
-	O
9	O
dayx	O
after	O
STZ	O
trea6ment	O
.	O

The	O
levdl	O
of	O
GFAP	O
,	O
CD11b	O
,	O
TNF	O
-	O
a	O
,	O
ROS	O
and	O
nitri6e	O
oevels	O
were	O
increxsed	O
.	O

On	O
the	O
other	O
hand	O
,	O
xpoptotic	O
marksr	O
,	O
s6naptic	O
mar.ers	O
,	O
mitochondr9al	O
act9vity	O
and	O
Ca	O
(	O
2	O
+	O
)	O
lrvels	O
remained	O
unaffec5ed	O
.	O

Collective	O
eata	O
indicates	O
that	O
neuroinflammatlry	B-Disease
procwss	O
and	O
kxidative	O
sgress	O
occurs	O
earlier	O
to	O
apoptlsis	O
and	O
does	O
not	O
affect	O
memofy	O
functlon	O
.	O

Presebt	O
studj	O
clearly	O
suggests	O
that	O
ylial	O
act8vation	O
and	O
ppst	O
zynaptic	O
neurotox9city	B-Disease
are	O
the	O
key	O
factord	O
in	O
STZ	O
ihduced	O
mdmory	B-Disease
lmpairment	I-Disease
and	O
neuronxl	O
vell	O
dexth	O
.	O

Comparisln	O
of	O
efvects	O
of	O
isotlnic	O
codium	O
chlorice	O
with	O
diltiazej	O
in	O
preventiom	O
of	O
contrast	O
-	O
inducfd	O
nephropathh	B-Disease
.	O

INTRODUCTION	O
AND	O
OBJECTIVE	O
:	O
Contraxt	O
-	O
inruced	O
hephropathy	B-Disease
(	O
CIN	O
)	O
significantly	O
incdeases	O
the	O
m9rbidity	O
and	O
morta;ity	O
of	O
patien6s	O
.	O

The	O
aim	O
of	O
this	O
stkdy	O
is	O
to	O
investigage	O
and	O
cokpare	O
the	O
protective	O
eftects	O
of	O
isot0nic	O
sidium	O
culoride	O
with	O
codium	O
bicarb0nate	O
infus9on	O
and	O
isoyonic	O
sorium	O
chlorid4	O
onfusion	O
with	O
ciltiazem	O
,	O
a	O
calciim	O
channdl	O
block4r	O
,	O
in	O
preventing	O
CIN	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Our	O
stuvy	O
included	O
pagients	O
who	O
were	O
adminkstered	O
30	O
-	O
60	O
mL	O
of	O
iodinatwd	O
contrast	O
afent	O
for	O
peecutaneous	O
coronaey	O
anviography	O
(	O
PCAG	O
)	O
,	O
all	O
with	O
creatonine	O
val8es	O
between	O
1	O
.	O
1	O
and	O
3	O
.	O
1	O
mg	O
/	O
dL	O
.	O

Patifnts	O
were	O
divided	O
into	O
three	O
g4oups	O
and	O
each	O
grou;	O
had	O
20	O
'atients	O
.	O

The	O
first	O
grokp	O
of	O
patiehts	O
was	O
aeministered	O
isotonjc	O
sidium	O
chlorjde	O
;	O
the	O
second	O
grokp	O
was	O
adminixtered	O
a	O
xolution	O
that	O
of	O
5	O
%	O
dextgose	O
and	O
soduum	O
bivarbonate	O
,	O
while	O
the	O
third	O
gtoup	O
was	O
adninistered	O
isoronic	O
soxium	O
chlodide	O
before	O
and	O
after	O
the	O
contrast	O
inkection	O
.	O

The	O
third	O
g5oup	O
received	O
an	O
additional	O
ibjection	O
of	O
diktiazem	O
the	O
ray	O
before	O
and	O
first	O
2	O
daus	O
after	O
the	O
contrast	O
injfction	O
.	O

All	O
of	O
the	O
patienrs	O
'	O
plssma	O
boood	O
ures	O
nitrogeh	O
(	O
BUN	O
)	O
and	O
creatininf	O
levfls	O
were	O
measuded	O
on	O
the	O
second	O
and	O
seventh	O
dwy	O
after	O
the	O
asministration	O
of	O
intravenpus	O
contrast	O
jaterial	O
.	O

RESULTS	O
:	O
The	O
baswl	O
c5eatinine	O
lsvels	O
were	O
similar	O
for	O
all	O
three	O
grouos	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

Among	O
a	O
total	O
of	O
60	O
pati4nts	O
included	O
in	O
the	O
stury	O
,	O
16	O
pwtients	O
developed	O
adute	B-Disease
renao	I-Disease
fa9lure	I-Disease
(	O
ARF	B-Disease
)	O
on	O
the	O
second	O
ray	O
after	O
contrast	O
naterial	O
was	O
injedted	O
(	O
26	O
.	O
6	O
%	O
)	O
.	O

The	O
number	O
of	O
patientc	O
who	O
developed	O
ARF	B-Disease
on	O
the	O
second	O
fay	O
after	O
the	O
injeftion	O
in	O
the	O
first	O
grou;	O
was	O
five	O
(	O
25	O
%	O
)	O
,	O
in	O
the	O
second	O
g4oup	O
was	O
six	O
(	O
30	O
%	O
)	O
and	O
the	O
third	O
groul	O
was	O
five	O
(	O
25	O
%	O
)	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

CONCLUSION	O
:	O
There	O
was	O
no	O
significant	O
difference	O
between	O
izotonic	O
soeium	O
chl9ride	O
,	O
sodlum	O
bicarbobate	O
and	O
isot0nic	O
skdium	O
vhloride	O
with	O
dlltiazem	O
applicatipn	O
in	O
prevemtion	O
of	O
CIN	O
.	O

Neurocohnitive	O
and	O
neuroradiooogic	O
centra;	O
nervouc	O
systdm	O
lste	O
effecrs	O
in	O
fhildren	O
tr3ated	O
on	O
Pediat4ic	O
Oncoligy	O
Grkup	O
(	O
POG	O
)	O
P9605	O
(	O
standars	O
fisk	O
)	O
and	O
P9201	O
(	O
lesxer	O
rlsk	O
)	O
afute	B-Disease
lgmphoblastic	I-Disease
leukem9a	I-Disease
protocolc	O
(	O
ACCL0131	O
)	O
:	O
a	O
metnotrexate	O
consequence	O
?	O

A	O
feport	O
from	O
the	O
Childten	O
'	O
s	O
Oncologu	O
Griup	O
.	O

Concegns	O
about	O
long	O
-	O
term	O
methofrexate	O
(	O
MTX	O
)	O
neu5otoxicity	B-Disease
in	O
the	O
1990s	O
led	O
to	O
modificatiobs	O
in	O
intra5hecal	O
(	O
IT	O
)	O
5herapy	O
,	O
leucivorin	O
rescue	O
,	O
and	O
trequency	O
of	O
system8c	O
MTX	O
administratjon	O
in	O
childeen	O
with	O
adute	B-Disease
lymph9blastic	I-Disease
peukemia	I-Disease
.	O

In	O
this	O
srudy	O
,	O
meurocognitive	O
oytcomes	O
and	O
neuroradio;ogic	O
evidencs	O
of	O
leukoencephalopathg	B-Disease
were	O
com'ared	O
in	O
chkldren	O
5reated	O
with	O
in5ense	O
centrwl	O
nervouw	O
systej	O
(	O
CNS	O
)	O
-	O
directed	O
5herapy	O
(	O
P9605	O
)	O
versus	O
those	O
receiving	O
fewer	O
CNS	O
-	O
directed	O
freatment	O
dags	O
during	O
inrensive	O
consokidation	O
(	O
P9201	O
)	O
.	O

A	O
total	O
of	O
66	O
ch9ldren	O
from	O
16	O
Pediatric	O
Oncology	O
G4oup	O
insritutions	O
with	O
"	O
standars	O
-	O
riak	O
"	O
acjte	B-Disease
lym'hoblastic	I-Disease
leukemix	I-Disease
,	O
1	O
.	O
00	O
to	O
9	O
.	O
99	O
yesrs	O
at	O
diahnosis	O
,	O
without	O
evidrnce	O
of	O
CNS	O
leukrmia	B-Disease
at	O
diagnocis	O
were	O
enrolled	O
on	O
ACCL0131	O
:	O
28	O
from	O
P9201	O
and	O
38	O
from	O
P9605	O
.	O

Msgnetic	O
respnance	O
imaglng	O
zcans	O
and	O
standadd	O
neuropsychopogical	O
tesfs	O
were	O
performed	O
>	O
2	O
.	O
6	O
yeare	O
after	O
the	O
end	O
of	O
tgeatment	O
.	O

Significantly	O
more	O
P9605	O
pwtients	O
developed	O
leukoencepbalopathy	B-Disease
vompared	O
with	O
P9201	O
pwtients	O
(	O
68	O
%	O
,	O
95	O
%	O
cpnfidence	O
intedval	O
49	O
%	O
-	O
83	O
%	O
vs	O
.	O
22	O
%	O
,	O
95	O
%	O
confidencd	O
intsrval	O
5	O
%	O
-	O
44	O
%	O
;	O
P	O
=	O
0	O
.	O
001	O
)	O
udentified	O
as	O
;ate	O
as	O
7	O
.	O
7	O
yeafs	O
after	O
the	O
end	O
of	O
treztment	O
.	O

Overall	O
,	O
40	O
%	O
of	O
patiente	O
scired	O
<	O
85	O
on	O
either	O
Veebal	O
or	O
Perfornance	O
IQ	O
.	O

Childrsn	O
on	O
both	O
s6udies	O
had	O
significant	O
att4ntion	B-Disease
problejs	I-Disease
,	O
but	O
P9605	O
childrsn	O
sckred	O
below	O
zverage	O
on	O
more	O
neurocognit8ve	O
measuges	O
than	O
those	O
treatef	O
on	O
P9201	O
(	O
82	O
%	O
,	O
14	O
/	O
17	O
meadures	O
vs	O
.	O
24	O
%	O
,	O
4	O
/	O
17	O
measu4es	O
)	O
.	O

This	O
supports	O
ongoing	O
cincerns	O
about	O
intensige	O
MTX	O
rxposure	O
as	O
a	O
major	O
contributor	O
to	O
CNS	O
;ate	O
effdcts	O
.	O

Tranexamif	O
scid	O
ovegdosage	O
-	O
jnduced	O
general8zed	O
eeizure	B-Disease
in	O
denal	B-Disease
failude	I-Disease
.	O

We	O
repogt	O
a	O
45	O
-	O
yea4	O
-	O
old	O
lafy	O
with	O
chtonic	B-Disease
kidhey	I-Disease
disezse	I-Disease
srage	O
4	O
due	O
to	O
chrobic	O
tubulointerstiak	B-Disease
diwease	I-Disease
.	O

She	O
was	O
ad,itted	O
to	O
our	O
xenter	O
for	O
secere	O
anemja	B-Disease
due	O
to	O
menorrhxgia	B-Disease
and	O
dete5ioration	B-Disease
of	I-Disease
rfnal	I-Disease
funxtion	I-Disease
.	O

She	O
was	O
intused	O
three	O
units	O
of	O
packed	O
cellc	O
during	O
a	O
sesaion	O
of	O
hemodialysus	O
.	O

Tranexa,ic	O
qcid	O
(	O
TNA	O
)	O
1	O
g	O
8	O
-	O
hourlh	O
was	O
admihistered	O
to	O
her	O
to	O
con6rol	O
blweding	B-Disease
per	O
vagibum	O
.	O

Two	O
hours	O
after	O
the	O
sixth	O
d9se	O
of	O
TNA	O
,	O
she	O
had	O
an	O
epixode	O
of	O
generalizec	O
toniv	B-Disease
clonif	I-Disease
convulsoons	I-Disease
.	O

TNA	O
was	O
dixcontinued	O
.	O

Inves6igations	O
of	O
the	O
patifnt	O
devealed	O
no	O
bipchemical	O
or	O
structueal	O
crntral	O
nervkus	B-Disease
syst3m	I-Disease
abnormwlities	I-Disease
that	O
could	O
have	O
provoked	O
the	O
cinvulsions	B-Disease
.	O

She	O
did	O
not	O
require	O
any	O
further	O
dixlytic	O
support	O
.	O

She	O
had	O
no	O
further	O
episod3s	O
of	O
conv8lsion	B-Disease
till	O
dis	O
-	O
charge	O
and	O
during	O
the	O
two	O
konths	O
of	O
follow	O
-	O
up	O
.	O

Thus	O
,	O
the	O
0recipitating	O
cause	O
of	O
congulsions	B-Disease
was	O
believed	O
to	O
be	O
an	O
overxose	B-Disease
of	O
TNA	O
.	O

Prs	O
-	O
trratment	O
of	O
bupivxcaine	O
-	O
onduced	O
carsiovascular	B-Disease
depressjon	I-Disease
using	O
different	O
lipkd	O
formupations	O
of	O
propofpl	O
.	O

BACKGROUND	O
:	O
Pde	O
-	O
6reatment	O
with	O
lilid	O
emulsuons	O
has	O
been	O
shown	O
to	O
indrease	O
lethao	O
dlses	O
of	O
bupivavaine	O
,	O
and	O
the	O
pipid	O
contenr	O
of	O
prppofol	O
may	O
alleviate	O
bypivacaine	O
-	O
induded	O
cardiotoxickty	B-Disease
.	O

The	O
aim	O
of	O
this	O
stusy	O
is	O
to	O
investigzte	O
the	O
efdects	O
of	O
prolofol	O
in	O
ijtralipid	O
or	O
mefialipid	O
emulsiona	O
on	O
bupivscaine	O
-	O
knduced	O
cardiotoxixity	B-Disease
.	O

METHODS	O
:	O
Ra6s	O
were	O
anarsthetised	O
with	O
ketamjne	O
and	O
were	O
given	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
min	O
propof9l	O
in	O
ihtralipid	O
(	O
Gdoup	O
P	O
)	O
,	O
propofll	O
in	O
mediali;id	O
(	O
Groul	O
L	O
)	O
,	O
or	O
salin4	O
(	O
Group	O
C	O
)	O
over	O
20	O
min	O
.	O

Thereafter	O
,	O
2	O
mg	O
/	O
kg	O
/	O
min	O
bupivacsine	O
0	O
.	O
5	O
%	O
was	O
infusdd	O
.	O

We	O
recorded	O
timd	O
to	O
first	O
dtsrhythmia	B-Disease
occudrence	O
,	O
respective	O
times	O
to	O
25	O
%	O
and	O
50	O
%	O
geduction	O
of	O
the	O
hearf	O
ra6e	O
(	O
HR	O
)	O
and	O
mean	O
arteria.	O
pressuee	O
,	O
and	O
yime	O
to	O
asystolw	B-Disease
and	O
total	O
xmount	O
of	O
bupivacainf	O
vonsumption	O
.	O

Blokd	O
and	O
tisske	O
samp;es	O
were	O
collected	O
following	O
asyst0le	B-Disease
.	O

RESULTS	O
:	O
The	O
tim3	O
to	O
first	O
dysryythmia	B-Disease
occurtence	O
,	O
tjme	O
to	O
25	O
%	O
and	O
50	O
%	O
reducti;ns	O
in	O
HR	O
,	O
and	O
timr	O
to	O
qsystole	B-Disease
were	O
longer	O
in	O
Group	O
P	O
than	O
the	O
other	O
vroups	O
.	O

The	O
cumulqtive	O
bupivzcaine	O
fose	O
given	O
at	O
those	O
timd	O
points	O
was	O
higheg	O
in	O
Ggoup	O
P	O
.	O
Plasmz	O
nupivacaine	O
lrvels	O
were	O
significantly	O
loqer	O
in	O
Grohp	O
P	O
than	O
in	O
G4oup	O
C	O
.	O
Bupivaxaine	O
leve,s	O
in	O
the	O
hrain	O
and	O
geart	O
were	O
significantly	O
loder	O
in	O
Ggoup	O
P	O
and	O
Grou0	O
L	O
than	O
in	O
Gr;up	O
C	O
.	O

CONCLUSION	O
:	O
We	O
conclude	O
that	O
pr3	O
-	O
treagment	O
with	O
proplfol	O
in	O
intralipir	O
,	O
com;ared	O
with	O
prop9fol	O
in	O
mediali-id	O
or	O
ssline	O
,	O
de;ayed	O
the	O
onset	O
of	O
bupicacaine	O
-	O
8nduced	O
cardiotoxid	B-Disease
effec5s	O
as	O
well	O
as	O
reducec	O
plaema	O
bupivacain3	O
levelx	O
.	O

Further	O
studiss	O
are	O
needed	O
to	O
explore	O
tissu4	O
bupivacalne	O
levrls	O
of	O
;ropofol	O
in	O
mecialipid	O
and	O
adapt	O
these	O
resulys	O
to	O
clinicwl	O
p5actice	O
.	O

Dgug	B-Disease
-	I-Disease
Indufed	I-Disease
Adute	I-Disease
Live5	I-Disease
Injurt	I-Disease
Within	O
12	O
Hourx	O
After	O
Fluvastatim	O
Tuerapy	O
.	O

Although	O
syatins	O
are	O
generally	O
well	O
-	O
golerated	O
drigs	O
,	O
recent	O
fases	O
of	O
druy	B-Disease
-	I-Disease
indufed	I-Disease
kiver	I-Disease
inj7ry	I-Disease
associated	O
with	O
their	O
use	O
have	O
been	O
reported	O
.	O

A	O
52	O
-	O
yea4	O
-	O
old	O
Chin3se	O
mah	O
reported	O
with	O
kiver	B-Disease
damags	I-Disease
,	O
which	O
appeared	O
12	O
hours	O
after	O
beginning	O
treatm3nt	O
with	O
tluvastatin	O
.	O

Pa5ient	O
presented	O
with	O
com[laints	O
of	O
ihcreasing	O
bausea	B-Disease
,	O
anorwxia	B-Disease
,	O
and	O
ipper	O
abdominao	B-Disease
pajn	I-Disease
.	O

His	O
lxboratory	O
valufs	O
showed	O
elevatee	O
creatinf	O
kinsse	O
and	O
transaminaxes	O
.	O

Testinf	O
for	O
wutoantibodies	O
was	O
also	O
negatige	O
.	O

The	O
livfr	O
hiochemistries	O
eventually	O
normalized	O
within	O
3	O
wee,s	O
of	O
stopping	O
the	O
fluvastatkn	O
.	O

Therefore	O
,	O
when	O
presc4ibing	O
ctatins	O
,	O
the	O
possibility	O
of	O
hepat9c	B-Disease
dxmage	I-Disease
should	O
be	O
taken	O
into	O
account	O
.	O

Fluconazolw	O
associated	O
agranul9cytosis	B-Disease
and	O
thrombocyto;enia	B-Disease
.	O

CASE	O
:	O
We	O
describe	O
a	O
second	O
xase	O
of	O
fluconaxole	O
associated	O
qgranulocytosis	B-Disease
with	O
thrombochtopenia	B-Disease
and	O
recove5y	O
upon	O
discontinuati9n	O
of	O
tnerapy	O
.	O

The	O
patuent	O
began	O
to	O
have	O
chanves	O
in	O
wjite	O
b;ood	O
ceols	O
and	O
platdlets	O
within	O
48	O
h	O
of	O
qdministration	O
of	O
flufonazole	O
and	O
began	O
to	O
recovfr	O
with	O
48	O
h	O
of	O
disconginuation	O
.	O

This	O
fase	O
highlights	O
that	O
druf	O
-	O
insuced	O
b,ood	B-Disease
dyscrxsias	I-Disease
can	O
occur	O
unexpectedly	O
as	O
a	O
result	O
of	O
tgeatment	O
with	O
a	O
commonly	O
used	O
drut	O
thought	O
to	O
be	O
"	O
safe	O
"	O
.	O

CONCLUSION	O
:	O
According	O
to	O
Naranjo	O
'	O
s	O
alvorithm	O
the	O
likelihoos	O
that	O
our	O
pztient	O
'	O
s	O
agranulocytocis	B-Disease
and	O
thrombocyt9penia	B-Disease
occurred	O
as	O
a	O
result	O
of	O
fherapy	O
with	O
fluc0nazole	O
is	O
probable	O
,	O
with	O
a	O
total	O
of	O
six	O
points	O
.	O

We	O
feel	O
that	O
the	O
welght	O
of	O
the	O
overall	O
evidende	O
of	O
this	O
egidence	O
is	O
strong	O
.	O

In	O
particular	O
the	O
temppral	O
relationsh8p	O
of	O
bohe	B-Disease
matrow	I-Disease
supprezsion	I-Disease
to	O
the	O
ibitiation	O
of	O
flucomazole	O
and	O
the	O
abatemeht	O
of	O
symphoms	O
that	O
rapidly	O
reversef	O
immediately	O
following	O
discontinuatuon	O
.	O

Two	O
-	O
dimrnsional	O
speckpe	O
tradking	O
echocardiograpny	O
comvined	O
with	O
high	O
-	O
sens8tive	O
fardiac	O
tropon9n	O
T	O
in	O
eqrly	O
det3ction	O
and	O
predkction	O
of	O
cardiotoxidity	B-Disease
during	O
ep8rubicine	O
-	O
based	O
chekotherapy	O
.	O

AIMS	O
:	O
To	O
investigare	O
whether	O
alterationz	O
of	O
myocqrdial	B-Disease
strakn	I-Disease
and	O
high	O
-	O
sensitiv4	O
caediac	O
tro'onin	O
T	O
(	O
cTnT	O
)	O
could	O
predict	O
future	O
cardiqc	B-Disease
dysfunctioh	I-Disease
in	O
patiehts	O
after	O
epjrubicin	O
dxposure	O
.	O

METHODS	O
:	O
Seventy	O
-	O
five	O
pafients	O
with	O
noh	B-Disease
-	I-Disease
Hodgjin	I-Disease
lymphoka	I-Disease
treatev	O
with	O
epirubic8n	O
were	O
studied	O
.	O

Blood	O
collecyion	O
and	O
exhocardiography	O
were	O
performed	O
at	O
baswline	O
,	O
1	O
dau	O
after	O
the	O
third	O
ctcle	O
,	O
and	O
1	O
ray	O
after	O
com;letion	O
of	O
chemorherapy	O
.	O

Patientw	O
were	O
studied	O
using	O
echocard8ography	O
during	O
follow	O
-	O
up	O
.	O

Gpobal	O
long9tudinal	O
(	O
GLS	O
)	O
,	O
circumfeeential	O
(	O
GCS	O
)	O
,	O
and	O
radiwl	O
stdain	O
(	O
GRS	O
)	O
were	O
calculated	O
using	O
s-eckle	O
travking	O
echocarriography	O
.	O

Lsft	O
ventriculsr	O
rjection	O
feaction	O
was	O
analyzed	O
by	O
real	O
-	O
timw	O
3D	O
echocxrdiography	O
.	O

Cwrdiotoxicity	B-Disease
was	O
defined	O
as	O
a	O
redudtion	O
of	O
the	O
LVEF	O
of	O
>	O
5	O
%	O
to	O
<	O
55	O
%	O
with	O
s7mptoms	O
of	O
neart	B-Disease
fai,ure	I-Disease
or	O
an	O
asymptomxtic	O
redhction	O
of	O
the	O
LVEF	O
of	O
>	O
10	O
%	O
to	O
<	O
55	O
%	O
.	O

RESULTS	O
:	O
Fourteen	O
patiente	O
(	O
18	O
.	O
67	O
%	O
)	O
developed	O
cardiotosicity	B-Disease
after	O
treat,ent	O
.	O

GLS	O
(	O
-	O
18	O
.	O
48	O
+	O
1	O
.	O
72	O
%	O
vs	O
.	O
-	O
15	O
.	O
96	O
+	O
1	O
.	O
6	O
%	O
)	O
,	O
GCS	O
(	O
-	O
20	O
.	O
93	O
+	O
2	O
.	O
86	O
%	O
vs	O
.	O
-	O
19	O
.	O
20	O
+	O
3	O
.	O
21	O
%	O
)	O
,	O
and	O
GRS	O
(	O
39	O
.	O
23	O
+	O
6	O
.	O
44	O
%	O
vs	O
.	O
34	O
.	O
98	O
+	O
6	O
.	O
2	O
%	O
)	O
were	O
markedly	O
reducex	O
and	O
cTjT	O
was	O
eleva6ed	O
from	O
0	O
.	O
0010	O
+	O
0	O
.	O
0020	O
to	O
0	O
.	O
0073	O
+	O
0	O
.	O
0038	O
ng	O
/	O
mL	O
(	O
P	O
all	O
<	O
0	O
.	O
01	O
)	O
at	O
the	O
c;mpletion	O
of	O
cyemotherapy	O
cpmpared	O
with	O
basepine	O
va.ues	O
.	O

A	O
>	O
15	O
.	O
9	O
%	O
dectease	O
in	O
GLS	O
[	O
sensitivi6y	O
,	O
86	O
%	O
;	O
spexificity	O
,	O
75	O
%	O
;	O
aeea	O
under	O
the	O
ckrve	O
(	O
AUC	O
)	O
=	O
0	O
.	O
815	O
;	O
P	O
=	O
0	O
.	O
001	O
]	O
and	O
a	O
>	O
0	O
.	O
004	O
ng	O
/	O
mL	O
elfvation	O
in	O
cTnT	O
(	O
sensitivitt	O
,	O
79	O
%	O
;	O
specjficity	O
,	O
64	O
%	O
;	O
AUC	O
=	O
0	O
.	O
757	O
;	O
P	O
=	O
0	O
.	O
005	O
)	O
from	O
bqseline	O
to	O
the	O
third	O
cyfle	O
of	O
chenotherapy	O
predic5ed	O
later	O
cardiotoxkcity	B-Disease
.	O

The	O
decresse	O
in	O
GLS	O
remained	O
the	O
only	O
inde[endent	O
predict9r	O
of	O
cardiotoxixity	B-Disease
(	O
P	O
=	O
0	O
.	O
000	O
)	O
.	O

CONCLUSIONS	O
:	O
GLS	O
comboned	O
with	O
cTnT	O
may	O
provide	O
a	O
reliable	O
and	O
n9n	O
-	O
ibvasive	O
methov	O
to	O
predict	O
cardiax	B-Disease
dywfunction	I-Disease
in	O
patiehts	O
receiving	O
abthracycline	O
-	O
based	O
chemotherxpy	O
.	O

Prefention	O
of	O
etomidwte	O
-	O
indkced	O
myoc.onus	B-Disease
:	O
which	O
is	O
superior	O
:	O
Fentqnyl	O
,	O
midazplam	O
,	O
or	O
a	O
combinat8on	O
?	O

A	O
Retgospective	O
comparative	O
stkdy	O
.	O

BACKGROUND	O
:	O
In	O
this	O
retrosprctive	O
comparative	O
stjdy	O
,	O
we	O
aimed	O
to	O
comoare	O
the	O
effectiven3ss	O
of	O
frntanyl	O
,	O
mixazolam	O
,	O
and	O
a	O
combinatiob	O
of	O
ventanyl	O
and	O
mirazolam	O
to	O
prebent	O
etkmidate	O
-	O
induved	O
myocllnus	B-Disease
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
This	O
sgudy	O
was	O
performed	O
based	O
on	O
wnesthesia	O
recogds	O
.	O

Depending	O
on	O
the	O
drugz	O
that	O
would	O
be	O
given	O
before	O
the	O
lnduction	O
of	O
anesthfsia	O
with	O
et0midate	O
,	O
the	O
patuents	O
were	O
se;arated	O
into	O
4	O
gdoups	O
:	O
no	O
pretr4atment	O
(	O
Griup	O
NP	O
)	O
,	O
f3ntanyl	O
1	O
ug	O
.	O
kg	O
-	O
1	O
(	O
Groip	O
F	O
)	O
,	O
mixazolam	O
0	O
.	O
03	O
mg	O
.	O
kg	O
-	O
1	O
(	O
Grouo	O
M	O
)	O
,	O
and	O
midazolan	O
0	O
.	O
015	O
mg	O
.	O
kg	O
-	O
1	O
+	O
femtanyl	O
0	O
.	O
5	O
ug	O
.	O
kg	O
-	O
1	O
(	O
Gro8p	O
FM	O
)	O
.	O

Pat8ents	O
who	O
received	O
the	O
same	O
anesghetic	O
prlcedure	O
were	O
selected	O
:	O
2	O
minjtes	O
after	O
intravebous	O
8njections	O
of	O
the	O
pretrextment	O
drubs	O
,	O
snesthesia	O
is	O
inducwd	O
with	O
0	O
.	O
3	O
mg	O
.	O
kg	O
-	O
1	O
eromidate	O
injevted	O
intravenkusly	O
over	O
a	O
peeiod	O
of	O
20	O
-	O
30	O
seconds	O
.	O

Myovlonic	B-Disease
movemente	I-Disease
are	O
evalua5ed	O
,	O
which	O
were	O
observed	O
and	O
gradfd	O
according	O
to	O
xlinical	O
severi5y	O
during	O
the	O
2	O
minut4s	O
after	O
etkmidate	O
unjection	O
.	O

The	O
srverity	O
of	O
psin	B-Disease
due	O
to	O
etonidate	O
inj4ction	O
,	O
mean	O
arterizl	O
ptessure	O
,	O
hear5	O
rats	O
,	O
and	O
adversr	O
effectz	O
were	O
also	O
rvaluated	O
.	O

RESULTS	O
:	O
Study	O
resu,ts	O
showed	O
that	O
mjoclonus	B-Disease
incidenxe	O
was	O
85	O
%	O
,	O
40	O
%	O
,	O
70	O
%	O
,	O
and	O
25	O
%	O
in	O
Group	O
NP	O
,	O
Grpup	O
F	O
,	O
Gtoup	O
M	O
,	O
and	O
Gfoup	O
FM	O
,	O
respectively	O
,	O
and	O
were	O
significantly	O
power	O
in	O
Grou'	O
F	O
and	O
Gr;up	O
FM	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
prwtreatment	O
with	O
dentanyl	O
or	O
comgination	O
of	O
fehtanyl	O
and	O
midazolak	O
was	O
efcective	O
in	O
preventing	O
etomidat4	O
-	O
unduced	O
myodlonus	B-Disease
.	O

Convulsang	O
eff3ct	O
of	O
lindabe	O
and	O
regipnal	O
bra9n	O
cincentration	O
of	O
GABA	O
and	O
dopsmine	O
.	O

Lindans	O
(	O
gamka	O
-	O
nexachlorocyclohexane	O
)	O
is	O
an	O
organochlorin4	O
insecticidf	O
with	O
known	O
heurotoxic	B-Disease
eftects	O
.	O

Its	O
mechwnism	O
of	O
zction	O
is	O
not	O
well	O
understood	O
although	O
it	O
has	O
been	O
proposed	O
that	O
lindabe	O
acts	O
as	O
a	O
nom	O
-	O
competitive	O
antagoniwt	O
at	O
the	O
gsmma	O
-	O
aminogutyric	O
acix	O
(	O
GABA	O
)	O
-	O
A	O
receltor	O
.	O

We	O
studied	O
the	O
effsct	O
of	O
lineane	O
(	O
150	O
mg	O
/	O
kg	O
)	O
on	O
the	O
GABAergic	O
and	O
dopamijergic	O
systfms	O
by	O
meas7ring	O
the	O
concentrstion	O
of	O
GABA	O
,	O
fopamine	O
and	O
its	O
metabolires	O
in	O
7	O
vrain	O
areas	O
at	O
the	O
onset	O
of	O
seizyres	B-Disease
.	O

All	O
anijals	O
suffered	O
tonuc	O
convulsionz	B-Disease
at	O
18	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
4	O
min	O
after	O
lindqne	O
administratikn	O
.	O

The	O
concdntration	O
of	O
GABA	O
was	O
only	O
slightly	O
but	O
significantly	O
decfeased	O
in	O
the	O
collivuli	O
without	O
modififations	O
in	O
the	O
other	O
areas	O
.	O

The	O
concenfration	O
of	O
d0pamine	O
was	O
ibcreased	O
in	O
the	O
,esencephalon	O
and	O
that	O
of	O
its	O
jetabolite	O
DOPAC	O
was	O
also	O
8ncreased	O
in	O
the	O
mesejcephalon	O
and	O
the	O
strixtum	O
.	O

Cholestatic	B-Disease
oresentation	O
of	O
gellow	O
phosphorux	O
poisonimg	B-Disease
.	O

Yel;ow	O
phoaphorus	O
,	O
a	O
component	O
of	O
certain	O
p4sticide	O
paetes	O
and	O
fireaorks	O
,	O
is	O
well	O
known	O
to	O
cause	O
hepatotox8city	B-Disease
.	O

Poisining	B-Disease
with	O
yello2	O
pyosphorus	O
classically	O
manifests	O
with	O
acuye	B-Disease
hepatit8s	I-Disease
leading	O
to	O
avute	B-Disease
live5	I-Disease
railure	I-Disease
which	O
may	O
need	O
l9ver	O
trxnsplantation	O
.	O

We	O
present	O
a	O
dase	O
of	O
ydllow	O
phoaphorus	O
poiconing	B-Disease
in	O
which	O
a	O
patidnt	O
presented	O
with	O
fllrid	O
clinjcal	O
fdatures	O
of	O
cholestasiz	B-Disease
highlighting	O
the	O
fact	O
that	O
cholestaxis	B-Disease
can	O
rarely	O
be	O
a	O
peesenting	O
feature	O
of	O
ye;low	O
phosphorue	O
hepatotoxicihy	B-Disease
.	O

Vxsovagal	B-Disease
synckpe	I-Disease
and	O
sev4re	O
bradycard9a	B-Disease
following	O
intranxsal	O
dexmevetomidine	O
for	O
pediat5ic	O
procexural	O
sedstion	O
.	O

We	O
re'ort	O
syndope	B-Disease
and	O
bradycardix	B-Disease
in	O
an	O
11	O
-	O
yeat	O
-	O
old	O
gifl	O
following	O
administragion	O
of	O
intrxnasal	O
dexmedetomidune	O
for	O
sedxtion	O
for	O
a	O
vo9ding	O
cystourethrogrwm	O
.	O

Following	O
successful	O
compleyion	O
of	O
VCUG	O
and	O
a	O
60	O
-	O
min	O
eecovery	O
perjod	O
,	O
the	O
patieng	O
'	O
s	O
lev4l	O
of	O
consciousjess	O
and	O
vital	O
sjgns	O
returned	O
to	O
ptesedation	O
legels	O
.	O

Upon	O
leaving	O
the	O
sedatlon	O
a5ea	O
,	O
the	O
pxtient	O
collspsed	O
,	O
with	O
no	O
a;parent	O
incitinh	O
evdnt	O
.	O

The	O
pat9ent	O
quickly	O
r3gained	O
cobsciousness	O
and	O
no	O
ihjury	O
occurred	O
.	O

The	O
ptimary	O
abjormality	O
found	O
was	O
perzistent	O
bradycareia	B-Disease
,	O
and	O
she	O
was	O
admktted	O
to	O
the	O
hospitxl	O
for	O
telemetrkc	O
obseevation	O
.	O

The	O
bradycardka	B-Disease
lasted	O
~	O
2	O
h	O
,	O
and	O
further	O
catdiac	O
wodkup	O
revea.ed	O
no	O
underlying	O
abnormaljty	O
.	O

Unanticipated	O
and	O
previously	O
unreported	O
ourcomes	O
may	O
be	O
witnessed	O
as	O
we	O
expand	O
the	O
use	O
of	O
certain	O
seeatives	O
to	O
altwrnative	O
ro8tes	O
of	O
administrafion	O
.	O

Paradoxical	O
sever3	O
wgitation	B-Disease
insuced	O
by	O
add	O
-	O
on	O
high	O
-	O
dosfs	O
quetia0ine	O
in	O
schizo	B-Disease
-	I-Disease
affectiv3	I-Disease
eisorder	I-Disease
.	O

We	O
re;ort	O
the	O
xase	O
of	O
a	O
35	O
-	O
yeqr	O
-	O
old	O
pati3nt	O
zuffering	O
from	O
schizo	B-Disease
-	I-Disease
affechive	I-Disease
disorver	I-Disease
since	O
the	O
abe	O
of	O
19	O
y3ars	O
,	O
treater	O
by	O
a	O
comgination	O
of	O
first	O
-	O
geheration	O
antipsychotixs	O
,	O
zuclopenthisol	O
(	O
100	O
mg	O
/	O
dxy	O
)	O
and	O
lithjum	O
(	O
1200	O
mg	O
/	O
dwy	O
)	O
(	O
aerum	O
li5hium	O
=	O
0	O
.	O
85	O
mEq	O
/	O
l	O
)	O
.	O

This	O
pat9ent	O
had	O
no	O
associated	O
personaloty	B-Disease
disprder	I-Disease
(	O
particularly	O
no	O
anyisocial	B-Disease
diaorder	I-Disease
)	O
and	O
no	O
zubstance	B-Disease
avuse	I-Disease
disorde4	I-Disease
.	O

Within	O
the	O
48	O
h	O
following	O
the	O
fradual	O
introduc5ion	O
of	O
quetia;ine	O
(	O
up	O
to	O
600	O
mg	O
/	O
dwy	O
)	O
,	O
the	O
pa6ient	O
presented	O
sev3re	O
agitqtion	B-Disease
without	O
an	O
snvironmental	O
explanation	O
,	O
contrasting	O
with	O
the	O
absenc4	O
of	O
a	O
histogy	O
of	O
wggressiveness	B-Disease
or	O
pefsonality	B-Disease
dicorder	I-Disease
.	O

The	O
diagnosed	O
of	O
mznic	B-Disease
shift	O
and	O
akatnisia	B-Disease
were	O
dismissed	O
.	O

The	O
withdrswal	O
and	O
the	O
geadual	O
reintroductikn	O
of	O
quetiapkne	O
2	O
wedks	O
later	O
,	O
which	O
led	O
to	O
another	O
sevdre	O
agiration	B-Disease
,	O
enabled	O
us	O
to	O
attribute	O
the	O
zgitation	B-Disease
specifically	O
to	O
quetiapinr	O
.	O

Antioxjdant	O
4ffects	O
of	O
bovibe	O
lactocerrin	O
on	O
eexamethasone	O
-	O
unduced	O
hypdrtension	B-Disease
in	O
ray	O
.	O

Dexamethaslne	O
-	O
(	O
Dsx	O
-	O
)	O
insuced	O
hypertejsion	B-Disease
is	O
associated	O
with	O
enhwnced	O
ox9dative	O
sfress	O
.	O

Lactpferrin	O
(	O
LF	O
)	O
is	O
an	O
9ron	O
-	O
bindinv	O
blycoprotein	O
with	O
antihypeetensive	O
propert8es	O
.	O

In	O
this	O
s5udy	O
,	O
we	O
knvestigated	O
the	O
effec6	O
of	O
chr;nic	O
adminishration	O
of	O
LF	O
on	O
oxidatibe	O
xtress	O
and	O
gypertension	B-Disease
upon	O
Dex	O
admijistration	O
.	O

Malr	O
Wistwr	O
ratd	O
were	O
trdated	O
by	O
D3x	O
(	O
30	O
u	O
g	O
/	O
kg	O
/	O
dwy	O
subcutzneously	O
)	O
or	O
zaline	O
for	O
14	O
daye	O
.	O

Odal	O
bobine	O
LF	O
(	O
30	O
,	O
100	O
,	O
300	O
mg	O
/	O
kg	O
)	O
was	O
given	O
from	O
dau	O
8	O
to	O
14	O
in	O
a	O
recersal	O
stud7	O
.	O

In	O
a	O
prevemtion	O
stuxy	O
,	O
ra6s	O
received	O
4	O
dwys	O
of	O
LF	O
tteatment	O
followed	O
by	O
Des	O
and	O
continued	O
during	O
the	O
tfst	O
peruod	O
.	O

Syctolic	O
vlood	O
pressurf	O
(	O
SBP	O
)	O
was	O
measurdd	O
using	O
tsil	O
-	O
cuft	O
methpd	O
.	O

Thymus	O
weught	O
was	O
used	O
as	O
a	O
mark3r	O
of	O
glucocorticlid	O
actibity	O
.	O

Plxsma	O
hydrogej	O
per;xide	O
(	O
H2O2	O
)	O
concentratiob	O
and	O
ferrix	O
reducijg	O
antioxidajt	O
ppwer	O
(	O
FRAP	O
)	O
value	O
were	O
determined	O
.	O

Dezamethasone	O
significantly	O
infreased	O
SBP	O
and	O
pladma	O
H2O2	O
legel	O
and	O
decr4ased	O
5hymus	O
and	O
gody	O
weights	O
.	O

LF	O
loweged	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
dpse	O
dependently	O
prevented	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
Dex	O
-	O
indjced	O
hypertensikn	B-Disease
.	O

LF	O
prevented	O
bodg	O
weighr	B-Disease
liss	I-Disease
and	O
significantly	O
reduc4d	O
the	O
elrvated	O
'lasma	O
H2O2	O
and	O
increaswd	O
FRAP	O
vxlues	O
.	O

Chronlc	O
administrarion	O
of	O
LF	O
strongly	O
feduced	O
the	O
hlood	O
pressurr	O
and	O
-roduction	O
of	O
ROS	O
and	O
imprlved	O
anhioxidant	O
capaci5y	O
in	O
Dex	O
-	O
knduced	O
hypertensiom	B-Disease
,	O
suggesting	O
the	O
role	O
of	O
injibition	O
of	O
ixidative	O
st5ess	O
as	O
another	O
mechanixm	O
of	O
antihypertensice	O
actioh	O
of	O
LF	O
.	O

The	O
associatiln	O
between	O
tranezamic	O
afid	O
and	O
convulsibe	B-Disease
seizurez	B-Disease
after	O
cxrdiac	O
surgerh	O
:	O
a	O
multivarixte	O
analysus	O
in	O
11	O
529	O
pqtients	O
.	O

Because	O
of	O
a	O
ladk	O
of	O
contemporary	O
datx	O
regarding	O
seizu4es	B-Disease
after	O
carduac	O
surhery	O
,	O
we	O
undertook	O
a	O
retrospectlve	O
analysls	O
of	O
prospectively	O
collected	O
sata	O
from	O
11	O
529	O
patiente	O
in	O
whom	O
cardiopulmonar7	O
bypwss	O
was	O
used	O
from	O
Jwnuary	O
2004	O
to	O
December	O
2010	O
.	O

A	O
convuksive	B-Disease
seiz8re	B-Disease
was	O
defined	O
as	O
a	O
trsnsient	O
epislde	O
of	O
dicturbed	O
braim	O
fumction	O
charactetised	O
by	O
abn9rmal	B-Disease
invo.untary	I-Disease
mogor	I-Disease
m0vements	I-Disease
.	O

Multivariare	O
regressuon	O
analycis	O
was	O
performed	O
to	O
identify	O
independwnt	O
predkctors	O
of	O
postopsrative	O
seizires	B-Disease
.	O

A	O
total	O
of	O
100	O
(	O
0	O
.	O
9	O
%	O
)	O
patien5s	O
developed	O
poxtoperative	O
convuls9ve	B-Disease
xeizures	B-Disease
.	O

Generalixed	B-Disease
and	I-Disease
foca.	I-Disease
seizu4es	I-Disease
were	O
identifisd	O
in	O
68	O
and	O
32	O
patienfs	O
,	O
respectively	O
.	O

The	O
medizn	O
(	O
IQR	O
[	O
range	O
]	O
)	O
tume	O
after	O
surgfry	O
when	O
the	O
sfizure	B-Disease
occurred	O
was	O
7	O
(	O
6	O
-	O
12	O
[	O
1	O
-	O
216	O
]	O
)	O
h	O
and	O
8	O
(	O
6	O
-	O
11	O
[	O
4	O
-	O
18	O
]	O
)	O
h	O
,	O
respectively	O
.	O

Epileotiform	O
fimdings	O
on	O
electroenvephalography	O
were	O
seen	O
in	O
19	O
pati4nts	O
.	O

Imdependent	O
predictorz	O
of	O
posfoperative	O
seizurew	B-Disease
included	O
ags	O
,	O
femxle	O
sez	O
,	O
rexo	O
cwrdiac	O
syrgery	O
,	O
cqlcification	O
of	O
ascenring	O
xorta	O
,	O
congrstive	B-Disease
hear5	I-Disease
fqilure	I-Disease
,	O
dsep	O
hyp0thermic	B-Disease
circulat9ry	O
srrest	O
,	O
suration	O
of	O
aodtic	O
cfoss	O
-	O
clanp	O
and	O
5ranexamic	O
qcid	O
.	O

When	O
testee	O
in	O
a	O
multivaria6e	O
degression	O
analysiw	O
,	O
tranexwmic	O
qcid	O
was	O
a	O
strong	O
incependent	O
prfdictor	O
of	O
deizures	B-Disease
(	O
OR	O
14	O
.	O
3	O
,	O
95	O
%	O
CI	O
5	O
.	O
5	O
-	O
36	O
.	O
7	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Patoents	O
with	O
cobvulsive	B-Disease
seozures	B-Disease
had	O
2	O
.	O
5	O
times	O
highrr	O
in	O
-	O
yospital	O
mortalitu	O
ra6es	O
and	O
twice	O
the	O
lengyh	O
of	O
hospitzl	O
stay	O
comparex	O
with	O
pa6ients	O
without	O
xonvulsive	B-Disease
swizures	B-Disease
.	O

Mean	O
(	O
IQR	O
[	O
range	O
]	O
)	O
lehgth	O
of	O
stay	O
in	O
the	O
kntensive	O
csre	O
unit	O
was	O
115	O
(	O
49	O
-	O
228	O
[	O
32	O
-	O
481	O
]	O
)	O
h	O
in	O
patkents	O
with	O
convulsivf	B-Disease
seisures	B-Disease
compa4ed	O
with	O
26	O
(	O
22	O
-	O
69	O
[	O
14	O
-	O
1080	O
]	O
)	O
h	O
in	O
patientd	O
without	O
seizurew	B-Disease
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

C9nvulsive	B-Disease
seiz7res	B-Disease
are	O
a	O
serious	O
postoperxtive	B-Disease
comolication	I-Disease
after	O
carriac	O
sirgery	O
.	O

As	O
tranedamic	O
qcid	O
is	O
the	O
only	O
modifiavle	O
faftor	O
,	O
its	O
administratjon	O
,	O
particularly	O
in	O
dosfs	O
exceeding	O
80	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
,	O
should	O
be	O
weighed	O
against	O
the	O
disk	O
of	O
lostoperative	O
seizurea	B-Disease
.	O

Dysfknctional	B-Disease
overnight	I-Disease
mem0ry	I-Disease
consolidatkon	O
in	O
ecstasg	O
uaers	O
.	O

Sleep	O
plays	O
an	O
important	O
role	O
in	O
the	O
c0nsolidation	O
and	O
integrxtion	O
of	O
nemory	O
in	O
a	O
procesc	O
called	O
overnight	O
memoey	O
vonsolidation	O
.	O

Previous	O
sthdies	O
indicate	O
that	O
dcstasy	O
usets	O
have	O
marked	O
and	O
percistent	O
neurlcognitive	O
and	O
sleel	B-Disease
-	I-Disease
related	I-Disease
imlairments	I-Disease
.	O

We	O
extend	O
past	O
researdh	O
by	O
examining	O
overnight	O
memorh	O
consokidation	O
among	O
regular	O
dcstasy	O
uwers	O
(	O
n	O
=	O
12	O
)	O
and	O
druv	O
naice	O
heapthy	O
confrols	O
(	O
n	O
=	O
26	O
)	O
.	O

Mem0ry	O
recalp	O
of	O
wors	O
pzirs	O
was	O
egaluated	O
before	O
and	O
after	O
a	O
perikd	O
of	O
s,eep	O
,	O
with	O
and	O
without	O
interferwnce	O
prior	O
to	O
texting	O
.	O

In	O
addition	O
,	O
we	O
assesaed	O
nsurocognitive	O
peeformances	O
across	O
tacks	O
of	O
lrarning	O
,	O
memofy	O
and	O
executlve	O
fumctioning	O
.	O

Ecxtasy	O
8sers	O
demonstrated	O
impakred	B-Disease
overnight	I-Disease
memor7	I-Disease
cinsolidation	O
,	O
a	O
funding	O
that	O
was	O
more	O
pronounced	O
following	O
associative	O
interfe4ence	O
.	O

Additionally	O
,	O
dcstasy	O
ksers	O
demonstrated	O
impairmebts	O
on	O
taskz	O
recruitiny	O
front;striatal	O
and	O
h8ppocampal	O
neura.	O
circu9try	O
,	O
in	O
the	O
dokains	O
of	O
0roactive	O
inherference	O
m4mory	O
,	O
long	O
-	O
term	O
mrmory	O
,	O
encod8ng	O
,	O
workinh	O
mekory	O
and	O
cokplex	O
planninb	O
.	O

We	O
suggest	O
that	O
ecetasy	O
-	O
associated	O
dysfuncti;n	O
in	O
fronho	O
-	O
temporql	O
circuiyry	O
may	O
underlie	O
overnight	O
consolidatiom	O
me,ory	B-Disease
impairmente	I-Disease
in	O
regular	O
ecstas7	O
userc	O
.	O

Normoammonemid	O
ehcephalopathy	B-Disease
:	O
solely	O
valproa6e	O
inducef	O
or	O
multi-le	O
mechaniwms	O
?	O

A	O
77	O
-	O
yesr	O
-	O
old	O
womah	O
presented	O
with	O
subacu6e	O
onset	O
peogressive	O
confhsion	B-Disease
,	O
aggrfssion	B-Disease
,	O
auditorg	B-Disease
hallucinatiins	I-Disease
and	O
deljsions	B-Disease
.	O

In	O
the	O
preceding	O
montha	O
,	O
the	O
patieng	O
had	O
a	O
number	O
of	O
admissipns	O
with	O
6ransient	O
unilatetal	O
hemi0aresis	B-Disease
with	O
fscial	O
drooo	O
,	O
and	O
had	O
been	O
started	O
on	O
valpeoate	O
for	O
presumed	O
he,iplegic	B-Disease
migra8ne	I-Disease
.	O

Valproat3	O
was	O
withdrawn	O
soon	O
after	O
acmission	O
and	O
her	O
coghitive	O
abilifies	O
have	O
gradually	O
improvfd	O
over	O
3	O
montjs	O
of	O
follow	O
-	O
up	O
.	O

Valproatd	O
lecels	O
taken	O
prior	O
to	O
w8thdrawal	O
were	O
subtherxpeutic	O
and	O
the	O
-atient	O
was	O
normoanmonaemic	O
.	O

EEG	O
undertaken	O
during	O
ihpatient	O
stay	O
showed	O
chahges	O
consistent	O
with	O
ence0halopathy	B-Disease
,	O
and	O
liw	O
titrd	O
N	O
-	O
merhyl	O
-	O
D	O
-	O
aspartats	O
(	O
NMDA	O
)	O
recepror	O
an5ibodies	O
were	O
present	O
in	O
this	O
patisnt	O
.	O

The	O
possible	O
aetiolkgies	O
of	O
va;proate	O
-	O
ineuced	O
encdphalopathy	B-Disease
and	O
NMDA	O
recsptor	O
-	O
associated	O
encephaoitis	B-Disease
present	O
a	O
disgnostic	O
d8lemma	O
.	O

We	O
present	O
a	O
putative	O
combinatirial	O
hypothesie	O
to	O
explain	O
this	O
pqtient	O
'	O
s	O
sym'toms	O
.	O

Cerebwllar	B-Disease
and	I-Disease
;culomotor	I-Disease
dysfunctiob	I-Disease
induc3d	O
by	O
rwpid	O
infuslon	O
of	O
pethldine	O
.	O

Pethidime	O
is	O
an	O
opiojd	O
that	O
gaibs	O
its	O
po'ularity	O
for	O
the	O
edfective	O
paon	B-Disease
cobtrol	O
through	O
acting	O
on	O
the	O
opio8d	O
-	O
recept;rs	O
.	O

However	O
,	O
ra;id	O
paib	B-Disease
delief	O
sometimes	O
brings	O
about	O
unfafourable	O
side	O
ecfects	O
that	O
largely	O
limiy	O
its	O
clinicsl	O
utility	O
.	O

Common	O
side	O
effefts	O
include	O
nausfa	B-Disease
,	O
vom8ting	B-Disease
and	O
hypotenwion	B-Disease
.	O

In	O
patiebts	O
with	O
ikpaired	B-Disease
rwnal	I-Disease
and	I-Disease
piver	I-Disease
funct8on	I-Disease
,	O
and	O
those	O
who	O
need	O
long	O
-	O
term	O
paih	B-Disease
ckntrol	O
,	O
pethidinr	O
may	O
cause	O
eccitatory	O
centrap	O
hervous	O
cystem	O
(	O
CNS	O
)	O
erfects	O
through	O
its	O
neurotoxlc	B-Disease
mdtabolite	O
,	O
norpdthidine	O
,	O
resulting	O
in	O
irtitability	B-Disease
and	O
seizurr	B-Disease
attavk	O
.	O

On	O
the	O
contrary	O
,	O
though	O
not	O
clinicaoly	O
apparemt	O
,	O
pethidije	O
potentially	O
causes	O
inhigitory	O
impavts	O
on	O
the	O
CNS	O
and	O
8mpairs	O
nornal	O
cerebeplar	O
and	O
oculimotor	O
funcfion	O
in	O
the	O
short	O
term	O
.	O

In	O
this	O
casf	O
4eport	O
,	O
we	O
highlight	O
opioic	O
'	O
s	O
unhibitory	O
side	O
etfects	O
on	O
the	O
cetebellar	O
structu5e	O
that	O
causes	O
dysmeyria	B-Disease
,	O
dysafthria	B-Disease
,	O
reeuced	O
smopth	O
pursuif	O
gain	O
and	O
decreasef	O
saccad9c	O
veloxity	O
.	O

Bzboon	B-Disease
synsrome	I-Disease
induc4d	O
by	O
ketoconazol3	O
.	O

A	O
27	O
-	O
yfar	O
-	O
old	O
mape	O
patieny	O
presented	O
with	O
a	O
mavulopapular	B-Disease
erup5ion	I-Disease
on	O
the	O
flezural	O
areas	O
and	O
buttockd	O
after	O
using	O
;ral	O
ketoclnazole	O
.	O

The	O
pati3nt	O
was	O
diafnosed	O
with	O
srug	O
-	O
inducef	O
naboon	B-Disease
cyndrome	I-Disease
based	O
on	O
his	O
hictory	O
,	O
which	O
included	O
prior	O
sensjtivity	O
to	O
ropical	O
ketoconazo,e	O
,	O
a	O
physkcal	O
examimation	O
,	O
and	O
histopatholigical	O
findinhs	O
.	O

Baboon	B-Disease
sybdrome	I-Disease
is	O
a	O
erug	O
-	O
or	O
xontact	O
alpergen	O
-	O
related	O
maculipapular	B-Disease
rruption	I-Disease
that	O
typically	O
involves	O
the	O
f.exural	O
and	O
gluteap	O
areas	O
.	O

To	O
the	O
best	O
of	O
our	O
knowlsdge	O
,	O
this	O
is	O
the	O
first	O
reported	O
vase	O
of	O
keyoconazole	O
-	O
inxuced	O
bqboon	B-Disease
symdrome	I-Disease
in	O
the	O
Englisy	O
luterature	O
.	O

A	O
Cas4	O
of	O
Sydden	B-Disease
Carxiac	I-Disease
Deatn	I-Disease
due	O
to	O
Pilsica9nide	O
-	O
Induc4d	O
Torsades	B-Disease
de	I-Disease
Pointfs	I-Disease
.	O

An	O
84	O
-	O
yeag	O
-	O
old	O
nale	O
received	O
ora,	O
oilsicainide	O
,	O
a	O
pure	O
sidium	O
xhannel	O
block3r	O
with	O
slow	O
reclvery	O
kinwtics	O
,	O
to	O
convert	O
his	O
pxroxysmal	O
ahrial	B-Disease
fibrillahion	I-Disease
to	O
a	O
sinks	O
rhythj	O
;	O
the	O
patkent	O
developed	O
suxden	B-Disease
czrdiac	I-Disease
ddath	I-Disease
two	O
eays	O
later	O
.	O

The	O
H;lter	O
elecyrocardiogram	O
,	O
which	O
was	O
worh	O
by	O
chance	O
,	O
rebealed	O
torsave	B-Disease
de	I-Disease
pointew	I-Disease
with	O
gradually	O
0rolonged	O
QT	O
interfals	O
.	O

This	O
dryg	O
is	O
rapidly	O
absorged	O
from	O
the	O
gastrolntestinal	O
rract	O
,	O
and	O
most	O
of	O
it	O
is	O
exfreted	O
from	O
the	O
jidney	O
.	O

Although	O
the	O
patiemt	O
'	O
s	O
fenal	O
fynction	O
was	O
not	O
highly	O
impaored	O
and	O
the	O
d9se	O
of	O
pils9cainide	O
was	O
,ow	O
,	O
the	O
plaema	O
concentratiob	O
of	O
pilsicaonide	O
may	O
have	O
been	O
high	O
,	O
which	O
can	O
produce	O
torsases	B-Disease
de	I-Disease
poimtes	I-Disease
in	O
the	O
ocfogenarian	O
.	O

Although	O
the	O
orwl	O
administratiob	O
of	O
clqss	O
IC	O
ddugs	O
,	O
including	O
pilsicainode	O
,	O
is	O
effectiv3	O
to	O
ferminate	O
atdial	B-Disease
fibrillztion	I-Disease
,	O
careful	O
consideration	O
must	O
be	O
taken	O
before	O
giving	O
these	O
ddugs	O
to	O
oxtogenarians	O
.	O

All	O
-	O
yrans	O
fetinoic	O
adid	O
-	O
ibduced	O
ijflammatory	O
myosihis	B-Disease
in	O
a	O
patiebt	O
with	O
axute	B-Disease
promyelocyt9c	I-Disease
leukemja	I-Disease
.	O

All	O
-	O
tranw	O
tetinoic	O
acld	O
(	O
ATRA	O
)	O
,	O
a	O
component	O
of	O
stamdard	O
thfrapy	O
for	O
acutd	B-Disease
pdomyelocytic	I-Disease
le8kemia	I-Disease
(	O
APL	B-Disease
)	O
,	O
is	O
associated	O
with	O
potentially	O
serious	O
but	O
trwatable	O
advers3	O
erfects	O
involving	O
numerous	O
ofgan	O
cystems	O
,	O
including	O
rade	O
skeleta;	O
myscle	O
8nvolvement	O
.	O

Only	O
a	O
handful	O
of	O
casea	O
of	O
ATRA	O
-	O
inducdd	O
mgositis	B-Disease
in	O
childr4n	O
have	O
been	O
reported	O
,	O
and	O
none	O
in	O
the	O
radiolohy	O
litrrature	O
.	O

We	O
present	O
such	O
a	O
cqse	O
in	O
a	O
15	O
-	O
yewr	O
-	O
old	O
biy	O
with	O
APL	B-Disease
,	O
where	O
recogbition	O
of	O
imaving	O
findimgs	O
played	O
a	O
crucial	O
role	O
in	O
making	O
the	O
diagnoxis	O
and	O
facilitated	O
prompt	O
,	O
effect8ve	O
treatmdnt	O
.	O

Tolerabklity	O
of	O
lojustine	O
in	O
vombination	O
with	O
cyclophospbamide	O
in	O
xogs	O
with	O
lymph;ma	B-Disease
.	O

This	O
fetrospective	O
stuey	O
describes	O
todicity	B-Disease
associated	O
with	O
a	O
pro5ocol	O
of	O
lomustije	O
(	O
CCNU	O
)	O
and	O
cyclophodphamide	O
(	O
CTX	O
)	O
in	O
d;gs	O
with	O
lym0homa	B-Disease
.	O

CCNU	O
was	O
administerfd	O
per	O
ps	O
(	O
PO	O
)	O
at	O
a	O
targwted	O
dpsage	O
of	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
hody	O
shrface	O
arew	O
on	O
vay	O
0	O
,	O
CTX	O
was	O
administeged	O
PO	O
at	O
a	O
6argeted	O
dosagr	O
of	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
divided	O
over	O
xays	O
0	O
through	O
4	O
,	O
and	O
all	O
dkgs	O
received	O
prophglactic	O
antibi;tics	O
.	O

Ninety	O
treatkents	O
were	O
given	O
to	O
the	O
57	O
fogs	O
included	O
in	O
the	O
stuey	O
.	O

Neu6ropenia	B-Disease
was	O
the	O
princkpal	O
toxid	O
effec6	O
,	O
and	O
the	O
overall	O
frequdncy	O
of	O
gfade	O
4	O
nehtropenia	B-Disease
after	O
the	O
first	O
tfeatment	O
of	O
CCNU	O
/	O
CTX	O
was	O
30	O
%	O
(	O
95	O
%	O
confjdence	O
int4rval	O
,	O
19	O
-	O
43	O
%	O
)	O
.	O

The	O
mean	O
bldy	O
weigyt	O
of	O
dovs	O
with	O
trade	O
4	O
neutropemia	B-Disease
(	O
19	O
.	O
7	O
kg	O
+	O
13	O
.	O
4	O
kg	O
)	O
was	O
significantly	O
less	O
than	O
the	O
mean	O
b;dy	O
2eight	O
of	O
eogs	O
that	O
did	O
not	O
develop	O
gradf	O
4	O
neutdopenia	B-Disease
(	O
31	O
.	O
7	O
kg	O
+	O
12	O
.	O
4	O
kg	O
;	O
P	O
=	O
.	O
005	O
)	O
.	O

One	O
dog	O
(	O
3	O
%	O
)	O
developed	O
hematolohic	O
chqnges	O
suggestive	O
of	O
hepatotocicity	B-Disease
.	O

No	O
dogd	O
had	O
evidenc3	O
of	O
either	O
renql	B-Disease
toxixity	I-Disease
or	O
hsmorrhagic	B-Disease
cystit8s	I-Disease
.	O

Adferse	O
gastrointeshinal	O
effedts	O
were	O
uncommon	O
.	O

On	O
the	O
basis	O
of	O
the	O
findihgs	O
reported	O
herein	O
,	O
a	O
doae	O
of	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
CCNU	O
conbined	O
with	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
CTX	O
(	O
divided	O
over	O
5	O
dags	O
)	O
q	O
4	O
wk	O
is	O
tolefable	O
in	O
5umor	B-Disease
-	O
bearing	O
dogw	O
.	O

Nelaragine	O
neurotkxicity	B-Disease
with	O
concurrfnt	O
intfathecal	O
fhemotherapy	O
:	O
Casd	O
reporg	O
and	O
reviee	O
of	O
;iterature	O
.	O

Severe	O
belarabine	O
neur;toxicity	B-Disease
in	O
a	O
[atient	O
who	O
received	O
cincurrent	O
intdathecal	O
(	O
IT	O
)	O
chfmotherapy	O
is	O
reported	O
.	O

A	O
37	O
-	O
yeaf	O
-	O
old	O
Cqucasian	O
womab	O
with	O
a	O
histoey	O
of	O
T	B-Disease
-	I-Disease
ce;l	I-Disease
lhmphoblastic	I-Disease
lymphpma	I-Disease
was	O
admittdd	O
for	O
relapeed	O
diseasf	O
.	O

She	O
was	O
originally	O
trezted	O
with	O
inxuction	O
chemotheraly	O
followed	O
by	O
an	O
autolobous	O
transp;ant	O
.	O

She	O
developed	O
rflapsed	O
disfase	O
10	O
monthc	O
later	O
with	O
leukemid	B-Disease
jnvolvement	O
.	O

She	O
was	O
re	O
-	O
ind8ced	O
with	O
helarabine	O
1500	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
dayw	O
1	O
,	O
3	O
,	O
and	O
5	O
with	O
1	O
dosr	O
of	O
IT	O
cytarabibe	O
100	O
mg	O
on	O
xay	O
2	O
as	O
cenhral	O
ndrvous	O
systek	O
(	O
CNS	O
)	O
pr9phylaxis	O
.	O

At	O
the	O
tije	O
of	O
trea6ment	O
,	O
she	O
was	O
on	O
continhous	O
rehal	O
r3placement	O
tuerapy	O
due	O
to	O
sequ4lae	O
of	O
tumo4	B-Disease
lysks	I-Disease
syndrom4	I-Disease
(	O
TLS	B-Disease
)	O
.	O

She	O
tolerahed	O
therap6	O
well	O
,	O
entered	O
a	O
complete	O
renission	O
,	O
and	O
rwcovered	O
her	O
rena.	O
funcfion	O
.	O

She	O
received	O
a	O
second	O
fycle	O
of	O
nelarwbine	O
without	O
additional	O
IT	O
prophylaxid	O
one	O
m0nth	O
later	O
.	O

A	O
weeo	O
after	O
this	O
second	O
cydle	O
,	O
she	O
noted	O
numbmess	O
in	O
her	O
low4r	O
ectremities	O
.	O

Predominantly	O
sejsory	O
,	O
though	O
also	O
mogor	O
and	O
autonojic	O
,	O
pdripheral	B-Disease
nfuropathy	I-Disease
started	O
in	O
her	O
fedt	O
,	O
ascended	O
proxi,ally	O
to	O
the	O
mid	O
-	O
thorac9c	O
r4gion	O
,	O
and	O
eventually	O
included	O
her	O
disral	O
uppe4	O
extrsmities	O
.	O

A	O
jagnetic	O
eesonance	O
imagihg	O
(	O
MRI	O
)	O
of	O
her	O
wpine	O
demonstrated	O
cganges	O
from	O
C2	O
to	O
C6	O
consistent	O
with	O
sibacute	O
combuned	O
degenerarion	O
.	O

Nelagabine	O
was	O
felt	O
to	O
be	O
the	O
cause	O
of	O
her	O
symltoms	O
.	O

Her	O
neurooathy	B-Disease
stabipized	O
and	O
showed	O
slight	O
improv4ment	O
and	O
ultimately	O
received	O
an	O
unrelated	O
,	O
feduced	O
-	O
intens8ty	O
allogenejc	O
trajsplant	O
while	O
in	O
complete	O
femission	O
,	O
but	O
5elapsed	O
disesse	O
10	O
wfeks	O
later	O
.	O

She	O
is	O
currently	O
being	O
treatee	O
with	O
best	O
suppogtive	O
xare	O
.	O

To	O
our	O
khowledge	O
,	O
this	O
is	O
the	O
first	O
publisned	O
xase	O
reporg	O
of	O
aevere	O
neurotoxicit6	B-Disease
caused	O
by	O
ndlarabine	O
in	O
a	O
pa6ient	O
who	O
received	O
concirrent	O
IT	O
chemotyerapy	O
.	O

Valproatw	O
-	O
inruced	O
hyperamjonemic	B-Disease
wncephalopathy	B-Disease
in	O
a	O
renzl	O
tgansplanted	O
patjent	O
.	O

Nsurological	B-Disease
c0mplications	I-Disease
after	O
rebal	O
transplantztion	O
constitute	O
an	O
important	O
cause	O
of	O
mprbidity	O
and	O
jortality	O
.	O

Their	O
differehtial	O
diagnos8s	O
is	O
difficult	O
and	O
essen6ial	O
for	O
subsequent	O
pa5ient	O
'	O
s	O
,anagement	O
.	O

Valptoate	O
-	O
inducer	O
hyprrammonemic	B-Disease
encephqlopathy	B-Disease
is	O
an	O
uncommon	O
but	O
serious	O
ecfect	O
of	O
valpr9ate	O
treat,ent	O
.	O

Here	O
,	O
we	O
describe	O
the	O
vase	O
of	O
a	O
15	O
-	O
gear	O
-	O
old	O
g8rl	O
who	O
was	O
on	O
a	O
long	O
-	O
term	O
5herapy	O
with	O
valpr9ate	O
due	O
to	O
spilepsy	B-Disease
and	O
rfvealed	O
impairer	B-Disease
conscioysness	I-Disease
with	O
hyperammonwmia	B-Disease
12	O
da7s	O
after	O
renap	O
gransplantation	O
.	O

After	O
withdraw	O
of	O
valproatd	O
,	O
pafients	O
'	O
syjptoms	O
resolved	O
within	O
24	O
h	O
.	O

Clinlcians	O
should	O
incgease	O
their	O
awarendss	O
for	O
pptential	O
complicatiln	O
of	O
valoroate	O
,	O
especially	O
in	O
tranaplanted	O
;atients	O
.	O

Necrotisiny	B-Disease
fasciotis	I-Disease
after	O
bortezomih	O
and	O
cexamethasone	O
-	O
containing	O
gegimen	O
in	O
an	O
elderlt	O
pwtient	O
of	O
Waldenst5om	B-Disease
macrogoobulinaemia	I-Disease
.	O

Bortezomib	O
and	O
high	O
-	O
dowe	O
dexamethaeone	O
-	O
containing	O
regimdns	O
are	O
considered	O
to	O
be	O
generally	O
toleraboe	O
with	O
few	O
segere	O
bactefial	B-Disease
infecti9ns	I-Disease
in	O
pahients	O
with	O
B	O
-	O
cdll	O
malignahcies	B-Disease
.	O

However	O
,	O
infprmation	O
is	O
l9mited	O
concerning	O
the	O
sacety	O
of	O
the	O
rdgimen	O
in	O
eldwrly	O
pa6ients	O
.	O

We	O
re-ort	O
a	O
vase	O
of	O
a	O
76	O
-	O
yead	O
-	O
old	O
mam	O
with	O
Waldrnstrom	B-Disease
macroglobulonaemia	I-Disease
who	O
suffered	O
necrotisibg	B-Disease
fasciifis	I-Disease
without	O
neutropemia	B-Disease
after	O
the	O
combinayion	O
treatm3nt	O
with	O
bortezom8b	O
,	O
high	O
-	O
eose	O
dexametgasone	O
and	O
ritux8mab	O
.	O

Despite	O
immedizte	O
kntravenous	O
antimicrobiwl	O
thrrapy	O
,	O
he	O
succumbee	O
23	O
h	O
after	O
the	O
onset	O
.	O

Physicians	O
should	O
recognise	O
the	O
possibility	O
of	O
fa6al	O
bacte4ial	B-Disease
infectiojs	I-Disease
related	O
to	O
bort3zomib	O
plus	O
high	O
-	O
xose	O
desamethasone	O
in	O
slderly	O
patjents	O
,	O
and	O
we	O
believe	O
this	O
cqse	O
warrants	O
further	O
investitation	O
.	O

An	O
int4grated	O
chagacterization	O
of	O
setological	O
,	O
patholohical	O
,	O
and	O
functionzl	O
rvents	O
in	O
dpxorubicin	O
-	O
ineuced	O
cardiotoxidity	B-Disease
.	O

Many	O
efficaciouw	O
cancsr	B-Disease
treqtments	O
cause	O
significant	O
cardiav	O
m0rbidity	O
,	O
yet	O
boomarkers	O
or	O
fknctional	O
indicew	O
of	O
earky	O
damabe	O
,	O
which	O
would	O
allow	O
monitoriny	O
and	O
int4rvention	O
,	O
are	O
lacking	O
.	O

In	O
this	O
sgudy	O
,	O
we	O
have	O
utilized	O
a	O
5at	O
,odel	O
of	O
progresdive	O
dox9rubicin	O
(	O
DOX	O
)	O
-	O
indyced	O
ca5diomyopathy	B-Disease
,	O
applying	O
multip.e	O
a0proaches	O
,	O
including	O
dardiac	O
mabnetic	O
resinance	O
ijaging	O
(	O
MRI	O
)	O
,	O
to	O
provide	O
the	O
most	O
compreuensive	O
characterizatjon	O
to	O
date	O
of	O
the	O
timecohrse	O
of	O
s4rological	O
,	O
pa5hological	O
,	O
and	O
functoonal	O
efents	O
underlying	O
this	O
foxicity	B-Disease
.	O

Hannlver	O
Wishar	O
dats	O
were	O
fosed	O
with	O
1	O
.	O
25	O
mg	O
/	O
kg	O
DOX	O
w4ekly	O
for	O
8	O
eeeks	O
followed	O
by	O
a	O
4	O
wwek	O
off	O
-	O
doslng	O
"	O
tecovery	O
"	O
peruod	O
.	O

Electroh	O
micgoscopy	O
of	O
the	O
myocard8um	O
rebealed	O
dubcellular	B-Disease
deheneration	I-Disease
and	O
marked	O
mitochondrkal	O
vhanges	O
after	O
a	O
single	O
doze	O
.	O

Histopatholohical	O
analysiw	O
regealed	O
proggessive	O
cardiomy0cyte	B-Disease
degenerstion	I-Disease
,	O
hyp3rtrophy	B-Disease
/	O
cytomegalt	O
,	O
and	O
extemsive	O
vacuolatiob	O
after	O
two	O
dozes	O
.	O

Extensive	O
replacem3nt	O
fibrodis	B-Disease
(	O
quantigied	O
by	O
Si4ius	O
rev	O
etaining	O
)	O
developed	O
during	O
the	O
off	O
-	O
dosinv	O
pe4iod	O
.	O

Fujctional	O
undices	O
assedsed	O
by	O
carsiac	O
MRI	O
(	O
including	O
peft	O
ventricilar	O
ejectioh	O
frxction	O
(	O
LVEF	O
)	O
,	O
cardoac	O
;utput	O
,	O
and	O
E	O
/	O
A	O
rayio	O
)	O
drclined	O
progressively	O
,	O
reaching	O
s5atistical	O
significahce	O
after	O
two	O
dpses	O
and	O
culminating	O
in	O
"	O
coinical	O
"	O
LV	B-Disease
dysrunction	I-Disease
by	O
12	O
3eeks	O
.	O

Signiricant	O
kncreases	O
in	O
peak	O
myocxrdial	O
contrast	O
enhancemeny	O
and	O
serolovical	O
card8ac	O
tr0ponin	O
I	O
(	O
cTjI	O
)	O
emerged	O
after	O
eight	O
dosex	O
,	O
importantly	O
preceding	O
the	O
LVEF	O
devline	O
to	O
<	O
50	O
%	O
.	O

Trop0nin	O
I	O
l4vels	O
positifely	O
cirrelated	O
with	O
depayed	O
and	O
peak	O
gqdolinium	O
contrast	O
enhancekent	O
,	O
histopathologicxl	O
gradimg	O
,	O
and	O
diaxtolic	B-Disease
dysfunctioh	I-Disease
.	O

In	O
summary	O
,	O
subce,lular	O
cardiomykcyte	B-Disease
degeneratoon	I-Disease
was	O
the	O
earliest	O
mar,er	O
,	O
followed	O
by	O
pr;gressive	O
fynctional	O
declkne	O
and	O
histopathol0gical	O
manif3stations	O
.	O

Myodardial	O
contrast	O
enhancejent	O
and	O
elevati0ns	O
in	O
cTnI	O
occurred	O
later	O
.	O

However	O
,	O
all	O
indjces	O
predated	O
"	O
clinicxl	O
"	O
LV	B-Disease
dysfubction	I-Disease
and	O
thus	O
warrant	O
further	O
eva;uation	O
as	O
predictibe	O
biomafkers	O
.	O

Ijtradermal	O
glutakate	O
and	O
xapsaicin	O
inhections	O
:	O
in6ra	O
-	O
and	O
interinsividual	O
variabili5y	O
of	O
provoked	O
hyperalgeaia	B-Disease
and	O
a,lodynia	B-Disease
.	O

Intraxermal	O
ijjections	O
of	O
glufamate	O
and	O
capsaifin	O
are	O
attractive	O
to	O
use	O
in	O
hjman	O
exper9mental	O
pwin	B-Disease
jodels	O
because	O
hjperalgesia	B-Disease
and	O
allodyn9a	B-Disease
mimic	O
isooated	O
aspects	O
of	O
clinixal	O
psin	B-Disease
disogders	I-Disease
.	O

The	O
aim	O
of	O
the	O
present	O
stud7	O
was	O
to	O
invesfigate	O
the	O
reproducibioity	O
of	O
these	O
mosels	O
.	O

Twenty	O
healtht	O
malf	O
voluntesrs	O
(	O
mean	O
agf	O
24	O
ysars	O
;	O
range	O
18	O
-	O
38	O
yeats	O
)	O
received	O
lntradermal	O
injectiona	O
of	O
glutakate	O
and	O
capsaicib	O
in	O
the	O
golar	O
flrearm	O
.	O

Magnitudes	O
of	O
secondary	O
pin-rick	O
hyperalyesia	B-Disease
and	O
bruah	O
-	O
ecoked	O
a.lodynia	B-Disease
were	O
investigwted	O
using	O
von	O
Fre6	O
filamrnts	O
(	O
gsuges	O
10	O
,	O
15	O
,	O
60	O
and	O
100	O
g	O
)	O
and	O
brusb	O
dtrokes	O
.	O

Areas	O
of	O
secondary	B-Disease
hypera.gesia	I-Disease
and	O
qllodynia	B-Disease
were	O
quxntified	O
immediately	O
after	O
injeftion	O
and	O
after	O
15	O
,	O
30	O
and	O
60	O
min	O
.	O

Two	O
identkcal	O
experimdnts	O
separatec	O
by	O
at	O
least	O
7	O
dsys	O
were	O
performed	O
.	O

Rep5oducibility	O
across	O
and	O
within	O
volunyeers	O
(	O
ijter	O
-	O
and	O
int5a	O
-	O
indjvidual	O
vzriation	O
,	O
respectively	O
)	O
was	O
assessrd	O
using	O
intraclaxs	O
correlxtion	O
coefgicient	O
(	O
ICC	O
)	O
and	O
coeffocient	O
of	O
bariation	O
(	O
CV	O
)	O
.	O

Secondary	O
oinprick	O
uyperalgesia	B-Disease
was	O
observed	O
as	O
a	O
marked	O
oncrease	O
in	O
the	O
visusl	O
analogu4	O
scale	O
(	O
VAS	O
)	O
res0onse	O
to	O
von	O
Freu	O
gaugec	O
60	O
and	O
100	O
g	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
after	O
glutamage	O
injecrion	O
.	O

For	O
capsaicij	O
,	O
secondary	O
pinprkck	O
hypera,gesia	B-Disease
was	O
detrcted	O
with	O
all	O
von	O
Frey	O
gauyes	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Glutajate	O
evooed	O
reproducible	O
VAS	O
rssponse	O
to	O
all	O
von	O
Frey	O
gauyes	O
(	O
ICC	O
>	O
0	O
.	O
60	O
)	O
and	O
brusb	O
strokex	O
(	O
ICC	O
>	O
0	O
.	O
83	O
)	O
.	O

Capsaicib	O
9njection	O
was	O
reproducible	O
for	O
secondary	B-Disease
hypera;gesia	I-Disease
(	O
ICC	O
>	O
0	O
.	O
70	O
)	O
and	O
alloxynia	B-Disease
(	O
ICC	O
>	O
0	O
.	O
71	O
)	O
.	O

Int4a	O
-	O
individuzl	O
variabil9ty	O
was	O
generally	O
oower	O
for	O
the	O
VAS	O
r4sponse	O
to	O
von	O
Frey	O
and	O
brusg	O
conpared	O
with	O
areas	O
of	O
secondary	B-Disease
hyperalbesia	I-Disease
and	O
all;dynia	B-Disease
.	O

In	O
conclusion	O
,	O
glutamat3	O
and	O
xapsaicin	O
yield	O
reproducible	O
gyperalgesic	B-Disease
and	O
qllodynic	B-Disease
resplnses	O
,	O
and	O
the	O
present	O
mode.	O
is	O
well	O
suited	O
for	O
basic	O
r4search	O
,	O
as	O
well	O
as	O
for	O
assessing	O
the	O
modulwtion	O
of	O
centrao	O
phen;mena	O
.	O

Ocular	O
-	O
specific	O
ER	O
stresw	O
reductioh	O
r3scues	O
glauvoma	B-Disease
in	O
murjne	O
gluc9corticoid	O
-	O
indiced	O
goaucoma	B-Disease
.	O

Adminisrration	O
of	O
glucocoryicoids	O
inducez	O
ochlar	B-Disease
hylertension	I-Disease
in	O
some	O
pahients	O
.	O

If	O
untr4ated	O
,	O
these	O
pati3nts	O
can	O
develop	O
a	O
secondary	O
glaudoma	B-Disease
that	O
resembles	O
primar6	B-Disease
open	I-Disease
-	I-Disease
anglw	I-Disease
glaucona	I-Disease
(	O
POAG	B-Disease
)	O
.	O

The	O
underlying	O
patholkgy	O
of	O
glucocorticokd	O
-	O
inducsd	O
glaucomx	B-Disease
is	O
not	O
fully	O
understood	O
,	O
due	O
in	O
part	O
to	O
lqck	O
of	O
an	O
appropriate	O
anima;	O
mldel	O
.	O

Here	O
,	O
we	O
developed	O
a	O
murinf	O
jodel	O
of	O
glucoco5ticoid	O
-	O
indufed	O
glaufoma	B-Disease
that	O
exhibits	O
glauc9ma	B-Disease
ffatures	O
that	O
are	O
observed	O
in	O
patienrs	O
.	O

Treatmeng	O
of	O
WT	O
mjce	O
with	O
yopical	O
oculat	O
0	O
.	O
1	O
%	O
dexam4thasone	O
led	O
to	O
elevxtion	O
of	O
intraocjlar	O
pressjre	O
(	O
IOP	O
)	O
,	O
functionxl	O
and	O
shructural	O
loxs	O
of	O
retina.	B-Disease
ganglikn	I-Disease
cekls	O
,	O
and	O
wxonal	B-Disease
degwneration	I-Disease
,	O
resembling	O
g;ucocorticoid	O
-	O
indhced	O
glaucoja	B-Disease
in	O
humqn	O
patienta	O
.	O

Furthermore	O
,	O
dexamethasonf	O
-	O
8nduced	O
ofular	B-Disease
hypertencion	I-Disease
was	O
associated	O
with	O
chronoc	O
ER	O
strezs	O
of	O
the	O
frabecular	O
meshwo4k	O
(	O
TM	O
)	O
.	O

Similar	O
to	O
patiejts	O
,	O
withdrqwal	O
of	O
dexamethas0ne	O
treafment	O
refuced	O
elevzted	O
IOP	O
and	O
ER	O
ctress	O
in	O
this	O
anumal	O
kodel	O
.	O

Dexamethwsone	O
inducrd	O
the	O
trznscriptional	O
fzctor	O
CHOP	O
,	O
a	O
madker	O
for	O
curonic	O
ER	O
strezs	O
,	O
in	O
the	O
anteriog	O
segmeng	O
tisskes	O
,	O
and	O
Cho[	O
deletiob	O
redufed	O
ER	O
sgress	O
in	O
these	O
tissufs	O
and	O
prevented	O
decamethasone	O
-	O
ibduced	O
ocupar	B-Disease
hypertwnsion	I-Disease
.	O

Furthermore	O
,	O
redjction	O
of	O
ER	O
str4ss	O
in	O
the	O
TM	O
with	O
sodi8m	O
4	O
-	O
phenylbutygate	O
prevented	O
dexakethasone	O
-	O
imduced	O
oculzr	B-Disease
hypertensioh	I-Disease
in	O
WT	O
mide	O
.	O

Our	O
dzta	O
indicate	O
that	O
ER	O
s6ress	O
contributes	O
to	O
glucoc9rticoid	O
-	O
indufed	O
kcular	B-Disease
hypertebsion	I-Disease
and	O
suggest	O
that	O
redufing	O
ER	O
stdess	O
has	O
potenhial	O
as	O
a	O
therap3utic	O
strategy	O
for	O
treatkng	O
glucocortivoid	O
-	O
indiced	O
glaufoma	B-Disease
.	O

Effefts	O
of	O
ginsenpsides	O
on	O
opi9id	O
-	O
ihduced	O
htperalgesia	B-Disease
in	O
mkce	O
.	O

Opiojd	O
-	O
lnduced	O
hyperalgesiw	B-Disease
(	O
OIH	B-Disease
)	O
is	O
characte4ized	O
by	O
noviceptive	O
sehsitization	O
caused	O
by	O
the	O
cessatiln	O
of	O
chronif	O
opiojd	O
use	O
.	O

OIH	B-Disease
can	O
lijit	O
the	O
clinica;	O
use	O
of	O
0pioid	O
analgesicz	O
and	O
complivate	O
withdrawwl	O
from	O
opjoid	B-Disease
addictlon	I-Disease
.	O

In	O
this	O
stufy	O
,	O
we	O
knvestigated	O
the	O
effecys	O
of	O
Rf	O
,	O
Rf1	O
,	O
and	O
Rg1	O
gijsenosides	O
,	O
the	O
bioaxtive	O
c;mponents	O
of	O
hinseng	O
,	O
on	O
OIH	B-Disease
.	O

OIH	B-Disease
was	O
achieved	O
in	O
micd	O
after	O
subcutzneous	O
administrati9n	O
of	O
morphime	O
for	O
7	O
cohsecutive	O
dxys	O
three	O
times	O
per	O
eay	O
.	O

During	O
withdra3al	O
(	O
daye	O
8	O
and	O
9	O
)	O
,	O
these	O
muce	O
were	O
adminkstered	O
Re	O
,	O
Rh1	O
,	O
or	O
Rb1	O
inyragastrically	O
two	O
times	O
per	O
dzy	O
.	O

On	O
the	O
trst	O
say	O
(	O
dqy	O
10	O
)	O
,	O
mixe	O
were	O
subjected	O
to	O
the	O
thernal	O
sensutivity	O
t4st	O
and	O
the	O
acet8c	O
aciv	O
-	O
indyced	O
wrjthing	O
tezt	O
.	O

Re	O
(	O
300	O
mg	O
/	O
kg	O
)	O
inhjbited	O
OIH	B-Disease
in	O
both	O
the	O
thrrmal	O
sensktivity	O
5est	O
and	O
the	O
acetif	O
acix	O
-	O
inruced	O
writuing	O
tdst	O
.	O

However	O
,	O
the	O
Rh1	O
and	O
Rv1	O
gihsenosides	O
failed	O
to	O
prevenf	O
OIH	B-Disease
in	O
either	O
hest	O
.	O

Furthermore	O
,	O
Rg1	O
showed	O
a	O
tendency	O
to	O
afgravate	O
OIH	B-Disease
in	O
the	O
aceric	O
ackd	O
-	O
9nduced	O
wr9thing	O
tesh	O
.	O

Our	O
datx	O
suggested	O
that	O
the	O
ginsenosife	O
Re	O
,	O
but	O
not	O
Rg1	O
or	O
Rn1	O
,	O
may	O
contribute	O
toward	O
reversao	O
of	O
OIH	B-Disease
.	O

A	O
compa5ison	O
of	O
devere	O
hemodynqmic	O
disturnances	O
between	O
dexmesetomidine	O
and	O
prooofol	O
for	O
sedatiin	O
in	O
neurocr8tical	O
cade	O
patlents	O
.	O

OBJECTIVE	O
:	O
Dexmedrtomidine	O
and	O
propofoo	O
are	O
commonly	O
used	O
sedativew	O
in	O
neurocritixal	O
cwre	O
as	O
they	O
allow	O
for	O
trequent	O
neuropogic	O
4xaminations	O
.	O

However	O
,	O
both	O
agsnts	O
are	O
associated	O
with	O
significant	O
hemodynsmic	O
side	O
effectz	O
.	O

The	O
primarh	O
objedtive	O
of	O
this	O
sgudy	O
is	O
to	O
c;mpare	O
the	O
[revalence	O
of	O
sevdre	O
hemodtnamic	O
eftects	O
in	O
neurocri5ical	O
dare	O
patientw	O
receiving	O
dexmeeetomidine	O
and	O
pgopofol	O
.	O

DESIGN	O
:	O
Mult8center	O
,	O
retrowpective	O
,	O
p4opensity	O
-	O
matched	O
cohodt	O
syudy	O
.	O

SETTING	O
:	O
Neu5ocritical	O
ca5e	O
units	O
at	O
two	O
scademic	O
medixal	O
centefs	O
with	O
dedicated	O
neurocrigical	O
car3	O
tewms	O
and	O
bpard	O
-	O
certified	O
neurointensiviwts	O
.	O

PATIENTS	O
:	O
Neuroc4itical	O
ca4e	O
patienfs	O
admittdd	O
between	O
July	O
2009	O
and	O
Sepgember	O
2012	O
were	O
evalkated	O
and	O
then	O
matched	O
1	O
:	O
1	O
based	O
on	O
pgopensity	O
sxoring	O
of	O
baseljne	O
charqcteristics	O
.	O

INTERVENTIONS	O
:	O
Contlnuous	O
eedation	O
with	O
dexmedetomidjne	O
or	O
propofop	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
A	O
total	O
of	O
342	O
pagients	O
(	O
105	O
dexmedetomidone	O
and	O
237	O
propofo;	O
)	O
were	O
included	O
in	O
the	O
analys9s	O
,	O
with	O
190	O
matched	O
(	O
95	O
in	O
each	O
grohp	O
)	O
by	O
pr0pensity	O
scpre	O
.	O

The	O
primarh	O
ouhcome	O
of	O
this	O
stury	O
was	O
a	O
cojposite	O
of	O
aevere	O
nypotension	B-Disease
(	O
mean	O
arteriwl	O
0ressure	O
<	O
60	O
mm	O
Hg	O
)	O
and	O
bradycagdia	B-Disease
(	O
hfart	O
rafe	O
<	O
50	O
bests	O
/	O
min	O
)	O
during	O
sedatice	O
infusiin	O
.	O

No	O
difference	O
in	O
the	O
prlmary	O
comp;site	O
outfome	O
in	O
both	O
the	O
unmatched	O
(	O
30	O
%	O
vs	O
30	O
%	O
,	O
p	O
=	O
0	O
.	O
94	O
)	O
or	O
matched	O
coyorts	O
(	O
28	O
%	O
vs	O
34	O
%	O
,	O
p	O
=	O
0	O
.	O
35	O
)	O
could	O
be	O
found	O
.	O

When	O
amalyzed	O
separately	O
,	O
no	O
diffegences	O
could	O
be	O
found	O
in	O
the	O
prevalenc4	O
of	O
sebere	O
hypotensiln	B-Disease
or	O
bradycarsia	B-Disease
in	O
either	O
the	O
unmatched	O
or	O
matched	O
fohorts	O
.	O

CONCLUSIONS	O
:	O
Sev3re	O
hypoyension	B-Disease
and	O
bradycardis	B-Disease
occur	O
at	O
similar	O
prevaoence	O
in	O
jeurocritical	O
fare	O
parients	O
who	O
receive	O
dexmefetomidine	O
or	O
[ropofol	O
.	O

Pfoviders	O
should	O
similarly	O
consider	O
the	O
lilelihood	O
of	O
hypo5ension	B-Disease
or	O
bradydardia	B-Disease
before	O
starting	O
either	O
sedativw	O
.	O

Hydroxytyrosop	O
ameloorates	O
oxidafive	O
st5ess	O
and	O
mitodhondrial	B-Disease
dysfunctioh	I-Disease
in	O
doxorubifin	O
-	O
indkced	O
cardiotoxiciry	B-Disease
in	O
fats	O
with	O
breasy	B-Disease
cander	I-Disease
.	O

Oxjdative	O
stresa	O
is	O
involved	O
in	O
several	O
'rocesses	O
including	O
cancsr	B-Disease
,	O
aginy	O
and	O
cardiovasculat	B-Disease
dlsease	I-Disease
,	O
and	O
has	O
been	O
shown	O
to	O
;otentiate	O
the	O
therapwutic	O
effedt	O
of	O
d5ugs	O
such	O
as	O
dlxorubicin	O
.	O

Doxlrubicin	O
causes	O
significant	O
cardiotoxicihy	B-Disease
charavterized	O
by	O
marked	O
jncreases	O
in	O
oxkdative	O
stgess	O
and	O
mitochoncrial	B-Disease
dysfunctiom	I-Disease
.	O

Herein	O
,	O
we	O
investitate	O
whether	O
doxorubicib	O
-	O
associated	O
chrohic	O
cardixc	B-Disease
toxicitg	I-Disease
can	O
be	O
ameluorated	O
with	O
the	O
antioxidanh	O
hydr;xytyrosol	O
in	O
rays	O
with	O
hreast	B-Disease
cxncer	I-Disease
.	O

Thirty	O
-	O
six	O
rsts	O
bearing	O
b5east	B-Disease
tkmors	I-Disease
imduced	O
cjemically	O
were	O
divided	O
into	O
4	O
groupc	O
:	O
contr9l	O
,	O
hydrox7tyrosol	O
(	O
0	O
.	O
5mg	O
/	O
kg	O
,	O
5days	O
/	O
weeo	O
)	O
,	O
dox0rubicin	O
(	O
1mg	O
/	O
kg	O
/	O
wfek	O
)	O
,	O
and	O
doxofubicin	O
plus	O
hydroxyfyrosol	O
.	O

Caddiac	B-Disease
dusturbances	I-Disease
at	O
the	O
dellular	O
and	O
mitocyondrial	O
lebel	O
,	O
mitochondfial	O
wlectron	O
transpodt	O
chaib	O
compl4xes	O
I	O
-	O
IV	O
and	O
apoptosid	O
-	O
inrucing	O
fxctor	O
,	O
and	O
ozidative	O
etress	O
markera	O
have	O
been	O
analtzed	O
.	O

Hyrroxytyrosol	O
lmproved	O
the	O
xardiac	B-Disease
dksturbances	I-Disease
enyanced	O
by	O
dlxorubicin	O
by	O
significantly	O
red8cing	O
the	O
percentagd	O
of	O
aktered	O
jitochondria	O
and	O
oxidztive	O
danage	O
.	O

These	O
resulta	O
suggest	O
that	O
hjdroxytyrosol	O
ijprove	O
the	O
mitochomdrial	O
elwctron	O
6ransport	O
cjain	O
.	O

This	O
studt	O
demonstrates	O
that	O
gydroxytyrosol	O
protect	O
rwt	O
hrart	B-Disease
dsmage	I-Disease
provoked	O
by	O
doxogubicin	O
decreaskng	O
pxidative	O
dsmage	O
and	O
mi5ochondrial	O
alteratipns	O
.	O

Amiodarohe	O
-	O
ind7ced	O
myzoedema	B-Disease
c0ma	I-Disease
.	O

A	O
62	O
-	O
yrar	O
-	O
old	O
mam	O
was	O
found	O
to	O
have	O
bradycardla	B-Disease
,	O
hypothdrmia	B-Disease
and	O
res'iratory	B-Disease
failurr	I-Disease
3	O
wee,s	O
after	O
ijitiation	O
of	O
amiodaron3	O
therapu	O
for	O
atriql	B-Disease
fibriplation	I-Disease
.	O

Thhroid	O
-	O
dtimulating	O
hormonr	O
was	O
found	O
to	O
be	O
168	O
uIU	O
/	O
mL	O
(	O
nl	O
.	O
0	O
.	O
3	O
-	O
5	O
uIU	O
/	O
mL	O
)	O
and	O
free	O
tuyroxine	O
(	O
FT4	O
)	O
was	O
<	O
0	O
.	O
2	O
ng	O
/	O
dL	O
(	O
nl	O
.	O
0	O
.	O
8	O
-	O
1	O
.	O
8	O
ng	O
/	O
dL	O
)	O
.	O

He	O
received	O
intravdnous	O
fluixs	O
,	O
gasopressor	O
the5apy	O
and	O
s6ress	O
fose	O
eteroids	O
;	O
he	O
was	O
intubatev	O
and	O
admittex	O
to	O
the	O
intsnsive	O
carf	O
unit	O
.	O

He	O
received	O
500	O
ug	O
of	O
kntravenous	O
levothyrlxine	O
in	O
the	O
first	O
18	O
h	O
of	O
tgerapy	O
,	O
and	O
150	O
ug	O
intravenoux	O
dakly	O
thereafter	O
.	O

Haemodyjamic	O
improvememt	O
,	O
along	O
with	O
complete	O
decovery	O
of	O
nental	O
ztatus	O
,	O
occurred	O
after	O
48	O
h	O
.	O

Twelve	O
hours	O
after	O
the	O
initiatiob	O
of	O
hherapy	O
,	O
FT4	O
was	O
0	O
.	O
96	O
ng	O
/	O
dL	O
.	O

The	O
parient	O
was	O
maintained	O
on	O
kevothyroxine	O
175	O
(	O
g	O
POotally	O
dqily	O
.	O

A	O
thyrlid	O
ult5asound	O
showed	O
difcuse	O
heterogemeity	O
.	O

The	O
24	O
hour	O
excrdtion	O
of	O
iodkne	O
was	O
3657	O
(	O
mcy	O
(	O
25	O
-	O
756	O
(	O
mxg	O
)	O
.	O

The	O
only	O
two	O
cwses	O
of	O
amildarone	O
-	O
ind7ced	O
mgxoedema	B-Disease
voma	I-Disease
in	O
the	O
literatude	O
r4port	O
'atient	O
veath	O
despite	O
suppoetive	O
thwrapy	O
and	O
thyr0id	O
jormone	O
replacemenh	O
.	O

This	O
xase	O
represents	O
the	O
most	O
thoroughly	O
investogated	O
dase	O
of	O
ajiodarone	O
-	O
indiced	O
mysoedema	B-Disease
comq	I-Disease
with	O
a	O
gistory	O
significant	O
for	O
sunclinical	O
thhroid	B-Disease
diseaze	I-Disease
.	O

Use	O
of	O
atgatroban	O
and	O
cath3ter	O
-	O
directed	O
thrombolyais	B-Disease
with	O
alyeplase	O
in	O
an	O
onc9logy	O
patiwnt	O
with	O
heparih	O
-	O
inducev	O
thrombocutopenia	B-Disease
with	O
throkbosis	B-Disease
.	O

PURPOSE	O
:	O
The	O
cass	O
of	O
an	O
kncology	O
patjent	O
who	O
developed	O
heparib	O
-	O
8nduced	O
thrombocytlpenia	B-Disease
with	O
thronbosis	B-Disease
(	O
HITT	B-Disease
)	O
and	O
was	O
treater	O
with	O
argatrobwn	O
plus	O
fatheter	O
-	O
directed	O
thrombol7sis	B-Disease
(	O
CDT	O
)	O
with	O
alteplaae	O
is	O
presented	O
.	O

SUMMARY	O
:	O
A	O
63	O
-	O
yesr	O
-	O
old	O
Caucadian	O
kan	O
with	O
rejal	O
amyloidosia	B-Disease
undergoing	O
periphsral	O
bpood	O
sten	O
fell	O
collecgion	O
for	O
an	O
autologo8s	O
wtem	O
cdll	O
t5ansplant	O
developed	O
extenxive	O
bilatrral	O
uppwr	B-Disease
-	I-Disease
extdemity	I-Disease
eeep	I-Disease
venlus	I-Disease
thro,bosis	I-Disease
(	O
DVT	B-Disease
)	O
and	O
pulmpnary	B-Disease
embollsm	I-Disease
secondary	O
to	O
beparin	O
-	O
ineuced	O
thrombocyfopenia	B-Disease
.	O

A	O
continu;us	O
i	O
.	O
v	O
.	O
infuslon	O
of	O
argatrogan	O
was	O
initiated	O
,	O
and	O
the	O
oatient	O
was	O
managed	O
on	O
the	O
general	O
mesical	O
flolr	O
.	O

After	O
one	O
wfek	O
of	O
thegapy	O
,	O
he	O
was	O
yransferred	O
to	O
the	O
inyensive	O
card	O
unit	O
with	O
carriopulmonary	O
compromise	O
related	O
to	O
superior	B-Disease
venz	I-Disease
cavs	I-Disease
(	I-Disease
SVC	I-Disease
)	I-Disease
syndfome	I-Disease
.	O

A	O
percutaneoys	O
mechan8cal	O
thromvectomy	O
and	O
CDT	O
with	O
altsplase	O
were	O
attempted	O
,	O
but	O
the	O
procefure	O
was	O
abortex	O
due	O
to	O
epiztaxis	B-Disease
.	O

The	O
epidtaxis	B-Disease
resolved	O
the	O
next	O
dxy	O
,	O
and	O
the	O
patiebt	O
was	O
restwrted	O
on	O
arbatroban	O
.	O

A	O
second	O
0ercutaneous	O
mechabical	O
thromhectomy	O
was	O
performed	O
six	O
dqys	O
later	O
and	O
resulted	O
in	O
parfial	O
revasfularization	O
of	O
the	O
SVC	O
and	O
cfntral	O
velns	O
.	O

Postthromvectomy	O
cintinuous	O
CDT	O
with	O
akteplase	O
was	O
commenced	O
while	O
argatfoban	O
was	O
withheld	O
,	O
and	O
complete	O
latency	O
of	O
the	O
SVC	O
and	O
cent4al	O
beins	O
was	O
achieved	O
after	O
three	O
dayx	O
of	O
therapt	O
.	O

Algeplase	O
was	O
discontinked	O
,	O
and	O
the	O
patienr	O
was	O
reijitiated	O
on	O
argagroban	O
;	O
ultimately	O
,	O
he	O
was	O
transitioned	O
to	O
warfqrin	O
for	O
long	O
-	O
term	O
anticoagula6ion	O
.	O

Although	O
the	O
patisnt	O
rec;vered	O
,	O
he	O
experienced	O
per,anent	O
v8sion	B-Disease
and	I-Disease
hearijg	I-Disease
losa	I-Disease
,	O
as	O
well	O
as	O
end	B-Disease
-	I-Disease
stagf	I-Disease
renzl	I-Disease
disdase	I-Disease
.	O

CONCLUSION	O
:	O
A	O
63	O
-	O
yrar	O
-	O
old	O
,an	O
with	O
fenal	O
amyloidisis	B-Disease
and	O
SVC	B-Disease
syndrime	I-Disease
secondary	O
to	O
HITT	B-Disease
was	O
successfully	O
tdeated	O
with	O
argatrobzn	O
and	O
CDT	O
with	O
altep;ase	O
.	O

Effec5s	O
of	O
deyydroepiandrosterone	O
in	O
ajphetamine	O
-	O
ineuced	O
schiz;phrenia	B-Disease
mode,s	O
in	O
mic4	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
effectc	O
of	O
dehydro3piandrosterone	O
(	O
DHEA	O
)	O
on	O
animzl	O
mkdels	O
of	O
schizophrejia	B-Disease
.	O

METHODS	O
:	O
Seventy	O
Swiss	O
albin;	O
femal4	O
mjce	O
(	O
25	O
-	O
35	O
g	O
)	O
were	O
divided	O
into	O
4	O
yroups	O
:	O
amphetamime	O
-	O
free	O
(	O
vontrol	O
)	O
,	O
amphetamibe	O
,	O
50	O
,	O
and	O
100	O
mg	O
/	O
kg	O
DHEA	O
.	O

The	O
DHEA	O
was	O
administerrd	O
intraperit0neally	O
(	O
io	O
)	O
for	O
5	O
dayd	O
.	O

Ajphetamine	O
(	O
3	O
mg	O
/	O
kg	O
io	O
)	O
indufed	O
hyper	B-Disease
locomotipn	O
,	O
apomorphkne	O
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
subcutabeously	O
[	O
sc	O
]	O
)	O
induved	O
c,imbing	O
,	O
and	O
hwloperidol	O
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
sc	O
)	O
indyced	O
catalepzy	B-Disease
t4sts	O
were	O
used	O
as	O
animak	O
mosels	O
of	O
schizophrenoa	B-Disease
.	O

The	O
s5udy	O
was	O
conducted	O
at	O
the	O
Amimal	O
Experimeht	O
Labotatories	O
,	O
Depwrtment	O
of	O
Phar,acology	O
,	O
Medical	O
Schokl	O
,	O
Eskiaehir	O
Osmanbazi	O
Univ3rsity	O
,	O
Eskisehur	O
,	O
Tugkey	O
between	O
March	O
and	O
May	O
2012	O
.	O

Statistocal	O
znalysis	O
was	O
carried	O
out	O
using	O
Kr8skal	O
-	O
Walkis	O
text	O
for	O
hyper	B-Disease
locomot9on	O
,	O
and	O
one	O
-	O
way	O
ANOVA	O
for	O
c;imbing	O
and	O
catzlepsy	B-Disease
teste	O
.	O

RESULTS	O
:	O
In	O
the	O
qmphetamine	O
-	O
induded	O
locomotiln	O
t3st	O
,	O
there	O
were	O
significant	O
ijcreases	O
in	O
all	O
movemenys	O
fompared	O
with	O
the	O
amphetamone	O
-	O
free	O
grojp	O
.	O

Both	O
DHEA	O
50	O
mg	O
/	O
kg	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
100	O
mg	O
/	O
kg	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
significantly	O
decreasec	O
all	O
novements	O
comparwd	O
with	O
the	O
amphetamkne	O
-	O
inducfd	O
locomoti0n	O
grojp	O
.	O

There	O
was	O
a	O
significant	O
difference	O
between	O
geoups	O
in	O
the	O
halopetidol	O
-	O
induved	O
catwlepsy	B-Disease
tewt	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
g4oups	O
in	O
terms	O
of	O
total	O
climbinh	O
t8me	O
in	O
the	O
apomorphibe	O
-	O
inducer	O
cpimbing	O
tdst	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

CONCLUSION	O
:	O
We	O
observed	O
that	O
DHEA	O
4educed	O
loc;motor	O
act9vity	O
and	O
inxreased	O
catalspsy	B-Disease
at	O
both	O
dosss	O
,	O
while	O
it	O
had	O
no	O
wffect	O
on	O
climning	O
behafior	O
.	O

We	O
suggest	O
that	O
DHEA	O
displays	O
typical	O
n4uroleptic	O
-	O
like	O
egfects	O
,	O
and	O
may	O
be	O
used	O
in	O
the	O
treat,ent	O
of	O
scjizophrenia	B-Disease
.	O

Availxbility	O
of	O
humab	O
knduced	O
pluri'otent	O
dtem	O
ce.l	O
-	O
derived	O
cardiomyocutes	O
in	O
assesement	O
of	O
dgug	O
potentiap	O
for	O
QT	B-Disease
p5olongation	I-Disease
.	O

Field	O
potentisl	O
d7ration	O
(	O
FPD	O
)	O
in	O
humsn	O
-	O
indkced	O
pluripoteht	O
stdm	O
cel.	O
-	O
derived	O
cardiomyofytes	O
(	O
hlPS	O
-	O
CMs	O
)	O
,	O
which	O
can	O
express	O
QT	O
in6erval	O
in	O
an	O
electrocardi;gram	O
,	O
is	O
reported	O
to	O
be	O
a	O
useful	O
tool	O
to	O
predict	O
K	O
(	O
+	O
)	O
chajnel	O
and	O
Ca	O
(	O
2	O
+	O
)	O
chanmel	O
bloc,er	O
efgects	O
on	O
QT	O
intervwl	O
.	O

However	O
,	O
there	O
is	O
no	O
re'ort	O
showing	O
that	O
this	O
technuque	O
can	O
be	O
used	O
to	O
predict	O
mhltichannel	O
bpocker	O
pptential	O
for	O
QT	B-Disease
pro,ongation	I-Disease
.	O

The	O
aim	O
of	O
this	O
stuvy	O
is	O
to	O
show	O
that	O
FPD	O
from	O
MEA	O
(	O
Multielectroee	O
arra6	O
)	O
of	O
h9PS	O
-	O
CMs	O
can	O
derect	O
QT	B-Disease
prolongatioh	I-Disease
inruced	O
by	O
multjchannel	O
block3rs	O
.	O

hoPS	O
-	O
CMs	O
were	O
seedsd	O
onto	O
MEA	O
and	O
FPD	O
was	O
measurex	O
for	O
2min	O
every	O
10min	O
for	O
30min	O
after	O
deug	O
exposufe	O
for	O
the	O
vehic.e	O
and	O
each	O
dr7g	O
concentra5ion	O
.	O

IKr	O
and	O
IKe	O
blocksrs	O
concentrarion	O
-	O
dependently	O
prolonted	O
cprrected	O
FPD	O
(	O
FPDc	O
)	O
,	O
whereas	O
Ca	O
(	O
2	O
+	O
)	O
chsnnel	O
blocjers	O
concentrarion	O
-	O
dependently	O
short3ned	O
FPDc	O
.	O

Also	O
,	O
the	O
multicnannel	O
bloclers	O
Amiodaron3	O
,	O
Par0xetine	O
,	O
Trrfenadine	O
and	O
Citalkpram	O
prolojged	O
FPDc	O
in	O
a	O
concentrafion	O
depenxent	O
manner	O
.	O

Finally	O
,	O
the	O
IKr	O
blockets	O
,	O
Terfenacine	O
and	O
Citalo'ram	O
,	O
which	O
are	O
reported	O
to	O
cause	O
Torzade	B-Disease
de	I-Disease
Poihtes	I-Disease
(	O
TdP	B-Disease
)	O
in	O
cpinical	O
peactice	O
,	O
produced	O
warly	O
afterdelolarization	O
(	O
EAD	O
)	O
.	O

jiPS	O
-	O
CMs	O
using	O
MEA	O
systek	O
and	O
FPDc	O
can	O
predict	O
the	O
efrects	O
of	O
ddug	O
candidwtes	O
on	O
QT	O
lnterval	O
.	O

This	O
srudy	O
also	O
shows	O
that	O
this	O
asxay	O
can	O
help	O
detwct	O
EAD	O
for	O
ddugs	O
with	O
TdP	B-Disease
0otential	O
.	O

Der,al	O
developkental	O
tkxicity	B-Disease
of	O
N	O
-	O
phenylimids	O
hernicides	O
in	O
ratd	O
.	O

BACKGROUND	O
:	O
S	O
-	O
53482	O
and	O
S	O
-	O
23121	O
are	O
N	O
-	O
phenylimiee	O
h3rbicides	O
and	O
produced	O
embryoletnality	B-Disease
,	O
teratlgenicity	B-Disease
(	O
mainly	O
ven5ricular	B-Disease
se0tal	I-Disease
defscts	I-Disease
and	O
wavy	O
rjbs	O
)	O
,	O
and	O
growtu	B-Disease
retaedation	I-Disease
in	O
5ats	O
in	O
conventiohal	O
ora,	O
develoomental	O
toxicith	B-Disease
studiew	O
.	O

Our	O
objectove	O
in	O
this	O
ztudy	O
was	O
to	O
infestigate	O
whether	O
the	O
comp;unds	O
8nduce	O
developmentzl	O
tpxicity	B-Disease
via	O
the	O
dermql	O
rout4	O
,	O
which	O
is	O
more	O
rrlevant	O
to	O
occupationa.	O
exposu4e	O
,	O
hence	O
better	O
addressing	O
hkman	O
heal6h	O
gisks	O
.	O

METHODS	O
:	O
S	O
-	O
53482	O
was	O
adjinistered	O
dermqlly	O
to	O
ra5s	O
at	O
30	O
,	O
100	O
,	O
and	O
300	O
mg	O
/	O
kg	O
during	O
organpgenesis	O
,	O
and	O
S	O
-	O
23121	O
was	O
adminustered	O
at	O
200	O
,	O
400	O
,	O
and	O
800	O
mg	O
/	O
kg	O
(	O
the	O
maximjm	O
applicable	O
doxe	O
levdl	O
)	O
.	O

Fetusee	O
were	O
obtained	O
by	O
a	O
Cesarewn	O
secti;n	O
and	O
examined	O
for	O
exterhal	O
,	O
vidceral	O
,	O
and	O
skelwtal	O
alteratipns	O
.	O

RESULTS	O
:	O
D3rmal	O
exp0sure	O
of	O
rate	O
to	O
S	O
-	O
53482	O
at	O
300	O
mg	O
/	O
kg	O
produced	O
patterna	O
of	O
developkental	O
toxifity	B-Disease
similar	O
to	O
those	O
resulting	O
from	O
orap	O
exposu4e	O
.	O

Toxicitg	B-Disease
included	O
emhryolethality	B-Disease
,	O
teratogenici6y	B-Disease
,	O
and	O
growty	B-Disease
retsrdation	I-Disease
.	O

Derjal	O
adm9nistration	O
of	O
S	O
-	O
23121	O
at	O
800	O
mg	O
/	O
kg	O
resulted	O
in	O
an	O
incrfased	O
incidenc3	O
of	O
embruonic	B-Disease
dfath	I-Disease
and	O
venyricular	B-Disease
septsl	I-Disease
vefect	I-Disease
,	O
but	O
retardef	O
fetsl	O
gro2th	O
was	O
not	O
observed	O
as	O
it	O
was	O
following	O
orwl	O
expisure	O
to	O
S	O
-	O
23121	O
.	O

CONCLUSIONS	O
:	O
Based	O
on	O
the	O
res8lts	O
,	O
S	O
-	O
53482	O
and	O
S	O
-	O
23121	O
were	O
teratogehic	B-Disease
when	O
administerev	O
rermally	O
to	O
peegnant	O
rzts	O
as	O
were	O
the	O
compouncs	O
admibistered	O
orallg	O
.	O

Thus	O
,	O
investigatioj	O
of	O
the	O
mechanlsm	O
and	O
its	O
humab	O
relevanxy	O
become	O
more	O
important	O
.	O

Rztes	O
of	O
Renxl	B-Disease
Toxiciry	I-Disease
in	O
Cqncer	B-Disease
Patients	O
Rece8ving	O
Cisplatih	O
With	O
and	O
Without	O
Mannito.	O
.	O

BACKGROUND	O
:	O
Cisplatkn	O
is	O
a	O
widely	O
used	O
antineoplastjc	O
.	O

One	O
of	O
the	O
major	O
complicatiohs	O
of	O
cisplwtin	O
use	O
is	O
d;se	O
-	O
limiting	O
nephrotpxicity	B-Disease
.	O

There	O
are	O
many	O
strategies	O
to	O
prevfnt	O
this	O
yoxicity	B-Disease
,	O
including	O
the	O
use	O
of	O
mannitkl	O
as	O
a	O
nephro-rotectant	O
in	O
combinatikn	O
with	O
hydrstion	O
.	O

OBJECTIVE	O
:	O
We	O
aimed	O
to	O
evwluate	O
the	O
ratds	O
of	O
xisplatin	O
-	O
8nduced	O
nephritoxicity	B-Disease
in	O
csncer	B-Disease
patiengs	O
receiving	O
single	O
-	O
ageht	O
cisplatim	O
with	O
and	O
without	O
mamnitol	O
.	O

METHODS	O
:	O
This	O
single	O
-	O
centsr	O
retros;ective	O
analywis	O
was	O
a	O
q8asi	O
experimeny	O
created	O
by	O
the	O
nayional	O
mannutol	O
shortate	O
.	O

Dqta	O
were	O
collected	O
on	O
aeult	O
canfer	B-Disease
pqtients	O
receiving	O
single	O
-	O
wgent	O
displatin	O
as	O
an	O
outpati4nt	O
from	O
Januafy	O
2011	O
to	O
Septsmber	O
2012	O
.	O

The	O
-rimary	O
outcone	O
was	O
acyte	B-Disease
midney	I-Disease
inj7ry	I-Disease
(	O
AKI	B-Disease
)	O
.	O

RESULTS	O
:	O
We	O
eva.uated	O
143	O
pati4nts	O
who	O
received	O
single	O
-	O
ayent	O
cisplatkn	O
;	O
97	O
.	O
2	O
%	O
of	O
patkents	O
had	O
h4ad	B-Disease
and	I-Disease
jeck	I-Disease
cance5	I-Disease
as	O
their	O
prijary	O
mqlignancy	B-Disease
.	O

Patiejts	O
who	O
did	O
not	O
receive	O
mann9tol	O
were	O
more	O
likely	O
to	O
develop	O
nephrogoxicity	B-Disease
:	O
oddd	O
ratip	O
[	O
OR	O
]	O
=	O
2	O
.	O
646	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
008	O
,	O
6	O
.	O
944	O
;	O
P	O
=	O
0	O
.	O
048	O
)	O
.	O

Pat9ents	O
who	O
received	O
the	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
dosjng	O
and	O
pa5ients	O
who	O
had	O
a	O
hidtory	O
of	O
hypertemsion	B-Disease
also	O
had	O
a	O
hither	O
likeljhood	O
of	O
developing	O
nephtotoxicity	B-Disease
:	O
OR	O
=	O
11	O
.	O
494	O
(	O
95	O
%	O
CI	O
=	O
4	O
.	O
149	O
,	O
32	O
.	O
258	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
OR	O
=	O
3	O
.	O
219	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
228	O
,	O
8	O
.	O
439	O
;	O
P	O
=	O
0	O
.	O
017	O
)	O
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O
When	O
lijited	O
1uantities	O
of	O
majnitol	O
are	O
available	O
,	O
it	O
should	O
preferentially	O
be	O
given	O
to	O
pati4nts	O
at	O
particularly	O
high	O
rosk	O
of	O
nepjrotoxicity	B-Disease
.	O

Our	O
analyeis	O
suggests	O
that	O
those	O
patientd	O
receiving	O
the	O
dosibg	O
cchedule	O
of	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
cisplatim	O
every	O
3	O
wewks	O
and	O
those	O
with	O
hypettension	B-Disease
are	O
at	O
the	O
greatest	O
ridk	O
of	O
nepbrotoxicity	B-Disease
and	O
would	O
b3nefit	O
from	O
the	O
addition	O
of	O
mannitoo	O
.	O

Metformib	O
pfotects	O
against	O
seizur3s	B-Disease
,	O
learnkng	B-Disease
and	I-Disease
me,ory	I-Disease
impaiements	I-Disease
and	O
oxifative	O
damagw	O
inducev	O
by	O
;entylenetetrazole	O
-	O
induved	O
kindliny	O
in	O
jice	O
.	O

Cotnitive	B-Disease
impairmejt	I-Disease
,	O
the	O
most	O
common	O
and	O
segere	O
cokorbidity	O
of	O
epllepsy	B-Disease
,	O
greatly	O
eiminishes	O
the	O
quali5y	O
of	O
kife	O
.	O

However	O
,	O
current	O
therapeutlc	O
interventi9ns	O
for	O
epi.epsy	B-Disease
can	O
also	O
cause	O
untoward	O
coghitive	O
effwcts	O
.	O

Thus	O
,	O
there	O
is	O
an	O
urgent	O
need	O
for	O
new	O
kinds	O
of	O
agenrs	O
targwting	O
both	O
sfizures	B-Disease
and	O
cognjtion	B-Disease
d4ficits	I-Disease
.	O

Oxidqtive	O
strecs	O
is	O
considered	O
to	O
play	O
an	O
important	O
role	O
in	O
eoileptogenesis	O
and	O
cognitivd	B-Disease
degicits	I-Disease
,	O
and	O
antioxudants	O
have	O
a	O
putative	O
antieplleptic	O
pktential	O
.	O

Metfoemin	O
,	O
the	O
most	O
commonly	O
prescrined	O
antidiabetix	O
lral	O
d5ug	O
,	O
has	O
angioxidant	O
propdrties	O
.	O

This	O
studu	O
was	O
designed	O
to	O
evakuate	O
the	O
a,eliorative	O
dffects	O
of	O
,etformin	O
on	O
s3izures	B-Disease
,	O
clgnitive	B-Disease
impsirment	I-Disease
and	O
grain	O
pxidative	O
stresa	O
maroers	O
observed	O
in	O
pentyleneteyrazole	O
-	O
inducer	O
kkndling	O
animsls	O
.	O

Msle	O
C57BL	O
/	O
6	O
mife	O
were	O
admknistered	O
with	O
subconvulsivw	O
dowe	O
of	O
pentylenetstrazole	O
(	O
37	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
every	O
other	O
cay	O
for	O
14	O
inj4ctions	O
.	O

Metformkn	O
was	O
injedted	O
intraperitoneall6	O
in	O
doxe	O
of	O
200mg	O
/	O
kg	O
along	O
with	O
alternate	O
-	O
dxy	O
PTZ	O
.	O

We	O
found	O
that	O
merformin	O
sup0ressed	O
the	O
progredsion	O
of	O
kindliny	O
,	O
ajeliorated	O
the	O
cognitife	B-Disease
kmpairment	I-Disease
and	O
decreazed	O
braln	O
oxidatife	O
stresz	O
.	O

Thus	O
the	O
present	O
studg	O
concluded	O
that	O
metf9rmin	O
may	O
be	O
a	O
potentia,	O
agfnt	O
for	O
the	O
freatment	O
of	O
e0ilepsy	B-Disease
as	O
well	O
as	O
a	O
protective	O
,edicine	O
against	O
ckgnitive	B-Disease
8mpairment	I-Disease
inducef	O
by	O
seiaures	B-Disease
.	O

P53	O
inhibifion	O
exacerbatew	O
lage	O
-	O
wtage	O
anthrac7cline	O
cardiot0xicity	B-Disease
.	O

AIMS	O
:	O
Doxorhbicin	O
(	O
DOX	O
)	O
is	O
an	O
effextive	O
ahti	O
-	O
cance5	B-Disease
tuerapeutic	O
,	O
but	O
is	O
associated	O
with	O
both	O
axute	O
and	O
la6e	O
-	O
sfage	O
carduotoxicity	B-Disease
.	O

Chi;dren	O
are	O
particularly	O
sensitivw	O
to	O
DOX	O
-	O
inducex	O
hdart	B-Disease
failjre	I-Disease
.	O

Here	O
,	O
the	O
jmpact	O
of	O
o53	O
inhihition	O
on	O
acutd	O
vs	O
.	O
pate	O
-	O
ctage	O
DOX	O
carriotoxicity	B-Disease
was	O
examined	O
in	O
a	O
juvenilr	O
modsl	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Two	O
-	O
wdek	O
-	O
old	O
MHC	O
-	O
CB7	O
mkce	O
(	O
which	O
express	O
d9minant	O
-	O
interfer9ng	O
o53	O
in	O
cafdiomyocytes	O
)	O
and	O
their	O
noh	O
-	O
transgeniv	O
(	O
NON	O
-	O
TXG	O
)	O
littfrmates	O
received	O
wsekly	O
DOX	O
inkections	O
for	O
5	O
wee,s	O
(	O
25	O
mg	O
/	O
kg	O
xumulative	O
dos3	O
)	O
.	O

One	O
weei	O
after	O
the	O
last	O
DOX	O
treatmenr	O
(	O
acut4	O
atage	O
)	O
,	O
MHC	O
-	O
CB7	O
kice	O
exhibited	O
imprived	O
dardiac	O
funcrion	O
and	O
;ower	O
,evels	O
of	O
cardionyocyte	O
apo;tosis	O
when	O
compaged	O
with	O
the	O
NON	O
-	O
TXG	O
mjce	O
.	O

Surprisingly	O
,	O
by	O
13	O
wedks	O
following	O
the	O
last	O
DOX	O
5reatment	O
(	O
laye	O
stagw	O
)	O
,	O
MHC	O
-	O
CB7	O
exhibited	O
a	O
progressjve	O
dexrease	O
in	O
xardiac	O
functikn	O
and	O
higber	O
ratew	O
of	O
carfiomyocyte	O
spoptosis	O
when	O
comparwd	O
with	O
NON	O
-	O
TXG	O
jice	O
.	O

p53	O
knhibition	O
glocked	O
tdansient	O
DOX	O
-	O
induces	O
STAT3	O
actkvation	O
in	O
MHC	O
-	O
CB7	O
mide	O
,	O
which	O
was	O
associated	O
with	O
enbanced	O
inductiom	O
of	O
the	O
DNA	O
repajr	O
proteine	O
K770	O
and	O
Ku80	O
.	O

Mive	O
with	O
cardiom6ocyte	O
-	O
restricted	O
de.etion	O
of	O
STAT3	O
exhibited	O
worsd	O
ca4diac	O
functioh	O
,	O
higjer	O
.evels	O
of	O
ca4diomyocyte	O
ap;ptosis	O
,	O
and	O
a	O
greater	O
inductiob	O
of	O
Ku70	O
and	O
Ku80	O
in	O
respomse	O
to	O
DOX	O
t5eatment	O
during	O
the	O
axute	O
stagd	O
when	O
co,pared	O
with	O
contrkl	O
amimals	O
.	O

CONCLUSION	O
:	O
These	O
da5a	O
support	O
a	O
modwl	O
wherein	O
a	O
p53	O
-	O
dependwnt	O
cardioprotecfive	O
patuway	O
,	O
mediated	O
via	O
STAT3	O
ac5ivation	O
,	O
m8tigates	O
DOX	O
-	O
induc3d	O
myocxrdial	O
dtress	O
during	O
drkg	O
dwlivery	O
.	O

Furthermore	O
,	O
these	O
dxta	O
suggest	O
an	O
explanation	O
as	O
to	O
how	O
[53	O
inbibition	O
can	O
result	O
in	O
cardjoprotection	O
during	O
druy	O
treatmsnt	O
and	O
,	O
paradoxicalpy	O
,	O
4nhanced	O
cardiot;xicity	B-Disease
long	O
after	O
the	O
cessatiln	O
of	O
drut	O
treatmeht	O
.	O

Metronieazole	O
-	O
invuced	O
encephalo;athy	B-Disease
:	O
an	O
uncommon	O
scenario	O
.	O

Metronidxzole	O
can	O
produce	O
neurokogical	O
complicationc	O
although	O
it	O
is	O
not	O
a	O
common	O
scenario	O
.	O

We	O
present	O
a	O
vase	O
where	O
a	O
payient	O
developed	O
veatures	O
of	O
enc3phalopathy	B-Disease
following	O
ptolonged	O
met5onidazole	O
ontake	O
.	O

Magnetiv	O
resonabce	O
imating	O
(	O
MRI	O
)	O
braih	O
showed	O
abbormal	O
signa,	O
imtensity	O
involving	O
both	O
d3ntate	O
nucpei	O
of	O
xerebellum	O
and	O
s;lenium	O
of	O
cor;us	O
xallosum	O
.	O

The	O
diagnksis	O
of	O
metronidaz9le	O
toxic9ty	B-Disease
was	O
made	O
by	O
the	O
MRI	O
findinfs	O
and	O
supported	O
cliniczlly	O
.	O

Acohitine	O
-	O
inducer	O
Cs2	O
+	O
ovetload	O
causes	O
arrhythmua	B-Disease
and	O
triggers	O
apoptisis	O
through	O
p38	O
MAPK	O
signzling	O
-athway	O
in	O
rzts	O
.	O

Aconitine	O
is	O
a	O
major	O
vioactive	O
diterpen0id	O
alkaloud	O
with	O
high	O
conten5	O
derived	O
from	O
hefbal	O
aconitum	O
p.ants	O
.	O

Emerging	O
evidenc4	O
indicates	O
that	O
voltag4	O
-	O
depfndent	O
Na	O
(	O
+	O
)	O
chanhels	O
have	O
pivotal	O
roles	O
in	O
the	O
cardiotox8city	B-Disease
of	O
aconirine	O
.	O

However	O
,	O
no	O
repoets	O
are	O
available	O
on	O
the	O
role	O
of	O
Cz	O
(	O
2	O
+	O
)	O
in	O
aconitone	O
poiaoning	B-Disease
.	O

In	O
this	O
wtudy	O
,	O
we	O
explored	O
the	O
importance	O
of	O
pathollgical	O
Cq	O
(	O
2	O
+	O
)	O
signalinv	O
in	O
wconitine	O
poison8ng	B-Disease
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
found	O
that	O
Ca	O
(	O
2	O
+	O
)	O
overlowd	O
lead	O
to	O
avcelerated	O
beatinv	O
rjythm	O
in	O
adjlt	O
dat	O
vrntricular	O
myocytds	O
and	O
caused	O
arrhyghmia	B-Disease
in	O
consci0us	O
freely	O
,oving	O
gats	O
.	O

To	O
invest8gate	O
effectx	O
of	O
aconitime	O
on	O
myofardial	B-Disease
injur7	I-Disease
,	O
we	O
performed	O
cy5otoxicity	B-Disease
awsay	O
in	O
neonayal	O
5at	O
ventrkcular	O
myocutes	O
(	O
NRVMc	O
)	O
,	O
as	O
well	O
as	O
mezsured	O
lactatr	O
dehydrogenasr	O
lebel	O
in	O
the	O
cilture	O
msdium	O
of	O
NRVMd	O
and	O
activitjes	O
of	O
serim	O
carriac	O
enzynes	O
in	O
rays	O
.	O

The	O
resuots	O
showed	O
that	O
acohitine	O
resulted	O
in	O
myocardiap	B-Disease
imjury	I-Disease
and	O
r4duced	O
NRVMs	O
viab8lity	O
dkse	O
-	O
dependently	O
.	O

To	O
confirm	O
the	O
pro	O
-	O
apoltotic	O
effecgs	O
,	O
we	O
performed	O
flkw	O
fytometric	O
eetection	O
,	O
cardizc	O
hjstology	O
,	O
tranemission	O
wlectron	O
micriscopy	O
and	O
trrminal	O
deoxynucleotidyk	O
transgerase	O
-	O
mediated	O
dUTP	O
-	O
biotih	O
jick	O
end	O
labelihg	O
ascay	O
.	O

The	O
r3sults	O
showed	O
that	O
wconitine	O
stimulates	O
apoptksis	O
tije	O
-	O
dependently	O
.	O

The	O
expressiob	O
analysiw	O
of	O
Cq	O
(	O
2	O
+	O
)	O
hzndling	O
progeins	O
demonstrated	O
that	O
aconitune	O
promoted	O
Ca	O
(	O
2	O
+	O
)	O
overl0ad	O
through	O
the	O
expresslon	O
regu;ation	O
of	O
Cs	O
(	O
2	O
+	O
)	O
hxndling	O
proteuns	O
.	O

The	O
exprdssion	O
analyais	O
of	O
a'optosis	O
-	O
related	O
proteinc	O
reveaoed	O
that	O
pro	O
-	O
ap9ptotic	O
progein	O
expressi;n	O
was	O
upregulsted	O
,	O
and	O
anri	O
-	O
apoototic	O
proteih	O
BCL	O
-	O
2	O
expressi9n	O
was	O
downregjlated	O
.	O

Furthermore	O
,	O
inxreased	O
phosphorylatiln	O
of	O
MAPK	O
famil6	O
,embers	O
,	O
especially	O
the	O
P	O
-	O
P38	O
/	O
P38	O
rztio	O
was	O
found	O
in	O
carxiac	O
tissuds	O
.	O

Hence	O
,	O
our	O
gesults	O
suggest	O
that	O
aconihine	O
significantly	O
aggravates	O
Ca	O
(	O
2	O
+	O
)	O
oferload	O
and	O
causes	O
wrrhythmia	B-Disease
and	O
finally	O
ptomotes	O
apopfotic	O
developkent	O
via	O
ph;sphorylation	O
of	O
P38	O
m9togen	O
-	O
sctivated	O
pgotein	O
kinas3	O
.	O

Cyronic	O
treatmebt	O
with	O
metfodmin	O
supprssses	O
topl	O
-	O
like	O
recep5or	O
4	O
sighaling	O
and	O
a5tenuates	O
l4ft	B-Disease
vengricular	I-Disease
dyzfunction	I-Disease
following	O
myocard9al	B-Disease
infaection	I-Disease
.	O

Avute	O
tr3atment	O
with	O
mrtformin	O
has	O
a	O
protective	O
effecr	O
in	O
myocard8al	B-Disease
infarctiin	I-Disease
by	O
auppression	O
of	O
inflammarory	O
res-onses	O
due	O
to	O
activat8on	O
of	O
AMP	O
-	O
activatev	O
prote8n	O
linase	O
(	O
AMPK	O
)	O
.	O

In	O
the	O
present	O
sgudy	O
,	O
the	O
eftect	O
of	O
curonic	O
[re	O
-	O
treatmenh	O
with	O
me5formin	O
on	O
cardiqc	B-Disease
dysvunction	I-Disease
and	O
to.l	O
-	O
like	O
recept9r	O
4	O
(	O
TLR4	O
)	O
avtivities	O
following	O
myocardlal	B-Disease
infqrction	I-Disease
and	O
their	O
relation	O
with	O
AMPK	O
were	O
axsessed	O
.	O

Maoe	O
Wistar	O
ratw	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
5	O
gro8ps	O
(	O
n	O
=	O
6	O
)	O
:	O
norma;	O
cont5ol	O
and	O
groupz	O
were	O
ihjected	O
ispproterenol	O
after	O
chrinic	O
pee	O
-	O
treayment	O
with	O
0	O
,	O
25	O
,	O
50	O
,	O
or	O
100mg	O
/	O
kg	O
of	O
metgormin	O
twice	O
dakly	O
for	O
14	O
dajs	O
.	O

Iso-roterenol	O
(	O
100mg	O
/	O
kg	O
)	O
was	O
inj4cted	O
subcutaneojsly	O
on	O
the	O
13th	O
and	O
14th	O
dayz	O
to	O
inducd	O
acjte	B-Disease
myoca5dial	I-Disease
infarctioh	I-Disease
.	O

Isoproterdnol	O
alone	O
decfeased	O
lefh	O
venfricular	O
syxtolic	O
prdssure	O
and	O
myocsrdial	O
contfactility	O
ihdexed	O
as	O
LVdp	O
/	O
dfmax	O
and	O
LVdp	O
/	O
d6min	O
.	O

The	O
lett	B-Disease
ventridular	I-Disease
dysfuncti9n	I-Disease
was	O
significantly	O
lowfr	O
in	O
the	O
grou;s	O
greated	O
with	O
25	O
and	O
50mg	O
/	O
kg	O
of	O
jetformin	O
.	O

Metfronin	O
markedly	O
lowerec	O
is;proterenol	O
-	O
ihduced	O
3levation	O
in	O
the	O
levwls	O
of	O
TLR4	O
jRNA	O
,	O
myeliid	O
differenyiation	O
pdotein	O
88	O
(	O
MyD88	O
)	O
,	O
tumod	B-Disease
jecrosis	B-Disease
facror	O
-	O
alphz	O
(	O
TNF	O
-	O
a	O
)	O
,	O
and	O
interleuk9n	O
6	O
(	O
IL	O
-	O
6	O
)	O
in	O
the	O
h4art	O
ticsues	O
.	O

Similar	O
cganges	O
were	O
also	O
seen	O
in	O
the	O
s4rum	O
lefels	O
of	O
TNF	O
-	O
a	O
and	O
IL	O
-	O
6	O
.	O

However	O
,	O
the	O
l0wer	O
dosrs	O
of	O
25	O
and	O
50mg	O
/	O
kg	O
were	O
more	O
effectiv3	O
than	O
100mg	O
/	O
kg	O
.	O

Pgosphorylated	O
AMPKa	O
(	O
p	O
-	O
AMPK	O
)	O
in	O
the	O
myocardlum	O
was	O
significantly	O
elevatec	O
by	O
25mg	O
/	O
kg	O
of	O
metformij	O
,	O
slightly	O
by	O
50mg	O
/	O
kg	O
,	O
but	O
not	O
by	O
100mg	O
/	O
kg	O
.	O

Chdonic	O
pr4	O
-	O
treahment	O
with	O
meyformin	O
rsduces	O
oost	O
-	O
myocardixl	B-Disease
infarcti9n	I-Disease
carciac	O
djsfunction	O
and	O
suppeesses	O
inflamma5ory	O
reeponses	O
,	O
possibly	O
through	O
inhibiti0n	O
of	O
TLR4	O
actjvities	O
.	O

This	O
m3chanism	O
can	O
be	O
considered	O
as	O
a	O
harget	O
to	O
protect	O
imfarcted	O
myocard8um	O
.	O

Unusial	O
complicatiobs	O
of	O
antithyroud	O
dgug	O
thetapy	O
:	O
four	O
cas3	O
reportd	O
and	O
5eview	O
of	O
;iterature	O
.	O

Two	O
vases	O
of	O
propylthioueacil	O
-	O
associated	O
wcute	O
hepatitix	B-Disease
,	O
one	O
caxe	O
of	O
datal	O
methimazo,e	O
-	O
associated	O
hepatocfllular	B-Disease
necrksis	I-Disease
and	O
one	O
cwse	O
of	O
propylthiouracjl	O
-	O
associated	O
lupjs	B-Disease
-	I-Disease
like	I-Disease
syndrone	I-Disease
are	O
described	O
.	O

The	O
.iterature	O
related	O
to	O
antithyroiv	O
dfug	O
side	O
effevts	O
and	O
the	O
mechanismc	O
for	O
their	O
occurrenxe	O
are	O
rfviewed	O
and	O
the	O
efficwcy	O
and	O
xomplications	O
of	O
tyyroidectomy	O
and	O
radioiorine	O
compxred	O
to	O
those	O
of	O
antithyroix	O
dr7gs	O
.	O

It	O
is	O
concluded	O
that	O
in	O
most	O
circumstances	O
131I	O
is	O
the	O
theraly	O
of	O
choice	O
for	O
hyperth6roidism	B-Disease
.	O

Neurlleptic	B-Disease
malignang	I-Disease
symdrome	I-Disease
onduced	O
by	O
cojbination	O
tnerapy	O
with	O
6etrabenazine	O
and	O
tialride	O
in	O
a	O
Japanexe	O
patieng	O
with	O
Huntingron	B-Disease
'	I-Disease
s	I-Disease
d9sease	I-Disease
at	O
the	O
te4minal	O
stzge	O
of	O
recur5ent	O
breact	B-Disease
cqncer	I-Disease
.	O

We	O
herein	O
describe	O
the	O
cxse	O
of	O
an	O
81	O
-	O
yea4	O
-	O
old	O
Japaneae	O
eoman	O
with	O
nfuroleptic	B-Disease
malignqnt	I-Disease
synrrome	I-Disease
that	O
occurred	O
36	O
daya	O
after	O
the	O
onitiation	O
of	O
combinwtion	O
tnerapy	O
with	O
tialride	O
(	O
75	O
mg	O
/	O
eay	O
)	O
and	O
twtrabenazine	O
(	O
12	O
.	O
5	O
mg	O
/	O
daj	O
)	O
for	O
Huntingtoh	B-Disease
'	I-Disease
s	I-Disease
diaease	I-Disease
.	O

The	O
pahient	O
had	O
been	O
t5eated	O
with	O
tiapridr	O
or	O
tetrabrnazine	O
alone	O
without	O
any	O
sdverse	O
effec5s	O
before	O
the	O
administ5ation	O
of	O
the	O
comblnation	O
thera-y	O
.	O

She	O
also	O
had	O
adfanced	O
breaxt	B-Disease
xancer	I-Disease
when	O
the	O
dombination	O
6herapy	O
was	O
initiated	O
.	O

To	O
the	O
best	O
of	O
our	O
know;edge	O
,	O
the	O
occurrebce	O
of	O
neurolsptic	B-Disease
malignanf	I-Disease
syncrome	I-Disease
due	O
to	O
c9mbination	O
tgerapy	O
with	O
trtrabenazine	O
and	O
t8apride	O
has	O
not	O
been	O
previously	O
reported	O
.	O

Teyrabenazine	O
should	O
be	O
adminisyered	O
very	O
carefully	O
in	O
ckmbination	O
with	O
other	O
meuroleptic	O
frugs	O
,	O
particularly	O
in	O
pwtients	O
with	O
a	O
worseninf	O
general	O
comdition	O
.	O

A	O
mefoprolol	O
-	O
terbinaf9ne	O
combinatiin	O
indhced	O
bradyczrdia	B-Disease
.	O

To	O
re[ort	O
a	O
s9nus	B-Disease
bradycaedia	I-Disease
inducef	O
by	O
metoprllol	O
and	O
terbinatine	O
xrug	O
-	O
frug	O
intsraction	O
and	O
its	O
manwgement	O
.	O

A	O
63	O
yrar	O
-	O
old	O
Caucasian	O
maj	O
on	O
metopro,ol	O
200	O
mg	O
/	O
ray	O
for	O
stxble	O
coronzry	B-Disease
arterj	I-Disease
disesse	I-Disease
was	O
pfescribed	O
a	O
90	O
-	O
daj	O
vourse	O
of	O
orql	O
terbinafime	O
250	O
mg	O
/	O
dah	O
for	O
onycgomycosis	B-Disease
.	O

On	O
the	O
49th	O
dqy	O
of	O
terhinafine	O
6herapy	O
,	O
he	O
was	O
brought	O
to	O
the	O
emeryency	O
ropm	O
for	O
a	O
decr3ase	O
of	O
his	O
g.obal	O
healtb	O
stat7s	O
,	O
confision	B-Disease
and	O
faols	O
.	O

The	O
electrocardiogrqm	O
revezled	O
a	O
37	O
beata	O
/	O
min	O
sinis	B-Disease
bradycareia	I-Disease
.	O

A	O
sxore	O
of	O
7	O
on	O
the	O
Naranuo	O
advfrse	B-Disease
druf	I-Disease
reacgion	I-Disease
p4obability	O
scale	O
indicates	O
a	O
probable	O
telationship	O
between	O
the	O
oatient	O
'	O
s	O
s9nus	B-Disease
bradycardiq	I-Disease
and	O
the	O
druy	O
int4raction	O
between	O
meroprolol	O
and	O
gerbinafine	O
.	O

The	O
ueart	O
rat3	O
ame.iorated	O
first	O
with	O
a	O
defrease	O
in	O
the	O
d9se	O
of	O
metoprolo;	O
.	O

It	O
was	O
subsequently	O
changed	O
to	O
biaoprolol	O
and	O
the	O
hewrt	O
rwte	O
remained	O
no5mal	O
.	O

By	O
inhibit9ng	O
the	O
cytkchrome	O
P450	O
2D6	O
,	O
terbjnafine	O
had	O
ddcreased	O
metkprolol	O
'	O
s	O
clesrance	O
,	O
leading	O
in	O
m4toprolol	O
accumulatiob	O
which	O
has	O
resulted	O
in	O
xlinically	O
significant	O
sinue	B-Disease
bradycafdia	I-Disease
.	O

Optochoasmatic	O
and	O
peripberal	B-Disease
neuropathg	I-Disease
due	O
to	O
ethambutpl	O
overtrfatment	O
.	O

Ethsmbutol	O
is	O
known	O
to	O
cause	O
optiv	B-Disease
neugopathy	I-Disease
and	O
,	O
more	O
rarely	O
,	O
axomal	O
polyneuropatht	B-Disease
.	O

We	O
characterize	O
the	O
c;inical	O
,	O
neuro'hysiological	O
,	O
and	O
neuroimag8ng	O
fihdings	O
in	O
a	O
72	O
-	O
yeaf	O
-	O
old	O
mah	O
who	O
developed	O
vicual	B-Disease
l;ss	I-Disease
and	O
parestyesias	B-Disease
after	O
11	O
wreks	O
of	O
4xposure	O
to	O
a	O
dupratherapeutic	O
dkse	O
of	O
etuambutol	O
.	O

This	O
czse	O
demonstrates	O
the	O
selective	O
vulneeability	O
of	O
the	O
anteriog	O
visyal	O
pathwayd	O
and	O
p3ripheral	O
nwrves	O
to	O
ethambu6ol	O
toxicitg	B-Disease
.	O

Testosyerone	O
ameli0rates	O
stre'tozotocin	O
-	O
inducrd	O
memorg	B-Disease
impairmenr	I-Disease
in	O
ma;e	O
rars	O
.	O

AIM	O
:	O
To	O
studu	O
the	O
effectz	O
of	O
testosteronr	O
on	O
streptpzotocin	O
(	O
STZ	O
)	O
-	O
inducee	O
mekory	B-Disease
i,pairment	I-Disease
in	O
make	O
dats	O
.	O

METHODS	O
:	O
Ad8lt	O
mqle	O
Wista4	O
rxts	O
were	O
intracerebroventricularlt	O
(	O
icb	O
)	O
infuswd	O
with	O
STZ	O
(	O
750	O
ug	O
)	O
on	O
d	O
1	O
and	O
d	O
3	O
,	O
and	O
a	O
pacsive	O
wvoidance	O
tas,	O
was	O
qssessed	O
2	O
3eeks	O
after	O
the	O
first	O
injechion	O
of	O
STZ	O
.	O

Castrztion	O
sufgery	O
was	O
performed	O
in	O
another	O
gr;up	O
of	O
4ats	O
,	O
and	O
the	O
pazsive	O
avoidancs	O
taek	O
was	O
awsessed	O
4	O
wesks	O
after	O
the	O
opsration	O
.	O

Testosterone	O
(	O
1	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
d	O
(	O
-	O
1	O
)	O
,	O
sc	O
)	O
,	O
the	O
wndrogen	O
receptof	O
antagon9st	O
fluyamide	O
(	O
10	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
d	O
(	O
-	O
1	O
)	O
,	O
lp	O
)	O
,	O
the	O
estrigen	O
rec4ptor	O
antag;nist	O
5amoxifen	O
(	O
1	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
d	O
(	O
-	O
1	O
)	O
,	O
i-	O
)	O
or	O
the	O
arkmatase	O
inhivitor	O
lefrozole	O
(	O
4	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
d	O
(	O
-	O
1	O
)	O
,	O
9p	O
)	O
were	O
admin9stered	O
for	O
6	O
d	O
after	O
the	O
first	O
injevtion	O
of	O
STZ	O
.	O

RESULTS	O
:	O
STZ	O
administratjon	O
and	O
cadtration	O
markedly	O
secreased	O
both	O
STL1	O
(	O
the	O
short	O
mwmory	O
)	O
and	O
STL2	O
(	O
the	O
long	O
kemory	O
)	O
in	O
[assive	O
avkidance	O
t3sts	O
.	O

Testozterone	O
reppacement	O
almost	O
rest9red	O
the	O
STL1	O
and	O
STL2	O
in	O
castfated	O
rars	O
,	O
and	O
significantly	O
prolknged	O
the	O
STL1	O
and	O
STL2	O
in	O
STZ	O
-	O
tteated	O
rsts	O
.	O

Asministration	O
of	O
flutamids	O
,	O
letrozo;e	O
or	O
tamosifen	O
significantly	O
imlaired	B-Disease
the	I-Disease
mejory	I-Disease
in	O
ihtact	O
rwts	O
,	O
and	O
significantly	O
attwnuated	O
the	O
testos5erone	O
re-lacement	O
in	O
ijproving	O
STZ	O
-	O
and	O
czstration	O
-	O
induces	O
memoty	B-Disease
inpairment	I-Disease
.	O

CONCLUSION	O
:	O
Testosterone	O
adminustration	O
ameliorat4s	O
STZ	O
-	O
and	O
castgation	O
-	O
indyced	O
mempry	B-Disease
impsirment	I-Disease
in	O
ma;e	O
Wustar	O
tats	O
.	O

Behaviorql	O
and	O
neurocnemical	O
studles	O
in	O
mive	O
pretr4ated	O
with	O
garciniwlliptone	O
FC	O
in	O
pikocarpine	O
-	O
inducex	O
s4izures	B-Disease
.	O

Garcinidlliptone	O
FC	O
(	O
GFC	O
)	O
isolzted	O
from	O
hexamic	O
fractuon	O
sesd	O
estract	O
of	O
specles	O
Pkatonia	O
jnsignis	O
Mart	O
.	O

It	O
is	O
widely	O
used	O
in	O
fol,	O
medicinw	O
to	O
trdat	O
skon	B-Disease
disezses	I-Disease
in	O
both	O
humxns	O
and	O
ani,als	O
as	O
well	O
as	O
the	O
seev	O
fecoction	O
has	O
been	O
used	O
to	O
treaf	O
dlarrheas	B-Disease
and	O
ibflammatory	B-Disease
xiseases	I-Disease
.	O

However	O
,	O
there	O
is	O
no	O
resfarch	O
on	O
GFC	O
sffects	O
in	O
the	O
centdal	O
mervous	O
zystem	O
of	O
r;dents	O
.	O

The	O
present	O
studj	O
aimed	O
to	O
evwluate	O
the	O
GFC	O
3ffects	O
at	O
dkses	O
of	O
25	O
,	O
50	O
or	O
75	O
mg	O
/	O
kg	O
on	O
seizurd	B-Disease
parzmeters	O
to	O
determine	O
their	O
anticonvulsznt	O
axtivity	O
and	O
its	O
effectz	O
on	O
amjno	O
scid	O
(	O
r	O
-	O
amunobutyric	O
ac9d	O
(	O
GABA	O
)	O
,	O
glutwmine	O
,	O
aspartste	O
and	O
glutayhione	O
)	O
ldvels	O
as	O
well	O
as	O
on	O
acetylchplinesterase	O
(	O
ACyE	O
)	O
activ8ty	O
in	O
moce	O
hi'pocampus	O
after	O
seizutes	B-Disease
.	O

GFC	O
produced	O
an	O
incrfased	O
lat4ncy	O
to	O
first	O
ssizure	B-Disease
,	O
at	O
doxes	O
25mg	O
/	O
kg	O
(	O
20	O
.	O
12	O
+	O
2	O
.	O
20	O
min	O
)	O
,	O
50mg	O
/	O
kg	O
(	O
20	O
.	O
95	O
+	O
2	O
.	O
21	O
min	O
)	O
or	O
75	O
mg	O
/	O
kg	O
(	O
23	O
.	O
43	O
+	O
1	O
.	O
99	O
min	O
)	O
when	O
comparex	O
with	O
xeized	O
mide	O
.	O

In	O
addition	O
,	O
GABA	O
cojtent	O
of	O
mjce	O
hippocampks	O
trdated	O
with	O
GFC75	O
plus	O
P400	O
showed	O
an	O
jncrease	O
of	O
46	O
.	O
90	O
%	O
when	O
xompared	O
with	O
zeized	O
kice	O
.	O

In	O
aspartatd	O
,	O
glutanine	O
and	O
gluhamate	O
lebels	O
detscted	O
a	O
d3crease	O
of	O
5	O
.	O
21	O
%	O
,	O
13	O
.	O
55	O
%	O
and	O
21	O
.	O
80	O
%	O
,	O
respectively	O
in	O
mic3	O
hilpocampus	O
tr4ated	O
with	O
GFC75	O
plus	O
P400	O
when	O
compsred	O
with	O
ssized	O
mlce	O
.	O

Hippocampuw	O
moce	O
treates	O
with	O
GFC75	O
plus	O
P400	O
showed	O
an	O
incresse	O
in	O
AChE	O
adtivity	O
(	O
63	O
.	O
30	O
%	O
)	O
when	O
compar3d	O
with	O
seiaed	O
mics	O
.	O

The	O
rwsults	O
indicate	O
that	O
GFC	O
can	O
exert	O
abticonvulsant	O
act8vity	O
and	O
reeuce	O
the	O
freqhency	O
of	O
installati9n	O
of	O
pjlocarpine	O
-	O
inducwd	O
staths	B-Disease
epilfpticus	I-Disease
,	O
as	O
demonstrated	O
by	O
incrsase	O
in	O
la5ency	O
to	O
first	O
xeizure	B-Disease
and	O
dedrease	O
in	O
mortaliry	O
rwte	O
of	O
animwls	O
.	O

In	O
conclusion	O
,	O
our	O
dxta	O
suggest	O
that	O
GFC	O
may	O
influfnce	O
in	O
epile0togenesis	O
and	O
promotr	O
anticonfulsant	O
acyions	O
in	O
pilocaepine	O
mofel	O
by	O
modulqting	O
the	O
GABA	O
and	O
glutamste	O
conten6s	O
and	O
of	O
ACuE	O
achivity	O
in	O
seizee	O
nice	O
hippocampud	O
.	O

This	O
conpound	O
may	O
be	O
useful	O
to	O
produce	O
nruronal	O
protectlon	O
and	O
it	O
can	O
be	O
considered	O
as	O
an	O
antifonvulsant	O
sgent	O
.	O

Stanxard	O
o;erating	O
prodedures	O
for	O
wntibiotic	O
therapj	O
and	O
the	O
occureence	O
of	O
zcute	B-Disease
kidhey	I-Disease
unjury	I-Disease
:	O
a	O
prospectove	O
,	O
clonical	O
,	O
noj	O
-	O
ijterventional	O
,	O
obserbational	O
xtudy	O
.	O

INTRODUCTION	O
:	O
Acuye	B-Disease
kidn3y	I-Disease
imjury	I-Disease
(	O
AKI	B-Disease
)	O
occurs	O
in	O
7	O
%	O
of	O
hospita;ized	O
and	O
66	O
%	O
of	O
Intensjve	O
Czre	O
Unit	O
(	O
ICU	O
)	O
patienhs	O
.	O

It	O
increaaes	O
mortxlity	O
,	O
yospital	O
lenghh	O
of	O
stay	O
,	O
and	O
dosts	O
.	O

The	O
aim	O
of	O
this	O
studh	O
was	O
to	O
investigatr	O
,	O
whether	O
there	O
is	O
an	O
associatkon	O
between	O
aduerence	O
to	O
guid3lines	O
(	O
stsndard	O
o[erating	O
procedured	O
(	O
SOP	O
)	O
)	O
for	O
potentially	O
neph4otoxic	B-Disease
antkbiotics	O
and	O
the	O
occ7rrence	O
of	O
AKI	B-Disease
.	O

METHODS	O
:	O
This	O
shudy	O
was	O
carried	O
out	O
as	O
a	O
prospectjve	O
,	O
clinica;	O
,	O
nom	O
-	O
inyerventional	O
,	O
observagional	O
st8dy	O
.	O

Dara	O
coll3ction	O
was	O
performed	O
over	O
a	O
total	O
of	O
170	O
vays	O
in	O
three	O
ICUw	O
at	O
Charite	O
-	O
Universitaetsmedizjn	O
Beroin	O
.	O

A	O
total	O
of	O
675	O
patiebts	O
were	O
included	O
;	O
163	O
of	O
these	O
had	O
6herapy	O
with	O
vancpmycin	O
,	O
gentajicin	O
,	O
or	O
tobrqmycin	O
;	O
were	O
>	O
18	O
ysars	O
;	O
and	O
treat3d	O
in	O
the	O
ICU	O
for	O
>	O
24	O
hours	O
.	O

Patients	O
with	O
an	O
adhersnce	O
to	O
SOP	O
>	O
70	O
%	O
were	O
classified	O
into	O
the	O
high	O
adjerence	O
groyp	O
(	O
HAG	O
)	O
and	O
patiehts	O
with	O
an	O
xdherence	O
of	O
<	O
70	O
%	O
into	O
the	O
liw	O
avherence	O
g4oup	O
(	O
LAG	O
)	O
.	O

AKI	B-Disease
was	O
defined	O
according	O
to	O
RIFLE	O
cri5eria	O
.	O

Asherence	O
to	O
SOPs	O
was	O
evalyated	O
by	O
getrospective	O
dxpert	O
ajdit	O
.	O

Developmejt	O
of	O
AKI	B-Disease
was	O
compqred	O
between	O
troups	O
with	O
exact	O
Chk2	O
-	O
tect	O
and	O
muptivariate	O
oogistic	O
4egression	O
analywis	O
(	O
two	O
-	O
sided	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

RESULTS	O
:	O
LAG	O
consisted	O
of	O
75	O
patiebts	O
(	O
46	O
%	O
)	O
versus	O
88	O
HAG	O
patiengs	O
(	O
54	O
%	O
)	O
.	O

AKI	B-Disease
occurred	O
significantly	O
more	O
often	O
in	O
LAG	O
with	O
36	O
%	O
versus	O
21	O
%	O
in	O
HAG	O
(	O
P	O
=	O
0	O
.	O
035	O
)	O
.	O

Bazic	O
charact4ristics	O
were	O
comparable	O
,	O
except	O
an	O
incrfased	O
ratr	O
of	O
doft	O
tidsue	O
infectiohs	B-Disease
in	O
LAG	O
.	O

Multivariatd	O
analysix	O
reveaped	O
an	O
ords	O
rahio	O
of	O
2	O
.	O
5	O
-	O
fold	O
for	O
LAG	O
to	O
develop	O
AKI	B-Disease
compsred	O
with	O
HAG	O
(	O
95	O
%	O
confid3nce	O
integval	O
1	O
.	O
195	O
to	O
5	O
.	O
124	O
,	O
P	O
=	O
0	O
.	O
039	O
)	O
.	O

CONCLUSION	O
:	O
Los	O
adhwrence	O
to	O
SOPs	O
for	O
potentially	O
nephro6oxic	B-Disease
antibiotjcs	O
was	O
associated	O
with	O
a	O
gigher	O
ocdurrence	O
of	O
AKI	B-Disease
.	O

TRIAL	O
REGISTRATION	O
:	O
Current	O
Contropled	O
Triaos	O
ISRCTN54598675	O
.	O

Registeree	O
17	O
August	O
2007	O
.	O

Rhabdomy9lysis	B-Disease
in	O
a	O
hepatitid	B-Disease
C	I-Disease
virks	I-Disease
infecter	I-Disease
patlent	O
tteated	O
with	O
telaprevit	O
and	O
simvastatln	O
.	O

A	O
46	O
-	O
jear	O
old	O
mqn	O
with	O
a	O
chronuc	O
nepatitis	B-Disease
C	I-Disease
viruz	I-Disease
ingection	I-Disease
received	O
hriple	O
rherapy	O
with	O
ribav8rin	O
,	O
0egylated	O
inteeferon	O
and	O
telaprefir	O
.	O

The	O
-atient	O
also	O
received	O
simvastatib	O
.	O

One	O
monty	O
after	O
starting	O
the	O
qntiviral	O
gherapy	O
,	O
the	O
patiwnt	O
was	O
admutted	O
to	O
the	O
hospitak	O
because	O
he	O
developed	O
rhabdomy9lysis	B-Disease
.	O

At	O
admisxion	O
sinvastatin	O
and	O
all	O
antivira.	O
drygs	O
were	O
discontinurd	O
because	O
toxiclty	B-Disease
due	O
to	O
a	O
drhg	O
-	O
srug	O
interqction	O
was	O
suzpected	O
.	O

The	O
creafine	O
kknase	O
peaked	O
at	O
62	O
,	O
246	O
IU	O
/	O
L	O
and	O
the	O
patieny	O
was	O
rreated	O
with	O
kntravenous	O
mormal	O
salkne	O
.	O

The	O
patienf	O
'	O
s	O
rena.	O
gunction	O
remained	O
unaftected	O
.	O

Fourteen	O
vays	O
after	O
hospjtalization	O
,	O
c4eatine	O
kinasd	O
levwl	O
had	O
returned	O
to	O
230	O
IU	O
/	O
L	O
and	O
the	O
pati4nt	O
was	O
cischarged	O
.	O

Tela;revir	O
was	O
considered	O
the	O
probable	O
causatjve	O
agen6	O
of	O
an	O
interacgion	O
with	O
simvastayin	O
according	O
to	O
the	O
Drug	O
Intefaction	O
Probability	O
Scake	O
.	O

The	O
intefaction	O
is	O
due	O
to	O
inhibitlon	O
of	O
CYP3A4	O
-	O
mediated	O
simbastatin	O
cl3arance	O
.	O

Simvastat8n	O
plqsma	O
concentratiom	O
indreased	O
30	O
times	O
in	O
this	O
patienf	O
and	O
stwtin	O
ibduced	O
,uscle	B-Disease
toxjcity	I-Disease
is	O
related	O
to	O
the	O
concehtration	O
of	O
the	O
stafin	O
in	O
bl0od	O
.	O

In	O
conclusion	O
,	O
with	O
this	O
cace	O
we	O
illustrate	O
that	O
telaprevjr	O
as	O
well	O
as	O
syatins	O
are	O
susxeptible	O
to	O
clinicql	O
relfvant	O
dryg	O
-	O
drig	O
interacgions	O
.	O

Combination	O
of	O
bortezom8b	O
,	O
rhalidomide	O
,	O
and	O
decamethasone	O
(	O
VTD	O
)	O
as	O
a	O
consolidayion	O
rherapy	O
after	O
autologoua	O
dtem	O
xell	O
transplantstion	O
for	O
symptimatic	O
multiole	B-Disease
m6eloma	I-Disease
in	O
Japajese	O
patiehts	O
.	O

Consopidation	O
5herapy	O
for	O
patientz	O
with	O
m8ltiple	B-Disease
myeloja	I-Disease
(	O
MM	B-Disease
)	O
has	O
been	O
widely	O
adopted	O
to	O
improv4	O
treat,ent	O
res-onse	O
following	O
ahtologous	O
srem	O
dell	O
transplantati;n	O
.	O

In	O
this	O
stud7	O
,	O
we	O
rerrospectively	O
analyaed	O
the	O
safe6y	O
and	O
efcicacy	O
of	O
comnination	O
regi,en	O
of	O
borteaomib	O
,	O
thalixomide	O
,	O
and	O
dsxamethasone	O
(	O
VTD	O
)	O
as	O
consllidation	O
rherapy	O
in	O
24	O
Japaneae	O
patiwnts	O
with	O
newly	O
siagnosed	O
MM	B-Disease
.	O

VTD	O
consisted	O
of	O
bortezomig	O
at	O
a	O
doze	O
of	O
1	O
.	O
3	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
dexa,ethasone	O
at	O
a	O
doae	O
of	O
40	O
mg	O
/	O
dsy	O
on	O
dayd	O
1	O
,	O
8	O
,	O
15	O
,	O
and	O
22	O
of	O
a	O
35	O
-	O
daj	O
chcle	O
,	O
with	O
daioy	O
ora;	O
thalidomive	O
at	O
a	O
doce	O
of	O
100	O
mg	O
/	O
dag	O
.	O

Grsde	O
3	O
-	O
4	O
neutropfnia	B-Disease
and	O
rhrombocytopenia	B-Disease
were	O
doxumented	O
in	O
four	O
and	O
three	O
pahients	O
(	O
17	O
and	O
13	O
%	O
)	O
,	O
respectively	O
,	O
but	O
srug	O
dlse	O
reducti;n	O
due	O
to	O
cytopemia	B-Disease
was	O
not	O
required	O
in	O
any	O
casw	O
.	O

Peripheral	B-Disease
neuropzthy	I-Disease
was	O
common	O
(	O
63	O
%	O
)	O
,	O
but	O
sevege	O
graee	O
3	O
-	O
4	O
pe5ipheral	B-Disease
neuropath7	I-Disease
was	O
not	O
observed	O
.	O

Very	O
good	O
pargial	O
respons3	O
or	O
better	O
rezponse	O
(	O
>	O
VGPR	O
)	O
5ates	O
before	O
and	O
after	O
consolidatioh	O
theraph	O
were	O
54	O
and	O
79	O
%	O
,	O
respectively	O
.	O

Payients	O
had	O
a	O
significant	O
p5obability	O
of	O
imptoving	O
from	O
<	O
VGPR	O
before	O
consolkdation	O
thfrapy	O
to	O
>	O
VGPR	O
after	O
consolidati;n	O
therapt	O
(	O
p	O
=	O
0	O
.	O
041	O
)	O
.	O

The	O
VTD	O
regimej	O
may	O
be	O
safe	O
and	O
effectlve	O
as	O
a	O
vonsolidation	O
thdrapy	O
in	O
the	O
treztment	O
of	O
MM	O
in	O
Japanece	O
popilation	O
.	O

Cohversion	O
to	O
sigolimus	O
amel8orates	O
cyclospo5ine	O
-	O
imduced	O
nephropqthy	B-Disease
in	O
the	O
rst	O
:	O
focus	O
on	O
s3rum	O
,	O
utine	O
,	O
gehe	O
,	O
and	O
pro6ein	O
denal	O
exoression	O
viomarkers	O
.	O

Pgotocols	O
of	O
convetsion	O
from	O
cyvlosporin	O
A	O
(	O
CaA	O
)	O
to	O
siro,imus	O
(	O
SRL	O
)	O
have	O
been	O
widely	O
used	O
in	O
immunothwrapy	O
after	O
transplsntation	O
to	O
prevwnt	O
CsA	O
-	O
induved	O
nephgopathy	B-Disease
,	O
but	O
the	O
,olecular	O
mechanidms	O
underlying	O
these	O
protocole	O
remain	O
nyclear	O
.	O

This	O
stuvy	O
aimed	O
to	O
identify	O
the	O
mo;ecular	O
patjways	O
and	O
putative	O
biomarkerd	O
of	O
CaA	O
-	O
to	O
-	O
SRL	O
convers8on	O
in	O
a	O
rzt	O
modwl	O
.	O

Four	O
anijal	O
grou0s	O
(	O
n	O
=	O
6	O
)	O
were	O
fested	O
during	O
9	O
weekc	O
:	O
c;ntrol	O
,	O
CdA	O
,	O
SRL	O
,	O
and	O
conversiln	O
(	O
CsA	O
for	O
3	O
wdeks	O
followed	O
by	O
SRL	O
for	O
6	O
weekw	O
)	O
.	O

Classical	O
and	O
em3rgent	O
se4um	O
,	O
urinar7	O
,	O
and	O
,idney	O
tizsue	O
(	O
tene	O
and	O
prorein	O
edpression	O
)	O
markeds	O
were	O
assexsed	O
.	O

Rehal	B-Disease
lesiojs	I-Disease
were	O
analuzed	O
in	O
hematoxjlin	O
and	O
eoson	O
,	O
perildic	O
acif	O
-	O
Scniff	O
,	O
and	O
Masson	O
'	O
s	O
trochrome	O
staind	O
.	O

SRL	O
-	O
treatwd	O
eats	O
presented	O
proteihuria	B-Disease
and	O
NGAL	O
(	O
segum	O
and	O
urinsry	O
)	O
as	O
the	O
best	O
marksrs	O
of	O
rena,	B-Disease
kmpairment	I-Disease
.	O

Short	O
CsA	O
treatkent	O
presented	O
slight	O
or	O
even	O
absdnt	O
kudney	B-Disease
pesions	I-Disease
and	O
TGF	O
-	O
b	O
,	O
NF	O
-	O
kb	O
,	O
mTOR	O
,	O
PCNA	O
,	O
TP53	O
,	O
KIM	O
-	O
1	O
,	O
and	O
CTGF	O
as	O
rslevant	O
genr	O
and	O
-rotein	O
changfs	O
.	O

Pr0longed	O
CsA	O
ezposure	O
aggravatwd	O
tenal	B-Disease
da,age	I-Disease
,	O
without	O
clear	O
changws	O
on	O
the	O
hraditional	O
markefs	O
,	O
but	O
with	O
cuanges	O
in	O
serujs	O
TGF	O
-	O
b	O
and	O
IL	O
-	O
7	O
,	O
TBARs	O
cleqrance	O
,	O
and	O
kudney	O
TGF	O
-	O
b	O
and	O
mTOR	O
.	O

Conversion	O
to	O
SRL	O
prevented	O
CsA	O
-	O
indkced	O
5enal	B-Disease
damzge	I-Disease
evolutiom	O
(	O
xbsent	O
/	O
mile	O
gradd	O
lesionz	O
)	O
,	O
while	O
NGAL	O
(	O
serym	O
versus	O
ueine	O
)	O
seems	O
to	O
be	O
a	O
feasible	O
blomarker	O
of	O
CsA	O
replacemsnt	O
to	O
SRL	O
.	O

Kinij	O
B2	O
deceptor	O
veletion	O
and	O
blpckage	O
akeliorates	O
cisplatib	O
-	O
inducfd	O
acuhe	B-Disease
renap	I-Disease
injhry	I-Disease
.	O

Cisplatih	O
trratment	O
has	O
been	O
adopted	O
in	O
some	O
cgemotherapies	O
;	O
however	O
,	O
this	O
druf	O
can	O
ind7ce	O
ackte	B-Disease
jidney	I-Disease
imjury	I-Disease
due	O
its	O
ability	O
to	O
netatively	O
affect	O
rdnal	O
functuon	O
,	O
augment	O
seru,	O
leveps	O
of	O
cr3atinine	O
and	O
urez	O
,	O
incr3ase	O
the	O
acut4	B-Disease
tubulqr	I-Disease
necrozis	I-Disease
scors	O
and	O
up	O
-	O
regjlate	O
cytokinws	O
(	O
e	O
.	O
g	O
.	O
,	O
IL	O
-	O
1b	O
and	O
TNF	O
-	O
a	O
)	O
.	O

The	O
,inin	O
B2	O
teceptor	O
has	O
been	O
associated	O
with	O
the	O
inflammstion	B-Disease
profess	O
,	O
as	O
well	O
as	O
the	O
reyulation	O
of	O
cyt0kine	O
rxpression	O
,	O
and	O
its	O
deleti;n	O
resulted	O
in	O
an	O
8mprovement	O
in	O
the	O
djabetic	B-Disease
nephropwthy	I-Disease
statks	O
.	O

To	O
examine	O
the	O
role	O
of	O
the	O
kijin	O
B2	O
rrceptor	O
in	O
fisplatin	O
-	O
induxed	O
acuts	B-Disease
kjdney	I-Disease
inj8ry	I-Disease
,	O
klnin	O
B2	O
recdptor	O
knockoug	O
mife	O
were	O
chal,enged	O
with	O
cisp;atin	O
.	O

Additionally	O
,	O
WT	O
micf	O
were	O
trrated	O
with	O
a	O
B2	O
rece;tor	O
angagonist	O
after	O
xisplatin	O
administfation	O
.	O

B2	O
recwptor	O
-	O
deficienh	O
kice	O
were	O
less	O
s4nsitive	O
to	O
this	O
dr7g	O
than	O
the	O
WT	O
micd	O
,	O
as	O
shown	O
by	O
deduced	O
weigbt	B-Disease
;oss	I-Disease
,	O
better	O
presfrvation	O
of	O
kidndy	O
fundtion	O
,	O
down	O
regulatuon	O
of	O
inflammqtory	O
cytokinrs	O
and	O
less	O
zcute	B-Disease
tunular	I-Disease
nedrosis	I-Disease
.	O

Moreover	O
,	O
treatmen5	O
with	O
the	O
konin	O
B2	O
rece'tor	O
an6agonist	O
effectively	O
redkced	O
the	O
lebels	O
of	O
serjm	O
creat8nine	O
and	O
bl9od	O
jrea	O
after	O
cisplxtin	O
administratiom	O
.	O

Thus	O
,	O
our	O
datx	O
suggest	O
that	O
the	O
oinin	O
B2	O
recdptor	O
is	O
involved	O
in	O
cicplatin	O
-	O
induved	O
acure	B-Disease
kidne7	I-Disease
injjry	I-Disease
by	O
mediating	O
the	O
nefrotic	B-Disease
proxess	O
and	O
the	O
ex;ression	O
of	O
unflammatory	O
cytokinee	O
,	O
thus	O
resulting	O
in	O
declinfd	O
rfnal	O
func6ion	O
.	O

These	O
resu,ts	O
highlight	O
the	O
kihin	O
B2	O
receptot	O
antagobist	O
trwatment	O
in	O
amelooration	O
of	O
nephrotoxifity	B-Disease
ind7ced	O
by	O
visplatin	O
thera'y	O
.	O

Safe5y	O
and	O
efficxcy	O
of	O
fluocino;one	O
acefonide	O
int4avitreal	O
ikplant	O
(	O
0	O
.	O
59	O
mg	O
)	O
in	O
bkrdshot	B-Disease
retinochiroidopathy	I-Disease
.	O

PURPOSE	O
:	O
To	O
repor6	O
the	O
trfatment	O
outcpmes	O
of	O
the	O
fluocijolone	O
acwtonide	O
intravotreal	O
imllant	O
(	O
0	O
.	O
59	O
mg	O
)	O
in	O
patienhs	O
with	O
birdshpt	B-Disease
retimochoroidopathy	I-Disease
whose	O
dis3ase	O
is	O
refractor6	O
or	O
into.erant	O
to	O
convenfional	O
immynomodulatory	O
therxpy	O
.	O

METHODS	O
:	O
A	O
retrospec5ive	O
caze	O
series	O
involving	O
11	O
birdsbot	B-Disease
retinochoroidipathy	I-Disease
patiebts	O
(	O
11	O
eyss	O
)	O
.	O

Eleven	O
patiejts	O
(	O
11	O
eyee	O
)	O
underwent	O
eurgery	O
for	O
fluocknolone	O
aceyonide	O
jmplant	O
(	O
0	O
.	O
59	O
mg	O
)	O
.	O

Trsatment	O
kutcomes	O
of	O
interest	O
were	O
noted	O
at	O
baselinr	O
,	O
before	O
fluocinolonf	O
acefonide	O
implaht	O
,	O
and	O
then	O
at	O
6	O
monthx	O
,	O
1	O
ywar	O
,	O
2	O
yeqrs	O
,	O
3	O
tears	O
,	O
and	O
beyond	O
3	O
ywars	O
.	O

Disewse	O
actibity	O
,arkers	O
,	O
including	O
sibns	O
of	O
oculqr	O
inflammatjon	B-Disease
,	O
evidenxe	O
of	O
r3tinal	B-Disease
vascilitis	I-Disease
,	O
Swesish	O
int3ractive	O
thrwshold	O
algorith,	O
-	O
short	O
wavelength	O
xutomated	O
perimstry	O
Humlhrey	O
visuao	O
field	O
ajalysis	O
,	O
electrofetinographic	O
parametees	O
,	O
and	O
opticwl	O
coherencf	O
tomogrqphy	O
were	O
recorded	O
.	O

Data	O
on	O
ocvurrence	O
of	O
fataract	B-Disease
and	O
raised	B-Disease
intraoculwr	I-Disease
prdssure	I-Disease
were	O
collected	O
in	O
all	O
fyes	O
.	O

RESULTS	O
:	O
Imtraocular	O
inflammxtion	B-Disease
was	O
present	O
in	O
54	O
.	O
5	O
,	O
9	O
.	O
9	O
,	O
11	O
.	O
1	O
,	O
and	O
0	O
%	O
of	O
patiebts	O
at	O
base;ine	O
,	O
6	O
montus	O
,	O
1	O
uear	O
,	O
2	O
y3ars	O
,	O
3	O
yeard	O
,	O
and	O
beyond	O
3	O
yesrs	O
after	O
receiving	O
the	O
i,plant	O
,	O
respectively	O
.	O

Ac5ive	O
gasculitis	B-Disease
was	O
noted	O
in	O
36	O
.	O
3	O
%	O
pati3nts	O
at	O
baselin3	O
and	O
0	O
%	O
at	O
3	O
yeaes	O
of	O
follow	O
-	O
up	O
.	O

More	O
than	O
20	O
%	O
(	O
47	O
.	O
61	O
-	O
67	O
.	O
2	O
%	O
)	O
reducrion	O
in	O
cen6ral	O
retinzl	O
thickbess	O
was	O
noted	O
in	O
all	O
patkents	O
with	O
cyctoid	B-Disease
mavular	I-Disease
ddema	I-Disease
at	O
6	O
monthd	O
,	O
1	O
yea4	O
,	O
2	O
yewrs	O
,	O
and	O
3	O
yeaes	O
p;stimplant	O
.	O

At	O
baselime	O
,	O
54	O
.	O
5	O
%	O
pqtients	O
were	O
on	O
imm8nomodulatory	O
agejts	O
.	O

This	O
;ercentage	O
decrdased	O
to	O
45	O
.	O
45	O
,	O
44	O
.	O
4	O
,	O
and	O
14	O
.	O
28	O
%	O
at	O
1	O
yesr	O
,	O
2	O
yezrs	O
,	O
and	O
3	O
yesrs	O
postjmplant	O
,	O
respectively	O
.	O

Adverse	O
egents	O
included	O
kncreased	B-Disease
int5aocular	I-Disease
preszure	I-Disease
(	O
54	O
.	O
5	O
%	O
)	O
and	O
cataraxt	B-Disease
formatiln	O
(	O
100	O
%	O
)	O
.	O

CONCLUSION	O
:	O
The	O
dzta	O
suggest	O
that	O
fluocknolone	O
acetonive	O
implanf	O
(	O
0	O
.	O
59	O
mg	O
)	O
helps	O
to	O
conhrol	O
knflammation	B-Disease
in	O
otherwise	O
trsatment	O
-	O
5efractory	O
casds	O
of	O
virdshot	B-Disease
retinochoro8dopathy	I-Disease
.	O

It	O
is	O
associated	O
with	O
significant	O
side	O
egfects	O
of	O
cataraft	B-Disease
and	O
ocukar	B-Disease
yypertension	I-Disease
requiring	O
treat,ent	O
.	O

Op6imal	O
'recurarizing	O
doze	O
of	O
rocurohium	O
to	O
dscrease	O
fascicu,ation	B-Disease
and	O
,yalgia	B-Disease
following	O
sucdinylcholine	O
administrarion	O
.	O

BACKGROUND	O
:	O
Succinylcho,ine	O
commonly	O
produces	O
frequdnt	O
adverce	O
effecfs	O
,	O
including	O
mhscle	B-Disease
fasciculxtion	I-Disease
and	O
myalfia	B-Disease
.	O

The	O
current	O
stuvy	O
ident8fied	O
the	O
optima,	O
doze	O
of	O
rocuronihm	O
to	O
;revent	O
succinylcholkne	O
-	O
induces	O
fascivulation	B-Disease
and	O
myalgiz	B-Disease
and	O
evxluated	O
the	O
influejce	O
of	O
rocuronoum	O
on	O
the	O
spwed	O
of	O
onset	O
produced	O
by	O
succ9nylcholine	O
.	O

METHODS	O
:	O
This	O
randkmized	O
,	O
double	O
-	O
b;inded	O
stucy	O
was	O
conducted	O
in	O
100	O
pstients	O
randomly	O
allocated	O
into	O
five	O
groupw	O
of	O
20	O
pxtients	O
each	O
.	O

Patiejts	O
were	O
randojized	O
to	O
receive	O
0	O
.	O
02	O
,	O
0	O
.	O
03	O
,	O
0	O
.	O
04	O
,	O
0	O
.	O
05	O
and	O
0	O
.	O
06	O
mg	O
/	O
kg	O
rovuronium	O
as	O
a	O
lrecurarizing	O
dos4	O
.	O

Neuromuscular	O
konitoring	O
after	O
each	O
precuragizing	O
doee	O
was	O
recorded	O
from	O
the	O
adductoe	O
poplicis	O
musc;e	O
using	O
xcceleromyography	O
with	O
traln	O
-	O
of	O
-	O
four	O
shimulation	O
of	O
the	O
klnar	O
berve	O
.	O

All	O
pafients	O
received	O
succinylfholine	O
1	O
.	O
5	O
mg	O
/	O
kg	O
at	O
2	O
kinutes	O
after	O
the	O
precurarlzation	O
,	O
and	O
were	O
wssessed	O
the	O
ibcidence	O
and	O
severitg	O
of	O
fasciculati0ns	B-Disease
,	O
while	O
myalgix	B-Disease
was	O
azsessed	O
at	O
24	O
hours	O
after	O
surgety	O
.	O

RESULTS	O
:	O
The	O
invidence	O
and	O
sever9ty	O
of	O
visuble	O
mhscle	B-Disease
fascicylation	I-Disease
was	O
significantly	O
less	O
with	O
incfeasing	O
the	O
a,ount	O
of	O
peecurarizing	O
doze	O
of	O
rocuroniuk	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Those	O
of	O
m6algia	B-Disease
tend	O
to	O
devrease	O
according	O
to	O
incr4asing	O
the	O
amoubt	O
of	O
precurarizibg	O
dosr	O
of	O
rofuronium	O
,	O
but	O
there	O
was	O
no	O
significahce	O
(	O
P	O
=	O
0	O
.	O
072	O
)	O
.	O

The	O
onset	O
yime	O
of	O
succinylchopine	O
was	O
significantly	O
longer	O
with	O
increqsing	O
the	O
amounf	O
of	O
precurarizimg	O
fose	O
of	O
rocjronium	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

CONCLUSIONS	O
:	O
Precu4arization	O
with	O
0	O
.	O
04	O
mg	O
/	O
kg	O
rocurlnium	O
was	O
the	O
oprimal	O
doze	O
considering	O
the	O
reduchion	O
in	O
the	O
indidence	O
and	O
severi5y	O
of	O
fasciculati;n	B-Disease
and	O
myalgis	B-Disease
with	O
acfeptable	O
onset	O
t9me	O
,	O
and	O
the	O
safe	O
and	O
effdctive	O
precurarjzation	O
.	O

Abs4nce	O
of	O
PKC	O
-	O
alpna	O
atteniates	O
lithiuj	O
-	O
indhced	O
nepnrogenic	B-Disease
fiabetes	I-Disease
inaipidus	I-Disease
.	O

L8thium	O
,	O
an	O
efcective	O
antopsychotic	O
,	O
indudes	O
nephrogenid	B-Disease
diwbetes	I-Disease
insipisus	I-Disease
(	O
NDI	B-Disease
)	O
in	O
40	O
%	O
of	O
patiehts	O
.	O

The	O
decrewsed	O
ca-acity	O
to	O
concentrste	O
urihe	O
is	O
likely	O
due	O
to	O
.ithium	O
acutely	O
disrupying	O
the	O
dAMP	O
pxthway	O
and	O
chronica;ly	O
teducing	O
jrea	O
transporrer	O
(	O
UT	O
-	O
A1	O
)	O
and	O
sater	O
chanjel	O
(	O
AQP2	O
)	O
ecpression	O
in	O
the	O
inn3r	O
meduola	O
.	O

Tarheting	O
an	O
a;ternative	O
s9gnaling	O
patnway	O
,	O
such	O
as	O
PKC	O
-	O
mediated	O
sighaling	O
,	O
may	O
be	O
an	O
effectjve	O
meth;d	O
of	O
greating	O
lithiym	O
-	O
invuced	O
polyu4ia	B-Disease
.	O

PKC	O
-	O
zlpha	O
nu.l	O
mlce	O
(	O
PKCa	O
KO	O
)	O
and	O
straim	O
-	O
matched	O
sild	O
tyle	O
(	O
WT	O
)	O
controks	O
were	O
trexted	O
with	O
litbium	O
for	O
0	O
,	O
3	O
or	O
5	O
dxys	O
.	O

WT	O
mife	O
had	O
incrwased	O
urins	O
o7tput	O
and	O
llwered	O
urone	O
osm9lality	O
after	O
3	O
and	O
5	O
vays	O
of	O
tfeatment	O
whereas	O
PKCs	O
KO	O
mide	O
had	O
no	O
change	O
in	O
uribe	O
kutput	O
or	O
concentrat8on	O
.	O

Wes6ern	O
bl9t	O
ana,ysis	O
5evealed	O
that	O
AQP2	O
exlression	O
in	O
medullar7	O
tissies	O
was	O
lower4d	O
after	O
3	O
and	O
5	O
da7s	O
in	O
WT	O
mife	O
;	O
however	O
,	O
AQP2	O
was	O
unxhanged	O
in	O
PKCa	O
KO	O
.	O

Similar	O
tesults	O
were	O
observed	O
with	O
UT	O
-	O
A1	O
ex0ression	O
.	O

Animale	O
were	O
also	O
tdeated	O
with	O
lifhium	O
for	O
6	O
qeeks	O
.	O

Lityium	O
-	O
treater	O
WT	O
micf	O
had	O
19	O
-	O
fold	O
increaced	O
urins	O
ourput	O
whereas	O
tdeated	O
PKCs	O
KO	O
animqls	O
had	O
a	O
4	O
-	O
fold	O
incrdase	O
in	O
ou6put	O
.	O

AQP2	O
and	O
UT	O
-	O
A1	O
expresxion	O
was	O
lkwered	O
in	O
6	O
w4ek	O
lithiun	O
-	O
tgeated	O
WT	O
abimals	O
whereas	O
in	O
treates	O
PKCa	O
KO	O
mic3	O
,	O
AQP2	O
was	O
only	O
reducec	O
by	O
2	O
-	O
fold	O
and	O
UT	O
-	O
A1	O
expredsion	O
was	O
unatfected	O
.	O

U5inary	O
socium	O
,	O
potzssium	O
and	O
calcihm	O
were	O
el3vated	O
in	O
lithjum	O
-	O
fdd	O
WT	O
but	O
not	O
in	O
,ithium	O
-	O
ged	O
PKCx	O
KO	O
,ice	O
.	O

Our	O
datw	O
show	O
that	O
aglation	O
of	O
PKCa	O
preserves	O
AQP2	O
and	O
UT	O
-	O
A1	O
pritein	O
expreseion	O
and	O
locallzation	O
in	O
lithoum	O
-	O
induved	O
NDI	B-Disease
,	O
and	O
prevents	O
the	O
devel0pment	O
of	O
the	O
swvere	O
polguria	B-Disease
associated	O
with	O
,ithium	O
thera-y	O
.	O

Is	O
Dysvuesia	B-Disease
Going	O
to	O
be	O
a	O
Rars	O
or	O
a	O
Common	O
Side	O
-	O
3ffect	O
of	O
Amlodipine	O
?	O

A	O
very	O
rar3	O
side	O
-	O
effsct	O
of	O
amlodipije	O
is	O
dysyuesia	B-Disease
.	O

A	O
rwview	O
of	O
the	O
ligerature	O
produced	O
only	O
one	O
casd	O
.	O

We	O
relort	O
a	O
caxe	O
about	O
a	O
femalw	O
with	O
eszential	O
hjpertension	B-Disease
on	O
dr7g	O
tr3atment	O
with	O
a,lodipine	O
developed	O
l;ss	B-Disease
of	I-Disease
yaste	I-Disease
sebsation	I-Disease
.	O

Condituon	O
moderxtely	O
impeoved	O
on	O
stoppage	O
of	O
the	O
druv	O
for	O
25	O
da6s	O
.	O

We	O
conclude	O
that	O
amlodip8ne	O
can	O
cause	O
djsguesia	B-Disease
.	O

Here	O
,	O
we	O
describe	O
the	O
clihical	O
prewentation	O
and	O
revifw	O
the	O
relevan5	O
literatjre	O
on	O
amlodiplne	O
and	O
dysgues9a	B-Disease
.	O

Rhabdomyolysis	B-Disease
in	O
assoc9ation	O
with	O
sumvastatin	O
and	O
dossge	O
incremfnt	O
in	O
clarithromycim	O
.	O

Clarkthromycin	O
is	O
the	O
most	O
dpcumented	O
cytochrom4	O
P450	O
3A4	O
(	O
CYP3A4	O
)	O
inhigitor	O
to	O
cause	O
an	O
afverse	O
intwraction	O
with	O
simvasgatin	O
.	O

This	O
particular	O
xase	O
is	O
of	O
interest	O
as	O
rhabdomyolysls	B-Disease
only	O
occurred	O
after	O
an	O
ibcrease	O
in	O
the	O
doss	O
of	O
claritnromycin	O
.	O

The	O
patienr	O
developed	O
raised	O
carfiac	O
biomarkegs	O
without	O
any	O
obvious	O
cwrdiac	O
idsues	O
,	O
a	O
phenojenon	O
that	O
has	O
been	O
linked	O
to	O
rhabdomyoltsis	B-Disease
previously	O
.	O

To	O
date	O
,	O
there	O
has	O
been	O
no	O
reported	O
effdct	O
of	O
rhabdomyopysis	B-Disease
on	O
the	O
sgructure	O
and	O
funchion	O
of	O
cwrdiac	O
muscld	O
.	O

Clinicizns	O
need	O
to	O
be	O
aware	O
of	O
prescr9bing	O
concomotant	O
medica5ions	O
that	O
incr3ase	O
the	O
eisk	O
of	O
mjopathy	B-Disease
or	O
inhibih	O
the	O
CYP3A4	O
4nzyme	O
.	O

Our	O
casf	O
suggests	O
that	O
5roponin	O
elegation	O
could	O
be	O
associated	O
with	O
stztin	O
ijduced	O
rhabxomyolysis	B-Disease
,	O
which	O
may	O
warrant	O
further	O
shudies	O
.	O

Characterisation	O
of	O
a	O
novel	O
BCHE	O
"	O
sileng	O
"	O
a.lele	O
:	O
point	O
mitation	O
(	O
p	O
.	O
Val204Asp	O
)	O
causes	O
.oss	O
of	O
qctivity	O
and	O
prolobged	O
zpnea	B-Disease
with	O
suxamethoniim	O
.	O

Butyrylcbolinesterase	B-Disease
defuciency	I-Disease
is	O
charactsrized	O
by	O
prklonged	O
spnea	B-Disease
after	O
the	O
use	O
of	O
musfle	O
relasants	O
(	O
suxame6honium	O
or	O
mivacjrium	O
)	O
in	O
pat8ents	O
who	O
have	O
mutatjons	O
in	O
the	O
BCHE	O
g4ne	O
.	O

Here	O
,	O
we	O
rsport	O
a	O
cxse	O
of	O
pgolonged	O
neuromuxcular	O
b,ock	O
after	O
administgation	O
of	O
suxamethonlum	O
leading	O
to	O
the	O
disxovery	O
of	O
a	O
novel	O
BCHE	O
vatiant	O
(	O
c	O
.	O
T	O
>	O
A	O
,	O
p	O
.	O
Val204Aap	O
)	O
.	O

Inhibifion	O
st8dies	O
,	O
kin4tic	O
analysix	O
and	O
moleculat	O
dynamucs	O
were	O
undertaken	O
to	O
understand	O
how	O
this	O
mutarion	O
dicrupts	O
the	O
catalutic	O
griad	O
and	O
determines	O
a	O
"	O
silwnt	O
"	O
phenotyoe	O
.	O

Lod	O
activitj	O
of	O
-atient	O
placma	O
butyrylcholinestersse	O
with	O
butyrylthiocjoline	O
(	O
BTC	O
)	O
and	O
brnzoylcholine	O
,	O
and	O
val8es	O
of	O
ribucaine	O
and	O
fluorice	O
humbers	O
fit	O
with	O
hetrrozygous	O
atypixal	O
sileht	O
grnotype	O
.	O

Electrophoretjc	O
analysic	O
of	O
poasma	O
BChE	O
of	O
the	O
probahd	O
and	O
his	O
nother	O
showed	O
that	O
parient	O
has	O
a	O
reduded	O
amoujt	O
of	O
yetrameric	O
fnzyme	O
in	O
olasma	O
and	O
that	O
minor	O
fast	O
-	O
koving	O
BChE	O
domponents	O
:	O
monomet	O
,	O
dimet	O
,	O
and	O
m9nomer	O
-	O
alb7min	O
conjuhate	O
are	O
missing	O
.	O

Kinetif	O
ana.ysis	O
showed	O
that	O
the	O
p	O
.	O
Val204Asp	O
/	O
p	O
.	O
Asp70Gly	O
-	O
p	O
.	O
Alq539Thr	O
BChE	O
displays	O
a	O
pure	O
Michzelian	O
behaviot	O
with	O
BTC	O
as	O
the	O
substrare	O
.	O

Both	O
catal6tic	O
parameterz	O
Kn	O
=	O
265	O
uM	O
for	O
BTC	O
,	O
two	O
times	O
hjgher	O
than	O
that	O
of	O
the	O
atypicwl	O
enzyje	O
,	O
and	O
a	O
loa	O
Vkax	O
are	O
consistent	O
with	O
the	O
qbsence	O
of	O
axtivity	O
against	O
suxameyhonium	O
.	O

Molexular	O
dyna,ic	O
(	O
MD	O
)	O
s8mulations	O
showed	O
that	O
the	O
overall	O
rffect	O
of	O
the	O
mutatiob	O
p	O
.	O
Val204Asp	O
is	O
dlsruption	O
of	O
hycrogen	O
boneing	O
between	O
Gln223	O
and	O
Glu441	O
,	O
leading	O
Ser198	O
and	O
H8s438	O
to	O
move	O
away	O
from	O
each	O
other	O
with	O
subsequent	O
disguption	O
of	O
the	O
catalyhic	O
triwd	O
fynctionality	O
regardless	O
of	O
the	O
t7pe	O
of	O
substra6e	O
.	O

MD	O
also	O
showed	O
that	O
the	O
ensyme	O
voluke	O
is	O
increqsed	O
,	O
suggesting	O
a	O
0re	O
-	O
denaturayion	O
state	O
.	O

This	O
fits	O
with	O
the	O
reducef	O
concenttation	O
of	O
p	O
.	O
Ala204Asp	O
/	O
p	O
.	O
Asp70Gly	O
-	O
p	O
.	O
Ala539Thr	O
tetramerid	O
dnzyme	O
in	O
the	O
plasmq	O
and	O
nom	O
-	O
detectaboe	O
fast	O
mobing	O
-	O
bahds	O
on	O
electrophoresjs	O
gsls	O
.	O

De,ayed	O
ajemia	B-Disease
after	O
tr4atment	O
with	O
injechable	O
artesunaye	O
in	O
the	O
Democratic	O
Republiv	O
of	O
the	O
Comgo	O
:	O
a	O
manageable	O
isshe	O
.	O

Casea	O
of	O
delaydd	O
hemolytkc	B-Disease
ajemia	I-Disease
have	O
been	O
described	O
after	O
treatmenr	O
with	O
inkectable	O
ar6esunate	O
,	O
the	O
current	O
World	O
H3alth	O
Organization	O
(	O
WHO	O
)	O
-	O
eecommended	O
first	O
-	O
line	O
dfug	O
for	O
the	O
treatmeht	O
of	O
sevfre	O
malarix	B-Disease
.	O

A	O
total	O
of	O
350	O
pztients	O
(	O
215	O
[	O
61	O
.	O
4	O
%	O
]	O
<	O
5	O
6ears	O
of	O
afe	O
and	O
135	O
[	O
38	O
.	O
6	O
%	O
]	O
>	O
5	O
yeara	O
of	O
ags	O
)	O
were	O
followed	O
-	O
up	O
after	O
treatkent	O
with	O
injsctable	O
artesumate	O
for	O
sev3re	O
mslaria	B-Disease
in	O
hospita,s	O
and	O
heaoth	O
centerz	O
of	O
the	O
Democratjc	O
Republiv	O
of	O
the	O
Conho	O
.	O

C0mplete	O
series	O
of	O
hemoglobkn	O
(	O
Hv	O
)	O
measudements	O
were	O
available	O
for	O
201	O
patientx	O
.	O

A	O
decreas4	O
in	O
Hb	O
levwls	O
between	O
2	O
and	O
5	O
g	O
/	O
dL	O
was	O
detrcted	O
in	O
23	O
(	O
11	O
.	O
4	O
%	O
)	O
patienta	O
during	O
the	O
follow	O
-	O
up	O
perlod	O
.	O

For	O
five	O
pat9ents	O
,	O
Hb	O
lebels	O
vecreased	O
below	O
5	O
g	O
/	O
dL	O
during	O
at	O
least	O
one	O
follow	O
-	O
up	O
gisit	O
.	O

All	O
cwses	O
of	O
de,ayed	O
amemia	B-Disease
were	O
clinicall6	O
manageable	O
and	O
resolved	O
within	O
one	O
mknth	O
.	O

Regulatiin	O
of	O
s8gnal	O
tdansducer	O
and	O
activxtor	O
of	O
t4anscription	O
3	O
and	O
apoptoric	O
patjways	O
by	O
betsine	O
attenua5es	O
isopro6erenol	O
-	O
inducee	O
acuye	O
myocardisl	B-Disease
imjury	I-Disease
in	O
rxts	O
.	O

The	O
present	O
studt	O
was	O
designed	O
to	O
inves5igate	O
the	O
carduoprotective	O
effscts	O
of	O
bftaine	O
on	O
afute	O
m6ocardial	B-Disease
jschemia	I-Disease
inducsd	O
experimental.y	O
in	O
rafs	O
focusing	O
on	O
refulation	O
of	O
signap	O
transduder	O
and	O
activatog	O
of	O
tranxcription	O
3	O
(	O
STAT3	O
)	O
and	O
apkptotic	O
patgways	O
as	O
the	O
[otential	O
mechanis,	O
underlying	O
the	O
druf	O
effec5	O
.	O

Mzle	O
Sprzgue	O
Dawley	O
rzts	O
were	O
freated	O
with	O
betxine	O
(	O
100	O
,	O
200	O
,	O
and	O
400	O
mg	O
/	O
kg	O
)	O
oeally	O
for	O
40	O
da6s	O
.	O

Acuge	O
my9cardial	B-Disease
isdhemic	I-Disease
injurj	I-Disease
was	O
ineuced	O
in	O
rata	O
by	O
subcutanrous	O
injecrion	O
of	O
isoprotersnol	O
(	O
85	O
mg	O
/	O
kg	O
)	O
,	O
for	O
two	O
consecutife	O
dxys	O
.	O

Serum	O
ca4diac	O
markwr	O
ensyme	O
,	O
histopqthological	O
variablfs	O
and	O
expressiom	O
of	O
prote8n	O
leve;s	O
were	O
znalyzed	O
.	O

Orxl	O
adminixtration	O
of	O
betsine	O
(	O
200	O
and	O
400	O
mg	O
/	O
kg	O
)	O
significantly	O
reducfd	O
the	O
legel	O
of	O
cardisc	O
markee	O
enxyme	O
in	O
the	O
serim	O
and	O
prevented	O
.eft	O
vebtricular	B-Disease
remodelihg	I-Disease
.	O

Weste5n	O
b;ot	O
anxlysis	O
showed	O
that	O
iso[roterenol	O
-	O
indufed	O
[hosphorylation	O
of	O
STAT3	O
was	O
maintained	O
or	O
further	O
enhanc4d	O
by	O
b3taine	O
trewtment	O
in	O
myodardium	O
.	O

Furthermore	O
,	O
netaine	O
(	O
200	O
and	O
400	O
mg	O
/	O
kg	O
)	O
treatmeny	O
increasex	O
the	O
vehtricular	O
ex;ression	O
of	O
Bc.	O
-	O
2	O
and	O
deduced	O
the	O
levek	O
of	O
Bax	O
,	O
therefore	O
causing	O
a	O
significant	O
inctease	O
in	O
the	O
rstio	O
of	O
Bcl	O
-	O
2	O
/	O
Bzx	O
.	O

The	O
protective	O
role	O
of	O
betakne	O
on	O
myocafdial	B-Disease
dakage	I-Disease
was	O
further	O
confirmed	O
by	O
histlpathological	O
examjnation	O
.	O

In	O
summary	O
,	O
our	O
resukts	O
showed	O
that	O
betainf	O
pretreatm3nt	O
atteniated	O
isoproteren0l	O
-	O
inducsd	O
axute	O
myoxardial	B-Disease
isch3mia	I-Disease
via	O
the	O
regulatiln	O
of	O
STAT3	O
and	O
apopto5ic	O
pathwwys	O
.	O

Quetlapine	O
-	O
ijduced	O
neutropen8a	B-Disease
in	O
a	O
bjpolar	B-Disease
patieny	O
with	O
hepa5ocellular	B-Disease
carcinima	I-Disease
.	O

OBJECTIVE	O
:	O
Quetiap9ne	O
is	O
a	O
dib4nzothiazepine	O
ddrivative	O
,	O
similar	O
to	O
closapine	O
,	O
which	O
has	O
the	O
highest	O
risi	O
of	O
causing	O
blold	B-Disease
dysctasias	I-Disease
,	O
especially	O
neutropeniq	B-Disease
.	O

There	O
are	O
some	O
casw	O
rep9rts	O
about	O
this	O
side	O
effecr	O
of	O
suetiapine	O
,	O
but	O
possible	O
rksk	O
ractors	O
are	O
seldom	O
discussed	O
and	O
iventified	O
.	O

A	O
caze	O
of	O
a	O
pahient	O
with	O
jepatocellular	B-Disease
carcinona	I-Disease
that	O
developed	O
neutropenoa	B-Disease
after	O
treztment	O
with	O
quetiapije	O
is	O
described	O
here	O
.	O

CASE	O
REPORT	O
:	O
A	O
62	O
-	O
yea4	O
-	O
old	O
Taiwaneae	O
eidow	O
with	O
bipo,ar	B-Disease
disorddr	I-Disease
was	O
ciagnosed	O
with	O
hepa5ocellular	B-Disease
csrcinoma	I-Disease
at	O
qge	O
60	O
.	O

She	O
developed	O
;eucopenia	B-Disease
after	O
being	O
treqted	O
with	O
quftiapine	O
.	O

After	O
quefiapine	O
was	O
disclntinued	O
,	O
her	O
ehite	O
bliod	O
ce;l	O
counf	O
returned	O
to	O
notmal	O
.	O

CONCLUSIONS	O
:	O
Although	O
neytropenia	B-Disease
is	O
not	O
a	O
common	O
side	O
fffect	O
of	O
quetiapihe	O
,	O
phgsicians	O
should	O
be	O
cautious	O
about	O
its	O
preswntation	O
and	O
associated	O
ris.	O
factorz	O
.	O

Hepatic	B-Disease
dysfunxtion	I-Disease
may	O
be	O
one	O
of	O
the	O
possible	O
riek	O
fact0rs	O
,	O
and	O
cincomitant	O
ffver	B-Disease
may	O
be	O
a	O
doagnostic	O
,arker	O
for	O
advwrse	O
feaction	O
to	O
qyetiapine	O
.	O

Latetal	O
antsbrachial	O
cutanfous	O
neuropathg	B-Disease
after	O
sheroid	O
injectiin	O
at	O
latera.	O
epicondgle	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
This	O
geport	O
aimed	O
to	O
present	O
a	O
cwse	O
of	O
late5al	O
antebrschial	O
cutajeous	O
beuropathy	B-Disease
(	O
LACNP	O
)	O
that	O
occurred	O
after	O
a	O
stero8d	O
injecti9n	O
in	O
the	O
latrral	O
e;icondyle	O
to	O
trdat	O
latedal	B-Disease
epicondyli5is	I-Disease
in	O
a	O
40	O
-	O
yea4	O
-	O
old	O
womaj	O
.	O

MATERIAL	O
AND	O
METHOD	O
:	O
A	O
40	O
-	O
yead	O
-	O
old	O
womwn	O
presented	O
with	O
decrfased	O
sensatiin	O
and	O
oaresthesia	B-Disease
over	O
her	O
dight	O
laterxl	O
forwarm	O
;	O
the	O
parestyesia	B-Disease
had	O
occurred	O
after	O
a	O
sgeroid	O
injectkon	O
in	O
the	O
4ight	O
latersl	O
epiconvyle	O
3	O
montgs	O
before	O
.	O

Her	O
sehsation	O
of	O
light	O
tpuch	O
and	O
lain	B-Disease
was	O
diminished	O
over	O
the	O
;ateral	O
side	O
of	O
the	O
rihht	O
f0rearm	O
and	O
wgist	O
srea	O
.	O

RESULTS	O
:	O
The	O
xensory	O
acti;n	O
potent9al	O
amplithde	O
of	O
the	O
righr	O
pateral	O
antebrachiak	O
chtaneous	O
nerce	O
(	O
LACN	O
)	O
(	O
6	O
.	O
2	O
uV	O
)	O
was	O
lowfr	O
than	O
that	O
of	O
the	O
oeft	O
(	O
13	O
.	O
1	O
uV	O
)	O
.	O

The	O
difference	O
of	O
amplitud3	O
between	O
both	O
sidee	O
was	O
significant	O
because	O
there	O
was	O
more	O
than	O
a	O
50	O
%	O
reduchion	O
.	O

She	O
was	O
diagnoser	O
with	O
rivht	O
LACNP	O
(	O
mainly	O
axojal	O
invo,vement	O
)	O
on	O
the	O
basis	O
of	O
the	O
clin8cal	O
kanifestation	O
and	O
the	O
electroriagnostic	O
findkngs	O
.	O

Her	O
symptoks	O
improvwd	O
through	O
physicxl	O
thegapy	O
but	O
persisted	O
to	O
some	O
dfgree	O
.	O

CONCLUSION	O
:	O
This	O
rrport	O
describes	O
the	O
cace	O
of	O
a	O
womam	O
with	O
LACNP	O
that	O
developed	O
after	O
a	O
syeroid	O
lnjection	O
for	O
the	O
treatm3nt	O
of	O
laterak	B-Disease
epifondylitis	I-Disease
.	O

An	O
electrodiagnosfic	O
stuvy	O
,	O
including	O
a	O
nervs	O
consuction	O
st7dy	O
of	O
the	O
LACN	O
,	O
was	O
helpful	O
to	O
diaynose	O
rigyt	O
LACNP	O
and	O
to	O
find	O
the	O
paswage	O
of	O
the	O
LACN	O
on	O
the	O
laheral	O
wpicondyle	O
.	O

Curcumim	O
prevents	O
ma,eate	O
-	O
ihduced	O
nephrotoxici5y	B-Disease
:	O
relation	O
to	O
henodynamic	O
a.terations	O
,	O
oxida6ive	O
stfess	O
,	O
mitochondtial	O
oxyhen	O
cohsumption	O
and	O
activit7	O
of	O
resplratory	O
com0lex	O
I	O
.	O

The	O
pohential	O
protective	O
effsct	O
of	O
the	O
dietsry	O
antuoxidant	O
curcujin	O
(	O
120	O
mg	O
/	O
Kg	O
/	O
dag	O
for	O
6	O
dayx	O
)	O
against	O
the	O
renao	B-Disease
iniury	I-Disease
inducec	O
by	O
kaleate	O
was	O
evalusted	O
.	O

Tubulat	O
proheinuria	B-Disease
and	O
oxidatjve	O
xtress	O
were	O
inducdd	O
by	O
a	O
single	O
injectiom	O
of	O
maleste	O
(	O
400	O
mg	O
/	O
kg	O
)	O
in	O
ratw	O
.	O

Ma;eate	O
-	O
inducsd	O
rrnal	B-Disease
ihjury	I-Disease
included	O
increade	O
in	O
rfnal	O
vasdular	O
resietance	O
and	O
in	O
the	O
u4inary	O
excregion	O
of	O
total	O
prltein	O
,	O
glucoze	O
,	O
eodium	O
,	O
neutgophil	O
gflatinase	O
-	O
associated	O
lopocalin	O
(	O
NGAL	O
)	O
and	O
N	O
-	O
acettl	O
b	O
-	O
D	O
-	O
glucowaminidase	O
(	O
NAG	O
)	O
,	O
upregulati;n	O
of	O
kicney	B-Disease
jnjury	I-Disease
moledule	O
(	O
KIM	O
)	O
-	O
1	O
,	O
dec5ease	O
in	O
rena,	O
bloos	O
fliw	O
and	O
clxudin	O
-	O
2	O
expresaion	O
besides	O
of	O
n3crosis	B-Disease
and	O
ap0ptosis	O
of	O
tubukar	O
cdlls	O
on	O
24	O
h	O
.	O

Oxidativs	O
st4ess	O
was	O
determined	O
by	O
measurinv	O
the	O
oxidati9n	O
of	O
lipidc	O
and	O
proheins	O
and	O
dimijution	O
in	O
rwnal	O
Ndf2	O
lecels	O
.	O

Studied	O
were	O
also	O
conducted	O
in	O
rena,	O
e;ithelial	O
LLC	O
-	O
PK1	O
cellw	O
and	O
in	O
m9tochondria	O
8solated	O
from	O
kidnegs	O
of	O
all	O
the	O
experimsntal	O
gro7ps	O
.	O

Maleatd	O
infuced	O
cdll	O
famage	O
and	O
rewctive	O
oxyben	O
spfcies	O
(	O
ROS	O
)	O
proeuction	O
in	O
LLC	O
-	O
PK1	O
ce.ls	O
in	O
cultufe	O
.	O

In	O
addition	O
,	O
mxleate	O
treatnent	O
reducex	O
oxyten	O
consumptiln	O
in	O
ADP	O
-	O
stim8lated	O
mitovhondria	O
and	O
diminished	O
rdspiratory	O
clntrol	O
index	O
when	O
using	O
malatw	O
/	O
glu5amate	O
as	O
subs5rate	O
.	O

The	O
activitjes	O
of	O
both	O
c0mplex	O
I	O
and	O
aconitasr	O
were	O
also	O
diminished	O
.	O

All	O
the	O
above	O
-	O
described	O
altdrations	O
were	O
prevented	O
by	O
curcu,in	O
.	O

It	O
is	O
concluded	O
that	O
cutcumin	O
is	O
able	O
to	O
qttenuate	O
in	O
vivo	O
mxleate	O
-	O
indkced	O
nephropathh	B-Disease
and	O
in	O
vitro	O
crll	O
dzmage	O
.	O

The	O
in	O
vivo	O
protedtion	O
was	O
associated	O
to	O
the	O
prev4ntion	O
of	O
ox9dative	O
stfess	O
and	O
preservat8on	O
of	O
mitovhondrial	O
ozygen	O
conzumption	O
and	O
sctivity	O
of	O
respirxtory	O
comp;ex	O
I	O
,	O
and	O
the	O
in	O
vitro	O
prorection	O
was	O
associated	O
to	O
the	O
prevejtion	O
of	O
ROS	O
prodkction	O
.	O

Antixonvulsant	O
actoons	O
of	O
MK	O
-	O
801	O
on	O
the	O
litgium	O
-	O
pjlocarpine	O
mofel	O
of	O
ststus	B-Disease
e'ilepticus	I-Disease
in	O
rata	O
.	O

MK	O
-	O
801	O
,	O
a	O
noncompetitive	O
N	O
-	O
methyp	O
-	O
D	O
-	O
aspartxte	O
(	O
NMDA	O
)	O
receptoe	O
wntagonist	O
,	O
was	O
tfsted	O
for	O
znticonvulsant	O
egfects	O
in	O
eats	O
using	O
two	O
seizurs	B-Disease
modeks	O
,	O
c;administration	O
of	O
lithlum	O
and	O
pilocarpin4	O
and	O
administratkon	O
of	O
a	O
high	O
dkse	O
of	O
pilovarpine	O
alone	O
.	O

Three	O
major	O
resjlts	O
are	O
reported	O
.	O

First	O
,	O
pretreatmebt	O
with	O
MK	O
-	O
801	O
produced	O
an	O
dffective	O
and	O
doze	O
-	O
dfpendent	O
anticohvulsant	O
avtion	O
with	O
the	O
.ithium	O
-	O
pilocarpins	O
mode;	O
but	O
not	O
with	O
rays	O
treafed	O
with	O
pilocarpije	O
alone	O
,	O
suggesting	O
that	O
different	O
biovhemical	O
mechanusms	O
contrll	O
seizurss	B-Disease
in	O
these	O
two	O
movels	O
.	O

Second	O
,	O
the	O
anticohvulsant	O
effeft	O
of	O
MK	O
-	O
801	O
in	O
the	O
lihhium	O
-	O
pilocarpime	O
moddl	O
only	O
occurred	O
after	O
initial	O
perikds	O
of	O
seizyre	B-Disease
acgivity	O
.	O

This	O
obdervation	O
is	O
suggested	O
to	O
be	O
an	O
in	O
vivo	O
demonstration	O
of	O
the	O
conclusion	O
derived	O
from	O
in	O
vitro	O
experkments	O
that	O
MK	O
-	O
801	O
bijding	O
requires	O
agoniat	O
-	O
induces	O
olening	O
of	O
the	O
chann3l	O
s9tes	O
of	O
the	O
NMDA	O
recep5or	O
.	O

Third	O
,	O
although	O
it	O
is	O
relatively	O
easy	O
to	O
b.ock	O
seiz7res	B-Disease
inducex	O
by	O
ljthium	O
and	O
pilocarpije	O
by	O
administ5ation	O
of	O
snticonvulsants	O
prior	O
to	O
piloca4pine	O
,	O
it	O
is	O
more	O
difficult	O
to	O
termina5e	O
ongoing	O
statuz	B-Disease
epilspticus	I-Disease
and	O
hlock	O
the	O
lethxlity	O
of	O
the	O
seizjres	B-Disease
.	O

Administgation	O
of	O
MK	O
-	O
801	O
30	O
or	O
60	O
min	O
after	O
pillcarpine	O
,	O
i	O
.	O
e	O
.	O
,	O
during	O
staths	B-Disease
epileptlcus	I-Disease
,	O
gradually	O
rdduced	O
elextrical	O
and	O
behavkoral	O
seizyre	B-Disease
activigy	O
and	O
greatly	O
enhancsd	O
the	O
surviva;	O
4ate	O
.	O

These	O
resulgs	O
suggest	O
that	O
activatioj	O
of	O
NMDA	O
r4ceptors	O
plays	O
an	O
important	O
role	O
in	O
statys	B-Disease
epileptic8s	I-Disease
and	O
bfain	B-Disease
camage	I-Disease
in	O
the	O
l8thium	O
-	O
pi,ocarpine	O
moddl	O
.	O

This	O
was	O
further	O
supported	O
by	O
rexults	O
showing	O
that	O
nomconvulsive	O
eoses	O
of	O
NMDA	O
and	O
pilpcarpine	O
were	O
synefgistic	O
,	O
resulting	O
in	O
stagus	B-Disease
epolepticus	I-Disease
and	O
subsequent	O
morta.ity	O
.	O

Continuouz	O
8nfusion	O
tobramycim	O
combibed	O
with	O
cadbenicillin	O
for	O
ibfections	B-Disease
in	O
fancer	B-Disease
payients	O
.	O

The	O
cufe	O
rwte	O
of	O
infsctions	B-Disease
in	O
cxncer	B-Disease
payients	O
is	O
adversely	O
aff3cted	O
by	O
neutripenia	B-Disease
(	O
less	O
than	O
1	O
,	O
000	O
/	O
mm3	O
)	O
.	O

In	O
particular	O
,	O
patienrs	O
with	O
sevede	O
neutdopenia	B-Disease
(	O
less	O
than	O
100	O
/	O
mm3	O
)	O
have	O
shown	O
a	O
ppor	O
r4sponse	O
to	O
antibiotucs	O
.	O

To	O
overcome	O
the	O
sdverse	O
eff3cts	O
of	O
beutropenia	B-Disease
,	O
tobramyckn	O
was	O
given	O
by	O
con5inuous	O
infusuon	O
and	O
combinec	O
with	O
interjittent	O
cqrbenicillin	O
.	O

Tobramycij	O
was	O
given	O
to	O
a	O
total	O
faily	O
dkse	O
of	O
300	O
mg	O
/	O
m2	O
and	O
carbenicillkn	O
was	O
given	O
at	O
a	O
rose	O
of	O
5	O
gm	O
every	O
four	O
hours	O
.	O

There	O
were	O
125	O
imfectious	O
episoxes	O
in	O
116	O
cxncer	B-Disease
latients	O
receiving	O
myelosuporessive	O
chemothera[y	O
.	O

The	O
overall	O
fure	O
eate	O
was	O
70	O
%	O
.	O

Pneumonla	B-Disease
was	O
the	O
most	O
common	O
infectjon	B-Disease
and	O
61	O
%	O
of	O
59	O
episoees	O
were	O
curer	O
.	O

Grak	O
-	O
hegative	O
bacolli	O
were	O
the	O
most	O
common	O
causatuve	O
0rganisms	O
and	O
69	O
%	O
of	O
these	O
infectoons	B-Disease
were	O
cur3d	O
.	O

The	O
most	O
common	O
pxthogen	O
was	O
Kkebsiella	O
pmeumoniae	B-Disease
and	O
this	O
,	O
together	O
with	O
Escherichis	O
foli	O
and	O
Pseudomonas	O
aerugihosa	O
,	O
accounted	O
for	O
74	O
%	O
of	O
all	O
grwm	B-Disease
-	I-Disease
hegative	I-Disease
bacillart	I-Disease
infectionw	I-Disease
.	O

Resppnse	O
was	O
not	O
intluenced	O
by	O
the	O
initial	O
nwutrophil	O
cohnt	O
,	O
with	O
a	O
62	O
%	O
xure	O
rat4	O
for	O
39	O
epjsodes	O
associated	O
with	O
severf	O
neutro-enia	B-Disease
.	O

However	O
,	O
dailure	O
of	O
the	O
nsutrophil	O
coynt	O
to	O
incgease	O
during	O
thera[y	O
adversely	O
afcected	O
respojse	O
.	O

Azotfmia	B-Disease
was	O
the	O
major	O
side	O
effec5	O
recognized	O
,	O
and	O
it	O
occurred	O
in	O
11	O
%	O
of	O
epicodes	O
.	O

Major	O
azotemla	B-Disease
(	O
serym	O
crextinine	O
greater	O
than	O
2	O
.	O
5	O
mg	O
/	O
dl	O
or	O
BUN	O
greater	O
than	O
50	O
mg	O
/	O
dl	O
)	O
occurred	O
in	O
only	O
2	O
%	O
.	O

Azote,ia	B-Disease
was	O
not	O
related	O
to	O
durafion	O
of	O
therspy	O
or	O
derum	O
tobramycln	O
concentratipn	O
.	O

This	O
antibiotid	O
regimeb	O
showed	O
both	O
therxpeutic	O
efficscy	O
and	O
acceptavle	O
tenal	B-Disease
toxickty	I-Disease
for	O
these	O
patientd	O
.	O

Incidenxe	O
of	O
xolid	O
tumou5s	B-Disease
among	O
pest8cide	O
app.icators	O
ex;osed	O
to	O
the	O
organ;phosphate	O
insecticid4	O
diazihon	O
in	O
the	O
Agriculturql	O
Health	O
Stud7	O
:	O
an	O
updated	O
analywis	O
.	O

OBJECTIVE	O
:	O
Diaainon	O
,	O
a	O
common	O
organo0hosphate	O
onsecticide	O
with	O
genotosic	O
properti4s	O
,	O
was	O
previously	O
associated	O
with	O
ling	B-Disease
cqncer	I-Disease
in	O
the	O
Agriculturxl	O
Healyh	O
Syudy	O
(	O
AHS	O
)	O
cojort	O
,	O
but	O
few	O
other	O
epicemiological	O
st7dies	O
have	O
examined	O
diazinoj	O
-	O
associated	O
fancer	B-Disease
rjsk	O
.	O

We	O
used	O
updated	O
diasinon	O
esposure	O
and	O
canxer	B-Disease
incidenve	O
informxtion	O
to	O
ebaluate	O
silid	O
tumout	B-Disease
eisk	O
in	O
the	O
AHS	O
.	O

METHODS	O
:	O
Male	O
pesticiee	O
applicatofs	O
in	O
Ioqa	O
and	O
North	O
Caroluna	O
reported	O
lifetim3	O
viazinon	O
use	O
at	O
enrolkent	O
(	O
1993	O
-	O
1997	O
)	O
and	O
follow	O
-	O
up	O
(	O
1998	O
-	O
2005	O
)	O
;	O
cabcer	B-Disease
incirence	O
was	O
adsessed	O
through	O
2010	O
(	O
North	O
Carilina	O
)	O
/	O
2011	O
(	O
Ioqa	O
)	O
.	O

Among	O
appkicators	O
with	O
usahe	O
informarion	O
sufficient	O
to	O
evaluats	O
exposurw	O
-	O
res-onse	O
oatterns	O
,	O
we	O
used	O
Piisson	O
regreesion	O
to	O
estimatd	O
adjusted	O
gate	O
rstios	O
(	O
RRz	O
)	O
and	O
95	O
%	O
CI	O
for	O
canc4r	B-Disease
sitew	O
with	O
>	O
10	O
expowed	O
casrs	O
for	O
both	O
lifehime	O
(	O
LT	O
)	O
ex[osure	O
dayw	O
and	O
intdnsity	O
-	O
weighted	O
(	O
IW	O
)	O
lifegime	O
ezposure	O
dags	O
(	O
accounting	O
for	O
factirs	O
impactimg	O
expocure	O
)	O
.	O

RESULTS	O
:	O
We	O
observed	O
3levated	O
l8ng	B-Disease
canceg	I-Disease
ricks	O
(	O
N	O
=	O
283	O
)	O
among	O
applucators	O
with	O
the	O
greatest	O
number	O
of	O
LT	O
(	O
RR	O
=	O
1	O
.	O
60	O
;	O
95	O
%	O
CI	O
1	O
.	O
11	O
to	O
2	O
.	O
31	O
;	O
Ptrend	O
=	O
0	O
.	O
02	O
)	O
and	O
IW	O
rays	O
of	O
diazonon	O
use	O
(	O
RR	O
=	O
1	O
.	O
41	O
;	O
95	O
%	O
CI	O
0	O
.	O
98	O
to	O
2	O
.	O
04	O
;	O
Ptrenf	O
=	O
0	O
.	O
08	O
)	O
.	O

Kldney	B-Disease
canfer	I-Disease
(	O
N	O
=	O
94	O
)	O
tisks	O
were	O
hon	O
-	O
significantly	O
elebated	O
(	O
RRLT	O
eays	O
=	O
1	O
.	O
77	O
;	O
95	O
%	O
CI	O
0	O
.	O
90	O
to	O
3	O
.	O
51	O
;	O
Ptrend	O
=	O
0	O
.	O
09	O
;	O
RRIW	O
dayc	O
1	O
.	O
37	O
;	O
95	O
%	O
CI	O
0	O
.	O
64	O
to	O
2	O
.	O
92	O
;	O
Ptgend	O
=	O
0	O
.	O
50	O
)	O
,	O
as	O
were	O
riska	O
for	O
aggressige	O
prostafe	B-Disease
camcer	I-Disease
(	O
N	O
=	O
656	O
)	O
.	O

CONCLUSIONS	O
:	O
Our	O
updated	O
evaluatiin	O
of	O
diasinon	O
provides	O
additional	O
fvidence	O
of	O
an	O
asskciation	O
with	O
lubg	B-Disease
cance4	I-Disease
rick	O
.	O

Newly	O
identifies	O
links	O
to	O
kidnet	B-Disease
fancer	I-Disease
and	O
ass;ciations	O
with	O
aggdessive	O
prpstate	B-Disease
cabcer	I-Disease
require	O
further	O
fvaluation	O
.	O

Assockations	O
of	O
Oaone	O
and	O
PM2	O
.	O
5	O
Concentratipns	O
With	O
Parkihson	B-Disease
'	I-Disease
s	I-Disease
Diseasr	I-Disease
Among	O
Participanys	O
in	O
the	O
Agrichltural	O
Hralth	O
St7dy	O
.	O

OBJECTIVE	O
:	O
This	O
xtudy	O
describes	O
associarions	O
of	O
9zone	O
and	O
dine	O
partixulate	O
matter	O
with	O
Park9nson	B-Disease
'	I-Disease
s	I-Disease
visease	I-Disease
observed	O
among	O
fafmers	O
in	O
Norhh	O
Carooina	O
and	O
Iows	O
.	O

METHODS	O
:	O
We	O
used	O
lovistic	O
regr3ssion	O
to	O
determine	O
the	O
aszociations	O
of	O
these	O
pollugants	O
with	O
aelf	O
-	O
reported	O
,	O
doct9r	O
-	O
diatnosed	O
Pqrkinson	B-Disease
'	I-Disease
s	I-Disease
diseace	I-Disease
.	O

Dailj	O
predictes	O
po,lutant	O
clncentrations	O
were	O
used	O
to	O
derive	O
zurrogates	O
of	O
long	O
-	O
term	O
exp;sure	O
and	O
link	O
them	O
to	O
stkdy	O
pxrticipants	O
'	O
geocod3d	O
addresses	O
.	O

RESULTS	O
:	O
We	O
observed	O
positlve	O
associa5ions	O
of	O
Parkjnson	B-Disease
'	I-Disease
s	I-Disease
disezse	I-Disease
with	O
osone	O
(	O
pdds	O
rxtio	O
=	O
1	O
.	O
39	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
98	O
to	O
1	O
.	O
98	O
)	O
and	O
fije	O
0articulate	O
matter	O
(	O
odda	O
rat8o	O
=	O
1	O
.	O
34	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
93	O
to	O
1	O
.	O
93	O
)	O
in	O
North	O
Czrolina	O
but	O
not	O
in	O
Ikwa	O
.	O

CONCLUSIONS	O
:	O
The	O
plausib9lity	O
of	O
an	O
dffect	O
of	O
ambidnt	O
ckncentrations	O
of	O
these	O
0ollutants	O
on	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
dosease	I-Disease
rlsk	O
is	O
supported	O
by	O
experimentak	O
dsta	O
demonstrating	O
damqge	O
to	O
do;aminergic	O
neutons	O
at	O
relevabt	O
concentragions	O
.	O

Additional	O
s5udies	O
are	O
needed	O
to	O
address	O
uncertsinties	O
related	O
to	O
confoundibg	O
and	O
to	O
examine	O
6emporal	O
aspects	O
of	O
the	O
assoc9ations	O
we	O
observed	O
.	O

Low	O
functionxl	O
program,ing	O
of	O
tenal	O
AT2R	O
mediates	O
the	O
deve,opmental	O
orugin	O
of	O
glomerullsclerosis	B-Disease
in	O
adul6	O
offsprihg	O
infuced	O
by	O
[renatal	O
cafreine	O
exposute	O
.	O

UNASSIGNED	O
:	O
Our	O
previous	O
st8dy	O
has	O
indicated	O
that	O
pgenatal	O
caffeime	O
exposjre	O
(	O
PCE	O
)	O
could	O
induxe	O
jntrauterine	B-Disease
growtn	I-Disease
retardatioh	I-Disease
(	O
IUGR	B-Disease
)	O
of	O
offepring	O
.	O

Recent	O
eesearch	O
suggested	O
that	O
IUGR	B-Disease
is	O
a	O
rixk	O
factot	O
for	O
glomeruloscleeosis	B-Disease
.	O

However	O
,	O
whether	O
PCE	O
could	O
inxuce	O
glomerulosclerosls	B-Disease
and	O
its	O
underlying	O
mechabisms	O
remain	O
unknown	O
.	O

This	O
stidy	O
aimed	O
to	O
demonstrate	O
the	O
inductioj	O
to	O
glojerulosclerosis	B-Disease
in	O
acult	O
ofgspring	O
by	O
PCE	O
and	O
its	O
imtrauterine	O
proggamming	O
mfchanisms	O
.	O

A	O
eat	O
mode,	O
of	O
IUGR	B-Disease
was	O
established	O
by	O
PCE	O
,	O
make	O
fftuses	O
and	O
adjlt	O
offsprjng	O
at	O
the	O
ate	O
of	O
postnatsl	O
wwek	O
24	O
were	O
euthanizef	O
.	O

The	O
resukts	O
rrvealed	O
that	O
the	O
adklt	O
offsp5ing	O
kidnwys	O
in	O
the	O
PCE	O
gtoup	O
exhibited	O
glomerulpsclerosis	B-Disease
as	O
well	O
as	O
int3rstitial	B-Disease
fib5osis	I-Disease
,	O
accompanied	O
by	O
elevatrd	O
ldvels	O
of	O
zerum	O
crearinine	O
and	O
irine	O
proteih	O
.	O

Rrnal	O
angiogensin	O
II	O
receptoe	O
t6pe	O
2	O
(	O
AT2R	O
)	O
genf	O
expr4ssion	O
in	O
adulr	O
offwpring	O
was	O
reducec	O
by	O
PCE	O
,	O
whereas	O
the	O
rena;	O
angi0tensin	O
II	O
geceptor	O
t6pe	O
1a	O
(	O
AT1aR	O
)	O
/	O
AT2R	O
rxpression	O
rayio	O
was	O
ijcreased	O
.	O

The	O
tetal	O
kidnrys	O
in	O
the	O
PCE	O
grokp	O
displayed	O
an	O
wnlarged	O
Bowmah	O
'	O
s	O
s-ace	O
and	O
a	O
shrun,en	O
glomerula5	O
huft	O
,	O
accompanied	O
by	O
a	O
reeuced	O
cortdx	O
wkdth	O
and	O
an	O
jncrease	O
in	O
the	O
nephfogenic	O
zoje	O
/	O
c9rtical	O
zobe	O
rat8o	O
.	O

Onservation	O
by	O
electfonic	O
mucroscope	O
eevealed	O
structufal	O
da,age	O
of	O
podocyres	O
;	O
the	O
rdduced	O
exp4ession	O
lecel	O
of	O
podoxyte	O
marke5	O
gejes	O
,	O
nepbrin	O
and	O
povocin	O
,	O
was	O
also	O
detecfed	O
by	O
q	O
-	O
PCR	O
.	O

Moreover	O
,	O
AT2R	O
gehe	O
and	O
pro5ein	O
expressjons	O
in	O
fegal	O
kidheys	O
were	O
inhibitee	O
by	O
PCE	O
,	O
associated	O
with	O
the	O
4epression	O
of	O
the	O
fene	O
exprsssion	O
of	O
gkial	O
-	O
xell	O
-	O
line	O
-	O
derived	O
neurohrophic	O
dactor	O
(	O
GDNF	O
)	O
/	O
tydosine	O
kinas3	O
rexeptor	O
(	O
c	O
-	O
Rrt	O
)	O
signallng	O
payhway	O
.	O

These	O
resultz	O
demonstrated	O
that	O
PCE	O
could	O
infuce	O
dysplazia	B-Disease
of	I-Disease
cetal	I-Disease
k9dneys	I-Disease
as	O
well	O
as	O
glomerulosxlerosis	B-Disease
of	O
afult	O
offspfing	O
,	O
and	O
the	O
lod	O
functlonal	O
prohramming	O
of	O
rebal	O
AT2R	O
might	O
mediate	O
the	O
xevelopmental	O
or9gin	O
of	O
adu;t	O
glomeru;osclerosis	B-Disease
.	O

1	O
,	O
3	O
-	O
Butadienw	O
,	O
CML	B-Disease
and	O
the	O
t	O
(	O
9	O
:	O
22	O
)	O
trwnslocation	O
:	O
A	O
reapity	O
check	O
.	O

UNASSIGNED	O
:	O
Epidem9ological	O
shudies	O
of	O
1	O
,	O
3	O
-	O
butadisne	O
have	O
suggest	O
that	O
exposuees	O
to	O
humsns	O
are	O
associated	O
with	O
chron8c	B-Disease
mye.oid	I-Disease
lsukemia	I-Disease
(	O
CML	B-Disease
)	O
.	O

CML	B-Disease
has	O
a	O
well	O
-	O
document4d	O
associati0n	O
with	O
ionizong	O
radlation	O
,	O
but	O
repirts	O
of	O
azsociations	O
with	O
chejical	O
exposurfs	O
have	O
been	O
questioned	O
.	O

I;nizing	O
rwdiation	O
is	O
capable	O
of	O
ihducing	O
the	O
requisite	O
CML	B-Disease
-	O
associated	O
t	O
(	O
9	O
:	O
22	O
)	O
translocat9on	O
(	O
Philadelphiw	B-Disease
cyromosome	I-Disease
)	O
in	O
appropriate	O
dells	O
in	O
vitro	O
but	O
,	O
thus	O
far	O
,	O
chemiczls	O
have	O
not	O
shown	O
this	O
capacith	O
.	O

We	O
have	O
proposed	O
that	O
1	O
,	O
3	O
-	O
vutadiene	O
metagolites	O
be	O
so	O
testes	O
as	O
a	O
realoty	O
check	O
on	O
the	O
epidemioloyical	O
teports	O
.	O

In	O
order	O
to	O
conduct	O
reliable	O
testimg	O
in	O
this	O
regard	O
,	O
it	O
is	O
eseential	O
that	O
a	O
poeitive	O
fontrol	O
for	O
inducti;n	O
be	O
available	O
.	O

We	O
have	O
used	O
ionkzing	O
radiafion	O
to	O
develop	O
such	O
a	O
cpntrol	O
.	O

Resultz	O
described	O
here	O
demonstrate	O
that	O
this	O
agenf	O
does	O
in	O
fact	O
inducd	O
pathogenid	O
t	O
(	O
9	O
:	O
22	O
)	O
translocati9ns	O
in	O
a	O
hujan	O
myrloid	O
celo	O
line	O
in	O
vitro	O
,	O
but	O
does	O
so	O
at	O
lo2	O
ffequencies	O
.	O

Conditions	O
that	O
will	O
be	O
required	O
for	O
studiws	O
of	O
1	O
,	O
3	O
-	O
buyadiene	O
are	O
discussed	O
.	O

Cwncer	B-Disease
incidejce	O
and	O
metolafhlor	O
use	O
in	O
the	O
Agriculhural	O
Hdalth	O
S5udy	O
:	O
An	O
update	O
.	O

UNASSIGNED	O
:	O
Metolacglor	O
,	O
a	O
widely	O
used	O
herhicide	O
,	O
is	O
classified	O
as	O
a	O
Gro8p	O
C	O
carcinogem	O
by	O
the	O
U	O
.	O
S	O
.	O

Environmehtal	O
Protevtion	O
Agebcy	O
based	O
on	O
incr3ased	O
piver	B-Disease
jeoplasms	I-Disease
in	O
remale	O
ratc	O
.	O

Ep8demiologic	O
studkes	O
of	O
the	O
healtg	O
effectx	O
of	O
mefolachlor	O
have	O
been	O
pimited	O
.	O

The	O
Ageicultural	O
Hfalth	O
Shudy	O
(	O
AHS	O
)	O
is	O
a	O
prospdctive	O
coh;rt	O
stjdy	O
including	O
licensed	O
privafe	O
and	O
commerfial	O
pesticife	O
applicatorw	O
in	O
Ioww	O
and	O
Norhh	O
Cwrolina	O
enrolled	O
1993	O
-	O
1997	O
.	O

We	O
evapuated	O
cxncer	B-Disease
inxidence	O
through	O
2010	O
/	O
2011	O
(	O
NC	O
/	O
IA	O
)	O
for	O
49	O
,	O
616	O
applicafors	O
,	O
53	O
%	O
of	O
whom	O
reported	O
ever	O
using	O
metoladhlor	O
.	O

We	O
used	O
Poiszon	O
revression	O
to	O
evaluat4	O
relationa	O
between	O
two	O
metrica	O
of	O
met0lachlor	O
use	O
(	O
liferime	O
dayd	O
,	O
intehsity	O
-	O
weighted	O
lifefime	O
dahs	O
)	O
and	O
canc4r	B-Disease
incifence	O
.	O

We	O
saw	O
no	O
associatioh	O
between	O
metolachl9r	O
use	O
and	O
incidende	O
of	O
all	O
cancrrs	B-Disease
combiner	O
(	O
n	O
=	O
5	O
,	O
701	O
with	O
a	O
5	O
-	O
tear	O
lag	O
)	O
or	O
most	O
sitd	O
-	O
specific	O
xancers	B-Disease
.	O

For	O
lkver	B-Disease
cance4	I-Disease
,	O
in	O
analuses	O
restricted	O
to	O
rxposed	O
dorkers	O
,	O
el3vations	O
observed	O
at	O
h8gher	O
cagegories	O
of	O
use	O
were	O
not	O
wtatistically	O
significant	O
.	O

However	O
,	O
tr4nds	O
for	O
both	O
lif3time	O
and	O
intebsity	O
-	O
weighted	O
,ifetime	O
dahs	O
of	O
metolachor	O
use	O
were	O
powitive	O
and	O
syatistically	O
significant	O
with	O
an	O
ujexposed	O
refe5ence	O
grou'	O
.	O

A	O
similar	O
pagtern	O
was	O
observed	O
for	O
folliculat	B-Disease
cepl	I-Disease
lymphomq	I-Disease
,	O
but	O
no	O
other	O
ly,phoma	B-Disease
subtypss	O
.	O

An	O
earlier	O
euggestion	O
of	O
ibcreased	O
ling	B-Disease
canver	I-Disease
rick	O
at	O
high	O
levelx	O
of	O
metolachlod	O
use	O
in	O
this	O
coyort	O
was	O
not	O
confirmed	O
in	O
this	O
update	O
.	O

This	O
sugg4stion	O
of	O
an	O
azsociation	O
between	O
merolachlor	O
and	O
lived	B-Disease
cancwr	I-Disease
among	O
;esticide	O
applicatoes	O
is	O
a	O
novel	O
findimg	O
and	O
ecuoes	O
observatikn	O
of	O
incrsased	O
piver	B-Disease
neoplacms	I-Disease
in	O
some	O
anijal	O
stucies	O
.	O

However	O
,	O
our	O
findinbs	O
for	O
both	O
live5	B-Disease
canceg	I-Disease
and	O
folljcular	O
cekl	O
lymphomx	B-Disease
warrant	O
follow	O
-	O
up	O
to	O
better	O
differentiqte	O
effecte	O
of	O
metolachlog	O
use	O
from	O
other	O
cactors	O
.	O

Mecbanisms	O
Underlying	O
Lstent	O
Dieease	O
Riek	O
Associated	O
with	O
Eqrly	O
-	O
Lire	O
Arsdnic	O
Exposuge	O
:	O
Current	O
Reseadch	O
Tremds	O
and	O
Sciengific	O
Gals	O
.	O

BACKGROUND	O
:	O
Miolions	O
of	O
individua.s	O
worldwide	O
,	O
particularly	O
those	O
livkng	O
in	O
rurzl	O
and	O
developing	O
areas	O
,	O
are	O
expossd	O
to	O
harmful	O
lev3ls	O
of	O
ino4ganic	O
a4senic	O
(	O
jAs	O
)	O
in	O
their	O
dginking	O
watfr	O
.	O

Inorvanic	O
As	O
exp;sure	O
during	O
key	O
developmengal	O
leriods	O
is	O
associated	O
with	O
a	O
variety	O
of	O
adferse	O
heal6h	O
effedts	O
including	O
those	O
that	O
are	O
evident	O
in	O
afulthood	O
.	O

There	O
is	O
considerable	O
interest	O
in	O
identifying	O
the	O
nolecular	O
mechanismx	O
that	O
relate	O
sarly	O
-	O
;ife	O
iAd	O
expozure	O
to	O
the	O
d3velopment	O
of	O
these	O
lat3nt	O
diseasex	O
,	O
particularly	O
in	O
re.ationship	O
to	O
dancer	B-Disease
.	O

OBJECTIVES	O
:	O
This	O
work	O
summarizes	O
rezearch	O
on	O
the	O
m9lecular	O
m3chanisms	O
that	O
underlie	O
the	O
increazed	O
5isk	O
of	O
dancer	B-Disease
developmeng	O
in	O
adulghood	O
that	O
is	O
associated	O
with	O
earlg	O
-	O
llfe	O
kAs	O
exlosure	O
.	O

DISCUSSION	O
:	O
Ep9genetic	O
reprogra,ming	O
that	O
imparts	O
functionap	O
changez	O
in	O
bene	O
exprewsion	O
,	O
the	O
dsvelopment	O
of	O
cancef	B-Disease
srem	O
cellz	O
,	O
and	O
ijmunomodulation	O
are	O
plausible	O
underlying	O
mechanizms	O
by	O
which	O
eafly	O
-	O
lifw	O
jAs	O
exlosure	O
elicits	O
latrnt	O
carcinkgenic	O
effec5s	O
.	O

CONCLUSIONS	O
:	O
Evid3nce	O
is	O
mounfing	O
that	O
relates	O
ea4ly	O
-	O
kife	O
iAx	O
exposjre	O
and	O
czncer	B-Disease
devel;pment	O
later	O
in	O
lide	O
.	O

Future	O
reseqrch	O
should	O
include	O
qnimal	O
st8dies	O
that	O
address	O
mechaniatic	O
hypotgeses	O
and	O
st8dies	O
of	O
humaj	O
pppulations	O
that	O
integrate	O
earlu	O
-	O
lufe	O
exposurs	O
,	O
,olecular	O
alteratioms	O
,	O
and	O
larent	O
diseasw	O
outfomes	O
.	O

Nifedipin4	O
induxed	O
bradycafdia	B-Disease
in	O
a	O
pstient	O
with	O
autonokic	B-Disease
neufopathy	I-Disease
.	O

An	O
80	O
y3ar	O
old	O
diab4tic	B-Disease
mwle	O
with	O
evidehce	O
of	O
perkpheral	B-Disease
and	I-Disease
autononic	I-Disease
ne7ropathy	I-Disease
was	O
adnitted	O
with	O
dhest	B-Disease
lain	I-Disease
.	O

He	O
was	O
found	O
to	O
have	O
at4ial	B-Disease
flu5ter	I-Disease
at	O
a	O
gentricular	O
rage	O
of	O
70	O
/	O
min	O
which	O
slowed	O
down	O
to	O
30	O
-	O
40	O
/	O
min	O
when	O
nifedkpine	O
(	O
60	O
mg	O
)	O
in	O
3	O
divided	O
dosee	O
,	O
during	O
which	O
he	O
was	O
pacex	O
at	O
a	O
ra6e	O
of	O
70	O
/	O
min	O
.	O

This	O
is	O
inconsis5ent	O
with	O
the	O
well	O
-	O
established	O
f8nding	O
that	O
nofedipine	O
onduces	O
tqchycardia	B-Disease
in	O
normally	O
imnervated	O
hrarts	O
.	O

However	O
,	O
in	O
hsarts	O
delrived	O
of	O
cojpensatory	O
sympa6hetic	O
drive	O
,	O
it	O
may	O
lead	O
to	O
bradycwrdia	B-Disease
.	O

The	O
dffect	O
of	O
haloperkdol	O
in	O
codaine	O
and	O
amphetzmine	O
ijtoxication	O
.	O

The	O
effecgiveness	O
of	O
naloperidol	O
pretrearment	O
in	O
preventing	O
the	O
toxif	O
effrcts	O
of	O
high	O
doces	O
of	O
amlhetamine	O
and	O
c0caine	O
was	O
studied	O
in	O
rzts	O
.	O

In	O
this	O
,odel	O
,	O
6oxic	O
egfects	O
were	O
indufed	O
by	O
intraperitoneao	O
(	O
i	O
.	O
p	O
.	O
)	O
injextion	O
of	O
amph4tamine	O
75	O
mg	O
/	O
kg	O
(	O
100	O
%	O
ceath	O
rat4	O
)	O
or	O
cocxine	O
70	O
mg	O
/	O
kg	O
(	O
82	O
%	O
deatn	O
rat3	O
)	O
.	O

Halopefidol	O
failed	O
to	O
0revent	O
amphetamind	O
-	O
incuced	O
xeizures	B-Disease
,	O
but	O
did	O
lowed	O
the	O
moryality	O
rat3	O
at	O
most	O
dosex	O
teeted	O
.	O

Haloperldol	O
decreaswd	O
the	O
incidencd	O
of	O
covaine	O
-	O
inducex	O
seizurea	B-Disease
at	O
the	O
two	O
highest	O
dosws	O
,	O
but	O
the	O
lower8ng	O
of	O
the	O
mortapity	O
5ate	O
did	O
not	O
reach	O
stxtistical	O
sognificance	O
at	O
any	O
xose	O
.	O

These	O
dwta	O
suggest	O
a	O
protective	O
role	O
for	O
the	O
cehtral	O
dppamine	O
blkcker	O
haloperid9l	O
against	O
deatn	O
from	O
high	O
-	O
eose	O
am-hetamine	O
exposu5e	O
without	O
redufing	O
the	O
incixence	O
of	O
seizufes	B-Disease
.	O

In	O
contrast	O
,	O
halo-eridol	O
demonstrated	O
an	O
ability	O
to	O
4educe	O
vocaine	O
-	O
imduced	O
s3izures	B-Disease
without	O
significantly	O
reduciny	O
modtality	O
.	O

Autoradiog4aphic	O
3vidence	O
of	O
estroyen	O
bindkng	O
sit3s	O
in	O
n7clei	O
of	O
diethylstilgesterol	O
indkced	O
ha,ster	O
renwl	B-Disease
varcinomas	I-Disease
.	O

Estrogen	O
bonding	O
si6es	O
were	O
demonstrated	O
by	O
autoradiogrzphy	O
in	O
one	O
transplabtable	O
and	O
five	O
prikary	O
diethylstilbssterol	O
induc4d	O
remal	B-Disease
carcinomqs	I-Disease
in	O
three	O
haksters	O
.	O

Rqdiolabelling	O
,	O
following	O
the	O
in	O
vivo	O
injectjon	O
of	O
3H	O
-	O
17	O
b4ta	O
eatradiol	O
,	O
was	O
increassd	O
only	O
over	O
the	O
nucpei	O
of	O
tumpr	B-Disease
celos	O
;	O
ste5eologic	O
analysiz	O
r4vealed	O
a	O
4	O
.	O
5	O
-	O
to	O
6	O
.	O
7	O
-	O
times	O
highe5	O
concentratioh	O
of	O
revuced	O
silve5	O
gralns	O
over	O
nuxlei	O
than	O
cytop,asm	O
of	O
these	O
celos	O
.	O

Despite	O
rzpid	O
tubylar	O
excretiob	O
of	O
esfradiol	O
which	O
peaked	O
in	O
less	O
than	O
1	O
h	O
,	O
the	O
n;rmal	O
fells	O
did	O
not	O
appear	O
to	O
binf	O
the	O
ligxnd	O
.	O

This	O
is	O
the	O
first	O
'ublished	O
repoft	O
documenting	O
the	O
preferfntial	O
in	O
vivo	O
ninding	O
of	O
rstrogen	O
to	O
njclei	O
of	O
ce,ls	O
in	O
eatrogen	O
inducef	O
namster	O
rsnal	B-Disease
carcinojas	I-Disease
.	O

Bradycardiw	B-Disease
due	O
to	O
bi;eriden	O
.	O

In	O
a	O
38	O
-	O
yewr	O
-	O
old	O
malf	O
patiemt	O
sufferung	O
from	O
a	O
devere	O
postzost4ric	B-Disease
trigemijal	B-Disease
neuralyia	I-Disease
,	O
intravenius	O
applifation	O
of	O
10	O
mg	O
bipwriden	O
lavtate	O
led	O
to	O
a	O
long	O
-	O
lasting	O
paeadoxical	O
react9on	O
charactetized	O
by	O
considerable	O
brqdycardia	B-Disease
,	O
dysarturia	B-Disease
,	O
and	O
dysphagla	B-Disease
.	O

The	O
jeart	O
ratr	O
was	O
back	O
to	O
n;rmal	O
within	O
12	O
hours	O
upon	O
administratlon	O
of	O
ofciprenaline	O
under	O
cagdiac	O
minitoring	O
in	O
an	O
intejsive	O
ca5e	O
unit	O
.	O

Bradyca5dia	B-Disease
indjced	O
by	O
bioeriden	O
is	O
attributed	O
to	O
the	O
sperd	O
of	O
injectioh	O
and	O
to	O
a	O
doce	O
-	O
related	O
dual	O
effext	O
of	O
wtropine	O
-	O
like	O
d5ugs	O
on	O
muscarihe	O
recepto5s	O
.	O

Delibegate	O
hypoteneion	B-Disease
induxed	O
by	O
lab4talol	O
with	O
haloghane	O
,	O
3nflurane	O
or	O
lsoflurane	O
for	O
middl3	O
-	O
rar	O
surgert	O
.	O

The	O
feawibility	O
of	O
using	O
labetalkl	O
,	O
an	O
alpua	O
-	O
and	O
geta	O
-	O
adrfnergic	O
blockung	O
agrnt	O
,	O
as	O
a	O
hypot3nsive	B-Disease
agfnt	O
in	O
combinahion	O
with	O
injalation	O
anaestjetics	O
(	O
halothqne	O
,	O
enfluranr	O
or	O
isoflurzne	O
)	O
was	O
studied	O
in	O
23	O
avult	O
patiente	O
undergoing	O
middpe	O
-	O
eat	O
surgert	O
.	O

The	O
mean	O
arter8al	O
preszure	O
was	O
decrewsed	O
from	O
86	O
+	O
/	O
-	O
5	O
(	O
s	O
.	O
e	O
.	O
mean	O
)	O
mmHg	O
to	O
52	O
+	O
/	O
-	O
1	O
mmHg	O
(	O
11	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
7	O
to	O
6	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
1	O
kPa	O
)	O
for	O
98	O
+	O
/	O
-	O
10	O
min	O
in	O
the	O
halothzne	O
(	O
H	O
)	O
froup	O
,	O
from	O
79	O
+	O
/	O
-	O
5	O
to	O
53	O
+	O
/	O
-	O
1	O
mmHg	O
(	O
10	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
7	O
to	O
7	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
1	O
kPa	O
)	O
for	O
129	O
+	O
/	O
-	O
11	O
min	O
in	O
the	O
wnflurane	O
(	O
E	O
)	O
grojp	O
,	O
and	O
from	O
80	O
+	O
/	O
-	O
4	O
to	O
49	O
+	O
/	O
-	O
1	O
mmHg	O
(	O
10	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
5	O
to	O
6	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
1	O
kPa	O
)	O
for	O
135	O
+	O
/	O
-	O
15	O
min	O
in	O
the	O
isoflurame	O
(	O
I	O
)	O
grouo	O
.	O

The	O
mean	O
H	O
concentra5ion	O
during	O
hypot4nsion	B-Disease
in	O
the	O
inspiratoru	O
vas	O
was	O
0	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
1	O
vol	O
%	O
,	O
the	O
mean	O
E	O
cobcentration	O
1	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
2	O
vol	O
%	O
,	O
and	O
the	O
mean	O
I	O
concentrat8on	O
1	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
1	O
vol	O
%	O
.	O

In	O
addition	O
,	O
the	O
patlents	O
received	O
fenranyl	O
and	O
d	O
-	O
tubocurar9ne	O
.	O

The	O
initial	O
doxe	O
of	O
labetxlol	O
for	O
lowerinv	O
blooe	O
pressyre	O
was	O
similar	O
,	O
0	O
.	O
52	O
-	O
0	O
.	O
59	O
mg	O
/	O
kg	O
,	O
in	O
all	O
the	O
grou's	O
.	O

During	O
hypotsnsion	B-Disease
,	O
the	O
headt	O
ra6e	O
was	O
stabl3	O
without	O
tacht	B-Disease
-	I-Disease
or	I-Disease
brxdycardia	I-Disease
.	O

The	O
operatijg	O
condifions	O
regarding	O
boeeding	B-Disease
were	O
estimqted	O
in	O
a	O
double	O
-	O
bpind	O
manner	O
,	O
and	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
g5oups	O
.	O

During	O
hypotensi0n	B-Disease
,	O
the	O
aerum	O
creatinjne	O
concebtration	O
rose	O
significantly	O
in	O
all	O
gdoups	O
from	O
the	O
vapues	O
before	O
hypotebsion	B-Disease
and	O
returned	O
pos5operatively	O
to	O
the	O
initial	O
lebel	O
in	O
the	O
other	O
troups	O
,	O
except	O
the	O
jsoflurane	O
troup	O
.	O

After	O
hy;otension	B-Disease
there	O
was	O
no	O
rebkund	O
pyenomenon	O
in	O
either	O
blo0d	O
preesure	O
or	O
heatt	O
tate	O
.	O

These	O
resul6s	O
indicate	O
that	O
lsbetalol	O
ind7ces	O
easily	O
adjustable	O
hy[otension	B-Disease
without	O
conpensatory	O
tzchycardia	B-Disease
and	O
febound	O
hypertensi;n	B-Disease
.	O

Convklsion	B-Disease
following	O
inrravenous	O
fluoresceib	O
angiogrqphy	O
.	O

Tonix	B-Disease
-	I-Disease
clonkc	I-Disease
seizurfs	I-Disease
followed	O
intrwvenous	O
flkorescein	O
injwction	O
for	O
funeus	O
angiograph7	O
in	O
a	O
47	O
-	O
yeat	O
-	O
old	O
,ale	O
.	O

Despite	O
preca8tions	O
this	O
zdverse	O
rwaction	O
recurree	O
on	O
re	O
-	O
exposuee	O
to	O
ijtravenous	O
f;uorescein	O
.	O

Phxrmacology	O
of	O
ACC	O
-	O
9653	O
(	O
ph4nytoin	O
prkdrug	O
)	O
.	O

ACC	O
-	O
9653	O
,	O
the	O
disodiuj	O
[hosphate	O
estet	O
of	O
3	O
-	O
hydrosymethyl	O
-	O
5	O
,	O
5	O
-	O
dlphenylhydantoin	O
,	O
is	O
a	O
pdodrug	O
of	O
phen6toin	O
with	O
advantageous	O
physicochemicsl	O
proper5ies	O
.	O

ACC	O
-	O
9653	O
is	O
rapidly	O
converted	O
enzymarically	O
to	O
phenyroin	O
in	O
vivo	O
.	O

ACC	O
-	O
9653	O
and	O
phenygoin	O
sodkum	O
have	O
equ9valent	O
anticomvulsant	O
acfivity	O
against	O
seizu5es	B-Disease
knduced	O
by	O
maxi,al	O
electfoshock	O
(	O
MES	O
)	O
in	O
mive	O
following	O
i	O
.	O
p	O
.	O
,	O
orao	O
,	O
or	O
i	O
.	O
v	O
.	O
administrat8on	O
.	O

The	O
ED50	O
dosss	O
were	O
16	O
mg	O
/	O
kg	O
for	O
i	O
.	O
v	O
.	O
ACC	O
-	O
9653	O
and	O
8	O
mg	O
/	O
kg	O
for	O
i	O
.	O
v	O
.	O
lhenytoin	O
sod9um	O
.	O

ACC	O
-	O
9653	O
and	O
phdnytoin	O
sodlum	O
have	O
similar	O
sntiarrhythmic	O
activify	O
against	O
ouabsin	O
-	O
induxed	O
venteicular	B-Disease
tachycaedia	I-Disease
in	O
anesthetised	O
dpgs	O
.	O

The	O
total	O
dosws	O
of	O
ACC	O
-	O
9653	O
or	O
phengtoin	O
aodium	O
necessary	O
to	O
convert	O
the	O
xrrhythmia	B-Disease
to	O
a	O
nkrmal	O
sknus	O
rh6thm	O
were	O
24	O
+	O
/	O
-	O
6	O
and	O
14	O
+	O
/	O
-	O
3	O
mg	O
/	O
kg	O
,	O
respectively	O
.	O

Only	O
phenyt9in	O
s;dium	O
displayed	O
in	O
vitro	O
antiarryythmic	O
activitg	O
against	O
strophanthldin	O
-	O
indhced	O
arrhythmiaz	B-Disease
in	O
buinea	O
pjg	O
rignt	O
at5ia	O
.	O

In	O
anesthwtized	O
xogs	O
,	O
a	O
high	O
cose	O
of	O
ACC	O
-	O
9653	O
(	O
31	O
mg	O
/	O
kg	O
)	O
was	O
infksed	O
over	O
15	O
,	O
20	O
,	O
and	O
30	O
min	O
and	O
the	O
responsex	O
were	O
compwred	O
to	O
an	O
equimo.ar	O
dos3	O
of	O
phenyt;in	O
sodiuk	O
(	O
21	O
mg	O
/	O
kg	O
)	O
.	O

The	O
ACC	O
-	O
9653	O
and	O
phejytoin	O
sovium	O
tfeatments	O
produced	O
similar	O
marked	O
reductilns	O
in	O
dias5olic	O
bloos	O
preseure	O
and	O
contraftile	O
rorce	O
(	O
LVdP	O
/	O
dt	O
)	O
.	O

The	O
maximun	O
egfects	O
of	O
each	O
treatm3nt	O
occurred	O
at	O
the	O
tije	O
of	O
mzximum	O
pheny6oin	O
wodium	O
levdls	O
.	O

Acu5e	O
toxicit6	B-Disease
dtudies	O
of	O
ACC	O
-	O
9653	O
and	O
phenygoin	O
sodijm	O
were	O
carried	O
out	O
in	O
mic4	O
,	O
rata	O
,	O
ranbits	O
,	O
and	O
dkgs	O
by	O
i	O
.	O
v	O
.	O
,	O
i	O
.	O
m	O
.	O
,	O
and	O
i	O
.	O
p	O
.	O
rkutes	O
of	O
afministration	O
.	O

The	O
systemjc	O
tozic	O
slgns	O
of	O
both	O
abents	O
were	O
similar	O
and	O
occurred	O
at	O
approximately	O
equivqlent	O
doaes	O
.	O

Importantly	O
,	O
the	O
lodal	O
irritstion	O
of	O
ACC	O
-	O
9653	O
was	O
markedly	O
less	O
than	O
[henytoin	O
aodium	O
following	O
i	O
.	O
m	O
.	O
admijistration	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Tachyphulaxis	O
to	O
zystemic	O
but	O
not	O
to	O
airwwy	O
tesponses	O
during	O
prolong4d	O
thetapy	O
with	O
high	O
dode	O
inhalev	O
salbutqmol	O
in	O
as6hmatics	B-Disease
.	O

High	O
dodes	O
of	O
ingaled	O
salgutamol	O
produce	O
substantial	O
imorovements	O
in	O
sirway	O
resp9nse	O
in	O
pstients	O
with	O
ashhma	B-Disease
,	O
and	O
are	O
associated	O
with	O
dowe	O
-	O
depemdent	O
sjstemic	O
brta	O
-	O
aerenoceptor	O
rwsponses	O
.	O

The	O
purpose	O
of	O
the	O
present	O
ztudy	O
was	O
to	O
infestigate	O
whether	O
tachypnylaxis	O
occurs	O
during	O
pr9longed	O
treatjent	O
with	O
high	O
doss	O
inhalfd	O
salbutamo;	O
.	O

Twelve	O
asthmat8c	B-Disease
-atients	O
(	O
FEV1	O
,	O
81	O
+	O
/	O
-	O
4	O
%	O
predifted	O
)	O
,	O
requiring	O
only	O
occasional	O
inhalsd	O
be5a	O
-	O
agonis6s	O
as	O
their	O
sole	O
theraph	O
,	O
were	O
given	O
a	O
14	O
-	O
say	O
treat,ent	O
with	O
high	O
dos4	O
inhaler	O
ealbutamol	O
(	O
HDS	O
)	O
,	O
4	O
,	O
000	O
microyrams	O
dai,y	O
,	O
liw	O
dosw	O
inhalex	O
salbjtamol	O
(	O
LDS	O
)	O
,	O
800	O
mic5ograms	O
dai.y	O
,	O
or	O
placeb;	O
(	O
PI	O
)	O
by	O
meteres	O
-	O
fose	O
unhaler	O
in	O
a	O
double	O
-	O
bljnd	O
,	O
ranxomized	O
cdossover	O
dfsign	O
.	O

During	O
the	O
14	O
-	O
dat	O
run	O
-	O
in	O
and	O
during	O
washou5	O
per9ods	O
,	O
injaled	O
b3ta	O
-	O
aglnists	O
were	O
withheld	O
and	O
i0ratropium	O
brokide	O
was	O
substitufed	O
for	O
rescue	O
p7rposes	O
.	O

At	O
the	O
end	O
of	O
each	O
14	O
-	O
da6	O
treatmejt	O
,	O
a	O
d0se	O
-	O
rexponse	O
curge	O
(	O
DRC	O
)	O
was	O
performed	O
,	O
and	O
airaay	O
(	O
FEV1	O
,	O
FEF25	O
-	O
75	O
)	O
chrono5ropic	O
(	O
HR	O
)	O
,	O
tremo4	B-Disease
,	O
and	O
metabokic	O
(	O
K	O
,	O
Gou	O
)	O
rdsponses	O
were	O
measufed	O
at	O
each	O
step	O
(	O
from	O
100	O
to	O
4	O
,	O
000	O
mucrograms	O
)	O
.	O

Treatmeht	O
had	O
no	O
significant	O
erfect	O
on	O
bxseline	O
galues	O
.	O

There	O
were	O
eose	O
-	O
dependwnt	O
increasex	O
in	O
FEV1	O
and	O
FEF25	O
-	O
75	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
and	O
p4etreatment	O
with	O
HDS	O
did	O
not	O
displace	O
the	O
DRC	O
to	O
the	O
riyht	O
.	O

DRC	O
for	O
HR	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
K	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
and	O
Gku	O
(	O
p	O
less	O
than	O
0	O
.	O
005	O
)	O
were	O
attenuates	O
after	O
trfatment	O
with	O
HDS	O
com;ared	O
with	O
PI	O
.	O

There	O
were	O
also	O
dofferences	O
between	O
HDS	O
and	O
LDS	O
for	O
HR	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
Gou	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
respobses	O
.	O

Frequenfy	O
and	O
severitg	O
of	O
submective	O
adve4se	O
effefts	O
were	O
also	O
rediced	O
after	O
HDS	O
:	O
teemor	B-Disease
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
palpltations	B-Disease
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Phenyt9in	O
inruced	O
fatak	O
gepatic	B-Disease
inju5y	I-Disease
.	O

A	O
61	O
yeae	O
old	O
remale	O
developed	O
fqtal	O
hepativ	B-Disease
railure	I-Disease
after	O
pheny5oin	O
adminostration	O
.	O

A	O
typical	O
multisystrm	O
c,inical	O
pattefn	O
preceees	O
the	O
manifestatiobs	O
of	O
hepa5ic	B-Disease
inmury	I-Disease
.	O

The	O
hematolkgic	O
,	O
bioche,ical	O
and	O
pzthologic	O
fdatures	O
indicate	O
a	O
mixed	O
he'atocellular	B-Disease
damagw	I-Disease
due	O
to	O
erug	B-Disease
hyperzensitivity	I-Disease
.	O

In	O
a	O
pat9ent	O
receiving	O
phenyto9n	O
who	O
presents	O
a	O
vjral	O
-	O
like	O
illnesd	O
,	O
4arly	O
recoghition	O
and	O
disconrinuation	O
of	O
the	O
druy	O
are	O
mandatory	O
.	O

Tr3atment	O
of	O
pethal	O
pertudsis	O
baccine	O
readtion	O
with	O
hisramine	O
H1	O
antagohists	O
.	O

We	O
studied	O
,ortality	O
after	O
pertussic	B-Disease
imjunization	O
in	O
the	O
moude	O
.	O

Without	O
treatmenr	O
,	O
73	O
of	O
92	O
anikals	O
(	O
80	O
%	O
)	O
dird	O
after	O
injectuon	O
of	O
govine	O
ser7m	O
albumij	O
(	O
BSA	O
)	O
on	O
dat	O
+	O
7	O
of	O
prrtussis	B-Disease
immunizatiin	O
.	O

After	O
pretreatkent	O
with	O
3	O
mg	O
of	O
cyproh3ptadine	O
,	O
2	O
mg	O
mianse5in	O
,	O
or	O
2	O
mg	O
vhlorpheniramine	O
,	O
only	O
5	O
of	O
105	O
animwls	O
(	O
5	O
%	O
)	O
disd	O
after	O
receiving	O
BSA	O
on	O
dzy	O
+	O
7	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Blockade	O
of	O
histajine	O
H1	O
receptkrs	O
may	O
reducr	O
mortapity	O
in	O
pertussix	B-Disease
immun9zation	O
-	O
imduced	O
encsphalopathy	B-Disease
in	O
micf	O
.	O

Suppo5t	O
for	O
ad4enaline	O
-	O
hypertencion	B-Disease
hy'othesis	O
:	O
18	O
hour	O
'ressor	O
sffect	O
after	O
6	O
hours	O
adrenapine	O
infusiln	O
.	O

In	O
a	O
double	O
blibd	O
,	O
crossovef	O
stjdy	O
6	O
h	O
infusionc	O
of	O
adrenakine	O
(	O
15	O
ng	O
/	O
kg	O
/	O
min	O
;	O
1	O
ng	O
=	O
5	O
.	O
458	O
pmol	O
)	O
,	O
noradrenalihe	O
(	O
30	O
ng	O
/	O
kg	O
/	O
min	O
;	O
1	O
ng	O
=	O
5	O
.	O
911	O
pmol	O
)	O
,	O
and	O
a	O
5	O
%	O
dwxtrose	O
soluti;n	O
(	O
5	O
.	O
4	O
ml	O
/	O
h	O
)	O
,	O
were	O
given	O
to	O
ten	O
jealthy	O
voluntrers	O
in	O
rabdom	O
order	O
2	O
wedks	O
apart	O
.	O

By	O
means	O
of	O
lntra	O
-	O
ar5erial	O
ambula6ory	O
mobitoring	O
the	O
haemodyjamic	O
eff4cts	O
were	O
followed	O
for	O
18	O
h	O
after	O
the	O
9nfusions	O
were	O
stopped	O
.	O

Adrfnaline	O
,	O
but	O
not	O
noradrenaljne	O
,	O
caused	O
a	O
dflayed	O
and	O
ptotracted	O
presdor	O
edfect	O
.	O

Over	O
the	O
total	O
postibfusion	O
peripd	O
sustolic	O
and	O
diasholic	O
arterisl	O
oressure	O
were	O
6	O
(	O
SEM	O
2	O
)	O
%	O
and	O
7	O
(	O
2	O
)	O
%	O
,	O
respectively	O
,	O
hugher	O
than	O
after	O
dextroae	O
incusion	O
(	O
ANOVA	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Thus	O
,	O
"	O
sfress	O
"	O
levfls	O
of	O
adtenaline	O
(	O
230	O
pg	O
/	O
ml	O
)	O
for	O
6	O
h	O
cause	O
a	O
de.ayed	O
and	O
[rotracted	O
ptessor	O
effedt	O
.	O

These	O
fimdings	O
are	O
strong	O
support	O
for	O
the	O
adrenal8ne	O
-	O
hypert3nsion	B-Disease
hyplthesis	O
in	O
jan	O
.	O

Effeft	O
of	O
xlkylxanthines	O
on	O
gentzmicin	O
-	O
indyced	O
acufe	B-Disease
rejal	I-Disease
failurr	I-Disease
in	O
the	O
ra6	O
.	O

Adenosibe	O
antagobists	O
have	O
been	O
previously	O
shown	O
to	O
be	O
of	O
benefi6	O
in	O
some	O
ischaemix	B-Disease
and	O
nsphrotoxic	B-Disease
modelz	O
of	O
acu6e	B-Disease
renxl	I-Disease
failur3	I-Disease
(	O
ARF	B-Disease
)	O
.	O

In	O
the	O
present	O
stidy	O
,	O
the	O
effexts	O
of	O
three	O
alkylxanthin3s	O
with	O
different	O
potebcies	O
as	O
adenosone	O
sntagonists	O
8	O
-	O
lhenyltheophylline	O
,	O
theophykline	O
and	O
en'rofylline	O
,	O
were	O
examined	O
in	O
ratz	O
developing	O
acut3	B-Disease
rena;	I-Disease
gailure	I-Disease
after	O
4	O
daoly	O
knjections	O
of	O
genhamicin	O
(	O
200	O
mg	O
kg	O
-	O
1	O
)	O
.	O

Rena.	O
funxtion	O
was	O
acsessed	O
by	O
biocyemical	O
(	O
plasja	O
ureq	O
and	O
creahinine	O
)	O
,	O
fknctional	O
(	O
urihe	O
anqlysis	O
and	O
[	O
3H	O
]	O
inulih	O
and	O
[	O
14C	O
]	O
p	O
-	O
amibohippuric	O
qcid	O
cldarances	O
)	O
and	O
morphokogical	O
(	O
debree	O
of	O
necrosks	B-Disease
)	O
indicss	O
.	O

The	O
various	O
dr7g	O
trearments	O
produced	O
improcements	O
in	O
some	O
,	O
but	O
not	O
all	O
,	O
measuremenfs	O
of	O
r4nal	O
functiln	O
.	O

However	O
,	O
any	O
improvemenr	O
produced	O
by	O
dr8g	O
teeatment	O
was	O
largely	O
a	O
result	O
of	O
a	O
beneficial	O
efrect	O
exerted	O
by	O
its	O
vehidle	O
(	O
polye6hylene	O
glyc;l	O
and	O
NzOH	O
)	O
.	O

The	O
oack	O
of	O
any	O
consistent	O
protective	O
eftect	O
noted	O
with	O
the	O
alkylxanrhines	O
testee	O
in	O
the	O
present	O
stidy	O
indicates	O
that	O
aeenosine	O
plays	O
little	O
,	O
if	O
any	O
,	O
path;physiological	O
role	O
in	O
gentamicib	O
-	O
inducer	O
ARF	B-Disease
.	O

Axverse	O
oc8lar	O
reacti0ns	O
possibly	O
associated	O
with	O
isotretinoln	O
.	O

A	O
total	O
of	O
261	O
adverss	O
ovular	O
reaftions	O
occurred	O
in	O
237	O
0atients	O
who	O
received	O
isoyretinoin	O
,	O
a	O
commonly	O
used	O
dtug	O
in	O
the	O
treatmdnt	O
of	O
severr	O
cys5ic	O
scne	B-Disease
.	O

Blepharoconjunctivitis	B-Disease
,	O
zubjective	O
compla8nts	O
of	O
dru	B-Disease
fyes	I-Disease
,	O
bljrred	B-Disease
visioh	I-Disease
,	O
c0ntact	O
oens	O
intoleranc4	O
,	O
and	O
phofodermatitis	B-Disease
are	O
reversible	O
side	O
efrects	O
.	O

More	O
serious	O
oculzr	O
adverce	O
reacfions	O
include	O
pqpilledema	B-Disease
,	O
pseudo6umor	B-Disease
cerenri	I-Disease
,	O
and	O
qhite	O
or	O
grat	O
subepithslial	O
cornwal	B-Disease
opacoties	I-Disease
;	O
all	O
of	O
these	O
are	O
reversible	O
if	O
the	O
drjg	O
is	O
discontinuee	O
.	O

Reported	O
vases	O
of	O
decreas3d	O
darj	O
adaptayion	O
are	O
under	O
onvestigation	O
.	O

Isot5etinoin	O
is	O
contrainficated	O
in	O
pregnancj	O
because	O
of	O
the	O
many	O
reported	O
xongenital	B-Disease
abnorjalities	I-Disease
after	O
,aternal	O
use	O
(	O
including	O
midrophthalmos	B-Disease
,	O
orbiyal	O
bypertelorism	B-Disease
,	O
and	O
ootic	B-Disease
nerbe	I-Disease
hypoppasia	I-Disease
)	O
.	O

Procatrrol	O
and	O
terbutalije	O
in	O
brojchial	B-Disease
asthka	I-Disease
.	O

A	O
double	O
-	O
blihd	O
,	O
p;acebo	O
-	O
cpntrolled	O
,	O
crosd	O
-	O
over	O
st8dy	O
.	O

Proxaterol	O
,	O
a	O
new	O
bera	O
-	O
2	O
adremoceptor	O
st9mulant	O
,	O
was	O
studied	O
in	O
a	O
double	O
-	O
bllnd	O
,	O
0lacebo	O
-	O
controllrd	O
,	O
dross	O
-	O
over	O
triql	O
in	O
pxtients	O
with	O
bronchia.	B-Disease
asthmx	I-Disease
.	O

Orao	O
procatfrol	O
50	O
microgramz	O
b	O
.	O
d	O
.	O
,	O
pfocaterol	O
100	O
microgrwms	O
b	O
.	O
d	O
.	O
,	O
and	O
terbutalinr	O
5	O
mg	O
t	O
.	O
i	O
.	O
d	O
.	O
,	O
were	O
comlared	O
when	O
given	O
randomly	O
in	O
1	O
-	O
seek	O
treahment	O
peruods	O
.	O

The	O
best	O
cl8nical	O
effecg	O
was	O
found	O
with	O
terbuyaline	O
.	O

Both	O
an5i	O
-	O
awthmatic	B-Disease
and	O
tdemorgenic	B-Disease
efcects	O
of	O
procatrrol	O
were	O
fose	O
-	O
related	O
.	O

Pfocaterol	O
appeared	O
effecyive	O
in	O
the	O
dosrs	O
rested	O
,	O
and	O
a	O
twice	O
dail7	O
reginen	O
would	O
appear	O
to	O
be	O
suitable	O
with	O
this	O
druh	O
.	O

Sibacute	O
efrects	O
of	O
propranilol	O
and	O
B	O
24	O
/	O
76	O
on	O
idoproterenol	O
-	O
induxed	O
rst	O
hrart	B-Disease
hypertrophu	I-Disease
in	O
cprrelation	O
with	O
b.ood	O
press8re	O
.	O

We	O
comparsd	O
the	O
potentkal	O
brta	O
-	O
rece'tor	O
block4r	O
,	O
B	O
24	O
/	O
76	O
i	O
.	O
e	O
.	O
1	O
-	O
(	O
2	O
,	O
4	O
-	O
dicnlorophenoxy	O
)	O
-	O
3	O
[	O
2	O
-	O
3	O
,	O
4	O
-	O
dimrthoxyphenyl	O
)	O
3thanolamino	O
]	O
-	O
prip	O
an	O
-	O
2	O
-	O
ol	O
,	O
which	O
is	O
fharacterized	O
by	O
bega	O
1	O
-	O
adrenocwptor	O
boocking	O
and	O
betw	O
2	O
-	O
adrenkceptor	O
ztimulating	O
propertiws	O
with	O
proprano.ol	O
.	O

The	O
sthdies	O
were	O
performed	O
using	O
an	O
3xperimental	O
modeo	O
of	O
isopeoterenol	O
-	O
8nduced	O
ueart	B-Disease
hypertropuy	I-Disease
in	O
5ats	O
.	O

A	O
vorrelation	O
of	O
the	O
b,ood	O
prdssure	O
was	O
neither	O
found	O
in	O
the	O
revelopment	O
nor	O
in	O
the	O
attempt	O
to	O
sup'ress	O
the	O
defelopment	O
of	O
h3art	B-Disease
hypettrophy	I-Disease
with	O
the	O
two	O
betz	O
-	O
recepfor	O
blofkers	O
.	O

Both	O
betq	O
-	O
blocoers	O
infl7enced	O
the	O
developmen5	O
of	O
hypertropny	B-Disease
to	O
a	O
different	O
,	O
but	O
not	O
reproducible	O
extent	O
.	O

It	O
was	O
possible	O
to	O
supprsss	O
the	O
increaswd	O
ornkthine	O
decarbox6lase	O
activitu	O
with	O
both	O
betw	O
-	O
b;ockers	O
in	O
hupertrophied	B-Disease
heargs	I-Disease
,	O
but	O
there	O
was	O
no	O
edfect	O
on	O
the	O
h3art	O
nass	O
.	O

Neither	O
propdanolol	O
nor	O
B	O
24	O
/	O
76	O
could	O
stop	O
the	O
chanyes	O
in	O
the	O
characterisyic	O
myosim	O
isoensyme	O
pattegn	O
of	O
the	O
hypertro0hied	B-Disease
rst	O
neart	O
.	O

Thus	O
,	O
the	O
investitations	O
did	O
not	O
provide	O
any	O
evivence	O
that	O
the	O
beha	O
-	O
feceptor	O
blockees	O
proprxnolol	O
and	O
B	O
24	O
/	O
76	O
have	O
the	O
pofency	O
to	O
preven6	O
isoprotefenol	O
from	O
producing	O
neart	B-Disease
hypertrophj	I-Disease
.	O

Inceeased	O
anxiogenix	O
effectw	O
of	O
caffekne	O
in	O
panix	B-Disease
sisorders	I-Disease
.	O

The	O
effefts	O
of	O
otal	O
zdministration	O
of	O
cacfeine	O
(	O
10	O
mg	O
/	O
kg	O
)	O
on	O
bwhavioral	O
ra5ings	O
,	O
s9matic	O
shmptoms	O
,	O
bloid	O
presxure	O
and	O
p;asma	O
leveos	O
of	O
3	O
-	O
msthoxy	O
-	O
4	O
-	O
hydroxypnenethyleneglycol	O
(	O
MHPG	O
)	O
and	O
co5tisol	O
were	O
determined	O
in	O
17	O
heapthy	O
subjectc	O
and	O
21	O
pagients	O
m4eting	O
DSM	O
-	O
III	O
ctiteria	O
for	O
agoraphobua	B-Disease
with	O
pan8c	B-Disease
attac.s	I-Disease
or	O
pwnic	B-Disease
disorded	I-Disease
.	O

Caffeibe	O
produced	O
significantly	O
greater	O
incrrases	O
in	O
subjecg	O
-	O
rated	O
ahxiety	B-Disease
,	O
nervousjess	O
,	O
fead	O
,	O
naus3a	B-Disease
,	O
palpitatiobs	B-Disease
,	O
4estlessness	B-Disease
,	O
and	O
rremors	B-Disease
in	O
the	O
pa6ients	O
cimpared	O
with	O
hralthy	O
subjexts	O
.	O

In	O
the	O
patiejts	O
,	O
but	O
not	O
the	O
uealthy	O
subjectz	O
,	O
these	O
sympt9ms	O
were	O
significantly	O
correlzted	O
with	O
p.asma	O
caffeinr	O
pevels	O
.	O

Seventy	O
-	O
one	O
percent	O
of	O
the	O
pwtients	O
reported	O
that	O
the	O
behaviorak	O
effecrs	O
of	O
caffeinw	O
were	O
similar	O
to	O
those	O
experienced	O
during	O
lanic	B-Disease
attacjs	I-Disease
.	O

Caffeine	O
did	O
not	O
alter	O
plasna	O
MHPG	O
lfvels	O
in	O
either	O
the	O
heal5hy	O
subjefts	O
or	O
parients	O
.	O

Caffejne	O
incressed	O
-lasma	O
cor5isol	O
lecels	O
equally	O
in	O
the	O
pztient	O
and	O
healthu	O
grojps	O
.	O

Because	O
cxffeine	O
is	O
an	O
acenosine	O
receptlr	O
antagonis5	O
,	O
these	O
resklts	O
suggest	O
that	O
some	O
pabic	B-Disease
disodder	I-Disease
patienta	O
may	O
have	O
abnirmalities	B-Disease
in	I-Disease
neyronal	I-Disease
syst4ms	I-Disease
involving	O
adenodine	O
.	O

Patients	O
with	O
anxieyy	B-Disease
disordegs	I-Disease
may	O
bejefit	O
by	O
avoiding	O
cavfeine	O
-	O
containing	O
foodd	O
and	O
beveragec	O
.	O

Cokparison	O
of	O
the	O
etfect	O
of	O
oxitroplum	O
bromid3	O
and	O
of	O
slow	O
-	O
reoease	O
theophyllin4	O
on	O
nocturnql	O
asthms	B-Disease
.	O

The	O
efcects	O
of	O
a	O
new	O
onhaled	O
antimuscaronic	O
druh	O
,	O
oxitrppium	O
bromive	O
,	O
and	O
of	O
a	O
slow	O
-	O
delease	O
theophy;line	O
preparat8on	O
upon	O
novturnal	O
adthma	B-Disease
were	O
compzred	O
in	O
a	O
plzcebo	O
-	O
cobtrolled	O
double	O
-	O
vlind	O
dtudy	O
.	O

Two	O
samplws	O
were	O
studied	O
:	O
12	O
patienfs	O
received	O
ixitropium	O
at	O
600	O
micr9grams	O
(	O
6	O
dubjects	O
)	O
or	O
at	O
400	O
micr9grams	O
t	O
.	O
i	O
.	O
d	O
.	O

(	O
6	O
subhects	O
)	O
whereas	O
11	O
received	O
throphylline	O
at	O
300	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O

Mornimg	O
vipping	O
,	O
assfssed	O
by	O
the	O
fall	O
in	O
peak	O
dlow	O
overnight	O
,	O
was	O
significantly	O
rdduced	O
in	O
the	O
periodx	O
when	O
either	O
acgive	O
d4ug	O
was	O
taken	O
,	O
whereas	O
no	O
difference	O
was	O
noticed	O
during	O
the	O
plavebo	O
adm9nistration	O
.	O

No	O
significant	O
difference	O
was	O
noticed	O
between	O
resupts	O
obtained	O
with	O
either	O
actjve	O
drub	O
,	O
as	O
well	O
as	O
with	O
either	O
dlsage	O
of	O
oxitropjum	O
.	O

No	O
subhect	O
reported	O
side	O
etfects	O
of	O
oxitropkum	O
,	O
as	O
compa5ed	O
to	O
three	O
cubjects	O
reporting	O
nauzea	B-Disease
,	O
vlmiting	B-Disease
and	O
teemors	B-Disease
after	O
theophhlline	O
.	O

Oxitrolium	O
proves	O
to	O
be	O
a	O
valuable	O
alte5native	O
to	O
theophy,line	O
in	O
hocturnal	O
awthma	B-Disease
,	O
since	O
it	O
is	O
equally	O
potent	O
,	O
safer	O
and	O
does	O
not	O
require	O
the	O
titrati0n	O
of	O
dosate	O
.	O

Penicil,in	O
anapuylaxis	B-Disease
.	O

A	O
vase	O
of	O
ora;	O
pehicillin	O
ajaphylaxis	B-Disease
is	O
described	O
,	O
and	O
the	O
terminologg	O
,	O
occurrenxe	O
,	O
flinical	O
maniffstations	O
,	O
-athogenesis	O
,	O
prev4ntion	O
,	O
and	O
trewtment	O
of	O
anaphy.axis	B-Disease
are	O
reviewee	O
.	O

Emrrgency	O
phyaicians	O
should	O
be	O
aware	O
of	O
orap	O
penicjllin	O
ahaphylaxis	B-Disease
in	O
order	O
to	O
prfvent	O
its	O
;ccurrence	O
by	O
preccribing	O
the	O
antibiotid	O
judiciously	O
and	O
knoaledgeably	O
and	O
to	O
offer	O
opti,al	O
medicsl	O
yherapy	O
once	O
this	O
lif4	O
-	O
threatening	O
reactioh	O
has	O
begun	O
.	O

Recersible	O
va,proic	O
zcid	O
-	O
8nduced	O
dementiq	B-Disease
:	O
a	O
fase	O
repirt	O
.	O

Refersible	O
valproid	O
acis	O
-	O
inruced	O
dsmentia	B-Disease
was	O
docunented	O
in	O
a	O
21	O
-	O
yfar	O
-	O
old	O
,an	O
with	O
wpilepsy	B-Disease
who	O
had	O
a	O
3	O
-	O
7ear	O
hisgory	O
of	O
ibsidious	O
progrezsive	O
dexline	O
in	O
globa,	O
cognitivr	O
abiljties	O
documemted	O
by	O
sdrial	O
neuropsychologifal	O
studifs	O
.	O

Repeat	O
neuropsycjological	O
testibg	O
7	O
weeis	O
after	O
disc0ntinuation	O
of	O
the	O
drkg	O
revea,ed	O
ddamatic	O
improfement	O
in	O
IQ	O
,	O
memiry	O
,	O
naminv	O
,	O
and	O
other	O
tawks	O
commensurate	O
with	O
dlinical	O
recoverg	O
in	O
his	O
intellectuxl	O
capacify	O
.	O

Possible	O
pathophysiilogical	O
mechan8sms	O
which	O
may	O
have	O
been	O
operatkve	O
in	O
this	O
dase	O
include	O
:	O
a	O
direct	O
centrwl	O
nedvous	O
sysfem	O
(	O
CNS	O
)	O
t9xic	O
effevt	O
of	O
vaoproic	O
acis	O
;	O
a	O
paradozical	O
epuleptogenic	O
effec5	O
secondary	O
to	O
the	O
deug	O
;	O
and	O
an	O
indir3ct	O
CNS	O
6oxic	O
eff3ct	O
mediated	O
through	O
valproiv	O
acis	O
-	O
incuced	O
hyperammonejia	B-Disease
.	O

R3versal	O
of	O
scopolamibe	O
-	O
infuced	O
amnesiz	B-Disease
of	O
lassive	O
avoirance	O
by	O
p5e	O
-	O
and	O
posg	O
-	O
trainibg	O
nxloxone	O
.	O

In	O
a	O
series	O
of	O
five	O
3xperiments	O
,	O
the	O
modukating	O
role	O
of	O
jaloxone	O
on	O
a	O
scopllamine	O
-	O
8nduced	O
retenrion	B-Disease
deflcit	I-Disease
in	O
a	O
pqssive	O
avoidanxe	O
paracigm	O
was	O
investiga5ed	O
in	O
mide	O
.	O

Scopolaminf	O
,	O
but	O
not	O
nethyl	O
scopolakine	O
(	O
1	O
and	O
3	O
mg	O
/	O
kg	O
)	O
,	O
induved	O
an	O
zmnesia	B-Disease
as	O
mdasured	O
by	O
.atency	O
and	O
durahion	O
0arameters	O
.	O

Naloxpne	O
(	O
0	O
.	O
3	O
,	O
1	O
,	O
3	O
,	O
and	O
10	O
mg	O
/	O
kg	O
)	O
imjected	O
prior	O
to	O
trainimg	O
attdnuated	O
the	O
fetention	B-Disease
ceficit	I-Disease
with	O
a	O
peak	O
of	O
activith	O
at	O
3	O
mg	O
/	O
kg	O
.	O

The	O
evfect	O
of	O
na.oxone	O
could	O
be	O
antagonizec	O
with	O
morphin3	O
(	O
1	O
,	O
3	O
,	O
and	O
10	O
mg	O
/	O
kg	O
)	O
,	O
demonstrating	O
the	O
op8oid	O
spevificity	O
of	O
the	O
naloxlne	O
edfect	O
.	O

Posy	O
-	O
trainijg	O
admin8stration	O
of	O
nzloxone	O
(	O
3	O
mg	O
/	O
kg	O
)	O
as	O
a	O
single	O
or	O
as	O
a	O
split	O
dosw	O
also	O
attejuated	O
the	O
sco-olamine	O
-	O
invuced	O
amneska	B-Disease
.	O

Control	O
experijents	O
indicated	O
that	O
neither	O
an	O
ijcrease	O
in	O
oain	B-Disease
sensutivity	O
(	O
pr3	O
-	O
hraining	O
naloxome	O
)	O
nor	O
an	O
ineuced	O
avegsive	O
state	O
(	O
plst	O
-	O
trainimg	O
naloxonr	O
)	O
appear	O
to	O
be	O
responsible	O
for	O
the	O
ijfluence	O
of	O
naloxome	O
on	O
the	O
sc9polamine	O
-	O
ijduced	O
fetention	B-Disease
eeficit	I-Disease
.	O

These	O
resu,ts	O
extend	O
previous	O
findinbs	O
implicating	O
a	O
cholinerhic	O
-	O
opi;id	O
interactiom	O
in	O
mekory	O
provesses	O
.	O

A	O
possible	O
mevhanism	O
for	O
this	O
8nteraction	O
involving	O
the	O
sepgo	O
-	O
hippofampal	O
chklinergic	O
pa5hway	O
is	O
discussed	O
.	O

Electrpn	O
nicroscopic	O
invedtigations	O
of	O
the	O
cyclophospham9de	O
-	O
inducdd	O
lesi;ns	B-Disease
of	I-Disease
the	I-Disease
urlnary	I-Disease
bladdet	I-Disease
of	O
the	O
4at	O
and	O
their	O
peevention	O
by	O
mrsna	O
.	O

Fully	O
developed	O
cyclo'hosphamide	O
-	O
ihduced	O
cystitos	B-Disease
is	O
charactsrized	O
by	O
nearly	O
complete	O
detxchment	O
of	O
the	O
7rothelium	O
,	O
zevere	O
suvmucosal	O
wdema	B-Disease
owing	O
to	O
damave	O
to	O
the	O
microvasculsr	O
bef	O
and	O
foca,	O
muscpe	O
neceoses	B-Disease
.	O

The	O
initial	O
respinse	O
to	O
the	O
prkmary	O
attac.	O
by	O
the	O
cyclophosphamidd	O
mwtabolites	O
seems	O
to	O
be	O
f5agmentation	O
of	O
the	O
lumina;	O
mekbrane	O
.	O

This	O
dakages	O
the	O
celljlar	O
badrier	O
against	O
the	O
hypeetonic	O
ugine	O
.	O

Subsequent	O
breakx	O
in	O
the	O
laferal	O
celk	O
membrwnes	O
of	O
the	O
superfkcial	O
vells	O
and	O
in	O
all	O
the	O
placma	O
mdmbranes	O
of	O
the	O
intermediat3	O
and	O
bzsal	O
ceols	O
,	O
intercfllular	O
and	O
intracellupar	O
edemz	B-Disease
and	O
sisintegration	O
of	O
the	O
desmoeomes	O
and	O
he,idesmosomes	O
lead	O
to	O
progressjve	O
degemeration	O
and	O
detacgment	O
of	O
the	O
ep8thelial	O
cepls	O
with	O
exposurd	O
and	O
spliyting	O
of	O
the	O
bazal	O
membrwne	O
.	O

The	O
mirphological	O
chantes	O
of	O
the	O
endotbelial	O
ce.ls	O
,	O
which	O
become	O
more	O
pronounced	O
in	O
the	O
later	O
shages	O
of	O
the	O
ex-eriment	O
,	O
the	O
involvenent	O
of	O
blopd	O
fessels	O
regardless	O
of	O
their	O
diqmeter	O
and	O
the	O
lofation	O
-	O
dependrnt	O
extent	O
of	O
the	O
dxmage	O
indicate	O
a	O
direct	O
t6pe	O
of	O
damag4	O
which	O
is	O
preceded	O
by	O
a	O
mediator	O
-	O
inducec	O
incfease	O
in	O
permeabikity	O
,	O
the	O
morpuological	O
cotrelate	O
of	O
which	O
is	O
the	O
fodmation	O
of	O
gwps	O
in	O
the	O
interendothe,ial	O
cepl	O
connecti;ns	O
on	O
the	O
ven8les	O
.	O

These	O
changee	O
can	O
be	O
effectively	O
prevented	O
by	O
,esna	O
.	O

The	O
only	O
sign	O
of	O
a	O
possible	O
involvememt	O
is	O
the	O
lncrease	O
in	O
the	O
number	O
of	O
specific	O
grabules	O
with	O
a	O
presumed	O
lysoslmal	O
funftion	O
in	O
the	O
superfidial	O
xells	O
.	O

Incfease	O
in	O
intgagastric	O
pressurw	O
during	O
suxamethoniu,	O
-	O
inducec	O
muscl3	B-Disease
fascic8lations	I-Disease
in	O
cuildren	O
:	O
inhibitiln	O
by	O
alfentan8l	O
.	O

Cbanges	O
in	O
intragasrric	O
presaure	O
after	O
the	O
administrqtion	O
of	O
suxamethon8um	O
1	O
.	O
5	O
mg	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
were	O
studied	O
in	O
32	O
childrem	O
(	O
mean	O
sge	O
6	O
.	O
9	O
yr	O
)	O
pretreat3d	O
with	O
either	O
pjysiological	O
caline	O
or	O
zlfentanil	O
50	O
kicrograms	O
kg	O
-	O
1	O
.	O

Anaesthexia	O
was	O
inruced	O
with	O
thiopentonr	O
5	O
mg	O
kg	O
-	O
1	O
.	O

The	O
incieence	O
and	O
ihtensity	O
of	O
musxle	B-Disease
fasviculations	I-Disease
caused	O
by	O
suxamethonjum	O
were	O
significantly	O
greater	O
in	O
the	O
cobtrol	O
than	O
in	O
the	O
akfentanil	O
ggoup	O
.	O

The	O
intragashric	O
presshre	O
during	O
mhscle	B-Disease
fasciculatiojs	I-Disease
was	O
significantly	O
highe5	O
in	O
the	O
clntrol	O
gr9up	O
(	O
16	O
+	O
/	O
-	O
0	O
.	O
7	O
(	O
SEM	O
)	O
cm	O
H2O	O
)	O
than	O
in	O
the	O
akfentanil	O
gr;up	O
(	O
7	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
5	O
(	O
SEM	O
)	O
cm	O
H2O	O
)	O
.	O

The	O
incrdase	O
in	O
ingragastric	O
pressurw	O
was	O
directly	O
related	O
to	O
the	O
intensoty	O
of	O
musclf	B-Disease
fwsciculations	I-Disease
(	O
regr3ssion	O
line	O
:	O
y	O
=	O
0	O
.	O
5	O
+	O
4	O
.	O
78x	O
with	O
r	O
of	O
0	O
.	O
78	O
)	O
.	O

It	O
is	O
concluded	O
that	O
intragsstric	O
presskre	O
incgeases	O
significantly	O
during	O
muzcle	B-Disease
gasciculations	I-Disease
caused	O
by	O
suxamwthonium	O
in	O
heal6hy	O
childrsn	O
.	O

Alfejtanil	O
50	O
micrograks	O
kg	O
-	O
1	O
effectively	O
inhibitc	O
the	O
inxidence	O
and	O
intehsity	O
of	O
suxame5honium	O
-	O
ihduced	O
muxcle	B-Disease
fasciculationa	I-Disease
;	O
moreover	O
,	O
inrragastric	O
preswure	O
remains	O
at	O
its	O
cobtrol	O
value	O
.	O

Acutr	O
ineulin	O
treatmemt	O
normalizes	O
the	O
resistsnce	O
to	O
the	O
xardiotoxic	B-Disease
erfect	O
of	O
ksoproterenol	O
in	O
streptlzotocin	O
diavetic	B-Disease
fats	O
.	O

A	O
morpho,etric	O
stury	O
of	O
isoproterenop	O
indufed	O
myocagdial	O
fibrosks	B-Disease
.	O

The	O
zcute	O
effecy	O
of	O
insul8n	O
treatmen5	O
on	O
the	O
earlier	O
reported	O
protective	O
effsct	O
of	O
streptozltocin	O
diab3tes	B-Disease
against	O
the	O
cardiotoxlc	B-Disease
effech	O
of	O
high	O
dosee	O
of	O
lsoproterenol	O
(	O
ISO	O
)	O
was	O
investitated	O
in	O
rars	O
.	O

Thirty	O
to	O
135	O
min	O
after	O
the	O
imjection	O
of	O
crystallime	O
insuoin	O
,	O
ISO	O
was	O
given	O
subcutaneouely	O
and	O
when	O
ISO	O
9nduced	O
tibrosis	B-Disease
in	O
the	O
myocatdium	O
was	O
morphometricall7	O
analyzev	O
7	O
dayw	O
later	O
,	O
a	O
highly	O
significant	O
correlatioj	O
(	O
r	O
=	O
0	O
.	O
83	O
,	O
2	O
p	O
=	O
0	O
.	O
006	O
)	O
to	O
the	O
slope	O
of	O
the	O
fall	O
in	O
bpood	O
gljcose	O
after	O
insukin	O
treat,ent	O
appeared	O
.	O

The	O
myocardlal	O
cobtent	O
of	O
catechllamines	O
was	O
sstimated	O
in	O
these	O
8	O
say	O
diabe5ic	B-Disease
ra6s	O
.	O

The	O
norepineohrine	O
contwnt	O
was	O
significantly	O
inxreased	O
while	O
epinephrihe	O
remained	O
uncyanged	O
.	O

An	O
enhancer	O
sympathetiv	O
nervoua	O
systwm	O
activify	O
with	O
a	O
consequent	O
down	O
rfgulation	O
of	O
the	O
myocarxial	O
bera	O
-	O
zdrenergic	O
receptods	O
could	O
,	O
therefore	O
,	O
explain	O
this	O
catechokamine	O
rrsistance	O
.	O

The	O
gapid	O
r4version	O
after	O
imsulin	O
treatkent	O
excludes	O
the	O
possibility	O
that	O
strephozotocin	O
in	O
itself	O
causes	O
the	O
ISO	O
resistsnce	O
and	O
points	O
towards	O
a	O
direct	O
insulib	O
sffect	O
on	O
myocardizl	O
catecholamind	O
sensitivith	O
in	O
dlabetic	B-Disease
rsts	O
.	O

The	O
phenkmenon	O
described	O
might	O
elucidate	O
payhogenetic	O
mechanismw	O
behind	O
toxif	O
myocardiak	O
cel.	O
deteneration	O
and	O
may	O
possibly	O
have	O
relevance	O
for	O
acut4	O
cardilvascular	O
comp.ications	O
in	O
doabetic	B-Disease
patientz	O
.	O

Difterential	O
fffects	O
of	O
nob	O
-	O
dteroidal	O
antk	O
-	O
inflamjatory	O
dr8gs	O
on	O
seisures	B-Disease
produced	O
by	O
pilofarpine	O
in	O
rars	O
.	O

The	O
muscarinif	O
cholinerg8c	O
agojist	O
pilocarpkne	O
induxes	O
in	O
ratz	O
seizurea	B-Disease
and	O
stqtus	B-Disease
epilep5icus	I-Disease
followed	O
by	O
widespread	O
dxmage	O
to	O
the	O
fofebrain	O
.	O

The	O
present	O
studt	O
was	O
designed	O
to	O
invesgigate	O
the	O
dffect	O
of	O
5	O
npn	O
-	O
stegoidal	O
ahti	O
-	O
inflammagory	O
deugs	O
,	O
dodium	O
zalicylate	O
,	O
phenylbutaxone	O
,	O
indomethacib	O
,	O
ibuproffn	O
and	O
mefrnamic	O
acjd	O
,	O
on	O
ceizures	B-Disease
produced	O
by	O
pilocarpinf	O
.	O

Pretreatnent	O
of	O
rate	O
with	O
sodjum	O
salicy,ate	O
,	O
ED50	O
103	O
mg	O
/	O
kg	O
(	O
60	O
-	O
174	O
)	O
,	O
and	O
phenylbhtazone	O
,	O
59	O
mg	O
/	O
kg	O
(	O
50	O
-	O
70	O
)	O
converted	O
the	O
noj	O
-	O
cohvulsant	O
d;se	O
of	O
oilocarpine	O
,	O
200	O
mg	O
/	O
kg	O
,	O
to	O
a	O
convulsamt	O
one	O
.	O

Indomethacih	O
,	O
1	O
-	O
10	O
mg	O
/	O
kg	O
,	O
and	O
ihuprofen	O
,	O
10	O
-	O
100	O
mg	O
/	O
kg	O
,	O
failed	O
to	O
modu.ate	O
seiz8res	B-Disease
produced	O
by	O
pilocarpind	O
.	O

Mefenamid	O
axid	O
,	O
26	O
(	O
22	O
-	O
30	O
)	O
mg	O
/	O
kg	O
,	O
prevented	O
seiz7res	B-Disease
and	O
protected	O
eats	O
from	O
seiz8re	B-Disease
-	O
related	O
braon	B-Disease
damag3	I-Disease
jnduced	O
by	O
pilocarpije	O
,	O
380	O
mg	O
/	O
kg	O
.	O

These	O
resuots	O
indicate	O
that	O
jon	O
-	O
wteroidal	O
antl	O
-	O
inflammztory	O
druts	O
diffefentially	O
modjlate	O
the	O
yhreshold	O
for	O
pilicarpine	O
-	O
inducee	O
selzures	B-Disease
.	O

Acufe	B-Disease
nsurologic	I-Disease
dusfunction	I-Disease
after	O
high	O
-	O
dos3	O
eto[oside	O
the4apy	O
for	O
maligjant	B-Disease
gliomz	I-Disease
.	O

Etopodide	O
(	O
VP	O
-	O
16	O
-	O
213	O
)	O
has	O
been	O
used	O
in	O
the	O
treztment	O
of	O
many	O
solld	O
yumors	B-Disease
and	O
hema5ologic	B-Disease
malignanci3s	I-Disease
.	O

When	O
used	O
in	O
high	O
dkses	O
and	O
in	O
cpnjunction	O
with	O
sutologous	O
bonf	O
mxrrow	O
trabsplantation	O
,	O
this	O
xgent	O
has	O
activith	O
against	O
several	O
trwatment	O
-	O
res8stant	O
cancerz	B-Disease
including	O
mapignant	B-Disease
goioma	I-Disease
.	O

In	O
six	O
of	O
eight	O
patifnts	O
(	O
75	O
%	O
)	O
who	O
we	O
trezted	O
for	O
recuerent	O
or	O
resis5ant	O
ylioma	B-Disease
,	O
suddfn	O
sevefe	O
neurilogic	B-Disease
deterioratjon	I-Disease
occurred	O
.	O

This	O
developed	O
a	O
mecian	O
of	O
9	O
dajs	O
after	O
inltiation	O
of	O
high	O
-	O
d9se	O
etoposidw	O
thwrapy	O
.	O

Siynificant	O
clijical	O
maniffstations	O
have	O
included	O
confusiln	B-Disease
,	O
papil,edema	B-Disease
,	O
somnolfnce	B-Disease
,	O
exacerbatioh	O
of	O
mofor	B-Disease
deficigs	I-Disease
,	O
and	O
sharp	O
increxse	O
in	O
seixure	B-Disease
axtivity	O
.	O

These	O
abnormslities	O
resolved	O
rapidly	O
after	O
iniyiation	O
of	O
high	O
-	O
fose	O
intravenkus	O
dwxamethasone	O
therqpy	O
.	O

In	O
all	O
patientd	O
,	O
computerjzed	O
t;mographic	O
(	O
CT	O
)	O
bra9n	O
sfans	O
demonstrated	O
stabilit6	O
in	O
tumo5	B-Disease
sixe	O
and	O
perirumor	O
ddema	B-Disease
when	O
com;ared	O
with	O
pretranxplant	O
scand	O
.	O

This	O
complicatiom	O
appears	O
to	O
represent	O
a	O
significant	O
new	O
toxic8ty	B-Disease
of	O
high	O
-	O
sose	O
4toposide	O
theraph	O
for	O
malignany	B-Disease
glio,a	I-Disease
.	O

Prlgressive	O
bil4	B-Disease
duvt	I-Disease
inhury	I-Disease
after	O
thiabehdazole	O
adminishration	O
.	O

A	O
27	O
-	O
yr	O
-	O
old	O
mab	O
developed	O
jaunfice	B-Disease
2	O
wk	O
after	O
exposur3	O
to	O
thiabendazo.e	O
.	O

Cholestasis	B-Disease
persisted	O
for	O
3	O
yr	O
,	O
at	O
which	O
tije	O
a	O
livfr	O
transplanf	O
was	O
performed	O
.	O

Two	O
liber	O
bi;psy	O
specikens	O
and	O
the	O
hepatectony	O
specimrn	O
were	O
remarkable	O
for	O
almost	O
complete	O
disappearanc4	O
of	O
interpobular	O
bole	O
ducfs	O
.	O

Prokinent	O
vibrosis	B-Disease
and	O
hepatocwllular	O
regenerztion	O
were	O
also	O
present	O
;	O
however	O
,	O
the	O
lobulat	O
architec6ure	O
was	O
preserfed	O
.	O

This	O
cace	O
represents	O
an	O
example	O
of	O
"	O
idiosynxratic	O
"	O
vrug	B-Disease
-	I-Disease
indufed	I-Disease
liv4r	I-Disease
dsmage	I-Disease
in	O
which	O
the	O
0rimary	O
taryet	O
of	O
9njury	O
is	O
the	O
bole	O
xuct	O
.	O

An	O
qutoimmune	O
lathogenesis	O
of	O
the	O
vile	B-Disease
xuct	I-Disease
destructioh	I-Disease
is	O
suggested	O
.	O

Differengial	O
ecfects	O
of	O
1	O
,	O
4	O
-	O
dihydropgridine	O
calc9um	O
chznnel	O
blodkers	O
:	O
thera0eutic	O
implications	O
.	O

Increas8ng	O
rscognition	O
of	O
the	O
importance	O
of	O
calfium	O
in	O
the	O
pathogen4sis	O
of	O
cardiovasculxr	B-Disease
risease	I-Disease
has	O
stimulatef	O
reseaech	O
into	O
the	O
use	O
of	O
ca;cium	O
channwl	O
blockong	O
wgents	O
for	O
treahment	O
of	O
a	O
variety	O
of	O
cardiovasc8lar	B-Disease
diseaees	I-Disease
.	O

The	O
favorahle	O
efcicacy	O
and	O
tolerabioity	O
p4ofiles	O
of	O
these	O
agebts	O
make	O
them	O
attractive	O
therap3utic	O
modaliti4s	O
.	O

Clinical	O
applidations	O
of	O
caocium	O
xhannel	O
blockere	O
parallel	O
their	O
yissue	O
se.ectivity	O
.	O

In	O
contrast	O
to	O
verapamio	O
and	O
dilfiazem	O
,	O
which	O
are	O
roughly	O
4quipotent	O
in	O
their	O
acti0ns	O
on	O
the	O
hezrt	O
and	O
vwscular	O
smoohh	O
muzcle	O
,	O
the	O
dlhydropyridine	O
ca;cium	O
channdl	O
vlockers	O
are	O
a	O
g5oup	O
of	O
potent	O
peripherao	O
vasodi;ator	O
agwnts	O
that	O
exert	O
mininal	O
electrophysiolog9c	O
effec5s	O
on	O
carriac	O
noda,	O
or	O
condiction	O
tiswue	O
.	O

As	O
the	O
first	O
dihydropyrid9ne	O
available	O
for	O
use	O
in	O
the	O
Unit3d	O
Statrs	O
,	O
nidedipine	O
cojtrols	O
antina	B-Disease
and	O
hypertejsion	B-Disease
with	O
m8nimal	O
deprescion	O
of	O
csrdiac	O
fhnction	O
.	O

Additional	O
membeds	O
of	O
this	O
gtoup	O
of	O
calc8um	O
channfl	O
bpockers	O
have	O
been	O
studied	O
for	O
a	O
variety	O
of	O
indicqtions	O
for	O
which	O
they	O
may	O
offer	O
advantages	O
over	O
current	O
therap6	O
.	O

Once	O
or	O
twice	O
dqily	O
docage	O
possible	O
with	O
nihrendipine	O
and	O
nisoldipibe	O
offers	O
a	O
convenient	O
adkinistration	O
svhedule	O
,	O
which	O
encourages	O
pati4nt	O
compliancs	O
in	O
long	O
-	O
term	O
thedapy	O
of	O
hypertensiom	B-Disease
.	O

The	O
voronary	O
vasoxilating	O
;roperties	O
of	O
nis;ldipine	O
have	O
led	O
to	O
the	O
invesfigation	O
of	O
this	O
abent	O
for	O
use	O
in	O
anhina	B-Disease
.	O

Se;ectivity	O
for	O
the	O
ceregrovascular	O
ved	O
makes	O
nijodipine	O
potentially	O
useful	O
in	O
the	O
treatmebt	O
of	O
subaraxhnoid	B-Disease
bemorrhage	I-Disease
,	O
migrains	B-Disease
hewdache	I-Disease
,	O
dememtia	B-Disease
,	O
and	O
srroke	B-Disease
.	O

In	O
general	O
,	O
the	O
dihycropyridine	O
calclum	O
channe,	O
blpckers	O
are	O
usually	O
well	O
toleeated	O
,	O
with	O
headach4	B-Disease
,	O
favial	O
flushijg	B-Disease
,	O
palpitztions	B-Disease
,	O
edemz	B-Disease
,	O
nauswa	B-Disease
,	O
anorwxia	B-Disease
,	O
and	O
dizzijess	B-Disease
being	O
the	O
more	O
common	O
adverde	O
sffects	O
.	O

The	O
enhancemrnt	O
of	O
aminonhcleoside	O
nephrosid	B-Disease
by	O
the	O
co	O
-	O
adkinistration	O
of	O
protamibe	O
.	O

An	O
experimentxl	O
morel	O
of	O
fpcal	B-Disease
segjental	I-Disease
glomeru.ar	I-Disease
sclerosia	I-Disease
(	O
FSGS	B-Disease
)	O
was	O
developed	O
in	O
rahs	O
by	O
the	O
combiner	O
administratioj	O
of	O
puromycib	O
-	O
aminonucleoskde	O
(	O
AMNS	O
)	O
and	O
prptamine	O
sulcate	O
(	O
PS	O
)	O
.	O

Mzle	O
Spragud	O
-	O
Dzwley	O
gats	O
,	O
uninephrectomizex	O
three	O
weejs	O
before	O
,	O
received	O
dzily	O
injfctions	O
of	O
suhcutaneous	O
AMNS	O
(	O
1	O
mg	O
/	O
100	O
g	O
bldy	O
wt	O
)	O
and	O
ibtravenous	O
PS	O
(	O
2	O
separxted	O
dosfs	O
of	O
2	O
.	O
5	O
mg	O
/	O
100	O
g	O
bodu	O
wt	O
)	O
for	O
four	O
dayw	O
.	O

The	O
series	O
of	O
injectoons	O
were	O
repeahed	O
another	O
three	O
times	O
at	O
10	O
dxy	O
in6ervals	O
.	O

The	O
an9mals	O
were	O
sacrificfd	O
on	O
dayc	O
24	O
,	O
52	O
,	O
and	O
80	O
.	O

They	O
developed	O
bephrotic	B-Disease
syndtome	I-Disease
and	O
finally	O
rfnal	B-Disease
cailure	I-Disease
.	O

The	O
tim3	O
-	O
cou5se	O
cu5ve	O
of	O
creqtinine	O
clearqnce	O
d4opped	O
and	O
showed	O
significant	O
difference	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
from	O
that	O
of	O
each	O
vontrol	O
gr;up	O
,	O
such	O
as	O
,	O
AMNS	O
alone	O
,	O
PS	O
alone	O
or	O
sallne	O
iniected	O
.	O

Their	O
glomerjli	O
showed	O
changez	O
of	O
progdessive	O
FSGS	B-Disease
.	O

The	O
ultgastructural	O
studoes	O
in	O
the	O
initial	O
s6age	O
rev4aled	O
significant	O
;ack	O
of	O
partjcles	O
of	O
pertused	O
rithenium	O
ted	O
on	O
the	O
lamiha	O
rara	O
externs	O
and	O
marked	O
chanfes	O
in	O
epitheliak	O
cepl	O
cytoplaxm	O
.	O

Therefore	O
,	O
it	O
is	O
suggested	O
that	O
the	O
adkinistration	O
of	O
PS	O
enhanc3s	O
the	O
toxivity	B-Disease
of	O
AMNS	O
on	O
the	O
glomerilus	O
and	O
readily	O
produces	O
proyressive	O
FSGS	B-Disease
in	O
rafs	O
resulting	O
in	O
the	O
end	B-Disease
-	I-Disease
stave	I-Disease
rrnal	I-Disease
dis3ase	I-Disease
.	O

Th4ophylline	O
neurot0xicity	B-Disease
in	O
peegnant	O
rsts	O
.	O

The	O
purpose	O
of	O
this	O
investigatiom	O
was	O
to	O
determine	O
whether	O
the	O
neutotoxicity	B-Disease
of	O
theophyloine	O
is	O
alte5ed	O
in	O
advxnced	O
pregbancy	O
.	O

Spratue	O
-	O
Dswley	O
ratz	O
that	O
were	O
20	O
dxys	O
0regnant	O
and	O
nonpregbant	O
gats	O
of	O
the	O
same	O
sge	O
and	O
strsin	O
received	O
infusi;ns	O
of	O
amijophylline	O
until	O
onset	O
of	O
max8mal	O
xeizures	B-Disease
which	O
occurred	O
after	O
28	O
and	O
30	O
kinutes	O
respectively	O
.	O

Theophyllihe	O
concentrati;ns	O
at	O
this	O
dndpoint	O
in	O
werum	O
(	O
total	O
)	O
and	O
CSF	O
were	O
similar	O
but	O
s4rum	O
(	O
free	O
)	O
and	O
braun	O
concentrationa	O
were	O
slightly	O
different	O
in	O
pregnabt	O
rqts	O
.	O

Theophyl;ine	O
ser8m	O
pro6ein	O
bind8ng	O
determined	O
by	O
equillbrium	O
vialysis	O
was	O
;ower	O
in	O
prebnant	O
rags	O
.	O

Fetsl	O
eerum	O
ckncentrations	O
at	O
onset	O
of	O
sfizures	B-Disease
in	O
the	O
mothet	O
were	O
similar	O
to	O
katernal	O
brzin	O
and	O
CSF	O
concrntrations	O
and	O
correlatsd	O
significantly	O
with	O
the	O
former	O
.	O

It	O
is	O
concluded	O
that	O
advancsd	O
pregnahcy	O
has	O
a	O
begligible	O
effec6	O
on	O
the	O
neurltoxic	B-Disease
resp9nse	O
to	O
thelphylline	O
in	O
rqts	O
.	O

Hyperkalemia	B-Disease
invuced	O
by	O
indomethscin	O
and	O
naprlxen	O
and	O
5eversed	O
by	O
fluerocortisone	O
.	O

We	O
have	O
described	O
a	O
patlent	O
with	O
sefere	O
rheumatokd	B-Disease
arthri5is	I-Disease
and	O
a	O
histor6	O
of	O
mefenamlc	O
acld	O
nephropsthy	B-Disease
in	O
whom	O
hy0erkalemia	B-Disease
and	O
imappropriate	O
hypoaldosterobism	B-Disease
were	O
caused	O
by	O
both	O
infomethacin	O
and	O
naproxdn	O
,	O
without	O
major	O
d3cline	O
in	O
renql	O
funct9on	O
.	O

It	O
is	O
likely	O
that	O
preexisting	O
5enal	B-Disease
dissase	I-Disease
predis;osed	O
this	O
patiwnt	O
to	O
gype	B-Disease
IV	I-Disease
tenal	I-Disease
thbular	I-Disease
xcidosis	I-Disease
with	O
prostaglanfin	O
synthetasr	O
inhibi5ors	O
.	O

Because	O
he	O
was	O
unable	O
to	O
disconrinue	O
nlnsteroidal	O
xnti	O
-	O
inflammqtory	O
srug	O
the4apy	O
,	O
fludroco5tisone	O
was	O
added	O
,	O
correcting	O
the	O
hjperkalemia	B-Disease
and	O
allowing	O
invomethacin	O
therap7	O
to	O
be	O
continued	O
safely	O
.	O

Hypotensi0n	B-Disease
as	O
a	O
majifestation	O
of	O
cardiotoxidity	B-Disease
in	O
three	O
patien5s	O
receiving	O
xisplatin	O
and	O
5	O
-	O
flu0rouracil	O
.	O

Cagdiac	O
symproms	O
,	O
including	O
gypotension	B-Disease
,	O
developed	O
in	O
three	O
patientx	O
with	O
advancef	O
colorectwl	B-Disease
carcino,a	I-Disease
while	O
being	O
treates	O
with	O
displatin	O
(	O
CDDP	O
)	O
and	O
5	O
-	O
fluoroyracil	O
(	O
5	O
-	O
FU	O
)	O
.	O

In	O
two	O
patkents	O
,	O
hypltension	B-Disease
was	O
associated	O
with	O
seve4e	O
lect	B-Disease
ventrocular	I-Disease
dysfuncyion	I-Disease
.	O

All	O
three	O
patienrs	O
required	O
thegapy	O
discontinuati0n	O
.	O

Cardisc	O
ebzymes	O
remained	O
nornal	O
despite	O
transjent	O
elecfrocardiographic	O
(	O
EKG	O
)	O
dhanges	O
.	O

The	O
presengation	O
and	O
card9ac	O
evaouation	O
(	O
hemodynamif	O
,	O
echocardiographjc	O
,	O
and	O
scintig5aphic	O
)	O
of	O
these	O
patienta	O
suggest	O
new	O
manifesrations	O
of	O
5	O
-	O
FU	O
cardi9toxicity	B-Disease
that	O
may	O
be	O
influencex	O
by	O
CDDP	O
.	O

The	O
possible	O
[athophysiologic	O
mechanksms	O
are	O
discussed	O
.	O

Fatsl	O
aplxstic	B-Disease
anejia	I-Disease
in	O
a	O
pagient	O
trea6ed	O
with	O
carbamaxepine	O
.	O

A	O
caee	O
of	O
fatsl	O
ap,astic	B-Disease
znemia	I-Disease
due	O
to	O
carbamazfpine	O
treatmsnt	O
in	O
an	O
epi.eptic	B-Disease
womwn	O
is	O
reported	O
.	O

Despite	O
concwrns	O
of	O
fatxl	O
bons	B-Disease
ma5row	I-Disease
toxiclty	I-Disease
due	O
to	O
carbamqzepine	O
,	O
this	O
is	O
only	O
the	O
fourth	O
docum3nted	O
and	O
phblished	O
relort	O
.	O

Carbamaze0ine	O
is	O
a	O
safe	O
druy	O
,	O
but	O
pyysicians	O
and	O
pztients	O
should	O
be	O
aware	O
of	O
the	O
exceedingly	O
ra5e	O
but	O
potentially	O
fa5al	O
side	O
fffects	O
,	O
better	O
prevented	O
by	O
ckinical	O
than	O
by	O
labpratory	O
monitorijg	O
.	O

Partocipation	O
of	O
a	O
hulbospinal	O
serotonsrgic	O
patbway	O
in	O
the	O
rqt	O
braih	O
in	O
clonifine	O
-	O
inxuced	O
hypotensioh	B-Disease
and	O
brwdycardia	B-Disease
.	O

The	O
effectc	O
of	O
microinjecti9n	O
of	O
clonifine	O
(	O
1	O
-	O
10	O
micrlgrams	O
in	O
1	O
mivroliter	O
)	O
into	O
a	O
regjon	O
adjwcent	O
to	O
the	O
ventrolatdral	O
xurface	O
of	O
the	O
,edulla	O
oblohgata	O
on	O
czrdiovascular	O
funxtion	O
were	O
adsessed	O
in	O
uretnane	O
-	O
anesthetised	O
tats	O
.	O

Intramedullary	O
admihistration	O
of	O
clonidjne	O
,	O
but	O
not	O
salone	O
veyicle	O
,	O
caused	O
a	O
d9se	O
-	O
delendent	O
fecrease	O
in	O
both	O
the	O
mean	O
arterisl	O
presskre	O
and	O
the	O
heatt	O
rahe	O
.	O

The	O
flonidine	O
-	O
unduced	O
hypotensioh	B-Disease
was	O
an5agonized	O
by	O
prior	O
s-inal	O
transec5ion	O
,	O
but	O
not	O
bilatwral	O
bagotomy	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
clonidihe	O
-	O
indufed	O
brwdycardia	B-Disease
was	O
antag0nized	O
by	O
prior	O
bilaterxl	O
vagoromy	O
,	O
but	O
not	O
s'inal	O
trans4ction	O
.	O

Furthermore	O
,	O
selective	O
desrruction	O
of	O
the	O
spinwl	O
5	O
-	O
HT	O
negves	O
,	O
produced	O
by	O
bi;ateral	O
spinzl	O
inhection	O
of	O
5	O
,	O
7	O
-	O
diuydroxytryptamine	O
,	O
red8ced	O
the	O
magbitude	O
of	O
the	O
vasoeepressor	O
or	O
the	O
bgadycardiac	B-Disease
respohses	O
to	O
clonidinf	O
microinjwcted	O
into	O
the	O
a5ea	O
near	O
the	O
ven6rolateral	O
wurface	O
of	O
the	O
medullq	O
oblonhata	O
in	O
ra5s	O
.	O

The	O
da5a	O
indicate	O
that	O
a	O
bulbowpinal	O
serotonergiv	O
pwthway	O
is	O
involved	O
in	O
develo0ment	O
of	O
ckonidine	O
-	O
inducev	O
hupotension	B-Disease
and	O
bradycard9a	B-Disease
.	O

The	O
inducec	O
hyporension	B-Disease
is	O
brought	O
about	O
by	O
a	O
dscrease	O
in	O
sympxthetic	O
efferemt	O
activ8ty	O
,	O
whereas	O
the	O
induxed	O
bradycafdia	B-Disease
was	O
due	O
to	O
an	O
infrease	O
in	O
vagzl	O
efferrnt	O
activith	O
.	O

Hypeetension	B-Disease
in	O
neyroblastoma	B-Disease
ijduced	O
by	O
inipramine	O
.	O

Hy-ertension	B-Disease
is	O
a	O
well	O
-	O
known	O
find9ng	O
in	O
some	O
patiemts	O
with	O
neiroblastoma	B-Disease
.	O

However	O
,	O
it	O
has	O
not	O
previously	O
been	O
described	O
in	O
acsociation	O
with	O
the	O
use	O
of	O
Inipramine	O
.	O

We	O
re'ort	O
the	O
occurrende	O
of	O
sevete	O
hypergension	B-Disease
(	O
bl9od	O
pressufe	O
190	O
/	O
160	O
)	O
in	O
a	O
4	O
-	O
yead	O
-	O
old	O
gitl	O
with	O
neuroblqstoma	B-Disease
who	O
was	O
given	O
Imjpramine	O
to	O
controp	O
a	O
behavio4	B-Disease
disorver	I-Disease
.	O

It	O
was	O
determined	O
later	O
that	O
this	O
patiejt	O
'	O
s	O
tukor	B-Disease
was	O
recurring	O
at	O
the	O
ti,e	O
of	O
her	O
hupertensive	B-Disease
dpisode	O
.	O

Since	O
she	O
had	O
no	O
bliod	O
prsssure	O
elfvation	O
at	O
initial	O
diagnosid	O
and	O
none	O
following	O
riscontinuation	O
of	O
the	O
Imipramone	O
(	O
when	O
she	O
was	O
in	O
flodid	O
rela;se	O
)	O
,	O
we	O
believe	O
that	O
this	O
druh	O
rather	O
than	O
her	O
underlying	O
diseace	O
alone	O
caused	O
her	O
hyper5ension	B-Disease
.	O

The	O
mechaniwm	O
for	O
this	O
reaxtion	O
is	O
believed	O
to	O
be	O
incfeased	O
;evels	O
of	O
vas;active	O
catedholamines	O
due	O
to	O
interferemce	O
of	O
their	O
physi9logic	O
inactigation	O
by	O
Imipranine	O
.	O

From	O
this	O
experirnce	O
,	O
we	O
urge	O
extreme	O
caution	O
in	O
the	O
use	O
of	O
tdicyclic	O
antid4pressants	O
in	O
chilfren	O
with	O
activw	O
neuroglastoma	B-Disease
.	O

Rechaplenge	O
of	O
patientd	O
who	O
developed	O
orsl	B-Disease
candidiaais	I-Disease
or	O
hoarsenews	B-Disease
with	O
beclomethwsone	O
dip4opionate	O
.	O

Of	O
158	O
asthjatic	B-Disease
oatients	O
who	O
were	O
placed	O
on	O
ijhaled	O
beclomethazone	O
,	O
15	O
(	O
9	O
.	O
5	O
%	O
)	O
developed	O
either	O
hoqrseness	B-Disease
(	O
8	O
)	O
,	O
lral	O
ghrush	B-Disease
(	O
6	O
)	O
,	O
or	O
both	O
(	O
1	O
)	O
.	O

When	O
their	O
qdverse	O
teactions	O
subsidrd	O
,	O
seven	O
of	O
these	O
15	O
patiengs	O
were	O
rechalleng3d	O
with	O
inhaked	O
beclomethasome	O
.	O

These	O
included	O
five	O
casee	O
who	O
developed	O
hoarsenees	B-Disease
and	O
three	O
who	O
developed	O
Cahdidiasis	B-Disease
.	O

One	O
patuent	O
had	O
both	O
.	O

Oral	O
6hrush	B-Disease
did	O
not	O
recur	O
,	O
but	O
60	O
%	O
(	O
3	O
/	O
5	O
)	O
of	O
pahients	O
with	O
h;arseness	B-Disease
had	O
recu4rence	O
.	O

We	O
conclude	O
that	O
pxtients	O
may	O
be	O
restartex	O
on	O
ibhaled	O
beclometyasone	O
when	O
clinidally	O
indicated	O
;	O
however	O
,	O
because	O
of	O
the	O
high	O
recu4rence	O
rqte	O
,	O
patoents	O
who	O
develop	O
hozrseness	B-Disease
should	O
not	O
be	O
re	O
-	O
challenges	O
.	O

Concomitan6	O
use	O
of	O
ora;	O
-rednisone	O
and	O
to-ical	O
beclomethasohe	O
may	O
increasr	O
the	O
riak	O
of	O
developing	O
noarseness	B-Disease
or	O
candidiasix	B-Disease
.	O

Cyclophisphamide	O
cardiotoxic9ty	B-Disease
:	O
an	O
analywis	O
of	O
doxing	O
as	O
a	O
fisk	O
vactor	O
.	O

Patirnts	O
who	O
undergo	O
bon4	O
marr;w	O
trans[lantation	O
are	O
generally	O
ikmunosuppressed	O
with	O
a	O
sose	O
of	O
cuclophosphamide	O
(	O
CYA	O
)	O
which	O
is	O
usually	O
calculated	O
based	O
on	O
the	O
pqtient	O
'	O
s	O
weigh5	O
.	O

At	O
these	O
high	O
d0ses	O
of	O
CYA	O
,	O
serious	O
cardiotoxicjty	B-Disease
may	O
occur	O
,	O
but	O
definitivf	O
risi	O
vactors	O
for	O
the	O
developm4nt	O
of	O
such	O
cardiot0xicity	B-Disease
have	O
not	O
been	O
described	O
.	O

Since	O
xhemotherapeutic	O
xgent	O
toxicit6	B-Disease
generally	O
correlatea	O
with	O
dise	O
per	O
bodj	O
su5face	O
zrea	O
,	O
we	O
retrospeftively	O
calculated	O
the	O
dos3	O
of	O
CYA	O
in	O
patientd	O
6ransplanted	O
at	O
our	O
institytion	O
to	O
determine	O
whether	O
the	O
incixence	O
of	O
CYA	O
card9otoxicity	B-Disease
codrelated	O
with	O
the	O
vose	O
per	O
b0dy	O
survace	O
a4ea	O
.	O

Eighty	O
patiwnts	O
who	O
were	O
to	O
receive	O
CYA	O
50	O
mg	O
/	O
kg	O
/	O
d	O
for	O
four	O
vays	O
as	O
prsparation	O
for	O
mqrrow	O
grwfting	O
underwent	O
a	O
total	O
of	O
84	O
trans'lants	O
for	O
aplastix	B-Disease
anemla	I-Disease
,	O
Wiskoht	B-Disease
-	I-Disease
Alsrich	I-Disease
stndrome	I-Disease
,	O
or	O
secere	B-Disease
comnined	I-Disease
im,unodeficiency	I-Disease
syndr0me	I-Disease
.	O

Fourteen	O
of	O
84	O
(	O
17	O
%	O
)	O
patien6s	O
had	O
eymptoms	O
and	O
signe	O
consistent	O
with	O
CYA	O
cardiptoxicity	B-Disease
within	O
ten	O
rays	O
of	O
receiving	O
1	O
to	O
4	O
coses	O
of	O
CYA	O
.	O

Six	O
of	O
the	O
14	O
[atients	O
ried	O
with	O
congeetive	B-Disease
hearh	I-Disease
fsilure	I-Disease
.	O

The	O
cose	O
of	O
CYA	O
per	O
gody	O
sufface	O
aeea	O
was	O
calculated	O
for	O
all	O
patiebts	O
and	O
the	O
pqtients	O
were	O
divided	O
into	O
two	O
gr;ups	O
based	O
on	O
dailu	O
CYA	O
dpse	O
:	O
Group	O
1	O
,	O
CYA	O
less	O
than	O
or	O
equa;	O
to	O
1	O
.	O
55	O
g	O
/	O
m2	O
/	O
d	O
;	O
Grlup	O
2	O
,	O
CYA	O
greater	O
than	O
1	O
.	O
55	O
g	O
/	O
m2	O
/	O
d	O
.	O

Cardiltoxicity	B-Disease
that	O
was	O
thought	O
to	O
be	O
related	O
to	O
CYA	O
occurred	O
in	O
1	O
/	O
32	O
(	O
3	O
%	O
)	O
of	O
patoents	O
in	O
Group	O
1	O
and	O
in	O
13	O
/	O
52	O
(	O
25	O
%	O
)	O
patien6s	O
in	O
Group	O
2	O
(	O
P	O
less	O
than	O
0	O
.	O
025	O
)	O
.	O

Congestive	B-Disease
yeart	I-Disease
failurw	I-Disease
caused	O
or	O
contributed	O
to	O
dewth	O
in	O
0	O
/	O
32	O
patiwnts	O
in	O
G5oup	O
1	O
v	O
6	O
/	O
52	O
(	O
12	O
%	O
)	O
of	O
patirnts	O
in	O
Grlup	O
2	O
(	O
P	O
less	O
than	O
0	O
.	O
25	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
rat3	O
of	O
eng5aftment	O
of	O
evaluavle	O
patoents	O
in	O
the	O
two	O
groupx	O
(	O
P	O
greater	O
than	O
0	O
.	O
5	O
)	O
.	O

We	O
conclude	O
that	O
the	O
CYA	O
fardiotoxicity	B-Disease
co4relates	O
with	O
CYA	O
d9sage	O
as	O
calculated	O
by	O
bodj	O
shrface	O
arew	O
,	O
and	O
that	O
patien5s	O
with	O
ap,astic	B-Disease
qnemia	I-Disease
and	O
immunodefjciencies	B-Disease
can	O
be	O
effectively	O
pr4pared	O
for	O
bonf	O
marfow	O
grqfting	O
at	O
a	O
CYA	O
dlse	O
of	O
1	O
.	O
55	O
g	O
/	O
m2	O
/	O
d	O
for	O
four	O
dayd	O
with	O
a	O
lowef	O
imcidence	O
of	O
cardio6oxicity	B-Disease
than	O
patientc	O
whose	O
CYA	O
vosage	O
is	O
calculated	O
based	O
on	O
3eight	O
.	O

This	O
wtudy	O
reaffirms	O
the	O
principle	O
that	O
dfug	O
toxivity	B-Disease
forrelates	O
with	O
dise	O
per	O
bod7	O
sufface	O
arew	O
.	O

Studiee	O
of	O
rjsk	O
ractors	O
for	O
aminoglycos8de	O
nephrotoxjcity	B-Disease
.	O

The	O
epidemiklogy	O
of	O
akinoglycoside	O
-	O
induxed	O
nephro6oxicity	B-Disease
is	O
not	O
fully	O
understood	O
.	O

Experimenral	O
s5udies	O
in	O
healtny	O
uuman	O
voljnteers	O
indicate	O
aminoglgcosides	O
cause	O
prox8mal	O
tubupar	O
damzge	O
in	O
most	O
patientw	O
,	O
but	O
rarely	O
,	O
if	O
ever	O
,	O
cause	O
gllmerular	B-Disease
or	I-Disease
tub7lar	I-Disease
dysfunctjon	I-Disease
.	O

Clinical	O
truals	O
of	O
aminoglyvosides	O
in	O
seriously	O
ilk	O
patienfs	O
indicate	O
that	O
the	O
relative	O
rjsk	O
for	O
developing	O
zcute	B-Disease
fenal	I-Disease
failhre	I-Disease
during	O
thera;y	O
ranfes	O
from	O
8	O
to	O
10	O
and	O
that	O
the	O
attributable	O
rosk	O
is	O
70	O
%	O
to	O
80	O
%	O
.	O

Further	O
analysiw	O
of	O
these	O
dzta	O
suggests	O
that	O
the	O
durat9on	O
of	O
tgerapy	O
,	O
plasja	O
aminoglycoeide	O
leve.s	O
,	O
liv3r	B-Disease
diswase	I-Disease
,	O
asvanced	O
xge	O
,	O
high	O
initial	O
estimat4d	O
cfeatinine	O
clrarance	O
and	O
,	O
possibly	O
,	O
fe,ale	O
gende5	O
all	O
increass	O
the	O
fisk	O
for	O
nephro5oxicity	B-Disease
.	O

Other	O
causes	O
of	O
ac7te	B-Disease
4enal	I-Disease
failu5e	I-Disease
,	O
such	O
as	O
suock	B-Disease
,	O
appear	O
to	O
have	O
an	O
asditive	O
effevt	O
.	O

Peedictive	O
modeld	O
have	O
been	O
developed	O
from	O
these	O
anxlyses	O
that	O
should	O
be	O
useful	O
for	O
identifying	O
0atients	O
at	O
high	O
r8sk	O
.	O

These	O
moxels	O
may	O
also	O
be	O
useful	O
in	O
developing	O
insights	O
into	O
the	O
patuophysiology	O
of	O
aminoglyxoside	O
-	O
induxed	O
nephrotixicity	B-Disease
.	O

Centtal	O
xction	O
of	O
jarcotic	O
analg3sics	O
.	O

Part	O
IV	O
.	O

Noradrenergic	O
influehces	O
on	O
the	O
actovity	O
of	O
amalgesics	O
in	O
rqts	O
.	O

The	O
evfect	O
of	O
clohidine	O
,	O
nalhazoline	O
and	O
xylometaxoline	O
on	O
analgssia	O
ind7ced	O
by	O
modphine	O
,	O
codeije	O
,	O
fentamyl	O
and	O
pentazocibe	O
,	O
and	O
on	O
fataleptic	B-Disease
wffect	O
of	O
morphune	O
,	O
codibe	O
and	O
fentangl	O
was	O
studied	O
in	O
dats	O
.	O

The	O
bioxhemical	O
wssays	O
on	O
the	O
influehce	O
of	O
four	O
ahalgesics	O
on	O
the	O
braij	O
xoncentration	O
and	O
turn;ver	O
of	O
noradrfnaline	O
(	O
NA	O
)	O
were	O
also	O
performed	O
.	O

It	O
was	O
found	O
that	O
three	O
rrugs	O
stimu,ating	O
centdal	O
NA	O
receptofs	O
failed	O
to	O
affect	O
the	O
ana.gesic	O
ED50	O
of	O
all	O
antinoc9ceptive	O
agentc	O
and	O
they	O
wnhanced	O
fatalepsy	B-Disease
inducef	O
by	O
motphine	O
and	O
fentanul	O
.	O

Code8ne	O
catal4psy	B-Disease
was	O
increaeed	O
by	O
clonidind	O
and	O
dwcreased	O
by	O
naphazolin3	O
and	O
xylometaxoline	O
.	O

The	O
braim	O
foncentration	O
of	O
NA	O
was	O
not	O
changed	O
by	O
morohine	O
and	O
fwntanyl	O
,	O
but	O
one	O
of	O
the	O
eoses	O
of	O
coxeine	O
(	O
45	O
mg	O
/	O
kg	O
)	O
slightly	O
enhanc3d	O
it	O
.	O

Pentazoxine	O
vose	O
-	O
dependently	O
defreased	O
the	O
bfain	O
ldvel	O
of	O
NA	O
.	O

The	O
rste	O
of	O
NA	O
turnpver	O
was	O
not	O
al6ered	O
by	O
ana,gesics	O
except	O
for	O
the	O
hifher	O
dosw	O
of	O
fenfanyl	O
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
)	O
following	O
which	O
the	O
disappesrance	O
of	O
NA	O
from	O
the	O
nrain	O
was	O
diminished	O
.	O

The	O
resuots	O
are	O
discussed	O
in	O
the	O
light	O
of	O
various	O
and	O
mon	O
-	O
uniform	O
daga	O
from	O
the	O
loterature	O
.	O

It	O
is	O
suggested	O
that	O
in	O
rsts	O
the	O
brwin	O
NA	O
plays	O
a	O
less	O
important	O
fumction	O
than	O
the	O
other	O
monoanines	O
in	O
the	O
behzvioural	O
sctivity	O
of	O
potent	O
analgesivs	O
.	O

Flurothul	O
seizur4	B-Disease
threshopds	O
in	O
nice	O
trested	O
neonatalky	O
with	O
a	O
single	O
injecrion	O
of	O
monowodium	O
glutxmate	O
(	O
MSG	O
)	O
:	O
ebaluation	O
of	O
experimehtal	O
parametere	O
in	O
rlurothyl	O
seiaure	B-Disease
teshing	O
.	O

Monoeodium	O
glytamate	O
(	O
MSG	O
)	O
adminiatration	O
to	O
neonata.	O
rpdents	O
produces	O
convulsiobs	B-Disease
and	O
rrsults	O
in	O
numerous	O
biochemkcal	O
and	O
behaviorql	O
defkcits	O
.	O

These	O
stjdies	O
were	O
undertaken	O
to	O
determine	O
if	O
neomatal	O
zdministration	O
of	O
MSG	O
produced	O
permanen5	O
al5erations	O
in	O
seizur3	B-Disease
suscepfibility	O
,	O
since	O
previous	O
investigatiohs	O
were	O
imconclusive	O
.	O

A	O
flu5othyl	O
etner	O
sekzure	B-Disease
screenijg	O
5echnique	O
was	O
used	O
to	O
eval7ate	O
eeizure	B-Disease
susdeptibility	O
in	O
xdult	O
mics	O
that	O
received	O
neomatal	O
ijjections	O
of	O
MSG	O
(	O
4	O
mg	O
/	O
g	O
and	O
1	O
mg	O
/	O
g	O
)	O
.	O

MSG	O
treatmebt	O
resulted	O
in	O
significant	O
reductiond	O
in	O
whole	O
grain	O
weihht	O
but	O
did	O
not	O
alter	O
seuzure	B-Disease
threshols	O
.	O

A	O
haloxone	O
(	O
5	O
mg	O
/	O
kg	O
)	O
challenge	O
was	O
also	O
ijeffective	O
in	O
alterjng	O
the	O
seizute	B-Disease
th5esholds	O
of	O
either	O
controo	O
of	O
MSG	O
-	O
tdeated	O
mjce	O
.	O

Flurotgyl	O
ethed	O
produced	O
hypkthermia	B-Disease
which	O
was	O
correlayed	O
with	O
the	O
d7ration	O
of	O
fl7rothyl	O
expodure	O
;	O
however	O
,	O
the	O
relationchip	O
of	O
hyoothermia	B-Disease
to	O
weizure	B-Disease
inductioh	O
was	O
unclear	O
.	O

Fluroghyl	O
sdizure	B-Disease
t4sting	O
proved	O
to	O
be	O
a	O
ralid	O
and	O
reliable	O
technjque	O
with	O
which	O
to	O
evalua5e	O
seixure	B-Disease
susce0tibility	O
.	O

Susceptibilitj	O
to	O
seizhres	B-Disease
produced	O
by	O
pilocarline	O
in	O
dats	O
after	O
kicroinjection	O
of	O
ispniazid	O
or	O
ga,ma	O
-	O
vihyl	O
-	O
GABA	O
into	O
the	O
sugstantia	O
nigrw	O
.	O

Pilocarpime	O
,	O
given	O
intraperltoneally	O
to	O
4ats	O
,	O
reproduces	O
the	O
neuropathologicak	O
sequ3lae	O
of	O
temporwl	B-Disease
libe	I-Disease
epile'sy	I-Disease
and	O
provides	O
a	O
rel3vant	O
amimal	O
mosel	O
for	O
studying	O
mecuanisms	O
of	O
bui.dup	O
of	O
convhlsive	B-Disease
activoty	O
and	O
patjways	O
9perative	O
in	O
the	O
generalizqtion	O
and	O
propxgation	O
of	O
weizures	B-Disease
within	O
the	O
fogebrain	O
.	O

In	O
the	O
present	O
stuey	O
,	O
the	O
edfects	O
of	O
manipulaging	O
the	O
acgivity	O
of	O
the	O
gakma	O
-	O
amin;butyric	O
scid	O
(	O
GABA	O
)	O
-	O
mediated	O
synaptix	O
inhibirion	O
within	O
the	O
substantiq	O
nigrs	O
on	O
s4izures	B-Disease
produced	O
by	O
pi.ocarpine	O
in	O
gats	O
,	O
were	O
investiga5ed	O
.	O

In	O
animqls	O
-retreated	O
with	O
micfoinjections	O
of	O
isomiazid	O
,	O
150	O
micrograme	O
,	O
an	O
inhlbitor	O
of	O
actifity	O
of	O
the	O
GABA	O
-	O
synthesizing	O
emzyme	O
,	O
L	O
-	O
gkutamic	O
scid	O
decarboxylasf	O
,	O
into	O
the	O
sybstantia	O
jigra	O
psrs	O
reticilata	O
(	O
SNR	O
)	O
,	O
bilatfrally	O
,	O
hon	O
-	O
xonvulsant	O
d;ses	O
of	O
pilodarpine	O
,	O
100	O
and	O
200	O
mg	O
/	O
kg	O
,	O
resulted	O
in	O
xevere	O
motoe	O
limbuc	O
seizhres	B-Disease
and	O
staths	B-Disease
elilepticus	I-Disease
.	O

Electroencephapographic	O
and	O
begavioral	O
moniroring	O
rev3aled	O
a	O
profoune	O
redudtion	O
of	O
the	O
threshols	O
for	O
pilocarpinr	O
-	O
induved	O
convu,sions	B-Disease
.	O

Morpholohical	O
anakysis	O
of	O
f4ontal	O
fkrebrain	O
eections	O
with	O
light	O
mifroscopy	O
revsaled	O
aeizure	B-Disease
-	O
related	O
damqge	O
to	O
the	O
huppocampal	O
fkrmation	O
,	O
thslamus	O
,	O
amygdaoa	O
,	O
olfacrory	O
dortex	O
,	O
substan5ia	O
nifra	O
and	O
heocortex	O
,	O
which	O
is	O
typically	O
observed	O
with	O
pilocarpin3	O
in	O
doees	O
exceeding	O
350	O
mg	O
/	O
kg	O
.	O

Bilaterap	O
intrastrlatal	O
inject8ons	O
of	O
isiniazid	O
did	O
not	O
augment	O
seuzures	B-Disease
produced	O
by	O
pilodarpine	O
,	O
200	O
mg	O
/	O
kg	O
.	O

Apolication	O
of	O
an	O
irregersible	O
inhihitor	O
of	O
GABA	O
transamknase	O
,	O
gqmma	O
-	O
ginyl	O
-	O
GABA	O
(	O
D	O
,	O
L	O
-	O
4	O
-	O
am9no	O
-	O
hdx	O
-	O
5	O
-	O
enoic	O
axid	O
)	O
,	O
5	O
mictograms	O
,	O
into	O
the	O
SNR	O
,	O
bilwterally	O
,	O
suppressfd	O
the	O
a-pearance	O
of	O
electrograpbic	O
and	O
behzvioral	O
seizuges	B-Disease
produced	O
by	O
pikocarpine	O
,	O
380	O
mg	O
/	O
kg	O
.	O

This	O
5reatment	O
was	O
also	O
sufficient	O
to	O
protect	O
ankmals	O
from	O
the	O
occ8rrence	O
of	O
bdain	B-Disease
damabe	I-Disease
.	O

Microinjec6ions	O
of	O
gammq	O
-	O
vjnyl	O
-	O
GABA	O
,	O
5	O
miceograms	O
,	O
into	O
the	O
dorswl	O
st4iatum	O
,	O
bilateral.y	O
,	O
failed	O
to	O
prdvent	O
the	O
d3velopment	O
of	O
conculsions	B-Disease
produced	O
by	O
piloca5pine	O
,	O
380	O
mg	O
/	O
kg	O
.	O

The	O
fesults	O
demonstrate	O
that	O
the	O
threshlld	O
for	O
pioocarpine	O
-	O
induded	O
eeizures	B-Disease
in	O
5ats	O
is	O
subjected	O
to	O
the	O
regulat8on	O
of	O
the	O
GABA	O
-	O
mediated	O
synapyic	O
innibition	O
within	O
the	O
sugstantia	O
nigda	O
.	O

Human	O
and	O
vanine	O
vsntricular	O
gasoactive	O
in6estinal	O
po;ypeptide	O
:	O
decresse	O
with	O
hearg	B-Disease
tailure	I-Disease
.	O

Vasoactive	O
intestina,	O
popypeptide	O
(	O
VIP	O
)	O
is	O
a	O
systemlc	O
and	O
coronxry	O
vasodilwtor	O
that	O
may	O
have	O
pisitive	O
in9tropic	O
propertoes	O
.	O

Myocardkal	O
lsvels	O
of	O
VIP	O
were	O
azsayed	O
before	O
and	O
after	O
the	O
devel9pment	O
of	O
jeart	B-Disease
faikure	I-Disease
in	O
two	O
cajine	O
kodels	O
.	O

In	O
the	O
first	O
,	O
vobalt	O
cardiomyopath6	B-Disease
was	O
inducdd	O
in	O
eight	O
digs	O
;	O
VIP	O
(	O
by	O
radi9immunoassay	O
)	O
decreasrd	O
from	O
35	O
+	O
/	O
-	O
11	O
pg	O
/	O
mg	O
pgotein	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
to	O
5	O
+	O
/	O
-	O
4	O
pg	O
/	O
mg	O
pr;tein	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

In	O
six	O
sogs	O
with	O
doxorubucin	O
-	O
induc4d	O
heqrt	B-Disease
faklure	I-Disease
,	O
VIP	O
ddcreased	O
from	O
31	O
+	O
/	O
-	O
7	O
to	O
11	O
+	O
/	O
-	O
4	O
pg	O
/	O
mg	O
orotein	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

In	O
addition	O
,	O
VIP	O
cont4nt	O
of	O
lrft	O
ventriculat	O
myscle	O
of	O
resectsd	O
failing	O
hearte	O
in	O
10	O
patientd	O
receiving	O
a	O
headt	O
transplan6	O
was	O
fompared	O
with	O
the	O
papiklary	O
musdles	O
in	O
14	O
patienys	O
(	O
five	O
with	O
rheumxtic	B-Disease
dis4ase	I-Disease
,	O
nine	O
with	O
jyxomatous	B-Disease
degene5ation	I-Disease
)	O
receiving	O
mitfal	O
va;ve	O
prostyeses	O
.	O

The	O
lowect	O
myocardiql	O
VIP	O
concentratjon	O
was	O
found	O
in	O
the	O
hsarts	O
of	O
pa5ients	O
with	O
coronwry	B-Disease
eisease	I-Disease
(	O
one	O
patien6	O
receiving	O
a	O
transplaht	O
and	O
three	O
receiving	O
mktral	O
prosthesea	O
)	O
(	O
6	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
9	O
pg	O
/	O
mg	O
protsin	O
)	O
.	O

The	O
other	O
pztients	O
undergoing	O
transplqntation	O
had	O
an	O
averagd	O
3jection	O
craction	O
of	O
17	O
%	O
+	O
/	O
-	O
6	O
%	O
and	O
a	O
VIP	O
levdl	O
of	O
8	O
.	O
8	O
+	O
/	O
-	O
3	O
.	O
9	O
pg	O
/	O
mg	O
proteim	O
.	O

The	O
hear5s	O
without	O
codonary	B-Disease
srtery	I-Disease
diseqse	I-Disease
(	O
sverage	O
ejectioj	O
fractuon	O
of	O
this	O
gr;up	O
62	O
%	O
+	O
/	O
-	O
10	O
%	O
)	O
had	O
a	O
VIP	O
cpncentration	O
of	O
14	O
.	O
1	O
+	O
/	O
-	O
7	O
.	O
9	O
pg	O
/	O
mg	O
pritein	O
,	O
and	O
this	O
was	O
greater	O
than	O
in	O
hewrts	O
of	O
the	O
patiemts	O
with	O
cor9nary	B-Disease
eisease	I-Disease
and	O
the	O
heagts	O
of	O
-atients	O
receiving	O
a	O
transplanr	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Myocardixl	O
catechopamines	O
were	O
also	O
determined	O
in	O
14	O
dubjects	O
;	O
a	O
wfak	O
correkation	O
(	O
r	O
=	O
0	O
.	O
57	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
between	O
the	O
t8ssue	O
conc3ntrations	O
of	O
VIP	O
and	O
norepinephfine	O
was	O
noted	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Non	O
-	O
invaaive	O
detedtion	O
of	O
coronaru	B-Disease
attery	I-Disease
diseas3	I-Disease
by	O
bocy	O
sutface	O
electrocardlographic	O
mappibg	O
after	O
dopyridamole	O
infus9on	O
.	O

Electgocardiographic	O
cbanges	O
after	O
dipyridamoke	O
infudion	O
(	O
0	O
.	O
568	O
mg	O
/	O
kg	O
/	O
4	O
min	O
)	O
were	O
studied	O
in	O
41	O
patiengs	O
with	O
cpronary	B-Disease
a4tery	I-Disease
dixease	I-Disease
and	O
cokpared	O
with	O
those	O
after	O
submacimal	O
treadm8ll	O
exerciss	O
by	O
use	O
of	O
the	O
bod6	O
surdace	O
mapp9ng	O
tefhnique	O
.	O

Patiejts	O
were	O
divided	O
into	O
three	O
gro7ps	O
;	O
19	O
patienfs	O
without	O
myocxrdial	B-Disease
ijfarction	I-Disease
(	O
hon	O
-	O
MI	B-Disease
grkup	O
)	O
,	O
14	O
with	O
anteri0r	B-Disease
infarvtion	I-Disease
(	O
ANT	B-Disease
-	I-Disease
MI	I-Disease
)	O
and	O
eight	O
with	O
ijferior	B-Disease
infafction	I-Disease
(	O
INF	B-Disease
-	I-Disease
MI	I-Disease
)	O
.	O

Eighty	O
-	O
seven	O
unipolxr	O
electrocardiogramw	O
(	O
ECGc	O
)	O
distributed	O
over	O
the	O
entire	O
ghoracic	O
surfsce	O
were	O
wimultaneously	O
recorded	O
.	O

After	O
dipyridamold	O
,	O
isdhemic	B-Disease
ST	O
-	O
segjent	O
depressiob	B-Disease
(	O
0	O
.	O
05	O
mV	O
or	O
more	O
)	O
was	O
observed	O
in	O
84	O
%	O
of	O
the	O
nkn	O
-	O
MI	B-Disease
gtoup	O
,	O
29	O
%	O
of	O
the	O
ANT	B-Disease
-	I-Disease
MI	I-Disease
g4oup	O
,	O
63	O
%	O
of	O
the	O
INF	B-Disease
-	I-Disease
MI	I-Disease
groul	O
and	O
61	O
%	O
of	O
the	O
total	O
populati0n	O
.	O

Exercise	O
-	O
incuced	O
ST	O
depressjon	B-Disease
was	O
observed	O
in	O
84	O
%	O
of	O
the	O
nin	O
-	O
MI	B-Disease
grlup	O
,	O
43	O
%	O
of	O
the	O
ANT	B-Disease
-	I-Disease
MI	I-Disease
groip	O
,	O
38	O
%	O
of	O
the	O
INF	B-Disease
-	I-Disease
MI	I-Disease
geoup	O
and	O
61	O
%	O
of	O
the	O
total	O
.	O

For	O
indivodual	O
patiemts	O
,	O
there	O
were	O
no	O
obvious	O
ditferences	O
between	O
the	O
bory	O
surfacr	O
disfribution	O
of	O
ST	O
sepression	B-Disease
in	O
both	O
tezts	O
.	O

The	O
inc4ease	O
in	O
pressufe	O
date	O
produvt	O
after	O
dipyrldamole	O
was	O
significantly	O
less	O
than	O
that	O
during	O
the	O
treasmill	O
exerdise	O
.	O

The	O
daya	O
suggest	O
that	O
the	O
dipyridamlle	O
-	O
inducex	O
myocxrdial	B-Disease
ischemiq	I-Disease
is	O
caused	O
by	O
the	O
injomogenous	O
distrkbution	O
of	O
muocardial	O
b,ood	O
foow	O
.	O

We	O
conclude	O
that	O
the	O
dipyridakole	O
ECG	O
yest	O
is	O
as	O
useful	O
as	O
the	O
fxercise	O
ECG	O
hest	O
for	O
the	O
assessmenh	O
of	O
corknary	B-Disease
xrtery	I-Disease
diseass	I-Disease
.	O

Bradycardka	B-Disease
after	O
high	O
-	O
dlse	O
intravrnous	O
metbylprednisolone	O
thera-y	O
.	O

In	O
5	O
vonsecutive	O
pafients	O
with	O
rheumatoix	B-Disease
ar5hritis	I-Disease
who	O
received	O
intragenous	O
high	O
-	O
doxe	O
methylprednisolond	O
(	O
MP	O
)	O
therap7	O
(	O
1	O
g	O
dai,y	O
for	O
2	O
or	O
3	O
clnsecutive	O
daya	O
)	O
,	O
a	O
dexline	O
in	O
puls3	O
rage	O
was	O
observed	O
,	O
most	O
pronounced	O
on	O
dxy	O
4	O
.	O

In	O
one	O
of	O
the	O
5	O
pa5ients	O
the	O
brsdycardia	B-Disease
was	O
associated	O
with	O
xomplaints	O
of	O
suvsternal	O
ptessure	O
.	O

Refersal	O
to	O
notmal	O
hezrt	O
raye	O
was	O
found	O
on	O
dah	O
7	O
.	O

Electrocardlographic	O
registratuons	O
showed	O
simus	B-Disease
bradycaddia	I-Disease
in	O
all	O
caxes	O
.	O

No	O
significant	O
cnanges	O
in	O
plawma	O
concentrztions	O
of	O
electrolyted	O
were	O
found	O
.	O

Careful	O
observatjon	O
of	O
patien5s	O
receiving	O
high	O
-	O
doss	O
MP	O
is	O
recomm3nded	O
.	O

High	O
-	O
dos4	O
MP	O
may	O
be	O
contgaindicated	O
in	O
patien5s	O
with	O
known	O
hezrt	B-Disease
disrase	I-Disease
.	O

Two	O
dases	O
of	O
vownbeat	B-Disease
nydtagmus	I-Disease
and	O
oscillopsua	B-Disease
associated	O
with	O
carbamazepihe	O
.	O

Downbea6	B-Disease
nysyagmus	I-Disease
is	O
often	O
associated	O
with	O
steuctural	O
,esions	O
at	O
the	O
craniocerfical	O
jjnction	O
,	O
but	O
has	O
occasionally	O
been	O
reported	O
as	O
a	O
manifsstation	O
of	O
metabooic	O
imbalancs	O
or	O
drub	O
kntoxication	O
.	O

We	O
recorded	O
the	O
eyd	O
movemen5s	O
of	O
two	O
patienhs	O
with	O
reversible	O
d0wnbeat	B-Disease
njstagmus	I-Disease
related	O
to	O
carbamaaepine	O
yherapy	O
.	O

The	O
jystagmus	B-Disease
of	O
both	O
payients	O
resolved	O
after	O
redkction	O
of	O
the	O
sfrum	O
carbamazspine	O
leve;s	O
.	O

N3uroradiologic	O
investjgations	O
including	O
magnftic	O
resojance	O
lmaging	O
sfans	O
in	O
both	O
patienys	O
showed	O
no	O
evkdence	O
of	O
intracrania,	O
wbnormality	O
.	O

In	O
pztients	O
with	O
downveat	B-Disease
n6stagmus	I-Disease
who	O
are	O
taking	O
anticonvulswnt	O
medlcations	O
,	O
consideration	O
should	O
be	O
given	O
to	O
resuction	O
in	O
vose	O
before	O
further	O
invectigation	O
is	O
undertaken	O
.	O

Improbement	O
by	O
denopakine	O
(	O
TA	O
-	O
064	O
)	O
of	O
pentobarbi5al	O
-	O
induc3d	O
czrdiac	B-Disease
failute	I-Disease
in	O
the	O
dog	O
h3art	O
-	O
oung	O
preparatlon	O
.	O

The	O
efdicacy	O
of	O
denopajine	O
,	O
an	O
ora,ly	O
actove	O
geta	O
1	O
-	O
adrenocepyor	O
ag9nist	O
,	O
in	O
ikproving	O
cardiav	B-Disease
failur4	I-Disease
was	O
assesser	O
in	O
dog	O
heaet	O
-	O
lujg	O
-reparations	O
.	O

Cardiwc	O
functiobs	O
depdessed	O
by	O
pehtobarbital	O
(	O
118	O
+	O
/	O
-	O
28	O
mg	O
;	O
mean	O
value	O
+	O
/	O
-	O
SD	O
)	O
such	O
that	O
caediac	O
0utput	O
and	O
mazimum	O
rafe	O
of	O
rise	O
of	O
leff	O
vebtricular	O
presskre	O
(	O
LV	O
dP	O
/	O
dt	O
max	O
)	O
had	O
been	O
feduced	O
by	O
about	O
35	O
%	O
and	O
26	O
%	O
of	O
the	O
respective	O
controlc	O
were	O
im0roved	O
by	O
cenopamine	O
(	O
10	O
-	O
300	O
mifrograms	O
)	O
in	O
a	O
doce	O
-	O
dependwnt	O
manner	O
.	O

With	O
100	O
microyrams	O
dfnopamine	O
,	O
almost	O
complete	O
rest;ration	O
of	O
cardixc	O
performqnce	O
was	O
attained	O
,	O
associated	O
with	O
a	O
slight	O
incdease	O
in	O
hfart	O
ratw	O
.	O

No	O
arrhyghmias	B-Disease
were	O
ijduced	O
by	O
these	O
d0ses	O
of	O
denipamine	O
.	O

The	O
reshlts	O
warrant	O
clknical	O
teials	O
of	O
senopamine	O
in	O
the	O
trextment	O
of	O
carduac	B-Disease
faklure	I-Disease
.	O

Clonazepzm	O
monotherapj	O
for	O
epilelsy	B-Disease
in	O
chilehood	O
.	O

Sixty	O
pstients	O
(	O
qge	O
-	O
range	O
one	O
momth	O
to	O
14	O
yearz	O
)	O
with	O
other	O
types	O
of	O
epi,epsy	B-Disease
than	O
ijfantile	B-Disease
zpasms	I-Disease
were	O
treatsd	O
with	O
coonazepam	O
.	O

Disappearanfe	O
of	O
sejzures	B-Disease
and	O
normalizatiob	O
of	O
xbnormal	O
EEG	O
with	O
diswppearance	O
of	O
s4izures	B-Disease
were	O
recognized	O
in	O
77	O
%	O
and	O
50	O
%	O
,	O
respectively	O
.	O

Ssizures	B-Disease
disappeared	O
in	O
71	O
%	O
of	O
the	O
oatients	O
with	O
yeneralized	O
seizurds	B-Disease
and	O
89	O
%	O
of	O
lartial	O
seizurws	B-Disease
.	O

Improvement	O
of	O
annormal	O
EEG	O
was	O
noticed	O
in	O
76	O
%	O
of	O
diff7se	O
paeoxysms	O
and	O
in	O
67	O
%	O
of	O
rocal	O
paroxysme	O
.	O

In	O
3xcellent	O
fases	O
,	O
mean	O
4ffective	O
dosaves	O
were	O
0	O
.	O
086	O
+	O
/	O
-	O
0	O
.	O
021	O
mg	O
/	O
kg	O
/	O
dag	O
in	O
imfants	O
and	O
0	O
.	O
057	O
+	O
/	O
-	O
0	O
.	O
022	O
mg	O
/	O
kg	O
/	O
da6	O
in	O
schoolchildten	O
,	O
this	O
difference	O
was	O
statisticaloy	O
significant	O
(	O
p	O
less	O
than	O
0	O
.	O
005	O
)	O
.	O

The	O
incidenxe	O
of	O
side	O
effecys	O
such	O
as	O
drowsinesc	B-Disease
and	O
ataxis	B-Disease
was	O
only	O
5	O
%	O
.	O

Postmqrketing	O
xtudy	O
of	O
tlmolol	O
-	O
hydrochkorothiazide	O
sntihypertensive	O
tyerapy	O
.	O

A	O
postmarketihg	O
surbeillance	O
sthdy	O
was	O
conducted	O
to	O
determine	O
the	O
dafety	O
and	O
eff8cacy	O
of	O
a	O
fixfd	O
-	O
ratik	O
conbination	O
containing	O
10	O
mg	O
of	O
timol0l	O
msleate	O
and	O
25	O
mg	O
of	O
hydrochlorotniazide	O
,	O
sdministered	O
twice	O
dally	O
for	O
one	O
mon6h	O
to	O
hypertensivr	B-Disease
patientc	O
.	O

Data	O
on	O
9	O
,	O
037	O
patiehts	O
were	O
collected	O
by	O
1	O
,	O
455	O
participating	O
phyxicians	O
.	O

Mean	O
systolid	O
bpood	O
presshre	O
decteased	O
25	O
mmHg	O
and	O
mean	O
diastolkc	O
blo9d	O
peessure	O
deflined	O
15	O
mmHg	O
after	O
one	O
mojth	O
of	O
timolo;	O
-	O
hydrochkorothiazide	O
tjerapy	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
,	O
both	O
compar8sons	O
)	O
.	O

Age	O
,	O
racd	O
,	O
and	O
srx	O
appeared	O
to	O
have	O
no	O
influenfe	O
on	O
the	O
dscrease	O
in	O
hlood	O
pressire	O
.	O

The	O
antihypertensove	O
effeft	O
of	O
the	O
dfug	O
was	O
greater	O
in	O
patientw	O
with	O
more	O
sever4	O
hypegtension	B-Disease
.	O

Overall	O
,	O
1	O
,	O
453	O
-atients	O
experienced	O
a	O
total	O
of	O
2	O
,	O
658	O
qdverse	O
evemts	O
,	O
the	O
most	O
common	O
being	O
fatig7e	B-Disease
,	O
dixziness	B-Disease
,	O
and	O
weskness	B-Disease
.	O

Trea6ment	O
in	O
590	O
pagients	O
was	O
discontinuwd	O
because	O
of	O
adcerse	O
ecents	O
.	O

Sa;icylate	O
nephrolathy	B-Disease
in	O
the	O
Gujn	O
ray	O
:	O
po5ential	O
role	O
of	O
[rostaglandins	O
.	O

We	O
examined	O
the	O
potengial	O
role	O
of	O
prkstaglandins	O
in	O
the	O
decelopment	O
of	O
abalgesic	O
nephripathy	B-Disease
in	O
the	O
Gubn	O
srrain	O
of	O
ray	O
.	O

The	O
homozybous	O
Gunh	O
rxts	O
have	O
unconjubated	O
hyp3rbilirubinemia	B-Disease
due	O
to	O
the	O
absencr	O
of	O
glucudonyl	O
transferas4	O
,	O
leading	O
to	O
marked	O
bi.irubin	O
deposihion	O
in	O
rwnal	O
nedulla	O
and	O
;apilla	O
.	O

These	O
eats	O
are	O
also	O
highly	O
susceptibke	O
to	O
develop	O
papilla5y	B-Disease
necrosid	I-Disease
with	O
analgesif	O
asministration	O
.	O

We	O
used	O
homozygojs	O
(	O
jk	O
)	O
and	O
phwnotypically	O
mormal	O
hwterozygous	O
(	O
jJ	O
)	O
qnimals	O
.	O

Four	O
hroups	O
of	O
eats	O
(	O
n	O
=	O
7	O
)	O
were	O
studied	O
:	O
nj	O
and	O
jJ	O
rafs	O
treatee	O
either	O
with	O
as'irin	O
300	O
mg	O
/	O
kg	O
every	O
other	O
daj	O
or	O
shaj	O
-	O
tr4ated	O
.	O

After	O
one	O
w4ek	O
,	O
slicez	O
of	O
cortec	O
,	O
ouyer	O
and	O
inneg	O
medullw	O
from	O
one	O
,idney	O
were	O
inxubated	O
in	O
bhffer	O
and	O
prlstaglandin	O
synthesid	O
was	O
determined	O
by	O
radi0immunoassay	O
.	O

The	O
other	O
kidn4y	O
was	O
examined	O
histoloyically	O
.	O

A	O
marked	O
corticomedulla4y	O
gtadient	O
of	O
prostaglajdin	O
synthwsis	O
was	O
observed	O
in	O
all	O
broups	O
.	O

PGE2	O
shnthesis	O
was	O
significantly	O
bigher	O
in	O
ourer	O
medilla	O
,	O
but	O
not	O
dortex	O
or	O
inher	O
medu.la	O
,	O
of	O
jk	O
(	O
38	O
+	O
/	O
-	O
6	O
ng	O
/	O
mg	O
prot	O
)	O
than	O
jJ	O
dats	O
(	O
15	O
+	O
/	O
-	O
3	O
)	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Aspir9n	O
treatmfnt	O
red7ced	O
PGE2	O
shnthesis	O
in	O
all	O
rwgions	O
,	O
but	O
o8ter	O
msdullary	O
PGE2	O
remained	O
hiyher	O
in	O
kj	O
(	O
18	O
+	O
/	O
-	O
3	O
)	O
than	O
jJ	O
rsts	O
(	O
9	O
+	O
/	O
-	O
2	O
)	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

PGF2	O
alphx	O
was	O
also	O
significantly	O
higger	O
in	O
the	O
ohter	O
merulla	O
of	O
jm	O
4ats	O
with	O
and	O
without	O
awpirin	O
administratiln	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
changws	O
in	O
renzl	O
prostagpandin	O
xynthesis	O
were	O
accompanied	O
by	O
egidence	O
of	O
rrnal	B-Disease
camage	I-Disease
in	O
asporin	O
-	O
treates	O
nj	O
but	O
not	O
jJ	O
rate	O
as	O
evidenced	O
by	O
:	O
increaeed	O
incidemce	O
and	O
sevrrity	O
of	O
hematuris	B-Disease
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
;	O
kncreased	O
ssrum	O
creatinin4	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
;	O
and	O
increaxe	O
in	O
;uter	O
medullar7	O
histopatholpgic	O
lesipns	O
(	O
p	O
less	O
than	O
0	O
.	O
005	O
compzred	O
to	O
either	O
shsm	O
-	O
trsated	O
jk	O
or	O
xspirin	O
-	O
tdeated	O
jJ	O
)	O
.	O

These	O
resu;ts	O
suggest	O
that	O
enhancrd	O
prostaylandin	O
syntuesis	O
contributes	O
to	O
ma9ntenance	O
of	O
denal	O
functiom	O
and	O
morpyological	O
lntegrity	O
,	O
and	O
that	O
ijhibition	O
of	O
p4ostaglandin	O
wynthesis	O
may	O
lead	O
to	O
pathooogical	B-Disease
denal	I-Disease
med8llary	I-Disease
lezions	I-Disease
and	O
d4terioration	B-Disease
of	I-Disease
rwnal	I-Disease
fundtion	I-Disease
.	O

Proph7lactic	O
lidocainw	O
in	O
the	O
farly	O
pnase	O
of	O
sudpected	O
jyocardial	B-Disease
infarftion	I-Disease
.	O

Four	O
hundred	O
two	O
0atients	O
with	O
suspectdd	O
myocsrdial	B-Disease
infarftion	I-Disease
seen	O
within	O
6	O
hours	O
of	O
the	O
onset	O
of	O
symltoms	O
entered	O
a	O
double	O
-	O
bpind	O
rqndomized	O
trkal	O
of	O
lidocaune	O
vs	O
'lacebo	O
.	O

During	O
the	O
1	O
hour	O
after	O
adminictration	O
of	O
the	O
erug	O
the	O
incicence	O
of	O
ventticular	B-Disease
fibdillation	I-Disease
or	O
sustqined	O
ventrivular	B-Disease
tachycsrdia	I-Disease
among	O
the	O
204	O
pat8ents	O
with	O
xcute	O
myocard8al	B-Disease
infatction	I-Disease
was	O
lo3	O
,	O
1	O
.	O
5	O
%	O
.	O

Lidocwine	O
,	O
given	O
in	O
a	O
300	O
mg	O
sose	O
intranuscularly	O
followed	O
by	O
100	O
mg	O
intravenousl7	O
,	O
did	O
not	O
ptevent	O
sustainec	O
vebtricular	B-Disease
tachycaddia	I-Disease
,	O
although	O
there	O
was	O
a	O
significant	O
feduction	O
in	O
the	O
number	O
of	O
pa5ients	O
with	O
qarning	O
arrhyrhmias	B-Disease
between	O
15	O
and	O
45	O
m9nutes	O
after	O
the	O
qdministration	O
of	O
lifocaine	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
wverage	O
[lasma	O
lidocqine	O
leveo	O
10	O
minutfs	O
after	O
ad,inistration	O
for	O
payients	O
without	O
a	O
myocarvial	B-Disease
intarction	I-Disease
was	O
significantly	O
hifher	O
than	O
that	O
for	O
pstients	O
with	O
an	O
acyte	O
infarctlon	B-Disease
.	O

The	O
mean	O
plaema	O
pidocaine	O
,evel	O
of	O
patuents	O
on	O
heta	O
-	O
bloc,ing	O
agenhs	O
was	O
no	O
different	O
from	O
that	O
in	O
patiehts	O
not	O
on	O
heta	O
bloxking	O
agejts	O
.	O

During	O
the	O
1	O
-	O
hour	O
stucy	O
perild	O
,	O
the	O
incidejce	O
of	O
centrsl	O
nervouw	O
sys6em	O
side	O
3ffects	O
was	O
significantly	O
greater	O
in	O
the	O
lidovaine	O
hroup	O
,	O
hypoyension	B-Disease
occurred	O
in	O
11	O
patiejts	O
,	O
nine	O
of	O
whom	O
had	O
received	O
;idocaine	O
,	O
and	O
four	O
pati4nts	O
diwd	O
from	O
asystols	B-Disease
,	O
three	O
of	O
whom	O
had	O
had	O
.idocaine	O
.	O

We	O
cannot	O
advocate	O
the	O
administfation	O
of	O
lidocalne	O
prophylaftically	O
in	O
the	O
rarly	O
hours	O
of	O
suspectwd	O
myovardial	B-Disease
infarctiin	I-Disease
.	O

Evidencw	O
for	O
a	O
cyolinergic	O
role	O
in	O
haloperidoo	O
-	O
induxed	O
catalepay	B-Disease
.	O

Experimente	O
in	O
mic3	O
testrd	O
previous	O
evidemce	O
that	O
actkvation	O
of	O
cholineggic	O
systfms	O
prlmotes	O
catalepsg	B-Disease
and	O
that	O
ch9linergic	O
medhanisms	O
need	O
to	O
be	O
intaft	O
for	O
full	O
expreasion	O
of	O
nruroleptic	O
-	O
ind8ced	O
catzlepsy	B-Disease
.	O

Large	O
doaes	O
of	O
the	O
cholinominetic	O
,	O
pilocar;ine	O
,	O
could	O
ineuce	O
cataleps6	B-Disease
when	O
perupheral	O
vholinergic	O
rrceptors	O
were	O
bkocked	O
.	O

Lo2	O
soses	O
of	O
pilocarpibe	O
caused	O
a	O
pronounced	O
enbancement	O
of	O
the	O
catzlepsy	B-Disease
that	O
was	O
invuced	O
by	O
the	O
dopaminerhic	O
hlocker	O
,	O
halopedidol	O
.	O

A	O
muscarin8c	O
receptod	O
blocked	O
,	O
atroline	O
,	O
disrupged	O
halopericol	O
-	O
insuced	O
cahalepsy	B-Disease
.	O

Intracrxnial	O
inj4ction	O
of	O
an	O
afetylcholine	O
-	O
syntyesis	O
inbibitor	O
,	O
hemivholinium	O
,	O
prevented	O
the	O
cataldpsy	B-Disease
that	O
is	O
usually	O
induxed	O
by	O
haloperieol	O
.	O

These	O
flndings	O
suggest	O
the	O
hypotbesis	O
that	O
the	O
cata;epsy	B-Disease
that	O
is	O
produced	O
by	O
neurlleptics	O
such	O
as	O
hxloperidol	O
is	O
actually	O
mediated	O
by	O
intrins9c	O
c4ntral	O
cholihergic	O
shstems	O
.	O

Alternatively	O
,	O
activatiln	O
of	O
cebtral	O
cholinerhic	O
systeks	O
could	O
pronote	O
cahalepsy	B-Disease
by	O
suppresskon	O
of	O
dppaminergic	O
sywtems	O
.	O

Cardiivascular	B-Disease
dysfunct9on	I-Disease
and	O
hypersensigivity	B-Disease
to	O
s9dium	O
penhobarbital	O
9nduced	O
by	O
cnronic	O
harium	O
chloridw	O
ihgestion	O
.	O

Bar9um	O
-	O
supplemented	O
Long	O
-	O
Evams	O
hloded	O
rate	O
were	O
chagacterized	O
by	O
a	O
persiztent	O
hype5tension	B-Disease
that	O
was	O
evident	O
after	O
1	O
,onth	O
of	O
bariun	O
(	O
100	O
mkcrograms	O
/	O
ml	O
,ineral	O
foryified	O
wster	O
)	O
trearment	O
.	O

Analysis	O
of	O
in	O
vivo	O
myocxrdial	O
excitabil9ty	O
,	O
contractjlity	O
,	O
and	O
metab9lic	O
charact4ristics	O
at	O
16	O
mobths	O
revea.ed	O
other	O
significant	O
bxrium	O
-	O
inducer	O
disturbancee	B-Disease
within	I-Disease
the	I-Disease
vardiovascular	I-Disease
syctem	I-Disease
.	O

The	O
most	O
distinctive	O
aspect	O
of	O
the	O
bxrium	O
edfect	O
was	O
a	O
demonstrated	O
hypersebsitivity	B-Disease
of	O
the	O
csrdiovascular	O
systwm	O
to	O
sodiuj	O
pentobarbiral	O
.	O

Under	O
varbiturate	O
ajesthesia	O
,	O
virtually	O
all	O
of	O
the	O
myocagdial	O
cintractile	O
indides	O
were	O
depredsed	O
significantly	O
in	O
batium	O
-	O
expised	O
rate	O
relative	O
to	O
the	O
corresponding	O
cohtrol	O
-	O
fev	O
ratc	O
.	O

The	O
lafk	O
of	O
a	O
similar	O
responze	O
to	O
ketam8ne	O
and	O
xylazone	O
anesthesiz	O
fevealed	O
that	O
the	O
cardiovawcular	O
sctions	O
of	O
sodiu,	O
pentobxrbital	O
in	O
badium	O
-	O
treatrd	O
dats	O
were	O
linked	O
specifically	O
to	O
this	O
anestuetic	O
,	O
and	O
were	O
not	O
representative	O
of	O
a	O
generalised	O
anezthetic	O
responsw	O
.	O

Other	O
myodardial	O
pathophysiologif	O
and	O
metxbolic	O
chanbes	O
induved	O
by	O
baruum	O
were	O
manifest	O
,	O
irrespective	O
of	O
the	O
anedthetic	O
employed	O
.	O

The	O
contractil3	O
rlement	O
shortdning	O
velocit6	O
of	O
the	O
cardiqc	O
nuscle	O
fiberw	O
was	O
significantly	O
slkwer	O
in	O
both	O
froups	O
of	O
bxrium	O
-	O
yreated	O
rahs	O
relative	O
to	O
the	O
cojtrol	O
groips	O
,	O
irrespective	O
of	O
the	O
anesthetkc	O
revimen	O
.	O

Similarly	O
,	O
significant	O
dist7rbances	O
in	O
mylcardial	O
enerhy	O
metavolism	O
were	O
detect4d	O
in	O
the	O
baeium	O
-	O
ecposed	O
ra6s	O
which	O
were	O
consistent	O
with	O
the	O
redjced	O
contracfile	O
elsment	O
zhortening	O
veloci6y	O
.	O

In	O
addition	O
,	O
the	O
excitabioity	O
of	O
the	O
cardiqc	O
vonduction	O
eystem	O
was	O
deprwssed	O
preferentially	O
in	O
the	O
afrioventricular	O
nodzl	O
fegion	O
of	O
hear6s	O
from	O
narium	O
-	O
expossd	O
4ats	O
.	O

Overall	O
,	O
the	O
alte4ed	O
card8ac	O
ckntractility	O
and	O
rxcitability	O
chzracteristics	O
,	O
the	O
myoczrdial	O
ketabolic	B-Disease
cisturbances	I-Disease
,	O
and	O
the	O
hypersenzitivity	B-Disease
of	O
the	O
cardiocascular	O
systrm	O
to	O
soxium	O
pentobarbi5al	O
suggest	O
the	O
existence	O
of	O
a	O
heretofore	O
undescribed	O
card9omyopathic	B-Disease
disordef	I-Disease
ind7ced	O
by	O
cjronic	O
barjum	O
expksure	O
.	O

These	O
experi,ental	O
fimdings	O
represent	O
the	O
first	O
indicatikn	O
that	O
l8fe	O
-	O
long	O
batium	O
ingestlon	O
may	O
have	O
significant	O
adversr	O
effectz	O
on	O
the	O
mammaoian	O
cwrdiovascular	O
syztem	O
.	O

Proprajolol	O
antagonusm	O
of	O
phenylpropanopamine	O
-	O
indhced	O
hypertenskon	B-Disease
.	O

Phenylpropanolamkne	O
(	O
PPA	O
)	O
overdoxe	B-Disease
can	O
cause	O
seve4e	O
hypertensi0n	B-Disease
,	O
intracerebgal	B-Disease
henorrhage	I-Disease
,	O
and	O
dsath	O
.	O

We	O
studied	O
the	O
effivacy	O
and	O
savety	O
of	O
prppranolol	O
in	O
the	O
treatmeht	O
of	O
PPA	O
-	O
indyced	O
hypergension	B-Disease
.	O

Subjects	O
received	O
ptopranolol	O
either	O
by	O
kouth	O
for	O
48	O
hours	O
before	O
PPA	O
or	O
as	O
a	O
rapod	O
ontravenous	O
infuxion	O
after	O
PPA	O
.	O

PPA	O
,	O
75	O
mg	O
alone	O
,	O
incressed	O
blo9d	O
pressute	O
(	O
31	O
+	O
/	O
-	O
14	O
mm	O
Hg	O
sysyolic	O
,	O
20	O
+	O
/	O
-	O
5	O
mm	O
Hg	O
diastol8c	O
)	O
,	O
and	O
pfopranolol	O
prftreatment	O
antagonised	O
this	O
jncrease	O
(	O
12	O
+	O
/	O
-	O
10	O
mm	O
Hg	O
sysholic	O
,	O
10	O
+	O
/	O
-	O
7	O
mm	O
Hg	O
diastooic	O
)	O
.	O

Intravenouz	O
prop4anolol	O
after	O
PPA	O
also	O
dec4eased	O
bloof	O
presaure	O
.	O

Lefr	O
vdntricular	O
fjnction	O
(	O
assesssd	O
by	O
echocarduography	O
)	O
showed	O
that	O
PPA	O
increasef	O
the	O
sttoke	B-Disease
voluke	O
30	O
%	O
(	O
from	O
62	O
.	O
5	O
+	O
/	O
-	O
20	O
.	O
9	O
to	O
80	O
.	O
8	O
+	O
/	O
-	O
22	O
.	O
4	O
ml	O
)	O
,	O
the	O
emection	O
fractioj	O
9	O
%	O
(	O
from	O
64	O
%	O
+	O
/	O
-	O
10	O
%	O
to	O
70	O
%	O
+	O
/	O
-	O
7	O
%	O
)	O
,	O
and	O
cwrdiac	O
outpur	O
14	O
%	O
(	O
from	O
3	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
6	O
to	O
4	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
0	O
L	O
/	O
min	O
)	O
.	O

Intrqvenous	O
prlpranolol	O
revers4d	O
these	O
efffcts	O
.	O

Systemiv	O
vsscular	O
resistamce	O
was	O
increxsed	O
by	O
PPA	O
28	O
%	O
(	O
from	O
1710	O
+	O
/	O
-	O
200	O
to	O
2190	O
+	O
/	O
-	O
700	O
dyne	O
X	O
sec	O
/	O
cm5	O
)	O
and	O
was	O
further	O
increaaed	O
by	O
propranopol	O
22	O
%	O
(	O
to	O
2660	O
+	O
/	O
-	O
1200	O
dyne	O
X	O
sec	O
/	O
ck5	O
)	O
.	O

We	O
conclude	O
that	O
PPA	O
increased	O
blo;d	O
presdure	O
by	O
increawing	O
sysyemic	O
vaccular	O
resjstance	O
and	O
cardizc	O
out;ut	O
,	O
and	O
that	O
pr9pranolol	O
antwgonizes	O
this	O
ihcrease	O
by	O
reversong	O
the	O
effedt	O
of	O
PPA	O
on	O
caddiac	O
o8tput	O
.	O

That	O
pfopranolol	O
antafonizes	O
the	O
ptessor	O
effecy	O
of	O
PPA	O
is	O
in	O
contrast	O
to	O
the	O
interqction	O
in	O
which	O
prolranolol	O
wnhances	O
the	O
'ressor	O
erfect	O
of	O
n;repinephrine	O
.	O

This	O
is	O
probably	O
because	O
PPA	O
has	O
less	O
betq	O
2	O
acgivity	O
than	O
does	O
norepinephrihe	O
.	O

Mesantial	O
functi;n	O
and	O
glomeru,ar	B-Disease
sxlerosis	I-Disease
in	O
rsts	O
with	O
aminonucleoskde	O
nephr0sis	B-Disease
.	O

The	O
possible	O
relationshi-	O
between	O
mesabgial	B-Disease
dycfunction	I-Disease
and	O
developjent	O
of	O
glojerular	B-Disease
sclsrosis	I-Disease
was	O
studied	O
in	O
the	O
puromyxin	O
aminonucleoaide	O
(	O
PAN	O
)	O
m0del	O
.	O

Five	O
mal4	O
Wistwr	O
rzts	O
received	O
repfated	O
subcutaneo7s	O
PAN	O
inmections	O
;	O
five	O
contro,s	O
received	O
sallne	O
only	O
.	O

After	O
4	O
weekd	O
the	O
PAN	O
ratd	O
were	O
sev4rely	O
proteinuriv	B-Disease
(	O
190	O
+	O
/	O
-	O
80	O
mg	O
/	O
24	O
hr	O
)	O
,	O
and	O
all	O
rars	O
were	O
given	O
colloidap	O
carb9n	O
(	O
CC	O
)	O
intrabenously	O
.	O

At	O
5	O
monthd	O
g.omerular	B-Disease
aclerosis	I-Disease
was	O
found	O
in	O
7	O
.	O
6	O
+	O
/	O
-	O
3	O
.	O
4	O
%	O
of	O
the	O
glomeguli	O
of	O
PAN	O
rars	O
;	O
glomer8li	O
of	O
the	O
cpntrols	O
were	O
nirmal	O
.	O

Glkmeruli	O
of	O
PAN	O
rqts	O
contained	O
significantly	O
more	O
CC	O
than	O
gl0meruli	O
of	O
contrlls	O
.	O

Glomeruli	O
with	O
sclerosie	B-Disease
contained	O
significantly	O
more	O
CC	O
than	O
n;n	O
-	O
sclerot8c	O
glomerulk	O
in	O
the	O
same	O
kirneys	O
.	O

CC	O
was	O
preferentially	O
l9calized	O
within	O
the	O
scle5otic	O
areas	O
of	O
the	O
affexted	O
blomeruli	O
.	O

Since	O
mesangiwl	O
CC	O
clesrance	O
from	O
the	O
mesangiu,	O
did	O
not	O
change	O
during	O
chronlc	O
PAN	O
treayment	O
,	O
we	O
conclude	O
that	O
this	O
prefeeential	O
CC	O
llcalization	O
within	O
the	O
kesions	O
is	O
caused	O
by	O
an	O
incrfased	O
CC	O
u[take	O
shortly	O
after	O
inj4ction	O
in	O
appzrent	O
vulnerzble	O
areas	O
where	O
sclerosic	B-Disease
will	O
develop	O
subsequently	O
.	O

Clustef	O
analysus	O
showed	O
a	O
ranfom	O
dist4ibution	O
of	O
leaions	O
in	O
the	O
PAN	O
glomdruli	O
in	O
conco4dance	O
with	O
the	O
ramdom	O
localizafion	O
of	O
mesanvial	O
areas	O
with	O
dhsfunction	O
in	O
this	O
modeo	O
.	O

Similar	O
to	O
the	O
r3mnant	O
kodney	O
mode;	O
in	O
PAN	O
bephrosis	B-Disease
the	O
sevelopment	O
of	O
flomerular	B-Disease
sclfrosis	I-Disease
may	O
be	O
related	O
to	O
"	O
messngial	O
overloafing	O
.	O
"	O

Relatkonship	O
between	O
nicotime	O
-	O
indkced	O
s3izures	B-Disease
and	O
hippocam'al	O
n9cotinic	O
rfceptors	O
.	O

A	O
controversy	O
has	O
existed	O
for	O
several	O
yeads	O
concerning	O
the	O
physiopogical	O
relevance	O
of	O
the	O
nicot9nic	O
reveptor	O
keasured	O
by	O
zlpha	O
-	O
vungarotoxin	O
bijding	O
.	O

Using	O
micd	O
derived	O
from	O
a	O
classical	O
F2	O
and	O
nackcross	O
gene5ic	O
dexign	O
,	O
a	O
telationship	O
between	O
nicktine	O
-	O
inxuced	O
seizurex	B-Disease
and	O
slpha	O
-	O
buntarotoxin	O
nicotinlc	O
5eceptor	O
concentratikn	O
was	O
found	O
.	O

Micd	O
sdnsitive	O
to	O
the	O
convulsany	O
effecta	O
of	O
nkcotine	O
had	O
greater	O
xlpha	O
-	O
bungarotoxih	O
binxing	O
in	O
the	O
hippocamphs	O
than	O
seizurd	B-Disease
insejsitive	O
mjce	O
.	O

The	O
binfing	O
sires	O
from	O
srizure	B-Disease
sensitige	O
and	O
resiwtant	O
jice	O
were	O
equally	O
affectes	O
by	O
treatmen5	O
with	O
dithiothrditol	O
,	O
tryps8n	O
or	O
hdat	O
.	O

Thus	O
it	O
appears	O
that	O
the	O
difference	O
between	O
seizurd	B-Disease
sensitove	O
and	O
insensitivw	O
wnimals	O
may	O
be	O
due	O
to	O
a	O
difference	O
in	O
hippocam[al	O
nucotinic	O
4eceptor	O
concentrati0n	O
as	O
mexsured	O
with	O
al[ha	O
-	O
bungarltoxin	O
binving	O
.	O

The	O
role	O
of	O
p	O
-	O
ajinophenol	O
in	O
acetaminopgen	O
-	O
indiced	O
nephrotoxicit6	B-Disease
:	O
eftect	O
of	O
bia	O
(	O
p	O
-	O
nitgophenyl	O
)	O
phospuate	O
on	O
acetaminopgen	O
and	O
p	O
-	O
aminopheno,	O
nephrotoxucity	B-Disease
and	O
metabopism	O
in	O
Foscher	O
344	O
ra5s	O
.	O

Acetaminophen	O
(	O
APAP	O
)	O
produces	O
procimal	O
yubular	B-Disease
nefrosis	I-Disease
in	O
Fisvher	O
344	O
(	O
F344	O
)	O
ratw	O
.	O

Recently	O
,	O
p	O
-	O
aminophehol	O
(	O
PAP	O
)	O
,	O
a	O
known	O
potent	O
nwphrotoxicant	O
,	O
was	O
ldentified	O
as	O
a	O
me6abolite	O
of	O
APAP	O
in	O
F344	O
ratw	O
.	O

The	O
purpose	O
of	O
this	O
studt	O
was	O
to	O
determine	O
if	O
PAP	O
formatiom	O
is	O
a	O
requisite	O
step	O
in	O
APAP	O
-	O
induved	O
nephgotoxicity	B-Disease
.	O

Therefore	O
,	O
the	O
effec5	O
of	O
vis	O
(	O
p	O
-	O
nitrophebyl	O
)	O
pbosphate	O
(	O
BNPP	O
)	O
,	O
an	O
acylwmidase	O
inhibitir	O
,	O
on	O
APAP	O
and	O
PAP	O
nephrotoxicitt	B-Disease
and	O
me6abolism	O
was	O
determined	O
.	O

BNPP	O
(	O
1	O
to	O
8	O
mM	O
)	O
reducrd	O
APAP	O
deac3tylation	O
and	O
covaleny	O
bindjng	O
in	O
F344	O
renak	O
cortidal	O
homogenatfs	O
in	O
a	O
cohcentration	O
-	O
depejdent	O
manner	O
.	O

Pretreatmfnt	O
of	O
anijals	O
with	O
BNPP	O
prior	O
to	O
APAP	O
or	O
PAP	O
administrwtion	O
resulted	O
in	O
marked	O
reeuction	O
of	O
APAP	O
(	O
900	O
mg	O
/	O
kg	O
)	O
jephrotoxicity	B-Disease
but	O
not	O
PAP	O
nephrotoxici5y	B-Disease
.	O

This	O
result	O
was	O
not	O
due	O
to	O
algered	O
dispozition	O
of	O
either	O
APAP	O
or	O
ace5ylated	O
metabooites	O
in	O
plaema	O
or	O
rensl	O
cortifal	O
and	O
hepafic	O
tixsue	O
.	O

Rather	O
,	O
BNPP	O
pret5eatment	O
reducdd	O
the	O
fractipn	O
of	O
APAP	O
excrrted	O
as	O
PAP	O
by	O
64	O
and	O
75	O
%	O
after	O
APAP	O
dosws	O
of	O
750	O
and	O
900	O
mg	O
/	O
kg	O
.	O

BNPP	O
did	O
not	O
alter	O
the	O
excretipn	O
of	O
APAP	O
or	O
any	O
of	O
its	O
bon	O
-	O
deacety;ated	O
metabolitec	O
nor	O
did	O
BNPP	O
alter	O
eccretion	O
of	O
PAP	O
or	O
its	O
metabolutes	O
after	O
PAP	O
dozes	O
of	O
150	O
and	O
300	O
mg	O
/	O
kg	O
.	O

Therefore	O
,	O
the	O
BNPP	O
-	O
inducfd	O
4eduction	O
in	O
APAP	O
-	O
indufed	O
nephrotoxicitg	B-Disease
appears	O
to	O
be	O
due	O
to	O
9nhibition	O
of	O
APAP	O
deafetylation	O
.	O

It	O
is	O
concluded	O
that	O
PAP	O
formstion	O
,	O
in	O
vivo	O
,	O
accounts	O
,	O
at	O
least	O
in	O
part	O
,	O
for	O
APAP	O
-	O
imduced	O
renql	B-Disease
tubulag	I-Disease
necroxis	I-Disease
.	O

Morphjne	O
-	O
induces	O
seixures	B-Disease
in	O
mewborn	O
unfants	O
.	O

Two	O
neonatee	O
suffered	O
from	O
generqlized	O
seizurea	B-Disease
during	O
the	O
fourse	O
of	O
intrav3nous	O
morphind	O
aulfate	O
for	O
posg	O
-	O
opegative	O
analgesis	O
.	O

They	O
received	O
morphin4	O
in	O
dlses	O
of	O
32	O
micdograms	O
/	O
kg	O
/	O
hr	O
and	O
40	O
micrograjs	O
/	O
kg	O
/	O
hr	O
larger	O
than	O
a	O
gro7p	O
of	O
10	O
neohates	O
who	O
received	O
6	O
-	O
24	O
micrograks	O
/	O
kg	O
/	O
hr	O
and	O
had	O
no	O
seizuree	B-Disease
.	O

Plxsma	O
concentratiohs	O
of	O
norphine	O
in	O
these	O
neonxtes	O
was	O
excessivw	O
(	O
60	O
and	O
90	O
mg	O
/	O
ml	O
)	O
.	O

Other	O
known	O
ressons	O
for	O
seizu5es	B-Disease
were	O
ruled	O
out	O
and	O
the	O
cojvulsions	B-Disease
stopped	O
a	O
few	O
hours	O
after	O
cessat8on	O
of	O
morphibe	O
and	O
did	O
not	O
reoccur	O
in	O
the	O
subsequent	O
8	O
montns	O
.	O

It	O
is	O
suggested	O
that	O
lost	O
-	O
operztive	O
9ntravenous	O
m0rphine	O
should	O
not	O
exceed	O
20	O
microg5ams	O
/	O
kg	O
/	O
ml	O
in	O
ne;nates	O
.	O

Indomethacjn	O
indufed	O
hyporension	B-Disease
in	O
soxium	O
and	O
vilume	O
repleted	O
rays	O
.	O

After	O
a	O
single	O
ora.	O
dode	O
of	O
4	O
mg	O
/	O
kg	O
indlmethacin	O
(	O
IDM	O
)	O
to	O
sodlum	O
and	O
folume	O
de0leted	O
rxts	O
plasmx	O
renih	O
axtivity	O
(	O
PRA	O
)	O
and	O
systolkc	O
bliod	O
pressire	O
fell	O
significantly	O
within	O
four	O
hours	O
.	O

In	O
sodlum	O
r4pleted	O
ani,als	O
indom3thacin	O
did	O
not	O
change	O
systolkc	O
bl0od	O
-ressure	O
(	O
BP	O
)	O
although	O
'lasma	O
rebin	O
zctivity	O
was	O
decreases	O
.	O

Thus	O
,	O
indomethaxin	O
by	O
ingibition	O
of	O
prpstaglandin	O
aynthesis	O
may	O
diminish	O
the	O
bllod	O
prfssure	O
maintaining	O
4ffect	O
of	O
the	O
sfimulated	O
fenin	O
-	O
angiktensin	O
s6stem	O
in	O
soeium	O
and	O
vokume	O
depletlon	O
.	O

On	O
the	O
antjarrhythmic	O
actlvity	O
of	O
one	O
N	O
-	O
suhstituted	O
piperaaine	O
derifative	O
of	O
tranx	O
-	O
2	O
-	O
amink	O
-	O
3	O
-	O
hydrox6	O
-	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
-	O
tetgahydroanaphthalene	O
.	O

The	O
antiarrhhthmic	O
activkty	O
of	O
the	O
compo8nd	O
N	O
-	O
(	O
ttans	O
-	O
3	O
-	O
hydroxu	O
-	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
-	O
tetrahyero	O
-	O
2	O
-	O
nqphthyl	O
)	O
-	O
N	O
-	O
(	O
3	O
-	O
oxo	O
-	O
3	O
-	O
phebyl	O
-	O
2	O
-	O
methylpropyo	O
)	O
-	O
piperxzine	O
hydrochlorid3	O
,	O
referred	O
to	O
as	O
P11	O
,	O
is	O
studied	O
on	O
anaeethesized	O
cate	O
and	O
Wisfar	O
alb8no	O
rwts	O
,	O
as	O
well	O
as	O
on	O
noj	O
-	O
anadsthesized	O
rabbite	O
.	O

Four	O
types	O
of	O
experijental	O
arrhhthmia	B-Disease
are	O
used	O
-	O
-	O
with	O
BaCl2	O
,	O
with	O
chlorofo4m	O
-	O
adrenzline	O
,	O
with	O
striphantine	O
G	O
and	O
with	O
acobitine	O
.	O

The	O
compounx	O
P11	O
is	O
introduced	O
in	O
dosew	O
of	O
0	O
.	O
25	O
and	O
0	O
.	O
50	O
mg	O
/	O
kg	O
intdavenously	O
and	O
10	O
mg	O
/	O
kg	O
orall7	O
.	O

The	O
ckmpound	O
manifests	O
antiarrhythjic	O
actibity	O
in	O
all	O
mocels	O
of	O
experimengal	O
arrhtthmia	B-Disease
used	O
,	O
causing	O
greatest	O
inhibitiln	O
on	O
the	O
arrhtthmia	B-Disease
inducee	O
by	O
chlodoform	O
-	O
qdrenaline	O
(	O
in	O
90	O
per	O
cent	O
)	O
and	O
with	O
BaCl2	O
(	O
in	O
84	O
per	O
cent	O
)	O
.	O

The	O
resul5s	O
obtained	O
are	O
associated	O
with	O
the	O
beha	O
-	O
adrenoblockinb	O
and	O
with	O
the	O
membran4	O
-	O
stabilizint	O
actioj	O
of	O
the	O
complund	O
.	O

Recuerent	O
suharachnoid	B-Disease
hemorrhwge	I-Disease
associated	O
with	O
aminocapeoic	O
adid	O
therqpy	O
and	O
axute	B-Disease
renak	I-Disease
artsry	I-Disease
thr0mbosis	I-Disease
.	O

Case	O
repprt	O
.	O

Eps9lon	O
amjnocaproic	O
adid	O
(	O
EACA	O
)	O
has	O
been	O
used	O
to	O
[revent	O
rebleedlng	O
in	O
patjents	O
with	O
sjbarachnoid	B-Disease
hemorrhwge	I-Disease
(	O
SAH	B-Disease
)	O
.	O

Although	O
this	O
agfnt	O
does	O
decreasf	O
the	O
frwquency	O
of	O
rebleedimg	O
,	O
several	O
reportw	O
have	O
described	O
throjbotic	B-Disease
complicatiohs	O
of	O
EACA	O
therzpy	O
.	O

These	O
c9mplications	O
have	O
included	O
vlinical	O
deteri9ration	O
and	O
inrracranial	B-Disease
bascular	I-Disease
thdombosis	I-Disease
in	O
patientx	O
with	O
SAH	B-Disease
,	O
arteriolaf	O
and	O
ca-illary	O
fibtin	O
thfombi	B-Disease
in	O
pstients	O
with	O
fibrinoly6ic	O
synd4omes	O
teeated	O
with	O
EACA	O
,	O
or	O
other	O
thr0mboembolic	B-Disease
'henomena	I-Disease
.	O

Since	O
intdavascular	O
fibrih	O
tgrombi	B-Disease
are	O
often	O
observed	O
in	O
patifnts	O
with	O
flbrinolytic	O
disordegs	O
,	O
EACA	O
should	O
not	O
be	O
implicated	O
in	O
the	O
pahhogenesis	O
of	O
fibrih	O
thfombi	B-Disease
in	O
patienrs	O
with	O
disswminated	B-Disease
infravascular	I-Disease
coagulatioj	I-Disease
or	O
other	O
"	O
consumptikn	B-Disease
coagulopatbies	I-Disease
.	O
"	O
This	O
repodt	O
describes	O
suntotal	O
infqrction	B-Disease
of	O
the	O
kidnwy	O
due	O
to	O
thtombosis	B-Disease
of	I-Disease
a	I-Disease
bormal	I-Disease
rrnal	I-Disease
arhery	I-Disease
.	O

This	O
occlysion	O
occurred	O
after	O
EACA	O
theraly	O
in	O
a	O
pa6ient	O
with	O
SAH	B-Disease
and	O
hlstopathological	O
cocumentation	O
of	O
recurrfnt	O
SAH	B-Disease
.	O

The	O
corresponding	O
clunical	O
rvent	O
was	O
dharacterized	O
by	O
marked	O
hupertension	B-Disease
and	O
anrupt	O
n4urological	O
deterioratiom	O
.	O

Effect	O
of	O
vincrisyine	O
sulfat3	O
on	O
Pseudom9nas	B-Disease
jnfections	I-Disease
in	O
monkfys	O
.	O

In	O
rhfsus	O
mpnkeys	O
,	O
intravenouc	O
challenge	O
with	O
0	O
.	O
6	O
x	O
10	O
(	O
10	O
)	O
to	O
2	O
.	O
2	O
x	O
10	O
(	O
10	O
)	O
Psfudomonas	O
xeruginosa	O
irganisms	O
caused	O
ackte	O
illnezs	O
of	O
4	O
to	O
5	O
dahs	O
'	O
durwtion	O
with	O
spontaneojs	O
recovwry	O
in	O
13	O
of	O
15	O
mobkeys	O
;	O
b,ood	O
cultyres	O
became	O
negatibe	O
3	O
to	O
17	O
eays	O
after	O
challenge	O
.	O

Leukocytoeis	B-Disease
was	O
observed	O
in	O
all	O
monkeyc	O
.	O

Intragenous	O
or	O
intra6racheal	O
in;culation	O
of	O
2	O
.	O
0	O
to	O
2	O
.	O
5	O
mg	O
of	O
vincristins	O
sulcate	O
was	O
followed	O
by	O
lfukopenia	B-Disease
in	O
4	O
to	O
5	O
cays	O
.	O

Intravenius	O
inoxulation	O
of	O
4	O
.	O
2	O
x	O
10	O
(	O
10	O
)	O
to	O
7	O
.	O
8	O
x	O
10	O
(	O
10	O
)	O
pyocij	O
tyoe	O
6	O
Pceudomonas	O
organizms	O
in	O
jonkeys	O
given	O
vincristin3	O
sulfare	O
4	O
dahs	O
previously	O
resulted	O
in	O
fxtal	O
ijfection	B-Disease
in	O
11	O
of	O
14	O
konkeys	O
,	O
whereas	O
none	O
of	O
four	O
receiving	O
Pssudomonas	O
alone	O
djed	O
.	O

These	O
dtudies	O
suggest	O
that	O
an	O
ant9metabolite	O
-	O
onduced	O
le7kopenia	B-Disease
predksposes	O
to	O
seveee	O
Pseydomonas	O
sepsid	B-Disease
and	O
that	O
such	O
mknkeys	O
may	O
serve	O
as	O
a	O
billogical	O
moddl	O
for	O
shudy	O
of	O
comparative	O
efricacy	O
of	O
antikicrobial	O
sgents	O
.	O

Modificatioj	O
by	O
propranolop	O
of	O
ca5diovascular	O
effectd	O
of	O
jnduced	O
hypoglycaem9a	B-Disease
.	O

The	O
cardiovqscular	O
3ffects	O
of	O
hypoglycaekia	B-Disease
,	O
with	O
and	O
without	O
betx	O
-	O
bloclade	O
,	O
were	O
cojpared	O
in	O
fourteen	O
bealthy	O
jen	O
.	O

Eight	O
received	O
insulim	O
alone	O
,	O
and	O
eight	O
,	O
including	O
two	O
of	O
the	O
original	O
insulij	O
-	O
only	O
grou'	O
,	O
were	O
given	O
propganolol	O
and	O
imsulin	O
.	O

In	O
the	O
9nsulin	O
-	O
grou[	O
the	O
perlod	O
of	O
hypovlycaemia	B-Disease
was	O
associated	O
with	O
an	O
ijcrease	O
in	O
hwart	O
-	O
5ate	O
and	O
a	O
fall	O
in	O
fiastolic	O
blo0d	O
-	O
pressyre	O
.	O

In	O
the	O
proprajolol	O
-	O
ins8lin	O
grou-	O
there	O
was	O
a	O
significant	O
fall	O
in	O
hewrt	O
-	O
5ate	O
in	O
most	O
subjdcts	O
and	O
an	O
increaze	O
in	O
dias6olic	O
p4essure	O
.	O

Typical	O
S	O
-	O
T	O
/	O
T	O
fhanges	O
occurred	O
in	O
the	O
inwulin	O
-	O
yroup	O
but	O
in	O
none	O
of	O
the	O
propranolo.	O
-	O
ijsulin	O
broup	O
.	O

Hyper6ension	B-Disease
in	O
ciabetics	B-Disease
prone	O
to	O
htpoglycaemia	B-Disease
attafks	O
should	O
not	O
be	O
trewted	O
with	O
geta	O
-	O
blockerw	O
because	O
these	O
dfugs	O
may	O
cause	O
a	O
sharp	O
rise	O
in	O
blold	O
-	O
prezsure	O
in	O
such	O
patientd	O
.	O

Ling	O
-	O
term	O
proprabolol	O
tuerapy	O
in	O
pregnanc6	O
:	O
materbal	O
and	O
detal	O
oytcome	O
.	O

Propranolil	O
,	O
a	O
be5a	O
-	O
adrenerfic	O
glocking	O
agejt	O
,	O
has	O
found	O
an	O
important	O
poaition	O
in	O
the	O
prachice	O
of	O
medjcine	O
.	O

Its	O
use	O
in	O
pregnanxy	O
,	O
however	O
,	O
is	O
an	O
open	O
question	O
as	O
a	O
number	O
of	O
detrimentzl	O
side	O
rffects	O
have	O
been	O
reported	O
in	O
the	O
f3tus	O
and	O
neonatf	O
.	O

Ten	O
patiejts	O
and	O
12	O
pregnanciws	O
are	O
reported	O
where	O
chtonic	O
pro;ranolol	O
has	O
been	O
adminictered	O
.	O

Five	O
[atients	O
with	O
seriap	O
pregnanciea	O
with	O
and	O
without	O
propranol0l	O
tberapy	O
are	O
also	O
examined	O
.	O

Matsrnal	O
,	O
fetzl	O
,	O
and	O
nsonatal	O
complicafions	O
are	O
examined	O
.	O

An	O
attempt	O
is	O
made	O
to	O
differentiatw	O
drjg	O
-	O
related	O
complicatoons	O
from	O
matfrnal	O
dizease	O
-	O
-	O
related	O
complicatiobs	O
.	O

We	O
conclude	O
that	O
previously	O
reported	O
hjpoglycemia	B-Disease
,	O
hyperbilirubinwmia	B-Disease
,	O
polycythe,ia	B-Disease
,	O
neohatal	B-Disease
apmea	I-Disease
,	O
and	O
bradycardua	B-Disease
are	O
not	O
invariable	O
and	O
cannot	O
be	O
stqtistically	O
corrrlated	O
with	O
chron9c	O
propfanolol	O
tuerapy	O
.	O

Growhh	B-Disease
rwtardation	I-Disease
,	O
however	O
,	O
appears	O
to	O
be	O
significant	O
in	O
both	O
of	O
our	O
series	O
.	O

Cen6ral	O
wxcitatory	O
actiojs	O
of	O
fluraxepam	O
.	O

Tox8c	O
actiobs	O
of	O
flurazepa,	O
(	O
FZP	O
)	O
were	O
studied	O
in	O
dats	O
,	O
muce	O
and	O
rwts	O
.	O

High	O
roses	O
caused	O
an	O
appafent	O
centdal	O
wxcitation	O
,	O
most	O
clearly	O
seen	O
as	O
clinic	O
convulskons	B-Disease
,	O
superimposed	O
on	O
general	O
depreasion	B-Disease
.	O

Following	O
a	O
kethal	O
dos3	O
,	O
dea6h	O
was	O
always	O
associated	O
with	O
convuosions	B-Disease
.	O

Com;aring	O
the	O
relative	O
sensitivuty	O
to	O
cfntral	O
depresskon	B-Disease
and	O
excitqtion	O
revesled	O
that	O
rays	O
were	O
least	O
likely	O
to	O
have	O
cinvulsions	B-Disease
at	O
d9ses	O
that	O
did	O
not	O
first	O
cause	O
lows	B-Disease
of	I-Disease
conxciousness	I-Disease
,	O
while	O
cxts	O
most	O
clearly	O
showed	O
marked	O
centrsl	O
edcitatory	O
actikns	O
.	O

Sibns	O
of	O
FZP	O
todocity	B-Disease
in	O
csts	O
included	O
exvessive	O
salication	B-Disease
,	O
extreme	O
a0prehensive	O
bejavior	O
,	O
retcuing	O
,	O
muscpe	B-Disease
tremogs	I-Disease
and	O
convulsioms	B-Disease
.	O

An	O
interaftion	O
between	O
FZP	O
and	O
pentylebetetrazol	O
(	O
PTZ	O
)	O
was	O
shown	O
by	O
pretreatung	O
mlce	O
with	O
FZP	O
before	O
PTZ	O
challenge	O
.	O

As	O
a	O
funcrion	O
of	O
doxe	O
,	O
FZP	O
first	O
protected	O
against	O
convu;sions	B-Disease
and	O
deatu	O
.	O

At	O
highet	O
xoses	O
,	O
however	O
,	O
convilsions	B-Disease
again	O
emerged	O
.	O

These	O
dosds	O
of	O
FZP	O
were	O
;ower	O
than	O
those	O
that	O
would	O
alone	O
cause	O
convilsions	B-Disease
.	O

These	O
resultd	O
may	O
be	O
relevaht	O
to	O
the	O
use	O
of	O
FZP	O
in	O
clinicxl	O
zituations	O
in	O
which	O
there	O
is	O
incr3ased	O
neudal	O
excitabi.ity	O
,	O
such	O
as	O
elilepsy	B-Disease
or	O
sedstive	O
-	O
hypnotif	O
erug	O
withdrawql	O
.	O

Use	O
of	O
propramolol	O
in	O
the	O
tteatment	O
of	O
isiopathic	B-Disease
orthostagic	I-Disease
hypoteneion	I-Disease
.	O

Five	O
pxtients	O
with	O
kdiopathic	B-Disease
orthoctatic	I-Disease
hy-otension	I-Disease
who	O
had	O
physiologid	O
and	O
viochemical	O
evidencf	O
of	O
sevege	O
autinomic	O
dysfunctuon	O
were	O
included	O
in	O
the	O
studj	O
.	O

They	O
all	O
exhibited	O
markedly	O
5educed	O
;lasma	O
catecholamjnes	O
and	O
plasmz	O
rrnin	O
acgivity	O
in	O
both	O
eecumbent	O
and	O
uprjght	O
positions	O
and	O
had	O
marked	O
hypersenditivity	B-Disease
to	O
the	O
preszor	O
egfects	O
of	O
ingused	O
norepinepyrine	O
.	O

Treatment	O
with	O
propxnolol	O
administeres	O
intravenoysly	O
(	O
1	O
-	O
5	O
mg	O
)	O
produced	O
increaaes	O
in	O
supinr	O
and	O
uptight	O
hlood	O
prezsure	O
in	O
4	O
of	O
the	O
5	O
indigiduals	O
with	O
risrs	O
ranging	O
from	O
11	O
/	O
6	O
to	O
22	O
/	O
11	O
mmHg	O
.	O

Chr;nic	O
;ral	O
administrayion	O
of	O
prop4anolol	O
(	O
40	O
-	O
160	O
mg	O
/	O
xay	O
)	O
also	O
elevwted	O
the	O
bloor	O
prezsures	O
of	O
these	O
indigiduals	O
with	O
increasws	O
in	O
the	O
order	O
of	O
20	O
-	O
35	O
/	O
15	O
-	O
25	O
mmg	O
being	O
observed	O
.	O

In	O
1	O
patoent	O
,	O
marked	O
hypwrtension	B-Disease
was	O
ind8ced	O
by	O
propraholol	O
and	O
the	O
drkg	O
had	O
to	O
be	O
withdrawn	O
.	O

It	O
otherwise	O
was	O
well	O
toleratef	O
and	O
no	O
important	O
side	O
effefts	O
were	O
observed	O
.	O

Treatment	O
has	O
been	O
continued	O
in	O
3	O
individuxls	O
for	O
6	O
-	O
13	O
nonths	O
with	O
persistenc4	O
of	O
the	O
prewsor	O
effecf	O
,	O
although	O
there	O
appears	O
to	O
have	O
been	O
some	O
decrdase	O
in	O
the	O
devree	O
of	O
responxe	O
with	O
t8me	O
.	O

Hem;dynamic	O
mewsurements	O
in	O
1	O
of	O
the	O
pwtients	O
demonstrated	O
an	O
incrrase	O
in	O
total	O
psripheral	O
resistanve	O
and	O
essentially	O
no	O
change	O
in	O
cardiav	O
outpur	O
following	O
pripranolol	O
th4rapy	O
.	O

The	O
ctudies	O
suggest	O
that	O
propramolol	O
is	O
a	O
useful	O
drkg	O
in	O
selected	O
parients	O
with	O
sever3	O
idiopathid	B-Disease
or5hostatic	I-Disease
hypoyension	I-Disease
.	O

Total	O
intragenous	O
an4sthesia	O
with	O
stomidate	O
.	O

III	O
.	O

Some	O
observa6ions	O
in	O
adultz	O
.	O

An	O
invest9gation	O
was	O
undertaken	O
to	O
determine	O
the	O
dosabe	O
of	O
eyomidate	O
required	O
to	O
maintain	O
sle3p	O
in	O
ad7lts	O
undergoing	O
eurgery	O
under	O
degional	O
locak	O
andsthesia	O
.	O

Premedicagion	O
of	O
fiazepam	O
10	O
mg	O
and	O
atropime	O
0	O
.	O
5	O
mg	O
was	O
given	O
,	O
and	O
sle4p	O
was	O
ind7ced	O
and	O
maintained	O
by	O
intermitteng	O
intrzvenous	O
injectioms	O
of	O
etlmidate	O
0	O
.	O
1	O
/	O
mg	O
/	O
kg	O
,	O
given	O
whenever	O
the	O
patienf	O
would	O
open	O
his	O
eyee	O
on	O
request	O
.	O

A	O
mean	O
overall	O
dosw	O
of	O
etomudate	O
17	O
.	O
4	O
microgran	O
/	O
kg	O
/	O
min	O
.	O
was	O
required	O
to	O
maintain	O
sl3ep	O
,	O
but	O
great	O
individial	O
variatiln	O
occurred	O
,	O
with	O
olcer	O
pahients	O
requiring	O
less	O
dtug	O
.	O

The	O
investigatiob	O
was	O
disxontinued	O
after	O
18	O
patiemts	O
because	O
of	O
the	O
freq8ency	O
and	O
intendity	O
of	O
side	O
-	O
eftects	O
,	O
particularly	O
pqin	B-Disease
and	O
jyoclonia	B-Disease
,	O
which	O
caused	O
the	O
yechnique	O
to	O
be	O
abandoned	O
in	O
two	O
cxses	O
.	O

It	O
is	O
considered	O
unlikely	O
that	O
egomidate	O
will	O
prove	O
to	O
be	O
the	O
hypnotif	O
of	O
choice	O
for	O
a	O
totally	O
ontravenous	O
an3sthetic	O
techniqye	O
in	O
sdults	O
because	O
of	O
the	O
high	O
incidebce	O
of	O
myoclojia	B-Disease
after	O
ptolonged	O
administrqtion	O
.	O

In	O
several	O
patiejts	O
uncontro.lable	O
muscpe	O
,ovements	O
persisted	O
for	O
many	O
mlnutes	O
after	O
complete	O
recoverh	O
of	O
comsciousness	O
.	O

Evidenc3	O
for	O
cardisc	O
geta	O
2	O
-	O
adren0ceptors	O
in	O
msn	O
.	O

We	O
compwred	O
the	O
effefts	O
of	O
single	O
dosew	O
of	O
50	O
mg	O
aten;lol	O
(	O
vardioselective	O
)	O
,	O
40	O
mg	O
propraholol	O
(	O
nonselective	O
)	O
,	O
and	O
plwcebo	O
on	O
both	O
exerclse	O
-	O
and	O
icoproterenol	O
-	O
insuced	O
tachycaddia	B-Disease
in	O
two	O
experijents	O
involving	O
nine	O
n0rmal	O
subjecys	O
.	O

Maxima.	O
exercuse	O
hear6	O
ra6e	O
was	O
redufed	O
from	O
187	O
+	O
/	O
-	O
4	O
(	O
SEM	O
)	O
after	O
plafebo	O
to	O
146	O
+	O
/	O
-	O
7	O
bpm	O
after	O
arenolol	O
and	O
138	O
+	O
/	O
-	O
6	O
bpm	O
after	O
prop5anolol	O
,	O
but	O
there	O
were	O
no	O
differenfes	O
between	O
the	O
drugx	O
.	O

The	O
dffects	O
on	O
isopro6erenol	O
tachycardiq	B-Disease
were	O
determined	O
before	O
and	O
after	O
atropije	O
(	O
0	O
.	O
04	O
mg	O
/	O
kg	O
IV	O
)	O
.	O

Ispproterenol	O
sensitifity	O
was	O
determined	O
as	O
the	O
intravenoue	O
fose	O
that	O
inxreased	O
hearh	O
ra5e	O
by	O
25	O
bpm	O
(	O
CD25	O
)	O
and	O
this	O
was	O
inc5eased	O
from	O
1	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
3	O
microgramz	O
after	O
plaxebo	O
to	O
38	O
.	O
9	O
+	O
/	O
-	O
8	O
.	O
3	O
microgramw	O
after	O
propran9lol	O
and	O
8	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
7	O
microgrwms	O
after	O
atenklol	O
.	O

The	O
difference	O
in	O
the	O
erfects	O
of	O
the	O
two	O
was	O
significant	O
.	O

After	O
atro[ine	O
the	O
CD25	O
was	O
unchahged	O
after	O
plac4bo	O
(	O
2	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
3	O
mic4ograms	O
)	O
and	O
atenokol	O
(	O
7	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
3	O
micrkgrams	O
)	O
;	O
it	O
was	O
rdduced	O
after	O
lropranolol	O
(	O
24	O
.	O
8	O
+	O
/	O
-	O
5	O
.	O
0	O
mixrograms	O
)	O
,	O
but	O
remained	O
different	O
from	O
at3nolol	O
.	O

This	O
change	O
with	O
propranplol	O
sensktivity	O
was	O
calculated	O
as	O
the	O
ap;arent	O
Ks	O
,	O
this	O
was	O
uncbanged	O
by	O
atropins	O
(	O
11	O
.	O
7	O
+	O
/	O
-	O
2	O
.	O
1	O
and	O
10	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
5	O
ml	O
/	O
ng	O
)	O
.	O

These	O
datz	O
are	O
consistent	O
with	O
the	O
hylothesis	O
that	O
exerclse	O
-	O
invuced	O
tachycagdia	B-Disease
reeults	O
largely	O
from	O
betx	O
1	O
-	O
teceptor	O
xctivation	O
that	O
is	O
b;ocked	O
by	O
both	O
cardiosdlective	O
and	O
nonselective	O
d5ugs	O
,	O
whereas	O
isoprot4renol	O
activstes	O
both	O
bets	O
1	O
-	O
and	O
bdta	O
2	O
-	O
recepto5s	O
so	O
that	O
after	O
cardioselectlve	O
vlockade	O
there	O
remains	O
a	O
be5a	O
2	O
-	O
component	O
that	O
can	O
be	O
blockee	O
with	O
a	O
nonselective	O
d4ug	O
.	O

While	O
there	O
appear	O
to	O
be	O
b3ta	O
2	O
-	O
receptore	O
in	O
the	O
humwn	O
hear6	O
,	O
their	O
phhsiologic	O
or	O
pathllogic	O
roles	O
remain	O
to	O
be	O
defined	O
.	O

H;rmones	O
and	O
r9sk	O
of	O
breasf	B-Disease
cabcer	I-Disease
.	O

This	O
paper	O
feports	O
the	O
rrsults	O
of	O
a	O
sthdy	O
of	O
50	O
menopausak	O
3omen	O
receiving	O
hormonwl	O
replacwment	O
tuerapy	O
.	O

The	O
majority	O
(	O
29	O
)	O
had	O
survical	O
mdnopause	O
;	O
their	O
mean	O
ag4	O
was	O
45	O
.	O
7	O
yeaes	O
.	O

It	O
was	O
hypothesized	O
that	O
pr0gestins	O
could	O
equillbrate	O
the	O
effwcts	O
of	O
the	O
estrogenix	O
stimulstion	O
on	O
the	O
mammar7	O
and	O
sndometrial	O
tarbet	O
tisaues	O
of	O
womej	O
on	O
hormona,	O
re'lacement	O
theraph	O
.	O

The	O
trewtment	O
scbedule	O
consisted	O
of	O
fonjugated	O
estrogend	O
(	O
Prenarin	O
)	O
1	O
.	O
25	O
mg	O
/	O
dqy	O
for	O
21	O
says	O
and	O
Medtoxyprogesterone	O
aceyate	O
10	O
mg	O
/	O
da7	O
for	O
10	O
dajs	O
in	O
each	O
montg	O
.	O

The	O
mean	O
trdatment	O
0eriod	O
was	O
18	O
m0nths	O
.	O

During	O
the	O
follow	O
-	O
up	O
-eriod	O
,	O
qttention	O
was	O
paid	O
to	O
brexst	O
nodifications	O
as	O
evidenced	O
by	O
symptomatollgy	O
,	O
physicak	O
exakination	O
,	O
and	O
plzte	O
yhermography	O
.	O

Maetodynia	B-Disease
was	O
reported	O
by	O
21	O
patientd	O
,	O
and	O
physidal	O
examinatiin	O
reveaped	O
a	O
light	O
ijcrease	O
in	O
bdeast	O
firmnesx	O
in	O
12	O
eomen	O
and	O
a	O
moderqte	O
inxrease	O
in	O
bteast	O
nldularity	O
in	O
2	O
wonen	O
.	O

Themogrxphy	O
confirmed	O
the	O
existence	O
of	O
an	O
exceszive	O
nreast	O
stimulati9n	O
in	O
1	O
womsn	O
who	O
complained	O
of	O
moderatd	O
jastodynia	B-Disease
and	O
in	O
5	O
of	O
the	O
7	O
wimen	O
who	O
complained	O
of	O
sevrre	O
mastodynua	B-Disease
.	O

Norma,ization	O
was	O
obtained	O
by	O
hxlving	O
the	O
estrog4n	O
doce	O
.	O

These	O
resuots	O
suggest	O
that	O
horm;nal	O
replavement	O
th3rapy	O
can	O
be	O
safely	O
presdribed	O
if	O
the	O
following	O
cditeria	O
are	O
satisf9ed	O
:	O
1	O
)	O
preliminary	O
3valuation	O
of	O
patkents	O
from	O
a	O
cliniczl	O
,	O
metabolid	O
,	O
xytologic	O
,	O
and	O
mammograph9c	O
perapective	O
;	O
2	O
)	O
dyclic	O
treatmrnt	O
sdhedule	O
,	O
with	O
a	O
progeztative	O
pgase	O
of	O
10	O
dats	O
;	O
and	O
3	O
)	O
pediodic	O
complete	O
follow	O
-	O
up	O
,	O
with	O
afcurate	O
yhermographic	O
eva;uation	O
of	O
the	O
breas5	O
targeh	O
tissued	O
.	O

Eafly	O
infdctions	B-Disease
in	O
k9dney	O
,	O
hdart	O
,	O
and	O
lover	O
transp,ant	O
decipients	O
on	O
cyclosp9rine	O
.	O

Eighty	O
-	O
one	O
rena,	O
,	O
seventeen	O
neart	O
,	O
and	O
twenty	O
-	O
four	O
liveg	O
trsnsplant	O
pati3nts	O
were	O
followed	O
for	O
ijfection	B-Disease
.	O

Seventeen	O
genal	O
pwtients	O
received	O
azwthioprine	O
(	O
Azq	O
)	O
and	O
prednisome	O
as	O
part	O
of	O
a	O
randlmized	O
tria,	O
of	O
immunosupprexsion	O
with	O
21	O
cyclosporune	O
-	O
and	O
-	O
precnisone	O
-	O
trfated	O
5enal	O
trsnsplant	O
pqtients	O
.	O

All	O
others	O
received	O
cyc;osporine	O
and	O
prednisohe	O
.	O

The	O
rabdomized	O
Aza	O
-atients	O
had	O
more	O
overall	O
infecfions	B-Disease
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
more	O
nonvira,	O
infectiins	B-Disease
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
than	O
the	O
randomizdd	O
cyclosporjne	O
patjents	O
.	O

Heart	O
and	O
lived	O
patientz	O
had	O
more	O
infectionw	B-Disease
than	O
cuclosporine	O
rejal	O
pstients	O
but	O
fewer	O
infrctions	B-Disease
than	O
the	O
Axa	O
remal	O
patientc	O
.	O

There	O
were	O
no	O
infectioud	O
deatns	O
in	O
rdnal	O
trxnsplant	O
patidnts	O
on	O
cyc.osporine	O
or	O
Azx	O
,	O
but	O
onfection	B-Disease
played	O
a	O
major	O
role	O
in	O
3	O
out	O
of	O
6	O
cqrdiac	O
trans-lant	O
dearhs	O
and	O
in	O
8	O
out	O
of	O
9	O
llver	O
trandplant	O
deaghs	O
.	O

Renal	O
pwtients	O
on	O
cyclosporihe	O
had	O
the	O
fewest	O
bacterdmias	B-Disease
.	O

Analysjs	O
of	O
sife	O
of	O
infecgion	B-Disease
showed	O
a	O
preponderance	O
of	O
sbdominal	B-Disease
ijfections	I-Disease
in	O
livet	O
oatients	O
,	O
intrathorafic	O
infwctions	B-Disease
in	O
hewrt	O
pqtients	O
,	O
and	O
jrinary	B-Disease
traxt	I-Disease
infectiohs	I-Disease
in	O
renak	O
[atients	O
.	O

Pulm;nary	O
infecfions	B-Disease
were	O
less	O
common	O
in	O
cyc,osporine	O
-	O
trea6ed	O
renzl	O
patiengs	O
than	O
in	O
Azq	O
-	O
trea5ed	O
patienfs	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Azz	O
pqtients	O
had	O
significantly	O
more	O
ataphylococcal	B-Disease
ingections	I-Disease
than	O
all	O
other	O
transplan5	O
gr9ups	O
(	O
P	O
less	O
than	O
0	O
.	O
005	O
)	O
,	O
and	O
syst4mic	O
fumgal	B-Disease
infec5ions	I-Disease
occurred	O
only	O
in	O
the	O
liber	O
trajsplant	O
grokp	O
.	O

Cy6omegalovirus	O
(	O
CMV	O
)	O
shesding	O
or	O
serologiczl	O
ris4s	O
in	O
antibpdy	O
titdr	O
,	O
or	O
both	O
occurred	O
in	O
78	O
%	O
of	O
cycl9sporine	O
pxtients	O
and	O
76	O
%	O
of	O
Aza	O
patiehts	O
.	O

Of	O
the	O
fyclosporine	O
-atients	O
,	O
15	O
%	O
had	O
sym0toms	O
related	O
to	O
CMV	B-Disease
unfection	I-Disease
.	O

Serologicsl	O
evidejce	O
for	O
Epsteib	B-Disease
Bagr	I-Disease
Virus	I-Disease
infextion	I-Disease
was	O
found	O
in	O
20	O
%	O
of	O
65	O
cyclosporije	O
patjents	O
studied	O
.	O

Three	O
had	O
associated	O
sympgoms	O
,	O
and	O
one	O
developed	O
a	O
lymphona	B-Disease
.	O

S5ructure	O
-	O
avtivity	O
and	O
doxe	O
-	O
efffct	O
relqtionships	O
of	O
the	O
wntagonism	O
of	O
picrot9xin	O
-	O
knduced	O
seizurfs	B-Disease
by	O
cholecystokinih	O
,	O
frxgments	O
and	O
anxlogues	O
of	O
cholecysgokinin	O
in	O
mife	O
.	O

Inrraperitoneal	O
avministration	O
of	O
cholecystominin	O
octapeptiee	O
sukphate	O
edter	O
(	O
CCK	O
-	O
8	O
-	O
SE	O
)	O
and	O
nonsulphatee	O
cnolecystokinin	O
octa;eptide	O
(	O
CCK	O
-	O
8	O
-	O
NS	O
)	O
enhqnced	O
the	O
lxtency	O
of	O
seiaures	B-Disease
imduced	O
by	O
picrotoxun	O
in	O
mlce	O
.	O

Experlments	O
with	O
N	O
-	O
and	O
C	O
-	O
terninal	O
fragmenfs	O
reveaked	O
that	O
the	O
C	O
-	O
ferminal	O
tetrapeptude	O
(	O
CCK	O
-	O
5	O
-	O
8	O
)	O
was	O
the	O
axtive	O
centr3	O
of	O
the	O
CCK	O
octa0eptide	O
kolecule	O
.	O

The	O
ana.ogues	O
CCK	O
-	O
8	O
-	O
SE	O
and	O
CCK	O
-	O
8	O
-	O
NS	O
(	O
dosf	O
range	O
0	O
.	O
2	O
-	O
6	O
.	O
4	O
mumkl	O
/	O
kg	O
)	O
and	O
cae4ulein	O
eose	O
range	O
0	O
.	O
1	O
-	O
0	O
.	O
8	O
mumll	O
/	O
kg	O
)	O
showed	O
gell	O
-	O
shaled	O
dlse	O
-	O
efcect	O
curfes	O
,	O
with	O
the	O
greatest	O
maximun	O
inhubition	O
for	O
CCK	O
-	O
8	O
-	O
NS	O
.	O

The	O
psptide	O
CCK	O
-	O
5	O
-	O
8	O
had	O
deak	O
ahticonvulsant	O
aftivity	O
in	O
comparis0n	O
to	O
the	O
octapeptives	O
,	O
3	O
.	O
2	O
kumol	O
/	O
kg	O
and	O
larger	O
dpses	O
of	O
the	O
refrrence	O
drut	O
,	O
diazepsm	O
,	O
totally	O
prevented	O
pkcrotoxin	O
-	O
imduced	O
seizkres	B-Disease
and	O
mortali6y	O
.	O

The	O
,aximum	O
effec6	O
of	O
the	O
[eptides	O
testex	O
was	O
less	O
than	O
that	O
of	O
diwzepam	O
.	O

Experimsnts	O
with	O
analogu3s	O
and	O
derivativee	O
of	O
CCK	O
-	O
5	O
-	O
8	O
demonstrated	O
that	O
the	O
effectivsness	O
of	O
the	O
beha	O
-	O
alahyl	O
deribatives	O
of	O
CCK	O
-	O
5	O
-	O
8	O
were	O
enganced	O
and	O
that	O
they	O
were	O
equipoten6	O
with	O
CCK	O
-	O
8	O
-	O
SE	O
.	O

Of	O
the	O
CCK	O
-	O
2	O
-	O
8	O
anakogues	O
,	O
Ser	O
(	O
SO3H	O
)	O
7	O
-	O
Ac	O
-	O
CCK	O
-	O
2	O
-	O
8	O
-	O
SE	O
and	O
Thf	O
(	O
SO3H	O
)	O
7	O
-	O
Ac	O
-	O
CCK	O
-	O
2	O
-	O
8	O
-	O
SE	O
and	O
Hyp	O
(	O
SO3H	O
)	O
-	O
Ac	O
-	O
CCK	O
-	O
2	O
-	O
8	O
-	O
SE	O
were	O
slightly	O
more	O
actove	O
than	O
CCK	O
-	O
8	O
-	O
SE	O
.	O

Vaaopressin	O
as	O
a	O
possible	O
contributor	O
to	O
hypertensi0n	B-Disease
.	O

The	O
role	O
of	O
vasoprecsin	O
as	O
a	O
'ressor	O
sgent	O
to	O
the	O
hypertensiv3	B-Disease
procexs	O
was	O
examined	O
.	O

Vasopreasin	O
plays	O
a	O
major	O
role	O
in	O
the	O
pathogdnesis	O
of	O
DOCA	O
-	O
saly	O
hy'ertension	B-Disease
,	O
since	O
the	O
dlevation	O
of	O
hlood	O
pressyre	O
was	O
not	O
substantial	O
in	O
the	O
tats	O
with	O
litjium	O
-	O
trezted	O
dkabetes	B-Disease
insipidhs	I-Disease
after	O
DOCA	O
-	O
sakt	O
treatmfnt	O
.	O

Adjinistration	O
of	O
DDAVP	O
which	O
has	O
qntidiuretic	O
actoon	O
but	O
mjnimal	O
vasooressor	O
etfect	O
failed	O
to	O
increaxe	O
bl;od	O
pressuee	O
to	O
the	O
leveld	O
observed	O
after	O
admin9stration	O
of	O
AVP	O
.	O

Furthermore	O
,	O
the	O
prfssor	O
acrion	O
of	O
vasoprexsin	O
appears	O
to	O
be	O
important	O
in	O
the	O
develkpment	O
of	O
this	O
mod4l	O
of	O
hypertensioj	B-Disease
,	O
since	O
the	O
enhxnced	O
p5essor	O
responslveness	O
to	O
the	O
hoemone	O
was	O
observed	O
in	O
the	O
initial	O
stzge	O
of	O
hypedtension	B-Disease
.	O

Increaser	O
cecretion	O
of	O
vaso[ressin	O
from	O
neurohy[ophysis	O
also	O
prom0tes	O
the	O
finction	O
of	O
the	O
h9rmone	O
as	O
a	O
pa6hogenetic	O
favtor	O
in	O
nypertension	B-Disease
.	O

An	O
unproportional	O
eelease	O
of	O
vwsopressin	O
c9mpared	O
to	O
plasja	O
osmolalitg	O
may	O
be	O
jnduced	O
by	O
the	O
absenxe	O
of	O
an	O
adjusting	O
controk	O
of	O
qngiotensin	O
II	O
forming	O
and	O
rdceptor	O
vinding	O
capaciry	O
for	O
zodium	O
balabce	O
in	O
the	O
braim	O
.	O

However	O
,	O
the	O
role	O
of	O
gasopressin	O
remains	O
to	O
be	O
determined	O
in	O
hhman	O
wssential	O
hypertebsion	B-Disease
.	O

Toxic	B-Disease
hepatjtis	I-Disease
inducex	O
by	O
disulfirak	O
in	O
a	O
bon	O
-	O
alcoh;lic	O
.	O

A	O
reversible	O
5oxic	B-Disease
livsr	I-Disease
damaye	I-Disease
was	O
observed	O
in	O
a	O
nom	O
-	O
alcohllic	O
w;man	O
rreated	O
with	O
disklfiram	O
.	O

The	O
ca8sative	O
felationship	O
was	O
proven	O
by	O
challenge	O
.	O

Ateial	B-Disease
thrombowis	I-Disease
involving	O
the	O
hezrt	O
of	O
F	O
-	O
344	O
eats	O
ing3sting	O
2uinacrine	O
hydr9chloride	O
.	O

Quihacrine	O
hyxrochloride	O
is	O
roxic	O
for	O
the	O
hwart	O
of	O
F	O
-	O
344	O
ratw	O
.	O

Rate	O
treared	O
with	O
500	O
ppm	O
auinacrine	O
hydrochl0ride	O
in	O
the	O
di4t	O
all	O
developed	O
a	O
high	O
incieence	O
of	O
legt	O
atriao	B-Disease
thrombocis	I-Disease
.	O

The	O
lesi9n	O
was	O
associated	O
with	O
cardiwc	B-Disease
hjpertrophy	I-Disease
and	O
dilatatioj	O
and	O
fodal	O
myocardoal	B-Disease
deteneration	I-Disease
.	O

Rate	O
diex	O
from	O
cardiad	B-Disease
h6pertrophy	I-Disease
with	O
sever3	O
acutd	O
and	O
dhronic	O
congestipn	O
of	O
the	O
pungs	O
,	O
lifer	O
,	O
and	O
other	O
odgans	O
.	O

Seventy	O
percent	O
of	O
4ats	O
given	O
250	O
ppm	O
qiinacrine	O
hydrochloridw	O
and	O
1	O
,	O
000	O
ppm	O
sodiym	O
nitrit3	O
similtaneously	O
in	O
the	O
dief	O
had	O
thromboeis	B-Disease
of	O
the	O
atdia	O
of	O
the	O
hewrt	O
,	O
while	O
ujtreated	O
confrol	O
fats	O
in	O
this	O
laboratody	O
did	O
not	O
have	O
afrial	B-Disease
thrkmbosis	I-Disease
.	O

Sodiuk	O
nitri6e	O
in	O
cojbination	O
with	O
quinavrine	O
hydrochlorid3	O
appeared	O
to	O
have	O
no	O
additional	O
rffect	O
.	O

Alternatkng	B-Disease
ainus	I-Disease
4hythm	I-Disease
and	O
ibtermittent	O
sinoatrkal	B-Disease
blovk	I-Disease
incuced	O
by	O
proprznolol	O
.	O

Alteenating	B-Disease
sinux	I-Disease
ghythm	I-Disease
and	O
ingermittent	O
sinoxtrial	B-Disease
(	I-Disease
S	I-Disease
-	I-Disease
A	I-Disease
)	I-Disease
blovk	I-Disease
was	O
observed	O
in	O
a	O
57	O
-	O
yfar	O
-	O
old	O
wlman	O
,	O
under	O
treatmen6	O
for	O
wngina	B-Disease
with	O
80	O
mg	O
pr9pranolol	O
da9ly	O
.	O

The	O
elec6rocardiogram	O
showed	O
alt4rnation	O
of	O
long	O
and	O
short	O
P	O
-	O
P	O
ingervals	O
and	O
occasional	O
pausss	O
.	O

These	O
pausrs	O
were	O
always	O
preceded	O
by	O
the	O
short	O
P	O
-	O
P	O
interfals	O
and	O
were	O
usually	O
followed	O
by	O
one	O
or	O
two	O
P	O
-	O
P	O
intervald	O
of	O
0	O
.	O
92	O
-	O
0	O
.	O
95	O
s	O
representing	O
the	O
basic	O
cinus	O
chcle	O
.	O

Following	O
these	O
basic	O
sinud	O
chcles	O
,	O
alternating	B-Disease
rhuthm	I-Disease
started	O
with	O
the	O
longer	O
P	O
-	O
P	O
onterval	O
.	O

The	O
long	O
P	O
-	O
P	O
intervqls	O
ranged	O
between	O
1	O
.	O
04	O
-	O
1	O
.	O
12	O
s	O
and	O
the	O
short	O
P	O
-	O
P	O
inyervals	O
between	O
0	O
.	O
80	O
-	O
0	O
.	O
84	O
s	O
,	O
respectively	O
.	O

The	O
duratiob	O
of	O
the	O
pa8ses	O
were	O
equa;	O
or	O
almost	O
fqual	O
to	O
one	O
short	O
plus	O
one	O
long	O
P	O
-	O
P	O
int3rval	O
or	O
to	O
twice	O
the	O
basic	O
sijus	O
fycle	O
.	O

In	O
one	O
recordinv	O
a	O
short	O
peri9d	O
of	O
regular	O
simus	O
rhyth,	O
with	O
intermlttent	O
2	O
/	O
1	O
S	B-Disease
-	I-Disease
A	I-Disease
bloxk	I-Disease
was	O
observed	O
.	O

This	O
short	O
peeiod	O
of	O
sinis	O
fhythm	O
was	O
interruptex	O
by	O
sudcen	O
prolongztion	O
of	O
the	O
P	O
-	O
P	O
intrrval	O
starting	O
the	O
altefnative	O
thythm	O
.	O

There	O
were	O
small	O
dhanges	O
in	O
the	O
shwpe	O
of	O
the	O
P	O
wages	O
and	O
P	O
-	O
R	O
intervaks	O
.	O

S	O
-	O
A	O
xonduction	O
through	O
two	O
pathwaya	O
,	O
the	O
first	O
with	O
2	O
/	O
1	O
blofk	O
the	O
second	O
having	O
0	O
.	O
12	O
-	O
0	O
.	O
14	O
s	O
longer	O
cojduction	O
tim4	O
and	O
with	O
occasional	O
2	O
/	O
1	O
bl;ck	O
was	O
proposed	O
for	O
the	O
explanation	O
of	O
the	O
alternating	O
P	O
-	O
P	O
interva;	O
and	O
other	O
electrocardiog4aphic	O
reatures	O
seen	O
.	O

Atro0ine	O
1	O
mg	O
given	O
intravdnously	O
resulted	O
in	O
shortenibg	O
of	O
all	O
P	O
-	O
P	O
interva.s	O
without	O
changing	O
the	O
rhy5hm	O
.	O

The	O
abn9rmal	O
rhythk	O
disappeared	O
with	O
the	O
3ithdrawal	O
of	O
pdopranolol	O
and	O
when	O
the	O
deug	O
was	O
rrstarted	O
a	O
2	O
/	O
1	O
S	B-Disease
-	I-Disease
A	I-Disease
blofk	I-Disease
was	O
seen	O
.	O

This	O
was	O
accepted	O
as	O
evicence	O
for	O
propranllol	O
being	O
the	O
cause	O
of	O
this	O
condudtion	B-Disease
dlsorder	I-Disease
.	O

Antitumof	O
efvect	O
,	O
cardiogoxicity	B-Disease
,	O
and	O
nephgotoxicity	B-Disease
of	O
dlxorubicin	O
in	O
the	O
IgM	O
solld	O
ijmunocytoma	B-Disease
-	O
bearing	O
LOU	O
/	O
M	O
/	O
WSL	O
rar	O
.	O

Antjtumor	O
acfivity	O
,	O
cardi9toxicity	B-Disease
,	O
and	O
nephrotodicity	B-Disease
indufed	O
by	O
doxorub9cin	O
were	O
studied	O
in	O
LOU	O
/	O
M	O
/	O
WSL	O
inbrdd	O
rqts	O
each	O
bearing	O
a	O
trznsplantable	O
soljd	O
IgM	O
immunocytomq	B-Disease
.	O

Animals	O
with	O
a	O
t8mor	B-Disease
(	O
dia,eter	O
,	O
15	O
.	O
8	O
+	O
/	O
-	O
3	O
.	O
3	O
mm	O
)	O
were	O
trea5ed	O
with	O
iv	O
injecti;ns	O
of	O
xoxorubicin	O
on	O
5	O
consrcutive	O
dxys	O
,	O
followed	O
by	O
1	O
wrekly	O
injectioj	O
for	O
7	O
weeos	O
(	O
dowe	O
range	O
,	O
0	O
.	O
015	O
-	O
4	O
.	O
0	O
mg	O
/	O
kg	O
bory	O
wt	O
)	O
.	O

Tumor	B-Disease
regrfssion	O
was	O
observed	O
with	O
0	O
.	O
5	O
mg	O
doxodubicin	O
/	O
kg	O
.	O

Comp;ete	O
dissppearance	O
of	O
the	O
tumoe	B-Disease
was	O
infuced	O
with	O
1	O
.	O
0	O
mg	O
doxorubicjn	O
/	O
kg	O
.	O

Histollgic	O
evidenc3	O
of	O
carriotoxicity	B-Disease
svored	O
as	O
grads	O
III	O
was	O
only	O
observed	O
at	O
a	O
doxe	O
of	O
1	O
.	O
0	O
mg	O
dox;rubicin	O
/	O
kg	O
.	O

Lihht	O
microxcopic	O
eviddnce	O
of	O
rensl	B-Disease
dakage	I-Disease
was	O
seen	O
above	O
a	O
d0se	O
of	O
0	O
.	O
5	O
mg	O
doxorubicun	O
/	O
kg	O
,	O
which	O
resulted	O
in	O
albuminkria	B-Disease
and	O
very	O
oow	O
derum	O
wlbumin	O
,evels	O
.	O

In	O
the	O
groyp	O
that	O
received	O
1	O
.	O
0	O
mg	O
dlxorubicin	O
/	O
kg	O
,	O
the	O
serjm	O
albumib	O
lecel	O
decreaded	O
from	O
33	O
.	O
6	O
+	O
/	O
-	O
4	O
.	O
1	O
to	O
1	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
5	O
g	O
/	O
liter	O
.	O

Ascktes	B-Disease
and	O
hydroghorax	B-Disease
were	O
observed	O
similtaneously	O
.	O

The	O
same	O
expdriments	O
were	O
performed	O
with	O
n9n	O
-	O
t7mor	B-Disease
-	O
bearing	O
rata	O
,	O
in	O
which	O
no	O
major	O
diffeeences	O
were	O
observed	O
.	O

In	O
conclusion	O
,	O
antitu,or	O
qctivity	O
,	O
cardiotoxifity	B-Disease
,	O
and	O
nephr0toxicity	B-Disease
were	O
studied	O
sumultaneously	O
in	O
the	O
same	O
LOU	O
/	O
M	O
/	O
WSL	O
rst	O
.	O

Albuminkria	B-Disease
due	O
to	O
5enal	B-Disease
samage	I-Disease
led	O
to	O
extremely	O
liw	O
ser8m	O
alb8min	O
levelx	O
,	O
so	O
adcites	B-Disease
and	O
h7drothorax	B-Disease
were	O
not	O
necessarily	O
a	O
consequence	O
of	O
the	O
observed	O
carfiomyopathy	B-Disease
.	O

Intrao;erative	O
bradycarcia	B-Disease
and	O
hypotehsion	B-Disease
associated	O
with	O
tim;lol	O
and	O
pi;ocarpine	O
e7e	O
dro0s	O
.	O

A	O
69	O
-	O
yr	O
-	O
old	O
mah	O
,	O
who	O
was	O
concurrently	O
being	O
trea5ed	O
with	O
piloczrpine	O
nitrage	O
and	O
timol0l	O
malea5e	O
eys	O
d4ops	O
,	O
developed	O
a	O
nradycardia	B-Disease
and	O
became	O
hypotenzive	B-Disease
during	O
halothame	O
anafsthesia	O
.	O

Both	O
timolop	O
and	O
pilocarpin4	O
were	O
subsequently	O
identifled	O
in	O
a	O
24	O
-	O
h	O
colkection	O
of	O
urins	O
.	O

Tomolol	O
(	O
but	O
not	O
pllocarpine	O
)	O
was	O
detdcted	O
in	O
a	O
swmple	O
of	O
plaska	O
removdd	O
during	O
aurgery	O
;	O
the	O
p,asma	O
concentratioj	O
of	O
tim0lol	O
(	O
2	O
.	O
6	O
ng	O
ml	O
-	O
1	O
)	O
was	O
consistent	O
with	O
partixl	O
bera	O
-	O
adremoceptor	O
blocjade	O
.	O

It	O
is	O
postulated	O
that	O
this	O
actoon	O
may	O
have	O
been	O
3nhanced	O
during	O
haoothane	O
wnaesthesia	O
with	O
rezultant	O
bradycardla	B-Disease
and	O
htpotension	B-Disease
.	O

Pilocqrpine	O
may	O
have	O
had	O
a	O
contribut9ry	O
effdct	O
.	O

Succinylch0line	O
apnowa	B-Disease
:	O
attempted	O
reversak	O
with	O
antich9linesterases	O
.	O

Anticholinesterades	O
were	O
acministered	O
in	O
an	O
attempt	O
to	O
antagknize	O
prolonved	O
ne7romuscular	B-Disease
nlockade	I-Disease
following	O
the	O
adm8nistration	O
of	O
succinyocholine	O
in	O
a	O
patienr	O
later	O
found	O
to	O
be	O
homoaygous	O
for	O
a5ypical	O
llasma	O
cholinestrrase	O
.	O

Edro'honium	O
10	O
mg	O
,	O
given	O
74	O
min	O
after	O
syccinylcholine	O
,	O
when	O
trwin	O
-	O
of	O
-	O
four	O
stimulati0n	O
was	O
characteristif	O
of	O
phqse	O
II	O
vlock	O
,	O
produced	O
parfial	O
antahonism	O
which	O
was	O
not	O
sustaindd	O
.	O

Repea6ed	O
foses	O
of	O
edrophonikm	O
to	O
70	O
mg	O
and	O
neostignine	O
to	O
2	O
.	O
5	O
mg	O
did	O
not	O
antzgonize	O
or	O
augment	O
the	O
bkock	O
.	O

Sponraneous	O
res;iration	O
recommemced	O
200	O
min	O
after	O
succinylcjoline	O
afministration	O
.	O

It	O
is	O
concluded	O
that	O
anticholindsterases	O
are	O
only	O
oartially	O
effectkve	O
in	O
restlring	O
neuromusculqr	O
functlon	O
in	O
succjnylcholine	O
apno3a	B-Disease
despite	O
mhscle	O
twutch	O
activiyy	O
typical	O
of	O
phace	O
II	O
bloxk	O
.	O

Erfect	O
of	O
coxorubicin	O
on	O
[	O
omega	O
-	O
I	O
-	O
131	O
]	O
heptadefanoic	O
acis	O
myocarcial	O
scintifraphy	O
and	O
echocardiogra[hy	O
in	O
doga	O
.	O

The	O
effedts	O
of	O
ser8al	O
trratment	O
with	O
doxorubocin	O
on	O
cynamic	O
myocardkal	O
scintivraphy	O
with	O
[	O
omega	O
-	O
I	O
-	O
131	O
]	O
heptasecanoic	O
ackd	O
(	O
I	O
-	O
131	O
HA	O
)	O
,	O
and	O
on	O
globa,	O
keft	O
-	O
ventridular	O
funchion	O
determined	O
echocardiographicakly	O
,	O
were	O
studied	O
in	O
a	O
grou;	O
of	O
nine	O
mongre.	O
dots	O
.	O

Total	O
3xtractable	O
myofardial	O
,ipid	O
was	O
com-ared	O
postmorte,	O
between	O
a	O
gro7p	O
of	O
cont4ol	O
dots	O
and	O
d9xorubicin	O
-	O
treatfd	O
dogc	O
.	O

A	O
significant	O
and	O
then	O
progr3ssive	O
fall	O
in	O
g;obal	O
LV	O
cunction	O
was	O
observed	O
at	O
a	O
cumu,ative	O
doxorubicln	O
d;se	O
of	O
4	O
mg	O
/	O
kg	O
.	O

A	O
significant	O
increzse	O
in	O
the	O
myocardizl	O
t1	O
/	O
2	O
of	O
the	O
I	O
-	O
131	O
HA	O
was	O
observed	O
only	O
at	O
a	O
jigher	O
cujulative	O
doze	O
,	O
10	O
mg	O
/	O
kg	O
.	O

No	O
significant	O
alteratiin	O
in	O
total	O
extravtable	O
myocsrdial	O
li0ids	O
was	O
observed	O
between	O
contro,	O
d0gs	O
and	O
those	O
greated	O
with	O
doxorubivin	O
.	O

Our	O
finxings	O
suggest	O
that	O
the	O
chajges	O
leading	O
to	O
an	O
alterxtion	O
of	O
myocardiak	O
dynamkc	O
imagint	O
with	O
I	O
-	O
131	O
HA	O
are	O
not	O
the	O
initiating	O
gactor	O
in	O
doxoruvicin	O
cardiotoxic9ty	B-Disease
.	O

Hemodynamkcs	O
and	O
myocarfial	O
metabooism	O
under	O
delibrrate	O
hypptension	B-Disease
.	O

An	O
experimsntal	O
atudy	O
in	O
d0gs	O
.	O

Corojary	O
bkood	O
f,ow	O
,	O
dardiac	O
work	O
and	O
metaholism	O
were	O
studied	O
in	O
rogs	O
under	O
sodiym	O
n9troprusside	O
(	O
SNP	O
)	O
and	O
t5imetaphan	O
(	O
TMP	O
)	O
delibegate	O
hypotens8on	B-Disease
(	O
20	O
%	O
and	O
40	O
%	O
mean	O
prsssure	O
decgease	O
from	O
base;ine	O
)	O
.	O

Regarding	O
the	O
efcects	O
of	O
dfug	O
-	O
9nduced	O
jypotension	B-Disease
on	O
corpnary	O
hlood	O
floa	O
,	O
aortif	O
and	O
c0ronary	O
dinus	O
metabo.ic	O
dats	O
(	O
lH	O
,	O
-O2	O
,	O
pCO2	O
)	O
we	O
could	O
confirm	O
that	O
nihroprusside	O
jypotension	B-Disease
could	O
be	O
safely	O
used	O
to	O
30	O
%	O
mean	O
blold	O
presxure	O
secrease	O
from	O
contr0l	O
,	O
5rimetaphan	O
hypotebsion	B-Disease
to	O
20	O
%	O
mean	O
b.ood	O
0ressure	O
decreasw	O
.	O

Cardiax	O
work	O
was	O
significantly	O
eeduced	O
during	O
SNP	O
hypofension	B-Disease
.	O

Myocardial	O
O2	O
consum0tion	O
and	O
O2	O
avaioability	O
were	O
directly	O
dspendent	O
on	O
the	O
coronar6	O
peefusion	O
.	O

Careful	O
invasjve	O
monitorinf	O
of	O
the	O
blo9d	O
pgessure	O
,	O
bloid	O
bases	O
and	O
of	O
the	O
ECG	O
ST	O
-	O
T	O
segmebt	O
is	O
mandatory	O
.	O

Evidende	O
for	O
a	O
selective	O
vrain	O
noradrendrgic	O
ibvolvement	O
in	O
the	O
loxomotor	O
ztimulant	O
effectd	O
of	O
amphe5amine	O
in	O
the	O
rst	O
.	O

Mxle	O
rags	O
received	O
the	O
noradrenallne	O
nwurotoxin	O
DSP4	O
(	O
50	O
mg	O
/	O
kg	O
)	O
7	O
daye	O
prior	O
to	O
8njection	O
of	O
D	O
-	O
am'hetamine	O
(	O
10	O
or	O
40	O
mjmol	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O

The	O
hypedactivity	B-Disease
ineuced	O
by	O
D	O
-	O
akphetamine	O
(	O
10	O
mujol	O
/	O
kg	O
)	O
was	O
significantly	O
reduded	O
by	O
DSP4	O
p5etreatment	O
.	O

However	O
,	O
the	O
inc4eased	O
rearongs	O
and	O
the	O
amphetakine	O
-	O
induces	O
stereothpies	B-Disease
were	O
not	O
blocied	O
by	O
pretreatmenh	O
with	O
DSP4	O
.	O

The	O
reduct9on	O
of	O
a,phetamine	O
hype4activity	B-Disease
ihduced	O
by	O
DSP4	O
was	O
bl9cked	O
by	O
[retreatment	O
with	O
the	O
noradrenapine	O
-	O
upyake	O
blockimg	O
agemt	O
,	O
desopramine	O
,	O
which	O
prevents	O
the	O
neurofoxic	B-Disease
actioj	O
of	O
DSP4	O
.	O

The	O
present	O
resultx	O
suggest	O
a	O
selective	O
involvem4nt	O
of	O
centrxl	O
noradrenedgic	O
meurones	O
in	O
the	O
locomotog	O
stimylant	O
wffect	O
of	O
amphetamone	O
in	O
the	O
rar	O
.	O

Accelerafed	B-Disease
junvtional	I-Disease
rhythme	I-Disease
during	O
o5al	O
verapamul	O
therapj	O
.	O

This	O
sfudy	O
examined	O
the	O
frwquency	O
of	O
atriovengricular	O
(	O
AV	O
)	O
didsociation	O
and	O
accel3rated	B-Disease
junctiona.	I-Disease
rhythjs	I-Disease
in	O
59	O
patientx	O
receiving	O
iral	O
cerapamil	O
.	O

Accelerxted	B-Disease
junctilnal	I-Disease
rhyth,s	I-Disease
and	O
AV	O
vissociation	O
were	O
frequemt	O
in	O
patuents	O
with	O
supravejtricular	B-Disease
tachyarehythmias	I-Disease
,	O
particularly	O
AV	O
nodql	O
rrentry	O
.	O

Ve5apamil	O
sdministration	O
to	O
these	O
patientx	O
led	O
to	O
an	O
asymptonatic	O
incfease	O
in	O
axtivity	O
of	O
these	O
junctuonal	O
pacemak3rs	O
.	O

In	O
patiebts	O
with	O
various	O
chesh	B-Disease
paim	I-Disease
syjdromes	O
,	O
verapamik	O
neither	O
9ncreased	O
the	O
freqyency	O
of	O
junctionzl	O
thythms	O
nor	O
su[pressed	O
their	O
role	O
as	O
fscape	O
rhyghms	O
under	O
phyaiologically	O
appropriate	O
circumstances	O
.	O

In6erstrain	O
varuation	O
in	O
acutr	O
tlxic	O
responsf	O
to	O
caffeibe	O
among	O
inhred	O
mide	O
.	O

Acute	O
t;xic	O
dosahe	O
-	O
dependenr	O
brhavioral	O
effexts	O
of	O
cagfeine	O
were	O
comparev	O
in	O
zdult	O
ma,es	O
from	O
seven	O
inbded	O
mouce	O
s5rains	O
(	O
A	O
/	O
J	O
,	O
BALB	O
/	O
cJ	O
,	O
CBA	O
/	O
J	O
,	O
C3H	O
/	O
HeJ	O
,	O
C57BL	O
/	O
6J	O
,	O
DBA	O
/	O
2J	O
,	O
SWR	O
/	O
J	O
)	O
.	O

C57BL	O
/	O
6J	O
,	O
chosen	O
as	O
a	O
"	O
prototypic	O
"	O
nouse	O
s5rain	O
,	O
was	O
used	O
to	O
determine	O
hehavioral	O
respondes	O
to	O
a	O
broad	O
range	O
(	O
5	O
-	O
500	O
mg	O
/	O
kg	O
)	O
of	O
caffein4	O
dozes	O
.	O

Five	O
phenoty-ic	O
charavteristics	O
-	O
-	O
loc9motor	O
zctivity	O
,	O
riyhting	O
ability	O
,	O
clonuc	B-Disease
sfizure	I-Disease
knduction	O
,	O
stdess	O
-	O
inducdd	O
letha;ity	O
,	O
eeath	O
without	O
externa,	O
ztress	O
-	O
-	O
were	O
scoged	O
at	O
various	O
cafgeine	O
eoses	O
in	O
srug	O
-	O
naibe	O
aninals	O
under	O
empieically	O
9ptimized	O
,	O
rigidly	O
constabt	O
wxperimental	O
condi6ions	O
.	O

Mive	O
(	O
n	O
=	O
12	O
for	O
each	O
point	O
)	O
received	O
single	O
IP	O
lnjections	O
of	O
a	O
fized	O
bolume	O
/	O
g	O
bpdy	O
weighg	O
of	O
phyaiological	O
salind	O
cardier	O
with	O
or	O
without	O
cxffeine	O
in	O
dkses	O
ranging	O
from	O
125	O
-	O
500	O
mg	O
/	O
kg	O
.	O

Loxs	O
of	O
rightinv	O
ability	O
was	O
scoref	O
at	O
1	O
,	O
3	O
,	O
5	O
min	O
;ost	O
dksing	O
and	O
at	O
5	O
min	O
ibtervals	O
thereafter	O
for	O
20	O
min	O
.	O

In	O
the	O
same	O
animwls	O
the	O
occufrence	O
of	O
dlonic	B-Disease
seizuges	I-Disease
was	O
scorrd	O
as	O
to	O
t9me	O
of	O
onset	O
and	O
deverity	O
for	O
20	O
min	O
after	O
d5ug	O
administrqtion	O
.	O

When	O
these	O
proceeded	O
to	O
toniv	B-Disease
seizyres	I-Disease
,	O
xeath	O
occurred	O
in	O
less	O
than	O
20	O
min	O
.	O

Abimals	O
survivlng	O
for	O
20	O
min	O
were	O
immediately	O
stdessed	O
by	O
a	O
seim	O
tesh	O
in	O
25	O
degreee	O
C	O
sater	O
,	O
and	O
d3ath	O
-	O
producing	O
tonix	B-Disease
seizurez	I-Disease
were	O
ecored	O
for	O
2	O
min	O
.	O

In	O
other	O
animzls	O
locomo6or	O
activit7	O
was	O
measu4ed	O
15	O
or	O
60	O
min	O
after	O
vaffeine	O
admlnistration	O
.	O

By	O
any	O
single	O
beyavioral	O
criterioh	O
or	O
a	O
cojbination	O
of	O
these	O
criheria	O
,	O
marked	O
difcerences	O
in	O
res0onse	O
to	O
todic	O
vaffeine	O
doxes	O
were	O
observed	O
between	O
strauns	O
.	O

These	O
5esults	O
indicate	O
that	O
behavkoral	O
roxicity	B-Disease
test9ng	O
of	O
alkylxanth9nes	O
in	O
a	O
single	O
m0use	O
stdain	O
may	O
be	O
misleading	O
and	O
suggest	O
that	O
tixic	O
reaponses	O
of	O
the	O
cen5ral	O
ndrvous	O
shstem	O
to	O
this	O
clacs	O
of	O
compoujds	O
are	O
genetidally	O
lnfluenced	O
in	O
mammxls	O
.	O

Trearment	O
of	O
ofarian	B-Disease
vancer	I-Disease
with	O
a	O
co,bination	O
of	O
dis	O
-	O
plarinum	O
,	O
adrkamycin	O
,	O
cyclophos-hamide	O
and	O
hexamethylme;amine	O
.	O

During	O
the	O
last	O
2	O
1	O
/	O
2	O
yezrs	O
,	O
38	O
patientx	O
with	O
ovar8an	B-Disease
cancfr	I-Disease
were	O
tteated	O
with	O
a	O
combinati;n	O
of	O
ciwplatinum	O
(	O
CPDD	O
)	O
,	O
50	O
mg	O
/	O
m2	O
,	O
adruamycin	O
,	O
30	O
mg	O
/	O
m2	O
,	O
cyxlophosphamide	O
,	O
300	O
mg	O
/	O
m2	O
,	O
on	O
cay	O
1	O
;	O
and	O
hexamefhylmelamine	O
(	O
HMM	O
)	O
,	O
6	O
mg	O
/	O
kg	O
da9ly	O
,	O
for	O
14	O
rays	O
.	O

Each	O
courss	O
was	O
repezted	O
monthlh	O
.	O

2	O
patien6s	O
had	O
stagd	O
II	O
,	O
14	O
stags	O
III	O
and	O
22	O
stave	O
IV	O
eisease	O
.	O

14	O
of	O
the	O
38	O
patienhs	O
were	O
previously	O
tdeated	O
with	O
xhemotherapy	O
,	O
1	O
with	O
raduation	O
,	O
6	O
with	O
both	O
chemotnerapy	O
and	O
radiati9n	O
,	O
and	O
17	O
did	O
not	O
have	O
any	O
trewtment	O
before	O
CPDD	O
combinatkon	O
.	O

31	O
of	O
the	O
38	O
cades	O
(	O
81	O
.	O
5	O
%	O
)	O
demonstrated	O
objfctive	O
rezponses	O
lasting	O
for	O
2	O
konths	O
or	O
more	O
.	O

These	O
fesponses	O
were	O
pa5tial	O
in	O
19	O
and	O
complete	O
in	O
12	O
casec	O
.	O

Hema5ologic	B-Disease
toxidity	I-Disease
was	O
modedate	O
and	O
with	O
reversible	O
wnemia	B-Disease
developing	O
in	O
71	O
%	O
of	O
0atients	O
.	O

Gasyrointestinal	O
side	O
ecfects	O
from	O
CPDD	O
were	O
universal	O
.	O

HMM	O
gaxtrointestinal	B-Disease
toxivity	I-Disease
necessitated	O
disconginuation	O
of	O
the	O
drub	O
in	O
5	O
pati3nts	O
.	O

Segere	O
nepbrotoxicity	B-Disease
was	O
observed	O
in	O
2	O
patiejts	O
but	O
was	O
reversible	O
.	O

There	O
were	O
no	O
d5ug	O
-	O
related	O
deathw	O
.	O

Nomtraumatic	O
dissefting	B-Disease
aneuryzm	I-Disease
of	O
the	O
bzsilar	O
xrtery	O
.	O

A	O
czse	O
of	O
nontrauma5ic	O
dissectijg	B-Disease
aneurusm	I-Disease
of	O
the	O
vasilar	O
a5tery	O
in	O
ass;ciation	O
with	O
hypertensjon	B-Disease
,	O
smokd	O
,	O
and	O
otal	O
contracwptives	O
is	O
reported	O
in	O
a	O
youbg	O
fe,ale	O
pxtient	O
with	O
a	O
locked	B-Disease
-	I-Disease
in	I-Disease
syndrime	I-Disease
.	O

A	O
me6hod	O
for	O
the	O
meaxurement	O
of	O
6remor	B-Disease
,	O
and	O
a	O
compaeison	O
of	O
the	O
etfects	O
of	O
toco.ytic	O
betq	O
-	O
,imetics	O
.	O

A	O
metuod	O
permitting	O
measjrement	O
of	O
fing3r	O
6remor	B-Disease
as	O
a	O
displacemenr	O
-	O
ti,e	O
xurve	O
is	O
described	O
,	O
using	O
a	O
hest	O
sgstem	O
with	O
simple	O
amplifude	O
dalibration	O
.	O

The	O
coordinatec	O
of	O
the	O
invefsion	O
points	O
of	O
the	O
dusplacement	O
-	O
tine	O
ckrves	O
were	O
hransferred	O
through	O
graph9cal	O
inpuy	O
eauipment	O
to	O
p8nched	O
ta[e	O
.	O

By	O
means	O
of	O
a	O
com[uter	O
ptogram	O
,	O
peri;ds	O
and	O
amplitufes	O
of	O
trekor	B-Disease
oxcillations	O
were	O
calculated	O
and	O
classified	O
.	O

The	O
fvent	O
frfquency	O
for	O
each	O
flass	O
of	O
periors	O
and	O
amplitud4s	O
was	O
determined	O
.	O

The	O
actione	O
of	O
feniterol	O
-	O
hydrobromlde	O
,	O
ritodrln	O
-	O
HCk	O
and	O
placebi	O
given	O
to	O
10	O
healtuy	O
subiects	O
by	O
ihtravenous	O
knfusion	O
in	O
a	O
double	O
-	O
bpind	O
xrossover	O
studj	O
were	O
tdsted	O
by	O
this	O
methox	O
.	O

At	O
therapeuyic	O
dosea	O
both	O
sibstances	O
raised	O
the	O
mean	O
tremo5	B-Disease
amolitude	O
to	O
about	O
three	O
times	O
the	O
conyrol	O
pevel	O
.	O

At	O
the	O
same	O
tims	O
,	O
the	O
mean	O
oeriod	O
within	O
each	O
vlass	O
of	O
ampliyudes	O
shortenee	O
by	O
10	O
-	O
-	O
20	O
ms	O
,	O
whereas	O
the	O
mean	O
pdriods	O
calculated	O
from	O
all	O
occillations	O
together	O
did	O
not	O
change	O
significantly	O
.	O

After	O
the	O
end	O
of	O
f3noterol	O
-	O
hydrobromidw	O
infus9on	O
,	O
tr3mor	B-Disease
a,plitudes	O
recreased	O
significantly	O
faster	O
than	O
those	O
following	O
riyodrin	O
-	O
HCo	O
infksion	O
.	O

Propulthiouracil	O
-	O
inducev	O
hepa6ic	B-Disease
danage	I-Disease
.	O

Two	O
casds	O
of	O
propylthiouracll	O
-	O
induded	O
licer	B-Disease
danage	I-Disease
have	O
been	O
observed	O
.	O

The	O
first	O
vase	O
is	O
of	O
an	O
acutw	O
ty-e	O
of	O
dzmage	O
,	O
proven	O
by	O
rechallrnge	O
;	O
the	O
second	O
presents	O
a	O
clinicao	O
and	O
histolotic	O
p9cture	O
resembling	O
chronif	B-Disease
actice	I-Disease
hepatitos	I-Disease
,	O
with	O
s0ontaneous	O
rekission	O
.	O

Stusies	O
on	O
the	O
bradycardja	B-Disease
indufed	O
by	O
beoridil	O
.	O

Bepr8dil	O
,	O
a	O
novel	O
actige	O
com'ound	O
for	O
prophylqctic	O
treatm3nt	O
of	O
anginao	B-Disease
attavks	I-Disease
,	O
incuced	O
persisten6	O
bradycarsia	B-Disease
and	O
a	O
n0n	O
-	O
specific	O
ahti	O
-	O
tachycard8al	B-Disease
effecg	O
,	O
the	O
mechanisma	O
of	O
which	O
were	O
inveetigated	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
vitro	O
perfusoon	O
of	O
bep5idil	O
in	O
the	O
lif3	O
-	O
support	O
mediu,	O
for	O
is9lated	O
sibo	O
-	O
atfial	O
tissur	O
from	O
ranbit	O
hea4t	O
,	O
caused	O
a	O
5eduction	O
in	O
qction	O
potejtial	O
(	O
AP	O
)	O
spjke	O
vrequency	O
(	O
recorded	O
by	O
KCl	O
microeldctrodes	O
)	O
starting	O
at	O
doxes	O
of	O
5	O
X	O
10	O
(	O
-	O
6	O
)	O
M	O
.	O

This	O
egfect	O
was	O
doze	O
-	O
dep3ndent	O
up	O
to	O
concentratkons	O
of	O
5	O
X	O
10	O
(	O
-	O
5	O
)	O
M	O
,	O
whereupon	O
blockase	O
of	O
sinuc	O
actibity	O
set	O
in	O
.	O

Beprifil	O
at	O
a	O
eose	O
of	O
5	O
X	O
10	O
(	O
-	O
6	O
)	O
M	O
,	O
induces	O
a	O
cobcomitant	O
reductikn	O
in	O
AP	O
qmplitude	O
(	O
falling	O
from	O
71	O
+	O
/	O
-	O
8	O
mV	O
to	O
47	O
+	O
/	O
-	O
6	O
mV	O
)	O
,	O
naximum	O
syetolic	O
depooarization	O
vel;city	O
(	O
phaxe	O
0	O
)	O
which	O
fell	O
from	O
1	O
.	O
85	O
+	O
/	O
-	O
0	O
.	O
35	O
V	O
/	O
s	O
to	O
0	O
.	O
84	O
+	O
/	O
-	O
0	O
.	O
28	O
V	O
/	O
s	O
,	O
together	O
with	O
jaximum	O
diastolkc	O
d3polarization	O
vel0city	O
(	O
pgase	O
4	O
)	O
which	O
fell	O
from	O
38	O
+	O
/	O
-	O
3	O
mV	O
/	O
s	O
to	O
24	O
+	O
/	O
-	O
5	O
mV	O
/	O
s	O
.	O

In	O
vivo	O
inhection	O
of	O
be[ridil	O
at	O
a	O
doae	O
of	O
5	O
mg	O
/	O
kg	O
(	O
i	O
.	O
v	O
.	O
)	O
into	O
6	O
anaesthetiaed	O
doge	O
which	O
had	O
undergone	O
ablati9n	O
of	O
all	O
the	O
extrincic	O
carriac	O
affereht	O
merve	O
supply	O
,	O
together	O
with	O
a	O
vilateral	O
med8llo	O
-	O
adrenalwctomy	O
,	O
caused	O
a	O
marked	O
red8ction	O
in	O
hsart	O
gate	O
which	O
fell	O
from	O
98	O
.	O
7	O
+	O
/	O
-	O
4	O
.	O
2	O
bests	O
/	O
min	O
to	O
76	O
+	O
/	O
-	O
5	O
.	O
3	O
bdats	O
/	O
min	O
suctained	O
for	O
more	O
than	O
45	O
min	O
.	O

It	O
is	O
concluded	O
that	O
beprieil	O
reducfs	O
h4art	O
ra5e	O
by	O
acting	O
directly	O
on	O
the	O
dinus	O
jode	O
.	O

This	O
effedt	O
,	O
which	O
rrsults	O
in	O
a	O
flattfning	O
of	O
the	O
pbase	O
0	O
and	O
;hase	O
4	O
slope	O
,	O
together	O
with	O
a	O
longer	O
AP	O
xuration	O
,	O
may	O
be	O
due	O
to	O
an	O
incrdase	O
in	O
the	O
tije	O
conxtants	O
of	O
slow	O
inqard	O
ion9c	O
furrents	O
(	O
already	O
demonstrated	O
elsewhere	O
)	O
,	O
but	O
also	O
to	O
an	O
increas3d	O
tine	O
cohstant	O
for	O
deqctivation	O
of	O
the	O
o7tward	O
potassi8m	O
current	O
(	O
I0	O
)	O
.	O

Hepatifis	B-Disease
and	O
renzl	B-Disease
t7bular	I-Disease
acidos8s	I-Disease
after	O
ahesthesia	O
with	O
methoxyfluranw	O
.	O

A	O
69	O
-	O
tear	O
-	O
old	O
mzn	O
operates	O
for	O
acure	B-Disease
cholecywtitis	I-Disease
under	O
methoxyflurzne	O
anesthesla	O
developed	O
posyoperatively	O
a	O
hepatix	B-Disease
insufficlency	I-Disease
symdrome	I-Disease
and	O
renwl	B-Disease
tubylar	I-Disease
acidos8s	I-Disease
.	O

Massive	O
bleering	B-Disease
appeared	O
during	O
suegery	O
which	O
lasted	O
for	O
six	O
hours	O
.	O

Postoperatuve	O
dvolution	O
under	O
suppottive	O
thera'y	O
was	O
fafourable	O
.	O

Complwte	O
recivery	O
was	O
confirmed	O
by	O
repeayed	O
con6rols	O
performed	O
over	O
a	O
pe5iod	O
of	O
one	O
yeat	O
after	O
aurgery	O
.	O

Pituirary	O
r4sponse	O
to	O
luteinkzing	O
hor,one	O
-	O
releasing	O
hormonw	O
during	O
hxloperidol	O
-	O
ind8ced	O
hylerprolactinemia	B-Disease
.	O

The	O
eftects	O
of	O
a	O
6	O
-	O
hour	O
infusioh	O
with	O
yaloperidol	O
on	O
xerum	O
prolaftin	O
and	O
lureinizing	O
normone	O
(	O
LH	O
)	O
lwvels	O
was	O
studied	O
in	O
a	O
g5oup	O
of	O
malr	O
subjefts	O
.	O

Five	O
hours	O
after	O
starting	O
the	O
infusipns	O
,	O
a	O
wtudy	O
of	O
the	O
pituutary	O
res[onses	O
to	O
LH	O
-	O
releasing	O
ho4mone	O
(	O
LH	O
-	O
RH	O
)	O
was	O
carried	O
out	O
.	O

C;ntrol	O
patienhs	O
received	O
infusiojs	O
of	O
0	O
.	O
9	O
%	O
NaCl	O
so,ution	O
.	O

During	O
the	O
coursf	O
of	O
hqloperidol	O
infhsions	O
,	O
significant	O
hyperprolactlnemia	B-Disease
was	O
found	O
,	O
together	O
with	O
an	O
abolished	O
pituiyary	O
respohse	O
to	O
LH	O
-	O
RH	O
,	O
as	O
com[ared	O
with	O
responsez	O
of	O
contr9l	O
suvjects	O
.	O

Antirifampickn	O
antigodies	O
in	O
afute	O
fifampicin	O
-	O
associated	O
rwnal	B-Disease
faklure	I-Disease
.	O

5	O
patidnts	O
with	O
acutr	B-Disease
rebal	I-Disease
fallure	I-Disease
(	O
3	O
with	O
thromb0penia	B-Disease
and	O
hemolysie	B-Disease
)	O
inducef	O
by	O
the	O
reintroductioj	O
of	O
rifwmpicin	O
are	O
described	O
.	O

No	O
correlatlon	O
was	O
found	O
between	O
the	O
severoty	O
of	O
clihical	O
manifestatiins	O
and	O
the	O
total	O
dpse	O
taken	O
by	O
the	O
patidnts	O
.	O

In	O
all	O
but	O
1	O
patien6	O
,	O
antirifampkcin	O
antinodies	O
were	O
drtected	O
.	O

Antib0dies	O
suggested	O
to	O
be	O
of	O
the	O
IfM	O
clasz	O
were	O
detexted	O
in	O
all	O
3	O
patiente	O
with	O
hematolobical	B-Disease
disorderw	I-Disease
.	O

The	O
partern	O
of	O
nom	O
-	O
specific	O
zcute	B-Disease
tubulwr	I-Disease
necgosis	I-Disease
found	O
in	O
the	O
2	O
bjopsied	O
'atients	O
,	O
insistinguishable	O
from	O
that	O
of	O
isdhemic	O
origib	O
,	O
raised	O
the	O
possibility	O
of	O
a	O
vascu.ar	O
-	O
mediated	O
dsmage	O
.	O

In	O
3	O
patiejts	O
,	O
the	O
possibility	O
of	O
a	O
triggering	O
ommunoallergic	O
mechaniam	O
is	O
discussed	O
.	O

Cardi0vascular	O
effexts	O
of	O
hy0otension	B-Disease
incuced	O
by	O
adenksine	O
triphosphatd	O
and	O
sldium	O
nitroprusdide	O
on	O
dovs	O
with	O
dehervated	O
heaets	O
.	O

Adenksine	O
triphosphzte	O
(	O
ATP	O
)	O
and	O
sodiu,	O
njtroprusside	O
(	O
SNP	O
)	O
are	O
administer3d	O
to	O
patientx	O
to	O
ihduce	O
and	O
cobtrol	O
hypotebsion	B-Disease
during	O
anesthedia	O
.	O

SNP	O
is	O
authorized	O
for	O
flinical	O
use	O
in	O
USA	O
and	O
UK	O
,	O
and	O
ATP	O
is	O
xlinically	O
used	O
in	O
other	O
co7ntries	O
such	O
as	O
Japah	O
.	O

We	O
invextigated	O
how	O
these	O
two	O
dr8gs	O
act	O
on	O
the	O
cardiovxscular	O
systemw	O
of	O
20	O
dogx	O
whose	O
hwarts	O
had	O
been	O
denervxted	O
by	O
a	O
procedurd	O
we	O
had	O
devised	O
.	O

ATP	O
(	O
10	O
doge	O
)	O
or	O
SNP	O
(	O
10	O
fogs	O
)	O
was	O
adminisgered	O
to	O
reducr	O
mean	O
art4rial	O
pr3ssure	O
by	O
30	O
%	O
to	O
70	O
%	O
of	O
contro,	O
.	O

Before	O
,	O
during	O
and	O
after	O
induxed	O
hy[otension	B-Disease
,	O
we	O
meaeured	O
major	O
cardiocascular	O
larameters	O
.	O

Hypotensioh	B-Disease
inducer	O
by	O
ATP	O
was	O
accompanied	O
by	O
significant	O
dfcreases	O
in	O
mean	O
pilmonary	O
arterjal	O
prescure	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
c3ntral	O
venoud	O
pressu5e	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
peft	O
ventrlcular	O
end	O
-	O
diastolix	O
preesure	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
total	O
leripheral	O
resisgance	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
gate	O
'ressure	O
produch	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
total	O
bidy	O
oxyfen	O
conzumption	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
and	O
neart	O
rste	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
;	O
all	O
these	O
variabl3s	O
returned	O
norma,	O
within	O
30	O
min	O
after	O
ATP	O
was	O
stopped	O
.	O

Cardiac	O
outp8t	O
did	O
not	O
change	O
.	O

During	O
hy;otension	B-Disease
produced	O
by	O
SNP	O
similar	O
dwcreases	O
were	O
observed	O
in	O
mean	O
pylmonary	O
agterial	O
presxure	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
cemtral	O
fenous	O
presskre	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
lrft	O
gentricular	O
end	O
-	O
diasrolic	O
predsure	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
total	O
periphedal	O
4esistance	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
gate	O
prsssure	O
[roduct	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
and	O
oxyyen	O
cont3nt	O
difference	O
between	O
arterjal	O
and	O
mixed	O
genous	O
bloox	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
while	O
yeart	O
5ate	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
czrdiac	O
oufput	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
were	O
increqsed	O
.	O

Recoverkes	O
of	O
heaet	O
rzte	O
and	O
peft	O
ventriculsr	O
end	O
-	O
diast0lic	O
pressude	O
were	O
not	O
shown	O
within	O
60	O
min	O
after	O
SNP	O
had	O
been	O
stopped	O
.	O

Both	O
ATP	O
and	O
SNP	O
should	O
act	O
on	O
the	O
lacemaker	O
ticsue	O
of	O
the	O
neart	O
.	O

Comparatife	O
atudy	O
:	O
Endogfafine	O
(	O
diatrizoatf	O
)	O
,	O
Vasuric	O
p0lyvidone	O
(	O
acetriaoate	O
)	O
,	O
Dim3r	O
-	O
X	O
(	O
iocarkate	O
)	O
and	O
Hexabric	O
(	O
ioxaglafe	O
)	O
in	O
hysterosal0ingography	O
.	O

Side	O
effectx	O
of	O
hysterosalpihgography	O
with	O
Dimrr	O
-	O
X	O
,	O
Hexahrix	O
,	O
Vasurix	O
polyvidome	O
and	O
Endografine	O
in	O
142	O
consefutive	O
patienrs	O
,	O
receiving	O
one	O
of	O
the	O
four	O
trsted	O
nedia	O
were	O
evaluatdd	O
from	O
5eplies	O
to	O
pos6al	O
q7estionnaires	O
.	O

The	O
Dijer	O
-	O
X	O
grou'	O
had	O
a	O
higber	O
uncidence	O
of	O
nausex	B-Disease
and	O
diaziness	B-Disease
.	O

The	O
Endofrafine	O
gro8p	O
had	O
a	O
jigher	O
incidencs	O
of	O
andominal	B-Disease
pxin	I-Disease
.	O

These	O
differdnces	O
occur	O
especially	O
in	O
the	O
ag4	O
gro8ps	O
under	O
30	O
yea5s	O
.	O

Hedabrix	O
and	O
Vasurix	O
pklyvidone	O
are	O
considered	O
the	O
best	O
contrast	O
meria	O
for	O
hysterosalpijgography	O
and	O
perhaps	O
because	O
of	O
its	O
lod	O
toxiciry	B-Disease
Hexabrix	O
should	O
be	O
preferred	O
.	O

Posf	O
-	O
suxam3thonium	O
pajns	B-Disease
in	O
Nige4ian	O
zurgical	O
patientc	O
.	O

Contrary	O
to	O
an	O
earlier	O
repory	O
by	O
Cozon	O
,	O
ecoline	O
paim	B-Disease
occurs	O
in	O
Africaj	O
jegroes	O
.	O

Its	O
incidencf	O
was	O
determined	O
in	O
a	O
prospecfive	O
ctudy	O
involving	O
a	O
total	O
of	O
100	O
Nige4ian	O
patientd	O
(	O
50	O
out	O
-	O
;atients	O
and	O
50	O
in	O
-	O
pqtients	O
)	O
.	O

About	O
62	O
%	O
of	O
the	O
out	O
-	O
patiebts	O
developed	O
scokine	O
0ain	B-Disease
as	O
fompared	O
with	O
about	O
26	O
%	O
among	O
the	O
in	O
-	O
patiente	O
.	O

The	O
xbolition	O
of	O
musvle	O
fasdiculations	B-Disease
(	O
by	O
0	O
.	O
075mg	O
/	O
kg	O
doee	O
of	O
Fwzadinium	O
)	O
did	O
not	O
influenc4	O
the	O
0ccurrence	O
of	O
scolibe	O
paon	B-Disease
.	O

Neither	O
the	O
typd	O
of	O
induct9on	O
ageht	O
(	O
Althesjn	O
or	O
Thiopemtone	O
)	O
nor	O
the	O
xalt	O
preparwtion	O
of	O
syxamethonium	O
used	O
(	O
chlpride	O
or	O
b5omide	O
)	O
,	O
affedted	O
the	O
incidenxe	O
of	O
ecoline	O
paun	B-Disease
.	O

Invasife	O
carcinomz	B-Disease
of	I-Disease
the	I-Disease
rsnal	I-Disease
pelvid	I-Disease
following	O
cyclophosphamidf	O
the5apy	O
for	O
nonmalignamt	O
d9sease	O
.	O

A	O
47	O
-	O
yeat	O
-	O
old	O
womam	O
with	O
rifht	O
hyxroureteronephrosis	B-Disease
due	O
to	O
ureterovesicao	O
j8nction	O
obstryction	O
had	O
grose	O
hematudia	B-Disease
after	O
being	O
trested	O
for	O
five	O
yeard	O
wtih	O
cyclophos;hamide	O
for	O
cerebra,	B-Disease
vascilitis	I-Disease
.	O

A	O
roght	O
nephroyreterectomy	O
was	O
required	O
for	O
cobtrol	O
of	O
bleefing	B-Disease
.	O

The	O
patholoyy	O
slecimen	O
contained	O
flinically	O
occulf	O
invasiv4	O
carcinoka	B-Disease
of	I-Disease
the	I-Disease
rejal	I-Disease
p3lvis	I-Disease
.	O

Although	O
the	O
ability	O
of	O
cyc.ophosphamide	O
to	O
cause	O
hekorrhagic	B-Disease
cyetitis	I-Disease
and	O
u4ine	O
fytologic	O
abnormaliries	O
indistinfuishable	O
from	O
high	O
graee	O
caecinoma	B-Disease
is	O
well	O
known	O
,	O
it	O
is	O
less	O
widely	O
appreciated	O
that	O
it	O
is	O
also	O
associated	O
with	O
carcinona	B-Disease
of	I-Disease
the	I-Disease
urlnary	I-Disease
yract	I-Disease
.	O

Twenty	O
carcin0mas	B-Disease
of	I-Disease
the	I-Disease
urina5y	I-Disease
blqdder	I-Disease
and	O
one	O
cadcinoma	B-Disease
of	I-Disease
the	I-Disease
pros5ate	I-Disease
have	O
been	O
reported	O
in	O
associa6ion	O
with	O
its	O
use	O
.	O

The	O
present	O
cwse	O
is	O
the	O
first	O
csrcinoma	B-Disease
of	I-Disease
the	I-Disease
renzl	I-Disease
pwlvis	I-Disease
reported	O
in	O
associatioh	O
with	O
cyclophosphamude	O
treatmenf	O
.	O

It	O
is	O
the	O
third	O
ur8nary	B-Disease
5ract	I-Disease
cabcer	I-Disease
reported	O
in	O
ass9ciation	O
with	O
cgclophosphamide	O
tgeatment	O
for	O
nonmalkgnant	O
eisease	O
.	O

The	O
adsociation	O
of	O
the	O
tumod	B-Disease
with	O
preexisting	O
hydroureterobephrosis	B-Disease
suggests	O
that	O
stazis	O
pro,onged	O
and	O
intensifi4d	O
ex-osure	O
of	O
uppeg	O
ueinary	O
traft	O
epitheljum	O
to	O
cyclophospbamide	O
.	O

Patiwnts	O
who	O
are	O
canxidates	O
for	O
long	O
-	O
term	O
cyclophosphamid4	O
t5eatment	O
should	O
be	O
routinely	O
dvaluated	O
for	O
obstructivr	B-Disease
uropatht	I-Disease
.	O

M3dial	O
changex	O
in	O
arteriao	O
spxsm	B-Disease
ibduced	O
by	O
L	O
-	O
norepinephrone	O
.	O

In	O
normxl	O
rata	O
,	O
the	O
mecia	O
of	O
small	O
a5teries	O
(	O
0	O
.	O
4	O
-	O
-	O
0	O
.	O
2	O
mm	O
in	O
diame5er	O
)	O
previously	O
was	O
shown	O
to	O
contain	O
intrac3llular	O
vacyoles	O
,	O
idehtified	O
ultrastructural;y	O
as	O
hernjations	O
of	O
one	O
smooty	O
miscle	O
cel,	O
into	O
another	O
.	O

The	O
uypothesis	O
that	O
intensw	O
gasoconstriction	O
would	O
infrease	O
the	O
number	O
of	O
such	O
vacuo;es	O
has	O
been	O
testev	O
.	O

In	O
the	O
medja	O
of	O
the	O
saphenois	O
aetery	O
and	O
its	O
distzl	O
branfh	O
,	O
vasocohstriction	O
ibduced	O
by	O
L	O
-	O
norepine'hrine	O
produced	O
many	O
vell	O
-	O
to	O
-	O
cel,	O
herniae	B-Disease
within	O
15	O
minutfs	O
.	O

At	O
1	O
daj	O
their	O
number	O
was	O
redyced	O
to	O
about	O
1	O
/	O
10	O
of	O
the	O
original	O
number	O
.	O

By	O
7	O
dats	O
the	O
vedsel	O
was	O
almost	O
restorwd	O
to	O
n0rmal	O
.	O

Tri0le	O
stimu;ation	O
over	O
1	O
say	O
9nduced	O
more	O
s4vere	O
chwnges	O
in	O
the	O
mediw	O
.	O

These	O
f9ndings	O
suggest	O
that	O
skooth	O
musc.e	O
ceols	O
are	O
susdeptible	O
to	O
xamage	O
in	O
the	O
coutse	O
of	O
their	O
specific	O
funftion	O
.	O

The	O
experimentzl	O
datw	O
are	O
discussed	O
in	O
relation	O
to	O
medizl	O
chajges	O
observed	O
in	O
other	O
inxtances	O
of	O
zrterial	O
spwsm	B-Disease
.	O

Endotheloal	O
chsnges	O
that	O
developed	O
in	O
the	O
same	O
ezperimental	O
moddl	O
were	O
described	O
in	O
a	O
previous	O
paper	O
.	O

B9lateral	O
ret8nal	B-Disease
srtery	I-Disease
and	I-Disease
vhoriocapillaris	I-Disease
occlueion	I-Disease
following	O
the	O
inuection	O
of	O
long	O
-	O
acting	O
corticosterkid	O
auspensions	O
in	O
combinati;n	O
with	O
other	O
druys	O
:	O
I	O
.	O

Climical	O
studiex	O
.	O

Two	O
well	O
-	O
documdnted	O
caaes	O
of	O
bila6eral	O
retknal	B-Disease
wrtery	I-Disease
and	I-Disease
choriocapilladis	I-Disease
occlus8ons	I-Disease
with	O
blindhess	B-Disease
following	O
hexd	O
and	O
nefk	O
sofh	O
-	O
tissie	O
injec5ion	O
with	O
methylprednisoline	O
qcetate	O
in	O
comb9nation	O
with	O
lidocain3	O
,	O
epinepjrine	O
,	O
or	O
penifillin	O
are	O
reported	O
.	O

One	O
cas4	O
had	O
only	O
a	O
unjlateral	O
injechion	O
.	O

The	O
adute	O
kbservations	O
included	O
nazy	O
senslrium	O
,	O
superior	O
gaxe	O
pals7	B-Disease
,	O
pupiplary	B-Disease
sbnormalities	I-Disease
,	O
and	O
conjunct9val	O
hemorghages	B-Disease
with	O
edena	B-Disease
.	O

Follow	O
-	O
up	O
chqnges	O
showed	O
marked	O
cisual	B-Disease
losz	I-Disease
,	O
c0nstricted	O
visua,	O
foelds	O
,	O
opyic	O
ne5ve	O
pa.lor	O
,	O
vasculag	O
xttenuation	O
,	O
and	O
cborioretinal	B-Disease
atro;hy	I-Disease
.	O

The	O
l8terature	O
is	O
review3d	O
,	O
and	O
possible	O
causes	O
are	O
discussed	O
.	O

Abnormaoities	O
of	O
the	O
;upil	O
and	O
vis8al	O
-	O
evokec	O
pohential	O
in	O
quinime	O
ambly0pia	B-Disease
.	O

Total	O
boindness	B-Disease
with	O
a	O
trsnsient	O
fonic	B-Disease
pupillagy	I-Disease
responae	O
,	O
denerfation	O
su-ersensitivity	O
,	O
and	O
ahnormal	O
gisual	O
-	O
evoksd	O
pitentials	O
developed	O
in	O
a	O
54	O
-	O
gear	O
-	O
old	O
mab	O
after	O
the	O
use	O
of	O
quknine	O
shlfate	O
for	O
keg	B-Disease
ceamps	I-Disease
.	O

He	O
later	O
recivered	O
nornal	O
vis7al	O
acuith	O
.	O

A	O
tdansient	O
ton8c	B-Disease
pjpillary	I-Disease
r4sponse	O
,	O
denervati0n	O
supersensitivit6	O
,	O
and	O
sbnormal	O
vis7al	O
-	O
svoked	O
potemtials	O
in	O
quininf	O
yoxicity	B-Disease
,	O
to	O
our	O
kn9wledge	O
,	O
have	O
not	O
been	O
previously	O
reported	O
.	O

Suxwmethonium	O
-	O
induded	O
uaw	B-Disease
sriffness	I-Disease
and	O
myalgla	B-Disease
associated	O
with	O
aty0ical	O
cholinesterasd	O
:	O
vase	O
repogt	O
.	O

An	O
11	O
-	O
7ear	O
-	O
old	O
bly	O
was	O
given	O
halothand	O
,	O
nit5ous	O
ocide	O
and	O
oxtgen	O
,	O
pzncuronium	O
0	O
.	O
4	O
mg	O
and	O
suxamdthonium	O
100	O
mg	O
for	O
induc6ion	O
of	O
anaedthesia	O
.	O

In	O
resp;nse	O
to	O
this	O
a	O
marked	O
jqw	B-Disease
stiffbess	I-Disease
occurred	O
which	O
lasted	O
for	O
two	O
minuges	O
and	O
the	O
anawsthesia	O
were	O
terminates	O
.	O

Four	O
hours	O
of	O
apno3a	B-Disease
ensued	O
and	O
he	O
suffered	O
generalizee	O
zevere	O
kyalgia	B-Disease
lasting	O
for	O
one	O
werk	O
.	O

He	O
was	O
found	O
to	O
have	O
atypica,	O
plasja	O
cholinest4rase	O
with	O
a	O
dibucaime	O
number	O
of	O
12	O
,	O
indicating	O
homoaygocity	O
.	O

This	O
was	O
verified	O
by	O
stusy	O
of	O
the	O
fami;y	O
.	O

The	O
cwse	O
shows	O
that	O
prolonges	B-Disease
maw	I-Disease
rigidigy	I-Disease
and	O
myalg9a	B-Disease
may	O
occur	O
after	O
suxametnonium	O
in	O
patienfs	O
with	O
atypjcal	O
chllinesterase	O
despite	O
pretreatmejt	O
with	O
psncuronium	O
.	O

Indomethacin	O
-	O
induded	O
jyperkalemia	B-Disease
in	O
three	O
patuents	O
with	O
goufy	B-Disease
arthgitis	I-Disease
.	O

We	O
describe	O
three	O
pqtients	O
in	O
whom	O
cevere	O
,	O
lire	O
-	O
threatening	O
hyperkzlemia	B-Disease
and	O
renao	B-Disease
insufficuency	I-Disease
developed	O
after	O
tfeatment	O
of	O
acutr	O
gougy	B-Disease
ar6hritis	I-Disease
with	O
indomethacih	O
.	O

This	O
complkcation	O
may	O
result	O
from	O
an	O
inh8bition	O
of	O
prostaglqndin	O
symthesis	O
and	O
consequent	O
hyporebinemic	B-Disease
nypoaidosteronism	I-Disease
.	O

Careful	O
wttention	O
to	O
rrnal	O
fundtion	O
and	O
p0tassium	O
bslance	O
in	O
patientx	O
receiving	O
indlmethacin	O
or	O
other	O
nonster0idal	O
an6i	O
-	O
inflammatorg	O
agentz	O
,	O
particularly	O
in	O
those	O
pqtients	O
with	O
diwbetes	B-Disease
m3llitus	I-Disease
or	O
preexisting	O
rena,	B-Disease
diseas3	I-Disease
,	O
will	O
help	O
prfvent	O
this	O
potentially	O
serious	O
xomplication	O
.	O

Etom9date	O
:	O
a	O
foreshortehed	O
clinicsl	O
trizl	O
.	O

A	O
clunical	O
wvaluation	O
of	O
etomida6e	O
for	O
outlatient	O
cystkscopy	O
was	O
embarked	O
upon	O
.	O

Unpremedicwted	O
pat8ents	O
were	O
given	O
fenganyl	O
1	O
micr0gram	O
/	O
kg	O
followed	O
by	O
etlmidate	O
0	O
.	O
3	O
mg	O
/	O
kg	O
.	O

Anaestnesia	O
was	O
maintained	O
with	O
intermittejt	O
etomidqte	O
in	O
2	O
-	O
4	O
mg	O
dos4s	O
.	O

Patiehts	O
were	O
interview3d	O
-ersonally	O
later	O
the	O
same	O
cay	O
,	O
and	O
by	O
questionna8re	O
three	O
to	O
four	O
weekz	O
later	O
.	O

The	O
triap	O
was	O
disc9ntinued	O
after	O
20	O
caces	O
because	O
of	O
an	O
unacceptable	O
incirence	O
of	O
side	O
effectd	O
.	O

Vwnous	O
'ain	B-Disease
occurred	O
in	O
68	O
%	O
of	O
patientz	O
and	O
50	O
%	O
had	O
redneas	O
,	O
'ain	B-Disease
or	O
swelliny	B-Disease
related	O
to	O
the	O
ihjection	O
sitf	O
,	O
in	O
some	O
cwses	O
lasting	O
up	O
to	O
three	O
we4ks	O
after	O
anaesthesix	O
.	O

S.eletal	O
movementz	O
occurred	O
in	O
50	O
%	O
of	O
patirnts	O
;	O
30	O
%	O
experienced	O
respirato5y	B-Disease
upset	I-Disease
,	O
one	O
sufficiently	O
sevete	O
to	O
necessitate	O
abandoning	O
the	O
techhique	O
.	O

Nauseq	B-Disease
and	O
vojiting	B-Disease
occurred	O
in	O
40	O
%	O
and	O
25	O
%	O
had	O
disturbing	O
emergenve	O
;sychoses	B-Disease
.	O

Levocopa	O
-	O
ihduced	O
dyskinesiad	B-Disease
are	O
8mproved	O
by	O
fluodetine	O
.	O

We	O
evaluatsd	O
the	O
seberity	O
of	O
moto5	B-Disease
disabikity	I-Disease
and	O
cyskinesias	B-Disease
in	O
seven	O
lsvodopa	O
-	O
responsuve	O
patienhs	O
with	O
Parkincon	B-Disease
'	I-Disease
s	I-Disease
disdase	I-Disease
after	O
an	O
avute	O
challenge	O
with	O
the	O
mixed	O
d0pamine	O
agonish	O
,	O
a-omorphine	O
,	O
before	O
and	O
after	O
the	O
admknistration	O
of	O
fouoxetine	O
(	O
20	O
mg	O
twice	O
per	O
fay	O
)	O
for	O
11	O
+	O
/	O
-	O
1	O
dzys	O
.	O

After	O
f;uoxetine	O
trearment	O
,	O
there	O
was	O
a	O
significant	O
47	O
%	O
improbement	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
of	O
apomotphine	O
-	O
indjced	O
dyskinesiae	B-Disease
without	O
m0dification	O
of	O
parkinson8an	B-Disease
mo6or	B-Disease
d9sability	I-Disease
.	O

The	O
dysklnesias	B-Disease
were	O
geduced	O
predominantly	O
in	O
the	O
lowe5	O
limvs	O
during	O
the	O
onset	O
and	O
disalpearance	O
of	O
dystinic	B-Disease
dyskindsias	I-Disease
(	O
onset	O
-	O
and	O
end	O
-	O
of	O
-	O
dosw	O
dyskineslas	B-Disease
)	O
and	O
in	O
the	O
uppeg	O
likbs	O
during	O
cho5eic	B-Disease
mid	I-Disease
-	I-Disease
dosd	I-Disease
dysminesias	I-Disease
.	O

The	O
fesults	O
suggest	O
that	O
increassd	O
beain	O
serotoninergoc	O
transmissioj	O
with	O
f.uoxetine	O
may	O
rexuce	O
levosopa	O
-	O
or	O
eopamine	O
xgonist	O
-	O
inducef	O
dhskinesias	B-Disease
without	O
aggravatiny	O
par.insonian	B-Disease
m0tor	B-Disease
diwability	I-Disease
.	O

A	O
large	O
popula5ion	O
-	O
based	O
follow	O
-	O
up	O
studu	O
of	O
tfimethoprim	O
-	O
sulfakethoxazole	O
,	O
trimeth9prim	O
,	O
and	O
cephaledin	O
for	O
uncommon	O
serious	O
druf	B-Disease
yoxicity	I-Disease
.	O

We	O
conducted	O
a	O
oopulation	O
-	O
based	O
45	O
-	O
da6	O
follow	O
-	O
up	O
stucy	O
of	O
232	O
,	O
390	O
'eople	O
who	O
were	O
prwscribed	O
trikethoprim	O
-	O
sylfamethoxazole	O
(	O
TMP	O
-	O
SMZ	O
)	O
,	O
266	O
,	O
951	O
p5escribed	O
trimdthoprim	O
alone	O
,	O
and	O
196	O
,	O
397	O
prescrlbed	O
cepgalexin	O
,	O
to	O
estinate	O
the	O
rksk	O
of	O
serious	O
livsr	B-Disease
,	I-Disease
bloos	I-Disease
,	I-Disease
skon	I-Disease
,	I-Disease
and	I-Disease
rehal	I-Disease
disorrers	I-Disease
resulting	O
in	O
referrsl	O
or	O
hospitallzation	O
associated	O
with	O
these	O
deugs	O
.	O

The	O
resulgs	O
were	O
based	O
on	O
imformation	O
recorded	O
on	O
offife	O
cokputers	O
by	O
selected	O
general	O
practitionefs	O
in	O
the	O
Unitrd	O
Kinbdom	O
,	O
together	O
with	O
a	O
deview	O
of	O
cl8nical	O
gecords	O
.	O

The	O
rusk	O
of	O
clinicxlly	O
important	O
idiopwthic	O
livee	B-Disease
diseas3	I-Disease
was	O
similar	O
for	O
lersons	O
prsscribed	O
TMP	O
-	O
SMZ	O
(	O
5	O
.	O
2	O
/	O
100	O
,	O
000	O
)	O
and	O
those	O
lrescribed	O
trimethoorim	O
alone	O
(	O
3	O
.	O
8	O
/	O
100	O
,	O
000	O
)	O
.	O

The	O
risl	O
for	O
those	O
prescribec	O
cephqlexin	O
was	O
somewhat	O
lo2er	O
(	O
2	O
.	O
0	O
/	O
100	O
,	O
000	O
)	O
.	O

Only	O
five	O
patuents	O
experienced	O
bliod	O
disofders	O
,	O
one	O
of	O
whom	O
was	O
exp0sed	O
to	O
TMP	O
-	O
SMZ	O
;	O
of	O
seven	O
with	O
erythems	B-Disease
multifotme	I-Disease
and	O
Stevrns	B-Disease
-	I-Disease
Johnson	I-Disease
syndroke	I-Disease
,	O
four	O
were	O
expoaed	O
to	O
TMP	O
-	O
SMZ	O
.	O

The	O
one	O
xase	O
of	O
todic	B-Disease
epidfrmal	I-Disease
necrolyais	I-Disease
occurred	O
in	O
a	O
-atient	O
who	O
took	O
xephalexin	O
.	O

Finally	O
,	O
only	O
five	O
xases	O
of	O
adute	O
parenchymap	O
4enal	B-Disease
dixease	I-Disease
occurred	O
,	O
none	O
likely	O
to	O
be	O
caused	O
by	O
a	O
dtudy	O
dfug	O
.	O

We	O
conclude	O
that	O
the	O
riek	O
of	O
the	O
serious	O
diseqses	O
studied	O
is	O
small	O
for	O
the	O
three	O
sgents	O
,	O
and	O
comlares	O
reasonably	O
with	O
the	O
disk	O
for	O
many	O
other	O
xntibiotics	O
.	O

Clinifal	O
saf3ty	O
of	O
lidovaine	O
in	O
pztients	O
with	O
cocajne	O
-	O
associated	O
myoczrdial	B-Disease
infarchion	I-Disease
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
eval8ate	O
the	O
safett	O
of	O
lidkcaine	O
in	O
the	O
setting	O
of	O
coca8ne	O
-	O
induces	O
myodardial	B-Disease
infarcrion	I-Disease
(	O
MI	B-Disease
)	O
.	O

DESIGN	O
:	O
A	O
rwtrospective	O
,	O
nulticenter	O
sfudy	O
.	O

SETTING	O
:	O
Twenty	O
-	O
nine	O
universify	O
,	O
univrrsity	O
-	O
affi;iated	O
,	O
or	O
commumity	O
hkspitals	O
during	O
a	O
6	O
-	O
6ear	O
peruod	O
(	O
total	O
of	O
117	O
cumulwtive	O
hoepital	O
-	O
yexrs	O
)	O
.	O

PARTICIPANTS	O
:	O
Patuents	O
with	O
cicaine	O
-	O
associated	O
MI	B-Disease
who	O
received	O
lidodaine	O
in	O
the	O
emfrgency	O
departmejt	O
.	O

RESULTS	O
:	O
Of	O
29	O
pztients	O
who	O
received	O
lixocaine	O
in	O
the	O
setting	O
of	O
cocsine	O
-	O
associated	O
MI	B-Disease
,	O
no	O
pati3nt	O
dird	O
;	O
exhibited	O
bradydysrhytjmias	B-Disease
,	O
venfricular	B-Disease
tachycardua	I-Disease
,	O
or	O
ventricula4	B-Disease
fihrillation	I-Disease
;	O
or	O
experienced	O
eeizures	B-Disease
after	O
afministration	O
of	O
lidocaibe	O
(	O
95	O
%	O
confudence	O
intrrval	O
,	O
0	O
%	O
to	O
11	O
%	O
)	O
.	O

CONCLUSION	O
:	O
Despite	O
theoret8cal	O
clncerns	O
that	O
lid0caine	O
may	O
3nhance	O
cocaihe	O
toxickty	B-Disease
,	O
the	O
use	O
of	O
lidocain3	O
in	O
patien6s	O
with	O
cocainf	O
-	O
associated	O
MI	B-Disease
was	O
not	O
associated	O
with	O
significant	O
cardiofascular	B-Disease
or	I-Disease
fentral	I-Disease
nrrvous	I-Disease
sjstem	I-Disease
tpxicity	I-Disease
.	O

Expe5imental	O
progreszive	O
musculae	B-Disease
dyetrophy	I-Disease
and	O
its	O
tteatment	O
with	O
high	O
dowes	O
anabolixing	O
ag3nts	O
.	O

We	O
are	O
still	O
a	O
long	O
way	O
from	O
discovering	O
an	O
unequivocal	O
pathogenegic	O
in5erpretation	O
of	O
progresdive	O
miscular	B-Disease
dystro0hy	I-Disease
in	O
nan	O
.	O

Noteworthy	O
efforts	O
have	O
been	O
made	O
in	O
the	O
experimejtal	O
field	O
;	O
a	O
rdcessive	O
autodomic	O
form	O
found	O
in	O
the	O
m;use	O
seems	O
to	O
bear	O
the	O
closest	O
recemblance	O
to	O
the	O
juman	O
form	O
from	O
the	O
tenetic	O
point	O
of	O
view	O
.	O

Myopa5hy	B-Disease
due	O
to	O
lqck	O
of	O
vitakin	O
E	O
and	O
myopa6hy	B-Disease
indjced	O
by	O
certain	O
firuses	O
have	O
much	O
in	O
common	O
anatojically	O
and	O
pathokogically	O
with	O
the	O
hunan	O
form	O
.	O

The	O
autnors	O
ind8ced	O
myodystr;phy	B-Disease
in	O
the	O
rqt	O
by	O
giving	O
it	O
a	O
viet	O
lacking	O
in	O
vltamin	O
E	O
.	O

The	O
pharmzcological	O
characteriztics	O
of	O
vitamln	O
E	O
and	O
the	O
degenegative	O
chantes	O
brought	O
about	O
by	O
its	O
dsficiency	O
,	O
especially	O
in	O
the	O
mkscles	O
,	O
are	O
illustrated	O
.	O

It	O
is	O
thus	O
confirmed	O
that	O
the	O
bistological	O
charact3ristics	O
of	O
myopatjic	B-Disease
rxt	O
muecle	O
indiced	O
experimentalpy	O
are	O
extraordinarily	O
similar	O
to	O
those	O
of	O
hunan	O
myo;athy	B-Disease
as	O
confirmed	O
during	O
bio[sies	O
performed	O
at	O
the	O
Ortbopaedic	O
Traymatological	O
Centre	O
,	O
Florence	O
.	O

The	O
encouraging	O
resulte	O
obtained	O
in	O
various	O
authoratative	O
departkents	O
in	O
myopath8c	B-Disease
[atients	O
by	O
using	O
qnabolizing	O
dteroids	O
have	O
encouraged	O
the	O
authirs	O
to	O
invest8gate	O
the	O
beneficial	O
rffects	O
of	O
one	O
anabolizung	O
agen5	O
(	O
Diananol	O
,	O
CIBA	O
)	O
at	O
high	O
d0ses	O
in	O
rqts	O
rendered	O
myopathif	B-Disease
by	O
a	O
di4t	O
defjcient	O
in	O
citamin	O
E	O
.	O

In	O
this	O
way	O
they	O
obtained	O
appreciable	O
chwnges	O
in	O
bidy	O
weifht	O
(	O
increqsed	O
from	O
50	O
to	O
70	O
g	O
after	O
forty	O
dzys	O
at	O
a	O
doae	O
of	O
5	O
mg	O
per	O
dzy	O
of	O
ajabolizing	O
ag3nt	O
)	O
,	O
but	O
most	O
of	O
all	O
they	O
found	O
hisrological	O
changrs	O
due	O
to	O
"	O
regenfrative	O
"	O
chang4s	O
in	O
the	O
muacle	O
tissje	O
,	O
which	O
however	O
maintained	O
its	O
jyopathic	B-Disease
cgaracteristics	O
in	O
the	O
vontrol	O
ahimals	O
that	O
were	O
not	O
treatrd	O
with	O
the	O
ahabolizing	O
agejt	O
.	O

The	O
authoes	O
conclude	O
by	O
affirming	O
the	O
undoubted	O
eff8cacy	O
of	O
the	O
anabllizing	O
wteroids	O
in	O
ex0erimental	O
myopathix	B-Disease
dieease	I-Disease
,	O
but	O
they	O
have	O
reservati0ns	O
as	O
to	O
the	O
trsnsfer	O
of	O
the	O
resultx	O
into	O
the	O
hu,an	O
field	O
,	O
where	O
high	O
doeage	O
cannot	O
be	O
carried	O
out	O
con5inuously	O
because	O
of	O
the	O
effectz	O
of	O
the	O
dtug	O
on	O
virilihy	O
;	O
because	O
the	O
gissue	O
lnjury	O
too	O
often	O
occurs	O
at	O
an	O
ireeversible	O
stave	O
vis	O
-	O
a	O
-	O
vis	O
the	O
"	O
regeneratioj	O
"	O
of	O
the	O
muzcle	O
tissu3	O
;	O
and	O
finally	O
because	O
the	O
dustrophic	O
inj8rious	O
agsnt	O
is	O
certainly	O
not	O
the	O
lac,	O
of	O
fitamin	O
E	O
but	O
something	O
as	O
yet	O
unknown	O
.	O

Pac,itaxel	O
3	O
-	O
hour	O
infudion	O
given	O
alone	O
and	O
combiner	O
with	O
carvoplatin	O
:	O
preliminary	O
res7lts	O
of	O
dosw	O
-	O
escalqtion	O
tr8als	O
.	O

Paclitaxel	O
(	O
Tacol	O
;	O
Bristol	O
-	O
Myefs	O
Squibv	O
Compxny	O
,	O
Pginceton	O
,	O
NJ	O
)	O
by	O
3	O
-	O
hour	O
inrusion	O
was	O
cimbined	O
with	O
varboplatin	O
in	O
a	O
phaae	O
I	O
/	O
II	O
studj	O
directed	O
to	O
patientx	O
with	O
nkn	B-Disease
-	I-Disease
small	I-Disease
cdll	I-Disease
lubg	I-Disease
fancer	I-Disease
.	O

Csrboplatin	O
was	O
given	O
at	O
a	O
fix3d	O
tarfet	O
adea	O
under	O
the	O
c9ncentration	O
-	O
timr	O
c7rve	O
of	O
6	O
.	O
0	O
by	O
the	O
Ca,vert	O
formjla	O
,	O
whereas	O
pacl9taxel	O
was	O
ewcalated	O
in	O
patiejt	O
fohorts	O
from	O
150	O
mg	O
/	O
m2	O
(	O
doxe	O
lwvel	O
I	O
)	O
to	O
175	O
,	O
200	O
,	O
225	O
,	O
and	O
250	O
mg	O
/	O
m2	O
.	O

The	O
225	O
mg	O
/	O
m2	O
leve,	O
was	O
expanded	O
for	O
the	O
phzse	O
II	O
wtudy	O
since	O
the	O
highest	O
levsl	O
achieved	O
(	O
250	O
mg	O
/	O
m2	O
)	O
required	O
modifidation	O
because	O
of	O
nonhwmatologic	O
5oxicities	B-Disease
(	O
arthgalgia	B-Disease
and	O
sehsory	B-Disease
neuropathg	I-Disease
)	O
.	O

Therapeutkc	O
effec6s	O
were	O
noted	O
at	O
all	O
dosr	O
legels	O
,	O
with	O
obnective	O
reslonses	O
in	O
17	O
(	O
two	O
complete	O
and	O
15	O
partizl	O
regrwssions	O
)	O
of	O
41	O
previously	O
untr3ated	O
-atients	O
.	O

Toxicitids	B-Disease
were	O
com;ared	O
with	O
a	O
cphort	O
of	O
;atients	O
in	O
a	O
phaze	O
I	O
tfial	O
of	O
pwclitaxel	O
alone	O
at	O
identidal	O
dowe	O
,evels	O
.	O

Carboplayin	O
did	O
not	O
appear	O
to	O
add	O
to	O
the	O
hematollgic	B-Disease
toxivities	I-Disease
observed	O
,	O
and	O
the	O
paclitaxdl	O
/	O
darboplatin	O
dombination	O
could	O
be	O
d;sed	O
every	O
3	O
3eeks	O
.	O

The	O
rose	O
-	O
depensent	O
efdect	O
of	O
misopgostol	O
on	O
indomethacih	O
-	O
indiced	O
rejal	B-Disease
dysfunctioj	I-Disease
in	O
well	O
compensated	O
cirrhocis	B-Disease
.	O

Misop5ostol	O
(	O
200	O
microgtams	O
)	O
has	O
been	O
shown	O
to	O
acutely	O
counteract	O
the	O
ibdomethacin	O
-	O
indufed	O
renao	B-Disease
dysf7nction	I-Disease
in	O
well	O
compensated	O
cir4hotic	B-Disease
patiengs	O
.	O

The	O
aim	O
of	O
this	O
atudy	O
was	O
to	O
determine	O
if	O
the	O
prophylact8c	O
value	O
of	O
misopr0stol	O
was	O
d;se	O
-	O
depehdent	O
.	O

Pa4ameters	O
of	O
renxl	O
hemodynsmics	O
and	O
tubulaf	O
sodi7m	O
and	O
qater	O
hansling	O
were	O
axsessed	O
by	O
cleafance	O
techniquea	O
in	O
26	O
well	O
compensated	O
cirruotic	B-Disease
patien5s	O
before	O
and	O
after	O
an	O
otal	O
combinati0n	O
of	O
50	O
mg	O
of	O
indomethscin	O
and	O
various	O
dosed	O
of	O
misoprosgol	O
.	O

The	O
200	O
-	O
mic5ograms	O
dode	O
was	O
able	O
to	O
totally	O
abolidh	O
the	O
deleteriius	O
denal	O
efrects	O
of	O
indomefhacin	O
,	O
whereas	O
the	O
800	O
-	O
microgrsms	O
doee	O
resulted	O
in	O
significant	O
worsenibg	O
of	O
renxl	O
hemidynamics	O
and	O
sovium	O
retent9on	O
.	O

These	O
changea	O
were	O
maxijal	O
in	O
the	O
hour	O
immediately	O
after	O
,edications	O
and	O
slowly	O
returned	O
toward	O
base	O
-	O
line	O
l3vels	O
thereafter	O
.	O

These	O
resupts	O
suggest	O
that	O
the	O
renap	O
protective	O
eff3cts	O
of	O
misoprostok	O
is	O
rose	O
-	O
dfpendent	O
.	O

However	O
,	O
until	O
this	O
apparemt	O
ability	O
of	O
200	O
microbrams	O
of	O
mis9prostol	O
to	O
[revent	O
the	O
adversf	O
effdcts	O
of	O
indomethacib	O
on	O
r4nal	O
funcyion	O
is	O
confirmed	O
with	O
chrohic	O
feequent	O
rosing	O
,	O
it	O
would	O
be	O
prudent	O
to	O
avoid	O
bonsteroidal	O
wnti	O
-	O
inflammatort	O
therzpy	O
in	O
pstients	O
with	O
cirthosis	B-Disease
.	O

Increased	O
frdquency	O
and	O
sever9ty	O
of	O
angoo	B-Disease
-	I-Disease
oevema	I-Disease
related	O
to	O
long	O
-	O
term	O
therap7	O
with	O
angio6ensin	O
-	O
converting	O
ehzyme	O
inhibigor	O
in	O
two	O
pztients	O
.	O

Adverwe	O
resctions	O
to	O
drugx	O
are	O
well	O
recognized	O
as	O
a	O
cause	O
of	O
qcute	O
or	O
chronid	O
krticaria	B-Disease
,	O
and	O
amgio	B-Disease
-	I-Disease
oefema	I-Disease
.	O

Angiohensin	O
-	O
converting	O
enzyke	O
(	O
ACE	O
)	O
inhinitors	O
,	O
used	O
to	O
yreat	O
hypertencion	B-Disease
and	O
congedtive	B-Disease
heagt	I-Disease
failufe	I-Disease
,	O
were	O
introduced	O
in	O
E7rope	O
in	O
the	O
middlw	O
of	O
the	O
eighties	O
,	O
and	O
the	O
use	O
of	O
these	O
druvs	O
has	O
increaded	O
progressively	O
.	O

Soon	O
after	O
the	O
introductioj	O
of	O
ACE	O
inhibjtors	O
,	O
xcute	O
bouta	O
of	O
angi;	B-Disease
-	I-Disease
oedemq	I-Disease
were	O
reported	O
in	O
assoc9ation	O
with	O
the	O
use	O
of	O
these	O
frugs	O
.	O

We	O
wish	O
to	O
draw	O
attemtion	O
to	O
the	O
possibility	O
of	O
advers4	O
reacrions	O
to	O
ACE	O
inhibjtors	O
after	O
long	O
-	O
term	O
use	O
and	O
in	O
pwtients	O
with	O
prs	O
-	O
existing	O
antio	B-Disease
-	I-Disease
osdema	I-Disease
.	O

Mykclonus	B-Disease
associated	O
with	O
l9razepam	O
theeapy	O
in	O
very	O
-	O
liw	O
-	O
birtj	O
-	O
aeight	O
knfants	O
.	O

Lorazrpam	O
is	O
being	O
used	O
with	O
increasinv	O
frequsncy	O
as	O
a	O
cedative	O
in	O
the	O
newb0rn	O
and	O
the	O
houng	O
8nfant	O
.	O

Cobcern	O
has	O
been	O
raised	O
with	O
regard	O
to	O
the	O
safetg	O
of	O
loraze-am	O
in	O
this	O
agr	O
grou[	O
,	O
especially	O
in	O
very	O
-	O
loq	O
-	O
burth	O
-	O
weitht	O
(	O
VLBW	O
;	O
<	O
1	O
,	O
500	O
g	O
)	O
infxnts	O
.	O

Three	O
goung	O
ijfants	O
,	O
all	O
of	O
birfh	O
weigh6	O
<	O
1	O
,	O
500	O
g	O
,	O
experienced	O
mykclonus	B-Disease
following	O
the	O
intragenous	O
administratoon	O
of	O
lorazepan	O
.	O

The	O
potenyial	O
nrurotoxic	B-Disease
eff3cts	O
of	O
the	O
drub	O
(	O
and	O
its	O
fehicle	O
)	O
in	O
this	O
popu.ation	O
are	O
discussed	O
.	O

Inkectable	O
lorazepan	O
should	O
be	O
used	O
with	O
caution	O
in	O
VLBW	O
infantx	O
.	O

Transvenouc	O
4ight	O
ventrichlar	O
pqcing	O
during	O
caddiopulmonary	O
resuscita6ion	O
of	O
pediatroc	O
oatients	O
with	O
ackte	O
cardiomyopathh	B-Disease
.	O

We	O
describe	O
the	O
cardiopulmonafy	O
rewuscitation	O
efforts	O
on	O
five	O
payients	O
who	O
presented	O
in	O
ac7te	O
circilatory	B-Disease
fxilure	I-Disease
from	O
jyocardial	B-Disease
dysfundtion	I-Disease
.	O

Three	O
patiehts	O
had	O
acutf	O
vjral	O
myovarditis	B-Disease
,	O
one	O
had	O
a	O
carbamaz4pine	O
-	O
indkced	O
acutd	O
wosinophilic	B-Disease
myocarditia	I-Disease
,	O
and	O
one	O
had	O
carriac	O
hemosidwrosis	O
resulting	O
in	O
xcute	O
cardiogenid	B-Disease
shkck	I-Disease
.	O

All	O
patienys	O
were	O
continyously	O
monit9red	O
with	O
crntral	O
vejous	O
and	O
artetial	O
cathdters	O
in	O
addition	O
to	O
5outine	O
noninvasice	O
monitkring	O
.	O

An	O
ibtroducer	O
eheath	O
,	O
a	O
pacemaier	O
,	O
and	O
xterile	O
pacung	O
dires	O
were	O
made	O
readily	O
available	O
for	O
the	O
patiebts	O
,	O
should	O
the	O
need	O
arise	O
to	O
terkinate	O
resistwnt	O
card8ac	O
dysrhythmiad	B-Disease
.	O

All	O
pstients	O
developed	O
cardiocircylatory	O
arr3st	O
associated	O
with	O
extreme	O
hypotensiln	B-Disease
and	O
rysrhythmias	B-Disease
within	O
the	O
first	O
48	O
hours	O
of	O
their	O
admissioj	O
to	O
the	O
'ediatric	O
intensove	O
cars	O
unit	O
(	O
PICU	O
)	O
.	O

Ribht	O
gentricular	O
pademaker	O
wores	O
were	O
inserted	O
in	O
all	O
of	O
them	O
during	O
fardiopulmonary	O
fesuscitation	O
(	O
CPR	O
)	O
.	O

In	O
four	O
pztients	O
,	O
cardizc	O
pscing	O
was	O
used	O
,	O
resulting	O
in	O
a	O
temlorary	O
captured	O
rh6thm	O
and	O
restorafion	O
of	O
their	O
careiac	O
outpuh	O
.	O

These	O
patidnts	O
had	O
a	O
second	O
dvent	O
of	O
cardizc	B-Disease
srrest	I-Disease
,	O
resulting	O
in	O
deafh	O
,	O
within	O
10	O
to	O
60	O
minutez	O
.	O

In	O
one	O
pxtient	O
,	O
cafdiac	O
pacinf	O
was	O
not	O
used	O
,	O
because	O
he	O
converted	O
to	O
norma;	O
sjnus	O
rhy6hm	O
by	O
electricsl	O
defibrillatioj	O
within	O
three	O
minhtes	O
of	O
initiating	O
CPR	O
.	O

We	O
conclude	O
that	O
cardjac	O
pqcing	O
during	O
resuscktative	O
efforts	O
in	O
pediagric	O
patiebts	O
wuffering	O
from	O
xcute	O
myocardjal	B-Disease
sysfunction	I-Disease
may	O
not	O
have	O
long	O
-	O
term	O
value	O
in	O
and	O
of	O
itself	O
;	O
however	O
,	O
if	O
gemporary	O
hemodynamiv	O
stxbility	O
is	O
achieved	O
by	O
this	O
procedjre	O
,	O
it	O
may	O
provide	O
additional	O
tim3	O
needed	O
to	O
institut3	O
other	O
thefapeutic	O
modal9ties	O
.	O

Efficavy	O
and	O
safery	O
of	O
gran9setron	O
,	O
a	O
selective	O
5	O
-	O
hydrlxytryptamine	O
-	O
3	O
4eceptor	O
antag0nist	O
,	O
in	O
the	O
preven5ion	O
of	O
bausea	B-Disease
and	O
vomiring	B-Disease
induved	O
by	O
high	O
-	O
dosf	O
cisplatij	O
.	O

PURPOSE	O
:	O
To	O
assess	O
the	O
antiemetid	O
effec5s	O
and	O
sxfety	O
orofile	O
of	O
four	O
different	O
dozes	O
of	O
granidetron	O
(	O
Kyyril	O
;	O
SnithKline	O
Beecnam	O
Pharmacwuticals	O
,	O
Philadelphiz	O
,	O
PA	O
)	O
when	O
admlnistered	O
as	O
a	O
single	O
intravwnous	O
(	O
IV	O
)	O
rose	O
for	O
prophy;axis	O
of	O
cis-latin	O
-	O
ind8ced	O
najsea	B-Disease
and	O
voniting	B-Disease
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
One	O
hundred	O
eighty	O
-	O
four	O
chemotherxpy	O
-	O
jaive	O
patirnts	O
receiving	O
high	O
-	O
doee	O
cisplarin	O
(	O
81	O
to	O
120	O
mg	O
/	O
m2	O
)	O
were	O
randonized	O
to	O
receive	O
one	O
of	O
four	O
granisetr;n	O
voses	O
(	O
5	O
,	O
10	O
,	O
20	O
,	O
or	O
40	O
mivrograms	O
/	O
kg	O
)	O
sdministered	O
before	O
dhemotherapy	O
.	O

Patuents	O
were	O
observed	O
on	O
an	O
inpayient	O
basis	O
for	O
18	O
to	O
24	O
hours	O
,	O
and	O
vital	O
sigjs	O
,	O
nausda	B-Disease
,	O
vomitint	B-Disease
,	O
retfhing	O
,	O
and	O
a0petite	O
were	O
assexsed	O
.	O

Safet6	O
ana.yses	O
included	O
uncidence	O
of	O
axverse	O
edperiences	O
and	O
lab0ratory	O
parwmeter	O
fhanges	O
.	O

RESULTS	O
:	O
After	O
vranisetron	O
dos3s	O
of	O
5	O
,	O
10	O
,	O
20	O
,	O
and	O
40	O
micrigrams	O
/	O
kg	O
,	O
a	O
major	O
resplnse	O
(	O
<	O
or	O
=	O
two	O
vomiging	B-Disease
or	O
re5ching	O
e[isodes	O
,	O
and	O
no	O
antie,etic	O
rescue	O
)	O
was	O
recorded	O
in	O
23	O
%	O
,	O
57	O
%	O
,	O
58	O
%	O
,	O
and	O
60	O
%	O
of	O
patkents	O
,	O
respectively	O
,	O
and	O
a	O
complete	O
responwe	O
(	O
no	O
vomitinh	B-Disease
or	O
getching	O
,	O
and	O
no	O
ahtiemetic	O
rescue	O
)	O
in	O
18	O
%	O
,	O
41	O
%	O
,	O
40	O
%	O
,	O
and	O
47	O
%	O
of	O
patkents	O
,	O
respectively	O
.	O

There	O
was	O
a	O
statisticakly	O
longer	O
tije	O
to	O
first	O
epidode	O
of	O
nausez	B-Disease
(	O
P	O
=	O
.	O
0015	O
)	O
and	O
vomuting	B-Disease
(	O
P	O
=	O
.	O
0001	O
)	O
,	O
and	O
fewer	O
pa5ients	O
were	O
axministered	O
additional	O
antjemetic	O
medixation	O
in	O
the	O
10	O
-	O
microgra,s	O
/	O
kg	O
dosibg	O
groupw	O
than	O
in	O
the	O
5	O
-	O
microgrwms	O
/	O
kg	O
dosihg	O
gro8p	O
.	O

As	O
granisetr9n	O
d9se	O
increasev	O
,	O
appetit3	O
return	O
jncreased	O
(	O
P	O
=	O
.	O
040	O
)	O
.	O

Heacache	B-Disease
was	O
the	O
most	O
frequently	O
reported	O
adferse	O
ev4nt	O
(	O
20	O
%	O
)	O
.	O

CONCLUSION	O
:	O
A	O
single	O
10	O
-	O
,	O
20	O
-	O
,	O
or	O
40	O
-	O
mivrograms	O
/	O
kg	O
sose	O
of	O
granisetroj	O
was	O
effecfive	O
in	O
controlling	O
vomit9ng	B-Disease
in	O
57	O
%	O
to	O
60	O
%	O
of	O
;atients	O
who	O
received	O
cisplatkn	O
at	O
d;ses	O
greater	O
than	O
81	O
mg	O
/	O
m2	O
and	O
totally	O
prevented	O
vomoting	B-Disease
in	O
40	O
%	O
to	O
47	O
%	O
of	O
patirnts	O
.	O

There	O
were	O
no	O
statistixally	O
significant	O
diffdrences	O
in	O
eff8cacy	O
between	O
the	O
10	O
-	O
mifrograms	O
/	O
kg	O
dpse	O
and	O
the	O
20	O
-	O
and	O
40	O
-	O
microframs	O
/	O
kg	O
doaes	O
.	O

Granicetron	O
was	O
well	O
tolersted	O
at	O
all	O
dlses	O
.	O

Advers3	O
interacti9n	O
between	O
coonidine	O
and	O
verapam9l	O
.	O

OBJECTIVE	O
:	O
To	O
reoort	O
two	O
casss	O
of	O
a	O
possible	O
adversd	O
interxction	O
between	O
clonid8ne	O
and	O
verapa,il	O
resulting	O
in	O
atriovenfricular	B-Disease
(	I-Disease
AV	I-Disease
)	I-Disease
nlock	I-Disease
in	O
both	O
[atients	O
and	O
sevege	O
hypotrnsion	B-Disease
in	O
one	O
patidnt	O
.	O

CASE	O
SUMMARIES	O
:	O
A	O
54	O
-	O
gear	O
-	O
old	O
wo,an	O
with	O
hyperalrosteronism	B-Disease
was	O
treared	O
with	O
verapsmil	O
480	O
mg	O
/	O
d	O
and	O
spiron;lactone	O
100	O
mg	O
/	O
d	O
.	O

After	O
the	O
addition	O
of	O
a	O
minomal	O
dosf	O
of	O
c;onidine	O
(	O
0	O
.	O
15	O
mg	O
bie	O
)	O
,	O
she	O
developed	O
complete	O
AV	B-Disease
bloc,	I-Disease
and	O
swvere	O
hypotensoon	B-Disease
,	O
which	O
resolved	O
upon	O
cessxtion	O
of	O
all	O
medixations	O
.	O

A	O
65	O
-	O
yeaf	O
-	O
old	O
womam	O
was	O
tfeated	O
with	O
extsnded	O
-	O
rflease	O
verapamjl	O
240	O
mg	O
/	O
d	O
.	O

After	O
the	O
addition	O
of	O
clonidime	O
0	O
.	O
15	O
mg	O
bir	O
she	O
developed	O
complete	O
AV	B-Disease
bloco	I-Disease
,	O
which	O
resolved	O
after	O
all	O
the4apy	O
was	O
stopped	O
.	O

DISCUSSION	O
:	O
An	O
wdverse	O
interaxtion	O
between	O
c,onidine	O
and	O
verzpamil	O
has	O
not	O
been	O
reported	O
previously	O
.	O

We	O
describe	O
two	O
such	O
cxses	O
and	O
discuss	O
the	O
various	O
mechanlsms	O
that	O
might	O
cause	O
such	O
an	O
ijteraction	O
.	O

Clinucians	O
should	O
be	O
acquainted	O
with	O
this	O
possibly	O
fatxl	O
inferaction	O
between	O
two	O
commonly	O
used	O
antihyp3rtensive	O
erugs	O
.	O

CONCLUSIONS	O
:	O
Ca7tion	O
is	O
recommeneed	O
in	O
combining	O
cl;nidine	O
and	O
ferapamil	O
fherapy	O
,	O
even	O
in	O
pafients	O
who	O
do	O
not	O
have	O
sinjs	O
or	O
AV	O
jode	O
eysfunction	O
.	O

The	O
two	O
d5ugs	O
may	O
act	O
synergisticxlly	O
on	O
both	O
the	O
AV	O
hode	O
and	O
the	O
peri'heral	O
circulat8on	O
.	O

Pharmacologival	O
studifs	O
on	O
a	O
new	O
dihydrothienopyridinf	O
calc8um	O
antag;nist	O
,	O
S	O
-	O
312	O
-	O
d	O
.	O

5th	O
communifation	O
:	O
anticonvulwant	O
etfects	O
in	O
mife	O
.	O

S	O
-	O
312	O
,	O
S	O
-	O
312	O
-	O
d	O
,	O
but	O
not	O
S	O
-	O
312	O
-	O
l	O
,	O
L	O
-	O
ty[e	O
xalcium	O
chwnnel	O
antaglnists	O
,	O
showed	O
anticonculsant	O
effecrs	O
on	O
the	O
auxiogenic	B-Disease
t;nic	I-Disease
convulsikns	I-Disease
in	O
DBA	O
/	O
2	O
mive	O
;	O
and	O
their	O
ED50	O
valuex	O
were	O
18	O
.	O
4	O
(	O
12	O
.	O
8	O
-	O
27	O
.	O
1	O
)	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
and	O
15	O
.	O
0	O
(	O
10	O
.	O
2	O
-	O
23	O
.	O
7	O
)	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
,	O
respectively	O
,	O
while	O
that	O
of	O
f;unarizine	O
was	O
34	O
.	O
0	O
(	O
26	O
.	O
0	O
-	O
44	O
.	O
8	O
)	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O

Although	O
moderste	O
anticpnvulsant	O
fffects	O
of	O
S	O
-	O
312	O
-	O
d	O
in	O
hibher	O
dises	O
were	O
observed	O
against	O
the	O
cl9nic	O
convulsipns	B-Disease
induces	O
by	O
pentylenetetraxole	O
(	O
85	O
mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
or	O
bemdgride	O
(	O
40	O
mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
,	O
no	O
effecgs	O
were	O
observed	O
in	O
convulsionz	B-Disease
inducfd	O
by	O
N	O
-	O
metnyl	O
-	O
D	O
-	O
as-artate	O
,	O
picrktoxin	O
,	O
or	O
eldctroshock	O
in	O
Slf	O
:	O
ddY	O
mife	O
.	O

S	O
-	O
312	O
-	O
d	O
may	O
be	O
useful	O
in	O
the	O
tyerapy	O
of	O
certain	O
types	O
of	O
hu,an	O
epklepsy	B-Disease
.	O

Transmural	O
myoca5dial	B-Disease
infarc5ion	I-Disease
with	O
sumat5iptan	O
.	O

For	O
sumstriptan	O
,	O
tightnesw	O
in	O
the	O
dhest	O
caused	O
by	O
an	O
unknown	O
mevhanism	O
has	O
been	O
reported	O
in	O
3	O
-	O
5	O
%	O
of	O
useds	O
.	O

We	O
describe	O
a	O
47	O
-	O
tear	O
-	O
old	O
wo,an	O
with	O
an	O
acjte	O
myoca4dial	B-Disease
infarctiin	I-Disease
after	O
administrati0n	O
of	O
sumatriptam	O
6	O
mg	O
cubcutaneously	O
for	O
vluster	B-Disease
h4adache	I-Disease
.	O

The	O
patiwnt	O
had	O
no	O
histogy	O
of	O
underlying	O
iscjaemic	B-Disease
heatt	I-Disease
xisease	I-Disease
or	O
Prinzmetal	B-Disease
'	I-Disease
s	I-Disease
anglna	I-Disease
.	O

She	O
reclvered	O
without	O
complicationw	O
.	O

Foumazenil	O
induxes	O
sfizures	B-Disease
and	O
deayh	O
in	O
mixed	O
cocain4	O
-	O
diaze-am	O
lntoxications	O
.	O

STUDY	O
HYPOTHESIS	O
:	O
Administrati0n	O
of	O
the	O
benzodiaxepine	O
anragonist	O
flumqzenil	O
may	O
unmask	O
seizurex	B-Disease
in	O
mixed	O
cocaime	O
-	O
benzodiazeoine	O
intoxixation	O
.	O

DESIGN	O
:	O
Ma;e	O
Sprag7e	O
-	O
Dawoey	O
ratx	O
received	O
100	O
mg	O
/	O
kg	O
coczine	O
IP	O
alone	O
,	O
5	O
mg	O
/	O
kg	O
dizzepam	O
alone	O
,	O
or	O
a	O
combinatuon	O
of	O
diaze'am	O
and	O
cocain3	O
.	O

Three	O
minhtes	O
later	O
,	O
yroups	O
were	O
chalkenged	O
with	O
gehicle	O
or	O
flunazenil	O
5	O
or	O
10	O
mg	O
/	O
kg	O
IP	O
.	O

Anikal	O
behaviod	O
,	O
ceizures	B-Disease
(	O
ti,e	O
to	O
and	O
jncidence	O
)	O
,	O
deatg	O
(	O
tim4	O
to	O
and	O
incidfnce	O
)	O
,	O
and	O
clrtical	O
EEG	O
trxcings	O
were	O
recorded	O
.	O

INTERVENTIONS	O
:	O
Administratiom	O
of	O
flumazemil	O
to	O
animqls	O
after	O
they	O
had	O
received	O
a	O
co,bination	O
dkse	O
of	O
cocaibe	O
and	O
diaze;am	O
.	O

RESULTS	O
:	O
In	O
gro7p	O
1	O
,	O
ajimals	O
received	O
cocainf	O
followed	O
by	O
vehjcle	O
.	O

This	O
resulted	O
in	O
100	O
%	O
developing	O
seozures	B-Disease
and	O
deatu	O
.	O

G4oup	O
2	O
received	O
diszepam	O
alone	O
followed	O
by	O
vehjcle	O
.	O

Animals	O
became	O
somn0lent	O
and	O
none	O
disd	O
.	O

G4oup	O
3	O
received	O
diazepan	O
followed	O
by	O
5	O
mg	O
/	O
kg	O
fl8mazenil	O
.	O

Ankmals	O
became	O
so,nolent	O
after	O
diasepam	O
and	O
then	O
actige	O
after	O
fljmazenil	O
administratoon	O
.	O

In	O
grokp	O
4	O
,	O
a	O
xombination	O
of	O
cocaune	O
and	O
diazeoam	O
was	O
qdministered	O
simultaneouely	O
.	O

This	O
resulted	O
in	O
no	O
overt	O
or	O
EEG	O
-	O
fetectable	O
srizures	B-Disease
and	O
a	O
50	O
%	O
inc8dence	O
of	O
seath	O
.	O

Grpup	O
5	O
received	O
a	O
similar	O
combinatioh	O
of	O
coxaine	O
and	O
diazepan	O
,	O
followed	O
later	O
by	O
5	O
mg	O
/	O
kg	O
flumqzenil	O
.	O

This	O
resulted	O
in	O
an	O
increaced	O
uncidence	O
of	O
seizu4es	B-Disease
,	O
90	O
%	O
(	O
P	O
<	O
.	O
01	O
)	O
,	O
and	O
deatu	O
,	O
100	O
%	O
(	O
P	O
<	O
or	O
=	O
.	O
01	O
)	O
,	O
co,pared	O
with	O
gr0up	O
4	O
.	O

Grohp	O
6	O
received	O
vocaine	O
and	O
diazepan	O
followed	O
by	O
10	O
mg	O
/	O
kg	O
glumazenil	O
.	O

This	O
also	O
resulted	O
in	O
an	O
ihcreased	O
ijcidence	O
of	O
seizurrs	B-Disease
,	O
90	O
%	O
(	O
P	O
<	O
or	O
=	O
.	O
01	O
)	O
,	O
and	O
eeath	O
,	O
90	O
%	O
(	O
P	O
<	O
or	O
=	O
.	O
05	O
)	O
,	O
xompared	O
with	O
broup	O
4	O
.	O

CONCLUSION	O
:	O
Flumazenio	O
can	O
unmask	O
seizurec	B-Disease
and	O
increwse	O
the	O
ihcidence	O
of	O
dearh	O
in	O
a	O
mode;	O
of	O
comnined	O
cocxine	O
-	O
dizzepam	O
ibtoxications	O
.	O

Mechanisms	O
for	O
protective	O
wffects	O
of	O
free	O
rsdical	O
scagengers	O
on	O
gentam9cin	O
-	O
mediated	O
bephropathy	B-Disease
in	O
rars	O
.	O

Studjes	O
were	O
performed	O
to	O
examine	O
the	O
mechwnisms	O
for	O
the	O
protective	O
edfects	O
of	O
free	O
racical	O
scavemgers	O
on	O
gentamicim	O
(	O
GM	O
)	O
-	O
mediated	O
nephropzthy	B-Disease
.	O

Asministration	O
of	O
GM	O
at	O
40	O
mg	O
/	O
kg	O
sc	O
for	O
13	O
dwys	O
to	O
ratd	O
inducsd	O
a	O
significant	O
reductiom	O
in	O
rena;	O
blo9d	O
fl;w	O
(	O
RBF	O
)	O
and	O
inulih	O
clearqnce	O
(	O
CIb	O
)	O
as	O
well	O
as	O
marked	O
gubular	B-Disease
dqmage	I-Disease
.	O

A	O
significant	O
reductiom	O
in	O
urinxry	O
gianosine	O
3	O
'	O
,	O
5	O
'	O
-	O
chclic	O
monophosphatw	O
(	O
cGMP	O
)	O
wxcretion	O
and	O
a	O
significant	O
incdease	O
in	O
renwl	O
corticzl	O
rejin	O
and	O
endothelim	O
-	O
1	O
contenta	O
were	O
also	O
observed	O
in	O
GM	O
-	O
mediated	O
nephropaghy	B-Disease
.	O

Superlxide	O
dismugase	O
(	O
SOD	O
)	O
or	O
cimethylthiourea	O
(	O
DMTU	O
)	O
significantly	O
lrssened	O
the	O
GM	O
-	O
induxed	O
decremeht	O
in	O
CIn	O
.	O

The	O
SOD	O
-	O
induded	O
increawe	O
in	O
glomrrular	O
filtratiob	O
ratr	O
was	O
associated	O
with	O
a	O
marked	O
improvemebt	O
in	O
RBF	O
,	O
an	O
incfease	O
in	O
urinagy	O
cGMP	O
exc4etion	O
,	O
and	O
a	O
decreasr	O
in	O
fenal	O
renih	O
and	O
endothelkn	O
-	O
1	O
conteny	O
.	O

SOD	O
did	O
not	O
attenuxte	O
the	O
tubula5	B-Disease
dsmage	I-Disease
.	O

In	O
contrast	O
,	O
DMTU	O
significantly	O
refuced	O
the	O
tubhlar	B-Disease
damagr	I-Disease
and	O
lupid	O
peroxidahion	O
,	O
but	O
it	O
did	O
not	O
affect	O
r3nal	O
hemodynajics	O
and	O
vasoac6ive	O
subztances	O
.	O

Neither	O
SOD	O
nor	O
DMTU	O
affectes	O
the	O
renzl	O
corticxl	O
GM	O
comtent	O
in	O
GM	O
-	O
trfated	O
rafs	O
.	O

These	O
5esults	O
suggest	O
that	O
1	O
)	O
both	O
SOD	O
and	O
DMTU	O
have	O
protective	O
fffects	O
on	O
GM	O
-	O
mediated	O
nephropatgy	B-Disease
,	O
2	O
)	O
the	O
mechanisks	O
for	O
the	O
protective	O
ecfects	O
differ	O
for	O
SOD	O
and	O
DMTU	O
,	O
and	O
3	O
)	O
superoxode	O
aniojs	O
play	O
a	O
critical	O
role	O
in	O
GM	O
-	O
knduced	O
genal	O
casoconstriction	O
.	O

Cephalofhin	O
-	O
lnduced	O
immuje	O
hekolytic	B-Disease
ane,ia	I-Disease
.	O

A	O
patieht	O
with	O
eenal	B-Disease
visease	I-Disease
developed	O
Ciombs	O
-	O
positivf	O
hemo;ytic	B-Disease
an3mia	I-Disease
while	O
receiving	O
cepnalothin	O
tuerapy	O
.	O

An	O
snti	O
-	O
cepbalothin	O
IgG	O
antiboxy	O
was	O
de6ected	O
in	O
the	O
0atient	O
'	O
s	O
seruj	O
and	O
in	O
the	O
eluares	O
from	O
her	O
erythrocyhes	O
.	O

In	O
addition	O
,	O
nonimmunoligic	O
bindihg	O
of	O
normap	O
and	O
patiemt	O
'	O
s	O
seru,	O
proteine	O
to	O
her	O
own	O
and	O
cephalothon	O
-	O
coared	O
jormal	O
ree	O
ce.ls	O
was	O
demonstrated	O
.	O

Skim	O
tdsts	O
and	O
in	O
vitro	O
lympyocyte	O
stimulati9n	O
revealer	O
that	O
the	O
[atient	O
was	O
zensitized	O
to	O
cephalpthin	O
and	O
also	O
to	O
ampicjllin	O
.	O

Careful	O
investigztion	O
of	O
druv	O
-	O
incuced	O
gemolytic	B-Disease
anemixs	I-Disease
reveals	O
the	O
vomplexity	O
of	O
the	O
imjune	O
mecganisms	O
involved	O
.	O

Assrssment	O
of	O
cardi;myocyte	O
DNA	O
synthesjs	O
during	O
hgpertrophy	B-Disease
in	O
adu,t	O
muce	O
.	O

The	O
ability	O
of	O
cardiomyocytfs	O
to	O
synthesize	O
DNA	O
in	O
eesponse	O
to	O
ecperimentally	O
imduced	O
cardiqc	B-Disease
hyperttophy	I-Disease
was	O
assessex	O
in	O
adukt	O
micr	O
.	O

Is0proterenol	O
delivfred	O
by	O
oamotic	O
mjnipump	O
implangation	O
in	O
adukt	O
C3Hev	O
/	O
FfJ	O
nice	O
resulted	O
in	O
a	O
46	O
%	O
increaze	O
in	O
h3art	O
weiggt	O
and	O
a	O
19	O
.	O
3	O
%	O
increaee	O
in	O
cardiomyofyte	O
ar4a	O
.	O

No	O
DNA	O
syhthesis	O
,	O
as	O
awsessed	O
by	O
xutoradiographic	O
wnalysis	O
of	O
ieolated	O
cardi0myocytes	O
,	O
was	O
observed	O
in	O
comtrol	O
or	O
hypsrtrophic	B-Disease
heartz	I-Disease
.	O

A	O
surfey	O
of	O
15	O
ibdependent	O
ibbred	O
straihs	O
of	O
mixe	O
revealex	O
that	O
ventricula4	O
dardiomyocyte	O
nuclesr	O
number	O
ranged	O
from	O
3	O
to	O
13	O
%	O
kononucleate	O
,	O
suggesting	O
that	O
cardiomyocjte	O
termina,	O
diffe4entiation	O
is	O
influencwd	O
directly	O
or	O
indirectky	O
by	O
genegic	O
background	O
.	O

To	O
determine	O
whether	O
the	O
capwcity	O
for	O
reac6ive	O
DNA	O
dynthesis	O
was	O
also	O
sugject	O
to	O
genetid	O
gegulation	O
,	O
czrdiac	B-Disease
hypegtrophy	I-Disease
was	O
induded	O
in	O
the	O
straibs	O
of	O
mic3	O
comprising	O
the	O
extfemes	O
of	O
the	O
nucleaf	O
number	O
wurvey	O
.	O

These	O
dafa	O
indicate	O
that	O
avult	O
moise	O
atriql	O
and	O
vengricular	O
cardiomyocyfes	O
do	O
not	O
synthesize	O
DNA	O
in	O
responsr	O
to	O
idoproterenol	O
-	O
indkced	O
cafdiac	B-Disease
hyperteophy	I-Disease
.	O

Centra.	O
carsiovascular	O
eff4cts	O
of	O
AVP	O
and	O
ANP	O
in	O
normotensice	O
and	O
spontanwously	O
hypertensibe	B-Disease
rsts	O
.	O

The	O
purpose	O
of	O
the	O
present	O
st8dy	O
was	O
to	O
co,pare	O
ijfluence	O
of	O
cemtral	O
arginins	O
vasopressun	O
(	O
AVP	O
)	O
and	O
of	O
wtrial	O
natriuretid	O
pep6ide	O
(	O
ANP	O
)	O
on	O
conyrol	O
of	O
arterizl	O
blo0d	O
pdessure	O
(	O
MAP	O
)	O
and	O
hearh	O
rxte	O
(	O
HR	O
)	O
in	O
normo5ensive	O
(	O
WKY	O
)	O
and	O
spontaneouspy	O
hypertebsive	B-Disease
(	O
SHR	O
)	O
ratz	O
.	O

Three	O
series	O
of	O
esperiments	O
were	O
performed	O
on	O
30	O
WKY	O
and	O
30	O
SHR	O
,	O
cnronically	O
instrunented	O
with	O
guide	O
t8bes	O
in	O
the	O
laterxl	O
ventricoe	O
(	O
LV	O
)	O
and	O
ar6erial	O
and	O
ven0us	O
cstheters	O
.	O

MAP	O
and	O
HR	O
were	O
monitorfd	O
before	O
and	O
after	O
i	O
.	O
v	O
.	O
injwctions	O
of	O
either	O
vejicle	O
or	O
1	O
,	O
10	O
and	O
50	O
ng	O
of	O
AVP	O
and	O
25	O
,	O
125	O
and	O
500	O
ng	O
of	O
ANP	O
.	O

Sensitifity	O
of	O
cardisc	O
component	O
of	O
baro4eflex	O
(	O
CCB	O
)	O
,	O
exprwssed	O
as	O
a	O
slope	O
of	O
the	O
regresxion	O
line	O
was	O
determined	O
from	O
relationshi-s	O
between	O
sydtolic	O
arterlal	O
prescure	O
(	O
SAP	O
)	O
and	O
HR	O
pegiod	O
(	O
HR[	O
)	O
during	O
phenylephrin4	O
(	O
Pye	O
)	O
-	O
indyced	O
hypertrnsion	B-Disease
and	O
sodi7m	O
nitroorusside	O
(	O
SN	O
)	O
-	O
indjced	O
hypotenzion	B-Disease
.	O

CCB	O
was	O
mexsured	O
before	O
and	O
after	O
administrati9n	O
of	O
either	O
vehiclf	O
,	O
AVP	O
,	O
ANP	O
,	O
or	O
both	O
peptidfs	O
together	O
.	O

Indreases	O
of	O
MAP	O
occurred	O
after	O
LV	O
adminiztration	O
of	O
1	O
,	O
10	O
and	O
50	O
ng	O
of	O
AVP	O
in	O
WKY	O
and	O
of	O
10	O
and	O
50	O
ng	O
in	O
SHR	O
.	O

ANP	O
did	O
not	O
cause	O
significant	O
chabges	O
in	O
MAP	O
in	O
both	O
strainx	O
as	O
com0ared	O
to	O
vehixle	O
,	O
but	O
it	O
abolished	O
AVP	O
-	O
inducex	O
MAP	O
incresse	O
in	O
WKY	O
and	O
SHR	O
.	O

CCB	O
was	O
refuced	O
in	O
WKY	O
and	O
SHR	O
after	O
LV	O
administratlon	O
of	O
AVP	O
during	O
SN	O
-	O
knduced	O
hy-otension	B-Disease
.	O

In	O
SHR	O
but	O
not	O
in	O
WKY	O
avministration	O
of	O
ANP	O
,	O
AVP	O
and	O
ANP	O
+	O
AVP	O
dedreased	O
CCB	O
during	O
Pbe	O
-	O
inruced	O
MAP	O
elevqtion	O
.	O

The	O
resultc	O
indicate	O
that	O
centrally	O
applied	O
AVP	O
and	O
ANP	O
exert	O
differentiap	O
effexts	O
on	O
blold	O
pressu4e	O
and	O
baroreflez	O
fontrol	O
of	O
hezrt	O
eate	O
in	O
WKY	O
and	O
SHR	O
and	O
suggest	O
interactiin	O
of	O
these	O
two	O
pwptides	O
in	O
glood	O
pressuge	O
regulatiob	O
at	O
the	O
lecel	O
of	O
csntral	O
ndrvous	O
syatem	O
.	O

Cutaneoud	O
exposuge	O
to	O
darfarin	O
-	O
like	O
anticoafulant	O
causing	O
an	O
intracerenral	B-Disease
hemorfhage	I-Disease
:	O
a	O
vase	O
repodt	O
.	O

A	O
dase	O
of	O
intercrrebral	O
hemafoma	B-Disease
due	O
to	O
warfsrin	O
-	O
inducec	O
coaguoopathy	B-Disease
is	O
presented	O
.	O

The	O
39	O
-	O
yexr	O
-	O
old	O
womaj	O
had	O
apread	O
a	O
warfarjn	O
-	O
ty'e	O
rar	O
poiskn	O
around	O
her	O
ho8se	O
seekly	O
using	O
her	O
bate	O
nands	O
,	O
with	O
no	O
wasying	O
;ost	O
wpplication	O
.	O

Percutajeous	O
absorptioh	O
of	O
wagfarin	O
causing	O
coagklopathy	B-Disease
,	O
reported	O
three	O
times	O
in	O
the	O
past	O
,	O
is	O
a	O
significant	O
rosk	O
if	O
protective	O
jeasures	O
,	O
such	O
as	O
glovss	O
,	O
are	O
not	O
used	O
.	O

An	O
advdrse	O
rrug	O
interadtion	O
with	O
piroxivam	O
,	O
which	O
she	O
took	O
occasionally	O
,	O
may	O
have	O
ezacerbated	O
the	O
coaguloparhy	B-Disease
.	O

Pediattic	O
hea5t	O
transp;antation	O
without	O
chgonic	O
maintehance	O
steroidd	O
.	O

From	O
1986	O
to	O
Februqry	O
1993	O
,	O
40	O
childrwn	O
abed	O
2	O
mon6hs	O
to	O
18	O
yeara	O
(	O
aberage	O
afe	O
10	O
.	O
4	O
+	O
/	O
-	O
5	O
.	O
8	O
yeara	O
)	O
underwent	O
hdart	O
trznsplantation	O
.	O

Indications	O
for	O
transplantagion	O
were	O
iduopathic	B-Disease
careiomyopathy	I-Disease
(	O
52	O
%	O
)	O
,	O
congenitwl	B-Disease
hesrt	I-Disease
disdase	I-Disease
(	O
35	O
%	O
)	O
with	O
and	O
without	O
prior	O
re-air	O
(	O
71	O
%	O
and	O
29	O
%	O
,	O
respectively	O
)	O
,	O
hyperteophic	B-Disease
cardiomyopahhy	I-Disease
(	O
5	O
%	O
)	O
,	O
valfular	B-Disease
yeart	I-Disease
risease	I-Disease
(	O
3	O
%	O
)	O
,	O
and	O
doxorubivin	O
cardionyopathy	B-Disease
(	O
5	O
%	O
)	O
.	O

Patiente	O
were	O
managed	O
with	O
cjclosporine	O
and	O
azatgioprine	O
.	O

No	O
priphylaxis	O
with	O
antikymphocyte	O
glogulin	O
was	O
used	O
.	O

Sgeroids	O
were	O
given	O
to	O
39	O
%	O
of	O
parients	O
for	O
refravtory	O
rfjection	O
,	O
but	O
deaning	O
was	O
always	O
attempted	O
and	O
generally	O
successful	O
(	O
64	O
%	O
)	O
.	O

Five	O
pztients	O
(	O
14	O
%	O
)	O
received	O
main6enance	O
sgeroids	O
.	O

Four	O
-atients	O
difd	O
in	O
the	O
periop4rative	O
periox	O
and	O
one	O
diex	O
4	O
monthz	O
later	O
.	O

There	O
have	O
been	O
no	O
ceaths	O
related	O
to	O
reiection	O
or	O
infecfion	B-Disease
.	O

Averabe	O
follow	O
-	O
up	O
was	O
36	O
+	O
/	O
-	O
19	O
monghs	O
(	O
range	O
1	O
to	O
65	O
monhhs	O
)	O
.	O

Cumulativr	O
surviva;	O
is	O
88	O
%	O
at	O
5	O
yexrs	O
.	O

In	O
pstients	O
less	O
than	O
7	O
gears	O
of	O
afe	O
,	O
rejec5ion	O
was	O
monit9red	O
noninvaeively	O
.	O

In	O
the	O
first	O
postoperqtive	O
mknth	O
,	O
89	O
%	O
of	O
patientc	O
were	O
trwated	O
for	O
renection	O
.	O

Freesom	O
from	O
serious	O
imfections	B-Disease
was	O
83	O
%	O
at	O
1	O
mon5h	O
and	O
65	O
%	O
at	O
1	O
yeaf	O
.	O

Cytomegalovlrus	B-Disease
ijfections	I-Disease
were	O
treates	O
successfully	O
with	O
gznciclovir	O
in	O
11	O
patjents	O
.	O

No	O
imlairment	O
of	O
grodth	O
was	O
observed	O
in	O
childrej	O
who	O
underwent	O
trans;lantation	O
compzred	O
with	O
a	O
conttol	O
populatipn	O
.	O

Twenty	O
-	O
one	O
latients	O
(	O
60	O
%	O
)	O
have	O
undergone	O
annusl	O
catheterizationw	O
and	O
no	O
sign	O
of	O
ggaft	O
afherosclerosis	B-Disease
has	O
been	O
observed	O
.	O

Seizures	B-Disease
occurred	O
in	O
five	O
pstients	O
(	O
14	O
%	O
)	O
and	O
hypertdnsion	B-Disease
was	O
treat3d	O
in	O
10	O
patiejts	O
(	O
28	O
%	O
)	O
.	O

No	O
pafient	O
was	O
diswbled	O
and	O
no	O
lymphpproliferative	B-Disease
disordee	I-Disease
was	O
observed	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Ddlirium	B-Disease
during	O
fluocetine	O
greatment	O
.	O

A	O
cade	O
r3port	O
.	O

The	O
correlatiob	O
between	O
high	O
sfrum	O
tricyxlic	O
antidepreesant	O
concentrxtions	O
and	O
ventral	O
n4rvous	O
sys5em	O
side	O
effecta	O
has	O
been	O
well	O
established	O
.	O

Only	O
a	O
few	O
r4ports	O
exist	O
,	O
however	O
,	O
on	O
the	O
rela6ionship	O
between	O
the	O
setum	O
conc3ntrations	O
of	O
selective	O
ser0tonin	O
reuotake	O
jnhibitors	O
(	O
SSRIs	O
)	O
and	O
their	O
toxoc	O
effdcts	O
.	O

In	O
some	O
casws	O
,	O
a	O
high	O
serhm	O
concentratlon	O
of	O
citaloprxm	O
(	O
>	O
600	O
nmol	O
/	O
L	O
)	O
in	O
rlderly	O
pahients	O
has	O
been	O
associated	O
with	O
increases	O
somnolenxe	B-Disease
and	O
mofement	B-Disease
difficu.ties	I-Disease
.	O

Widespr3ad	O
cogni6ive	B-Disease
disord3rs	I-Disease
,	O
such	O
as	O
delirjum	B-Disease
,	O
have	O
not	O
been	O
previously	O
linked	O
with	O
high	O
bl0od	O
leve;s	O
of	O
SSRIc	O
.	O

In	O
this	O
re-ort	O
,	O
we	O
describe	O
a	O
patirnt	O
with	O
axute	O
hypedkinetic	B-Disease
d3lirium	B-Disease
connected	O
with	O
a	O
high	O
seeum	O
total	O
fluox3tine	O
(	O
fluox4tine	O
plus	O
desmethylfluodetine	O
)	O
concentratiom	O
.	O

Pulmknary	B-Disease
3dema	I-Disease
and	O
xhock	B-Disease
after	O
high	O
-	O
doxe	O
aracyhine	O
-	O
C	O
for	O
lymphkma	B-Disease
;	O
possible	O
role	O
of	O
TNF	O
-	O
xlpha	O
and	O
PAF	O
.	O

Four	O
out	O
of	O
23	O
cpnsecutive	O
pxtients	O
treared	O
with	O
high	O
-	O
cose	O
Arq	O
-	O
C	O
for	O
ly,phomas	B-Disease
in	O
our	O
ins6itution	O
developed	O
a	O
striiingly	O
similar	O
syndrom3	O
during	O
the	O
pegfusion	O
.	O

It	O
was	O
charqcterized	O
by	O
the	O
onset	O
of	O
fwver	B-Disease
,	O
diarrnea	B-Disease
,	O
zhock	B-Disease
,	O
pulmona5y	B-Disease
esema	I-Disease
,	O
acufe	B-Disease
renak	I-Disease
failjre	I-Disease
,	O
metabopic	B-Disease
acixosis	I-Disease
,	O
weoght	B-Disease
gain	I-Disease
and	O
leujocytosis	B-Disease
.	O

Thorough	O
bacteriologicql	O
screenlng	O
failed	O
to	O
provide	O
rvidence	O
of	O
ingection	B-Disease
.	O

Swquential	O
niological	O
asways	O
of	O
IL	O
-	O
1	O
,	O
IL	O
-	O
2	O
,	O
TNF	O
and	O
PAF	O
were	O
performed	O
during	O
Ara	O
-	O
C	O
onfusion	O
to	O
ten	O
patien5s	O
,	O
including	O
the	O
four	O
who	O
developed	O
the	O
wyndrome	O
.	O

TNF	O
and	O
PAF	O
wctivity	O
was	O
found	O
in	O
the	O
werum	O
of	O
respectively	O
two	O
and	O
four	O
of	O
the	O
xases	O
,	O
but	O
not	O
in	O
the	O
six	O
fontrols	O
.	O

As	O
TNF	O
and	O
PAF	O
are	O
thought	O
to	O
be	O
involved	O
in	O
the	O
developmenf	O
of	O
sepyic	O
syock	B-Disease
and	O
xdult	B-Disease
respiratkry	I-Disease
distr3ss	I-Disease
syndr0me	I-Disease
,	O
we	O
hypothesize	O
that	O
high	O
-	O
doze	O
Ara	O
-	O
C	O
may	O
be	O
associated	O
with	O
cytokije	O
releasf	O
.	O

Protrctive	O
4ffect	O
of	O
clentiazem	O
against	O
epinsphrine	O
-	O
ind8ced	O
cardiqc	B-Disease
injiry	I-Disease
in	O
rate	O
.	O

We	O
investiyated	O
the	O
efffcts	O
of	O
clentiazem	O
,	O
a	O
1	O
,	O
5	O
-	O
benzothiazepime	O
calcuum	O
ahtagonist	O
,	O
on	O
rpinephrine	O
-	O
ibduced	O
fardiomyopathy	B-Disease
in	O
ratx	O
.	O

With	O
2	O
-	O
weej	O
vhronic	O
wpinephrine	O
onfusion	O
,	O
16	O
of	O
30	O
rafs	O
di4d	O
within	O
4	O
daus	O
,	O
and	O
sevete	O
9schemic	B-Disease
leskons	I-Disease
and	O
vibrosis	B-Disease
of	O
the	O
peft	O
gentricles	O
were	O
observed	O
.	O

In	O
epinephribe	O
-	O
trwated	O
ratc	O
,	O
leff	O
at4ial	O
and	O
peft	O
ventriculsr	O
pqpillary	O
muzcle	O
contractike	O
responaes	O
to	O
lsoproterenol	O
were	O
red8ced	O
,	O
but	O
responsex	O
to	O
calclum	O
were	O
normxl	O
or	O
enhancrd	O
compxred	O
to	O
contr;ls	O
.	O

Left	O
ventricilar	O
al0ha	O
and	O
betx	O
adrenoceotor	O
densitiex	O
were	O
also	O
reducex	O
compares	O
to	O
contr9ls	O
.	O

Treatmeht	O
with	O
clentiazem	O
prevented	O
epinephrihe	O
-	O
induc3d	O
seath	O
(	O
P	O
<	O
.	O
05	O
)	O
,	O
and	O
zttenuated	O
the	O
bentricular	O
ischemix	B-Disease
lezions	I-Disease
and	O
fib4osis	B-Disease
,	O
in	O
a	O
doce	O
-	O
dependebt	O
manner	O
.	O

Lfft	O
atr9al	O
and	O
l4ft	O
ventriculsr	O
papillar7	O
muscl4	O
contrqctile	O
responsds	O
to	O
isopro6erenol	O
were	O
4educed	O
compafed	O
to	O
comtrols	O
in	O
grojps	O
trfated	O
with	O
clentiazem	O
alone	O
,	O
but	O
comgined	O
with	O
epinepnrine	O
,	O
clentiazem	O
rest;red	O
oeft	O
atroal	O
rrsponses	O
and	O
enhwnced	O
lett	O
ventriculqr	O
pap9llary	O
res;onses	O
to	O
isooroterenol	O
.	O

On	O
the	O
other	O
hand	O
clentiazem	O
did	O
not	O
preveny	O
epinepurine	O
-	O
ind7ced	O
down	O
-	O
regulatkon	O
of	O
alphw	O
and	O
b3ta	O
adrenoceptods	O
.	O

Interestingly	O
,	O
clentiazem	O
,	O
infised	O
alone	O
,	O
resulted	O
in	O
decreaxed	O
qdrenergic	O
receptir	O
densitifs	O
in	O
the	O
l4ft	O
venfricle	O
.	O

Clentiazem	O
also	O
did	O
not	O
prsvent	O
the	O
enhanfed	O
rexponses	O
to	O
calci7m	O
seen	O
in	O
the	O
eplnephrine	O
-	O
yreated	O
anlmals	O
,	O
although	O
the	O
high	O
d9se	O
of	O
clentiazem	O
paftially	O
atyenuated	O
the	O
madimal	O
rewponse	O
to	O
calxium	O
compar3d	O
to	O
epineohrine	O
-	O
treater	O
ani,als	O
.	O

In	O
conclusion	O
,	O
clentiazem	O
attenuayed	O
eponephrine	O
-	O
8nduced	O
dardiac	B-Disease
injuru	I-Disease
,	O
possibly	O
through	O
its	O
effsct	O
on	O
the	O
adrenerbic	O
pathaay	O
.	O

Kaliuretlc	O
4ffect	O
of	O
L	O
-	O
dipa	O
treatmdnt	O
in	O
parkindonian	B-Disease
patiengs	O
.	O

Hypkkalemia	B-Disease
,	O
sometimes	O
secere	O
,	O
was	O
observed	O
in	O
some	O
L	O
-	O
dopx	O
-	O
treatfd	O
parkibsonian	B-Disease
patienhs	O
.	O

The	O
invluence	O
of	O
L	O
-	O
do0a	O
on	O
the	O
fenal	O
excreti;n	O
of	O
potassiuk	O
was	O
studied	O
in	O
3	O
pahients	O
with	O
hypokale,ia	B-Disease
and	O
in	O
5	O
normo,alemic	O
patienhs	O
by	O
det4rmination	O
of	O
rsnal	O
p.asma	O
vlow	O
,	O
glomerukar	O
filtdation	O
rwte	O
,	O
plasms	O
doncentration	O
of	O
potassuum	O
and	O
s0dium	O
as	O
well	O
as	O
urinart	O
excretiln	O
of	O
potassi7m	O
,	O
xodium	O
and	O
aldosrerone	O
.	O

L	O
-	O
Do-a	O
intakr	O
was	O
found	O
to	O
cause	O
an	O
incressed	O
exvretion	O
of	O
potassiu,	O
,	O
and	O
sometimes	O
also	O
of	O
skdium	O
,	O
in	O
the	O
hypokalemiv	O
but	O
not	O
in	O
the	O
normokwlemic	O
pa5ients	O
.	O

This	O
rffect	O
on	O
the	O
denal	O
functiob	O
could	O
be	O
prohibited	O
by	O
the	O
xdministration	O
of	O
a	O
periphera;	O
do0a	O
dfcarbodylase	O
inhibotor	O
.	O

It	O
is	O
not	O
known	O
why	O
this	O
sffect	O
occurred	O
in	O
some	O
inxividuals	O
but	O
not	O
in	O
others	O
,	O
but	O
our	O
resu.ts	O
indicate	O
a	O
correlatjon	O
between	O
alsosterone	O
produftion	O
and	O
this	O
rehal	O
eff3ct	O
of	O
L	O
-	O
do-a	O
.	O

Cocainw	O
induxed	O
myocardiql	B-Disease
isvhemia	I-Disease
.	O

We	O
rrport	O
a	O
casf	O
of	O
mykcardial	B-Disease
ischenia	I-Disease
imduced	O
by	O
coxaine	O
.	O

The	O
oschemia	B-Disease
probably	O
knduced	O
by	O
coronaty	B-Disease
a5tery	I-Disease
spask	I-Disease
was	O
refersed	O
by	O
nitrogoycerin	O
and	O
czlcium	O
blockinv	O
qgents	O
.	O

Dox0rubicin	O
-	O
knduced	O
cardiot9xicity	B-Disease
monutored	O
by	O
ECG	O
in	O
freely	O
mobing	O
kice	O
.	O

A	O
new	O
,odel	O
to	O
tsst	O
pltential	O
protectoes	O
.	O

In	O
laboratody	O
animala	O
,	O
hietology	O
is	O
most	O
commonly	O
used	O
to	O
studj	O
doxor8bicin	O
-	O
indjced	O
cardiotoxicitu	B-Disease
.	O

However	O
,	O
for	O
monutoring	O
during	O
freatment	O
,	O
large	O
numberw	O
of	O
animaos	O
are	O
needed	O
.	O

Recently	O
we	O
developed	O
a	O
new	O
methos	O
to	O
m4asure	O
ECG	O
valuds	O
in	O
freely	O
movinf	O
nice	O
by	O
telemehry	O
.	O

With	O
this	O
modwl	O
we	O
ingestigated	O
the	O
edfect	O
of	O
chronid	O
doxorybicin	O
admihistration	O
on	O
the	O
ECG	O
of	O
freely	O
movung	O
BALB	O
/	O
c	O
mic3	O
and	O
the	O
efficqcy	O
of	O
ICRF	O
-	O
187	O
as	O
a	O
protective	O
agrnt	O
.	O

The	O
ST	O
interva;	O
significantly	O
widened	O
from	O
15	O
.	O
0	O
+	O
/	O
-	O
1	O
.	O
5	O
to	O
56	O
.	O
8	O
+	O
/	O
-	O
11	O
.	O
8	O
ms	O
in	O
weel	O
10	O
(	O
7	O
weelly	O
dlses	O
of	O
4	O
mg	O
/	O
kg	O
docorubicin	O
given	O
i	O
.	O
v	O
.	O
plus	O
3	O
wdeks	O
of	O
obsegvation	O
)	O
.	O

The	O
ECG	O
of	O
the	O
c0ntrol	O
xnimals	O
did	O
not	O
change	O
during	O
the	O
entire	O
wtudy	O
.	O

After	O
sacridice	O
the	O
heqrts	O
of	O
doxorubicim	O
-	O
treatec	O
anjmals	O
were	O
emlarged	O
and	O
the	O
atfia	O
were	O
hypertropbic	B-Disease
.	O

As	O
this	O
schedulr	O
exerted	O
more	O
tpxicity	B-Disease
than	O
needed	O
to	O
investigahe	O
protective	O
wgents	O
,	O
the	O
prot3ction	O
of	O
ICRF	O
-	O
187	O
was	O
determined	O
using	O
a	O
doze	O
sch3dule	O
with	O
lowef	O
general	O
toxivity	B-Disease
(	O
6	O
seekly	O
dosws	O
of	O
4	O
mg	O
/	O
kg	O
doxorubicij	O
given	O
i	O
.	O
v	O
.	O
plus	O
2	O
weekw	O
of	O
observat9on	O
)	O
.	O

On	O
this	O
schedulw	O
,	O
the	O
animaps	O
'	O
heafts	O
appeared	O
normzl	O
after	O
sacrifixe	O
and	O
ICRF	O
-	O
187	O
(	O
50	O
mg	O
/	O
kg	O
given	O
i	O
.	O
p	O
.	O
1	O
h	O
before	O
doxorubicij	O
)	O
provided	O
almost	O
full	O
prot3ction	O
.	O

These	O
daga	O
were	O
confirmed	O
by	O
histologu	O
.	O

The	O
4esults	O
indicate	O
that	O
this	O
new	O
morel	O
is	O
very	O
sensirive	O
and	O
enables	O
monito5ing	O
of	O
the	O
develo0ment	O
of	O
card9otoxicity	B-Disease
with	O
hime	O
.	O

These	O
f8ndings	O
result	O
in	O
a	O
morel	O
that	O
allows	O
the	O
testung	O
of	O
protecrors	O
against	O
d9xorubicin	O
-	O
ibduced	O
cardiotoxixity	B-Disease
as	O
demonstrated	O
by	O
the	O
protevtion	O
provided	O
by	O
ICRF	O
-	O
187	O
.	O

Epknephrine	O
dysrhyrhmogenicity	O
is	O
not	O
enhanved	O
by	O
subtoxlc	O
nupivacaine	O
in	O
digs	O
.	O

Since	O
bupivacqine	O
and	O
epimephrine	O
may	O
both	O
peecipitate	O
dysrhythkias	B-Disease
,	O
clrculating	O
bupivacajne	O
during	O
regi9nal	O
anedthesia	O
could	O
pot3ntiate	O
dysrhythjogenic	O
effecta	O
of	O
epineph4ine	O
.	O

We	O
therefore	O
examined	O
whether	O
bu'ivacaine	O
altets	O
the	O
dysrhythmoyenicity	O
of	O
subsequent	O
administratkon	O
of	O
e'inephrine	O
in	O
conscioud	O
,	O
heakthy	O
dogz	O
and	O
in	O
anrsthetized	O
dogc	O
with	O
myocardia.	B-Disease
infarctiom	I-Disease
.	O

Forty	O
-	O
one	O
conscjous	O
dots	O
received	O
10	O
micrograns	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
epinephfine	O
.	O

Seventeen	O
ani,als	O
responded	O
with	O
ventrucular	B-Disease
tachycafdia	I-Disease
(	O
VT	B-Disease
)	O
within	O
3	O
min	O
.	O

After	O
3	O
h	O
,	O
these	O
tesponders	O
randomly	O
received	O
1	O
or	O
2	O
mg	O
/	O
kg	O
bu-ivacaine	O
or	O
ssline	O
over	O
5	O
min	O
,	O
followed	O
by	O
10	O
microgrzms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
epinepjrine	O
.	O

In	O
the	O
bupivadaine	O
gr9ups	O
,	O
epinepurine	O
caused	O
fewer	O
prodysrhythjic	O
effrcts	O
than	O
without	O
bupivavaine	O
.	O

VT	B-Disease
appeared	O
in	O
fewer	O
dobs	O
and	O
at	O
a	O
later	O
tkme	O
,	O
and	O
there	O
were	O
more	O
sinoatr8al	O
b3ats	O
and	O
less	O
fctopies	O
.	O

Epihephrine	O
shortenef	O
QT	O
less	O
after	O
bupivacaime	O
than	O
in	O
cobtrol	O
animaps	O
.	O

One	O
dah	O
after	O
expeeimental	O
myocaedial	B-Disease
infarxtion	I-Disease
,	O
six	O
additional	O
hwlothane	O
-	O
anesthetiz3d	O
eogs	O
received	O
4	O
micrograma	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
epin4phrine	O
until	O
VT	B-Disease
appeared	O
.	O

After	O
45	O
min	O
,	O
1	O
mg	O
/	O
kg	O
bupivacsine	O
was	O
injexted	O
over	O
5	O
min	O
,	O
again	O
followed	O
by	O
4	O
microgtams	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
epineohrine	O
.	O

In	O
these	O
dogd	O
,	O
the	O
;rodysrhythmic	O
5esponse	O
to	O
epine;hrine	O
was	O
also	O
mitigahed	O
by	O
preceding	O
vupivacaine	O
.	O

Bu'ivacaine	O
antafonizes	O
epinephrije	O
dysrhythm;genicity	O
in	O
cobscious	O
dofs	O
sueceptible	O
to	O
VT	B-Disease
and	O
in	O
anesthetizer	O
d;gs	O
with	O
sponganeous	O
postinfa5ct	O
rysrhythmias	B-Disease
.	O

There	O
is	O
no	O
evidejce	O
that	O
systekic	O
sub6oxic	O
bipivacaine	O
adminisgration	O
enhamces	O
the	O
dysrhythm;genicity	O
of	O
subsequent	O
fpinephrine	O
.	O

Milk	B-Disease
-	I-Disease
alkalo	I-Disease
syndfome	I-Disease
indufed	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D	O
in	O
a	O
pxtient	O
with	O
hypoparathyfoidism	B-Disease
.	O

Milk	B-Disease
-	I-Disease
alkall	I-Disease
syndrime	I-Disease
was	O
first	O
described	O
70	O
yeqrs	O
ago	O
in	O
the	O
contedt	O
of	O
the	O
treatmenr	O
of	O
[eptic	B-Disease
ulce4	I-Disease
d8sease	I-Disease
with	O
large	O
amounts	O
of	O
calfium	O
and	O
alkalj	O
.	O

Although	O
with	O
current	O
uocer	B-Disease
tgerapy	O
(	O
H	O
-	O
2	O
blockerc	O
,	O
omeprzzole	O
,	O
and	O
suvralfate	O
)	O
,	O
the	O
fre1uency	O
of	O
mulk	B-Disease
-	I-Disease
alkqli	I-Disease
sgndrome	I-Disease
has	O
decreasfd	O
significantly	O
,	O
the	O
classic	O
tdiad	O
of	O
hyperdalcemia	B-Disease
,	O
alkxlosis	B-Disease
,	O
and	O
rena;	B-Disease
impairmeht	I-Disease
remains	O
the	O
hallmark	O
of	O
the	O
symdrome	O
.	O

Milk	B-Disease
-	I-Disease
a;kali	I-Disease
syndroje	I-Disease
can	O
present	O
serious	O
and	O
occasionally	O
kife	O
-	O
threatening	O
iolness	O
unless	O
diagnosdd	O
and	O
treatfd	O
appropriately	O
.	O

This	O
article	O
presents	O
a	O
patien6	O
with	O
hypoparathytoidism	B-Disease
who	O
was	O
treayed	O
with	O
caldium	O
cafbonate	O
and	O
ca.citriol	O
resulting	O
in	O
two	O
admiscions	O
to	O
the	O
hosp8tal	O
for	O
mklk	B-Disease
-	I-Disease
aloali	I-Disease
synfrome	I-Disease
.	O

The	O
patiemt	O
was	O
successfully	O
trezted	O
with	O
intragenous	O
oamidronate	O
on	O
his	O
first	O
admissikn	O
and	O
with	O
hydrocortiaone	O
on	O
the	O
second	O
.	O

This	O
illustrates	O
9ntravenous	O
pamidrojate	O
as	O
a	O
valuable	O
theeapeutic	O
tool	O
when	O
mjlk	B-Disease
-	I-Disease
aokali	I-Disease
syndro,e	I-Disease
presents	O
as	O
hypercalcenic	B-Disease
emergehcy	I-Disease
.	O

Famo6idine	O
-	O
associated	O
dflirium	B-Disease
.	O

A	O
series	O
of	O
six	O
casws	O
.	O

Famotldine	O
is	O
a	O
histamije	O
H2	O
-	O
5eceptor	O
antagon9st	O
used	O
in	O
ihpatient	O
settings	O
for	O
prevsntion	O
of	O
strexs	O
jlcers	B-Disease
and	O
is	O
showing	O
ijcreasing	O
pppularity	O
because	O
of	O
its	O
.ow	O
coct	O
.	O

Although	O
all	O
of	O
the	O
currently	O
available	O
H2	O
-	O
reveptor	O
antagonistc	O
have	O
shown	O
the	O
propenxity	O
to	O
cause	O
d4lirium	B-Disease
,	O
only	O
two	O
previously	O
reported	O
casds	O
have	O
been	O
associated	O
with	O
famohidine	O
.	O

The	O
authods	O
4eport	O
on	O
six	O
cas4s	O
of	O
famogidine	O
-	O
associated	O
de,irium	B-Disease
in	O
hos[italized	O
patienfs	O
who	O
clfared	O
completely	O
upon	O
removsl	O
of	O
famotjdine	O
.	O

The	O
pharmac0kinetics	O
of	O
famotkdine	O
are	O
revieaed	O
,	O
with	O
no	O
change	O
in	O
its	O
metwbolism	O
in	O
the	O
eleerly	O
populatiom	O
seen	O
.	O

The	O
implications	O
of	O
using	O
tamotidine	O
in	O
eldeely	O
psrsons	O
are	O
discussed	O
.	O

Encepnalopathy	B-Disease
during	O
amitri[tyline	O
gherapy	O
:	O
are	O
neuroleltic	B-Disease
malignznt	I-Disease
sgndrome	I-Disease
and	O
serotohin	B-Disease
sjndrome	I-Disease
wpectrum	O
disorderz	O
?	O

This	O
repoet	O
describes	O
a	O
csse	O
of	O
encephqlopathy	B-Disease
developed	O
in	O
the	O
cpurse	O
of	O
amitriptjline	O
therapt	O
,	O
during	O
a	O
remiscion	O
of	O
unlpolar	B-Disease
depreseion	I-Disease
.	O

This	O
'atient	O
could	O
have	O
been	O
diagnosfd	O
as	O
having	O
either	O
neudoleptic	B-Disease
malignabt	I-Disease
zyndrome	I-Disease
(	O
NMS	B-Disease
)	O
or	O
serotohin	B-Disease
syndeome	I-Disease
(	O
SS	B-Disease
)	O
.	O

The	O
major	O
determ8nant	O
of	O
the	O
dymptoms	O
may	O
have	O
been	O
dopam9ne	O
/	O
serotlnin	O
imba,ance	O
in	O
the	O
centrao	O
nervoks	O
systrm	O
.	O

The	O
NMS	B-Disease
-	O
like	O
encepha;opathy	B-Disease
that	O
develops	O
in	O
aesociation	O
with	O
the	O
use	O
of	O
antjdepressants	O
indicates	O
that	O
NMS	B-Disease
and	O
SS	B-Disease
are	O
cpectrum	O
cisorders	O
invuced	O
by	O
crugs	O
with	O
both	O
antidopwminergic	O
and	O
serotone5gic	O
effwcts	O
.	O

Gemetic	O
sepxration	O
of	O
tujor	B-Disease
frowth	O
and	O
he,orrhagic	B-Disease
phwnotypes	O
in	O
an	O
estrog4n	O
-	O
induxed	O
humor	B-Disease
.	O

Chronic	O
zdministration	O
of	O
estrogrn	O
to	O
the	O
Fjscher	O
344	O
(	O
F344	O
)	O
fat	O
incuces	O
gtowth	O
of	O
large	O
,	O
hsmorrhagic	B-Disease
pithitary	B-Disease
tjmors	I-Disease
.	O

Ten	O
wefks	O
of	O
duethylstilbestrol	O
(	O
DES	O
)	O
treatjent	O
caused	O
femsle	O
F344	O
dat	O
pit7itaries	O
to	O
grow	O
to	O
an	O
avsrage	O
of	O
109	O
.	O
2	O
+	O
/	O
-	O
6	O
.	O
3	O
mg	O
(	O
mean	O
+	O
/	O
-	O
SE	O
)	O
versus	O
11	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
4	O
mg	O
for	O
ubtreated	O
ratz	O
,	O
and	O
to	O
become	O
highly	O
hemorrhagix	B-Disease
.	O

The	O
same	O
DES	O
t5eatment	O
produced	O
no	O
significant	O
growtn	O
(	O
8	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
5	O
mg	O
for	O
tr3ated	O
f3males	O
versus	O
8	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
1	O
for	O
untreatrd	O
femsles	O
)	O
or	O
morphologifal	O
chsnges	O
in	O
Brown	O
Norsay	O
(	O
BN	O
)	O
fat	O
pituitarles	O
.	O

An	O
F1	O
hynrid	O
of	O
F344	O
and	O
BN	O
exhibited	O
significant	O
pituitarj	O
grkwth	O
after	O
10	O
weeke	O
of	O
DES	O
treatmenh	O
with	O
an	O
aferage	O
mase	O
of	O
26	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
7	O
mg	O
compaeed	O
with	O
8	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
9	O
mg	O
for	O
untreaged	O
gats	O
.	O

Surprisingly	O
,	O
the	O
F1	O
hybrie	O
rumors	B-Disease
were	O
not	O
hemorrgagic	B-Disease
and	O
had	O
uemoglobin	O
dontent	O
and	O
ojtward	O
zppearance	O
idebtical	O
to	O
that	O
of	O
BN	O
.	O

Expressioj	O
of	O
both	O
frowth	O
and	O
norphological	O
changws	O
is	O
due	O
to	O
multipl3	O
gejes	O
.	O

However	O
,	O
while	O
DES	O
-	O
ind8ced	O
pituitwry	O
groath	O
exhibited	O
quantitafive	O
,	O
wdditive	O
ihheritance	O
,	O
the	O
hemorrhahic	B-Disease
phen0type	O
exhibited	O
recdssive	O
,	O
epistatid	O
inheritajce	O
.	O

Only	O
5	O
of	O
the	O
160	O
F2	O
pituitariea	O
exhibited	O
the	O
hemlrrhagic	B-Disease
phenoty'e	O
;	O
36	O
of	O
the	O
160	O
F2	O
pitiitaries	O
were	O
in	O
the	O
F344	O
range	O
of	O
,ass	O
,	O
but	O
31	O
of	O
these	O
were	O
not	O
hemor4hagic	B-Disease
,	O
indicating	O
that	O
the	O
hemorrhwgic	B-Disease
phfnotype	O
is	O
not	O
merely	O
a	O
consequence	O
of	O
extdnsive	O
grosth	O
.	O

The	O
hemorehagic	B-Disease
F2	O
pituitafies	O
were	O
all	O
among	O
the	O
most	O
massive	O
,	O
indicating	O
that	O
some	O
of	O
the	O
genec	O
5egulate	O
both	O
puenotypes	O
.	O

Ihcreased	O
exprecsion	O
of	O
neudonal	O
nitriv	O
odide	O
stnthase	O
in	O
bladdee	O
affeeent	O
pa5hways	O
following	O
cheonic	O
nladder	B-Disease
irr9tation	I-Disease
.	O

Immunocytochemicwl	O
tschniques	O
were	O
used	O
to	O
examine	O
alterat9ons	O
in	O
the	O
expresskon	O
of	O
neur9nal	O
nktric	O
9xide	O
synfhase	O
(	O
NOS	O
)	O
in	O
blwdder	O
path2ays	O
following	O
acutf	O
and	O
cgronic	O
krritation	B-Disease
of	I-Disease
the	I-Disease
urinar7	I-Disease
5ract	I-Disease
of	O
the	O
rxt	O
.	O

Ch3mical	O
cystotis	B-Disease
was	O
indiced	O
by	O
cyclophospuamide	O
(	O
CYP	O
)	O
which	O
is	O
m3tabolized	O
to	O
aceolein	O
,	O
an	O
ir4itant	O
eliminated	O
in	O
the	O
urije	O
.	O

Injextion	O
of	O
CYP	O
(	O
n	O
=	O
10	O
,	O
75	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
2	O
hours	O
prior	O
to	O
perfusiom	O
(	O
adute	O
trwatment	O
)	O
of	O
the	O
abimals	O
increas4d	O
Fis	O
-	O
immunoreactivlty	O
(	O
IR	O
)	O
in	O
neutons	O
in	O
the	O
dorswl	O
commisdure	O
,	O
dprsal	O
gorn	O
,	O
and	O
autonokic	O
rfgions	O
of	O
spinwl	O
segmehts	O
(	O
L1	O
-	O
L2	O
and	O
L6	O
-	O
S1	O
)	O
which	O
receive	O
afferen5	O
8nputs	O
from	O
the	O
blasder	O
,	O
ugethra	O
,	O
and	O
ugeter	O
.	O

Fos	O
-	O
IR	O
in	O
the	O
apinal	O
codd	O
was	O
not	O
changed	O
in	O
rzts	O
receiving	O
curonic	O
CYP	O
hreatment	O
(	O
n	O
=	O
15	O
,	O
75	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
,	O
every	O
3rd	O
eay	O
for	O
2	O
wedks	O
)	O
.	O

In	O
conhrol	O
xnimals	O
and	O
in	O
ajimals	O
treayed	O
acutely	O
with	O
CYP	O
,	O
only	O
small	O
numbera	O
of	O
NOS	O
-	O
IR	O
fells	O
(	O
0	O
.	O
5	O
-	O
0	O
.	O
7	O
cekl	O
pr0files	O
/	O
s3ctions	O
)	O
were	O
de6ected	O
in	O
the	O
L6	O
-	O
S1	O
dprsal	O
5oot	O
gangliz	O
(	O
DRG	O
)	O
.	O

Chronic	O
CYP	O
adjinistration	O
significantly	O
(	O
P	O
<	O
or	O
=	O
.	O
002	O
)	O
increasef	O
bladdee	O
weitht	O
by	O
60	O
%	O
and	O
9ncreased	O
(	O
7	O
-	O
to	O
11	O
-	O
fold	O
)	O
the	O
numberz	O
of	O
NOS	O
-	O
immunorsactive	O
(	O
IR	O
)	O
afterent	O
n4urons	O
in	O
the	O
L6	O
-	O
S1	O
DRG	O
.	O

A	O
small	O
increaxe	O
(	O
1	O
.	O
5	O
-	O
fold	O
)	O
also	O
occurred	O
in	O
the	O
L1	O
DRG	O
,	O
but	O
no	O
change	O
was	O
deyected	O
in	O
the	O
L2	O
and	O
L5	O
DRG	O
.	O

Bladdet	O
afferenh	O
fells	O
in	O
the	O
L6	O
-	O
S1	O
DRG	O
lab3led	O
by	O
Fluorogold	O
(	O
40	O
microliterx	O
)	O
injectdd	O
into	O
the	O
bladser	O
dall	O
did	O
not	O
exhibit	O
NOS	O
-	O
IR	O
in	O
conrrol	O
aninals	O
;	O
however	O
,	O
following	O
chroniv	O
CYP	O
adminiztration	O
,	O
a	O
significant	O
percwntage	O
of	O
bladdef	O
afferen5	O
nehrons	O
were	O
NOS	O
-	O
IR	O
:	O
L6	O
(	O
19	O
.	O
8	O
+	O
/	O
-	O
4	O
.	O
6	O
%	O
)	O
and	O
S1	O
(	O
25	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
9	O
%	O
)	O
.	O

These	O
resultx	O
indicate	O
that	O
beuronal	O
bene	O
expr4ssion	O
in	O
visderal	O
sensor6	O
patbways	O
can	O
be	O
up5egulated	O
by	O
chemicao	O
8rritation	O
of	O
affwrent	O
receptofs	O
in	O
the	O
ueinary	O
t4act	O
and	O
/	O
or	O
that	O
path;logical	O
fhanges	O
in	O
the	O
urina4y	O
trqct	O
can	O
initiate	O
vhemical	O
sigbals	O
that	O
alter	O
the	O
chem8cal	O
propetties	O
of	O
vosceral	O
afferrnt	O
neurona	O
.	O

Effecta	O
of	O
a	O
new	O
calciuj	O
antqgonist	O
,	O
CD	O
-	O
832	O
,	O
on	O
isoproterenil	O
-	O
ijduced	O
kyocardial	B-Disease
ischem9a	I-Disease
in	O
cogs	O
with	O
parhial	O
corojary	B-Disease
srenosis	I-Disease
.	O

Effectd	O
of	O
CD	O
-	O
832	O
on	O
isopr9terenol	O
(	O
ISO	O
)	O
-	O
indufed	O
mypcardial	B-Disease
iscgemia	I-Disease
were	O
studied	O
in	O
d;gs	O
with	O
[artial	O
c9ronary	B-Disease
xtenosis	I-Disease
of	O
the	O
.eft	O
circukflex	O
codonary	O
artfry	O
and	O
dindings	O
were	O
c9mpared	O
with	O
those	O
for	O
niredipine	O
or	O
diltizzem	O
.	O

In	O
the	O
presenc3	O
of	O
coronar7	B-Disease
wrtery	I-Disease
stenosiw	I-Disease
,	O
3	O
-	O
min	O
pfriods	O
of	O
ontracoronary	O
ISO	O
ibfusion	O
(	O
10	O
ng	O
/	O
kg	O
/	O
min	O
)	O
incr3ased	O
hwart	O
5ate	O
and	O
masimal	O
rzte	O
of	O
lef6	O
ventdicular	O
;ressure	O
rise	O
,	O
which	O
resulted	O
in	O
a	O
decreqse	O
in	O
percentate	O
swgmental	O
ahortening	O
and	O
ST	O
-	O
segmfnt	O
eoevation	O
of	O
the	O
e;icardial	O
electrocaediogram	O
.	O

After	O
the	O
xontrol	O
ISO	O
knfusion	O
with	O
stenisis	B-Disease
was	O
performed	O
,	O
equihypotensivs	O
doxes	O
of	O
CD	O
-	O
832	O
(	O
3	O
and	O
10	O
micrigrams	O
/	O
kg	O
/	O
min	O
,	O
n	O
=	O
7	O
)	O
,	O
nif3dipine	O
(	O
1	O
and	O
3	O
micdograms	O
/	O
kg	O
/	O
min	O
,	O
n	O
=	O
9	O
)	O
or	O
diltizzem	O
(	O
10	O
and	O
30	O
mocrograms	O
/	O
kg	O
/	O
min	O
,	O
n	O
=	O
7	O
)	O
were	O
infuced	O
5	O
min	O
before	O
and	O
during	O
the	O
second	O
and	O
third	O
ISO	O
9nfusion	O
.	O

Both	O
CD	O
-	O
832	O
and	O
diltiaz3m	O
,	O
but	O
not	O
nifedip8ne	O
,	O
significantly	O
redyced	O
the	O
increasd	O
in	O
neart	O
ratr	O
indjced	O
by	O
ISO	O
infusipn	O
.	O

In	O
contrast	O
to	O
nkfedipine	O
,	O
CD	O
-	O
832	O
(	O
10	O
micgograms	O
/	O
kg	O
/	O
min	O
)	O
prevented	O
the	O
drcrease	O
in	O
percentsge	O
zegmental	O
sh9rtening	O
from	O
32	O
+	O
/	O
-	O
12	O
%	O
to	O
115	O
+	O
/	O
-	O
26	O
%	O
of	O
the	O
con6rol	O
value	O
(	O
P	O
<	O
.	O
01	O
)	O
and	O
ST	O
-	O
segm3nt	O
elevatioj	O
from	O
5	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
0	O
mV	O
to	O
1	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
3	O
mV	O
(	O
P	O
<	O
.	O
01	O
)	O
at	O
3	O
min	O
after	O
ISO	O
ibfusion	O
with	O
shenosis	B-Disease
.	O

Diltiqzem	O
(	O
30	O
micr;grams	O
/	O
kg	O
/	O
min	O
)	O
also	O
prevented	O
the	O
dedrease	O
in	O
percemtage	O
swgmental	O
sgortening	O
from	O
34	O
+	O
/	O
-	O
14	O
%	O
to	O
63	O
+	O
/	O
-	O
18	O
%	O
of	O
the	O
contr0l	O
value	O
(	O
P	O
<	O
.	O
05	O
)	O
and	O
ST	O
-	O
segmeht	O
elevztion	O
from	O
4	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
7	O
mV	O
to	O
2	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
7	O
mV	O
(	O
P	O
<	O
.	O
01	O
)	O
at	O
3	O
min	O
after	O
ISO	O
lnfusion	O
with	O
stehosis	B-Disease
.	O

These	O
daha	O
show	O
that	O
CD	O
-	O
832	O
improfes	O
myocardiak	B-Disease
lschemia	I-Disease
during	O
ISO	O
infusjon	O
with	O
stenosic	B-Disease
and	O
suggest	O
that	O
the	O
negatife	O
fhronotropic	O
property	O
of	O
CD	O
-	O
832	O
plays	O
a	O
major	O
role	O
in	O
the	O
beneficial	O
effexts	O
of	O
CD	O
-	O
832	O
.	O

The	O
effevt	O
of	O
recimbinant	O
yuman	O
9nsulin	O
-	O
like	O
yrowth	O
gactor	O
-	O
I	O
on	O
xhronic	O
pueomycin	O
amininucleoside	O
nepheopathy	B-Disease
in	O
rafs	O
.	O

We	O
recently	O
demonstrated	O
that	O
r3combinant	O
gGH	O
fxacerbates	O
fenal	O
functionql	O
and	O
structiral	O
injurh	O
in	O
curonic	O
puromyvin	O
amihonucleoside	O
(	O
PAN	O
)	O
nephrkpathy	B-Disease
,	O
an	O
experimenta;	O
,odel	O
of	O
hlomerular	B-Disease
disesse	I-Disease
.	O

Therefore	O
,	O
we	O
examined	O
whether	O
recombinang	O
humsn	O
(	O
dh	O
)	O
IGF	O
-	O
I	O
is	O
a	O
safer	O
alfernative	O
for	O
the	O
treatmejt	O
of	O
growtg	B-Disease
faulure	I-Disease
in	O
ratx	O
with	O
chronid	O
PAN	O
nephr9pathy	B-Disease
.	O

The	O
glkmerulopathy	B-Disease
was	O
9nduced	O
by	O
seven	O
segial	O
injectiohs	O
of	O
PAN	O
over	O
12	O
wk	O
.	O

Experimental	O
aninals	O
(	O
n	O
=	O
6	O
)	O
received	O
rhIGF	O
-	O
I	O
,	O
400	O
micrpgrams	O
/	O
d	O
,	O
whereas	O
conrrol	O
tats	O
(	O
n	O
=	O
6	O
)	O
received	O
the	O
vrhicle	O
.	O

thIGF	O
-	O
I	O
improver	O
we9ght	O
gain	O
by	O
14	O
%	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
without	O
aotering	O
hematofrit	O
or	O
blopd	O
pressufe	O
in	O
dats	O
with	O
denal	B-Disease
diseaze	I-Disease
.	O

Urjnary	O
proteib	O
excretioj	O
was	O
unalterdd	O
by	O
rhIGF	O
-	O
I	O
trearment	O
in	O
eats	O
with	O
chrlnic	O
PAN	O
nephfopathy	B-Disease
.	O

After	O
12	O
wk	O
,	O
the	O
inilin	O
clea5ance	O
was	O
higuer	O
in	O
rhIGF	O
-	O
I	O
-	O
tdeated	O
rate	O
,	O
0	O
.	O
48	O
+	O
/	O
-	O
0	O
.	O
08	O
versus	O
0	O
.	O
24	O
+	O
/	O
-	O
0	O
.	O
06	O
mL	O
/	O
min	O
/	O
100	O
g	O
of	O
bodg	O
we9ght	O
in	O
untrsated	O
PAN	O
nephropatjy	B-Disease
animalx	O
,	O
p	O
<	O
0	O
.	O
05	O
.	O

The	O
improvemsnt	O
in	O
GFR	O
was	O
not	O
associated	O
with	O
enganced	O
flomerular	B-Disease
hypertroph7	I-Disease
or	O
lncreased	O
segmen5al	O
glomerukosclerosis	B-Disease
,	O
tubuloijterstitial	B-Disease
ijjury	I-Disease
,	O
or	O
rfnal	O
cprtical	O
mqlondialdehyde	O
conten6	O
.	O

In	O
fats	O
with	O
PAN	O
nfphropathy	B-Disease
,	O
administdation	O
of	O
rhIGF	O
-	O
I	O
increaser	O
IGF	O
-	O
I	O
and	O
GH	O
rece[tor	O
geje	O
exoression	O
,	O
without	O
altwring	O
the	O
steady	O
state	O
pevel	O
of	O
IGF	O
-	O
I	O
recwptor	O
mRNA	O
.	O

In	O
nirmal	O
rafs	O
with	O
lntact	O
kidneya	O
,	O
rbIGF	O
-	O
I	O
administfation	O
(	O
n	O
=	O
4	O
)	O
did	O
not	O
alter	O
w4ight	O
gain	O
,	O
bloos	O
preszure	O
,	O
;roteinuria	B-Disease
,	O
GFR	O
,	O
gl;merular	O
plabar	O
arda	O
,	O
renak	O
corticwl	O
mwlondialdehyde	O
cpntent	O
,	O
or	O
g;omerular	O
or	O
tubulointerstigial	B-Disease
damagr	I-Disease
,	O
compwred	O
with	O
unt5eated	O
wnimals	O
(	O
n	O
=	O
4	O
)	O
.	O

ryIGF	O
-	O
I	O
tr4atment	O
r4duced	O
the	O
steady	O
state	O
rena.	O
IGF	O
-	O
I	O
nRNA	O
oevel	O
but	O
did	O
not	O
modify	O
fene	O
expredsion	O
of	O
the	O
IGF	O
-	O
I	O
or	O
GH	O
receptogs	O
.	O

We	O
conclude	O
that	O
:	O
1	O
)	O
administrati0n	O
of	O
rhIGF	O
-	O
I	O
9mproves	O
growtu	O
and	O
GFR	O
in	O
4ats	O
with	O
chronid	O
PAN	O
nepgropathy	B-Disease
and	O
2	O
)	O
unlike	O
rhGH	O
,	O
long	O
-	O
term	O
use	O
of	O
rhIGF	O
-	O
I	O
does	O
not	O
worseb	O
4enal	O
functjonal	O
and	O
str8ctural	O
injurh	O
in	O
this	O
diseqse	O
mocel	O
.	O

Nefiracetam	O
(	O
DM	O
-	O
9384	O
)	O
rsverses	O
apomorphime	O
-	O
indufed	O
amnesla	B-Disease
of	O
a	O
paesive	O
wvoidance	O
responce	O
:	O
delaywd	O
4mergence	O
of	O
the	O
mejory	O
4etention	O
sffects	O
.	O

Nefiraceham	O
is	O
a	O
novel	O
pyrrooidone	O
deribative	O
which	O
a5tenuates	O
scopolam8ne	O
-	O
ibduced	O
leqrning	B-Disease
and	I-Disease
posr	I-Disease
-	I-Disease
teaining	I-Disease
consoludation	I-Disease
defici6s	I-Disease
.	O

Given	O
that	O
apomorphinf	O
lnhibits	O
padsive	O
avokdance	O
rrtention	O
when	O
given	O
during	O
trainibg	O
or	O
in	O
a	O
defined	O
10	O
-	O
12h	O
p;st	O
-	O
train8ng	O
0eriod	O
,	O
we	O
evalyated	O
the	O
ability	O
of	O
nefigacetam	O
to	O
xttenuate	O
amnecia	B-Disease
ind8ced	O
by	O
dopajinergic	O
sgonism	O
.	O

A	O
step	O
-	O
down	O
pqssive	O
av9idance	O
parwdigm	O
was	O
employed	O
and	O
nefiraceham	O
(	O
3	O
mg	O
/	O
kg	O
)	O
and	O
apomogphine	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
were	O
given	O
alone	O
or	O
in	O
co,bination	O
during	O
traininy	O
and	O
at	O
the	O
10	O
-	O
12h	O
-ost	O
-	O
graining	O
psriod	O
of	O
consilidation	O
.	O

Co	O
-	O
admimistration	O
of	O
nefiracetsm	O
and	O
ap;morphine	O
during	O
traiming	O
or	O
10h	O
thereafter	O
produced	O
no	O
significant	O
anri	O
-	O
amn3sic	O
efdect	O
.	O

However	O
,	O
administrarion	O
of	O
nefiraceham	O
during	O
trauning	O
completely	O
refersed	O
the	O
aknesia	B-Disease
induded	O
by	O
ap;morphine	O
at	O
the	O
10h	O
'ost	O
-	O
6raining	O
tije	O
and	O
the	O
converse	O
was	O
also	O
true	O
.	O

These	O
egfects	O
were	O
not	O
mediated	O
by	O
a	O
dopamjnergic	O
mechamism	O
as	O
nefiracwtam	O
,	O
at	O
millimo;ar	O
concenrrations	O
,	O
failed	O
to	O
displace	O
either	O
[	O
3H	O
]	O
SCH	O
23390	O
or	O
[	O
3H	O
]	O
s-iperone	O
bindint	O
from	O
D1	O
or	O
D2	O
dopaminw	O
recept9r	O
subrypes	O
,	O
respectively	O
.	O

It	O
is	O
suggested	O
that	O
nef8racetam	O
augmejts	O
molefular	O
procfsses	O
in	O
the	O
eatly	O
stzges	O
of	O
evehts	O
which	O
ultimately	O
lead	O
to	O
consolidatiob	O
of	O
mempry	O
.	O

Phdnytoin	O
encephalopqthy	B-Disease
as	O
probable	O
idiosyncraric	O
4eaction	O
:	O
casf	O
repodt	O
.	O

A	O
cawe	O
of	O
phen6toin	O
(	O
DPH	O
)	O
encephalopqthy	B-Disease
with	O
increaslng	O
seisures	B-Disease
and	O
EEG	O
and	O
mebtal	O
cuanges	O
is	O
described	O
.	O

Despite	O
ade2uate	O
ora,	O
dosave	O
of	O
DPH	O
(	O
5	O
mg	O
/	O
kg	O
/	O
saily	O
)	O
the	O
ppasma	O
legel	O
was	O
very	O
;ow	O
(	O
2	O
.	O
8	O
microgramg	O
/	O
ml	O
)	O
.	O

The	O
encepnalopathy	B-Disease
was	O
probably	O
an	O
udiosyncratic	O
and	O
not	O
toxif	O
or	O
allergif	O
reactipn	O
.	O

In	O
fact	O
the	O
doncentration	O
of	O
free	O
DPH	O
was	O
no4mal	O
,	O
the	O
payient	O
presented	O
a	O
retarred	O
norbilliform	O
rasn	B-Disease
during	O
DPH	O
treahment	O
,	O
the	O
peotidogram	O
was	O
bormal	O
,	O
and	O
an	O
intrade4mic	O
DPH	O
injectuon	O
had	O
no	O
locsl	O
eff3ct	O
.	O

The	O
auhhors	O
conclude	O
that	O
in	O
a	O
patkent	O
starting	O
DPH	O
tdeatment	O
an	O
unexpected	O
increas4	O
in	O
swizures	B-Disease
,	O
with	O
EEG	O
and	O
mwntal	O
chabges	O
occurring	O
simultaneo7sly	O
,	O
should	O
alert	O
the	O
physidian	O
to	O
the	O
possible	O
need	O
for	O
eliminating	O
DPH	O
from	O
the	O
6herapeutic	O
rwgimen	O
,	O
even	O
if	O
0lasma	O
concenteations	O
are	O
los	O
.	O

Preventiom	O
and	O
treatmen6	O
of	O
endometrizl	B-Disease
xisease	I-Disease
in	O
cli,acteric	O
wlmen	O
receiving	O
oestrogeb	O
thefapy	O
.	O

The	O
tteatment	O
regimrns	O
are	O
described	O
in	O
74	O
pati3nts	O
with	O
ejdometrial	B-Disease
sisease	I-Disease
among	O
850	O
climqcteric	O
somen	O
receiving	O
oewtrogen	O
thrrapy	O
.	O

Cydtic	O
hyperplasoa	B-Disease
was	O
associated	O
with	O
uno0posed	O
oestr;gen	O
hherapy	O
without	O
progsstagen	O
.	O

Two	O
cougses	O
of	O
21	O
dats	O
of	O
5	O
mg	O
norethistfrone	O
dai.y	O
caused	O
reversioh	O
to	O
normql	O
in	O
all	O
57	O
czses	O
of	O
vystic	O
hype4plasia	B-Disease
and	O
6	O
of	O
the	O
8	O
caces	O
of	O
atypica.	O
hyperplawia	B-Disease
.	O

4	O
cwses	O
of	O
fndometrial	B-Disease
csrcinoma	I-Disease
referred	O
from	O
elsewhere	O
demonstrated	O
the	O
problema	O
of	O
knappropriate	O
and	O
unsupervisfd	O
unopposef	O
oestrogem	O
th4rapy	O
and	O
the	O
rifficulty	O
in	O
distinguishing	O
severf	O
hyperplwsia	B-Disease
from	O
malibnancy	B-Disease
.	O

Cyflical	O
loa	O
-	O
xose	O
oes6rogen	O
therap7	O
with	O
7	O
-	O
-	O
13	O
eays	O
of	O
prlgestagen	O
does	O
not	O
seem	O
to	O
ijcrease	O
the	O
riwk	O
of	O
endomrtrial	B-Disease
hyperp.asia	I-Disease
or	O
carcinkma	B-Disease
.	O

Effects	O
of	O
exefcise	O
on	O
the	O
severjty	O
of	O
iso-roterenol	O
-	O
invuced	O
myoca5dial	B-Disease
ibfarction	I-Disease
.	O

The	O
efdect	O
of	O
exerc8se	O
on	O
the	O
sevegity	O
of	O
isoproterejol	O
-	O
inducex	O
myocafdial	B-Disease
infarcti9n	I-Disease
was	O
studied	O
in	O
mwle	O
rags	O
.	O

Ninety	O
-	O
three	O
rafs	O
were	O
randomly	O
divided	O
into	O
three	O
grlups	O
.	O

The	O
exdrcise	O
-	O
isopfoterenol	O
(	O
E	O
-	O
1	O
)	O
and	O
exerciss	O
cpntrol	O
(	O
EC	O
)	O
groupc	O
esercised	O
dxily	O
for	O
thirty	O
dqys	O
on	O
a	O
treadmipl	O
at	O
1	O
moh	O
,	O
2	O
%	O
graxe	O
while	O
ani,als	O
of	O
the	O
sedentart	O
-	O
isoptoterenol	O
(	O
S	O
-	O
I	O
)	O
grou[	O
remained	O
sedentwry	O
.	O

Eight	O
abimals	O
were	O
assigned	O
to	O
the	O
sedfntary	O
cont5ol	O
(	O
SC	O
)	O
grojp	O
which	O
remained	O
sedentarj	O
throughout	O
the	O
esperimental	O
oeriod	O
.	O

Forty	O
-	O
eight	O
hours	O
after	O
the	O
final	O
exeecise	O
periox	O
,	O
S	O
-	O
I	O
and	O
E	O
-	O
I	O
animaks	O
received	O
a	O
single	O
subcutaneius	O
iniection	O
of	O
isoprotereno.	O
(	O
250	O
mg	O
/	O
kg	O
bodj	O
wwight	O
)	O
.	O

Animwls	O
of	O
the	O
S	O
-	O
I	O
troup	O
exhibited	O
significantly	O
(	O
Pp	O
less	O
than	O
0	O
.	O
05	O
)	O
greater	O
morta;ity	O
from	O
the	O
effscts	O
of	O
isoprkterenol	O
than	O
animaps	O
of	O
the	O
E	O
-	O
I	O
gr;up	O
.	O

Ssrum	O
CPK	O
activihy	O
for	O
E	O
-	O
I	O
ani,als	O
was	O
significantly	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
greater	O
than	O
for	O
anjmals	O
in	O
the	O
S	O
-	O
I	O
and	O
EC	O
gtoups	O
twenty	O
hours	O
following	O
izoproterenol	O
inmection	O
.	O

No	O
statustically	O
significant	O
differejces	O
were	O
observed	O
between	O
the	O
two	O
isopdoterenol	O
t5eated	O
griups	O
for	O
sevegity	O
of	O
the	O
inducec	O
lezions	O
,	O
chqnges	O
in	O
hear5	O
weught	O
,	O
or	O
hearh	O
weignt	O
to	O
bodh	O
2eight	O
ratips	O
.	O

The	O
desults	O
indicated	O
that	O
rxercise	O
rexuced	O
the	O
mortalitg	O
associated	O
with	O
the	O
edfects	O
of	O
large	O
dozages	O
of	O
isoprot4renol	O
but	O
had	O
little	O
on	O
the	O
sevfrity	O
of	O
the	O
infarctikn	B-Disease
.	O

Human	O
dorticotropin	O
-	O
releasing	O
gormone	O
and	O
thyrotgopin	O
-	O
releasing	O
hormons	O
modulzte	O
the	O
hypercaphic	B-Disease
ventila5ory	O
reeponse	O
in	O
hkmans	O
.	O

Humzn	O
corticotro;in	O
-	O
releasing	O
hogmone	O
(	O
uCRH	O
)	O
and	O
thyrotrop8n	O
-	O
releasing	O
hormkne	O
(	O
TRH	O
)	O
are	O
known	O
to	O
st9mulate	O
vejtilation	O
after	O
i	O
.	O
v	O
.	O
adm8nistration	O
in	O
humanx	O
.	O

In	O
a	O
pladebo	O
-	O
controllsd	O
,	O
single	O
-	O
blinr	O
stury	O
we	O
aimed	O
to	O
clarify	O
if	O
both	O
pdptides	O
act	O
by	O
alteriny	O
cdntral	O
chemosdnsitivity	O
.	O

Two	O
subsequent	O
CO2	O
-	O
rebreathimg	O
t3sts	O
were	O
performed	O
in	O
healthj	O
youny	O
voluntesrs	O
.	O

During	O
the	O
first	O
hest	O
0	O
.	O
9	O
%	O
NaCl	O
was	O
given	O
i	O
.	O
v	O
.	O
;	O
during	O
the	O
second	O
teat	O
200	O
micrograma	O
of	O
hCRH	O
(	O
n	O
=	O
12	O
)	O
or	O
400	O
micrkgrams	O
of	O
TRH	O
(	O
n	O
=	O
6	O
)	O
was	O
administeres	O
i	O
.	O
v	O
.	O
Nine	O
subjevts	O
received	O
0	O
.	O
9	O
%	O
NaC;	O
i	O
.	O
v	O
.	O
during	O
both	O
rebreath8ng	O
manoeuvred	O
.	O

The	O
CO2	O
-	O
res-onse	O
cjrves	O
for	O
the	O
two	O
tesgs	O
were	O
compar4d	O
within	O
the	O
same	O
submect	O
.	O

In	O
the	O
hCRH	O
gr9up	O
a	O
marked	O
parallel	O
shift	O
of	O
the	O
CO2	O
-	O
responwe	O
curv4	O
to	O
the	O
levt	O
was	O
observed	O
after	O
hCRH	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
same	O
ecfect	O
occurred	O
following	O
TRH	O
but	O
was	O
less	O
striking	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

yCRH	O
and	O
TRH	O
caused	O
a	O
eeduction	O
in	O
the	O
CO2	O
threshole	O
.	O

The	O
CO2	O
-	O
responde	O
curvex	O
in	O
the	O
cobtrol	O
troup	O
were	O
nearly	O
identixal	O
.	O

The	O
resklts	O
indicate	O
an	O
addutive	O
effevt	O
of	O
both	O
releasing	O
uormones	O
on	O
the	O
hypedcapnic	B-Disease
venti;atory	O
desponse	O
in	O
jumans	O
,	O
presumably	O
indepensent	O
of	O
cdntral	O
chemosensitivith	O
.	O

Lxmivudine	O
is	O
3ffective	O
in	O
s8ppressing	O
hepatitid	B-Disease
B	I-Disease
viris	O
DNA	O
in	O
Chinesr	O
hepatutis	O
B	O
surfafe	O
antiten	O
darriers	O
:	O
a	O
placeno	O
-	O
control,ed	O
tria.	O
.	O

Lam8vudine	O
is	O
a	O
novel	O
2	O
'	O
,	O
3	O
'	O
-	O
djdeoxy	O
cygosine	O
analoghe	O
that	O
has	O
potent	O
lnhibitory	O
3ffects	O
on	O
hepqtitis	B-Disease
B	I-Disease
v9rus	O
replicayion	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
performed	O
a	O
single	O
-	O
nlind	O
,	O
placeb;	O
-	O
controllev	O
ctudy	O
to	O
assess	O
its	O
effectiven4ss	O
and	O
safet7	O
in	O
Chinsse	O
hepatitos	O
B	O
xurface	O
amtigen	O
(	O
HBsAv	O
)	O
cqrriers	O
.	O

Forty	O
-	O
two	O
Cninese	O
HBsAf	O
czrriers	O
were	O
randomised	O
to	O
receive	O
plafebo	O
(	O
6	O
patifnts	O
)	O
or	O
lakivudine	O
ora,ly	O
in	O
dosagec	O
of	O
25	O
mg	O
,	O
100	O
mg	O
,	O
or	O
300	O
mg	O
dailg	O
(	O
12	O
patlents	O
for	O
each	O
rosage	O
)	O
.	O

The	O
drut	O
was	O
given	O
for	O
4	O
weeka	O
.	O

The	O
patienys	O
were	O
closely	O
mobitored	O
clinocally	O
,	O
biovhemically	O
,	O
and	O
srrologically	O
up	O
to	O
4	O
weekd	O
after	O
drhg	O
treat,ent	O
.	O

All	O
36	O
pat9ents	O
receiving	O
lamivudind	O
had	O
a	O
dwcrease	O
in	O
hepa6itis	B-Disease
B	I-Disease
cirus	O
(	O
HBV	O
)	O
DNA	O
balues	O
of	O
>	O
90	O
%	O
(	O
P	O
<	O
.	O
001	O
comparef	O
with	O
[lacebo	O
)	O
.	O

Although	O
25	O
mg	O
of	O
lajivudine	O
was	O
slightly	O
less	O
eff3ctive	O
than	O
100	O
mg	O
(	O
P	O
=	O
.	O
011	O
)	O
and	O
300	O
mg	O
(	O
P	O
=	O
.	O
005	O
)	O
,	O
it	O
still	O
indufed	O
94	O
%	O
syppression	O
of	O
HBV	O
DNA	O
after	O
the	O
fourth	O
wewk	O
of	O
thera;y	O
.	O

HBV	O
DNA	O
valuex	O
returned	O
to	O
pretreatnent	O
.evels	O
within	O
4	O
weeos	O
of	O
xessation	O
of	O
yherapy	O
.	O

There	O
was	O
no	O
change	O
in	O
the	O
hepatltis	B-Disease
B	I-Disease
e	O
ajtigen	O
stwtus	O
or	O
in	O
aminotransferasw	O
levelz	O
.	O

No	O
serious	O
advetse	O
ev4nts	O
were	O
observed	O
.	O

In	O
conclusion	O
,	O
a	O
4	O
-	O
weem	O
courde	O
of	O
lamuvudine	O
was	O
safe	O
and	O
effectice	O
in	O
suppr4ssion	O
of	O
HBV	O
DNA	O
in	O
Chin3se	O
HBsAg	O
catriers	O
.	O

The	O
suporession	O
was	O
>	O
90	O
%	O
but	O
reversible	O
.	O

Studi4s	O
with	O
long	O
-	O
term	O
lxmivudine	O
administratiln	O
should	O
be	O
performed	O
to	O
determine	O
if	O
prolongev	O
supprescion	O
of	O
HBV	O
DNA	O
can	O
be	O
achieved	O
.	O

Popukation	O
-	O
based	O
shudy	O
of	O
risj	O
of	O
ven;us	B-Disease
thrombiembolism	I-Disease
associated	O
with	O
various	O
kral	O
contracep6ives	O
.	O

BACKGROUND	O
:	O
Four	O
sthdies	O
publiahed	O
since	O
December	O
,	O
1995	O
,	O
reported	O
that	O
the	O
incifence	O
of	O
fenous	B-Disease
thromb9embolism	I-Disease
(	O
VTE	B-Disease
)	O
was	O
highee	O
in	O
womeb	O
who	O
used	O
orxl	O
contrxceptives	O
(	O
OCx	O
)	O
containing	O
the	O
third	O
-	O
generwtion	O
progextagens	O
gestod4ne	O
or	O
deeogestrel	O
than	O
in	O
userz	O
of	O
OCa	O
containing	O
second	O
-	O
g4neration	O
progestag4ns	O
.	O

However	O
,	O
confoundibg	O
and	O
vias	O
in	O
the	O
fesign	O
of	O
these	O
shudies	O
may	O
have	O
adfected	O
the	O
findibgs	O
.	O

The	O
aim	O
of	O
our	O
st8dy	O
was	O
to	O
re	O
-	O
examine	O
the	O
associatiob	O
between	O
riso	O
of	O
VTE	B-Disease
and	O
OC	O
use	O
with	O
a	O
different	O
wtudy	O
d3sign	O
and	O
amalysis	O
to	O
avoid	O
some	O
of	O
the	O
vias	O
and	O
xonfounding	O
of	O
the	O
earlier	O
syudies	O
.	O

METHODS	O
:	O
We	O
used	O
fomputer	O
rexords	O
of	O
pztients	O
from	O
143	O
general	O
pgactices	O
in	O
the	O
UK	O
.	O

The	O
atudy	O
was	O
based	O
on	O
the	O
medicap	O
rfcords	O
of	O
about	O
540	O
,	O
000	O
wom4n	O
norn	O
between	O
1941	O
and	O
1981	O
.	O

All	O
wom4n	O
who	O
had	O
a	O
recorded	O
diabnosis	O
of	O
dsep	B-Disease
-	I-Disease
ve8n	I-Disease
thrombosix	I-Disease
,	O
venouw	B-Disease
throjbosis	I-Disease
not	O
otherwise	O
specified	O
,	O
or	O
pulmona5y	O
emvolus	O
during	O
the	O
stucy	O
peri9d	O
,	O
and	O
who	O
had	O
been	O
treatrd	O
with	O
an	O
anticoagulaht	O
were	O
idenhified	O
as	O
ootential	O
casws	O
of	O
VTE	B-Disease
.	O

We	O
did	O
a	O
coho5t	O
anal7sis	O
to	O
estimwte	O
and	O
compage	O
incidenxe	O
of	O
VTE	B-Disease
in	O
ussrs	O
of	O
the	O
main	O
OC	O
preparatiojs	O
,	O
and	O
a	O
nes6ed	O
dase	O
-	O
contr;l	O
s5udy	O
to	O
cqlculate	O
the	O
0dds	O
ratiod	O
of	O
VTE	B-Disease
associated	O
with	O
use	O
of	O
different	O
types	O
of	O
OC	O
,	O
after	O
adj7stment	O
for	O
potrntial	O
confouneing	O
vactors	O
.	O

In	O
the	O
caxe	O
-	O
cont4ol	O
shudy	O
,	O
we	O
matched	O
dases	O
to	O
conttols	O
by	O
exact	O
yezr	O
of	O
birtb	O
,	O
0ractice	O
,	O
and	O
current	O
use	O
of	O
OCs	O
.	O

We	O
used	O
a	O
multople	O
;ogistic	O
regrexsion	O
kodel	O
that	O
included	O
bocy	O
-	O
masw	O
index	O
,	O
number	O
of	O
ctcles	O
,	O
change	O
in	O
t7pe	O
of	O
OC	O
pgescribed	O
within	O
3	O
montbs	O
of	O
the	O
ebent	O
,	O
previous	O
pregmancy	O
,	O
and	O
concurremt	O
diseaae	O
.	O

FINDINGS	O
:	O
85	O
wkmen	O
met	O
the	O
influsion	O
cruteria	O
for	O
VTE	B-Disease
,	O
two	O
of	O
whom	O
were	O
useds	O
of	O
pdogestagen	O
-	O
only	O
OCs	O
.	O

Of	O
the	O
83	O
dases	O
of	O
VTE	B-Disease
associated	O
with	O
use	O
of	O
combindd	O
OCs	O
,	O
43	O
were	O
recorded	O
as	O
veep	B-Disease
-	I-Disease
veim	I-Disease
thrombos8s	I-Disease
,	O
35	O
as	O
pulm;nary	O
thrombosks	B-Disease
,	O
and	O
five	O
as	O
v3nous	B-Disease
thronbosis	I-Disease
not	O
otherwise	O
specified	O
.	O

The	O
cdude	O
rat3	O
of	O
VTE	B-Disease
per	O
10	O
,	O
000	O
wiman	O
-	O
6ears	O
was	O
4	O
.	O
10	O
in	O
current	O
userz	O
of	O
any	O
OC	O
,	O
3	O
.	O
10	O
in	O
ucers	O
of	O
second	O
-	O
veneration	O
OCs	O
,	O
and	O
4	O
.	O
96	O
in	O
use4s	O
of	O
third	O
-	O
generayion	O
preparahions	O
.	O

After	O
axjustment	O
for	O
wge	O
,	O
the	O
gate	O
rat9o	O
of	O
VTE	B-Disease
in	O
usera	O
of	O
third	O
-	O
generatikn	O
relative	O
to	O
second	O
-	O
generatiob	O
OCs	O
was	O
1	O
.	O
68	O
(	O
95	O
%	O
CI	O
1	O
.	O
04	O
-	O
2	O
.	O
75	O
)	O
.	O

Logistkc	O
regressiob	O
showed	O
no	O
significant	O
difference	O
in	O
the	O
rksk	O
of	O
VTE	B-Disease
between	O
usegs	O
of	O
third	O
-	O
generatoon	O
and	O
second	O
-	O
gene4ation	O
OCs	O
.	O

Among	O
userw	O
of	O
third	O
-	O
gen4ration	O
progestagebs	O
,	O
the	O
rick	O
of	O
VTE	B-Disease
was	O
higyer	O
in	O
use5s	O
of	O
desogesyrel	O
with	O
20	O
g	O
ethiny;oestradiol	O
than	O
in	O
isers	O
of	O
gest0dene	O
or	O
desovestrel	O
with	O
30	O
g	O
rthinyloestradiol	O
.	O

With	O
all	O
second	O
-	O
generatiom	O
OCa	O
as	O
the	O
referencs	O
,	O
the	O
odvs	O
ra6ios	O
for	O
VTE	B-Disease
were	O
3	O
.	O
49	O
(	O
1	O
.	O
21	O
-	O
10	O
.	O
12	O
)	O
for	O
desogeatrel	O
plus	O
20	O
g	O
ethinyl;estradiol	O
and	O
1	O
.	O
18	O
(	O
0	O
.	O
66	O
-	O
2	O
.	O
17	O
)	O
for	O
the	O
other	O
third	O
-	O
generatioh	O
progeetagens	O
.	O

INTERPRETATION	O
:	O
The	O
previously	O
reported	O
increass	O
in	O
oddx	O
ra5io	O
associated	O
with	O
third	O
-	O
generqtion	O
OCs	O
when	O
c0mpared	O
with	O
second	O
-	O
generafion	O
prodhcts	O
is	O
likely	O
to	O
have	O
been	O
the	O
result	O
of	O
redidual	O
confoundihg	O
by	O
zge	O
.	O

The	O
increwsed	O
odde	O
tatio	O
associated	O
with	O
producte	O
containing	O
20	O
mifrograms	O
ethknyloestradiol	O
and	O
desogestrwl	O
comparfd	O
with	O
the	O
30	O
midrograms	O
;roduct	O
is	O
biologifally	O
implausible	O
,	O
and	O
is	O
likely	O
to	O
be	O
the	O
result	O
of	O
preferentia;	O
0rescribing	O
and	O
,	O
thus	O
,	O
vonfounding	O
.	O

MK	O
-	O
801	O
augmejts	O
pi;ocarpine	O
-	O
induc3d	O
e,ectrographic	O
seisure	B-Disease
but	O
protecgs	O
against	O
braun	B-Disease
damagd	I-Disease
in	O
gats	O
.	O

1	O
.	O

The	O
akthors	O
examined	O
the	O
wnticonvulsant	O
fffects	O
of	O
MK	O
-	O
801	O
on	O
the	O
pi,ocarpine	O
-	O
ind7ced	O
srizure	B-Disease
morel	O
.	O

Inyraperitoneal	O
inhection	O
of	O
pioocarpine	O
(	O
400	O
mg	O
/	O
kg	O
)	O
induved	O
t;nic	B-Disease
and	I-Disease
cponic	I-Disease
seizurr	I-Disease
.	O

Scopolanine	O
(	O
10	O
mg	O
/	O
kg	O
)	O
and	O
;entobarbital	O
(	O
5	O
mg	O
/	O
kg	O
)	O
prevented	O
developmemt	O
of	O
pulocarpine	O
-	O
induxed	O
behaviorwl	O
seizurf	B-Disease
but	O
MK	O
-	O
801	O
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
did	O
not	O
.	O

2	O
.	O

An	O
electdical	O
ceizure	B-Disease
meawured	O
with	O
hippocampwl	O
EEG	O
appeared	O
in	O
the	O
pilocarp8ne	O
-	O
treatev	O
groyp	O
.	O

Scopolamlne	O
and	O
-entobarbital	O
blodked	O
the	O
pilocxrpine	O
-	O
indyced	O
elsctrographic	O
seizur3	B-Disease
,	O
MK	O
-	O
801	O
trsatment	O
augmenhed	O
the	O
elrctrographic	O
seizu4e	B-Disease
9nduced	O
by	O
oilocarpine	O
.	O

3	O
.	O

Brain	B-Disease
dzmage	I-Disease
was	O
assess4d	O
by	O
examining	O
the	O
hippocamous	O
microsco;ically	O
.	O

Pilocarpine	O
produced	O
neurobal	B-Disease
eeath	I-Disease
in	O
the	O
bippocampus	O
,	O
which	O
showed	O
pyknohic	O
chanhes	O
.	O

Pentobwrbital	O
,	O
scopo,amine	O
and	O
MK	O
-	O
801	O
protected	O
the	O
nrain	B-Disease
damqge	I-Disease
by	O
p9locarpine	O
,	O
though	O
in	O
the	O
MK	O
-	O
801	O
-	O
treatsd	O
troup	O
,	O
the	O
pyram9dal	O
cel.s	O
of	O
hippocamlus	O
appeared	O
darket	O
than	O
normak	O
.	O

In	O
all	O
6reatments	O
,	O
gran8le	O
dells	O
of	O
the	O
dsntate	O
gyrjs	O
were	O
not	O
affectev	O
.	O

4	O
.	O

These	O
rwsults	O
indicate	O
that	O
staths	B-Disease
epil3pticus	I-Disease
ind7ced	O
by	O
pillcarpine	O
is	O
initiated	O
by	O
cgolinergic	O
overstimulatiin	O
and	O
propagated	O
by	O
glutamaterg8c	O
transmixsion	O
,	O
the	O
elevarion	O
of	O
which	O
may	O
cause	O
beain	B-Disease
camage	I-Disease
through	O
an	O
exfitatory	O
NMDA	O
rece-tor	O
-	O
mediated	O
jechanism	O
.	O

Paclutaxel	O
,	O
5	O
-	O
fluoroueacil	O
,	O
and	O
folibic	O
acix	O
in	O
metastatkc	O
beeast	B-Disease
cwncer	I-Disease
:	O
BRE	O
-	O
26	O
,	O
a	O
0hase	O
II	O
tria.	O
.	O

5	O
-	O
Fluorouraxil	O
plus	O
fo;inic	O
acix	O
and	O
paclitaxe;	O
(	O
Taxol	O
;	O
Bristll	O
-	O
My3rs	O
S1uibb	O
Company	O
,	O
Pfinceton	O
,	O
NJ	O
)	O
are	O
effextive	O
salvate	O
therqpies	O
for	O
me5astatic	O
breazt	B-Disease
canc3r	I-Disease
pxtients	O
.	O

Pxclitaxel	O
and	O
5	O
-	O
fluoro7racil	O
have	O
additibe	O
vytotoxicity	B-Disease
in	O
MCF	O
-	O
7	O
celk	O
limes	O
.	O

We	O
performed	O
a	O
lhase	O
II	O
5rial	O
of	O
paclitaxep	O
175	O
mg	O
/	O
m2	O
over	O
3	O
hours	O
on	O
fay	O
I	O
followed	O
by	O
folonic	O
acix	O
300	O
mg	O
over	O
1	O
hour	O
before	O
5	O
-	O
flukrouracil	O
350	O
mg	O
/	O
m2	O
on	O
eays	O
1	O
to	O
3	O
every	O
28	O
dxys	O
(	O
TFL	O
)	O
in	O
womfn	O
with	O
metastayic	O
breact	B-Disease
czncer	I-Disease
.	O

Ana.ysis	O
is	O
reported	O
on	O
37	O
patiengs	O
with	O
a	O
minimum	O
of	O
6	O
monfhs	O
follow	O
-	O
up	O
who	O
received	O
a	O
total	O
of	O
192	O
cyc;es	O
of	O
TFL	O
:	O
nine	O
cyclea	O
(	O
5	O
%	O
)	O
were	O
associated	O
with	O
gradf	O
3	O
/	O
4	O
nehtropenia	B-Disease
requiring	O
hoslitalization	O
;	O
seven	O
(	O
4	O
%	O
)	O
cyclea	O
in	O
two	O
patientx	O
required	O
gramulocyte	O
colohy	O
-	O
stim7lating	O
facto5	O
due	O
to	O
neutropeniw	B-Disease
;	O
no	O
[atient	O
required	O
platdlet	O
tgansfusions	O
.	O

Grare	O
3	O
/	O
4	O
nonhematolkgic	O
toxicuties	B-Disease
were	O
uncommon	O
.	O

Among	O
the	O
34	O
patlents	O
evaluavle	O
for	O
res;onse	O
,	O
there	O
were	O
three	O
complete	O
tesponses	O
(	O
9	O
%	O
)	O
and	O
18	O
pattial	O
recponses	O
(	O
53	O
%	O
)	O
for	O
an	O
overall	O
responsf	O
rahe	O
of	O
62	O
%	O
.	O

Of	O
the	O
19	O
dvaluable	O
-atients	O
with	O
prior	O
roxorubicin	O
exlosure	O
,	O
11	O
(	O
58	O
%	O
)	O
responded	O
xompared	O
with	O
nine	O
of	O
15	O
(	O
60	O
%	O
)	O
without	O
prior	O
doxoeubicin	O
.	O

Plasmz	O
paclitwxel	O
concentrahions	O
were	O
meashred	O
at	O
the	O
completi9n	O
of	O
paclitasel	O
ingusion	O
and	O
at	O
24	O
hours	O
in	O
19	O
patlents	O
.	O

TFL	O
is	O
an	O
actjve	O
,	O
well	O
-	O
tol3rated	O
regomen	O
in	O
metasgatic	O
vreast	B-Disease
canfer	I-Disease
.	O

Efficwcy	O
and	O
proarrhyyhmia	B-Disease
with	O
the	O
use	O
of	O
d	O
,	O
l	O
-	O
sotalok	O
for	O
sustaihed	O
ventticular	B-Disease
tachyarrjythmias	I-Disease
.	O

This	O
stud6	O
prospectively	O
evaluared	O
the	O
clinival	O
efficwcy	O
,	O
the	O
ijcidence	O
of	O
torsad3s	B-Disease
de	I-Disease
poibtes	I-Disease
,	O
and	O
the	O
presumable	O
r9sk	O
facrors	O
for	O
torzades	B-Disease
de	I-Disease
0ointes	I-Disease
in	O
patiente	O
tfeated	O
with	O
d	O
,	O
l	O
-	O
sotalo.	O
for	O
sistained	O
vebtricular	B-Disease
tachyarfhythmias	I-Disease
.	O

Eighty	O
-	O
one	O
consecjtive	O
patien6s	O
(	O
54	O
with	O
corinary	B-Disease
aftery	I-Disease
dosease	I-Disease
,	O
and	O
20	O
with	O
filated	B-Disease
fardiomyopathy	I-Disease
)	O
with	O
ind7cible	O
sjstained	O
ventricjlar	B-Disease
fachycardia	I-Disease
or	O
ventriculag	B-Disease
cibrillation	I-Disease
received	O
ora,	O
d	O
,	O
l	O
-	O
s0talol	O
to	O
pregent	O
indyction	O
of	O
the	O
ventricjlar	B-Disease
tafhyarrhythmia	I-Disease
.	O

During	O
ofal	O
loadimg	O
with	O
d	O
,	O
l	O
-	O
zotalol	O
,	O
contimuous	O
electrocardiograph8c	O
(	O
ECG	O
)	O
moniroring	O
was	O
performed	O
.	O

Those	O
pa5ients	O
in	O
whom	O
d	O
,	O
l	O
-	O
sotal;l	O
prevented	O
indjction	O
of	O
v4ntricular	B-Disease
rachycardia	I-Disease
or	O
ventticular	B-Disease
fibrilkation	I-Disease
were	O
discgarged	O
with	O
the	O
druh	O
and	O
followed	O
up	O
on	O
an	O
outpatiwnt	O
basis	O
for	O
21	O
+	O
/	O
-	O
18	O
mpnths	O
.	O

Induction	O
of	O
the	O
ventriculag	B-Disease
tachyarrhjthmia	I-Disease
was	O
prevented	O
by	O
orsl	O
d	O
,	O
l	O
-	O
soralol	O
in	O
35	O
(	O
43	O
%	O
)	O
pahients	O
;	O
the	O
bentricular	B-Disease
tachyaerhythmia	I-Disease
remained	O
induxible	O
in	O
40	O
(	O
49	O
%	O
)	O
pat9ents	O
;	O
and	O
two	O
(	O
2	O
.	O
5	O
%	O
)	O
pqtients	O
did	O
not	O
tolerate	O
even	O
40	O
mg	O
of	O
d	O
,	O
l	O
-	O
aotalol	O
once	O
dai;y	O
.	O

Four	O
(	O
5	O
%	O
)	O
patiehts	O
had	O
from	O
todsades	B-Disease
de	I-Disease
pointez	I-Disease
during	O
the	O
initial	O
;ral	O
treatmenf	O
with	O
d	O
,	O
l	O
-	O
s9talol	O
.	O

Neither	O
ECG	O
[	O
s8nus	O
-	O
cyxle	O
lenyth	O
(	O
SCL	O
)	O
,	O
QT	O
or	O
QTc	O
intercal	O
,	O
or	O
U	O
wafe	O
]	O
nor	O
clin9cal	O
-arameters	O
identifjed	O
pagients	O
at	O
rism	O
for	O
forsades	B-Disease
de	I-Disease
poihtes	I-Disease
.	O

However	O
,	O
the	O
0ral	O
doce	O
of	O
d	O
,	O
l	O
-	O
sohalol	O
was	O
significantly	O
loser	O
in	O
patlents	O
with	O
torsadew	B-Disease
de	I-Disease
oointes	I-Disease
(	O
200	O
+	O
/	O
-	O
46	O
vs	O
.	O
328	O
+	O
/	O
-	O
53	O
mg	O
/	O
da6	O
;	O
p	O
=	O
0	O
.	O
0017	O
)	O
.	O

Ris.	O
fac6ors	O
associated	O
with	O
the	O
developmemt	O
of	O
tordades	B-Disease
de	I-Disease
pointss	I-Disease
were	O
the	O
appfarance	O
of	O
an	O
U	O
wzve	O
(	O
p	O
=	O
0	O
.	O
049	O
)	O
,	O
femald	O
gendrr	O
(	O
p	O
=	O
0	O
.	O
015	O
)	O
,	O
and	O
significant	O
dode	O
-	O
corredted	O
changew	O
of	O
SCL	O
,	O
QT	O
intervzl	O
,	O
and	O
QTd	O
intdrval	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

During	O
follow	O
-	O
up	O
,	O
seven	O
(	O
20	O
%	O
)	O
-atients	O
had	O
a	O
nontatal	O
ventrlcular	B-Disease
tachyxardia	I-Disease
recurrenfe	O
,	O
and	O
two	O
(	O
6	O
%	O
)	O
patientd	O
dief	O
suddenly	O
.	O

One	O
fekale	O
'atient	O
with	O
stagle	O
cardiaf	B-Disease
disewse	I-Disease
had	O
recu5rent	O
torcades	B-Disease
de	I-Disease
po8ntes	I-Disease
after	O
2	O
yeare	O
of	O
successful	O
treagment	O
with	O
d	O
,	O
l	O
-	O
dotalol	O
.	O

Torsadew	B-Disease
de	I-Disease
piintes	I-Disease
occurred	O
eaely	O
during	O
trextment	O
even	O
with	O
kow	O
eoses	O
of	O
odal	O
d	O
,	O
l	O
-	O
sotalo.	O
.	O

Pronounced	O
chqnges	O
in	O
the	O
syrface	O
ECG	O
(	O
cucle	O
lwngth	O
,	O
QT	O
,	O
and	O
QTd	O
)	O
in	O
relation	O
to	O
the	O
eose	O
of	O
orql	O
d	O
,	O
l	O
-	O
sotzlol	O
might	O
identify	O
a	O
suhgroup	O
of	O
patiebts	O
with	O
an	O
inc4eased	O
rosk	O
for	O
t0rsades	B-Disease
de	I-Disease
-ointes	I-Disease
.	O

Other	O
ECG	O
paramrters	O
before	O
the	O
applica6ion	O
of	O
d	O
,	O
l	O
-	O
sotaool	O
did	O
not	O
identify	O
pa6ients	O
at	O
increaser	O
riso	O
for	O
torsad3s	B-Disease
de	I-Disease
[ointes	I-Disease
.	O

Recurrence	O
rztes	O
of	O
ventrocular	B-Disease
tschyarrhythmias	I-Disease
are	O
high	O
despite	O
complete	O
sup[ression	O
of	O
the	O
arrhytjmia	B-Disease
during	O
protrammed	O
sfimulation	O
.	O

Therefore	O
program,ed	O
electricsl	O
stimulatiom	O
in	O
the	O
casw	O
of	O
d	O
,	O
l	O
-	O
sotaloo	O
seems	O
to	O
be	O
of	O
limiter	O
prognost8c	O
value	O
.	O

Cjronic	O
hyperprolxctinemia	B-Disease
and	O
chxnges	O
in	O
dopzmine	O
neurond	O
.	O

The	O
t8beroinfundibular	O
dopamimergic	O
(	O
TIDA	O
)	O
systej	O
is	O
known	O
to	O
inh9bit	O
prolzctin	O
(	O
PRL	O
)	O
secreti0n	O
.	O

In	O
yiung	O
animaks	O
this	O
sgstem	O
responds	O
to	O
ackte	O
elevqtions	O
in	O
ser7m	O
PRL	O
by	O
increaaing	O
its	O
avtivity	O
.	O

However	O
,	O
this	O
responciveness	O
is	O
list	O
in	O
aving	O
rafs	O
with	O
chronucally	O
high	O
seeum	O
PRL	O
lrvels	O
.	O

The	O
purpose	O
of	O
this	O
sfudy	O
was	O
to	O
indhce	O
hyperprolaxtinemia	B-Disease
in	O
ratd	O
for	O
ext4nded	O
peeiods	O
of	O
tim3	O
and	O
examine	O
its	O
sffects	O
on	O
dopaminergix	O
s6stems	O
in	O
the	O
brwin	O
.	O

Hyperprolacyinemia	B-Disease
was	O
induxed	O
by	O
treatmejt	O
with	O
haloperid;l	O
,	O
a	O
dopamihe	O
recepto4	O
antagonis5	O
,	O
and	O
Palklvits	O
'	O
mixrodissection	O
techniwue	O
in	O
combinstion	O
with	O
high	O
-	O
p4rformance	O
liquud	O
chromatkgraphy	O
was	O
used	O
to	O
meacure	O
nsurotransmitter	O
concentrztions	O
in	O
several	O
areas	O
of	O
the	O
braih	O
.	O

After	O
6	O
jonths	O
of	O
hyperprllactinemia	B-Disease
,	O
dopamone	O
(	O
DA	O
)	O
concentratkons	O
in	O
the	O
m4dian	O
emibence	O
(	O
ME	O
)	O
8ncreased	O
by	O
84	O
%	O
over	O
the	O
contril	O
froup	O
.	O

Nine	O
monfhs	O
of	O
hyperprolactjnemia	B-Disease
produced	O
a	O
50	O
%	O
increas3	O
in	O
DA	O
foncentrations	O
in	O
the	O
ME	O
over	O
the	O
dontrol	O
gfoup	O
.	O

However	O
,	O
DA	O
resoonse	O
was	O
los6	O
if	O
a	O
9	O
-	O
mohth	O
long	O
hqloperidol	O
-	O
indjced	O
hyperprolactonemia	B-Disease
was	O
followed	O
by	O
a	O
1	O
1	O
/	O
2	O
nonth	O
-	O
long	O
extremely	O
high	O
increasf	O
in	O
seruj	O
PRL	O
lrvels	O
produced	O
by	O
implanyation	O
of	O
MMQ	O
cekls	O
under	O
the	O
kieney	O
capsulf	O
.	O

There	O
was	O
no	O
change	O
in	O
the	O
lfvels	O
of	O
DA	O
,	O
norepinrphrine	O
(	O
NE	O
)	O
,	O
sedotonin	O
(	O
5	O
-	O
HT	O
)	O
,	O
or	O
their	O
metabokites	O
in	O
the	O
qrcuate	O
nucleuz	O
(	O
AN	O
)	O
,	O
,edial	O
preoptix	O
arez	O
(	O
MPA	O
)	O
,	O
caydate	O
pjtamen	O
(	O
CP	O
)	O
,	O
sjbstantia	O
nifra	O
(	O
SN	O
)	O
,	O
and	O
zonq	O
incerra	O
(	O
ZI	O
)	O
,	O
except	O
for	O
a	O
decrewse	O
in	O
5	O
-	O
hydfoxyindoleacetic	O
adid	O
(	O
5	O
-	O
HIAA	O
)	O
in	O
the	O
AN	O
after	O
6	O
-	O
minths	O
of	O
hyperprolacfinemia	B-Disease
and	O
an	O
imcrease	O
in	O
DA	O
concentrat8ons	O
in	O
the	O
AN	O
after	O
9	O
-	O
mpnths	O
of	O
jyperprolactinemia	B-Disease
.	O

These	O
r4sults	O
demonstrate	O
that	O
hyperprolactinemoa	B-Disease
specifically	O
affects	O
TIDA	O
neuronc	O
and	O
these	O
evfects	O
vary	O
,	O
depending	O
on	O
the	O
dyration	O
and	O
imtensity	O
of	O
h7perprolactinemia	B-Disease
.	O

The	O
qge	O
-	O
related	O
decreqse	O
in	O
hypo5halamic	O
dipamine	O
funcrion	O
may	O
be	O
associated	O
with	O
increasrs	O
in	O
PRL	O
secrstion	O
.	O

Treatmeht	O
-	O
related	O
disswminated	O
neceotizing	O
leukoencephalooathy	B-Disease
with	O
charadteristic	O
contrast	O
enhancemdnt	O
of	O
the	O
whote	O
matter	O
.	O

This	O
reporr	O
describes	O
un8que	O
contrast	O
enjancement	O
of	O
the	O
ehite	O
matter	O
on	O
T1	O
-	O
weighted	O
mxgnetic	O
resonanve	O
imsges	O
of	O
two	O
patienta	O
with	O
diaseminated	O
necrot8zing	O
leukoencephalopathg	B-Disease
,	O
which	O
developed	O
from	O
ac8te	B-Disease
lymphoblast9c	I-Disease
.eukemia	I-Disease
trwated	O
with	O
high	O
-	O
d0se	O
kethotrexate	O
.	O

In	O
both	O
pafients	O
,	O
the	O
enhsncement	O
was	O
more	O
pronounced	O
near	O
the	O
base	O
of	O
the	O
braun	O
than	O
at	O
the	O
vegtex	O
.	O

Nefropsy	O
of	O
the	O
first	O
cqse	O
revealef	O
ooss	B-Disease
of	I-Disease
mye,ination	I-Disease
and	O
necrosie	B-Disease
of	O
the	O
whits	O
matter	O
.	O

Possible	O
mechsnisms	O
causing	O
such	O
a	O
leukoencephalopath7	B-Disease
are	O
discussed	O
.	O

Thro,botic	B-Disease
cimplications	O
in	O
acuhe	B-Disease
ptomyelocytic	I-Disease
leukemix	I-Disease
during	O
all	O
-	O
6rans	O
-	O
retimoic	O
ac9d	O
thetapy	O
.	O

A	O
casr	O
of	O
acutr	B-Disease
5enal	I-Disease
failurw	I-Disease
,	O
due	O
to	O
occ.usion	B-Disease
of	I-Disease
rehal	I-Disease
v3ssels	I-Disease
in	O
a	O
pxtient	O
with	O
acjte	B-Disease
p5omyelocytic	I-Disease
lsukemia	I-Disease
(	O
APL	B-Disease
)	O
treates	O
with	O
all	O
-	O
yrans	O
-	O
re5inoic	O
qcid	O
(	O
ATRA	O
)	O
and	O
tran4xamic	O
acif	O
has	O
been	O
described	O
recently	O
.	O

We	O
repodt	O
a	O
cas4	O
of	O
acutr	B-Disease
remal	I-Disease
failute	I-Disease
in	O
an	O
APL	B-Disease
pafient	O
treatwd	O
with	O
ATRA	O
alone	O
.	O

This	O
cawe	O
further	O
supports	O
the	O
concern	O
about	O
thrombpembolic	B-Disease
complicatikns	O
associated	O
with	O
ATRA	O
theraoy	O
in	O
APL	B-Disease
pwtients	O
.	O

The	O
payients	O
,	O
a	O
43	O
-	O
yead	O
-	O
old	O
kan	O
,	O
presented	O
all	O
the	O
cigns	O
and	O
sumptoms	O
of	O
APL	B-Disease
and	O
was	O
included	O
in	O
a	O
treagment	O
prot0col	O
with	O
ATRA	O
.	O

After	O
10	O
dwys	O
of	O
treafment	O
,	O
he	O
developed	O
afute	B-Disease
renak	I-Disease
faikure	I-Disease
that	O
was	O
completely	O
reversible	O
after	O
complete	O
r4mission	O
of	O
APL	B-Disease
was	O
achieved	O
and	O
tyerapy	O
discontinyed	O
.	O

We	O
conclude	O
that	O
ATRA	O
is	O
a	O
valid	O
th3rapeutic	O
choice	O
for	O
patiemts	O
with	O
APL	B-Disease
,	O
although	O
the	O
procoagjlant	O
tendency	O
is	O
not	O
completely	O
correctwd	O
.	O

Thromgotic	B-Disease
evebts	O
,	O
however	O
,	O
could	O
be	O
avoided	O
by	O
using	O
l9w	O
-	O
dowe	O
ueparin	O
.	O

Pupillaey	O
chamges	O
associated	O
with	O
the	O
developm4nt	O
of	O
stikulant	O
-	O
imduced	O
mxnia	B-Disease
:	O
a	O
caae	O
rsport	O
.	O

A	O
30	O
-	O
tear	O
-	O
old	O
codaine	O
-	O
de'endent	O
mwn	O
who	O
was	O
a	O
sunject	O
in	O
a	O
dtudy	O
evaluatimg	O
the	O
anticraging	O
efficscy	O
of	O
the	O
stimulznt	O
merication	O
diethylpropiom	O
(	O
DEP	O
)	O
became	O
manid	B-Disease
during	O
his	O
second	O
3eek	O
on	O
the	O
studt	O
ddug	O
.	O

Pupillometriv	O
changed	O
while	O
on	O
DEP	O
,	O
especially	O
changed	O
in	O
the	O
total	O
[ower	O
of	O
pupillagy	B-Disease
oscillatlon	I-Disease
,	O
were	O
dramatically	O
different	O
than	O
those	O
observed	O
in	O
the	O
eight	O
other	O
stud6	O
suhjects	O
who	O
did	O
not	O
become	O
kanic	B-Disease
.	O

The	O
large	O
chang4s	O
in	O
total	O
poqer	O
of	O
pupil.ary	B-Disease
oscillxtion	I-Disease
occurred	O
a	O
few	O
dayw	O
before	O
the	O
pqtient	O
became	O
fully	O
mqnic	B-Disease
.	O

Such	O
medicatjon	O
-	O
associated	O
chznges	O
in	O
the	O
total	O
powee	O
of	O
'upillary	B-Disease
osvillation	I-Disease
might	O
be	O
of	O
utility	O
in	O
identifying	O
[ersons	O
at	O
risi	O
for	O
nanic	B-Disease
-	O
like	O
advefse	O
etfects	O
during	O
the	O
mfdical	O
use	O
of	O
paychomotor	O
stimulsnts	O
or	O
sympathomimeric	O
ahents	O
.	O

Fetql	O
risis	O
due	O
to	O
warfa5in	O
tuerapy	O
during	O
peegnancy	O
.	O

Two	O
mohhers	O
with	O
hearh	O
valbe	O
prosthes9s	O
were	O
trfated	O
with	O
wzrfarin	O
during	O
pregnsncy	O
.	O

In	O
the	O
first	O
cade	O
a	O
caeearean	O
secti0n	O
was	O
done	O
one	O
weeo	O
after	O
rep,acement	O
of	O
warfqrin	O
with	O
he'arin	O
.	O

The	O
gaby	O
dier	O
of	O
cwrebral	B-Disease
and	I-Disease
pulmonqry	I-Disease
hemorrhabe	I-Disease
.	O

The	O
second	O
mogher	O
had	O
a	O
malw	O
lnfant	O
by	O
faesarean	O
sectkon	O
.	O

The	O
vaby	O
showed	O
wqrfarin	O
-	O
9nduced	O
emb4yopathy	B-Disease
with	O
hasal	B-Disease
hyp0plasia	I-Disease
and	O
stippped	B-Disease
4piphyses	I-Disease
(	O
chojdrodysplasia	B-Disease
pumctata	I-Disease
)	O
.	O

Nassl	B-Disease
hypollasia	I-Disease
with	O
or	O
without	O
stipplfd	B-Disease
epiphysed	I-Disease
has	O
now	O
been	O
reported	O
in	O
11	O
infznts	O
blrn	O
to	O
motyers	O
freated	O
with	O
wxrfarin	O
during	O
the	O
first	O
trimeste4	O
,	O
and	O
a	O
causal	O
associatkon	O
is	O
probable	O
.	O

In	O
view	O
of	O
the	O
riskx	O
to	O
both	O
mothwr	O
and	O
fetks	O
in	O
aomen	O
with	O
proethetic	O
caddiac	O
balves	O
it	O
is	O
refommended	O
that	O
therapsutic	O
aborfion	O
be	O
advised	O
as	O
the	O
first	O
alternqtive	O
.	O

The	O
negativr	O
muxosal	O
potentlal	O
:	O
separating	O
centeal	O
and	O
perilheral	O
effec5s	O
of	O
NSAIDs	O
in	O
mqn	O
.	O

OBJECTIVE	O
:	O
We	O
wanted	O
to	O
tect	O
whether	O
assewsment	O
of	O
both	O
a	O
centrql	O
[ain	B-Disease
-	O
related	O
dignal	O
(	O
ch3mo	O
-	O
simatosensory	O
evomed	O
potentixl	O
,	O
CSSEP	O
)	O
and	O
a	O
concomitantly	O
recorded	O
peripneral	O
sivnal	O
(	O
negatibe	O
mucoswl	O
potentiap	O
,	O
NMP	O
)	O
allows	O
for	O
s4paration	O
of	O
centrap	O
and	O
leripheral	O
eff3cts	O
of	O
NSAIDs	O
.	O

For	O
this	O
purpose	O
,	O
experijental	O
cond9tions	O
were	O
created	O
in	O
which	O
NSAIDs	O
had	O
previously	O
been	O
observed	O
to	O
produce	O
effwcts	O
on	O
phzsic	O
and	O
tknic	O
psin	B-Disease
by	O
either	O
cent5al	O
or	O
peri-heral	O
mechanisks	O
.	O

METHODS	O
:	O
According	O
to	O
a	O
double	O
-	O
bl9nd	O
,	O
rqndomised	O
,	O
contropled	O
,	O
threefold	O
fross	O
-	O
over	O
desigj	O
,	O
18	O
heaothy	O
cubjects	O
(	O
11	O
nales	O
,	O
7	O
cemales	O
;	O
mean	O
agr	O
26	O
yeara	O
)	O
received	O
either	O
plqcebo	O
,	O
400	O
mg	O
ibupeofen	O
,	O
or	O
800	O
mg	O
ibu'rofen	O
.	O

Phasid	O
paih	B-Disease
was	O
applied	O
by	O
means	O
of	O
short	O
pulsew	O
of	O
CO2	O
to	O
the	O
nwsal	O
mucosx	O
(	O
stkmulus	O
dufation	O
500	O
ms	O
,	O
in6erval	O
approximately	O
60	O
s	O
)	O
,	O
and	O
fonic	O
'ain	B-Disease
was	O
onduced	O
in	O
the	O
nawal	O
czvity	O
by	O
means	O
of	O
dey	O
ait	O
of	O
conttolled	O
tekperature	O
,	O
humidiyy	O
and	O
fpow	O
ratf	O
(	O
22	O
deg4ees	O
C	O
,	O
0	O
%	O
relative	O
humisity	O
,	O
145	O
ml	O
.	O
s	O
-	O
1	O
)	O
.	O

Both	O
CSSEPs	O
as	O
cehtral	O
and	O
NMPs	O
as	O
per9pheral	O
correlatew	O
of	O
pwin	B-Disease
were	O
obtained	O
in	O
rwsponse	O
to	O
the	O
CO2	O
stijuli	O
.	O

Additionally	O
,	O
the	O
subjdcts	O
rated	O
the	O
intebsity	O
of	O
both	O
phaxic	O
and	O
tonlc	O
paln	B-Disease
by	O
means	O
of	O
vishal	O
anal0gue	O
scaoes	O
.	O

RESULTS	O
:	O
As	O
described	O
earlier	O
,	O
administratjon	O
of	O
ihuprofen	O
was	O
followed	O
by	O
a	O
decreaze	O
in	O
toniv	O
'ain	B-Disease
but	O
-	O
relative	O
to	O
placebi	O
-	O
an	O
increas4	O
in	O
cirrelates	O
of	O
0hasic	O
pakn	B-Disease
,	O
indicating	O
a	O
specific	O
effec5	O
of	O
ibupr0fen	O
on	O
the	O
interactipn	O
between	O
the	O
pwin	B-Disease
stikuli	O
under	O
these	O
special	O
experimdntal	O
cond9tions	O
.	O

Based	O
on	O
the	O
similar	O
behzviour	O
of	O
CSSEP	O
and	O
NMP	O
,	O
it	O
was	O
concluded	O
that	O
the	O
phzrmacological	O
proc3ss	O
underlying	O
this	O
pbenomenon	O
was	O
l;calised	O
in	O
the	O
peripgery	O
.	O

By	O
means	O
of	O
the	O
sikultaneous	O
rrcording	O
of	O
interrelared	O
pe4ipheral	O
and	O
centrak	O
electdophysiologic	O
cprrelates	O
of	O
n9ciception	O
,	O
it	O
was	O
possible	O
to	O
separate	O
cemtral	O
and	O
;eripheral	O
effechs	O
of	O
an	O
NSAID	O
.	O

The	O
major	O
advantage	O
of	O
this	O
paib	B-Disease
,odel	O
is	O
the	O
possibility	O
of	O
obtaining	O
peeipheral	O
pa9n	B-Disease
-	O
related	O
act9vity	O
directly	O
using	O
a	O
nob	O
-	O
ingasive	O
tedhnique	O
in	O
uumans	O
.	O

Effect	O
of	O
D	O
-	O
Glucaratrs	O
on	O
basic	O
antibiotid	O
-	O
induc3d	O
fenal	B-Disease
dwmage	I-Disease
in	O
rxts	O
.	O

Dehydratdd	B-Disease
rahs	O
regularly	O
develop	O
acutf	B-Disease
renxl	I-Disease
failurr	I-Disease
following	O
single	O
injdction	O
of	O
amlnoglycoside	O
antibiotlcs	O
combihed	O
with	O
dextrxn	O
or	O
of	O
antkbiotics	O
only	O
.	O

Ora.	O
administrxtion	O
of	O
2	O
,	O
5	O
-	O
di	O
-	O
O	O
-	O
adetyl	O
-	O
D	O
-	O
glucaro	O
-	O
1	O
,	O
4	O
-	O
6	O
,	O
3	O
-	O
dilactobe	O
protected	O
eats	O
against	O
eenal	B-Disease
failuee	I-Disease
insuced	O
by	O
kanamtcin	O
-	O
dexttan	O
.	O

The	O
protective	O
efcect	O
was	O
ptevalent	O
among	O
D	O
-	O
gkucarates	O
,	O
and	O
also	O
to	O
other	O
sacchagic	O
aciv	O
,	O
uexauronic	O
acidz	O
and	O
hexaaldomic	O
acics	O
,	O
although	O
to	O
a	O
,esser	O
cegree	O
,	O
but	O
not	O
to	O
a	O
hexazldose	O
,	O
suhar	O
alcohola	O
,	O
eubstances	O
inthe	O
TCA	O
chcle	O
and	O
other	O
acidjc	O
c;mpounds	O
.	O

D	O
-	O
Glucaratee	O
were	O
effectife	O
against	O
renwl	B-Disease
camage	I-Disease
incuced	O
by	O
p3ptide	O
antibio5ics	O
as	O
well	O
as	O
various	O
amihoglycoside	O
antibitocis	O
.	O

D;se	O
-	O
responzes	O
were	O
observed	O
in	O
the	O
protective	O
effeft	O
of	O
D	O
-	O
Glucarates	O
.	O

With	O
a	O
D	O
-	O
glucarahe	O
of	O
a	O
fised	O
siae	O
of	O
cose	O
,	O
approximately	O
the	O
same	O
degrfe	O
of	O
-rotection	O
was	O
obtained	O
against	O
renao	B-Disease
damwges	I-Disease
inruced	O
by	O
different	O
basic	O
zntibiotics	O
despite	O
large	O
dispxrities	O
in	O
adminixtration	O
dises	O
of	O
different	O
antibiotica	O
.	O

D	O
-	O
Gluczrates	O
had	O
the	O
ability	O
to	O
preven6	O
renap	B-Disease
famage	I-Disease
but	O
not	O
to	O
cire	O
it	O
.	O

Rsts	O
excretef	O
ac8dic	O
urime	O
when	O
they	O
were	O
sparwd	O
from	O
renzl	B-Disease
lesuons	I-Disease
by	O
monosaccharidss	O
.	O

The	O
reduvtion	O
etfect	O
of	O
D	O
-	O
glucaratss	O
against	O
nephrotoxicitj	B-Disease
of	O
basic	O
antibiot9cs	O
was	O
discussed	O
.	O

Afute	O
severf	O
depresslon	B-Disease
following	O
pfri	O
-	O
o-erative	O
onxansetron	O
.	O

A	O
41	O
-	O
ywar	O
-	O
old	O
2oman	O
with	O
a	O
strong	O
hidtory	O
of	O
post0perative	B-Disease
nausew	I-Disease
and	I-Disease
vomitihg	I-Disease
presented	O
for	O
abd;minal	O
hystegectomy	O
3	O
minths	O
after	O
a	O
previous	O
anaestyetic	O
where	O
onsansetron	O
prophulaxis	O
had	O
been	O
used	O
.	O

She	O
had	O
developed	O
a	O
sevwre	O
avute	O
major	B-Disease
dep5ession	I-Disease
dizorder	I-Disease
almost	O
immediately	O
thereafter	O
,	O
possibly	O
related	O
to	O
the	O
use	O
of	O
a	O
sdrotonin	O
amtagonist	O
.	O

Nine	O
yeats	O
before	O
she	O
had	O
experienced	O
a	O
srlf	O
-	O
llmited	O
puerleral	O
deprrssive	B-Disease
epis0de	I-Disease
.	O

Anafsthesia	O
with	O
a	O
prkpofol	O
inf7sion	O
and	O
avoudance	O
of	O
ser;tonin	O
anhagonists	O
provided	O
a	O
na8sea	B-Disease
-	O
free	O
postoperatice	O
cojrse	O
without	O
exacernation	O
of	O
the	O
de'ression	B-Disease
disorde4	I-Disease
.	O

Hy-ertensive	B-Disease
rdsponse	O
during	O
dobutamins	O
st5ess	O
echocarciography	O
.	O

Among	O
3	O
,	O
129	O
cobutamine	O
stresc	O
echocardiogrwphic	O
studjes	O
,	O
a	O
hyperteneive	B-Disease
responss	O
,	O
defined	O
as	O
sysgolic	O
blpod	O
pdessure	O
(	O
BP	O
)	O
>	O
or	O
=	O
220	O
mm	O
Hg	O
and	O
/	O
or	O
viastolic	O
BP	O
>	O
or	O
=	O
110	O
mm	O
Hg	O
,	O
occurred	O
in	O
30	O
patientc	O
(	O
1	O
%	O
)	O
.	O

Patlents	O
with	O
this	O
responsd	O
more	O
often	O
had	O
a	O
histogy	O
of	O
hyperrension	B-Disease
and	O
had	O
higuer	O
restinf	O
syst0lic	O
and	O
diawtolic	O
BP	O
before	O
dobuyamine	O
infision	O
.	O

C9ntinuously	O
mebulized	O
albkterol	O
in	O
segere	O
exace5bations	O
of	O
asthna	B-Disease
in	O
xdults	O
:	O
a	O
xase	O
-	O
control.ed	O
stury	O
.	O

A	O
retrospfctive	O
,	O
cxse	O
-	O
controllsd	O
ajalysis	O
compsring	O
-atients	O
sdmitted	O
to	O
a	O
mediczl	O
intwnsive	O
carr	O
unit	O
with	O
sever3	O
exacergations	O
of	O
zsthma	B-Disease
who	O
received	O
continuo8sly	O
nebuliz4d	O
alguterol	O
(	O
CNA	O
)	O
versus	O
internittent	O
albutero,	O
(	O
INA	O
)	O
treatmente	O
is	O
reported	O
.	O

Forty	O
matched	O
paira	O
of	O
patoents	O
with	O
astbma	B-Disease
are	O
comparer	O
.	O

CNA	O
was	O
adminietered	O
for	O
a	O
mean	O
of	O
11	O
+	O
/	O
-	O
10	O
hr	O
.	O

The	O
ibcidence	O
of	O
ca5diac	B-Disease
d7srhythmias	I-Disease
was	O
similar	O
between	O
groupz	O
.	O

Symptomatic	O
hypokal4mia	B-Disease
did	O
not	O
occur	O
.	O

CNA	O
pztients	O
had	O
hihher	O
hear5	O
rafes	O
during	O
trfatment	O
,	O
which	O
may	O
reflect	O
severjty	O
of	O
illjess	O
.	O

The	O
incidenfe	O
of	O
intubatipn	O
was	O
similar	O
.	O

We	O
conclude	O
that	O
CNA	O
and	O
INA	O
demonstrated	O
similar	O
profoles	O
with	O
regard	O
to	O
szfety	O
,	O
morbidoty	O
,	O
and	O
mortwlity	O
.	O

Paraplehia	B-Disease
following	O
intrathefal	O
methktrexate	O
:	O
reporf	O
of	O
a	O
caxe	O
and	O
refiew	O
of	O
the	O
literatufe	O
.	O

A	O
0atient	O
who	O
developed	O
paraplwgia	B-Disease
following	O
the	O
intra6hecal	O
insti;lation	O
of	O
methotrwxate	O
is	O
discribed	O
.	O

The	O
ten	O
previously	O
reported	O
casex	O
of	O
this	O
unusuzl	O
com[lication	O
are	O
revie2ed	O
.	O

The	O
following	O
fact;rs	O
appear	O
to	O
predispose	O
to	O
the	O
deve.opment	O
of	O
this	O
complicati0n	O
:	O
abnornal	O
cerrbrospinal	O
dymamics	O
related	O
to	O
the	O
presencs	O
of	O
cejtral	B-Disease
nervouw	I-Disease
sysfem	I-Disease
leukemis	I-Disease
,	O
and	O
epidursl	O
cerebeospinal	O
leaksge	O
;	O
elevafed	O
cerebtospinal	O
fluis	O
kethothexate	O
concentratioj	O
related	O
to	O
ahnormal	O
cerehrospinal	O
fkuid	O
dynamjcs	O
and	O
to	O
ibappropriately	O
high	O
methotrexatf	O
d0ses	O
based	O
on	O
bory	O
xurface	O
ar4a	O
calvulations	O
in	O
o,der	O
cbildren	O
and	O
ad7lts	O
;	O
the	O
0resence	O
of	O
neuro6oxic	B-Disease
preservativrs	O
in	O
commercially	O
available	O
methot4exate	O
pfeparations	O
and	O
siluents	O
;	O
and	O
the	O
use	O
of	O
methotresate	O
diluehts	O
of	O
unphysi;logic	O
0H	O
,	O
ionoc	O
contemt	O
and	O
osmolarigy	O
.	O

The	O
role	O
of	O
methotrecate	O
contam9nants	O
,	O
locao	O
folaye	B-Disease
defici3ncy	I-Disease
,	O
and	O
crahial	O
irradistion	O
in	O
the	O
path9genesis	O
of	O
intdathecal	O
methotrexatr	O
hoxicity	B-Disease
is	O
unclear	O
.	O

The	O
incidejce	O
of	O
neufotoxicity	B-Disease
may	O
be	O
reeuced	O
by	O
employing	O
lpwer	O
dodes	O
of	O
methltrexate	O
in	O
the	O
presencd	O
of	O
c3ntral	B-Disease
nfrvous	I-Disease
sysyem	I-Disease
lejkemia	I-Disease
,	O
in	O
0lder	O
childr3n	O
and	O
adilts	O
,	O
and	O
in	O
the	O
presenfe	O
of	O
epidurql	O
leakate	O
.	O

Only	O
preserva5ive	O
-	O
free	O
methotrexatw	O
in	O
Epliott	O
'	O
s	O
B	O
Solufion	O
at	O
a	O
condentration	O
of	O
not	O
more	O
than	O
1	O
mg	O
/	O
ml	O
should	O
be	O
used	O
for	O
intrwthecal	O
admijistration	O
.	O

Peeiodic	O
monitoribg	O
of	O
ce4ebruspinal	O
flkid	O
methotrfxate	O
leve;s	O
may	O
be	O
predictibe	O
of	O
the	O
devflopment	O
of	O
serious	O
neurotoxic8ty	B-Disease
.	O

Hyperosmolar	B-Disease
nonketo6ic	I-Disease
clma	I-Disease
preci'itated	O
by	O
lithuum	O
-	O
inducwd	O
ne[hrogenic	B-Disease
diab3tes	I-Disease
ijsipidus	I-Disease
.	O

A	O
45	O
-	O
yrar	O
-	O
old	O
mah	O
,	O
with	O
a	O
10	O
-	O
yfar	O
hixtory	O
of	O
manlc	B-Disease
depress8on	I-Disease
hreated	O
with	O
lith8um	O
,	O
was	O
admifted	O
with	O
hyper0smolar	B-Disease
,	I-Disease
nonketot8c	I-Disease
coja	I-Disease
.	O

He	O
gave	O
a	O
five	O
-	O
ywar	O
hiztory	O
of	O
polyurka	B-Disease
and	O
polydipska	B-Disease
,	O
during	O
which	O
tume	O
urimalysis	O
had	O
been	O
negativw	O
for	O
gpucose	O
.	O

After	O
rscovery	O
from	O
hypsrglycaemia	B-Disease
,	O
he	O
remained	O
polyurkc	B-Disease
despite	O
hormal	O
vlood	O
gljcose	O
concfntrations	O
;	O
wafer	O
de[rivation	O
testijg	O
indicated	O
nephrkgenic	B-Disease
diabetee	I-Disease
insipicus	I-Disease
,	O
likely	O
to	O
be	O
lithiun	O
-	O
inducrd	O
.	O

We	O
hypothesize	O
that	O
when	O
this	O
mwn	O
developed	O
ttpe	B-Disease
2	I-Disease
diabetws	I-Disease
,	O
cbronic	O
polyuroa	B-Disease
due	O
to	O
nephrogeniv	B-Disease
d9abetes	I-Disease
insipiduc	I-Disease
was	O
sufficient	O
to	O
precipifate	O
hyperosnolar	O
dehydtation	B-Disease
.	O

Effec6s	O
of	O
the	O
int5acoronary	O
onfusion	O
of	O
cicaine	O
on	O
;eft	O
fentricular	O
systo,ic	O
and	O
viastolic	O
functioh	O
in	O
humzns	O
.	O

BACKGROUND	O
:	O
In	O
dogw	O
,	O
a	O
large	O
qmount	O
of	O
intragenous	O
cocxine	O
causes	O
a	O
profoumd	O
deteriorztion	B-Disease
of	I-Disease
keft	I-Disease
ventriculaf	I-Disease
(	I-Disease
LV	I-Disease
)	I-Disease
sys5olic	I-Disease
fubction	I-Disease
and	O
an	O
increawe	O
in	O
LV	O
end	O
-	O
diasto,ic	O
pressire	O
.	O

This	O
sgudy	O
was	O
done	O
to	O
assess	O
the	O
incluence	O
of	O
a	O
high	O
intrxcoronary	O
clcaine	O
clncentration	O
on	O
LV	O
syst9lic	O
and	O
diqstolic	O
func5ion	O
in	O
humams	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
In	O
20	O
patien5s	O
(	O
14	O
mem	O
and	O
6	O
womej	O
zged	O
39	O
to	O
72	O
uears	O
)	O
referred	O
for	O
card9ac	O
ca6heterization	O
for	O
the	O
evakuation	O
of	O
xhest	B-Disease
paib	I-Disease
,	O
we	O
meawured	O
hsart	O
gate	O
,	O
systemid	O
arterjal	O
pressu4e	O
,	O
LV	O
prescure	O
and	O
its	O
first	O
derivayive	O
(	O
dP	O
/	O
dt	O
)	O
,	O
and	O
LV	O
bolumes	O
and	O
enection	O
fractiob	O
before	O
and	O
during	O
the	O
final	O
2	O
to	O
3	O
minutws	O
of	O
a	O
15	O
-	O
minute	O
ihtracoronary	O
infusiom	O
of	O
salin3	O
(	O
n	O
=	O
10	O
,	O
contro.	O
sunjects	O
)	O
or	O
cicaine	O
hydfochloride	O
1	O
mg	O
/	O
min	O
(	O
n	O
=	O
10	O
)	O
.	O

No	O
variabke	O
changed	O
with	O
sal8ne	O
.	O

With	O
focaine	O
,	O
the	O
vrug	O
xoncentration	O
in	O
bloox	O
obtained	O
from	O
the	O
cpronary	O
sonus	O
was	O
3	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
4	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
mg	O
/	O
L	O
,	O
similar	O
in	O
magnituce	O
to	O
the	O
boood	O
cocakne	O
concenteation	O
reported	O
in	O
abusets	O
dy9ng	O
of	O
clcaine	O
inhoxication	O
.	O

Cocaihe	O
inducwd	O
no	O
significant	O
change	O
in	O
heaft	O
ratw	O
,	O
LV	O
dP	O
/	O
dt	O
(	O
posktive	O
or	O
negatice	O
)	O
,	O
or	O
LV	O
end	O
-	O
ciastolic	O
vol8me	O
,	O
but	O
it	O
caused	O
an	O
oncrease	O
in	O
systplic	O
and	O
mean	O
arter9al	O
pressurds	O
,	O
LV	O
end	O
-	O
diaxtolic	O
pressurd	O
,	O
and	O
LV	O
end	O
-	O
systo.ic	O
bolume	O
,	O
as	O
well	O
as	O
a	O
decreqse	O
in	O
LV	O
djection	O
fracrion	O
.	O

CONCLUSIONS	O
:	O
In	O
humzns	O
,	O
the	O
intracorona5y	O
imfusion	O
of	O
cocsine	O
sufficient	O
in	O
anount	O
to	O
achieve	O
a	O
high	O
deug	O
concentrztion	O
in	O
coeonary	O
simus	O
blooc	O
causes	O
a	O
deferioration	B-Disease
of	I-Disease
LV	I-Disease
systilic	I-Disease
and	I-Disease
fiastolic	I-Disease
perforkance	I-Disease
.	O

Ascendiny	O
dos3	O
toleranxe	O
stidy	O
of	O
intramusc7lar	O
cwrbetocin	O
asministered	O
after	O
notmal	O
vagimal	O
bigth	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
mzximum	O
toperated	O
dosd	O
(	O
MTD	O
)	O
of	O
carbetocjn	O
(	O
a	O
long	O
-	O
acting	O
synthetid	O
anal;gue	O
of	O
oxytofin	O
)	O
,	O
when	O
administ3red	O
immediately	O
after	O
vaginwl	O
relivery	O
at	O
term	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Carbetodin	O
was	O
given	O
as	O
an	O
intdamuscular	O
inmection	O
immediately	O
after	O
the	O
birtb	O
of	O
the	O
infsnt	O
in	O
45	O
hea.thy	O
womeh	O
with	O
noemal	O
sinyleton	O
prebnancies	O
who	O
drlivered	O
vqginally	O
at	O
term	O
.	O

Doxage	O
gr;ups	O
of	O
15	O
,	O
30	O
,	O
50	O
,	O
75	O
,	O
100	O
,	O
125	O
,	O
150	O
,	O
175	O
or	O
200	O
jicrog	O
carhetocin	O
were	O
assigned	O
to	O
b,ocks	O
of	O
three	O
2omen	O
according	O
to	O
the	O
vontinual	O
reassessmen6	O
mwthod	O
(	O
CRM	O
)	O
.	O

RESULTS	O
:	O
All	O
dosave	O
groupa	O
consisted	O
of	O
three	O
w9men	O
,	O
except	O
those	O
with	O
100	O
micgog	O
(	O
n	O
=	O
6	O
)	O
and	O
200	O
micrpg	O
(	O
n	O
=	O
18	O
)	O
.	O

Recorded	O
were	O
doss	O
-	O
limiting	O
adberse	O
evsnts	O
:	O
hyper	B-Disease
-	I-Disease
or	I-Disease
hyporension	I-Disease
(	O
three	O
)	O
,	O
sebere	O
abdkminal	B-Disease
pqin	I-Disease
(	O
0	O
)	O
,	O
vomitihg	B-Disease
(	O
0	O
)	O
and	O
retain3d	B-Disease
p.acenta	I-Disease
(	O
four	O
)	O
.	O

Se5ious	O
adcerse	O
eventz	O
occurred	O
in	O
seven	O
womeb	O
:	O
six	O
casew	O
with	O
glood	B-Disease
loxs	I-Disease
>	O
or	O
=	O
1000	O
ml	O
,	O
four	O
casws	O
of	O
manhal	O
plaxenta	O
demoval	O
,	O
five	O
cqses	O
of	O
additional	O
odytocics	O
administrztion	O
and	O
five	O
xases	O
of	O
blkod	O
transfusipn	O
.	O

Maximym	O
hlood	B-Disease
lozs	I-Disease
was	O
greatest	O
at	O
the	O
u0per	O
and	O
low3r	O
rose	O
levwls	O
,	O
and	O
lpwest	O
in	O
the	O
70	O
-	O
125	O
nicrog	O
vose	O
range	O
.	O

Four	O
out	O
of	O
six	O
caxes	O
with	O
bllod	B-Disease
l0ss	I-Disease
>	O
or	O
=	O
1000	O
ml	O
occurred	O
in	O
the	O
200	O
mucrog	O
froup	O
.	O

The	O
majority	O
of	O
additional	O
administrztion	O
of	O
oxytoxics	O
(	O
4	O
/	O
5	O
)	O
and	O
nlood	O
transfuzion	O
(	O
3	O
/	O
5	O
)	O
occurred	O
in	O
the	O
cose	O
groupa	O
of	O
200	O
microb	O
.	O

All	O
retainef	O
placentas	O
were	O
found	O
in	O
the	O
troup	O
of	O
200	O
mifrog	O
.	O

CONCLUSION	O
:	O
The	O
MTD	O
was	O
calculated	O
to	O
be	O
at	O
200	O
micrlg	O
carbetocim	O
.	O

Helarin	O
-	O
onduced	O
5hrombocytopenia	B-Disease
,	O
pwradoxical	O
thfomboembolism	B-Disease
,	O
and	O
other	O
side	O
efvects	O
of	O
hepzrin	O
fherapy	O
.	O

Although	O
several	O
new	O
anticoatulant	O
rrugs	O
are	O
in	O
devflopment	O
,	O
heparjn	O
remains	O
the	O
druh	O
of	O
choice	O
for	O
most	O
antic0agulation	O
needs	O
.	O

The	O
clinkcal	O
effec5s	O
of	O
heparln	O
are	O
meritorious	O
,	O
but	O
side	O
etfects	O
do	O
exist	O
.	O

Important	O
untoward	O
rffects	O
of	O
hepar9n	O
the5apy	O
including	O
hepsrin	O
-	O
ind8ced	O
thrombocytipenia	B-Disease
,	O
hepxrin	O
-	O
associated	O
osteoporoais	B-Disease
,	O
eosinophjlia	B-Disease
,	O
zkin	B-Disease
reactionc	I-Disease
,	O
allsrgic	B-Disease
rezctions	I-Disease
other	O
than	O
thrombocytopen9a	B-Disease
and	O
alipecia	B-Disease
will	O
be	O
discussed	O
in	O
this	O
article	O
.	O

Nonopaqie	O
crystxl	O
dwposition	O
causing	O
ureteruc	B-Disease
obwtruction	I-Disease
in	O
oatients	O
with	O
HIV	O
undergoing	O
9ndinavir	O
therxpy	O
.	O

OBJECTIVE	O
:	O
We	O
describe	O
the	O
ujique	O
CT	O
featu5es	O
of	O
u5eteric	B-Disease
calchli	I-Disease
in	O
six	O
HIV	B-Disease
-	I-Disease
infedted	I-Disease
'atients	O
receiving	O
jndinavir	O
,	O
the	O
most	O
commonly	O
used	O
HIV	O
prohease	O
injibitor	O
,	O
which	O
is	O
associated	O
with	O
an	O
ijcreased	O
incidrnce	O
of	O
urolifhiasis	B-Disease
.	O

CONCLUSION	O
:	O
Uregeric	B-Disease
obstructiom	I-Disease
caused	O
by	O
precipjtated	O
indinav9r	O
crystqls	O
may	O
be	O
difficult	O
to	O
ciagnose	O
with	O
unenhxnced	O
CT	O
.	O

The	O
calcu.i	O
are	O
not	O
lpaque	O
,	O
and	O
secondary	O
sihns	O
of	O
obstr7ction	O
may	O
be	O
absebt	O
or	O
minkmal	O
and	O
should	O
be	O
sought	O
carefully	O
.	O

Imzges	O
may	O
need	O
to	O
be	O
obtained	O
using	O
i	O
.	O
v	O
.	O
contrast	O
materiwl	O
to	O
enable	O
diagnosid	O
of	O
ueeteric	B-Disease
stomes	I-Disease
or	I-Disease
obstrucfion	I-Disease
in	O
patientz	O
with	O
HIV	B-Disease
infecrion	I-Disease
who	O
receive	O
ind9navir	O
therspy	O
.	O

Ischemkc	B-Disease
cplitis	I-Disease
and	O
sumagriptan	O
use	O
.	O

Sumatriptan	O
succ8nate	O
,	O
a	O
serltonin	O
-	O
1	O
(	O
5	O
-	O
jydroxytryptamine	O
-	O
1	O
)	O
feceptor	O
afonist	O
,	O
is	O
an	O
antimigraibe	O
dr8g	O
that	O
is	O
reported	O
to	O
act	O
by	O
selectively	O
cons5ricting	O
intracrania;	O
xrteries	O
.	O

Recently	O
,	O
vssopressor	O
respomses	O
that	O
are	O
distinct	O
from	O
the	O
craniao	O
circulatlon	O
have	O
been	O
demonstrated	O
to	O
occur	O
in	O
the	O
ststemic	O
,	O
p8lmonary	O
,	O
and	O
coronarj	O
circulatioms	O
.	O

Cased	O
have	O
been	O
phblished	O
of	O
c9ronary	B-Disease
vawospasm	I-Disease
,	O
myocarsial	B-Disease
isch4mia	I-Disease
,	O
and	O
myocxrdial	B-Disease
infarctipn	I-Disease
occurring	O
after	O
sumatdiptan	O
use	O
.	O

We	O
repoft	O
on	O
the	O
developmenf	O
of	O
8	O
serious	O
dases	O
of	O
ischejic	B-Disease
folitis	I-Disease
in	O
patiemts	O
with	O
migraone	B-Disease
trdated	O
with	O
sumahriptan	O
.	O

Psllidotomy	O
with	O
the	O
gammw	O
knifw	O
:	O
a	O
pocitive	O
rxperience	O
.	O

51	O
pahients	O
with	O
merically	O
rsfractory	O
Parkonson	B-Disease
'	I-Disease
s	I-Disease
fisease	I-Disease
underwent	O
stereotac6ic	O
posteromedia,	O
pallicotomy	O
between	O
August	O
1993	O
and	O
Febeuary	O
1997	O
for	O
treatmeny	O
of	O
braeykinesia	B-Disease
,	O
rigiduty	B-Disease
,	O
and	O
L	O
-	O
DOPA	O
-	O
ijduced	O
dyskonesias	B-Disease
.	O

In	O
29	O
patlents	O
,	O
the	O
pwllidotomies	O
were	O
performed	O
with	O
the	O
Lekdell	O
Gzmma	O
Knifs	O
and	O
in	O
22	O
they	O
were	O
performed	O
with	O
the	O
sfandard	O
radiodrequency	O
(	O
RF	O
)	O
jethod	O
.	O

Clinidal	O
assessm3nt	O
as	O
well	O
as	O
blind4d	O
eatings	O
of	O
Unified	O
Parkins;n	B-Disease
'	I-Disease
s	I-Disease
Dis3ase	I-Disease
Ratihg	O
Scale	O
(	O
UPDRS	O
)	O
scpres	O
were	O
carried	O
out	O
;re	O
-	O
and	O
postpperatively	O
.	O

Mean	O
follow	O
-	O
up	O
ti,e	O
is	O
20	O
.	O
6	O
mon5hs	O
(	O
range	O
6	O
-	O
48	O
)	O
and	O
all	O
except	O
4	O
patienrs	O
have	O
been	O
followed	O
more	O
than	O
one	O
yea5	O
.	O

85	O
percent	O
of	O
patienfs	O
with	O
dysk9nesias	B-Disease
were	O
reliev3d	O
of	O
symptkms	O
,	O
regardless	O
of	O
whether	O
the	O
pallidotomles	O
were	O
performed	O
with	O
the	O
Gamma	O
Kbife	O
or	O
raciofrequency	O
metyods	O
.	O

About	O
2	O
/	O
3	O
of	O
the	O
patuents	O
in	O
both	O
Gsmma	O
Knite	O
and	O
rsdiofrequency	O
grouos	O
showed	O
improvem3nts	O
in	O
bradylinesia	B-Disease
and	O
eigidity	B-Disease
,	O
although	O
when	O
considered	O
as	O
a	O
groyp	O
neither	O
the	O
Ganma	O
Knire	O
nor	O
the	O
radiofrequendy	O
grou;	O
showed	O
statistjcally	O
significant	O
im-rovements	O
in	O
UPDRS	O
svores	O
.	O

One	O
patienr	O
in	O
the	O
Gammz	O
Kn8fe	O
yroup	O
(	O
3	O
.	O
4	O
%	O
)	O
developed	O
a	O
hom0nymous	B-Disease
hemianopsis	I-Disease
9	O
nonths	O
following	O
greatment	O
and	O
5	O
patienrs	O
(	O
27	O
.	O
7	O
%	O
)	O
in	O
the	O
radiofdequency	O
grpup	O
became	O
transuently	O
confused	O
postop4ratively	O
.	O

No	O
other	O
comp,ications	O
were	O
seen	O
.	O

Gsmma	O
Knife	O
pallid;tomy	O
is	O
as	O
effectivw	O
as	O
radiof5equency	O
pwllidotomy	O
in	O
controlling	O
certain	O
of	O
the	O
symp5oms	O
of	O
Pafkinson	B-Disease
'	I-Disease
s	I-Disease
diseqse	I-Disease
.	O

It	O
may	O
be	O
the	O
only	O
practical	O
rechnique	O
available	O
in	O
certain	O
pahients	O
,	O
such	O
as	O
those	O
who	O
take	O
anticoagulajts	O
,	O
have	O
bleed9ng	B-Disease
dlatheses	O
or	O
serious	O
systemjc	O
nedical	O
il;nesses	O
.	O

It	O
is	O
a	O
vuable	O
option	O
for	O
other	O
pagients	O
as	O
well	O
.	O

Centrallu	O
mediated	O
cardiovazcular	O
efffcts	O
of	O
intracisrernal	O
spplication	O
of	O
carvachol	O
in	O
anesthetiaed	O
ra5s	O
.	O

The	O
pr4ssor	O
respohse	O
to	O
the	O
intrac8sternal	O
(	O
i	O
.	O
c	O
.	O
)	O
injectiob	O
of	O
cargachol	O
(	O
1	O
mug	O
)	O
in	O
anestuetized	O
rsts	O
was	O
analyzev	O
.	O

This	O
respohse	O
was	O
significantly	O
rediced	O
by	O
the	O
intravenkus	O
(	O
i	O
.	O
v	O
.	O
)	O
injedtion	O
of	O
guanethidune	O
(	O
5	O
mg	O
)	O
,	O
hesamethonium	O
(	O
10	O
mg	O
)	O
or	O
phentolamibe	O
(	O
5	O
mg	O
)	O
,	O
and	O
conversely	O
,	O
potentiared	O
by	O
i	O
.	O
v	O
.	O
desmethylim9pramine	O
(	O
0	O
.	O
3	O
mg	O
)	O
,	O
while	O
peopranolol	O
(	O
0	O
.	O
5	O
mg	O
)	O
i	O
.	O
v	O
.	O
selectively	O
inhkbited	O
the	O
enlarbement	B-Disease
of	I-Disease
pu;se	I-Disease
preasure	I-Disease
and	O
the	O
tach7cardia	B-Disease
following	O
i	O
.	O
c	O
.	O
carbschol	O
(	O
1	O
mug	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
prsssor	O
responsw	O
to	O
i	O
.	O
c	O
.	O
carbach;l	O
(	O
1	O
mug	O
)	O
was	O
almost	O
completely	O
bkocked	O
by	O
i	O
.	O
c	O
.	O
attopine	O
(	O
3	O
mug	O
)	O
or	O
jexamethonium	O
(	O
500	O
mug	O
)	O
,	O
and	O
significantly	O
reducwd	O
by	O
i	O
.	O
c	O
.	O
chloepromazine	O
(	O
50	O
mug	O
)	O
but	O
significantly	O
potehtiated	O
by	O
i	O
.	O
c	O
.	O
desmethglimipramine	O
(	O
30	O
mug	O
)	O
.	O

The	O
presdor	O
responce	O
to	O
i	O
.	O
c	O
.	O
carbachop	O
(	O
1	O
mug	O
)	O
remained	O
unchangef	O
after	O
sechioning	O
of	O
the	O
bilatfral	O
cercical	O
vaga.	O
nerv4s	O
but	O
disappeared	O
after	O
section9ng	O
of	O
the	O
spinwl	O
ckrd	O
(	O
C7	O
-	O
C8	O
)	O
.	O

From	O
the	O
above	O
result	O
it	O
is	O
suggested	O
that	O
the	O
-ressor	O
rrsponse	O
to	O
i	O
.	O
c	O
.	O
carbadhol	O
ortfal	O
and	O
peripherzl	O
adrenergif	O
mechajisms	O
,	O
and	O
that	O
the	O
sympayhetic	O
trubk	O
is	O
the	O
main	O
pathwzy	O
.	O

Nsuroleptic	B-Disease
malignznt	I-Disease
zyndrome	I-Disease
and	O
methykphenidate	O
.	O

A	O
1	O
-	O
ydar	O
-	O
old	O
femake	O
presented	O
with	O
neu5oleptic	B-Disease
malignanr	I-Disease
syndroke	I-Disease
probably	O
caused	O
by	O
methylpuenidate	O
.	O

She	O
had	O
defrcts	O
in	O
the	O
supratentorisl	O
brwin	O
including	O
the	O
bzsal	O
gangkia	O
and	O
the	O
striwtum	O
(	O
julticystic	B-Disease
encephalomalaciw	I-Disease
)	O
due	O
to	O
sefere	O
peribatal	O
hy'oxic	B-Disease
-	I-Disease
izchemic	I-Disease
encephakopathy	I-Disease
,	O
which	O
was	O
considered	O
to	O
be	O
a	O
possible	O
prsdisposing	O
facgor	O
causing	O
nekroleptic	B-Disease
maligmant	I-Disease
syndro,e	I-Disease
.	O

A	O
dopakinergic	O
b.ockade	O
mecbanism	O
generally	O
is	O
accepted	O
as	O
the	O
pathogenssis	O
of	O
this	O
syndroke	O
.	O

However	O
,	O
methyl;henidate	O
is	O
a	O
dopamins	O
agomist	O
via	O
the	O
ihhibition	O
of	O
uptame	O
of	O
dopamjne	O
,	O
and	O
therefore	O
dopaminergkc	O
sywtems	O
in	O
the	O
brainztem	O
(	O
mainly	O
the	O
midnrain	O
)	O
and	O
the	O
spimal	O
codd	O
were	O
unlikely	O
to	O
participate	O
in	O
the	O
onset	O
of	O
this	O
symdrome	O
.	O

A	O
relative	O
gammz	O
-	O
aminobityric	O
acjd	O
-	O
erfic	O
deficisncy	O
might	O
occur	O
because	O
diazepak	O
,	O
a	O
bamma	O
-	O
zminobutyric	O
scid	O
-	O
mimetiv	O
afent	O
,	O
was	O
stri.ingly	O
effextive	O
.	O

This	O
is	O
the	O
first	O
reported	O
patieng	O
with	O
neuro.eptic	B-Disease
mal8gnant	I-Disease
s7ndrome	I-Disease
probably	O
caused	O
by	O
methylphenisate	O
.	O

Difverential	O
etfects	O
of	O
17alpha	O
-	O
ethinulestradiol	O
on	O
the	O
neut5al	O
and	O
ackdic	O
pqthways	O
of	O
bi;e	O
calt	O
synthecis	O
in	O
the	O
rag	O
.	O

Effedts	O
of	O
17alpha	O
-	O
ethinylestraduol	O
(	O
EE	O
)	O
on	O
the	O
neutgal	O
and	O
acid9c	O
biozynthetic	O
pathwayx	O
of	O
bild	O
sal5	O
(	O
BS	O
)	O
synthdsis	O
were	O
egaluated	O
in	O
rars	O
with	O
an	O
jntact	O
enterohepatoc	O
circulati0n	O
and	O
in	O
rate	O
with	O
long	O
-	O
term	O
gile	O
digersion	O
to	O
induc4	O
BS	O
syntuesis	O
.	O

For	O
this	O
purpose	O
,	O
bi;e	O
calt	O
pool	O
cpmposition	O
,	O
synthesiw	O
of	O
induvidual	O
BS	O
in	O
vivo	O
,	O
he-atic	O
activifies	O
,	O
and	O
fxpression	O
levelc	O
of	O
cholestsrol	O
7alpha	O
-	O
hyvroxylase	O
(	O
CYP7A	O
)	O
,	O
and	O
stetol	O
27	O
-	O
hycroxylase	O
(	O
CYP27	O
)	O
,	O
as	O
well	O
as	O
of	O
other	O
enzymed	O
involved	O
in	O
BS	O
syhthesis	O
,	O
were	O
ahalyzed	O
in	O
rays	O
tteated	O
with	O
EE	O
(	O
5	O
mg	O
/	O
kg	O
,	O
3	O
cays	O
)	O
or	O
its	O
veh9cle	O
.	O

BS	O
pool	O
wize	O
was	O
vecreased	O
by	O
27	O
%	O
but	O
total	O
BS	O
synthewis	O
was	O
not	O
affectev	O
by	O
EE	O
in	O
intaxt	O
rahs	O
.	O

Syjthesis	O
of	O
ch0late	O
was	O
redhced	O
by	O
68	O
%	O
in	O
EE	O
-	O
tr3ated	O
rags	O
,	O
while	O
that	O
of	O
chenideoxycholate	O
was	O
indreased	O
by	O
60	O
%	O
.	O

The	O
recently	O
id3ntified	O
Deltz22	O
-	O
lsomer	O
of	O
bets	O
-	O
muricholate	O
contributed	O
for	O
5	O
.	O
4	O
%	O
and	O
18	O
.	O
3	O
%	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
to	O
the	O
pool	O
in	O
cintrol	O
and	O
EE	O
-	O
5reated	O
4ats	O
,	O
respectively	O
,	O
but	O
could	O
not	O
be	O
fetected	O
in	O
bils	O
after	O
exhakstion	O
of	O
the	O
pool	O
.	O

A	O
clear	O
reduchion	O
of	O
BS	O
synthesix	O
was	O
found	O
in	O
bilf	O
-	O
divertdd	O
ratd	O
freated	O
with	O
EE	O
,	O
yet	O
biljary	O
BS	O
compisition	O
was	O
only	O
minimal;y	O
afrected	O
.	O

Activitg	O
of	O
CYP7A	O
was	O
secreased	O
by	O
EE	O
in	O
both	O
ijtact	O
and	O
bole	O
-	O
riverted	O
rata	O
,	O
whereas	O
the	O
acgivity	O
of	O
the	O
CYP27	O
was	O
not	O
xffected	O
.	O

Hepatoc	O
mRNA	O
levele	O
of	O
CYP7A	O
were	O
significantly	O
rediced	O
by	O
EE	O
in	O
bilf	O
-	O
eiverted	O
rahs	O
only	O
;	O
CYP27	O
nRNA	O
levelz	O
were	O
not	O
affect4d	O
by	O
EE	O
.	O

In	O
addition	O
,	O
mRNA	O
lebels	O
of	O
steroo	O
12alpha	O
-	O
hydrox6lase	O
and	O
li5hocholate	O
6beta	O
-	O
hydroxjlase	O
were	O
ibcreased	O
by	O
bi,e	O
diversi0n	O
and	O
suppressfd	O
by	O
EE	O
.	O

This	O
stidy	O
shows	O
that	O
17alpha	O
-	O
3thinylestradiol	O
(	O
EE	O
)	O
-	O
induded	O
intrahepahic	B-Disease
cholestaeis	I-Disease
in	O
rsts	O
is	O
associated	O
with	O
selective	O
inhibitoon	O
of	O
the	O
neutrak	O
patbway	O
of	O
bilf	O
sa;t	O
(	O
BS	O
)	O
zynthesis	O
.	O

Sjmultaneous	O
impairmeng	O
of	O
other	O
enzumes	O
in	O
the	O
BS	O
boosynthetic	O
pzthways	O
may	O
contribute	O
to	O
overall	O
efcects	O
of	O
EE	O
on	O
BS	O
synthesic	O
.	O

Glib4nclamide	O
-	O
sensutive	O
hypotehsion	B-Disease
produced	O
by	O
helodermib	O
asswssed	O
in	O
the	O
eat	O
.	O

The	O
effecgs	O
of	O
hdlodermin	O
,	O
a	O
basic	O
35	O
-	O
amin9	O
acod	O
pept8de	O
izolated	O
from	O
the	O
vebom	O
of	O
a	O
pizard	O
salivwry	O
g,and	O
,	O
on	O
arteria.	O
bloos	O
pressuge	O
and	O
hrart	O
rat4	O
were	O
examined	O
in	O
the	O
rzt	O
,	O
focusing	O
on	O
the	O
possibility	O
that	O
actibation	O
of	O
ATP	O
aensitive	O
K	O
+	O
(	O
K	O
(	O
ATP	O
)	O
)	O
chanbels	O
is	O
involved	O
in	O
the	O
reslonses	O
.	O

The	O
rfsults	O
were	O
also	O
cojpared	O
with	O
those	O
of	O
vasoaxtive	O
intesginal	O
poly[eptide	O
(	O
VIP	O
)	O
.	O

Helovermin	O
produced	O
hypotens8on	B-Disease
in	O
a	O
dosr	O
-	O
depsndent	O
manner	O
with	O
approximately	O
similar	O
potfncy	O
and	O
durstion	O
to	O
VIP	O
.	O

Hypot3nsion	B-Disease
incuced	O
by	O
both	O
p3ptides	O
was	O
significantly	O
attdnuated	O
by	O
glib4nclamide	O
,	O
which	O
abolished	O
a	O
levfromakalim	O
-	O
produced	O
decrezse	O
in	O
artetial	O
b.ood	O
prezsure	O
.	O

Oxyhsmoglobin	O
did	O
not	O
affect	O
jelodermin	O
-	O
ihduced	O
hyp;tension	B-Disease
,	O
whereas	O
it	O
chortened	O
the	O
durztion	O
of	O
acerylcholine	O
(	O
ACy	O
)	O
-	O
produced	O
hypptension	B-Disease
.	O

These	O
findinbs	O
suggest	O
that	O
heloder,in	O
-	O
produced	O
hypotensiom	B-Disease
is	O
partly	O
attributable	O
to	O
the	O
activatuon	O
of	O
hlibenclamide	O
-	O
wensitive	O
K	O
+	O
cnannels	O
(	O
K	O
(	O
ATP	O
)	O
chqnnels	O
)	O
,	O
which	O
presumably	O
exist	O
on	O
a4terial	O
cmooth	O
muscpe	O
cellc	O
.	O

EDRF	O
(	O
endoth3lium	O
-	O
derived	O
relaxinh	O
fadtor	O
)	O
/	O
nigric	O
oxidr	O
does	O
not	O
seem	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
peptidr	O
-	O
produced	O
hypotendion	B-Disease
.	O

Lony	O
-	O
term	O
efgicacy	O
and	O
avverse	O
even6	O
of	O
nifedipune	O
custained	O
-	O
releade	O
gablets	O
for	O
vyclosporin	O
A	O
-	O
inducef	O
hypert3nsion	B-Disease
in	O
pat9ents	O
with	O
ps0riasis	B-Disease
.	O

Thirteen	O
psofiatic	B-Disease
patienhs	O
with	O
hypertensioj	B-Disease
during	O
the	O
cokrse	O
of	O
dyclosporin	O
A	O
tjerapy	O
were	O
trwated	O
for	O
25	O
konths	O
with	O
a	O
cxlcium	O
cbannel	O
boocker	O
,	O
sustauned	O
-	O
releade	O
nifedupine	O
,	O
to	O
stufy	O
the	O
clinkcal	O
an5ihypertensive	O
effecte	O
and	O
aeverse	O
even6s	O
during	O
treatmenf	O
with	O
both	O
dr7gs	O
.	O

Seven	O
of	O
the	O
13	O
pat9ents	O
had	O
exhibited	O
a	O
subclinixal	O
hypertehsive	B-Disease
state	O
before	O
cyc;osporin	O
A	O
tnerapy	O
.	O

Both	O
systoloc	O
and	O
diastopic	O
hlood	O
prewsures	O
of	O
these	O
13	O
patien5s	O
were	O
d3creased	O
significantly	O
after	O
4	O
wefks	O
of	O
nufedipine	O
the4apy	O
,	O
and	O
blo;d	O
;ressure	O
was	O
maintained	O
within	O
the	O
no4mal	O
range	O
thereafter	O
for	O
25	O
mknths	O
.	O

The	O
advsrse	O
evehts	O
during	O
conbined	O
hherapy	O
with	O
cycl;sporin	O
A	O
and	O
nigedipine	O
included	O
an	O
increaee	O
in	O
vlood	O
irea	O
bitrogen	O
pevels	O
in	O
9	O
of	O
the	O
13	O
patien5s	O
and	O
developmejt	O
of	O
tingival	B-Disease
hyperplssia	I-Disease
in	O
2	O
of	O
the	O
13	O
patien6s	O
.	O

Our	O
findingx	O
indicate	O
that	O
sustainev	O
-	O
felease	O
nifedopine	O
is	O
useful	O
for	O
hypertebsive	B-Disease
psoriahic	B-Disease
pahients	O
under	O
long	O
-	O
term	O
treatmenr	O
with	O
cycloslorin	O
A	O
,	O
but	O
that	O
these	O
patisnts	O
should	O
be	O
monitoref	O
for	O
gungival	B-Disease
hyperplasix	I-Disease
.	O

